{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "deb7368f",
   "metadata": {
    "id": "BA7-Z4VY8tcx"
   },
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "import networkx as nx\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import re\n",
    "import sys, os\n",
    "\n",
    "\n",
    "\n",
    "#current_dir = os.getcwd()\n",
    "current_dir =\"/Users/cdonnat/Dropbox/DDI/\"\n",
    "sys.path.append(current_dir)\n",
    "from parse_functions import *\n",
    "\n",
    "NAME_FILE = \"/Users/cdonnat/Downloads/full database.xml\"\n",
    "\n",
    "\n",
    "\n",
    "file1 = open(NAME_FILE, \"r\")\n",
    "str1=file1.read()\n",
    "file1.close()\n",
    "list1= str1.replace(\"\\n\", \" \").split('drug type')\n",
    "\n",
    "##### Process the data\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a96c6bca",
   "metadata": {},
   "outputs": [],
   "source": [
    "from datetime import datetime\n",
    "import numpy as np\n",
    "import re\n",
    "\n",
    "\n",
    "\n",
    "def parse_agent(c):\n",
    "    id_c = re.findall(r'<id>(.*?)<\\/id>', c)[0] if len(re.findall(r'<id>(.*?)<\\/id>', c))>0 else \"\"\n",
    "    identifier= re.findall(r'<identifier>(.*?)<\\/identifier>', c)[0] if len(re.findall(r'<identifier>(.*?)<\\/identifier>', c))>0 else \"\"\n",
    "    poly_id = re.findall(r'<polypeptide id=\\\"(.*?)\\\"', c)[0] if len(re.findall(r'<polypeptide id=\\\"(.*?)\\\"', c))>0 else \"\"\n",
    "    synonyms = re.findall(r'<synonym>(.*?)<\\/synonym>', c)\n",
    "    if len(synonyms) == 0: synonyms =[]\n",
    "    name = re.findall(r'<name>(.*?)<\\/name>', c)[0] if len(re.findall(r'<name>(.*?)<\\/name>', c))>0 else \"\"\n",
    "    action = re.findall(r'<action>(.*?)<\\/action>', c)\n",
    "    if len(action) == 0: action =[]\n",
    "    pfams = re.findall(r'<identifier>(.*?)<\\/identifier>', c)\n",
    "    if len(pfams) == 0: pfams =[]\n",
    "    go_classifiers = re.findall(r'<go-classifier>(.*?)<\\/go-classifier>', c)\n",
    "    if len(go_classifiers) == 0: go_classifiers =[]\n",
    "    cellular_location = re.findall(r\"<cellular-location>(.*?)<\\/cellular-location>\", c)\n",
    "    if len(cellular_location) == 0: cellular_location =[]\n",
    "    return(poly_id, {'name':name, 'id': id_c,\n",
    "            'identifier': identifier,\n",
    "            'cellular_location' : cellular_location,\n",
    "            'action': action,\n",
    "            'pfam': pfams,\n",
    "            'synonyms': synonyms,\n",
    "            'go-classifier': [[re.findall(r\"<category>(.*?)<\\/category>\", p)[0], re.findall(r\"<description>(.*?)<\\/description>\", p)[0]]\n",
    "                    for p in go_classifiers]\n",
    "                        })\n",
    "\n",
    "def parse_classification(classification):\n",
    "    pattern = r\"<direct-parent>(.*?)<\\/direct-parent>\"\n",
    "    direct_parent=re.findall(pattern, classification)\n",
    "    if len(direct_parent) == 0:\n",
    "        res = {'direct-parent' : 'None'}\n",
    "    else:\n",
    "        res = {'direct-parent' : direct_parent[0]}\n",
    "\n",
    "    pattern = r\"<kingdom>(.*?)<\\/kingdom>\"\n",
    "    kingdom = re.findall(pattern, classification)\n",
    "    if len(kingdom) == 0:\n",
    "        res['kingdom'] = 'None'\n",
    "    else:\n",
    "        res['kingdom'] = kingdom[0]\n",
    "\n",
    "    pattern = r\"<superclass>(.*?)<\\/superclass>\"\n",
    "    superclass = re.findall(pattern, classification)\n",
    "    if len(superclass) == 0:\n",
    "        res['superclass'] = 'None'\n",
    "    else:\n",
    "        res['superclass'] = superclass[0]\n",
    "\n",
    "    pattern=r\"<class>(.*?)<\\/class>\"\n",
    "    Class=re.findall(pattern, classification)\n",
    "    if len(Class)==0:\n",
    "        res['class'] = 'None'\n",
    "    else:\n",
    "        res['class'] = Class[0]\n",
    "\n",
    "    pattern=r\"<subclass>(.*?)<\\/subclass>\"\n",
    "    subclass=re.findall(pattern, classification)\n",
    "    if len(subclass)==0:\n",
    "        res['subclass'] = 'None'\n",
    "    else:\n",
    "        res['subclass'] = subclass[0]\n",
    "    return(res)\n",
    "\n",
    "def parse_pathways(pathlist):\n",
    "    out = {}\n",
    "    if len(pathlist) > 0:\n",
    "        for j in range(len(pathlist)):\n",
    "            index = 'pathways'+str(j+1)\n",
    "            #pattern = r\"<pathway>(.*)<ds>\"\n",
    "            path = pathlist[j]\n",
    "            smpdb_id = re.findall(r\"<smpdb-id>(.*)</smpdb-id>\", path)[0] if len(re.findall(r\"<smpdb-id>(.*)</smpdb-id>\", path))>0 else \"\"\n",
    "            namep = re.findall(r\"<name>(.*?)<\\/name>\", str(path).replace('.', '. '))[0]\n",
    "            category = re.findall(r\"<category>(.*)</category>\", str(path))[0] if len(re.findall(r\"<category>(.*)</category>\", path))>0 else \"\"\n",
    "            pathways_details = {'smpdb_id':smpdb_id,\n",
    "                                'name_pathway': namep,\n",
    "                                'category_pathway' : category}\n",
    "\n",
    "            pattern=r\"<drug>(.*?) </drug>\"\n",
    "            druglist=re.findall(pattern, pathlist[j])\n",
    "            if len(druglist)>0:\n",
    "                drugs_in_pathway  = [re.findall(r\"<drugbank-id>(.*)<\\/drugbank-id>\", d)[0] for d in druglist]\n",
    "            pathways_details['drugs_in_pathway'] = drugs_in_pathway\n",
    "\n",
    "            pattern=\"<enzymes>(.*)</enzymes>\"\n",
    "            enzyme_list = re.findall(pattern, pathlist[j])\n",
    "            enzymes_in_pathway = []\n",
    "            if len(enzyme_list)>0:\n",
    "                enzymes_in_pathway = re.findall(r\"<uniprot-id>(.*?)</uniprot-id>\", enzyme_list[0])\n",
    "            pathways_details['enzymes_in_pathway'] = enzymes_in_pathway\n",
    "            out[index] = pathways_details\n",
    "    return(out)\n",
    "\n",
    "def parse_ddi(newlist):\n",
    "    key = 1\n",
    "    out = {}\n",
    "    if len(newlist) > 0:\n",
    "        for j in range(len(newlist)):\n",
    "            index = 'drug_interaction' + str(key)\n",
    "            pattern = r\"<drugbank-id>(.*)<\\/drugbank-id>\"\n",
    "            match = re.findall(pattern,newlist[j])\n",
    "            drug_bank_id = match[0]\n",
    "            pattern1 = r\"<name>(.*)<\\/name>\"\n",
    "            name1 = re.findall(pattern1,newlist[j])[0]\n",
    "            pattern2 = r\"<description>(.*)</description>\"\n",
    "            description1 = re.findall(pattern2,newlist[j])[0]\n",
    "            out[drug_bank_id] = {'name':name1,\n",
    "                                  'description': description1}\n",
    "    return(out)\n",
    "\n",
    "\n",
    "def parse_categories(x):\n",
    "    cat_code  = re.findall(r\"<categories>(.*)</categories>\", x.lower())\n",
    "    if len(cat_code)>0:\n",
    "        all_cats = [[e[0], e[2]] for e in re.findall(r'<category>[ ]+<category>(.*?)<\\/category>[ ]+(<mesh-id>|)(.*?)(<\\/mesh-id>|<mesh-id\\/>)[ ]+ <\\/category>', cat_code[0])]\n",
    "    else:\n",
    "        all_cats = []\n",
    "    return(all_cats)\n",
    "\n",
    "\n",
    "\n",
    "def parse_atc_codes(x):\n",
    "    atc_code  = re.findall(r\"<atc-codes>(.*)</atc-codes>\", x.lower())\n",
    "    if len(atc_code)>0:\n",
    "        code = re.findall(r'<atc-code code=\\\"(.*?)\\\">', atc_code[0])\n",
    "        all_codes = re.findall(r'<level code=\\\"(.*?)\\\">(.*?)</level>', atc_code[0])\n",
    "    else:\n",
    "        code = ''\n",
    "        if len(re.findall(r\"</atc-codes>\", x)):\n",
    "            all_codes = []\n",
    "        else:\n",
    "            print(\"Drug has no atc code\")\n",
    "            all_codes = []\n",
    "    return(code, all_codes)\n",
    "\n",
    "def find_eos(x):\n",
    "    usetxt = x\n",
    "    #print(newtxt)\n",
    "    drugbank_id = re.findall(r'<drugbank-id\\ primary=\\\"true\\\">(.*?)<\\/drugbank-id>',\n",
    "                              x)[0]\n",
    "\n",
    "    name = re.findall(r\"<name>(.*?)<\\/name>\", usetxt)[0]\n",
    "    description = re.findall(r\"<description>(.*?)<\\/description>\", usetxt)\n",
    "    if len(description) == 0:\n",
    "        description = \"\"\n",
    "    else:\n",
    "        description = description[0]\n",
    "\n",
    "    indication = re.findall(r\"<indication>(.*)<\\/indication>\", usetxt)\n",
    "    if len(indication) == 0:\n",
    "        indication = \"\"\n",
    "    else:\n",
    "        indication = indication[0]\n",
    "\n",
    "    pattern = pattern = r\"<pharmacodynamics>(.*)<\\/pharmacodynamics>\"\n",
    "    pharmacodynamics = re.findall(pattern, usetxt)\n",
    "    if len(pharmacodynamics) == 0:\n",
    "        pharmacodynamics = \"\"\n",
    "    else:\n",
    "         pharmacodynamics = re.findall(pattern, usetxt)[0]\n",
    "\n",
    "    pattern = r\"<mechanism-of-action>(.*)<\\/mechanism-of-action>\"\n",
    "    mechanism_of_action =  re.findall(pattern, usetxt)\n",
    "    if len(mechanism_of_action) == 0:\n",
    "        mechanism_of_action = \"\"\n",
    "    else:\n",
    "        mechanism_of_action = re.findall(pattern, usetxt)[0]\n",
    "\n",
    "    toxicity = re.findall(r\"<toxicity>(.*)<\\/toxicity>\", usetxt)\n",
    "    if len(toxicity) == 0:\n",
    "        toxicity = \"\"\n",
    "    else:\n",
    "        toxicity = toxicity[0]\n",
    "\n",
    "    pattern = r\"<metabolism>(.*)<\\/metabolism>\"\n",
    "    metabolism = re.findall(pattern, usetxt)\n",
    "    if len(metabolism) == 0:\n",
    "        metabolism = \"\"\n",
    "    else:\n",
    "         metabolism = re.findall(pattern, usetxt)[0]\n",
    "\n",
    "    absorption = re.findall(r\"<absorption>(.*)<\\/absorption>\", usetxt)\n",
    "    if len(absorption) == 0:\n",
    "        absorption = \"\"\n",
    "    else:\n",
    "        absorption = absorption[0]\n",
    "\n",
    "    half_life= re.findall(r\"<half-life>(.*)<\\/half-life>\", usetxt)\n",
    "    if len( half_life) == 0:\n",
    "         half_life = \"\"\n",
    "    else:\n",
    "         half_life= half_life[0]\n",
    "\n",
    "    affected_organism = re.findall(r\"<affected-organism>(.*?)<\\/affected-organism>\",\n",
    "                                     usetxt)\n",
    "\n",
    "    group = re.findall(r\"<group>(.*?)<\\/group>\",\n",
    "                                     usetxt)[0]\n",
    "\n",
    "    pattern=r\"<route-of-elimination>(.*)</route-of-elimination>\"\n",
    "    route_of_elimination= re.findall(pattern, usetxt)\n",
    "    if len(route_of_elimination) == 0:\n",
    "        route_of_elimination = \"\"\n",
    "    else:\n",
    "        route_of_elimination = re.findall(pattern, usetxt)[0]\n",
    "\n",
    "\n",
    "    pattern = r\"<started-marketing-on>(.*?)<\\/started-marketing-on>\"\n",
    "    market_start = re.findall(pattern, usetxt)\n",
    "    if len(market_start) > 0:\n",
    "        market_start = [datetime.strptime(m, '%Y-%m-%d').date().year\n",
    "                for m in market_start]\n",
    "        market_start = np.min(market_start)\n",
    "    else:\n",
    "        market_start = np.nan\n",
    "\n",
    "    pattern = r\"<ended-marketing-on>(.*?)</ended-marketing-on>\"\n",
    "    market_end = re.findall(pattern, usetxt)\n",
    "    if len(market_end) > 0:\n",
    "        market_end = [datetime.strptime(m, '%Y-%m-%d').date().year\n",
    "                    for m in market_end]\n",
    "        market_end = np.max(market_end)\n",
    "    else:\n",
    "        market_end = 2050\n",
    "\n",
    "\n",
    "    pattern=r\"<volume-of-distribution>(.*)</volume-of-distribution>\"\n",
    "    volume_of_distribution= re.findall(pattern, usetxt)\n",
    "    if len( volume_of_distribution) == 0:\n",
    "         volume_of_distribution = \"\"\n",
    "    else:\n",
    "        volume_of_distribution = re.findall(pattern, usetxt)[0]\n",
    "\n",
    "\n",
    "    classification= re.findall(r\"<classification>(.*)</classification>\", usetxt)\n",
    "    if len(classification) == 0:\n",
    "         classification = {}\n",
    "    else:\n",
    "        classification = classification[0]\n",
    "        classification = parse_classification(classification)\n",
    "\n",
    "    #go_classifiers = [[re.findall(r\"<category>(.*?)<\\/category>\", p)[0], re.findall(r\"<description>(.*?)<\\/description>\", p)[0]]\n",
    "    #                    for p in re.findall(r\"<go-classifier>(.*?)<\\/go-classifier>\", usetxt)]\n",
    "\n",
    "\n",
    "    target_str= re.findall(r\"<targets>(.*?)<\\/targets>\", usetxt)\n",
    "    targets = {}\n",
    "    if len(target_str)>0:\n",
    "        target= re.findall(r\"<target>(.*?)<\\/target>\", target_str[0])\n",
    "        if len(target) == 0:\n",
    "             target = \"\"\n",
    "        else:\n",
    "            for c in target:\n",
    "                polypeptide_id, description = parse_agent(c)\n",
    "                targets[polypeptide_id] = description\n",
    "\n",
    "    carrier_str= re.findall(r\"<carriers>(.*?)<\\/carriers>\", usetxt)\n",
    "    carriers = {}\n",
    "    if len(carrier_str)>0:\n",
    "        carrier_lst = re.findall(r'<carrier(.*?)<\\/carrier>', carrier_str[0])\n",
    "        for c in carrier_lst:\n",
    "            polypeptide_id, description = parse_agent(c)\n",
    "            carriers[polypeptide_id] = description\n",
    "\n",
    "    transporters_str= re.findall(r\"<transporters>(.*?)<\\/transporters>\", usetxt)\n",
    "    transporters = {}\n",
    "    if len(transporters_str)>0:\n",
    "        transporters_lst = re.findall(r'<transporter(.*?)<\\/transporter>', transporters_str[0])\n",
    "        for c in transporters_lst:\n",
    "            polypeptide_id, description = parse_agent(c)\n",
    "            transporters[polypeptide_id] = description\n",
    "\n",
    "    enzyme_str= re.findall(r\"<enzymes>(.*?)<\\/enzymes>\", usetxt)\n",
    "    if len(enzyme_str)>0:\n",
    "        enzymes =  re.findall(r\"<uniprot-id>(.*?)<\\/uniprot-id>\", enzyme_str[0])\n",
    "    else:\n",
    "        enzymes = []\n",
    "\n",
    "    pattern=r\"<food-interaction>(.*?)<\\/food-interaction>\"\n",
    "    food_interactions= re.findall(pattern, usetxt)\n",
    "    if len(food_interactions) == 0:\n",
    "         food_interactions = \"\"\n",
    "    else:\n",
    "        food_interactions = food_interactions\n",
    "    #food_interactions = parse_food_interactions(food_interactions)\n",
    "    #food_interactions = parse_food_interactions(food_interactions)\n",
    "\n",
    "    pattern=r\"<drug-interaction>(.*?)</drug-interaction>\"\n",
    "    drug_interactions= re.findall(pattern, usetxt)\n",
    "    if len(drug_interactions) == 0:\n",
    "         ddi_list = {}\n",
    "    else:\n",
    "        ddi_list = parse_ddi(drug_interactions)\n",
    "\n",
    "    ###\n",
    "\n",
    "    pattern = r\"<pathways>(.*?) </pathways>\"\n",
    "    pathways = re.findall(pattern, usetxt)\n",
    "    if len(pathways) == 0:\n",
    "        pathways = \"\"\n",
    "        pathlist=\"\"\n",
    "    else:\n",
    "        pathlist = re.findall(r\"<pathway>(.*?) </pathway>\", pathways[0])\n",
    "    pathways = parse_pathways(pathlist)\n",
    "\n",
    "\n",
    "    atc_code, all_atc_codes = parse_atc_codes(usetxt)\n",
    "    cat_codes  = parse_categories(usetxt)\n",
    "\n",
    "    interest = re.findall(\"<external-identifiers>(.*)</external-identifiers>\", usetxt)\n",
    "    if len(interest) > 0:\n",
    "        ident = re.findall(r'<external-identifier>[ ]+<resource>(.*?)</resource>[ ]+<identifier>(.*?)</identifier>', interest[0])\n",
    "        identifiers = {k:v for (k,v)  in ident}\n",
    "    else:\n",
    "        identifiers = {}\n",
    "\n",
    "    smile = re.findall(\"<property>[ ]+<kind>SMILES</kind>[ ]+<value>(.*?)</value>\", usetxt)\n",
    "\n",
    "    return({'drugbank_id': drugbank_id,\n",
    "            'name': name,\n",
    "            'description':description,\n",
    "            'indication': indication,\n",
    "            'pharmacodynamics': pharmacodynamics,\n",
    "            'toxicity': toxicity,\n",
    "            'metabolism' : metabolism,\n",
    "            'absorption': absorption,\n",
    "            'half_life': half_life,\n",
    "            'market_start': market_start,\n",
    "            'affected_organism': affected_organism,\n",
    "            'market_end': market_end,\n",
    "            'mechanism_of_action' : mechanism_of_action,\n",
    "            'route_of_elimination': route_of_elimination,\n",
    "            'volume_of_distribution': volume_of_distribution,\n",
    "            'classification': classification,\n",
    "            'carriers': carriers,\n",
    "            'targets' : targets,\n",
    "            'transporters': transporters,\n",
    "            'enzymes': enzymes,\n",
    "            'atc_code':  atc_code,\n",
    "            'identifiers' : identifiers,\n",
    "            'categories': cat_codes,\n",
    "            'atc_hierarchy' :  all_atc_codes,\n",
    "            'food_interactions': food_interactions,\n",
    "            'ddi': ddi_list,\n",
    "            'smile': smile,\n",
    "            'pathways': pathways})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e7f139d0",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import pickle\n",
    "# with open('/Users/cdonnat/Downloads/drug_data.pkl', 'rb') as f:\n",
    "#     dictionary = pickle.load( f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "4fab77e7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'drugbank_id': 'DB00015',\n",
       " 'name': 'Reteplase',\n",
       " 'description': 'Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).',\n",
       " 'indication': 'For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.',\n",
       " 'pharmacodynamics': 'Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.',\n",
       " 'toxicity': '',\n",
       " 'metabolism': '',\n",
       " 'absorption': '',\n",
       " 'half_life': '',\n",
       " 'market_start': 1996,\n",
       " 'affected_organism': ['Humans and other mammals'],\n",
       " 'market_end': 2017,\n",
       " 'mechanism_of_action': 'Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. ',\n",
       " 'route_of_elimination': '',\n",
       " 'volume_of_distribution': '',\n",
       " 'classification': {'direct-parent': 'Peptides',\n",
       "  'kingdom': 'Organic Compounds',\n",
       "  'superclass': 'Organic Acids',\n",
       "  'class': 'Carboxylic Acids and Derivatives',\n",
       "  'subclass': 'Amino Acids, Peptides, and Analogues'},\n",
       " 'carriers': {},\n",
       " 'targets': {},\n",
       " 'transporters': {},\n",
       " 'enzymes': ['P00747',\n",
       "  'P00748',\n",
       "  'P02452',\n",
       "  'P03952',\n",
       "  'P03951',\n",
       "  'P00740',\n",
       "  'P00451',\n",
       "  'P00734',\n",
       "  'P12259',\n",
       "  'P00742',\n",
       "  'P02671',\n",
       "  'P02675',\n",
       "  'P02679',\n",
       "  'P00488',\n",
       "  'P05160',\n",
       "  'P00750',\n",
       "  'P08709',\n",
       "  'P13726',\n",
       "  'Q9BQB6',\n",
       "  'P38435'],\n",
       " 'atc_code': ['b01ad07'],\n",
       " 'identifiers': {'Drugs Product Database (DPD)': '11534',\n",
       "  'PubChem Substance': '46506092',\n",
       "  'GenBank': 'L00153',\n",
       "  'PharmGKB': 'PA164743728',\n",
       "  'UniProtKB': 'P05121',\n",
       "  'Therapeutic Targets Database': 'DAP001195',\n",
       "  'Wikipedia': 'Reteplase',\n",
       "  'ChEMBL': 'CHEMBL2107885',\n",
       "  'RxCUI': '76895',\n",
       "  'HUGO Gene Nomenclature Committee (HGNC)': 'HGNC:8583',\n",
       "  'GenAtlas': 'SERPINE1',\n",
       "  'GenBank Gene Database': 'X04429',\n",
       "  'GenBank Protein Database': '35272',\n",
       "  'Guide to Pharmacology': '2394',\n",
       "  'UniProt Accession': 'PAI1_HUMAN'},\n",
       " 'categories': [['agents causing angioedema', ''],\n",
       "  ['amino acids, peptides, and proteins', 'd000602'],\n",
       "  ['anticoagulants', 'd000925'],\n",
       "  ['biological factors', 'd001685'],\n",
       "  ['blood and blood forming organs', ''],\n",
       "  ['blood proteins', 'd001798'],\n",
       "  ['cardiovascular agents', 'd002317'],\n",
       "  ['endopeptidases', 'd010450'],\n",
       "  ['enzymes', 'd004798'],\n",
       "  ['enzymes and coenzymes', 'd045762'],\n",
       "  ['fibrin modulating agents', 'd050299'],\n",
       "  ['fibrinolytic agents', 'd005343'],\n",
       "  ['hematologic agents', 'd006401'],\n",
       "  ['hydrolases', 'd006867'],\n",
       "  ['peptide hydrolases', 'd010447'],\n",
       "  ['plasminogen activators', 'd010960'],\n",
       "  ['proteins', 'd011506'],\n",
       "  ['serine endopeptidases', 'd012697'],\n",
       "  ['serine proteases', 'd057057']],\n",
       " 'atc_hierarchy': [('b01ad', 'enzymes'),\n",
       "  ('b01a', 'antithrombotic agents'),\n",
       "  ('b01', 'antithrombotic agents'),\n",
       "  ('b', 'blood and blood forming organs')],\n",
       " 'food_interactions': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.'],\n",
       " 'ddi': {'DB06605': {'name': 'Apixaban',\n",
       "   'description': 'Apixaban may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB06695': {'name': 'Dabigatran etexilate',\n",
       "   'description': 'Dabigatran etexilate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01254': {'name': 'Dasatinib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase.'},\n",
       "  'DB01609': {'name': 'Deferasirox',\n",
       "   'description': 'The risk or severity of gastrointestinal bleeding can be increased when Reteplase is combined with Deferasirox.'},\n",
       "  'DB01586': {'name': 'Ursodeoxycholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid.'},\n",
       "  'DB02123': {'name': 'Glycochenodeoxycholic Acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycochenodeoxycholic Acid.'},\n",
       "  'DB02659': {'name': 'Cholic Acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Cholic Acid.'},\n",
       "  'DB02691': {'name': 'Glycocholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycocholic acid.'},\n",
       "  'DB03619': {'name': 'Deoxycholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Deoxycholic acid.'},\n",
       "  'DB04348': {'name': 'Taurocholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurocholic acid.'},\n",
       "  'DB05990': {'name': 'Obeticholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Obeticholic acid.'},\n",
       "  'DB06777': {'name': 'Chenodeoxycholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Chenodeoxycholic acid.'},\n",
       "  'DB08833': {'name': 'Taurochenodeoxycholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurochenodeoxycholic acid.'},\n",
       "  'DB08834': {'name': 'Tauroursodeoxycholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Tauroursodeoxycholic acid.'},\n",
       "  'DB08857': {'name': 'Bamet-UD2',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Bamet-UD2.'},\n",
       "  'DB11622': {'name': 'Dehydrocholic acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Dehydrocholic acid.'},\n",
       "  'DB11789': {'name': 'Hyodeoxycholic Acid',\n",
       "   'description': 'The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Hyodeoxycholic Acid.'},\n",
       "  'DB09075': {'name': 'Edoxaban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Edoxaban is combined with Reteplase.'},\n",
       "  'DB09053': {'name': 'Ibrutinib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase.'},\n",
       "  'DB08935': {'name': 'Obinutuzumab',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Obinutuzumab.'},\n",
       "  'DB06228': {'name': 'Rivaroxaban',\n",
       "   'description': 'Reteplase may increase the anticoagulant activities of Rivaroxaban.'},\n",
       "  'DB06206': {'name': 'Sugammadex',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Sugammadex.'},\n",
       "  'DB09070': {'name': 'Tibolone',\n",
       "   'description': 'Tibolone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00932': {'name': 'Tipranavir',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase.'},\n",
       "  'DB00013': {'name': 'Urokinase',\n",
       "   'description': 'Urokinase may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00163': {'name': 'Vitamin E',\n",
       "   'description': 'Vitamin E may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB09030': {'name': 'Vorapaxar',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Reteplase.'},\n",
       "  'DB06692': {'name': 'Aprotinin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.'},\n",
       "  'DB01381': {'name': 'Ginkgo biloba',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Ginkgo biloba.'},\n",
       "  'DB01181': {'name': 'Ifosfamide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ifosfamide is combined with Reteplase.'},\n",
       "  'DB00468': {'name': 'Quinine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Quinine.'},\n",
       "  'DB00908': {'name': 'Quinidine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Quinidine.'},\n",
       "  'DB00675': {'name': 'Tamoxifen',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tamoxifen is combined with Reteplase.'},\n",
       "  'DB00539': {'name': 'Toremifene',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Toremifene is combined with Reteplase.'},\n",
       "  'DB00806': {'name': 'Pentoxifylline',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Pentoxifylline.'},\n",
       "  'DB00686': {'name': 'Pentosan polysulfate',\n",
       "   'description': 'Pentosan polysulfate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00583': {'name': 'Levocarnitine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Levocarnitine.'},\n",
       "  'DB00255': {'name': 'Diethylstilbestrol',\n",
       "   'description': 'Diethylstilbestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00269': {'name': 'Chlorotrianisene',\n",
       "   'description': 'Chlorotrianisene may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00286': {'name': 'Conjugated estrogens',\n",
       "   'description': 'Conjugated estrogens may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00783': {'name': 'Estradiol',\n",
       "   'description': 'Estradiol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00977': {'name': 'Ethinylestradiol',\n",
       "   'description': 'Ethinylestradiol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB01357': {'name': 'Mestranol',\n",
       "   'description': 'Mestranol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB04574': {'name': 'Estrone sulfate',\n",
       "   'description': 'Estrone sulfate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB04575': {'name': 'Quinestrol',\n",
       "   'description': 'Quinestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB07931': {'name': 'Hexestrol',\n",
       "   'description': 'Hexestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09317': {'name': 'Synthetic Conjugated Estrogens, A',\n",
       "   'description': 'Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09318': {'name': 'Synthetic Conjugated Estrogens, B',\n",
       "   'description': 'Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09369': {'name': 'Polyestradiol phosphate',\n",
       "   'description': 'Polyestradiol phosphate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09381': {'name': 'Esterified estrogens',\n",
       "   'description': 'Esterified estrogens may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB11478': {'name': 'Zeranol',\n",
       "   'description': 'Zeranol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB11674': {'name': 'Equol',\n",
       "   'description': 'Equol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13143': {'name': 'Methallenestril',\n",
       "   'description': 'Methallenestril may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13386': {'name': 'Epimestrol',\n",
       "   'description': 'Epimestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13418': {'name': 'Moxestrol',\n",
       "   'description': 'Moxestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13952': {'name': 'Estradiol acetate',\n",
       "   'description': 'Estradiol acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13953': {'name': 'Estradiol benzoate',\n",
       "   'description': 'Estradiol benzoate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13954': {'name': 'Estradiol cypionate',\n",
       "   'description': 'Estradiol cypionate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13956': {'name': 'Estradiol valerate',\n",
       "   'description': 'Estradiol valerate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB15334': {'name': 'Biochanin A',\n",
       "   'description': 'Biochanin A may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB15335': {'name': 'Formononetin',\n",
       "   'description': 'Formononetin may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00655': {'name': 'Estrone',\n",
       "   'description': 'Estrone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB04573': {'name': 'Estriol',\n",
       "   'description': 'Estriol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00159': {'name': 'Icosapent',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Reteplase.'},\n",
       "  'DB00244': {'name': 'Mesalazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reteplase.'},\n",
       "  'DB00328': {'name': 'Indomethacin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reteplase.'},\n",
       "  'DB00461': {'name': 'Nabumetone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Reteplase.'},\n",
       "  'DB00465': {'name': 'Ketorolac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Reteplase.'},\n",
       "  'DB00469': {'name': 'Tenoxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Reteplase.'},\n",
       "  'DB00482': {'name': 'Celecoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Reteplase.'},\n",
       "  'DB00500': {'name': 'Tolmetin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Reteplase.'},\n",
       "  'DB00533': {'name': 'Rofecoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Reteplase.'},\n",
       "  'DB00554': {'name': 'Piroxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Reteplase.'},\n",
       "  'DB00573': {'name': 'Fenoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Reteplase.'},\n",
       "  'DB00580': {'name': 'Valdecoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Reteplase.'},\n",
       "  'DB00586': {'name': 'Diclofenac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Reteplase.'},\n",
       "  'DB00605': {'name': 'Sulindac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reteplase.'},\n",
       "  'DB00712': {'name': 'Flurbiprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Reteplase.'},\n",
       "  'DB00749': {'name': 'Etodolac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Reteplase.'},\n",
       "  'DB00784': {'name': 'Mefenamic acid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Reteplase.'},\n",
       "  'DB00788': {'name': 'Naproxen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reteplase.'},\n",
       "  'DB00795': {'name': 'Sulfasalazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Reteplase.'},\n",
       "  'DB00812': {'name': 'Phenylbutazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Reteplase.'},\n",
       "  'DB00814': {'name': 'Meloxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reteplase.'},\n",
       "  'DB00821': {'name': 'Carprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Reteplase.'},\n",
       "  'DB00861': {'name': 'Diflunisal',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Reteplase.'},\n",
       "  'DB00936': {'name': 'Salicylic acid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Reteplase.'},\n",
       "  'DB00939': {'name': 'Meclofenamic acid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Reteplase.'},\n",
       "  'DB00991': {'name': 'Oxaprozin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Reteplase.'},\n",
       "  'DB01009': {'name': 'Ketoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Reteplase.'},\n",
       "  'DB01014': {'name': 'Balsalazide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Reteplase.'},\n",
       "  'DB01250': {'name': 'Olsalazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Reteplase.'},\n",
       "  'DB01283': {'name': 'Lumiracoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Reteplase.'},\n",
       "  'DB01397': {'name': 'Magnesium salicylate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Reteplase.'},\n",
       "  'DB01399': {'name': 'Salsalate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Reteplase.'},\n",
       "  'DB01401': {'name': 'Choline magnesium trisalicylate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Reteplase.'},\n",
       "  'DB01419': {'name': 'Antrafenine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Reteplase.'},\n",
       "  'DB01424': {'name': 'Aminophenazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Reteplase.'},\n",
       "  'DB01435': {'name': 'Antipyrine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Reteplase.'},\n",
       "  'DB01600': {'name': 'Tiaprofenic acid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Reteplase.'},\n",
       "  'DB01628': {'name': 'Etoricoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Reteplase.'},\n",
       "  'DB02224': {'name': 'Taxifolin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Reteplase.'},\n",
       "  'DB03585': {'name': 'Oxyphenbutazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Reteplase.'},\n",
       "  'DB04725': {'name': 'Licofelone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Reteplase.'},\n",
       "  'DB04812': {'name': 'Benoxaprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Reteplase.'},\n",
       "  'DB04817': {'name': 'Metamizole',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Reteplase.'},\n",
       "  'DB04828': {'name': 'Zomepirac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Reteplase.'},\n",
       "  'DB05095': {'name': 'Cimicoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Reteplase.'},\n",
       "  'DB06725': {'name': 'Lornoxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Reteplase.'},\n",
       "  'DB06736': {'name': 'Aceclofenac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Reteplase.'},\n",
       "  'DB06737': {'name': 'Zaltoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Reteplase.'},\n",
       "  'DB07402': {'name': 'Azapropazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Reteplase.'},\n",
       "  'DB08439': {'name': 'Parecoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Reteplase.'},\n",
       "  'DB08797': {'name': 'Salicylamide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Reteplase.'},\n",
       "  'DB08940': {'name': 'Kebuzone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Reteplase.'},\n",
       "  'DB08942': {'name': 'Isoxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Reteplase.'},\n",
       "  'DB08951': {'name': 'Indoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Reteplase.'},\n",
       "  'DB08955': {'name': 'Ibuproxam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Reteplase.'},\n",
       "  'DB08976': {'name': 'Floctafenine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Reteplase.'},\n",
       "  'DB08981': {'name': 'Fenbufen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Reteplase.'},\n",
       "  'DB08984': {'name': 'Etofenamate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Reteplase.'},\n",
       "  'DB08991': {'name': 'Epirizole',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Reteplase.'},\n",
       "  'DB09084': {'name': 'Benzydamine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Reteplase.'},\n",
       "  'DB09214': {'name': 'Dexketoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Reteplase.'},\n",
       "  'DB09215': {'name': 'Droxicam',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Reteplase.'},\n",
       "  'DB09216': {'name': 'Tolfenamic acid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Reteplase.'},\n",
       "  'DB09217': {'name': 'Firocoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Reteplase.'},\n",
       "  'DB09218': {'name': 'Clonixin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Reteplase.'},\n",
       "  'DB09285': {'name': 'Morniflumate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Reteplase.'},\n",
       "  'DB09288': {'name': 'Propacetamol',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Reteplase.'},\n",
       "  'DB09295': {'name': 'Talniflumate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Reteplase.'},\n",
       "  'DB11455': {'name': 'Robenacoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Reteplase.'},\n",
       "  'DB11466': {'name': 'Tepoxalin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Reteplase.'},\n",
       "  'DB11518': {'name': 'Flunixin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Reteplase.'},\n",
       "  'DB12399': {'name': 'Polmacoxib',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Reteplase.'},\n",
       "  'DB12610': {'name': 'Ebselen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Reteplase.'},\n",
       "  'DB13001': {'name': 'Tinoridine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Reteplase.'},\n",
       "  'DB13167': {'name': 'Alclofenac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Reteplase.'},\n",
       "  'DB13217': {'name': 'Fentiazac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Reteplase.'},\n",
       "  'DB13232': {'name': 'Suxibuzone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Reteplase.'},\n",
       "  'DB13286': {'name': 'Bumadizone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Reteplase.'},\n",
       "  'DB13314': {'name': 'Alminoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Reteplase.'},\n",
       "  'DB13371': {'name': 'Difenpiramide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Reteplase.'},\n",
       "  'DB13407': {'name': 'Nifenazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Reteplase.'},\n",
       "  'DB13432': {'name': 'Lonazolac',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Reteplase.'},\n",
       "  'DB13481': {'name': 'Tenidap',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Reteplase.'},\n",
       "  'DB13524': {'name': 'Propyphenazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Reteplase.'},\n",
       "  'DB13527': {'name': 'Proglumetacin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Reteplase.'},\n",
       "  'DB13538': {'name': 'Guacetisal',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Reteplase.'},\n",
       "  'DB13544': {'name': 'Ethenzamide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Reteplase.'},\n",
       "  'DB13612': {'name': 'Carbaspirin calcium',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Reteplase.'},\n",
       "  'DB13629': {'name': 'Mofebutazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Reteplase.'},\n",
       "  'DB13649': {'name': 'Proquazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Reteplase.'},\n",
       "  'DB13657': {'name': 'Benorilate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Reteplase.'},\n",
       "  'DB13722': {'name': 'Pirprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Reteplase.'},\n",
       "  'DB13860': {'name': 'Imidazole salicylate',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Reteplase.'},\n",
       "  'DB14059': {'name': 'SC-236',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Reteplase.'},\n",
       "  'DB14060': {'name': 'NS-398',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Reteplase.'},\n",
       "  'DB14938': {'name': 'Flurbiprofen axetil',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Reteplase.'},\n",
       "  'DB09212': {'name': 'Loxoprofen',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Reteplase.'},\n",
       "  'DB04865': {'name': 'Omacetaxine mepesuccinate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Omacetaxine mepesuccinate.'},\n",
       "  'DB11133': {'name': 'Omega-3 fatty acids',\n",
       "   'description': 'Omega-3 fatty acids may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00081': {'name': 'Tositumomab',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.'},\n",
       "  'DB09211': {'name': 'Limaprost',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.'},\n",
       "  'DB00048': {'name': 'Collagenase clostridium histolyticum',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Reteplase is combined with Collagenase clostridium histolyticum.'},\n",
       "  'DB00389': {'name': 'Carbimazole',\n",
       "   'description': 'Carbimazole may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00550': {'name': 'Propylthiouracil',\n",
       "   'description': 'Propylthiouracil may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00763': {'name': 'Methimazole',\n",
       "   'description': 'Methimazole may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB03374': {'name': '3,5-Diiodotyrosine',\n",
       "   'description': '3,5-Diiodotyrosine may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB06715': {'name': 'Potassium Iodide',\n",
       "   'description': 'Potassium Iodide may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB07637': {'name': 'Dibromotyrosine',\n",
       "   'description': 'Dibromotyrosine may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB09418': {'name': 'Potassium perchlorate',\n",
       "   'description': 'Potassium perchlorate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13644': {'name': 'Methylthiouracil',\n",
       "   'description': 'Methylthiouracil may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13804': {'name': 'Benzylthiouracil',\n",
       "   'description': 'Benzylthiouracil may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB00834': {'name': 'Mifepristone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Mifepristone.'},\n",
       "  'DB04066': {'name': 'p-Coumaric acid',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with p-Coumaric acid.'},\n",
       "  'DB04682': {'name': 'Octylphenoxy polyethoxyethanol',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.'},\n",
       "  'DB05830': {'name': 'Trestolone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Trestolone.'},\n",
       "  'DB06266': {'name': 'Lonidamine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Lonidamine.'},\n",
       "  'DB08867': {'name': 'Ulipristal',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ulipristal.'},\n",
       "  'DB09401': {'name': 'Isosorbide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Isosorbide.'},\n",
       "  'DB11507': {'name': 'Cloprostenol',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cloprostenol.'},\n",
       "  'DB12025': {'name': 'Triptolide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Triptolide.'},\n",
       "  'DB13044': {'name': 'Gossypol',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Gossypol.'},\n",
       "  'DB13310': {'name': 'Ormeloxifene',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ormeloxifene.'},\n",
       "  'DB00294': {'name': 'Etonogestrel',\n",
       "   'description': 'Etonogestrel may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00304': {'name': 'Desogestrel',\n",
       "   'description': 'Desogestrel may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00351': {'name': 'Megestrol acetate',\n",
       "   'description': 'Megestrol acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00367': {'name': 'Levonorgestrel',\n",
       "   'description': 'Levonorgestrel may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00378': {'name': 'Dydrogesterone',\n",
       "   'description': 'Dydrogesterone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00396': {'name': 'Progesterone',\n",
       "   'description': 'Progesterone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00603': {'name': 'Medroxyprogesterone acetate',\n",
       "   'description': 'Medroxyprogesterone acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00717': {'name': 'Norethisterone',\n",
       "   'description': 'Norethisterone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00823': {'name': 'Ethynodiol diacetate',\n",
       "   'description': 'Ethynodiol diacetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00957': {'name': 'Norgestimate',\n",
       "   'description': 'Norgestimate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB01395': {'name': 'Drospirenone',\n",
       "   'description': 'Drospirenone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB01431': {'name': 'Allylestrenol',\n",
       "   'description': 'Allylestrenol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB04839': {'name': 'Cyproterone acetate',\n",
       "   'description': 'Cyproterone acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB06713': {'name': 'Norelgestromin',\n",
       "   'description': 'Norelgestromin may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB06730': {'name': 'Gestodene',\n",
       "   'description': 'Gestodene may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB06789': {'name': 'Hydroxyprogesterone caproate',\n",
       "   'description': 'Hydroxyprogesterone caproate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09123': {'name': 'Dienogest',\n",
       "   'description': 'Dienogest may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09124': {'name': 'Medrogestone',\n",
       "   'description': 'Medrogestone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09371': {'name': 'Norethynodrel',\n",
       "   'description': 'Norethynodrel may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB09389': {'name': 'Norgestrel',\n",
       "   'description': 'Norgestrel may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB11372': {'name': 'Altrenogest',\n",
       "   'description': 'Altrenogest may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB11619': {'name': 'Gestrinone',\n",
       "   'description': 'Gestrinone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB11636': {'name': 'Nomegestrol',\n",
       "   'description': 'Nomegestrol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB12474': {'name': 'Lynestrenol',\n",
       "   'description': 'Lynestrenol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13230': {'name': 'Gestonorone',\n",
       "   'description': 'Gestonorone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13528': {'name': 'Chlormadinone',\n",
       "   'description': 'Chlormadinone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13533': {'name': 'Methylestrenolone',\n",
       "   'description': 'Methylestrenolone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13563': {'name': 'Norgestrienone',\n",
       "   'description': 'Norgestrienone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13602': {'name': 'Promegestone',\n",
       "   'description': 'Promegestone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13685': {'name': 'Quingestanol',\n",
       "   'description': 'Quingestanol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13857': {'name': 'Demegestone',\n",
       "   'description': 'Demegestone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13866': {'name': 'Etynodiol',\n",
       "   'description': 'Etynodiol may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB13981': {'name': 'Nomegestrol acetate',\n",
       "   'description': 'Nomegestrol acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB14570': {'name': 'Hydroxyprogesterone',\n",
       "   'description': 'Hydroxyprogesterone may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB14678': {'name': 'Norethindrone enanthate',\n",
       "   'description': 'Norethindrone enanthate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB14679': {'name': 'Quingestanol acetate',\n",
       "   'description': 'Quingestanol acetate may decrease the anticoagulant activities of Reteplase.'},\n",
       "  'DB00233': {'name': 'Aminosalicylic acid',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.'},\n",
       "  'DB01294': {'name': 'Bismuth subsalicylate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Reteplase.'},\n",
       "  'DB06251': {'name': 'Dersalazine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Dersalazine is combined with Reteplase.'},\n",
       "  'DB06807': {'name': 'Phenyl aminosalicylate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Reteplase.'},\n",
       "  'DB09543': {'name': 'Methyl salicylate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Methyl salicylate is combined with Reteplase.'},\n",
       "  'DB11079': {'name': 'Trolamine salicylate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Reteplase.'},\n",
       "  'DB13509': {'name': 'Aloxiprin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Aloxiprin is combined with Reteplase.'},\n",
       "  'DB14006': {'name': 'Choline salicylate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Choline salicylate is combined with Reteplase.'},\n",
       "  'DB14026': {'name': 'Thiosalicylic acid',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Reteplase.'},\n",
       "  'DB00054': {'name': 'Abciximab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Abciximab is combined with Reteplase.'},\n",
       "  'DB00063': {'name': 'Eptifibatide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.'},\n",
       "  'DB00208': {'name': 'Ticlopidine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ticlopidine is combined with Reteplase.'},\n",
       "  'DB00261': {'name': 'Anagrelide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Anagrelide is combined with Reteplase.'},\n",
       "  'DB00758': {'name': 'Clopidogrel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Clopidogrel is combined with Reteplase.'},\n",
       "  'DB00775': {'name': 'Tirofiban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tirofiban is combined with Reteplase.'},\n",
       "  'DB00975': {'name': 'Dipyridamole',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Dipyridamole is combined with Reteplase.'},\n",
       "  'DB01088': {'name': 'Iloprost',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Iloprost is combined with Reteplase.'},\n",
       "  'DB01138': {'name': 'Sulfinpyrazone',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reteplase.'},\n",
       "  'DB01166': {'name': 'Cilostazol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Cilostazol is combined with Reteplase.'},\n",
       "  'DB01207': {'name': 'Ridogrel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ridogrel is combined with Reteplase.'},\n",
       "  'DB01236': {'name': 'Sevoflurane',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sevoflurane is combined with Reteplase.'},\n",
       "  'DB01240': {'name': 'Epoprostenol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Epoprostenol is combined with Reteplase.'},\n",
       "  'DB02709': {'name': 'Resveratrol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Resveratrol is combined with Reteplase.'},\n",
       "  'DB04743': {'name': 'Nimesulide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Nimesulide is combined with Reteplase.'},\n",
       "  'DB04905': {'name': 'Tesmilifene',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tesmilifene is combined with Reteplase.'},\n",
       "  'DB04932': {'name': 'Defibrotide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Defibrotide is combined with Reteplase.'},\n",
       "  'DB05229': {'name': 'Beraprost',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Beraprost is combined with Reteplase.'},\n",
       "  'DB05266': {'name': 'Ibudilast',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ibudilast is combined with Reteplase.'},\n",
       "  'DB05767': {'name': 'Andrographolide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Andrographolide is combined with Reteplase.'},\n",
       "  'DB06081': {'name': 'Caplacizumab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Caplacizumab is combined with Reteplase.'},\n",
       "  'DB06209': {'name': 'Prasugrel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Prasugrel is combined with Reteplase.'},\n",
       "  'DB06441': {'name': 'Cangrelor',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Cangrelor is combined with Reteplase.'},\n",
       "  'DB07615': {'name': 'Tranilast',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tranilast is combined with Reteplase.'},\n",
       "  'DB08814': {'name': 'Triflusal',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Triflusal is combined with Reteplase.'},\n",
       "  'DB08816': {'name': 'Ticagrelor',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ticagrelor is combined with Reteplase.'},\n",
       "  'DB08887': {'name': 'Icosapent ethyl',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Reteplase.'},\n",
       "  'DB09283': {'name': 'Trapidil',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Trapidil is combined with Reteplase.'},\n",
       "  'DB12092': {'name': 'Naftopidil',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Naftopidil is combined with Reteplase.'},\n",
       "  'DB12163': {'name': 'Sarpogrelate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sarpogrelate is combined with Reteplase.'},\n",
       "  'DB12321': {'name': 'Ifetroban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ifetroban is combined with Reteplase.'},\n",
       "  'DB12445': {'name': 'Nitroaspirin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Nitroaspirin is combined with Reteplase.'},\n",
       "  'DB12465': {'name': 'Ketanserin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ketanserin is combined with Reteplase.'},\n",
       "  'DB12545': {'name': 'Indobufen',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Indobufen is combined with Reteplase.'},\n",
       "  'DB12749': {'name': 'Butylphthalide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Butylphthalide is combined with Reteplase.'},\n",
       "  'DB12771': {'name': 'Hydroxytyrosol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Reteplase.'},\n",
       "  'DB13036': {'name': 'Ramatroban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ramatroban is combined with Reteplase.'},\n",
       "  'DB13327': {'name': 'Picotamide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Picotamide is combined with Reteplase.'},\n",
       "  'DB13367': {'name': 'Cloricromen',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Cloricromen is combined with Reteplase.'},\n",
       "  'DB13400': {'name': 'Linsidomine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Linsidomine is combined with Reteplase.'},\n",
       "  'DB13510': {'name': 'Buflomedil',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Buflomedil is combined with Reteplase.'},\n",
       "  'DB13929': {'name': 'Relcovaptan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Relcovaptan is combined with Reteplase.'},\n",
       "  'DB00374': {'name': 'Treprostinil',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.'},\n",
       "  'DB03404': {'name': 'Hemin',\n",
       "   'description': 'Hemin may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13783': {'name': 'Acemetacin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Reteplase.'},\n",
       "  'DB00624': {'name': 'Testosterone',\n",
       "   'description': 'Testosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01420': {'name': 'Testosterone propionate',\n",
       "   'description': 'Testosterone propionate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01481': {'name': '1-Testosterone',\n",
       "   'description': '1-Testosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01485': {'name': '4-Hydroxytestosterone',\n",
       "   'description': '4-Hydroxytestosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01510': {'name': 'Dehydrochloromethyltestosterone',\n",
       "   'description': 'Dehydrochloromethyltestosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01541': {'name': 'Boldenone',\n",
       "   'description': 'Boldenone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01543': {'name': '18-methyl-19-nortestosterone',\n",
       "   'description': '18-methyl-19-nortestosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01564': {'name': 'Calusterone',\n",
       "   'description': 'Calusterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01569': {'name': 'Formebolone',\n",
       "   'description': 'Formebolone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01572': {'name': 'Methyl-1-testosterone',\n",
       "   'description': 'Methyl-1-testosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB07447': {'name': '5beta-dihydrotestosterone',\n",
       "   'description': '5beta-dihydrotestosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB08619': {'name': 'Testosterone succinate',\n",
       "   'description': 'Testosterone succinate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB11429': {'name': 'Mibolerone',\n",
       "   'description': 'Mibolerone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13943': {'name': 'Testosterone cypionate',\n",
       "   'description': 'Testosterone cypionate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13944': {'name': 'Testosterone enanthate',\n",
       "   'description': 'Testosterone enanthate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13946': {'name': 'Testosterone undecanoate',\n",
       "   'description': 'Testosterone undecanoate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13947': {'name': 'Testosterone enantate benzilic acid hydrazone',\n",
       "   'description': 'Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13951': {'name': 'Stanolone acetate',\n",
       "   'description': 'Stanolone acetate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB13958': {'name': 'Trestolone acetate',\n",
       "   'description': 'Trestolone acetate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB14093': {'name': '(1,2,6,7-3H)Testosterone',\n",
       "   'description': '(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB14655': {'name': 'Drostanolone propionate',\n",
       "   'description': 'Drostanolone propionate may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB11051': {'name': 'Azficel-T',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Reteplase is combined with Azficel-T.'},\n",
       "  'DB09568': {'name': 'Omega-3-carboxylic acids',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be increased when used in combination with Omega-3-carboxylic acids.'},\n",
       "  'DB00258': {'name': 'Calcium acetate',\n",
       "   'description': 'The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB01164': {'name': 'Calcium chloride',\n",
       "   'description': 'The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Reteplase.'},\n",
       "  'DB01373': {'name': 'Calcium',\n",
       "   'description': 'The therapeutic efficacy of Calcium can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11126': {'name': 'Calcium gluconate',\n",
       "   'description': 'The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11608': {'name': 'Eftrenonacog alfa',\n",
       "   'description': 'The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13884': {'name': 'Albutrepenonacog alfa',\n",
       "   'description': 'The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13923': {'name': 'Emicizumab',\n",
       "   'description': 'The therapeutic efficacy of Emicizumab can be decreased when used in combination with Reteplase.'},\n",
       "  'DB14738': {'name': 'Turoctocog alfa pegol',\n",
       "   'description': 'The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Reteplase.'},\n",
       "  'DB00025': {'name': 'Antihemophilic factor, human recombinant',\n",
       "   'description': 'The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reteplase.'},\n",
       "  'DB00036': {'name': 'Coagulation factor VIIa Recombinant Human',\n",
       "   'description': 'The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB00100': {'name': 'Coagulation Factor IX (Recombinant)',\n",
       "   'description': 'The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.'},\n",
       "  'DB01783': {'name': 'Pantothenic acid',\n",
       "   'description': 'The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Reteplase.'},\n",
       "  'DB01942': {'name': 'Formic acid',\n",
       "   'description': 'The therapeutic efficacy of Formic acid can be decreased when used in combination with Reteplase.'},\n",
       "  'DB02261': {'name': 'Platelet Activating Factor',\n",
       "   'description': 'The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Reteplase.'},\n",
       "  'DB06724': {'name': 'Calcium carbonate',\n",
       "   'description': 'The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB09109': {'name': 'Turoctocog alfa',\n",
       "   'description': 'The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB09222': {'name': 'Fibrinogen human',\n",
       "   'description': 'The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB09310': {'name': 'Catridecacog',\n",
       "   'description': 'The therapeutic efficacy of Catridecacog can be decreased when used in combination with Reteplase.'},\n",
       "  'DB09329': {'name': 'Antihemophilic Factor (Recombinant), PEGylated',\n",
       "   'description': 'The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11093': {'name': 'Calcium citrate',\n",
       "   'description': 'The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11168': {'name': 'Calcium threonate',\n",
       "   'description': 'The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11311': {'name': 'Prothrombin',\n",
       "   'description': 'The therapeutic efficacy of Prothrombin can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11330': {'name': 'Factor IX Complex (Human)',\n",
       "   'description': 'The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11348': {'name': 'Calcium Phosphate',\n",
       "   'description': 'The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11606': {'name': 'Susoctocog alfa',\n",
       "   'description': 'The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB11668': {'name': 'Rusalatide acetate',\n",
       "   'description': 'The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Reteplase.'},\n",
       "  'DB12409': {'name': 'Vatreptacog alfa',\n",
       "   'description': 'The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB12909': {'name': 'Factor XIII (human)',\n",
       "   'description': 'The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13133': {'name': 'Von Willebrand Factor Human',\n",
       "   'description': 'The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13148': {'name': 'Coagulation factor X human',\n",
       "   'description': 'The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13150': {'name': 'Coagulation factor VII human',\n",
       "   'description': 'The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13151': {'name': 'Anti-inhibitor coagulant complex',\n",
       "   'description': 'The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13152': {'name': 'Coagulation Factor IX Human',\n",
       "   'description': 'The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13192': {'name': 'Antihemophilic factor human',\n",
       "   'description': 'The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13197': {'name': 'Kallidinogenase',\n",
       "   'description': 'The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13201': {'name': 'Trenonacog alfa',\n",
       "   'description': 'The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13933': {'name': 'Nonacog beta pegol',\n",
       "   'description': 'The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Reteplase.'},\n",
       "  'DB13999': {'name': 'Moroctocog alfa',\n",
       "   'description': 'The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB14473': {'name': 'Beroctocog alfa',\n",
       "   'description': 'The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB14562': {'name': 'Andexanet alfa',\n",
       "   'description': 'The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Reteplase.'},\n",
       "  'DB14577': {'name': 'Calcium cation',\n",
       "   'description': 'The therapeutic efficacy of Calcium cation can be decreased when used in combination with Reteplase.'},\n",
       "  'DB14700': {'name': 'Damoctocog alfa pegol',\n",
       "   'description': 'The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Reteplase.'},\n",
       "  'DB00176': {'name': 'Fluvoxamine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Reteplase.'},\n",
       "  'DB00215': {'name': 'Citalopram',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Citalopram is combined with Reteplase.'},\n",
       "  'DB00472': {'name': 'Fluoxetine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Reteplase.'},\n",
       "  'DB00715': {'name': 'Paroxetine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Paroxetine is combined with Reteplase.'},\n",
       "  'DB01149': {'name': 'Nefazodone',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Nefazodone is combined with Reteplase.'},\n",
       "  'DB04832': {'name': 'Zimelidine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Zimelidine is combined with Reteplase.'},\n",
       "  'DB04884': {'name': 'Dapoxetine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Reteplase.'},\n",
       "  'DB06731': {'name': 'Seproxetine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Seproxetine is combined with Reteplase.'},\n",
       "  'DB08953': {'name': 'Indalpine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Indalpine is combined with Reteplase.'},\n",
       "  'DB12693': {'name': 'Ritanserin',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Ritanserin is combined with Reteplase.'},\n",
       "  'DB13233': {'name': 'Alaproclate',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Alaproclate is combined with Reteplase.'},\n",
       "  'DB00476': {'name': 'Duloxetine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Duloxetine is combined with Reteplase.'},\n",
       "  'DB01105': {'name': 'Sibutramine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Sibutramine is combined with Reteplase.'},\n",
       "  'DB04896': {'name': 'Milnacipran',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Milnacipran is combined with Reteplase.'},\n",
       "  'DB06700': {'name': 'Desvenlafaxine',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Reteplase.'},\n",
       "  'DB08918': {'name': 'Levomilnacipran',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Reteplase.'},\n",
       "  'DB00285': {'name': 'Venlafaxine',\n",
       "   'description': 'Venlafaxine may increase the antiplatelet activities of Reteplase.'},\n",
       "  'DB00182': {'name': 'Amphetamine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Reteplase.'},\n",
       "  'DB00601': {'name': 'Linezolid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Reteplase.'},\n",
       "  'DB00614': {'name': 'Furazolidone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Reteplase.'},\n",
       "  'DB00721': {'name': 'Procaine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Reteplase.'},\n",
       "  'DB00752': {'name': 'Tranylcypromine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reteplase.'},\n",
       "  'DB00780': {'name': 'Phenelzine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Reteplase.'},\n",
       "  'DB00805': {'name': 'Minaprine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Reteplase.'},\n",
       "  'DB01037': {'name': 'Selegiline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Reteplase.'},\n",
       "  'DB01168': {'name': 'Procarbazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Reteplase.'},\n",
       "  'DB01171': {'name': 'Moclobemide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Reteplase.'},\n",
       "  'DB01247': {'name': 'Isocarboxazid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Reteplase.'},\n",
       "  'DB01367': {'name': 'Rasagiline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Reteplase.'},\n",
       "  'DB01626': {'name': 'Pargyline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Reteplase.'},\n",
       "  'DB04017': {'name': 'Clorgiline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Reteplase.'},\n",
       "  'DB04818': {'name': 'Iproniazid',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Reteplase.'},\n",
       "  'DB04820': {'name': 'Nialamide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Reteplase.'},\n",
       "  'DB06654': {'name': 'Safinamide',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Reteplase.'},\n",
       "  'DB08550': {'name': '7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reteplase.'},\n",
       "  'DB09241': {'name': 'Methylene blue',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Reteplase.'},\n",
       "  'DB09243': {'name': 'Hydracarbazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Reteplase.'},\n",
       "  'DB09244': {'name': 'Pirlindole',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Reteplase.'},\n",
       "  'DB09245': {'name': 'Toloxatone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Reteplase.'},\n",
       "  'DB09246': {'name': 'Benmoxin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Reteplase.'},\n",
       "  'DB09248': {'name': 'Mebanazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Reteplase.'},\n",
       "  'DB09249': {'name': 'Octamoxin',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Reteplase.'},\n",
       "  'DB09250': {'name': 'Pheniprazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Reteplase.'},\n",
       "  'DB09251': {'name': 'Phenoxypropazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Reteplase.'},\n",
       "  'DB09252': {'name': 'Pivhydrazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Reteplase.'},\n",
       "  'DB09253': {'name': 'Safrazine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Reteplase.'},\n",
       "  'DB09254': {'name': 'Caroxazone',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Reteplase.'},\n",
       "  'DB13875': {'name': 'Harmaline',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Reteplase.'},\n",
       "  'DB13876': {'name': 'Brofaromine',\n",
       "   'description': 'The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Reteplase.'},\n",
       "  'DB00006': {'name': 'Bivalirudin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Bivalirudin is combined with Reteplase.'},\n",
       "  'DB00266': {'name': 'Dicoumarol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Dicoumarol is combined with Reteplase.'},\n",
       "  'DB00278': {'name': 'Argatroban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Argatroban is combined with Reteplase.'},\n",
       "  'DB00407': {'name': 'Ardeparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ardeparin is combined with Reteplase.'},\n",
       "  'DB00498': {'name': 'Phenindione',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Phenindione is combined with Reteplase.'},\n",
       "  'DB00569': {'name': 'Fondaparinux',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Fondaparinux is combined with Reteplase.'},\n",
       "  'DB00682': {'name': 'Warfarin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Warfarin is combined with Reteplase.'},\n",
       "  'DB00946': {'name': 'Phenprocoumon',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Phenprocoumon is combined with Reteplase.'},\n",
       "  'DB00974': {'name': 'Edetic acid',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Edetic acid is combined with Reteplase.'},\n",
       "  'DB01109': {'name': 'Heparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Heparin is combined with Reteplase.'},\n",
       "  'DB01225': {'name': 'Enoxaparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Enoxaparin is combined with Reteplase.'},\n",
       "  'DB01418': {'name': 'Acenocoumarol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Acenocoumarol is combined with Reteplase.'},\n",
       "  'DB04898': {'name': 'Ximelagatran',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ximelagatran is combined with Reteplase.'},\n",
       "  'DB05099': {'name': 'Ancrod',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ancrod is combined with Reteplase.'},\n",
       "  'DB06271': {'name': 'Sulodexide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sulodexide is combined with Reteplase.'},\n",
       "  'DB06406': {'name': 'Idraparinux',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Idraparinux is combined with Reteplase.'},\n",
       "  'DB06635': {'name': 'Otamixaban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Otamixaban is combined with Reteplase.'},\n",
       "  'DB06754': {'name': 'Danaparoid',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Danaparoid is combined with Reteplase.'},\n",
       "  'DB06779': {'name': 'Dalteparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Dalteparin is combined with Reteplase.'},\n",
       "  'DB07767': {'name': 'Ferulic acid',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ferulic acid is combined with Reteplase.'},\n",
       "  'DB08794': {'name': 'Ethyl biscoumacetate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Reteplase.'},\n",
       "  'DB08813': {'name': 'Nadroparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Nadroparin is combined with Reteplase.'},\n",
       "  'DB09255': {'name': 'Dextran',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Dextran is combined with Reteplase.'},\n",
       "  'DB11095': {'name': 'Desirudin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Desirudin is combined with Reteplase.'},\n",
       "  'DB11268': {'name': 'Protocatechualdehyde',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Reteplase.'},\n",
       "  'DB11312': {'name': 'Protein C',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Protein C is combined with Reteplase.'},\n",
       "  'DB11598': {'name': 'Antithrombin III human',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Antithrombin III human is combined with Reteplase.'},\n",
       "  'DB11984': {'name': 'Letaxaban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Letaxaban is combined with Reteplase.'},\n",
       "  'DB12289': {'name': 'Darexaban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Darexaban is combined with Reteplase.'},\n",
       "  'DB12598': {'name': 'Nafamostat',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Nafamostat is combined with Reteplase.'},\n",
       "  'DB12831': {'name': 'Gabexate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Gabexate is combined with Reteplase.'},\n",
       "  'DB13124': {'name': 'Troxerutin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Troxerutin is combined with Reteplase.'},\n",
       "  'DB13136': {'name': 'Fluindione',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Fluindione is combined with Reteplase.'},\n",
       "  'DB13149': {'name': 'Protein S human',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Protein S human is combined with Reteplase.'},\n",
       "  'DB13616': {'name': 'Melagatran',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Melagatran is combined with Reteplase.'},\n",
       "  'DB09125': {'name': 'Potassium citrate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Potassium citrate is combined with Reteplase.'},\n",
       "  'DB09154': {'name': 'Sodium citrate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sodium citrate is combined with Reteplase.'},\n",
       "  'DB00031': {'name': 'Tenecteplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tenecteplase is combined with Reteplase.'},\n",
       "  'DB00055': {'name': 'Drotrecogin alfa',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.'},\n",
       "  'DB06822': {'name': 'Tinzaparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tinzaparin is combined with Reteplase.'},\n",
       "  'DB13199': {'name': 'Brinase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Brinase is combined with Reteplase.'},\n",
       "  'DB13646': {'name': 'Saruplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Saruplase is combined with Reteplase.'},\n",
       "  'DB00086': {'name': 'Streptokinase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.'},\n",
       "  'DB04925': {'name': 'Desmoteplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Desmoteplase is combined with Reteplase.'},\n",
       "  'DB05254': {'name': 'Fibrinolysin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Fibrinolysin is combined with Reteplase.'},\n",
       "  'DB06543': {'name': 'Astaxanthin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Astaxanthin is combined with Reteplase.'},\n",
       "  'DB08994': {'name': 'Ditazole',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Ditazole is combined with Reteplase.'},\n",
       "  'DB09258': {'name': 'Bemiparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Bemiparin is combined with Reteplase.'},\n",
       "  'DB09260': {'name': 'Parnaparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Parnaparin is combined with Reteplase.'},\n",
       "  'DB13275': {'name': 'Clorindione',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Clorindione is combined with Reteplase.'},\n",
       "  'DB13347': {'name': 'Diphenadione',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Diphenadione is combined with Reteplase.'},\n",
       "  'DB13451': {'name': 'Tioclomarol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tioclomarol is combined with Reteplase.'},\n",
       "  'DB00001': {'name': 'Lepirudin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.'},\n",
       "  'DB00009': {'name': 'Alteplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Alteplase is combined with Reteplase.'},\n",
       "  'DB00029': {'name': 'Anistreplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Anistreplase.'},\n",
       "  'DB14094': {'name': 'Tocopherylquinone',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Tocopherylquinone.'},\n",
       "  'DB06679': {'name': 'Amediplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Amediplase.'},\n",
       "  'DB03410': {'name': '4-hydroxycoumarin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with 4-hydroxycoumarin.'},\n",
       "  'DB08496': {'name': '(R)-warfarin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with (R)-warfarin.'},\n",
       "  'DB14055': {'name': '(S)-Warfarin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with (S)-Warfarin.'},\n",
       "  'DB12364': {'name': 'Betrixaban',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Betrixaban.'},\n",
       "  'DB14598': {'name': 'Edetate calcium disodium anhydrous',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Edetate calcium disodium anhydrous.'},\n",
       "  'DB11154': {'name': 'Zinc citrate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Zinc citrate.'},\n",
       "  'DB11166': {'name': 'Antithrombin Alfa',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Antithrombin Alfa.'},\n",
       "  'DB04665': {'name': 'Coumarin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Coumarin.'},\n",
       "  'DB14726': {'name': 'Dabigatran',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Dabigatran.'},\n",
       "  'DB06294': {'name': 'Semuloparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Semuloparin.'},\n",
       "  'DB12726': {'name': 'Monteplase',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Monteplase.'},\n",
       "  'DB09259': {'name': 'Reviparin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Reviparin.'},\n",
       "  'DB00177': {'name': 'Valsartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Valsartan.'},\n",
       "  'DB00178': {'name': 'Ramipril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Ramipril.'},\n",
       "  'DB00230': {'name': 'Pregabalin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Pregabalin.'},\n",
       "  'DB00492': {'name': 'Fosinopril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Fosinopril.'},\n",
       "  'DB00519': {'name': 'Trandolapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Trandolapril.'},\n",
       "  'DB00542': {'name': 'Benazepril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Benazepril.'},\n",
       "  'DB00584': {'name': 'Enalapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Enalapril.'},\n",
       "  'DB00678': {'name': 'Losartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Losartan.'},\n",
       "  'DB00691': {'name': 'Moexipril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Moexipril.'},\n",
       "  'DB00722': {'name': 'Lisinopril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Lisinopril.'},\n",
       "  'DB00790': {'name': 'Perindopril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Perindopril.'},\n",
       "  'DB00876': {'name': 'Eprosartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Eprosartan.'},\n",
       "  'DB00877': {'name': 'Sirolimus',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Sirolimus.'},\n",
       "  'DB00881': {'name': 'Quinapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Quinapril.'},\n",
       "  'DB00886': {'name': 'Omapatrilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Omapatrilat.'},\n",
       "  'DB00966': {'name': 'Telmisartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Telmisartan.'},\n",
       "  'DB01050': {'name': 'Ibuprofen',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Ibuprofen.'},\n",
       "  'DB01180': {'name': 'Rescinnamine',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Rescinnamine.'},\n",
       "  'DB01197': {'name': 'Captopril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Captopril.'},\n",
       "  'DB01261': {'name': 'Sitagliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Sitagliptin.'},\n",
       "  'DB01340': {'name': 'Cilazapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Cilazapril.'},\n",
       "  'DB01342': {'name': 'Forasartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Forasartan.'},\n",
       "  'DB01347': {'name': 'Saprisartan',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Saprisartan.'},\n",
       "  'DB01348': {'name': 'Spirapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Spirapril.'},\n",
       "  'DB04876': {'name': 'Vildagliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Vildagliptin.'},\n",
       "  'DB06011': {'name': 'AMG-222',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with AMG-222.'},\n",
       "  'DB06127': {'name': 'Bisegliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Bisegliptin.'},\n",
       "  'DB06196': {'name': 'Icatibant',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Icatibant.'},\n",
       "  'DB06203': {'name': 'Alogliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Alogliptin.'},\n",
       "  'DB06245': {'name': 'Lanoteplase',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Lanoteplase.'},\n",
       "  'DB06287': {'name': 'Temsirolimus',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Temsirolimus.'},\n",
       "  'DB06335': {'name': 'Saxagliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Saxagliptin.'},\n",
       "  'DB08382': {'name': 'Gosogliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Gosogliptin.'},\n",
       "  'DB08822': {'name': 'Azilsartan medoxomil',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Azilsartan medoxomil.'},\n",
       "  'DB08836': {'name': 'Temocapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Temocapril.'},\n",
       "  'DB08882': {'name': 'Linagliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Linagliptin.'},\n",
       "  'DB09292': {'name': 'Sacubitril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Sacubitril.'},\n",
       "  'DB09477': {'name': 'Enalaprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Enalaprilat.'},\n",
       "  'DB11723': {'name': 'Dutogliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Dutogliptin.'},\n",
       "  'DB11783': {'name': 'Imidapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Imidapril.'},\n",
       "  'DB11950': {'name': 'Teneligliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Teneligliptin.'},\n",
       "  'DB11992': {'name': 'Omarigliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Omarigliptin.'},\n",
       "  'DB12268': {'name': 'Carmegliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Carmegliptin.'},\n",
       "  'DB12412': {'name': 'Gemigliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Gemigliptin.'},\n",
       "  'DB12417': {'name': 'Anagliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Anagliptin.'},\n",
       "  'DB12625': {'name': 'Evogliptin',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Evogliptin.'},\n",
       "  'DB13166': {'name': 'Zofenopril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Zofenopril.'},\n",
       "  'DB13312': {'name': 'Delapril',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Delapril.'},\n",
       "  'DB14125': {'name': 'Benazeprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Benazeprilat.'},\n",
       "  'DB14207': {'name': 'Fosinoprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Fosinoprilat.'},\n",
       "  'DB14208': {'name': 'Ramiprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Ramiprilat.'},\n",
       "  'DB14209': {'name': 'Trandolaprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Trandolaprilat.'},\n",
       "  'DB14210': {'name': 'Moexiprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Moexiprilat.'},\n",
       "  'DB14213': {'name': 'Perindoprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Perindoprilat.'},\n",
       "  'DB14217': {'name': 'Quinaprilat',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Quinaprilat.'},\n",
       "  'DB14231': {'name': 'Quinoline Yellow WS',\n",
       "   'description': 'The risk or severity of angioedema can be increased when Reteplase is combined with Quinoline Yellow WS.'},\n",
       "  'DB00203': {'name': 'Sildenafil',\n",
       "   'description': 'The risk or severity of hemorrhage can be increased when Reteplase is combined with Sildenafil.'},\n",
       "  'DB00008': {'name': 'Peginterferon alfa-2a',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2a.'},\n",
       "  'DB00011': {'name': 'Interferon alfa-n1',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n1.'},\n",
       "  'DB00018': {'name': 'Interferon alfa-n3',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n3.'},\n",
       "  'DB00022': {'name': 'Peginterferon alfa-2b',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2b.'},\n",
       "  'DB00033': {'name': 'Interferon gamma-1b',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon gamma-1b.'},\n",
       "  'DB00034': {'name': 'Interferon alfa-2a, Recombinant',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2a, Recombinant.'},\n",
       "  'DB00041': {'name': 'Aldesleukin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Aldesleukin.'},\n",
       "  'DB00056': {'name': 'Gemtuzumab ozogamicin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.'},\n",
       "  'DB00068': {'name': 'Interferon beta-1b',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.'},\n",
       "  'DB00069': {'name': 'Interferon alfacon-1',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.'},\n",
       "  'DB00073': {'name': 'Rituximab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.'},\n",
       "  'DB00078': {'name': 'Ibritumomab tiuxetan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.'},\n",
       "  'DB00087': {'name': 'Alemtuzumab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.'},\n",
       "  'DB00105': {'name': 'Interferon alfa-2b',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.'},\n",
       "  'DB00120': {'name': 'Phenylalanine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Phenylalanine.'},\n",
       "  'DB00188': {'name': 'Bortezomib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Bortezomib.'},\n",
       "  'DB00242': {'name': 'Cladribine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cladribine.'},\n",
       "  'DB00262': {'name': 'Carmustine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Carmustine.'},\n",
       "  'DB00276': {'name': 'Amsacrine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Amsacrine.'},\n",
       "  'DB00291': {'name': 'Chlorambucil',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Chlorambucil.'},\n",
       "  'DB00293': {'name': 'Raltitrexed',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Raltitrexed.'},\n",
       "  'DB00305': {'name': 'Mitomycin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Mitomycin.'},\n",
       "  'DB00307': {'name': 'Bexarotene',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Bexarotene.'},\n",
       "  'DB00309': {'name': 'Vindesine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Vindesine.'},\n",
       "  'DB00322': {'name': 'Floxuridine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Floxuridine.'},\n",
       "  'DB00352': {'name': 'Tioguanine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Tioguanine.'},\n",
       "  'DB00361': {'name': 'Vinorelbine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Vinorelbine.'},\n",
       "  'DB00380': {'name': 'Dexrazoxane',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane.'},\n",
       "  'DB00398': {'name': 'Sorafenib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Sorafenib.'},\n",
       "  'DB00428': {'name': 'Streptozocin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Streptozocin.'},\n",
       "  'DB00441': {'name': 'Gemcitabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Gemcitabine.'},\n",
       "  'DB00444': {'name': 'Teniposide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Teniposide.'},\n",
       "  'DB00445': {'name': 'Epirubicin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Epirubicin.'},\n",
       "  'DB00446': {'name': 'Chloramphenicol',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Chloramphenicol.'},\n",
       "  'DB00480': {'name': 'Lenalidomide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Lenalidomide.'},\n",
       "  'DB00488': {'name': 'Altretamine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Altretamine.'},\n",
       "  'DB00495': {'name': 'Zidovudine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Zidovudine.'},\n",
       "  'DB00515': {'name': 'Cisplatin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin.'},\n",
       "  'DB00526': {'name': 'Oxaliplatin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin.'},\n",
       "  'DB00531': {'name': 'Cyclophosphamide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cyclophosphamide.'},\n",
       "  'DB00544': {'name': 'Fluorouracil',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Fluorouracil.'},\n",
       "  'DB00552': {'name': 'Pentostatin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Pentostatin.'},\n",
       "  'DB00563': {'name': 'Methotrexate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Methotrexate.'},\n",
       "  'DB00564': {'name': 'Carbamazepine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Carbamazepine.'},\n",
       "  'DB00570': {'name': 'Vinblastine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Vinblastine.'},\n",
       "  'DB00619': {'name': 'Imatinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Imatinib.'},\n",
       "  'DB00631': {'name': 'Clofarabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Clofarabine.'},\n",
       "  'DB00642': {'name': 'Pemetrexed',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Pemetrexed.'},\n",
       "  'DB00694': {'name': 'Daunorubicin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.'},\n",
       "  'DB00762': {'name': 'Irinotecan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Irinotecan.'},\n",
       "  'DB00773': {'name': 'Etoposide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Etoposide.'},\n",
       "  'DB00851': {'name': 'Dacarbazine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Dacarbazine.'},\n",
       "  'DB00853': {'name': 'Temozolomide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Temozolomide.'},\n",
       "  'DB00859': {'name': 'Penicillamine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Penicillamine.'},\n",
       "  'DB00864': {'name': 'Tacrolimus',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Tacrolimus.'},\n",
       "  'DB00888': {'name': 'Mechlorethamine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Mechlorethamine.'},\n",
       "  'DB00928': {'name': 'Azacitidine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Azacitidine.'},\n",
       "  'DB00958': {'name': 'Carboplatin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Carboplatin.'},\n",
       "  'DB00970': {'name': 'Dactinomycin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Dactinomycin.'},\n",
       "  'DB00987': {'name': 'Cytarabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.'},\n",
       "  'DB00997': {'name': 'Doxorubicin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Doxorubicin.'},\n",
       "  'DB01005': {'name': 'Hydroxyurea',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Hydroxyurea.'},\n",
       "  'DB01008': {'name': 'Busulfan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Busulfan.'},\n",
       "  'DB01030': {'name': 'Topotecan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Topotecan.'},\n",
       "  'DB01033': {'name': 'Mercaptopurine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Mercaptopurine.'},\n",
       "  'DB01041': {'name': 'Thalidomide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Thalidomide.'},\n",
       "  'DB01042': {'name': 'Melphalan',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Melphalan.'},\n",
       "  'DB01073': {'name': 'Fludarabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Fludarabine.'},\n",
       "  'DB01099': {'name': 'Flucytosine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Flucytosine.'},\n",
       "  'DB01101': {'name': 'Capecitabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Capecitabine.'},\n",
       "  'DB01169': {'name': 'Arsenic trioxide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Arsenic trioxide.'},\n",
       "  'DB01177': {'name': 'Idarubicin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Idarubicin.'},\n",
       "  'DB01204': {'name': 'Mitoxantrone',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Mitoxantrone.'},\n",
       "  'DB01206': {'name': 'Lomustine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Lomustine.'},\n",
       "  'DB01229': {'name': 'Paclitaxel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Paclitaxel.'},\n",
       "  'DB01248': {'name': 'Docetaxel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Docetaxel.'},\n",
       "  'DB01262': {'name': 'Decitabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Decitabine.'},\n",
       "  'DB01280': {'name': 'Nelarabine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Nelarabine.'},\n",
       "  'DB01590': {'name': 'Everolimus',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Everolimus.'},\n",
       "  'DB02546': {'name': 'Vorinostat',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Vorinostat.'},\n",
       "  'DB04572': {'name': 'Thiotepa',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Thiotepa.'},\n",
       "  'DB04845': {'name': 'Ixabepilone',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Ixabepilone.'},\n",
       "  'DB04868': {'name': 'Nilotinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Nilotinib.'},\n",
       "  'DB05015': {'name': 'Belinostat',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Belinostat.'},\n",
       "  'DB05109': {'name': 'Trabectedin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Trabectedin.'},\n",
       "  'DB05258': {'name': 'Interferon alfa',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa.'},\n",
       "  'DB05472': {'name': 'Human interferon omega-1',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Human interferon omega-1.'},\n",
       "  'DB05773': {'name': 'Trastuzumab emtansine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Trastuzumab emtansine.'},\n",
       "  'DB06616': {'name': 'Bosutinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Bosutinib.'},\n",
       "  'DB06769': {'name': 'Bendamustine',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Bendamustine.'},\n",
       "  'DB06772': {'name': 'Cabazitaxel',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cabazitaxel.'},\n",
       "  'DB08871': {'name': 'Eribulin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Eribulin.'},\n",
       "  'DB08877': {'name': 'Ruxolitinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Ruxolitinib.'},\n",
       "  'DB08889': {'name': 'Carfilzomib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Carfilzomib.'},\n",
       "  'DB08895': {'name': 'Tofacitinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Tofacitinib.'},\n",
       "  'DB08901': {'name': 'Ponatinib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Ponatinib.'},\n",
       "  'DB08910': {'name': 'Pomalidomide',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Pomalidomide.'},\n",
       "  'DB09042': {'name': 'Tedizolid phosphate',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Tedizolid phosphate.'},\n",
       "  'DB09052': {'name': 'Blinatumomab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Blinatumomab.'},\n",
       "  'DB09073': {'name': 'Palbociclib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Palbociclib.'},\n",
       "  'DB09074': {'name': 'Olaparib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Olaparib.'},\n",
       "  'DB09077': {'name': 'Dinutuximab',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Dinutuximab.'},\n",
       "  'DB09122': {'name': 'Peginterferon beta-1a',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon beta-1a.'},\n",
       "  'DB12814': {'name': 'Cepeginterferon alfa-2B',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Cepeginterferon alfa-2B.'},\n",
       "  'DB00229': {'name': 'Cefotiam',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotiam.'},\n",
       "  'DB00267': {'name': 'Cefmenoxime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmenoxime.'},\n",
       "  'DB00274': {'name': 'Cefmetazole',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmetazole.'},\n",
       "  'DB00430': {'name': 'Cefpiramide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpiramide.'},\n",
       "  'DB00438': {'name': 'Ceftazidime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftazidime.'},\n",
       "  'DB00447': {'name': 'Loracarbef',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Loracarbef.'},\n",
       "  'DB00456': {'name': 'Cefalotin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefalotin.'},\n",
       "  'DB00493': {'name': 'Cefotaxime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotaxime.'},\n",
       "  'DB00535': {'name': 'Cefdinir',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefdinir.'},\n",
       "  'DB00567': {'name': 'Cephalexin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephalexin.'},\n",
       "  'DB00671': {'name': 'Cefixime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefixime.'},\n",
       "  'DB00689': {'name': 'Cephaloglycin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephaloglycin.'},\n",
       "  'DB00833': {'name': 'Cefaclor',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaclor.'},\n",
       "  'DB00923': {'name': 'Ceforanide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceforanide.'},\n",
       "  'DB01066': {'name': 'Cefditoren',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefditoren.'},\n",
       "  'DB01112': {'name': 'Cefuroxime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefuroxime.'},\n",
       "  'DB01139': {'name': 'Cefapirin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefapirin.'},\n",
       "  'DB01140': {'name': 'Cefadroxil',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefadroxil.'},\n",
       "  'DB01150': {'name': 'Cefprozil',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefprozil.'},\n",
       "  'DB01212': {'name': 'Ceftriaxone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftriaxone.'},\n",
       "  'DB01326': {'name': 'Cefamandole',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole.'},\n",
       "  'DB01327': {'name': 'Cefazolin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazolin.'},\n",
       "  'DB01328': {'name': 'Cefonicid',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefonicid.'},\n",
       "  'DB01329': {'name': 'Cefoperazone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoperazone.'},\n",
       "  'DB01330': {'name': 'Cefotetan',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotetan.'},\n",
       "  'DB01331': {'name': 'Cefoxitin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoxitin.'},\n",
       "  'DB01332': {'name': 'Ceftizoxime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftizoxime.'},\n",
       "  'DB01333': {'name': 'Cefradine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefradine.'},\n",
       "  'DB01413': {'name': 'Cefepime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefepime.'},\n",
       "  'DB01414': {'name': 'Cefacetrile',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefacetrile.'},\n",
       "  'DB01415': {'name': 'Ceftibuten',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftibuten.'},\n",
       "  'DB01416': {'name': 'Cefpodoxime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpodoxime.'},\n",
       "  'DB04570': {'name': 'Latamoxef',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Latamoxef.'},\n",
       "  'DB04918': {'name': 'Ceftobiprole',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftobiprole.'},\n",
       "  'DB06590': {'name': 'Ceftaroline fosamil',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftaroline fosamil.'},\n",
       "  'DB09008': {'name': 'Cefaloridine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaloridine.'},\n",
       "  'DB09050': {'name': 'Ceftolozane',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftolozane.'},\n",
       "  'DB09062': {'name': 'Cefminox',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefminox.'},\n",
       "  'DB11367': {'name': 'Cefroxadine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefroxadine.'},\n",
       "  'DB11935': {'name': 'Flomoxef',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Flomoxef.'},\n",
       "  'DB13266': {'name': 'Cefatrizine',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefatrizine.'},\n",
       "  'DB13461': {'name': 'Cefcapene',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefcapene.'},\n",
       "  'DB13470': {'name': 'Cefodizime',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefodizime.'},\n",
       "  'DB13499': {'name': 'Cefsulodin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefsulodin.'},\n",
       "  'DB13504': {'name': 'Cefetamet',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefetamet.'},\n",
       "  'DB13638': {'name': 'Cefbuperazone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefbuperazone.'},\n",
       "  'DB13667': {'name': 'Cefozopran',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefozopran.'},\n",
       "  'DB13682': {'name': 'Cefpirome',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpirome.'},\n",
       "  'DB13778': {'name': 'Cefazedone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazedone.'},\n",
       "  'DB13821': {'name': 'Ceftezole',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftezole.'},\n",
       "  'DB14725': {'name': 'Cefamandole nafate',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole nafate.'},\n",
       "  'DB00254': {'name': 'Doxycycline',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Doxycycline is combined with Reteplase.'},\n",
       "  'DB00207': {'name': 'Azithromycin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Azithromycin is combined with Reteplase.'},\n",
       "  'DB09539': {'name': 'Omega-3-acid ethyl esters',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reteplase.'},\n",
       "  'DB00945': {'name': 'Acetylsalicylic acid',\n",
       "   'description': 'Acetylsalicylic acid may increase the anticoagulant activities of Reteplase.'},\n",
       "  'DB01606': {'name': 'Tazobactam',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Tazobactam is combined with Reteplase.'},\n",
       "  'DB00727': {'name': 'Nitroglycerin',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.'},\n",
       "  'DB00199': {'name': 'Erythromycin',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Erythromycin is combined with Reteplase.'},\n",
       "  'DB00656': {'name': 'Trazodone',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Trazodone is combined with Reteplase.'},\n",
       "  'DB00620': {'name': 'Triamcinolone',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Triamcinolone.'},\n",
       "  'DB09079': {'name': 'Nintedanib',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Reteplase is combined with Nintedanib.'},\n",
       "  'DB01175': {'name': 'Escitalopram',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Escitalopram is combined with Reteplase.'},\n",
       "  'DB01104': {'name': 'Sertraline',\n",
       "   'description': 'The risk or severity of bleeding can be increased when Sertraline is combined with Reteplase.'},\n",
       "  'DB00232': {'name': 'Methyclothiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Methyclothiazide.'},\n",
       "  'DB00436': {'name': 'Bendroflumethiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Bendroflumethiazide.'},\n",
       "  'DB00562': {'name': 'Benzthiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Benzthiazide.'},\n",
       "  'DB00606': {'name': 'Cyclothiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclothiazide.'},\n",
       "  'DB00774': {'name': 'Hydroflumethiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydroflumethiazide.'},\n",
       "  'DB00880': {'name': 'Chlorothiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Chlorothiazide.'},\n",
       "  'DB00999': {'name': 'Hydrochlorothiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydrochlorothiazide.'},\n",
       "  'DB01021': {'name': 'Trichlormethiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Trichlormethiazide.'},\n",
       "  'DB01324': {'name': 'Polythiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Polythiazide.'},\n",
       "  'DB13430': {'name': 'Mebutizide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Mebutizide.'},\n",
       "  'DB13532': {'name': 'Cyclopenthiazide',\n",
       "   'description': 'The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclopenthiazide.'}},\n",
       " 'smile': [],\n",
       " 'pathways': {'pathways1': {'smpdb_id': 'SMP0000285',\n",
       "   'name_pathway': 'Reteplase Action Pathway',\n",
       "   'category_pathway': 'drug_action',\n",
       "   'drugs_in_pathway': ['DB00015', 'DB01022', 'DB01373'],\n",
       "   'enzymes_in_pathway': ['P00747',\n",
       "    'P00748',\n",
       "    'P02452',\n",
       "    'P03952',\n",
       "    'P03951',\n",
       "    'P00740',\n",
       "    'P00451',\n",
       "    'P00734',\n",
       "    'P12259',\n",
       "    'P00742',\n",
       "    'P02671',\n",
       "    'P02675',\n",
       "    'P02679',\n",
       "    'P00488',\n",
       "    'P05160',\n",
       "    'P00750',\n",
       "    'P08709',\n",
       "    'P13726',\n",
       "    'Q9BQB6',\n",
       "    'P38435']}}}"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "find_eos(list1[15])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "d09819dc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'=\"biotech\" created=\"2005-06-13\" updated=\"2020-12-24\">   <drugbank-id primary=\"true\">DB00015</drugbank-id>   <drugbank-id>BTD00013</drugbank-id>   <drugbank-id>BIOD00013</drugbank-id>   <name>Reteplase</name>   <description>Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).</description>   <cas-number>133652-38-7</cas-number>   <unii>DQA630RIE9</unii>   <state>liquid</state>   <groups>     <group>approved</group>     <group>investigational</group>   </groups>   <general-references>     <articles/>     <textbooks/>     <links/>     <attachments/>   </general-references>   <synthesis-reference/>   <indication>For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.</indication>   <pharmacodynamics>Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>   <mechanism-of-action>Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>   <toxicity/>   <metabolism/>   <absorption/>   <half-life/>   <protein-binding/>   <route-of-elimination/>   <volume-of-distribution/>   <clearance/>   <classification>     <description/>     <direct-parent>Peptides</direct-parent>     <kingdom>Organic Compounds</kingdom>     <superclass>Organic Acids</superclass>     <class>Carboxylic Acids and Derivatives</class>     <subclass>Amino Acids, Peptides, and Analogues</subclass>   </classification>   <salts/>   <synonyms>     <synonym language=\"english\" coder=\"\">Human t-PA (residues 1-3 and 176-527)</synonym>     <synonym language=\"spanish\" coder=\"\">Reteplasa</synonym>     <synonym language=\"english\" coder=\"\">Reteplase, recombinant</synonym>     <synonym language=\"english\" coder=\"\">Reteplase,recombinant</synonym>   </synonyms>   <products>     <product>       <name>Rapilysin</name>       <labeller>Actavis Group Ptc Ehf.</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id/>       <ema-product-code>EMEA/H/C/000105</ema-product-code>       <ema-ma-number>EU/1/96/018/001</ema-ma-number>       <started-marketing-on>1996-08-29</started-marketing-on>       <ended-marketing-on/>       <dosage-form>Injection, powder, for solution</dosage-form>       <strength/>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>EU</country>       <source>EMA</source>     </product>     <product>       <name>Retavase</name>       <labeller>Ekr Therapeutics</labeller>       <ndc-id/>       <ndc-product-code>24477-041</ndc-product-code>       <dpd-id/>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1996-10-30</started-marketing-on>       <ended-marketing-on>2017-07-01</ended-marketing-on>       <dosage-form>Kit</dosage-form>       <strength>1.81 mg/1mL</strength>       <route>Intravenous</route>       <fda-application-number>BLA103786</fda-application-number>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>US</country>       <source>FDA NDC</source>     </product>     <product>       <name>Retavase</name>       <labeller>Ekr Therapeutics</labeller>       <ndc-id/>       <ndc-product-code>24477-040</ndc-product-code>       <dpd-id/>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1996-10-30</started-marketing-on>       <ended-marketing-on>2017-07-01</ended-marketing-on>       <dosage-form>Kit</dosage-form>       <strength>1.81 mg/1mL</strength>       <route>Intravenous</route>       <fda-application-number>BLA103786</fda-application-number>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>US</country>       <source>FDA NDC</source>     </product>     <product>       <name>Retavase</name>       <labeller>Chiesi USA, Inc.</labeller>       <ndc-id/>       <ndc-product-code>10122-143</ndc-product-code>       <dpd-id/>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1996-10-30</started-marketing-on>       <ended-marketing-on/>       <dosage-form>Kit</dosage-form>       <strength>1.81 mg/1mL</strength>       <route>Intravenous</route>       <fda-application-number>BLA103786</fda-application-number>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>US</country>       <source>FDA NDC</source>     </product>     <product>       <name>Retavase</name>       <labeller>Chiesi USA, Inc.</labeller>       <ndc-id/>       <ndc-product-code>10122-141</ndc-product-code>       <dpd-id/>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1996-10-30</started-marketing-on>       <ended-marketing-on/>       <dosage-form>Kit</dosage-form>       <strength>1.81 mg/1mL</strength>       <route>Intravenous</route>       <fda-application-number>BLA103786</fda-application-number>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>US</country>       <source>FDA NDC</source>     </product>     <product>       <name>Retavase</name>       <labeller>Ekr Therapeutics</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id>02233013</dpd-id>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1999-02-19</started-marketing-on>       <ended-marketing-on>2013-08-29</ended-marketing-on>       <dosage-form>Powder, for solution</dosage-form>       <strength>10.4 unit</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>Canada</country>       <source>DPD</source>     </product>   </products>   <international-brands/>   <mixtures>     <mixture>       <name>Retavase</name>       <ingredients>Reteplase</ingredients>     </mixture>     <mixture>       <name>Retavase</name>       <ingredients>Reteplase</ingredients>     </mixture>     <mixture>       <name>Retavase</name>       <ingredients>Reteplase</ingredients>     </mixture>     <mixture>       <name>Retavase</name>       <ingredients>Reteplase</ingredients>     </mixture>     <mixture>       <name>Rapilysin</name>       <ingredients>Reteplase</ingredients>     </mixture>     <mixture>       <name>Retavase</name>       <ingredients>Reteplase</ingredients>     </mixture>   </mixtures>   <packagers>     <packager>       <name>EKR Therapeutics Inc.</name>       <url>http://www.ekrtx.com</url>     </packager>     <packager>       <name>Hospira Inc.</name>       <url>http://www.hospira.com</url>     </packager>     <packager>       <name>PDL BioPharma Inc.</name>       <url>http://www.pdl.com</url>     </packager>   </packagers>   <manufacturers/>   <prices>     <price>       <description>Retavase vial half-kit</description>       <cost currency=\"USD\">2605.93</cost>       <unit>vial</unit>     </price>   </prices>   <categories>     <category>       <category>Agents causing angioedema</category>       <mesh-id/>     </category>     <category>       <category>Amino Acids, Peptides, and Proteins</category>       <mesh-id>D000602</mesh-id>     </category>     <category>       <category>Anticoagulants</category>       <mesh-id>D000925</mesh-id>     </category>     <category>       <category>Biological Factors</category>       <mesh-id>D001685</mesh-id>     </category>     <category>       <category>Blood and Blood Forming Organs</category>       <mesh-id/>     </category>     <category>       <category>Blood Proteins</category>       <mesh-id>D001798</mesh-id>     </category>     <category>       <category>Cardiovascular Agents</category>       <mesh-id>D002317</mesh-id>     </category>     <category>       <category>Endopeptidases</category>       <mesh-id>D010450</mesh-id>     </category>     <category>       <category>Enzymes</category>       <mesh-id>D004798</mesh-id>     </category>     <category>       <category>Enzymes and Coenzymes</category>       <mesh-id>D045762</mesh-id>     </category>     <category>       <category>Fibrin Modulating Agents</category>       <mesh-id>D050299</mesh-id>     </category>     <category>       <category>Fibrinolytic Agents</category>       <mesh-id>D005343</mesh-id>     </category>     <category>       <category>Hematologic Agents</category>       <mesh-id>D006401</mesh-id>     </category>     <category>       <category>Hydrolases</category>       <mesh-id>D006867</mesh-id>     </category>     <category>       <category>Peptide Hydrolases</category>       <mesh-id>D010447</mesh-id>     </category>     <category>       <category>Plasminogen Activators</category>       <mesh-id>D010960</mesh-id>     </category>     <category>       <category>Proteins</category>       <mesh-id>D011506</mesh-id>     </category>     <category>       <category>Serine Endopeptidases</category>       <mesh-id>D012697</mesh-id>     </category>     <category>       <category>Serine Proteases</category>       <mesh-id>D057057</mesh-id>     </category>   </categories>   <affected-organisms>     <affected-organism>Humans and other mammals</affected-organism>   </affected-organisms>   <dosages>     <dosage>       <form/>       <route/>       <strength>10 U</strength>     </dosage>     <dosage>       <form>Injection, powder, for solution</form>       <route>Intravenous</route>       <strength/>     </dosage>     <dosage>       <form>Injection, powder, lyophilized, for solution</form>       <route>Intravenous</route>       <strength>10 IU</strength>     </dosage>     <dosage>       <form>Kit</form>       <route>Intravenous</route>       <strength>1.81 mg/1mL</strength>     </dosage>     <dosage>       <form>Powder, for solution</form>       <route>Intravenous</route>       <strength>10.4 unit</strength>     </dosage>     <dosage>       <form>Injection, powder, lyophilized, for solution</form>       <route>Intravenous</route>       <strength>18 mg</strength>     </dosage>   </dosages>   <atc-codes>     <atc-code code=\"B01AD07\">       <level code=\"B01AD\">Enzymes</level>       <level code=\"B01A\">ANTITHROMBOTIC AGENTS</level>       <level code=\"B01\">ANTITHROMBOTIC AGENTS</level>       <level code=\"B\">BLOOD AND BLOOD FORMING ORGANS</level>     </atc-code>   </atc-codes>   <ahfs-codes/>   <pdb-entries/>   <patents>     <patent>       <number>2107476</number>       <country>Canada</country>       <approved>2007-12-18</approved>       <expires>2012-04-15</expires>       <pediatric-extension>false</pediatric-extension>     </patent>   </patents>   <food-interactions>     <food-interaction>Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.</food-interaction>   </food-interactions>   <drug-interactions>     <drug-interaction>       <drugbank-id>DB06605</drugbank-id>       <name>Apixaban</name>       <description>Apixaban may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06695</drugbank-id>       <name>Dabigatran etexilate</name>       <description>Dabigatran etexilate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01254</drugbank-id>       <name>Dasatinib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01609</drugbank-id>       <name>Deferasirox</name>       <description>The risk or severity of gastrointestinal bleeding can be increased when Reteplase is combined with Deferasirox.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01586</drugbank-id>       <name>Ursodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02123</drugbank-id>       <name>Glycochenodeoxycholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycochenodeoxycholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02659</drugbank-id>       <name>Cholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Cholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02691</drugbank-id>       <name>Glycocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03619</drugbank-id>       <name>Deoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Deoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04348</drugbank-id>       <name>Taurocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05990</drugbank-id>       <name>Obeticholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Obeticholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06777</drugbank-id>       <name>Chenodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Chenodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08833</drugbank-id>       <name>Taurochenodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurochenodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08834</drugbank-id>       <name>Tauroursodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Tauroursodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08857</drugbank-id>       <name>Bamet-UD2</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Bamet-UD2.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11622</drugbank-id>       <name>Dehydrocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Dehydrocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11789</drugbank-id>       <name>Hyodeoxycholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Hyodeoxycholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09075</drugbank-id>       <name>Edoxaban</name>       <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09053</drugbank-id>       <name>Ibrutinib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08935</drugbank-id>       <name>Obinutuzumab</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Obinutuzumab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06228</drugbank-id>       <name>Rivaroxaban</name>       <description>Reteplase may increase the anticoagulant activities of Rivaroxaban.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06206</drugbank-id>       <name>Sugammadex</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Sugammadex.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09070</drugbank-id>       <name>Tibolone</name>       <description>Tibolone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00932</drugbank-id>       <name>Tipranavir</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00013</drugbank-id>       <name>Urokinase</name>       <description>Urokinase may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00163</drugbank-id>       <name>Vitamin E</name>       <description>Vitamin E may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09030</drugbank-id>       <name>Vorapaxar</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06692</drugbank-id>       <name>Aprotinin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01381</drugbank-id>       <name>Ginkgo biloba</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Ginkgo biloba.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01181</drugbank-id>       <name>Ifosfamide</name>       <description>The risk or severity of bleeding can be increased when Ifosfamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00468</drugbank-id>       <name>Quinine</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Quinine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00908</drugbank-id>       <name>Quinidine</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Quinidine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00675</drugbank-id>       <name>Tamoxifen</name>       <description>The risk or severity of bleeding can be increased when Tamoxifen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00539</drugbank-id>       <name>Toremifene</name>       <description>The risk or severity of bleeding can be increased when Toremifene is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00806</drugbank-id>       <name>Pentoxifylline</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Pentoxifylline.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00686</drugbank-id>       <name>Pentosan polysulfate</name>       <description>Pentosan polysulfate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00583</drugbank-id>       <name>Levocarnitine</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Levocarnitine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00255</drugbank-id>       <name>Diethylstilbestrol</name>       <description>Diethylstilbestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00269</drugbank-id>       <name>Chlorotrianisene</name>       <description>Chlorotrianisene may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00286</drugbank-id>       <name>Conjugated estrogens</name>       <description>Conjugated estrogens may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00783</drugbank-id>       <name>Estradiol</name>       <description>Estradiol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00977</drugbank-id>       <name>Ethinylestradiol</name>       <description>Ethinylestradiol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01357</drugbank-id>       <name>Mestranol</name>       <description>Mestranol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04574</drugbank-id>       <name>Estrone sulfate</name>       <description>Estrone sulfate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04575</drugbank-id>       <name>Quinestrol</name>       <description>Quinestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07931</drugbank-id>       <name>Hexestrol</name>       <description>Hexestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09317</drugbank-id>       <name>Synthetic Conjugated Estrogens, A</name>       <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09318</drugbank-id>       <name>Synthetic Conjugated Estrogens, B</name>       <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09369</drugbank-id>       <name>Polyestradiol phosphate</name>       <description>Polyestradiol phosphate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09381</drugbank-id>       <name>Esterified estrogens</name>       <description>Esterified estrogens may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11478</drugbank-id>       <name>Zeranol</name>       <description>Zeranol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11674</drugbank-id>       <name>Equol</name>       <description>Equol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13143</drugbank-id>       <name>Methallenestril</name>       <description>Methallenestril may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13386</drugbank-id>       <name>Epimestrol</name>       <description>Epimestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13418</drugbank-id>       <name>Moxestrol</name>       <description>Moxestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13952</drugbank-id>       <name>Estradiol acetate</name>       <description>Estradiol acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13953</drugbank-id>       <name>Estradiol benzoate</name>       <description>Estradiol benzoate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13954</drugbank-id>       <name>Estradiol cypionate</name>       <description>Estradiol cypionate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13956</drugbank-id>       <name>Estradiol valerate</name>       <description>Estradiol valerate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB15334</drugbank-id>       <name>Biochanin A</name>       <description>Biochanin A may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB15335</drugbank-id>       <name>Formononetin</name>       <description>Formononetin may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00655</drugbank-id>       <name>Estrone</name>       <description>Estrone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04573</drugbank-id>       <name>Estriol</name>       <description>Estriol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00159</drugbank-id>       <name>Icosapent</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00244</drugbank-id>       <name>Mesalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00328</drugbank-id>       <name>Indomethacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00461</drugbank-id>       <name>Nabumetone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00465</drugbank-id>       <name>Ketorolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00469</drugbank-id>       <name>Tenoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00482</drugbank-id>       <name>Celecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00500</drugbank-id>       <name>Tolmetin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00533</drugbank-id>       <name>Rofecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00554</drugbank-id>       <name>Piroxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00573</drugbank-id>       <name>Fenoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00580</drugbank-id>       <name>Valdecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00586</drugbank-id>       <name>Diclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00605</drugbank-id>       <name>Sulindac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00712</drugbank-id>       <name>Flurbiprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00749</drugbank-id>       <name>Etodolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00784</drugbank-id>       <name>Mefenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00788</drugbank-id>       <name>Naproxen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00795</drugbank-id>       <name>Sulfasalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00812</drugbank-id>       <name>Phenylbutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00814</drugbank-id>       <name>Meloxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00821</drugbank-id>       <name>Carprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00861</drugbank-id>       <name>Diflunisal</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00936</drugbank-id>       <name>Salicylic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00939</drugbank-id>       <name>Meclofenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00991</drugbank-id>       <name>Oxaprozin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01009</drugbank-id>       <name>Ketoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01014</drugbank-id>       <name>Balsalazide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01250</drugbank-id>       <name>Olsalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01283</drugbank-id>       <name>Lumiracoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01397</drugbank-id>       <name>Magnesium salicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01399</drugbank-id>       <name>Salsalate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01401</drugbank-id>       <name>Choline magnesium trisalicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01419</drugbank-id>       <name>Antrafenine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01424</drugbank-id>       <name>Aminophenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01435</drugbank-id>       <name>Antipyrine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01600</drugbank-id>       <name>Tiaprofenic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01628</drugbank-id>       <name>Etoricoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02224</drugbank-id>       <name>Taxifolin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03585</drugbank-id>       <name>Oxyphenbutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04725</drugbank-id>       <name>Licofelone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04812</drugbank-id>       <name>Benoxaprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04817</drugbank-id>       <name>Metamizole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04828</drugbank-id>       <name>Zomepirac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05095</drugbank-id>       <name>Cimicoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06725</drugbank-id>       <name>Lornoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06736</drugbank-id>       <name>Aceclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06737</drugbank-id>       <name>Zaltoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07402</drugbank-id>       <name>Azapropazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08439</drugbank-id>       <name>Parecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08797</drugbank-id>       <name>Salicylamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08940</drugbank-id>       <name>Kebuzone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08942</drugbank-id>       <name>Isoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08951</drugbank-id>       <name>Indoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08955</drugbank-id>       <name>Ibuproxam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08976</drugbank-id>       <name>Floctafenine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08981</drugbank-id>       <name>Fenbufen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08984</drugbank-id>       <name>Etofenamate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08991</drugbank-id>       <name>Epirizole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09084</drugbank-id>       <name>Benzydamine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09214</drugbank-id>       <name>Dexketoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09215</drugbank-id>       <name>Droxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09216</drugbank-id>       <name>Tolfenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09217</drugbank-id>       <name>Firocoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09218</drugbank-id>       <name>Clonixin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09285</drugbank-id>       <name>Morniflumate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09288</drugbank-id>       <name>Propacetamol</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09295</drugbank-id>       <name>Talniflumate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11455</drugbank-id>       <name>Robenacoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11466</drugbank-id>       <name>Tepoxalin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11518</drugbank-id>       <name>Flunixin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12399</drugbank-id>       <name>Polmacoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12610</drugbank-id>       <name>Ebselen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13001</drugbank-id>       <name>Tinoridine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13167</drugbank-id>       <name>Alclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13217</drugbank-id>       <name>Fentiazac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13232</drugbank-id>       <name>Suxibuzone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13286</drugbank-id>       <name>Bumadizone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13314</drugbank-id>       <name>Alminoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13371</drugbank-id>       <name>Difenpiramide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13407</drugbank-id>       <name>Nifenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13432</drugbank-id>       <name>Lonazolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13481</drugbank-id>       <name>Tenidap</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13524</drugbank-id>       <name>Propyphenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13527</drugbank-id>       <name>Proglumetacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13538</drugbank-id>       <name>Guacetisal</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13544</drugbank-id>       <name>Ethenzamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13612</drugbank-id>       <name>Carbaspirin calcium</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13629</drugbank-id>       <name>Mofebutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13649</drugbank-id>       <name>Proquazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13657</drugbank-id>       <name>Benorilate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13722</drugbank-id>       <name>Pirprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13860</drugbank-id>       <name>Imidazole salicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14059</drugbank-id>       <name>SC-236</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14060</drugbank-id>       <name>NS-398</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14938</drugbank-id>       <name>Flurbiprofen axetil</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09212</drugbank-id>       <name>Loxoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04865</drugbank-id>       <name>Omacetaxine mepesuccinate</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Omacetaxine mepesuccinate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11133</drugbank-id>       <name>Omega-3 fatty acids</name>       <description>Omega-3 fatty acids may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00081</drugbank-id>       <name>Tositumomab</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09211</drugbank-id>       <name>Limaprost</name>       <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00048</drugbank-id>       <name>Collagenase clostridium histolyticum</name>       <description>The risk or severity of adverse effects can be increased when Reteplase is combined with Collagenase clostridium histolyticum.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00389</drugbank-id>       <name>Carbimazole</name>       <description>Carbimazole may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00550</drugbank-id>       <name>Propylthiouracil</name>       <description>Propylthiouracil may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00763</drugbank-id>       <name>Methimazole</name>       <description>Methimazole may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03374</drugbank-id>       <name>3,5-Diiodotyrosine</name>       <description>3,5-Diiodotyrosine may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06715</drugbank-id>       <name>Potassium Iodide</name>       <description>Potassium Iodide may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07637</drugbank-id>       <name>Dibromotyrosine</name>       <description>Dibromotyrosine may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09418</drugbank-id>       <name>Potassium perchlorate</name>       <description>Potassium perchlorate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13644</drugbank-id>       <name>Methylthiouracil</name>       <description>Methylthiouracil may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13804</drugbank-id>       <name>Benzylthiouracil</name>       <description>Benzylthiouracil may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00834</drugbank-id>       <name>Mifepristone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Mifepristone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04066</drugbank-id>       <name>p-Coumaric acid</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with p-Coumaric acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04682</drugbank-id>       <name>Octylphenoxy polyethoxyethanol</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05830</drugbank-id>       <name>Trestolone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Trestolone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06266</drugbank-id>       <name>Lonidamine</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Lonidamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08867</drugbank-id>       <name>Ulipristal</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ulipristal.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09401</drugbank-id>       <name>Isosorbide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Isosorbide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11507</drugbank-id>       <name>Cloprostenol</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cloprostenol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12025</drugbank-id>       <name>Triptolide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Triptolide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13044</drugbank-id>       <name>Gossypol</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Gossypol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13310</drugbank-id>       <name>Ormeloxifene</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ormeloxifene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00294</drugbank-id>       <name>Etonogestrel</name>       <description>Etonogestrel may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00304</drugbank-id>       <name>Desogestrel</name>       <description>Desogestrel may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00351</drugbank-id>       <name>Megestrol acetate</name>       <description>Megestrol acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00367</drugbank-id>       <name>Levonorgestrel</name>       <description>Levonorgestrel may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00378</drugbank-id>       <name>Dydrogesterone</name>       <description>Dydrogesterone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00396</drugbank-id>       <name>Progesterone</name>       <description>Progesterone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00603</drugbank-id>       <name>Medroxyprogesterone acetate</name>       <description>Medroxyprogesterone acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00717</drugbank-id>       <name>Norethisterone</name>       <description>Norethisterone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00823</drugbank-id>       <name>Ethynodiol diacetate</name>       <description>Ethynodiol diacetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00957</drugbank-id>       <name>Norgestimate</name>       <description>Norgestimate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01395</drugbank-id>       <name>Drospirenone</name>       <description>Drospirenone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01431</drugbank-id>       <name>Allylestrenol</name>       <description>Allylestrenol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04839</drugbank-id>       <name>Cyproterone acetate</name>       <description>Cyproterone acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06713</drugbank-id>       <name>Norelgestromin</name>       <description>Norelgestromin may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06730</drugbank-id>       <name>Gestodene</name>       <description>Gestodene may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06789</drugbank-id>       <name>Hydroxyprogesterone caproate</name>       <description>Hydroxyprogesterone caproate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09123</drugbank-id>       <name>Dienogest</name>       <description>Dienogest may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09124</drugbank-id>       <name>Medrogestone</name>       <description>Medrogestone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09371</drugbank-id>       <name>Norethynodrel</name>       <description>Norethynodrel may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09389</drugbank-id>       <name>Norgestrel</name>       <description>Norgestrel may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11372</drugbank-id>       <name>Altrenogest</name>       <description>Altrenogest may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11619</drugbank-id>       <name>Gestrinone</name>       <description>Gestrinone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11636</drugbank-id>       <name>Nomegestrol</name>       <description>Nomegestrol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12474</drugbank-id>       <name>Lynestrenol</name>       <description>Lynestrenol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13230</drugbank-id>       <name>Gestonorone</name>       <description>Gestonorone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13528</drugbank-id>       <name>Chlormadinone</name>       <description>Chlormadinone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13533</drugbank-id>       <name>Methylestrenolone</name>       <description>Methylestrenolone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13563</drugbank-id>       <name>Norgestrienone</name>       <description>Norgestrienone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13602</drugbank-id>       <name>Promegestone</name>       <description>Promegestone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13685</drugbank-id>       <name>Quingestanol</name>       <description>Quingestanol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13857</drugbank-id>       <name>Demegestone</name>       <description>Demegestone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13866</drugbank-id>       <name>Etynodiol</name>       <description>Etynodiol may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13981</drugbank-id>       <name>Nomegestrol acetate</name>       <description>Nomegestrol acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14570</drugbank-id>       <name>Hydroxyprogesterone</name>       <description>Hydroxyprogesterone may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14678</drugbank-id>       <name>Norethindrone enanthate</name>       <description>Norethindrone enanthate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14679</drugbank-id>       <name>Quingestanol acetate</name>       <description>Quingestanol acetate may decrease the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00233</drugbank-id>       <name>Aminosalicylic acid</name>       <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01294</drugbank-id>       <name>Bismuth subsalicylate</name>       <description>The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06251</drugbank-id>       <name>Dersalazine</name>       <description>The risk or severity of bleeding can be increased when Dersalazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06807</drugbank-id>       <name>Phenyl aminosalicylate</name>       <description>The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09543</drugbank-id>       <name>Methyl salicylate</name>       <description>The risk or severity of bleeding can be increased when Methyl salicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11079</drugbank-id>       <name>Trolamine salicylate</name>       <description>The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13509</drugbank-id>       <name>Aloxiprin</name>       <description>The risk or severity of bleeding can be increased when Aloxiprin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14006</drugbank-id>       <name>Choline salicylate</name>       <description>The risk or severity of bleeding can be increased when Choline salicylate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14026</drugbank-id>       <name>Thiosalicylic acid</name>       <description>The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00054</drugbank-id>       <name>Abciximab</name>       <description>The risk or severity of bleeding can be increased when Abciximab is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00063</drugbank-id>       <name>Eptifibatide</name>       <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00208</drugbank-id>       <name>Ticlopidine</name>       <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00261</drugbank-id>       <name>Anagrelide</name>       <description>The risk or severity of bleeding can be increased when Anagrelide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00758</drugbank-id>       <name>Clopidogrel</name>       <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00775</drugbank-id>       <name>Tirofiban</name>       <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00975</drugbank-id>       <name>Dipyridamole</name>       <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01088</drugbank-id>       <name>Iloprost</name>       <description>The risk or severity of bleeding can be increased when Iloprost is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01138</drugbank-id>       <name>Sulfinpyrazone</name>       <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01166</drugbank-id>       <name>Cilostazol</name>       <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01207</drugbank-id>       <name>Ridogrel</name>       <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01236</drugbank-id>       <name>Sevoflurane</name>       <description>The risk or severity of bleeding can be increased when Sevoflurane is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01240</drugbank-id>       <name>Epoprostenol</name>       <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02709</drugbank-id>       <name>Resveratrol</name>       <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04743</drugbank-id>       <name>Nimesulide</name>       <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04905</drugbank-id>       <name>Tesmilifene</name>       <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04932</drugbank-id>       <name>Defibrotide</name>       <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05229</drugbank-id>       <name>Beraprost</name>       <description>The risk or severity of bleeding can be increased when Beraprost is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05266</drugbank-id>       <name>Ibudilast</name>       <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05767</drugbank-id>       <name>Andrographolide</name>       <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06081</drugbank-id>       <name>Caplacizumab</name>       <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06209</drugbank-id>       <name>Prasugrel</name>       <description>The risk or severity of bleeding can be increased when Prasugrel is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06441</drugbank-id>       <name>Cangrelor</name>       <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07615</drugbank-id>       <name>Tranilast</name>       <description>The risk or severity of bleeding can be increased when Tranilast is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08814</drugbank-id>       <name>Triflusal</name>       <description>The risk or severity of bleeding can be increased when Triflusal is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08816</drugbank-id>       <name>Ticagrelor</name>       <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08887</drugbank-id>       <name>Icosapent ethyl</name>       <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09283</drugbank-id>       <name>Trapidil</name>       <description>The risk or severity of bleeding can be increased when Trapidil is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12092</drugbank-id>       <name>Naftopidil</name>       <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12163</drugbank-id>       <name>Sarpogrelate</name>       <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12321</drugbank-id>       <name>Ifetroban</name>       <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12445</drugbank-id>       <name>Nitroaspirin</name>       <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12465</drugbank-id>       <name>Ketanserin</name>       <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12545</drugbank-id>       <name>Indobufen</name>       <description>The risk or severity of bleeding can be increased when Indobufen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12749</drugbank-id>       <name>Butylphthalide</name>       <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12771</drugbank-id>       <name>Hydroxytyrosol</name>       <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13036</drugbank-id>       <name>Ramatroban</name>       <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13327</drugbank-id>       <name>Picotamide</name>       <description>The risk or severity of bleeding can be increased when Picotamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13367</drugbank-id>       <name>Cloricromen</name>       <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13400</drugbank-id>       <name>Linsidomine</name>       <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13510</drugbank-id>       <name>Buflomedil</name>       <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13929</drugbank-id>       <name>Relcovaptan</name>       <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00374</drugbank-id>       <name>Treprostinil</name>       <description>The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03404</drugbank-id>       <name>Hemin</name>       <description>Hemin may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13783</drugbank-id>       <name>Acemetacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00624</drugbank-id>       <name>Testosterone</name>       <description>Testosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01420</drugbank-id>       <name>Testosterone propionate</name>       <description>Testosterone propionate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01481</drugbank-id>       <name>1-Testosterone</name>       <description>1-Testosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01485</drugbank-id>       <name>4-Hydroxytestosterone</name>       <description>4-Hydroxytestosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01510</drugbank-id>       <name>Dehydrochloromethyltestosterone</name>       <description>Dehydrochloromethyltestosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01541</drugbank-id>       <name>Boldenone</name>       <description>Boldenone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01543</drugbank-id>       <name>18-methyl-19-nortestosterone</name>       <description>18-methyl-19-nortestosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01564</drugbank-id>       <name>Calusterone</name>       <description>Calusterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01569</drugbank-id>       <name>Formebolone</name>       <description>Formebolone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01572</drugbank-id>       <name>Methyl-1-testosterone</name>       <description>Methyl-1-testosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07447</drugbank-id>       <name>5beta-dihydrotestosterone</name>       <description>5beta-dihydrotestosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08619</drugbank-id>       <name>Testosterone succinate</name>       <description>Testosterone succinate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11429</drugbank-id>       <name>Mibolerone</name>       <description>Mibolerone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13943</drugbank-id>       <name>Testosterone cypionate</name>       <description>Testosterone cypionate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13944</drugbank-id>       <name>Testosterone enanthate</name>       <description>Testosterone enanthate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13946</drugbank-id>       <name>Testosterone undecanoate</name>       <description>Testosterone undecanoate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13947</drugbank-id>       <name>Testosterone enantate benzilic acid hydrazone</name>       <description>Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13951</drugbank-id>       <name>Stanolone acetate</name>       <description>Stanolone acetate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13958</drugbank-id>       <name>Trestolone acetate</name>       <description>Trestolone acetate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14093</drugbank-id>       <name>(1,2,6,7-3H)Testosterone</name>       <description>(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14655</drugbank-id>       <name>Drostanolone propionate</name>       <description>Drostanolone propionate may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11051</drugbank-id>       <name>Azficel-T</name>       <description>The risk or severity of adverse effects can be increased when Reteplase is combined with Azficel-T.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09568</drugbank-id>       <name>Omega-3-carboxylic acids</name>       <description>The therapeutic efficacy of Reteplase can be increased when used in combination with Omega-3-carboxylic acids.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00258</drugbank-id>       <name>Calcium acetate</name>       <description>The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01164</drugbank-id>       <name>Calcium chloride</name>       <description>The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01373</drugbank-id>       <name>Calcium</name>       <description>The therapeutic efficacy of Calcium can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11126</drugbank-id>       <name>Calcium gluconate</name>       <description>The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11608</drugbank-id>       <name>Eftrenonacog alfa</name>       <description>The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13884</drugbank-id>       <name>Albutrepenonacog alfa</name>       <description>The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13923</drugbank-id>       <name>Emicizumab</name>       <description>The therapeutic efficacy of Emicizumab can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14738</drugbank-id>       <name>Turoctocog alfa pegol</name>       <description>The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00025</drugbank-id>       <name>Antihemophilic factor, human recombinant</name>       <description>The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00036</drugbank-id>       <name>Coagulation factor VIIa Recombinant Human</name>       <description>The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00100</drugbank-id>       <name>Coagulation Factor IX (Recombinant)</name>       <description>The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01783</drugbank-id>       <name>Pantothenic acid</name>       <description>The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01942</drugbank-id>       <name>Formic acid</name>       <description>The therapeutic efficacy of Formic acid can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02261</drugbank-id>       <name>Platelet Activating Factor</name>       <description>The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06724</drugbank-id>       <name>Calcium carbonate</name>       <description>The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09109</drugbank-id>       <name>Turoctocog alfa</name>       <description>The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09222</drugbank-id>       <name>Fibrinogen human</name>       <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09310</drugbank-id>       <name>Catridecacog</name>       <description>The therapeutic efficacy of Catridecacog can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09329</drugbank-id>       <name>Antihemophilic Factor (Recombinant), PEGylated</name>       <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11093</drugbank-id>       <name>Calcium citrate</name>       <description>The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11168</drugbank-id>       <name>Calcium threonate</name>       <description>The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11311</drugbank-id>       <name>Prothrombin</name>       <description>The therapeutic efficacy of Prothrombin can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11330</drugbank-id>       <name>Factor IX Complex (Human)</name>       <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11348</drugbank-id>       <name>Calcium Phosphate</name>       <description>The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11606</drugbank-id>       <name>Susoctocog alfa</name>       <description>The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11668</drugbank-id>       <name>Rusalatide acetate</name>       <description>The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12409</drugbank-id>       <name>Vatreptacog alfa</name>       <description>The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12909</drugbank-id>       <name>Factor XIII (human)</name>       <description>The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13133</drugbank-id>       <name>Von Willebrand Factor Human</name>       <description>The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13148</drugbank-id>       <name>Coagulation factor X human</name>       <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13150</drugbank-id>       <name>Coagulation factor VII human</name>       <description>The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13151</drugbank-id>       <name>Anti-inhibitor coagulant complex</name>       <description>The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13152</drugbank-id>       <name>Coagulation Factor IX Human</name>       <description>The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13192</drugbank-id>       <name>Antihemophilic factor human</name>       <description>The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13197</drugbank-id>       <name>Kallidinogenase</name>       <description>The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13201</drugbank-id>       <name>Trenonacog alfa</name>       <description>The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13933</drugbank-id>       <name>Nonacog beta pegol</name>       <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13999</drugbank-id>       <name>Moroctocog alfa</name>       <description>The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14473</drugbank-id>       <name>Beroctocog alfa</name>       <description>The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14562</drugbank-id>       <name>Andexanet alfa</name>       <description>The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14577</drugbank-id>       <name>Calcium cation</name>       <description>The therapeutic efficacy of Calcium cation can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14700</drugbank-id>       <name>Damoctocog alfa pegol</name>       <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00176</drugbank-id>       <name>Fluvoxamine</name>       <description>The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00215</drugbank-id>       <name>Citalopram</name>       <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00472</drugbank-id>       <name>Fluoxetine</name>       <description>The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00715</drugbank-id>       <name>Paroxetine</name>       <description>The risk or severity of hemorrhage can be increased when Paroxetine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01149</drugbank-id>       <name>Nefazodone</name>       <description>The risk or severity of hemorrhage can be increased when Nefazodone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04832</drugbank-id>       <name>Zimelidine</name>       <description>The risk or severity of hemorrhage can be increased when Zimelidine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04884</drugbank-id>       <name>Dapoxetine</name>       <description>The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06731</drugbank-id>       <name>Seproxetine</name>       <description>The risk or severity of hemorrhage can be increased when Seproxetine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08953</drugbank-id>       <name>Indalpine</name>       <description>The risk or severity of hemorrhage can be increased when Indalpine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12693</drugbank-id>       <name>Ritanserin</name>       <description>The risk or severity of hemorrhage can be increased when Ritanserin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13233</drugbank-id>       <name>Alaproclate</name>       <description>The risk or severity of hemorrhage can be increased when Alaproclate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00476</drugbank-id>       <name>Duloxetine</name>       <description>The risk or severity of hemorrhage can be increased when Duloxetine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01105</drugbank-id>       <name>Sibutramine</name>       <description>The risk or severity of hemorrhage can be increased when Sibutramine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04896</drugbank-id>       <name>Milnacipran</name>       <description>The risk or severity of hemorrhage can be increased when Milnacipran is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06700</drugbank-id>       <name>Desvenlafaxine</name>       <description>The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08918</drugbank-id>       <name>Levomilnacipran</name>       <description>The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00285</drugbank-id>       <name>Venlafaxine</name>       <description>Venlafaxine may increase the antiplatelet activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00182</drugbank-id>       <name>Amphetamine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00601</drugbank-id>       <name>Linezolid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00614</drugbank-id>       <name>Furazolidone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00721</drugbank-id>       <name>Procaine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00752</drugbank-id>       <name>Tranylcypromine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00780</drugbank-id>       <name>Phenelzine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00805</drugbank-id>       <name>Minaprine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01037</drugbank-id>       <name>Selegiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01168</drugbank-id>       <name>Procarbazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01171</drugbank-id>       <name>Moclobemide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01247</drugbank-id>       <name>Isocarboxazid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01367</drugbank-id>       <name>Rasagiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01626</drugbank-id>       <name>Pargyline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04017</drugbank-id>       <name>Clorgiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04818</drugbank-id>       <name>Iproniazid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04820</drugbank-id>       <name>Nialamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06654</drugbank-id>       <name>Safinamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08550</drugbank-id>       <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09241</drugbank-id>       <name>Methylene blue</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09243</drugbank-id>       <name>Hydracarbazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09244</drugbank-id>       <name>Pirlindole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09245</drugbank-id>       <name>Toloxatone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09246</drugbank-id>       <name>Benmoxin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09248</drugbank-id>       <name>Mebanazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09249</drugbank-id>       <name>Octamoxin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09250</drugbank-id>       <name>Pheniprazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09251</drugbank-id>       <name>Phenoxypropazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09252</drugbank-id>       <name>Pivhydrazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09253</drugbank-id>       <name>Safrazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09254</drugbank-id>       <name>Caroxazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13875</drugbank-id>       <name>Harmaline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13876</drugbank-id>       <name>Brofaromine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00006</drugbank-id>       <name>Bivalirudin</name>       <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00266</drugbank-id>       <name>Dicoumarol</name>       <description>The risk or severity of bleeding can be increased when Dicoumarol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00278</drugbank-id>       <name>Argatroban</name>       <description>The risk or severity of bleeding can be increased when Argatroban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00407</drugbank-id>       <name>Ardeparin</name>       <description>The risk or severity of bleeding can be increased when Ardeparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00498</drugbank-id>       <name>Phenindione</name>       <description>The risk or severity of bleeding can be increased when Phenindione is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00569</drugbank-id>       <name>Fondaparinux</name>       <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00682</drugbank-id>       <name>Warfarin</name>       <description>The risk or severity of bleeding can be increased when Warfarin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00946</drugbank-id>       <name>Phenprocoumon</name>       <description>The risk or severity of bleeding can be increased when Phenprocoumon is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00974</drugbank-id>       <name>Edetic acid</name>       <description>The risk or severity of bleeding can be increased when Edetic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01109</drugbank-id>       <name>Heparin</name>       <description>The risk or severity of bleeding can be increased when Heparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01225</drugbank-id>       <name>Enoxaparin</name>       <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01418</drugbank-id>       <name>Acenocoumarol</name>       <description>The risk or severity of bleeding can be increased when Acenocoumarol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04898</drugbank-id>       <name>Ximelagatran</name>       <description>The risk or severity of bleeding can be increased when Ximelagatran is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05099</drugbank-id>       <name>Ancrod</name>       <description>The risk or severity of bleeding can be increased when Ancrod is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06271</drugbank-id>       <name>Sulodexide</name>       <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06406</drugbank-id>       <name>Idraparinux</name>       <description>The risk or severity of bleeding can be increased when Idraparinux is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06635</drugbank-id>       <name>Otamixaban</name>       <description>The risk or severity of bleeding can be increased when Otamixaban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06754</drugbank-id>       <name>Danaparoid</name>       <description>The risk or severity of bleeding can be increased when Danaparoid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06779</drugbank-id>       <name>Dalteparin</name>       <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07767</drugbank-id>       <name>Ferulic acid</name>       <description>The risk or severity of bleeding can be increased when Ferulic acid is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08794</drugbank-id>       <name>Ethyl biscoumacetate</name>       <description>The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08813</drugbank-id>       <name>Nadroparin</name>       <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09255</drugbank-id>       <name>Dextran</name>       <description>The risk or severity of bleeding can be increased when Dextran is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11095</drugbank-id>       <name>Desirudin</name>       <description>The risk or severity of bleeding can be increased when Desirudin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11268</drugbank-id>       <name>Protocatechualdehyde</name>       <description>The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11312</drugbank-id>       <name>Protein C</name>       <description>The risk or severity of bleeding can be increased when Protein C is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11598</drugbank-id>       <name>Antithrombin III human</name>       <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11984</drugbank-id>       <name>Letaxaban</name>       <description>The risk or severity of bleeding can be increased when Letaxaban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12289</drugbank-id>       <name>Darexaban</name>       <description>The risk or severity of bleeding can be increased when Darexaban is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12598</drugbank-id>       <name>Nafamostat</name>       <description>The risk or severity of bleeding can be increased when Nafamostat is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12831</drugbank-id>       <name>Gabexate</name>       <description>The risk or severity of bleeding can be increased when Gabexate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13124</drugbank-id>       <name>Troxerutin</name>       <description>The risk or severity of bleeding can be increased when Troxerutin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13136</drugbank-id>       <name>Fluindione</name>       <description>The risk or severity of bleeding can be increased when Fluindione is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13149</drugbank-id>       <name>Protein S human</name>       <description>The risk or severity of bleeding can be increased when Protein S human is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13616</drugbank-id>       <name>Melagatran</name>       <description>The risk or severity of bleeding can be increased when Melagatran is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09125</drugbank-id>       <name>Potassium citrate</name>       <description>The risk or severity of bleeding can be increased when Potassium citrate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09154</drugbank-id>       <name>Sodium citrate</name>       <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00031</drugbank-id>       <name>Tenecteplase</name>       <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00055</drugbank-id>       <name>Drotrecogin alfa</name>       <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06822</drugbank-id>       <name>Tinzaparin</name>       <description>The risk or severity of bleeding can be increased when Tinzaparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13199</drugbank-id>       <name>Brinase</name>       <description>The risk or severity of bleeding can be increased when Brinase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13646</drugbank-id>       <name>Saruplase</name>       <description>The risk or severity of bleeding can be increased when Saruplase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00086</drugbank-id>       <name>Streptokinase</name>       <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04925</drugbank-id>       <name>Desmoteplase</name>       <description>The risk or severity of bleeding can be increased when Desmoteplase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05254</drugbank-id>       <name>Fibrinolysin</name>       <description>The risk or severity of bleeding can be increased when Fibrinolysin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06543</drugbank-id>       <name>Astaxanthin</name>       <description>The risk or severity of bleeding can be increased when Astaxanthin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08994</drugbank-id>       <name>Ditazole</name>       <description>The risk or severity of bleeding can be increased when Ditazole is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09258</drugbank-id>       <name>Bemiparin</name>       <description>The risk or severity of bleeding can be increased when Bemiparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09260</drugbank-id>       <name>Parnaparin</name>       <description>The risk or severity of bleeding can be increased when Parnaparin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13275</drugbank-id>       <name>Clorindione</name>       <description>The risk or severity of bleeding can be increased when Clorindione is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13347</drugbank-id>       <name>Diphenadione</name>       <description>The risk or severity of bleeding can be increased when Diphenadione is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13451</drugbank-id>       <name>Tioclomarol</name>       <description>The risk or severity of bleeding can be increased when Tioclomarol is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00001</drugbank-id>       <name>Lepirudin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00009</drugbank-id>       <name>Alteplase</name>       <description>The risk or severity of bleeding can be increased when Alteplase is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00029</drugbank-id>       <name>Anistreplase</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Anistreplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14094</drugbank-id>       <name>Tocopherylquinone</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Tocopherylquinone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06679</drugbank-id>       <name>Amediplase</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Amediplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03410</drugbank-id>       <name>4-hydroxycoumarin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with 4-hydroxycoumarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08496</drugbank-id>       <name>(R)-warfarin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with (R)-warfarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14055</drugbank-id>       <name>(S)-Warfarin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with (S)-Warfarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12364</drugbank-id>       <name>Betrixaban</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Betrixaban.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14598</drugbank-id>       <name>Edetate calcium disodium anhydrous</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Edetate calcium disodium anhydrous.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11154</drugbank-id>       <name>Zinc citrate</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Zinc citrate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11166</drugbank-id>       <name>Antithrombin Alfa</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Antithrombin Alfa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04665</drugbank-id>       <name>Coumarin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Coumarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14726</drugbank-id>       <name>Dabigatran</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Dabigatran.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06294</drugbank-id>       <name>Semuloparin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Semuloparin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12726</drugbank-id>       <name>Monteplase</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Monteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09259</drugbank-id>       <name>Reviparin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Reviparin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00177</drugbank-id>       <name>Valsartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Valsartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00178</drugbank-id>       <name>Ramipril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Ramipril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00230</drugbank-id>       <name>Pregabalin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Pregabalin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00492</drugbank-id>       <name>Fosinopril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Fosinopril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00519</drugbank-id>       <name>Trandolapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Trandolapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00542</drugbank-id>       <name>Benazepril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Benazepril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00584</drugbank-id>       <name>Enalapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Enalapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00678</drugbank-id>       <name>Losartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Losartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00691</drugbank-id>       <name>Moexipril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Moexipril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00722</drugbank-id>       <name>Lisinopril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Lisinopril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00790</drugbank-id>       <name>Perindopril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Perindopril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00876</drugbank-id>       <name>Eprosartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Eprosartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00877</drugbank-id>       <name>Sirolimus</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Sirolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00881</drugbank-id>       <name>Quinapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Quinapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00886</drugbank-id>       <name>Omapatrilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Omapatrilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00966</drugbank-id>       <name>Telmisartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Telmisartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01050</drugbank-id>       <name>Ibuprofen</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Ibuprofen.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01180</drugbank-id>       <name>Rescinnamine</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Rescinnamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01197</drugbank-id>       <name>Captopril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Captopril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01261</drugbank-id>       <name>Sitagliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Sitagliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01340</drugbank-id>       <name>Cilazapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Cilazapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01342</drugbank-id>       <name>Forasartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Forasartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01347</drugbank-id>       <name>Saprisartan</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Saprisartan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01348</drugbank-id>       <name>Spirapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Spirapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04876</drugbank-id>       <name>Vildagliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Vildagliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06011</drugbank-id>       <name>AMG-222</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with AMG-222.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06127</drugbank-id>       <name>Bisegliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Bisegliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06196</drugbank-id>       <name>Icatibant</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Icatibant.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06203</drugbank-id>       <name>Alogliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Alogliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06245</drugbank-id>       <name>Lanoteplase</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Lanoteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06287</drugbank-id>       <name>Temsirolimus</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Temsirolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06335</drugbank-id>       <name>Saxagliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Saxagliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08382</drugbank-id>       <name>Gosogliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Gosogliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08822</drugbank-id>       <name>Azilsartan medoxomil</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Azilsartan medoxomil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08836</drugbank-id>       <name>Temocapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Temocapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08882</drugbank-id>       <name>Linagliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Linagliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09292</drugbank-id>       <name>Sacubitril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Sacubitril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09477</drugbank-id>       <name>Enalaprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Enalaprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11723</drugbank-id>       <name>Dutogliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Dutogliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11783</drugbank-id>       <name>Imidapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Imidapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11950</drugbank-id>       <name>Teneligliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Teneligliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11992</drugbank-id>       <name>Omarigliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Omarigliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12268</drugbank-id>       <name>Carmegliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Carmegliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12412</drugbank-id>       <name>Gemigliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Gemigliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12417</drugbank-id>       <name>Anagliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Anagliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12625</drugbank-id>       <name>Evogliptin</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Evogliptin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13166</drugbank-id>       <name>Zofenopril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Zofenopril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13312</drugbank-id>       <name>Delapril</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Delapril.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14125</drugbank-id>       <name>Benazeprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Benazeprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14207</drugbank-id>       <name>Fosinoprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Fosinoprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14208</drugbank-id>       <name>Ramiprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Ramiprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14209</drugbank-id>       <name>Trandolaprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Trandolaprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14210</drugbank-id>       <name>Moexiprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Moexiprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14213</drugbank-id>       <name>Perindoprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Perindoprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14217</drugbank-id>       <name>Quinaprilat</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Quinaprilat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14231</drugbank-id>       <name>Quinoline Yellow WS</name>       <description>The risk or severity of angioedema can be increased when Reteplase is combined with Quinoline Yellow WS.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00203</drugbank-id>       <name>Sildenafil</name>       <description>The risk or severity of hemorrhage can be increased when Reteplase is combined with Sildenafil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00008</drugbank-id>       <name>Peginterferon alfa-2a</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2a.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00011</drugbank-id>       <name>Interferon alfa-n1</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00018</drugbank-id>       <name>Interferon alfa-n3</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n3.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00022</drugbank-id>       <name>Peginterferon alfa-2b</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00033</drugbank-id>       <name>Interferon gamma-1b</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon gamma-1b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00034</drugbank-id>       <name>Interferon alfa-2a, Recombinant</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2a, Recombinant.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00041</drugbank-id>       <name>Aldesleukin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Aldesleukin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00056</drugbank-id>       <name>Gemtuzumab ozogamicin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00068</drugbank-id>       <name>Interferon beta-1b</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00069</drugbank-id>       <name>Interferon alfacon-1</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00073</drugbank-id>       <name>Rituximab</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00078</drugbank-id>       <name>Ibritumomab tiuxetan</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00087</drugbank-id>       <name>Alemtuzumab</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00105</drugbank-id>       <name>Interferon alfa-2b</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00120</drugbank-id>       <name>Phenylalanine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Phenylalanine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00188</drugbank-id>       <name>Bortezomib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Bortezomib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00242</drugbank-id>       <name>Cladribine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cladribine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00262</drugbank-id>       <name>Carmustine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Carmustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00276</drugbank-id>       <name>Amsacrine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Amsacrine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00291</drugbank-id>       <name>Chlorambucil</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Chlorambucil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00293</drugbank-id>       <name>Raltitrexed</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Raltitrexed.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00305</drugbank-id>       <name>Mitomycin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Mitomycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00307</drugbank-id>       <name>Bexarotene</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Bexarotene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00309</drugbank-id>       <name>Vindesine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Vindesine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00322</drugbank-id>       <name>Floxuridine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Floxuridine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00352</drugbank-id>       <name>Tioguanine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Tioguanine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00361</drugbank-id>       <name>Vinorelbine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Vinorelbine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00380</drugbank-id>       <name>Dexrazoxane</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00398</drugbank-id>       <name>Sorafenib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Sorafenib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00428</drugbank-id>       <name>Streptozocin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Streptozocin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00441</drugbank-id>       <name>Gemcitabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Gemcitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00444</drugbank-id>       <name>Teniposide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Teniposide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00445</drugbank-id>       <name>Epirubicin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Epirubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00446</drugbank-id>       <name>Chloramphenicol</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Chloramphenicol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00480</drugbank-id>       <name>Lenalidomide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Lenalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00488</drugbank-id>       <name>Altretamine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Altretamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00495</drugbank-id>       <name>Zidovudine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Zidovudine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00515</drugbank-id>       <name>Cisplatin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00526</drugbank-id>       <name>Oxaliplatin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00531</drugbank-id>       <name>Cyclophosphamide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cyclophosphamide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00544</drugbank-id>       <name>Fluorouracil</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Fluorouracil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00552</drugbank-id>       <name>Pentostatin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Pentostatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00563</drugbank-id>       <name>Methotrexate</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Methotrexate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00564</drugbank-id>       <name>Carbamazepine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Carbamazepine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00570</drugbank-id>       <name>Vinblastine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Vinblastine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00619</drugbank-id>       <name>Imatinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Imatinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00631</drugbank-id>       <name>Clofarabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Clofarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00642</drugbank-id>       <name>Pemetrexed</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Pemetrexed.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00694</drugbank-id>       <name>Daunorubicin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00762</drugbank-id>       <name>Irinotecan</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Irinotecan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00773</drugbank-id>       <name>Etoposide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Etoposide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00851</drugbank-id>       <name>Dacarbazine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Dacarbazine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00853</drugbank-id>       <name>Temozolomide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Temozolomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00859</drugbank-id>       <name>Penicillamine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Penicillamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00864</drugbank-id>       <name>Tacrolimus</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Tacrolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00888</drugbank-id>       <name>Mechlorethamine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Mechlorethamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00928</drugbank-id>       <name>Azacitidine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Azacitidine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00958</drugbank-id>       <name>Carboplatin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Carboplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00970</drugbank-id>       <name>Dactinomycin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Dactinomycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00987</drugbank-id>       <name>Cytarabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00997</drugbank-id>       <name>Doxorubicin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Doxorubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01005</drugbank-id>       <name>Hydroxyurea</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Hydroxyurea.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01008</drugbank-id>       <name>Busulfan</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Busulfan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01030</drugbank-id>       <name>Topotecan</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Topotecan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01033</drugbank-id>       <name>Mercaptopurine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Mercaptopurine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01041</drugbank-id>       <name>Thalidomide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Thalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01042</drugbank-id>       <name>Melphalan</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Melphalan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01073</drugbank-id>       <name>Fludarabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Fludarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01099</drugbank-id>       <name>Flucytosine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Flucytosine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01101</drugbank-id>       <name>Capecitabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Capecitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01169</drugbank-id>       <name>Arsenic trioxide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Arsenic trioxide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01177</drugbank-id>       <name>Idarubicin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Idarubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01204</drugbank-id>       <name>Mitoxantrone</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Mitoxantrone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01206</drugbank-id>       <name>Lomustine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Lomustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01229</drugbank-id>       <name>Paclitaxel</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Paclitaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01248</drugbank-id>       <name>Docetaxel</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Docetaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01262</drugbank-id>       <name>Decitabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Decitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01280</drugbank-id>       <name>Nelarabine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Nelarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01590</drugbank-id>       <name>Everolimus</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Everolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02546</drugbank-id>       <name>Vorinostat</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Vorinostat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04572</drugbank-id>       <name>Thiotepa</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Thiotepa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04845</drugbank-id>       <name>Ixabepilone</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Ixabepilone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04868</drugbank-id>       <name>Nilotinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Nilotinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05015</drugbank-id>       <name>Belinostat</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Belinostat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05109</drugbank-id>       <name>Trabectedin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Trabectedin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05258</drugbank-id>       <name>Interferon alfa</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05472</drugbank-id>       <name>Human interferon omega-1</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Human interferon omega-1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05773</drugbank-id>       <name>Trastuzumab emtansine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Trastuzumab emtansine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06616</drugbank-id>       <name>Bosutinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Bosutinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06769</drugbank-id>       <name>Bendamustine</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Bendamustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06772</drugbank-id>       <name>Cabazitaxel</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cabazitaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08871</drugbank-id>       <name>Eribulin</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Eribulin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08877</drugbank-id>       <name>Ruxolitinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Ruxolitinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08889</drugbank-id>       <name>Carfilzomib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Carfilzomib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08895</drugbank-id>       <name>Tofacitinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Tofacitinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08901</drugbank-id>       <name>Ponatinib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Ponatinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08910</drugbank-id>       <name>Pomalidomide</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Pomalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09042</drugbank-id>       <name>Tedizolid phosphate</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Tedizolid phosphate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09052</drugbank-id>       <name>Blinatumomab</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Blinatumomab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09073</drugbank-id>       <name>Palbociclib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Palbociclib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09074</drugbank-id>       <name>Olaparib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Olaparib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09077</drugbank-id>       <name>Dinutuximab</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Dinutuximab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09122</drugbank-id>       <name>Peginterferon beta-1a</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon beta-1a.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12814</drugbank-id>       <name>Cepeginterferon alfa-2B</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Cepeginterferon alfa-2B.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00229</drugbank-id>       <name>Cefotiam</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotiam.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00267</drugbank-id>       <name>Cefmenoxime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmenoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00274</drugbank-id>       <name>Cefmetazole</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmetazole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00430</drugbank-id>       <name>Cefpiramide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpiramide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00438</drugbank-id>       <name>Ceftazidime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftazidime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00447</drugbank-id>       <name>Loracarbef</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Loracarbef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00456</drugbank-id>       <name>Cefalotin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefalotin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00493</drugbank-id>       <name>Cefotaxime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotaxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00535</drugbank-id>       <name>Cefdinir</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefdinir.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00567</drugbank-id>       <name>Cephalexin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephalexin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00671</drugbank-id>       <name>Cefixime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefixime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00689</drugbank-id>       <name>Cephaloglycin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephaloglycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00833</drugbank-id>       <name>Cefaclor</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaclor.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00923</drugbank-id>       <name>Ceforanide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceforanide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01066</drugbank-id>       <name>Cefditoren</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefditoren.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01112</drugbank-id>       <name>Cefuroxime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefuroxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01139</drugbank-id>       <name>Cefapirin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefapirin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01140</drugbank-id>       <name>Cefadroxil</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefadroxil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01150</drugbank-id>       <name>Cefprozil</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefprozil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01212</drugbank-id>       <name>Ceftriaxone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftriaxone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01326</drugbank-id>       <name>Cefamandole</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01327</drugbank-id>       <name>Cefazolin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazolin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01328</drugbank-id>       <name>Cefonicid</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefonicid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01329</drugbank-id>       <name>Cefoperazone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoperazone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01330</drugbank-id>       <name>Cefotetan</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotetan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01331</drugbank-id>       <name>Cefoxitin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoxitin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01332</drugbank-id>       <name>Ceftizoxime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftizoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01333</drugbank-id>       <name>Cefradine</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefradine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01413</drugbank-id>       <name>Cefepime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefepime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01414</drugbank-id>       <name>Cefacetrile</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefacetrile.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01415</drugbank-id>       <name>Ceftibuten</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftibuten.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01416</drugbank-id>       <name>Cefpodoxime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpodoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04570</drugbank-id>       <name>Latamoxef</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Latamoxef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04918</drugbank-id>       <name>Ceftobiprole</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftobiprole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06590</drugbank-id>       <name>Ceftaroline fosamil</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftaroline fosamil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09008</drugbank-id>       <name>Cefaloridine</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaloridine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09050</drugbank-id>       <name>Ceftolozane</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftolozane.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09062</drugbank-id>       <name>Cefminox</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefminox.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11367</drugbank-id>       <name>Cefroxadine</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefroxadine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11935</drugbank-id>       <name>Flomoxef</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Flomoxef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13266</drugbank-id>       <name>Cefatrizine</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefatrizine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13461</drugbank-id>       <name>Cefcapene</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefcapene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13470</drugbank-id>       <name>Cefodizime</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefodizime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13499</drugbank-id>       <name>Cefsulodin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefsulodin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13504</drugbank-id>       <name>Cefetamet</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefetamet.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13638</drugbank-id>       <name>Cefbuperazone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefbuperazone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13667</drugbank-id>       <name>Cefozopran</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefozopran.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13682</drugbank-id>       <name>Cefpirome</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpirome.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13778</drugbank-id>       <name>Cefazedone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazedone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13821</drugbank-id>       <name>Ceftezole</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftezole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14725</drugbank-id>       <name>Cefamandole nafate</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole nafate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00254</drugbank-id>       <name>Doxycycline</name>       <description>The risk or severity of bleeding can be increased when Doxycycline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00207</drugbank-id>       <name>Azithromycin</name>       <description>The risk or severity of adverse effects can be increased when Azithromycin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09539</drugbank-id>       <name>Omega-3-acid ethyl esters</name>       <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00945</drugbank-id>       <name>Acetylsalicylic acid</name>       <description>Acetylsalicylic acid may increase the anticoagulant activities of Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01606</drugbank-id>       <name>Tazobactam</name>       <description>The risk or severity of bleeding can be increased when Tazobactam is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00727</drugbank-id>       <name>Nitroglycerin</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00199</drugbank-id>       <name>Erythromycin</name>       <description>The risk or severity of bleeding can be increased when Erythromycin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00656</drugbank-id>       <name>Trazodone</name>       <description>The risk or severity of bleeding can be increased when Trazodone is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00620</drugbank-id>       <name>Triamcinolone</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Triamcinolone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09079</drugbank-id>       <name>Nintedanib</name>       <description>The risk or severity of bleeding can be increased when Reteplase is combined with Nintedanib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01175</drugbank-id>       <name>Escitalopram</name>       <description>The risk or severity of bleeding can be increased when Escitalopram is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01104</drugbank-id>       <name>Sertraline</name>       <description>The risk or severity of bleeding can be increased when Sertraline is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00232</drugbank-id>       <name>Methyclothiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Methyclothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00436</drugbank-id>       <name>Bendroflumethiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Bendroflumethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00562</drugbank-id>       <name>Benzthiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Benzthiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00606</drugbank-id>       <name>Cyclothiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00774</drugbank-id>       <name>Hydroflumethiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydroflumethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00880</drugbank-id>       <name>Chlorothiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Chlorothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00999</drugbank-id>       <name>Hydrochlorothiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydrochlorothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01021</drugbank-id>       <name>Trichlormethiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Trichlormethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01324</drugbank-id>       <name>Polythiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Polythiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13430</drugbank-id>       <name>Mebutizide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Mebutizide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13532</drugbank-id>       <name>Cyclopenthiazide</name>       <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclopenthiazide.</description>     </drug-interaction>   </drug-interactions>   <sequences>     <sequence format=\"FASTA\">&gt;DB00015 sequence SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYC RNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAA IFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKF EVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELS GYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHD ACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>   </sequences>   <experimental-properties>     <property>       <kind>Melting Point</kind>       <value>60 C</value>       <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>     </property>     <property>       <kind>Hydrophobicity</kind>       <value>-0.435</value>       <source/>     </property>     <property>       <kind>Isoelectric Point</kind>       <value>6.86</value>       <source/>     </property>     <property>       <kind>Molecular Weight</kind>       <value>39589.6</value>       <source/>     </property>     <property>       <kind>Molecular Formula</kind>       <value>C1736H2671N499O522S22</value>       <source/>     </property>   </experimental-properties>   <external-identifiers>     <external-identifier>       <resource>Drugs Product Database (DPD)</resource>       <identifier>11534</identifier>     </external-identifier>     <external-identifier>       <resource>PubChem Substance</resource>       <identifier>46506092</identifier>     </external-identifier>     <external-identifier>       <resource>GenBank</resource>       <identifier>L00153</identifier>     </external-identifier>     <external-identifier>       <resource>PharmGKB</resource>       <identifier>PA164743728</identifier>     </external-identifier>     <external-identifier>       <resource>UniProtKB</resource>       <identifier>P00750</identifier>     </external-identifier>     <external-identifier>       <resource>Therapeutic Targets Database</resource>       <identifier>DAP001195</identifier>     </external-identifier>     <external-identifier>       <resource>Wikipedia</resource>       <identifier>Reteplase</identifier>     </external-identifier>     <external-identifier>       <resource>ChEMBL</resource>       <identifier>CHEMBL2107885</identifier>     </external-identifier>     <external-identifier>       <resource>RxCUI</resource>       <identifier>76895</identifier>     </external-identifier>   </external-identifiers>   <external-links>     <external-link>       <resource>RxList</resource>       <url>http://www.rxlist.com/cgi/generic2/reteplase.htm</url>     </external-link>     <external-link>       <resource>Drugs.com</resource>       <url>http://www.drugs.com/cdi/reteplase.html</url>     </external-link>   </external-links>   <pathways>     <pathway>       <smpdb-id>SMP0000285</smpdb-id>       <name>Reteplase Action Pathway</name>       <category>drug_action</category>       <drugs>         <drug>           <drugbank-id>DB00015</drugbank-id>           <name>Reteplase</name>         </drug>         <drug>           <drugbank-id>DB01022</drugbank-id>           <name>Phylloquinone</name>         </drug>         <drug>           <drugbank-id>DB01373</drugbank-id>           <name>Calcium</name>         </drug>       </drugs>       <enzymes>         <uniprot-id>P00747</uniprot-id>         <uniprot-id>P00748</uniprot-id>         <uniprot-id>P02452</uniprot-id>         <uniprot-id>P03952</uniprot-id>         <uniprot-id>P03951</uniprot-id>         <uniprot-id>P00740</uniprot-id>         <uniprot-id>P00451</uniprot-id>         <uniprot-id>P00734</uniprot-id>         <uniprot-id>P12259</uniprot-id>         <uniprot-id>P00742</uniprot-id>         <uniprot-id>P02671</uniprot-id>         <uniprot-id>P02675</uniprot-id>         <uniprot-id>P02679</uniprot-id>         <uniprot-id>P00488</uniprot-id>         <uniprot-id>P05160</uniprot-id>         <uniprot-id>P00750</uniprot-id>         <uniprot-id>P08709</uniprot-id>         <uniprot-id>P13726</uniprot-id>         <uniprot-id>Q9BQB6</uniprot-id>         <uniprot-id>P38435</uniprot-id>       </enzymes>     </pathway>   </pathways>   <reactions/>   <snp-effects/>   <snp-adverse-drug-reactions/>   <targets>     <target position=\"1\">       <id>BE0000211</id>       <name>Plasminogen</name>       <organism>Humans</organism>       <actions>         <action>activator</action>       </actions>       <references>         <articles>           <article>             <ref-id>A6691</ref-id>             <pubmed-id>17963464</pubmed-id>             <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>           </article>           <article>             <ref-id>A6689</ref-id>             <pubmed-id>18673235</pubmed-id>             <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>           </article>           <article>             <ref-id>A6690</ref-id>             <pubmed-id>19436656</pubmed-id>             <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>           </article>           <article>             <ref-id>A9</ref-id>             <pubmed-id>11752352</pubmed-id>             <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>           </article>         </articles>         <textbooks/>         <links/>         <attachments/>       </references>       <known-action>yes</known-action>       <polypeptide id=\"P00747\" source=\"Swiss-Prot\">         <name>Plasminogen</name>         <general-function>Serine-type peptidase activity</general-function>         <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>         <gene-name>PLG</gene-name>         <locus>6q26</locus>         <cellular-location>Secreted</cellular-location>         <transmembrane-regions/>         <signal-regions>1-19</signal-regions>         <theoretical-pi>7.25</theoretical-pi>         <molecular-weight>90568.415</molecular-weight>         <chromosome-location>6</chromosome-location>         <organism ncbi-taxonomy-id=\"9606\">Humans</organism>         <external-identifiers>           <external-identifier>             <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>             <identifier>HGNC:9071</identifier>           </external-identifier>           <external-identifier>             <resource>GenAtlas</resource>             <identifier>PLG</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Gene Database</resource>             <identifier>X05199</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Protein Database</resource>             <identifier>387026</identifier>           </external-identifier>           <external-identifier>             <resource>Guide to Pharmacology</resource>             <identifier>2394</identifier>           </external-identifier>           <external-identifier>             <resource>UniProtKB</resource>             <identifier>P00747</identifier>           </external-identifier>           <external-identifier>             <resource>UniProt Accession</resource>             <identifier>PLMN_HUMAN</identifier>           </external-identifier>         </external-identifiers>         <synonyms>           <synonym>3.4.21.7</synonym>         </synonyms>         <amino-acid-sequence format=\"FASTA\">&gt;lcl|BSEQ0016037|Plasminogen MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>         <gene-sequence format=\"FASTA\">&gt;lcl|BSEQ0016038|Plasminogen (PLG) ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>         <pfams>           <pfam>             <identifier>PF00051</identifier>             <name>Kringle</name>           </pfam>           <pfam>             <identifier>PF00089</identifier>             <name>Trypsin</name>           </pfam>           <pfam>             <identifier>PF00024</identifier>             <name>PAN_1</name>           </pfam>         </pfams>         <go-classifiers>           <go-classifier>             <category>component</category>             <description>blood microparticle</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>cell surface</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular exosome</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular region</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular space</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extrinsic component of external side of plasma membrane</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>plasma membrane</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>platelet alpha granule lumen</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>apolipoprotein binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>protein domain specific binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>receptor binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>serine-type endopeptidase activity</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>serine-type peptidase activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular protein metabolic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>extracellular matrix disassembly</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>extracellular matrix organization</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of cell proliferation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of cell-cell adhesion mediated by cadherin</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of cell-substrate adhesion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet degranulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>proteolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>tissue remodeling</description>           </go-classifier>         </go-classifiers>       </polypeptide>     </target>     <target position=\"2\">       <id>BE0000538</id>       <name>Fibrinogen alpha chain</name>       <organism>Humans</organism>       <actions/>       <references>         <articles>           <article>             <ref-id>A6689</ref-id>             <pubmed-id>18673235</pubmed-id>             <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>           </article>           <article>             <ref-id>A6690</ref-id>             <pubmed-id>19436656</pubmed-id>             <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>           </article>           <article>             <ref-id>A6691</ref-id>             <pubmed-id>17963464</pubmed-id>             <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>           </article>         </articles>         <textbooks/>         <links/>         <attachments/>       </references>       <known-action>yes</known-action>       <polypeptide id=\"P02671\" source=\"Swiss-Prot\">         <name>Fibrinogen alpha chain</name>         <general-function>Structural molecule activity</general-function>         <specific-function>Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.</specific-function>         <gene-name>FGA</gene-name>         <locus>4q28</locus>         <cellular-location>Secreted</cellular-location>         <transmembrane-regions/>         <signal-regions>1-19</signal-regions>         <theoretical-pi>5.87</theoretical-pi>         <molecular-weight>94972.455</molecular-weight>         <chromosome-location>4</chromosome-location>         <organism ncbi-taxonomy-id=\"9606\">Humans</organism>         <external-identifiers>           <external-identifier>             <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>             <identifier>HGNC:3661</identifier>           </external-identifier>           <external-identifier>             <resource>GenAtlas</resource>             <identifier>FGA</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Gene Database</resource>             <identifier>AF361104</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Protein Database</resource>             <identifier>13591824</identifier>           </external-identifier>           <external-identifier>             <resource>UniProtKB</resource>             <identifier>P02671</identifier>           </external-identifier>           <external-identifier>             <resource>UniProt Accession</resource>             <identifier>FIBA_HUMAN</identifier>           </external-identifier>         </external-identifiers>         <synonyms>           <synonym>Fibrinogen alpha chain precursor</synonym>         </synonyms>         <amino-acid-sequence format=\"FASTA\">&gt;lcl|BSEQ0001074|Fibrinogen alpha chain MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>         <gene-sequence format=\"FASTA\">&gt;lcl|BSEQ0021267|Fibrinogen alpha chain (FGA) ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT AGGCCCCTTGTGACCCAATAG</gene-sequence>         <pfams>           <pfam>             <identifier>PF00147</identifier>             <name>Fibrinogen_C</name>           </pfam>           <pfam>             <identifier>PF08702</identifier>             <name>Fib_alpha</name>           </pfam>           <pfam>             <identifier>PF12160</identifier>             <name>Fibrinogen_aC</name>           </pfam>         </pfams>         <go-classifiers>           <go-classifier>             <category>component</category>             <description>blood microparticle</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>cell cortex</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>cell surface</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>external side of plasma membrane</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular exosome</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular region</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular space</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular vesicle</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>fibrinogen complex</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>plasma membrane</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>platelet alpha granule</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>platelet alpha granule lumen</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>rough endoplasmic reticulum</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>structural molecule activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>acute-phase response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>adaptive immune response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation, common pathway</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation, fibrin clot formation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cell-matrix adhesion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular protein complex assembly</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular protein metabolic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular response to granulocyte colony-stimulating factor</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular response to interleukin-6</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular response to organic cyclic compound</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>extracellular matrix organization</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>induction of bacterial agglutination</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>innate immune response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>liver regeneration</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of blood coagulation, common pathway</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of endothelial cell apoptotic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>plasminogen activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet aggregation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet degranulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of ERK1 and ERK2 cascade</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of exocytosis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of heterotypic cell-cell adhesion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of peptide hormone secretion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of protein secretion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of substrate adhesion-dependent cell spreading</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of vasoconstriction</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>protein complex assembly</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>protein polymerization</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to calcium ion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to cycloheximide</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to estradiol</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to genistein</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to morphine</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>signal transduction</description>           </go-classifier>         </go-classifiers>       </polypeptide>     </target>     <target position=\"3\">       <id>BE0000240</id>       <name>Plasminogen activator inhibitor 1</name>       <organism>Humans</organism>       <actions/>       <references>         <articles>           <article>             <ref-id>A6691</ref-id>             <pubmed-id>17963464</pubmed-id>             <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>           </article>         </articles>         <textbooks/>         <links/>         <attachments/>       </references>       <known-action>unknown</known-action>       <polypeptide id=\"P05121\" source=\"Swiss-Prot\">         <name>Plasminogen activator inhibitor 1</name>         <general-function>Serine-type endopeptidase inhibitor activity</general-function>         <specific-function>Serine protease inhibitor. This inhibitor acts as \\'bait\\' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>         <gene-name>SERPINE1</gene-name>         <locus>7q21.3-q22</locus>         <cellular-location>Secreted</cellular-location>         <transmembrane-regions/>         <signal-regions>1-23</signal-regions>         <theoretical-pi>7.22</theoretical-pi>         <molecular-weight>45059.695</molecular-weight>         <chromosome-location>7</chromosome-location>         <organism ncbi-taxonomy-id=\"9606\">Humans</organism>         <external-identifiers>           <external-identifier>             <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>             <identifier>HGNC:8583</identifier>           </external-identifier>           <external-identifier>             <resource>GenAtlas</resource>             <identifier>SERPINE1</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Gene Database</resource>             <identifier>X04429</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Protein Database</resource>             <identifier>35272</identifier>           </external-identifier>           <external-identifier>             <resource>UniProtKB</resource>             <identifier>P05121</identifier>           </external-identifier>           <external-identifier>             <resource>UniProt Accession</resource>             <identifier>PAI1_HUMAN</identifier>           </external-identifier>         </external-identifiers>         <synonyms>           <synonym>Endothelial plasminogen activator inhibitor</synonym>           <synonym>PAI</synonym>           <synonym>PAI1</synonym>           <synonym>PLANH1</synonym>           <synonym>Serpin E1</synonym>         </synonyms>         <amino-acid-sequence format=\"FASTA\">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1 MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>         <gene-sequence format=\"FASTA\">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1) ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG GAACCCTGA</gene-sequence>         <pfams>           <pfam>             <identifier>PF00079</identifier>             <name>Serpin</name>           </pfam>         </pfams>         <go-classifiers>           <go-classifier>             <category>component</category>             <description>extracellular exosome</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular matrix</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular region</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular space</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>plasma membrane</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>platelet alpha granule lumen</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>protease binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>receptor binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>serine-type endopeptidase inhibitor activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>angiogenesis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular response to lipopolysaccharide</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>chronological cell aging</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>circadian rhythm</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>defense response to Gram-negative bacterium</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>extracellular matrix organization</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>gene expression</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of cell adhesion mediated by integrin</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of cell migration</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of endopeptidase activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of endothelial cell apoptotic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of plasminogen activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of smooth muscle cell migration</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of smooth muscle cell-matrix adhesion</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of vascular wound healing</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of wound healing</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet degranulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of angiogenesis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of inflammatory response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of interleukin-8 production</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of leukotriene production involved in inflammatory response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of monocyte chemotaxis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of receptor-mediated endocytosis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of transcription from RNA polymerase II promoter</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>regulation of receptor activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>transcription initiation from RNA polymerase II promoter</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>transcription, DNA-templated</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>transforming growth factor beta receptor signaling pathway</description>           </go-classifier>         </go-classifiers>       </polypeptide>     </target>   </targets>   <enzymes/>   <carriers/>   <transporters/> </drug> <'"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list1[15]\n",
    "#### How to deal with all the disconnection in the graph?\n",
    "#### We need some type of generative model to account for the absence of information everywhere\n",
    "#### We might always have some information on the types of molecules"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "0b327f2d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "14316"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "bed9f227",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB00001\n",
      "DB00002\n",
      "DB00003\n",
      "DB00004\n",
      "DB00005\n",
      "DB00006\n",
      "DB00007\n",
      "DB00008\n",
      "DB00009\n",
      "DB00010\n",
      "DB00011\n",
      "DB00012\n",
      "DB00013\n",
      "DB00014\n",
      "DB00015\n",
      "DB00016\n",
      "DB00017\n",
      "Drug has no atc code\n",
      "DB00018\n",
      "DB00019\n",
      "DB00020\n",
      "DB00022\n",
      "DB00023\n",
      "DB00024\n",
      "DB00025\n",
      "DB00026\n",
      "DB00027\n",
      "Drug has no atc code\n",
      "DB00028\n",
      "DB00029\n",
      "DB00030\n",
      "DB00031\n",
      "DB00032\n",
      "Drug has no atc code\n",
      "DB00033\n",
      "DB00034\n",
      "DB00035\n",
      "DB00036\n",
      "DB00038\n",
      "DB00039\n",
      "DB00040\n",
      "DB00041\n",
      "DB00042\n",
      "DB00043\n",
      "DB00044\n",
      "Drug has no atc code\n",
      "DB00045\n",
      "DB00046\n",
      "DB00047\n",
      "DB00048\n",
      "DB00049\n",
      "DB00050\n",
      "DB00051\n",
      "DB00052\n",
      "DB00053\n",
      "DB00054\n",
      "DB00055\n",
      "DB00056\n",
      "DB00057\n",
      "DB00058\n",
      "DB00059\n",
      "DB00060\n",
      "DB00061\n",
      "Drug has no atc code\n",
      "DB00062\n",
      "DB00063\n",
      "DB00065\n",
      "DB00066\n",
      "Drug has no atc code\n",
      "DB00067\n",
      "DB00068\n",
      "DB00069\n",
      "Drug has no atc code\n",
      "DB00070\n",
      "DB00071\n",
      "DB00072\n",
      "DB00073\n",
      "DB00074\n",
      "DB00075\n",
      "DB00076\n",
      "DB00078\n",
      "DB00080\n",
      "DB00081\n",
      "DB00082\n",
      "DB00083\n",
      "DB00085\n",
      "DB00086\n",
      "DB00087\n",
      "DB00088\n",
      "DB00089\n",
      "DB00090\n",
      "DB00091\n",
      "DB00092\n",
      "Drug has no atc code\n",
      "DB00093\n",
      "DB00094\n",
      "DB00095\n",
      "DB00097\n",
      "DB00098\n",
      "DB00099\n",
      "Drug has no atc code\n",
      "DB00100\n",
      "DB00102\n",
      "DB00103\n",
      "DB00104\n",
      "DB00105\n",
      "DB00106\n",
      "DB00107\n",
      "DB00108\n",
      "DB00109\n",
      "DB00110\n",
      "DB00111\n",
      "DB00112\n",
      "DB00113\n",
      "DB00114\n",
      "DB00115\n",
      "Drug has no atc code\n",
      "DB00116\n",
      "Drug has no atc code\n",
      "DB00117\n",
      "DB00118\n",
      "Drug has no atc code\n",
      "DB00119\n",
      "Drug has no atc code\n",
      "DB00120\n",
      "DB00121\n",
      "Drug has no atc code\n",
      "DB00122\n",
      "DB00123\n",
      "DB00125\n",
      "DB00126\n",
      "Drug has no atc code\n",
      "DB00127\n",
      "Drug has no atc code\n",
      "DB00128\n",
      "DB00129\n",
      "DB00130\n",
      "Drug has no atc code\n",
      "DB00131\n",
      "Drug has no atc code\n",
      "DB00132\n",
      "Drug has no atc code\n",
      "DB00133\n",
      "DB00134\n",
      "Drug has no atc code\n",
      "DB00135\n",
      "DB00136\n",
      "Drug has no atc code\n",
      "DB00137\n",
      "Drug has no atc code\n",
      "DB00138\n",
      "Drug has no atc code\n",
      "DB00139\n",
      "DB00140\n",
      "Drug has no atc code\n",
      "DB00141\n",
      "DB00142\n",
      "DB00143\n",
      "Drug has no atc code\n",
      "DB00144\n",
      "DB00145\n",
      "DB00146\n",
      "Drug has no atc code\n",
      "DB00147\n",
      "Drug has no atc code\n",
      "DB00148\n",
      "Drug has no atc code\n",
      "DB00149\n",
      "DB00150\n",
      "Drug has no atc code\n",
      "DB00151\n",
      "DB00152\n",
      "DB00153\n",
      "Drug has no atc code\n",
      "DB00154\n",
      "Drug has no atc code\n",
      "DB00155\n",
      "Drug has no atc code\n",
      "DB00156\n",
      "Drug has no atc code\n",
      "DB00157\n",
      "DB00158\n",
      "Drug has no atc code\n",
      "DB00159\n",
      "Drug has no atc code\n",
      "DB00160\n",
      "Drug has no atc code\n",
      "DB00161\n",
      "DB00162\n",
      "Drug has no atc code\n",
      "DB00163\n",
      "DB00165\n",
      "DB00166\n",
      "Drug has no atc code\n",
      "DB00167\n",
      "Drug has no atc code\n",
      "DB00168\n",
      "DB00169\n",
      "DB00170\n",
      "Drug has no atc code\n",
      "DB00171\n",
      "Drug has no atc code\n",
      "DB00172\n",
      "Drug has no atc code\n",
      "DB00173\n",
      "Drug has no atc code\n",
      "DB00174\n",
      "DB00175\n",
      "DB00176\n",
      "DB00177\n",
      "DB00178\n",
      "DB00179\n",
      "DB00180\n",
      "DB00181\n",
      "DB00182\n",
      "DB00183\n",
      "DB00184\n",
      "DB00185\n",
      "DB00186\n",
      "DB00187\n",
      "DB00188\n",
      "DB00189\n",
      "Drug has no atc code\n",
      "DB00190\n",
      "DB00191\n",
      "Drug has no atc code\n",
      "DB00192\n",
      "DB00193\n",
      "DB00194\n",
      "DB00195\n",
      "DB00196\n",
      "DB00197\n",
      "DB00198\n",
      "DB00199\n",
      "DB00200\n",
      "DB00201\n",
      "DB00202\n",
      "DB00203\n",
      "DB00204\n",
      "DB00205\n",
      "DB00206\n",
      "DB00207\n",
      "DB00208\n",
      "DB00209\n",
      "DB00210\n",
      "DB00211\n",
      "DB00212\n",
      "DB00213\n",
      "DB00214\n",
      "DB00215\n",
      "DB00216\n",
      "DB00217\n",
      "DB00218\n",
      "DB00219\n",
      "DB00220\n",
      "Drug has no atc code\n",
      "DB00221\n",
      "DB00222\n",
      "DB00223\n",
      "DB00224\n",
      "DB00225\n",
      "Drug has no atc code\n",
      "DB00226\n",
      "DB00227\n",
      "DB00228\n",
      "DB00229\n",
      "DB00230\n",
      "DB00231\n",
      "DB00232\n",
      "DB00233\n",
      "DB00234\n",
      "DB00235\n",
      "DB00236\n",
      "DB00237\n",
      "DB00238\n",
      "DB00239\n",
      "DB00240\n",
      "DB00241\n",
      "DB00242\n",
      "DB00243\n",
      "DB00244\n",
      "DB00245\n",
      "DB00246\n",
      "DB00247\n",
      "DB00248\n",
      "DB00249\n",
      "DB00250\n",
      "DB00251\n",
      "DB00252\n",
      "DB00253\n",
      "DB00254\n",
      "DB00255\n",
      "DB00256\n",
      "DB00257\n",
      "DB00258\n",
      "DB00259\n",
      "DB00260\n",
      "DB00261\n",
      "DB00262\n",
      "DB00263\n",
      "DB00264\n",
      "Drug has no atc code\n",
      "DB00265\n",
      "DB00266\n",
      "DB00267\n",
      "DB00268\n",
      "DB00269\n",
      "DB00270\n",
      "DB00271\n",
      "DB00272\n",
      "DB00273\n",
      "DB00274\n",
      "DB00275\n",
      "DB00276\n",
      "DB00277\n",
      "DB00278\n",
      "DB00279\n",
      "DB00280\n",
      "DB00281\n",
      "DB00282\n",
      "DB00283\n",
      "DB00284\n",
      "DB00285\n",
      "DB00286\n",
      "DB00287\n",
      "DB00288\n",
      "DB00289\n",
      "DB00290\n",
      "DB00291\n",
      "DB00292\n",
      "DB00293\n",
      "DB00294\n",
      "DB00295\n",
      "DB00296\n",
      "DB00297\n",
      "DB00298\n",
      "DB00299\n",
      "DB00300\n",
      "DB00301\n",
      "DB00302\n",
      "DB00303\n",
      "DB00304\n",
      "DB00305\n",
      "DB00306\n",
      "DB00307\n",
      "DB00308\n",
      "DB00309\n",
      "DB00310\n",
      "Drug has no atc code\n",
      "DB00311\n",
      "DB00312\n",
      "DB00313\n",
      "DB00314\n",
      "DB00315\n",
      "DB00316\n",
      "DB00317\n",
      "DB00318\n",
      "DB00319\n",
      "DB00320\n",
      "DB00321\n",
      "DB00322\n",
      "DB00323\n",
      "DB00324\n",
      "DB00325\n",
      "DB00326\n",
      "DB00327\n",
      "DB00328\n",
      "DB00330\n",
      "DB00331\n",
      "DB00332\n",
      "DB00333\n",
      "DB00334\n",
      "DB00335\n",
      "DB00336\n",
      "DB00337\n",
      "DB00338\n",
      "DB00339\n",
      "DB00340\n",
      "DB00341\n",
      "DB00342\n",
      "DB00343\n",
      "DB00344\n",
      "DB00345\n",
      "DB00346\n",
      "DB00347\n",
      "DB00348\n",
      "DB00349\n",
      "DB00350\n",
      "DB00351\n",
      "DB00352\n",
      "DB00353\n",
      "DB00354\n",
      "DB00355\n",
      "DB00356\n",
      "DB00357\n",
      "DB00358\n",
      "DB00359\n",
      "DB00360\n",
      "DB00361\n",
      "DB00362\n",
      "DB00363\n",
      "DB00364\n",
      "DB00365\n",
      "DB00366\n",
      "DB00367\n",
      "DB00368\n",
      "DB00369\n",
      "DB00370\n",
      "DB00371\n",
      "DB00372\n",
      "DB00373\n",
      "DB00374\n",
      "DB00375\n",
      "DB00376\n",
      "DB00377\n",
      "DB00378\n",
      "DB00379\n",
      "DB00380\n",
      "DB00381\n",
      "DB00382\n",
      "DB00383\n",
      "DB00384\n",
      "DB00385\n",
      "DB00387\n",
      "DB00388\n",
      "DB00389\n",
      "DB00390\n",
      "DB00391\n",
      "DB00392\n",
      "DB00393\n",
      "DB00394\n",
      "DB00395\n",
      "DB00396\n",
      "DB00397\n",
      "DB00398\n",
      "DB00399\n",
      "DB00400\n",
      "DB00401\n",
      "DB00402\n",
      "DB00403\n",
      "DB00404\n",
      "DB00405\n",
      "DB00406\n",
      "Drug has no atc code\n",
      "DB00407\n",
      "DB00408\n",
      "DB00409\n",
      "DB00410\n",
      "DB00411\n",
      "DB00412\n",
      "DB00413\n",
      "DB00414\n",
      "DB00415\n",
      "Drug has no atc code\n",
      "DB00416\n",
      "DB00417\n",
      "DB00418\n",
      "DB00419\n",
      "DB00420\n",
      "DB00421\n",
      "DB00422\n",
      "DB00423\n",
      "DB00424\n",
      "DB00425\n",
      "DB00426\n",
      "DB00427\n",
      "DB00428\n",
      "DB00429\n",
      "DB00430\n",
      "DB00431\n",
      "DB00432\n",
      "DB00433\n",
      "DB00434\n",
      "DB00435\n",
      "DB00436\n",
      "DB00437\n",
      "DB00438\n",
      "DB00439\n",
      "DB00440\n",
      "DB00441\n",
      "DB00442\n",
      "DB00443\n",
      "DB00444\n",
      "DB00445\n",
      "DB00446\n",
      "DB00447\n",
      "DB00448\n",
      "DB00449\n",
      "DB00450\n",
      "DB00451\n",
      "DB00452\n",
      "DB00453\n",
      "DB00454\n",
      "DB00455\n",
      "DB00456\n",
      "DB00457\n",
      "DB00458\n",
      "DB00459\n",
      "DB00460\n",
      "DB00461\n",
      "Drug has no atc code\n",
      "DB00462\n",
      "DB00463\n",
      "DB00464\n",
      "DB00465\n",
      "Drug has no atc code\n",
      "DB00466\n",
      "DB00467\n",
      "DB00468\n",
      "DB00469\n",
      "DB00470\n",
      "DB00471\n",
      "DB00472\n",
      "Drug has no atc code\n",
      "DB00473\n",
      "DB00474\n",
      "DB00475\n",
      "DB00476\n",
      "DB00477\n",
      "DB00478\n",
      "DB00479\n",
      "DB00480\n",
      "DB00481\n",
      "DB00482\n",
      "Drug has no atc code\n",
      "DB00483\n",
      "DB00484\n",
      "DB00485\n",
      "DB00486\n",
      "DB00487\n",
      "DB00488\n",
      "DB00489\n",
      "DB00490\n",
      "DB00491\n",
      "DB00492\n",
      "DB00493\n",
      "DB00494\n",
      "DB00495\n",
      "DB00496\n",
      "DB00497\n",
      "DB00498\n",
      "DB00499\n",
      "DB00500\n",
      "DB00501\n",
      "DB00502\n",
      "DB00503\n",
      "Drug has no atc code\n",
      "DB00504\n",
      "DB00505\n",
      "DB00507\n",
      "DB00508\n",
      "DB00509\n",
      "DB00511\n",
      "DB00512\n",
      "DB00513\n",
      "DB00514\n",
      "DB00515\n",
      "Drug has no atc code\n",
      "DB00516\n",
      "Drug has no atc code\n",
      "DB00517\n",
      "DB00518\n",
      "DB00519\n",
      "DB00520\n",
      "DB00521\n",
      "DB00522\n",
      "DB00523\n",
      "DB00524\n",
      "DB00525\n",
      "DB00526\n",
      "DB00527\n",
      "DB00528\n",
      "DB00529\n",
      "DB00530\n",
      "DB00531\n",
      "DB00532\n",
      "DB00533\n",
      "Drug has no atc code\n",
      "DB00534\n",
      "DB00535\n",
      "Drug has no atc code\n",
      "DB00536\n",
      "DB00537\n",
      "DB00538\n",
      "DB00539\n",
      "DB00540\n",
      "DB00541\n",
      "DB00542\n",
      "DB00543\n",
      "DB00544\n",
      "DB00545\n",
      "DB00546\n",
      "DB00547\n",
      "DB00548\n",
      "DB00549\n",
      "DB00550\n",
      "DB00551\n",
      "DB00552\n",
      "DB00553\n",
      "DB00554\n",
      "DB00555\n",
      "Drug has no atc code\n",
      "DB00556\n",
      "DB00557\n",
      "DB00558\n",
      "DB00559\n",
      "DB00560\n",
      "DB00561\n",
      "DB00562\n",
      "DB00563\n",
      "DB00564\n",
      "DB00565\n",
      "Drug has no atc code\n",
      "DB00566\n",
      "DB00567\n",
      "DB00568\n",
      "DB00569\n",
      "DB00570\n",
      "DB00571\n",
      "DB00572\n",
      "DB00573\n",
      "DB00574\n",
      "DB00575\n",
      "DB00576\n",
      "DB00577\n",
      "DB00578\n",
      "DB00579\n",
      "DB00580\n",
      "DB00581\n",
      "DB00582\n",
      "DB00583\n",
      "DB00584\n",
      "DB00585\n",
      "DB00586\n",
      "Drug has no atc code\n",
      "DB00587\n",
      "Drug has no atc code\n",
      "DB00588\n",
      "DB00589\n",
      "DB00590\n",
      "DB00591\n",
      "DB00592\n",
      "DB00593\n",
      "DB00594\n",
      "DB00595\n",
      "DB00596\n",
      "DB00597\n",
      "DB00598\n",
      "DB00599\n",
      "DB00600\n",
      "DB00601\n",
      "DB00602\n",
      "DB00603\n",
      "DB00604\n",
      "DB00605\n",
      "DB00606\n",
      "DB00607\n",
      "DB00608\n",
      "DB00609\n",
      "DB00610\n",
      "DB00611\n",
      "DB00612\n",
      "DB00613\n",
      "DB00614\n",
      "DB00615\n",
      "Drug has no atc code\n",
      "DB00616\n",
      "DB00617\n",
      "DB00618\n",
      "DB00619\n",
      "DB00620\n",
      "DB00621\n",
      "DB00622\n",
      "DB00623\n",
      "DB00624\n",
      "DB00625\n",
      "DB00626\n",
      "DB00627\n",
      "DB00628\n",
      "Drug has no atc code\n",
      "DB00629\n",
      "DB00630\n",
      "DB00631\n",
      "DB00632\n",
      "DB00633\n",
      "DB00634\n",
      "DB00635\n",
      "DB00636\n",
      "DB00637\n",
      "DB00638\n",
      "DB00639\n",
      "DB00640\n",
      "DB00641\n",
      "DB00642\n",
      "DB00643\n",
      "DB00644\n",
      "DB00645\n",
      "DB00646\n",
      "DB00647\n",
      "DB00648\n",
      "DB00649\n",
      "DB00650\n",
      "DB00651\n",
      "DB00652\n",
      "DB00653\n",
      "DB00654\n",
      "DB00655\n",
      "DB00656\n",
      "DB00657\n",
      "DB00658\n",
      "DB00659\n",
      "Drug has no atc code\n",
      "DB00660\n",
      "DB00661\n",
      "DB00662\n",
      "DB00663\n",
      "DB00664\n",
      "DB00665\n",
      "DB00666\n",
      "DB00668\n",
      "DB00669\n",
      "DB00670\n",
      "DB00671\n",
      "DB00672\n",
      "DB00673\n",
      "DB00674\n",
      "DB00675\n",
      "DB00676\n",
      "Drug has no atc code\n",
      "DB00677\n",
      "DB00678\n",
      "DB00679\n",
      "DB00680\n",
      "DB00681\n",
      "DB00682\n",
      "DB00683\n",
      "DB00684\n",
      "DB00685\n",
      "DB00686\n",
      "DB00687\n",
      "Drug has no atc code\n",
      "DB00688\n",
      "Drug has no atc code\n",
      "DB00689\n",
      "DB00690\n",
      "DB00691\n",
      "DB00692\n",
      "DB00693\n",
      "DB00694\n",
      "DB00695\n",
      "DB00696\n",
      "DB00697\n",
      "DB00698\n",
      "DB00699\n",
      "DB00700\n",
      "DB00701\n",
      "Drug has no atc code\n",
      "DB00702\n",
      "DB00703\n",
      "DB00704\n",
      "DB00705\n",
      "DB00706\n",
      "DB00707\n",
      "DB00708\n",
      "DB00709\n",
      "DB00710\n",
      "DB00711\n",
      "DB00712\n",
      "DB00713\n",
      "DB00714\n",
      "DB00715\n",
      "DB00716\n",
      "DB00717\n",
      "DB00718\n",
      "DB00719\n",
      "DB00720\n",
      "DB00721\n",
      "DB00722\n",
      "DB00723\n",
      "DB00724\n",
      "DB00725\n",
      "DB00726\n",
      "DB00727\n",
      "DB00728\n",
      "DB00730\n",
      "DB00731\n",
      "Drug has no atc code\n",
      "DB00732\n",
      "DB00733\n",
      "DB00734\n",
      "DB00735\n",
      "DB00736\n",
      "DB00737\n",
      "DB00738\n",
      "DB00739\n",
      "DB00740\n",
      "DB00741\n",
      "DB00742\n",
      "DB00743\n",
      "Drug has no atc code\n",
      "DB00744\n",
      "DB00745\n",
      "DB00746\n",
      "DB00747\n",
      "DB00748\n",
      "DB00749\n",
      "DB00750\n",
      "DB00751\n",
      "DB00752\n",
      "DB00753\n",
      "DB00754\n",
      "DB00755\n",
      "DB00756\n",
      "DB00757\n",
      "DB00758\n",
      "DB00759\n",
      "DB00760\n",
      "DB00761\n",
      "DB00762\n",
      "DB00763\n",
      "DB00764\n",
      "DB00765\n",
      "Drug has no atc code\n",
      "DB00766\n",
      "Drug has no atc code\n",
      "DB00767\n",
      "DB00768\n",
      "Drug has no atc code\n",
      "DB00769\n",
      "DB00770\n",
      "DB00771\n",
      "DB00772\n",
      "DB00773\n",
      "DB00774\n",
      "DB00775\n",
      "DB00776\n",
      "DB00777\n",
      "DB00778\n",
      "DB00779\n",
      "DB00780\n",
      "DB00782\n",
      "DB00783\n",
      "DB00784\n",
      "Drug has no atc code\n",
      "DB00785\n",
      "Drug has no atc code\n",
      "DB00786\n",
      "DB00787\n",
      "DB00788\n",
      "DB00789\n",
      "DB00790\n",
      "DB00791\n",
      "DB00792\n",
      "DB00793\n",
      "DB00794\n",
      "DB00795\n",
      "Drug has no atc code\n",
      "DB00796\n",
      "DB00797\n",
      "DB00798\n",
      "DB00799\n",
      "DB00800\n",
      "DB00801\n",
      "DB00802\n",
      "DB00803\n",
      "DB00804\n",
      "DB00805\n",
      "DB00806\n",
      "DB00807\n",
      "DB00808\n",
      "DB00809\n",
      "DB00810\n",
      "DB00811\n",
      "DB00812\n",
      "DB00813\n",
      "DB00814\n",
      "Drug has no atc code\n",
      "DB00815\n",
      "DB00816\n",
      "DB00817\n",
      "DB00818\n",
      "DB00819\n",
      "DB00820\n",
      "Drug has no atc code\n",
      "DB00821\n",
      "DB00822\n",
      "Drug has no atc code\n",
      "DB00823\n",
      "Drug has no atc code\n",
      "DB00824\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB00825\n",
      "DB00826\n",
      "DB00827\n",
      "DB00828\n",
      "DB00829\n",
      "Drug has no atc code\n",
      "DB00830\n",
      "DB00831\n",
      "DB00832\n",
      "DB00833\n",
      "DB00834\n",
      "DB00835\n",
      "DB00836\n",
      "DB00837\n",
      "DB00838\n",
      "DB00839\n",
      "Drug has no atc code\n",
      "DB00840\n",
      "DB00841\n",
      "DB00842\n",
      "DB00843\n",
      "DB00844\n",
      "DB00845\n",
      "DB00846\n",
      "DB00847\n",
      "DB00848\n",
      "DB00849\n",
      "DB00850\n",
      "DB00851\n",
      "DB00852\n",
      "DB00853\n",
      "Drug has no atc code\n",
      "DB00854\n",
      "DB00855\n",
      "DB00856\n",
      "DB00857\n",
      "Drug has no atc code\n",
      "DB00858\n",
      "DB00859\n",
      "DB00860\n",
      "DB00861\n",
      "DB00862\n",
      "DB00863\n",
      "DB00864\n",
      "Drug has no atc code\n",
      "DB00865\n",
      "DB00866\n",
      "DB00867\n",
      "DB00868\n",
      "DB00869\n",
      "DB00870\n",
      "DB00871\n",
      "DB00872\n",
      "Drug has no atc code\n",
      "DB14596\n",
      "DB00874\n",
      "DB00875\n",
      "DB00876\n",
      "DB00877\n",
      "DB00878\n",
      "DB00879\n",
      "DB00880\n",
      "DB00881\n",
      "DB00882\n",
      "DB00883\n",
      "DB00884\n",
      "Drug has no atc code\n",
      "DB00885\n",
      "Drug has no atc code\n",
      "DB00886\n",
      "DB00887\n",
      "DB00888\n",
      "DB00889\n",
      "DB00890\n",
      "DB00891\n",
      "DB00892\n",
      "Drug has no atc code\n",
      "DB00893\n",
      "Drug has no atc code\n",
      "DB00894\n",
      "DB00895\n",
      "DB00896\n",
      "DB00897\n",
      "DB00898\n",
      "DB00899\n",
      "DB00900\n",
      "DB00901\n",
      "DB00902\n",
      "DB00903\n",
      "DB00904\n",
      "DB00905\n",
      "DB00906\n",
      "DB00907\n",
      "DB00908\n",
      "DB00909\n",
      "DB00910\n",
      "DB00911\n",
      "DB00912\n",
      "DB00913\n",
      "DB00914\n",
      "DB00915\n",
      "DB00916\n",
      "DB00917\n",
      "DB00918\n",
      "DB00919\n",
      "DB00920\n",
      "DB00921\n",
      "DB00922\n",
      "DB00923\n",
      "DB00924\n",
      "DB00925\n",
      "DB00926\n",
      "DB00927\n",
      "DB00928\n",
      "DB00929\n",
      "DB00930\n",
      "DB00931\n",
      "DB00932\n",
      "DB00933\n",
      "DB00934\n",
      "DB00935\n",
      "DB00936\n",
      "DB00937\n",
      "DB00938\n",
      "DB00939\n",
      "DB00940\n",
      "DB00941\n",
      "Drug has no atc code\n",
      "DB00942\n",
      "DB00943\n",
      "DB00944\n",
      "DB00945\n",
      "DB00946\n",
      "DB00947\n",
      "DB00948\n",
      "DB00949\n",
      "DB00950\n",
      "DB00951\n",
      "DB00952\n",
      "DB00953\n",
      "DB00954\n",
      "DB00955\n",
      "DB00956\n",
      "DB00957\n",
      "DB00958\n",
      "DB00959\n",
      "DB00960\n",
      "DB00961\n",
      "DB00962\n",
      "DB00963\n",
      "DB00964\n",
      "Drug has no atc code\n",
      "DB00965\n",
      "DB00966\n",
      "DB00967\n",
      "Drug has no atc code\n",
      "DB00968\n",
      "DB00969\n",
      "DB00970\n",
      "DB00971\n",
      "DB00972\n",
      "DB00973\n",
      "Drug has no atc code\n",
      "DB00974\n",
      "DB00975\n",
      "DB00976\n",
      "DB00977\n",
      "DB00978\n",
      "DB00979\n",
      "DB00980\n",
      "DB00981\n",
      "DB00982\n",
      "DB00983\n",
      "Drug has no atc code\n",
      "DB00984\n",
      "Drug has no atc code\n",
      "DB00985\n",
      "DB00986\n",
      "DB00987\n",
      "DB00988\n",
      "DB00989\n",
      "DB00990\n",
      "DB00991\n",
      "DB00992\n",
      "DB00993\n",
      "DB00994\n",
      "DB00995\n",
      "DB00996\n",
      "DB00997\n",
      "DB00998\n",
      "DB00999\n",
      "DB01000\n",
      "DB01001\n",
      "DB01002\n",
      "DB01003\n",
      "DB01004\n",
      "DB01005\n",
      "DB01006\n",
      "DB01007\n",
      "DB01008\n",
      "DB01009\n",
      "DB01010\n",
      "DB01011\n",
      "DB01012\n",
      "Drug has no atc code\n",
      "DB01013\n",
      "DB01014\n",
      "DB01015\n",
      "DB01016\n",
      "DB01017\n",
      "DB01018\n",
      "DB01019\n",
      "DB01020\n",
      "DB01021\n",
      "DB01022\n",
      "DB01023\n",
      "DB01024\n",
      "DB01025\n",
      "DB01026\n",
      "DB01028\n",
      "DB01029\n",
      "DB01030\n",
      "Drug has no atc code\n",
      "DB01031\n",
      "DB01032\n",
      "DB01033\n",
      "Drug has no atc code\n",
      "DB01034\n",
      "DB01035\n",
      "DB01036\n",
      "DB01037\n",
      "Drug has no atc code\n",
      "DB01038\n",
      "DB01039\n",
      "DB01041\n",
      "DB01042\n",
      "DB01043\n",
      "DB01044\n",
      "DB01045\n",
      "DB01046\n",
      "DB01047\n",
      "DB01048\n",
      "Drug has no atc code\n",
      "DB01049\n",
      "DB01050\n",
      "Drug has no atc code\n",
      "DB01051\n",
      "DB01053\n",
      "DB01054\n",
      "Drug has no atc code\n",
      "DB01055\n",
      "DB01056\n",
      "DB01057\n",
      "DB01058\n",
      "DB01059\n",
      "DB01060\n",
      "DB01061\n",
      "DB01062\n",
      "DB01063\n",
      "DB01064\n",
      "DB01065\n",
      "DB01066\n",
      "DB01067\n",
      "DB01068\n",
      "DB01069\n",
      "DB01070\n",
      "DB01071\n",
      "DB01072\n",
      "DB01073\n",
      "DB01074\n",
      "DB01075\n",
      "DB01076\n",
      "DB01077\n",
      "DB01078\n",
      "DB01079\n",
      "DB01080\n",
      "DB01081\n",
      "DB01082\n",
      "DB01083\n",
      "DB01084\n",
      "DB01085\n",
      "DB01086\n",
      "DB01087\n",
      "DB01088\n",
      "DB01089\n",
      "Drug has no atc code\n",
      "DB01090\n",
      "DB01091\n",
      "DB01092\n",
      "DB01093\n",
      "Drug has no atc code\n",
      "DB01094\n",
      "DB01095\n",
      "DB01096\n",
      "DB01097\n",
      "DB01098\n",
      "DB01099\n",
      "DB01100\n",
      "DB01101\n",
      "DB01102\n",
      "DB01103\n",
      "DB01104\n",
      "DB01105\n",
      "DB01106\n",
      "DB01107\n",
      "DB01108\n",
      "DB01109\n",
      "DB01110\n",
      "Drug has no atc code\n",
      "DB01111\n",
      "DB01112\n",
      "DB01113\n",
      "DB01114\n",
      "DB01115\n",
      "DB01116\n",
      "DB01117\n",
      "DB01118\n",
      "DB01119\n",
      "DB01120\n",
      "DB01121\n",
      "DB01122\n",
      "Drug has no atc code\n",
      "DB01123\n",
      "DB01124\n",
      "Drug has no atc code\n",
      "DB01125\n",
      "DB01126\n",
      "DB01127\n",
      "DB01128\n",
      "DB01129\n",
      "DB01130\n",
      "DB01131\n",
      "DB01132\n",
      "DB01133\n",
      "Drug has no atc code\n",
      "DB01134\n",
      "DB01135\n",
      "DB01136\n",
      "DB01137\n",
      "DB01138\n",
      "DB01139\n",
      "DB01140\n",
      "DB01141\n",
      "DB01142\n",
      "DB01143\n",
      "DB01144\n",
      "DB01145\n",
      "DB01146\n",
      "DB01147\n",
      "DB01148\n",
      "DB01149\n",
      "DB01150\n",
      "DB01151\n",
      "DB01152\n",
      "DB01153\n",
      "DB01154\n",
      "DB01155\n",
      "DB01156\n",
      "DB01157\n",
      "DB01158\n",
      "DB01159\n",
      "Drug has no atc code\n",
      "DB01160\n",
      "DB01161\n",
      "DB01162\n",
      "DB01163\n",
      "DB01164\n",
      "DB01165\n",
      "DB01166\n",
      "DB01167\n",
      "DB01168\n",
      "DB01169\n",
      "DB01170\n",
      "DB01171\n",
      "DB01172\n",
      "DB01173\n",
      "DB01174\n",
      "DB01175\n",
      "DB01176\n",
      "DB01177\n",
      "DB01178\n",
      "DB01179\n",
      "DB01180\n",
      "DB01181\n",
      "DB01182\n",
      "DB01183\n",
      "DB01184\n",
      "DB01185\n",
      "DB01186\n",
      "DB01187\n",
      "DB01188\n",
      "DB01189\n",
      "DB01190\n",
      "DB01191\n",
      "Drug has no atc code\n",
      "DB01192\n",
      "DB01193\n",
      "DB01194\n",
      "DB01195\n",
      "DB01196\n",
      "DB01197\n",
      "DB01198\n",
      "DB01199\n",
      "DB01200\n",
      "DB01201\n",
      "DB01202\n",
      "DB01203\n",
      "DB01204\n",
      "DB01205\n",
      "DB01206\n",
      "Drug has no atc code\n",
      "DB01207\n",
      "DB01208\n",
      "DB01209\n",
      "DB01210\n",
      "DB01211\n",
      "DB01212\n",
      "DB01213\n",
      "DB01214\n",
      "DB01215\n",
      "DB01216\n",
      "DB01217\n",
      "DB01218\n",
      "DB01219\n",
      "DB01220\n",
      "DB01221\n",
      "DB01222\n",
      "DB01223\n",
      "DB01224\n",
      "DB01225\n",
      "DB01226\n",
      "DB01227\n",
      "DB01228\n",
      "DB01229\n",
      "DB01230\n",
      "Drug has no atc code\n",
      "DB01231\n",
      "DB01232\n",
      "DB01233\n",
      "DB01234\n",
      "DB01235\n",
      "DB01236\n",
      "DB01237\n",
      "DB01238\n",
      "DB01239\n",
      "DB01240\n",
      "DB01241\n",
      "DB01242\n",
      "Drug has no atc code\n",
      "DB01243\n",
      "DB01244\n",
      "Drug has no atc code\n",
      "DB01245\n",
      "DB01246\n",
      "DB01247\n",
      "DB01248\n",
      "DB01249\n",
      "DB01250\n",
      "DB01251\n",
      "DB01252\n",
      "DB01253\n",
      "DB01254\n",
      "DB01255\n",
      "DB01256\n",
      "DB01257\n",
      "DB01259\n",
      "DB01260\n",
      "DB01261\n",
      "DB01262\n",
      "DB01263\n",
      "DB01264\n",
      "DB01265\n",
      "DB01266\n",
      "DB01267\n",
      "DB01268\n",
      "DB01269\n",
      "DB01270\n",
      "DB01271\n",
      "DB01272\n",
      "DB01273\n",
      "Drug has no atc code\n",
      "DB01274\n",
      "DB01275\n",
      "DB01276\n",
      "DB01277\n",
      "DB01278\n",
      "DB01279\n",
      "DB01280\n",
      "DB01281\n",
      "DB01282\n",
      "DB01283\n",
      "DB01284\n",
      "DB01285\n",
      "DB01288\n",
      "DB01289\n",
      "DB01291\n",
      "Drug has no atc code\n",
      "DB01294\n",
      "DB01295\n",
      "DB01296\n",
      "DB01297\n",
      "DB01298\n",
      "DB01299\n",
      "DB01301\n",
      "DB01303\n",
      "DB01306\n",
      "DB01307\n",
      "DB01309\n",
      "DB01319\n",
      "DB01320\n",
      "DB01321\n",
      "Drug has no atc code\n",
      "DB01322\n",
      "DB01323\n",
      "DB01324\n",
      "DB01325\n",
      "DB01326\n",
      "DB01327\n",
      "DB01328\n",
      "DB01329\n",
      "DB01330\n",
      "DB01331\n",
      "DB01332\n",
      "DB01333\n",
      "Drug has no atc code\n",
      "DB01336\n",
      "DB01337\n",
      "DB01338\n",
      "DB01339\n",
      "DB01340\n",
      "Drug has no atc code\n",
      "DB01341\n",
      "Drug has no atc code\n",
      "DB01342\n",
      "DB01344\n",
      "Drug has no atc code\n",
      "DB01345\n",
      "Drug has no atc code\n",
      "DB01346\n",
      "Drug has no atc code\n",
      "DB01347\n",
      "DB01348\n",
      "DB01349\n",
      "DB01351\n",
      "DB01352\n",
      "DB01353\n",
      "DB01354\n",
      "DB01355\n",
      "Drug has no atc code\n",
      "DB01356\n",
      "Drug has no atc code\n",
      "DB01357\n",
      "DB01359\n",
      "DB01362\n",
      "Drug has no atc code\n",
      "DB01363\n",
      "DB01364\n",
      "DB01365\n",
      "DB01366\n",
      "DB01367\n",
      "Drug has no atc code\n",
      "DB01369\n",
      "Drug has no atc code\n",
      "DB01370\n",
      "DB01373\n",
      "Drug has no atc code\n",
      "DB01375\n",
      "DB01377\n",
      "Drug has no atc code\n",
      "DB01378\n",
      "Drug has no atc code\n",
      "DB01380\n",
      "DB01381\n",
      "DB01382\n",
      "DB01384\n",
      "DB01388\n",
      "DB01390\n",
      "DB01392\n",
      "DB01393\n",
      "DB01394\n",
      "DB01395\n",
      "DB01396\n",
      "Drug has no atc code\n",
      "DB01397\n",
      "DB01399\n",
      "DB01400\n",
      "Drug has no atc code\n",
      "DB01401\n",
      "DB01403\n",
      "Drug has no atc code\n",
      "DB01404\n",
      "DB01405\n",
      "DB01406\n",
      "DB01407\n",
      "DB01408\n",
      "DB01409\n",
      "DB01410\n",
      "DB01411\n",
      "DB01412\n",
      "DB01413\n",
      "DB01414\n",
      "DB01415\n",
      "DB01416\n",
      "DB01418\n",
      "Drug has no atc code\n",
      "DB01419\n",
      "Drug has no atc code\n",
      "DB01420\n",
      "DB01421\n",
      "DB01422\n",
      "DB01423\n",
      "DB01424\n",
      "DB01425\n",
      "DB01426\n",
      "DB01427\n",
      "Drug has no atc code\n",
      "DB01428\n",
      "DB01429\n",
      "DB01430\n",
      "DB01431\n",
      "DB01432\n",
      "Drug has no atc code\n",
      "DB01433\n",
      "Drug has no atc code\n",
      "DB01434\n",
      "DB01435\n",
      "DB01436\n",
      "DB01437\n",
      "DB01438\n",
      "Drug has no atc code\n",
      "DB01439\n",
      "Drug has no atc code\n",
      "DB01440\n",
      "Drug has no atc code\n",
      "DB01441\n",
      "Drug has no atc code\n",
      "DB01442\n",
      "Drug has no atc code\n",
      "DB01443\n",
      "Drug has no atc code\n",
      "DB01444\n",
      "Drug has no atc code\n",
      "DB01445\n",
      "Drug has no atc code\n",
      "DB01446\n",
      "Drug has no atc code\n",
      "DB01447\n",
      "Drug has no atc code\n",
      "DB01448\n",
      "Drug has no atc code\n",
      "DB01450\n",
      "Drug has no atc code\n",
      "DB01451\n",
      "DB01452\n",
      "Drug has no atc code\n",
      "DB01453\n",
      "Drug has no atc code\n",
      "DB01454\n",
      "Drug has no atc code\n",
      "DB01455\n",
      "Drug has no atc code\n",
      "DB01456\n",
      "Drug has no atc code\n",
      "DB01458\n",
      "DB01459\n",
      "Drug has no atc code\n",
      "DB01460\n",
      "Drug has no atc code\n",
      "DB01461\n",
      "Drug has no atc code\n",
      "DB01462\n",
      "DB01463\n",
      "Drug has no atc code\n",
      "DB01464\n",
      "Drug has no atc code\n",
      "DB01465\n",
      "DB01466\n",
      "Drug has no atc code\n",
      "DB01467\n",
      "Drug has no atc code\n",
      "DB01468\n",
      "Drug has no atc code\n",
      "DB01469\n",
      "Drug has no atc code\n",
      "DB01470\n",
      "Drug has no atc code\n",
      "DB01471\n",
      "Drug has no atc code\n",
      "DB01472\n",
      "Drug has no atc code\n",
      "DB01473\n",
      "Drug has no atc code\n",
      "DB01474\n",
      "Drug has no atc code\n",
      "DB01475\n",
      "Drug has no atc code\n",
      "DB01476\n",
      "Drug has no atc code\n",
      "DB01477\n",
      "Drug has no atc code\n",
      "DB01478\n",
      "Drug has no atc code\n",
      "DB01479\n",
      "Drug has no atc code\n",
      "DB01480\n",
      "Drug has no atc code\n",
      "DB01481\n",
      "DB01482\n",
      "DB01483\n",
      "Drug has no atc code\n",
      "DB01484\n",
      "Drug has no atc code\n",
      "DB01485\n",
      "DB01486\n",
      "Drug has no atc code\n",
      "DB01487\n",
      "Drug has no atc code\n",
      "DB01488\n",
      "DB01489\n",
      "Drug has no atc code\n",
      "DB01490\n",
      "Drug has no atc code\n",
      "DB01491\n",
      "DB01493\n",
      "Drug has no atc code\n",
      "DB01494\n",
      "DB01495\n",
      "Drug has no atc code\n",
      "DB01496\n",
      "Drug has no atc code\n",
      "DB01497\n",
      "Drug has no atc code\n",
      "DB01498\n",
      "Drug has no atc code\n",
      "DB01499\n",
      "Drug has no atc code\n",
      "DB01500\n",
      "DB01501\n",
      "Drug has no atc code\n",
      "DB01502\n",
      "Drug has no atc code\n",
      "DB01503\n",
      "Drug has no atc code\n",
      "DB01505\n",
      "Drug has no atc code\n",
      "DB01506\n",
      "Drug has no atc code\n",
      "DB01509\n",
      "Drug has no atc code\n",
      "DB01510\n",
      "Drug has no atc code\n",
      "DB01511\n",
      "Drug has no atc code\n",
      "DB01512\n",
      "Drug has no atc code\n",
      "DB01513\n",
      "Drug has no atc code\n",
      "DB01514\n",
      "Drug has no atc code\n",
      "DB01515\n",
      "Drug has no atc code\n",
      "DB01516\n",
      "Drug has no atc code\n",
      "DB01518\n",
      "Drug has no atc code\n",
      "DB01520\n",
      "Drug has no atc code\n",
      "DB01521\n",
      "Drug has no atc code\n",
      "DB01522\n",
      "Drug has no atc code\n",
      "DB01523\n",
      "Drug has no atc code\n",
      "DB01524\n",
      "Drug has no atc code\n",
      "DB01525\n",
      "Drug has no atc code\n",
      "DB01526\n",
      "Drug has no atc code\n",
      "DB01527\n",
      "Drug has no atc code\n",
      "DB01528\n",
      "DB01529\n",
      "Drug has no atc code\n",
      "DB01530\n",
      "Drug has no atc code\n",
      "DB01531\n",
      "Drug has no atc code\n",
      "DB01532\n",
      "Drug has no atc code\n",
      "DB01533\n",
      "DB01534\n",
      "Drug has no atc code\n",
      "DB01535\n",
      "Drug has no atc code\n",
      "DB01536\n",
      "Drug has no atc code\n",
      "DB01537\n",
      "DB01538\n",
      "Drug has no atc code\n",
      "DB01539\n",
      "Drug has no atc code\n",
      "DB01540\n",
      "Drug has no atc code\n",
      "DB01541\n",
      "Drug has no atc code\n",
      "DB01542\n",
      "Drug has no atc code\n",
      "DB01543\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB01544\n",
      "DB01545\n",
      "Drug has no atc code\n",
      "DB01546\n",
      "Drug has no atc code\n",
      "DB01547\n",
      "Drug has no atc code\n",
      "DB01548\n",
      "Drug has no atc code\n",
      "DB01549\n",
      "Drug has no atc code\n",
      "DB01550\n",
      "DB01551\n",
      "Drug has no atc code\n",
      "DB01552\n",
      "DB01553\n",
      "Drug has no atc code\n",
      "DB01554\n",
      "Drug has no atc code\n",
      "DB01555\n",
      "Drug has no atc code\n",
      "DB01556\n",
      "Drug has no atc code\n",
      "DB01557\n",
      "DB01558\n",
      "DB01559\n",
      "Drug has no atc code\n",
      "DB01560\n",
      "Drug has no atc code\n",
      "DB01561\n",
      "Drug has no atc code\n",
      "DB01562\n",
      "DB01563\n",
      "Drug has no atc code\n",
      "DB01564\n",
      "Drug has no atc code\n",
      "DB01565\n",
      "Drug has no atc code\n",
      "DB01566\n",
      "DB01567\n",
      "Drug has no atc code\n",
      "DB01568\n",
      "Drug has no atc code\n",
      "DB01569\n",
      "Drug has no atc code\n",
      "DB01570\n",
      "Drug has no atc code\n",
      "DB01571\n",
      "Drug has no atc code\n",
      "DB01572\n",
      "Drug has no atc code\n",
      "DB01573\n",
      "DB01574\n",
      "DB01575\n",
      "DB01576\n",
      "DB01577\n",
      "DB01578\n",
      "Drug has no atc code\n",
      "DB01579\n",
      "DB01580\n",
      "DB01581\n",
      "DB01582\n",
      "Drug has no atc code\n",
      "DB01583\n",
      "Drug has no atc code\n",
      "DB01584\n",
      "DB01586\n",
      "DB01587\n",
      "DB01588\n",
      "DB01589\n",
      "DB01590\n",
      "DB01591\n",
      "DB01592\n",
      "DB01593\n",
      "DB01594\n",
      "DB01595\n",
      "DB01597\n",
      "DB01598\n",
      "DB01599\n",
      "DB01600\n",
      "DB01601\n",
      "DB01602\n",
      "DB01603\n",
      "DB01604\n",
      "DB01605\n",
      "DB01606\n",
      "DB01607\n",
      "DB01608\n",
      "DB01609\n",
      "DB01610\n",
      "DB01611\n",
      "DB01612\n",
      "DB01613\n",
      "DB01614\n",
      "Drug has no atc code\n",
      "DB01615\n",
      "DB01616\n",
      "DB01618\n",
      "DB01619\n",
      "DB01620\n",
      "DB01621\n",
      "DB01622\n",
      "DB01623\n",
      "DB01624\n",
      "DB01625\n",
      "DB01626\n",
      "DB01627\n",
      "DB01628\n",
      "Drug has no atc code\n",
      "DB01629\n",
      "Drug has no atc code\n",
      "DB01630\n",
      "Drug has no atc code\n",
      "DB01631\n",
      "Drug has no atc code\n",
      "DB01632\n",
      "Drug has no atc code\n",
      "DB01633\n",
      "Drug has no atc code\n",
      "DB01634\n",
      "Drug has no atc code\n",
      "DB01635\n",
      "Drug has no atc code\n",
      "DB01637\n",
      "DB01638\n",
      "Drug has no atc code\n",
      "DB01639\n",
      "Drug has no atc code\n",
      "DB01640\n",
      "Drug has no atc code\n",
      "DB01641\n",
      "Drug has no atc code\n",
      "DB01642\n",
      "Drug has no atc code\n",
      "DB01643\n",
      "Drug has no atc code\n",
      "DB01644\n",
      "Drug has no atc code\n",
      "DB01645\n",
      "Drug has no atc code\n",
      "DB01646\n",
      "Drug has no atc code\n",
      "DB01647\n",
      "Drug has no atc code\n",
      "DB01648\n",
      "Drug has no atc code\n",
      "DB01649\n",
      "Drug has no atc code\n",
      "DB01650\n",
      "Drug has no atc code\n",
      "DB01651\n",
      "Drug has no atc code\n",
      "DB01652\n",
      "Drug has no atc code\n",
      "DB01655\n",
      "DB01656\n",
      "Drug has no atc code\n",
      "DB01657\n",
      "Drug has no atc code\n",
      "DB01658\n",
      "Drug has no atc code\n",
      "DB01659\n",
      "Drug has no atc code\n",
      "DB01661\n",
      "Drug has no atc code\n",
      "DB01662\n",
      "Drug has no atc code\n",
      "DB01663\n",
      "Drug has no atc code\n",
      "DB01664\n",
      "Drug has no atc code\n",
      "DB01665\n",
      "Drug has no atc code\n",
      "DB01666\n",
      "Drug has no atc code\n",
      "DB01667\n",
      "Drug has no atc code\n",
      "DB01668\n",
      "Drug has no atc code\n",
      "DB01669\n",
      "Drug has no atc code\n",
      "DB01670\n",
      "Drug has no atc code\n",
      "DB01671\n",
      "Drug has no atc code\n",
      "DB01672\n",
      "Drug has no atc code\n",
      "DB01673\n",
      "Drug has no atc code\n",
      "DB01674\n",
      "Drug has no atc code\n",
      "DB01675\n",
      "Drug has no atc code\n",
      "DB01676\n",
      "DB01677\n",
      "Drug has no atc code\n",
      "DB01678\n",
      "Drug has no atc code\n",
      "DB01679\n",
      "Drug has no atc code\n",
      "DB01681\n",
      "Drug has no atc code\n",
      "DB01682\n",
      "Drug has no atc code\n",
      "DB01683\n",
      "Drug has no atc code\n",
      "DB01684\n",
      "Drug has no atc code\n",
      "DB01685\n",
      "Drug has no atc code\n",
      "DB01686\n",
      "Drug has no atc code\n",
      "DB01687\n",
      "Drug has no atc code\n",
      "DB01688\n",
      "Drug has no atc code\n",
      "DB01689\n",
      "Drug has no atc code\n",
      "DB01690\n",
      "Drug has no atc code\n",
      "DB01691\n",
      "Drug has no atc code\n",
      "DB01692\n",
      "Drug has no atc code\n",
      "DB01694\n",
      "Drug has no atc code\n",
      "DB01695\n",
      "Drug has no atc code\n",
      "DB01697\n",
      "DB01698\n",
      "Drug has no atc code\n",
      "DB01699\n",
      "Drug has no atc code\n",
      "DB01700\n",
      "Drug has no atc code\n",
      "DB01701\n",
      "Drug has no atc code\n",
      "DB01702\n",
      "Drug has no atc code\n",
      "DB01703\n",
      "Drug has no atc code\n",
      "DB01704\n",
      "Drug has no atc code\n",
      "DB01705\n",
      "Drug has no atc code\n",
      "DB01706\n",
      "Drug has no atc code\n",
      "DB01707\n",
      "DB01708\n",
      "Drug has no atc code\n",
      "DB01709\n",
      "Drug has no atc code\n",
      "DB01710\n",
      "Drug has no atc code\n",
      "DB01711\n",
      "Drug has no atc code\n",
      "DB01712\n",
      "Drug has no atc code\n",
      "DB01713\n",
      "Drug has no atc code\n",
      "DB01714\n",
      "Drug has no atc code\n",
      "DB01715\n",
      "Drug has no atc code\n",
      "DB01716\n",
      "Drug has no atc code\n",
      "DB01717\n",
      "DB01718\n",
      "Drug has no atc code\n",
      "DB01719\n",
      "Drug has no atc code\n",
      "DB01720\n",
      "Drug has no atc code\n",
      "DB01721\n",
      "Drug has no atc code\n",
      "DB01723\n",
      "Drug has no atc code\n",
      "DB01724\n",
      "Drug has no atc code\n",
      "DB01725\n",
      "Drug has no atc code\n",
      "DB01726\n",
      "Drug has no atc code\n",
      "DB01727\n",
      "Drug has no atc code\n",
      "DB01728\n",
      "Drug has no atc code\n",
      "DB01729\n",
      "Drug has no atc code\n",
      "DB01731\n",
      "Drug has no atc code\n",
      "DB01732\n",
      "Drug has no atc code\n",
      "DB01733\n",
      "Drug has no atc code\n",
      "DB01734\n",
      "Drug has no atc code\n",
      "DB01735\n",
      "Drug has no atc code\n",
      "DB01736\n",
      "Drug has no atc code\n",
      "DB01737\n",
      "Drug has no atc code\n",
      "DB01738\n",
      "Drug has no atc code\n",
      "DB01739\n",
      "Drug has no atc code\n",
      "DB01740\n",
      "Drug has no atc code\n",
      "DB01741\n",
      "Drug has no atc code\n",
      "DB01742\n",
      "DB01744\n",
      "Drug has no atc code\n",
      "DB01745\n",
      "Drug has no atc code\n",
      "DB01746\n",
      "Drug has no atc code\n",
      "DB01747\n",
      "Drug has no atc code\n",
      "DB01748\n",
      "Drug has no atc code\n",
      "DB01749\n",
      "Drug has no atc code\n",
      "DB01750\n",
      "Drug has no atc code\n",
      "DB01751\n",
      "Drug has no atc code\n",
      "DB01752\n",
      "Drug has no atc code\n",
      "DB01753\n",
      "Drug has no atc code\n",
      "DB01754\n",
      "Drug has no atc code\n",
      "DB01755\n",
      "Drug has no atc code\n",
      "DB01756\n",
      "Drug has no atc code\n",
      "DB01758\n",
      "Drug has no atc code\n",
      "DB01759\n",
      "Drug has no atc code\n",
      "DB01760\n",
      "Drug has no atc code\n",
      "DB01761\n",
      "Drug has no atc code\n",
      "DB01762\n",
      "Drug has no atc code\n",
      "DB01763\n",
      "Drug has no atc code\n",
      "DB01764\n",
      "Drug has no atc code\n",
      "DB01765\n",
      "Drug has no atc code\n",
      "DB01766\n",
      "Drug has no atc code\n",
      "DB01767\n",
      "Drug has no atc code\n",
      "DB01768\n",
      "Drug has no atc code\n",
      "DB01771\n",
      "Drug has no atc code\n",
      "DB01772\n",
      "Drug has no atc code\n",
      "DB01773\n",
      "Drug has no atc code\n",
      "DB01774\n",
      "Drug has no atc code\n",
      "DB01775\n",
      "Drug has no atc code\n",
      "DB01776\n",
      "Drug has no atc code\n",
      "DB01777\n",
      "Drug has no atc code\n",
      "DB01778\n",
      "Drug has no atc code\n",
      "DB01779\n",
      "Drug has no atc code\n",
      "DB01780\n",
      "Drug has no atc code\n",
      "DB01782\n",
      "DB01783\n",
      "Drug has no atc code\n",
      "DB01784\n",
      "Drug has no atc code\n",
      "DB01785\n",
      "Drug has no atc code\n",
      "DB01786\n",
      "Drug has no atc code\n",
      "DB01788\n",
      "Drug has no atc code\n",
      "DB01789\n",
      "Drug has no atc code\n",
      "DB01790\n",
      "Drug has no atc code\n",
      "DB01791\n",
      "Drug has no atc code\n",
      "DB01792\n",
      "Drug has no atc code\n",
      "DB01793\n",
      "Drug has no atc code\n",
      "DB01794\n",
      "Drug has no atc code\n",
      "DB01795\n",
      "Drug has no atc code\n",
      "DB01796\n",
      "Drug has no atc code\n",
      "DB01797\n",
      "Drug has no atc code\n",
      "DB01798\n",
      "Drug has no atc code\n",
      "DB01799\n",
      "Drug has no atc code\n",
      "DB01800\n",
      "Drug has no atc code\n",
      "DB01802\n",
      "Drug has no atc code\n",
      "DB01803\n",
      "Drug has no atc code\n",
      "DB01804\n",
      "Drug has no atc code\n",
      "DB01805\n",
      "Drug has no atc code\n",
      "DB01806\n",
      "Drug has no atc code\n",
      "DB01807\n",
      "Drug has no atc code\n",
      "DB01808\n",
      "Drug has no atc code\n",
      "DB01809\n",
      "Drug has no atc code\n",
      "DB01810\n",
      "Drug has no atc code\n",
      "DB01811\n",
      "Drug has no atc code\n",
      "DB01812\n",
      "Drug has no atc code\n",
      "DB01813\n",
      "Drug has no atc code\n",
      "DB01814\n",
      "Drug has no atc code\n",
      "DB01815\n",
      "Drug has no atc code\n",
      "DB01816\n",
      "Drug has no atc code\n",
      "DB01817\n",
      "Drug has no atc code\n",
      "DB01818\n",
      "Drug has no atc code\n",
      "DB01819\n",
      "Drug has no atc code\n",
      "DB01820\n",
      "Drug has no atc code\n",
      "DB01821\n",
      "Drug has no atc code\n",
      "DB01822\n",
      "Drug has no atc code\n",
      "DB01823\n",
      "Drug has no atc code\n",
      "DB01824\n",
      "Drug has no atc code\n",
      "DB01825\n",
      "Drug has no atc code\n",
      "DB01826\n",
      "Drug has no atc code\n",
      "DB01827\n",
      "Drug has no atc code\n",
      "DB01828\n",
      "Drug has no atc code\n",
      "DB01829\n",
      "Drug has no atc code\n",
      "DB01830\n",
      "Drug has no atc code\n",
      "DB01831\n",
      "Drug has no atc code\n",
      "DB01832\n",
      "Drug has no atc code\n",
      "DB01833\n",
      "Drug has no atc code\n",
      "DB01834\n",
      "Drug has no atc code\n",
      "DB01835\n",
      "Drug has no atc code\n",
      "DB01836\n",
      "Drug has no atc code\n",
      "DB01837\n",
      "Drug has no atc code\n",
      "DB01838\n",
      "Drug has no atc code\n",
      "DB01839\n",
      "Drug has no atc code\n",
      "DB01840\n",
      "Drug has no atc code\n",
      "DB01841\n",
      "Drug has no atc code\n",
      "DB01842\n",
      "Drug has no atc code\n",
      "DB01843\n",
      "Drug has no atc code\n",
      "DB01844\n",
      "Drug has no atc code\n",
      "DB01846\n",
      "Drug has no atc code\n",
      "DB01847\n",
      "Drug has no atc code\n",
      "DB01849\n",
      "Drug has no atc code\n",
      "DB01850\n",
      "Drug has no atc code\n",
      "DB01851\n",
      "Drug has no atc code\n",
      "DB01852\n",
      "Drug has no atc code\n",
      "DB01853\n",
      "Drug has no atc code\n",
      "DB01854\n",
      "Drug has no atc code\n",
      "DB01855\n",
      "Drug has no atc code\n",
      "DB01856\n",
      "Drug has no atc code\n",
      "DB01857\n",
      "Drug has no atc code\n",
      "DB01858\n",
      "Drug has no atc code\n",
      "DB01859\n",
      "Drug has no atc code\n",
      "DB01860\n",
      "Drug has no atc code\n",
      "DB01861\n",
      "Drug has no atc code\n",
      "DB01862\n",
      "Drug has no atc code\n",
      "DB01863\n",
      "Drug has no atc code\n",
      "DB01864\n",
      "Drug has no atc code\n",
      "DB01865\n",
      "Drug has no atc code\n",
      "DB01866\n",
      "Drug has no atc code\n",
      "DB01868\n",
      "Drug has no atc code\n",
      "DB01870\n",
      "Drug has no atc code\n",
      "DB01871\n",
      "Drug has no atc code\n",
      "DB01872\n",
      "Drug has no atc code\n",
      "DB01873\n",
      "Drug has no atc code\n",
      "DB01874\n",
      "Drug has no atc code\n",
      "DB01875\n",
      "Drug has no atc code\n",
      "DB01876\n",
      "Drug has no atc code\n",
      "DB01877\n",
      "Drug has no atc code\n",
      "DB01878\n",
      "Drug has no atc code\n",
      "DB01879\n",
      "Drug has no atc code\n",
      "DB01880\n",
      "Drug has no atc code\n",
      "DB01881\n",
      "Drug has no atc code\n",
      "DB01882\n",
      "Drug has no atc code\n",
      "DB01883\n",
      "Drug has no atc code\n",
      "DB01884\n",
      "Drug has no atc code\n",
      "DB01885\n",
      "Drug has no atc code\n",
      "DB01887\n",
      "Drug has no atc code\n",
      "DB01888\n",
      "Drug has no atc code\n",
      "DB01889\n",
      "Drug has no atc code\n",
      "DB01890\n",
      "Drug has no atc code\n",
      "DB01891\n",
      "Drug has no atc code\n",
      "DB01892\n",
      "Drug has no atc code\n",
      "DB01893\n",
      "Drug has no atc code\n",
      "DB01895\n",
      "Drug has no atc code\n",
      "DB01896\n",
      "Drug has no atc code\n",
      "DB01897\n",
      "Drug has no atc code\n",
      "DB01898\n",
      "Drug has no atc code\n",
      "DB01899\n",
      "Drug has no atc code\n",
      "DB01901\n",
      "Drug has no atc code\n",
      "DB01902\n",
      "Drug has no atc code\n",
      "DB01903\n",
      "Drug has no atc code\n",
      "DB01905\n",
      "Drug has no atc code\n",
      "DB01906\n",
      "Drug has no atc code\n",
      "DB01908\n",
      "Drug has no atc code\n",
      "DB01909\n",
      "Drug has no atc code\n",
      "DB01910\n",
      "Drug has no atc code\n",
      "DB01911\n",
      "Drug has no atc code\n",
      "DB01912\n",
      "Drug has no atc code\n",
      "DB01914\n",
      "Drug has no atc code\n",
      "DB01915\n",
      "Drug has no atc code\n",
      "DB01917\n",
      "Drug has no atc code\n",
      "DB01918\n",
      "Drug has no atc code\n",
      "DB01919\n",
      "Drug has no atc code\n",
      "DB01920\n",
      "Drug has no atc code\n",
      "DB01921\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB01922\n",
      "Drug has no atc code\n",
      "DB01923\n",
      "Drug has no atc code\n",
      "DB01924\n",
      "Drug has no atc code\n",
      "DB01925\n",
      "Drug has no atc code\n",
      "DB01926\n",
      "Drug has no atc code\n",
      "DB01927\n",
      "Drug has no atc code\n",
      "DB01929\n",
      "Drug has no atc code\n",
      "DB01930\n",
      "Drug has no atc code\n",
      "DB01931\n",
      "Drug has no atc code\n",
      "DB01932\n",
      "Drug has no atc code\n",
      "DB01933\n",
      "Drug has no atc code\n",
      "DB01934\n",
      "Drug has no atc code\n",
      "DB01935\n",
      "Drug has no atc code\n",
      "DB01936\n",
      "Drug has no atc code\n",
      "DB01937\n",
      "Drug has no atc code\n",
      "DB01938\n",
      "Drug has no atc code\n",
      "DB01939\n",
      "Drug has no atc code\n",
      "DB01940\n",
      "Drug has no atc code\n",
      "DB01941\n",
      "Drug has no atc code\n",
      "DB01942\n",
      "Drug has no atc code\n",
      "DB01944\n",
      "Drug has no atc code\n",
      "DB01945\n",
      "Drug has no atc code\n",
      "DB01946\n",
      "Drug has no atc code\n",
      "DB01947\n",
      "Drug has no atc code\n",
      "DB01948\n",
      "Drug has no atc code\n",
      "DB01949\n",
      "Drug has no atc code\n",
      "DB01950\n",
      "Drug has no atc code\n",
      "DB01951\n",
      "Drug has no atc code\n",
      "DB01952\n",
      "Drug has no atc code\n",
      "DB01953\n",
      "Drug has no atc code\n",
      "DB01954\n",
      "Drug has no atc code\n",
      "DB01955\n",
      "Drug has no atc code\n",
      "DB01956\n",
      "Drug has no atc code\n",
      "DB01957\n",
      "Drug has no atc code\n",
      "DB01958\n",
      "Drug has no atc code\n",
      "DB01959\n",
      "Drug has no atc code\n",
      "DB01960\n",
      "Drug has no atc code\n",
      "DB01961\n",
      "Drug has no atc code\n",
      "DB01962\n",
      "Drug has no atc code\n",
      "DB01963\n",
      "Drug has no atc code\n",
      "DB01964\n",
      "Drug has no atc code\n",
      "DB01965\n",
      "Drug has no atc code\n",
      "DB01966\n",
      "Drug has no atc code\n",
      "DB01967\n",
      "Drug has no atc code\n",
      "DB01968\n",
      "Drug has no atc code\n",
      "DB01969\n",
      "Drug has no atc code\n",
      "DB01970\n",
      "Drug has no atc code\n",
      "DB01971\n",
      "Drug has no atc code\n",
      "DB01972\n",
      "Drug has no atc code\n",
      "DB01973\n",
      "Drug has no atc code\n",
      "DB01974\n",
      "Drug has no atc code\n",
      "DB01975\n",
      "Drug has no atc code\n",
      "DB01976\n",
      "Drug has no atc code\n",
      "DB01977\n",
      "Drug has no atc code\n",
      "DB01978\n",
      "Drug has no atc code\n",
      "DB01979\n",
      "Drug has no atc code\n",
      "DB01980\n",
      "Drug has no atc code\n",
      "DB01981\n",
      "Drug has no atc code\n",
      "DB01982\n",
      "Drug has no atc code\n",
      "DB01983\n",
      "Drug has no atc code\n",
      "DB01984\n",
      "Drug has no atc code\n",
      "DB01985\n",
      "Drug has no atc code\n",
      "DB01986\n",
      "Drug has no atc code\n",
      "DB01987\n",
      "Drug has no atc code\n",
      "DB01988\n",
      "Drug has no atc code\n",
      "DB01989\n",
      "Drug has no atc code\n",
      "DB01990\n",
      "Drug has no atc code\n",
      "DB01991\n",
      "Drug has no atc code\n",
      "DB01992\n",
      "Drug has no atc code\n",
      "DB01993\n",
      "Drug has no atc code\n",
      "DB01994\n",
      "Drug has no atc code\n",
      "DB01995\n",
      "Drug has no atc code\n",
      "DB01996\n",
      "Drug has no atc code\n",
      "DB01997\n",
      "Drug has no atc code\n",
      "DB01998\n",
      "Drug has no atc code\n",
      "DB01999\n",
      "Drug has no atc code\n",
      "DB02001\n",
      "Drug has no atc code\n",
      "DB02002\n",
      "Drug has no atc code\n",
      "DB02004\n",
      "Drug has no atc code\n",
      "DB02005\n",
      "Drug has no atc code\n",
      "DB02006\n",
      "Drug has no atc code\n",
      "DB02007\n",
      "Drug has no atc code\n",
      "DB02008\n",
      "Drug has no atc code\n",
      "DB02009\n",
      "Drug has no atc code\n",
      "DB02010\n",
      "Drug has no atc code\n",
      "DB02011\n",
      "Drug has no atc code\n",
      "DB02013\n",
      "Drug has no atc code\n",
      "DB02014\n",
      "Drug has no atc code\n",
      "DB02015\n",
      "Drug has no atc code\n",
      "DB02016\n",
      "Drug has no atc code\n",
      "DB02017\n",
      "Drug has no atc code\n",
      "DB02018\n",
      "Drug has no atc code\n",
      "DB02019\n",
      "Drug has no atc code\n",
      "DB02020\n",
      "Drug has no atc code\n",
      "DB02021\n",
      "Drug has no atc code\n",
      "DB02022\n",
      "Drug has no atc code\n",
      "DB02023\n",
      "Drug has no atc code\n",
      "DB02024\n",
      "Drug has no atc code\n",
      "DB02025\n",
      "Drug has no atc code\n",
      "DB02026\n",
      "Drug has no atc code\n",
      "DB02027\n",
      "Drug has no atc code\n",
      "DB02028\n",
      "Drug has no atc code\n",
      "DB02029\n",
      "Drug has no atc code\n",
      "DB02030\n",
      "Drug has no atc code\n",
      "DB02031\n",
      "Drug has no atc code\n",
      "DB02032\n",
      "Drug has no atc code\n",
      "DB02033\n",
      "Drug has no atc code\n",
      "DB02034\n",
      "Drug has no atc code\n",
      "DB02035\n",
      "Drug has no atc code\n",
      "DB02036\n",
      "Drug has no atc code\n",
      "DB02037\n",
      "Drug has no atc code\n",
      "DB02038\n",
      "Drug has no atc code\n",
      "DB02039\n",
      "Drug has no atc code\n",
      "DB02041\n",
      "Drug has no atc code\n",
      "DB02042\n",
      "Drug has no atc code\n",
      "DB02043\n",
      "Drug has no atc code\n",
      "DB02044\n",
      "Drug has no atc code\n",
      "DB02045\n",
      "Drug has no atc code\n",
      "DB02046\n",
      "Drug has no atc code\n",
      "DB02047\n",
      "Drug has no atc code\n",
      "DB02048\n",
      "Drug has no atc code\n",
      "DB02049\n",
      "Drug has no atc code\n",
      "DB02051\n",
      "Drug has no atc code\n",
      "DB02052\n",
      "Drug has no atc code\n",
      "DB02053\n",
      "Drug has no atc code\n",
      "DB02054\n",
      "Drug has no atc code\n",
      "DB02055\n",
      "Drug has no atc code\n",
      "DB02056\n",
      "Drug has no atc code\n",
      "DB02057\n",
      "Drug has no atc code\n",
      "DB02058\n",
      "Drug has no atc code\n",
      "DB02059\n",
      "Drug has no atc code\n",
      "DB02060\n",
      "Drug has no atc code\n",
      "DB02061\n",
      "Drug has no atc code\n",
      "DB02062\n",
      "Drug has no atc code\n",
      "DB02063\n",
      "Drug has no atc code\n",
      "DB02065\n",
      "Drug has no atc code\n",
      "DB02066\n",
      "Drug has no atc code\n",
      "DB02067\n",
      "Drug has no atc code\n",
      "DB02068\n",
      "Drug has no atc code\n",
      "DB02069\n",
      "Drug has no atc code\n",
      "DB02070\n",
      "Drug has no atc code\n",
      "DB02071\n",
      "Drug has no atc code\n",
      "DB02072\n",
      "Drug has no atc code\n",
      "DB02073\n",
      "Drug has no atc code\n",
      "DB02074\n",
      "Drug has no atc code\n",
      "DB02075\n",
      "Drug has no atc code\n",
      "DB02076\n",
      "Drug has no atc code\n",
      "DB02077\n",
      "Drug has no atc code\n",
      "DB02078\n",
      "Drug has no atc code\n",
      "DB02079\n",
      "Drug has no atc code\n",
      "DB02080\n",
      "Drug has no atc code\n",
      "DB02081\n",
      "Drug has no atc code\n",
      "DB02082\n",
      "Drug has no atc code\n",
      "DB02083\n",
      "Drug has no atc code\n",
      "DB02084\n",
      "Drug has no atc code\n",
      "DB02085\n",
      "Drug has no atc code\n",
      "DB02086\n",
      "Drug has no atc code\n",
      "DB02087\n",
      "Drug has no atc code\n",
      "DB02088\n",
      "Drug has no atc code\n",
      "DB02089\n",
      "Drug has no atc code\n",
      "DB02090\n",
      "Drug has no atc code\n",
      "DB02091\n",
      "Drug has no atc code\n",
      "DB02092\n",
      "Drug has no atc code\n",
      "DB02093\n",
      "Drug has no atc code\n",
      "DB02094\n",
      "Drug has no atc code\n",
      "DB02095\n",
      "Drug has no atc code\n",
      "DB02096\n",
      "Drug has no atc code\n",
      "DB02097\n",
      "Drug has no atc code\n",
      "DB02098\n",
      "Drug has no atc code\n",
      "DB02099\n",
      "Drug has no atc code\n",
      "DB02100\n",
      "Drug has no atc code\n",
      "DB02101\n",
      "Drug has no atc code\n",
      "DB02102\n",
      "Drug has no atc code\n",
      "DB02103\n",
      "Drug has no atc code\n",
      "DB02104\n",
      "Drug has no atc code\n",
      "DB02105\n",
      "Drug has no atc code\n",
      "DB02106\n",
      "Drug has no atc code\n",
      "DB02107\n",
      "Drug has no atc code\n",
      "DB02108\n",
      "Drug has no atc code\n",
      "DB02109\n",
      "Drug has no atc code\n",
      "DB02110\n",
      "Drug has no atc code\n",
      "DB02111\n",
      "Drug has no atc code\n",
      "DB02112\n",
      "Drug has no atc code\n",
      "DB02113\n",
      "Drug has no atc code\n",
      "DB02114\n",
      "Drug has no atc code\n",
      "DB02115\n",
      "Drug has no atc code\n",
      "DB02116\n",
      "Drug has no atc code\n",
      "DB02118\n",
      "Drug has no atc code\n",
      "DB02119\n",
      "Drug has no atc code\n",
      "DB02120\n",
      "Drug has no atc code\n",
      "DB02121\n",
      "Drug has no atc code\n",
      "DB02122\n",
      "Drug has no atc code\n",
      "DB02123\n",
      "Drug has no atc code\n",
      "DB02124\n",
      "Drug has no atc code\n",
      "DB02125\n",
      "Drug has no atc code\n",
      "DB02126\n",
      "Drug has no atc code\n",
      "DB02127\n",
      "Drug has no atc code\n",
      "DB02128\n",
      "Drug has no atc code\n",
      "DB02129\n",
      "Drug has no atc code\n",
      "DB02130\n",
      "Drug has no atc code\n",
      "DB02131\n",
      "Drug has no atc code\n",
      "DB02132\n",
      "Drug has no atc code\n",
      "DB02133\n",
      "Drug has no atc code\n",
      "DB02134\n",
      "Drug has no atc code\n",
      "DB02135\n",
      "Drug has no atc code\n",
      "DB02136\n",
      "Drug has no atc code\n",
      "DB02137\n",
      "Drug has no atc code\n",
      "DB02138\n",
      "Drug has no atc code\n",
      "DB02139\n",
      "Drug has no atc code\n",
      "DB02140\n",
      "Drug has no atc code\n",
      "DB02141\n",
      "Drug has no atc code\n",
      "DB02142\n",
      "Drug has no atc code\n",
      "DB02143\n",
      "Drug has no atc code\n",
      "DB02144\n",
      "Drug has no atc code\n",
      "DB02145\n",
      "Drug has no atc code\n",
      "DB02146\n",
      "Drug has no atc code\n",
      "DB02147\n",
      "Drug has no atc code\n",
      "DB02148\n",
      "Drug has no atc code\n",
      "DB02151\n",
      "Drug has no atc code\n",
      "DB02152\n",
      "Drug has no atc code\n",
      "DB02153\n",
      "Drug has no atc code\n",
      "DB02154\n",
      "Drug has no atc code\n",
      "DB02155\n",
      "Drug has no atc code\n",
      "DB02156\n",
      "Drug has no atc code\n",
      "DB02158\n",
      "Drug has no atc code\n",
      "DB02159\n",
      "Drug has no atc code\n",
      "DB02160\n",
      "Drug has no atc code\n",
      "DB02161\n",
      "Drug has no atc code\n",
      "DB02162\n",
      "Drug has no atc code\n",
      "DB02163\n",
      "Drug has no atc code\n",
      "DB02164\n",
      "Drug has no atc code\n",
      "DB02165\n",
      "Drug has no atc code\n",
      "DB02166\n",
      "Drug has no atc code\n",
      "DB02167\n",
      "Drug has no atc code\n",
      "DB02168\n",
      "Drug has no atc code\n",
      "DB02169\n",
      "Drug has no atc code\n",
      "DB02170\n",
      "Drug has no atc code\n",
      "DB02172\n",
      "Drug has no atc code\n",
      "DB02173\n",
      "Drug has no atc code\n",
      "DB02174\n",
      "Drug has no atc code\n",
      "DB02175\n",
      "Drug has no atc code\n",
      "DB02176\n",
      "Drug has no atc code\n",
      "DB02177\n",
      "Drug has no atc code\n",
      "DB02178\n",
      "Drug has no atc code\n",
      "DB02179\n",
      "Drug has no atc code\n",
      "DB02180\n",
      "Drug has no atc code\n",
      "DB02181\n",
      "Drug has no atc code\n",
      "DB02182\n",
      "Drug has no atc code\n",
      "DB02183\n",
      "Drug has no atc code\n",
      "DB02184\n",
      "Drug has no atc code\n",
      "DB02185\n",
      "Drug has no atc code\n",
      "DB02186\n",
      "Drug has no atc code\n",
      "DB02187\n",
      "Drug has no atc code\n",
      "DB02188\n",
      "Drug has no atc code\n",
      "DB02189\n",
      "Drug has no atc code\n",
      "DB02190\n",
      "Drug has no atc code\n",
      "DB02191\n",
      "Drug has no atc code\n",
      "DB02192\n",
      "Drug has no atc code\n",
      "DB02194\n",
      "Drug has no atc code\n",
      "DB02195\n",
      "Drug has no atc code\n",
      "DB02196\n",
      "Drug has no atc code\n",
      "DB02197\n",
      "Drug has no atc code\n",
      "DB02198\n",
      "Drug has no atc code\n",
      "DB02199\n",
      "Drug has no atc code\n",
      "DB02200\n",
      "Drug has no atc code\n",
      "DB02201\n",
      "Drug has no atc code\n",
      "DB02202\n",
      "Drug has no atc code\n",
      "DB02203\n",
      "Drug has no atc code\n",
      "DB02205\n",
      "Drug has no atc code\n",
      "DB02207\n",
      "Drug has no atc code\n",
      "DB02209\n",
      "Drug has no atc code\n",
      "DB02210\n",
      "Drug has no atc code\n",
      "DB02211\n",
      "Drug has no atc code\n",
      "DB02213\n",
      "Drug has no atc code\n",
      "DB02214\n",
      "Drug has no atc code\n",
      "DB02215\n",
      "Drug has no atc code\n",
      "DB02216\n",
      "Drug has no atc code\n",
      "DB02217\n",
      "Drug has no atc code\n",
      "DB02218\n",
      "Drug has no atc code\n",
      "DB02219\n",
      "Drug has no atc code\n",
      "DB02220\n",
      "Drug has no atc code\n",
      "DB02221\n",
      "Drug has no atc code\n",
      "DB02222\n",
      "Drug has no atc code\n",
      "DB02223\n",
      "Drug has no atc code\n",
      "DB02224\n",
      "Drug has no atc code\n",
      "DB02225\n",
      "Drug has no atc code\n",
      "DB02226\n",
      "Drug has no atc code\n",
      "DB02227\n",
      "Drug has no atc code\n",
      "DB02228\n",
      "Drug has no atc code\n",
      "DB02229\n",
      "Drug has no atc code\n",
      "DB02230\n",
      "Drug has no atc code\n",
      "DB02232\n",
      "Drug has no atc code\n",
      "DB02233\n",
      "Drug has no atc code\n",
      "DB02234\n",
      "Drug has no atc code\n",
      "DB02235\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB02236\n",
      "Drug has no atc code\n",
      "DB02237\n",
      "Drug has no atc code\n",
      "DB02238\n",
      "Drug has no atc code\n",
      "DB02239\n",
      "Drug has no atc code\n",
      "DB02240\n",
      "Drug has no atc code\n",
      "DB02241\n",
      "Drug has no atc code\n",
      "DB02242\n",
      "Drug has no atc code\n",
      "DB02243\n",
      "Drug has no atc code\n",
      "DB02245\n",
      "Drug has no atc code\n",
      "DB02247\n",
      "Drug has no atc code\n",
      "DB02248\n",
      "Drug has no atc code\n",
      "DB02249\n",
      "Drug has no atc code\n",
      "DB02251\n",
      "Drug has no atc code\n",
      "DB02252\n",
      "Drug has no atc code\n",
      "DB02253\n",
      "Drug has no atc code\n",
      "DB02254\n",
      "Drug has no atc code\n",
      "DB02255\n",
      "Drug has no atc code\n",
      "DB02256\n",
      "Drug has no atc code\n",
      "DB02257\n",
      "Drug has no atc code\n",
      "DB02258\n",
      "Drug has no atc code\n",
      "DB02259\n",
      "Drug has no atc code\n",
      "DB02260\n",
      "Drug has no atc code\n",
      "DB02261\n",
      "Drug has no atc code\n",
      "DB02262\n",
      "Drug has no atc code\n",
      "DB02263\n",
      "Drug has no atc code\n",
      "DB02264\n",
      "Drug has no atc code\n",
      "DB02265\n",
      "DB02266\n",
      "Drug has no atc code\n",
      "DB02267\n",
      "Drug has no atc code\n",
      "DB02268\n",
      "Drug has no atc code\n",
      "DB02269\n",
      "Drug has no atc code\n",
      "DB02270\n",
      "Drug has no atc code\n",
      "DB02271\n",
      "Drug has no atc code\n",
      "DB02272\n",
      "Drug has no atc code\n",
      "DB02273\n",
      "Drug has no atc code\n",
      "DB02274\n",
      "Drug has no atc code\n",
      "DB02275\n",
      "Drug has no atc code\n",
      "DB02276\n",
      "Drug has no atc code\n",
      "DB02277\n",
      "Drug has no atc code\n",
      "DB02278\n",
      "Drug has no atc code\n",
      "DB02279\n",
      "Drug has no atc code\n",
      "DB02280\n",
      "Drug has no atc code\n",
      "DB02281\n",
      "Drug has no atc code\n",
      "DB02282\n",
      "Drug has no atc code\n",
      "DB02283\n",
      "Drug has no atc code\n",
      "DB02285\n",
      "Drug has no atc code\n",
      "DB02286\n",
      "Drug has no atc code\n",
      "DB02287\n",
      "Drug has no atc code\n",
      "DB02288\n",
      "Drug has no atc code\n",
      "DB02289\n",
      "Drug has no atc code\n",
      "DB02290\n",
      "Drug has no atc code\n",
      "DB02292\n",
      "Drug has no atc code\n",
      "DB02293\n",
      "Drug has no atc code\n",
      "DB02294\n",
      "Drug has no atc code\n",
      "DB02295\n",
      "Drug has no atc code\n",
      "DB02296\n",
      "Drug has no atc code\n",
      "DB02297\n",
      "Drug has no atc code\n",
      "DB02298\n",
      "Drug has no atc code\n",
      "DB02299\n",
      "DB02300\n",
      "Drug has no atc code\n",
      "DB02301\n",
      "Drug has no atc code\n",
      "DB02302\n",
      "Drug has no atc code\n",
      "DB02303\n",
      "Drug has no atc code\n",
      "DB02304\n",
      "Drug has no atc code\n",
      "DB02305\n",
      "Drug has no atc code\n",
      "DB02306\n",
      "Drug has no atc code\n",
      "DB02307\n",
      "Drug has no atc code\n",
      "DB02308\n",
      "Drug has no atc code\n",
      "DB02309\n",
      "Drug has no atc code\n",
      "DB02310\n",
      "Drug has no atc code\n",
      "DB02311\n",
      "Drug has no atc code\n",
      "DB02312\n",
      "Drug has no atc code\n",
      "DB02313\n",
      "Drug has no atc code\n",
      "DB02314\n",
      "Drug has no atc code\n",
      "DB02315\n",
      "Drug has no atc code\n",
      "DB02316\n",
      "Drug has no atc code\n",
      "DB02317\n",
      "Drug has no atc code\n",
      "DB02318\n",
      "Drug has no atc code\n",
      "DB02319\n",
      "Drug has no atc code\n",
      "DB02320\n",
      "Drug has no atc code\n",
      "DB02321\n",
      "Drug has no atc code\n",
      "DB02322\n",
      "Drug has no atc code\n",
      "DB02323\n",
      "Drug has no atc code\n",
      "DB02324\n",
      "DB02325\n",
      "Drug has no atc code\n",
      "DB02326\n",
      "Drug has no atc code\n",
      "DB02327\n",
      "Drug has no atc code\n",
      "DB02328\n",
      "DB02329\n",
      "Drug has no atc code\n",
      "DB02331\n",
      "Drug has no atc code\n",
      "DB02332\n",
      "Drug has no atc code\n",
      "DB02333\n",
      "Drug has no atc code\n",
      "DB02334\n",
      "Drug has no atc code\n",
      "DB02335\n",
      "Drug has no atc code\n",
      "DB02336\n",
      "Drug has no atc code\n",
      "DB02337\n",
      "Drug has no atc code\n",
      "DB02338\n",
      "Drug has no atc code\n",
      "DB02339\n",
      "Drug has no atc code\n",
      "DB02340\n",
      "Drug has no atc code\n",
      "DB02341\n",
      "Drug has no atc code\n",
      "DB02342\n",
      "Drug has no atc code\n",
      "DB02343\n",
      "Drug has no atc code\n",
      "DB02345\n",
      "Drug has no atc code\n",
      "DB02346\n",
      "Drug has no atc code\n",
      "DB02347\n",
      "Drug has no atc code\n",
      "DB02348\n",
      "Drug has no atc code\n",
      "DB02349\n",
      "Drug has no atc code\n",
      "DB02350\n",
      "Drug has no atc code\n",
      "DB02352\n",
      "Drug has no atc code\n",
      "DB02353\n",
      "Drug has no atc code\n",
      "DB02354\n",
      "Drug has no atc code\n",
      "DB02355\n",
      "Drug has no atc code\n",
      "DB02356\n",
      "Drug has no atc code\n",
      "DB02357\n",
      "Drug has no atc code\n",
      "DB02358\n",
      "Drug has no atc code\n",
      "DB02359\n",
      "Drug has no atc code\n",
      "DB02360\n",
      "Drug has no atc code\n",
      "DB02361\n",
      "DB02362\n",
      "Drug has no atc code\n",
      "DB02363\n",
      "Drug has no atc code\n",
      "DB02364\n",
      "Drug has no atc code\n",
      "DB02365\n",
      "Drug has no atc code\n",
      "DB02366\n",
      "Drug has no atc code\n",
      "DB02367\n",
      "Drug has no atc code\n",
      "DB02368\n",
      "Drug has no atc code\n",
      "DB02369\n",
      "Drug has no atc code\n",
      "DB02370\n",
      "Drug has no atc code\n",
      "DB02371\n",
      "Drug has no atc code\n",
      "DB02372\n",
      "Drug has no atc code\n",
      "DB02373\n",
      "Drug has no atc code\n",
      "DB02374\n",
      "Drug has no atc code\n",
      "DB02375\n",
      "Drug has no atc code\n",
      "DB02376\n",
      "Drug has no atc code\n",
      "DB02377\n",
      "Drug has no atc code\n",
      "DB02378\n",
      "Drug has no atc code\n",
      "DB02379\n",
      "Drug has no atc code\n",
      "DB02380\n",
      "Drug has no atc code\n",
      "DB02381\n",
      "Drug has no atc code\n",
      "DB02382\n",
      "DB02383\n",
      "Drug has no atc code\n",
      "DB02384\n",
      "Drug has no atc code\n",
      "DB02385\n",
      "Drug has no atc code\n",
      "DB02386\n",
      "Drug has no atc code\n",
      "DB02388\n",
      "Drug has no atc code\n",
      "DB02390\n",
      "Drug has no atc code\n",
      "DB02391\n",
      "Drug has no atc code\n",
      "DB02393\n",
      "Drug has no atc code\n",
      "DB02394\n",
      "Drug has no atc code\n",
      "DB02395\n",
      "Drug has no atc code\n",
      "DB02396\n",
      "Drug has no atc code\n",
      "DB02397\n",
      "Drug has no atc code\n",
      "DB02398\n",
      "Drug has no atc code\n",
      "DB02399\n",
      "Drug has no atc code\n",
      "DB02400\n",
      "Drug has no atc code\n",
      "DB02401\n",
      "Drug has no atc code\n",
      "DB02402\n",
      "Drug has no atc code\n",
      "DB02403\n",
      "Drug has no atc code\n",
      "DB02404\n",
      "Drug has no atc code\n",
      "DB02405\n",
      "Drug has no atc code\n",
      "DB02406\n",
      "Drug has no atc code\n",
      "DB02407\n",
      "Drug has no atc code\n",
      "DB02408\n",
      "Drug has no atc code\n",
      "DB02409\n",
      "Drug has no atc code\n",
      "DB02410\n",
      "Drug has no atc code\n",
      "DB02411\n",
      "Drug has no atc code\n",
      "DB02412\n",
      "Drug has no atc code\n",
      "DB02413\n",
      "Drug has no atc code\n",
      "DB02414\n",
      "Drug has no atc code\n",
      "DB02415\n",
      "Drug has no atc code\n",
      "DB02416\n",
      "Drug has no atc code\n",
      "DB02417\n",
      "Drug has no atc code\n",
      "DB02418\n",
      "Drug has no atc code\n",
      "DB02419\n",
      "Drug has no atc code\n",
      "DB02420\n",
      "Drug has no atc code\n",
      "DB02421\n",
      "Drug has no atc code\n",
      "DB02422\n",
      "Drug has no atc code\n",
      "DB02423\n",
      "Drug has no atc code\n",
      "DB02424\n",
      "Drug has no atc code\n",
      "DB02425\n",
      "Drug has no atc code\n",
      "DB02426\n",
      "Drug has no atc code\n",
      "DB02427\n",
      "Drug has no atc code\n",
      "DB02428\n",
      "Drug has no atc code\n",
      "DB02429\n",
      "Drug has no atc code\n",
      "DB02430\n",
      "Drug has no atc code\n",
      "DB02431\n",
      "Drug has no atc code\n",
      "DB02432\n",
      "Drug has no atc code\n",
      "DB02433\n",
      "Drug has no atc code\n",
      "DB02434\n",
      "Drug has no atc code\n",
      "DB02435\n",
      "Drug has no atc code\n",
      "DB02436\n",
      "Drug has no atc code\n",
      "DB02437\n",
      "Drug has no atc code\n",
      "DB02438\n",
      "Drug has no atc code\n",
      "DB02441\n",
      "Drug has no atc code\n",
      "DB02442\n",
      "Drug has no atc code\n",
      "DB02443\n",
      "Drug has no atc code\n",
      "DB02445\n",
      "Drug has no atc code\n",
      "DB02446\n",
      "Drug has no atc code\n",
      "DB02447\n",
      "Drug has no atc code\n",
      "DB02448\n",
      "Drug has no atc code\n",
      "DB02449\n",
      "Drug has no atc code\n",
      "DB02450\n",
      "Drug has no atc code\n",
      "DB02451\n",
      "Drug has no atc code\n",
      "DB02452\n",
      "Drug has no atc code\n",
      "DB02453\n",
      "Drug has no atc code\n",
      "DB02454\n",
      "Drug has no atc code\n",
      "DB02455\n",
      "Drug has no atc code\n",
      "DB02456\n",
      "Drug has no atc code\n",
      "DB02457\n",
      "Drug has no atc code\n",
      "DB02458\n",
      "Drug has no atc code\n",
      "DB02459\n",
      "Drug has no atc code\n",
      "DB02460\n",
      "Drug has no atc code\n",
      "DB02461\n",
      "Drug has no atc code\n",
      "DB02462\n",
      "Drug has no atc code\n",
      "DB02463\n",
      "Drug has no atc code\n",
      "DB02464\n",
      "Drug has no atc code\n",
      "DB02465\n",
      "Drug has no atc code\n",
      "DB02466\n",
      "Drug has no atc code\n",
      "DB02467\n",
      "Drug has no atc code\n",
      "DB02468\n",
      "Drug has no atc code\n",
      "DB02469\n",
      "Drug has no atc code\n",
      "DB02470\n",
      "Drug has no atc code\n",
      "DB02471\n",
      "Drug has no atc code\n",
      "DB02472\n",
      "Drug has no atc code\n",
      "DB02473\n",
      "Drug has no atc code\n",
      "DB02474\n",
      "Drug has no atc code\n",
      "DB02475\n",
      "Drug has no atc code\n",
      "DB02477\n",
      "Drug has no atc code\n",
      "DB02479\n",
      "Drug has no atc code\n",
      "DB02480\n",
      "Drug has no atc code\n",
      "DB02481\n",
      "Drug has no atc code\n",
      "DB02482\n",
      "Drug has no atc code\n",
      "DB02483\n",
      "Drug has no atc code\n",
      "DB02484\n",
      "Drug has no atc code\n",
      "DB02485\n",
      "Drug has no atc code\n",
      "DB02486\n",
      "Drug has no atc code\n",
      "DB02488\n",
      "Drug has no atc code\n",
      "DB02489\n",
      "Drug has no atc code\n",
      "DB02490\n",
      "Drug has no atc code\n",
      "DB02491\n",
      "Drug has no atc code\n",
      "DB02492\n",
      "Drug has no atc code\n",
      "DB02493\n",
      "Drug has no atc code\n",
      "DB02494\n",
      "Drug has no atc code\n",
      "DB02495\n",
      "Drug has no atc code\n",
      "DB02496\n",
      "Drug has no atc code\n",
      "DB02497\n",
      "Drug has no atc code\n",
      "DB02498\n",
      "Drug has no atc code\n",
      "DB02499\n",
      "Drug has no atc code\n",
      "DB02500\n",
      "Drug has no atc code\n",
      "DB02501\n",
      "Drug has no atc code\n",
      "DB02502\n",
      "Drug has no atc code\n",
      "DB02503\n",
      "Drug has no atc code\n",
      "DB02504\n",
      "Drug has no atc code\n",
      "DB02505\n",
      "Drug has no atc code\n",
      "DB02506\n",
      "Drug has no atc code\n",
      "DB02508\n",
      "Drug has no atc code\n",
      "DB02509\n",
      "Drug has no atc code\n",
      "DB02510\n",
      "Drug has no atc code\n",
      "DB02511\n",
      "Drug has no atc code\n",
      "DB02512\n",
      "Drug has no atc code\n",
      "DB02513\n",
      "Drug has no atc code\n",
      "DB02514\n",
      "Drug has no atc code\n",
      "DB02515\n",
      "Drug has no atc code\n",
      "DB02516\n",
      "Drug has no atc code\n",
      "DB02517\n",
      "Drug has no atc code\n",
      "DB02518\n",
      "Drug has no atc code\n",
      "DB02519\n",
      "Drug has no atc code\n",
      "DB02520\n",
      "Drug has no atc code\n",
      "DB02521\n",
      "Drug has no atc code\n",
      "DB02522\n",
      "Drug has no atc code\n",
      "DB02523\n",
      "Drug has no atc code\n",
      "DB02524\n",
      "Drug has no atc code\n",
      "DB02525\n",
      "Drug has no atc code\n",
      "DB02526\n",
      "Drug has no atc code\n",
      "DB02527\n",
      "Drug has no atc code\n",
      "DB02528\n",
      "Drug has no atc code\n",
      "DB02529\n",
      "Drug has no atc code\n",
      "DB02530\n",
      "Drug has no atc code\n",
      "DB02531\n",
      "Drug has no atc code\n",
      "DB02532\n",
      "Drug has no atc code\n",
      "DB02534\n",
      "Drug has no atc code\n",
      "DB02535\n",
      "Drug has no atc code\n",
      "DB02536\n",
      "Drug has no atc code\n",
      "DB02537\n",
      "Drug has no atc code\n",
      "DB02538\n",
      "Drug has no atc code\n",
      "DB02540\n",
      "Drug has no atc code\n",
      "DB02541\n",
      "Drug has no atc code\n",
      "DB02542\n",
      "Drug has no atc code\n",
      "DB02543\n",
      "Drug has no atc code\n",
      "DB02544\n",
      "Drug has no atc code\n",
      "DB02545\n",
      "DB02546\n",
      "Drug has no atc code\n",
      "DB02547\n",
      "Drug has no atc code\n",
      "DB02548\n",
      "Drug has no atc code\n",
      "DB02549\n",
      "Drug has no atc code\n",
      "DB02550\n",
      "Drug has no atc code\n",
      "DB02551\n",
      "Drug has no atc code\n",
      "DB02552\n",
      "Drug has no atc code\n",
      "DB02553\n",
      "Drug has no atc code\n",
      "DB02554\n",
      "Drug has no atc code\n",
      "DB02555\n",
      "Drug has no atc code\n",
      "DB02556\n",
      "Drug has no atc code\n",
      "DB02557\n",
      "Drug has no atc code\n",
      "DB02558\n",
      "Drug has no atc code\n",
      "DB02559\n",
      "Drug has no atc code\n",
      "DB02560\n",
      "Drug has no atc code\n",
      "DB02561\n",
      "Drug has no atc code\n",
      "DB02562\n",
      "Drug has no atc code\n",
      "DB02563\n",
      "Drug has no atc code\n",
      "DB02565\n",
      "Drug has no atc code\n",
      "DB02566\n",
      "Drug has no atc code\n",
      "DB02567\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB02568\n",
      "Drug has no atc code\n",
      "DB02569\n",
      "Drug has no atc code\n",
      "DB02570\n",
      "Drug has no atc code\n",
      "DB02571\n",
      "Drug has no atc code\n",
      "DB02572\n",
      "Drug has no atc code\n",
      "DB02573\n",
      "Drug has no atc code\n",
      "DB02574\n",
      "Drug has no atc code\n",
      "DB02576\n",
      "Drug has no atc code\n",
      "DB02577\n",
      "Drug has no atc code\n",
      "DB02578\n",
      "Drug has no atc code\n",
      "DB02579\n",
      "Drug has no atc code\n",
      "DB02580\n",
      "Drug has no atc code\n",
      "DB02581\n",
      "Drug has no atc code\n",
      "DB02582\n",
      "Drug has no atc code\n",
      "DB02583\n",
      "Drug has no atc code\n",
      "DB02585\n",
      "Drug has no atc code\n",
      "DB02586\n",
      "Drug has no atc code\n",
      "DB02587\n",
      "Drug has no atc code\n",
      "DB02588\n",
      "Drug has no atc code\n",
      "DB02589\n",
      "Drug has no atc code\n",
      "DB02590\n",
      "Drug has no atc code\n",
      "DB02591\n",
      "Drug has no atc code\n",
      "DB02592\n",
      "Drug has no atc code\n",
      "DB02593\n",
      "Drug has no atc code\n",
      "DB02594\n",
      "Drug has no atc code\n",
      "DB02595\n",
      "Drug has no atc code\n",
      "DB02596\n",
      "Drug has no atc code\n",
      "DB02597\n",
      "Drug has no atc code\n",
      "DB02598\n",
      "Drug has no atc code\n",
      "DB02599\n",
      "Drug has no atc code\n",
      "DB02600\n",
      "Drug has no atc code\n",
      "DB02601\n",
      "Drug has no atc code\n",
      "DB02602\n",
      "Drug has no atc code\n",
      "DB02603\n",
      "Drug has no atc code\n",
      "DB02604\n",
      "Drug has no atc code\n",
      "DB02606\n",
      "Drug has no atc code\n",
      "DB02607\n",
      "Drug has no atc code\n",
      "DB02608\n",
      "Drug has no atc code\n",
      "DB02609\n",
      "Drug has no atc code\n",
      "DB02610\n",
      "Drug has no atc code\n",
      "DB02611\n",
      "Drug has no atc code\n",
      "DB02613\n",
      "Drug has no atc code\n",
      "DB02614\n",
      "Drug has no atc code\n",
      "DB02615\n",
      "Drug has no atc code\n",
      "DB02616\n",
      "Drug has no atc code\n",
      "DB02617\n",
      "Drug has no atc code\n",
      "DB02618\n",
      "Drug has no atc code\n",
      "DB02619\n",
      "Drug has no atc code\n",
      "DB02620\n",
      "Drug has no atc code\n",
      "DB02621\n",
      "Drug has no atc code\n",
      "DB02622\n",
      "Drug has no atc code\n",
      "DB02623\n",
      "Drug has no atc code\n",
      "DB02624\n",
      "Drug has no atc code\n",
      "DB02625\n",
      "Drug has no atc code\n",
      "DB02626\n",
      "Drug has no atc code\n",
      "DB02627\n",
      "Drug has no atc code\n",
      "DB02628\n",
      "Drug has no atc code\n",
      "DB02629\n",
      "Drug has no atc code\n",
      "DB02630\n",
      "Drug has no atc code\n",
      "DB02632\n",
      "Drug has no atc code\n",
      "DB02633\n",
      "Drug has no atc code\n",
      "DB02635\n",
      "Drug has no atc code\n",
      "DB02636\n",
      "Drug has no atc code\n",
      "DB02637\n",
      "DB02638\n",
      "Drug has no atc code\n",
      "DB02639\n",
      "DB02640\n",
      "Drug has no atc code\n",
      "DB02641\n",
      "Drug has no atc code\n",
      "DB02642\n",
      "Drug has no atc code\n",
      "DB02643\n",
      "Drug has no atc code\n",
      "DB02644\n",
      "Drug has no atc code\n",
      "DB02645\n",
      "Drug has no atc code\n",
      "DB02646\n",
      "Drug has no atc code\n",
      "DB02647\n",
      "Drug has no atc code\n",
      "DB02648\n",
      "Drug has no atc code\n",
      "DB02649\n",
      "Drug has no atc code\n",
      "DB02650\n",
      "Drug has no atc code\n",
      "DB02651\n",
      "Drug has no atc code\n",
      "DB02652\n",
      "Drug has no atc code\n",
      "DB02654\n",
      "Drug has no atc code\n",
      "DB02655\n",
      "Drug has no atc code\n",
      "DB02656\n",
      "Drug has no atc code\n",
      "DB02657\n",
      "Drug has no atc code\n",
      "DB02658\n",
      "DB02659\n",
      "Drug has no atc code\n",
      "DB02660\n",
      "Drug has no atc code\n",
      "DB02661\n",
      "Drug has no atc code\n",
      "DB02662\n",
      "Drug has no atc code\n",
      "DB02663\n",
      "Drug has no atc code\n",
      "DB02664\n",
      "Drug has no atc code\n",
      "DB02665\n",
      "Drug has no atc code\n",
      "DB02666\n",
      "Drug has no atc code\n",
      "DB02667\n",
      "Drug has no atc code\n",
      "DB02668\n",
      "Drug has no atc code\n",
      "DB02669\n",
      "Drug has no atc code\n",
      "DB02670\n",
      "Drug has no atc code\n",
      "DB02671\n",
      "Drug has no atc code\n",
      "DB02673\n",
      "Drug has no atc code\n",
      "DB02674\n",
      "Drug has no atc code\n",
      "DB02675\n",
      "Drug has no atc code\n",
      "DB02676\n",
      "Drug has no atc code\n",
      "DB02677\n",
      "Drug has no atc code\n",
      "DB02678\n",
      "Drug has no atc code\n",
      "DB02679\n",
      "Drug has no atc code\n",
      "DB02680\n",
      "Drug has no atc code\n",
      "DB02681\n",
      "Drug has no atc code\n",
      "DB02683\n",
      "Drug has no atc code\n",
      "DB02684\n",
      "Drug has no atc code\n",
      "DB02685\n",
      "Drug has no atc code\n",
      "DB02686\n",
      "Drug has no atc code\n",
      "DB02688\n",
      "Drug has no atc code\n",
      "DB02689\n",
      "Drug has no atc code\n",
      "DB02690\n",
      "Drug has no atc code\n",
      "DB02691\n",
      "Drug has no atc code\n",
      "DB02693\n",
      "Drug has no atc code\n",
      "DB02694\n",
      "Drug has no atc code\n",
      "DB02695\n",
      "Drug has no atc code\n",
      "DB02696\n",
      "Drug has no atc code\n",
      "DB02697\n",
      "Drug has no atc code\n",
      "DB02698\n",
      "Drug has no atc code\n",
      "DB02699\n",
      "Drug has no atc code\n",
      "DB02700\n",
      "DB02701\n",
      "Drug has no atc code\n",
      "DB02702\n",
      "DB02703\n",
      "Drug has no atc code\n",
      "DB02704\n",
      "Drug has no atc code\n",
      "DB02705\n",
      "Drug has no atc code\n",
      "DB02706\n",
      "Drug has no atc code\n",
      "DB02707\n",
      "Drug has no atc code\n",
      "DB02709\n",
      "Drug has no atc code\n",
      "DB02710\n",
      "Drug has no atc code\n",
      "DB02711\n",
      "Drug has no atc code\n",
      "DB02712\n",
      "Drug has no atc code\n",
      "DB02713\n",
      "Drug has no atc code\n",
      "DB02714\n",
      "Drug has no atc code\n",
      "DB02715\n",
      "Drug has no atc code\n",
      "DB02716\n",
      "Drug has no atc code\n",
      "DB02717\n",
      "Drug has no atc code\n",
      "DB02719\n",
      "Drug has no atc code\n",
      "DB02720\n",
      "Drug has no atc code\n",
      "DB02721\n",
      "Drug has no atc code\n",
      "DB02722\n",
      "Drug has no atc code\n",
      "DB02723\n",
      "Drug has no atc code\n",
      "DB02724\n",
      "Drug has no atc code\n",
      "DB02725\n",
      "Drug has no atc code\n",
      "DB02726\n",
      "Drug has no atc code\n",
      "DB02727\n",
      "Drug has no atc code\n",
      "DB02728\n",
      "Drug has no atc code\n",
      "DB02729\n",
      "Drug has no atc code\n",
      "DB02730\n",
      "Drug has no atc code\n",
      "DB02731\n",
      "Drug has no atc code\n",
      "DB02732\n",
      "Drug has no atc code\n",
      "DB02733\n",
      "Drug has no atc code\n",
      "DB02734\n",
      "Drug has no atc code\n",
      "DB02735\n",
      "Drug has no atc code\n",
      "DB02736\n",
      "Drug has no atc code\n",
      "DB02738\n",
      "Drug has no atc code\n",
      "DB02740\n",
      "Drug has no atc code\n",
      "DB02741\n",
      "Drug has no atc code\n",
      "DB02742\n",
      "Drug has no atc code\n",
      "DB02743\n",
      "Drug has no atc code\n",
      "DB02744\n",
      "Drug has no atc code\n",
      "DB02745\n",
      "Drug has no atc code\n",
      "DB02746\n",
      "Drug has no atc code\n",
      "DB02747\n",
      "Drug has no atc code\n",
      "DB02749\n",
      "Drug has no atc code\n",
      "DB02750\n",
      "Drug has no atc code\n",
      "DB02751\n",
      "Drug has no atc code\n",
      "DB02752\n",
      "Drug has no atc code\n",
      "DB02753\n",
      "Drug has no atc code\n",
      "DB02754\n",
      "Drug has no atc code\n",
      "DB02755\n",
      "Drug has no atc code\n",
      "DB02756\n",
      "Drug has no atc code\n",
      "DB02757\n",
      "Drug has no atc code\n",
      "DB02758\n",
      "Drug has no atc code\n",
      "DB02759\n",
      "Drug has no atc code\n",
      "DB02760\n",
      "Drug has no atc code\n",
      "DB02761\n",
      "Drug has no atc code\n",
      "DB02762\n",
      "Drug has no atc code\n",
      "DB02763\n",
      "Drug has no atc code\n",
      "DB02765\n",
      "Drug has no atc code\n",
      "DB02766\n",
      "Drug has no atc code\n",
      "DB02767\n",
      "Drug has no atc code\n",
      "DB02768\n",
      "Drug has no atc code\n",
      "DB02770\n",
      "Drug has no atc code\n",
      "DB02772\n",
      "Drug has no atc code\n",
      "DB02773\n",
      "Drug has no atc code\n",
      "DB02774\n",
      "Drug has no atc code\n",
      "DB02776\n",
      "Drug has no atc code\n",
      "DB02777\n",
      "Drug has no atc code\n",
      "DB02778\n",
      "Drug has no atc code\n",
      "DB02779\n",
      "Drug has no atc code\n",
      "DB02780\n",
      "Drug has no atc code\n",
      "DB02781\n",
      "Drug has no atc code\n",
      "DB02783\n",
      "Drug has no atc code\n",
      "DB02784\n",
      "Drug has no atc code\n",
      "DB02785\n",
      "Drug has no atc code\n",
      "DB02786\n",
      "Drug has no atc code\n",
      "DB02787\n",
      "Drug has no atc code\n",
      "DB02788\n",
      "Drug has no atc code\n",
      "DB02789\n",
      "Drug has no atc code\n",
      "DB02790\n",
      "Drug has no atc code\n",
      "DB02792\n",
      "Drug has no atc code\n",
      "DB02793\n",
      "Drug has no atc code\n",
      "DB02794\n",
      "Drug has no atc code\n",
      "DB02795\n",
      "Drug has no atc code\n",
      "DB02796\n",
      "Drug has no atc code\n",
      "DB02797\n",
      "Drug has no atc code\n",
      "DB02798\n",
      "Drug has no atc code\n",
      "DB02799\n",
      "Drug has no atc code\n",
      "DB02800\n",
      "Drug has no atc code\n",
      "DB02801\n",
      "Drug has no atc code\n",
      "DB02802\n",
      "Drug has no atc code\n",
      "DB02803\n",
      "Drug has no atc code\n",
      "DB02804\n",
      "Drug has no atc code\n",
      "DB02805\n",
      "Drug has no atc code\n",
      "DB02806\n",
      "Drug has no atc code\n",
      "DB02807\n",
      "Drug has no atc code\n",
      "DB02808\n",
      "Drug has no atc code\n",
      "DB02809\n",
      "Drug has no atc code\n",
      "DB02810\n",
      "Drug has no atc code\n",
      "DB02811\n",
      "Drug has no atc code\n",
      "DB02812\n",
      "Drug has no atc code\n",
      "DB02813\n",
      "Drug has no atc code\n",
      "DB02814\n",
      "Drug has no atc code\n",
      "DB02816\n",
      "Drug has no atc code\n",
      "DB02817\n",
      "Drug has no atc code\n",
      "DB02818\n",
      "Drug has no atc code\n",
      "DB02819\n",
      "Drug has no atc code\n",
      "DB02820\n",
      "Drug has no atc code\n",
      "DB02821\n",
      "Drug has no atc code\n",
      "DB02822\n",
      "Drug has no atc code\n",
      "DB02823\n",
      "Drug has no atc code\n",
      "DB02824\n",
      "Drug has no atc code\n",
      "DB02825\n",
      "Drug has no atc code\n",
      "DB02827\n",
      "Drug has no atc code\n",
      "DB02828\n",
      "Drug has no atc code\n",
      "DB02829\n",
      "Drug has no atc code\n",
      "DB02830\n",
      "Drug has no atc code\n",
      "DB02831\n",
      "Drug has no atc code\n",
      "DB02832\n",
      "Drug has no atc code\n",
      "DB02833\n",
      "Drug has no atc code\n",
      "DB02834\n",
      "Drug has no atc code\n",
      "DB02835\n",
      "Drug has no atc code\n",
      "DB02836\n",
      "Drug has no atc code\n",
      "DB02837\n",
      "Drug has no atc code\n",
      "DB02838\n",
      "Drug has no atc code\n",
      "DB02839\n",
      "Drug has no atc code\n",
      "DB02840\n",
      "Drug has no atc code\n",
      "DB02841\n",
      "Drug has no atc code\n",
      "DB02842\n",
      "Drug has no atc code\n",
      "DB02843\n",
      "Drug has no atc code\n",
      "DB02844\n",
      "Drug has no atc code\n",
      "DB02845\n",
      "Drug has no atc code\n",
      "DB02846\n",
      "Drug has no atc code\n",
      "DB02847\n",
      "Drug has no atc code\n",
      "DB02848\n",
      "Drug has no atc code\n",
      "DB02849\n",
      "Drug has no atc code\n",
      "DB02850\n",
      "Drug has no atc code\n",
      "DB02851\n",
      "Drug has no atc code\n",
      "DB02852\n",
      "Drug has no atc code\n",
      "DB02853\n",
      "Drug has no atc code\n",
      "DB02854\n",
      "Drug has no atc code\n",
      "DB02855\n",
      "Drug has no atc code\n",
      "DB02856\n",
      "Drug has no atc code\n",
      "DB02857\n",
      "Drug has no atc code\n",
      "DB02858\n",
      "Drug has no atc code\n",
      "DB02859\n",
      "Drug has no atc code\n",
      "DB02860\n",
      "Drug has no atc code\n",
      "DB02861\n",
      "Drug has no atc code\n",
      "DB02862\n",
      "Drug has no atc code\n",
      "DB02864\n",
      "Drug has no atc code\n",
      "DB02865\n",
      "Drug has no atc code\n",
      "DB02866\n",
      "Drug has no atc code\n",
      "DB02867\n",
      "Drug has no atc code\n",
      "DB02868\n",
      "Drug has no atc code\n",
      "DB02869\n",
      "Drug has no atc code\n",
      "DB02870\n",
      "Drug has no atc code\n",
      "DB02871\n",
      "Drug has no atc code\n",
      "DB02872\n",
      "Drug has no atc code\n",
      "DB02873\n",
      "Drug has no atc code\n",
      "DB02875\n",
      "Drug has no atc code\n",
      "DB02876\n",
      "Drug has no atc code\n",
      "DB02877\n",
      "Drug has no atc code\n",
      "DB02878\n",
      "Drug has no atc code\n",
      "DB02879\n",
      "Drug has no atc code\n",
      "DB02880\n",
      "Drug has no atc code\n",
      "DB02881\n",
      "Drug has no atc code\n",
      "DB02882\n",
      "Drug has no atc code\n",
      "DB02883\n",
      "Drug has no atc code\n",
      "DB02884\n",
      "Drug has no atc code\n",
      "DB02885\n",
      "Drug has no atc code\n",
      "DB02887\n",
      "Drug has no atc code\n",
      "DB02888\n",
      "Drug has no atc code\n",
      "DB02889\n",
      "Drug has no atc code\n",
      "DB02890\n",
      "Drug has no atc code\n",
      "DB02891\n",
      "Drug has no atc code\n",
      "DB02892\n",
      "Drug has no atc code\n",
      "DB02893\n",
      "Drug has no atc code\n",
      "DB02894\n",
      "Drug has no atc code\n",
      "DB02895\n",
      "Drug has no atc code\n",
      "DB02896\n",
      "Drug has no atc code\n",
      "DB02897\n",
      "Drug has no atc code\n",
      "DB02898\n",
      "Drug has no atc code\n",
      "DB02899\n",
      "Drug has no atc code\n",
      "DB02900\n",
      "DB02901\n",
      "Drug has no atc code\n",
      "DB02902\n",
      "Drug has no atc code\n",
      "DB02903\n",
      "Drug has no atc code\n",
      "DB02904\n",
      "Drug has no atc code\n",
      "DB02905\n",
      "Drug has no atc code\n",
      "DB02906\n",
      "Drug has no atc code\n",
      "DB02907\n",
      "Drug has no atc code\n",
      "DB02908\n",
      "Drug has no atc code\n",
      "DB02909\n",
      "Drug has no atc code\n",
      "DB02910\n",
      "Drug has no atc code\n",
      "DB02911\n",
      "Drug has no atc code\n",
      "DB02912\n",
      "Drug has no atc code\n",
      "DB02914\n",
      "Drug has no atc code\n",
      "DB02915\n",
      "Drug has no atc code\n",
      "DB02916\n",
      "Drug has no atc code\n",
      "DB02917\n",
      "Drug has no atc code\n",
      "DB02918\n",
      "Drug has no atc code\n",
      "DB02919\n",
      "Drug has no atc code\n",
      "DB02920\n",
      "Drug has no atc code\n",
      "DB02921\n",
      "Drug has no atc code\n",
      "DB02922\n",
      "Drug has no atc code\n",
      "DB02923\n",
      "Drug has no atc code\n",
      "DB02924\n",
      "DB02925\n",
      "Drug has no atc code\n",
      "DB02927\n",
      "Drug has no atc code\n",
      "DB02928\n",
      "Drug has no atc code\n",
      "DB02929\n",
      "Drug has no atc code\n",
      "DB02930\n",
      "Drug has no atc code\n",
      "DB02931\n",
      "Drug has no atc code\n",
      "DB02932\n",
      "Drug has no atc code\n",
      "DB02933\n",
      "Drug has no atc code\n",
      "DB02934\n",
      "Drug has no atc code\n",
      "DB02935\n",
      "Drug has no atc code\n",
      "DB02936\n",
      "Drug has no atc code\n",
      "DB02937\n",
      "Drug has no atc code\n",
      "DB02938\n",
      "Drug has no atc code\n",
      "DB02940\n",
      "Drug has no atc code\n",
      "DB02941\n",
      "Drug has no atc code\n",
      "DB02942\n",
      "Drug has no atc code\n",
      "DB02943\n",
      "Drug has no atc code\n",
      "DB02945\n",
      "Drug has no atc code\n",
      "DB02946\n",
      "Drug has no atc code\n",
      "DB02947\n",
      "Drug has no atc code\n",
      "DB02948\n",
      "Drug has no atc code\n",
      "DB02949\n",
      "Drug has no atc code\n",
      "DB02950\n",
      "Drug has no atc code\n",
      "DB02951\n",
      "Drug has no atc code\n",
      "DB02952\n",
      "Drug has no atc code\n",
      "DB02953\n",
      "Drug has no atc code\n",
      "DB02954\n",
      "Drug has no atc code\n",
      "DB02955\n",
      "Drug has no atc code\n",
      "DB02956\n",
      "Drug has no atc code\n",
      "DB02957\n",
      "Drug has no atc code\n",
      "DB02958\n",
      "DB02959\n",
      "Drug has no atc code\n",
      "DB02960\n",
      "Drug has no atc code\n",
      "DB02961\n",
      "Drug has no atc code\n",
      "DB02962\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB02963\n",
      "Drug has no atc code\n",
      "DB02964\n",
      "Drug has no atc code\n",
      "DB02965\n",
      "Drug has no atc code\n",
      "DB02966\n",
      "Drug has no atc code\n",
      "DB02967\n",
      "Drug has no atc code\n",
      "DB02968\n",
      "Drug has no atc code\n",
      "DB02969\n",
      "Drug has no atc code\n",
      "DB02970\n",
      "Drug has no atc code\n",
      "DB02971\n",
      "Drug has no atc code\n",
      "DB02972\n",
      "Drug has no atc code\n",
      "DB02973\n",
      "Drug has no atc code\n",
      "DB02974\n",
      "Drug has no atc code\n",
      "DB02975\n",
      "Drug has no atc code\n",
      "DB02976\n",
      "Drug has no atc code\n",
      "DB02977\n",
      "Drug has no atc code\n",
      "DB02978\n",
      "Drug has no atc code\n",
      "DB02979\n",
      "Drug has no atc code\n",
      "DB02980\n",
      "Drug has no atc code\n",
      "DB02981\n",
      "Drug has no atc code\n",
      "DB02982\n",
      "Drug has no atc code\n",
      "DB02983\n",
      "Drug has no atc code\n",
      "DB02984\n",
      "Drug has no atc code\n",
      "DB02985\n",
      "Drug has no atc code\n",
      "DB02986\n",
      "Drug has no atc code\n",
      "DB02987\n",
      "Drug has no atc code\n",
      "DB02988\n",
      "Drug has no atc code\n",
      "DB02989\n",
      "Drug has no atc code\n",
      "DB02990\n",
      "Drug has no atc code\n",
      "DB02991\n",
      "Drug has no atc code\n",
      "DB02992\n",
      "Drug has no atc code\n",
      "DB02993\n",
      "Drug has no atc code\n",
      "DB02994\n",
      "Drug has no atc code\n",
      "DB02995\n",
      "Drug has no atc code\n",
      "DB02996\n",
      "Drug has no atc code\n",
      "DB02998\n",
      "Drug has no atc code\n",
      "DB02999\n",
      "Drug has no atc code\n",
      "DB03000\n",
      "Drug has no atc code\n",
      "DB03001\n",
      "Drug has no atc code\n",
      "DB03002\n",
      "Drug has no atc code\n",
      "DB03003\n",
      "Drug has no atc code\n",
      "DB03004\n",
      "Drug has no atc code\n",
      "DB03005\n",
      "Drug has no atc code\n",
      "DB03006\n",
      "Drug has no atc code\n",
      "DB03007\n",
      "Drug has no atc code\n",
      "DB03008\n",
      "Drug has no atc code\n",
      "DB03009\n",
      "Drug has no atc code\n",
      "DB03010\n",
      "Drug has no atc code\n",
      "DB03011\n",
      "Drug has no atc code\n",
      "DB03012\n",
      "Drug has no atc code\n",
      "DB03013\n",
      "Drug has no atc code\n",
      "DB03015\n",
      "Drug has no atc code\n",
      "DB03016\n",
      "Drug has no atc code\n",
      "DB03017\n",
      "Drug has no atc code\n",
      "DB03018\n",
      "Drug has no atc code\n",
      "DB03019\n",
      "Drug has no atc code\n",
      "DB03020\n",
      "Drug has no atc code\n",
      "DB03021\n",
      "Drug has no atc code\n",
      "DB03022\n",
      "Drug has no atc code\n",
      "DB03023\n",
      "Drug has no atc code\n",
      "DB03024\n",
      "Drug has no atc code\n",
      "DB03025\n",
      "Drug has no atc code\n",
      "DB03026\n",
      "Drug has no atc code\n",
      "DB03028\n",
      "Drug has no atc code\n",
      "DB03030\n",
      "Drug has no atc code\n",
      "DB03031\n",
      "Drug has no atc code\n",
      "DB03032\n",
      "Drug has no atc code\n",
      "DB03033\n",
      "Drug has no atc code\n",
      "DB03034\n",
      "Drug has no atc code\n",
      "DB03035\n",
      "Drug has no atc code\n",
      "DB03037\n",
      "Drug has no atc code\n",
      "DB03038\n",
      "Drug has no atc code\n",
      "DB03039\n",
      "Drug has no atc code\n",
      "DB03040\n",
      "Drug has no atc code\n",
      "DB03041\n",
      "Drug has no atc code\n",
      "DB03042\n",
      "Drug has no atc code\n",
      "DB03043\n",
      "Drug has no atc code\n",
      "DB03044\n",
      "Drug has no atc code\n",
      "DB03045\n",
      "Drug has no atc code\n",
      "DB03046\n",
      "Drug has no atc code\n",
      "DB03047\n",
      "Drug has no atc code\n",
      "DB03048\n",
      "Drug has no atc code\n",
      "DB03049\n",
      "Drug has no atc code\n",
      "DB03051\n",
      "Drug has no atc code\n",
      "DB03052\n",
      "Drug has no atc code\n",
      "DB03053\n",
      "Drug has no atc code\n",
      "DB03054\n",
      "Drug has no atc code\n",
      "DB03056\n",
      "Drug has no atc code\n",
      "DB03057\n",
      "Drug has no atc code\n",
      "DB03058\n",
      "Drug has no atc code\n",
      "DB03059\n",
      "Drug has no atc code\n",
      "DB03060\n",
      "Drug has no atc code\n",
      "DB03061\n",
      "Drug has no atc code\n",
      "DB03062\n",
      "Drug has no atc code\n",
      "DB03063\n",
      "Drug has no atc code\n",
      "DB03064\n",
      "Drug has no atc code\n",
      "DB03065\n",
      "Drug has no atc code\n",
      "DB03066\n",
      "Drug has no atc code\n",
      "DB03067\n",
      "Drug has no atc code\n",
      "DB03068\n",
      "Drug has no atc code\n",
      "DB03069\n",
      "Drug has no atc code\n",
      "DB03070\n",
      "Drug has no atc code\n",
      "DB03071\n",
      "Drug has no atc code\n",
      "DB03072\n",
      "Drug has no atc code\n",
      "DB03073\n",
      "Drug has no atc code\n",
      "DB03074\n",
      "Drug has no atc code\n",
      "DB03075\n",
      "Drug has no atc code\n",
      "DB03076\n",
      "Drug has no atc code\n",
      "DB03077\n",
      "Drug has no atc code\n",
      "DB03078\n",
      "Drug has no atc code\n",
      "DB03079\n",
      "Drug has no atc code\n",
      "DB03081\n",
      "Drug has no atc code\n",
      "DB03082\n",
      "Drug has no atc code\n",
      "DB03083\n",
      "Drug has no atc code\n",
      "DB03084\n",
      "Drug has no atc code\n",
      "DB03085\n",
      "Drug has no atc code\n",
      "DB03086\n",
      "Drug has no atc code\n",
      "DB03087\n",
      "DB03088\n",
      "Drug has no atc code\n",
      "DB03090\n",
      "Drug has no atc code\n",
      "DB03091\n",
      "Drug has no atc code\n",
      "DB03092\n",
      "Drug has no atc code\n",
      "DB03093\n",
      "Drug has no atc code\n",
      "DB03094\n",
      "Drug has no atc code\n",
      "DB03095\n",
      "Drug has no atc code\n",
      "DB03096\n",
      "Drug has no atc code\n",
      "DB03097\n",
      "Drug has no atc code\n",
      "DB03098\n",
      "Drug has no atc code\n",
      "DB03099\n",
      "Drug has no atc code\n",
      "DB03100\n",
      "Drug has no atc code\n",
      "DB03101\n",
      "Drug has no atc code\n",
      "DB03102\n",
      "Drug has no atc code\n",
      "DB03103\n",
      "Drug has no atc code\n",
      "DB03104\n",
      "Drug has no atc code\n",
      "DB03105\n",
      "Drug has no atc code\n",
      "DB03106\n",
      "Drug has no atc code\n",
      "DB03107\n",
      "Drug has no atc code\n",
      "DB03108\n",
      "Drug has no atc code\n",
      "DB03109\n",
      "Drug has no atc code\n",
      "DB03110\n",
      "Drug has no atc code\n",
      "DB03111\n",
      "Drug has no atc code\n",
      "DB03112\n",
      "Drug has no atc code\n",
      "DB03113\n",
      "Drug has no atc code\n",
      "DB03114\n",
      "Drug has no atc code\n",
      "DB03115\n",
      "Drug has no atc code\n",
      "DB03116\n",
      "Drug has no atc code\n",
      "DB03117\n",
      "Drug has no atc code\n",
      "DB03118\n",
      "Drug has no atc code\n",
      "DB03120\n",
      "Drug has no atc code\n",
      "DB03121\n",
      "Drug has no atc code\n",
      "DB03124\n",
      "Drug has no atc code\n",
      "DB03125\n",
      "Drug has no atc code\n",
      "DB03126\n",
      "Drug has no atc code\n",
      "DB03127\n",
      "DB03128\n",
      "Drug has no atc code\n",
      "DB03129\n",
      "Drug has no atc code\n",
      "DB03130\n",
      "Drug has no atc code\n",
      "DB03132\n",
      "Drug has no atc code\n",
      "DB03133\n",
      "Drug has no atc code\n",
      "DB03134\n",
      "Drug has no atc code\n",
      "DB03135\n",
      "Drug has no atc code\n",
      "DB03136\n",
      "Drug has no atc code\n",
      "DB03137\n",
      "Drug has no atc code\n",
      "DB03138\n",
      "Drug has no atc code\n",
      "DB03139\n",
      "Drug has no atc code\n",
      "DB03140\n",
      "Drug has no atc code\n",
      "DB03141\n",
      "Drug has no atc code\n",
      "DB03142\n",
      "Drug has no atc code\n",
      "DB03143\n",
      "Drug has no atc code\n",
      "DB03144\n",
      "Drug has no atc code\n",
      "DB03145\n",
      "Drug has no atc code\n",
      "DB03146\n",
      "Drug has no atc code\n",
      "DB03147\n",
      "Drug has no atc code\n",
      "DB03148\n",
      "Drug has no atc code\n",
      "DB03150\n",
      "Drug has no atc code\n",
      "DB03151\n",
      "Drug has no atc code\n",
      "DB03152\n",
      "Drug has no atc code\n",
      "DB03153\n",
      "Drug has no atc code\n",
      "DB03154\n",
      "Drug has no atc code\n",
      "DB03155\n",
      "Drug has no atc code\n",
      "DB03156\n",
      "Drug has no atc code\n",
      "DB03157\n",
      "Drug has no atc code\n",
      "DB03158\n",
      "Drug has no atc code\n",
      "DB03159\n",
      "Drug has no atc code\n",
      "DB03160\n",
      "Drug has no atc code\n",
      "DB03161\n",
      "Drug has no atc code\n",
      "DB03162\n",
      "Drug has no atc code\n",
      "DB03163\n",
      "Drug has no atc code\n",
      "DB03164\n",
      "Drug has no atc code\n",
      "DB03165\n",
      "DB03166\n",
      "Drug has no atc code\n",
      "DB03167\n",
      "Drug has no atc code\n",
      "DB03168\n",
      "Drug has no atc code\n",
      "DB03169\n",
      "Drug has no atc code\n",
      "DB03170\n",
      "Drug has no atc code\n",
      "DB03171\n",
      "Drug has no atc code\n",
      "DB03172\n",
      "Drug has no atc code\n",
      "DB03173\n",
      "Drug has no atc code\n",
      "DB03174\n",
      "DB03175\n",
      "Drug has no atc code\n",
      "DB03176\n",
      "Drug has no atc code\n",
      "DB03177\n",
      "Drug has no atc code\n",
      "DB03178\n",
      "Drug has no atc code\n",
      "DB03179\n",
      "Drug has no atc code\n",
      "DB03180\n",
      "Drug has no atc code\n",
      "DB03181\n",
      "Drug has no atc code\n",
      "DB03182\n",
      "Drug has no atc code\n",
      "DB03183\n",
      "Drug has no atc code\n",
      "DB03184\n",
      "Drug has no atc code\n",
      "DB03185\n",
      "Drug has no atc code\n",
      "DB03186\n",
      "Drug has no atc code\n",
      "DB03187\n",
      "Drug has no atc code\n",
      "DB03189\n",
      "Drug has no atc code\n",
      "DB03190\n",
      "Drug has no atc code\n",
      "DB03191\n",
      "Drug has no atc code\n",
      "DB03192\n",
      "Drug has no atc code\n",
      "DB03193\n",
      "Drug has no atc code\n",
      "DB03194\n",
      "Drug has no atc code\n",
      "DB03195\n",
      "Drug has no atc code\n",
      "DB03196\n",
      "Drug has no atc code\n",
      "DB03197\n",
      "Drug has no atc code\n",
      "DB03198\n",
      "Drug has no atc code\n",
      "DB03199\n",
      "Drug has no atc code\n",
      "DB03200\n",
      "Drug has no atc code\n",
      "DB03201\n",
      "Drug has no atc code\n",
      "DB03202\n",
      "Drug has no atc code\n",
      "DB03203\n",
      "Drug has no atc code\n",
      "DB03204\n",
      "Drug has no atc code\n",
      "DB03205\n",
      "Drug has no atc code\n",
      "DB03206\n",
      "Drug has no atc code\n",
      "DB03207\n",
      "Drug has no atc code\n",
      "DB03208\n",
      "Drug has no atc code\n",
      "DB03209\n",
      "Drug has no atc code\n",
      "DB03210\n",
      "Drug has no atc code\n",
      "DB03211\n",
      "Drug has no atc code\n",
      "DB03212\n",
      "Drug has no atc code\n",
      "DB03213\n",
      "Drug has no atc code\n",
      "DB03214\n",
      "Drug has no atc code\n",
      "DB03215\n",
      "Drug has no atc code\n",
      "DB03216\n",
      "Drug has no atc code\n",
      "DB03217\n",
      "Drug has no atc code\n",
      "DB03218\n",
      "Drug has no atc code\n",
      "DB03219\n",
      "Drug has no atc code\n",
      "DB03220\n",
      "Drug has no atc code\n",
      "DB03221\n",
      "Drug has no atc code\n",
      "DB03222\n",
      "Drug has no atc code\n",
      "DB03223\n",
      "Drug has no atc code\n",
      "DB03224\n",
      "Drug has no atc code\n",
      "DB03225\n",
      "Drug has no atc code\n",
      "DB03226\n",
      "Drug has no atc code\n",
      "DB03227\n",
      "Drug has no atc code\n",
      "DB03228\n",
      "Drug has no atc code\n",
      "DB03229\n",
      "Drug has no atc code\n",
      "DB03230\n",
      "Drug has no atc code\n",
      "DB03231\n",
      "Drug has no atc code\n",
      "DB03232\n",
      "Drug has no atc code\n",
      "DB03233\n",
      "Drug has no atc code\n",
      "DB03234\n",
      "Drug has no atc code\n",
      "DB03235\n",
      "Drug has no atc code\n",
      "DB03236\n",
      "Drug has no atc code\n",
      "DB03237\n",
      "Drug has no atc code\n",
      "DB03238\n",
      "Drug has no atc code\n",
      "DB03239\n",
      "Drug has no atc code\n",
      "DB03240\n",
      "Drug has no atc code\n",
      "DB03241\n",
      "Drug has no atc code\n",
      "DB03242\n",
      "Drug has no atc code\n",
      "DB03243\n",
      "Drug has no atc code\n",
      "DB03244\n",
      "Drug has no atc code\n",
      "DB03245\n",
      "Drug has no atc code\n",
      "DB03246\n",
      "Drug has no atc code\n",
      "DB03247\n",
      "Drug has no atc code\n",
      "DB03248\n",
      "Drug has no atc code\n",
      "DB03249\n",
      "Drug has no atc code\n",
      "DB03250\n",
      "Drug has no atc code\n",
      "DB03251\n",
      "Drug has no atc code\n",
      "DB03252\n",
      "Drug has no atc code\n",
      "DB03253\n",
      "Drug has no atc code\n",
      "DB03254\n",
      "DB03255\n",
      "Drug has no atc code\n",
      "DB03256\n",
      "Drug has no atc code\n",
      "DB03257\n",
      "Drug has no atc code\n",
      "DB03258\n",
      "Drug has no atc code\n",
      "DB03259\n",
      "Drug has no atc code\n",
      "DB03260\n",
      "Drug has no atc code\n",
      "DB03262\n",
      "Drug has no atc code\n",
      "DB03263\n",
      "Drug has no atc code\n",
      "DB03264\n",
      "Drug has no atc code\n",
      "DB03266\n",
      "Drug has no atc code\n",
      "DB03267\n",
      "Drug has no atc code\n",
      "DB03268\n",
      "Drug has no atc code\n",
      "DB03269\n",
      "Drug has no atc code\n",
      "DB03270\n",
      "Drug has no atc code\n",
      "DB03272\n",
      "Drug has no atc code\n",
      "DB03273\n",
      "Drug has no atc code\n",
      "DB03274\n",
      "Drug has no atc code\n",
      "DB03275\n",
      "Drug has no atc code\n",
      "DB03276\n",
      "Drug has no atc code\n",
      "DB03277\n",
      "Drug has no atc code\n",
      "DB03278\n",
      "Drug has no atc code\n",
      "DB03279\n",
      "Drug has no atc code\n",
      "DB03280\n",
      "Drug has no atc code\n",
      "DB03281\n",
      "Drug has no atc code\n",
      "DB03283\n",
      "Drug has no atc code\n",
      "DB03284\n",
      "Drug has no atc code\n",
      "DB03285\n",
      "Drug has no atc code\n",
      "DB03286\n",
      "Drug has no atc code\n",
      "DB03287\n",
      "Drug has no atc code\n",
      "DB03288\n",
      "Drug has no atc code\n",
      "DB03289\n",
      "Drug has no atc code\n",
      "DB03290\n",
      "Drug has no atc code\n",
      "DB03291\n",
      "Drug has no atc code\n",
      "DB03292\n",
      "Drug has no atc code\n",
      "DB03293\n",
      "Drug has no atc code\n",
      "DB03294\n",
      "Drug has no atc code\n",
      "DB03295\n",
      "Drug has no atc code\n",
      "DB03296\n",
      "Drug has no atc code\n",
      "DB03297\n",
      "Drug has no atc code\n",
      "DB03298\n",
      "Drug has no atc code\n",
      "DB03299\n",
      "Drug has no atc code\n",
      "DB03300\n",
      "Drug has no atc code\n",
      "DB03301\n",
      "Drug has no atc code\n",
      "DB03302\n",
      "Drug has no atc code\n",
      "DB03303\n",
      "Drug has no atc code\n",
      "DB03304\n",
      "Drug has no atc code\n",
      "DB03305\n",
      "Drug has no atc code\n",
      "DB03306\n",
      "Drug has no atc code\n",
      "DB03307\n",
      "Drug has no atc code\n",
      "DB03308\n",
      "Drug has no atc code\n",
      "DB03309\n",
      "Drug has no atc code\n",
      "DB03310\n",
      "Drug has no atc code\n",
      "DB03311\n",
      "DB03312\n",
      "Drug has no atc code\n",
      "DB03313\n",
      "Drug has no atc code\n",
      "DB03314\n",
      "Drug has no atc code\n",
      "DB03315\n",
      "Drug has no atc code\n",
      "DB03316\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB03317\n",
      "Drug has no atc code\n",
      "DB03318\n",
      "Drug has no atc code\n",
      "DB03319\n",
      "Drug has no atc code\n",
      "DB03320\n",
      "Drug has no atc code\n",
      "DB03321\n",
      "Drug has no atc code\n",
      "DB03322\n",
      "Drug has no atc code\n",
      "DB03323\n",
      "Drug has no atc code\n",
      "DB03325\n",
      "Drug has no atc code\n",
      "DB03326\n",
      "Drug has no atc code\n",
      "DB03327\n",
      "Drug has no atc code\n",
      "DB03328\n",
      "Drug has no atc code\n",
      "DB03329\n",
      "Drug has no atc code\n",
      "DB03330\n",
      "Drug has no atc code\n",
      "DB03331\n",
      "Drug has no atc code\n",
      "DB03332\n",
      "Drug has no atc code\n",
      "DB03333\n",
      "Drug has no atc code\n",
      "DB03335\n",
      "Drug has no atc code\n",
      "DB03336\n",
      "Drug has no atc code\n",
      "DB03337\n",
      "Drug has no atc code\n",
      "DB03338\n",
      "Drug has no atc code\n",
      "DB03339\n",
      "Drug has no atc code\n",
      "DB03340\n",
      "Drug has no atc code\n",
      "DB03341\n",
      "Drug has no atc code\n",
      "DB03342\n",
      "Drug has no atc code\n",
      "DB03343\n",
      "Drug has no atc code\n",
      "DB03344\n",
      "Drug has no atc code\n",
      "DB03345\n",
      "Drug has no atc code\n",
      "DB03346\n",
      "Drug has no atc code\n",
      "DB03347\n",
      "Drug has no atc code\n",
      "DB03348\n",
      "Drug has no atc code\n",
      "DB03349\n",
      "Drug has no atc code\n",
      "DB03350\n",
      "Drug has no atc code\n",
      "DB03351\n",
      "Drug has no atc code\n",
      "DB03352\n",
      "Drug has no atc code\n",
      "DB03353\n",
      "Drug has no atc code\n",
      "DB03354\n",
      "Drug has no atc code\n",
      "DB03355\n",
      "Drug has no atc code\n",
      "DB03357\n",
      "Drug has no atc code\n",
      "DB03358\n",
      "Drug has no atc code\n",
      "DB03359\n",
      "Drug has no atc code\n",
      "DB03360\n",
      "Drug has no atc code\n",
      "DB03361\n",
      "Drug has no atc code\n",
      "DB03362\n",
      "Drug has no atc code\n",
      "DB03363\n",
      "Drug has no atc code\n",
      "DB03364\n",
      "Drug has no atc code\n",
      "DB03365\n",
      "Drug has no atc code\n",
      "DB03366\n",
      "Drug has no atc code\n",
      "DB03367\n",
      "Drug has no atc code\n",
      "DB03368\n",
      "Drug has no atc code\n",
      "DB03369\n",
      "Drug has no atc code\n",
      "DB03370\n",
      "Drug has no atc code\n",
      "DB03371\n",
      "Drug has no atc code\n",
      "DB03372\n",
      "Drug has no atc code\n",
      "DB03373\n",
      "Drug has no atc code\n",
      "DB03374\n",
      "Drug has no atc code\n",
      "DB03376\n",
      "Drug has no atc code\n",
      "DB03378\n",
      "Drug has no atc code\n",
      "DB03379\n",
      "Drug has no atc code\n",
      "DB03380\n",
      "Drug has no atc code\n",
      "DB03381\n",
      "Drug has no atc code\n",
      "DB03382\n",
      "Drug has no atc code\n",
      "DB03383\n",
      "Drug has no atc code\n",
      "DB03384\n",
      "Drug has no atc code\n",
      "DB03385\n",
      "Drug has no atc code\n",
      "DB03386\n",
      "Drug has no atc code\n",
      "DB03387\n",
      "Drug has no atc code\n",
      "DB03388\n",
      "Drug has no atc code\n",
      "DB03389\n",
      "Drug has no atc code\n",
      "DB03390\n",
      "Drug has no atc code\n",
      "DB03391\n",
      "Drug has no atc code\n",
      "DB03392\n",
      "Drug has no atc code\n",
      "DB03393\n",
      "Drug has no atc code\n",
      "DB03394\n",
      "Drug has no atc code\n",
      "DB03395\n",
      "Drug has no atc code\n",
      "DB03396\n",
      "Drug has no atc code\n",
      "DB03397\n",
      "Drug has no atc code\n",
      "DB03399\n",
      "Drug has no atc code\n",
      "DB03400\n",
      "Drug has no atc code\n",
      "DB03401\n",
      "Drug has no atc code\n",
      "DB03402\n",
      "Drug has no atc code\n",
      "DB03403\n",
      "DB03404\n",
      "Drug has no atc code\n",
      "DB03405\n",
      "Drug has no atc code\n",
      "DB03406\n",
      "Drug has no atc code\n",
      "DB03407\n",
      "Drug has no atc code\n",
      "DB03408\n",
      "Drug has no atc code\n",
      "DB03409\n",
      "Drug has no atc code\n",
      "DB03410\n",
      "Drug has no atc code\n",
      "DB03411\n",
      "Drug has no atc code\n",
      "DB03412\n",
      "Drug has no atc code\n",
      "DB03413\n",
      "Drug has no atc code\n",
      "DB03414\n",
      "Drug has no atc code\n",
      "DB03415\n",
      "Drug has no atc code\n",
      "DB03416\n",
      "Drug has no atc code\n",
      "DB03417\n",
      "Drug has no atc code\n",
      "DB03418\n",
      "Drug has no atc code\n",
      "DB03419\n",
      "Drug has no atc code\n",
      "DB03420\n",
      "Drug has no atc code\n",
      "DB03421\n",
      "Drug has no atc code\n",
      "DB03422\n",
      "Drug has no atc code\n",
      "DB03423\n",
      "Drug has no atc code\n",
      "DB03424\n",
      "Drug has no atc code\n",
      "DB03425\n",
      "Drug has no atc code\n",
      "DB03426\n",
      "Drug has no atc code\n",
      "DB03427\n",
      "Drug has no atc code\n",
      "DB03428\n",
      "Drug has no atc code\n",
      "DB03429\n",
      "Drug has no atc code\n",
      "DB03430\n",
      "Drug has no atc code\n",
      "DB03432\n",
      "Drug has no atc code\n",
      "DB03433\n",
      "Drug has no atc code\n",
      "DB03434\n",
      "Drug has no atc code\n",
      "DB03435\n",
      "Drug has no atc code\n",
      "DB03436\n",
      "Drug has no atc code\n",
      "DB03437\n",
      "Drug has no atc code\n",
      "DB03438\n",
      "Drug has no atc code\n",
      "DB03439\n",
      "Drug has no atc code\n",
      "DB03440\n",
      "Drug has no atc code\n",
      "DB03441\n",
      "Drug has no atc code\n",
      "DB03442\n",
      "Drug has no atc code\n",
      "DB03443\n",
      "Drug has no atc code\n",
      "DB03444\n",
      "Drug has no atc code\n",
      "DB03445\n",
      "Drug has no atc code\n",
      "DB03446\n",
      "Drug has no atc code\n",
      "DB03447\n",
      "Drug has no atc code\n",
      "DB03448\n",
      "Drug has no atc code\n",
      "DB03449\n",
      "Drug has no atc code\n",
      "DB03450\n",
      "Drug has no atc code\n",
      "DB03451\n",
      "Drug has no atc code\n",
      "DB03452\n",
      "Drug has no atc code\n",
      "DB03453\n",
      "Drug has no atc code\n",
      "DB03454\n",
      "Drug has no atc code\n",
      "DB03455\n",
      "Drug has no atc code\n",
      "DB03456\n",
      "Drug has no atc code\n",
      "DB03458\n",
      "Drug has no atc code\n",
      "DB03459\n",
      "Drug has no atc code\n",
      "DB03460\n",
      "Drug has no atc code\n",
      "DB03461\n",
      "Drug has no atc code\n",
      "DB03462\n",
      "Drug has no atc code\n",
      "DB03464\n",
      "Drug has no atc code\n",
      "DB03466\n",
      "Drug has no atc code\n",
      "DB03467\n",
      "Drug has no atc code\n",
      "DB03468\n",
      "Drug has no atc code\n",
      "DB03469\n",
      "Drug has no atc code\n",
      "DB03470\n",
      "Drug has no atc code\n",
      "DB03471\n",
      "Drug has no atc code\n",
      "DB03472\n",
      "Drug has no atc code\n",
      "DB03473\n",
      "Drug has no atc code\n",
      "DB03474\n",
      "Drug has no atc code\n",
      "DB03475\n",
      "Drug has no atc code\n",
      "DB03476\n",
      "Drug has no atc code\n",
      "DB03477\n",
      "Drug has no atc code\n",
      "DB03478\n",
      "Drug has no atc code\n",
      "DB03479\n",
      "Drug has no atc code\n",
      "DB03480\n",
      "Drug has no atc code\n",
      "DB03481\n",
      "Drug has no atc code\n",
      "DB03482\n",
      "Drug has no atc code\n",
      "DB03483\n",
      "Drug has no atc code\n",
      "DB03484\n",
      "Drug has no atc code\n",
      "DB03485\n",
      "Drug has no atc code\n",
      "DB03486\n",
      "Drug has no atc code\n",
      "DB03487\n",
      "Drug has no atc code\n",
      "DB03488\n",
      "Drug has no atc code\n",
      "DB03489\n",
      "Drug has no atc code\n",
      "DB03490\n",
      "Drug has no atc code\n",
      "DB03491\n",
      "Drug has no atc code\n",
      "DB03492\n",
      "Drug has no atc code\n",
      "DB03493\n",
      "Drug has no atc code\n",
      "DB03495\n",
      "Drug has no atc code\n",
      "DB03496\n",
      "Drug has no atc code\n",
      "DB03497\n",
      "Drug has no atc code\n",
      "DB03498\n",
      "Drug has no atc code\n",
      "DB03499\n",
      "Drug has no atc code\n",
      "DB03500\n",
      "Drug has no atc code\n",
      "DB03501\n",
      "Drug has no atc code\n",
      "DB03502\n",
      "Drug has no atc code\n",
      "DB03503\n",
      "Drug has no atc code\n",
      "DB03504\n",
      "Drug has no atc code\n",
      "DB03505\n",
      "Drug has no atc code\n",
      "DB03506\n",
      "Drug has no atc code\n",
      "DB03507\n",
      "Drug has no atc code\n",
      "DB03508\n",
      "Drug has no atc code\n",
      "DB03509\n",
      "Drug has no atc code\n",
      "DB03510\n",
      "Drug has no atc code\n",
      "DB03511\n",
      "Drug has no atc code\n",
      "DB03512\n",
      "Drug has no atc code\n",
      "DB03513\n",
      "Drug has no atc code\n",
      "DB03514\n",
      "Drug has no atc code\n",
      "DB03515\n",
      "Drug has no atc code\n",
      "DB03516\n",
      "Drug has no atc code\n",
      "DB03517\n",
      "Drug has no atc code\n",
      "DB03518\n",
      "Drug has no atc code\n",
      "DB03520\n",
      "Drug has no atc code\n",
      "DB03522\n",
      "Drug has no atc code\n",
      "DB03523\n",
      "Drug has no atc code\n",
      "DB03524\n",
      "Drug has no atc code\n",
      "DB03525\n",
      "Drug has no atc code\n",
      "DB03526\n",
      "Drug has no atc code\n",
      "DB03528\n",
      "Drug has no atc code\n",
      "DB03530\n",
      "Drug has no atc code\n",
      "DB03531\n",
      "Drug has no atc code\n",
      "DB03532\n",
      "Drug has no atc code\n",
      "DB03533\n",
      "Drug has no atc code\n",
      "DB03534\n",
      "Drug has no atc code\n",
      "DB03535\n",
      "Drug has no atc code\n",
      "DB03536\n",
      "Drug has no atc code\n",
      "DB03537\n",
      "Drug has no atc code\n",
      "DB03539\n",
      "Drug has no atc code\n",
      "DB03540\n",
      "Drug has no atc code\n",
      "DB03541\n",
      "Drug has no atc code\n",
      "DB03542\n",
      "Drug has no atc code\n",
      "DB03543\n",
      "Drug has no atc code\n",
      "DB03544\n",
      "Drug has no atc code\n",
      "DB03546\n",
      "Drug has no atc code\n",
      "DB03548\n",
      "Drug has no atc code\n",
      "DB03549\n",
      "Drug has no atc code\n",
      "DB03550\n",
      "Drug has no atc code\n",
      "DB03551\n",
      "Drug has no atc code\n",
      "DB03552\n",
      "Drug has no atc code\n",
      "DB03553\n",
      "Drug has no atc code\n",
      "DB03554\n",
      "Drug has no atc code\n",
      "DB03555\n",
      "Drug has no atc code\n",
      "DB03556\n",
      "Drug has no atc code\n",
      "DB03557\n",
      "Drug has no atc code\n",
      "DB03558\n",
      "Drug has no atc code\n",
      "DB03559\n",
      "Drug has no atc code\n",
      "DB03560\n",
      "Drug has no atc code\n",
      "DB03562\n",
      "Drug has no atc code\n",
      "DB03564\n",
      "Drug has no atc code\n",
      "DB03565\n",
      "Drug has no atc code\n",
      "DB03566\n",
      "Drug has no atc code\n",
      "DB03567\n",
      "Drug has no atc code\n",
      "DB03568\n",
      "Drug has no atc code\n",
      "DB03569\n",
      "Drug has no atc code\n",
      "DB03570\n",
      "Drug has no atc code\n",
      "DB03571\n",
      "Drug has no atc code\n",
      "DB03572\n",
      "Drug has no atc code\n",
      "DB03573\n",
      "Drug has no atc code\n",
      "DB03574\n",
      "Drug has no atc code\n",
      "DB03575\n",
      "Drug has no atc code\n",
      "DB03576\n",
      "Drug has no atc code\n",
      "DB03577\n",
      "Drug has no atc code\n",
      "DB03578\n",
      "Drug has no atc code\n",
      "DB03581\n",
      "Drug has no atc code\n",
      "DB03582\n",
      "Drug has no atc code\n",
      "DB03583\n",
      "Drug has no atc code\n",
      "DB03584\n",
      "DB03585\n",
      "Drug has no atc code\n",
      "DB03586\n",
      "Drug has no atc code\n",
      "DB03587\n",
      "Drug has no atc code\n",
      "DB03588\n",
      "Drug has no atc code\n",
      "DB03589\n",
      "Drug has no atc code\n",
      "DB03590\n",
      "Drug has no atc code\n",
      "DB03591\n",
      "Drug has no atc code\n",
      "DB03592\n",
      "Drug has no atc code\n",
      "DB03593\n",
      "Drug has no atc code\n",
      "DB03594\n",
      "Drug has no atc code\n",
      "DB03595\n",
      "Drug has no atc code\n",
      "DB03596\n",
      "Drug has no atc code\n",
      "DB03597\n",
      "Drug has no atc code\n",
      "DB03598\n",
      "Drug has no atc code\n",
      "DB03600\n",
      "Drug has no atc code\n",
      "DB03601\n",
      "Drug has no atc code\n",
      "DB03602\n",
      "Drug has no atc code\n",
      "DB03603\n",
      "DB03604\n",
      "Drug has no atc code\n",
      "DB03605\n",
      "Drug has no atc code\n",
      "DB03606\n",
      "Drug has no atc code\n",
      "DB03607\n",
      "Drug has no atc code\n",
      "DB03608\n",
      "Drug has no atc code\n",
      "DB03609\n",
      "Drug has no atc code\n",
      "DB03610\n",
      "Drug has no atc code\n",
      "DB03611\n",
      "Drug has no atc code\n",
      "DB03612\n",
      "Drug has no atc code\n",
      "DB03613\n",
      "DB03614\n",
      "DB03615\n",
      "Drug has no atc code\n",
      "DB03616\n",
      "Drug has no atc code\n",
      "DB03617\n",
      "Drug has no atc code\n",
      "DB03618\n",
      "DB03619\n",
      "Drug has no atc code\n",
      "DB03621\n",
      "Drug has no atc code\n",
      "DB03622\n",
      "Drug has no atc code\n",
      "DB03623\n",
      "Drug has no atc code\n",
      "DB03624\n",
      "Drug has no atc code\n",
      "DB03626\n",
      "Drug has no atc code\n",
      "DB03627\n",
      "Drug has no atc code\n",
      "DB03628\n",
      "Drug has no atc code\n",
      "DB03629\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB03630\n",
      "Drug has no atc code\n",
      "DB03631\n",
      "Drug has no atc code\n",
      "DB03632\n",
      "Drug has no atc code\n",
      "DB03633\n",
      "Drug has no atc code\n",
      "DB03634\n",
      "Drug has no atc code\n",
      "DB03635\n",
      "Drug has no atc code\n",
      "DB03636\n",
      "Drug has no atc code\n",
      "DB03637\n",
      "Drug has no atc code\n",
      "DB03638\n",
      "Drug has no atc code\n",
      "DB03639\n",
      "Drug has no atc code\n",
      "DB03640\n",
      "Drug has no atc code\n",
      "DB03641\n",
      "Drug has no atc code\n",
      "DB03642\n",
      "Drug has no atc code\n",
      "DB03643\n",
      "Drug has no atc code\n",
      "DB03644\n",
      "Drug has no atc code\n",
      "DB03645\n",
      "Drug has no atc code\n",
      "DB03646\n",
      "Drug has no atc code\n",
      "DB03647\n",
      "Drug has no atc code\n",
      "DB03648\n",
      "Drug has no atc code\n",
      "DB03649\n",
      "Drug has no atc code\n",
      "DB03650\n",
      "Drug has no atc code\n",
      "DB03651\n",
      "Drug has no atc code\n",
      "DB03652\n",
      "Drug has no atc code\n",
      "DB03653\n",
      "Drug has no atc code\n",
      "DB03654\n",
      "Drug has no atc code\n",
      "DB03656\n",
      "Drug has no atc code\n",
      "DB03657\n",
      "Drug has no atc code\n",
      "DB03658\n",
      "Drug has no atc code\n",
      "DB03659\n",
      "Drug has no atc code\n",
      "DB03660\n",
      "Drug has no atc code\n",
      "DB03661\n",
      "Drug has no atc code\n",
      "DB03662\n",
      "Drug has no atc code\n",
      "DB03663\n",
      "Drug has no atc code\n",
      "DB03664\n",
      "Drug has no atc code\n",
      "DB03666\n",
      "Drug has no atc code\n",
      "DB03667\n",
      "Drug has no atc code\n",
      "DB03668\n",
      "Drug has no atc code\n",
      "DB03669\n",
      "Drug has no atc code\n",
      "DB03670\n",
      "Drug has no atc code\n",
      "DB03671\n",
      "Drug has no atc code\n",
      "DB03672\n",
      "Drug has no atc code\n",
      "DB03673\n",
      "Drug has no atc code\n",
      "DB03675\n",
      "Drug has no atc code\n",
      "DB03676\n",
      "Drug has no atc code\n",
      "DB03677\n",
      "Drug has no atc code\n",
      "DB03678\n",
      "Drug has no atc code\n",
      "DB03679\n",
      "Drug has no atc code\n",
      "DB03680\n",
      "Drug has no atc code\n",
      "DB03682\n",
      "Drug has no atc code\n",
      "DB03683\n",
      "Drug has no atc code\n",
      "DB03685\n",
      "Drug has no atc code\n",
      "DB03686\n",
      "Drug has no atc code\n",
      "DB03687\n",
      "Drug has no atc code\n",
      "DB03688\n",
      "Drug has no atc code\n",
      "DB03690\n",
      "Drug has no atc code\n",
      "DB03691\n",
      "Drug has no atc code\n",
      "DB03692\n",
      "Drug has no atc code\n",
      "DB03693\n",
      "Drug has no atc code\n",
      "DB03694\n",
      "Drug has no atc code\n",
      "DB03695\n",
      "Drug has no atc code\n",
      "DB03696\n",
      "Drug has no atc code\n",
      "DB03697\n",
      "Drug has no atc code\n",
      "DB03698\n",
      "Drug has no atc code\n",
      "DB03699\n",
      "Drug has no atc code\n",
      "DB03700\n",
      "Drug has no atc code\n",
      "DB03701\n",
      "Drug has no atc code\n",
      "DB03702\n",
      "Drug has no atc code\n",
      "DB03703\n",
      "Drug has no atc code\n",
      "DB03704\n",
      "Drug has no atc code\n",
      "DB03705\n",
      "Drug has no atc code\n",
      "DB03706\n",
      "Drug has no atc code\n",
      "DB03707\n",
      "Drug has no atc code\n",
      "DB03708\n",
      "Drug has no atc code\n",
      "DB03709\n",
      "Drug has no atc code\n",
      "DB03710\n",
      "Drug has no atc code\n",
      "DB03711\n",
      "Drug has no atc code\n",
      "DB03712\n",
      "Drug has no atc code\n",
      "DB03714\n",
      "Drug has no atc code\n",
      "DB03716\n",
      "Drug has no atc code\n",
      "DB03717\n",
      "Drug has no atc code\n",
      "DB03718\n",
      "Drug has no atc code\n",
      "DB03719\n",
      "Drug has no atc code\n",
      "DB03720\n",
      "Drug has no atc code\n",
      "DB03721\n",
      "Drug has no atc code\n",
      "DB03722\n",
      "Drug has no atc code\n",
      "DB03723\n",
      "Drug has no atc code\n",
      "DB03724\n",
      "Drug has no atc code\n",
      "DB03725\n",
      "Drug has no atc code\n",
      "DB03726\n",
      "Drug has no atc code\n",
      "DB03727\n",
      "Drug has no atc code\n",
      "DB03728\n",
      "Drug has no atc code\n",
      "DB03729\n",
      "Drug has no atc code\n",
      "DB03730\n",
      "Drug has no atc code\n",
      "DB03731\n",
      "Drug has no atc code\n",
      "DB03732\n",
      "Drug has no atc code\n",
      "DB03733\n",
      "Drug has no atc code\n",
      "DB03734\n",
      "Drug has no atc code\n",
      "DB03735\n",
      "Drug has no atc code\n",
      "DB03736\n",
      "Drug has no atc code\n",
      "DB03737\n",
      "Drug has no atc code\n",
      "DB03738\n",
      "Drug has no atc code\n",
      "DB03739\n",
      "Drug has no atc code\n",
      "DB03740\n",
      "Drug has no atc code\n",
      "DB03741\n",
      "Drug has no atc code\n",
      "DB03742\n",
      "Drug has no atc code\n",
      "DB03744\n",
      "Drug has no atc code\n",
      "DB03745\n",
      "Drug has no atc code\n",
      "DB03746\n",
      "Drug has no atc code\n",
      "DB03747\n",
      "Drug has no atc code\n",
      "DB03748\n",
      "Drug has no atc code\n",
      "DB03749\n",
      "Drug has no atc code\n",
      "DB03750\n",
      "Drug has no atc code\n",
      "DB03751\n",
      "Drug has no atc code\n",
      "DB03752\n",
      "Drug has no atc code\n",
      "DB03753\n",
      "DB03754\n",
      "Drug has no atc code\n",
      "DB03755\n",
      "Drug has no atc code\n",
      "DB03756\n",
      "Drug has no atc code\n",
      "DB03757\n",
      "Drug has no atc code\n",
      "DB03758\n",
      "Drug has no atc code\n",
      "DB03759\n",
      "Drug has no atc code\n",
      "DB03760\n",
      "Drug has no atc code\n",
      "DB03761\n",
      "Drug has no atc code\n",
      "DB03763\n",
      "Drug has no atc code\n",
      "DB03764\n",
      "Drug has no atc code\n",
      "DB03765\n",
      "DB03766\n",
      "Drug has no atc code\n",
      "DB03767\n",
      "Drug has no atc code\n",
      "DB03768\n",
      "Drug has no atc code\n",
      "DB03769\n",
      "Drug has no atc code\n",
      "DB03770\n",
      "Drug has no atc code\n",
      "DB03771\n",
      "Drug has no atc code\n",
      "DB03772\n",
      "Drug has no atc code\n",
      "DB03773\n",
      "Drug has no atc code\n",
      "DB03774\n",
      "Drug has no atc code\n",
      "DB03775\n",
      "Drug has no atc code\n",
      "DB03776\n",
      "Drug has no atc code\n",
      "DB03777\n",
      "Drug has no atc code\n",
      "DB03779\n",
      "Drug has no atc code\n",
      "DB03780\n",
      "Drug has no atc code\n",
      "DB03781\n",
      "Drug has no atc code\n",
      "DB03782\n",
      "DB03783\n",
      "Drug has no atc code\n",
      "DB03784\n",
      "Drug has no atc code\n",
      "DB03785\n",
      "Drug has no atc code\n",
      "DB03787\n",
      "Drug has no atc code\n",
      "DB03788\n",
      "Drug has no atc code\n",
      "DB03789\n",
      "Drug has no atc code\n",
      "DB03790\n",
      "Drug has no atc code\n",
      "DB03791\n",
      "Drug has no atc code\n",
      "DB03792\n",
      "DB03793\n",
      "Drug has no atc code\n",
      "DB03794\n",
      "Drug has no atc code\n",
      "DB03795\n",
      "Drug has no atc code\n",
      "DB03796\n",
      "Drug has no atc code\n",
      "DB03797\n",
      "Drug has no atc code\n",
      "DB03798\n",
      "Drug has no atc code\n",
      "DB03799\n",
      "Drug has no atc code\n",
      "DB03800\n",
      "Drug has no atc code\n",
      "DB03801\n",
      "Drug has no atc code\n",
      "DB03802\n",
      "Drug has no atc code\n",
      "DB03803\n",
      "Drug has no atc code\n",
      "DB03804\n",
      "Drug has no atc code\n",
      "DB03807\n",
      "DB03808\n",
      "Drug has no atc code\n",
      "DB03809\n",
      "Drug has no atc code\n",
      "DB03810\n",
      "Drug has no atc code\n",
      "DB03811\n",
      "Drug has no atc code\n",
      "DB03812\n",
      "Drug has no atc code\n",
      "DB03813\n",
      "Drug has no atc code\n",
      "DB03814\n",
      "Drug has no atc code\n",
      "DB03815\n",
      "Drug has no atc code\n",
      "DB03816\n",
      "Drug has no atc code\n",
      "DB03817\n",
      "Drug has no atc code\n",
      "DB03818\n",
      "Drug has no atc code\n",
      "DB03819\n",
      "Drug has no atc code\n",
      "DB03820\n",
      "Drug has no atc code\n",
      "DB03821\n",
      "Drug has no atc code\n",
      "DB03822\n",
      "Drug has no atc code\n",
      "DB03823\n",
      "Drug has no atc code\n",
      "DB03824\n",
      "Drug has no atc code\n",
      "DB03825\n",
      "Drug has no atc code\n",
      "DB03826\n",
      "Drug has no atc code\n",
      "DB03827\n",
      "Drug has no atc code\n",
      "DB03828\n",
      "Drug has no atc code\n",
      "DB03829\n",
      "Drug has no atc code\n",
      "DB03830\n",
      "Drug has no atc code\n",
      "DB03831\n",
      "Drug has no atc code\n",
      "DB03832\n",
      "Drug has no atc code\n",
      "DB03833\n",
      "Drug has no atc code\n",
      "DB03834\n",
      "Drug has no atc code\n",
      "DB03835\n",
      "Drug has no atc code\n",
      "DB03836\n",
      "Drug has no atc code\n",
      "DB03837\n",
      "Drug has no atc code\n",
      "DB03839\n",
      "Drug has no atc code\n",
      "DB03840\n",
      "Drug has no atc code\n",
      "DB03841\n",
      "Drug has no atc code\n",
      "DB03842\n",
      "Drug has no atc code\n",
      "DB03843\n",
      "Drug has no atc code\n",
      "DB03844\n",
      "Drug has no atc code\n",
      "DB03845\n",
      "Drug has no atc code\n",
      "DB03846\n",
      "Drug has no atc code\n",
      "DB03847\n",
      "Drug has no atc code\n",
      "DB03848\n",
      "Drug has no atc code\n",
      "DB03849\n",
      "Drug has no atc code\n",
      "DB03850\n",
      "Drug has no atc code\n",
      "DB03851\n",
      "DB03852\n",
      "Drug has no atc code\n",
      "DB03853\n",
      "Drug has no atc code\n",
      "DB03854\n",
      "Drug has no atc code\n",
      "DB03855\n",
      "Drug has no atc code\n",
      "DB03856\n",
      "Drug has no atc code\n",
      "DB03857\n",
      "Drug has no atc code\n",
      "DB03858\n",
      "Drug has no atc code\n",
      "DB03859\n",
      "Drug has no atc code\n",
      "DB03860\n",
      "Drug has no atc code\n",
      "DB03861\n",
      "Drug has no atc code\n",
      "DB03862\n",
      "Drug has no atc code\n",
      "DB03863\n",
      "Drug has no atc code\n",
      "DB03864\n",
      "Drug has no atc code\n",
      "DB03865\n",
      "Drug has no atc code\n",
      "DB03866\n",
      "Drug has no atc code\n",
      "DB03867\n",
      "Drug has no atc code\n",
      "DB03868\n",
      "Drug has no atc code\n",
      "DB03869\n",
      "Drug has no atc code\n",
      "DB03870\n",
      "Drug has no atc code\n",
      "DB03871\n",
      "Drug has no atc code\n",
      "DB03872\n",
      "Drug has no atc code\n",
      "DB03874\n",
      "Drug has no atc code\n",
      "DB03876\n",
      "Drug has no atc code\n",
      "DB03877\n",
      "Drug has no atc code\n",
      "DB03878\n",
      "Drug has no atc code\n",
      "DB03879\n",
      "Drug has no atc code\n",
      "DB03880\n",
      "Drug has no atc code\n",
      "DB03881\n",
      "Drug has no atc code\n",
      "DB03882\n",
      "Drug has no atc code\n",
      "DB03883\n",
      "Drug has no atc code\n",
      "DB03884\n",
      "Drug has no atc code\n",
      "DB03885\n",
      "Drug has no atc code\n",
      "DB03886\n",
      "Drug has no atc code\n",
      "DB03887\n",
      "Drug has no atc code\n",
      "DB03888\n",
      "Drug has no atc code\n",
      "DB03889\n",
      "Drug has no atc code\n",
      "DB03890\n",
      "Drug has no atc code\n",
      "DB03891\n",
      "Drug has no atc code\n",
      "DB03892\n",
      "Drug has no atc code\n",
      "DB03893\n",
      "Drug has no atc code\n",
      "DB03894\n",
      "Drug has no atc code\n",
      "DB03895\n",
      "Drug has no atc code\n",
      "DB03896\n",
      "Drug has no atc code\n",
      "DB03897\n",
      "Drug has no atc code\n",
      "DB03898\n",
      "Drug has no atc code\n",
      "DB03899\n",
      "Drug has no atc code\n",
      "DB03900\n",
      "Drug has no atc code\n",
      "DB03901\n",
      "Drug has no atc code\n",
      "DB03902\n",
      "Drug has no atc code\n",
      "DB03903\n",
      "DB03904\n",
      "Drug has no atc code\n",
      "DB03905\n",
      "Drug has no atc code\n",
      "DB03906\n",
      "Drug has no atc code\n",
      "DB03907\n",
      "Drug has no atc code\n",
      "DB03908\n",
      "Drug has no atc code\n",
      "DB03909\n",
      "Drug has no atc code\n",
      "DB03910\n",
      "Drug has no atc code\n",
      "DB03911\n",
      "Drug has no atc code\n",
      "DB03912\n",
      "Drug has no atc code\n",
      "DB03913\n",
      "Drug has no atc code\n",
      "DB03914\n",
      "Drug has no atc code\n",
      "DB03915\n",
      "Drug has no atc code\n",
      "DB03916\n",
      "Drug has no atc code\n",
      "DB03917\n",
      "Drug has no atc code\n",
      "DB03918\n",
      "Drug has no atc code\n",
      "DB03919\n",
      "Drug has no atc code\n",
      "DB03920\n",
      "Drug has no atc code\n",
      "DB03921\n",
      "Drug has no atc code\n",
      "DB03923\n",
      "Drug has no atc code\n",
      "DB03924\n",
      "Drug has no atc code\n",
      "DB03925\n",
      "Drug has no atc code\n",
      "DB03926\n",
      "Drug has no atc code\n",
      "DB03927\n",
      "Drug has no atc code\n",
      "DB03928\n",
      "Drug has no atc code\n",
      "DB03929\n",
      "Drug has no atc code\n",
      "DB03930\n",
      "Drug has no atc code\n",
      "DB03931\n",
      "Drug has no atc code\n",
      "DB03932\n",
      "Drug has no atc code\n",
      "DB03933\n",
      "Drug has no atc code\n",
      "DB03934\n",
      "Drug has no atc code\n",
      "DB03935\n",
      "Drug has no atc code\n",
      "DB03936\n",
      "Drug has no atc code\n",
      "DB03937\n",
      "Drug has no atc code\n",
      "DB03938\n",
      "Drug has no atc code\n",
      "DB03939\n",
      "Drug has no atc code\n",
      "DB03940\n",
      "Drug has no atc code\n",
      "DB03941\n",
      "Drug has no atc code\n",
      "DB03942\n",
      "Drug has no atc code\n",
      "DB03943\n",
      "Drug has no atc code\n",
      "DB03944\n",
      "Drug has no atc code\n",
      "DB03945\n",
      "Drug has no atc code\n",
      "DB03946\n",
      "Drug has no atc code\n",
      "DB03947\n",
      "Drug has no atc code\n",
      "DB03948\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB03949\n",
      "Drug has no atc code\n",
      "DB03950\n",
      "Drug has no atc code\n",
      "DB03951\n",
      "Drug has no atc code\n",
      "DB03952\n",
      "Drug has no atc code\n",
      "DB03953\n",
      "Drug has no atc code\n",
      "DB03955\n",
      "Drug has no atc code\n",
      "DB03956\n",
      "Drug has no atc code\n",
      "DB03957\n",
      "Drug has no atc code\n",
      "DB03958\n",
      "Drug has no atc code\n",
      "DB03959\n",
      "Drug has no atc code\n",
      "DB03960\n",
      "Drug has no atc code\n",
      "DB03961\n",
      "Drug has no atc code\n",
      "DB03962\n",
      "Drug has no atc code\n",
      "DB03963\n",
      "Drug has no atc code\n",
      "DB03964\n",
      "Drug has no atc code\n",
      "DB03966\n",
      "Drug has no atc code\n",
      "DB03967\n",
      "Drug has no atc code\n",
      "DB03968\n",
      "Drug has no atc code\n",
      "DB03970\n",
      "Drug has no atc code\n",
      "DB03971\n",
      "Drug has no atc code\n",
      "DB03972\n",
      "Drug has no atc code\n",
      "DB03973\n",
      "Drug has no atc code\n",
      "DB03974\n",
      "Drug has no atc code\n",
      "DB03975\n",
      "Drug has no atc code\n",
      "DB03976\n",
      "Drug has no atc code\n",
      "DB03977\n",
      "Drug has no atc code\n",
      "DB03978\n",
      "Drug has no atc code\n",
      "DB03979\n",
      "Drug has no atc code\n",
      "DB03980\n",
      "Drug has no atc code\n",
      "DB03981\n",
      "Drug has no atc code\n",
      "DB03982\n",
      "Drug has no atc code\n",
      "DB03983\n",
      "Drug has no atc code\n",
      "DB03984\n",
      "Drug has no atc code\n",
      "DB03985\n",
      "Drug has no atc code\n",
      "DB03986\n",
      "Drug has no atc code\n",
      "DB03987\n",
      "Drug has no atc code\n",
      "DB03988\n",
      "Drug has no atc code\n",
      "DB03989\n",
      "Drug has no atc code\n",
      "DB03990\n",
      "Drug has no atc code\n",
      "DB03991\n",
      "Drug has no atc code\n",
      "DB03992\n",
      "Drug has no atc code\n",
      "DB03993\n",
      "Drug has no atc code\n",
      "DB03994\n",
      "Drug has no atc code\n",
      "DB03995\n",
      "Drug has no atc code\n",
      "DB03996\n",
      "Drug has no atc code\n",
      "DB03997\n",
      "Drug has no atc code\n",
      "DB03998\n",
      "Drug has no atc code\n",
      "DB03999\n",
      "Drug has no atc code\n",
      "DB04000\n",
      "Drug has no atc code\n",
      "DB04001\n",
      "Drug has no atc code\n",
      "DB04002\n",
      "Drug has no atc code\n",
      "DB04003\n",
      "Drug has no atc code\n",
      "DB04004\n",
      "Drug has no atc code\n",
      "DB04005\n",
      "Drug has no atc code\n",
      "DB04006\n",
      "Drug has no atc code\n",
      "DB04007\n",
      "Drug has no atc code\n",
      "DB04008\n",
      "Drug has no atc code\n",
      "DB04009\n",
      "Drug has no atc code\n",
      "DB04010\n",
      "Drug has no atc code\n",
      "DB04011\n",
      "Drug has no atc code\n",
      "DB04012\n",
      "Drug has no atc code\n",
      "DB04013\n",
      "Drug has no atc code\n",
      "DB04014\n",
      "Drug has no atc code\n",
      "DB04015\n",
      "Drug has no atc code\n",
      "DB04016\n",
      "Drug has no atc code\n",
      "DB04017\n",
      "Drug has no atc code\n",
      "DB04018\n",
      "Drug has no atc code\n",
      "DB04020\n",
      "Drug has no atc code\n",
      "DB04021\n",
      "Drug has no atc code\n",
      "DB04022\n",
      "Drug has no atc code\n",
      "DB04023\n",
      "Drug has no atc code\n",
      "DB04024\n",
      "Drug has no atc code\n",
      "DB04026\n",
      "Drug has no atc code\n",
      "DB04027\n",
      "Drug has no atc code\n",
      "DB04028\n",
      "Drug has no atc code\n",
      "DB04029\n",
      "Drug has no atc code\n",
      "DB04030\n",
      "Drug has no atc code\n",
      "DB04031\n",
      "Drug has no atc code\n",
      "DB04032\n",
      "Drug has no atc code\n",
      "DB04033\n",
      "Drug has no atc code\n",
      "DB04034\n",
      "Drug has no atc code\n",
      "DB04035\n",
      "Drug has no atc code\n",
      "DB04036\n",
      "Drug has no atc code\n",
      "DB04037\n",
      "Drug has no atc code\n",
      "DB04038\n",
      "Drug has no atc code\n",
      "DB04039\n",
      "Drug has no atc code\n",
      "DB04040\n",
      "Drug has no atc code\n",
      "DB04041\n",
      "Drug has no atc code\n",
      "DB04042\n",
      "Drug has no atc code\n",
      "DB04043\n",
      "Drug has no atc code\n",
      "DB04044\n",
      "Drug has no atc code\n",
      "DB04045\n",
      "Drug has no atc code\n",
      "DB04046\n",
      "Drug has no atc code\n",
      "DB04047\n",
      "Drug has no atc code\n",
      "DB04048\n",
      "Drug has no atc code\n",
      "DB04049\n",
      "Drug has no atc code\n",
      "DB04050\n",
      "Drug has no atc code\n",
      "DB04051\n",
      "Drug has no atc code\n",
      "DB04052\n",
      "Drug has no atc code\n",
      "DB04053\n",
      "Drug has no atc code\n",
      "DB04054\n",
      "Drug has no atc code\n",
      "DB04055\n",
      "Drug has no atc code\n",
      "DB04057\n",
      "Drug has no atc code\n",
      "DB04058\n",
      "Drug has no atc code\n",
      "DB04059\n",
      "Drug has no atc code\n",
      "DB04060\n",
      "Drug has no atc code\n",
      "DB04061\n",
      "Drug has no atc code\n",
      "DB04062\n",
      "Drug has no atc code\n",
      "DB04063\n",
      "Drug has no atc code\n",
      "DB04064\n",
      "Drug has no atc code\n",
      "DB04065\n",
      "Drug has no atc code\n",
      "DB04066\n",
      "Drug has no atc code\n",
      "DB04067\n",
      "Drug has no atc code\n",
      "DB04068\n",
      "Drug has no atc code\n",
      "DB04069\n",
      "Drug has no atc code\n",
      "DB04070\n",
      "Drug has no atc code\n",
      "DB04071\n",
      "Drug has no atc code\n",
      "DB04072\n",
      "Drug has no atc code\n",
      "DB04073\n",
      "Drug has no atc code\n",
      "DB04074\n",
      "Drug has no atc code\n",
      "DB04075\n",
      "Drug has no atc code\n",
      "DB04076\n",
      "Drug has no atc code\n",
      "DB04079\n",
      "Drug has no atc code\n",
      "DB04080\n",
      "Drug has no atc code\n",
      "DB04081\n",
      "Drug has no atc code\n",
      "DB04082\n",
      "Drug has no atc code\n",
      "DB04083\n",
      "Drug has no atc code\n",
      "DB04084\n",
      "Drug has no atc code\n",
      "DB04085\n",
      "Drug has no atc code\n",
      "DB04086\n",
      "Drug has no atc code\n",
      "DB04087\n",
      "Drug has no atc code\n",
      "DB04088\n",
      "Drug has no atc code\n",
      "DB04089\n",
      "Drug has no atc code\n",
      "DB04090\n",
      "Drug has no atc code\n",
      "DB04092\n",
      "Drug has no atc code\n",
      "DB04093\n",
      "Drug has no atc code\n",
      "DB04094\n",
      "Drug has no atc code\n",
      "DB04095\n",
      "Drug has no atc code\n",
      "DB04096\n",
      "Drug has no atc code\n",
      "DB04097\n",
      "Drug has no atc code\n",
      "DB04098\n",
      "Drug has no atc code\n",
      "DB04099\n",
      "Drug has no atc code\n",
      "DB04100\n",
      "Drug has no atc code\n",
      "DB04101\n",
      "Drug has no atc code\n",
      "DB04102\n",
      "Drug has no atc code\n",
      "DB04103\n",
      "Drug has no atc code\n",
      "DB04104\n",
      "Drug has no atc code\n",
      "DB04105\n",
      "DB04106\n",
      "Drug has no atc code\n",
      "DB04107\n",
      "Drug has no atc code\n",
      "DB04108\n",
      "Drug has no atc code\n",
      "DB04109\n",
      "Drug has no atc code\n",
      "DB04110\n",
      "Drug has no atc code\n",
      "DB04111\n",
      "Drug has no atc code\n",
      "DB04112\n",
      "Drug has no atc code\n",
      "DB04113\n",
      "Drug has no atc code\n",
      "DB04114\n",
      "Drug has no atc code\n",
      "DB04115\n",
      "Drug has no atc code\n",
      "DB04116\n",
      "Drug has no atc code\n",
      "DB04117\n",
      "Drug has no atc code\n",
      "DB04118\n",
      "Drug has no atc code\n",
      "DB04119\n",
      "Drug has no atc code\n",
      "DB04120\n",
      "Drug has no atc code\n",
      "DB04121\n",
      "Drug has no atc code\n",
      "DB04122\n",
      "Drug has no atc code\n",
      "DB04123\n",
      "Drug has no atc code\n",
      "DB04124\n",
      "Drug has no atc code\n",
      "DB04125\n",
      "Drug has no atc code\n",
      "DB04126\n",
      "Drug has no atc code\n",
      "DB04127\n",
      "Drug has no atc code\n",
      "DB04128\n",
      "Drug has no atc code\n",
      "DB04129\n",
      "Drug has no atc code\n",
      "DB04130\n",
      "Drug has no atc code\n",
      "DB04131\n",
      "Drug has no atc code\n",
      "DB04132\n",
      "Drug has no atc code\n",
      "DB04133\n",
      "Drug has no atc code\n",
      "DB04135\n",
      "Drug has no atc code\n",
      "DB04136\n",
      "Drug has no atc code\n",
      "DB04137\n",
      "Drug has no atc code\n",
      "DB04138\n",
      "Drug has no atc code\n",
      "DB04139\n",
      "Drug has no atc code\n",
      "DB04140\n",
      "Drug has no atc code\n",
      "DB04141\n",
      "Drug has no atc code\n",
      "DB04142\n",
      "Drug has no atc code\n",
      "DB04143\n",
      "Drug has no atc code\n",
      "DB04144\n",
      "DB04145\n",
      "Drug has no atc code\n",
      "DB04146\n",
      "Drug has no atc code\n",
      "DB04147\n",
      "Drug has no atc code\n",
      "DB04149\n",
      "Drug has no atc code\n",
      "DB04150\n",
      "Drug has no atc code\n",
      "DB04151\n",
      "Drug has no atc code\n",
      "DB04152\n",
      "Drug has no atc code\n",
      "DB04153\n",
      "Drug has no atc code\n",
      "DB04154\n",
      "Drug has no atc code\n",
      "DB04155\n",
      "Drug has no atc code\n",
      "DB04156\n",
      "Drug has no atc code\n",
      "DB04157\n",
      "Drug has no atc code\n",
      "DB04158\n",
      "Drug has no atc code\n",
      "DB04159\n",
      "Drug has no atc code\n",
      "DB04160\n",
      "Drug has no atc code\n",
      "DB04161\n",
      "Drug has no atc code\n",
      "DB04162\n",
      "Drug has no atc code\n",
      "DB04163\n",
      "Drug has no atc code\n",
      "DB04164\n",
      "DB04165\n",
      "Drug has no atc code\n",
      "DB04166\n",
      "Drug has no atc code\n",
      "DB04167\n",
      "Drug has no atc code\n",
      "DB04168\n",
      "Drug has no atc code\n",
      "DB04169\n",
      "Drug has no atc code\n",
      "DB04170\n",
      "Drug has no atc code\n",
      "DB04171\n",
      "Drug has no atc code\n",
      "DB04172\n",
      "DB04173\n",
      "Drug has no atc code\n",
      "DB04174\n",
      "Drug has no atc code\n",
      "DB04175\n",
      "Drug has no atc code\n",
      "DB04176\n",
      "Drug has no atc code\n",
      "DB04177\n",
      "Drug has no atc code\n",
      "DB04178\n",
      "Drug has no atc code\n",
      "DB04179\n",
      "Drug has no atc code\n",
      "DB04180\n",
      "Drug has no atc code\n",
      "DB04182\n",
      "Drug has no atc code\n",
      "DB04183\n",
      "Drug has no atc code\n",
      "DB04185\n",
      "Drug has no atc code\n",
      "DB04186\n",
      "Drug has no atc code\n",
      "DB04187\n",
      "Drug has no atc code\n",
      "DB04188\n",
      "Drug has no atc code\n",
      "DB04189\n",
      "Drug has no atc code\n",
      "DB04190\n",
      "Drug has no atc code\n",
      "DB04191\n",
      "Drug has no atc code\n",
      "DB04193\n",
      "Drug has no atc code\n",
      "DB04194\n",
      "Drug has no atc code\n",
      "DB04195\n",
      "Drug has no atc code\n",
      "DB04196\n",
      "Drug has no atc code\n",
      "DB04197\n",
      "Drug has no atc code\n",
      "DB04198\n",
      "Drug has no atc code\n",
      "DB04199\n",
      "Drug has no atc code\n",
      "DB04200\n",
      "Drug has no atc code\n",
      "DB04201\n",
      "Drug has no atc code\n",
      "DB04202\n",
      "Drug has no atc code\n",
      "DB04203\n",
      "Drug has no atc code\n",
      "DB04204\n",
      "Drug has no atc code\n",
      "DB04205\n",
      "Drug has no atc code\n",
      "DB04206\n",
      "Drug has no atc code\n",
      "DB04207\n",
      "Drug has no atc code\n",
      "DB04208\n",
      "DB04209\n",
      "Drug has no atc code\n",
      "DB04210\n",
      "Drug has no atc code\n",
      "DB04211\n",
      "Drug has no atc code\n",
      "DB04212\n",
      "Drug has no atc code\n",
      "DB04213\n",
      "Drug has no atc code\n",
      "DB04214\n",
      "Drug has no atc code\n",
      "DB04215\n",
      "Drug has no atc code\n",
      "DB04216\n",
      "Drug has no atc code\n",
      "DB04217\n",
      "Drug has no atc code\n",
      "DB04218\n",
      "Drug has no atc code\n",
      "DB04219\n",
      "Drug has no atc code\n",
      "DB04220\n",
      "DB04221\n",
      "Drug has no atc code\n",
      "DB04222\n",
      "Drug has no atc code\n",
      "DB04223\n",
      "Drug has no atc code\n",
      "DB04224\n",
      "Drug has no atc code\n",
      "DB04225\n",
      "Drug has no atc code\n",
      "DB04226\n",
      "Drug has no atc code\n",
      "DB04227\n",
      "Drug has no atc code\n",
      "DB04228\n",
      "Drug has no atc code\n",
      "DB04229\n",
      "Drug has no atc code\n",
      "DB04230\n",
      "Drug has no atc code\n",
      "DB04231\n",
      "Drug has no atc code\n",
      "DB04232\n",
      "Drug has no atc code\n",
      "DB04233\n",
      "Drug has no atc code\n",
      "DB04234\n",
      "Drug has no atc code\n",
      "DB04235\n",
      "Drug has no atc code\n",
      "DB04236\n",
      "Drug has no atc code\n",
      "DB04237\n",
      "Drug has no atc code\n",
      "DB04238\n",
      "Drug has no atc code\n",
      "DB04239\n",
      "Drug has no atc code\n",
      "DB04240\n",
      "Drug has no atc code\n",
      "DB04241\n",
      "Drug has no atc code\n",
      "DB04242\n",
      "Drug has no atc code\n",
      "DB04243\n",
      "Drug has no atc code\n",
      "DB04244\n",
      "Drug has no atc code\n",
      "DB04246\n",
      "Drug has no atc code\n",
      "DB04248\n",
      "Drug has no atc code\n",
      "DB04249\n",
      "Drug has no atc code\n",
      "DB04250\n",
      "Drug has no atc code\n",
      "DB04252\n",
      "Drug has no atc code\n",
      "DB04253\n",
      "Drug has no atc code\n",
      "DB04254\n",
      "Drug has no atc code\n",
      "DB04255\n",
      "Drug has no atc code\n",
      "DB04256\n",
      "Drug has no atc code\n",
      "DB04257\n",
      "Drug has no atc code\n",
      "DB04258\n",
      "Drug has no atc code\n",
      "DB04259\n",
      "Drug has no atc code\n",
      "DB04260\n",
      "Drug has no atc code\n",
      "DB04261\n",
      "Drug has no atc code\n",
      "DB04262\n",
      "Drug has no atc code\n",
      "DB04263\n",
      "Drug has no atc code\n",
      "DB04264\n",
      "Drug has no atc code\n",
      "DB04265\n",
      "Drug has no atc code\n",
      "DB04266\n",
      "Drug has no atc code\n",
      "DB04267\n",
      "Drug has no atc code\n",
      "DB04268\n",
      "Drug has no atc code\n",
      "DB04269\n",
      "Drug has no atc code\n",
      "DB04270\n",
      "Drug has no atc code\n",
      "DB04271\n",
      "DB04272\n",
      "Drug has no atc code\n",
      "DB04273\n",
      "Drug has no atc code\n",
      "DB04274\n",
      "Drug has no atc code\n",
      "DB04275\n",
      "Drug has no atc code\n",
      "DB04276\n",
      "Drug has no atc code\n",
      "DB04277\n",
      "Drug has no atc code\n",
      "DB04278\n",
      "Drug has no atc code\n",
      "DB04279\n",
      "Drug has no atc code\n",
      "DB04280\n",
      "Drug has no atc code\n",
      "DB04281\n",
      "Drug has no atc code\n",
      "DB04282\n",
      "Drug has no atc code\n",
      "DB04283\n",
      "Drug has no atc code\n",
      "DB04284\n",
      "Drug has no atc code\n",
      "DB04285\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB04286\n",
      "Drug has no atc code\n",
      "DB04287\n",
      "Drug has no atc code\n",
      "DB04288\n",
      "Drug has no atc code\n",
      "DB04289\n",
      "Drug has no atc code\n",
      "DB04291\n",
      "Drug has no atc code\n",
      "DB04292\n",
      "Drug has no atc code\n",
      "DB04293\n",
      "Drug has no atc code\n",
      "DB04294\n",
      "Drug has no atc code\n",
      "DB04295\n",
      "Drug has no atc code\n",
      "DB04296\n",
      "Drug has no atc code\n",
      "DB04297\n",
      "Drug has no atc code\n",
      "DB04298\n",
      "Drug has no atc code\n",
      "DB04299\n",
      "Drug has no atc code\n",
      "DB04300\n",
      "Drug has no atc code\n",
      "DB04301\n",
      "Drug has no atc code\n",
      "DB04302\n",
      "Drug has no atc code\n",
      "DB04303\n",
      "Drug has no atc code\n",
      "DB04304\n",
      "Drug has no atc code\n",
      "DB04306\n",
      "Drug has no atc code\n",
      "DB04307\n",
      "Drug has no atc code\n",
      "DB04308\n",
      "Drug has no atc code\n",
      "DB04310\n",
      "Drug has no atc code\n",
      "DB04311\n",
      "Drug has no atc code\n",
      "DB04312\n",
      "Drug has no atc code\n",
      "DB04313\n",
      "Drug has no atc code\n",
      "DB04314\n",
      "Drug has no atc code\n",
      "DB04315\n",
      "Drug has no atc code\n",
      "DB04316\n",
      "Drug has no atc code\n",
      "DB04317\n",
      "Drug has no atc code\n",
      "DB04318\n",
      "Drug has no atc code\n",
      "DB04320\n",
      "Drug has no atc code\n",
      "DB04321\n",
      "Drug has no atc code\n",
      "DB04322\n",
      "Drug has no atc code\n",
      "DB04323\n",
      "Drug has no atc code\n",
      "DB04324\n",
      "Drug has no atc code\n",
      "DB04325\n",
      "Drug has no atc code\n",
      "DB04326\n",
      "Drug has no atc code\n",
      "DB04327\n",
      "Drug has no atc code\n",
      "DB04328\n",
      "Drug has no atc code\n",
      "DB04329\n",
      "Drug has no atc code\n",
      "DB04330\n",
      "Drug has no atc code\n",
      "DB04331\n",
      "Drug has no atc code\n",
      "DB04332\n",
      "Drug has no atc code\n",
      "DB04333\n",
      "Drug has no atc code\n",
      "DB04334\n",
      "DB04335\n",
      "Drug has no atc code\n",
      "DB04336\n",
      "Drug has no atc code\n",
      "DB04337\n",
      "Drug has no atc code\n",
      "DB04338\n",
      "DB04339\n",
      "Drug has no atc code\n",
      "DB04340\n",
      "Drug has no atc code\n",
      "DB04341\n",
      "Drug has no atc code\n",
      "DB04342\n",
      "Drug has no atc code\n",
      "DB04343\n",
      "Drug has no atc code\n",
      "DB04345\n",
      "Drug has no atc code\n",
      "DB04346\n",
      "Drug has no atc code\n",
      "DB04347\n",
      "Drug has no atc code\n",
      "DB04348\n",
      "Drug has no atc code\n",
      "DB04349\n",
      "Drug has no atc code\n",
      "DB04350\n",
      "Drug has no atc code\n",
      "DB04351\n",
      "Drug has no atc code\n",
      "DB04352\n",
      "Drug has no atc code\n",
      "DB04353\n",
      "Drug has no atc code\n",
      "DB04356\n",
      "Drug has no atc code\n",
      "DB04357\n",
      "Drug has no atc code\n",
      "DB04359\n",
      "Drug has no atc code\n",
      "DB04360\n",
      "Drug has no atc code\n",
      "DB04361\n",
      "Drug has no atc code\n",
      "DB04362\n",
      "Drug has no atc code\n",
      "DB04363\n",
      "Drug has no atc code\n",
      "DB04364\n",
      "Drug has no atc code\n",
      "DB04365\n",
      "Drug has no atc code\n",
      "DB04366\n",
      "Drug has no atc code\n",
      "DB04367\n",
      "Drug has no atc code\n",
      "DB04368\n",
      "Drug has no atc code\n",
      "DB04369\n",
      "Drug has no atc code\n",
      "DB04370\n",
      "Drug has no atc code\n",
      "DB04371\n",
      "Drug has no atc code\n",
      "DB04372\n",
      "Drug has no atc code\n",
      "DB04373\n",
      "Drug has no atc code\n",
      "DB04374\n",
      "Drug has no atc code\n",
      "DB04376\n",
      "DB04377\n",
      "Drug has no atc code\n",
      "DB04378\n",
      "Drug has no atc code\n",
      "DB04379\n",
      "Drug has no atc code\n",
      "DB04380\n",
      "Drug has no atc code\n",
      "DB04381\n",
      "Drug has no atc code\n",
      "DB04382\n",
      "Drug has no atc code\n",
      "DB04383\n",
      "Drug has no atc code\n",
      "DB04384\n",
      "Drug has no atc code\n",
      "DB04385\n",
      "Drug has no atc code\n",
      "DB04386\n",
      "Drug has no atc code\n",
      "DB04387\n",
      "Drug has no atc code\n",
      "DB04388\n",
      "Drug has no atc code\n",
      "DB04389\n",
      "Drug has no atc code\n",
      "DB04391\n",
      "Drug has no atc code\n",
      "DB04392\n",
      "Drug has no atc code\n",
      "DB04393\n",
      "Drug has no atc code\n",
      "DB04394\n",
      "Drug has no atc code\n",
      "DB04395\n",
      "Drug has no atc code\n",
      "DB04396\n",
      "Drug has no atc code\n",
      "DB04397\n",
      "DB04398\n",
      "Drug has no atc code\n",
      "DB04400\n",
      "Drug has no atc code\n",
      "DB04401\n",
      "Drug has no atc code\n",
      "DB04404\n",
      "Drug has no atc code\n",
      "DB04405\n",
      "Drug has no atc code\n",
      "DB04406\n",
      "Drug has no atc code\n",
      "DB04407\n",
      "Drug has no atc code\n",
      "DB04408\n",
      "Drug has no atc code\n",
      "DB04409\n",
      "Drug has no atc code\n",
      "DB04410\n",
      "Drug has no atc code\n",
      "DB04411\n",
      "Drug has no atc code\n",
      "DB04414\n",
      "Drug has no atc code\n",
      "DB04415\n",
      "Drug has no atc code\n",
      "DB04416\n",
      "Drug has no atc code\n",
      "DB04417\n",
      "Drug has no atc code\n",
      "DB04418\n",
      "Drug has no atc code\n",
      "DB04419\n",
      "Drug has no atc code\n",
      "DB04421\n",
      "Drug has no atc code\n",
      "DB04422\n",
      "Drug has no atc code\n",
      "DB04423\n",
      "Drug has no atc code\n",
      "DB04424\n",
      "Drug has no atc code\n",
      "DB04425\n",
      "Drug has no atc code\n",
      "DB04426\n",
      "Drug has no atc code\n",
      "DB04427\n",
      "Drug has no atc code\n",
      "DB04429\n",
      "Drug has no atc code\n",
      "DB04430\n",
      "Drug has no atc code\n",
      "DB04431\n",
      "Drug has no atc code\n",
      "DB04432\n",
      "Drug has no atc code\n",
      "DB04433\n",
      "Drug has no atc code\n",
      "DB04434\n",
      "Drug has no atc code\n",
      "DB04436\n",
      "Drug has no atc code\n",
      "DB04437\n",
      "Drug has no atc code\n",
      "DB04438\n",
      "Drug has no atc code\n",
      "DB04439\n",
      "Drug has no atc code\n",
      "DB04440\n",
      "Drug has no atc code\n",
      "DB04441\n",
      "Drug has no atc code\n",
      "DB04442\n",
      "Drug has no atc code\n",
      "DB04444\n",
      "DB04445\n",
      "Drug has no atc code\n",
      "DB04446\n",
      "Drug has no atc code\n",
      "DB04447\n",
      "Drug has no atc code\n",
      "DB04448\n",
      "Drug has no atc code\n",
      "DB04449\n",
      "Drug has no atc code\n",
      "DB04450\n",
      "Drug has no atc code\n",
      "DB04451\n",
      "Drug has no atc code\n",
      "DB04452\n",
      "Drug has no atc code\n",
      "DB04453\n",
      "Drug has no atc code\n",
      "DB04454\n",
      "Drug has no atc code\n",
      "DB04455\n",
      "Drug has no atc code\n",
      "DB04456\n",
      "Drug has no atc code\n",
      "DB04457\n",
      "Drug has no atc code\n",
      "DB04458\n",
      "Drug has no atc code\n",
      "DB04459\n",
      "Drug has no atc code\n",
      "DB04460\n",
      "Drug has no atc code\n",
      "DB04461\n",
      "Drug has no atc code\n",
      "DB04462\n",
      "Drug has no atc code\n",
      "DB04463\n",
      "Drug has no atc code\n",
      "DB04464\n",
      "Drug has no atc code\n",
      "DB04465\n",
      "Drug has no atc code\n",
      "DB04466\n",
      "Drug has no atc code\n",
      "DB04467\n",
      "Drug has no atc code\n",
      "DB04468\n",
      "Drug has no atc code\n",
      "DB04469\n",
      "Drug has no atc code\n",
      "DB04470\n",
      "Drug has no atc code\n",
      "DB04471\n",
      "Drug has no atc code\n",
      "DB04472\n",
      "Drug has no atc code\n",
      "DB04473\n",
      "Drug has no atc code\n",
      "DB04474\n",
      "Drug has no atc code\n",
      "DB04476\n",
      "Drug has no atc code\n",
      "DB04477\n",
      "Drug has no atc code\n",
      "DB04478\n",
      "Drug has no atc code\n",
      "DB04479\n",
      "Drug has no atc code\n",
      "DB04480\n",
      "Drug has no atc code\n",
      "DB04481\n",
      "Drug has no atc code\n",
      "DB04482\n",
      "Drug has no atc code\n",
      "DB04483\n",
      "Drug has no atc code\n",
      "DB04484\n",
      "Drug has no atc code\n",
      "DB04485\n",
      "Drug has no atc code\n",
      "DB04486\n",
      "Drug has no atc code\n",
      "DB04487\n",
      "Drug has no atc code\n",
      "DB04488\n",
      "Drug has no atc code\n",
      "DB04489\n",
      "Drug has no atc code\n",
      "DB04490\n",
      "Drug has no atc code\n",
      "DB04491\n",
      "Drug has no atc code\n",
      "DB04492\n",
      "Drug has no atc code\n",
      "DB04493\n",
      "Drug has no atc code\n",
      "DB04494\n",
      "Drug has no atc code\n",
      "DB04495\n",
      "Drug has no atc code\n",
      "DB04496\n",
      "Drug has no atc code\n",
      "DB04497\n",
      "Drug has no atc code\n",
      "DB04498\n",
      "Drug has no atc code\n",
      "DB04499\n",
      "Drug has no atc code\n",
      "DB04500\n",
      "Drug has no atc code\n",
      "DB04501\n",
      "Drug has no atc code\n",
      "DB04502\n",
      "Drug has no atc code\n",
      "DB04503\n",
      "Drug has no atc code\n",
      "DB04504\n",
      "Drug has no atc code\n",
      "DB04505\n",
      "Drug has no atc code\n",
      "DB04506\n",
      "Drug has no atc code\n",
      "DB04508\n",
      "Drug has no atc code\n",
      "DB04509\n",
      "Drug has no atc code\n",
      "DB04510\n",
      "Drug has no atc code\n",
      "DB04511\n",
      "Drug has no atc code\n",
      "DB04512\n",
      "Drug has no atc code\n",
      "DB04513\n",
      "Drug has no atc code\n",
      "DB04514\n",
      "Drug has no atc code\n",
      "DB04515\n",
      "Drug has no atc code\n",
      "DB04516\n",
      "Drug has no atc code\n",
      "DB04517\n",
      "Drug has no atc code\n",
      "DB04518\n",
      "Drug has no atc code\n",
      "DB04519\n",
      "Drug has no atc code\n",
      "DB04520\n",
      "Drug has no atc code\n",
      "DB04521\n",
      "Drug has no atc code\n",
      "DB04522\n",
      "Drug has no atc code\n",
      "DB04523\n",
      "Drug has no atc code\n",
      "DB04524\n",
      "Drug has no atc code\n",
      "DB04525\n",
      "Drug has no atc code\n",
      "DB04526\n",
      "Drug has no atc code\n",
      "DB04527\n",
      "Drug has no atc code\n",
      "DB04528\n",
      "Drug has no atc code\n",
      "DB04529\n",
      "Drug has no atc code\n",
      "DB04530\n",
      "Drug has no atc code\n",
      "DB04531\n",
      "Drug has no atc code\n",
      "DB04532\n",
      "Drug has no atc code\n",
      "DB04533\n",
      "Drug has no atc code\n",
      "DB04534\n",
      "Drug has no atc code\n",
      "DB04537\n",
      "Drug has no atc code\n",
      "DB04538\n",
      "Drug has no atc code\n",
      "DB04539\n",
      "Drug has no atc code\n",
      "DB04540\n",
      "Drug has no atc code\n",
      "DB04541\n",
      "Drug has no atc code\n",
      "DB04542\n",
      "Drug has no atc code\n",
      "DB04543\n",
      "Drug has no atc code\n",
      "DB04544\n",
      "Drug has no atc code\n",
      "DB04545\n",
      "Drug has no atc code\n",
      "DB04546\n",
      "Drug has no atc code\n",
      "DB04547\n",
      "Drug has no atc code\n",
      "DB04548\n",
      "Drug has no atc code\n",
      "DB04549\n",
      "Drug has no atc code\n",
      "DB04551\n",
      "DB04552\n",
      "Drug has no atc code\n",
      "DB04553\n",
      "Drug has no atc code\n",
      "DB04554\n",
      "Drug has no atc code\n",
      "DB04555\n",
      "Drug has no atc code\n",
      "DB04556\n",
      "Drug has no atc code\n",
      "DB04557\n",
      "Drug has no atc code\n",
      "DB04559\n",
      "Drug has no atc code\n",
      "DB04560\n",
      "Drug has no atc code\n",
      "DB04561\n",
      "Drug has no atc code\n",
      "DB04562\n",
      "Drug has no atc code\n",
      "DB04563\n",
      "Drug has no atc code\n",
      "DB04564\n",
      "Drug has no atc code\n",
      "DB04565\n",
      "Drug has no atc code\n",
      "DB04566\n",
      "Drug has no atc code\n",
      "DB04567\n",
      "Drug has no atc code\n",
      "DB04568\n",
      "Drug has no atc code\n",
      "DB04569\n",
      "DB04570\n",
      "DB04571\n",
      "DB04572\n",
      "DB04573\n",
      "Drug has no atc code\n",
      "DB04574\n",
      "Drug has no atc code\n",
      "DB04575\n",
      "DB04576\n",
      "Drug has no atc code\n",
      "DB04577\n",
      "Drug has no atc code\n",
      "DB04578\n",
      "Drug has no atc code\n",
      "DB04579\n",
      "Drug has no atc code\n",
      "DB04580\n",
      "Drug has no atc code\n",
      "DB04581\n",
      "Drug has no atc code\n",
      "DB04582\n",
      "Drug has no atc code\n",
      "DB04583\n",
      "Drug has no atc code\n",
      "DB04584\n",
      "Drug has no atc code\n",
      "DB04585\n",
      "Drug has no atc code\n",
      "DB04586\n",
      "Drug has no atc code\n",
      "DB04587\n",
      "Drug has no atc code\n",
      "DB04588\n",
      "Drug has no atc code\n",
      "DB04590\n",
      "Drug has no atc code\n",
      "DB04591\n",
      "Drug has no atc code\n",
      "DB04592\n",
      "Drug has no atc code\n",
      "DB04593\n",
      "Drug has no atc code\n",
      "DB04594\n",
      "Drug has no atc code\n",
      "DB04595\n",
      "Drug has no atc code\n",
      "DB04596\n",
      "Drug has no atc code\n",
      "DB04597\n",
      "Drug has no atc code\n",
      "DB04598\n",
      "DB04599\n",
      "Drug has no atc code\n",
      "DB04600\n",
      "Drug has no atc code\n",
      "DB04601\n",
      "Drug has no atc code\n",
      "DB04602\n",
      "Drug has no atc code\n",
      "DB04603\n",
      "Drug has no atc code\n",
      "DB04604\n",
      "Drug has no atc code\n",
      "DB04605\n",
      "Drug has no atc code\n",
      "DB04606\n",
      "Drug has no atc code\n",
      "DB04607\n",
      "Drug has no atc code\n",
      "DB04608\n",
      "Drug has no atc code\n",
      "DB04609\n",
      "Drug has no atc code\n",
      "DB04610\n",
      "Drug has no atc code\n",
      "DB04612\n",
      "Drug has no atc code\n",
      "DB04613\n",
      "Drug has no atc code\n",
      "DB04614\n",
      "Drug has no atc code\n",
      "DB04615\n",
      "Drug has no atc code\n",
      "DB04616\n",
      "Drug has no atc code\n",
      "DB04617\n",
      "Drug has no atc code\n",
      "DB04618\n",
      "Drug has no atc code\n",
      "DB04619\n",
      "Drug has no atc code\n",
      "DB04620\n",
      "Drug has no atc code\n",
      "DB04622\n",
      "Drug has no atc code\n",
      "DB04623\n",
      "Drug has no atc code\n",
      "DB04624\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug has no atc code\n",
      "DB04626\n",
      "Drug has no atc code\n",
      "DB04627\n",
      "Drug has no atc code\n",
      "DB04628\n",
      "Drug has no atc code\n",
      "DB04629\n",
      "DB04630\n",
      "Drug has no atc code\n",
      "DB04631\n",
      "Drug has no atc code\n",
      "DB04632\n",
      "Drug has no atc code\n",
      "DB04633\n",
      "Drug has no atc code\n",
      "DB04634\n",
      "Drug has no atc code\n",
      "DB04636\n",
      "Drug has no atc code\n",
      "DB04637\n",
      "Drug has no atc code\n",
      "DB04638\n",
      "Drug has no atc code\n",
      "DB04639\n",
      "Drug has no atc code\n",
      "DB04640\n",
      "Drug has no atc code\n",
      "DB04641\n",
      "Drug has no atc code\n",
      "DB04642\n",
      "Drug has no atc code\n",
      "DB04643\n",
      "Drug has no atc code\n",
      "DB04644\n",
      "Drug has no atc code\n",
      "DB04645\n",
      "Drug has no atc code\n",
      "DB04646\n",
      "Drug has no atc code\n",
      "DB04647\n",
      "Drug has no atc code\n",
      "DB04648\n",
      "Drug has no atc code\n",
      "DB04649\n",
      "Drug has no atc code\n",
      "DB04650\n",
      "Drug has no atc code\n",
      "DB04651\n",
      "Drug has no atc code\n",
      "DB04652\n",
      "Drug has no atc code\n",
      "DB04653\n",
      "Drug has no atc code\n",
      "DB04654\n",
      "Drug has no atc code\n",
      "DB04655\n",
      "Drug has no atc code\n",
      "DB04656\n",
      "Drug has no atc code\n",
      "DB04657\n",
      "Drug has no atc code\n",
      "DB04658\n",
      "Drug has no atc code\n",
      "DB04659\n",
      "DB04660\n",
      "Drug has no atc code\n",
      "DB04661\n",
      "Drug has no atc code\n",
      "DB04662\n",
      "Drug has no atc code\n",
      "DB04663\n",
      "Drug has no atc code\n",
      "DB04664\n",
      "Drug has no atc code\n",
      "DB04665\n",
      "Drug has no atc code\n",
      "DB04666\n",
      "Drug has no atc code\n",
      "DB04667\n",
      "Drug has no atc code\n",
      "DB04668\n",
      "Drug has no atc code\n",
      "DB04669\n",
      "Drug has no atc code\n",
      "DB04671\n",
      "Drug has no atc code\n",
      "DB04672\n",
      "Drug has no atc code\n",
      "DB04673\n",
      "Drug has no atc code\n",
      "DB04674\n",
      "Drug has no atc code\n",
      "DB04676\n",
      "Drug has no atc code\n",
      "DB04677\n",
      "Drug has no atc code\n",
      "DB04678\n",
      "Drug has no atc code\n",
      "DB04679\n",
      "Drug has no atc code\n",
      "DB04680\n",
      "Drug has no atc code\n",
      "DB04681\n",
      "Drug has no atc code\n",
      "DB04682\n",
      "Drug has no atc code\n",
      "DB04683\n",
      "Drug has no atc code\n",
      "DB04684\n",
      "Drug has no atc code\n",
      "DB04685\n",
      "Drug has no atc code\n",
      "DB04686\n",
      "Drug has no atc code\n",
      "DB04687\n",
      "Drug has no atc code\n",
      "DB04688\n",
      "Drug has no atc code\n",
      "DB04689\n",
      "Drug has no atc code\n",
      "DB04690\n",
      "Drug has no atc code\n",
      "DB04691\n",
      "Drug has no atc code\n",
      "DB04692\n",
      "Drug has no atc code\n",
      "DB04693\n",
      "Drug has no atc code\n",
      "DB04694\n",
      "Drug has no atc code\n",
      "DB04695\n",
      "Drug has no atc code\n",
      "DB04696\n",
      "Drug has no atc code\n",
      "DB04697\n",
      "Drug has no atc code\n",
      "DB04698\n",
      "Drug has no atc code\n",
      "DB04699\n",
      "Drug has no atc code\n",
      "DB04700\n",
      "Drug has no atc code\n",
      "DB04701\n",
      "Drug has no atc code\n",
      "DB04702\n",
      "Drug has no atc code\n",
      "DB04703\n",
      "Drug has no atc code\n",
      "DB04704\n",
      "Drug has no atc code\n",
      "DB04705\n",
      "Drug has no atc code\n",
      "DB04706\n",
      "Drug has no atc code\n",
      "DB04707\n",
      "Drug has no atc code\n",
      "DB04708\n",
      "Drug has no atc code\n",
      "DB04709\n",
      "Drug has no atc code\n",
      "DB04710\n",
      "DB04711\n",
      "Drug has no atc code\n",
      "DB04712\n",
      "Drug has no atc code\n",
      "DB04713\n",
      "Drug has no atc code\n",
      "DB04714\n",
      "Drug has no atc code\n",
      "DB04715\n",
      "Drug has no atc code\n",
      "DB04716\n",
      "Drug has no atc code\n",
      "DB04717\n",
      "Drug has no atc code\n",
      "DB04718\n",
      "Drug has no atc code\n",
      "DB04719\n",
      "Drug has no atc code\n",
      "DB04720\n",
      "Drug has no atc code\n",
      "DB04721\n",
      "Drug has no atc code\n",
      "DB04722\n",
      "Drug has no atc code\n",
      "DB04723\n",
      "Drug has no atc code\n",
      "DB04724\n",
      "Drug has no atc code\n",
      "DB04725\n",
      "Drug has no atc code\n",
      "DB04726\n",
      "Drug has no atc code\n",
      "DB04727\n",
      "Drug has no atc code\n",
      "DB04728\n",
      "Drug has no atc code\n",
      "DB04729\n",
      "Drug has no atc code\n",
      "DB04731\n",
      "Drug has no atc code\n",
      "DB04732\n",
      "Drug has no atc code\n",
      "DB04733\n",
      "Drug has no atc code\n",
      "DB04734\n",
      "Drug has no atc code\n",
      "DB04735\n",
      "Drug has no atc code\n",
      "DB04736\n",
      "Drug has no atc code\n",
      "DB04737\n",
      "Drug has no atc code\n",
      "DB04738\n",
      "Drug has no atc code\n",
      "DB04739\n",
      "Drug has no atc code\n",
      "DB04740\n",
      "Drug has no atc code\n",
      "DB04741\n",
      "Drug has no atc code\n",
      "DB04742\n",
      "DB04743\n",
      "Drug has no atc code\n",
      "DB04744\n",
      "Drug has no atc code\n",
      "DB04745\n",
      "Drug has no atc code\n",
      "DB04746\n",
      "Drug has no atc code\n",
      "DB04747\n",
      "Drug has no atc code\n",
      "DB04748\n",
      "Drug has no atc code\n",
      "DB04749\n",
      "Drug has no atc code\n",
      "DB04750\n",
      "Drug has no atc code\n",
      "DB04751\n",
      "Drug has no atc code\n",
      "DB04752\n",
      "Drug has no atc code\n",
      "DB04753\n",
      "Drug has no atc code\n",
      "DB04754\n",
      "Drug has no atc code\n",
      "DB04755\n",
      "Drug has no atc code\n",
      "DB04756\n",
      "Drug has no atc code\n",
      "DB04757\n",
      "Drug has no atc code\n",
      "DB04758\n",
      "Drug has no atc code\n",
      "DB04759\n",
      "Drug has no atc code\n",
      "DB04760\n",
      "Drug has no atc code\n",
      "DB04761\n",
      "Drug has no atc code\n",
      "DB04762\n",
      "Drug has no atc code\n",
      "DB04763\n",
      "Drug has no atc code\n",
      "DB04764\n",
      "Drug has no atc code\n",
      "DB04765\n",
      "Drug has no atc code\n",
      "DB04767\n",
      "Drug has no atc code\n",
      "DB04768\n",
      "Drug has no atc code\n",
      "DB04769\n",
      "Drug has no atc code\n",
      "DB04770\n",
      "Drug has no atc code\n",
      "DB04771\n",
      "Drug has no atc code\n",
      "DB04772\n",
      "Drug has no atc code\n",
      "DB04773\n",
      "Drug has no atc code\n",
      "DB04774\n",
      "Drug has no atc code\n",
      "DB04775\n",
      "Drug has no atc code\n",
      "DB04776\n",
      "Drug has no atc code\n",
      "DB04777\n",
      "Drug has no atc code\n",
      "DB04778\n",
      "Drug has no atc code\n",
      "DB04779\n",
      "Drug has no atc code\n",
      "DB04780\n",
      "Drug has no atc code\n",
      "DB04781\n",
      "Drug has no atc code\n",
      "DB04782\n",
      "Drug has no atc code\n",
      "DB04783\n",
      "Drug has no atc code\n",
      "DB04784\n",
      "Drug has no atc code\n",
      "DB04785\n",
      "DB04786\n",
      "Drug has no atc code\n",
      "DB04787\n",
      "Drug has no atc code\n",
      "DB04788\n",
      "Drug has no atc code\n",
      "DB04789\n",
      "Drug has no atc code\n",
      "DB04790\n",
      "Drug has no atc code\n",
      "DB04791\n",
      "Drug has no atc code\n",
      "DB04792\n",
      "Drug has no atc code\n",
      "DB04793\n",
      "DB04794\n",
      "Drug has no atc code\n",
      "DB04795\n",
      "Drug has no atc code\n",
      "DB04796\n",
      "Drug has no atc code\n",
      "DB04797\n",
      "Drug has no atc code\n",
      "DB04798\n",
      "Drug has no atc code\n",
      "DB04799\n",
      "Drug has no atc code\n",
      "DB04800\n",
      "Drug has no atc code\n",
      "DB04801\n",
      "Drug has no atc code\n",
      "DB04802\n",
      "Drug has no atc code\n",
      "DB04803\n",
      "Drug has no atc code\n",
      "DB04804\n",
      "Drug has no atc code\n",
      "DB04805\n",
      "Drug has no atc code\n",
      "DB04806\n",
      "Drug has no atc code\n",
      "DB04807\n",
      "Drug has no atc code\n",
      "DB04808\n",
      "Drug has no atc code\n",
      "DB04809\n",
      "Drug has no atc code\n",
      "DB04810\n",
      "Drug has no atc code\n",
      "DB04811\n",
      "DB04812\n",
      "DB04813\n",
      "Drug has no atc code\n",
      "DB04814\n",
      "DB04815\n",
      "DB04816\n",
      "DB04817\n",
      "DB04818\n",
      "DB04819\n",
      "DB04820\n",
      "DB04821\n",
      "DB04822\n",
      "DB04823\n",
      "DB04824\n",
      "DB04825\n",
      "DB04826\n",
      "Drug has no atc code\n",
      "DB04827\n",
      "DB04828\n",
      "Drug has no atc code\n",
      "DB04829\n",
      "DB04830\n",
      "DB04831\n",
      "DB04832\n",
      "DB04833\n",
      "Drug has no atc code\n",
      "DB04834\n",
      "DB04835\n",
      "DB04836\n",
      "DB04837\n",
      "DB04838\n",
      "DB04839\n",
      "DB04840\n",
      "DB04841\n",
      "DB04842\n",
      "DB04843\n",
      "DB04844\n",
      "DB04845\n",
      "DB04846\n",
      "DB04847\n",
      "Drug has no atc code\n",
      "DB04848\n",
      "DB04849\n",
      "Drug has no atc code\n",
      "DB04850\n",
      "Drug has no atc code\n",
      "DB04851\n",
      "Drug has no atc code\n",
      "DB04852\n",
      "Drug has no atc code\n",
      "DB04853\n",
      "DB04854\n",
      "DB04855\n",
      "Drug has no atc code\n",
      "DB04856\n",
      "Drug has no atc code\n",
      "DB04857\n",
      "Drug has no atc code\n",
      "DB04858\n",
      "Drug has no atc code\n",
      "DB04859\n",
      "Drug has no atc code\n",
      "DB04860\n",
      "DB04861\n",
      "Drug has no atc code\n",
      "DB04862\n",
      "Drug has no atc code\n",
      "DB04863\n",
      "Drug has no atc code\n",
      "DB04864\n",
      "DB04865\n",
      "Drug has no atc code\n",
      "DB04866\n",
      "Drug has no atc code\n",
      "DB04867\n",
      "DB04868\n",
      "Drug has no atc code\n",
      "DB04869\n",
      "Drug has no atc code\n",
      "DB04870\n",
      "DB04871\n",
      "Drug has no atc code\n",
      "DB04872\n",
      "Drug has no atc code\n",
      "DB04873\n",
      "Drug has no atc code\n",
      "DB04874\n",
      "Drug has no atc code\n",
      "DB04875\n",
      "DB04876\n",
      "Drug has no atc code\n",
      "DB04877\n",
      "DB04878\n",
      "Drug has no atc code\n",
      "DB04879\n",
      "DB04880\n",
      "Drug has no atc code\n",
      "DB04881\n",
      "Drug has no atc code\n",
      "DB04882\n",
      "Drug has no atc code\n",
      "DB04883\n",
      "DB04884\n",
      "DB04885\n",
      "Drug has no atc code\n",
      "DB04886\n",
      "Drug has no atc code\n",
      "DB04887\n",
      "Drug has no atc code\n",
      "DB04888\n",
      "Drug has no atc code\n",
      "DB04889\n",
      "Drug has no atc code\n",
      "DB04890\n",
      "Drug has no atc code\n",
      "DB04891\n",
      "Drug has no atc code\n",
      "DB04892\n",
      "Drug has no atc code\n",
      "DB04893\n",
      "DB04894\n",
      "DB04895\n",
      "DB04896\n",
      "Drug has no atc code\n",
      "DB04897\n",
      "DB04898\n",
      "DB04899\n",
      "Drug has no atc code\n",
      "DB04900\n",
      "Drug has no atc code\n",
      "DB04901\n",
      "Drug has no atc code\n",
      "DB04903\n",
      "Drug has no atc code\n",
      "DB04904\n",
      "Drug has no atc code\n",
      "DB04905\n",
      "DB04907\n",
      "DB04908\n",
      "Drug has no atc code\n",
      "DB04909\n",
      "Drug has no atc code\n",
      "DB04910\n",
      "DB04911\n",
      "Drug has no atc code\n",
      "DB04912\n",
      "Drug has no atc code\n",
      "DB04914\n",
      "Drug has no atc code\n",
      "DB04915\n",
      "Drug has no atc code\n",
      "DB04917\n",
      "Drug has no atc code\n",
      "DB04918\n",
      "Drug has no atc code\n",
      "DB04919\n",
      "DB04920\n",
      "Drug has no atc code\n",
      "DB04921\n",
      "Drug has no atc code\n"
     ]
    },
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[0;32mIn [22]\u001b[0m, in \u001b[0;36m<cell line: 2>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[38;5;241m1\u001b[39m, \u001b[38;5;28mlen\u001b[39m(list1)):\n\u001b[1;32m      3\u001b[0m     x \u001b[38;5;241m=\u001b[39m list1[i]\n\u001b[0;32m----> 4\u001b[0m     res \u001b[38;5;241m=\u001b[39m \u001b[43mfind_eos\u001b[49m\u001b[43m(\u001b[49m\u001b[43mx\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m      5\u001b[0m     index_name \u001b[38;5;241m=\u001b[39m res[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mdrugbank_id\u001b[39m\u001b[38;5;124m'\u001b[39m]\n\u001b[1;32m      6\u001b[0m     dictionary[index_name] \u001b[38;5;241m=\u001b[39m res\n",
      "Input \u001b[0;32mIn [3]\u001b[0m, in \u001b[0;36mfind_eos\u001b[0;34m(x)\u001b[0m\n\u001b[1;32m    312\u001b[0m cat_codes  \u001b[38;5;241m=\u001b[39m parse_categories(usetxt)\n\u001b[1;32m    314\u001b[0m interest \u001b[38;5;241m=\u001b[39m re\u001b[38;5;241m.\u001b[39mfindall(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m<external-identifiers>(.*)</external-identifiers>\u001b[39m\u001b[38;5;124m\"\u001b[39m, usetxt)\n\u001b[0;32m--> 315\u001b[0m ident \u001b[38;5;241m=\u001b[39m re\u001b[38;5;241m.\u001b[39mfindall(\u001b[38;5;124mr\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m<external-identifier>[ ]+<resource>(.*?)</resource>[ ]+<identifier>(.*?)</identifier>\u001b[39m\u001b[38;5;124m'\u001b[39m, \u001b[43minterest\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m)\n\u001b[1;32m    316\u001b[0m identifiers  \u001b[38;5;241m=\u001b[39m {k:v \u001b[38;5;28;01mfor\u001b[39;00m (k,v)  \u001b[38;5;129;01min\u001b[39;00m ident}\n\u001b[1;32m    318\u001b[0m smile \u001b[38;5;241m=\u001b[39m re\u001b[38;5;241m.\u001b[39mfindall(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m<property>[ ]+<kind>SMILES</kind>[ ]+<value>(.*?)</value>\u001b[39m\u001b[38;5;124m\"\u001b[39m, usetxt)\n",
      "\u001b[0;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "dictionary = {}\n",
    "for i in range(1, len(list1)):\n",
    "    x = list1[i]\n",
    "    res = find_eos(x)\n",
    "    index_name = res['drugbank_id']\n",
    "    dictionary[index_name] = res\n",
    "    print(index_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "a84163d8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'=\"biotech\" created=\"2007-10-21\" updated=\"2020-06-12\">   <drugbank-id primary=\"true\">DB04923</drugbank-id>   <name>rhThrombin</name>   <description>rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that is not derived from animal or human blood, as an aid to controlling bleeding during surgery. Thrombin is used in more than 1 million surgeries each year in the United States. Currently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. Bovine-derived thrombin has been associated with the development of antibodies that may cross-react with human blood proteins and in some cases these antibodies appear to be related to serious bleeding complications. The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.</description>   <cas-number>1270043-60-1</cas-number>   <unii/>   <state>solid</state>   <groups>     <group>approved</group>     <group>investigational</group>   </groups>   <general-references>     <articles>       <article>         <ref-id>A2965</ref-id>         <pubmed-id>17660072</pubmed-id>         <citation>Chapman WC, Singla N, Genyk Y, McNeil JW, Renkens KL Jr, Reynolds TC, Murphy A, Weaver FA: A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 Aug;205(2):256-65. Epub 2007 Jun 27.</citation>       </article>       <article>         <ref-id>A2966</ref-id>         <pubmed-id>16971028</pubmed-id>         <citation>Heffernan JK, Ponce RA, Zuckerman LA, Volpone JP, Visich J, Giste EE, Jenkins N, Boster D, Pederson S, Knitter G, Palmer T, Wills M, Early RJ, Rogge MC: Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol. 2007 Feb;47(1):48-58. Epub 2006 Sep 12.</citation>       </article>     </articles>     <textbooks/>     <links/>     <attachments/>   </general-references>   <synthesis-reference/>   <indication>Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hemorrhage.</indication>   <pharmacodynamics>Plasma-derived bovine thrombin is used as a topical agent to improve surgical hemostasis, but development of antibodies to bovine hemostatic proteins has been associated with increased bleeding and thrombotic complications. rhThrombin has a superior immunogenicity profile compared with bovine thrombin (1.5% versus 22%, respectively, p&lt;0.0001; antibodies developed to the products, as defined by seroconversion or significant change in titer units).  Characterization of the binding antibodies demonstrated none of the anti-rhThrombin antibodies neutralized human plasma thrombin.&#13; &#13; </pharmacodynamics>   <mechanism-of-action>The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation simultaneously of a fibrin matrix. Application of exogenous thrombin bypasses the physiological process of generating a thrombin burst by directly initiating the terminal reactions of blood clot formation. rhThrombin rapidly binds to endogenous inhibitors following either i.v. or s.c. administration.</mechanism-of-action>   <toxicity/>   <metabolism/>   <absorption/>   <half-life>Approximately 15 hours (measured in non-human primates).</half-life>   <protein-binding/>   <route-of-elimination/>   <volume-of-distribution/>   <clearance/>   <classification>     <description/>     <direct-parent>Peptides</direct-parent>     <kingdom>Organic Compounds</kingdom>     <superclass>Organic Acids</superclass>     <class>Carboxylic Acids and Derivatives</class>     <subclass>Amino Acids, Peptides, and Analogues</subclass>   </classification>   <salts/>   <synonyms>     <synonym language=\"english\" coder=\"\">Recombinant thrombin</synonym>     <synonym language=\"english\" coder=\"\">Recothrom</synonym>     <synonym language=\"english\" coder=\"\">rhThrombin</synonym>     <synonym language=\"english\" coder=\"\">rThrombin</synonym>   </synonyms>   <products/>   <international-brands/>   <mixtures/>   <packagers/>   <manufacturers/>   <prices/>   <categories/>   <affected-organisms>     <affected-organism>Humans and other mammals</affected-organism>   </affected-organisms>   <dosages/>   <atc-codes/>   <ahfs-codes/>   <pdb-entries/>   <patents/>   <food-interactions/>   <drug-interactions/>   <sequences/>   <experimental-properties/>   <external-identifiers/>   <external-links/>   <pathways/>   <reactions/>   <snp-effects/>   <snp-adverse-drug-reactions/>   <targets/>   <enzymes/>   <carriers/>   <transporters/> </drug> <'"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dd1a2ccb",
   "metadata": {},
   "outputs": [],
   "source": [
    "len(dictionary)\n",
    "\n",
    "##### Edges: pathways + similarity smiles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "d80b01f2",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'dictionary' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Input \u001b[0;32mIn [9]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mdictionary\u001b[49m[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mDB00001\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mkeys()\n",
      "\u001b[0;31mNameError\u001b[0m: name 'dictionary' is not defined"
     ]
    }
   ],
   "source": [
    "dictionary['DB00001'].keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6a6a939a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "3e131cf6",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'dictionary' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Input \u001b[0;32mIn [13]\u001b[0m, in \u001b[0;36m<cell line: 6>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      3\u001b[0m no_pathway \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m      4\u001b[0m no_smiles \u001b[38;5;241m=\u001b[39m []\n\u001b[0;32m----> 6\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m k \u001b[38;5;129;01min\u001b[39;00m \u001b[43mdictionary\u001b[49m\u001b[38;5;241m.\u001b[39mkeys():\n\u001b[1;32m      7\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(dictionary[k][\u001b[38;5;124m'\u001b[39m\u001b[38;5;124msmiles\u001b[39m\u001b[38;5;124m'\u001b[39m]) \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[1;32m      8\u001b[0m         \u001b[38;5;28mprint\u001b[39m(k)\n",
      "\u001b[0;31mNameError\u001b[0m: name 'dictionary' is not defined"
     ]
    }
   ],
   "source": [
    "\n",
    "tuples =[]\n",
    "tuples2 = []\n",
    "no_pathway = []\n",
    "no_smiles = []\n",
    "\n",
    "for k in dictionary.keys():\n",
    "    if len(dictionary[k]['smiles']) != 0:\n",
    "        print(k)\n",
    "    if len(dictionary[k]['pathways'].keys()) == 0:\n",
    "        no_pathway += [k]\n",
    "    for u in dictionary[k]['pathways'].keys():\n",
    "        tuples += [(dictionary[k]['pathways'][u]['name_pathway'], dictionary[k]['pathways'][u]['smpdb_id'])]\n",
    "        tuples2 += [dictionary[k]['pathways'][u]['name_pathway'] + \";;\" + dictionary[k]['pathways'][u]['smpdb_id']]\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "5905b9f8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "645"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(dictionary.keys()) - len(no_pathway)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "a5958592",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['DB00003',\n",
       " 'DB00004',\n",
       " 'DB00005',\n",
       " 'DB00007',\n",
       " 'DB00008',\n",
       " 'DB00010',\n",
       " 'DB00011',\n",
       " 'DB00012',\n",
       " 'DB00014',\n",
       " 'DB00016',\n",
       " 'DB00017',\n",
       " 'DB00018',\n",
       " 'DB00019',\n",
       " 'DB00020',\n",
       " 'DB00022',\n",
       " 'DB00023',\n",
       " 'DB00024',\n",
       " 'DB00025',\n",
       " 'DB00026',\n",
       " 'DB00027',\n",
       " 'DB00028',\n",
       " 'DB00030',\n",
       " 'DB00032',\n",
       " 'DB00033',\n",
       " 'DB00034',\n",
       " 'DB00035',\n",
       " 'DB00036',\n",
       " 'DB00038',\n",
       " 'DB00039',\n",
       " 'DB00040',\n",
       " 'DB00041',\n",
       " 'DB00042',\n",
       " 'DB00043',\n",
       " 'DB00044',\n",
       " 'DB00045',\n",
       " 'DB00046',\n",
       " 'DB00047',\n",
       " 'DB00048',\n",
       " 'DB00049',\n",
       " 'DB00050',\n",
       " 'DB00051',\n",
       " 'DB00052',\n",
       " 'DB00053',\n",
       " 'DB00055',\n",
       " 'DB00056',\n",
       " 'DB00057',\n",
       " 'DB00058',\n",
       " 'DB00059',\n",
       " 'DB00060',\n",
       " 'DB00061',\n",
       " 'DB00062',\n",
       " 'DB00065',\n",
       " 'DB00066',\n",
       " 'DB00067',\n",
       " 'DB00068',\n",
       " 'DB00069',\n",
       " 'DB00070',\n",
       " 'DB00071',\n",
       " 'DB00073',\n",
       " 'DB00074',\n",
       " 'DB00075',\n",
       " 'DB00076',\n",
       " 'DB00078',\n",
       " 'DB00080',\n",
       " 'DB00081',\n",
       " 'DB00082',\n",
       " 'DB00083',\n",
       " 'DB00085',\n",
       " 'DB00087',\n",
       " 'DB00088',\n",
       " 'DB00089',\n",
       " 'DB00090',\n",
       " 'DB00091',\n",
       " 'DB00092',\n",
       " 'DB00093',\n",
       " 'DB00094',\n",
       " 'DB00095',\n",
       " 'DB00097',\n",
       " 'DB00098',\n",
       " 'DB00099',\n",
       " 'DB00100',\n",
       " 'DB00102',\n",
       " 'DB00103',\n",
       " 'DB00104',\n",
       " 'DB00105',\n",
       " 'DB00106',\n",
       " 'DB00107',\n",
       " 'DB00108',\n",
       " 'DB00109',\n",
       " 'DB00110',\n",
       " 'DB00111',\n",
       " 'DB00113',\n",
       " 'DB00115',\n",
       " 'DB00136',\n",
       " 'DB00137',\n",
       " 'DB00138',\n",
       " 'DB00146',\n",
       " 'DB00153',\n",
       " 'DB00163',\n",
       " 'DB00166',\n",
       " 'DB00168',\n",
       " 'DB00170',\n",
       " 'DB00176',\n",
       " 'DB00179',\n",
       " 'DB00180',\n",
       " 'DB00181',\n",
       " 'DB00182',\n",
       " 'DB00183',\n",
       " 'DB00185',\n",
       " 'DB00186',\n",
       " 'DB00188',\n",
       " 'DB00189',\n",
       " 'DB00190',\n",
       " 'DB00191',\n",
       " 'DB00192',\n",
       " 'DB00194',\n",
       " 'DB00196',\n",
       " 'DB00197',\n",
       " 'DB00198',\n",
       " 'DB00200',\n",
       " 'DB00202',\n",
       " 'DB00203',\n",
       " 'DB00204',\n",
       " 'DB00205',\n",
       " 'DB00206',\n",
       " 'DB00209',\n",
       " 'DB00210',\n",
       " 'DB00211',\n",
       " 'DB00212',\n",
       " 'DB00216',\n",
       " 'DB00217',\n",
       " 'DB00218',\n",
       " 'DB00219',\n",
       " 'DB00220',\n",
       " 'DB00221',\n",
       " 'DB00222',\n",
       " 'DB00223',\n",
       " 'DB00224',\n",
       " 'DB00225',\n",
       " 'DB00226',\n",
       " 'DB00228',\n",
       " 'DB00229',\n",
       " 'DB00230',\n",
       " 'DB00231',\n",
       " 'DB00233',\n",
       " 'DB00234',\n",
       " 'DB00235',\n",
       " 'DB00236',\n",
       " 'DB00237',\n",
       " 'DB00239',\n",
       " 'DB00240',\n",
       " 'DB00241',\n",
       " 'DB00242',\n",
       " 'DB00243',\n",
       " 'DB00244',\n",
       " 'DB00245',\n",
       " 'DB00246',\n",
       " 'DB00247',\n",
       " 'DB00248',\n",
       " 'DB00249',\n",
       " 'DB00250',\n",
       " 'DB00251',\n",
       " 'DB00253',\n",
       " 'DB00255',\n",
       " 'DB00257',\n",
       " 'DB00258',\n",
       " 'DB00259',\n",
       " 'DB00260',\n",
       " 'DB00261',\n",
       " 'DB00262',\n",
       " 'DB00263',\n",
       " 'DB00265',\n",
       " 'DB00267',\n",
       " 'DB00268',\n",
       " 'DB00269',\n",
       " 'DB00271',\n",
       " 'DB00273',\n",
       " 'DB00274',\n",
       " 'DB00276',\n",
       " 'DB00284',\n",
       " 'DB00286',\n",
       " 'DB00287',\n",
       " 'DB00288',\n",
       " 'DB00289',\n",
       " 'DB00290',\n",
       " 'DB00291',\n",
       " 'DB00292',\n",
       " 'DB00293',\n",
       " 'DB00294',\n",
       " 'DB00298',\n",
       " 'DB00299',\n",
       " 'DB00301',\n",
       " 'DB00303',\n",
       " 'DB00304',\n",
       " 'DB00305',\n",
       " 'DB00306',\n",
       " 'DB00307',\n",
       " 'DB00311',\n",
       " 'DB00312',\n",
       " 'DB00314',\n",
       " 'DB00315',\n",
       " 'DB00319',\n",
       " 'DB00320',\n",
       " 'DB00321',\n",
       " 'DB00322',\n",
       " 'DB00323',\n",
       " 'DB00324',\n",
       " 'DB00325',\n",
       " 'DB00326',\n",
       " 'DB00330',\n",
       " 'DB00331',\n",
       " 'DB00332',\n",
       " 'DB00334',\n",
       " 'DB00336',\n",
       " 'DB00337',\n",
       " 'DB00339',\n",
       " 'DB00340',\n",
       " 'DB00344',\n",
       " 'DB00345',\n",
       " 'DB00346',\n",
       " 'DB00347',\n",
       " 'DB00348',\n",
       " 'DB00349',\n",
       " 'DB00350',\n",
       " 'DB00351',\n",
       " 'DB00353',\n",
       " 'DB00355',\n",
       " 'DB00356',\n",
       " 'DB00357',\n",
       " 'DB00358',\n",
       " 'DB00359',\n",
       " 'DB00362',\n",
       " 'DB00363',\n",
       " 'DB00364',\n",
       " 'DB00365',\n",
       " 'DB00367',\n",
       " 'DB00369',\n",
       " 'DB00372',\n",
       " 'DB00374',\n",
       " 'DB00375',\n",
       " 'DB00376',\n",
       " 'DB00377',\n",
       " 'DB00378',\n",
       " 'DB00380',\n",
       " 'DB00382',\n",
       " 'DB00383',\n",
       " 'DB00385',\n",
       " 'DB00387',\n",
       " 'DB00388',\n",
       " 'DB00389',\n",
       " 'DB00390',\n",
       " 'DB00391',\n",
       " 'DB00392',\n",
       " 'DB00394',\n",
       " 'DB00395',\n",
       " 'DB00397',\n",
       " 'DB00400',\n",
       " 'DB00402',\n",
       " 'DB00403',\n",
       " 'DB00404',\n",
       " 'DB00406',\n",
       " 'DB00408',\n",
       " 'DB00409',\n",
       " 'DB00410',\n",
       " 'DB00411',\n",
       " 'DB00413',\n",
       " 'DB00414',\n",
       " 'DB00415',\n",
       " 'DB00416',\n",
       " 'DB00417',\n",
       " 'DB00418',\n",
       " 'DB00419',\n",
       " 'DB00420',\n",
       " 'DB00422',\n",
       " 'DB00423',\n",
       " 'DB00424',\n",
       " 'DB00425',\n",
       " 'DB00426',\n",
       " 'DB00428',\n",
       " 'DB00429',\n",
       " 'DB00430',\n",
       " 'DB00431',\n",
       " 'DB00432',\n",
       " 'DB00433',\n",
       " 'DB00437',\n",
       " 'DB00438',\n",
       " 'DB00440',\n",
       " 'DB00442',\n",
       " 'DB00443',\n",
       " 'DB00445',\n",
       " 'DB00447',\n",
       " 'DB00449',\n",
       " 'DB00450',\n",
       " 'DB00454',\n",
       " 'DB00456',\n",
       " 'DB00457',\n",
       " 'DB00459',\n",
       " 'DB00460',\n",
       " 'DB00462',\n",
       " 'DB00463',\n",
       " 'DB00464',\n",
       " 'DB00466',\n",
       " 'DB00467',\n",
       " 'DB00468',\n",
       " 'DB00470',\n",
       " 'DB00471',\n",
       " 'DB00473',\n",
       " 'DB00474',\n",
       " 'DB00475',\n",
       " 'DB00476',\n",
       " 'DB00477',\n",
       " 'DB00478',\n",
       " 'DB00480',\n",
       " 'DB00481',\n",
       " 'DB00483',\n",
       " 'DB00484',\n",
       " 'DB00485',\n",
       " 'DB00486',\n",
       " 'DB00487',\n",
       " 'DB00488',\n",
       " 'DB00490',\n",
       " 'DB00491',\n",
       " 'DB00493',\n",
       " 'DB00494',\n",
       " 'DB00496',\n",
       " 'DB00499',\n",
       " 'DB00502',\n",
       " 'DB00503',\n",
       " 'DB00505',\n",
       " 'DB00507',\n",
       " 'DB00508',\n",
       " 'DB00509',\n",
       " 'DB00511',\n",
       " 'DB00512',\n",
       " 'DB00514',\n",
       " 'DB00515',\n",
       " 'DB00516',\n",
       " 'DB00517',\n",
       " 'DB00518',\n",
       " 'DB00520',\n",
       " 'DB00522',\n",
       " 'DB00525',\n",
       " 'DB00526',\n",
       " 'DB00528',\n",
       " 'DB00529',\n",
       " 'DB00532',\n",
       " 'DB00534',\n",
       " 'DB00535',\n",
       " 'DB00536',\n",
       " 'DB00537',\n",
       " 'DB00538',\n",
       " 'DB00539',\n",
       " 'DB00540',\n",
       " 'DB00543',\n",
       " 'DB00545',\n",
       " 'DB00546',\n",
       " 'DB00547',\n",
       " 'DB00548',\n",
       " 'DB00549',\n",
       " 'DB00550',\n",
       " 'DB00551',\n",
       " 'DB00552',\n",
       " 'DB00553',\n",
       " 'DB00555',\n",
       " 'DB00556',\n",
       " 'DB00558',\n",
       " 'DB00559',\n",
       " 'DB00561',\n",
       " 'DB00562',\n",
       " 'DB00565',\n",
       " 'DB00566',\n",
       " 'DB00567',\n",
       " 'DB00572',\n",
       " 'DB00574',\n",
       " 'DB00575',\n",
       " 'DB00576',\n",
       " 'DB00577',\n",
       " 'DB00578',\n",
       " 'DB00579',\n",
       " 'DB00581',\n",
       " 'DB00582',\n",
       " 'DB00587',\n",
       " 'DB00588',\n",
       " 'DB00589',\n",
       " 'DB00590',\n",
       " 'DB00591',\n",
       " 'DB00592',\n",
       " 'DB00593',\n",
       " 'DB00596',\n",
       " 'DB00597',\n",
       " 'DB00599',\n",
       " 'DB00600',\n",
       " 'DB00601',\n",
       " 'DB00602',\n",
       " 'DB00603',\n",
       " 'DB00604',\n",
       " 'DB00607',\n",
       " 'DB00608',\n",
       " 'DB00609',\n",
       " 'DB00610',\n",
       " 'DB00611',\n",
       " 'DB00613',\n",
       " 'DB00614',\n",
       " 'DB00615',\n",
       " 'DB00616',\n",
       " 'DB00617',\n",
       " 'DB00620',\n",
       " 'DB00621',\n",
       " 'DB00622',\n",
       " 'DB00623',\n",
       " 'DB00626',\n",
       " 'DB00628',\n",
       " 'DB00629',\n",
       " 'DB00631',\n",
       " 'DB00632',\n",
       " 'DB00633',\n",
       " 'DB00634',\n",
       " 'DB00636',\n",
       " 'DB00638',\n",
       " 'DB00639',\n",
       " 'DB00642',\n",
       " 'DB00643',\n",
       " 'DB00644',\n",
       " 'DB00645',\n",
       " 'DB00646',\n",
       " 'DB00648',\n",
       " 'DB00651',\n",
       " 'DB00653',\n",
       " 'DB00654',\n",
       " 'DB00656',\n",
       " 'DB00657',\n",
       " 'DB00658',\n",
       " 'DB00659',\n",
       " 'DB00660',\n",
       " 'DB00662',\n",
       " 'DB00663',\n",
       " 'DB00664',\n",
       " 'DB00665',\n",
       " 'DB00666',\n",
       " 'DB00669',\n",
       " 'DB00671',\n",
       " 'DB00672',\n",
       " 'DB00673',\n",
       " 'DB00674',\n",
       " 'DB00676',\n",
       " 'DB00677',\n",
       " 'DB00679',\n",
       " 'DB00680',\n",
       " 'DB00681',\n",
       " 'DB00683',\n",
       " 'DB00685',\n",
       " 'DB00686',\n",
       " 'DB00687',\n",
       " 'DB00689',\n",
       " 'DB00690',\n",
       " 'DB00692',\n",
       " 'DB00693',\n",
       " 'DB00694',\n",
       " 'DB00696',\n",
       " 'DB00697',\n",
       " 'DB00698',\n",
       " 'DB00699',\n",
       " 'DB00701',\n",
       " 'DB00702',\n",
       " 'DB00703',\n",
       " 'DB00706',\n",
       " 'DB00707',\n",
       " 'DB00711',\n",
       " 'DB00713',\n",
       " 'DB00714',\n",
       " 'DB00715',\n",
       " 'DB00716',\n",
       " 'DB00717',\n",
       " 'DB00720',\n",
       " 'DB00723',\n",
       " 'DB00724',\n",
       " 'DB00725',\n",
       " 'DB00726',\n",
       " 'DB00727',\n",
       " 'DB00728',\n",
       " 'DB00730',\n",
       " 'DB00732',\n",
       " 'DB00733',\n",
       " 'DB00734',\n",
       " 'DB00735',\n",
       " 'DB00738',\n",
       " 'DB00739',\n",
       " 'DB00740',\n",
       " 'DB00742',\n",
       " 'DB00743',\n",
       " 'DB00744',\n",
       " 'DB00745',\n",
       " 'DB00746',\n",
       " 'DB00747',\n",
       " 'DB00752',\n",
       " 'DB00753',\n",
       " 'DB00754',\n",
       " 'DB00756',\n",
       " 'DB00757',\n",
       " 'DB00760',\n",
       " 'DB00761',\n",
       " 'DB00763',\n",
       " 'DB00764',\n",
       " 'DB00765',\n",
       " 'DB00766',\n",
       " 'DB00767',\n",
       " 'DB00769',\n",
       " 'DB00770',\n",
       " 'DB00771',\n",
       " 'DB00772',\n",
       " 'DB00779',\n",
       " 'DB00780',\n",
       " 'DB00782',\n",
       " 'DB00785',\n",
       " 'DB00786',\n",
       " 'DB00787',\n",
       " 'DB00789',\n",
       " 'DB00791',\n",
       " 'DB00793',\n",
       " 'DB00794',\n",
       " 'DB00795',\n",
       " 'DB00797',\n",
       " 'DB00799',\n",
       " 'DB00800',\n",
       " 'DB00801',\n",
       " 'DB00803',\n",
       " 'DB00804',\n",
       " 'DB00805',\n",
       " 'DB00806',\n",
       " 'DB00809',\n",
       " 'DB00810',\n",
       " 'DB00811',\n",
       " 'DB00815',\n",
       " 'DB00816',\n",
       " 'DB00817',\n",
       " 'DB00818',\n",
       " 'DB00819',\n",
       " 'DB00820',\n",
       " 'DB00823',\n",
       " 'DB00824',\n",
       " 'DB00825',\n",
       " 'DB00826',\n",
       " 'DB00827',\n",
       " 'DB00828',\n",
       " 'DB00829',\n",
       " 'DB00830',\n",
       " 'DB00831',\n",
       " 'DB00832',\n",
       " 'DB00833',\n",
       " 'DB00834',\n",
       " 'DB00836',\n",
       " 'DB00837',\n",
       " 'DB00838',\n",
       " 'DB00839',\n",
       " 'DB00840',\n",
       " 'DB00842',\n",
       " 'DB00843',\n",
       " 'DB00845',\n",
       " 'DB00846',\n",
       " 'DB00848',\n",
       " 'DB00849',\n",
       " 'DB00850',\n",
       " 'DB00851',\n",
       " 'DB00852',\n",
       " 'DB00853',\n",
       " 'DB00856',\n",
       " 'DB00857',\n",
       " 'DB00858',\n",
       " 'DB00859',\n",
       " 'DB00862',\n",
       " 'DB00864',\n",
       " 'DB00865',\n",
       " 'DB00867',\n",
       " 'DB00868',\n",
       " 'DB00869',\n",
       " 'DB00871',\n",
       " 'DB00872',\n",
       " 'DB14596',\n",
       " 'DB00874',\n",
       " 'DB00875',\n",
       " 'DB00877',\n",
       " 'DB00878',\n",
       " 'DB00882',\n",
       " 'DB00883',\n",
       " 'DB00885',\n",
       " 'DB00886',\n",
       " 'DB00888',\n",
       " 'DB00889',\n",
       " 'DB00890',\n",
       " 'DB00891',\n",
       " 'DB00893',\n",
       " 'DB00894',\n",
       " 'DB00895',\n",
       " 'DB00896',\n",
       " 'DB00897',\n",
       " 'DB00901',\n",
       " 'DB00904',\n",
       " 'DB00905',\n",
       " 'DB00906',\n",
       " 'DB00909',\n",
       " 'DB00910',\n",
       " 'DB00911',\n",
       " 'DB00914',\n",
       " 'DB00915',\n",
       " 'DB00916',\n",
       " 'DB00918',\n",
       " 'DB00922',\n",
       " 'DB00923',\n",
       " 'DB00924',\n",
       " 'DB00925',\n",
       " 'DB00926',\n",
       " 'DB00928',\n",
       " 'DB00929',\n",
       " 'DB00930',\n",
       " 'DB00932',\n",
       " 'DB00933',\n",
       " 'DB00934',\n",
       " 'DB00935',\n",
       " 'DB00937',\n",
       " 'DB00938',\n",
       " 'DB00939',\n",
       " 'DB00940',\n",
       " 'DB00941',\n",
       " 'DB00942',\n",
       " 'DB00944',\n",
       " 'DB00947',\n",
       " 'DB00948',\n",
       " 'DB00951',\n",
       " 'DB00952',\n",
       " 'DB00953',\n",
       " 'DB00954',\n",
       " 'DB00957',\n",
       " 'DB00958',\n",
       " 'DB00959',\n",
       " 'DB00962',\n",
       " 'DB00964',\n",
       " 'DB00965',\n",
       " 'DB00968',\n",
       " 'DB00969',\n",
       " 'DB00970',\n",
       " 'DB00971',\n",
       " 'DB00973',\n",
       " 'DB00974',\n",
       " 'DB00977',\n",
       " 'DB00978',\n",
       " 'DB00979',\n",
       " 'DB00980',\n",
       " 'DB00981',\n",
       " 'DB00982',\n",
       " 'DB00983',\n",
       " 'DB00984',\n",
       " 'DB00985',\n",
       " 'DB00986',\n",
       " 'DB00987',\n",
       " 'DB00989',\n",
       " 'DB00990',\n",
       " 'DB00992',\n",
       " 'DB00994',\n",
       " 'DB00995',\n",
       " 'DB00996',\n",
       " 'DB00998',\n",
       " 'DB01000',\n",
       " 'DB01001',\n",
       " 'DB01003',\n",
       " 'DB01004',\n",
       " 'DB01005',\n",
       " 'DB01006',\n",
       " 'DB01007',\n",
       " 'DB01008',\n",
       " 'DB01010',\n",
       " 'DB01011',\n",
       " 'DB01012',\n",
       " 'DB01013',\n",
       " 'DB01014',\n",
       " 'DB01015',\n",
       " 'DB01018',\n",
       " 'DB01019',\n",
       " 'DB01020',\n",
       " 'DB01025',\n",
       " 'DB01026',\n",
       " 'DB01028',\n",
       " 'DB01030',\n",
       " 'DB01031',\n",
       " 'DB01032',\n",
       " 'DB01034',\n",
       " 'DB01036',\n",
       " 'DB01037',\n",
       " 'DB01038',\n",
       " 'DB01039',\n",
       " 'DB01041',\n",
       " 'DB01042',\n",
       " 'DB01043',\n",
       " 'DB01044',\n",
       " 'DB01045',\n",
       " 'DB01046',\n",
       " 'DB01047',\n",
       " 'DB01049',\n",
       " 'DB01051',\n",
       " 'DB01053',\n",
       " 'DB01055',\n",
       " 'DB01057',\n",
       " 'DB01058',\n",
       " 'DB01059',\n",
       " 'DB01060',\n",
       " 'DB01061',\n",
       " 'DB01062',\n",
       " 'DB01063',\n",
       " 'DB01066',\n",
       " 'DB01067',\n",
       " 'DB01068',\n",
       " 'DB01070',\n",
       " 'DB01072',\n",
       " 'DB01073',\n",
       " 'DB01074',\n",
       " 'DB01076',\n",
       " 'DB01077',\n",
       " 'DB01078',\n",
       " 'DB01079',\n",
       " 'DB01080',\n",
       " 'DB01083',\n",
       " 'DB01085',\n",
       " 'DB01087',\n",
       " 'DB01088',\n",
       " 'DB01089',\n",
       " 'DB01090',\n",
       " 'DB01091',\n",
       " 'DB01092',\n",
       " 'DB01093',\n",
       " 'DB01094',\n",
       " 'DB01096',\n",
       " 'DB01097',\n",
       " 'DB01099',\n",
       " 'DB01100',\n",
       " 'DB01103',\n",
       " 'DB01104',\n",
       " 'DB01105',\n",
       " 'DB01107',\n",
       " 'DB01108',\n",
       " 'DB01110',\n",
       " 'DB01111',\n",
       " 'DB01112',\n",
       " 'DB01113',\n",
       " 'DB01116',\n",
       " 'DB01117',\n",
       " 'DB01119',\n",
       " 'DB01121',\n",
       " 'DB01122',\n",
       " 'DB01123',\n",
       " 'DB01124',\n",
       " 'DB01125',\n",
       " 'DB01126',\n",
       " 'DB01127',\n",
       " 'DB01128',\n",
       " 'DB01130',\n",
       " 'DB01131',\n",
       " 'DB01132',\n",
       " 'DB01133',\n",
       " 'DB01134',\n",
       " 'DB01135',\n",
       " 'DB01137',\n",
       " 'DB01138',\n",
       " 'DB01139',\n",
       " 'DB01140',\n",
       " 'DB01141',\n",
       " 'DB01143',\n",
       " 'DB01144',\n",
       " 'DB01145',\n",
       " 'DB01147',\n",
       " 'DB01148',\n",
       " 'DB01149',\n",
       " 'DB01150',\n",
       " 'DB01152',\n",
       " 'DB01153',\n",
       " 'DB01154',\n",
       " 'DB01155',\n",
       " 'DB01156',\n",
       " 'DB01157',\n",
       " 'DB01158',\n",
       " 'DB01159',\n",
       " 'DB01160',\n",
       " 'DB01162',\n",
       " 'DB01163',\n",
       " 'DB01164',\n",
       " 'DB01165',\n",
       " 'DB01167',\n",
       " 'DB01168',\n",
       " 'DB01169',\n",
       " 'DB01170',\n",
       " 'DB01171',\n",
       " 'DB01174',\n",
       " 'DB01177',\n",
       " 'DB01178',\n",
       " 'DB01179',\n",
       " 'DB01182',\n",
       " 'DB01184',\n",
       " 'DB01185',\n",
       " 'DB01186',\n",
       " 'DB01187',\n",
       " 'DB01188',\n",
       " 'DB01189',\n",
       " 'DB01191',\n",
       " 'DB01194',\n",
       " 'DB01196',\n",
       " 'DB01198',\n",
       " 'DB01199',\n",
       " 'DB01200',\n",
       " 'DB01201',\n",
       " 'DB01202',\n",
       " 'DB01204',\n",
       " 'DB01205',\n",
       " 'DB01206',\n",
       " 'DB01207',\n",
       " 'DB01208',\n",
       " 'DB01212',\n",
       " 'DB01213',\n",
       " 'DB01215',\n",
       " 'DB01216',\n",
       " 'DB01217',\n",
       " 'DB01218',\n",
       " 'DB01219',\n",
       " 'DB01220',\n",
       " 'DB01221',\n",
       " 'DB01222',\n",
       " 'DB01223',\n",
       " 'DB01225',\n",
       " 'DB01226',\n",
       " 'DB01228',\n",
       " 'DB01230',\n",
       " 'DB01231',\n",
       " 'DB01232',\n",
       " 'DB01233',\n",
       " 'DB01234',\n",
       " 'DB01236',\n",
       " 'DB01238',\n",
       " 'DB01239',\n",
       " 'DB01240',\n",
       " 'DB01241',\n",
       " 'DB01243',\n",
       " 'DB01244',\n",
       " 'DB01245',\n",
       " 'DB01247',\n",
       " 'DB01249',\n",
       " 'DB01250',\n",
       " 'DB01251',\n",
       " 'DB01252',\n",
       " 'DB01253',\n",
       " 'DB01255',\n",
       " 'DB01256',\n",
       " 'DB01257',\n",
       " 'DB01259',\n",
       " 'DB01260',\n",
       " 'DB01261',\n",
       " 'DB01262',\n",
       " 'DB01263',\n",
       " 'DB01264',\n",
       " 'DB01265',\n",
       " 'DB01266',\n",
       " 'DB01267',\n",
       " 'DB01268',\n",
       " 'DB01270',\n",
       " 'DB01271',\n",
       " 'DB01272',\n",
       " 'DB01273',\n",
       " 'DB01274',\n",
       " 'DB01275',\n",
       " 'DB01276',\n",
       " 'DB01277',\n",
       " 'DB01278',\n",
       " 'DB01279',\n",
       " 'DB01280',\n",
       " 'DB01281',\n",
       " 'DB01282',\n",
       " 'DB01284',\n",
       " 'DB01285',\n",
       " 'DB01288',\n",
       " 'DB01289',\n",
       " 'DB01291',\n",
       " 'DB01294',\n",
       " 'DB01298',\n",
       " 'DB01299',\n",
       " 'DB01303',\n",
       " 'DB01306',\n",
       " 'DB01307',\n",
       " 'DB01309',\n",
       " 'DB01319',\n",
       " 'DB01322',\n",
       " 'DB01323',\n",
       " 'DB01326',\n",
       " 'DB01327',\n",
       " 'DB01328',\n",
       " 'DB01329',\n",
       " 'DB01330',\n",
       " 'DB01331',\n",
       " 'DB01332',\n",
       " 'DB01333',\n",
       " 'DB01336',\n",
       " 'DB01337',\n",
       " 'DB01338',\n",
       " 'DB01339',\n",
       " 'DB01341',\n",
       " 'DB01344',\n",
       " 'DB01346',\n",
       " 'DB01347',\n",
       " 'DB01349',\n",
       " 'DB01351',\n",
       " 'DB01352',\n",
       " 'DB01353',\n",
       " 'DB01354',\n",
       " 'DB01355',\n",
       " 'DB01356',\n",
       " 'DB01357',\n",
       " 'DB01362',\n",
       " 'DB01363',\n",
       " 'DB01364',\n",
       " 'DB01365',\n",
       " 'DB01366',\n",
       " 'DB01367',\n",
       " 'DB01369',\n",
       " 'DB01370',\n",
       " 'DB01375',\n",
       " 'DB01377',\n",
       " 'DB01380',\n",
       " 'DB01381',\n",
       " 'DB01382',\n",
       " 'DB01384',\n",
       " 'DB01388',\n",
       " 'DB01390',\n",
       " 'DB01392',\n",
       " 'DB01393',\n",
       " 'DB01394',\n",
       " 'DB01395',\n",
       " 'DB01396',\n",
       " 'DB01400',\n",
       " 'DB01403',\n",
       " 'DB01404',\n",
       " 'DB01405',\n",
       " 'DB01406',\n",
       " 'DB01407',\n",
       " 'DB01408',\n",
       " 'DB01409',\n",
       " 'DB01410',\n",
       " 'DB01411',\n",
       " 'DB01413',\n",
       " 'DB01414',\n",
       " 'DB01415',\n",
       " 'DB01416',\n",
       " 'DB01420',\n",
       " 'DB01422',\n",
       " 'DB01423',\n",
       " 'DB01424',\n",
       " 'DB01425',\n",
       " 'DB01426',\n",
       " 'DB01427',\n",
       " 'DB01428',\n",
       " 'DB01429',\n",
       " 'DB01430',\n",
       " 'DB01431',\n",
       " 'DB01432',\n",
       " 'DB01434',\n",
       " 'DB01436',\n",
       " 'DB01437',\n",
       " 'DB01438',\n",
       " 'DB01440',\n",
       " 'DB01441',\n",
       " 'DB01442',\n",
       " 'DB01443',\n",
       " 'DB01445',\n",
       " 'DB01446',\n",
       " 'DB01447',\n",
       " 'DB01448',\n",
       " 'DB01450',\n",
       " 'DB01451',\n",
       " 'DB01453',\n",
       " 'DB01454',\n",
       " 'DB01455',\n",
       " 'DB01456',\n",
       " 'DB01458',\n",
       " 'DB01459',\n",
       " 'DB01460',\n",
       " 'DB01461',\n",
       " 'DB01462',\n",
       " 'DB01463',\n",
       " 'DB01464',\n",
       " 'DB01465',\n",
       " 'DB01467',\n",
       " 'DB01468',\n",
       " 'DB01469',\n",
       " 'DB01470',\n",
       " 'DB01471',\n",
       " 'DB01472',\n",
       " 'DB01473',\n",
       " 'DB01474',\n",
       " 'DB01475',\n",
       " 'DB01476',\n",
       " 'DB01477',\n",
       " 'DB01478',\n",
       " 'DB01479',\n",
       " 'DB01480',\n",
       " 'DB01481',\n",
       " 'DB01482',\n",
       " ...]"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "no_pathway"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "ad3a6e1d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'drugbank_id': 'DB00026',\n",
       " 'name': 'Anakinra',\n",
       " 'description': 'Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.',\n",
       " 'indication': 'For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). ',\n",
       " 'pharmacodynamics': 'Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.',\n",
       " 'toxicity': 'Most common adverse reactions (incidence  5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence &gt;10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis. ',\n",
       " 'metabolism': '',\n",
       " 'absorption': 'When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. &#13; Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;&#13; Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL. &#13; ',\n",
       " 'half_life': 'Healthy subjects = 4 - 6 hours;&#13; NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours). ',\n",
       " 'market_start': 2002,\n",
       " 'affected_organism': ['Humans and other mammals'],\n",
       " 'market_end': 2050,\n",
       " 'mechanism_of_action': 'Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.',\n",
       " 'route_of_elimination': '',\n",
       " 'volume_of_distribution': '',\n",
       " 'classification': {'direct-parent': 'Peptides',\n",
       "  'kingdom': 'Organic Compounds',\n",
       "  'superclass': 'Organic Acids',\n",
       "  'class': 'Carboxylic Acids and Derivatives',\n",
       "  'subclass': 'Amino Acids, Peptides, and Analogues'},\n",
       " 'carriers': {},\n",
       " 'targets': {},\n",
       " 'transporters': {},\n",
       " 'enzymes': [],\n",
       " 'atc_code': ['l04ac03'],\n",
       " 'identifiers': {'Drugs Product Database (DPD)': '12604',\n",
       "  'PubChem Substance': '46507944',\n",
       "  'KEGG Drug': 'D02934',\n",
       "  'GenBank': 'M55646',\n",
       "  'PharmGKB': 'PA10799',\n",
       "  'UniProtKB': 'P14778',\n",
       "  'Therapeutic Targets Database': 'DAP000095',\n",
       "  'Wikipedia': 'Anakinra',\n",
       "  'ChEMBL': 'CHEMBL1201570',\n",
       "  'RxCUI': '72435',\n",
       "  'HUGO Gene Nomenclature Committee (HGNC)': 'HGNC:5993',\n",
       "  'GenAtlas': 'IL1R1',\n",
       "  'GenBank Gene Database': 'X16896',\n",
       "  'GenBank Protein Database': '33801',\n",
       "  'UniProt Accession': 'IL1R1_HUMAN'},\n",
       " 'categories': [['agents reducing cytokine levels', ''],\n",
       "  ['amino acids, peptides, and proteins', 'd000602'],\n",
       "  ['antineoplastic and immunomodulating agents', ''],\n",
       "  ['antirheumatic agents', 'd018501'],\n",
       "  ['biological factors', 'd001685'],\n",
       "  ['biologics for rheumatoid arthritis treatment', ''],\n",
       "  ['cytokines', 'd016207'],\n",
       "  ['disease-modifying antirheumatic agents', ''],\n",
       "  ['immunosuppressive agents', 'd007166'],\n",
       "  ['intercellular signaling peptides and proteins', 'd036341'],\n",
       "  ['interleukin inhibitors', ''],\n",
       "  ['interleukin-1 receptor antagonist', ''],\n",
       "  ['peptides', 'd010455'],\n",
       "  ['proteins', 'd011506']],\n",
       " 'atc_hierarchy': [('l04ac', 'interleukin inhibitors'),\n",
       "  ('l04a', 'immunosuppressants'),\n",
       "  ('l04', 'immunosuppressants'),\n",
       "  ('l', 'antineoplastic and immunomodulating agents')],\n",
       " 'food_interactions': '',\n",
       " 'ddi': {'DB00005': {'name': 'Etanercept',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.'},\n",
       "  'DB00051': {'name': 'Adalimumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.'},\n",
       "  'DB00065': {'name': 'Infliximab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.'},\n",
       "  'DB04956': {'name': 'Afelimomab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.'},\n",
       "  'DB06674': {'name': 'Golimumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.'},\n",
       "  'DB08904': {'name': 'Certolizumab pegol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.'},\n",
       "  'DB06643': {'name': 'Denosumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.'},\n",
       "  'DB00008': {'name': 'Peginterferon alfa-2a',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Anakinra.'},\n",
       "  'DB00011': {'name': 'Interferon alfa-n1',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Anakinra.'},\n",
       "  'DB00018': {'name': 'Interferon alfa-n3',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Anakinra.'},\n",
       "  'DB00022': {'name': 'Peginterferon alfa-2b',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Anakinra.'},\n",
       "  'DB00033': {'name': 'Interferon gamma-1b',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon gamma-1b.'},\n",
       "  'DB00034': {'name': 'Interferon alfa-2a, Recombinant',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2a, Recombinant.'},\n",
       "  'DB00041': {'name': 'Aldesleukin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Aldesleukin.'},\n",
       "  'DB00056': {'name': 'Gemtuzumab ozogamicin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.'},\n",
       "  'DB00059': {'name': 'Pegaspargase',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Pegaspargase.'},\n",
       "  'DB00068': {'name': 'Interferon beta-1b',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.'},\n",
       "  'DB00069': {'name': 'Interferon alfacon-1',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1.'},\n",
       "  'DB00073': {'name': 'Rituximab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.'},\n",
       "  'DB00074': {'name': 'Basiliximab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Basiliximab.'},\n",
       "  'DB00075': {'name': 'Muromonab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Muromonab.'},\n",
       "  'DB00078': {'name': 'Ibritumomab tiuxetan',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.'},\n",
       "  'DB00081': {'name': 'Tositumomab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tositumomab.'},\n",
       "  'DB00087': {'name': 'Alemtuzumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.'},\n",
       "  'DB00092': {'name': 'Alefacept',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Alefacept.'},\n",
       "  'DB00095': {'name': 'Efalizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab.'},\n",
       "  'DB00098': {'name': 'Antithymocyte immunoglobulin (rabbit)',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit).'},\n",
       "  'DB00105': {'name': 'Interferon alfa-2b',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2b.'},\n",
       "  'DB00111': {'name': 'Daclizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.'},\n",
       "  'DB00112': {'name': 'Bevacizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Bevacizumab.'},\n",
       "  'DB00120': {'name': 'Phenylalanine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.'},\n",
       "  'DB00242': {'name': 'Cladribine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cladribine.'},\n",
       "  'DB00276': {'name': 'Amsacrine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Amsacrine.'},\n",
       "  'DB00290': {'name': 'Bleomycin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Bleomycin.'},\n",
       "  'DB00291': {'name': 'Chlorambucil',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Chlorambucil.'},\n",
       "  'DB00293': {'name': 'Raltitrexed',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Raltitrexed.'},\n",
       "  'DB00305': {'name': 'Mitomycin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mitomycin.'},\n",
       "  'DB00322': {'name': 'Floxuridine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Floxuridine.'},\n",
       "  'DB00352': {'name': 'Tioguanine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tioguanine.'},\n",
       "  'DB00380': {'name': 'Dexrazoxane',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane.'},\n",
       "  'DB00428': {'name': 'Streptozocin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Streptozocin.'},\n",
       "  'DB00432': {'name': 'Trifluridine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Trifluridine.'},\n",
       "  'DB00441': {'name': 'Gemcitabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Gemcitabine.'},\n",
       "  'DB00445': {'name': 'Epirubicin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Epirubicin.'},\n",
       "  'DB00446': {'name': 'Chloramphenicol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Chloramphenicol.'},\n",
       "  'DB00480': {'name': 'Lenalidomide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Lenalidomide.'},\n",
       "  'DB00488': {'name': 'Altretamine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Altretamine.'},\n",
       "  'DB00515': {'name': 'Cisplatin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin.'},\n",
       "  'DB00526': {'name': 'Oxaliplatin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Oxaliplatin.'},\n",
       "  'DB00550': {'name': 'Propylthiouracil',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Propylthiouracil.'},\n",
       "  'DB00552': {'name': 'Pentostatin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Pentostatin.'},\n",
       "  'DB00601': {'name': 'Linezolid',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Linezolid.'},\n",
       "  'DB00631': {'name': 'Clofarabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Clofarabine.'},\n",
       "  'DB00763': {'name': 'Methimazole',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Methimazole.'},\n",
       "  'DB00795': {'name': 'Sulfasalazine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Sulfasalazine.'},\n",
       "  'DB00853': {'name': 'Temozolomide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Temozolomide.'},\n",
       "  'DB00859': {'name': 'Penicillamine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Penicillamine.'},\n",
       "  'DB00888': {'name': 'Mechlorethamine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mechlorethamine.'},\n",
       "  'DB00928': {'name': 'Azacitidine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Azacitidine.'},\n",
       "  'DB00958': {'name': 'Carboplatin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Carboplatin.'},\n",
       "  'DB00970': {'name': 'Dactinomycin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Dactinomycin.'},\n",
       "  'DB01005': {'name': 'Hydroxyurea',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Hydroxyurea.'},\n",
       "  'DB01024': {'name': 'Mycophenolic acid',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mycophenolic acid.'},\n",
       "  'DB01030': {'name': 'Topotecan',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Topotecan.'},\n",
       "  'DB01033': {'name': 'Mercaptopurine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mercaptopurine.'},\n",
       "  'DB01042': {'name': 'Melphalan',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Melphalan.'},\n",
       "  'DB01073': {'name': 'Fludarabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fludarabine.'},\n",
       "  'DB01099': {'name': 'Flucytosine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Flucytosine.'},\n",
       "  'DB01168': {'name': 'Procarbazine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Procarbazine.'},\n",
       "  'DB01169': {'name': 'Arsenic trioxide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Arsenic trioxide.'},\n",
       "  'DB01204': {'name': 'Mitoxantrone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mitoxantrone.'},\n",
       "  'DB01206': {'name': 'Lomustine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Lomustine.'},\n",
       "  'DB01257': {'name': 'Eculizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Eculizumab.'},\n",
       "  'DB01262': {'name': 'Decitabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Decitabine.'},\n",
       "  'DB01280': {'name': 'Nelarabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Nelarabine.'},\n",
       "  'DB01423': {'name': 'Stepronin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Stepronin.'},\n",
       "  'DB01816': {'name': 'Castanospermine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Castanospermine.'},\n",
       "  'DB02546': {'name': 'Vorinostat',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Vorinostat.'},\n",
       "  'DB02806': {'name': '2-Methoxyethanol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with 2-Methoxyethanol.'},\n",
       "  'DB03523': {'name': 'Brequinar',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Brequinar.'},\n",
       "  'DB05258': {'name': 'Interferon alfa',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa.'},\n",
       "  'DB05259': {'name': 'Glatiramer',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Glatiramer.'},\n",
       "  'DB05260': {'name': 'Gallium nitrate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Gallium nitrate.'},\n",
       "  'DB05459': {'name': 'Briakinumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Briakinumab.'},\n",
       "  'DB05472': {'name': 'Human interferon omega-1',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Human interferon omega-1.'},\n",
       "  'DB06273': {'name': 'Tocilizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.'},\n",
       "  'DB06372': {'name': 'Rilonacept',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Rilonacept.'},\n",
       "  'DB06612': {'name': 'Mepolizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mepolizumab.'},\n",
       "  'DB06662': {'name': 'Abetimus',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.'},\n",
       "  'DB06681': {'name': 'Belatacept',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Belatacept.'},\n",
       "  'DB06813': {'name': 'Pralatrexate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Pralatrexate.'},\n",
       "  'DB08059': {'name': 'Wortmannin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Wortmannin.'},\n",
       "  'DB08871': {'name': 'Eribulin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Eribulin.'},\n",
       "  'DB08879': {'name': 'Belimumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Belimumab.'},\n",
       "  'DB08880': {'name': 'Teriflunomide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Teriflunomide.'},\n",
       "  'DB08889': {'name': 'Carfilzomib',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Carfilzomib.'},\n",
       "  'DB08908': {'name': 'Dimethyl fumarate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Dimethyl fumarate.'},\n",
       "  'DB08935': {'name': 'Obinutuzumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Obinutuzumab.'},\n",
       "  'DB09029': {'name': 'Secukinumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Secukinumab.'},\n",
       "  'DB09033': {'name': 'Vedolizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Vedolizumab.'},\n",
       "  'DB09036': {'name': 'Siltuximab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Siltuximab.'},\n",
       "  'DB09052': {'name': 'Blinatumomab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Blinatumomab.'},\n",
       "  'DB09077': {'name': 'Dinutuximab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Dinutuximab.'},\n",
       "  'DB09091': {'name': 'Tixocortol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tixocortol.'},\n",
       "  'DB09122': {'name': 'Peginterferon beta-1a',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Peginterferon beta-1a.'},\n",
       "  'DB09312': {'name': 'Antilymphocyte immunoglobulin (horse)',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Antilymphocyte immunoglobulin (horse).'},\n",
       "  'DB11466': {'name': 'Tepoxalin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tepoxalin.'},\n",
       "  'DB11569': {'name': 'Ixekizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Ixekizumab.'},\n",
       "  'DB11580': {'name': 'Ravulizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Ravulizumab.'},\n",
       "  'DB11616': {'name': 'Pirarubicin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Pirarubicin.'},\n",
       "  'DB11693': {'name': 'Voclosporin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Voclosporin.'},\n",
       "  'DB11708': {'name': 'Peficitinib',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Peficitinib.'},\n",
       "  'DB11767': {'name': 'Sarilumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Sarilumab.'},\n",
       "  'DB11776': {'name': 'Brodalumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Brodalumab.'},\n",
       "  'DB11803': {'name': 'Sirukumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Sirukumab.'},\n",
       "  'DB11834': {'name': 'Guselkumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Guselkumab.'},\n",
       "  'DB11988': {'name': 'Ocrelizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Ocrelizumab.'},\n",
       "  'DB12025': {'name': 'Triptolide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Triptolide.'},\n",
       "  'DB12612': {'name': 'Ozanimod',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Ozanimod.'},\n",
       "  'DB12617': {'name': 'Mizoribine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mizoribine.'},\n",
       "  'DB12692': {'name': 'Gusperimus',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Gusperimus.'},\n",
       "  'DB12814': {'name': 'Cepeginterferon alfa-2B',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cepeginterferon alfa-2B.'},\n",
       "  'DB12902': {'name': 'Trofosfamide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Trofosfamide.'},\n",
       "  'DB12947': {'name': 'Doxifluridine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Doxifluridine.'},\n",
       "  'DB12991': {'name': 'Deoxyspergualin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Deoxyspergualin.'},\n",
       "  'DB12996': {'name': 'Acteoside',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Acteoside.'},\n",
       "  'DB13003': {'name': 'Cortivazol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cortivazol.'},\n",
       "  'DB13014': {'name': 'Hypericin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Hypericin.'},\n",
       "  'DB13068': {'name': '9-(N-methyl-L-isoleucine)-cyclosporin A',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.'},\n",
       "  'DB13223': {'name': 'Fluocortin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortin.'},\n",
       "  'DB13241': {'name': 'Begelomab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Begelomab.'},\n",
       "  'DB13491': {'name': 'Fluperolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluperolone.'},\n",
       "  'DB13843': {'name': 'Cloprednol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cloprednol.'},\n",
       "  'DB13856': {'name': 'Fluclorolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluclorolone.'},\n",
       "  'DB14219': {'name': 'Monomethyl fumarate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Monomethyl fumarate.'},\n",
       "  'DB14724': {'name': 'Emapalumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Emapalumab.'},\n",
       "  'DB14762': {'name': 'Risankizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Risankizumab.'},\n",
       "  'DB14919': {'name': 'Rozanolixizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Rozanolixizumab.'},\n",
       "  'DB15253': {'name': 'Bleselumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Bleselumab.'},\n",
       "  'DB00180': {'name': 'Flunisolide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Flunisolide.'},\n",
       "  'DB00394': {'name': 'Beclomethasone dipropionate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Beclomethasone dipropionate.'},\n",
       "  'DB00443': {'name': 'Betamethasone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Betamethasone.'},\n",
       "  'DB00591': {'name': 'Fluocinolone acetonide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocinolone acetonide.'},\n",
       "  'DB00635': {'name': 'Prednisone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Prednisone.'},\n",
       "  'DB00687': {'name': 'Fludrocortisone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fludrocortisone.'},\n",
       "  'DB00860': {'name': 'Prednisolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Prednisolone.'},\n",
       "  'DB00959': {'name': 'Methylprednisolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Methylprednisolone.'},\n",
       "  'DB01196': {'name': 'Estramustine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Estramustine.'},\n",
       "  'DB01285': {'name': 'Corticotropin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Corticotropin.'},\n",
       "  'DB01380': {'name': 'Cortisone acetate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cortisone acetate.'},\n",
       "  'DB01384': {'name': 'Paramethasone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Paramethasone.'},\n",
       "  'DB04630': {'name': 'Aldosterone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Aldosterone.'},\n",
       "  'DB08970': {'name': 'Fluprednidene',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluprednidene.'},\n",
       "  'DB09082': {'name': 'Vilanterol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Vilanterol.'},\n",
       "  'DB09378': {'name': 'Fluprednisolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluprednisolone.'},\n",
       "  'DB09383': {'name': 'Meprednisone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Meprednisone.'},\n",
       "  'DB11487': {'name': 'Dexamethasone isonicotinate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Dexamethasone isonicotinate.'},\n",
       "  'DB11529': {'name': 'Melengestrol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Melengestrol.'},\n",
       "  'DB11921': {'name': 'Deflazacort',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Deflazacort.'},\n",
       "  'DB13208': {'name': 'Prednylidene',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Prednylidene.'},\n",
       "  'DB14066': {'name': 'Tetrandrine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tetrandrine.'},\n",
       "  'DB14512': {'name': 'Mometasone furoate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mometasone furoate.'},\n",
       "  'DB14545': {'name': 'Hydrocortisone succinate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Hydrocortisone succinate.'},\n",
       "  'DB01222': {'name': 'Budesonide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Budesonide.'},\n",
       "  'DB01394': {'name': 'Colchicine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Colchicine.'},\n",
       "  'DB00694': {'name': 'Daunorubicin',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Daunorubicin.'},\n",
       "  'DB00987': {'name': 'Cytarabine',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Cytarabine.'},\n",
       "  'DB01108': {'name': 'Trilostane',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Trilostane.'},\n",
       "  'DB05015': {'name': 'Belinostat',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Belinostat.'},\n",
       "  'DB01013': {'name': 'Clobetasol propionate',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Clobetasol propionate.'},\n",
       "  'DB01047': {'name': 'Fluocinonide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocinonide.'},\n",
       "  'DB00547': {'name': 'Desoximetasone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Desoximetasone.'},\n",
       "  'DB00764': {'name': 'Mometasone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Mometasone.'},\n",
       "  'DB08971': {'name': 'Fluocortolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortolone.'},\n",
       "  'DB11750': {'name': 'Clobetasol',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Clobetasol.'},\n",
       "  'DB00324': {'name': 'Fluorometholone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Fluorometholone.'},\n",
       "  'DB09095': {'name': 'Difluocortolone',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Difluocortolone.'},\n",
       "  'DB00108': {'name': 'Natalizumab',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.'},\n",
       "  'DB00337': {'name': 'Pimecrolimus',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.'},\n",
       "  'DB01656': {'name': 'Roflumilast',\n",
       "   'description': 'Anakinra may increase the immunosuppressive activities of Roflumilast.'},\n",
       "  'DB06688': {'name': 'Sipuleucel-T',\n",
       "   'description': 'The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.'},\n",
       "  'DB01281': {'name': 'Abatacept',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.'},\n",
       "  'DB06168': {'name': 'Canakinumab',\n",
       "   'description': 'Anakinra may increase the immunosuppressive activities of Canakinumab.'},\n",
       "  'DB08895': {'name': 'Tofacitinib',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.'},\n",
       "  'DB01015': {'name': 'Sulfamethoxazole',\n",
       "   'description': 'The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Anakinra.'},\n",
       "  'DB01097': {'name': 'Leflunomide',\n",
       "   'description': 'The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.'},\n",
       "  'DB00072': {'name': 'Trastuzumab',\n",
       "   'description': 'Trastuzumab may increase the neutropenic activities of Anakinra.'},\n",
       "  'DB08868': {'name': 'Fingolimod',\n",
       "   'description': 'Anakinra may increase the immunosuppressive activities of Fingolimod.'},\n",
       "  'DB00864': {'name': 'Tacrolimus',\n",
       "   'description': 'Tacrolimus may increase the immunosuppressive activities of Anakinra.'},\n",
       "  'DB04914': {'name': 'G17DT',\n",
       "   'description': 'The therapeutic efficacy of G17DT can be decreased when used in combination with Anakinra.'},\n",
       "  'DB05144': {'name': 'PEV3A',\n",
       "   'description': 'The therapeutic efficacy of PEV3A can be decreased when used in combination with Anakinra.'},\n",
       "  'DB05325': {'name': 'INGN 225',\n",
       "   'description': 'The therapeutic efficacy of INGN 225 can be decreased when used in combination with Anakinra.'},\n",
       "  'DB05374': {'name': 'Rindopepimut',\n",
       "   'description': 'The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Anakinra.'},\n",
       "  'DB05440': {'name': 'SRP 299',\n",
       "   'description': 'The therapeutic efficacy of SRP 299 can be decreased when used in combination with Anakinra.'},\n",
       "  'DB05942': {'name': 'GI-5005',\n",
       "   'description': 'The therapeutic efficacy of GI-5005 can be decreased when used in combination with Anakinra.'},\n",
       "  'DB06400': {'name': 'Vitespen',\n",
       "   'description': 'The therapeutic efficacy of Vitespen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB06584': {'name': 'TG4010',\n",
       "   'description': 'The therapeutic efficacy of TG4010 can be decreased when used in combination with Anakinra.'},\n",
       "  'DB09057': {'name': 'Anthrax immune globulin human',\n",
       "   'description': 'The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10062': {'name': 'Rabies virus inactivated antigen, B',\n",
       "   'description': 'The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10076': {'name': 'Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen',\n",
       "   'description': 'The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10276': {'name': 'Rotavirus vaccine',\n",
       "   'description': 'The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10283': {'name': 'Rabies virus inactivated antigen, A',\n",
       "   'description': 'The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10342': {'name': 'Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen',\n",
       "   'description': 'The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10583': {'name': 'Clostridium tetani toxoid antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10584': {'name': 'Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10600': {'name': 'Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10769': {'name': 'Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10794': {'name': 'Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10803': {'name': 'Typhoid Vi polysaccharide vaccine',\n",
       "   'description': 'The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10989': {'name': 'Hepatitis A Vaccine',\n",
       "   'description': 'The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10990': {'name': 'Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen',\n",
       "   'description': 'The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11038': {'name': 'Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11040': {'name': 'Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11041': {'name': 'Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11044': {'name': 'Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11603': {'name': 'Human rabies virus immune globulin',\n",
       "   'description': 'The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra.'},\n",
       "  'DB11627': {'name': 'Hepatitis B Vaccine (Recombinant)',\n",
       "   'description': 'The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB12568': {'name': 'Tecemotide',\n",
       "   'description': 'The therapeutic efficacy of Tecemotide can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14022': {'name': 'Typhoid vaccine',\n",
       "   'description': 'The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14384': {'name': 'Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14385': {'name': 'Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14394': {'name': 'Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14445': {'name': 'Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14449': {'name': 'Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14619': {'name': 'Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14620': {'name': 'Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14711': {'name': 'Smallpox (Vaccinia) Vaccine, Live',\n",
       "   'description': 'The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Anakinra.'},\n",
       "  'DB15274': {'name': 'Pertussis vaccine',\n",
       "   'description': 'The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB15461': {'name': 'Yersinia pestis 195/p antigen (formaldehyde inactivated)',\n",
       "   'description': 'The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB13924': {'name': 'Varicella Zoster Vaccine (Recombinant)',\n",
       "   'description': 'The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB15483': {'name': 'Modified vaccinia ankara',\n",
       "   'description': 'The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra.'},\n",
       "  'DB15595': {'name': 'Ebola Zaire vaccine (live, attenuated)',\n",
       "   'description': 'The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Anakinra.'},\n",
       "  'DB15654': {'name': 'Moderna COVID-19 Vaccine',\n",
       "   'description': 'The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Anakinra.'},\n",
       "  'DB10317': {'name': 'Rubella virus vaccine',\n",
       "   'description': 'The risk or severity of infection can be increased when Rubella virus vaccine is combined with Anakinra.'},\n",
       "  'DB10318': {'name': 'Varicella Zoster Vaccine (Live/attenuated)',\n",
       "   'description': 'The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Anakinra.'},\n",
       "  'DB10343': {'name': 'Bacillus calmette-guerin substrain tice live antigen',\n",
       "   'description': 'The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Anakinra.'},\n",
       "  'DB10804': {'name': 'Bacillus calmette-guerin substrain connaught live antigen',\n",
       "   'description': 'The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Anakinra.'},\n",
       "  'DB10805': {'name': 'Yellow Fever Vaccine',\n",
       "   'description': 'The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Anakinra.'},\n",
       "  'DB11003': {'name': 'Anthrax vaccine',\n",
       "   'description': 'The risk or severity of infection can be increased when Anthrax vaccine is combined with Anakinra.'},\n",
       "  'DB11050': {'name': 'Typhoid Vaccine Live',\n",
       "   'description': 'The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Anakinra.'},\n",
       "  'DB12386': {'name': 'Bacillus calmette-guerin substrain danish 1331 live antigen',\n",
       "   'description': 'The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Anakinra.'},\n",
       "  'DB12768': {'name': 'BCG vaccine',\n",
       "   'description': 'The risk or severity of infection can be increased when BCG vaccine is combined with Anakinra.'},\n",
       "  'DB14409': {'name': 'Human adenovirus e serotype 4 strain cl-68578 antigen',\n",
       "   'description': 'The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Anakinra.'},\n",
       "  'DB14443': {'name': 'Vibrio cholerae CVD 103-HgR strain live antigen',\n",
       "   'description': 'The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Anakinra.'},\n",
       "  'DB14685': {'name': 'Adenovirus type 7 vaccine live',\n",
       "   'description': 'The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Anakinra.'},\n",
       "  'DB00201': {'name': 'Caffeine',\n",
       "   'description': 'The metabolism of Caffeine can be increased when combined with Anakinra.'},\n",
       "  'DB00176': {'name': 'Fluvoxamine',\n",
       "   'description': 'The metabolism of Fluvoxamine can be increased when combined with Anakinra.'},\n",
       "  'DB00195': {'name': 'Betaxolol',\n",
       "   'description': 'The metabolism of Betaxolol can be increased when combined with Anakinra.'},\n",
       "  'DB00262': {'name': 'Carmustine',\n",
       "   'description': 'The metabolism of Carmustine can be increased when combined with Anakinra.'},\n",
       "  'DB00268': {'name': 'Ropinirole',\n",
       "   'description': 'The metabolism of Ropinirole can be increased when combined with Anakinra.'},\n",
       "  'DB00280': {'name': 'Disopyramide',\n",
       "   'description': 'The metabolism of Disopyramide can be increased when combined with Anakinra.'},\n",
       "  'DB00286': {'name': 'Conjugated estrogens',\n",
       "   'description': 'The metabolism of Conjugated estrogens can be increased when combined with Anakinra.'},\n",
       "  'DB00296': {'name': 'Ropivacaine',\n",
       "   'description': 'The metabolism of Ropivacaine can be increased when combined with Anakinra.'},\n",
       "  'DB00315': {'name': 'Zolmitriptan',\n",
       "   'description': 'The metabolism of Zolmitriptan can be increased when combined with Anakinra.'},\n",
       "  'DB00316': {'name': 'Acetaminophen',\n",
       "   'description': 'The metabolism of Acetaminophen can be increased when combined with Anakinra.'},\n",
       "  'DB00334': {'name': 'Olanzapine',\n",
       "   'description': 'The metabolism of Olanzapine can be increased when combined with Anakinra.'},\n",
       "  'DB00356': {'name': 'Chlorzoxazone',\n",
       "   'description': 'The metabolism of Chlorzoxazone can be increased when combined with Anakinra.'},\n",
       "  'DB00365': {'name': 'Grepafloxacin',\n",
       "   'description': 'The metabolism of Grepafloxacin can be increased when combined with Anakinra.'},\n",
       "  'DB00370': {'name': 'Mirtazapine',\n",
       "   'description': 'The metabolism of Mirtazapine can be increased when combined with Anakinra.'},\n",
       "  'DB00379': {'name': 'Mexiletine',\n",
       "   'description': 'The metabolism of Mexiletine can be increased when combined with Anakinra.'},\n",
       "  'DB00382': {'name': 'Tacrine',\n",
       "   'description': 'The metabolism of Tacrine can be increased when combined with Anakinra.'},\n",
       "  'DB00384': {'name': 'Triamterene',\n",
       "   'description': 'The metabolism of Triamterene can be increased when combined with Anakinra.'},\n",
       "  'DB00442': {'name': 'Entecavir',\n",
       "   'description': 'The metabolism of Entecavir can be increased when combined with Anakinra.'},\n",
       "  'DB00477': {'name': 'Chlorpromazine',\n",
       "   'description': 'The metabolism of Chlorpromazine can be increased when combined with Anakinra.'},\n",
       "  'DB00518': {'name': 'Albendazole',\n",
       "   'description': 'The metabolism of Albendazole can be increased when combined with Anakinra.'},\n",
       "  'DB00629': {'name': 'Guanabenz',\n",
       "   'description': 'The metabolism of Guanabenz can be increased when combined with Anakinra.'},\n",
       "  'DB00642': {'name': 'Pemetrexed',\n",
       "   'description': 'The metabolism of Pemetrexed can be increased when combined with Anakinra.'},\n",
       "  'DB00730': {'name': 'Thiabendazole',\n",
       "   'description': 'The metabolism of Thiabendazole can be increased when combined with Anakinra.'},\n",
       "  'DB00740': {'name': 'Riluzole',\n",
       "   'description': 'The metabolism of Riluzole can be increased when combined with Anakinra.'},\n",
       "  'DB00787': {'name': 'Acyclovir',\n",
       "   'description': 'The metabolism of Acyclovir can be increased when combined with Anakinra.'},\n",
       "  'DB00806': {'name': 'Pentoxifylline',\n",
       "   'description': 'The metabolism of Pentoxifylline can be increased when combined with Anakinra.'},\n",
       "  'DB00831': {'name': 'Trifluoperazine',\n",
       "   'description': 'The metabolism of Trifluoperazine can be increased when combined with Anakinra.'},\n",
       "  'DB00863': {'name': 'Ranitidine',\n",
       "   'description': 'The metabolism of Ranitidine can be increased when combined with Anakinra.'},\n",
       "  'DB00898': {'name': 'Ethanol',\n",
       "   'description': 'The metabolism of Ethanol can be increased when combined with Anakinra.'},\n",
       "  'DB00934': {'name': 'Maprotiline',\n",
       "   'description': 'The metabolism of Maprotiline can be increased when combined with Anakinra.'},\n",
       "  'DB00978': {'name': 'Lomefloxacin',\n",
       "   'description': 'The metabolism of Lomefloxacin can be increased when combined with Anakinra.'},\n",
       "  'DB00993': {'name': 'Azathioprine',\n",
       "   'description': 'The metabolism of Azathioprine can be increased when combined with Anakinra.'},\n",
       "  'DB00998': {'name': 'Frovatriptan',\n",
       "   'description': 'The metabolism of Frovatriptan can be increased when combined with Anakinra.'},\n",
       "  'DB01002': {'name': 'Levobupivacaine',\n",
       "   'description': 'The metabolism of Levobupivacaine can be increased when combined with Anakinra.'},\n",
       "  'DB01012': {'name': 'Cinacalcet',\n",
       "   'description': 'The metabolism of Cinacalcet can be increased when combined with Anakinra.'},\n",
       "  'DB01056': {'name': 'Tocainide',\n",
       "   'description': 'The metabolism of Tocainide can be increased when combined with Anakinra.'},\n",
       "  'DB01087': {'name': 'Primaquine',\n",
       "   'description': 'The metabolism of Primaquine can be increased when combined with Anakinra.'},\n",
       "  'DB01094': {'name': 'Hesperetin',\n",
       "   'description': 'The metabolism of Hesperetin can be increased when combined with Anakinra.'},\n",
       "  'DB01182': {'name': 'Propafenone',\n",
       "   'description': 'The metabolism of Propafenone can be increased when combined with Anakinra.'},\n",
       "  'DB01191': {'name': 'Dexfenfluramine',\n",
       "   'description': 'The metabolism of Dexfenfluramine can be increased when combined with Anakinra.'},\n",
       "  'DB01303': {'name': 'Oxtriphylline',\n",
       "   'description': 'The metabolism of Oxtriphylline can be increased when combined with Anakinra.'},\n",
       "  'DB01367': {'name': 'Rasagiline',\n",
       "   'description': 'The metabolism of Rasagiline can be increased when combined with Anakinra.'},\n",
       "  'DB01405': {'name': 'Temafloxacin',\n",
       "   'description': 'The metabolism of Temafloxacin can be increased when combined with Anakinra.'},\n",
       "  'DB01412': {'name': 'Theobromine',\n",
       "   'description': 'The metabolism of Theobromine can be increased when combined with Anakinra.'},\n",
       "  'DB01482': {'name': 'Fenethylline',\n",
       "   'description': 'The metabolism of Fenethylline can be increased when combined with Anakinra.'},\n",
       "  'DB01558': {'name': 'Bromazepam',\n",
       "   'description': 'The metabolism of Bromazepam can be increased when combined with Anakinra.'},\n",
       "  'DB01623': {'name': 'Thiothixene',\n",
       "   'description': 'The metabolism of Thiothixene can be increased when combined with Anakinra.'},\n",
       "  'DB01645': {'name': 'Genistein',\n",
       "   'description': 'The metabolism of Genistein can be increased when combined with Anakinra.'},\n",
       "  'DB01667': {'name': '8-azaguanine',\n",
       "   'description': 'The metabolism of 8-azaguanine can be increased when combined with Anakinra.'},\n",
       "  'DB02134': {'name': 'Xanthine',\n",
       "   'description': 'The metabolism of Xanthine can be increased when combined with Anakinra.'},\n",
       "  'DB02489': {'name': '9-Methylguanine',\n",
       "   'description': 'The metabolism of 9-Methylguanine can be increased when combined with Anakinra.'},\n",
       "  'DB02568': {'name': 'Peldesine',\n",
       "   'description': 'The metabolism of Peldesine can be increased when combined with Anakinra.'},\n",
       "  'DB02709': {'name': 'Resveratrol',\n",
       "   'description': 'The metabolism of Resveratrol can be increased when combined with Anakinra.'},\n",
       "  'DB04076': {'name': 'Hypoxanthine',\n",
       "   'description': 'The metabolism of Hypoxanthine can be increased when combined with Anakinra.'},\n",
       "  'DB04356': {'name': '9-Deazaguanine',\n",
       "   'description': 'The metabolism of 9-Deazaguanine can be increased when combined with Anakinra.'},\n",
       "  'DB04871': {'name': 'Lorcaserin',\n",
       "   'description': 'The metabolism of Lorcaserin can be increased when combined with Anakinra.'},\n",
       "  'DB04948': {'name': 'Lofexidine',\n",
       "   'description': 'The metabolism of Lofexidine can be increased when combined with Anakinra.'},\n",
       "  'DB04951': {'name': 'Pirfenidone',\n",
       "   'description': 'The metabolism of Pirfenidone can be increased when combined with Anakinra.'},\n",
       "  'DB06148': {'name': 'Mianserin',\n",
       "   'description': 'The metabolism of Mianserin can be increased when combined with Anakinra.'},\n",
       "  'DB06210': {'name': 'Eltrombopag',\n",
       "   'description': 'The metabolism of Eltrombopag can be increased when combined with Anakinra.'},\n",
       "  'DB06216': {'name': 'Asenapine',\n",
       "   'description': 'The metabolism of Asenapine can be increased when combined with Anakinra.'},\n",
       "  'DB06235': {'name': 'Vadimezan',\n",
       "   'description': 'The metabolism of Vadimezan can be increased when combined with Anakinra.'},\n",
       "  'DB06479': {'name': 'Propentofylline',\n",
       "   'description': 'The metabolism of Propentofylline can be increased when combined with Anakinra.'},\n",
       "  'DB06594': {'name': 'Agomelatine',\n",
       "   'description': 'The metabolism of Agomelatine can be increased when combined with Anakinra.'},\n",
       "  'DB06770': {'name': 'Benzyl alcohol',\n",
       "   'description': 'The metabolism of Benzyl alcohol can be increased when combined with Anakinra.'},\n",
       "  'DB06774': {'name': 'Capsaicin',\n",
       "   'description': 'The metabolism of Capsaicin can be increased when combined with Anakinra.'},\n",
       "  'DB08496': {'name': '(R)-warfarin',\n",
       "   'description': 'The metabolism of (R)-warfarin can be increased when combined with Anakinra.'},\n",
       "  'DB09071': {'name': 'Tasimelteon',\n",
       "   'description': 'The metabolism of Tasimelteon can be increased when combined with Anakinra.'},\n",
       "  'DB09118': {'name': 'Stiripentol',\n",
       "   'description': 'The metabolism of Stiripentol can be increased when combined with Anakinra.'},\n",
       "  'DB09225': {'name': 'Zotepine',\n",
       "   'description': 'The metabolism of Zotepine can be increased when combined with Anakinra.'},\n",
       "  'DB09273': {'name': 'Doxofylline',\n",
       "   'description': 'The metabolism of Doxofylline can be increased when combined with Anakinra.'},\n",
       "  'DB09290': {'name': 'Ramosetron',\n",
       "   'description': 'The metabolism of Ramosetron can be increased when combined with Anakinra.'},\n",
       "  'DB11919': {'name': '6-O-benzylguanine',\n",
       "   'description': 'The metabolism of 6-O-benzylguanine can be increased when combined with Anakinra.'},\n",
       "  'DB11967': {'name': 'Binimetinib',\n",
       "   'description': 'The metabolism of Binimetinib can be increased when combined with Anakinra.'},\n",
       "  'DB12026': {'name': 'Voxilaprevir',\n",
       "   'description': 'The metabolism of Voxilaprevir can be increased when combined with Anakinra.'},\n",
       "  'DB12245': {'name': 'Triclabendazole',\n",
       "   'description': 'The metabolism of Triclabendazole can be increased when combined with Anakinra.'},\n",
       "  'DB12332': {'name': 'Rucaparib',\n",
       "   'description': 'The metabolism of Rucaparib can be increased when combined with Anakinra.'},\n",
       "  'DB12406': {'name': 'Lisofylline',\n",
       "   'description': 'The metabolism of Lisofylline can be increased when combined with Anakinra.'},\n",
       "  'DB12531': {'name': 'Lobucavir',\n",
       "   'description': 'The metabolism of Lobucavir can be increased when combined with Anakinra.'},\n",
       "  'DB12926': {'name': 'Cafedrine',\n",
       "   'description': 'The metabolism of Cafedrine can be increased when combined with Anakinra.'},\n",
       "  'DB12927': {'name': 'Theodrenaline',\n",
       "   'description': 'The metabolism of Theodrenaline can be increased when combined with Anakinra.'},\n",
       "  'DB12945': {'name': 'Dihydralazine',\n",
       "   'description': 'The metabolism of Dihydralazine can be increased when combined with Anakinra.'},\n",
       "  'DB13203': {'name': 'Bamifylline',\n",
       "   'description': 'The metabolism of Bamifylline can be increased when combined with Anakinra.'},\n",
       "  'DB13449': {'name': 'Proxyphylline',\n",
       "   'description': 'The metabolism of Proxyphylline can be increased when combined with Anakinra.'},\n",
       "  'DB13573': {'name': 'Acefylline',\n",
       "   'description': 'The metabolism of Acefylline can be increased when combined with Anakinra.'},\n",
       "  'DB13592': {'name': 'Etamiphylline',\n",
       "   'description': 'The metabolism of Etamiphylline can be increased when combined with Anakinra.'},\n",
       "  'DB13634': {'name': 'Pentifylline',\n",
       "   'description': 'The metabolism of Pentifylline can be increased when combined with Anakinra.'},\n",
       "  'DB13812': {'name': 'Bufylline',\n",
       "   'description': 'The metabolism of Bufylline can be increased when combined with Anakinra.'},\n",
       "  'DB14018': {'name': 'Bromotheophylline',\n",
       "   'description': 'The metabolism of Bromotheophylline can be increased when combined with Anakinra.'},\n",
       "  'DB14132': {'name': '8-chlorotheophylline',\n",
       "   'description': 'The metabolism of 8-chlorotheophylline can be increased when combined with Anakinra.'},\n",
       "  'DB11757': {'name': 'Istradefylline',\n",
       "   'description': 'The metabolism of Istradefylline can be increased when combined with Anakinra.'},\n",
       "  'DB04889': {'name': 'Bicifadine',\n",
       "   'description': 'The metabolism of Bicifadine can be increased when combined with Anakinra.'},\n",
       "  'DB05708': {'name': 'GTS-21',\n",
       "   'description': 'The metabolism of GTS-21 can be increased when combined with Anakinra.'},\n",
       "  'DB00977': {'name': 'Ethinylestradiol',\n",
       "   'description': 'The metabolism of Ethinylestradiol can be increased when combined with Anakinra.'},\n",
       "  'DB00425': {'name': 'Zolpidem',\n",
       "   'description': 'The metabolism of Zolpidem can be increased when combined with Anakinra.'},\n",
       "  'DB00532': {'name': 'Mephenytoin',\n",
       "   'description': 'The metabolism of Mephenytoin can be increased when combined with Anakinra.'},\n",
       "  'DB00924': {'name': 'Cyclobenzaprine',\n",
       "   'description': 'The metabolism of Cyclobenzaprine can be increased when combined with Anakinra.'},\n",
       "  'DB11689': {'name': 'Selumetinib',\n",
       "   'description': 'The metabolism of Selumetinib can be increased when combined with Anakinra.'},\n",
       "  'DB00655': {'name': 'Estrone',\n",
       "   'description': 'The metabolism of Estrone can be increased when combined with Anakinra.'},\n",
       "  'DB00363': {'name': 'Clozapine',\n",
       "   'description': 'The metabolism of Clozapine can be increased when combined with Anakinra.'},\n",
       "  'DB00299': {'name': 'Penciclovir',\n",
       "   'description': 'The metabolism of Penciclovir can be increased when combined with Anakinra.'},\n",
       "  'DB00277': {'name': 'Theophylline',\n",
       "   'description': 'The metabolism of Theophylline can be increased when combined with Anakinra.'},\n",
       "  'DB00682': {'name': 'Warfarin',\n",
       "   'description': 'The metabolism of Warfarin can be increased when combined with Anakinra.'},\n",
       "  'DB00697': {'name': 'Tizanidine',\n",
       "   'description': 'The metabolism of Tizanidine can be increased when combined with Anakinra.'},\n",
       "  'DB01100': {'name': 'Pimozide',\n",
       "   'description': 'The metabolism of Pimozide can be increased when combined with Anakinra.'},\n",
       "  'DB01223': {'name': 'Aminophylline',\n",
       "   'description': 'The metabolism of Aminophylline can be increased when combined with Anakinra.'},\n",
       "  'DB01418': {'name': 'Acenocoumarol',\n",
       "   'description': 'The metabolism of Acenocoumarol can be increased when combined with Anakinra.'},\n",
       "  'DB09256': {'name': 'Tegafur',\n",
       "   'description': 'The metabolism of Tegafur can be increased when combined with Anakinra.'},\n",
       "  'DB00261': {'name': 'Anagrelide',\n",
       "   'description': 'The metabolism of Anagrelide can be increased when combined with Anakinra.'},\n",
       "  'DB00544': {'name': 'Fluorouracil',\n",
       "   'description': 'The metabolism of Fluorouracil can be increased when combined with Anakinra.'},\n",
       "  'DB00851': {'name': 'Dacarbazine',\n",
       "   'description': 'The metabolism of Dacarbazine can be increased when combined with Anakinra.'},\n",
       "  'DB06769': {'name': 'Bendamustine',\n",
       "   'description': 'The metabolism of Bendamustine can be increased when combined with Anakinra.'},\n",
       "  'DB08910': {'name': 'Pomalidomide',\n",
       "   'description': 'The metabolism of Pomalidomide can be increased when combined with Anakinra.'},\n",
       "  'DB00458': {'name': 'Imipramine',\n",
       "   'description': 'The metabolism of Imipramine can be increased when combined with Anakinra.'},\n",
       "  'DB00575': {'name': 'Clonidine',\n",
       "   'description': 'The metabolism of Clonidine can be increased when combined with Anakinra.'},\n",
       "  'DB01242': {'name': 'Clomipramine',\n",
       "   'description': 'The metabolism of Clomipramine can be increased when combined with Anakinra.'},\n",
       "  'DB00238': {'name': 'Nevirapine',\n",
       "   'description': 'The metabolism of Nevirapine can be increased when combined with Anakinra.'},\n",
       "  'DB00471': {'name': 'Montelukast',\n",
       "   'description': 'The metabolism of Montelukast can be increased when combined with Anakinra.'},\n",
       "  'DB00690': {'name': 'Flurazepam',\n",
       "   'description': 'The metabolism of Flurazepam can be increased when combined with Anakinra.'},\n",
       "  'DB00916': {'name': 'Metronidazole',\n",
       "   'description': 'The metabolism of Metronidazole can be increased when combined with Anakinra.'},\n",
       "  'DB00983': {'name': 'Formoterol',\n",
       "   'description': 'The metabolism of Formoterol can be increased when combined with Anakinra.'},\n",
       "  'DB01006': {'name': 'Letrozole',\n",
       "   'description': 'The metabolism of Letrozole can be increased when combined with Anakinra.'},\n",
       "  'DB01028': {'name': 'Methoxyflurane',\n",
       "   'description': 'The metabolism of Methoxyflurane can be increased when combined with Anakinra.'},\n",
       "  'DB01159': {'name': 'Halothane',\n",
       "   'description': 'The metabolism of Halothane can be increased when combined with Anakinra.'},\n",
       "  'DB01236': {'name': 'Sevoflurane',\n",
       "   'description': 'The metabolism of Sevoflurane can be increased when combined with Anakinra.'},\n",
       "  'DB01274': {'name': 'Arformoterol',\n",
       "   'description': 'The metabolism of Arformoterol can be increased when combined with Anakinra.'},\n",
       "  'DB01544': {'name': 'Flunitrazepam',\n",
       "   'description': 'The metabolism of Flunitrazepam can be increased when combined with Anakinra.'},\n",
       "  'DB06292': {'name': 'Dapagliflozin',\n",
       "   'description': 'The metabolism of Dapagliflozin can be increased when combined with Anakinra.'},\n",
       "  'DB06470': {'name': 'Clomethiazole',\n",
       "   'description': 'The metabolism of Clomethiazole can be increased when combined with Anakinra.'},\n",
       "  'DB09068': {'name': 'Vortioxetine',\n",
       "   'description': 'The metabolism of Vortioxetine can be increased when combined with Anakinra.'},\n",
       "  'DB09327': {'name': 'Tegafur-uracil',\n",
       "   'description': 'The metabolism of Tegafur-uracil can be increased when combined with Anakinra.'},\n",
       "  'DB11586': {'name': 'Asunaprevir',\n",
       "   'description': 'The metabolism of Asunaprevir can be increased when combined with Anakinra.'},\n",
       "  'DB04977': {'name': 'Plitidepsin',\n",
       "   'description': 'The metabolism of Plitidepsin can be increased when combined with Anakinra.'},\n",
       "  'DB06119': {'name': 'Cenobamate',\n",
       "   'description': 'The metabolism of Cenobamate can be increased when combined with Anakinra.'},\n",
       "  'DB00313': {'name': 'Valproic acid',\n",
       "   'description': 'The metabolism of Valproic acid can be increased when combined with Anakinra.'},\n",
       "  'DB00604': {'name': 'Cisapride',\n",
       "   'description': 'The metabolism of Cisapride can be increased when combined with Anakinra.'},\n",
       "  'DB00531': {'name': 'Cyclophosphamide',\n",
       "   'description': 'The metabolism of Cyclophosphamide can be increased when combined with Anakinra.'},\n",
       "  'DB00193': {'name': 'Tramadol',\n",
       "   'description': 'The metabolism of Tramadol can be increased when combined with Anakinra.'},\n",
       "  'DB00333': {'name': 'Methadone',\n",
       "   'description': 'The metabolism of Methadone can be increased when combined with Anakinra.'},\n",
       "  'DB00349': {'name': 'Clobazam',\n",
       "   'description': 'The metabolism of Clobazam can be increased when combined with Anakinra.'},\n",
       "  'DB00625': {'name': 'Efavirenz',\n",
       "   'description': 'The metabolism of Efavirenz can be increased when combined with Anakinra.'},\n",
       "  'DB00753': {'name': 'Isoflurane',\n",
       "   'description': 'The metabolism of Isoflurane can be increased when combined with Anakinra.'},\n",
       "  'DB00818': {'name': 'Propofol',\n",
       "   'description': 'The metabolism of Propofol can be increased when combined with Anakinra.'},\n",
       "  'DB00835': {'name': 'Brompheniramine',\n",
       "   'description': 'The metabolism of Brompheniramine can be increased when combined with Anakinra.'},\n",
       "  'DB00836': {'name': 'Loperamide',\n",
       "   'description': 'The metabolism of Loperamide can be increased when combined with Anakinra.'},\n",
       "  'DB00849': {'name': 'Methylphenobarbital',\n",
       "   'description': 'The metabolism of Methylphenobarbital can be increased when combined with Anakinra.'},\n",
       "  'DB00865': {'name': 'Benzphetamine',\n",
       "   'description': 'The metabolism of Benzphetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01069': {'name': 'Promethazine',\n",
       "   'description': 'The metabolism of Promethazine can be increased when combined with Anakinra.'},\n",
       "  'DB01074': {'name': 'Perhexiline',\n",
       "   'description': 'The metabolism of Perhexiline can be increased when combined with Anakinra.'},\n",
       "  'DB01221': {'name': 'Ketamine',\n",
       "   'description': 'The metabolism of Ketamine can be increased when combined with Anakinra.'},\n",
       "  'DB01466': {'name': 'Ethylmorphine',\n",
       "   'description': 'The metabolism of Ethylmorphine can be increased when combined with Anakinra.'},\n",
       "  'DB01559': {'name': 'Clotiazepam',\n",
       "   'description': 'The metabolism of Clotiazepam can be increased when combined with Anakinra.'},\n",
       "  'DB04938': {'name': 'Ospemifene',\n",
       "   'description': 'The metabolism of Ospemifene can be increased when combined with Anakinra.'},\n",
       "  'DB04975': {'name': 'Banoxantrone',\n",
       "   'description': 'The metabolism of Banoxantrone can be increased when combined with Anakinra.'},\n",
       "  'DB05541': {'name': 'Brivaracetam',\n",
       "   'description': 'The metabolism of Brivaracetam can be increased when combined with Anakinra.'},\n",
       "  'DB06209': {'name': 'Prasugrel',\n",
       "   'description': 'The metabolism of Prasugrel can be increased when combined with Anakinra.'},\n",
       "  'DB06697': {'name': 'Artemether',\n",
       "   'description': 'The metabolism of Artemether can be increased when combined with Anakinra.'},\n",
       "  'DB06710': {'name': 'Methyltestosterone',\n",
       "   'description': 'The metabolism of Methyltestosterone can be increased when combined with Anakinra.'},\n",
       "  'DB06738': {'name': 'Ketobemidone',\n",
       "   'description': 'The metabolism of Ketobemidone can be increased when combined with Anakinra.'},\n",
       "  'DB06739': {'name': 'Seratrodast',\n",
       "   'description': 'The metabolism of Seratrodast can be increased when combined with Anakinra.'},\n",
       "  'DB11613': {'name': 'Velpatasvir',\n",
       "   'description': 'The metabolism of Velpatasvir can be increased when combined with Anakinra.'},\n",
       "  'DB13132': {'name': 'Artemisinin',\n",
       "   'description': 'The metabolism of Artemisinin can be increased when combined with Anakinra.'},\n",
       "  'DB13943': {'name': 'Testosterone cypionate',\n",
       "   'description': 'The metabolism of Testosterone cypionate can be increased when combined with Anakinra.'},\n",
       "  'DB13944': {'name': 'Testosterone enanthate',\n",
       "   'description': 'The metabolism of Testosterone enanthate can be increased when combined with Anakinra.'},\n",
       "  'DB13946': {'name': 'Testosterone undecanoate',\n",
       "   'description': 'The metabolism of Testosterone undecanoate can be increased when combined with Anakinra.'},\n",
       "  'DB01156': {'name': 'Bupropion',\n",
       "   'description': 'The metabolism of Bupropion can be increased when combined with Anakinra.'},\n",
       "  'DB00956': {'name': 'Hydrocodone',\n",
       "   'description': 'The metabolism of Hydrocodone can be increased when combined with Anakinra.'},\n",
       "  'DB14975': {'name': 'Voxelotor',\n",
       "   'description': 'The metabolism of Voxelotor can be increased when combined with Anakinra.'},\n",
       "  'DB11837': {'name': 'Osilodrostat',\n",
       "   'description': 'The metabolism of Osilodrostat can be increased when combined with Anakinra.'},\n",
       "  'DB13384': {'name': 'Melitracen',\n",
       "   'description': 'The metabolism of Melitracen can be increased when combined with Anakinra.'},\n",
       "  'DB13411': {'name': 'Lofepramine',\n",
       "   'description': 'The metabolism of Lofepramine can be increased when combined with Anakinra.'},\n",
       "  'DB00714': {'name': 'Apomorphine',\n",
       "   'description': 'The metabolism of Apomorphine can be increased when combined with Anakinra.'},\n",
       "  'DB00751': {'name': 'Epinastine',\n",
       "   'description': 'The metabolism of Epinastine can be increased when combined with Anakinra.'},\n",
       "  'DB00957': {'name': 'Norgestimate',\n",
       "   'description': 'The metabolism of Norgestimate can be increased when combined with Anakinra.'},\n",
       "  'DB04930': {'name': 'Permethrin',\n",
       "   'description': 'The metabolism of Permethrin can be increased when combined with Anakinra.'},\n",
       "  'DB09167': {'name': 'Dosulepin',\n",
       "   'description': 'The metabolism of Dosulepin can be increased when combined with Anakinra.'},\n",
       "  'DB00213': {'name': 'Pantoprazole',\n",
       "   'description': 'The metabolism of Pantoprazole can be increased when combined with Anakinra.'},\n",
       "  'DB00215': {'name': 'Citalopram',\n",
       "   'description': 'The metabolism of Citalopram can be increased when combined with Anakinra.'},\n",
       "  'DB00312': {'name': 'Pentobarbital',\n",
       "   'description': 'The metabolism of Pentobarbital can be increased when combined with Anakinra.'},\n",
       "  'DB00338': {'name': 'Omeprazole',\n",
       "   'description': 'The metabolism of Omeprazole can be increased when combined with Anakinra.'},\n",
       "  'DB00347': {'name': 'Trimethadione',\n",
       "   'description': 'The metabolism of Trimethadione can be increased when combined with Anakinra.'},\n",
       "  'DB00395': {'name': 'Carisoprodol',\n",
       "   'description': 'The metabolism of Carisoprodol can be increased when combined with Anakinra.'},\n",
       "  'DB00448': {'name': 'Lansoprazole',\n",
       "   'description': 'The metabolism of Lansoprazole can be increased when combined with Anakinra.'},\n",
       "  'DB00474': {'name': 'Methohexital',\n",
       "   'description': 'The metabolism of Methohexital can be increased when combined with Anakinra.'},\n",
       "  'DB00582': {'name': 'Voriconazole',\n",
       "   'description': 'The metabolism of Voriconazole can be increased when combined with Anakinra.'},\n",
       "  'DB00679': {'name': 'Thioridazine',\n",
       "   'description': 'The metabolism of Thioridazine can be increased when combined with Anakinra.'},\n",
       "  'DB00736': {'name': 'Esomeprazole',\n",
       "   'description': 'The metabolism of Esomeprazole can be increased when combined with Anakinra.'},\n",
       "  'DB00794': {'name': 'Primidone',\n",
       "   'description': 'The metabolism of Primidone can be increased when combined with Anakinra.'},\n",
       "  'DB00909': {'name': 'Zonisamide',\n",
       "   'description': 'The metabolism of Zonisamide can be increased when combined with Anakinra.'},\n",
       "  'DB01129': {'name': 'Rabeprazole',\n",
       "   'description': 'The metabolism of Rabeprazole can be increased when combined with Anakinra.'},\n",
       "  'DB01131': {'name': 'Proguanil',\n",
       "   'description': 'The metabolism of Proguanil can be increased when combined with Anakinra.'},\n",
       "  'DB01175': {'name': 'Escitalopram',\n",
       "   'description': 'The metabolism of Escitalopram can be increased when combined with Anakinra.'},\n",
       "  'DB01259': {'name': 'Lapatinib',\n",
       "   'description': 'The metabolism of Lapatinib can be increased when combined with Anakinra.'},\n",
       "  'DB01323': {'name': \"St. John's Wort\",\n",
       "   'description': \"The metabolism of St. John's Wort can be increased when combined with Anakinra.\"},\n",
       "  'DB01355': {'name': 'Hexobarbital',\n",
       "   'description': 'The metabolism of Hexobarbital can be increased when combined with Anakinra.'},\n",
       "  'DB01483': {'name': 'Barbital',\n",
       "   'description': 'The metabolism of Barbital can be increased when combined with Anakinra.'},\n",
       "  'DB05246': {'name': 'Methsuximide',\n",
       "   'description': 'The metabolism of Methsuximide can be increased when combined with Anakinra.'},\n",
       "  'DB05351': {'name': 'Dexlansoprazole',\n",
       "   'description': 'The metabolism of Dexlansoprazole can be increased when combined with Anakinra.'},\n",
       "  'DB06218': {'name': 'Lacosamide',\n",
       "   'description': 'The metabolism of Lacosamide can be increased when combined with Anakinra.'},\n",
       "  'DB06414': {'name': 'Etravirine',\n",
       "   'description': 'The metabolism of Etravirine can be increased when combined with Anakinra.'},\n",
       "  'DB06605': {'name': 'Apixaban',\n",
       "   'description': 'The metabolism of Apixaban can be increased when combined with Anakinra.'},\n",
       "  'DB09166': {'name': 'Etizolam',\n",
       "   'description': 'The metabolism of Etizolam can be increased when combined with Anakinra.'},\n",
       "  'DB12130': {'name': 'Lorlatinib',\n",
       "   'description': 'The metabolism of Lorlatinib can be increased when combined with Anakinra.'},\n",
       "  'DB12474': {'name': 'Lynestrenol',\n",
       "   'description': 'The metabolism of Lynestrenol can be increased when combined with Anakinra.'},\n",
       "  'DB13762': {'name': 'Dexrabeprazole',\n",
       "   'description': 'The metabolism of Dexrabeprazole can be increased when combined with Anakinra.'},\n",
       "  'DB14055': {'name': '(S)-Warfarin',\n",
       "   'description': 'The metabolism of (S)-Warfarin can be increased when combined with Anakinra.'},\n",
       "  'DB00715': {'name': 'Paroxetine',\n",
       "   'description': 'The metabolism of Paroxetine can be increased when combined with Anakinra.'},\n",
       "  'DB12500': {'name': 'Fedratinib',\n",
       "   'description': 'The metabolism of Fedratinib can be increased when combined with Anakinra.'},\n",
       "  'DB04861': {'name': 'Nebivolol',\n",
       "   'description': 'The metabolism of Nebivolol can be increased when combined with Anakinra.'},\n",
       "  'DB06684': {'name': 'Vilazodone',\n",
       "   'description': 'The metabolism of Vilazodone can be increased when combined with Anakinra.'},\n",
       "  'DB01104': {'name': 'Sertraline',\n",
       "   'description': 'The metabolism of Sertraline can be increased when combined with Anakinra.'},\n",
       "  'DB11823': {'name': 'Esketamine',\n",
       "   'description': 'The metabolism of Esketamine can be increased when combined with Anakinra.'},\n",
       "  'DB00252': {'name': 'Phenytoin',\n",
       "   'description': 'The metabolism of Phenytoin can be increased when combined with Anakinra.'},\n",
       "  'DB00599': {'name': 'Thiopental',\n",
       "   'description': 'The metabolism of Thiopental can be increased when combined with Anakinra.'},\n",
       "  'DB01174': {'name': 'Phenobarbital',\n",
       "   'description': 'The metabolism of Phenobarbital can be increased when combined with Anakinra.'},\n",
       "  'DB01320': {'name': 'Fosphenytoin',\n",
       "   'description': 'The metabolism of Fosphenytoin can be increased when combined with Anakinra.'},\n",
       "  'DB00726': {'name': 'Trimipramine',\n",
       "   'description': 'The metabolism of Trimipramine can be increased when combined with Anakinra.'},\n",
       "  'DB00613': {'name': 'Amodiaquine',\n",
       "   'description': 'The metabolism of Amodiaquine can be increased when combined with Anakinra.'},\n",
       "  'DB00799': {'name': 'Tazarotene',\n",
       "   'description': 'The metabolism of Tazarotene can be increased when combined with Anakinra.'},\n",
       "  'DB05229': {'name': 'Beraprost',\n",
       "   'description': 'The metabolism of Beraprost can be increased when combined with Anakinra.'},\n",
       "  'DB06510': {'name': 'Muraglitazar',\n",
       "   'description': 'The metabolism of Muraglitazar can be increased when combined with Anakinra.'},\n",
       "  'DB09296': {'name': 'Ombitasvir',\n",
       "   'description': 'The metabolism of Ombitasvir can be increased when combined with Anakinra.'},\n",
       "  'DB01217': {'name': 'Anastrozole',\n",
       "   'description': 'The metabolism of Anastrozole can be increased when combined with Anakinra.'},\n",
       "  'DB00255': {'name': 'Diethylstilbestrol',\n",
       "   'description': 'The metabolism of Diethylstilbestrol can be increased when combined with Anakinra.'},\n",
       "  'DB00295': {'name': 'Morphine',\n",
       "   'description': 'The metabolism of Morphine can be increased when combined with Anakinra.'},\n",
       "  'DB00359': {'name': 'Sulfadiazine',\n",
       "   'description': 'The metabolism of Sulfadiazine can be increased when combined with Anakinra.'},\n",
       "  'DB00402': {'name': 'Eszopiclone',\n",
       "   'description': 'The metabolism of Eszopiclone can be increased when combined with Anakinra.'},\n",
       "  'DB00622': {'name': 'Nicardipine',\n",
       "   'description': 'The metabolism of Nicardipine can be increased when combined with Anakinra.'},\n",
       "  'DB00912': {'name': 'Repaglinide',\n",
       "   'description': 'The metabolism of Repaglinide can be increased when combined with Anakinra.'},\n",
       "  'DB01261': {'name': 'Sitagliptin',\n",
       "   'description': 'The metabolism of Sitagliptin can be increased when combined with Anakinra.'},\n",
       "  'DB06670': {'name': 'Odanacatib',\n",
       "   'description': 'The metabolism of Odanacatib can be increased when combined with Anakinra.'},\n",
       "  'DB08502': {'name': 'Capravirine',\n",
       "   'description': 'The metabolism of Capravirine can be increased when combined with Anakinra.'},\n",
       "  'DB08931': {'name': 'Riociguat',\n",
       "   'description': 'The metabolism of Riociguat can be increased when combined with Anakinra.'},\n",
       "  'DB09198': {'name': 'Lobeglitazone',\n",
       "   'description': 'The metabolism of Lobeglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB09199': {'name': 'Netoglitazone',\n",
       "   'description': 'The metabolism of Netoglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB09200': {'name': 'Rivoglitazone',\n",
       "   'description': 'The metabolism of Rivoglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB09201': {'name': 'Ciglitazone',\n",
       "   'description': 'The metabolism of Ciglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB11362': {'name': 'Selexipag',\n",
       "   'description': 'The metabolism of Selexipag can be increased when combined with Anakinra.'},\n",
       "  'DB11901': {'name': 'Apalutamide',\n",
       "   'description': 'The metabolism of Apalutamide can be increased when combined with Anakinra.'},\n",
       "  'DB11978': {'name': 'Glasdegib',\n",
       "   'description': 'The metabolism of Glasdegib can be increased when combined with Anakinra.'},\n",
       "  'DB12781': {'name': 'Balaglitazone',\n",
       "   'description': 'The metabolism of Balaglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB01132': {'name': 'Pioglitazone',\n",
       "   'description': 'The metabolism of Pioglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB11652': {'name': 'Tucatinib',\n",
       "   'description': 'The metabolism of Tucatinib can be increased when combined with Anakinra.'},\n",
       "  'DB00946': {'name': 'Phenprocoumon',\n",
       "   'description': 'The metabolism of Phenprocoumon can be increased when combined with Anakinra.'},\n",
       "  'DB01229': {'name': 'Paclitaxel',\n",
       "   'description': 'The metabolism of Paclitaxel can be increased when combined with Anakinra.'},\n",
       "  'DB06772': {'name': 'Cabazitaxel',\n",
       "   'description': 'The metabolism of Cabazitaxel can be increased when combined with Anakinra.'},\n",
       "  'DB00177': {'name': 'Valsartan',\n",
       "   'description': 'The metabolism of Valsartan can be increased when combined with Anakinra.'},\n",
       "  'DB00184': {'name': 'Nicotine',\n",
       "   'description': 'The metabolism of Nicotine can be increased when combined with Anakinra.'},\n",
       "  'DB00197': {'name': 'Troglitazone',\n",
       "   'description': 'The metabolism of Troglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB00214': {'name': 'Torasemide',\n",
       "   'description': 'The metabolism of Torasemide can be increased when combined with Anakinra.'},\n",
       "  'DB00222': {'name': 'Glimepiride',\n",
       "   'description': 'The metabolism of Glimepiride can be increased when combined with Anakinra.'},\n",
       "  'DB00285': {'name': 'Venlafaxine',\n",
       "   'description': 'The metabolism of Venlafaxine can be increased when combined with Anakinra.'},\n",
       "  'DB00304': {'name': 'Desogestrel',\n",
       "   'description': 'The metabolism of Desogestrel can be increased when combined with Anakinra.'},\n",
       "  'DB00307': {'name': 'Bexarotene',\n",
       "   'description': 'The metabolism of Bexarotene can be increased when combined with Anakinra.'},\n",
       "  'DB00327': {'name': 'Hydromorphone',\n",
       "   'description': 'The metabolism of Hydromorphone can be increased when combined with Anakinra.'},\n",
       "  'DB00328': {'name': 'Indomethacin',\n",
       "   'description': 'The metabolism of Indomethacin can be increased when combined with Anakinra.'},\n",
       "  'DB00343': {'name': 'Diltiazem',\n",
       "   'description': 'The metabolism of Diltiazem can be increased when combined with Anakinra.'},\n",
       "  'DB00374': {'name': 'Treprostinil',\n",
       "   'description': 'The metabolism of Treprostinil can be increased when combined with Anakinra.'},\n",
       "  'DB00412': {'name': 'Rosiglitazone',\n",
       "   'description': 'The metabolism of Rosiglitazone can be increased when combined with Anakinra.'},\n",
       "  'DB00414': {'name': 'Acetohexamide',\n",
       "   'description': 'The metabolism of Acetohexamide can be increased when combined with Anakinra.'},\n",
       "  'DB00420': {'name': 'Promazine',\n",
       "   'description': 'The metabolism of Promazine can be increased when combined with Anakinra.'},\n",
       "  'DB00440': {'name': 'Trimethoprim',\n",
       "   'description': 'The metabolism of Trimethoprim can be increased when combined with Anakinra.'},\n",
       "  'DB00461': {'name': 'Nabumetone',\n",
       "   'description': 'The metabolism of Nabumetone can be increased when combined with Anakinra.'},\n",
       "  'DB00468': {'name': 'Quinine',\n",
       "   'description': 'The metabolism of Quinine can be increased when combined with Anakinra.'},\n",
       "  'DB00469': {'name': 'Tenoxicam',\n",
       "   'description': 'The metabolism of Tenoxicam can be increased when combined with Anakinra.'},\n",
       "  'DB00472': {'name': 'Fluoxetine',\n",
       "   'description': 'The metabolism of Fluoxetine can be increased when combined with Anakinra.'},\n",
       "  'DB00476': {'name': 'Duloxetine',\n",
       "   'description': 'The metabolism of Duloxetine can be increased when combined with Anakinra.'},\n",
       "  'DB00482': {'name': 'Celecoxib',\n",
       "   'description': 'The metabolism of Celecoxib can be increased when combined with Anakinra.'},\n",
       "  'DB00495': {'name': 'Zidovudine',\n",
       "   'description': 'The metabolism of Zidovudine can be increased when combined with Anakinra.'},\n",
       "  'DB00502': {'name': 'Haloperidol',\n",
       "   'description': 'The metabolism of Haloperidol can be increased when combined with Anakinra.'},\n",
       "  'DB00533': {'name': 'Rofecoxib',\n",
       "   'description': 'The metabolism of Rofecoxib can be increased when combined with Anakinra.'},\n",
       "  'DB00549': {'name': 'Zafirlukast',\n",
       "   'description': 'The metabolism of Zafirlukast can be increased when combined with Anakinra.'},\n",
       "  'DB00554': {'name': 'Piroxicam',\n",
       "   'description': 'The metabolism of Piroxicam can be increased when combined with Anakinra.'},\n",
       "  'DB00559': {'name': 'Bosentan',\n",
       "   'description': 'The metabolism of Bosentan can be increased when combined with Anakinra.'},\n",
       "  'DB00568': {'name': 'Cinnarizine',\n",
       "   'description': 'The metabolism of Cinnarizine can be increased when combined with Anakinra.'},\n",
       "  'DB00580': {'name': 'Valdecoxib',\n",
       "   'description': 'The metabolism of Valdecoxib can be increased when combined with Anakinra.'},\n",
       "  'DB00586': {'name': 'Diclofenac',\n",
       "   'description': 'The metabolism of Diclofenac can be increased when combined with Anakinra.'},\n",
       "  'DB00617': {'name': 'Paramethadione',\n",
       "   'description': 'The metabolism of Paramethadione can be increased when combined with Anakinra.'},\n",
       "  'DB00661': {'name': 'Verapamil',\n",
       "   'description': 'The metabolism of Verapamil can be increased when combined with Anakinra.'},\n",
       "  'DB00672': {'name': 'Chlorpropamide',\n",
       "   'description': 'The metabolism of Chlorpropamide can be increased when combined with Anakinra.'},\n",
       "  'DB00678': {'name': 'Losartan',\n",
       "   'description': 'The metabolism of Losartan can be increased when combined with Anakinra.'},\n",
       "  'DB00701': {'name': 'Amprenavir',\n",
       "   'description': 'The metabolism of Amprenavir can be increased when combined with Anakinra.'},\n",
       "  'DB00712': {'name': 'Flurbiprofen',\n",
       "   'description': 'The metabolism of Flurbiprofen can be increased when combined with Anakinra.'},\n",
       "  'DB00731': {'name': 'Nateglinide',\n",
       "   'description': 'The metabolism of Nateglinide can be increased when combined with Anakinra.'},\n",
       "  'DB00744': {'name': 'Zileuton',\n",
       "   'description': 'The metabolism of Zileuton can be increased when combined with Anakinra.'},\n",
       "  'DB00749': {'name': 'Etodolac',\n",
       "   'description': 'The metabolism of Etodolac can be increased when combined with Anakinra.'},\n",
       "  'DB00755': {'name': 'Tretinoin',\n",
       "   'description': 'The metabolism of Tretinoin can be increased when combined with Anakinra.'},\n",
       "  'DB00758': {'name': 'Clopidogrel',\n",
       "   'description': 'The metabolism of Clopidogrel can be increased when combined with Anakinra.'},\n",
       "  'DB00783': {'name': 'Estradiol',\n",
       "   'description': 'The metabolism of Estradiol can be increased when combined with Anakinra.'},\n",
       "  'DB00784': {'name': 'Mefenamic acid',\n",
       "   'description': 'The metabolism of Mefenamic acid can be increased when combined with Anakinra.'},\n",
       "  'DB00788': {'name': 'Naproxen',\n",
       "   'description': 'The metabolism of Naproxen can be increased when combined with Anakinra.'},\n",
       "  'DB00796': {'name': 'Candesartan cilexetil',\n",
       "   'description': 'The metabolism of Candesartan cilexetil can be increased when combined with Anakinra.'},\n",
       "  'DB00812': {'name': 'Phenylbutazone',\n",
       "   'description': 'The metabolism of Phenylbutazone can be increased when combined with Anakinra.'},\n",
       "  'DB00814': {'name': 'Meloxicam',\n",
       "   'description': 'The metabolism of Meloxicam can be increased when combined with Anakinra.'},\n",
       "  'DB00839': {'name': 'Tolazamide',\n",
       "   'description': 'The metabolism of Tolazamide can be increased when combined with Anakinra.'},\n",
       "  'DB00843': {'name': 'Donepezil',\n",
       "   'description': 'The metabolism of Donepezil can be increased when combined with Anakinra.'},\n",
       "  'DB00857': {'name': 'Terbinafine',\n",
       "   'description': 'The metabolism of Terbinafine can be increased when combined with Anakinra.'},\n",
       "  'DB00904': {'name': 'Ondansetron',\n",
       "   'description': 'The metabolism of Ondansetron can be increased when combined with Anakinra.'},\n",
       "  'DB00921': {'name': 'Buprenorphine',\n",
       "   'description': 'The metabolism of Buprenorphine can be increased when combined with Anakinra.'},\n",
       "  'DB00936': {'name': 'Salicylic acid',\n",
       "   'description': 'The metabolism of Salicylic acid can be increased when combined with Anakinra.'},\n",
       "  'DB00945': {'name': 'Acetylsalicylic acid',\n",
       "   'description': 'The metabolism of Acetylsalicylic acid can be increased when combined with Anakinra.'},\n",
       "  'DB00969': {'name': 'Alosetron',\n",
       "   'description': 'The metabolism of Alosetron can be increased when combined with Anakinra.'},\n",
       "  'DB00972': {'name': 'Azelastine',\n",
       "   'description': 'The metabolism of Azelastine can be increased when combined with Anakinra.'},\n",
       "  'DB00980': {'name': 'Ramelteon',\n",
       "   'description': 'The metabolism of Ramelteon can be increased when combined with Anakinra.'},\n",
       "  'DB01016': {'name': 'Glyburide',\n",
       "   'description': 'The metabolism of Glyburide can be increased when combined with Anakinra.'},\n",
       "  'DB01029': {'name': 'Irbesartan',\n",
       "   'description': 'The metabolism of Irbesartan can be increased when combined with Anakinra.'},\n",
       "  'DB01036': {'name': 'Tolterodine',\n",
       "   'description': 'The metabolism of Tolterodine can be increased when combined with Anakinra.'},\n",
       "  'DB01037': {'name': 'Selegiline',\n",
       "   'description': 'The metabolism of Selegiline can be increased when combined with Anakinra.'},\n",
       "  'DB01041': {'name': 'Thalidomide',\n",
       "   'description': 'The metabolism of Thalidomide can be increased when combined with Anakinra.'},\n",
       "  'DB01050': {'name': 'Ibuprofen',\n",
       "   'description': 'The metabolism of Ibuprofen can be increased when combined with Anakinra.'},\n",
       "  'DB01065': {'name': 'Melatonin',\n",
       "   'description': 'The metabolism of Melatonin can be increased when combined with Anakinra.'},\n",
       "  'DB01067': {'name': 'Glipizide',\n",
       "   'description': 'The metabolism of Glipizide can be increased when combined with Anakinra.'},\n",
       "  'DB01072': {'name': 'Atazanavir',\n",
       "   'description': 'The metabolism of Atazanavir can be increased when combined with Anakinra.'},\n",
       "  'DB01075': {'name': 'Diphenhydramine',\n",
       "   'description': 'The metabolism of Diphenhydramine can be increased when combined with Anakinra.'},\n",
       "  'DB01095': {'name': 'Fluvastatin',\n",
       "   'description': 'The metabolism of Fluvastatin can be increased when combined with Anakinra.'},\n",
       "  'DB01098': {'name': 'Rosuvastatin',\n",
       "   'description': 'The metabolism of Rosuvastatin can be increased when combined with Anakinra.'},\n",
       "  'DB01120': {'name': 'Gliclazide',\n",
       "   'description': 'The metabolism of Gliclazide can be increased when combined with Anakinra.'},\n",
       "  'DB01124': {'name': 'Tolbutamide',\n",
       "   'description': 'The metabolism of Tolbutamide can be increased when combined with Anakinra.'},\n",
       "  'DB01136': {'name': 'Carvedilol',\n",
       "   'description': 'The metabolism of Carvedilol can be increased when combined with Anakinra.'},\n",
       "  'DB01154': {'name': 'Thiamylal',\n",
       "   'description': 'The metabolism of Thiamylal can be increased when combined with Anakinra.'},\n",
       "  'DB01171': {'name': 'Moclobemide',\n",
       "   'description': 'The metabolism of Moclobemide can be increased when combined with Anakinra.'},\n",
       "  'DB01177': {'name': 'Idarubicin',\n",
       "   'description': 'The metabolism of Idarubicin can be increased when combined with Anakinra.'},\n",
       "  'DB01198': {'name': 'Zopiclone',\n",
       "   'description': 'The metabolism of Zopiclone can be increased when combined with Anakinra.'},\n",
       "  'DB01251': {'name': 'Gliquidone',\n",
       "   'description': 'The metabolism of Gliquidone can be increased when combined with Anakinra.'},\n",
       "  'DB01283': {'name': 'Lumiracoxib',\n",
       "   'description': 'The metabolism of Lumiracoxib can be increased when combined with Anakinra.'},\n",
       "  'DB01289': {'name': 'Glisoxepide',\n",
       "   'description': 'The metabolism of Glisoxepide can be increased when combined with Anakinra.'},\n",
       "  'DB01357': {'name': 'Mestranol',\n",
       "   'description': 'The metabolism of Mestranol can be increased when combined with Anakinra.'},\n",
       "  'DB01424': {'name': 'Aminophenazone',\n",
       "   'description': 'The metabolism of Aminophenazone can be increased when combined with Anakinra.'},\n",
       "  'DB01435': {'name': 'Antipyrine',\n",
       "   'description': 'The metabolism of Antipyrine can be increased when combined with Anakinra.'},\n",
       "  'DB01589': {'name': 'Quazepam',\n",
       "   'description': 'The metabolism of Quazepam can be increased when combined with Anakinra.'},\n",
       "  'DB01628': {'name': 'Etoricoxib',\n",
       "   'description': 'The metabolism of Etoricoxib can be increased when combined with Anakinra.'},\n",
       "  'DB03756': {'name': 'Doconexent',\n",
       "   'description': 'The metabolism of Doconexent can be increased when combined with Anakinra.'},\n",
       "  'DB03783': {'name': 'Phenacetin',\n",
       "   'description': 'The metabolism of Phenacetin can be increased when combined with Anakinra.'},\n",
       "  'DB04557': {'name': 'Arachidonic Acid',\n",
       "   'description': 'The metabolism of Arachidonic Acid can be increased when combined with Anakinra.'},\n",
       "  'DB04574': {'name': 'Estrone sulfate',\n",
       "   'description': 'The metabolism of Estrone sulfate can be increased when combined with Anakinra.'},\n",
       "  'DB04665': {'name': 'Coumarin',\n",
       "   'description': 'The metabolism of Coumarin can be increased when combined with Anakinra.'},\n",
       "  'DB04725': {'name': 'Licofelone',\n",
       "   'description': 'The metabolism of Licofelone can be increased when combined with Anakinra.'},\n",
       "  'DB04841': {'name': 'Flunarizine',\n",
       "   'description': 'The metabolism of Flunarizine can be increased when combined with Anakinra.'},\n",
       "  'DB04898': {'name': 'Ximelagatran',\n",
       "   'description': 'The metabolism of Ximelagatran can be increased when combined with Anakinra.'},\n",
       "  'DB06204': {'name': 'Tapentadol',\n",
       "   'description': 'The metabolism of Tapentadol can be increased when combined with Anakinra.'},\n",
       "  'DB06268': {'name': 'Sitaxentan',\n",
       "   'description': 'The metabolism of Sitaxentan can be increased when combined with Anakinra.'},\n",
       "  'DB06370': {'name': 'Indisulam',\n",
       "   'description': 'The metabolism of Indisulam can be increased when combined with Anakinra.'},\n",
       "  'DB06652': {'name': 'Vicriviroc',\n",
       "   'description': 'The metabolism of Vicriviroc can be increased when combined with Anakinra.'},\n",
       "  'DB06725': {'name': 'Lornoxicam',\n",
       "   'description': 'The metabolism of Lornoxicam can be increased when combined with Anakinra.'},\n",
       "  'DB06737': {'name': 'Zaltoprofen',\n",
       "   'description': 'The metabolism of Zaltoprofen can be increased when combined with Anakinra.'},\n",
       "  'DB06803': {'name': 'Niclosamide',\n",
       "   'description': 'The metabolism of Niclosamide can be increased when combined with Anakinra.'},\n",
       "  'DB07615': {'name': 'Tranilast',\n",
       "   'description': 'The metabolism of Tranilast can be increased when combined with Anakinra.'},\n",
       "  'DB08439': {'name': 'Parecoxib',\n",
       "   'description': 'The metabolism of Parecoxib can be increased when combined with Anakinra.'},\n",
       "  'DB08828': {'name': 'Vismodegib',\n",
       "   'description': 'The metabolism of Vismodegib can be increased when combined with Anakinra.'},\n",
       "  'DB08860': {'name': 'Pitavastatin',\n",
       "   'description': 'The metabolism of Pitavastatin can be increased when combined with Anakinra.'},\n",
       "  'DB08899': {'name': 'Enzalutamide',\n",
       "   'description': 'The metabolism of Enzalutamide can be increased when combined with Anakinra.'},\n",
       "  'DB08962': {'name': 'Glibornuride',\n",
       "   'description': 'The metabolism of Glibornuride can be increased when combined with Anakinra.'},\n",
       "  'DB09048': {'name': 'Netupitant',\n",
       "   'description': 'The metabolism of Netupitant can be increased when combined with Anakinra.'},\n",
       "  'DB09061': {'name': 'Cannabidiol',\n",
       "   'description': 'The metabolism of Cannabidiol can be increased when combined with Anakinra.'},\n",
       "  'DB09080': {'name': 'Olodaterol',\n",
       "   'description': 'The metabolism of Olodaterol can be increased when combined with Anakinra.'},\n",
       "  'DB09288': {'name': 'Propacetamol',\n",
       "   'description': 'The metabolism of Propacetamol can be increased when combined with Anakinra.'},\n",
       "  'DB11560': {'name': 'Lesinurad',\n",
       "   'description': 'The metabolism of Lesinurad can be increased when combined with Anakinra.'},\n",
       "  'DB11614': {'name': 'Rupatadine',\n",
       "   'description': 'The metabolism of Rupatadine can be increased when combined with Anakinra.'},\n",
       "  'DB13406': {'name': 'Carbutamide',\n",
       "   'description': 'The metabolism of Carbutamide can be increased when combined with Anakinra.'},\n",
       "  'DB13675': {'name': 'Metahexamide',\n",
       "   'description': 'The metabolism of Metahexamide can be increased when combined with Anakinra.'},\n",
       "  'DB13919': {'name': 'Candesartan',\n",
       "   'description': 'The metabolism of Candesartan can be increased when combined with Anakinra.'},\n",
       "  'DB13941': {'name': 'Piperaquine',\n",
       "   'description': 'The metabolism of Piperaquine can be increased when combined with Anakinra.'},\n",
       "  'DB13952': {'name': 'Estradiol acetate',\n",
       "   'description': 'The metabolism of Estradiol acetate can be increased when combined with Anakinra.'},\n",
       "  'DB13953': {'name': 'Estradiol benzoate',\n",
       "   'description': 'The metabolism of Estradiol benzoate can be increased when combined with Anakinra.'},\n",
       "  'DB13954': {'name': 'Estradiol cypionate',\n",
       "   'description': 'The metabolism of Estradiol cypionate can be increased when combined with Anakinra.'},\n",
       "  'DB13955': {'name': 'Estradiol dienanthate',\n",
       "   'description': 'The metabolism of Estradiol dienanthate can be increased when combined with Anakinra.'},\n",
       "  'DB13956': {'name': 'Estradiol valerate',\n",
       "   'description': 'The metabolism of Estradiol valerate can be increased when combined with Anakinra.'},\n",
       "  'DB14009': {'name': 'Medical Cannabis',\n",
       "   'description': 'The metabolism of Medical Cannabis can be increased when combined with Anakinra.'},\n",
       "  'DB14011': {'name': 'Nabiximols',\n",
       "   'description': 'The metabolism of Nabiximols can be increased when combined with Anakinra.'},\n",
       "  'DB00829': {'name': 'Diazepam',\n",
       "   'description': 'The metabolism of Diazepam can be increased when combined with Anakinra.'},\n",
       "  'DB00514': {'name': 'Dextromethorphan',\n",
       "   'description': 'The metabolism of Dextromethorphan can be increased when combined with Anakinra.'},\n",
       "  'DB00470': {'name': 'Dronabinol',\n",
       "   'description': 'The metabolism of Dronabinol can be increased when combined with Anakinra.'},\n",
       "  'DB09213': {'name': 'Dexibuprofen',\n",
       "   'description': 'The metabolism of Dexibuprofen can be increased when combined with Anakinra.'},\n",
       "  'DB00465': {'name': 'Ketorolac',\n",
       "   'description': 'The metabolism of Ketorolac can be increased when combined with Anakinra.'},\n",
       "  'DB15233': {'name': 'Avapritinib',\n",
       "   'description': 'The metabolism of Avapritinib can be increased when combined with Anakinra.'},\n",
       "  'DB01142': {'name': 'Doxepin',\n",
       "   'description': 'The metabolism of Doxepin can be increased when combined with Anakinra.'},\n",
       "  'DB00216': {'name': 'Eletriptan',\n",
       "   'description': 'The metabolism of Eletriptan can be increased when combined with Anakinra.'},\n",
       "  'DB00619': {'name': 'Imatinib',\n",
       "   'description': 'The metabolism of Imatinib can be increased when combined with Anakinra.'},\n",
       "  'DB06448': {'name': 'Lonafarnib',\n",
       "   'description': 'The metabolism of Lonafarnib can be increased when combined with Anakinra.'},\n",
       "  'DB01101': {'name': 'Capecitabine',\n",
       "   'description': 'The metabolism of Capecitabine can be increased when combined with Anakinra.'},\n",
       "  'DB00266': {'name': 'Dicoumarol',\n",
       "   'description': 'The metabolism of Dicoumarol can be increased when combined with Anakinra.'},\n",
       "  'DB13136': {'name': 'Fluindione',\n",
       "   'description': 'The metabolism of Fluindione can be increased when combined with Anakinra.'},\n",
       "  'DB08875': {'name': 'Cabozantinib',\n",
       "   'description': 'The metabolism of Cabozantinib can be increased when combined with Anakinra.'},\n",
       "  'DB12371': {'name': 'Siponimod',\n",
       "   'description': 'The metabolism of Siponimod can be increased when combined with Anakinra.'},\n",
       "  'DB01224': {'name': 'Quetiapine',\n",
       "   'description': 'The metabolism of Quetiapine can be increased when combined with Anakinra.'},\n",
       "  'DB00182': {'name': 'Amphetamine',\n",
       "   'description': 'The metabolism of Amphetamine can be increased when combined with Anakinra.'},\n",
       "  'DB00187': {'name': 'Esmolol',\n",
       "   'description': 'The metabolism of Esmolol can be increased when combined with Anakinra.'},\n",
       "  'DB00245': {'name': 'Benzatropine',\n",
       "   'description': 'The metabolism of Benzatropine can be increased when combined with Anakinra.'},\n",
       "  'DB00289': {'name': 'Atomoxetine',\n",
       "   'description': 'The metabolism of Atomoxetine can be increased when combined with Anakinra.'},\n",
       "  'DB00335': {'name': 'Atenolol',\n",
       "   'description': 'The metabolism of Atenolol can be increased when combined with Anakinra.'},\n",
       "  'DB00373': {'name': 'Timolol',\n",
       "   'description': 'The metabolism of Timolol can be increased when combined with Anakinra.'},\n",
       "  'DB00409': {'name': 'Remoxipride',\n",
       "   'description': 'The metabolism of Remoxipride can be increased when combined with Anakinra.'},\n",
       "  'DB00592': {'name': 'Piperazine',\n",
       "   'description': 'The metabolism of Piperazine can be increased when combined with Anakinra.'},\n",
       "  'DB00699': {'name': 'Nicergoline',\n",
       "   'description': 'The metabolism of Nicergoline can be increased when combined with Anakinra.'},\n",
       "  'DB00737': {'name': 'Meclizine',\n",
       "   'description': 'The metabolism of Meclizine can be increased when combined with Anakinra.'},\n",
       "  'DB00805': {'name': 'Minaprine',\n",
       "   'description': 'The metabolism of Minaprine can be increased when combined with Anakinra.'},\n",
       "  'DB00866': {'name': 'Alprenolol',\n",
       "   'description': 'The metabolism of Alprenolol can be increased when combined with Anakinra.'},\n",
       "  'DB00914': {'name': 'Phenformin',\n",
       "   'description': 'The metabolism of Phenformin can be increased when combined with Anakinra.'},\n",
       "  'DB00933': {'name': 'Mesoridazine',\n",
       "   'description': 'The metabolism of Mesoridazine can be increased when combined with Anakinra.'},\n",
       "  'DB00960': {'name': 'Pindolol',\n",
       "   'description': 'The metabolism of Pindolol can be increased when combined with Anakinra.'},\n",
       "  'DB01071': {'name': 'Mequitazine',\n",
       "   'description': 'The metabolism of Mequitazine can be increased when combined with Anakinra.'},\n",
       "  'DB01079': {'name': 'Tegaserod',\n",
       "   'description': 'The metabolism of Tegaserod can be increased when combined with Anakinra.'},\n",
       "  'DB01193': {'name': 'Acebutolol',\n",
       "   'description': 'The metabolism of Acebutolol can be increased when combined with Anakinra.'},\n",
       "  'DB01203': {'name': 'Nadolol',\n",
       "   'description': 'The metabolism of Nadolol can be increased when combined with Anakinra.'},\n",
       "  'DB01228': {'name': 'Encainide',\n",
       "   'description': 'The metabolism of Encainide can be increased when combined with Anakinra.'},\n",
       "  'DB01233': {'name': 'Metoclopramide',\n",
       "   'description': 'The metabolism of Metoclopramide can be increased when combined with Anakinra.'},\n",
       "  'DB01255': {'name': 'Lisdexamfetamine',\n",
       "   'description': 'The metabolism of Lisdexamfetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01295': {'name': 'Bevantolol',\n",
       "   'description': 'The metabolism of Bevantolol can be increased when combined with Anakinra.'},\n",
       "  'DB01297': {'name': 'Practolol',\n",
       "   'description': 'The metabolism of Practolol can be increased when combined with Anakinra.'},\n",
       "  'DB01359': {'name': 'Penbutolol',\n",
       "   'description': 'The metabolism of Penbutolol can be increased when combined with Anakinra.'},\n",
       "  'DB01403': {'name': 'Methotrimeprazine',\n",
       "   'description': 'The metabolism of Methotrimeprazine can be increased when combined with Anakinra.'},\n",
       "  'DB01429': {'name': 'Aprindine',\n",
       "   'description': 'The metabolism of Aprindine can be increased when combined with Anakinra.'},\n",
       "  'DB01454': {'name': 'Midomafetamine',\n",
       "   'description': 'The metabolism of Midomafetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01472': {'name': '4-Methoxyamphetamine',\n",
       "   'description': 'The metabolism of 4-Methoxyamphetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01576': {'name': 'Dextroamphetamine',\n",
       "   'description': 'The metabolism of Dextroamphetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01577': {'name': 'Metamfetamine',\n",
       "   'description': 'The metabolism of Metamfetamine can be increased when combined with Anakinra.'},\n",
       "  'DB01580': {'name': 'Oxprenolol',\n",
       "   'description': 'The metabolism of Oxprenolol can be increased when combined with Anakinra.'},\n",
       "  'DB04840': {'name': 'Debrisoquine',\n",
       "   'description': 'The metabolism of Debrisoquine can be increased when combined with Anakinra.'},\n",
       "  'DB04844': {'name': 'Tetrabenazine',\n",
       "   'description': 'The metabolism of Tetrabenazine can be increased when combined with Anakinra.'},\n",
       "  'DB04846': {'name': 'Celiprolol',\n",
       "   'description': 'The metabolism of Celiprolol can be increased when combined with Anakinra.'},\n",
       "  'DB06217': {'name': 'Vernakalant',\n",
       "   'description': 'The metabolism of Vernakalant can be increased when combined with Anakinra.'},\n",
       "  'DB06506': {'name': 'Repinotan',\n",
       "   'description': 'The metabolism of Repinotan can be increased when combined with Anakinra.'},\n",
       "  'DB06608': {'name': 'Tafenoquine',\n",
       "   'description': 'The metabolism of Tafenoquine can be increased when combined with Anakinra.'},\n",
       "  'DB06678': {'name': 'Esmirtazapine',\n",
       "   'description': 'The metabolism of Esmirtazapine can be increased when combined with Anakinra.'},\n",
       "  'DB06726': {'name': 'Bufuralol',\n",
       "   'description': 'The metabolism of Bufuralol can be increased when combined with Anakinra.'},\n",
       "  'DB06727': {'name': 'Sparteine',\n",
       "   'description': 'The metabolism of Sparteine can be increased when combined with Anakinra.'},\n",
       "  'DB06735': {'name': 'Enclomiphene',\n",
       "   'description': 'The metabolism of Enclomiphene can be increased when combined with Anakinra.'},\n",
       "  'DB08807': {'name': 'Bopindolol',\n",
       "   'description': 'The metabolism of Bopindolol can be increased when combined with Anakinra.'},\n",
       "  'DB08808': {'name': 'Bupranolol',\n",
       "   'description': 'The metabolism of Bupranolol can be increased when combined with Anakinra.'},\n",
       "  'DB08952': {'name': 'Indenolol',\n",
       "   'description': 'The metabolism of Indenolol can be increased when combined with Anakinra.'},\n",
       "  'DB09076': {'name': 'Umeclidinium',\n",
       "   'description': 'The metabolism of Umeclidinium can be increased when combined with Anakinra.'},\n",
       "  'DB09204': {'name': 'Arotinolol',\n",
       "   'description': 'The metabolism of Arotinolol can be increased when combined with Anakinra.'},\n",
       "  'DB09351': {'name': 'Levobetaxolol',\n",
       "   'description': 'The metabolism of Levobetaxolol can be increased when combined with Anakinra.'},\n",
       "  'DB11770': {'name': 'Talinolol',\n",
       "   'description': 'The metabolism of Talinolol can be increased when combined with Anakinra.'},\n",
       "  'DB11785': {'name': 'Anisodamine',\n",
       "   'description': 'The metabolism of Anisodamine can be increased when combined with Anakinra.'},\n",
       "  'DB11855': {'name': 'Revefenacin',\n",
       "   'description': 'The metabolism of Revefenacin can be increased when combined with Anakinra.'},\n",
       "  'DB11979': {'name': 'Elagolix',\n",
       "   'description': 'The metabolism of Elagolix can be increased when combined with Anakinra.'},\n",
       "  'DB12070': {'name': 'Letermovir',\n",
       "   'description': 'The metabolism of Letermovir can be increased when combined with Anakinra.'},\n",
       "  'DB12212': {'name': 'Landiolol',\n",
       "   'description': 'The metabolism of Landiolol can be increased when combined with Anakinra.'},\n",
       "  'DB12752': {'name': 'Bucindolol',\n",
       "   'description': 'The metabolism of Bucindolol can be increased when combined with Anakinra.'},\n",
       "  'DB13443': {'name': 'Esatenolol',\n",
       "   'description': 'The metabolism of Esatenolol can be increased when combined with Anakinra.'},\n",
       "  'DB13508': {'name': 'Cloranolol',\n",
       "   'description': 'The metabolism of Cloranolol can be increased when combined with Anakinra.'},\n",
       "  'DB13530': {'name': 'Mepindolol',\n",
       "   'description': 'The metabolism of Mepindolol can be increased when combined with Anakinra.'},\n",
       "  'DB13679': {'name': 'Dexchlorpheniramine',\n",
       "   'description': 'The metabolism of Dexchlorpheniramine can be increased when combined with Anakinra.'},\n",
       "  'DB13757': {'name': 'Epanolol',\n",
       "   'description': 'The metabolism of Epanolol can be increased when combined with Anakinra.'},\n",
       "  'DB13775': {'name': 'Tertatolol',\n",
       "   'description': 'The metabolism of Tertatolol can be increased when combined with Anakinra.'},\n",
       "  'DB00850': {'name': 'Perphenazine',\n",
       "   'description': 'The metabolism of Perphenazine can be increased when combined with Anakinra.'},\n",
       "  'DB09173': {'name': 'Butyrfentanyl',\n",
       "   'description': 'The metabolism of Butyrfentanyl can be increased when combined with Anakinra.'},\n",
       "  'DB00281': {'name': 'Lidocaine',\n",
       "   'description': 'The metabolism of Lidocaine can be increased when combined with Anakinra.'},\n",
       "  'DB00598': {'name': 'Labetalol',\n",
       "   'description': 'The metabolism of Labetalol can be increased when combined with Anakinra.'},\n",
       "  'DB14010': {'name': '5-methoxy-N,N-dimethyltryptamine',\n",
       "   'description': 'The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Anakinra.'},\n",
       "  'DB01410': {'name': 'Ciclesonide',\n",
       "   'description': 'The metabolism of Ciclesonide can be increased when combined with Anakinra.'},\n",
       "  'DB01611': {'name': 'Hydroxychloroquine',\n",
       "   'description': 'The metabolism of Hydroxychloroquine can be increased when combined with Anakinra.'},\n",
       "  'DB00918': {'name': 'Almotriptan',\n",
       "   'description': 'The metabolism of Almotriptan can be increased when combined with Anakinra.'},\n",
       "  'DB08918': {'name': 'Levomilnacipran',\n",
       "   'description': 'The metabolism of Levomilnacipran can be increased when combined with Anakinra.'},\n",
       "  'DB08922': {'name': 'Perospirone',\n",
       "   'description': 'The metabolism of Perospirone can be increased when combined with Anakinra.'},\n",
       "  'DB09183': {'name': 'Dasabuvir',\n",
       "   'description': 'The metabolism of Dasabuvir can be increased when combined with Anakinra.'},\n",
       "  'DB00185': {'name': 'Cevimeline',\n",
       "   'description': 'The metabolism of Cevimeline can be increased when combined with Anakinra.'},\n",
       "  'DB00243': {'name': 'Ranolazine',\n",
       "   'description': 'The metabolism of Ranolazine can be increased when combined with Anakinra.'},\n",
       "  'DB00297': {'name': 'Bupivacaine',\n",
       "   'description': 'The metabolism of Bupivacaine can be increased when combined with Anakinra.'},\n",
       "  'DB00318': {'name': 'Codeine',\n",
       "   'description': 'The metabolism of Codeine can be increased when combined with Anakinra.'},\n",
       "  'DB00377': {'name': 'Palonosetron',\n",
       "   'description': 'The metabolism of Palonosetron can be increased when combined with Anakinra.'},\n",
       "  'DB00589': {'name': 'Lisuride',\n",
       "   'description': 'The metabolism of Lisuride can be increased when combined with Anakinra.'},\n",
       "  'DB00647': {'name': 'Dextropropoxyphene',\n",
       "   'description': 'The metabolism of Dextropropoxyphene can be increased when combined with Anakinra.'},\n",
       "  'DB00674': {'name': 'Galantamine',\n",
       "   'description': 'The metabolism of Galantamine can be increased when combined with Anakinra.'},\n",
       "  'DB00705': {'name': 'Delavirdine',\n",
       "   'description': 'The metabolism of Delavirdine can be increased when combined with Anakinra.'},\n",
       "  'DB00706': {'name': 'Tamsulosin',\n",
       "   'description': 'The metabolism of Tamsulosin can be increased when combined with Anakinra.'},\n",
       "  'DB00757': {'name': 'Dolasetron',\n",
       "   'description': 'The metabolism of Dolasetron can be increased when combined with Anakinra.'},\n",
       "  'DB01149': {'name': 'Nefazodone',\n",
       "   'description': 'The metabolism of Nefazodone can be increased when combined with Anakinra.'},\n",
       "  'DB01192': {'name': 'Oxymorphone',\n",
       "   'description': 'The metabolism of Oxymorphone can be increased when combined with Anakinra.'},\n",
       "  'DB01244': {'name': 'Bepridil',\n",
       "   'description': 'The metabolism of Bepridil can be increased when combined with Anakinra.'},\n",
       "  'DB01392': {'name': 'Yohimbine',\n",
       "   'description': 'The metabolism of Yohimbine can be increased when combined with Anakinra.'},\n",
       "  'DB01409': {'name': 'Tiotropium',\n",
       "   'description': 'The metabolism of Tiotropium can be increased when combined with Anakinra.'},\n",
       "  'DB01551': {'name': 'Dihydrocodeine',\n",
       "   'description': 'The metabolism of Dihydrocodeine can be increased when combined with Anakinra.'},\n",
       "  'DB01591': {'name': 'Solifenacin',\n",
       "   'description': 'The metabolism of Solifenacin can be increased when combined with Anakinra.'},\n",
       "  'DB01621': {'name': 'Pipotiazine',\n",
       "   'description': 'The metabolism of Pipotiazine can be increased when combined with Anakinra.'},\n",
       "  'DB02703': {'name': 'Fusidic acid',\n",
       "   'description': 'The metabolism of Fusidic acid can be increased when combined with Anakinra.'},\n",
       "  'DB04829': {'name': 'Lysergic acid diethylamide',\n",
       "   'description': 'The metabolism of Lysergic acid diethylamide can be increased when combined with Anakinra.'},\n",
       "  'DB04884': {'name': 'Dapoxetine',\n",
       "   'description': 'The metabolism of Dapoxetine can be increased when combined with Anakinra.'},\n",
       "  'DB04905': {'name': 'Tesmilifene',\n",
       "   'description': 'The metabolism of Tesmilifene can be increased when combined with Anakinra.'},\n",
       "  'DB04920': {'name': 'Clevidipine',\n",
       "   'description': 'The metabolism of Clevidipine can be increased when combined with Anakinra.'},\n",
       "  'DB05271': {'name': 'Rotigotine',\n",
       "   'description': 'The metabolism of Rotigotine can be increased when combined with Anakinra.'},\n",
       "  'DB06016': {'name': 'Cariprazine',\n",
       "   'description': 'The metabolism of Cariprazine can be increased when combined with Anakinra.'},\n",
       "  'DB06144': {'name': 'Sertindole',\n",
       "   'description': 'The metabolism of Sertindole can be increased when combined with Anakinra.'},\n",
       "  'DB06203': {'name': 'Alogliptin',\n",
       "   'description': 'The metabolism of Alogliptin can be increased when combined with Anakinra.'},\n",
       "  'DB06702': {'name': 'Fesoterodine',\n",
       "   'description': 'The metabolism of Fesoterodine can be increased when combined with Anakinra.'},\n",
       "  'DB08893': {'name': 'Mirabegron',\n",
       "   'description': 'The metabolism of Mirabegron can be increased when combined with Anakinra.'},\n",
       "  'DB09128': {'name': 'Brexpiprazole',\n",
       "   'description': 'The metabolism of Brexpiprazole can be increased when combined with Anakinra.'},\n",
       "  'DB09195': {'name': 'Lorpiprazole',\n",
       "   'description': 'The metabolism of Lorpiprazole can be increased when combined with Anakinra.'},\n",
       "  'DB09555': {'name': 'Dexchlorpheniramine maleate',\n",
       "   'description': 'The metabolism of Dexchlorpheniramine maleate can be increased when combined with Anakinra.'},\n",
       "  'DB11130': {'name': 'Opium',\n",
       "   'description': 'The metabolism of Opium can be increased when combined with Anakinra.'},\n",
       "  'DB11642': {'name': 'Pitolisant',\n",
       "   'description': 'The metabolism of Pitolisant can be increased when combined with Anakinra.'},\n",
       "  'DB13293': {'name': 'Ipecac',\n",
       "   'description': 'The metabolism of Ipecac can be increased when combined with Anakinra.'},\n",
       "  'DB00344': {'name': 'Protriptyline',\n",
       "   'description': 'The metabolism of Protriptyline can be increased when combined with Anakinra.'},\n",
       "  'DB00496': {'name': 'Darifenacin',\n",
       "   'description': 'The metabolism of Darifenacin can be increased when combined with Anakinra.'},\n",
       "  'DB00932': {'name': 'Tipranavir',\n",
       "   'description': 'The metabolism of Tipranavir can be increased when combined with Anakinra.'},\n",
       "  'DB09039': {'name': 'Eliglustat',\n",
       "   'description': 'The metabolism of Eliglustat can be increased when combined with Anakinra.'},\n",
       "  'DB12930': {'name': 'Opipramol',\n",
       "   'description': 'The metabolism of Opipramol can be increased when combined with Anakinra.'},\n",
       "  'DB14881': {'name': 'Oliceridine',\n",
       "   'description': 'The metabolism of Oliceridine can be increased when combined with Anakinra.'},\n",
       "  'DB09053': {'name': 'Ibrutinib',\n",
       "   'description': 'The metabolism of Ibrutinib can be increased when combined with Anakinra.'},\n",
       "  'DB11718': {'name': 'Encorafenib',\n",
       "   'description': 'The metabolism of Encorafenib can be increased when combined with Anakinra.'},\n",
       "  'DB00342': {'name': 'Terfenadine',\n",
       "   'description': 'The metabolism of Terfenadine can be increased when combined with Anakinra.'},\n",
       "  'DB00489': {'name': 'Sotalol',\n",
       "   'description': 'The metabolism of Sotalol can be increased when combined with Anakinra.'},\n",
       "  'DB01035': {'name': 'Procainamide',\n",
       "   'description': 'The metabolism of Procainamide can be increased when combined with Anakinra.'},\n",
       "  'DB01195': {'name': 'Flecainide',\n",
       "   'description': 'The metabolism of Flecainide can be increased when combined with Anakinra.'},\n",
       "  'DB00321': {'name': 'Amitriptyline',\n",
       "   'description': 'The metabolism of Amitriptyline can be increased when combined with Anakinra.'},\n",
       "  'DB00637': {'name': 'Astemizole',\n",
       "   'description': 'The metabolism of Astemizole can be increased when combined with Anakinra.'},\n",
       "  'DB00543': {'name': 'Amoxapine',\n",
       "   'description': 'The metabolism of Amoxapine can be increased when combined with Anakinra.'},\n",
       "  'DB00540': {'name': 'Nortriptyline',\n",
       "   'description': 'The metabolism of Nortriptyline can be increased when combined with Anakinra.'},\n",
       "  'DB01151': {'name': 'Desipramine',\n",
       "   'description': 'The metabolism of Desipramine can be increased when combined with Anakinra.'},\n",
       "  'DB00228': {'name': 'Enflurane',\n",
       "   'description': 'The metabolism of Enflurane can be increased when combined with Anakinra.'},\n",
       "  'DB06712': {'name': 'Nilvadipine',\n",
       "   'description': 'The metabolism of Nilvadipine can be increased when combined with Anakinra.'},\n",
       "  'DB06728': {'name': 'Aniline',\n",
       "   'description': 'The metabolism of Aniline can be increased when combined with Anakinra.'},\n",
       "  'DB00949': {'name': 'Felbamate',\n",
       "   'description': 'The metabolism of Felbamate can be increased when combined with Anakinra.'},\n",
       "  'DB00593': {'name': 'Ethosuximide',\n",
       "   'description': 'The metabolism of Ethosuximide can be increased when combined with Anakinra.'},\n",
       "  'DB00186': {'name': 'Lorazepam',\n",
       "   'description': 'The metabolism of Lorazepam can be increased when combined with Anakinra.'},\n",
       "  'DB00191': {'name': 'Phentermine',\n",
       "   'description': 'The metabolism of Phentermine can be increased when combined with Anakinra.'},\n",
       "  'DB00207': {'name': 'Azithromycin',\n",
       "   'description': 'The metabolism of Azithromycin can be increased when combined with Anakinra.'},\n",
       "  'DB00208': {'name': 'Ticlopidine',\n",
       "   'description': 'The metabolism of Ticlopidine can be increased when combined with Anakinra.'},\n",
       "  'DB00264': {'name': 'Metoprolol',\n",
       "   'description': 'The metabolism of Metoprolol can be increased when combined with Anakinra.'},\n",
       "  'DB00426': {'name': 'Famciclovir',\n",
       "   'description': 'The metabolism of Famciclovir can be increased when combined with Anakinra.'},\n",
       "  'DB00433': {'name': 'Prochlorperazine',\n",
       "   'description': 'The metabolism of Prochlorperazine can be increased when combined with Anakinra.'},\n",
       "  'DB00567': {'name': 'Cephalexin',\n",
       "   'description': 'The metabolism of Cephalexin can be increased when combined with Anakinra.'},\n",
       "  'DB00590': {'name': 'Doxazosin',\n",
       "   'description': 'The metabolism of Doxazosin can be increased when combined with Anakinra.'},\n",
       "  'DB01039': {'name': 'Fenofibrate',\n",
       "   'description': 'The metabolism of Fenofibrate can be increased when combined with Anakinra.'},\n",
       "  'DB01395': {'name': 'Drospirenone',\n",
       "   'description': 'The metabolism of Drospirenone can be increased when combined with Anakinra.'},\n",
       "  'DB01411': {'name': 'Pranlukast',\n",
       "   'description': 'The metabolism of Pranlukast can be increased when combined with Anakinra.'},\n",
       "  'DB01431': {'name': 'Allylestrenol',\n",
       "   'description': 'The metabolism of Allylestrenol can be increased when combined with Anakinra.'},\n",
       "  'DB01624': {'name': 'Zuclopenthixol',\n",
       "   'description': 'The metabolism of Zuclopenthixol can be increased when combined with Anakinra.'},\n",
       "  'DB06201': {'name': 'Rufinamide',\n",
       "   'description': 'The metabolism of Rufinamide can be increased when combined with Anakinra.'},\n",
       "  'DB06480': {'name': 'Prucalopride',\n",
       "   'description': 'The metabolism of Prucalopride can be increased when combined with Anakinra.'},\n",
       "  'DB08882': {'name': 'Linagliptin',\n",
       "   'description': 'The metabolism of Linagliptin can be increased when combined with Anakinra.'},\n",
       "  'DB09030': {'name': 'Vorapaxar',\n",
       "   'description': 'The metabolism of Vorapaxar can be increased when combined with Anakinra.'},\n",
       "  'DB09034': {'name': 'Suvorexant',\n",
       "   'description': 'The metabolism of Suvorexant can be increased when combined with Anakinra.'},\n",
       "  'DB09079': {'name': 'Nintedanib',\n",
       "   'description': 'The metabolism of Nintedanib can be increased when combined with Anakinra.'},\n",
       "  'DB09299': {'name': 'Tenofovir alafenamide',\n",
       "   'description': 'The metabolism of Tenofovir alafenamide can be increased when combined with Anakinra.'},\n",
       "  'DB11094': {'name': 'Vitamin D',\n",
       "   'description': 'The metabolism of Vitamin D can be increased when combined with Anakinra.'},\n",
       "  'DB11273': {'name': 'Dihydroergocornine',\n",
       "   'description': 'The metabolism of Dihydroergocornine can be increased when combined with Anakinra.'},\n",
       "  'DB11730': {'name': 'Ribociclib',\n",
       "   'description': 'The metabolism of Ribociclib can be increased when combined with Anakinra.'},\n",
       "  'DB11952': {'name': 'Duvelisib',\n",
       "   'description': 'The metabolism of Duvelisib can be increased when combined with Anakinra.'},\n",
       "  'DB12141': {'name': 'Gilteritinib',\n",
       "   'description': 'The metabolism of Gilteritinib can be increased when combined with Anakinra.'},\n",
       "  'DB12515': {'name': '9-aminocamptothecin',\n",
       "   'description': 'The metabolism of 9-aminocamptothecin can be increased when combined with Anakinra.'},\n",
       "  'DB12952': {'name': 'Methylprednisone',\n",
       "   'description': 'The metabolism of Methylprednisone can be increased when combined with Anakinra.'},\n",
       "  'DB13345': {'name': 'Dihydroergocristine',\n",
       "   'description': 'The metabolism of Dihydroergocristine can be increased when combined with Anakinra.'},\n",
       "  'DB13385': {'name': 'Dihydroergocryptine',\n",
       "   'description': 'The metabolism of Dihydroergocryptine can be increased when combined with Anakinra.'},\n",
       "  'DB14126': {'name': 'Tenofovir',\n",
       "   'description': 'The metabolism of Tenofovir can be increased when combined with Anakinra.'},\n",
       "  'DB15444': {'name': 'Elexacaftor',\n",
       "   'description': 'The metabolism of Elexacaftor can be increased when combined with Anakinra.'},\n",
       "  'DB06717': {'name': 'Fosaprepitant',\n",
       "   'description': 'The metabolism of Fosaprepitant can be increased when combined with Anakinra.'},\n",
       "  'DB12825': {'name': 'Lefamulin',\n",
       "   'description': 'The metabolism of Lefamulin can be increased when combined with Anakinra.'},\n",
       "  'DB12887': {'name': 'Tazemetostat',\n",
       "   'description': 'The metabolism of Tazemetostat can be increased when combined with Anakinra.'},\n",
       "  'DB00454': {'name': 'Meperidine',\n",
       "   'description': 'The metabolism of Meperidine can be increased when combined with Anakinra.'},\n",
       "  'DB00247': {'name': 'Methysergide',\n",
       "   'description': 'The metabolism of Methysergide can be increased when combined with Anakinra.'},\n",
       "  'DB11742': {'name': 'Ebastine',\n",
       "   'description': 'The metabolism of Ebastine can be increased when combined with Anakinra.'},\n",
       "  'DB11633': {'name': 'Isavuconazole',\n",
       "   'description': 'The metabolism of Isavuconazole can be increased when combined with Anakinra.'},\n",
       "  'DB01118': {'name': 'Amiodarone',\n",
       "   'description': 'The metabolism of Amiodarone can be increased when combined with Anakinra.'},\n",
       "  'DB00675': {'name': 'Tamoxifen',\n",
       "   'description': 'The metabolism of Tamoxifen can be increased when combined with Anakinra.'},\n",
       "  'DB06176': {'name': 'Romidepsin',\n",
       "   'description': 'The metabolism of Romidepsin can be increased when combined with Anakinra.'},\n",
       "  'DB00204': {'name': 'Dofetilide',\n",
       "   'description': 'The metabolism of Dofetilide can be increased when combined with Anakinra.'},\n",
       "  'DB00877': {'name': 'Sirolimus',\n",
       "   'description': 'The metabolism of Sirolimus can be increased when combined with Anakinra.'},\n",
       "  'DB01008': {'name': 'Busulfan',\n",
       "   'description': 'The metabolism of Busulfan can be increased when combined with Anakinra.'},\n",
       "  'DB01254': {'name': 'Dasatinib',\n",
       "   'description': 'The metabolism of Dasatinib can be increased when combined with Anakinra.'},\n",
       "  'DB01396': {'name': 'Digitoxin',\n",
       "   'description': 'The metabolism of Digitoxin can be increased when combined with Anakinra.'},\n",
       "  'DB01590': {'name': 'Everolimus',\n",
       "   'description': 'The metabolism of Everolimus can be increased when combined with Anakinra.'},\n",
       "  'DB04855': {'name': 'Dronedarone',\n",
       "   'description': 'The metabolism of Dronedarone can be increased when combined with Anakinra.'},\n",
       "  'DB06287': {'name': 'Temsirolimus',\n",
       "   'description': 'The metabolism of Temsirolimus can be increased when combined with Anakinra.'},\n",
       "  'DB09289': {'name': 'Tianeptine',\n",
       "   'description': 'The metabolism of Tianeptine can be increased when combined with Anakinra.'},\n",
       "  'DB00398': {'name': 'Sorafenib',\n",
       "   'description': 'The metabolism of Sorafenib can be increased when combined with Anakinra.'},\n",
       "  'DB00444': {'name': 'Teniposide',\n",
       "   'description': 'The metabolism of Teniposide can be increased when combined with Anakinra.'},\n",
       "  'DB00530': {'name': 'Erlotinib',\n",
       "   'description': 'The metabolism of Erlotinib can be increased when combined with Anakinra.'},\n",
       "  'DB00541': {'name': 'Vincristine',\n",
       "   'description': 'The metabolism of Vincristine can be increased when combined with Anakinra.'},\n",
       "  'DB00762': {'name': 'Irinotecan',\n",
       "   'description': 'The metabolism of Irinotecan can be increased when combined with Anakinra.'},\n",
       "  'DB00773': {'name': 'Etoposide',\n",
       "   'description': 'The metabolism of Etoposide can be increased when combined with Anakinra.'},\n",
       "  'DB01248': {'name': 'Docetaxel',\n",
       "   'description': 'The metabolism of Docetaxel can be increased when combined with Anakinra.'},\n",
       "  'DB01268': {'name': 'Sunitinib',\n",
       "   'description': 'The metabolism of Sunitinib can be increased when combined with Anakinra.'},\n",
       "  'DB05773': {'name': 'Trastuzumab emtansine',\n",
       "   'description': 'The metabolism of Trastuzumab emtansine can be increased when combined with Anakinra.'},\n",
       "  'DB06626': {'name': 'Axitinib',\n",
       "   'description': 'The metabolism of Axitinib can be increased when combined with Anakinra.'},\n",
       "  'DB08865': {'name': 'Crizotinib',\n",
       "   'description': 'The metabolism of Crizotinib can be increased when combined with Anakinra.'},\n",
       "  'DB08901': {'name': 'Ponatinib',\n",
       "   'description': 'The metabolism of Ponatinib can be increased when combined with Anakinra.'},\n",
       "  'DB09074': {'name': 'Olaparib',\n",
       "   'description': 'The metabolism of Olaparib can be increased when combined with Anakinra.'},\n",
       "  'DB12483': {'name': 'Copanlisib',\n",
       "   'description': 'The metabolism of Copanlisib can be increased when combined with Anakinra.'},\n",
       "  'DB00188': {'name': 'Bortezomib',\n",
       "   'description': 'The metabolism of Bortezomib can be increased when combined with Anakinra.'},\n",
       "  'DB01181': {'name': 'Ifosfamide',\n",
       "   'description': 'The metabolism of Ifosfamide can be increased when combined with Anakinra.'},\n",
       "  'DB05109': {'name': 'Trabectedin',\n",
       "   'description': 'The metabolism of Trabectedin can be increased when combined with Anakinra.'},\n",
       "  'DB12147': {'name': 'Erdafitinib',\n",
       "   'description': 'The metabolism of Erdafitinib can be increased when combined with Anakinra.'},\n",
       "  'DB13874': {'name': 'Enasidenib',\n",
       "   'description': 'The metabolism of Enasidenib can be increased when combined with Anakinra.'},\n",
       "  'DB06589': {'name': 'Pazopanib',\n",
       "   'description': 'The metabolism of Pazopanib can be increased when combined with Anakinra.'},\n",
       "  'DB05239': {'name': 'Cobimetinib',\n",
       "   'description': 'The metabolism of Cobimetinib can be increased when combined with Anakinra.'},\n",
       "  'DB09063': {'name': 'Ceritinib',\n",
       "   'description': 'The metabolism of Ceritinib can be increased when combined with Anakinra.'},\n",
       "  'DB09330': {'name': 'Osimertinib',\n",
       "   'description': 'The metabolism of Osimertinib can be increased when combined with Anakinra.'},\n",
       "  'DB11963': {'name': 'Dacomitinib',\n",
       "   'description': 'The metabolism of Dacomitinib can be increased when combined with Anakinra.'},\n",
       "  'DB12015': {'name': 'Alpelisib',\n",
       "   'description': 'The metabolism of Alpelisib can be increased when combined with Anakinra.'},\n",
       "  'DB00309': {'name': 'Vindesine',\n",
       "   'description': 'The metabolism of Vindesine can be increased when combined with Anakinra.'},\n",
       "  'DB00361': {'name': 'Vinorelbine',\n",
       "   'description': 'The metabolism of Vinorelbine can be increased when combined with Anakinra.'},\n",
       "  'DB00570': {'name': 'Vinblastine',\n",
       "   'description': 'The metabolism of Vinblastine can be increased when combined with Anakinra.'},\n",
       "  'DB00997': {'name': 'Doxorubicin',\n",
       "   'description': 'The metabolism of Doxorubicin can be increased when combined with Anakinra.'},\n",
       "  'DB04572': {'name': 'Thiotepa',\n",
       "   'description': 'The metabolism of Thiotepa can be increased when combined with Anakinra.'},\n",
       "  'DB04845': {'name': 'Ixabepilone',\n",
       "   'description': 'The metabolism of Ixabepilone can be increased when combined with Anakinra.'},\n",
       "  'DB04868': {'name': 'Nilotinib',\n",
       "   'description': 'The metabolism of Nilotinib can be increased when combined with Anakinra.'},\n",
       "  'DB06603': {'name': 'Panobinostat',\n",
       "   'description': 'The metabolism of Panobinostat can be increased when combined with Anakinra.'},\n",
       "  'DB06616': {'name': 'Bosutinib',\n",
       "   'description': 'The metabolism of Bosutinib can be increased when combined with Anakinra.'},\n",
       "  'DB08870': {'name': 'Brentuximab vedotin',\n",
       "   'description': 'The metabolism of Brentuximab vedotin can be increased when combined with Anakinra.'},\n",
       "  'DB08877': {'name': 'Ruxolitinib',\n",
       "   'description': 'The metabolism of Ruxolitinib can be increased when combined with Anakinra.'},\n",
       "  'DB09073': {'name': 'Palbociclib',\n",
       "   'description': 'The metabolism of Palbociclib can be increased when combined with Anakinra.'},\n",
       "  'DB11817': {'name': 'Baricitinib',\n",
       "   'description': 'The metabolism of Baricitinib can be increased when combined with Anakinra.'},\n",
       "  'DB08912': {'name': 'Dabrafenib',\n",
       "   'description': 'The metabolism of Dabrafenib can be increased when combined with Anakinra.'},\n",
       "  'DB12267': {'name': 'Brigatinib',\n",
       "   'description': 'The metabolism of Brigatinib can be increased when combined with Anakinra.'},\n",
       "  'DB00563': {'name': 'Methotrexate',\n",
       "   'description': 'The metabolism of Methotrexate can be increased when combined with Anakinra.'},\n",
       "  'DB08827': {'name': 'Lomitapide',\n",
       "   'description': 'The metabolism of Lomitapide can be increased when combined with Anakinra.'},\n",
       "  'DB05294': {'name': 'Vandetanib',\n",
       "   'description': 'The metabolism of Vandetanib can be increased when combined with Anakinra.'},\n",
       "  'DB08881': {'name': 'Vemurafenib',\n",
       "   'description': 'The metabolism of Vemurafenib can be increased when combined with Anakinra.'},\n",
       "  'DB11363': {'name': 'Alectinib',\n",
       "   'description': 'The metabolism of Alectinib can be increased when combined with Anakinra.'},\n",
       "  'DB11581': {'name': 'Venetoclax',\n",
       "   'description': 'The metabolism of Venetoclax can be increased when combined with Anakinra.'},\n",
       "  'DB11641': {'name': 'Vinflunine',\n",
       "   'description': 'The metabolism of Vinflunine can be increased when combined with Anakinra.'},\n",
       "  'DB11703': {'name': 'Acalabrutinib',\n",
       "   'description': 'The metabolism of Acalabrutinib can be increased when combined with Anakinra.'},\n",
       "  'DB15035': {'name': 'Zanubrutinib',\n",
       "   'description': 'The metabolism of Zanubrutinib can be increased when combined with Anakinra.'},\n",
       "  'DB00248': {'name': 'Cabergoline',\n",
       "   'description': 'The metabolism of Cabergoline can be increased when combined with Anakinra.'},\n",
       "  'DB06595': {'name': 'Midostaurin',\n",
       "   'description': 'The metabolism of Midostaurin can be increased when combined with Anakinra.'},\n",
       "  'DB09143': {'name': 'Sonidegib',\n",
       "   'description': 'The metabolism of Sonidegib can be increased when combined with Anakinra.'},\n",
       "  'DB11828': {'name': 'Neratinib',\n",
       "   'description': 'The metabolism of Neratinib can be increased when combined with Anakinra.'},\n",
       "  'DB11986': {'name': 'Entrectinib',\n",
       "   'description': 'The metabolism of Entrectinib can be increased when combined with Anakinra.'},\n",
       "  'DB12978': {'name': 'Pexidartinib',\n",
       "   'description': 'The metabolism of Pexidartinib can be increased when combined with Anakinra.'},\n",
       "  'DB14568': {'name': 'Ivosidenib',\n",
       "   'description': 'The metabolism of Ivosidenib can be increased when combined with Anakinra.'},\n",
       "  'DB09054': {'name': 'Idelalisib',\n",
       "   'description': 'The metabolism of Idelalisib can be increased when combined with Anakinra.'},\n",
       "  'DB09570': {'name': 'Ixazomib',\n",
       "   'description': 'The metabolism of Ixazomib can be increased when combined with Anakinra.'},\n",
       "  'DB06212': {'name': 'Tolvaptan',\n",
       "   'description': 'The metabolism of Tolvaptan can be increased when combined with Anakinra.'},\n",
       "  'DB08896': {'name': 'Regorafenib',\n",
       "   'description': 'The metabolism of Regorafenib can be increased when combined with Anakinra.'},\n",
       "  'DB12001': {'name': 'Abemaciclib',\n",
       "   'description': 'The metabolism of Abemaciclib can be increased when combined with Anakinra.'},\n",
       "  'DB00320': {'name': 'Dihydroergotamine',\n",
       "   'description': 'The metabolism of Dihydroergotamine can be increased when combined with Anakinra.'},\n",
       "  'DB00564': {'name': 'Carbamazepine',\n",
       "   'description': 'The metabolism of Carbamazepine can be increased when combined with Anakinra.'},\n",
       "  'DB00696': {'name': 'Ergotamine',\n",
       "   'description': 'The metabolism of Ergotamine can be increased when combined with Anakinra.'},\n",
       "  'DB00872': {'name': 'Conivaptan',\n",
       "   'description': 'The metabolism of Conivaptan can be increased when combined with Anakinra.'},\n",
       "  'DB00908': {'name': 'Quinidine',\n",
       "   'description': 'The metabolism of Quinidine can be increased when combined with Anakinra.'},\n",
       "  'DB01128': {'name': 'Bicalutamide',\n",
       "   'description': 'The metabolism of Bicalutamide can be increased when combined with Anakinra.'},\n",
       "  'DB01227': {'name': 'Levacetylmethadol',\n",
       "   'description': 'The metabolism of Levacetylmethadol can be increased when combined with Anakinra.'},\n",
       "  'DB00199': {'name': 'Erythromycin',\n",
       "   'description': 'The metabolism of Erythromycin can be increased when combined with Anakinra.'},\n",
       "  'DB00246': {'name': 'Ziprasidone',\n",
       "   'description': 'The metabolism of Ziprasidone can be increased when combined with Anakinra.'},\n",
       "  'DB00439': {'name': 'Cerivastatin',\n",
       "   'description': 'The metabolism of Cerivastatin can be increased when combined with Anakinra.'},\n",
       "  'DB00499': {'name': 'Flutamide',\n",
       "   'description': 'The metabolism of Flutamide can be increased when combined with Anakinra.'},\n",
       "  'DB00528': {'name': 'Lercanidipine',\n",
       "   'description': 'The metabolism of Lercanidipine can be increased when combined with Anakinra.'},\n",
       "  'DB00571': {'name': 'Propranolol',\n",
       "   'description': 'The metabolism of Propranolol can be increased when combined with Anakinra.'},\n",
       "  'DB00588': {'name': 'Fluticasone propionate',\n",
       "   'description': 'The metabolism of Fluticasone propionate can be increased when combined with Anakinra.'},\n",
       "  'DB00608': {'name': 'Chloroquine',\n",
       "   'description': 'The metabolism of Chloroquine can be increased when combined with Anakinra.'},\n",
       "  'DB00688': {'name': 'Mycophenolate mofetil',\n",
       "   'description': 'The metabolism of Mycophenolate mofetil can be increased when combined with Anakinra.'},\n",
       "  'DB00717': {'name': 'Norethisterone',\n",
       "   'description': 'The metabolism of Norethisterone can be increased when combined with Anakinra.'},\n",
       "  'DB00738': {'name': 'Pentamidine',\n",
       "   'description': 'The metabolism of Pentamidine can be increased when combined with Anakinra.'},\n",
       "  'DB00741': {'name': 'Hydrocortisone',\n",
       "   'description': 'The metabolism of Hydrocortisone can be increased when combined with Anakinra.'},\n",
       "  'DB00822': {'name': 'Disulfiram',\n",
       "   'description': 'The metabolism of Disulfiram can be increased when combined with Anakinra.'},\n",
       "  'DB00834': {'name': 'Mifepristone',\n",
       "   'description': 'The metabolism of Mifepristone can be increased when combined with Anakinra.'},\n",
       "  'DB00938': {'name': 'Salmeterol',\n",
       "   'description': 'The metabolism of Salmeterol can be increased when combined with Anakinra.'},\n",
       "  'DB00962': {'name': 'Zaleplon',\n",
       "   'description': 'The metabolism of Zaleplon can be increased when combined with Anakinra.'},\n",
       "  'DB00976': {'name': 'Telithromycin',\n",
       "   'description': 'The metabolism of Telithromycin can be increased when combined with Anakinra.'},\n",
       "  'DB01054': {'name': 'Nitrendipine',\n",
       "   'description': 'The metabolism of Nitrendipine can be increased when combined with Anakinra.'},\n",
       "  'DB01058': {'name': 'Praziquantel',\n",
       "   'description': 'The metabolism of Praziquantel can be increased when combined with Anakinra.'},\n",
       "  'DB01062': {'name': 'Oxybutynin',\n",
       "   'description': 'The metabolism of Oxybutynin can be increased when combined with Anakinra.'},\n",
       "  'DB01076': {'name': 'Atorvastatin',\n",
       "   'description': 'The metabolism of Atorvastatin can be increased when combined with Anakinra.'},\n",
       "  'DB01103': {'name': 'Quinacrine',\n",
       "   'description': 'The metabolism of Quinacrine can be increased when combined with Anakinra.'},\n",
       "  'DB01115': {'name': 'Nifedipine',\n",
       "   'description': 'The metabolism of Nifedipine can be increased when combined with Anakinra.'},\n",
       "  'DB01126': {'name': 'Dutasteride',\n",
       "   'description': 'The metabolism of Dutasteride can be increased when combined with Anakinra.'},\n",
       "  'DB01166': {'name': 'Cilostazol',\n",
       "   'description': 'The metabolism of Cilostazol can be increased when combined with Anakinra.'},\n",
       "  'DB01184': {'name': 'Domperidone',\n",
       "   'description': 'The metabolism of Domperidone can be increased when combined with Anakinra.'},\n",
       "  'DB01211': {'name': 'Clarithromycin',\n",
       "   'description': 'The metabolism of Clarithromycin can be increased when combined with Anakinra.'},\n",
       "  'DB01216': {'name': 'Finasteride',\n",
       "   'description': 'The metabolism of Finasteride can be increased when combined with Anakinra.'},\n",
       "  'DB01218': {'name': 'Halofantrine',\n",
       "   'description': 'The metabolism of Halofantrine can be increased when combined with Anakinra.'},\n",
       "  'DB05521': {'name': 'Telaprevir',\n",
       "   'description': 'The metabolism of Telaprevir can be increased when combined with Anakinra.'},\n",
       "  'DB06267': {'name': 'Udenafil',\n",
       "   'description': 'The metabolism of Udenafil can be increased when combined with Anakinra.'},\n",
       "  'DB06335': {'name': 'Saxagliptin',\n",
       "   'description': 'The metabolism of Saxagliptin can be increased when combined with Anakinra.'},\n",
       "  'DB06403': {'name': 'Ambrisentan',\n",
       "   'description': 'The metabolism of Ambrisentan can be increased when combined with Anakinra.'},\n",
       "  'DB06419': {'name': 'Cethromycin',\n",
       "   'description': 'The metabolism of Cethromycin can be increased when combined with Anakinra.'},\n",
       "  'DB06789': {'name': 'Hydroxyprogesterone caproate',\n",
       "   'description': 'The metabolism of Hydroxyprogesterone caproate can be increased when combined with Anakinra.'},\n",
       "  'DB08820': {'name': 'Ivacaftor',\n",
       "   'description': 'The metabolism of Ivacaftor can be increased when combined with Anakinra.'},\n",
       "  'DB08873': {'name': 'Boceprevir',\n",
       "   'description': 'The metabolism of Boceprevir can be increased when combined with Anakinra.'},\n",
       "  'DB08883': {'name': 'Perampanel',\n",
       "   'description': 'The metabolism of Perampanel can be increased when combined with Anakinra.'},\n",
       "  'DB08906': {'name': 'Fluticasone furoate',\n",
       "   'description': 'The metabolism of Fluticasone furoate can be increased when combined with Anakinra.'},\n",
       "  'DB09065': {'name': 'Cobicistat',\n",
       "   'description': 'The metabolism of Cobicistat can be increased when combined with Anakinra.'},\n",
       "  'DB09102': {'name': 'Daclatasvir',\n",
       "   'description': 'The metabolism of Daclatasvir can be increased when combined with Anakinra.'},\n",
       "  'DB09231': {'name': 'Benidipine',\n",
       "   'description': 'The metabolism of Benidipine can be increased when combined with Anakinra.'},\n",
       "  'DB09297': {'name': 'Paritaprevir',\n",
       "   'description': 'The metabolism of Paritaprevir can be increased when combined with Anakinra.'},\n",
       "  'DB11574': {'name': 'Elbasvir',\n",
       "   'description': 'The metabolism of Elbasvir can be increased when combined with Anakinra.'},\n",
       "  'DB11712': {'name': 'Tezacaftor',\n",
       "   'description': 'The metabolism of Tezacaftor can be increased when combined with Anakinra.'},\n",
       "  'DB11737': {'name': 'Icotinib',\n",
       "   'description': 'The metabolism of Icotinib can be increased when combined with Anakinra.'},\n",
       "  'DB12301': {'name': 'Doravirine',\n",
       "   'description': 'The metabolism of Doravirine can be increased when combined with Anakinra.'},\n",
       "  'DB13867': {'name': 'Fluticasone',\n",
       "   'description': 'The metabolism of Fluticasone can be increased when combined with Anakinra.'},\n",
       "  'DB14539': {'name': 'Hydrocortisone acetate',\n",
       "   'description': 'The metabolism of Hydrocortisone acetate can be increased when combined with Anakinra.'},\n",
       "  'DB14541': {'name': 'Hydrocortisone cypionate',\n",
       "   'description': 'The metabolism of Hydrocortisone cypionate can be increased when combined with Anakinra.'},\n",
       "  'DB00396': {'name': 'Progesterone',\n",
       "   'description': 'The metabolism of Progesterone can be increased when combined with Anakinra.'},\n",
       "  'DB04856': {'name': 'Dexloxiglumide',\n",
       "   'description': 'The metabolism of Dexloxiglumide can be increased when combined with Anakinra.'},\n",
       "  'DB04957': {'name': 'Azimilide',\n",
       "   'description': 'The metabolism of Azimilide can be increased when combined with Anakinra.'},\n",
       "  'DB00250': {'name': 'Dapsone',\n",
       "   'description': 'The metabolism of Dapsone can be increased when combined with Anakinra.'},\n",
       "  'DB00317': {'name': 'Gefitinib',\n",
       "   'description': 'The metabolism of Gefitinib can be increased when combined with Anakinra.'},\n",
       "  'DB00367': {'name': 'Levonorgestrel',\n",
       "   'description': 'The metabolism of Levonorgestrel can be increased when combined with Anakinra.'},\n",
       "  'DB00497': {'name': 'Oxycodone',\n",
       "   'description': 'The metabolism of Oxycodone can be increased when combined with Anakinra.'},\n",
       "  'DB00620': {'name': 'Triamcinolone',\n",
       "   'description': 'The metabolism of Triamcinolone can be increased when combined with Anakinra.'},\n",
       "  'DB00624': {'name': 'Testosterone',\n",
       "   'description': 'The metabolism of Testosterone can be increased when combined with Anakinra.'},\n",
       "  'DB00656': {'name': 'Trazodone',\n",
       "   'description': 'The metabolism of Trazodone can be increased when combined with Anakinra.'},\n",
       "  'DB00734': {'name': 'Risperidone',\n",
       "   'description': 'The metabolism of Risperidone can be increased when combined with Anakinra.'},\n",
       "  'DB01114': {'name': 'Chlorpheniramine',\n",
       "   'description': 'The metabolism of Chlorpheniramine can be increased when combined with Anakinra.'},\n",
       "  'DB01238': {'name': 'Aripiprazole',\n",
       "   'description': 'The metabolism of Aripiprazole can be increased when combined with Anakinra.'},\n",
       "  'DB01267': {'name': 'Paliperidone',\n",
       "   'description': 'The metabolism of Paliperidone can be increased when combined with Anakinra.'},\n",
       "  'DB04946': {'name': 'Iloperidone',\n",
       "   'description': 'The metabolism of Iloperidone can be increased when combined with Anakinra.'},\n",
       "  'DB11915': {'name': 'Valbenazine',\n",
       "   'description': 'The metabolism of Valbenazine can be increased when combined with Anakinra.'},\n",
       "  'DB12161': {'name': 'Deutetrabenazine',\n",
       "   'description': 'The metabolism of Deutetrabenazine can be increased when combined with Anakinra.'},\n",
       "  'DB14185': {'name': 'Aripiprazole lauroxil',\n",
       "   'description': 'The metabolism of Aripiprazole lauroxil can be increased when combined with Anakinra.'},\n",
       "  'DB01234': {'name': 'Dexamethasone',\n",
       "   'description': 'The metabolism of Dexamethasone can be increased when combined with Anakinra.'},\n",
       "  'DB09237': {'name': 'Levamlodipine',\n",
       "   'description': 'The metabolism of Levamlodipine can be increased when combined with Anakinra.'},\n",
       "  'DB11951': {'name': 'Lemborexant',\n",
       "   'description': 'The metabolism of Lemborexant can be increased when combined with Anakinra.'},\n",
       "  'DB00557': {'name': 'Hydroxyzine',\n",
       "   'description': 'The metabolism of Hydroxyzine can be increased when combined with Anakinra.'},\n",
       "  'DB00203': {'name': 'Sildenafil',\n",
       "   'description': 'The metabolism of Sildenafil can be increased when combined with Anakinra.'},\n",
       "  'DB00227': {'name': 'Lovastatin',\n",
       "   'description': 'The metabolism of Lovastatin can be increased when combined with Anakinra.'},\n",
       "  'DB00490': {'name': 'Buspirone',\n",
       "   'description': 'The metabolism of Buspirone can be increased when combined with Anakinra.'},\n",
       "  'DB00641': {'name': 'Simvastatin',\n",
       "   'description': 'The metabolism of Simvastatin can be increased when combined with Anakinra.'},\n",
       "  'DB00673': {'name': 'Aprepitant',\n",
       "   'description': 'The metabolism of Aprepitant can be increased when combined with Anakinra.'},\n",
       "  'DB00820': {'name': 'Tadalafil',\n",
       "   'description': 'The metabolism of Tadalafil can be increased when combined with Anakinra.'},\n",
       "  'DB00862': {'name': 'Vardenafil',\n",
       "   'description': 'The metabolism of Vardenafil can be increased when combined with Anakinra.'},\n",
       "  'DB01190': {'name': 'Clindamycin',\n",
       "   'description': 'The metabolism of Clindamycin can be increased when combined with Anakinra.'},\n",
       "  'DB00503': {'name': 'Ritonavir',\n",
       "   'description': 'The metabolism of Ritonavir can be increased when combined with Anakinra.'},\n",
       "  'DB00224': {'name': 'Indinavir',\n",
       "   'description': 'The metabolism of Indinavir can be increased when combined with Anakinra.'},\n",
       "  'DB00401': {'name': 'Nisoldipine',\n",
       "   'description': 'The metabolism of Nisoldipine can be increased when combined with Anakinra.'},\n",
       "  'DB00683': {'name': 'Midazolam',\n",
       "   'description': 'The metabolism of Midazolam can be increased when combined with Anakinra.'},\n",
       "  'DB00700': {'name': 'Eplerenone',\n",
       "   'description': 'The metabolism of Eplerenone can be increased when combined with Anakinra.'},\n",
       "  'DB00802': {'name': 'Alfentanil',\n",
       "   'description': 'The metabolism of Alfentanil can be increased when combined with Anakinra.'},\n",
       "  'DB00813': {'name': 'Fentanyl',\n",
       "   'description': 'The metabolism of Fentanyl can be increased when combined with Anakinra.'},\n",
       "  'DB00897': {'name': 'Triazolam',\n",
       "   'description': 'The metabolism of Triazolam can be increased when combined with Anakinra.'},\n",
       "  'DB01023': {'name': 'Felodipine',\n",
       "   'description': 'The metabolism of Felodipine can be increased when combined with Anakinra.'},\n",
       "  'DB01232': {'name': 'Saquinavir',\n",
       "   'description': 'The metabolism of Saquinavir can be increased when combined with Anakinra.'},\n",
       "  'DB06228': {'name': 'Rivaroxaban',\n",
       "   'description': 'The metabolism of Rivaroxaban can be increased when combined with Anakinra.'},\n",
       "  'DB00404': {'name': 'Alprazolam',\n",
       "   'description': 'The metabolism of Alprazolam can be increased when combined with Anakinra.'},\n",
       "  'DB14540': {'name': 'Hydrocortisone butyrate',\n",
       "   'description': 'The metabolism of Hydrocortisone butyrate can be increased when combined with Anakinra.'},\n",
       "  'DB14542': {'name': 'Hydrocortisone phosphate',\n",
       "   'description': 'The metabolism of Hydrocortisone phosphate can be increased when combined with Anakinra.'},\n",
       "  'DB05804': {'name': 'Prasterone sulfate',\n",
       "   'description': 'The metabolism of Prasterone sulfate can be increased when combined with Anakinra.'},\n",
       "  'DB00091': {'name': 'Cyclosporine',\n",
       "   'description': 'Anakinra may increase the immunosuppressive activities of Cyclosporine.'},\n",
       "  'DB05676': {'name': 'Apremilast',\n",
       "   'description': 'The therapeutic efficacy of Apremilast can be decreased when used in combination with Anakinra.'},\n",
       "  'DB14513': {'name': 'Magnesium',\n",
       "   'description': 'The serum concentration of Magnesium can be decreased when it is combined with Anakinra.'},\n",
       "  'DB01601': {'name': 'Lopinavir',\n",
       "   'description': 'The serum concentration of Anakinra can be increased when it is combined with Lopinavir.'},\n",
       "  'DB12530': {'name': 'Inebilizumab',\n",
       "   'description': 'The risk or severity of infection can be increased when Anakinra is combined with Inebilizumab.'}},\n",
       " 'pathways': {}}"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00026']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "c7f5a218",
   "metadata": {},
   "outputs": [],
   "source": [
    "tuples2 = np.unique(tuples2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "026f7340",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['11-beta-Hydroxylase Deficiency (CYP11B1);;SMP0000575',\n",
       "       '17-alpha-Hydroxylase Deficiency (CYP17);;SMP0000566',\n",
       "       '17-beta Hydroxysteroid Dehydrogenase III Deficiency;;SMP0000356',\n",
       "       '2-Aminoadipic 2-Oxoadipic Aciduria;;SMP0000719',\n",
       "       '2-Hydroxyglutric Aciduria (D and L Form);;SMP0000136',\n",
       "       '2-Ketoglutarate Dehydrogenase Complex Deficiency;;SMP0000549',\n",
       "       '2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency;;SMP0000137',\n",
       "       '21-Hydroxylase Deficiency (CYP21);;SMP0000576',\n",
       "       '27-Hydroxylase Deficiency;;SMP0000720',\n",
       "       '3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency;;SMP0000138',\n",
       "       '3-Hydroxyisobutyric Acid Dehydrogenase Deficiency;;SMP0000521',\n",
       "       '3-Hydroxyisobutyric Aciduria;;SMP0000522',\n",
       "       '3-Methylcrotonyl-CoA Carboxylase Deficiency Type I;;SMP0000237',\n",
       "       '3-Methylglutaconic Aciduria Type I;;SMP0000139',\n",
       "       '3-Methylglutaconic Aciduria Type III;;SMP0000140',\n",
       "       '3-Methylglutaconic Aciduria Type IV;;SMP0000141',\n",
       "       '3-Methylthiofentanyl Action Pathway;;SMP0000679',\n",
       "       '3-Phosphoglycerate Dehydrogenase Deficiency;;SMP0000721',\n",
       "       '3-beta-Hydroxysteroid Dehydrogenase Deficiency;;SMP0000718',\n",
       "       '4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency;;SMP0000243',\n",
       "       '5-Oxoprolinase Deficiency;;SMP0000500',\n",
       "       '5-Oxoprolinuria;;SMP0000143', 'AICA-Ribosiduria;;SMP0000168',\n",
       "       'Abacavir Action Pathway;;SMP0000737',\n",
       "       'Abciximab Action Pathway;;SMP0000265',\n",
       "       'Acebutolol Action Pathway;;SMP0000296',\n",
       "       'Acenocoumarol Action Pathway;;SMP0000269',\n",
       "       'Acetaminophen  Action Pathway;;SMP0000710',\n",
       "       'Acetaminophen Metabolism Pathway;;SMP0000640',\n",
       "       'Acetylsalicylic Acid Action Pathway;;SMP0000083',\n",
       "       'Acrivastine H1-Antihistamine Action;;SMP0059881',\n",
       "       'Acute Intermittent Porphyria;;SMP0000344',\n",
       "       'Adefovir Dipivoxil Metabolism Pathway;;SMP0000629',\n",
       "       'Adenine Phosphoribosyltransferase Deficiency (APRT);;SMP0000535',\n",
       "       'Adenosine Deaminase Deficiency;;SMP0000144',\n",
       "       'Adenylosuccinate Lyase Deficiency;;SMP0000167',\n",
       "       'Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency;;SMP0000373',\n",
       "       'Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency;;SMP0000372',\n",
       "       'Adrenoleukodystrophy, X-Linked;;SMP0000516',\n",
       "       'Alanine Metabolism;;SMP0000055',\n",
       "       'Alcaftadine H1-Antihistamine Action;;SMP0062881',\n",
       "       'Alendronate Action Pathway;;SMP0000095',\n",
       "       'Alfentanil Action Pathway;;SMP0000413',\n",
       "       'Alimemazine H1-Antihistamine Action;;SMP0059689',\n",
       "       'Alkaptonuria;;SMP0000169',\n",
       "       'Alpha Linolenic Acid and Linoleic Acid Metabolism;;SMP0000018',\n",
       "       'Alprenolol Action Pathway;;SMP0000297',\n",
       "       'Alteplase Action Pathway;;SMP0000280',\n",
       "       'Alvimopan Action Pathway;;SMP0000685',\n",
       "       'Amikacin Action Pathway;;SMP0000253',\n",
       "       'Amiloride Action Pathway;;SMP0000133',\n",
       "       'Amino Sugar Metabolism;;SMP0000045',\n",
       "       'Aminocaproic Acid Action Pathway;;SMP0000286',\n",
       "       'Amiodarone Action Pathway;;SMP0000665',\n",
       "       'Amlodipine Action Pathway;;SMP0000376',\n",
       "       'Ammonia Recycling;;SMP0000009',\n",
       "       'Androgen and Estrogen Metabolism;;SMP0000068',\n",
       "       'Androstenedione Metabolism;;SMP0030406',\n",
       "       'Anileridine Action Pathway;;SMP0000674',\n",
       "       'Anistreplase Action Pathway;;SMP0000281',\n",
       "       'Antazoline H1-Antihistamine Action;;SMP0057584',\n",
       "       'Antipyrine Action Pathway;;SMP0000692',\n",
       "       'Antrafenine Action Pathway;;SMP0000693',\n",
       "       'Apparent Mineralocorticoid Excess Syndrome;;SMP0000717',\n",
       "       'Aprotinin Action Pathway;;SMP0000288',\n",
       "       'Arachidonic Acid Metabolism;;SMP0000075',\n",
       "       'Arbekacin Action Pathway;;SMP0000713',\n",
       "       'Arbutamine Action Pathway;;SMP0000664',\n",
       "       'Ardeparin Action Pathway;;SMP0000275',\n",
       "       'Argatroban Action Pathway;;SMP0000276',\n",
       "       'Arginine and Proline Metabolism;;SMP0000020',\n",
       "       'Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);;SMP0000362',\n",
       "       'Argininemia;;SMP0000357', 'Argininosuccinic Aciduria;;SMP0000003',\n",
       "       'Aromatase Deficiency;;SMP0000565',\n",
       "       'Aromatic L-Aminoacid Decarboxylase Deficiency;;SMP0000170',\n",
       "       'Artemether Metabolism Pathway;;SMP0000651',\n",
       "       'Aspartate Metabolism;;SMP0000067',\n",
       "       'Astemizole H1-Antihistamine Action;;SMP0059897',\n",
       "       'Atenolol Action Pathway;;SMP0000298',\n",
       "       'Atorvastatin Action Pathway;;SMP0000131',\n",
       "       'Azatadine H1-Antihistamine Action;;SMP0059865',\n",
       "       'Azathioprine Action Pathway;;SMP0000427',\n",
       "       'Azathioprine Metabolism Pathway;;SMP0000645',\n",
       "       'Azelastine H1-Antihistamine Action;;SMP0060741',\n",
       "       'Azithromycin Action Pathway;;SMP0000247',\n",
       "       'Bafetinib Inhibition of BCR-ABL;;SMP0031699',\n",
       "       'Benazepril Action Pathway;;SMP0000145',\n",
       "       'Benazepril Metabolism Pathway;;SMP0000591',\n",
       "       'Bendroflumethiazide Action Pathway;;SMP0000090',\n",
       "       'Benzocaine Action Pathway;;SMP0000392',\n",
       "       'Bepotastine H1-Antihistamine Action;;SMP0060058',\n",
       "       'Beta Oxidation of Very Long Chain Fatty Acids;;SMP0000052',\n",
       "       'Betahistine H1-Antihistamine Action;;SMP0060744',\n",
       "       'Betaine Metabolism;;SMP0000123',\n",
       "       'Betaxolol Action Pathway;;SMP0000299',\n",
       "       'Betazole Action Pathway;;SMP0000736',\n",
       "       'Bevacizumab Action Pathway;;SMP0000420',\n",
       "       'Bevantolol Action Pathway;;SMP0000668',\n",
       "       'Bilastine H1-Antihistamine Action;;SMP0060170',\n",
       "       'Bile Acid Biosynthesis;;SMP0000035',\n",
       "       'Biotin Metabolism;;SMP0000066',\n",
       "       'Biotinidase Deficiency;;SMP0000174',\n",
       "       'Bisoprolol Action Pathway;;SMP0000300',\n",
       "       'Bivalirudin Action Pathway;;SMP0000277',\n",
       "       'Blue Diaper Syndrome;;SMP0000583',\n",
       "       'Bopindolol Action Pathway;;SMP0000657',\n",
       "       'Bosutinib Inhibition of BCR-ABL;;SMP0031698',\n",
       "       'Bromfenac Action Pathway;;SMP0000102',\n",
       "       'Bromodiphenhydramine H1-Antihistamine Action;;SMP0058813',\n",
       "       'Brompheniramine H1-Antihistamine Action;;SMP0057579',\n",
       "       'Buclizine H1-Antihistamine Action;;SMP0058964',\n",
       "       'Bumetanide Action Pathway;;SMP0000088',\n",
       "       'Bupivacaine Action Pathway;;SMP0000393',\n",
       "       'Bupranolol Action Pathway;;SMP0000670',\n",
       "       'Buprenorphine Action Pathway;;SMP0000684',\n",
       "       'Butyrate Metabolism;;SMP0000073', 'CHILD Syndrome;;SMP0000387',\n",
       "       'Caffeine Metabolism;;SMP0000028', 'Canavan Disease;;SMP0000175',\n",
       "       'Candesartan Action Pathway;;SMP0000158',\n",
       "       'Capecitabine Action Pathway;;SMP0000469',\n",
       "       'Capecitabine Metabolism Pathway;;SMP0000607',\n",
       "       'Captopril Action Pathway;;SMP0000146',\n",
       "       'Carbamazepine Metabolism Pathway;;SMP0000634',\n",
       "       'Carbamoyl Phosphate Synthetase Deficiency;;SMP0000002',\n",
       "       'Carbinoxamine H1-Antihistamine Action;;SMP0058797',\n",
       "       'Cardiolipin Biosynthesis CL(18:0/18:0/18:0/18:0);;SMP0028021',\n",
       "       'Carfentanil Action Pathway;;SMP0000414',\n",
       "       'Carnitine Palmitoyl Transferase Deficiency I;;SMP0000538',\n",
       "       'Carnitine Palmitoyl Transferase Deficiency II;;SMP0000541',\n",
       "       'Carnitine Synthesis;;SMP0000465',\n",
       "       'Carnitine-Acylcarnitine Translocase Deficiency;;SMP0000517',\n",
       "       'Carnosinuria, Carnosinemia;;SMP0000493',\n",
       "       'Carprofen Action Pathway;;SMP0000694',\n",
       "       'Carteolol Action Pathway;;SMP0000658',\n",
       "       'Carvedilol Action Pathway;;SMP0000367',\n",
       "       'Catecholamine Biosynthesis;;SMP0000012',\n",
       "       'Celecoxib Action Pathway;;SMP0000096',\n",
       "       'Celecoxib Metabolism Pathway;;SMP0000644',\n",
       "       'Cerebrotendinous Xanthomatosis (CTX);;SMP0000315',\n",
       "       'Cerivastatin Action Pathway;;SMP0000111',\n",
       "       'Cetirizine H1-Antihistamine Action;;SMP0059058',\n",
       "       'Cetuximab Action Pathway;;SMP0000474',\n",
       "       'Chloramphenicol Action Pathway;;SMP0000729',\n",
       "       'Chlorcyclizine H1-Antihistamine Action;;SMP0058931',\n",
       "       'Chloroprocaine Action Pathway;;SMP0000394',\n",
       "       'Chloropyramine H1-Antihistamine Action;;SMP0057585',\n",
       "       'Chlorothiazide Action Pathway;;SMP0000078',\n",
       "       'Chlorphenamine H1-Antihistamine Action;;SMP0056661',\n",
       "       'Chlorphenoxamine H1-Antihistamine Action;;SMP0058903',\n",
       "       'Chlorthalidone Action Pathway;;SMP0000122',\n",
       "       'Cholesteryl Ester Storage Disease;;SMP0000508',\n",
       "       'Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2);;SMP0000388',\n",
       "       'Cilazapril Action Pathway;;SMP0000147',\n",
       "       'Cilazapril Metabolism Pathway;;SMP0000592',\n",
       "       'Cilostazol Action Pathway;;SMP0000263',\n",
       "       'Cimetidine Action Pathway;;SMP0000232',\n",
       "       'Cimetidine Metabolism Pathway;;SMP0000617',\n",
       "       'Cinnarizine H1-Antihistamine Action;;SMP0059110',\n",
       "       'Citalopram Action Pathway;;SMP0000424',\n",
       "       'Citalopram Metabolism Pathway;;SMP0000627',\n",
       "       'Citric Acid Cycle;;SMP0000057',\n",
       "       'Citrullinemia Type I;;SMP0000001',\n",
       "       'Clarithromycin Action Pathway;;SMP0000248',\n",
       "       'Clemastine H1-Antihistamine Action;;SMP0058891',\n",
       "       'Clindamycin Action Pathway;;SMP0000249',\n",
       "       'Clomipramine Metabolism Pathway;;SMP0000639',\n",
       "       'Clomocycline Action Pathway;;SMP0000262',\n",
       "       'Clopidogrel Action Pathway;;SMP0000260',\n",
       "       'Clopidogrel Metabolism Pathway;;SMP0000610',\n",
       "       'Coagulation;;SMP0000586', 'Cocaine Action Pathway;;SMP0000395',\n",
       "       'Codeine Action Pathway;;SMP0000405',\n",
       "       'Codeine Metabolism Pathway;;SMP0000621',\n",
       "       'Congenital Bile Acid Synthesis Defect Type II;;SMP0000314',\n",
       "       'Congenital Bile Acid Synthesis Defect Type III;;SMP0000318',\n",
       "       'Congenital Disorder of Glycosylation CDG-IId;;SMP0000579',\n",
       "       'Congenital Erythropoietic Porphyria (CEP) or Gunther Disease;;SMP0000345',\n",
       "       'Congenital Lactic Acidosis;;SMP0000546',\n",
       "       'Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;;SMP0000371',\n",
       "       'Corticosterone Methyl Oxidase I Deficiency (CMO I);;SMP0000577',\n",
       "       'Corticosterone Methyl Oxidase II Deficiency (CMO II);;SMP0000578',\n",
       "       'Corticotropin Activation of Cortisol Production;;SMP0000310',\n",
       "       'Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency;;SMP0000504',\n",
       "       'Cyclizine H1-Antihistamine Action;;SMP0058923',\n",
       "       'Cyclophosphamide Action Pathway;;SMP0000447',\n",
       "       'Cyclophosphamide Metabolism Pathway;;SMP0000604',\n",
       "       'Cyclothiazide Action Pathway;;SMP0000103',\n",
       "       'Cyproheptadine H1-Antihistamine Action;;SMP0059694',\n",
       "       'Cystathionine beta-Synthase Deficiency;;SMP0000177',\n",
       "       'Cysteine Metabolism;;SMP0000013',\n",
       "       'Cystinosis, Ocular Nonnephropathic;;SMP0000722',\n",
       "       'Cystinuria;;SMP0000723',\n",
       "       'D-Arginine and D-Ornithine Metabolism;;SMP0000036',\n",
       "       'D-Glyceric Acidura;;SMP0000529',\n",
       "       'DOPA-Responsive Dystonia;;SMP0000486',\n",
       "       'Dasatinib Inhibition of BCR-ABL;;SMP0031696',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/16:0/16:0);;SMP0015901',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:1(9Z));;SMP0015922',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:2(9Z,12Z));;SMP0015924',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:0);;SMP0015910',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:1(9Z));;SMP0015912',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:0);;SMP0015911',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:4(5Z,8Z,11Z,14Z));;SMP0015915',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:1(9Z)/20:0);;SMP0015926',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/18:2(9Z,12Z)/18:2(9Z,12Z));;SMP0015935',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:0);;SMP0015916',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:4(5Z,8Z,11Z,14Z));;SMP0015918',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/18:1(9Z));;SMP0015983',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/18:2(9Z,12Z));;SMP0015985',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/20:1(11Z));;SMP0015984',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:0);;SMP0015971',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:1(11Z));;SMP0015972',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:4(5Z,8Z,11Z,14Z));;SMP0015973',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:1(11Z)/20:1(11Z));;SMP0015987',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/18:0);;SMP0015938',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/20:0);;SMP0015939',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:2(9Z,12Z));;SMP0015950',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:1(11Z));;SMP0015949',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z));;SMP0015951',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z));;SMP0015957',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:1(11Z));;SMP0015952',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(20:0/20:0/20:1(11Z));;SMP0015960',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:1(11Z));;SMP0015962',\n",
       "       'De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z));;SMP0015963',\n",
       "       'Delavirdine Action Pathway;;SMP0000738',\n",
       "       'Demeclocycline Action Pathway;;SMP0000290',\n",
       "       'Desipramine Action Pathway;;SMP0000423',\n",
       "       'Desipramine Metabolism Pathway;;SMP0000626',\n",
       "       'Desloratadine H1-Antihistamine Action;;SMP0060201',\n",
       "       'Desmosterolosis;;SMP0000386',\n",
       "       'Dexbrompheniramine H1-Antihistamine Action;;SMP0057580',\n",
       "       'Dexchlorpheniramine H1-Antihistamine Action;;SMP0056811',\n",
       "       'Dezocine Action Pathway;;SMP0000676',\n",
       "       'Dibucaine Action Pathway;;SMP0000396',\n",
       "       'Diclofenac Action Pathway;;SMP0000093',\n",
       "       'Dicoumarol Action Pathway;;SMP0000656',\n",
       "       'Dicumarol Action Pathway;;SMP0000270',\n",
       "       'Didanosine Action Pathway;;SMP0000739',\n",
       "       'Diflunisal Action Pathway;;SMP0000289',\n",
       "       'Dihydromorphine Action Pathway;;SMP0000689',\n",
       "       'Dihydropyrimidinase Deficiency;;SMP0000178',\n",
       "       'Dihydropyrimidine Dehydrogenase Deficiency (DHPD);;SMP0000179',\n",
       "       'Diltiazem Action Pathway;;SMP0000359',\n",
       "       'Dimethylglycine Dehydrogenase Deficiency;;SMP0000242',\n",
       "       'Dimethylglycine Dehydrogenase Deficiency;;SMP0000484',\n",
       "       'Dimethylthiambutene Action Pathway;;SMP0000680',\n",
       "       'Dimetindene H1-Antihistamine Action;;SMP0057582',\n",
       "       'Diphenhydramine H1-Antihistamine Action;;SMP0058785',\n",
       "       'Diphenoxylate Action Pathway;;SMP0000675',\n",
       "       'Diphenylpyraline H1-Antihistamine Action;;SMP0058908',\n",
       "       'Dipyridamole (Antiplatelet) Action Pathway;;SMP0000264',\n",
       "       'Disopyramide Action Pathway;;SMP0000325',\n",
       "       'Disulfiram Action Pathway;;SMP0000429',\n",
       "       'Dobutamine Action Pathway;;SMP0000662',\n",
       "       'Docetaxel Action Pathway;;SMP0000435',\n",
       "       'Dopamine Activation of Neurological Reward System;;SMP0000308',\n",
       "       'Dopamine beta-Hydroxylase Deficiency;;SMP0000498',\n",
       "       'Doxepin H1-Antihistamine Action;;SMP0059872',\n",
       "       'Doxepin Metabolism Pathway;;SMP0000641',\n",
       "       'Doxorubicin Metabolism Pathway;;SMP0000650',\n",
       "       'Doxycycline Action Pathway;;SMP0000291',\n",
       "       'Doxylamine H1-Antihistamine Action;;SMP0058803',\n",
       "       'Ebastine H1-Antihistamine Action;;SMP0060204',\n",
       "       'Efavirenz Action Pathway;;SMP0000740',\n",
       "       'Emedastine H1-Antihistamine Action;;SMP0061040',\n",
       "       'Emtricitabine Action Pathway;;SMP0000741',\n",
       "       'Enalapril Action Pathway;;SMP0000148',\n",
       "       'Enalapril Metabolism Pathway;;SMP0000593',\n",
       "       'Enoxaparin Action Pathway;;SMP0000272',\n",
       "       'Epinastine H1-Antihistamine Action;;SMP0061191',\n",
       "       'Epinephrine Action Pathway;;SMP0000661',\n",
       "       'Eplerenone Action Pathway;;SMP0000135',\n",
       "       'Eprosartan Action Pathway;;SMP0000159',\n",
       "       'Eptifibatide Action Pathway;;SMP0000266',\n",
       "       'Erlotinib Action Pathway;;SMP0000472',\n",
       "       'Erythromycin Action Pathway;;SMP0000250',\n",
       "       'Escitalopram Action Pathway;;SMP0000425',\n",
       "       'Esmolol Action Pathway;;SMP0000301',\n",
       "       'Esomeprazole Action Pathway;;SMP0000225',\n",
       "       'Esomeprazole Metabolism Pathway;;SMP0000612',\n",
       "       'Estrone Metabolism;;SMP0030880',\n",
       "       'Ethacrynic Acid Action Pathway;;SMP0000097',\n",
       "       'Ethanol Degradation;;SMP0000449',\n",
       "       'Ethylmalonic Encephalopathy;;SMP0000181',\n",
       "       'Ethylmorphine Action Pathway;;SMP0000681',\n",
       "       'Etodolac Action Pathway;;SMP0000084',\n",
       "       'Etoposide Action Pathway;;SMP0000442',\n",
       "       'Etoposide Metabolism Pathway;;SMP0000601',\n",
       "       'Etoricoxib Action Pathway;;SMP0000695',\n",
       "       'Excitatory Neural Signalling Through 5-HTR 4 and Serotonin;;SMP0000309',\n",
       "       'Excitatory Neural Signalling Through 5-HTR 6 and Serotonin;;SMP0000312',\n",
       "       'Excitatory Neural Signalling Through 5-HTR 7 and Serotonin;;SMP0000311',\n",
       "       'Fabry Disease;;SMP0000525',\n",
       "       'Familial Hypercholanemia (FHCA);;SMP0000317',\n",
       "       'Famotidine Action Pathway;;SMP0000231',\n",
       "       'Fanconi-Bickel Syndrome;;SMP0000572',\n",
       "       'Fatty Acid Biosynthesis;;SMP0000456',\n",
       "       'Fatty Acid Metabolism;;SMP0000051',\n",
       "       'Fc Epsilon Receptor I Signaling in Mast Cells;;SMP0000358',\n",
       "       'Felbamate Metabolism Pathway;;SMP0000633',\n",
       "       'Felodipine Action Pathway;;SMP0000377',\n",
       "       'Felodipine Metabolism Pathway;;SMP0000619',\n",
       "       'Fenoprofen Action Pathway;;SMP0000696',\n",
       "       'Fentanyl Action Pathway;;SMP0000415',\n",
       "       'Fexofenadine H1-Antihistamine Action;;SMP0060218',\n",
       "       'Flecainide Action Pathway;;SMP0000331',\n",
       "       'Flunarizine H1-Antihistamine Action;;SMP0061047',\n",
       "       'Fluorouracil Action Pathway;;SMP0000470',\n",
       "       'Fluorouracil Metabolism Pathway;;SMP0000608',\n",
       "       'Fluoxetine Action Pathway;;SMP0000426',\n",
       "       'Fluoxetine Metabolism Pathway;;SMP0000646',\n",
       "       'Flurbiprofen Action Pathway;;SMP0000697',\n",
       "       'Fluvastatin Action Pathway;;SMP0000119',\n",
       "       'Folate Malabsorption, Hereditary;;SMP0000724',\n",
       "       'Folate Metabolism;;SMP0000053',\n",
       "       'Fondaparinux Action Pathway;;SMP0000273',\n",
       "       'Forasartan Action Pathway;;SMP0000160',\n",
       "       'Fosinopril Action Pathway;;SMP0000149',\n",
       "       'Fosinopril Metabolism Pathway;;SMP0000594',\n",
       "       'Fosphenytoin (Antiarrhythmic) Action Pathway;;SMP0000326',\n",
       "       'Fosphenytoin (Antiarrhythmic) Metabolism Pathway;;SMP0000618',\n",
       "       'Fructose Intolerance, Hereditary;;SMP0000725',\n",
       "       'Fructose and Mannose Degradation;;SMP0000064',\n",
       "       'Fructose-1,6-diphosphatase Deficiency;;SMP0000562',\n",
       "       'Fructosuria;;SMP0000561', 'Fumarase Deficiency;;SMP0000547',\n",
       "       'Furosemide Action Pathway;;SMP0000115',\n",
       "       'G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease;;SMP0000534',\n",
       "       'GABA-Transaminase Deficiency;;SMP0000351',\n",
       "       'GLUT-1 Deficiency Syndrome;;SMP0000580',\n",
       "       'Galactose Metabolism;;SMP0000043',\n",
       "       'Galactosemia II (GALK);;SMP0000495',\n",
       "       'Galactosemia III;;SMP0000496', 'Galactosemia;;SMP0000182',\n",
       "       'Gastric Acid Production;;SMP0000589',\n",
       "       'Gaucher Disease;;SMP0000349',\n",
       "       'Gefitinib Action Pathway;;SMP0000473',\n",
       "       'Gemcitabine Action Pathway;;SMP0000446',\n",
       "       'Gemcitabine Metabolism Pathway;;SMP0000603',\n",
       "       'Gentamicin Action Pathway;;SMP0000254',\n",
       "       'Glibenclamide Action Pathway;;SMP0000460',\n",
       "       'Gliclazide Action Pathway;;SMP0000461',\n",
       "       'Globoid Cell Leukodystrophy;;SMP0000348',\n",
       "       'Gluconeogenesis;;SMP0000128',\n",
       "       'Glucose Transporter Defect (SGLT2);;SMP0000184',\n",
       "       'Glucose Transporter Defect (SGLT2);;SMP0000245',\n",
       "       'Glucose-6-phosphate Dehydrogenase Deficiency;;SMP0000518',\n",
       "       'Glucose-Alanine Cycle;;SMP0000127',\n",
       "       'Glutamate Metabolism;;SMP0000072',\n",
       "       'Glutaminolysis and Cancer;;SMP0002298',\n",
       "       'Glutaric Aciduria Type I;;SMP0000185',\n",
       "       'Glutaric Aciduria Type I;;SMP0000186',\n",
       "       'Glutathione Metabolism;;SMP0000015',\n",
       "       'Glutathione Synthetase Deficiency;;SMP0000337',\n",
       "       'Glycerol Kinase Deficiency;;SMP0000187',\n",
       "       'Glycerol Phosphate Shuttle;;SMP0000124',\n",
       "       'Glycerolipid Metabolism;;SMP0000039',\n",
       "       'Glycine N-Methyltransferase Deficiency;;SMP0000222',\n",
       "       'Glycine and Serine Metabolism;;SMP0000004',\n",
       "       'Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease;;SMP0000374',\n",
       "       'Glycogen Synthetase Deficiency;;SMP0000552',\n",
       "       'Glycogenosis, Type IA.  Von Gierke Disease;;SMP0000581',\n",
       "       'Glycogenosis, Type IB;;SMP0000573',\n",
       "       'Glycogenosis, Type IC;;SMP0000574',\n",
       "       'Glycogenosis, Type III.  Cori Disease, Debrancher Glycogenosis;;SMP0000553',\n",
       "       'Glycogenosis, Type IV.  Amylopectinosis, Anderson Disease;;SMP0000554',\n",
       "       'Glycogenosis, Type VI.  Hers Disease;;SMP0000555',\n",
       "       'Glycogenosis, Type VII.  Tarui Disease;;SMP0000531',\n",
       "       'Glycolysis;;SMP0000040',\n",
       "       'Gout or Kelley-Seegmiller Syndrome;;SMP0000365',\n",
       "       'Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);;SMP0000188',\n",
       "       'Hartnup Disorder;;SMP0000189', 'Hawkinsinuria;;SMP0000190',\n",
       "       'Heparin Action Pathway;;SMP0000274',\n",
       "       'Hereditary Coproporphyria (HCP);;SMP0000342',\n",
       "       'Heroin Action Pathway;;SMP0000407',\n",
       "       'Heroin Metabolism Pathway;;SMP0000623',\n",
       "       'Histapyrrodine H1-Antihistamine Action;;SMP0058732',\n",
       "       'Histidine Metabolism;;SMP0000044', 'Histidinemia;;SMP0000191',\n",
       "       'Homocarnosinosis;;SMP0000385',\n",
       "       'Homocysteine Degradation;;SMP0000455',\n",
       "       'Homocystinuria, Cystathionine beta-Synthase Deficiency;;SMP0000515',\n",
       "       'Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type;;SMP0000570',\n",
       "       'Hydrochlorothiazide Action Pathway;;SMP0000100',\n",
       "       'Hydrocodone Action Pathway;;SMP0000411',\n",
       "       'Hydroflumethiazide Action Pathway;;SMP0000108',\n",
       "       'Hydromorphone Action Pathway;;SMP0000410',\n",
       "       'Hydroxyethylpromethazine H1-Antihistamine Action;;SMP0059710',\n",
       "       'Hydroxyzine H1-Antihistamine Action;;SMP0058936',\n",
       "       'Hyper-IgD Syndrome;;SMP0000509',\n",
       "       'Hypercholesterolemia;;SMP0000209',\n",
       "       'Hyperglycinemia, Non-Ketotic;;SMP0000485',\n",
       "       'Hyperinsulinism-Hyperammonemia Syndrome;;SMP0000339',\n",
       "       'Hyperlysinemia I, Familial;;SMP0000527',\n",
       "       'Hyperlysinemia II or Saccharopinuria;;SMP0000528',\n",
       "       'Hypermethioninemia;;SMP0000341',\n",
       "       'Hyperornithinemia with Gyrate Atrophy (HOGA);;SMP0000505',\n",
       "       'Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome];;SMP0000506',\n",
       "       'Hyperphenylalaniemia Due to Guanosine Triphosphate Cyclohydrolase Deficiency;;SMP0000487',\n",
       "       'Hyperphenylalaninemia Due to 6-Pyruvoyltetrahydropterin Synthase Deficiency (ptps);;SMP0000488',\n",
       "       'Hyperphenylalaninemia Due to DHPR-Deficiency;;SMP0000489',\n",
       "       'Hyperprolinemia Type I;;SMP0000361',\n",
       "       'Hyperprolinemia Type II;;SMP0000360',\n",
       "       'Hypoacetylaspartia;;SMP0000192', 'Hypophosphatasia;;SMP0000503',\n",
       "       'Ibandronate Action Pathway;;SMP0000079',\n",
       "       'Ibuprofen Action Pathway;;SMP0000086',\n",
       "       'Ibuprofen Metabolism Pathway;;SMP0000590',\n",
       "       'Ibutilide Action Pathway;;SMP0000332',\n",
       "       'Ifosfamide Action Pathway;;SMP0000448',\n",
       "       'Ifosfamide Metabolism Pathway;;SMP0000605',\n",
       "       'Imatinib Inhibition of BCR-ABL;;SMP0031694',\n",
       "       'Iminoglycinuria;;SMP0000193',\n",
       "       'Imipramine Action Pathway;;SMP0000422',\n",
       "       'Imipramine Metabolism Pathway;;SMP0000625',\n",
       "       'Indapamide Action Pathway;;SMP0000110',\n",
       "       'Indomethacin Action Pathway;;SMP0000104',\n",
       "       'Inositol Metabolism;;SMP0000011',\n",
       "       'Inositol Phosphate Metabolism;;SMP0000462',\n",
       "       'Intracellular Signalling Through Adenosine Receptor A2a and Adenosine;;SMP0000320',\n",
       "       'Intracellular Signalling Through Adenosine Receptor A2b and Adenosine;;SMP0000321',\n",
       "       'Intracellular Signalling Through FSH Receptor and Follicle Stimulating Hormone;;SMP0000333',\n",
       "       'Intracellular Signalling Through Histamine H2 Receptor and Histamine;;SMP0000335',\n",
       "       'Intracellular Signalling Through PGD2 receptor and Prostaglandin D2;;SMP0000343',\n",
       "       'Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin;;SMP0000354',\n",
       "       'Irbesartan Action Pathway;;SMP0000161',\n",
       "       'Irinotecan Action Pathway;;SMP0000433',\n",
       "       'Irinotecan Metabolism Pathway;;SMP0000600',\n",
       "       'Isobutyryl-CoA Dehydrogenase Deficiency;;SMP0000523',\n",
       "       'Isoprenaline Action Pathway;;SMP0000663',\n",
       "       'Isothipendyl H1-Antihistamine Action;;SMP0059716',\n",
       "       'Isovaleric Acidemia;;SMP0000524',\n",
       "       'Isovaleric Aciduria;;SMP0000238',\n",
       "       'Isradipine Action Pathway;;SMP0000378',\n",
       "       'Josamycin Action Pathway;;SMP0000731',\n",
       "       'Joubert Syndrome;;SMP0000582',\n",
       "       'Kanamycin Action Pathway;;SMP0000255',\n",
       "       'Ketobemidone  Action Pathway;;SMP0000690',\n",
       "       'Ketone Body Metabolism;;SMP0000071',\n",
       "       'Ketoprofen Action Pathway;;SMP0000085',\n",
       "       'Ketorolac Action Pathway;;SMP0000098',\n",
       "       'Ketotifen H1-Antihistamine Action;;SMP0059868',\n",
       "       'Krabbe Disease;;SMP0000526',\n",
       "       'L-Arginine:Glycine Amidinotransferase Deficiency;;SMP0000507',\n",
       "       'Labetalol Action Pathway;;SMP0000368',\n",
       "       'Lactic Acidemia;;SMP0000313', 'Lactose Degradation;;SMP0000457',\n",
       "       'Lactose Intolerance;;SMP0000458', 'Lactose Synthesis;;SMP0000444',\n",
       "       'Lafutidine H2-Antihistamine Action;;SMP0051038',\n",
       "       'Lamivudine  Action Pathway;;SMP0000742',\n",
       "       'Lamivudine Metabolism Pathway;;SMP0000649',\n",
       "       'Lansoprazole Action Pathway;;SMP0000227',\n",
       "       'Lansoprazole Metabolism Pathway;;SMP0000614',\n",
       "       'Latrepirdine H1-Antihistamine Action;;SMP0062623',\n",
       "       'Leigh Syndrome;;SMP0000196',\n",
       "       'Lepirudin Action Pathway;;SMP0000278',\n",
       "       'Lesch-Nyhan Syndrome (LNS);;SMP0000364',\n",
       "       'Leukotriene C4 Synthesis Deficiency;;SMP0000353',\n",
       "       'Levallorphan Action Pathway;;SMP0000683',\n",
       "       'Levobunolol Action Pathway;;SMP0000666',\n",
       "       'Levobupivacaine Action Pathway;;SMP0000397',\n",
       "       'Levocabastine H1-Antihistamine Action;;SMP0060224',\n",
       "       'Levocetirizine H1-Antihistamine Action;;SMP0059114',\n",
       "       'Levomethadyl Acetate Action Action Pathway;;SMP0000677',\n",
       "       'Levomethadyl Acetate Metabolism Pathway;;SMP0000638',\n",
       "       'Levorphanol Action Pathway;;SMP0000673',\n",
       "       'Lidocaine (Antiarrhythmic) Action Pathway;;SMP0000328',\n",
       "       'Lidocaine (Local Anaesthetic) Action Pathway;;SMP0000398',\n",
       "       'Lidocaine (Local Anaesthetic) Metabolism Pathway;;SMP0000620',\n",
       "       'Lincomycin Action Pathway;;SMP0000728',\n",
       "       'Lisinopril Action Pathway;;SMP0000150',\n",
       "       'Long Chain Acyl-CoA Dehydrogenase Deficiency (LCAD);;SMP0000539',\n",
       "       'Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD);;SMP0000544',\n",
       "       'Loratadine H1-Antihistamine Action;;SMP0060195',\n",
       "       'Lornoxicam Action Pathway;;SMP0000700',\n",
       "       'Losartan Action Pathway;;SMP0000162',\n",
       "       'Lovastatin Action Pathway;;SMP0000099',\n",
       "       'Lumiracoxib Action Pathway;;SMP0000699',\n",
       "       'Lymecycline Action Pathway;;SMP0000295',\n",
       "       'Lysine Degradation;;SMP0000037',\n",
       "       'Lysinuric Protein Intolerance;;SMP0000197',\n",
       "       'Lysophosphatidic Acid LPA1 Signalling;;SMP0063746',\n",
       "       'Lysophosphatidic Acid LPA2 Signalling;;SMP0063753',\n",
       "       'Lysophosphatidic Acid LPA4 Signalling;;SMP0063756',\n",
       "       'Lysophosphatidic Acid LPA5 Signalling;;SMP0063757',\n",
       "       'Lysophosphatidic Acid LPA6 Signalling;;SMP0063759',\n",
       "       'Lysosomal Acid Lipase Deficiency (Wolman Disease);;SMP0000319',\n",
       "       'MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);;SMP0000202',\n",
       "       'Magnesium Salicylate Action Pathway;;SMP0000698',\n",
       "       'Malate-Aspartate Shuttle;;SMP0000129',\n",
       "       'Malonic Aciduria;;SMP0000198',\n",
       "       'Malonyl-CoA Decarboxylase Deficiency;;SMP0000502',\n",
       "       'Maple Syrup Urine Disease;;SMP0000199',\n",
       "       'Mebhydrolin H1-Antihistamine Action;;SMP0061052',\n",
       "       'Meclizine H1-Antihistamine Action;;SMP0058956',\n",
       "       'Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD);;SMP0000542',\n",
       "       'Mefenamic Acid Action Pathway;;SMP0000109',\n",
       "       'Meloxicam Action Pathway;;SMP0000106',\n",
       "       'Mepivacaine Action Pathway;;SMP0000399',\n",
       "       'Mepyramine H1-Antihistamine Action;;SMP0057583',\n",
       "       'Mequitazine H1-Antihistamine Action;;SMP0059720',\n",
       "       'Mercaptopurine Action Pathway;;SMP0000428',\n",
       "       'Mercaptopurine Metabolism Pathway;;SMP0000609',\n",
       "       'Metachromatic Leukodystrophy (MLD);;SMP0000347',\n",
       "       'Methacycline Action Pathway;;SMP0000727',\n",
       "       'Methadone Action Pathway;;SMP0000408',\n",
       "       'Methadone Metabolism Pathway;;SMP0000624',\n",
       "       'Methadyl Acetate Action Pathway;;SMP0000678',\n",
       "       'Methapyrilene H1-Antihistamine Action;;SMP0058741',\n",
       "       'Methdilazine H1-Antihistamine Action;;SMP0059730',\n",
       "       'Methionine Adenosyltransferase Deficiency;;SMP0000221',\n",
       "       'Methionine Metabolism;;SMP0000033',\n",
       "       'Methotrexate Action Pathway;;SMP0000432',\n",
       "       'Methyclothiazide Action Pathway;;SMP0000081',\n",
       "       'Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);;SMP0000340',\n",
       "       'Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);;SMP0000543',\n",
       "       'Methylhistidine Metabolism;;SMP0000715',\n",
       "       'Methylmalonate Semialdehyde Dehydrogenase Deficiency;;SMP0000384',\n",
       "       'Methylmalonic Aciduria Due to Cobalamin-Related Disorders;;SMP0000201',\n",
       "       'Methylmalonic Aciduria;;SMP0000200',\n",
       "       'Metiamide Action Pathway;;SMP0000735',\n",
       "       'Metipranolol Action Pathway;;SMP0000667',\n",
       "       'Metolazone Action Pathway;;SMP0000105',\n",
       "       'Metoprolol Action Pathway;;SMP0000302',\n",
       "       'Mevalonic Aciduria;;SMP0000510',\n",
       "       'Mexiletine Action Pathway;;SMP0000329',\n",
       "       'Minocycline Action Pathway;;SMP0000292',\n",
       "       'Mirtazapine H1-Antihistamine Action;;SMP0062885',\n",
       "       'Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids;;SMP0000482',\n",
       "       'Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty Acids;;SMP0000481',\n",
       "       'Mitochondrial Complex II Deficiency;;SMP0000548',\n",
       "       'Mitochondrial DNA Depletion Syndrome;;SMP0000536',\n",
       "       'Mitochondrial Electron Transport Chain;;SMP0000355',\n",
       "       'Mizolastine H1-Antihistamine Action;;SMP0060230',\n",
       "       'Moexipril Action Pathway;;SMP0000151',\n",
       "       'Moexipril Metabolism Pathway;;SMP0000595',\n",
       "       'Molybdenum Cofactor Deficiency;;SMP0000203',\n",
       "       'Monoamine Oxidase-A Deficiency (MAO-A);;SMP0000533',\n",
       "       'Morphine Action Pathway;;SMP0000406',\n",
       "       'Morphine Metabolism Pathway;;SMP0000622',\n",
       "       'Mucopolysaccharidosis VI.  Sly Syndrome;;SMP0000556',\n",
       "       'Multiple Carboxylase Deficiency, Neonatal or Early Onset Form;;SMP0000564',\n",
       "       'Mycophenolic Acid Metabolism Pathway;;SMP0000652',\n",
       "       'Myoadenylate Deaminase Deficiency;;SMP0000537',\n",
       "       'Nabumetone Action Pathway;;SMP0000114',\n",
       "       'Nadolol Action Pathway;;SMP0000303',\n",
       "       'Nalbuphine Action Pathway;;SMP0000691',\n",
       "       'Naloxone Action Pathway;;SMP0000688',\n",
       "       'Naltrexone Action Pathway;;SMP0000687',\n",
       "       'Naproxen Action Pathway;;SMP0000120',\n",
       "       'Nateglinide Action Pathway;;SMP0000453',\n",
       "       'Nebivolol Action Pathway;;SMP0000366',\n",
       "       'Neomycin Action Pathway;;SMP0000256',\n",
       "       'Nepafenac Action Pathway;;SMP0000702',\n",
       "       'Netilmicin Action Pathway;;SMP0000257',\n",
       "       'Nevirapine  Action Pathway;;SMP0000743',\n",
       "       'Nevirapine Metabolism Pathway;;SMP0000642',\n",
       "       'Nicotinate and Nicotinamide Metabolism;;SMP0000048',\n",
       "       'Nicotine Action Pathway;;SMP0000431',\n",
       "       'Nicotine Metabolism Pathway;;SMP0000628',\n",
       "       'Nifedipine Action Pathway;;SMP0000379',\n",
       "       'Nilotinib Inhibition of BCR-ABL;;SMP0031697',\n",
       "       'Nimodipine Action Pathway;;SMP0000380',\n",
       "       'Nisoldipine Action Pathway;;SMP0000381',\n",
       "       'Nitrendipine Action Pathway;;SMP0000382',\n",
       "       'Nitric Oxide Signaling Pathway;;SMP0063777',\n",
       "       'Nizatidine Action Pathway;;SMP0000233',\n",
       "       'Non-Ketotic Hyperglycinemia;;SMP0000223',\n",
       "       'Nucleotide Sugars Metabolism;;SMP0000010',\n",
       "       'Olmesartan Action Pathway;;SMP0000163',\n",
       "       'Olopatadine H1-Antihistamine Action;;SMP0060740',\n",
       "       'Omeprazole Action Pathway;;SMP0000226',\n",
       "       'Omeprazole Metabolism Pathway;;SMP0000613',\n",
       "       'Ornithine Aminotransferase Deficiency (OAT Deficiency);;SMP0000363',\n",
       "       'Ornithine Transcarbamylase Deficiency (OTC Deficiency);;SMP0000205',\n",
       "       'Orphenadrine H1-Antihistamine Action;;SMP0058808',\n",
       "       'Oxaprozin Action Pathway;;SMP0000113',\n",
       "       'Oxatomide H1-Antihistamine Action;;SMP0059044',\n",
       "       'Oxidation of Branched-Chain Fatty Acids;;SMP0000030',\n",
       "       'Oxomemazine H1-Antihistamine Action;;SMP0059738',\n",
       "       'Oxprenolol Action Pathway;;SMP0000304',\n",
       "       'Oxybuprocaine Action Pathway;;SMP0000400',\n",
       "       'Oxycodone Action Pathway;;SMP0000409',\n",
       "       'Oxymorphone Action Pathway;;SMP0000412',\n",
       "       'Oxytetracycline Action Pathway;;SMP0000293',\n",
       "       'Paclitaxel Action Pathway;;SMP0000434',\n",
       "       'Pamidronate Action Pathway;;SMP0000117',\n",
       "       'Panitumumab Action Pathway;;SMP0000475',\n",
       "       'Pantoprazole Action Pathway;;SMP0000228',\n",
       "       'Pantoprazole Metabolism Pathway;;SMP0000615',\n",
       "       'Pantothenate and CoA Biosynthesis;;SMP0000027',\n",
       "       'Paromomycin Action Pathway;;SMP0000714',\n",
       "       'Penbutolol Action Pathway;;SMP0000305',\n",
       "       'Pentazocine Action Pathway;;SMP0000686',\n",
       "       'Pentose Phosphate Pathway;;SMP0000031',\n",
       "       'Perindopril Action Pathway;;SMP0000152',\n",
       "       'Phenindamine H1-Antihistamine Action;;SMP0061190',\n",
       "       'Phenindione Action Pathway;;SMP0000655',\n",
       "       'Pheniramine H1-Antihistamine Action;;SMP0056662',\n",
       "       'Phenprocoumon Action Pathway;;SMP0000271',\n",
       "       'Phenylacetate Metabolism;;SMP0000126',\n",
       "       'Phenylalanine and Tyrosine Metabolism;;SMP0000008',\n",
       "       'Phenylbutazone Action Pathway;;SMP0000701',\n",
       "       'Phenylketonuria;;SMP0000206',\n",
       "       'Phenyltoloxamine H1-Antihistamine Action;;SMP0058916',\n",
       "       'Phenytoin (Antiarrhythmic) Action Pathway;;SMP0000327',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/14:0);;SMP0014216',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/15:0);;SMP0014218',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/16:1(9Z));;SMP0014220',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/18:2(9Z,12Z));;SMP0014224',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/20:0);;SMP0014228',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/20:1(11Z));;SMP0014229',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/20:2(11Z,14Z));;SMP0014230',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z));;SMP0014233',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z));;SMP0014235',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z));;SMP0014240',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));;SMP0014242',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/14:0);;SMP0014245',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:0);;SMP0014248',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:1(9Z));;SMP0014249',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:3(9Z,12Z,15Z));;SMP0014255',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:2(13Z,16Z));;SMP0014267',\n",
       "       'Phosphatidylcholine Biosynthesis PC(14:1(9Z)/24:0);;SMP0014272',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/14:0);;SMP0014274',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/16:0);;SMP0014277',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/16:1(9Z));;SMP0014278',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/18:0);;SMP0014279',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/20:1(11Z));;SMP0014287',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/20:3(8Z,11Z,14Z));;SMP0014290',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/20:4(5Z,8Z,11Z,14Z));;SMP0014291',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/22:0);;SMP0014294',\n",
       "       'Phosphatidylcholine Biosynthesis PC(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));;SMP0014300',\n",
       "       'Phosphatidylcholine Biosynthesis PC(16:0/14:0);;SMP0014303',\n",
       "       'Phosphatidylcholine Biosynthesis PC(16:0/14:1(9Z));;SMP0014304',\n",
       "       'Phosphatidylcholine Biosynthesis PC(16:0/16:0);;SMP0014306',\n",
       "       'Phosphatidylcholine Biosynthesis PC(16:0/18:1(9Z));;SMP0014310',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/14:0);;SMP0015056',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z));;SMP0015057',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/15:0);;SMP0015058',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z));;SMP0015062',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z));;SMP0015063',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z));;SMP0015074',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z));;SMP0015077',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z));;SMP0015078',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z));;SMP0015084',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z));;SMP0015086',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z));;SMP0015092',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z));;SMP0015094',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z));;SMP0015095',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0);;SMP0015097',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z));;SMP0015101',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z));;SMP0015103',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z));;SMP0015109',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0);;SMP0015112',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/14:0);;SMP0015114',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/15:0);;SMP0015116',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/16:0);;SMP0015117',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/18:0);;SMP0015119',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z));;SMP0015120',\n",
       "       'Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z));;SMP0015121',\n",
       "       'Phosphatidylinositol Phosphate Metabolism;;SMP0000463',\n",
       "       'Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1);;SMP0000560',\n",
       "       'Phospholipid Biosynthesis;;SMP0000025',\n",
       "       'Phytanic Acid Peroxisomal Oxidation;;SMP0000450',\n",
       "       'Pimethixene H1-Antihistamine Action;;SMP0062886',\n",
       "       'Pindolol Action Pathway;;SMP0000306',\n",
       "       'Pirenzepine Action Pathway;;SMP0000246',\n",
       "       'Piroxicam Action Pathway;;SMP0000077',\n",
       "       'Plasmalogen Synthesis;;SMP0000479',\n",
       "       'Polythiazide Action Pathway;;SMP0000080',\n",
       "       'Ponatinib Inhibition of BCR-ABL;;SMP0031700',\n",
       "       'Porphyria Variegata (PV);;SMP0000346',\n",
       "       'Porphyrin Metabolism;;SMP0000024',\n",
       "       'Practolol Action Pathway;;SMP0000669',\n",
       "       'Pravastatin Action Pathway;;SMP0000089',\n",
       "       'Prednisolone Action Pathway;;SMP0000441',\n",
       "       'Prednisolone Metabolism Pathway;;SMP0000632',\n",
       "       'Prednisone Action Pathway;;SMP0000440',\n",
       "       'Prednisone Metabolism Pathway;;SMP0000631',\n",
       "       'Prilocaine Action Pathway;;SMP0000401',\n",
       "       'Primary Hyperoxaluria II, PH2;;SMP0000558',\n",
       "       'Primary Hyperoxaluria Type I;;SMP0000352',\n",
       "       'Procainamide (Antiarrhythmic) Action Pathway;;SMP0000324',\n",
       "       'Procaine Action Pathway;;SMP0000402',\n",
       "       'Prolidase Deficiency (PD);;SMP0000207',\n",
       "       'Prolinemia Type II;;SMP0000208',\n",
       "       'Promethazine H1-Antihistamine Action;;SMP0059211',\n",
       "       'Propanoate Metabolism;;SMP0000016',\n",
       "       'Proparacaine Action Pathway;;SMP0000403',\n",
       "       'Propiomazine H1-Antihistamine Action;;SMP0062625',\n",
       "       'Propionic Acidemia;;SMP0000236',\n",
       "       'Propoxyphene Action Pathway;;SMP0000672',\n",
       "       'Propranolol Action Pathway;;SMP0000307',\n",
       "       'Pterine Biosynthesis;;SMP0000005',\n",
       "       'Purine Metabolism;;SMP0000050',\n",
       "       'Purine Nucleoside Phosphorylase Deficiency;;SMP0000210',\n",
       "       'Pyridoxine Dependency with Seizures;;SMP0000571',\n",
       "       'Pyrimidine Metabolism;;SMP0000046',\n",
       "       'Pyruvaldehyde Degradation;;SMP0000459',\n",
       "       'Pyruvate Carboxylase Deficiency;;SMP0000350',\n",
       "       'Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency);;SMP0000334',\n",
       "       'Pyruvate Dehydrogenase Complex Deficiency;;SMP0000212',\n",
       "       'Pyruvate Dehydrogenase Deficiency (E2);;SMP0000551',\n",
       "       'Pyruvate Dehydrogenase Deficiency (E3);;SMP0000550',\n",
       "       'Pyruvate Kinase Deficiency;;SMP0000559',\n",
       "       'Pyruvate Metabolism;;SMP0000060',\n",
       "       'Quetiapine H1-Antihistamine Action;;SMP0062884',\n",
       "       'Quinapril Action Pathway;;SMP0000153',\n",
       "       'Quinapril Metabolism Pathway;;SMP0000596',\n",
       "       'Quinethazone Action Pathway;;SMP0000091',\n",
       "       'Quinidine Action Pathway;;SMP0000323',\n",
       "       'Rabeprazole Action Pathway;;SMP0000229',\n",
       "       'Rabeprazole Metabolism Pathway;;SMP0000616',\n",
       "       'Ramipril Action Pathway;;SMP0000154',\n",
       "       'Ramipril Metabolism Pathway;;SMP0000597',\n",
       "       'Ranitidine Action Pathway;;SMP0000230',\n",
       "       'Refsum Disease;;SMP0000451',\n",
       "       'Remifentanil Action Pathway;;SMP0000416',\n",
       "       'Repaglinide Action Pathway;;SMP0000454',\n",
       "       'Rescinnamine Action Pathway;;SMP0000155',\n",
       "       'Reteplase Action Pathway;;SMP0000285',\n",
       "       'Retinol Metabolism;;SMP0000074',\n",
       "       'Riboflavin Metabolism;;SMP0000070',\n",
       "       'Ribose-5-phosphate Isomerase Deficiency;;SMP0000519',\n",
       "       'Risedronate Action Pathway;;SMP0000112',\n",
       "       'Rofecoxib Action Pathway;;SMP0000087',\n",
       "       'Rolitetracycline Action Pathway;;SMP0000726',\n",
       "       'Ropivacaine Action Pathway;;SMP0000404',\n",
       "       'Rosiglitazone Metabolism Pathway;;SMP0000653',\n",
       "       'Rosuvastatin Action Pathway;;SMP0000092',\n",
       "       'Roxatidine Acetate Action Pathway;;SMP0000734',\n",
       "       'Roxithromycin Action Pathway;;SMP0000251',\n",
       "       'Rupatadine H1-Antihistamine Action;;SMP0060235',\n",
       "       'S-Adenosylhomocysteine (SAH) Hydrolase Deficiency;;SMP0000214',\n",
       "       'Saccharopinuria/Hyperlysinemia II;;SMP0000239',\n",
       "       'Salicylate-Sodium Action Pathway;;SMP0000708',\n",
       "       'Salicylic Acid Action Pathway;;SMP0000709',\n",
       "       'Salla Disease/Infantile Sialic Acid Storage Disease;;SMP0000240',\n",
       "       'Salsalate Action Pathway;;SMP0000707',\n",
       "       'Sarcosine Oncometabolite Pathway;;SMP0002313',\n",
       "       'Sarcosinemia;;SMP0000244', 'Segawa Syndrome;;SMP0000490',\n",
       "       'Selenoamino Acid Metabolism;;SMP0000029',\n",
       "       'Sepiapterin Reductase Deficiency;;SMP0000491',\n",
       "       'Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency);;SMP0000235',\n",
       "       'Sialuria or French Type Sialuria;;SMP0000216',\n",
       "       'Sialuria or French Type Sialuria;;SMP0000217',\n",
       "       'Simvastatin Action Pathway;;SMP0000082',\n",
       "       'Smith-Lemli-Opitz Syndrome (SLOS);;SMP0000389',\n",
       "       'Sorafenib Metabolism Pathway;;SMP0000648',\n",
       "       'Sotalol Action Pathway;;SMP0000660',\n",
       "       'Spectinomycin Action Pathway;;SMP0000258',\n",
       "       'Spermidine and Spermine Biosynthesis;;SMP0000445',\n",
       "       'Sphingolipid Metabolism;;SMP0000034',\n",
       "       'Spirapril Action Pathway;;SMP0000156',\n",
       "       'Spirapril Metabolism Pathway;;SMP0000598',\n",
       "       'Spironolactone Action Pathway;;SMP0000134',\n",
       "       'Starch and Sucrose Metabolism;;SMP0000058',\n",
       "       'Stavudine Action Pathway;;SMP0000745',\n",
       "       'Steroid Biosynthesis;;SMP0000023', 'Steroidogenesis;;SMP0000130',\n",
       "       'Streptokinase Action Pathway;;SMP0000282',\n",
       "       'Streptomycin Action Pathway;;SMP0000259',\n",
       "       'Succinic Semialdehyde Dehydrogenase Deficiency;;SMP0000567',\n",
       "       'Sucrase-Isomaltase Deficiency;;SMP0000557',\n",
       "       'Sufentanil Action Pathway;;SMP0000417',\n",
       "       'Sulfate/Sulfite Metabolism;;SMP0000041',\n",
       "       'Sulfite Oxidase Deficiency;;SMP0000532',\n",
       "       'Sulindac Action Pathway;;SMP0000094',\n",
       "       'Suprofen Action Pathway;;SMP0000101',\n",
       "       'Talastine H1-Antihistamine Action;;SMP0057586',\n",
       "       'Tamoxifen Action Pathway;;SMP0000471',\n",
       "       'Tamoxifen Metabolism Pathway;;SMP0000606',\n",
       "       'Taurine and Hypotaurine Metabolism;;SMP0000021',\n",
       "       'Tay-Sachs Disease;;SMP0000390',\n",
       "       'Telithromycin Action Pathway;;SMP0000252',\n",
       "       'Telmisartan Action Pathway;;SMP0000164',\n",
       "       'Temocapril Action Pathway;;SMP0000733',\n",
       "       'Temocapril Metabolism Pathway;;SMP0000732',\n",
       "       'Tenecteplase Action Pathway;;SMP0000283',\n",
       "       'Teniposide Action Pathway;;SMP0000443',\n",
       "       'Teniposide Metabolism Pathway;;SMP0000602',\n",
       "       'Tenofovir Metabolism Pathway;;SMP0000630',\n",
       "       'Tenoxicam Action Pathway;;SMP0000706',\n",
       "       'Terfenadine H1-Antihistamine Action;;SMP0060208',\n",
       "       'Tetracycline Action Pathway;;SMP0000294',\n",
       "       'The Oncogenic Action of 2-Hydroxyglutarate;;SMP0002291',\n",
       "       'The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxygluaricaciduria;;SMP0002359',\n",
       "       'The Oncogenic Action of Fumarate;;SMP0002295',\n",
       "       'The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxygluaricaciduria;;SMP0002358',\n",
       "       'The Oncogenic Action of Succinate;;SMP0002292',\n",
       "       'Thenalidine H1-Antihistamine Action;;SMP0062894',\n",
       "       'Thiamine Metabolism;;SMP0000076',\n",
       "       'Thiazinamium H1-Antihistamine Action;;SMP0060742',\n",
       "       'Thioguanine Action Pathway;;SMP0000430',\n",
       "       'Thioguanine Metabolism Pathway;;SMP0000647',\n",
       "       'Thonzylamine H1-Antihistamine Action;;SMP0058769',\n",
       "       'Threonine and 2-Oxobutanoate Degradation;;SMP0000452',\n",
       "       'Thyroid Hormone Synthesis;;SMP0000716',\n",
       "       'Tiaprofenic Acid Action Pathway;;SMP0000705',\n",
       "       'Ticlopidine Action Pathway;;SMP0000261',\n",
       "       'Ticlopidine Metabolism Pathway;;SMP0000611',\n",
       "       'Tigecycline Action Pathway;;SMP0000712',\n",
       "       'Timolol Action Pathway;;SMP0000659',\n",
       "       'Tirofiban Action Pathway;;SMP0000267',\n",
       "       'Tobramycin Action Pathway;;SMP0000711',\n",
       "       'Tocainide Action Pathway;;SMP0000330',\n",
       "       'Tolmetin Action Pathway;;SMP0000704',\n",
       "       'Tolpropamine H1-Antihistamine Action;;SMP0062621',\n",
       "       'Torsemide Action Pathway;;SMP0000118',\n",
       "       'Tramadol Action Action Pathway;;SMP0000671',\n",
       "       'Tramadol Metabolism Pathway;;SMP0000637',\n",
       "       'Trandolapril Action Pathway;;SMP0000157',\n",
       "       'Trandolapril Metabolism Pathway;;SMP0000599',\n",
       "       'Tranexamic Acid Action Pathway;;SMP0000287',\n",
       "       'Transaldolase Deficiency;;SMP0000520',\n",
       "       'Transfer of Acetyl Groups into Mitochondria;;SMP0000466',\n",
       "       'Trastuzumab Action Pathway;;SMP0000476',\n",
       "       'Triamterene Action Pathway;;SMP0000132',\n",
       "       'Trichlormethiazide Action Pathway;;SMP0000121',\n",
       "       'Trifunctional Protein Deficiency;;SMP0000545',\n",
       "       'Triosephosphate Isomerase;;SMP0000563',\n",
       "       'Tripelennamine H1-Antihistamine Action;;SMP0057587',\n",
       "       'Triprolidine H1-Antihistamine Action;;SMP0057581',\n",
       "       'Trisalicylate-Choline Action Pathway;;SMP0000703',\n",
       "       'Tritoqualine H1-Antihistamine Action;;SMP0062895',\n",
       "       'Troleandomycin Action Pathway;;SMP0000730',\n",
       "       'Tryptophan Metabolism;;SMP0000063',\n",
       "       'Tyrosine Hydroxylase Deficiency;;SMP0000497',\n",
       "       'Tyrosine Metabolism;;SMP0000006',\n",
       "       'Tyrosinemia Type 2 (or Richner-Hanhart Syndrome);;SMP0000369',\n",
       "       'Tyrosinemia Type 3 (TYRO3);;SMP0000370',\n",
       "       'Tyrosinemia Type I;;SMP0000218',\n",
       "       'Tyrosinemia, Transient, of the Newborn;;SMP0000494',\n",
       "       'UMP Synthase Deficiency (Orotic Aciduria);;SMP0000219',\n",
       "       'Ubiquinone Biosynthesis;;SMP0000065', 'Urea Cycle;;SMP0000059',\n",
       "       'Ureidopropionase Deficiency;;SMP0000492',\n",
       "       'Urokinase Action Pathway;;SMP0000284',\n",
       "       'Valdecoxib Action Pathway;;SMP0000116',\n",
       "       'Valine, Leucine, and Isoleucine Degradation;;SMP0000032',\n",
       "       'Valproic Acid Metabolism Pathway;;SMP0000635',\n",
       "       'Valsartan Action Pathway;;SMP0000165',\n",
       "       'Vasopressin Regulation of Water Homeostasis;;SMP0000322',\n",
       "       'Vatalanib Action Pathway;;SMP0000421',\n",
       "       'Venlafaxine Metabolism Pathway;;SMP0000636',\n",
       "       'Verapamil Action Pathway;;SMP0000375',\n",
       "       'Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD);;SMP0000540',\n",
       "       'Vinblastine Action Pathway;;SMP0000436',\n",
       "       'Vincristine Action Pathway;;SMP0000437',\n",
       "       'Vindesine Action Pathway;;SMP0000438',\n",
       "       'Vinorelbine Action Pathway;;SMP0000439',\n",
       "       'Vitamin A Deficiency;;SMP0000336',\n",
       "       'Vitamin B6 Metabolism;;SMP0000017',\n",
       "       'Vitamin K Metabolism;;SMP0000464', 'Warburg Effect;;SMP0000654',\n",
       "       'Warfarin Action Pathway;;SMP0000268',\n",
       "       'Wolman Disease;;SMP0000511',\n",
       "       'Xanthine Dehydrogenase Deficiency (Xanthinuria);;SMP0000220',\n",
       "       'Xanthinuria Type I;;SMP0000512',\n",
       "       'Xanthinuria Type II;;SMP0000513',\n",
       "       'Ximelagatran Action Pathway;;SMP0000279',\n",
       "       'Zalcitabine Action Pathway;;SMP0000746',\n",
       "       'Zellweger Syndrome;;SMP0000316',\n",
       "       'Zidovudine Action Pathway;;SMP0000747',\n",
       "       'Zoledronate Action Pathway;;SMP0000107',\n",
       "       'beta-Alanine Metabolism;;SMP0000007',\n",
       "       'beta-Ketothiolase Deficiency;;SMP0000173',\n",
       "       'beta-Mercaptolactate-Cysteine Disulfiduria;;SMP0000499',\n",
       "       'beta-Ureidopropionase Deficiency;;SMP0000172',\n",
       "       'gamma-Cystathionase Deficiency (CTH);;SMP0000514',\n",
       "       'gamma-Glutamyltransferase Deficiency;;SMP0000183',\n",
       "       'gamma-Glutamyltranspeptidase Deficiency;;SMP0000501'],\n",
       "      dtype='<U112')"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tuples2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "3c82aa53",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "877"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(np.unique([dictionary[k]['pathways'][u]['smpdb_id'] for k in dictionary.keys() for u in dictionary[k]['pathways'].keys() ]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "7458c324",
   "metadata": {},
   "outputs": [],
   "source": [
    "pathways = pd.DataFrame()\n",
    "#pathways[\"pathway name\"] = np.unique([dictionary[k]['pathways'][u]['name_pathway'] for k in dictionary.keys() for u in dictionary[k]['pathways'].keys() ])\n",
    "pathways[\"smpdb_id\"] = np.array([u.split(\";;\")[1] for u in tuples2])\n",
    "pathways[\"name\"] = np.array([u.split(\";;\")[0] for u in tuples2])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "4aca8b24",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>smpdb_id</th>\n",
       "      <th>name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>SMP0000575</td>\n",
       "      <td>11-beta-Hydroxylase Deficiency (CYP11B1)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>SMP0000566</td>\n",
       "      <td>17-alpha-Hydroxylase Deficiency (CYP17)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>SMP0000356</td>\n",
       "      <td>17-beta Hydroxysteroid Dehydrogenase III Defic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>SMP0000719</td>\n",
       "      <td>2-Aminoadipic 2-Oxoadipic Aciduria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>SMP0000136</td>\n",
       "      <td>2-Hydroxyglutric Aciduria (D and L Form)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>872</th>\n",
       "      <td>SMP0000499</td>\n",
       "      <td>beta-Mercaptolactate-Cysteine Disulfiduria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>873</th>\n",
       "      <td>SMP0000172</td>\n",
       "      <td>beta-Ureidopropionase Deficiency</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>874</th>\n",
       "      <td>SMP0000514</td>\n",
       "      <td>gamma-Cystathionase Deficiency (CTH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>875</th>\n",
       "      <td>SMP0000183</td>\n",
       "      <td>gamma-Glutamyltransferase Deficiency</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>876</th>\n",
       "      <td>SMP0000501</td>\n",
       "      <td>gamma-Glutamyltranspeptidase Deficiency</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>877 rows  2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       smpdb_id                                               name\n",
       "0    SMP0000575           11-beta-Hydroxylase Deficiency (CYP11B1)\n",
       "1    SMP0000566            17-alpha-Hydroxylase Deficiency (CYP17)\n",
       "2    SMP0000356  17-beta Hydroxysteroid Dehydrogenase III Defic...\n",
       "3    SMP0000719                 2-Aminoadipic 2-Oxoadipic Aciduria\n",
       "4    SMP0000136           2-Hydroxyglutric Aciduria (D and L Form)\n",
       "..          ...                                                ...\n",
       "872  SMP0000499         beta-Mercaptolactate-Cysteine Disulfiduria\n",
       "873  SMP0000172                   beta-Ureidopropionase Deficiency\n",
       "874  SMP0000514               gamma-Cystathionase Deficiency (CTH)\n",
       "875  SMP0000183               gamma-Glutamyltransferase Deficiency\n",
       "876  SMP0000501            gamma-Glutamyltranspeptidase Deficiency\n",
       "\n",
       "[877 rows x 2 columns]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pathways"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "0aa6e905",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "872"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(np.unique([dictionary[k]['pathways'][u]['name_pathway'] for k in dictionary.keys() for u in dictionary[k]['pathways'].keys() ]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "db85ddef",
   "metadata": {},
   "outputs": [],
   "source": [
    "pathways.to_csv(\"~/Downloads/pathway_names.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "2bbf2170",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['SMP0000001', 'SMP0000002', 'SMP0000003', 'SMP0000004',\n",
       "       'SMP0000005', 'SMP0000006', 'SMP0000007', 'SMP0000008',\n",
       "       'SMP0000009', 'SMP0000010', 'SMP0000011', 'SMP0000012',\n",
       "       'SMP0000013', 'SMP0000015', 'SMP0000016', 'SMP0000017',\n",
       "       'SMP0000018', 'SMP0000020', 'SMP0000021', 'SMP0000023',\n",
       "       'SMP0000024', 'SMP0000025', 'SMP0000027', 'SMP0000028',\n",
       "       'SMP0000029', 'SMP0000030', 'SMP0000031', 'SMP0000032',\n",
       "       'SMP0000033', 'SMP0000034', 'SMP0000035', 'SMP0000036',\n",
       "       'SMP0000037', 'SMP0000039', 'SMP0000040', 'SMP0000041',\n",
       "       'SMP0000043', 'SMP0000044', 'SMP0000045', 'SMP0000046',\n",
       "       'SMP0000048', 'SMP0000050', 'SMP0000051', 'SMP0000052',\n",
       "       'SMP0000053', 'SMP0000055', 'SMP0000057', 'SMP0000058',\n",
       "       'SMP0000059', 'SMP0000060', 'SMP0000063', 'SMP0000064',\n",
       "       'SMP0000065', 'SMP0000066', 'SMP0000067', 'SMP0000068',\n",
       "       'SMP0000070', 'SMP0000071', 'SMP0000072', 'SMP0000073',\n",
       "       'SMP0000074', 'SMP0000075', 'SMP0000076', 'SMP0000077',\n",
       "       'SMP0000078', 'SMP0000079', 'SMP0000080', 'SMP0000081',\n",
       "       'SMP0000082', 'SMP0000083', 'SMP0000084', 'SMP0000085',\n",
       "       'SMP0000086', 'SMP0000087', 'SMP0000088', 'SMP0000089',\n",
       "       'SMP0000090', 'SMP0000091', 'SMP0000092', 'SMP0000093',\n",
       "       'SMP0000094', 'SMP0000095', 'SMP0000096', 'SMP0000097',\n",
       "       'SMP0000098', 'SMP0000099', 'SMP0000100', 'SMP0000101',\n",
       "       'SMP0000102', 'SMP0000103', 'SMP0000104', 'SMP0000105',\n",
       "       'SMP0000106', 'SMP0000107', 'SMP0000108', 'SMP0000109',\n",
       "       'SMP0000110', 'SMP0000111', 'SMP0000112', 'SMP0000113',\n",
       "       'SMP0000114', 'SMP0000115', 'SMP0000116', 'SMP0000117',\n",
       "       'SMP0000118', 'SMP0000119', 'SMP0000120', 'SMP0000121',\n",
       "       'SMP0000122', 'SMP0000123', 'SMP0000124', 'SMP0000126',\n",
       "       'SMP0000127', 'SMP0000128', 'SMP0000129', 'SMP0000130',\n",
       "       'SMP0000131', 'SMP0000132', 'SMP0000133', 'SMP0000134',\n",
       "       'SMP0000135', 'SMP0000136', 'SMP0000137', 'SMP0000138',\n",
       "       'SMP0000139', 'SMP0000140', 'SMP0000141', 'SMP0000143',\n",
       "       'SMP0000144', 'SMP0000145', 'SMP0000146', 'SMP0000147',\n",
       "       'SMP0000148', 'SMP0000149', 'SMP0000150', 'SMP0000151',\n",
       "       'SMP0000152', 'SMP0000153', 'SMP0000154', 'SMP0000155',\n",
       "       'SMP0000156', 'SMP0000157', 'SMP0000158', 'SMP0000159',\n",
       "       'SMP0000160', 'SMP0000161', 'SMP0000162', 'SMP0000163',\n",
       "       'SMP0000164', 'SMP0000165', 'SMP0000167', 'SMP0000168',\n",
       "       'SMP0000169', 'SMP0000170', 'SMP0000172', 'SMP0000173',\n",
       "       'SMP0000174', 'SMP0000175', 'SMP0000177', 'SMP0000178',\n",
       "       'SMP0000179', 'SMP0000181', 'SMP0000182', 'SMP0000183',\n",
       "       'SMP0000184', 'SMP0000185', 'SMP0000186', 'SMP0000187',\n",
       "       'SMP0000188', 'SMP0000189', 'SMP0000190', 'SMP0000191',\n",
       "       'SMP0000192', 'SMP0000193', 'SMP0000196', 'SMP0000197',\n",
       "       'SMP0000198', 'SMP0000199', 'SMP0000200', 'SMP0000201',\n",
       "       'SMP0000202', 'SMP0000203', 'SMP0000205', 'SMP0000206',\n",
       "       'SMP0000207', 'SMP0000208', 'SMP0000209', 'SMP0000210',\n",
       "       'SMP0000212', 'SMP0000214', 'SMP0000216', 'SMP0000217',\n",
       "       'SMP0000218', 'SMP0000219', 'SMP0000220', 'SMP0000221',\n",
       "       'SMP0000222', 'SMP0000223', 'SMP0000225', 'SMP0000226',\n",
       "       'SMP0000227', 'SMP0000228', 'SMP0000229', 'SMP0000230',\n",
       "       'SMP0000231', 'SMP0000232', 'SMP0000233', 'SMP0000235',\n",
       "       'SMP0000236', 'SMP0000237', 'SMP0000238', 'SMP0000239',\n",
       "       'SMP0000240', 'SMP0000242', 'SMP0000243', 'SMP0000244',\n",
       "       'SMP0000245', 'SMP0000246', 'SMP0000247', 'SMP0000248',\n",
       "       'SMP0000249', 'SMP0000250', 'SMP0000251', 'SMP0000252',\n",
       "       'SMP0000253', 'SMP0000254', 'SMP0000255', 'SMP0000256',\n",
       "       'SMP0000257', 'SMP0000258', 'SMP0000259', 'SMP0000260',\n",
       "       'SMP0000261', 'SMP0000262', 'SMP0000263', 'SMP0000264',\n",
       "       'SMP0000265', 'SMP0000266', 'SMP0000267', 'SMP0000268',\n",
       "       'SMP0000269', 'SMP0000270', 'SMP0000271', 'SMP0000272',\n",
       "       'SMP0000273', 'SMP0000274', 'SMP0000275', 'SMP0000276',\n",
       "       'SMP0000277', 'SMP0000278', 'SMP0000279', 'SMP0000280',\n",
       "       'SMP0000281', 'SMP0000282', 'SMP0000283', 'SMP0000284',\n",
       "       'SMP0000285', 'SMP0000286', 'SMP0000287', 'SMP0000288',\n",
       "       'SMP0000289', 'SMP0000290', 'SMP0000291', 'SMP0000292',\n",
       "       'SMP0000293', 'SMP0000294', 'SMP0000295', 'SMP0000296',\n",
       "       'SMP0000297', 'SMP0000298', 'SMP0000299', 'SMP0000300',\n",
       "       'SMP0000301', 'SMP0000302', 'SMP0000303', 'SMP0000304',\n",
       "       'SMP0000305', 'SMP0000306', 'SMP0000307', 'SMP0000308',\n",
       "       'SMP0000309', 'SMP0000310', 'SMP0000311', 'SMP0000312',\n",
       "       'SMP0000313', 'SMP0000314', 'SMP0000315', 'SMP0000316',\n",
       "       'SMP0000317', 'SMP0000318', 'SMP0000319', 'SMP0000320',\n",
       "       'SMP0000321', 'SMP0000322', 'SMP0000323', 'SMP0000324',\n",
       "       'SMP0000325', 'SMP0000326', 'SMP0000327', 'SMP0000328',\n",
       "       'SMP0000329', 'SMP0000330', 'SMP0000331', 'SMP0000332',\n",
       "       'SMP0000333', 'SMP0000334', 'SMP0000335', 'SMP0000336',\n",
       "       'SMP0000337', 'SMP0000339', 'SMP0000340', 'SMP0000341',\n",
       "       'SMP0000342', 'SMP0000343', 'SMP0000344', 'SMP0000345',\n",
       "       'SMP0000346', 'SMP0000347', 'SMP0000348', 'SMP0000349',\n",
       "       'SMP0000350', 'SMP0000351', 'SMP0000352', 'SMP0000353',\n",
       "       'SMP0000354', 'SMP0000355', 'SMP0000356', 'SMP0000357',\n",
       "       'SMP0000358', 'SMP0000359', 'SMP0000360', 'SMP0000361',\n",
       "       'SMP0000362', 'SMP0000363', 'SMP0000364', 'SMP0000365',\n",
       "       'SMP0000366', 'SMP0000367', 'SMP0000368', 'SMP0000369',\n",
       "       'SMP0000370', 'SMP0000371', 'SMP0000372', 'SMP0000373',\n",
       "       'SMP0000374', 'SMP0000375', 'SMP0000376', 'SMP0000377',\n",
       "       'SMP0000378', 'SMP0000379', 'SMP0000380', 'SMP0000381',\n",
       "       'SMP0000382', 'SMP0000384', 'SMP0000385', 'SMP0000386',\n",
       "       'SMP0000387', 'SMP0000388', 'SMP0000389', 'SMP0000390',\n",
       "       'SMP0000392', 'SMP0000393', 'SMP0000394', 'SMP0000395',\n",
       "       'SMP0000396', 'SMP0000397', 'SMP0000398', 'SMP0000399',\n",
       "       'SMP0000400', 'SMP0000401', 'SMP0000402', 'SMP0000403',\n",
       "       'SMP0000404', 'SMP0000405', 'SMP0000406', 'SMP0000407',\n",
       "       'SMP0000408', 'SMP0000409', 'SMP0000410', 'SMP0000411',\n",
       "       'SMP0000412', 'SMP0000413', 'SMP0000414', 'SMP0000415',\n",
       "       'SMP0000416', 'SMP0000417', 'SMP0000420', 'SMP0000421',\n",
       "       'SMP0000422', 'SMP0000423', 'SMP0000424', 'SMP0000425',\n",
       "       'SMP0000426', 'SMP0000427', 'SMP0000428', 'SMP0000429',\n",
       "       'SMP0000430', 'SMP0000431', 'SMP0000432', 'SMP0000433',\n",
       "       'SMP0000434', 'SMP0000435', 'SMP0000436', 'SMP0000437',\n",
       "       'SMP0000438', 'SMP0000439', 'SMP0000440', 'SMP0000441',\n",
       "       'SMP0000442', 'SMP0000443', 'SMP0000444', 'SMP0000445',\n",
       "       'SMP0000446', 'SMP0000447', 'SMP0000448', 'SMP0000449',\n",
       "       'SMP0000450', 'SMP0000451', 'SMP0000452', 'SMP0000453',\n",
       "       'SMP0000454', 'SMP0000455', 'SMP0000456', 'SMP0000457',\n",
       "       'SMP0000458', 'SMP0000459', 'SMP0000460', 'SMP0000461',\n",
       "       'SMP0000462', 'SMP0000463', 'SMP0000464', 'SMP0000465',\n",
       "       'SMP0000466', 'SMP0000469', 'SMP0000470', 'SMP0000471',\n",
       "       'SMP0000472', 'SMP0000473', 'SMP0000474', 'SMP0000475',\n",
       "       'SMP0000476', 'SMP0000479', 'SMP0000481', 'SMP0000482',\n",
       "       'SMP0000484', 'SMP0000485', 'SMP0000486', 'SMP0000487',\n",
       "       'SMP0000488', 'SMP0000489', 'SMP0000490', 'SMP0000491',\n",
       "       'SMP0000492', 'SMP0000493', 'SMP0000494', 'SMP0000495',\n",
       "       'SMP0000496', 'SMP0000497', 'SMP0000498', 'SMP0000499',\n",
       "       'SMP0000500', 'SMP0000501', 'SMP0000502', 'SMP0000503',\n",
       "       'SMP0000504', 'SMP0000505', 'SMP0000506', 'SMP0000507',\n",
       "       'SMP0000508', 'SMP0000509', 'SMP0000510', 'SMP0000511',\n",
       "       'SMP0000512', 'SMP0000513', 'SMP0000514', 'SMP0000515',\n",
       "       'SMP0000516', 'SMP0000517', 'SMP0000518', 'SMP0000519',\n",
       "       'SMP0000520', 'SMP0000521', 'SMP0000522', 'SMP0000523',\n",
       "       'SMP0000524', 'SMP0000525', 'SMP0000526', 'SMP0000527',\n",
       "       'SMP0000528', 'SMP0000529', 'SMP0000531', 'SMP0000532',\n",
       "       'SMP0000533', 'SMP0000534', 'SMP0000535', 'SMP0000536',\n",
       "       'SMP0000537', 'SMP0000538', 'SMP0000539', 'SMP0000540',\n",
       "       'SMP0000541', 'SMP0000542', 'SMP0000543', 'SMP0000544',\n",
       "       'SMP0000545', 'SMP0000546', 'SMP0000547', 'SMP0000548',\n",
       "       'SMP0000549', 'SMP0000550', 'SMP0000551', 'SMP0000552',\n",
       "       'SMP0000553', 'SMP0000554', 'SMP0000555', 'SMP0000556',\n",
       "       'SMP0000557', 'SMP0000558', 'SMP0000559', 'SMP0000560',\n",
       "       'SMP0000561', 'SMP0000562', 'SMP0000563', 'SMP0000564',\n",
       "       'SMP0000565', 'SMP0000566', 'SMP0000567', 'SMP0000570',\n",
       "       'SMP0000571', 'SMP0000572', 'SMP0000573', 'SMP0000574',\n",
       "       'SMP0000575', 'SMP0000576', 'SMP0000577', 'SMP0000578',\n",
       "       'SMP0000579', 'SMP0000580', 'SMP0000581', 'SMP0000582',\n",
       "       'SMP0000583', 'SMP0000586', 'SMP0000589', 'SMP0000590',\n",
       "       'SMP0000591', 'SMP0000592', 'SMP0000593', 'SMP0000594',\n",
       "       'SMP0000595', 'SMP0000596', 'SMP0000597', 'SMP0000598',\n",
       "       'SMP0000599', 'SMP0000600', 'SMP0000601', 'SMP0000602',\n",
       "       'SMP0000603', 'SMP0000604', 'SMP0000605', 'SMP0000606',\n",
       "       'SMP0000607', 'SMP0000608', 'SMP0000609', 'SMP0000610',\n",
       "       'SMP0000611', 'SMP0000612', 'SMP0000613', 'SMP0000614',\n",
       "       'SMP0000615', 'SMP0000616', 'SMP0000617', 'SMP0000618',\n",
       "       'SMP0000619', 'SMP0000620', 'SMP0000621', 'SMP0000622',\n",
       "       'SMP0000623', 'SMP0000624', 'SMP0000625', 'SMP0000626',\n",
       "       'SMP0000627', 'SMP0000628', 'SMP0000629', 'SMP0000630',\n",
       "       'SMP0000631', 'SMP0000632', 'SMP0000633', 'SMP0000634',\n",
       "       'SMP0000635', 'SMP0000636', 'SMP0000637', 'SMP0000638',\n",
       "       'SMP0000639', 'SMP0000640', 'SMP0000641', 'SMP0000642',\n",
       "       'SMP0000644', 'SMP0000645', 'SMP0000646', 'SMP0000647',\n",
       "       'SMP0000648', 'SMP0000649', 'SMP0000650', 'SMP0000651',\n",
       "       'SMP0000652', 'SMP0000653', 'SMP0000654', 'SMP0000655',\n",
       "       'SMP0000656', 'SMP0000657', 'SMP0000658', 'SMP0000659',\n",
       "       'SMP0000660', 'SMP0000661', 'SMP0000662', 'SMP0000663',\n",
       "       'SMP0000664', 'SMP0000665', 'SMP0000666', 'SMP0000667',\n",
       "       'SMP0000668', 'SMP0000669', 'SMP0000670', 'SMP0000671',\n",
       "       'SMP0000672', 'SMP0000673', 'SMP0000674', 'SMP0000675',\n",
       "       'SMP0000676', 'SMP0000677', 'SMP0000678', 'SMP0000679',\n",
       "       'SMP0000680', 'SMP0000681', 'SMP0000683', 'SMP0000684',\n",
       "       'SMP0000685', 'SMP0000686', 'SMP0000687', 'SMP0000688',\n",
       "       'SMP0000689', 'SMP0000690', 'SMP0000691', 'SMP0000692',\n",
       "       'SMP0000693', 'SMP0000694', 'SMP0000695', 'SMP0000696',\n",
       "       'SMP0000697', 'SMP0000698', 'SMP0000699', 'SMP0000700',\n",
       "       'SMP0000701', 'SMP0000702', 'SMP0000703', 'SMP0000704',\n",
       "       'SMP0000705', 'SMP0000706', 'SMP0000707', 'SMP0000708',\n",
       "       'SMP0000709', 'SMP0000710', 'SMP0000711', 'SMP0000712',\n",
       "       'SMP0000713', 'SMP0000714', 'SMP0000715', 'SMP0000716',\n",
       "       'SMP0000717', 'SMP0000718', 'SMP0000719', 'SMP0000720',\n",
       "       'SMP0000721', 'SMP0000722', 'SMP0000723', 'SMP0000724',\n",
       "       'SMP0000725', 'SMP0000726', 'SMP0000727', 'SMP0000728',\n",
       "       'SMP0000729', 'SMP0000730', 'SMP0000731', 'SMP0000732',\n",
       "       'SMP0000733', 'SMP0000734', 'SMP0000735', 'SMP0000736',\n",
       "       'SMP0000737', 'SMP0000738', 'SMP0000739', 'SMP0000740',\n",
       "       'SMP0000741', 'SMP0000742', 'SMP0000743', 'SMP0000745',\n",
       "       'SMP0000746', 'SMP0000747', 'SMP0002291', 'SMP0002292',\n",
       "       'SMP0002295', 'SMP0002298', 'SMP0002313', 'SMP0002358',\n",
       "       'SMP0002359', 'SMP0014216', 'SMP0014218', 'SMP0014220',\n",
       "       'SMP0014224', 'SMP0014228', 'SMP0014229', 'SMP0014230',\n",
       "       'SMP0014233', 'SMP0014235', 'SMP0014240', 'SMP0014242',\n",
       "       'SMP0014245', 'SMP0014248', 'SMP0014249', 'SMP0014255',\n",
       "       'SMP0014267', 'SMP0014272', 'SMP0014274', 'SMP0014277',\n",
       "       'SMP0014278', 'SMP0014279', 'SMP0014287', 'SMP0014290',\n",
       "       'SMP0014291', 'SMP0014294', 'SMP0014300', 'SMP0014303',\n",
       "       'SMP0014304', 'SMP0014306', 'SMP0014310', 'SMP0015056',\n",
       "       'SMP0015057', 'SMP0015058', 'SMP0015062', 'SMP0015063',\n",
       "       'SMP0015074', 'SMP0015077', 'SMP0015078', 'SMP0015084',\n",
       "       'SMP0015086', 'SMP0015092', 'SMP0015094', 'SMP0015095',\n",
       "       'SMP0015097', 'SMP0015101', 'SMP0015103', 'SMP0015109',\n",
       "       'SMP0015112', 'SMP0015114', 'SMP0015116', 'SMP0015117',\n",
       "       'SMP0015119', 'SMP0015120', 'SMP0015121', 'SMP0015901',\n",
       "       'SMP0015910', 'SMP0015911', 'SMP0015912', 'SMP0015915',\n",
       "       'SMP0015916', 'SMP0015918', 'SMP0015922', 'SMP0015924',\n",
       "       'SMP0015926', 'SMP0015935', 'SMP0015938', 'SMP0015939',\n",
       "       'SMP0015949', 'SMP0015950', 'SMP0015951', 'SMP0015952',\n",
       "       'SMP0015957', 'SMP0015960', 'SMP0015962', 'SMP0015963',\n",
       "       'SMP0015971', 'SMP0015972', 'SMP0015973', 'SMP0015983',\n",
       "       'SMP0015984', 'SMP0015985', 'SMP0015987', 'SMP0028021',\n",
       "       'SMP0030406', 'SMP0030880', 'SMP0031694', 'SMP0031696',\n",
       "       'SMP0031697', 'SMP0031698', 'SMP0031699', 'SMP0031700',\n",
       "       'SMP0051038', 'SMP0056661', 'SMP0056662', 'SMP0056811',\n",
       "       'SMP0057579', 'SMP0057580', 'SMP0057581', 'SMP0057582',\n",
       "       'SMP0057583', 'SMP0057584', 'SMP0057585', 'SMP0057586',\n",
       "       'SMP0057587', 'SMP0058732', 'SMP0058741', 'SMP0058769',\n",
       "       'SMP0058785', 'SMP0058797', 'SMP0058803', 'SMP0058808',\n",
       "       'SMP0058813', 'SMP0058891', 'SMP0058903', 'SMP0058908',\n",
       "       'SMP0058916', 'SMP0058923', 'SMP0058931', 'SMP0058936',\n",
       "       'SMP0058956', 'SMP0058964', 'SMP0059044', 'SMP0059058',\n",
       "       'SMP0059110', 'SMP0059114', 'SMP0059211', 'SMP0059689',\n",
       "       'SMP0059694', 'SMP0059710', 'SMP0059716', 'SMP0059720',\n",
       "       'SMP0059730', 'SMP0059738', 'SMP0059865', 'SMP0059868',\n",
       "       'SMP0059872', 'SMP0059881', 'SMP0059897', 'SMP0060058',\n",
       "       'SMP0060170', 'SMP0060195', 'SMP0060201', 'SMP0060204',\n",
       "       'SMP0060208', 'SMP0060218', 'SMP0060224', 'SMP0060230',\n",
       "       'SMP0060235', 'SMP0060740', 'SMP0060741', 'SMP0060742',\n",
       "       'SMP0060744', 'SMP0061040', 'SMP0061047', 'SMP0061052',\n",
       "       'SMP0061190', 'SMP0061191', 'SMP0062621', 'SMP0062623',\n",
       "       'SMP0062625', 'SMP0062881', 'SMP0062884', 'SMP0062885',\n",
       "       'SMP0062886', 'SMP0062894', 'SMP0062895', 'SMP0063746',\n",
       "       'SMP0063753', 'SMP0063756', 'SMP0063757', 'SMP0063759',\n",
       "       'SMP0063777'], dtype='<U10')"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.unique([dictionary[k]['pathways'][u]['smpdb_id'] for k in dictionary.keys() for u in dictionary[k]['pathways'].keys() ])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "da8e2701",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'pathways1': {'smpdb_id': 'SMP0000278',\n",
       "  'name_pathway': 'Lepirudin Action Pathway',\n",
       "  'category_pathway': 'drug_action',\n",
       "  'drugs_in_pathway': ['DB00001', 'DB01022', 'DB01373'],\n",
       "  'enzymes_in_pathway': ['P00734',\n",
       "   'P00748',\n",
       "   'P02452',\n",
       "   'P03952',\n",
       "   'P03951',\n",
       "   'P00740',\n",
       "   'P00451',\n",
       "   'P12259',\n",
       "   'P00742',\n",
       "   'P02671',\n",
       "   'P02675',\n",
       "   'P02679',\n",
       "   'P00488',\n",
       "   'P05160',\n",
       "   'P00747',\n",
       "   'P00750',\n",
       "   'P08709',\n",
       "   'P13726',\n",
       "   'Q9BQB6',\n",
       "   'P38435']}}"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001']['pathways']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "02bc3899",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pathway name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>11-beta-Hydroxylase Deficiency (CYP11B1)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>17-alpha-Hydroxylase Deficiency (CYP17)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>17-beta Hydroxysteroid Dehydrogenase III Defic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2-Aminoadipic 2-Oxoadipic Aciduria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2-Hydroxyglutric Aciduria (D and L Form)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>867</th>\n",
       "      <td>beta-Mercaptolactate-Cysteine Disulfiduria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>868</th>\n",
       "      <td>beta-Ureidopropionase Deficiency</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>869</th>\n",
       "      <td>gamma-Cystathionase Deficiency (CTH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>870</th>\n",
       "      <td>gamma-Glutamyltransferase Deficiency</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>871</th>\n",
       "      <td>gamma-Glutamyltranspeptidase Deficiency</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>872 rows  1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          pathway name\n",
       "0             11-beta-Hydroxylase Deficiency (CYP11B1)\n",
       "1              17-alpha-Hydroxylase Deficiency (CYP17)\n",
       "2    17-beta Hydroxysteroid Dehydrogenase III Defic...\n",
       "3                   2-Aminoadipic 2-Oxoadipic Aciduria\n",
       "4             2-Hydroxyglutric Aciduria (D and L Form)\n",
       "..                                                 ...\n",
       "867         beta-Mercaptolactate-Cysteine Disulfiduria\n",
       "868                   beta-Ureidopropionase Deficiency\n",
       "869               gamma-Cystathionase Deficiency (CTH)\n",
       "870               gamma-Glutamyltransferase Deficiency\n",
       "871            gamma-Glutamyltranspeptidase Deficiency\n",
       "\n",
       "[872 rows x 1 columns]"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pathways"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1302c099",
   "metadata": {},
   "outputs": [],
   "source": [
    "pathways"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "37ec3d83",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "with open('/Users/cdonnat/Downloads/drug_data.pkl', 'wb') as f:\n",
    "    pickle.dump(dictionary, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "caa5e94e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#### Process the description and indication in one go.\n",
    "#### Use the categories as a better way of understanding what the drug does.\n",
    "#### Need to understand what these pathways are\n",
    "\n",
    "import nltk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "ec68f90d",
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 263,
     "status": "ok",
     "timestamp": 1656115916155,
     "user": {
      "displayName": "Yumeng Shao",
      "userId": "13244839590576145111"
     },
     "user_tz": 300
    },
    "id": "3aBXb5Kp8tdD",
    "outputId": "75b32dba-8d1b-43b3-e35e-a7c69026de1f"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     /Users/cdonnat/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "from nltk.corpus import stopwords\n",
    "nltk.download('stopwords')\n",
    "stop_words = set(stopwords.words('english'))\n",
    "stop_words.add(\"may\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "fbb542d6",
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 304,
     "status": "ok",
     "timestamp": 1656115917540,
     "user": {
      "displayName": "Yumeng Shao",
      "userId": "13244839590576145111"
     },
     "user_tz": 300
    },
    "id": "EszR9RMk8tdD",
    "outputId": "1c8b1525-3cef-4b02-b6b1-2c1806f8daaa"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ourselves', 'is', 'haven', 'into', 'a', 'only', 'will', 'between', 'should', \"hasn't\", 'for', \"shouldn't\", 'being', 'hasn', 'there', 'here', 'that', 'll', 'which', \"you'll\", \"you've\", 'few', 'y', 'didn', 'own', 'until', \"weren't\", 'ours', 'by', 'why', 'wouldn', 'where', 'and', 'what', 'same', 'its', 'shouldn', 'himself', \"that'll\", 'have', 'do', \"won't\", 'further', 'with', 'any', 'won', 'him', 'me', 'hers', \"don't\", 'shan', 'no', \"you'd\", 'about', 'you', \"hadn't\", 'may', 'needn', 'yours', 'but', 'because', 'before', 'more', 'just', 'again', 'we', 'most', 'such', 'myself', 'itself', 'from', 'she', 'so', 'once', 'has', 'yourselves', 're', 'both', 'through', \"didn't\", 'against', \"couldn't\", 'my', 'your', 'during', 'too', \"wouldn't\", 'other', \"it's\", \"doesn't\", 's', \"wasn't\", 'couldn', 'who', 'very', 'themselves', 'yourself', 'the', 'below', \"aren't\", 'of', 'did', 'ma', 'when', 'nor', \"shan't\", 'am', \"you're\", 'each', 'theirs', 'does', 'under', \"mustn't\", 'isn', 'an', 'at', 'in', 'out', \"isn't\", 'wasn', 'now', 'be', 'their', 'they', 'them', 'are', 'were', 'm', 'hadn', 'some', 'above', \"haven't\", 'over', 'off', 'while', 'our', 'aren', 'how', 'it', 'can', 'his', 'mustn', 'her', 'been', 'than', \"she's\", \"should've\", 'o', 'doing', 'was', 'weren', 'on', 'if', 'mightn', 'after', 'those', 'these', 'to', 'doesn', 'up', 'then', 't', 'not', 'd', 'whom', 'this', \"mightn't\", 'all', 've', 'herself', 'having', \"needn't\", 'had', 'ain', 'as', 'down', 'he', 'don', 'i', 'or'}\n"
     ]
    }
   ],
   "source": [
    "print(stop_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "2228c83a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['DB00001', 'DB00002', 'DB00003', 'DB00004', 'DB00005', 'DB00006', 'DB00007', 'DB00008', 'DB00009', 'DB00010', 'DB00011', 'DB00012', 'DB00013', 'DB00014', 'DB00015', 'DB00016', 'DB00017', 'DB00018', 'DB00019', 'DB00020', 'DB00022', 'DB00023', 'DB00024', 'DB00025', 'DB00026', 'DB00027', 'DB00028', 'DB00029', 'DB00030', 'DB00031', 'DB00032', 'DB00033', 'DB00034', 'DB00035', 'DB00036', 'DB00038', 'DB00039', 'DB00040', 'DB00041', 'DB00042', 'DB00043', 'DB00044', 'DB00045', 'DB00046', 'DB00047', 'DB00048', 'DB00049', 'DB00050', 'DB00051', 'DB00052', 'DB00053', 'DB00054', 'DB00055', 'DB00056', 'DB00057', 'DB00058', 'DB00059', 'DB00060', 'DB00061', 'DB00062', 'DB00063', 'DB00065', 'DB00066', 'DB00067', 'DB00068', 'DB00069', 'DB00070', 'DB00071', 'DB00072', 'DB00073', 'DB00074', 'DB00075', 'DB00076', 'DB00078', 'DB00080', 'DB00081', 'DB00082', 'DB00083', 'DB00085', 'DB00086', 'DB00087', 'DB00088', 'DB00089', 'DB00090', 'DB00091', 'DB00092', 'DB00093', 'DB00094', 'DB00095', 'DB00097', 'DB00098', 'DB00099', 'DB00100', 'DB00102', 'DB00103', 'DB00104', 'DB00105', 'DB00106', 'DB00107', 'DB00108', 'DB00109', 'DB00110', 'DB00111', 'DB00112', 'DB00113', 'DB00114', 'DB00115', 'DB00116', 'DB00117', 'DB00118', 'DB00119', 'DB00120', 'DB00121', 'DB00122', 'DB00123', 'DB00125', 'DB00126', 'DB00127', 'DB00128', 'DB00129', 'DB00130', 'DB00131', 'DB00132', 'DB00133', 'DB00134', 'DB00135', 'DB00136', 'DB00137', 'DB00138', 'DB00139', 'DB00140', 'DB00141', 'DB00142', 'DB00143', 'DB00144', 'DB00145', 'DB00146', 'DB00147', 'DB00148', 'DB00149', 'DB00150', 'DB00151', 'DB00152', 'DB00153', 'DB00154', 'DB00155', 'DB00156', 'DB00157', 'DB00158', 'DB00159', 'DB00160', 'DB00161', 'DB00162', 'DB00163', 'DB00165', 'DB00166', 'DB00167', 'DB00168', 'DB00169', 'DB00170', 'DB00171', 'DB00172', 'DB00173', 'DB00174', 'DB00175', 'DB00176', 'DB00177', 'DB00178', 'DB00179', 'DB00180', 'DB00181', 'DB00182', 'DB00183', 'DB00184', 'DB00185', 'DB00186', 'DB00187', 'DB00188', 'DB00189', 'DB00190', 'DB00191', 'DB00192', 'DB00193', 'DB00194', 'DB00195', 'DB00196', 'DB00197', 'DB00198', 'DB00199', 'DB00200', 'DB00201', 'DB00202', 'DB00203', 'DB00204', 'DB00205', 'DB00206', 'DB00207', 'DB00208', 'DB00209', 'DB00210', 'DB00211', 'DB00212', 'DB00213', 'DB00214', 'DB00215', 'DB00216', 'DB00217', 'DB00218', 'DB00219', 'DB00220', 'DB00221', 'DB00222', 'DB00223', 'DB00224', 'DB00225', 'DB00226', 'DB00227', 'DB00228', 'DB00229', 'DB00230', 'DB00231', 'DB00232', 'DB00233', 'DB00234', 'DB00235', 'DB00236', 'DB00237', 'DB00238', 'DB00239', 'DB00240', 'DB00241', 'DB00242', 'DB00243', 'DB00244', 'DB00245', 'DB00246', 'DB00247', 'DB00248', 'DB00249', 'DB00250', 'DB00251', 'DB00252', 'DB00253', 'DB00254', 'DB00255', 'DB00256', 'DB00257', 'DB00258', 'DB00259', 'DB00260', 'DB00261', 'DB00262', 'DB00263', 'DB00264', 'DB00265', 'DB00266', 'DB00267', 'DB00268', 'DB00269', 'DB00270', 'DB00271', 'DB00272', 'DB00273', 'DB00274', 'DB00275', 'DB00276', 'DB00277', 'DB00278', 'DB00279', 'DB00280', 'DB00281', 'DB00282', 'DB00283', 'DB00284', 'DB00285', 'DB00286', 'DB00287', 'DB00288', 'DB00289', 'DB00290', 'DB00291', 'DB00292', 'DB00293', 'DB00294', 'DB00295', 'DB00296', 'DB00297', 'DB00298', 'DB00299', 'DB00300', 'DB00301', 'DB00302', 'DB00303', 'DB00304', 'DB00305', 'DB00306', 'DB00307', 'DB00308', 'DB00309', 'DB00310', 'DB00311', 'DB00312', 'DB00313', 'DB00314', 'DB00315', 'DB00316', 'DB00317', 'DB00318', 'DB00319', 'DB00320', 'DB00321', 'DB00322', 'DB00323', 'DB00324', 'DB00325', 'DB00326', 'DB00327', 'DB00328', 'DB00330', 'DB00331', 'DB00332', 'DB00333', 'DB00334', 'DB00335', 'DB00336', 'DB00337', 'DB00338', 'DB00339', 'DB00340', 'DB00341', 'DB00342', 'DB00343', 'DB00344', 'DB00345', 'DB00346', 'DB00347', 'DB00348', 'DB00349', 'DB00350', 'DB00351', 'DB00352', 'DB00353', 'DB00354', 'DB00355', 'DB00356', 'DB00357', 'DB00358', 'DB00359', 'DB00360', 'DB00361', 'DB00362', 'DB00363', 'DB00364', 'DB00365', 'DB00366', 'DB00367', 'DB00368', 'DB00369', 'DB00370', 'DB00371', 'DB00372', 'DB00373', 'DB00374', 'DB00375', 'DB00376', 'DB00377', 'DB00378', 'DB00379', 'DB00380', 'DB00381', 'DB00382', 'DB00383', 'DB00384', 'DB00385', 'DB00387', 'DB00388', 'DB00389', 'DB00390', 'DB00391', 'DB00392', 'DB00393', 'DB00394', 'DB00395', 'DB00396', 'DB00397', 'DB00398', 'DB00399', 'DB00400', 'DB00401', 'DB00402', 'DB00403', 'DB00404', 'DB00405', 'DB00406', 'DB00407', 'DB00408', 'DB00409', 'DB00410', 'DB00411', 'DB00412', 'DB00413', 'DB00414', 'DB00415', 'DB00416', 'DB00417', 'DB00418', 'DB00419', 'DB00420', 'DB00421', 'DB00422', 'DB00423', 'DB00424', 'DB00425', 'DB00426', 'DB00427', 'DB00428', 'DB00429', 'DB00430', 'DB00431', 'DB00432', 'DB00433', 'DB00434', 'DB00435', 'DB00436', 'DB00437', 'DB00438', 'DB00439', 'DB00440', 'DB00441', 'DB00442', 'DB00443', 'DB00444', 'DB00445', 'DB00446', 'DB00447', 'DB00448', 'DB00449', 'DB00450', 'DB00451', 'DB00452', 'DB00453', 'DB00454', 'DB00455', 'DB00456', 'DB00457', 'DB00458', 'DB00459', 'DB00460', 'DB00461', 'DB00462', 'DB00463', 'DB00464', 'DB00465', 'DB00466', 'DB00467', 'DB00468', 'DB00469', 'DB00470', 'DB00471', 'DB00472', 'DB00473', 'DB00474', 'DB00475', 'DB00476', 'DB00477', 'DB00478', 'DB00479', 'DB00480', 'DB00481', 'DB00482', 'DB00483', 'DB00484', 'DB00485', 'DB00486', 'DB00487', 'DB00488', 'DB00489', 'DB00490', 'DB00491', 'DB00492', 'DB00493', 'DB00494', 'DB00495', 'DB00496', 'DB00497', 'DB00498', 'DB00499', 'DB00500', 'DB00501', 'DB00502', 'DB00503', 'DB00504', 'DB00505', 'DB00507', 'DB00508', 'DB00509', 'DB00511', 'DB00512', 'DB00513', 'DB00514', 'DB00515', 'DB00516', 'DB00517', 'DB00518', 'DB00519', 'DB00520', 'DB00521', 'DB00522', 'DB00523', 'DB00524', 'DB00525', 'DB00526', 'DB00527', 'DB00528', 'DB00529', 'DB00530', 'DB00531', 'DB00532', 'DB00533', 'DB00534', 'DB00535', 'DB00536', 'DB00537', 'DB00538', 'DB00539', 'DB00540', 'DB00541', 'DB00542', 'DB00543', 'DB00544', 'DB00545', 'DB00546', 'DB00547', 'DB00548', 'DB00549', 'DB00550', 'DB00551', 'DB00552', 'DB00553', 'DB00554', 'DB00555', 'DB00556', 'DB00557', 'DB00558', 'DB00559', 'DB00560', 'DB00561', 'DB00562', 'DB00563', 'DB00564', 'DB00565', 'DB00566', 'DB00567', 'DB00568', 'DB00569', 'DB00570', 'DB00571', 'DB00572', 'DB00573', 'DB00574', 'DB00575', 'DB00576', 'DB00577', 'DB00578', 'DB00579', 'DB00580', 'DB00581', 'DB00582', 'DB00583', 'DB00584', 'DB00585', 'DB00586', 'DB00587', 'DB00588', 'DB00589', 'DB00590', 'DB00591', 'DB00592', 'DB00593', 'DB00594', 'DB00595', 'DB00596', 'DB00597', 'DB00598', 'DB00599', 'DB00600', 'DB00601', 'DB00602', 'DB00603', 'DB00604', 'DB00605', 'DB00606', 'DB00607', 'DB00608', 'DB00609', 'DB00610', 'DB00611', 'DB00612', 'DB00613', 'DB00614', 'DB00615', 'DB00616', 'DB00617', 'DB00618', 'DB00619', 'DB00620', 'DB00621', 'DB00622', 'DB00623', 'DB00624', 'DB00625', 'DB00626', 'DB00627', 'DB00628', 'DB00629', 'DB00630', 'DB00631', 'DB00632', 'DB00633', 'DB00634', 'DB00635', 'DB00636', 'DB00637', 'DB00638', 'DB00639', 'DB00640', 'DB00641', 'DB00642', 'DB00643', 'DB00644', 'DB00645', 'DB00646', 'DB00647', 'DB00648', 'DB00649', 'DB00650', 'DB00651', 'DB00652', 'DB00653', 'DB00654', 'DB00655', 'DB00656', 'DB00657', 'DB00658', 'DB00659', 'DB00660', 'DB00661', 'DB00662', 'DB00663', 'DB00664', 'DB00665', 'DB00666', 'DB00668', 'DB00669', 'DB00670', 'DB00671', 'DB00672', 'DB00673', 'DB00674', 'DB00675', 'DB00676', 'DB00677', 'DB00678', 'DB00679', 'DB00680', 'DB00681', 'DB00682', 'DB00683', 'DB00684', 'DB00685', 'DB00686', 'DB00687', 'DB00688', 'DB00689', 'DB00690', 'DB00691', 'DB00692', 'DB00693', 'DB00694', 'DB00695', 'DB00696', 'DB00697', 'DB00698', 'DB00699', 'DB00700', 'DB00701', 'DB00702', 'DB00703', 'DB00704', 'DB00705', 'DB00706', 'DB00707', 'DB00708', 'DB00709', 'DB00710', 'DB00711', 'DB00712', 'DB00713', 'DB00714', 'DB00715', 'DB00716', 'DB00717', 'DB00718', 'DB00719', 'DB00720', 'DB00721', 'DB00722', 'DB00723', 'DB00724', 'DB00725', 'DB00726', 'DB00727', 'DB00728', 'DB00730', 'DB00731', 'DB00732', 'DB00733', 'DB00734', 'DB00735', 'DB00736', 'DB00737', 'DB00738', 'DB00739', 'DB00740', 'DB00741', 'DB00742', 'DB00743', 'DB00744', 'DB00745', 'DB00746', 'DB00747', 'DB00748', 'DB00749', 'DB00750', 'DB00751', 'DB00752', 'DB00753', 'DB00754', 'DB00755', 'DB00756', 'DB00757', 'DB00758', 'DB00759', 'DB00760', 'DB00761', 'DB00762', 'DB00763', 'DB00764', 'DB00765', 'DB00766', 'DB00767', 'DB00768', 'DB00769', 'DB00770', 'DB00771', 'DB00772', 'DB00773', 'DB00774', 'DB00775', 'DB00776', 'DB00777', 'DB00778', 'DB00779', 'DB00780', 'DB00782', 'DB00783', 'DB00784', 'DB00785', 'DB00786', 'DB00787', 'DB00788', 'DB00789', 'DB00790', 'DB00791', 'DB00792', 'DB00793', 'DB00794', 'DB00795', 'DB00796', 'DB00797', 'DB00798', 'DB00799', 'DB00800', 'DB00801', 'DB00802', 'DB00803', 'DB00804', 'DB00805', 'DB00806', 'DB00807', 'DB00808', 'DB00809', 'DB00810', 'DB00811', 'DB00812', 'DB00813', 'DB00814', 'DB00815', 'DB00816', 'DB00817', 'DB00818', 'DB00819', 'DB00820', 'DB00821', 'DB00822', 'DB00823', 'DB00824', 'DB00825', 'DB00826', 'DB00827', 'DB00828', 'DB00829', 'DB00830', 'DB00831', 'DB00832', 'DB00833', 'DB00834', 'DB00835', 'DB00836', 'DB00837', 'DB00838', 'DB00839', 'DB00840', 'DB00841', 'DB00842', 'DB00843', 'DB00844', 'DB00845', 'DB00846', 'DB00847', 'DB00848', 'DB00849', 'DB00850', 'DB00851', 'DB00852', 'DB00853', 'DB00854', 'DB00855', 'DB00856', 'DB00857', 'DB00858', 'DB00859', 'DB00860', 'DB00861', 'DB00862', 'DB00863', 'DB00864', 'DB00865', 'DB00866', 'DB00867', 'DB00868', 'DB00869', 'DB00870', 'DB00871', 'DB00872', 'DB14596', 'DB00874', 'DB00875', 'DB00876', 'DB00877', 'DB00878', 'DB00879', 'DB00880', 'DB00881', 'DB00882', 'DB00883', 'DB00884', 'DB00885', 'DB00886', 'DB00887', 'DB00888', 'DB00889', 'DB00890', 'DB00891', 'DB00892', 'DB00893', 'DB00894', 'DB00895', 'DB00896', 'DB00897', 'DB00898', 'DB00899', 'DB00900', 'DB00901', 'DB00902', 'DB00903', 'DB00904', 'DB00905', 'DB00906', 'DB00907', 'DB00908', 'DB00909', 'DB00910', 'DB00911', 'DB00912', 'DB00913', 'DB00914', 'DB00915', 'DB00916', 'DB00917', 'DB00918', 'DB00919', 'DB00920', 'DB00921', 'DB00922', 'DB00923', 'DB00924', 'DB00925', 'DB00926', 'DB00927', 'DB00928', 'DB00929', 'DB00930', 'DB00931', 'DB00932', 'DB00933', 'DB00934', 'DB00935', 'DB00936', 'DB00937', 'DB00938', 'DB00939', 'DB00940', 'DB00941', 'DB00942', 'DB00943', 'DB00944', 'DB00945', 'DB00946', 'DB00947', 'DB00948', 'DB00949', 'DB00950', 'DB00951', 'DB00952', 'DB00953', 'DB00954', 'DB00955', 'DB00956', 'DB00957', 'DB00958', 'DB00959', 'DB00960', 'DB00961', 'DB00962', 'DB00963', 'DB00964', 'DB00965', 'DB00966', 'DB00967', 'DB00968', 'DB00969', 'DB00970', 'DB00971', 'DB00972', 'DB00973', 'DB00974', 'DB00975', 'DB00976', 'DB00977', 'DB00978', 'DB00979', 'DB00980', 'DB00981', 'DB00982', 'DB00983', 'DB00984', 'DB00985', 'DB00986', 'DB00987', 'DB00988', 'DB00989', 'DB00990', 'DB00991', 'DB00992', 'DB00993', 'DB00994', 'DB00995', 'DB00996', 'DB00997', 'DB00998', 'DB00999', 'DB01000', 'DB01001', 'DB01002', 'DB01003', 'DB01004', 'DB01005', 'DB01006', 'DB01007', 'DB01008', 'DB01009', 'DB01010', 'DB01011', 'DB01012', 'DB01013', 'DB01014', 'DB01015', 'DB01016', 'DB01017', 'DB01018', 'DB01019', 'DB01020', 'DB01021', 'DB01022', 'DB01023', 'DB01024', 'DB01025', 'DB01026', 'DB01028', 'DB01029', 'DB01030', 'DB01031', 'DB01032', 'DB01033', 'DB01034', 'DB01035', 'DB01036', 'DB01037', 'DB01038', 'DB01039', 'DB01041', 'DB01042', 'DB01043', 'DB01044', 'DB01045', 'DB01046', 'DB01047', 'DB01048', 'DB01049', 'DB01050', 'DB01051', 'DB01053', 'DB01054', 'DB01055', 'DB01056', 'DB01057', 'DB01058', 'DB01059', 'DB01060', 'DB01061', 'DB01062', 'DB01063', 'DB01064', 'DB01065', 'DB01066', 'DB01067', 'DB01068', 'DB01069', 'DB01070', 'DB01071', 'DB01072', 'DB01073', 'DB01074', 'DB01075', 'DB01076', 'DB01077', 'DB01078', 'DB01079', 'DB01080', 'DB01081', 'DB01082', 'DB01083', 'DB01084', 'DB01085', 'DB01086', 'DB01087', 'DB01088', 'DB01089', 'DB01090', 'DB01091', 'DB01092', 'DB01093', 'DB01094', 'DB01095', 'DB01096', 'DB01097', 'DB01098', 'DB01099', 'DB01100', 'DB01101', 'DB01102', 'DB01103', 'DB01104', 'DB01105', 'DB01106', 'DB01107', 'DB01108', 'DB01109', 'DB01110', 'DB01111', 'DB01112', 'DB01113', 'DB01114', 'DB01115', 'DB01116', 'DB01117', 'DB01118', 'DB01119', 'DB01120', 'DB01121', 'DB01122', 'DB01123', 'DB01124', 'DB01125', 'DB01126', 'DB01127', 'DB01128', 'DB01129', 'DB01130', 'DB01131', 'DB01132', 'DB01133', 'DB01134', 'DB01135', 'DB01136', 'DB01137', 'DB01138', 'DB01139', 'DB01140', 'DB01141', 'DB01142', 'DB01143', 'DB01144', 'DB01145', 'DB01146', 'DB01147', 'DB01148', 'DB01149', 'DB01150', 'DB01151', 'DB01152', 'DB01153', 'DB01154', 'DB01155', 'DB01156', 'DB01157', 'DB01158', 'DB01159', 'DB01160', 'DB01161', 'DB01162', 'DB01163', 'DB01164', 'DB01165', 'DB01166', 'DB01167', 'DB01168', 'DB01169', 'DB01170', 'DB01171', 'DB01172', 'DB01173', 'DB01174', 'DB01175', 'DB01176', 'DB01177', 'DB01178', 'DB01179', 'DB01180', 'DB01181', 'DB01182', 'DB01183', 'DB01184', 'DB01185', 'DB01186', 'DB01187', 'DB01188', 'DB01189', 'DB01190', 'DB01191', 'DB01192', 'DB01193', 'DB01194', 'DB01195', 'DB01196', 'DB01197', 'DB01198', 'DB01199', 'DB01200', 'DB01201', 'DB01202', 'DB01203', 'DB01204', 'DB01205', 'DB01206', 'DB01207', 'DB01208', 'DB01209', 'DB01210', 'DB01211', 'DB01212', 'DB01213', 'DB01214', 'DB01215', 'DB01216', 'DB01217', 'DB01218', 'DB01219', 'DB01220', 'DB01221', 'DB01222', 'DB01223', 'DB01224', 'DB01225', 'DB01226', 'DB01227', 'DB01228', 'DB01229', 'DB01230', 'DB01231', 'DB01232', 'DB01233', 'DB01234', 'DB01235', 'DB01236', 'DB01237', 'DB01238', 'DB01239', 'DB01240', 'DB01241', 'DB01242', 'DB01243', 'DB01244', 'DB01245', 'DB01246', 'DB01247', 'DB01248', 'DB01249', 'DB01250', 'DB01251', 'DB01252', 'DB01253', 'DB01254', 'DB01255', 'DB01256', 'DB01257', 'DB01259', 'DB01260', 'DB01261', 'DB01262', 'DB01263', 'DB01264', 'DB01265', 'DB01266', 'DB01267', 'DB01268', 'DB01269', 'DB01270', 'DB01271', 'DB01272', 'DB01273', 'DB01274', 'DB01275', 'DB01276', 'DB01277', 'DB01278', 'DB01279', 'DB01280', 'DB01281', 'DB01282', 'DB01283', 'DB01284', 'DB01285', 'DB01288', 'DB01289', 'DB01291', 'DB01294', 'DB01295', 'DB01296', 'DB01297', 'DB01298', 'DB01299', 'DB01301', 'DB01303', 'DB01306', 'DB01307', 'DB01309', 'DB01319', 'DB01320', 'DB01321', 'DB01322', 'DB01323', 'DB01324', 'DB01325', 'DB01326', 'DB01327', 'DB01328', 'DB01329', 'DB01330', 'DB01331', 'DB01332', 'DB01333', 'DB01336', 'DB01337', 'DB01338', 'DB01339', 'DB01340', 'DB01341', 'DB01342', 'DB01344', 'DB01345', 'DB01346', 'DB01347', 'DB01348', 'DB01349', 'DB01351', 'DB01352', 'DB01353', 'DB01354', 'DB01355', 'DB01356', 'DB01357', 'DB01359', 'DB01362', 'DB01363', 'DB01364', 'DB01365', 'DB01366', 'DB01367', 'DB01369', 'DB01370', 'DB01373', 'DB01375', 'DB01377', 'DB01378', 'DB01380', 'DB01381', 'DB01382', 'DB01384', 'DB01388', 'DB01390', 'DB01392', 'DB01393', 'DB01394', 'DB01395', 'DB01396', 'DB01397', 'DB01399', 'DB01400', 'DB01401', 'DB01403', 'DB01404', 'DB01405', 'DB01406', 'DB01407', 'DB01408', 'DB01409', 'DB01410', 'DB01411', 'DB01412', 'DB01413', 'DB01414', 'DB01415', 'DB01416', 'DB01418', 'DB01419', 'DB01420', 'DB01421', 'DB01422', 'DB01423', 'DB01424', 'DB01425', 'DB01426', 'DB01427', 'DB01428', 'DB01429', 'DB01430', 'DB01431', 'DB01432', 'DB01433', 'DB01434', 'DB01435', 'DB01436', 'DB01437', 'DB01438', 'DB01439', 'DB01440', 'DB01441', 'DB01442', 'DB01443', 'DB01444', 'DB01445', 'DB01446', 'DB01447', 'DB01448', 'DB01450', 'DB01451', 'DB01452', 'DB01453', 'DB01454', 'DB01455', 'DB01456', 'DB01458', 'DB01459', 'DB01460', 'DB01461', 'DB01462', 'DB01463', 'DB01464', 'DB01465', 'DB01466', 'DB01467', 'DB01468', 'DB01469', 'DB01470', 'DB01471', 'DB01472', 'DB01473', 'DB01474', 'DB01475', 'DB01476', 'DB01477', 'DB01478', 'DB01479', 'DB01480', 'DB01481', 'DB01482', 'DB01483', 'DB01484', 'DB01485', 'DB01486', 'DB01487', 'DB01488', 'DB01489', 'DB01490', 'DB01491', 'DB01493', 'DB01494', 'DB01495', 'DB01496', 'DB01497', 'DB01498', 'DB01499', 'DB01500', 'DB01501', 'DB01502', 'DB01503', 'DB01505', 'DB01506', 'DB01509', 'DB01510', 'DB01511', 'DB01512', 'DB01513', 'DB01514', 'DB01515', 'DB01516', 'DB01518', 'DB01520', 'DB01521', 'DB01522', 'DB01523', 'DB01524', 'DB01525', 'DB01526', 'DB01527', 'DB01528', 'DB01529', 'DB01530', 'DB01531', 'DB01532', 'DB01533', 'DB01534', 'DB01535', 'DB01536', 'DB01537', 'DB01538', 'DB01539', 'DB01540', 'DB01541', 'DB01542', 'DB01543', 'DB01544', 'DB01545', 'DB01546', 'DB01547', 'DB01548', 'DB01549', 'DB01550', 'DB01551', 'DB01552', 'DB01553', 'DB01554', 'DB01555', 'DB01556', 'DB01557', 'DB01558', 'DB01559', 'DB01560', 'DB01561', 'DB01562', 'DB01563', 'DB01564', 'DB01565', 'DB01566', 'DB01567', 'DB01568', 'DB01569', 'DB01570', 'DB01571', 'DB01572', 'DB01573', 'DB01574', 'DB01575', 'DB01576', 'DB01577', 'DB01578', 'DB01579', 'DB01580', 'DB01581', 'DB01582', 'DB01583', 'DB01584', 'DB01586', 'DB01587', 'DB01588', 'DB01589', 'DB01590', 'DB01591', 'DB01592', 'DB01593', 'DB01594', 'DB01595', 'DB01597', 'DB01598', 'DB01599', 'DB01600', 'DB01601', 'DB01602', 'DB01603', 'DB01604', 'DB01605', 'DB01606', 'DB01607', 'DB01608', 'DB01609', 'DB01610', 'DB01611', 'DB01612', 'DB01613', 'DB01614', 'DB01615', 'DB01616', 'DB01618', 'DB01619', 'DB01620', 'DB01621', 'DB01622', 'DB01623', 'DB01624', 'DB01625', 'DB01626', 'DB01627', 'DB01628', 'DB01629', 'DB01630', 'DB01631', 'DB01632', 'DB01633', 'DB01634', 'DB01635', 'DB01637', 'DB01638', 'DB01639', 'DB01640', 'DB01641', 'DB01642', 'DB01643', 'DB01644', 'DB01645', 'DB01646', 'DB01647', 'DB01648', 'DB01649', 'DB01650', 'DB01651', 'DB01652', 'DB01655', 'DB01656', 'DB01657', 'DB01658', 'DB01659', 'DB01661', 'DB01662', 'DB01663', 'DB01664', 'DB01665', 'DB01666', 'DB01667', 'DB01668', 'DB01669', 'DB01670', 'DB01671', 'DB01672', 'DB01673', 'DB01674', 'DB01675', 'DB01676', 'DB01677', 'DB01678', 'DB01679', 'DB01681', 'DB01682', 'DB01683', 'DB01684', 'DB01685', 'DB01686', 'DB01687', 'DB01688', 'DB01689', 'DB01690', 'DB01691', 'DB01692', 'DB01694', 'DB01695', 'DB01697', 'DB01698', 'DB01699', 'DB01700', 'DB01701', 'DB01702', 'DB01703', 'DB01704', 'DB01705', 'DB01706', 'DB01707', 'DB01708', 'DB01709', 'DB01710', 'DB01711', 'DB01712', 'DB01713', 'DB01714', 'DB01715', 'DB01716', 'DB01717', 'DB01718', 'DB01719', 'DB01720', 'DB01721', 'DB01723', 'DB01724', 'DB01725', 'DB01726', 'DB01727', 'DB01728', 'DB01729', 'DB01731', 'DB01732', 'DB01733', 'DB01734', 'DB01735', 'DB01736', 'DB01737', 'DB01738', 'DB01739', 'DB01740', 'DB01741', 'DB01742', 'DB01744', 'DB01745', 'DB01746', 'DB01747', 'DB01748', 'DB01749', 'DB01750', 'DB01751', 'DB01752', 'DB01753', 'DB01754', 'DB01755', 'DB01756', 'DB01758', 'DB01759', 'DB01760', 'DB01761', 'DB01762', 'DB01763', 'DB01764', 'DB01765', 'DB01766', 'DB01767', 'DB01768', 'DB01771', 'DB01772', 'DB01773', 'DB01774', 'DB01775', 'DB01776', 'DB01777', 'DB01778', 'DB01779', 'DB01780', 'DB01782', 'DB01783', 'DB01784', 'DB01785', 'DB01786', 'DB01788', 'DB01789', 'DB01790', 'DB01791', 'DB01792', 'DB01793', 'DB01794', 'DB01795', 'DB01796', 'DB01797', 'DB01798', 'DB01799', 'DB01800', 'DB01802', 'DB01803', 'DB01804', 'DB01805', 'DB01806', 'DB01807', 'DB01808', 'DB01809', 'DB01810', 'DB01811', 'DB01812', 'DB01813', 'DB01814', 'DB01815', 'DB01816', 'DB01817', 'DB01818', 'DB01819', 'DB01820', 'DB01821', 'DB01822', 'DB01823', 'DB01824', 'DB01825', 'DB01826', 'DB01827', 'DB01828', 'DB01829', 'DB01830', 'DB01831', 'DB01832', 'DB01833', 'DB01834', 'DB01835', 'DB01836', 'DB01837', 'DB01838', 'DB01839', 'DB01840', 'DB01841', 'DB01842', 'DB01843', 'DB01844', 'DB01846', 'DB01847', 'DB01849', 'DB01850', 'DB01851', 'DB01852', 'DB01853', 'DB01854', 'DB01855', 'DB01856', 'DB01857', 'DB01858', 'DB01859', 'DB01860', 'DB01861', 'DB01862', 'DB01863', 'DB01864', 'DB01865', 'DB01866', 'DB01868', 'DB01870', 'DB01871', 'DB01872', 'DB01873', 'DB01874', 'DB01875', 'DB01876', 'DB01877', 'DB01878', 'DB01879', 'DB01880', 'DB01881', 'DB01882', 'DB01883', 'DB01884', 'DB01885', 'DB01887', 'DB01888', 'DB01889', 'DB01890', 'DB01891', 'DB01892', 'DB01893', 'DB01895', 'DB01896', 'DB01897', 'DB01898', 'DB01899', 'DB01901', 'DB01902', 'DB01903', 'DB01905', 'DB01906', 'DB01908', 'DB01909', 'DB01910', 'DB01911', 'DB01912', 'DB01914', 'DB01915', 'DB01917', 'DB01918', 'DB01919', 'DB01920', 'DB01921', 'DB01922', 'DB01923', 'DB01924', 'DB01925', 'DB01926', 'DB01927', 'DB01929', 'DB01930', 'DB01931', 'DB01932', 'DB01933', 'DB01934', 'DB01935', 'DB01936', 'DB01937', 'DB01938', 'DB01939', 'DB01940', 'DB01941', 'DB01942', 'DB01944', 'DB01945', 'DB01946', 'DB01947', 'DB01948', 'DB01949', 'DB01950', 'DB01951', 'DB01952', 'DB01953', 'DB01954', 'DB01955', 'DB01956', 'DB01957', 'DB01958', 'DB01959', 'DB01960', 'DB01961', 'DB01962', 'DB01963', 'DB01964', 'DB01965', 'DB01966', 'DB01967', 'DB01968', 'DB01969', 'DB01970', 'DB01971', 'DB01972', 'DB01973', 'DB01974', 'DB01975', 'DB01976', 'DB01977', 'DB01978', 'DB01979', 'DB01980', 'DB01981', 'DB01982', 'DB01983', 'DB01984', 'DB01985', 'DB01986', 'DB01987', 'DB01988', 'DB01989', 'DB01990', 'DB01991', 'DB01992', 'DB01993', 'DB01994', 'DB01995', 'DB01996', 'DB01997', 'DB01998', 'DB01999', 'DB02001', 'DB02002', 'DB02004', 'DB02005', 'DB02006', 'DB02007', 'DB02008', 'DB02009', 'DB02010', 'DB02011', 'DB02013', 'DB02014', 'DB02015', 'DB02016', 'DB02017', 'DB02018', 'DB02019', 'DB02020', 'DB02021', 'DB02022', 'DB02023', 'DB02024', 'DB02025', 'DB02026', 'DB02027', 'DB02028', 'DB02029', 'DB02030', 'DB02031', 'DB02032', 'DB02033', 'DB02034', 'DB02035', 'DB02036', 'DB02037', 'DB02038', 'DB02039', 'DB02041', 'DB02042', 'DB02043', 'DB02044', 'DB02045', 'DB02046', 'DB02047', 'DB02048', 'DB02049', 'DB02051', 'DB02052', 'DB02053', 'DB02054', 'DB02055', 'DB02056', 'DB02057', 'DB02058', 'DB02059', 'DB02060', 'DB02061', 'DB02062', 'DB02063', 'DB02065', 'DB02066', 'DB02067', 'DB02068', 'DB02069', 'DB02070', 'DB02071', 'DB02072', 'DB02073', 'DB02074', 'DB02075', 'DB02076', 'DB02077', 'DB02078', 'DB02079', 'DB02080', 'DB02081', 'DB02082', 'DB02083', 'DB02084', 'DB02085', 'DB02086', 'DB02087', 'DB02088', 'DB02089', 'DB02090', 'DB02091', 'DB02092', 'DB02093', 'DB02094', 'DB02095', 'DB02096', 'DB02097', 'DB02098', 'DB02099', 'DB02100', 'DB02101', 'DB02102', 'DB02103', 'DB02104', 'DB02105', 'DB02106', 'DB02107', 'DB02108', 'DB02109', 'DB02110', 'DB02111', 'DB02112', 'DB02113', 'DB02114', 'DB02115', 'DB02116', 'DB02118', 'DB02119', 'DB02120', 'DB02121', 'DB02122', 'DB02123', 'DB02124', 'DB02125', 'DB02126', 'DB02127', 'DB02128', 'DB02129', 'DB02130', 'DB02131', 'DB02132', 'DB02133', 'DB02134', 'DB02135', 'DB02136', 'DB02137', 'DB02138', 'DB02139', 'DB02140', 'DB02141', 'DB02142', 'DB02143', 'DB02144', 'DB02145', 'DB02146', 'DB02147', 'DB02148', 'DB02151', 'DB02152', 'DB02153', 'DB02154', 'DB02155', 'DB02156', 'DB02158', 'DB02159', 'DB02160', 'DB02161', 'DB02162', 'DB02163', 'DB02164', 'DB02165', 'DB02166', 'DB02167', 'DB02168', 'DB02169', 'DB02170', 'DB02172', 'DB02173', 'DB02174', 'DB02175', 'DB02176', 'DB02177', 'DB02178', 'DB02179', 'DB02180', 'DB02181', 'DB02182', 'DB02183', 'DB02184', 'DB02185', 'DB02186', 'DB02187', 'DB02188', 'DB02189', 'DB02190', 'DB02191', 'DB02192', 'DB02194', 'DB02195', 'DB02196', 'DB02197', 'DB02198', 'DB02199', 'DB02200', 'DB02201', 'DB02202', 'DB02203', 'DB02205', 'DB02207', 'DB02209', 'DB02210', 'DB02211', 'DB02213', 'DB02214', 'DB02215', 'DB02216', 'DB02217', 'DB02218', 'DB02219', 'DB02220', 'DB02221', 'DB02222', 'DB02223', 'DB02224', 'DB02225', 'DB02226', 'DB02227', 'DB02228', 'DB02229', 'DB02230', 'DB02232', 'DB02233', 'DB02234', 'DB02235', 'DB02236', 'DB02237', 'DB02238', 'DB02239', 'DB02240', 'DB02241', 'DB02242', 'DB02243', 'DB02245', 'DB02247', 'DB02248', 'DB02249', 'DB02251', 'DB02252', 'DB02253', 'DB02254', 'DB02255', 'DB02256', 'DB02257', 'DB02258', 'DB02259', 'DB02260', 'DB02261', 'DB02262', 'DB02263', 'DB02264', 'DB02265', 'DB02266', 'DB02267', 'DB02268', 'DB02269', 'DB02270', 'DB02271', 'DB02272', 'DB02273', 'DB02274', 'DB02275', 'DB02276', 'DB02277', 'DB02278', 'DB02279', 'DB02280', 'DB02281', 'DB02282', 'DB02283', 'DB02285', 'DB02286', 'DB02287', 'DB02288', 'DB02289', 'DB02290', 'DB02292', 'DB02293', 'DB02294', 'DB02295', 'DB02296', 'DB02297', 'DB02298', 'DB02299', 'DB02300', 'DB02301', 'DB02302', 'DB02303', 'DB02304', 'DB02305', 'DB02306', 'DB02307', 'DB02308', 'DB02309', 'DB02310', 'DB02311', 'DB02312', 'DB02313', 'DB02314', 'DB02315', 'DB02316', 'DB02317', 'DB02318', 'DB02319', 'DB02320', 'DB02321', 'DB02322', 'DB02323', 'DB02324', 'DB02325', 'DB02326', 'DB02327', 'DB02328', 'DB02329', 'DB02331', 'DB02332', 'DB02333', 'DB02334', 'DB02335', 'DB02336', 'DB02337', 'DB02338', 'DB02339', 'DB02340', 'DB02341', 'DB02342', 'DB02343', 'DB02345', 'DB02346', 'DB02347', 'DB02348', 'DB02349', 'DB02350', 'DB02352', 'DB02353', 'DB02354', 'DB02355', 'DB02356', 'DB02357', 'DB02358', 'DB02359', 'DB02360', 'DB02361', 'DB02362', 'DB02363', 'DB02364', 'DB02365', 'DB02366', 'DB02367', 'DB02368', 'DB02369', 'DB02370', 'DB02371', 'DB02372', 'DB02373', 'DB02374', 'DB02375', 'DB02376', 'DB02377', 'DB02378', 'DB02379', 'DB02380', 'DB02381', 'DB02382', 'DB02383', 'DB02384', 'DB02385', 'DB02386', 'DB02388', 'DB02390', 'DB02391', 'DB02393', 'DB02394', 'DB02395', 'DB02396', 'DB02397', 'DB02398', 'DB02399', 'DB02400', 'DB02401', 'DB02402', 'DB02403', 'DB02404', 'DB02405', 'DB02406', 'DB02407', 'DB02408', 'DB02409', 'DB02410', 'DB02411', 'DB02412', 'DB02413', 'DB02414', 'DB02415', 'DB02416', 'DB02417', 'DB02418', 'DB02419', 'DB02420', 'DB02421', 'DB02422', 'DB02423', 'DB02424', 'DB02425', 'DB02426', 'DB02427', 'DB02428', 'DB02429', 'DB02430', 'DB02431', 'DB02432', 'DB02433', 'DB02434', 'DB02435', 'DB02436', 'DB02437', 'DB02438', 'DB02441', 'DB02442', 'DB02443', 'DB02445', 'DB02446', 'DB02447', 'DB02448', 'DB02449', 'DB02450', 'DB02451', 'DB02452', 'DB02453', 'DB02454', 'DB02455', 'DB02456', 'DB02457', 'DB02458', 'DB02459', 'DB02460', 'DB02461', 'DB02462', 'DB02463', 'DB02464', 'DB02465', 'DB02466', 'DB02467', 'DB02468', 'DB02469', 'DB02470', 'DB02471', 'DB02472', 'DB02473', 'DB02474', 'DB02475', 'DB02477', 'DB02479', 'DB02480', 'DB02481', 'DB02482', 'DB02483', 'DB02484', 'DB02485', 'DB02486', 'DB02488', 'DB02489', 'DB02490', 'DB02491', 'DB02492', 'DB02493', 'DB02494', 'DB02495', 'DB02496', 'DB02497', 'DB02498', 'DB02499', 'DB02500', 'DB02501', 'DB02502', 'DB02503', 'DB02504', 'DB02505', 'DB02506', 'DB02508', 'DB02509', 'DB02510', 'DB02511', 'DB02512', 'DB02513', 'DB02514', 'DB02515', 'DB02516', 'DB02517', 'DB02518', 'DB02519', 'DB02520', 'DB02521', 'DB02522', 'DB02523', 'DB02524', 'DB02525', 'DB02526', 'DB02527', 'DB02528', 'DB02529', 'DB02530', 'DB02531', 'DB02532', 'DB02534', 'DB02535', 'DB02536', 'DB02537', 'DB02538', 'DB02540', 'DB02541', 'DB02542', 'DB02543', 'DB02544', 'DB02545', 'DB02546', 'DB02547', 'DB02548', 'DB02549', 'DB02550', 'DB02551', 'DB02552', 'DB02553', 'DB02554', 'DB02555', 'DB02556', 'DB02557', 'DB02558', 'DB02559', 'DB02560', 'DB02561', 'DB02562', 'DB02563', 'DB02565', 'DB02566', 'DB02567', 'DB02568', 'DB02569', 'DB02570', 'DB02571', 'DB02572', 'DB02573', 'DB02574', 'DB02576', 'DB02577', 'DB02578', 'DB02579', 'DB02580', 'DB02581', 'DB02582', 'DB02583', 'DB02585', 'DB02586', 'DB02587', 'DB02588', 'DB02589', 'DB02590', 'DB02591', 'DB02592', 'DB02593', 'DB02594', 'DB02595', 'DB02596', 'DB02597', 'DB02598', 'DB02599', 'DB02600', 'DB02601', 'DB02602', 'DB02603', 'DB02604', 'DB02606', 'DB02607', 'DB02608', 'DB02609', 'DB02610', 'DB02611', 'DB02613', 'DB02614', 'DB02615', 'DB02616', 'DB02617', 'DB02618', 'DB02619', 'DB02620', 'DB02621', 'DB02622', 'DB02623', 'DB02624', 'DB02625', 'DB02626', 'DB02627', 'DB02628', 'DB02629', 'DB02630', 'DB02632', 'DB02633', 'DB02635', 'DB02636', 'DB02637', 'DB02638', 'DB02639', 'DB02640', 'DB02641', 'DB02642', 'DB02643', 'DB02644', 'DB02645', 'DB02646', 'DB02647', 'DB02648', 'DB02649', 'DB02650', 'DB02651', 'DB02652', 'DB02654', 'DB02655', 'DB02656', 'DB02657', 'DB02658', 'DB02659', 'DB02660', 'DB02661', 'DB02662', 'DB02663', 'DB02664', 'DB02665', 'DB02666', 'DB02667', 'DB02668', 'DB02669', 'DB02670', 'DB02671', 'DB02673', 'DB02674', 'DB02675', 'DB02676', 'DB02677', 'DB02678', 'DB02679', 'DB02680', 'DB02681', 'DB02683', 'DB02684', 'DB02685', 'DB02686', 'DB02688', 'DB02689', 'DB02690', 'DB02691', 'DB02693', 'DB02694', 'DB02695', 'DB02696', 'DB02697', 'DB02698', 'DB02699', 'DB02700', 'DB02701', 'DB02702', 'DB02703', 'DB02704', 'DB02705', 'DB02706', 'DB02707', 'DB02709', 'DB02710', 'DB02711', 'DB02712', 'DB02713', 'DB02714', 'DB02715', 'DB02716', 'DB02717', 'DB02719', 'DB02720', 'DB02721', 'DB02722', 'DB02723', 'DB02724', 'DB02725', 'DB02726', 'DB02727', 'DB02728', 'DB02729', 'DB02730', 'DB02731', 'DB02732', 'DB02733', 'DB02734', 'DB02735', 'DB02736', 'DB02738', 'DB02740', 'DB02741', 'DB02742', 'DB02743', 'DB02744', 'DB02745', 'DB02746', 'DB02747', 'DB02749', 'DB02750', 'DB02751', 'DB02752', 'DB02753', 'DB02754', 'DB02755', 'DB02756', 'DB02757', 'DB02758', 'DB02759', 'DB02760', 'DB02761', 'DB02762', 'DB02763', 'DB02765', 'DB02766', 'DB02767', 'DB02768', 'DB02770', 'DB02772', 'DB02773', 'DB02774', 'DB02776', 'DB02777', 'DB02778', 'DB02779', 'DB02780', 'DB02781', 'DB02783', 'DB02784', 'DB02785', 'DB02786', 'DB02787', 'DB02788', 'DB02789', 'DB02790', 'DB02792', 'DB02793', 'DB02794', 'DB02795', 'DB02796', 'DB02797', 'DB02798', 'DB02799', 'DB02800', 'DB02801', 'DB02802', 'DB02803', 'DB02804', 'DB02805', 'DB02806', 'DB02807', 'DB02808', 'DB02809', 'DB02810', 'DB02811', 'DB02812', 'DB02813', 'DB02814', 'DB02816', 'DB02817', 'DB02818', 'DB02819', 'DB02820', 'DB02821', 'DB02822', 'DB02823', 'DB02824', 'DB02825', 'DB02827', 'DB02828', 'DB02829', 'DB02830', 'DB02831', 'DB02832', 'DB02833', 'DB02834', 'DB02835', 'DB02836', 'DB02837', 'DB02838', 'DB02839', 'DB02840', 'DB02841', 'DB02842', 'DB02843', 'DB02844', 'DB02845', 'DB02846', 'DB02847', 'DB02848', 'DB02849', 'DB02850', 'DB02851', 'DB02852', 'DB02853', 'DB02854', 'DB02855', 'DB02856', 'DB02857', 'DB02858', 'DB02859', 'DB02860', 'DB02861', 'DB02862', 'DB02864', 'DB02865', 'DB02866', 'DB02867', 'DB02868', 'DB02869', 'DB02870', 'DB02871', 'DB02872', 'DB02873', 'DB02875', 'DB02876', 'DB02877', 'DB02878', 'DB02879', 'DB02880', 'DB02881', 'DB02882', 'DB02883', 'DB02884', 'DB02885', 'DB02887', 'DB02888', 'DB02889', 'DB02890', 'DB02891', 'DB02892', 'DB02893', 'DB02894', 'DB02895', 'DB02896', 'DB02897', 'DB02898', 'DB02899', 'DB02900', 'DB02901', 'DB02902', 'DB02903', 'DB02904', 'DB02905', 'DB02906', 'DB02907', 'DB02908', 'DB02909', 'DB02910', 'DB02911', 'DB02912', 'DB02914', 'DB02915', 'DB02916', 'DB02917', 'DB02918', 'DB02919', 'DB02920', 'DB02921', 'DB02922', 'DB02923', 'DB02924', 'DB02925', 'DB02927', 'DB02928', 'DB02929', 'DB02930', 'DB02931', 'DB02932', 'DB02933', 'DB02934', 'DB02935', 'DB02936', 'DB02937', 'DB02938', 'DB02940', 'DB02941', 'DB02942', 'DB02943', 'DB02945', 'DB02946', 'DB02947', 'DB02948', 'DB02949', 'DB02950', 'DB02951', 'DB02952', 'DB02953', 'DB02954', 'DB02955', 'DB02956', 'DB02957', 'DB02958', 'DB02959', 'DB02960', 'DB02961', 'DB02962', 'DB02963', 'DB02964', 'DB02965', 'DB02966', 'DB02967', 'DB02968', 'DB02969', 'DB02970', 'DB02971', 'DB02972', 'DB02973', 'DB02974', 'DB02975', 'DB02976', 'DB02977', 'DB02978', 'DB02979', 'DB02980', 'DB02981', 'DB02982', 'DB02983', 'DB02984', 'DB02985', 'DB02986', 'DB02987', 'DB02988', 'DB02989', 'DB02990', 'DB02991', 'DB02992', 'DB02993', 'DB02994', 'DB02995', 'DB02996', 'DB02998', 'DB02999', 'DB03000', 'DB03001', 'DB03002', 'DB03003', 'DB03004', 'DB03005', 'DB03006', 'DB03007', 'DB03008', 'DB03009', 'DB03010', 'DB03011', 'DB03012', 'DB03013', 'DB03015', 'DB03016', 'DB03017', 'DB03018', 'DB03019', 'DB03020', 'DB03021', 'DB03022', 'DB03023', 'DB03024', 'DB03025', 'DB03026', 'DB03028', 'DB03030', 'DB03031', 'DB03032', 'DB03033', 'DB03034', 'DB03035', 'DB03037', 'DB03038', 'DB03039', 'DB03040', 'DB03041', 'DB03042', 'DB03043', 'DB03044', 'DB03045', 'DB03046', 'DB03047', 'DB03048', 'DB03049', 'DB03051', 'DB03052', 'DB03053', 'DB03054', 'DB03056', 'DB03057', 'DB03058', 'DB03059', 'DB03060', 'DB03061', 'DB03062', 'DB03063', 'DB03064', 'DB03065', 'DB03066', 'DB03067', 'DB03068', 'DB03069', 'DB03070', 'DB03071', 'DB03072', 'DB03073', 'DB03074', 'DB03075', 'DB03076', 'DB03077', 'DB03078', 'DB03079', 'DB03081', 'DB03082', 'DB03083', 'DB03084', 'DB03085', 'DB03086', 'DB03087', 'DB03088', 'DB03090', 'DB03091', 'DB03092', 'DB03093', 'DB03094', 'DB03095', 'DB03096', 'DB03097', 'DB03098', 'DB03099', 'DB03100', 'DB03101', 'DB03102', 'DB03103', 'DB03104', 'DB03105', 'DB03106', 'DB03107', 'DB03108', 'DB03109', 'DB03110', 'DB03111', 'DB03112', 'DB03113', 'DB03114', 'DB03115', 'DB03116', 'DB03117', 'DB03118', 'DB03120', 'DB03121', 'DB03124', 'DB03125', 'DB03126', 'DB03127', 'DB03128', 'DB03129', 'DB03130', 'DB03132', 'DB03133', 'DB03134', 'DB03135', 'DB03136', 'DB03137', 'DB03138', 'DB03139', 'DB03140', 'DB03141', 'DB03142', 'DB03143', 'DB03144', 'DB03145', 'DB03146', 'DB03147', 'DB03148', 'DB03150', 'DB03151', 'DB03152', 'DB03153', 'DB03154', 'DB03155', 'DB03156', 'DB03157', 'DB03158', 'DB03159', 'DB03160', 'DB03161', 'DB03162', 'DB03163', 'DB03164', 'DB03165', 'DB03166', 'DB03167', 'DB03168', 'DB03169', 'DB03170', 'DB03171', 'DB03172', 'DB03173', 'DB03174', 'DB03175', 'DB03176', 'DB03177', 'DB03178', 'DB03179', 'DB03180', 'DB03181', 'DB03182', 'DB03183', 'DB03184', 'DB03185', 'DB03186', 'DB03187', 'DB03189', 'DB03190', 'DB03191', 'DB03192', 'DB03193', 'DB03194', 'DB03195', 'DB03196', 'DB03197', 'DB03198', 'DB03199', 'DB03200', 'DB03201', 'DB03202', 'DB03203', 'DB03204', 'DB03205', 'DB03206', 'DB03207', 'DB03208', 'DB03209', 'DB03210', 'DB03211', 'DB03212', 'DB03213', 'DB03214', 'DB03215', 'DB03216', 'DB03217', 'DB03218', 'DB03219', 'DB03220', 'DB03221', 'DB03222', 'DB03223', 'DB03224', 'DB03225', 'DB03226', 'DB03227', 'DB03228', 'DB03229', 'DB03230', 'DB03231', 'DB03232', 'DB03233', 'DB03234', 'DB03235', 'DB03236', 'DB03237', 'DB03238', 'DB03239', 'DB03240', 'DB03241', 'DB03242', 'DB03243', 'DB03244', 'DB03245', 'DB03246', 'DB03247', 'DB03248', 'DB03249', 'DB03250', 'DB03251', 'DB03252', 'DB03253', 'DB03254', 'DB03255', 'DB03256', 'DB03257', 'DB03258', 'DB03259', 'DB03260', 'DB03262', 'DB03263', 'DB03264', 'DB03266', 'DB03267', 'DB03268', 'DB03269', 'DB03270', 'DB03272', 'DB03273', 'DB03274', 'DB03275', 'DB03276', 'DB03277', 'DB03278', 'DB03279', 'DB03280', 'DB03281', 'DB03283', 'DB03284', 'DB03285', 'DB03286', 'DB03287', 'DB03288', 'DB03289', 'DB03290', 'DB03291', 'DB03292', 'DB03293', 'DB03294', 'DB03295', 'DB03296', 'DB03297', 'DB03298', 'DB03299', 'DB03300', 'DB03301', 'DB03302', 'DB03303', 'DB03304', 'DB03305', 'DB03306', 'DB03307', 'DB03308', 'DB03309', 'DB03310', 'DB03311', 'DB03312', 'DB03313', 'DB03314', 'DB03315', 'DB03316', 'DB03317', 'DB03318', 'DB03319', 'DB03320', 'DB03321', 'DB03322', 'DB03323', 'DB03325', 'DB03326', 'DB03327', 'DB03328', 'DB03329', 'DB03330', 'DB03331', 'DB03332', 'DB03333', 'DB03335', 'DB03336', 'DB03337', 'DB03338', 'DB03339', 'DB03340', 'DB03341', 'DB03342', 'DB03343', 'DB03344', 'DB03345', 'DB03346', 'DB03347', 'DB03348', 'DB03349', 'DB03350', 'DB03351', 'DB03352', 'DB03353', 'DB03354', 'DB03355', 'DB03357', 'DB03358', 'DB03359', 'DB03360', 'DB03361', 'DB03362', 'DB03363', 'DB03364', 'DB03365', 'DB03366', 'DB03367', 'DB03368', 'DB03369', 'DB03370', 'DB03371', 'DB03372', 'DB03373', 'DB03374', 'DB03376', 'DB03378', 'DB03379', 'DB03380', 'DB03381', 'DB03382', 'DB03383', 'DB03384', 'DB03385', 'DB03386', 'DB03387', 'DB03388', 'DB03389', 'DB03390', 'DB03391', 'DB03392', 'DB03393', 'DB03394', 'DB03395', 'DB03396', 'DB03397', 'DB03399', 'DB03400', 'DB03401', 'DB03402', 'DB03403', 'DB03404', 'DB03405', 'DB03406', 'DB03407', 'DB03408', 'DB03409', 'DB03410', 'DB03411', 'DB03412', 'DB03413', 'DB03414', 'DB03415', 'DB03416', 'DB03417', 'DB03418', 'DB03419', 'DB03420', 'DB03421', 'DB03422', 'DB03423', 'DB03424', 'DB03425', 'DB03426', 'DB03427', 'DB03428', 'DB03429', 'DB03430', 'DB03432', 'DB03433', 'DB03434', 'DB03435', 'DB03436', 'DB03437', 'DB03438', 'DB03439', 'DB03440', 'DB03441', 'DB03442', 'DB03443', 'DB03444', 'DB03445', 'DB03446', 'DB03447', 'DB03448', 'DB03449', 'DB03450', 'DB03451', 'DB03452', 'DB03453', 'DB03454', 'DB03455', 'DB03456', 'DB03458', 'DB03459', 'DB03460', 'DB03461', 'DB03462', 'DB03464', 'DB03466', 'DB03467', 'DB03468', 'DB03469', 'DB03470', 'DB03471', 'DB03472', 'DB03473', 'DB03474', 'DB03475', 'DB03476', 'DB03477', 'DB03478', 'DB03479', 'DB03480', 'DB03481', 'DB03482', 'DB03483', 'DB03484', 'DB03485', 'DB03486', 'DB03487', 'DB03488', 'DB03489', 'DB03490', 'DB03491', 'DB03492', 'DB03493', 'DB03495', 'DB03496', 'DB03497', 'DB03498', 'DB03499', 'DB03500', 'DB03501', 'DB03502', 'DB03503', 'DB03504', 'DB03505', 'DB03506', 'DB03507', 'DB03508', 'DB03509', 'DB03510', 'DB03511', 'DB03512', 'DB03513', 'DB03514', 'DB03515', 'DB03516', 'DB03517', 'DB03518', 'DB03520', 'DB03522', 'DB03523', 'DB03524', 'DB03525', 'DB03526', 'DB03528', 'DB03530', 'DB03531', 'DB03532', 'DB03533', 'DB03534', 'DB03535', 'DB03536', 'DB03537', 'DB03539', 'DB03540', 'DB03541', 'DB03542', 'DB03543', 'DB03544', 'DB03546', 'DB03548', 'DB03549', 'DB03550', 'DB03551', 'DB03552', 'DB03553', 'DB03554', 'DB03555', 'DB03556', 'DB03557', 'DB03558', 'DB03559', 'DB03560', 'DB03562', 'DB03564', 'DB03565', 'DB03566', 'DB03567', 'DB03568', 'DB03569', 'DB03570', 'DB03571', 'DB03572', 'DB03573', 'DB03574', 'DB03575', 'DB03576', 'DB03577', 'DB03578', 'DB03581', 'DB03582', 'DB03583', 'DB03584', 'DB03585', 'DB03586', 'DB03587', 'DB03588', 'DB03589', 'DB03590', 'DB03591', 'DB03592', 'DB03593', 'DB03594', 'DB03595', 'DB03596', 'DB03597', 'DB03598', 'DB03600', 'DB03601', 'DB03602', 'DB03603', 'DB03604', 'DB03605', 'DB03606', 'DB03607', 'DB03608', 'DB03609', 'DB03610', 'DB03611', 'DB03612', 'DB03613', 'DB03614', 'DB03615', 'DB03616', 'DB03617', 'DB03618', 'DB03619', 'DB03621', 'DB03622', 'DB03623', 'DB03624', 'DB03626', 'DB03627', 'DB03628', 'DB03629', 'DB03630', 'DB03631', 'DB03632', 'DB03633', 'DB03634', 'DB03635', 'DB03636', 'DB03637', 'DB03638', 'DB03639', 'DB03640', 'DB03641', 'DB03642', 'DB03643', 'DB03644', 'DB03645', 'DB03646', 'DB03647', 'DB03648', 'DB03649', 'DB03650', 'DB03651', 'DB03652', 'DB03653', 'DB03654', 'DB03656', 'DB03657', 'DB03658', 'DB03659', 'DB03660', 'DB03661', 'DB03662', 'DB03663', 'DB03664', 'DB03666', 'DB03667', 'DB03668', 'DB03669', 'DB03670', 'DB03671', 'DB03672', 'DB03673', 'DB03675', 'DB03676', 'DB03677', 'DB03678', 'DB03679', 'DB03680', 'DB03682', 'DB03683', 'DB03685', 'DB03686', 'DB03687', 'DB03688', 'DB03690', 'DB03691', 'DB03692', 'DB03693', 'DB03694', 'DB03695', 'DB03696', 'DB03697', 'DB03698', 'DB03699', 'DB03700', 'DB03701', 'DB03702', 'DB03703', 'DB03704', 'DB03705', 'DB03706', 'DB03707', 'DB03708', 'DB03709', 'DB03710', 'DB03711', 'DB03712', 'DB03714', 'DB03716', 'DB03717', 'DB03718', 'DB03719', 'DB03720', 'DB03721', 'DB03722', 'DB03723', 'DB03724', 'DB03725', 'DB03726', 'DB03727', 'DB03728', 'DB03729', 'DB03730', 'DB03731', 'DB03732', 'DB03733', 'DB03734', 'DB03735', 'DB03736', 'DB03737', 'DB03738', 'DB03739', 'DB03740', 'DB03741', 'DB03742', 'DB03744', 'DB03745', 'DB03746', 'DB03747', 'DB03748', 'DB03749', 'DB03750', 'DB03751', 'DB03752', 'DB03753', 'DB03754', 'DB03755', 'DB03756', 'DB03757', 'DB03758', 'DB03759', 'DB03760', 'DB03761', 'DB03763', 'DB03764', 'DB03765', 'DB03766', 'DB03767', 'DB03768', 'DB03769', 'DB03770', 'DB03771', 'DB03772', 'DB03773', 'DB03774', 'DB03775', 'DB03776', 'DB03777', 'DB03779', 'DB03780', 'DB03781', 'DB03782', 'DB03783', 'DB03784', 'DB03785', 'DB03787', 'DB03788', 'DB03789', 'DB03790', 'DB03791', 'DB03792', 'DB03793', 'DB03794', 'DB03795', 'DB03796', 'DB03797', 'DB03798', 'DB03799', 'DB03800', 'DB03801', 'DB03802', 'DB03803', 'DB03804', 'DB03807', 'DB03808', 'DB03809', 'DB03810', 'DB03811', 'DB03812', 'DB03813', 'DB03814', 'DB03815', 'DB03816', 'DB03817', 'DB03818', 'DB03819', 'DB03820', 'DB03821', 'DB03822', 'DB03823', 'DB03824', 'DB03825', 'DB03826', 'DB03827', 'DB03828', 'DB03829', 'DB03830', 'DB03831', 'DB03832', 'DB03833', 'DB03834', 'DB03835', 'DB03836', 'DB03837', 'DB03839', 'DB03840', 'DB03841', 'DB03842', 'DB03843', 'DB03844', 'DB03845', 'DB03846', 'DB03847', 'DB03848', 'DB03849', 'DB03850', 'DB03851', 'DB03852', 'DB03853', 'DB03854', 'DB03855', 'DB03856', 'DB03857', 'DB03858', 'DB03859', 'DB03860', 'DB03861', 'DB03862', 'DB03863', 'DB03864', 'DB03865', 'DB03866', 'DB03867', 'DB03868', 'DB03869', 'DB03870', 'DB03871', 'DB03872', 'DB03874', 'DB03876', 'DB03877', 'DB03878', 'DB03879', 'DB03880', 'DB03881', 'DB03882', 'DB03883', 'DB03884', 'DB03885', 'DB03886', 'DB03887', 'DB03888', 'DB03889', 'DB03890', 'DB03891', 'DB03892', 'DB03893', 'DB03894', 'DB03895', 'DB03896', 'DB03897', 'DB03898', 'DB03899', 'DB03900', 'DB03901', 'DB03902', 'DB03903', 'DB03904', 'DB03905', 'DB03906', 'DB03907', 'DB03908', 'DB03909', 'DB03910', 'DB03911', 'DB03912', 'DB03913', 'DB03914', 'DB03915', 'DB03916', 'DB03917', 'DB03918', 'DB03919', 'DB03920', 'DB03921', 'DB03923', 'DB03924', 'DB03925', 'DB03926', 'DB03927', 'DB03928', 'DB03929', 'DB03930', 'DB03931', 'DB03932', 'DB03933', 'DB03934', 'DB03935', 'DB03936', 'DB03937', 'DB03938', 'DB03939', 'DB03940', 'DB03941', 'DB03942', 'DB03943', 'DB03944', 'DB03945', 'DB03946', 'DB03947', 'DB03948', 'DB03949', 'DB03950', 'DB03951', 'DB03952', 'DB03953', 'DB03955', 'DB03956', 'DB03957', 'DB03958', 'DB03959', 'DB03960', 'DB03961', 'DB03962', 'DB03963', 'DB03964', 'DB03966', 'DB03967', 'DB03968', 'DB03970', 'DB03971', 'DB03972', 'DB03973', 'DB03974', 'DB03975', 'DB03976', 'DB03977', 'DB03978', 'DB03979', 'DB03980', 'DB03981', 'DB03982', 'DB03983', 'DB03984', 'DB03985', 'DB03986', 'DB03987', 'DB03988', 'DB03989', 'DB03990', 'DB03991', 'DB03992', 'DB03993', 'DB03994', 'DB03995', 'DB03996', 'DB03997', 'DB03998', 'DB03999', 'DB04000', 'DB04001', 'DB04002', 'DB04003', 'DB04004', 'DB04005', 'DB04006', 'DB04007', 'DB04008', 'DB04009', 'DB04010', 'DB04011', 'DB04012', 'DB04013', 'DB04014', 'DB04015', 'DB04016', 'DB04017', 'DB04018', 'DB04020', 'DB04021', 'DB04022', 'DB04023', 'DB04024', 'DB04026', 'DB04027', 'DB04028', 'DB04029', 'DB04030', 'DB04031', 'DB04032', 'DB04033', 'DB04034', 'DB04035', 'DB04036', 'DB04037', 'DB04038', 'DB04039', 'DB04040', 'DB04041', 'DB04042', 'DB04043', 'DB04044', 'DB04045', 'DB04046', 'DB04047', 'DB04048', 'DB04049', 'DB04050', 'DB04051', 'DB04052', 'DB04053', 'DB04054', 'DB04055', 'DB04057', 'DB04058', 'DB04059', 'DB04060', 'DB04061', 'DB04062', 'DB04063', 'DB04064', 'DB04065', 'DB04066', 'DB04067', 'DB04068', 'DB04069', 'DB04070', 'DB04071', 'DB04072', 'DB04073', 'DB04074', 'DB04075', 'DB04076', 'DB04079', 'DB04080', 'DB04081', 'DB04082', 'DB04083', 'DB04084', 'DB04085', 'DB04086', 'DB04087', 'DB04088', 'DB04089', 'DB04090', 'DB04092', 'DB04093', 'DB04094', 'DB04095', 'DB04096', 'DB04097', 'DB04098', 'DB04099', 'DB04100', 'DB04101', 'DB04102', 'DB04103', 'DB04104', 'DB04105', 'DB04106', 'DB04107', 'DB04108', 'DB04109', 'DB04110', 'DB04111', 'DB04112', 'DB04113', 'DB04114', 'DB04115', 'DB04116', 'DB04117', 'DB04118', 'DB04119', 'DB04120', 'DB04121', 'DB04122', 'DB04123', 'DB04124', 'DB04125', 'DB04126', 'DB04127', 'DB04128', 'DB04129', 'DB04130', 'DB04131', 'DB04132', 'DB04133', 'DB04135', 'DB04136', 'DB04137', 'DB04138', 'DB04139', 'DB04140', 'DB04141', 'DB04142', 'DB04143', 'DB04144', 'DB04145', 'DB04146', 'DB04147', 'DB04149', 'DB04150', 'DB04151', 'DB04152', 'DB04153', 'DB04154', 'DB04155', 'DB04156', 'DB04157', 'DB04158', 'DB04159', 'DB04160', 'DB04161', 'DB04162', 'DB04163', 'DB04164', 'DB04165', 'DB04166', 'DB04167', 'DB04168', 'DB04169', 'DB04170', 'DB04171', 'DB04172', 'DB04173', 'DB04174', 'DB04175', 'DB04176', 'DB04177', 'DB04178', 'DB04179', 'DB04180', 'DB04182', 'DB04183', 'DB04185', 'DB04186', 'DB04187', 'DB04188', 'DB04189', 'DB04190', 'DB04191', 'DB04193', 'DB04194', 'DB04195', 'DB04196', 'DB04197', 'DB04198', 'DB04199', 'DB04200', 'DB04201', 'DB04202', 'DB04203', 'DB04204', 'DB04205', 'DB04206', 'DB04207', 'DB04208', 'DB04209', 'DB04210', 'DB04211', 'DB04212', 'DB04213', 'DB04214', 'DB04215', 'DB04216', 'DB04217', 'DB04218', 'DB04219', 'DB04220', 'DB04221', 'DB04222', 'DB04223', 'DB04224', 'DB04225', 'DB04226', 'DB04227', 'DB04228', 'DB04229', 'DB04230', 'DB04231', 'DB04232', 'DB04233', 'DB04234', 'DB04235', 'DB04236', 'DB04237', 'DB04238', 'DB04239', 'DB04240', 'DB04241', 'DB04242', 'DB04243', 'DB04244', 'DB04246', 'DB04248', 'DB04249', 'DB04250', 'DB04252', 'DB04253', 'DB04254', 'DB04255', 'DB04256', 'DB04257', 'DB04258', 'DB04259', 'DB04260', 'DB04261', 'DB04262', 'DB04263', 'DB04264', 'DB04265', 'DB04266', 'DB04267', 'DB04268', 'DB04269', 'DB04270', 'DB04271', 'DB04272', 'DB04273', 'DB04274', 'DB04275', 'DB04276', 'DB04277', 'DB04278', 'DB04279', 'DB04280', 'DB04281', 'DB04282', 'DB04283', 'DB04284', 'DB04285', 'DB04286', 'DB04287', 'DB04288', 'DB04289', 'DB04291', 'DB04292', 'DB04293', 'DB04294', 'DB04295', 'DB04296', 'DB04297', 'DB04298', 'DB04299', 'DB04300', 'DB04301', 'DB04302', 'DB04303', 'DB04304', 'DB04306', 'DB04307', 'DB04308', 'DB04310', 'DB04311', 'DB04312', 'DB04313', 'DB04314', 'DB04315', 'DB04316', 'DB04317', 'DB04318', 'DB04320', 'DB04321', 'DB04322', 'DB04323', 'DB04324', 'DB04325', 'DB04326', 'DB04327', 'DB04328', 'DB04329', 'DB04330', 'DB04331', 'DB04332', 'DB04333', 'DB04334', 'DB04335', 'DB04336', 'DB04337', 'DB04338', 'DB04339', 'DB04340', 'DB04341', 'DB04342', 'DB04343', 'DB04345', 'DB04346', 'DB04347', 'DB04348', 'DB04349', 'DB04350', 'DB04351', 'DB04352', 'DB04353', 'DB04356', 'DB04357', 'DB04359', 'DB04360', 'DB04361', 'DB04362', 'DB04363', 'DB04364', 'DB04365', 'DB04366', 'DB04367', 'DB04368', 'DB04369', 'DB04370', 'DB04371', 'DB04372', 'DB04373', 'DB04374', 'DB04376', 'DB04377', 'DB04378', 'DB04379', 'DB04380', 'DB04381', 'DB04382', 'DB04383', 'DB04384', 'DB04385', 'DB04386', 'DB04387', 'DB04388', 'DB04389', 'DB04391', 'DB04392', 'DB04393', 'DB04394', 'DB04395', 'DB04396', 'DB04397', 'DB04398', 'DB04400', 'DB04401', 'DB04404', 'DB04405', 'DB04406', 'DB04407', 'DB04408', 'DB04409', 'DB04410', 'DB04411', 'DB04414', 'DB04415', 'DB04416', 'DB04417', 'DB04418', 'DB04419', 'DB04421', 'DB04422', 'DB04423', 'DB04424', 'DB04425', 'DB04426', 'DB04427', 'DB04429', 'DB04430', 'DB04431', 'DB04432', 'DB04433', 'DB04434', 'DB04436', 'DB04437', 'DB04438', 'DB04439', 'DB04440', 'DB04441', 'DB04442', 'DB04444', 'DB04445', 'DB04446', 'DB04447', 'DB04448', 'DB04449', 'DB04450', 'DB04451', 'DB04452', 'DB04453', 'DB04454', 'DB04455', 'DB04456', 'DB04457', 'DB04458', 'DB04459', 'DB04460', 'DB04461', 'DB04462', 'DB04463', 'DB04464', 'DB04465', 'DB04466', 'DB04467', 'DB04468', 'DB04469', 'DB04470', 'DB04471', 'DB04472', 'DB04473', 'DB04474', 'DB04476', 'DB04477', 'DB04478', 'DB04479', 'DB04480', 'DB04481', 'DB04482', 'DB04483', 'DB04484', 'DB04485', 'DB04486', 'DB04487', 'DB04488', 'DB04489', 'DB04490', 'DB04491', 'DB04492', 'DB04493', 'DB04494', 'DB04495', 'DB04496', 'DB04497', 'DB04498', 'DB04499', 'DB04500', 'DB04501', 'DB04502', 'DB04503', 'DB04504', 'DB04505', 'DB04506', 'DB04508', 'DB04509', 'DB04510', 'DB04511', 'DB04512', 'DB04513', 'DB04514', 'DB04515', 'DB04516', 'DB04517', 'DB04518', 'DB04519', 'DB04520', 'DB04521', 'DB04522', 'DB04523', 'DB04524', 'DB04525', 'DB04526', 'DB04527', 'DB04528', 'DB04529', 'DB04530', 'DB04531', 'DB04532', 'DB04533', 'DB04534', 'DB04537', 'DB04538', 'DB04539', 'DB04540', 'DB04541', 'DB04542', 'DB04543', 'DB04544', 'DB04545', 'DB04546', 'DB04547', 'DB04548', 'DB04549', 'DB04551', 'DB04552', 'DB04553', 'DB04554', 'DB04555', 'DB04556', 'DB04557', 'DB04559', 'DB04560', 'DB04561', 'DB04562', 'DB04563', 'DB04564', 'DB04565', 'DB04566', 'DB04567', 'DB04568', 'DB04569', 'DB04570', 'DB04571', 'DB04572', 'DB04573', 'DB04574', 'DB04575', 'DB04576', 'DB04577', 'DB04578', 'DB04579', 'DB04580', 'DB04581', 'DB04582', 'DB04583', 'DB04584', 'DB04585', 'DB04586', 'DB04587', 'DB04588', 'DB04590', 'DB04591', 'DB04592', 'DB04593', 'DB04594', 'DB04595', 'DB04596', 'DB04597', 'DB04598', 'DB04599', 'DB04600', 'DB04601', 'DB04602', 'DB04603', 'DB04604', 'DB04605', 'DB04606', 'DB04607', 'DB04608', 'DB04609', 'DB04610', 'DB04612', 'DB04613', 'DB04614', 'DB04615', 'DB04616', 'DB04617', 'DB04618', 'DB04619', 'DB04620', 'DB04622', 'DB04623', 'DB04624', 'DB04626', 'DB04627', 'DB04628', 'DB04629', 'DB04630', 'DB04631', 'DB04632', 'DB04633', 'DB04634', 'DB04636', 'DB04637', 'DB04638', 'DB04639', 'DB04640', 'DB04641', 'DB04642', 'DB04643', 'DB04644', 'DB04645', 'DB04646', 'DB04647', 'DB04648', 'DB04649', 'DB04650', 'DB04651', 'DB04652', 'DB04653', 'DB04654', 'DB04655', 'DB04656', 'DB04657', 'DB04658', 'DB04659', 'DB04660', 'DB04661', 'DB04662', 'DB04663', 'DB04664', 'DB04665', 'DB04666', 'DB04667', 'DB04668', 'DB04669', 'DB04671', 'DB04672', 'DB04673', 'DB04674', 'DB04676', 'DB04677', 'DB04678', 'DB04679', 'DB04680', 'DB04681', 'DB04682', 'DB04683', 'DB04684', 'DB04685', 'DB04686', 'DB04687', 'DB04688', 'DB04689', 'DB04690', 'DB04691', 'DB04692', 'DB04693', 'DB04694', 'DB04695', 'DB04696', 'DB04697', 'DB04698', 'DB04699', 'DB04700', 'DB04701', 'DB04702', 'DB04703', 'DB04704', 'DB04705', 'DB04706', 'DB04707', 'DB04708', 'DB04709', 'DB04710', 'DB04711', 'DB04712', 'DB04713', 'DB04714', 'DB04715', 'DB04716', 'DB04717', 'DB04718', 'DB04719', 'DB04720', 'DB04721', 'DB04722', 'DB04723', 'DB04724', 'DB04725', 'DB04726', 'DB04727', 'DB04728', 'DB04729', 'DB04731', 'DB04732', 'DB04733', 'DB04734', 'DB04735', 'DB04736', 'DB04737', 'DB04738', 'DB04739', 'DB04740', 'DB04741', 'DB04742', 'DB04743', 'DB04744', 'DB04745', 'DB04746', 'DB04747', 'DB04748', 'DB04749', 'DB04750', 'DB04751', 'DB04752', 'DB04753', 'DB04754', 'DB04755', 'DB04756', 'DB04757', 'DB04758', 'DB04759', 'DB04760', 'DB04761', 'DB04762', 'DB04763', 'DB04764', 'DB04765', 'DB04767', 'DB04768', 'DB04769', 'DB04770', 'DB04771', 'DB04772', 'DB04773', 'DB04774', 'DB04775', 'DB04776', 'DB04777', 'DB04778', 'DB04779', 'DB04780', 'DB04781', 'DB04782', 'DB04783', 'DB04784', 'DB04785', 'DB04786', 'DB04787', 'DB04788', 'DB04789', 'DB04790', 'DB04791', 'DB04792', 'DB04793', 'DB04794', 'DB04795', 'DB04796', 'DB04797', 'DB04798', 'DB04799', 'DB04800', 'DB04801', 'DB04802', 'DB04803', 'DB04804', 'DB04805', 'DB04806', 'DB04807', 'DB04808', 'DB04809', 'DB04810', 'DB04811', 'DB04812', 'DB04813', 'DB04814', 'DB04815', 'DB04816', 'DB04817', 'DB04818', 'DB04819', 'DB04820', 'DB04821', 'DB04822', 'DB04823', 'DB04824', 'DB04825', 'DB04826', 'DB04827', 'DB04828', 'DB04829', 'DB04830', 'DB04831', 'DB04832', 'DB04833', 'DB04834', 'DB04835', 'DB04836', 'DB04837', 'DB04838', 'DB04839', 'DB04840', 'DB04841', 'DB04842', 'DB04843', 'DB04844', 'DB04845', 'DB04846', 'DB04847', 'DB04848', 'DB04849', 'DB04850', 'DB04851', 'DB04852', 'DB04853', 'DB04854', 'DB04855', 'DB04856', 'DB04857', 'DB04858', 'DB04859', 'DB04860', 'DB04861', 'DB04862', 'DB04863', 'DB04864', 'DB04865', 'DB04866', 'DB04867', 'DB04868', 'DB04869', 'DB04870', 'DB04871', 'DB04872', 'DB04873', 'DB04874', 'DB04875', 'DB04876', 'DB04877', 'DB04878', 'DB04879', 'DB04880', 'DB04881', 'DB04882', 'DB04883', 'DB04884', 'DB04885', 'DB04886', 'DB04887', 'DB04888', 'DB04889', 'DB04890', 'DB04891', 'DB04892', 'DB04893', 'DB04894', 'DB04895', 'DB04896', 'DB04897', 'DB04898', 'DB04899', 'DB04900', 'DB04901', 'DB04903', 'DB04904', 'DB04905', 'DB04907', 'DB04908', 'DB04909', 'DB04910', 'DB04911', 'DB04912', 'DB04914', 'DB04915', 'DB04917', 'DB04918', 'DB04919', 'DB04920', 'DB04921', 'DB04923', 'DB04924', 'DB04925', 'DB04926', 'DB04928', 'DB04929', 'DB04930', 'DB04931', 'DB04932', 'DB04933', 'DB04934', 'DB04936', 'DB04938', 'DB04941', 'DB04942', 'DB04943', 'DB04944', 'DB04945', 'DB04946', 'DB04947', 'DB04948', 'DB04949', 'DB04950', 'DB04951', 'DB04952', 'DB04953', 'DB04954', 'DB04955', 'DB04956', 'DB04957', 'DB04958', 'DB04959', 'DB04960', 'DB04961', 'DB04962', 'DB04963', 'DB04964', 'DB04967', 'DB04968', 'DB04969', 'DB04970', 'DB04971', 'DB04972', 'DB04973', 'DB04974', 'DB04975', 'DB04976', 'DB04977', 'DB04978', 'DB04979', 'DB04980', 'DB04981', 'DB04982', 'DB04983', 'DB04985', 'DB04986', 'DB04987', 'DB04988', 'DB04989', 'DB04991', 'DB04992', 'DB04995', 'DB04996', 'DB04997', 'DB04998', 'DB04999', 'DB05000', 'DB05001', 'DB05003', 'DB05004', 'DB05006', 'DB05009', 'DB05010', 'DB05011', 'DB05012', 'DB05013', 'DB05014', 'DB05015', 'DB05016', 'DB05017', 'DB05018', 'DB05019', 'DB05020', 'DB05021', 'DB05022', 'DB05023', 'DB05024', 'DB05025', 'DB05027', 'DB05029', 'DB05032', 'DB05033', 'DB05034', 'DB05035', 'DB05036', 'DB05038', 'DB05039', 'DB05040', 'DB05042', 'DB05043', 'DB05044', 'DB05045', 'DB05046', 'DB05047', 'DB05048', 'DB05049', 'DB05050', 'DB05051', 'DB05052', 'DB05053', 'DB05054', 'DB05055', 'DB05056', 'DB05057', 'DB05059', 'DB05060', 'DB05061', 'DB05063', 'DB05064', 'DB05068', 'DB05069', 'DB05070', 'DB05071', 'DB05072', 'DB05075', 'DB05076', 'DB05077', 'DB05078', 'DB05079', 'DB05080', 'DB05081', 'DB05082', 'DB05084', 'DB05085', 'DB05087', 'DB05088', 'DB05089', 'DB05090', 'DB05091', 'DB05092', 'DB05093', 'DB05095', 'DB05096', 'DB05097', 'DB05098', 'DB05099', 'DB05100', 'DB05101', 'DB05102', 'DB05103', 'DB05104', 'DB05105', 'DB05106', 'DB05107', 'DB05108', 'DB05109', 'DB05110', 'DB05111', 'DB05112', 'DB05113', 'DB05114', 'DB05115', 'DB05116', 'DB05117', 'DB05118', 'DB05119', 'DB05120', 'DB05121', 'DB05122', 'DB05123', 'DB05124', 'DB05125', 'DB05126', 'DB05127', 'DB05128', 'DB05129', 'DB05130', 'DB05131', 'DB05132', 'DB05133', 'DB05134', 'DB05135', 'DB05136', 'DB05137', 'DB05138', 'DB05139', 'DB05140', 'DB05141', 'DB05142', 'DB05143', 'DB05144', 'DB05145', 'DB05146', 'DB05147', 'DB05148', 'DB05149', 'DB05150', 'DB05151', 'DB05152', 'DB05154', 'DB05155', 'DB05156', 'DB05157', 'DB05158', 'DB05159', 'DB05160', 'DB05161', 'DB05163', 'DB05164', 'DB05165', 'DB05166', 'DB05167', 'DB05168', 'DB05169', 'DB05170', 'DB05171', 'DB05172', 'DB05173', 'DB05174', 'DB05177', 'DB05178', 'DB05179', 'DB05180', 'DB05181', 'DB05182', 'DB05183', 'DB05184', 'DB05185', 'DB05186', 'DB05187', 'DB05188', 'DB05189', 'DB05190', 'DB05191', 'DB05192', 'DB05194', 'DB05195', 'DB05196', 'DB05197', 'DB05198', 'DB05199', 'DB05200', 'DB05201', 'DB05202', 'DB05203', 'DB05204', 'DB05205', 'DB05207', 'DB05209', 'DB05210', 'DB05211', 'DB05212', 'DB05214', 'DB05217', 'DB05218', 'DB05219', 'DB05220', 'DB05222', 'DB05223', 'DB05224', 'DB05225', 'DB05226', 'DB05227', 'DB05228', 'DB05229', 'DB05230', 'DB05232', 'DB05233', 'DB05234', 'DB05235', 'DB05236', 'DB05237', 'DB05239', 'DB05241', 'DB05242', 'DB05243', 'DB05244', 'DB05245', 'DB05246', 'DB05249', 'DB05252', 'DB05253', 'DB05254', 'DB05255', 'DB05257', 'DB05258', 'DB05259', 'DB05260', 'DB05262', 'DB05263', 'DB05264', 'DB05265', 'DB05266', 'DB05268', 'DB05271', 'DB05273', 'DB05276', 'DB05282', 'DB05284', 'DB05285', 'DB05288', 'DB05289', 'DB05290', 'DB05292', 'DB05293', 'DB05294', 'DB05295', 'DB05296', 'DB05297', 'DB05298', 'DB05299', 'DB05300', 'DB05301', 'DB05303', 'DB05304', 'DB05305', 'DB05306', 'DB05308', 'DB05309', 'DB05310', 'DB05311', 'DB05312', 'DB05313', 'DB05315', 'DB05316', 'DB05317', 'DB05319', 'DB05320', 'DB05321', 'DB05322', 'DB05325', 'DB05326', 'DB05327', 'DB05328', 'DB05329', 'DB05330', 'DB05332', 'DB05333', 'DB05336', 'DB05337', 'DB05339', 'DB05340', 'DB05343', 'DB05344', 'DB05345', 'DB05346', 'DB05351', 'DB05352', 'DB05353', 'DB05361', 'DB05362', 'DB05363', 'DB05364', 'DB05367', 'DB05368', 'DB05369', 'DB05371', 'DB05374', 'DB05377', 'DB05380', 'DB05381', 'DB05382', 'DB05383', 'DB05384', 'DB05385', 'DB05386', 'DB05387', 'DB05389', 'DB05390', 'DB05391', 'DB05393', 'DB05394', 'DB05395', 'DB05396', 'DB05398', 'DB05399', 'DB05400', 'DB05403', 'DB05404', 'DB05405', 'DB05406', 'DB05407', 'DB05408', 'DB05409', 'DB05410', 'DB05411', 'DB05412', 'DB05413', 'DB05414', 'DB05415', 'DB05416', 'DB05417', 'DB05418', 'DB05419', 'DB05420', 'DB05421', 'DB05422', 'DB05423', 'DB05424', 'DB05426', 'DB05427', 'DB05428', 'DB05429', 'DB05430', 'DB05431', 'DB05432', 'DB05433', 'DB05434', 'DB05437', 'DB05438', 'DB05439', 'DB05440', 'DB05441', 'DB05442', 'DB05443', 'DB05444', 'DB05445', 'DB05446', 'DB05447', 'DB05448', 'DB05449', 'DB05450', 'DB05451', 'DB05452', 'DB05454', 'DB05455', 'DB05456', 'DB05457', 'DB05458', 'DB05459', 'DB05460', 'DB05461', 'DB05462', 'DB05463', 'DB05464', 'DB05465', 'DB05466', 'DB05467', 'DB05468', 'DB05469', 'DB05470', 'DB05471', 'DB05472', 'DB05473', 'DB05474', 'DB05475', 'DB05476', 'DB05477', 'DB05478', 'DB05479', 'DB05480', 'DB05481', 'DB05482', 'DB05483', 'DB05484', 'DB05485', 'DB05487', 'DB05488', 'DB05489', 'DB05490', 'DB05491', 'DB05492', 'DB05493', 'DB05494', 'DB05495', 'DB05496', 'DB05498', 'DB05499', 'DB05500', 'DB05501', 'DB05502', 'DB05505', 'DB05506', 'DB05507', 'DB05509', 'DB05511', 'DB05512', 'DB05513', 'DB05514', 'DB05516', 'DB05518', 'DB05519', 'DB05520', 'DB05521', 'DB05524', 'DB05525', 'DB05528', 'DB05530', 'DB05531', 'DB05532', 'DB05533', 'DB05540', 'DB05541', 'DB05542', 'DB05545', 'DB05549', 'DB05550', 'DB05552', 'DB05553', 'DB05555', 'DB05559', 'DB05560', 'DB05562', 'DB05565', 'DB05575', 'DB05578', 'DB05580', 'DB05584', 'DB05585', 'DB05586', 'DB05590', 'DB05592', 'DB05594', 'DB05595', 'DB05596', 'DB05599', 'DB05606', 'DB05607', 'DB05608', 'DB05611', 'DB05616', 'DB05620', 'DB05624', 'DB05625', 'DB05626', 'DB05630', 'DB05631', 'DB05633', 'DB05638', 'DB05642', 'DB05643', 'DB05644', 'DB05645', 'DB05649', 'DB05650', 'DB05652', 'DB05653', 'DB05656', 'DB05659', 'DB05660', 'DB05662', 'DB05667', 'DB05668', 'DB05670', 'DB05671', 'DB05675', 'DB05676', 'DB05678', 'DB05679', 'DB05680', 'DB05683', 'DB05685', 'DB05686', 'DB05687', 'DB05688', 'DB05695', 'DB05698', 'DB05705', 'DB05706', 'DB05708', 'DB05710', 'DB05712', 'DB05713', 'DB05714', 'DB05718', 'DB05719', 'DB05721', 'DB05722', 'DB05723', 'DB05724', 'DB05730', 'DB05732', 'DB05735', 'DB05736', 'DB05737', 'DB05738', 'DB05739', 'DB05740', 'DB05741', 'DB05742', 'DB05744', 'DB05746', 'DB05747', 'DB05749', 'DB05750', 'DB05751', 'DB05752', 'DB05753', 'DB05754', 'DB05755', 'DB05756', 'DB05757', 'DB05758', 'DB05765', 'DB05766', 'DB05767', 'DB05768', 'DB05769', 'DB05771', 'DB05772', 'DB05773', 'DB05775', 'DB05776', 'DB05777', 'DB05778', 'DB05779', 'DB05780', 'DB05785', 'DB05786', 'DB05787', 'DB05789', 'DB05790', 'DB05791', 'DB05792', 'DB05793', 'DB05794', 'DB05796', 'DB05797', 'DB05798', 'DB05799', 'DB05800', 'DB05801', 'DB05803', 'DB05804', 'DB05805', 'DB05806', 'DB05807', 'DB05808', 'DB05809', 'DB05810', 'DB05811', 'DB05812', 'DB05814', 'DB05815', 'DB05817', 'DB05818', 'DB05819', 'DB05820', 'DB05821', 'DB05824', 'DB05825', 'DB05826', 'DB05827', 'DB05828', 'DB05829', 'DB05830', 'DB05831', 'DB05832', 'DB05834', 'DB05835', 'DB05836', 'DB05837', 'DB05838', 'DB05839', 'DB05840', 'DB05841', 'DB05842', 'DB05843', 'DB05845', 'DB05846', 'DB05848', 'DB05849', 'DB05851', 'DB05852', 'DB05854', 'DB05855', 'DB05856', 'DB05857', 'DB05858', 'DB05859', 'DB05860', 'DB05861', 'DB05863', 'DB05864', 'DB05865', 'DB05866', 'DB05867', 'DB05868', 'DB05869', 'DB05870', 'DB05871', 'DB05873', 'DB05874', 'DB05875', 'DB05879', 'DB05880', 'DB05881', 'DB05882', 'DB05883', 'DB05884', 'DB05885', 'DB05886', 'DB05887', 'DB05888', 'DB05889', 'DB05890', 'DB05892', 'DB05894', 'DB05895', 'DB05896', 'DB05897', 'DB05898', 'DB05899', 'DB05903', 'DB05904', 'DB05905', 'DB05906', 'DB05911', 'DB05912', 'DB05913', 'DB05915', 'DB05916', 'DB05918', 'DB05919', 'DB05920', 'DB05924', 'DB05928', 'DB05929', 'DB05930', 'DB05931', 'DB05932', 'DB05934', 'DB05936', 'DB05938', 'DB05939', 'DB05941', 'DB05942', 'DB05943', 'DB05944', 'DB05945', 'DB05950', 'DB05956', 'DB05959', 'DB05961', 'DB05964', 'DB05966', 'DB05967', 'DB05968', 'DB05969', 'DB05971', 'DB05973', 'DB05974', 'DB05983', 'DB05984', 'DB05990', 'DB05992', 'DB05993', 'DB05996', 'DB06005', 'DB06011', 'DB06013', 'DB06014', 'DB06016', 'DB06021', 'DB06022', 'DB06039', 'DB06040', 'DB06042', 'DB06043', 'DB06045', 'DB06049', 'DB06050', 'DB06058', 'DB06061', 'DB06063', 'DB06064', 'DB06069', 'DB06070', 'DB06071', 'DB06073', 'DB06075', 'DB06077', 'DB06080', 'DB06081', 'DB06082', 'DB06083', 'DB06087', 'DB06089', 'DB06090', 'DB06091', 'DB06093', 'DB06094', 'DB06096', 'DB06097', 'DB06098', 'DB06101', 'DB06103', 'DB06106', 'DB06109', 'DB06111', 'DB06112', 'DB06116', 'DB06117', 'DB06119', 'DB06124', 'DB06127', 'DB06129', 'DB06130', 'DB06133', 'DB06134', 'DB06137', 'DB06138', 'DB06140', 'DB06144', 'DB06145', 'DB06147', 'DB06148', 'DB06149', 'DB06150', 'DB06151', 'DB06152', 'DB06153', 'DB06154', 'DB06155', 'DB06156', 'DB06157', 'DB06159', 'DB06160', 'DB06161', 'DB06162', 'DB06163', 'DB06166', 'DB06168', 'DB06169', 'DB06171', 'DB06174', 'DB06176', 'DB06177', 'DB06178', 'DB06179', 'DB06180', 'DB06181', 'DB06182', 'DB06184', 'DB06185', 'DB06186', 'DB06187', 'DB06188', 'DB06190', 'DB06191', 'DB06192', 'DB06193', 'DB06194', 'DB06195', 'DB06196', 'DB06197', 'DB06198', 'DB06199', 'DB06200', 'DB06201', 'DB06202', 'DB06203', 'DB06204', 'DB06205', 'DB06206', 'DB06207', 'DB06209', 'DB06210', 'DB06211', 'DB06212', 'DB06213', 'DB06215', 'DB06216', 'DB06217', 'DB06218', 'DB06219', 'DB06224', 'DB06225', 'DB06226', 'DB06228', 'DB06229', 'DB06230', 'DB06231', 'DB06233', 'DB06234', 'DB06235', 'DB06236', 'DB06237', 'DB06239', 'DB06240', 'DB06241', 'DB06243', 'DB06244', 'DB06245', 'DB06246', 'DB06247', 'DB06248', 'DB06249', 'DB06250', 'DB06251', 'DB06253', 'DB06255', 'DB06256', 'DB06257', 'DB06258', 'DB06260', 'DB06261', 'DB06262', 'DB06263', 'DB06264', 'DB06266', 'DB06267', 'DB06268', 'DB06270', 'DB06271', 'DB06272', 'DB06273', 'DB06274', 'DB06276', 'DB06280', 'DB06281', 'DB06282', 'DB06283', 'DB06285', 'DB06287', 'DB06288', 'DB06290', 'DB06292', 'DB06293', 'DB06294', 'DB06295', 'DB06297', 'DB06299', 'DB06302', 'DB06303', 'DB06304', 'DB06305', 'DB06306', 'DB06307', 'DB06309', 'DB06310', 'DB06311', 'DB06313', 'DB06314', 'DB06317', 'DB06318', 'DB06321', 'DB06322', 'DB06323', 'DB06324', 'DB06325', 'DB06326', 'DB06328', 'DB06331', 'DB06333', 'DB06334', 'DB06335', 'DB06336', 'DB06342', 'DB06343', 'DB06345', 'DB06346', 'DB06347', 'DB06350', 'DB06354', 'DB06355', 'DB06356', 'DB06358', 'DB06360', 'DB06361', 'DB06362', 'DB06364', 'DB06365', 'DB06366', 'DB06367', 'DB06368', 'DB06370', 'DB06371', 'DB06372', 'DB06374', 'DB06376', 'DB06379', 'DB06393', 'DB06394', 'DB06395', 'DB06397', 'DB06399', 'DB06400', 'DB06401', 'DB06402', 'DB06403', 'DB06404', 'DB06405', 'DB06406', 'DB06408', 'DB06409', 'DB06410', 'DB06412', 'DB06413', 'DB06414', 'DB06415', 'DB06419', 'DB06420', 'DB06421', 'DB06422', 'DB06423', 'DB06429', 'DB06431', 'DB06433', 'DB06434', 'DB06435', 'DB06436', 'DB06437', 'DB06439', 'DB06440', 'DB06441', 'DB06442', 'DB06444', 'DB06445', 'DB06446', 'DB06447', 'DB06448', 'DB06449', 'DB06451', 'DB06453', 'DB06454', 'DB06455', 'DB06457', 'DB06458', 'DB06460', 'DB06461', 'DB06462', 'DB06463', 'DB06464', 'DB06465', 'DB06467', 'DB06468', 'DB06469', 'DB06470', 'DB06471', 'DB06472', 'DB06474', 'DB06475', 'DB06477', 'DB06478', 'DB06479', 'DB06480', 'DB06481', 'DB06482', 'DB06485', 'DB06486', 'DB06489', 'DB06492', 'DB06493', 'DB06494', 'DB06495', 'DB06496', 'DB06497', 'DB06498', 'DB06499', 'DB06503', 'DB06504', 'DB06506', 'DB06508', 'DB06510', 'DB06511', 'DB06512', 'DB06515', 'DB06518', 'DB06519', 'DB06521', 'DB06523', 'DB06525', 'DB06527', 'DB06529', 'DB06530', 'DB06532', 'DB06533', 'DB06534', 'DB06535', 'DB06536', 'DB06538', 'DB06543', 'DB06545', 'DB06548', 'DB06549', 'DB06550', 'DB06552', 'DB06554', 'DB06555', 'DB06556', 'DB06557', 'DB06558', 'DB06559', 'DB06560', 'DB06562', 'DB06568', 'DB06569', 'DB06573', 'DB06575', 'DB06576', 'DB06578', 'DB06579', 'DB06580', 'DB06581', 'DB06582', 'DB06584', 'DB06585', 'DB06586', 'DB06587', 'DB06588', 'DB06589', 'DB06590', 'DB06592', 'DB06594', 'DB06595', 'DB06597', 'DB06598', 'DB06599', 'DB06600', 'DB06602', 'DB06603', 'DB06604', 'DB06605', 'DB06606', 'DB06607', 'DB06608', 'DB06609', 'DB06610', 'DB06611', 'DB06612', 'DB06614', 'DB06616', 'DB06618', 'DB06619', 'DB06620', 'DB06622', 'DB06623', 'DB06624', 'DB06625', 'DB06626', 'DB06629', 'DB06630', 'DB06633', 'DB06634', 'DB06635', 'DB06636', 'DB06637', 'DB06638', 'DB06640', 'DB06641', 'DB06642', 'DB06643', 'DB06645', 'DB06647', 'DB06649', 'DB06650', 'DB06651', 'DB06652', 'DB06654', 'DB06655', 'DB06656', 'DB06657', 'DB06659', 'DB06660', 'DB06662', 'DB06663', 'DB06666', 'DB06669', 'DB06670', 'DB06673', 'DB06674', 'DB06677', 'DB06678', 'DB06679', 'DB06680', 'DB06681', 'DB06682', 'DB06683', 'DB06684', 'DB06685', 'DB06688', 'DB06689', 'DB06690', 'DB06691', 'DB06692', 'DB06693', 'DB06694', 'DB06695', 'DB06696', 'DB06697', 'DB06698', 'DB06699', 'DB06700', 'DB06701', 'DB06702', 'DB06703', 'DB06704', 'DB06705', 'DB06706', 'DB06707', 'DB06708', 'DB06709', 'DB06710', 'DB06711', 'DB06712', 'DB06713', 'DB06714', 'DB06715', 'DB06716', 'DB06717', 'DB06718', 'DB06719', 'DB06720', 'DB06721', 'DB06723', 'DB06724', 'DB06725', 'DB06726', 'DB06727', 'DB06728', 'DB06729', 'DB06730', 'DB06731', 'DB06732', 'DB06733', 'DB06734', 'DB06735', 'DB06736', 'DB06737', 'DB06738', 'DB06739', 'DB06740', 'DB06741', 'DB06742', 'DB06743', 'DB06744', 'DB06745', 'DB06746', 'DB06747', 'DB06748', 'DB06749', 'DB06750', 'DB06751', 'DB06752', 'DB06753', 'DB06754', 'DB06755', 'DB06756', 'DB06757', 'DB06759', 'DB06760', 'DB06761', 'DB06762', 'DB06763', 'DB06764', 'DB06766', 'DB06767', 'DB06768', 'DB06769', 'DB06770', 'DB06771', 'DB06772', 'DB06773', 'DB06774', 'DB06775', 'DB06776', 'DB06777', 'DB06778', 'DB06779', 'DB06780', 'DB06781', 'DB06782', 'DB06783', 'DB06784', 'DB06785', 'DB06786', 'DB06787', 'DB06788', 'DB06789', 'DB06791', 'DB06792', 'DB06793', 'DB06794', 'DB06795', 'DB06796', 'DB06797', 'DB06799', 'DB06800', 'DB06801', 'DB06802', 'DB06803', 'DB06804', 'DB06807', 'DB06809', 'DB06810', 'DB06811', 'DB06812', 'DB06813', 'DB06814', 'DB06815', 'DB06816', 'DB06817', 'DB06819', 'DB06820', 'DB06821', 'DB06822', 'DB06823', 'DB06824', 'DB06825', 'DB06826', 'DB06827', 'DB06828', 'DB06829', 'DB06830', 'DB06831', 'DB06832', 'DB06833', 'DB06834', 'DB06835', 'DB06836', 'DB06837', 'DB06838', 'DB06839', 'DB06840', 'DB06841', 'DB06842', 'DB06843', 'DB06844', 'DB06845', 'DB06847', 'DB06848', 'DB06849', 'DB06850', 'DB06851', 'DB06852', 'DB06853', 'DB06855', 'DB06856', 'DB06857', 'DB06858', 'DB06859', 'DB06860', 'DB06861', 'DB06862', 'DB06864', 'DB06865', 'DB06866', 'DB06867', 'DB06868', 'DB06869', 'DB06870', 'DB06871', 'DB06872', 'DB06873', 'DB06874', 'DB06875', 'DB06876', 'DB06877', 'DB06878', 'DB06879', 'DB06880', 'DB06881', 'DB06882', 'DB06883', 'DB06884', 'DB06885', 'DB06886', 'DB06887', 'DB06888', 'DB06889', 'DB06890', 'DB06891', 'DB06892', 'DB06893', 'DB06894', 'DB06896', 'DB06897', 'DB06898', 'DB06899', 'DB06900', 'DB06901', 'DB06902', 'DB06903', 'DB06904', 'DB06905', 'DB06906', 'DB06907', 'DB06908', 'DB06909', 'DB06910', 'DB06911', 'DB06912', 'DB06913', 'DB06914', 'DB06915', 'DB06916', 'DB06917', 'DB06918', 'DB06919', 'DB06920', 'DB06921', 'DB06922', 'DB06923', 'DB06924', 'DB06925', 'DB06926', 'DB06927', 'DB06928', 'DB06929', 'DB06930', 'DB06931', 'DB06932', 'DB06933', 'DB06934', 'DB06935', 'DB06936', 'DB06937', 'DB06938', 'DB06939', 'DB06940', 'DB06941', 'DB06942', 'DB06943', 'DB06944', 'DB06945', 'DB06946', 'DB06947', 'DB06948', 'DB06949', 'DB06950', 'DB06951', 'DB06952', 'DB06953', 'DB06954', 'DB06955', 'DB06956', 'DB06957', 'DB06958', 'DB06959', 'DB06960', 'DB06961', 'DB06962', 'DB06963', 'DB06964', 'DB06965', 'DB06966', 'DB06967', 'DB06968', 'DB06969', 'DB06970', 'DB06971', 'DB06972', 'DB06973', 'DB06974', 'DB06976', 'DB06977', 'DB06978', 'DB06979', 'DB06980', 'DB06981', 'DB06982', 'DB06983', 'DB06984', 'DB06985', 'DB06986', 'DB06987', 'DB06988', 'DB06989', 'DB06990', 'DB06991', 'DB06992', 'DB06993', 'DB06994', 'DB06995', 'DB06996', 'DB06997', 'DB06998', 'DB06999', 'DB07000', 'DB07001', 'DB07002', 'DB07003', 'DB07004', 'DB07005', 'DB07006', 'DB07007', 'DB07008', 'DB07009', 'DB07010', 'DB07011', 'DB07012', 'DB07013', 'DB07014', 'DB07015', 'DB07016', 'DB07017', 'DB07018', 'DB07019', 'DB07020', 'DB07021', 'DB07022', 'DB07023', 'DB07024', 'DB07025', 'DB07026', 'DB07027', 'DB07028', 'DB07029', 'DB07030', 'DB07031', 'DB07032', 'DB07033', 'DB07034', 'DB07035', 'DB07036', 'DB07037', 'DB07038', 'DB07039', 'DB07040', 'DB07041', 'DB07042', 'DB07043', 'DB07044', 'DB07045', 'DB07046', 'DB07047', 'DB07048', 'DB07049', 'DB07050', 'DB07051', 'DB07052', 'DB07053', 'DB07054', 'DB07055', 'DB07056', 'DB07057', 'DB07058', 'DB07059', 'DB07060', 'DB07061', 'DB07062', 'DB07063', 'DB07064', 'DB07065', 'DB07066', 'DB07067', 'DB07068', 'DB07069', 'DB07070', 'DB07071', 'DB07072', 'DB07073', 'DB07074', 'DB07075', 'DB07076', 'DB07077', 'DB07078', 'DB07079', 'DB07080', 'DB07081', 'DB07082', 'DB07083', 'DB07084', 'DB07085', 'DB07086', 'DB07087', 'DB07088', 'DB07089', 'DB07090', 'DB07091', 'DB07092', 'DB07093', 'DB07094', 'DB07095', 'DB07096', 'DB07097', 'DB07098', 'DB07099', 'DB07100', 'DB07101', 'DB07102', 'DB07103', 'DB07104', 'DB07105', 'DB07106', 'DB07107', 'DB07108', 'DB07109', 'DB07110', 'DB07111', 'DB07112', 'DB07113', 'DB07114', 'DB07115', 'DB07116', 'DB07117', 'DB07118', 'DB07119', 'DB07120', 'DB07121', 'DB07122', 'DB07123', 'DB07124', 'DB07125', 'DB07126', 'DB07127', 'DB07128', 'DB07129', 'DB07130', 'DB07131', 'DB07132', 'DB07133', 'DB07134', 'DB07135', 'DB07136', 'DB07137', 'DB07138', 'DB07139', 'DB07140', 'DB07141', 'DB07142', 'DB07143', 'DB07144', 'DB07145', 'DB07146', 'DB07147', 'DB07148', 'DB07149', 'DB07150', 'DB07151', 'DB07152', 'DB07153', 'DB07154', 'DB07155', 'DB07156', 'DB07157', 'DB07158', 'DB07159', 'DB07160', 'DB07161', 'DB07162', 'DB07163', 'DB07164', 'DB07165', 'DB07167', 'DB07168', 'DB07169', 'DB07170', 'DB07171', 'DB07172', 'DB07173', 'DB07174', 'DB07175', 'DB07176', 'DB07177', 'DB07178', 'DB07179', 'DB07180', 'DB07181', 'DB07182', 'DB07183', 'DB07184', 'DB07185', 'DB07186', 'DB07187', 'DB07188', 'DB07189', 'DB07190', 'DB07192', 'DB07193', 'DB07194', 'DB07195', 'DB07196', 'DB07197', 'DB07198', 'DB07199', 'DB07200', 'DB07201', 'DB07202', 'DB07203', 'DB07204', 'DB07205', 'DB07206', 'DB07207', 'DB07208', 'DB07209', 'DB07210', 'DB07211', 'DB07212', 'DB07213', 'DB07215', 'DB07216', 'DB07217', 'DB07218', 'DB07219', 'DB07220', 'DB07221', 'DB07222', 'DB07223', 'DB07224', 'DB07225', 'DB07226', 'DB07227', 'DB07228', 'DB07229', 'DB07230', 'DB07231', 'DB07232', 'DB07233', 'DB07234', 'DB07235', 'DB07236', 'DB07237', 'DB07238', 'DB07239', 'DB07240', 'DB07241', 'DB07242', 'DB07243', 'DB07244', 'DB07245', 'DB07246', 'DB07247', 'DB07248', 'DB07249', 'DB07250', 'DB07251', 'DB07252', 'DB07253', 'DB07254', 'DB07255', 'DB07256', 'DB07257', 'DB07258', 'DB07259', 'DB07260', 'DB07261', 'DB07262', 'DB07263', 'DB07264', 'DB07265', 'DB07266', 'DB07267', 'DB07268', 'DB07269', 'DB07270', 'DB07271', 'DB07272', 'DB07273', 'DB07274', 'DB07275', 'DB07276', 'DB07277', 'DB07278', 'DB07279', 'DB07280', 'DB07281', 'DB07282', 'DB07283', 'DB07284', 'DB07285', 'DB07286', 'DB07287', 'DB07288', 'DB07289', 'DB07290', 'DB07291', 'DB07292', 'DB07293', 'DB07294', 'DB07295', 'DB07296', 'DB07297', 'DB07298', 'DB07299', 'DB07300', 'DB07301', 'DB07302', 'DB07303', 'DB07304', 'DB07305', 'DB07306', 'DB07307', 'DB07308', 'DB07309', 'DB07310', 'DB07311', 'DB07312', 'DB07313', 'DB07314', 'DB07315', 'DB07316', 'DB07317', 'DB07318', 'DB07319', 'DB07320', 'DB07321', 'DB07322', 'DB07323', 'DB07324', 'DB07325', 'DB07326', 'DB07327', 'DB07328', 'DB07329', 'DB07330', 'DB07331', 'DB07332', 'DB07333', 'DB07334', 'DB07335', 'DB07336', 'DB07337', 'DB07338', 'DB07339', 'DB07340', 'DB07341', 'DB07342', 'DB07343', 'DB07344', 'DB07345', 'DB07346', 'DB07347', 'DB07348', 'DB07349', 'DB07350', 'DB07351', 'DB07352', 'DB07353', 'DB07354', 'DB07355', 'DB07356', 'DB07357', 'DB07358', 'DB07359', 'DB07360', 'DB07362', 'DB07363', 'DB07364', 'DB07365', 'DB07366', 'DB07367', 'DB07368', 'DB07369', 'DB07370', 'DB07371', 'DB07373', 'DB07374', 'DB07375', 'DB07376', 'DB07377', 'DB07378', 'DB07379', 'DB07380', 'DB07381', 'DB07382', 'DB07383', 'DB07384', 'DB07385', 'DB07387', 'DB07388', 'DB07389', 'DB07390', 'DB07391', 'DB07392', 'DB07393', 'DB07394', 'DB07395', 'DB07396', 'DB07397', 'DB07398', 'DB07400', 'DB07401', 'DB07402', 'DB07403', 'DB07404', 'DB07405', 'DB07406', 'DB07407', 'DB07408', 'DB07409', 'DB07410', 'DB07411', 'DB07412', 'DB07413', 'DB07414', 'DB07415', 'DB07416', 'DB07418', 'DB07419', 'DB07420', 'DB07421', 'DB07422', 'DB07423', 'DB07424', 'DB07425', 'DB07426', 'DB07427', 'DB07428', 'DB07429', 'DB07430', 'DB07431', 'DB07432', 'DB07433', 'DB07434', 'DB07435', 'DB07436', 'DB07437', 'DB07439', 'DB07440', 'DB07441', 'DB07443', 'DB07444', 'DB07445', 'DB07446', 'DB07447', 'DB07448', 'DB07449', 'DB07450', 'DB07451', 'DB07452', 'DB07453', 'DB07454', 'DB07455', 'DB07456', 'DB07457', 'DB07458', 'DB07459', 'DB07460', 'DB07461', 'DB07462', 'DB07463', 'DB07464', 'DB07465', 'DB07466', 'DB07467', 'DB07468', 'DB07469', 'DB07470', 'DB07471', 'DB07472', 'DB07473', 'DB07474', 'DB07476', 'DB07477', 'DB07478', 'DB07479', 'DB07480', 'DB07481', 'DB07482', 'DB07483', 'DB07484', 'DB07485', 'DB07486', 'DB07487', 'DB07488', 'DB07489', 'DB07490', 'DB07491', 'DB07492', 'DB07493', 'DB07494', 'DB07495', 'DB07496', 'DB07497', 'DB07498', 'DB07499', 'DB07500', 'DB07501', 'DB07502', 'DB07503', 'DB07504', 'DB07505', 'DB07506', 'DB07507', 'DB07508', 'DB07509', 'DB07510', 'DB07511', 'DB07512', 'DB07513', 'DB07514', 'DB07515', 'DB07516', 'DB07517', 'DB07518', 'DB07519', 'DB07520', 'DB07521', 'DB07522', 'DB07524', 'DB07525', 'DB07526', 'DB07527', 'DB07528', 'DB07529', 'DB07530', 'DB07531', 'DB07532', 'DB07533', 'DB07534', 'DB07535', 'DB07536', 'DB07537', 'DB07538', 'DB07539', 'DB07540', 'DB07541', 'DB07542', 'DB07543', 'DB07544', 'DB07545', 'DB07546', 'DB07547', 'DB07548', 'DB07549', 'DB07550', 'DB07551', 'DB07552', 'DB07553', 'DB07555', 'DB07556', 'DB07557', 'DB07558', 'DB07559', 'DB07560', 'DB07561', 'DB07562', 'DB07563', 'DB07564', 'DB07565', 'DB07567', 'DB07568', 'DB07569', 'DB07570', 'DB07571', 'DB07572', 'DB07573', 'DB07574', 'DB07575', 'DB07577', 'DB07578', 'DB07579', 'DB07580', 'DB07581', 'DB07582', 'DB07583', 'DB07584', 'DB07585', 'DB07586', 'DB07587', 'DB07588', 'DB07589', 'DB07590', 'DB07591', 'DB07592', 'DB07593', 'DB07594', 'DB07595', 'DB07596', 'DB07597', 'DB07598', 'DB07599', 'DB07601', 'DB07602', 'DB07603', 'DB07604', 'DB07605', 'DB07606', 'DB07607', 'DB07608', 'DB07609', 'DB07610', 'DB07611', 'DB07612', 'DB07613', 'DB07614', 'DB07615', 'DB07616', 'DB07617', 'DB07618', 'DB07619', 'DB07620', 'DB07621', 'DB07622', 'DB07623', 'DB07624', 'DB07625', 'DB07626', 'DB07627', 'DB07628', 'DB07629', 'DB07630', 'DB07631', 'DB07632', 'DB07633', 'DB07634', 'DB07635', 'DB07636', 'DB07637', 'DB07638', 'DB07639', 'DB07640', 'DB07641', 'DB07642', 'DB07643', 'DB07644', 'DB07645', 'DB07646', 'DB07647', 'DB07648', 'DB07649', 'DB07650', 'DB07651', 'DB07652', 'DB07653', 'DB07654', 'DB07655', 'DB07657', 'DB07658', 'DB07659', 'DB07660', 'DB07661', 'DB07662', 'DB07663', 'DB07664', 'DB07665', 'DB07666', 'DB07667', 'DB07668', 'DB07669', 'DB07670', 'DB07671', 'DB07672', 'DB07673', 'DB07674', 'DB07675', 'DB07676', 'DB07677', 'DB07678', 'DB07679', 'DB07680', 'DB07681', 'DB07683', 'DB07684', 'DB07685', 'DB07686', 'DB07687', 'DB07688', 'DB07689', 'DB07691', 'DB07692', 'DB07693', 'DB07694', 'DB07695', 'DB07696', 'DB07697', 'DB07698', 'DB07700', 'DB07701', 'DB07702', 'DB07703', 'DB07704', 'DB07705', 'DB07706', 'DB07707', 'DB07708', 'DB07710', 'DB07711', 'DB07712', 'DB07713', 'DB07714', 'DB07715', 'DB07716', 'DB07717', 'DB07718', 'DB07719', 'DB07720', 'DB07721', 'DB07722', 'DB07723', 'DB07724', 'DB07726', 'DB07728', 'DB07729', 'DB07730', 'DB07731', 'DB07732', 'DB07733', 'DB07734', 'DB07735', 'DB07736', 'DB07737', 'DB07738', 'DB07739', 'DB07740', 'DB07741', 'DB07742', 'DB07743', 'DB07744', 'DB07745', 'DB07746', 'DB07747', 'DB07748', 'DB07749', 'DB07750', 'DB07751', 'DB07753', 'DB07754', 'DB07755', 'DB07756', 'DB07757', 'DB07758', 'DB07759', 'DB07760', 'DB07761', 'DB07762', 'DB07763', 'DB07764', 'DB07765', 'DB07766', 'DB07767', 'DB07768', 'DB07769', 'DB07770', 'DB07771', 'DB07772', 'DB07773', 'DB07775', 'DB07776', 'DB07778', 'DB07779', 'DB07780', 'DB07781', 'DB07782', 'DB07783', 'DB07784', 'DB07785', 'DB07786', 'DB07787', 'DB07788', 'DB07789', 'DB07790', 'DB07791', 'DB07792', 'DB07793', 'DB07794', 'DB07795', 'DB07796', 'DB07797', 'DB07798', 'DB07800', 'DB07801', 'DB07802', 'DB07803', 'DB07804', 'DB07805', 'DB07806', 'DB07807', 'DB07808', 'DB07809', 'DB07810', 'DB07811', 'DB07812', 'DB07813', 'DB07814', 'DB07815', 'DB07816', 'DB07817', 'DB07818', 'DB07819', 'DB07820', 'DB07821', 'DB07823', 'DB07824', 'DB07825', 'DB07826', 'DB07827', 'DB07829', 'DB07830', 'DB07831', 'DB07832', 'DB07833', 'DB07834', 'DB07835', 'DB07836', 'DB07837', 'DB07838', 'DB07839', 'DB07840', 'DB07841', 'DB07842', 'DB07843', 'DB07844', 'DB07845', 'DB07846', 'DB07847', 'DB07848', 'DB07849', 'DB07850', 'DB07851', 'DB07852', 'DB07853', 'DB07854', 'DB07855', 'DB07856', 'DB07857', 'DB07858', 'DB07859', 'DB07860', 'DB07861', 'DB07862', 'DB07863', 'DB07864', 'DB07865', 'DB07866', 'DB07867', 'DB07868', 'DB07869', 'DB07870', 'DB07871', 'DB07872', 'DB07873', 'DB07874', 'DB07875', 'DB07876', 'DB07877', 'DB07878', 'DB07879', 'DB07880', 'DB07881', 'DB07882', 'DB07883', 'DB07884', 'DB07885', 'DB07887', 'DB07888', 'DB07889', 'DB07890', 'DB07891', 'DB07892', 'DB07893', 'DB07894', 'DB07895', 'DB07896', 'DB07897', 'DB07898', 'DB07899', 'DB07900', 'DB07901', 'DB07902', 'DB07903', 'DB07905', 'DB07906', 'DB07907', 'DB07908', 'DB07909', 'DB07910', 'DB07911', 'DB07912', 'DB07913', 'DB07914', 'DB07915', 'DB07916', 'DB07917', 'DB07918', 'DB07919', 'DB07920', 'DB07921', 'DB07922', 'DB07923', 'DB07924', 'DB07925', 'DB07926', 'DB07927', 'DB07928', 'DB07929', 'DB07930', 'DB07931', 'DB07932', 'DB07933', 'DB07934', 'DB07935', 'DB07936', 'DB07937', 'DB07938', 'DB07939', 'DB07940', 'DB07941', 'DB07942', 'DB07943', 'DB07944', 'DB07945', 'DB07946', 'DB07947', 'DB07949', 'DB07950', 'DB07951', 'DB07952', 'DB07953', 'DB07954', 'DB07955', 'DB07956', 'DB07957', 'DB07958', 'DB07959', 'DB07960', 'DB07961', 'DB07962', 'DB07963', 'DB07964', 'DB07965', 'DB07966', 'DB07967', 'DB07968', 'DB07969', 'DB07970', 'DB07971', 'DB07972', 'DB07973', 'DB07974', 'DB07975', 'DB07976', 'DB07977', 'DB07978', 'DB07979', 'DB07981', 'DB07982', 'DB07983', 'DB07984', 'DB07985', 'DB07986', 'DB07987', 'DB07988', 'DB07989', 'DB07990', 'DB07991', 'DB07992', 'DB07993', 'DB07994', 'DB07995', 'DB07996', 'DB07997', 'DB07999', 'DB08000', 'DB08001', 'DB08003', 'DB08004', 'DB08005', 'DB08006', 'DB08007', 'DB08008', 'DB08009', 'DB08010', 'DB08011', 'DB08012', 'DB08013', 'DB08014', 'DB08015', 'DB08016', 'DB08017', 'DB08018', 'DB08019', 'DB08020', 'DB08021', 'DB08022', 'DB08023', 'DB08024', 'DB08025', 'DB08026', 'DB08027', 'DB08028', 'DB08029', 'DB08030', 'DB08031', 'DB08032', 'DB08033', 'DB08034', 'DB08035', 'DB08036', 'DB08037', 'DB08038', 'DB08039', 'DB08040', 'DB08041', 'DB08042', 'DB08043', 'DB08044', 'DB08045', 'DB08046', 'DB08047', 'DB08048', 'DB08049', 'DB08050', 'DB08051', 'DB08052', 'DB08053', 'DB08054', 'DB08055', 'DB08056', 'DB08057', 'DB08058', 'DB08059', 'DB08060', 'DB08061', 'DB08062', 'DB08063', 'DB08064', 'DB08065', 'DB08066', 'DB08067', 'DB08068', 'DB08069', 'DB08070', 'DB08071', 'DB08072', 'DB08073', 'DB08074', 'DB08075', 'DB08076', 'DB08077', 'DB08078', 'DB08079', 'DB08080', 'DB08081', 'DB08082', 'DB08083', 'DB08084', 'DB08085', 'DB08086', 'DB08087', 'DB08088', 'DB08089', 'DB08090', 'DB08091', 'DB08092', 'DB08093', 'DB08094', 'DB08095', 'DB08096', 'DB08097', 'DB08098', 'DB08099', 'DB08100', 'DB08101', 'DB08102', 'DB08103', 'DB08104', 'DB08105', 'DB08106', 'DB08107', 'DB08108', 'DB08109', 'DB08110', 'DB08111', 'DB08112', 'DB08113', 'DB08114', 'DB08115', 'DB08116', 'DB08118', 'DB08119', 'DB08120', 'DB08121', 'DB08122', 'DB08123', 'DB08124', 'DB08125', 'DB08126', 'DB08127', 'DB08128', 'DB08129', 'DB08130', 'DB08131', 'DB08132', 'DB08133', 'DB08134', 'DB08135', 'DB08136', 'DB08137', 'DB08138', 'DB08139', 'DB08140', 'DB08141', 'DB08142', 'DB08143', 'DB08144', 'DB08145', 'DB08146', 'DB08147', 'DB08148', 'DB08149', 'DB08150', 'DB08151', 'DB08152', 'DB08153', 'DB08154', 'DB08155', 'DB08156', 'DB08157', 'DB08158', 'DB08159', 'DB08160', 'DB08161', 'DB08162', 'DB08163', 'DB08164', 'DB08165', 'DB08166', 'DB08167', 'DB08168', 'DB08169', 'DB08170', 'DB08171', 'DB08172', 'DB08173', 'DB08174', 'DB08175', 'DB08176', 'DB08177', 'DB08178', 'DB08179', 'DB08180', 'DB08181', 'DB08182', 'DB08184', 'DB08185', 'DB08186', 'DB08187', 'DB08188', 'DB08190', 'DB08191', 'DB08192', 'DB08193', 'DB08194', 'DB08195', 'DB08196', 'DB08197', 'DB08198', 'DB08199', 'DB08200', 'DB08201', 'DB08202', 'DB08203', 'DB08204', 'DB08205', 'DB08206', 'DB08207', 'DB08208', 'DB08209', 'DB08210', 'DB08211', 'DB08212', 'DB08213', 'DB08214', 'DB08215', 'DB08216', 'DB08217', 'DB08218', 'DB08219', 'DB08220', 'DB08221', 'DB08222', 'DB08223', 'DB08224', 'DB08226', 'DB08227', 'DB08228', 'DB08229', 'DB08230', 'DB08231', 'DB08232', 'DB08233', 'DB08234', 'DB08235', 'DB08236', 'DB08237', 'DB08238', 'DB08239', 'DB08240', 'DB08241', 'DB08242', 'DB08244', 'DB08245', 'DB08246', 'DB08247', 'DB08248', 'DB08249', 'DB08250', 'DB08251', 'DB08252', 'DB08253', 'DB08254', 'DB08255', 'DB08256', 'DB08257', 'DB08258', 'DB08259', 'DB08260', 'DB08261', 'DB08262', 'DB08263', 'DB08264', 'DB08265', 'DB08266', 'DB08267', 'DB08268', 'DB08270', 'DB08271', 'DB08272', 'DB08273', 'DB08274', 'DB08275', 'DB08276', 'DB08277', 'DB08278', 'DB08279', 'DB08280', 'DB08281', 'DB08282', 'DB08283', 'DB08284', 'DB08285', 'DB08286', 'DB08287', 'DB08288', 'DB08289', 'DB08291', 'DB08292', 'DB08293', 'DB08294', 'DB08295', 'DB08296', 'DB08297', 'DB08299', 'DB08300', 'DB08301', 'DB08302', 'DB08303', 'DB08304', 'DB08305', 'DB08306', 'DB08307', 'DB08308', 'DB08309', 'DB08310', 'DB08312', 'DB08313', 'DB08314', 'DB08315', 'DB08316', 'DB08317', 'DB08318', 'DB08319', 'DB08320', 'DB08321', 'DB08322', 'DB08323', 'DB08324', 'DB08325', 'DB08326', 'DB08327', 'DB08328', 'DB08329', 'DB08330', 'DB08331', 'DB08332', 'DB08333', 'DB08334', 'DB08335', 'DB08336', 'DB08337', 'DB08338', 'DB08339', 'DB08340', 'DB08341', 'DB08342', 'DB08344', 'DB08345', 'DB08346', 'DB08347', 'DB08348', 'DB08349', 'DB08350', 'DB08351', 'DB08352', 'DB08353', 'DB08354', 'DB08355', 'DB08356', 'DB08357', 'DB08358', 'DB08359', 'DB08360', 'DB08361', 'DB08362', 'DB08363', 'DB08364', 'DB08365', 'DB08366', 'DB08367', 'DB08368', 'DB08369', 'DB08370', 'DB08371', 'DB08372', 'DB08373', 'DB08374', 'DB08375', 'DB08376', 'DB08377', 'DB08378', 'DB08379', 'DB08382', 'DB08383', 'DB08384', 'DB08385', 'DB08386', 'DB08387', 'DB08388', 'DB08389', 'DB08390', 'DB08391', 'DB08392', 'DB08393', 'DB08394', 'DB08395', 'DB08396', 'DB08397', 'DB08398', 'DB08399', 'DB08400', 'DB08401', 'DB08402', 'DB08403', 'DB08404', 'DB08405', 'DB08406', 'DB08407', 'DB08408', 'DB08409', 'DB08410', 'DB08411', 'DB08412', 'DB08413', 'DB08414', 'DB08416', 'DB08418', 'DB08419', 'DB08420', 'DB08421', 'DB08422', 'DB08423', 'DB08424', 'DB08426', 'DB08427', 'DB08428', 'DB08429', 'DB08430', 'DB08431', 'DB08432', 'DB08433', 'DB08434', 'DB08435', 'DB08436', 'DB08437', 'DB08438', 'DB08439', 'DB08440', 'DB08441', 'DB08442', 'DB08443', 'DB08444', 'DB08445', 'DB08446', 'DB08447', 'DB08448', 'DB08449', 'DB08450', 'DB08451', 'DB08453', 'DB08454', 'DB08455', 'DB08456', 'DB08457', 'DB08458', 'DB08459', 'DB08460', 'DB08461', 'DB08462', 'DB08463', 'DB08464', 'DB08465', 'DB08466', 'DB08467', 'DB08469', 'DB08470', 'DB08471', 'DB08472', 'DB08473', 'DB08474', 'DB08475', 'DB08476', 'DB08478', 'DB08479', 'DB08480', 'DB08481', 'DB08482', 'DB08484', 'DB08485', 'DB08486', 'DB08487', 'DB08488', 'DB08489', 'DB08490', 'DB08491', 'DB08492', 'DB08493', 'DB08494', 'DB08495', 'DB08496', 'DB08497', 'DB08498', 'DB08499', 'DB08500', 'DB08501', 'DB08502', 'DB08503', 'DB08504', 'DB08505', 'DB08506', 'DB08507', 'DB08508', 'DB08509', 'DB08510', 'DB08511', 'DB08512', 'DB08513', 'DB08514', 'DB08515', 'DB08516', 'DB08517', 'DB08519', 'DB08520', 'DB08521', 'DB08522', 'DB08523', 'DB08524', 'DB08525', 'DB08526', 'DB08527', 'DB08528', 'DB08529', 'DB08530', 'DB08531', 'DB08532', 'DB08533', 'DB08534', 'DB08535', 'DB08536', 'DB08537', 'DB08538', 'DB08539', 'DB08540', 'DB08541', 'DB08542', 'DB08543', 'DB08544', 'DB08545', 'DB08546', 'DB08547', 'DB08548', 'DB08549', 'DB08550', 'DB08551', 'DB08552', 'DB08553', 'DB08554', 'DB08555', 'DB08556', 'DB08557', 'DB08558', 'DB08559', 'DB08560', 'DB08561', 'DB08562', 'DB08564', 'DB08565', 'DB08566', 'DB08568', 'DB08569', 'DB08570', 'DB08571', 'DB08572', 'DB08573', 'DB08574', 'DB08575', 'DB08576', 'DB08577', 'DB08578', 'DB08579', 'DB08580', 'DB08581', 'DB08582', 'DB08583', 'DB08585', 'DB08586', 'DB08587', 'DB08588', 'DB08589', 'DB08590', 'DB08591', 'DB08593', 'DB08594', 'DB08595', 'DB08596', 'DB08597', 'DB08598', 'DB08599', 'DB08600', 'DB08601', 'DB08602', 'DB08603', 'DB08604', 'DB08605', 'DB08606', 'DB08607', 'DB08608', 'DB08609', 'DB08610', 'DB08611', 'DB08612', 'DB08613', 'DB08614', 'DB08615', 'DB08617', 'DB08618', 'DB08619', 'DB08620', 'DB08621', 'DB08622', 'DB08623', 'DB08624', 'DB08626', 'DB08627', 'DB08628', 'DB08629', 'DB08631', 'DB08632', 'DB08633', 'DB08634', 'DB08635', 'DB08636', 'DB08637', 'DB08638', 'DB08639', 'DB08640', 'DB08641', 'DB08642', 'DB08643', 'DB08644', 'DB08645', 'DB08646', 'DB08647', 'DB08648', 'DB08649', 'DB08651', 'DB08652', 'DB08653', 'DB08654', 'DB08655', 'DB08656', 'DB08657', 'DB08658', 'DB08659', 'DB08660', 'DB08661', 'DB08662', 'DB08663', 'DB08664', 'DB08665', 'DB08666', 'DB08667', 'DB08668', 'DB08669', 'DB08670', 'DB08671', 'DB08672', 'DB08673', 'DB08674', 'DB08675', 'DB08676', 'DB08677', 'DB08678', 'DB08680', 'DB08681', 'DB08682', 'DB08683', 'DB08684', 'DB08685', 'DB08686', 'DB08687', 'DB08688', 'DB08689', 'DB08690', 'DB08691', 'DB08692', 'DB08693', 'DB08694', 'DB08695', 'DB08697', 'DB08698', 'DB08699', 'DB08701', 'DB08702', 'DB08703', 'DB08704', 'DB08705', 'DB08706', 'DB08707', 'DB08708', 'DB08709', 'DB08710', 'DB08711', 'DB08712', 'DB08713', 'DB08714', 'DB08715', 'DB08717', 'DB08718', 'DB08719', 'DB08720', 'DB08721', 'DB08722', 'DB08723', 'DB08724', 'DB08725', 'DB08726', 'DB08727', 'DB08728', 'DB08729', 'DB08730', 'DB08731', 'DB08732', 'DB08733', 'DB08734', 'DB08735', 'DB08736', 'DB08737', 'DB08738', 'DB08739', 'DB08740', 'DB08741', 'DB08742', 'DB08743', 'DB08744', 'DB08745', 'DB08746', 'DB08747', 'DB08748', 'DB08749', 'DB08750', 'DB08751', 'DB08752', 'DB08753', 'DB08754', 'DB08755', 'DB08756', 'DB08757', 'DB08758', 'DB08759', 'DB08760', 'DB08761', 'DB08762', 'DB08763', 'DB08765', 'DB08766', 'DB08767', 'DB08768', 'DB08770', 'DB08771', 'DB08772', 'DB08773', 'DB08774', 'DB08775', 'DB08776', 'DB08777', 'DB08778', 'DB08779', 'DB08780', 'DB08781', 'DB08782', 'DB08783', 'DB08784', 'DB08785', 'DB08786', 'DB08787', 'DB08788', 'DB08789', 'DB08790', 'DB08791', 'DB08792', 'DB08794', 'DB08795', 'DB08796', 'DB08797', 'DB08798', 'DB08799', 'DB08800', 'DB08801', 'DB08802', 'DB08803', 'DB08804', 'DB08805', 'DB08806', 'DB08807', 'DB08808', 'DB08809', 'DB08810', 'DB08811', 'DB08813', 'DB08814', 'DB08815', 'DB08816', 'DB08818', 'DB08819', 'DB08820', 'DB08822', 'DB08823', 'DB08824', 'DB08826', 'DB08827', 'DB08828', 'DB08830', 'DB08831', 'DB08833', 'DB08834', 'DB08835', 'DB08836', 'DB08837', 'DB08838', 'DB08839', 'DB08840', 'DB08841', 'DB08842', 'DB08843', 'DB08844', 'DB08845', 'DB08846', 'DB08847', 'DB08848', 'DB08849', 'DB08855', 'DB08856', 'DB08857', 'DB08858', 'DB08860', 'DB08861', 'DB08862', 'DB08864', 'DB08865', 'DB08867', 'DB08868', 'DB08869', 'DB08870', 'DB08871', 'DB08872', 'DB08873', 'DB08874', 'DB08875', 'DB08876', 'DB08877', 'DB08878', 'DB08879', 'DB08880', 'DB08881', 'DB08882', 'DB08883', 'DB08884', 'DB08885', 'DB08886', 'DB08887', 'DB08888', 'DB08889', 'DB08890', 'DB08891', 'DB08892', 'DB08893', 'DB08894', 'DB08895', 'DB08896', 'DB08897', 'DB08898', 'DB08899', 'DB08900', 'DB08901', 'DB08902', 'DB08903', 'DB08904', 'DB08905', 'DB08906', 'DB08907', 'DB08908', 'DB08909', 'DB08910', 'DB08911', 'DB08912', 'DB08913', 'DB08915', 'DB08916', 'DB08917', 'DB08918', 'DB08921', 'DB08922', 'DB08924', 'DB08925', 'DB08926', 'DB08927', 'DB08928', 'DB08930', 'DB08931', 'DB08932', 'DB08933', 'DB08934', 'DB08935', 'DB08936', 'DB08937', 'DB08938', 'DB08939', 'DB08940', 'DB08941', 'DB08942', 'DB08943', 'DB08944', 'DB08945', 'DB08946', 'DB08947', 'DB08948', 'DB08949', 'DB08950', 'DB08951', 'DB08952', 'DB08953', 'DB08954', 'DB08955', 'DB08956', 'DB08957', 'DB08958', 'DB08960', 'DB08961', 'DB08962', 'DB08964', 'DB08965', 'DB08966', 'DB08967', 'DB08968', 'DB08969', 'DB08970', 'DB08971', 'DB08972', 'DB08973', 'DB08974', 'DB08975', 'DB08976', 'DB08978', 'DB08979', 'DB08980', 'DB08981', 'DB08982', 'DB08983', 'DB08984', 'DB08985', 'DB08986', 'DB08987', 'DB08988', 'DB08989', 'DB08990', 'DB08991', 'DB08992', 'DB08993', 'DB08994', 'DB08995', 'DB08996', 'DB08997', 'DB08998', 'DB08999', 'DB09000', 'DB09001', 'DB09002', 'DB09003', 'DB09004', 'DB09005', 'DB09006', 'DB09007', 'DB09008', 'DB09009', 'DB09010', 'DB09011', 'DB09012', 'DB09013', 'DB09014', 'DB09015', 'DB09016', 'DB09017', 'DB09018', 'DB09019', 'DB09020', 'DB09021', 'DB09022', 'DB09023', 'DB09026', 'DB09027', 'DB09028', 'DB09029', 'DB09030', 'DB09031', 'DB09033', 'DB09034', 'DB09035', 'DB09036', 'DB09037', 'DB09038', 'DB09039', 'DB09040', 'DB09041', 'DB09042', 'DB09043', 'DB09045', 'DB09046', 'DB09047', 'DB09048', 'DB09049', 'DB09050', 'DB09051', 'DB09052', 'DB09053', 'DB09054', 'DB09055', 'DB09056', 'DB09057', 'DB09059', 'DB09060', 'DB09061', 'DB09062', 'DB09063', 'DB09064', 'DB09065', 'DB09066', 'DB09067', 'DB09068', 'DB09069', 'DB09070', 'DB09071', 'DB09072', 'DB09073', 'DB09074', 'DB09075', 'DB09076', 'DB09077', 'DB09078', 'DB09079', 'DB09080', 'DB09081', 'DB09082', 'DB09083', 'DB09084', 'DB09085', 'DB09086', 'DB09087', 'DB09088', 'DB09089', 'DB09090', 'DB09091', 'DB09092', 'DB09093', 'DB09094', 'DB09095', 'DB09096', 'DB09097', 'DB09098', 'DB09099', 'DB09100', 'DB09101', 'DB09102', 'DB09103', 'DB09104', 'DB09105', 'DB09106', 'DB09107', 'DB09108', 'DB09109', 'DB09110', 'DB09111', 'DB09112', 'DB09113', 'DB09114', 'DB09115', 'DB09116', 'DB09117', 'DB09118', 'DB09119', 'DB09120', 'DB09121', 'DB09122', 'DB09123', 'DB09124', 'DB09125', 'DB09126', 'DB09128', 'DB09129', 'DB09130', 'DB09131', 'DB09132', 'DB09133', 'DB09134', 'DB09135', 'DB09136', 'DB09137', 'DB09138', 'DB09139', 'DB09140', 'DB09141', 'DB09142', 'DB09143', 'DB09144', 'DB09145', 'DB09146', 'DB09147', 'DB09148', 'DB09149', 'DB09151', 'DB09152', 'DB09153', 'DB09154', 'DB09155', 'DB09156', 'DB09157', 'DB09158', 'DB09160', 'DB09161', 'DB09163', 'DB09164', 'DB09165', 'DB09166', 'DB09167', 'DB09168', 'DB09169', 'DB09170', 'DB09171', 'DB09172', 'DB09173', 'DB09174', 'DB09175', 'DB09177', 'DB09178', 'DB09179', 'DB09180', 'DB09181', 'DB09182', 'DB09183', 'DB09184', 'DB09185', 'DB09186', 'DB09187', 'DB09188', 'DB09189', 'DB09190', 'DB09191', 'DB09192', 'DB09193', 'DB09194', 'DB09195', 'DB09196', 'DB09197', 'DB09198', 'DB09199', 'DB09200', 'DB09201', 'DB09202', 'DB09203', 'DB09204', 'DB09205', 'DB09206', 'DB09207', 'DB09208', 'DB09209', 'DB09210', 'DB09211', 'DB09212', 'DB09213', 'DB09214', 'DB09215', 'DB09216', 'DB09217', 'DB09218', 'DB09219', 'DB09220', 'DB09221', 'DB09222', 'DB09223', 'DB09224', 'DB09225', 'DB09226', 'DB09227', 'DB09228', 'DB09229', 'DB09230', 'DB09231', 'DB09232', 'DB09233', 'DB09234', 'DB09235', 'DB09236', 'DB09237', 'DB09238', 'DB09239', 'DB09240', 'DB09241', 'DB09242', 'DB09243', 'DB09244', 'DB09245', 'DB09246', 'DB09247', 'DB09248', 'DB09249', 'DB09250', 'DB09251', 'DB09252', 'DB09253', 'DB09254', 'DB09255', 'DB09256', 'DB09257', 'DB09258', 'DB09259', 'DB09260', 'DB09261', 'DB09262', 'DB09263', 'DB09264', 'DB09265', 'DB09266', 'DB09267', 'DB09268', 'DB09269', 'DB09270', 'DB09271', 'DB09272', 'DB09273', 'DB09274', 'DB09275', 'DB09276', 'DB09277', 'DB09278', 'DB09279', 'DB09280', 'DB09281', 'DB09282', 'DB09283', 'DB09284', 'DB09285', 'DB09286', 'DB09287', 'DB09288', 'DB09289', 'DB09290', 'DB09291', 'DB09292', 'DB09293', 'DB09295', 'DB09296', 'DB09297', 'DB09298', 'DB09299', 'DB09300', 'DB09301', 'DB09302', 'DB09303', 'DB09304', 'DB09305', 'DB09306', 'DB09307', 'DB09308', 'DB09309', 'DB09310', 'DB09311', 'DB09312', 'DB09313', 'DB09314', 'DB09315', 'DB09316', 'DB09317', 'DB09318', 'DB09319', 'DB09320', 'DB09321', 'DB09322', 'DB09324', 'DB09325', 'DB09326', 'DB09327', 'DB09328', 'DB09329', 'DB09330', 'DB09331', 'DB09332', 'DB09333', 'DB09334', 'DB09335', 'DB09336', 'DB09337', 'DB09338', 'DB09339', 'DB09340', 'DB09341', 'DB09342', 'DB09343', 'DB09344', 'DB09345', 'DB09346', 'DB09347', 'DB09348', 'DB09349', 'DB09350', 'DB09351', 'DB09352', 'DB09353', 'DB09355', 'DB09357', 'DB09363', 'DB09364', 'DB09366', 'DB09369', 'DB09370', 'DB09371', 'DB09372', 'DB09373', 'DB09374', 'DB09375', 'DB09376', 'DB09377', 'DB09378', 'DB09379', 'DB09380', 'DB09381', 'DB09382', 'DB09383', 'DB09385', 'DB09389', 'DB09393', 'DB09394', 'DB09395', 'DB09397', 'DB09398', 'DB09400', 'DB09401', 'DB09403', 'DB09407', 'DB09409', 'DB09413', 'DB09414', 'DB09415', 'DB09418', 'DB09419', 'DB09420', 'DB09421', 'DB09422', 'DB09423', 'DB09425', 'DB09429', 'DB09430', 'DB09443', 'DB09446', 'DB09447', 'DB09448', 'DB09449', 'DB09456', 'DB09459', 'DB09460', 'DB09461', 'DB09462', 'DB09472', 'DB09473', 'DB09477', 'DB09479', 'DB09480', 'DB09481', 'DB09483', 'DB09484', 'DB09487', 'DB09488', 'DB09490', 'DB09493', 'DB09494', 'DB09495', 'DB09496', 'DB09498', 'DB09499', 'DB09501', 'DB09502', 'DB09507', 'DB09508', 'DB09510', 'DB09511', 'DB09512', 'DB09513', 'DB09516', 'DB09517', 'DB09526', 'DB09527', 'DB09531', 'DB09532', 'DB09534', 'DB09535', 'DB09536', 'DB09537', 'DB09539', 'DB09543', 'DB09546', 'DB09551', 'DB09552', 'DB09555', 'DB09559', 'DB09561', 'DB09563', 'DB09564', 'DB09567', 'DB09568', 'DB09570', 'DB09571', 'DB09876', 'DB09877', 'DB10061', 'DB10062', 'DB10076', 'DB10276', 'DB10283', 'DB10284', 'DB10285', 'DB10286', 'DB10287', 'DB10288', 'DB10289', 'DB10290', 'DB10291', 'DB10292', 'DB10293', 'DB10294', 'DB10295', 'DB10296', 'DB10297', 'DB10298', 'DB10299', 'DB10300', 'DB10301', 'DB10302', 'DB10310', 'DB10311', 'DB10312', 'DB10313', 'DB10314', 'DB10315', 'DB10316', 'DB10317', 'DB10318', 'DB10319', 'DB10320', 'DB10321', 'DB10322', 'DB10323', 'DB10324', 'DB10325', 'DB10326', 'DB10327', 'DB10328', 'DB10329', 'DB10330', 'DB10331', 'DB10332', 'DB10333', 'DB10334', 'DB10335', 'DB10336', 'DB10337', 'DB10338', 'DB10339', 'DB10340', 'DB10341', 'DB10342', 'DB10343', 'DB10344', 'DB10345', 'DB10346', 'DB10348', 'DB10349', 'DB10350', 'DB10351', 'DB10352', 'DB10353', 'DB10354', 'DB10355', 'DB10356', 'DB10357', 'DB10359', 'DB10360', 'DB10361', 'DB10362', 'DB10363', 'DB10364', 'DB10365', 'DB10366', 'DB10368', 'DB10369', 'DB10370', 'DB10371', 'DB10372', 'DB10373', 'DB10374', 'DB10375', 'DB10376', 'DB10377', 'DB10378', 'DB10379', 'DB10380', 'DB10381', 'DB10382', 'DB10383', 'DB10384', 'DB10385', 'DB10386', 'DB10387', 'DB10388', 'DB10389', 'DB10390', 'DB10391', 'DB10392', 'DB10393', 'DB10394', 'DB10395', 'DB10396', 'DB10397', 'DB10398', 'DB10399', 'DB10400', 'DB10401', 'DB10403', 'DB10404', 'DB10406', 'DB10408', 'DB10409', 'DB10410', 'DB10411', 'DB10412', 'DB10413', 'DB10415', 'DB10416', 'DB10417', 'DB10418', 'DB10419', 'DB10420', 'DB10421', 'DB10422', 'DB10423', 'DB10424', 'DB10425', 'DB10426', 'DB10427', 'DB10428', 'DB10429', 'DB10430', 'DB10431', 'DB10432', 'DB10433', 'DB10434', 'DB10435', 'DB10436', 'DB10437', 'DB10438', 'DB10439', 'DB10440', 'DB10441', 'DB10442', 'DB10443', 'DB10444', 'DB10445', 'DB10446', 'DB10447', 'DB10448', 'DB10449', 'DB10450', 'DB10451', 'DB10452', 'DB10453', 'DB10454', 'DB10455', 'DB10456', 'DB10457', 'DB10458', 'DB10459', 'DB10460', 'DB10461', 'DB10462', 'DB10463', 'DB10464', 'DB10465', 'DB10466', 'DB10467', 'DB10468', 'DB10469', 'DB10470', 'DB10471', 'DB10472', 'DB10473', 'DB10474', 'DB10475', 'DB10478', 'DB10479', 'DB10480', 'DB10481', 'DB10482', 'DB10483', 'DB10484', 'DB10485', 'DB10486', 'DB10487', 'DB10488', 'DB10489', 'DB10490', 'DB10491', 'DB10493', 'DB10494', 'DB10495', 'DB10496', 'DB10497', 'DB10498', 'DB10499', 'DB10500', 'DB10501', 'DB10502', 'DB10503', 'DB10504', 'DB10505', 'DB10506', 'DB10508', 'DB10509', 'DB10510', 'DB10511', 'DB10512', 'DB10513', 'DB10514', 'DB10515', 'DB10516', 'DB10517', 'DB10518', 'DB10519', 'DB10520', 'DB10523', 'DB10525', 'DB10526', 'DB10527', 'DB10528', 'DB10529', 'DB10530', 'DB10531', 'DB10532', 'DB10533', 'DB10534', 'DB10535', 'DB10536', 'DB10537', 'DB10538', 'DB10539', 'DB10540', 'DB10541', 'DB10542', 'DB10543', 'DB10544', 'DB10545', 'DB10546', 'DB10547', 'DB10548', 'DB10549', 'DB10550', 'DB10551', 'DB10552', 'DB10553', 'DB10554', 'DB10555', 'DB10556', 'DB10557', 'DB10558', 'DB10559', 'DB10560', 'DB10561', 'DB10562', 'DB10563', 'DB10564', 'DB10566', 'DB10567', 'DB10568', 'DB10569', 'DB10570', 'DB10571', 'DB10572', 'DB10573', 'DB10574', 'DB10575', 'DB10576', 'DB10577', 'DB10578', 'DB10579', 'DB10580', 'DB10581', 'DB10582', 'DB10583', 'DB10584', 'DB10596', 'DB10597', 'DB10598', 'DB10599', 'DB10600', 'DB10601', 'DB10602', 'DB10603', 'DB10604', 'DB10605', 'DB10606', 'DB10607', 'DB10608', 'DB10609', 'DB10610', 'DB10611', 'DB10612', 'DB10613', 'DB10614', 'DB10615', 'DB10616', 'DB10617', 'DB10618', 'DB10619', 'DB10620', 'DB10621', 'DB10622', 'DB10623', 'DB10624', 'DB10625', 'DB10626', 'DB10627', 'DB10628', 'DB10629', 'DB10630', 'DB10631', 'DB10632', 'DB10633', 'DB10634', 'DB10635', 'DB10636', 'DB10637', 'DB10638', 'DB10639', 'DB10640', 'DB10641', 'DB10642', 'DB10643', 'DB10644', 'DB10645', 'DB10646', 'DB10647', 'DB10648', 'DB10650', 'DB10651', 'DB10652', 'DB10653', 'DB10654', 'DB10655', 'DB10656', 'DB10657', 'DB10658', 'DB10659', 'DB10660', 'DB10661', 'DB10662', 'DB10663', 'DB10664', 'DB10666', 'DB10667', 'DB10669', 'DB10670', 'DB10671', 'DB10672', 'DB10673', 'DB10674', 'DB10675', 'DB10676', 'DB10677', 'DB10678', 'DB10679', 'DB10681', 'DB10683', 'DB10685', 'DB10686', 'DB10687', 'DB10688', 'DB10690', 'DB10691', 'DB10693', 'DB10694', 'DB10695', 'DB10696', 'DB10697', 'DB10698', 'DB10699', 'DB10700', 'DB10701', 'DB10702', 'DB10703', 'DB10704', 'DB10705', 'DB10706', 'DB10707', 'DB10708', 'DB10710', 'DB10711', 'DB10712', 'DB10713', 'DB10714', 'DB10715', 'DB10716', 'DB10717', 'DB10718', 'DB10719', 'DB10720', 'DB10721', 'DB10722', 'DB10723', 'DB10724', 'DB10725', 'DB10727', 'DB10728', 'DB10729', 'DB10730', 'DB10731', 'DB10732', 'DB10733', 'DB10734', 'DB10735', 'DB10736', 'DB10737', 'DB10738', 'DB10739', 'DB10740', 'DB10741', 'DB10742', 'DB10743', 'DB10744', 'DB10745', 'DB10746', 'DB10747', 'DB10748', 'DB10749', 'DB10750', 'DB10751', 'DB10752', 'DB10753', 'DB10754', 'DB10755', 'DB10756', 'DB10757', 'DB10758', 'DB10759', 'DB10760', 'DB10761', 'DB10762', 'DB10763', 'DB10764', 'DB10765', 'DB10766', 'DB10767', 'DB10768', 'DB10769', 'DB10770', 'DB10771', 'DB10772', 'DB10773', 'DB10774', 'DB10775', 'DB10776', 'DB10777', 'DB10778', 'DB10779', 'DB10780', 'DB10781', 'DB10782', 'DB10783', 'DB10784', 'DB10785', 'DB10786', 'DB10787', 'DB10788', 'DB10789', 'DB10790', 'DB10791', 'DB10792', 'DB10793', 'DB10794', 'DB10795', 'DB10796', 'DB10797', 'DB10798', 'DB10799', 'DB10800', 'DB10801', 'DB10802', 'DB10803', 'DB10804', 'DB10805', 'DB10806', 'DB10807', 'DB10808', 'DB10809', 'DB10810', 'DB10811', 'DB10812', 'DB10813', 'DB10814', 'DB10815', 'DB10816', 'DB10817', 'DB10818', 'DB10819', 'DB10820', 'DB10821', 'DB10822', 'DB10823', 'DB10824', 'DB10825', 'DB10826', 'DB10827', 'DB10828', 'DB10829', 'DB10830', 'DB10831', 'DB10832', 'DB10833', 'DB10834', 'DB10835', 'DB10836', 'DB10837', 'DB10838', 'DB10839', 'DB10840', 'DB10841', 'DB10842', 'DB10843', 'DB10844', 'DB10845', 'DB10846', 'DB10847', 'DB10848', 'DB10849', 'DB10850', 'DB10851', 'DB10852', 'DB10853', 'DB10855', 'DB10856', 'DB10857', 'DB10858', 'DB10859', 'DB10860', 'DB10861', 'DB10862', 'DB10864', 'DB10865', 'DB10866', 'DB10867', 'DB10868', 'DB10869', 'DB10870', 'DB10871', 'DB10872', 'DB10873', 'DB10874', 'DB10875', 'DB10876', 'DB10877', 'DB10879', 'DB10880', 'DB10881', 'DB10882', 'DB10883', 'DB10884', 'DB10885', 'DB10886', 'DB10887', 'DB10888', 'DB10889', 'DB10890', 'DB10891', 'DB10892', 'DB10893', 'DB10894', 'DB10895', 'DB10896', 'DB10897', 'DB10898', 'DB10899', 'DB10900', 'DB10901', 'DB10902', 'DB10903', 'DB10904', 'DB10905', 'DB10906', 'DB10907', 'DB10908', 'DB10909', 'DB10910', 'DB10911', 'DB10912', 'DB10913', 'DB10914', 'DB10915', 'DB10916', 'DB10917', 'DB10918', 'DB10919', 'DB10921', 'DB10922', 'DB10923', 'DB10924', 'DB10925', 'DB10926', 'DB10927', 'DB10928', 'DB10929', 'DB10930', 'DB10932', 'DB10933', 'DB10934', 'DB10935', 'DB10936', 'DB10937', 'DB10939', 'DB10940', 'DB10941', 'DB10942', 'DB10943', 'DB10945', 'DB10946', 'DB10947', 'DB10948', 'DB10949', 'DB10950', 'DB10952', 'DB10953', 'DB10954', 'DB10955', 'DB10956', 'DB10957', 'DB10958', 'DB10959', 'DB10961', 'DB10962', 'DB10963', 'DB10964', 'DB10965', 'DB10966', 'DB10967', 'DB10968', 'DB10969', 'DB10970', 'DB10971', 'DB10972', 'DB10973', 'DB10974', 'DB10975', 'DB10976', 'DB10977', 'DB10979', 'DB10980', 'DB10981', 'DB10982', 'DB10983', 'DB10984', 'DB10985', 'DB10986', 'DB10987', 'DB10988', 'DB10989', 'DB10990', 'DB10991', 'DB10992', 'DB10994', 'DB10995', 'DB10996', 'DB10997', 'DB10998', 'DB10999', 'DB11000', 'DB11001', 'DB11002', 'DB11003', 'DB11004', 'DB11005', 'DB11006', 'DB11007', 'DB11008', 'DB11009', 'DB11010', 'DB11011', 'DB11014', 'DB11017', 'DB11018', 'DB11019', 'DB11020', 'DB11021', 'DB11022', 'DB11023', 'DB11024', 'DB11025', 'DB11026', 'DB11027', 'DB11028', 'DB11029', 'DB11030', 'DB11031', 'DB11032', 'DB11033', 'DB11034', 'DB11035', 'DB11036', 'DB11037', 'DB11038', 'DB11039', 'DB11040', 'DB11041', 'DB11042', 'DB11043', 'DB11044', 'DB11045', 'DB11046', 'DB11047', 'DB11048', 'DB11050', 'DB11051', 'DB11054', 'DB11056', 'DB11057', 'DB11058', 'DB11059', 'DB11060', 'DB11061', 'DB11062', 'DB11063', 'DB11064', 'DB11065', 'DB11066', 'DB11067', 'DB11068', 'DB11069', 'DB11071', 'DB11072', 'DB11073', 'DB11074', 'DB11075', 'DB11077', 'DB11079', 'DB11080', 'DB11081', 'DB11082', 'DB11085', 'DB11086', 'DB11087', 'DB11088', 'DB11089', 'DB11090', 'DB11091', 'DB11092', 'DB11093', 'DB11094', 'DB11095', 'DB11096', 'DB11097', 'DB11098', 'DB11099', 'DB11100', 'DB11102', 'DB11104', 'DB11105', 'DB11107', 'DB11108', 'DB11109', 'DB11110', 'DB11111', 'DB11112', 'DB11113', 'DB11114', 'DB11115', 'DB11116', 'DB11117', 'DB11118', 'DB11119', 'DB11120', 'DB11121', 'DB11123', 'DB11124', 'DB11125', 'DB11126', 'DB11127', 'DB11128', 'DB11129', 'DB11130', 'DB11131', 'DB11132', 'DB11133', 'DB11134', 'DB11135', 'DB11136', 'DB11137', 'DB11140', 'DB11141', 'DB11142', 'DB11143', 'DB11144', 'DB11145', 'DB11147', 'DB11148', 'DB11149', 'DB11150', 'DB11151', 'DB11152', 'DB11153', 'DB11154', 'DB11155', 'DB11156', 'DB11157', 'DB11158', 'DB11159', 'DB11160', 'DB11161', 'DB11164', 'DB11165', 'DB11166', 'DB11168', 'DB11169', 'DB11171', 'DB11172', 'DB11174', 'DB11175', 'DB11176', 'DB11178', 'DB11179', 'DB11180', 'DB11181', 'DB11182', 'DB11183', 'DB11184', 'DB11185', 'DB11186', 'DB11187', 'DB11188', 'DB11189', 'DB11190', 'DB11191', 'DB11192', 'DB11193', 'DB11195', 'DB11197', 'DB11198', 'DB11199', 'DB11200', 'DB11201', 'DB11202', 'DB11203', 'DB11204', 'DB11205', 'DB11206', 'DB11207', 'DB11208', 'DB11209', 'DB11210', 'DB11211', 'DB11217', 'DB11218', 'DB11219', 'DB11220', 'DB11221', 'DB11222', 'DB11223', 'DB11224', 'DB11225', 'DB11226', 'DB11227', 'DB11228', 'DB11229', 'DB11230', 'DB11231', 'DB11232', 'DB11233', 'DB11234', 'DB11235', 'DB11236', 'DB11237', 'DB11238', 'DB11239', 'DB11242', 'DB11243', 'DB11244', 'DB11246', 'DB11247', 'DB11248', 'DB11250', 'DB11251', 'DB11252', 'DB11253', 'DB11254', 'DB11255', 'DB11256', 'DB11257', 'DB11259', 'DB11260', 'DB11261', 'DB11262', 'DB11263', 'DB11264', 'DB11265', 'DB11266', 'DB11267', 'DB11268', 'DB11269', 'DB11270', 'DB11271', 'DB11272', 'DB11273', 'DB11274', 'DB11275', 'DB11276', 'DB11277', 'DB11278', 'DB11279', 'DB11281', 'DB11282', 'DB11283', 'DB11284', 'DB11285', 'DB11286', 'DB11288', 'DB11289', 'DB11290', 'DB11291', 'DB11293', 'DB11294', 'DB11295', 'DB11296', 'DB11297', 'DB11298', 'DB11299', 'DB11300', 'DB11301', 'DB11302', 'DB11304', 'DB11305', 'DB11306', 'DB11309', 'DB11311', 'DB11312', 'DB11313', 'DB11315', 'DB11318', 'DB11321', 'DB11323', 'DB11324', 'DB11325', 'DB11326', 'DB11327', 'DB11328', 'DB11329', 'DB11330', 'DB11331', 'DB11332', 'DB11333', 'DB11335', 'DB11336', 'DB11337', 'DB11338', 'DB11340', 'DB11341', 'DB11342', 'DB11343', 'DB11344', 'DB11345', 'DB11346', 'DB11347', 'DB11348', 'DB11349', 'DB11350', 'DB11352', 'DB11355', 'DB11356', 'DB11357', 'DB11358', 'DB11359', 'DB11360', 'DB11361', 'DB11362', 'DB11363', 'DB11364', 'DB11365', 'DB11366', 'DB11367', 'DB11368', 'DB11369', 'DB11371', 'DB11372', 'DB11373', 'DB11374', 'DB11375', 'DB11376', 'DB11377', 'DB11378', 'DB11379', 'DB11380', 'DB11382', 'DB11383', 'DB11385', 'DB11386', 'DB11387', 'DB11389', 'DB11390', 'DB11392', 'DB11393', 'DB11394', 'DB11395', 'DB11396', 'DB11397', 'DB11398', 'DB11399', 'DB11400', 'DB11401', 'DB11403', 'DB11404', 'DB11405', 'DB11408', 'DB11409', 'DB11410', 'DB11411', 'DB11412', 'DB11413', 'DB11414', 'DB11416', 'DB11417', 'DB11419', 'DB11420', 'DB11421', 'DB11423', 'DB11424', 'DB11425', 'DB11426', 'DB11427', 'DB11428', 'DB11429', 'DB11430', 'DB11431', 'DB11432', 'DB11433', 'DB11434', 'DB11436', 'DB11437', 'DB11438', 'DB11440', 'DB11442', 'DB11443', 'DB11446', 'DB11447', 'DB11448', 'DB11449', 'DB11450', 'DB11451', 'DB11452', 'DB11453', 'DB11454', 'DB11455', 'DB11456', 'DB11457', 'DB11458', 'DB11459', 'DB11460', 'DB11461', 'DB11462', 'DB11463', 'DB11464', 'DB11466', 'DB11467', 'DB11468', 'DB11470', 'DB11471', 'DB11472', 'DB11473', 'DB11474', 'DB11475', 'DB11476', 'DB11477', 'DB11478', 'DB11479', 'DB11480', 'DB11481', 'DB11482', 'DB11485', 'DB11487', 'DB11490', 'DB11491', 'DB11493', 'DB11495', 'DB11496', 'DB11497', 'DB11499', 'DB11501', 'DB11502', 'DB11504', 'DB11505', 'DB11507', 'DB11509', 'DB11510', 'DB11511', 'DB11512', 'DB11513', 'DB11516', 'DB11517', 'DB11518', 'DB11519', 'DB11520', 'DB11521', 'DB11522', 'DB11525', 'DB11526', 'DB11528', 'DB11529', 'DB11530', 'DB11531', 'DB11534', 'DB11537', 'DB11540', 'DB11541', 'DB11542', 'DB11543', 'DB11544', 'DB11545', 'DB11547', 'DB11549', 'DB11551', 'DB11552', 'DB11554', 'DB11555', 'DB11556', 'DB11558', 'DB11560', 'DB11561', 'DB11562', 'DB11563', 'DB11564', 'DB11567', 'DB11568', 'DB11569', 'DB11570', 'DB11571', 'DB11572', 'DB11573', 'DB11574', 'DB11575', 'DB11576', 'DB11577', 'DB11578', 'DB11579', 'DB11580', 'DB11581', 'DB11582', 'DB11583', 'DB11584', 'DB11585', 'DB11586', 'DB11587', 'DB11588', 'DB11589', 'DB11590', 'DB11591', 'DB11592', 'DB11593', 'DB11594', 'DB11595', 'DB11596', 'DB11597', 'DB11598', 'DB11599', 'DB11600', 'DB11601', 'DB11602', 'DB11603', 'DB11604', 'DB11605', 'DB11606', 'DB11607', 'DB11608', 'DB11609', 'DB11610', 'DB11611', 'DB11613', 'DB11614', 'DB11616', 'DB11617', 'DB11618', 'DB11619', 'DB11620', 'DB11621', 'DB11622', 'DB11623', 'DB11624', 'DB11625', 'DB11626', 'DB11627', 'DB11628', 'DB11629', 'DB11630', 'DB11631', 'DB11632', 'DB11633', 'DB11634', 'DB11635', 'DB11636', 'DB11637', 'DB11638', 'DB11639', 'DB11640', 'DB11641', 'DB11642', 'DB11643', 'DB11644', 'DB11645', 'DB11646', 'DB11647', 'DB11648', 'DB11649', 'DB11650', 'DB11651', 'DB11652', 'DB11653', 'DB11654', 'DB11655', 'DB11656', 'DB11657', 'DB11658', 'DB11659', 'DB11660', 'DB11661', 'DB11662', 'DB11663', 'DB11664', 'DB11665', 'DB11666', 'DB11667', 'DB11668', 'DB11669', 'DB11670', 'DB11671', 'DB11672', 'DB11673', 'DB11674', 'DB11675', 'DB11676', 'DB11677', 'DB11678', 'DB11679', 'DB11680', 'DB11681', 'DB11682', 'DB11683', 'DB11684', 'DB11685', 'DB11686', 'DB11687', 'DB11688', 'DB11689', 'DB11690', 'DB11691', 'DB11692', 'DB11693', 'DB11694', 'DB11695', 'DB11696', 'DB11697', 'DB11698', 'DB11699', 'DB11700', 'DB11701', 'DB11702', 'DB11703', 'DB11704', 'DB11705', 'DB11706', 'DB11707', 'DB11708', 'DB11709', 'DB11710', 'DB11711', 'DB11712', 'DB11713', 'DB11714', 'DB11715', 'DB11716', 'DB11717', 'DB11718', 'DB11719', 'DB11720', 'DB11721', 'DB11723', 'DB11724', 'DB11725', 'DB11726', 'DB11727', 'DB11729', 'DB11730', 'DB11731', 'DB11732', 'DB11734', 'DB11735', 'DB11736', 'DB11737', 'DB11738', 'DB11739', 'DB11740', 'DB11741', 'DB11742', 'DB11743', 'DB11744', 'DB11745', 'DB11746', 'DB11747', 'DB11748', 'DB11749', 'DB11750', 'DB11751', 'DB11752', 'DB11753', 'DB11754', 'DB11755', 'DB11756', 'DB11757', 'DB11758', 'DB11759', 'DB11760', 'DB11761', 'DB11762', 'DB11763', 'DB11764', 'DB11765', 'DB11766', 'DB11767', 'DB11768', 'DB11769', 'DB11770', 'DB11771', 'DB11772', 'DB11773', 'DB11774', 'DB11775', 'DB11776', 'DB11777', 'DB11778', 'DB11779', 'DB11780', 'DB11781', 'DB11782', 'DB11783', 'DB11784', 'DB11785', 'DB11786', 'DB11787', 'DB11788', 'DB11789', 'DB11790', 'DB11791', 'DB11792', 'DB11793', 'DB11794', 'DB11795', 'DB11796', 'DB11797', 'DB11798', 'DB11799', 'DB11800', 'DB11801', 'DB11803', 'DB11804', 'DB11805', 'DB11806', 'DB11807', 'DB11808', 'DB11809', 'DB11810', 'DB11811', 'DB11812', 'DB11813', 'DB11814', 'DB11815', 'DB11816', 'DB11817', 'DB11818', 'DB11819', 'DB11820', 'DB11821', 'DB11822', 'DB11823', 'DB11824', 'DB11825', 'DB11826', 'DB11827', 'DB11828', 'DB11829', 'DB11830', 'DB11831', 'DB11832', 'DB11833', 'DB11834', 'DB11835', 'DB11836', 'DB11837', 'DB11838', 'DB11839', 'DB11840', 'DB11841', 'DB11842', 'DB11843', 'DB11844', 'DB11845', 'DB11846', 'DB11847', 'DB11848', 'DB11849', 'DB11850', 'DB11851', 'DB11852', 'DB11853', 'DB11854', 'DB11855', 'DB11856', 'DB11857', 'DB11858', 'DB11859', 'DB11860', 'DB11861', 'DB11862', 'DB11863', 'DB11864', 'DB11865', 'DB11866', 'DB11867', 'DB11868', 'DB11869', 'DB11870', 'DB11871', 'DB11872', 'DB11873', 'DB11874', 'DB11875', 'DB11876', 'DB11877', 'DB11878', 'DB11879', 'DB11880', 'DB11881', 'DB11882', 'DB11883', 'DB11884', 'DB11885', 'DB11886', 'DB11888', 'DB11889', 'DB11890', 'DB11891', 'DB11892', 'DB11893', 'DB11894', 'DB11895', 'DB11896', 'DB11898', 'DB11899', 'DB11900', 'DB11901', 'DB11902', 'DB11903', 'DB11904', 'DB11905', 'DB11906', 'DB11907', 'DB11909', 'DB11910', 'DB11911', 'DB11912', 'DB11913', 'DB11914', 'DB11915', 'DB11916', 'DB11917', 'DB11918', 'DB11919', 'DB11920', 'DB11921', 'DB11922', 'DB11923', 'DB11924', 'DB11925', 'DB11926', 'DB11927', 'DB11928', 'DB11929', 'DB11930', 'DB11932', 'DB11933', 'DB11934', 'DB11935', 'DB11936', 'DB11937', 'DB11938', 'DB11939', 'DB11940', 'DB11941', 'DB11942', 'DB11943', 'DB11944', 'DB11945', 'DB11946', 'DB11947', 'DB11948', 'DB11949', 'DB11950', 'DB11951', 'DB11952', 'DB11953', 'DB11954', 'DB11955', 'DB11956', 'DB11957', 'DB11958', 'DB11959', 'DB11960', 'DB11961', 'DB11962', 'DB11963', 'DB11964', 'DB11965', 'DB11966', 'DB11967', 'DB11968', 'DB11969', 'DB11970', 'DB11971', 'DB11972', 'DB11973', 'DB11974', 'DB11975', 'DB11976', 'DB11977', 'DB11978', 'DB11979', 'DB11980', 'DB11981', 'DB11982', 'DB11983', 'DB11984', 'DB11985', 'DB11986', 'DB11987', 'DB11988', 'DB11989', 'DB11990', 'DB11991', 'DB11992', 'DB11993', 'DB11994', 'DB11995', 'DB11996', 'DB11997', 'DB11998', 'DB11999', 'DB12000', 'DB12001', 'DB12002', 'DB12003', 'DB12004', 'DB12005', 'DB12006', 'DB12007', 'DB12008', 'DB12009', 'DB12010', 'DB12011', 'DB12012', 'DB12013', 'DB12014', 'DB12015', 'DB12016', 'DB12017', 'DB12018', 'DB12019', 'DB12020', 'DB12021', 'DB12022', 'DB12023', 'DB12024', 'DB12025', 'DB12026', 'DB12027', 'DB12028', 'DB12029', 'DB12030', 'DB12031', 'DB12032', 'DB12034', 'DB12035', 'DB12036', 'DB12037', 'DB12038', 'DB12039', 'DB12040', 'DB12041', 'DB12042', 'DB12043', 'DB12044', 'DB12045', 'DB12046', 'DB12047', 'DB12048', 'DB12049', 'DB12050', 'DB12051', 'DB12052', 'DB12053', 'DB12054', 'DB12055', 'DB12056', 'DB12057', 'DB12058', 'DB12059', 'DB12060', 'DB12061', 'DB12062', 'DB12063', 'DB12064', 'DB12065', 'DB12066', 'DB12067', 'DB12068', 'DB12069', 'DB12070', 'DB12071', 'DB12072', 'DB12073', 'DB12074', 'DB12075', 'DB12076', 'DB12077', 'DB12078', 'DB12079', 'DB12080', 'DB12081', 'DB12082', 'DB12083', 'DB12084', 'DB12085', 'DB12086', 'DB12087', 'DB12088', 'DB12089', 'DB12090', 'DB12091', 'DB12092', 'DB12093', 'DB12094', 'DB12095', 'DB12096', 'DB12097', 'DB12098', 'DB12099', 'DB12100', 'DB12101', 'DB12102', 'DB12104', 'DB12105', 'DB12106', 'DB12107', 'DB12108', 'DB12109', 'DB12110', 'DB12111', 'DB12112', 'DB12113', 'DB12114', 'DB12115', 'DB12116', 'DB12117', 'DB12118', 'DB12119', 'DB12120', 'DB12121', 'DB12122', 'DB12123', 'DB12124', 'DB12125', 'DB12126', 'DB12127', 'DB12128', 'DB12129', 'DB12130', 'DB12131', 'DB12132', 'DB12133', 'DB12134', 'DB12135', 'DB12136', 'DB12137', 'DB12138', 'DB12139', 'DB12140', 'DB12141', 'DB12142', 'DB12143', 'DB12144', 'DB12145', 'DB12146', 'DB12147', 'DB12148', 'DB12149', 'DB12150', 'DB12151', 'DB12152', 'DB12153', 'DB12154', 'DB12155', 'DB12156', 'DB12157', 'DB12158', 'DB12159', 'DB12160', 'DB12161', 'DB12162', 'DB12163', 'DB12165', 'DB12167', 'DB12168', 'DB12169', 'DB12170', 'DB12171', 'DB12172', 'DB12173', 'DB12174', 'DB12176', 'DB12177', 'DB12178', 'DB12179', 'DB12180', 'DB12181', 'DB12182', 'DB12183', 'DB12184', 'DB12185', 'DB12186', 'DB12187', 'DB12188', 'DB12189', 'DB12190', 'DB12191', 'DB12192', 'DB12193', 'DB12194', 'DB12195', 'DB12196', 'DB12197', 'DB12198', 'DB12199', 'DB12200', 'DB12201', 'DB12202', 'DB12203', 'DB12204', 'DB12205', 'DB12206', 'DB12207', 'DB12208', 'DB12209', 'DB12210', 'DB12211', 'DB12212', 'DB12213', 'DB12214', 'DB12216', 'DB12218', 'DB12219', 'DB12220', 'DB12221', 'DB12222', 'DB12223', 'DB12224', 'DB12225', 'DB12226', 'DB12227', 'DB12228', 'DB12229', 'DB12230', 'DB12231', 'DB12232', 'DB12233', 'DB12234', 'DB12235', 'DB12236', 'DB12237', 'DB12238', 'DB12239', 'DB12240', 'DB12241', 'DB12242', 'DB12243', 'DB12244', 'DB12245', 'DB12246', 'DB12247', 'DB12248', 'DB12249', 'DB12250', 'DB12251', 'DB12252', 'DB12253', 'DB12254', 'DB12255', 'DB12256', 'DB12257', 'DB12258', 'DB12259', 'DB12260', 'DB12261', 'DB12262', 'DB12263', 'DB12264', 'DB12265', 'DB12266', 'DB12267', 'DB12268', 'DB12269', 'DB12270', 'DB12271', 'DB12272', 'DB12273', 'DB12274', 'DB12275', 'DB12276', 'DB12277', 'DB12278', 'DB12279', 'DB12280', 'DB12281', 'DB12282', 'DB12283', 'DB12284', 'DB12285', 'DB12286', 'DB12287', 'DB12288', 'DB12289', 'DB12290', 'DB12291', 'DB12292', 'DB12293', 'DB12294', 'DB12295', 'DB12296', 'DB12297', 'DB12298', 'DB12299', 'DB12300', 'DB12301', 'DB12302', 'DB12303', 'DB12304', 'DB12305', 'DB12306', 'DB12307', 'DB12308', 'DB12309', 'DB12310', 'DB12311', 'DB12312', 'DB12313', 'DB12314', 'DB12316', 'DB12317', 'DB12318', 'DB12319', 'DB12320', 'DB12321', 'DB12322', 'DB12323', 'DB12325', 'DB12326', 'DB12327', 'DB12328', 'DB12329', 'DB12330', 'DB12331', 'DB12332', 'DB12333', 'DB12334', 'DB12335', 'DB12336', 'DB12337', 'DB12338', 'DB12339', 'DB12340', 'DB12341', 'DB12342', 'DB12343', 'DB12344', 'DB12345', 'DB12346', 'DB12347', 'DB12348', 'DB12349', 'DB12350', 'DB12351', 'DB12352', 'DB12353', 'DB12354', 'DB12355', 'DB12356', 'DB12357', 'DB12358', 'DB12359', 'DB12360', 'DB12361', 'DB12362', 'DB12363', 'DB12364', 'DB12365', 'DB12366', 'DB12367', 'DB12368', 'DB12369', 'DB12370', 'DB12371', 'DB12373', 'DB12374', 'DB12375', 'DB12376', 'DB12377', 'DB12378', 'DB12379', 'DB12380', 'DB12381', 'DB12382', 'DB12383', 'DB12384', 'DB12385', 'DB12386', 'DB12387', 'DB12388', 'DB12389', 'DB12390', 'DB12391', 'DB12392', 'DB12393', 'DB12394', 'DB12395', 'DB12396', 'DB12397', 'DB12398', 'DB12399', 'DB12400', 'DB12401', 'DB12402', 'DB12403', 'DB12404', 'DB12405', 'DB12406', 'DB12407', 'DB12408', 'DB12409', 'DB12410', 'DB12411', 'DB12412', 'DB12413', 'DB12414', 'DB12415', 'DB12416', 'DB12417', 'DB12418', 'DB12419', 'DB12420', 'DB12421', 'DB12422', 'DB12423', 'DB12424', 'DB12425', 'DB12426', 'DB12427', 'DB12428', 'DB12429', 'DB12431', 'DB12432', 'DB12433', 'DB12434', 'DB12435', 'DB12436', 'DB12438', 'DB12439', 'DB12440', 'DB12441', 'DB12442', 'DB12443', 'DB12444', 'DB12445', 'DB12446', 'DB12447', 'DB12448', 'DB12449', 'DB12450', 'DB12451', 'DB12452', 'DB12453', 'DB12454', 'DB12455', 'DB12456', 'DB12457', 'DB12458', 'DB12459', 'DB12460', 'DB12461', 'DB12462', 'DB12463', 'DB12464', 'DB12465', 'DB12466', 'DB12467', 'DB12468', 'DB12470', 'DB12471', 'DB12472', 'DB12473', 'DB12474', 'DB12475', 'DB12476', 'DB12477', 'DB12478', 'DB12479', 'DB12480', 'DB12481', 'DB12482', 'DB12483', 'DB12484', 'DB12485', 'DB12486', 'DB12487', 'DB12489', 'DB12490', 'DB12491', 'DB12492', 'DB12493', 'DB12494', 'DB12495', 'DB12497', 'DB12498', 'DB12499', 'DB12500', 'DB12501', 'DB12504', 'DB12505', 'DB12506', 'DB12507', 'DB12508', 'DB12509', 'DB12510', 'DB12511', 'DB12512', 'DB12513', 'DB12514', 'DB12515', 'DB12517', 'DB12518', 'DB12519', 'DB12520', 'DB12521', 'DB12522', 'DB12523', 'DB12524', 'DB12525', 'DB12526', 'DB12527', 'DB12528', 'DB12529', 'DB12530', 'DB12531', 'DB12532', 'DB12533', 'DB12534', 'DB12535', 'DB12536', 'DB12537', 'DB12538', 'DB12539', 'DB12540', 'DB12541', 'DB12542', 'DB12543', 'DB12545', 'DB12547', 'DB12548', 'DB12549', 'DB12550', 'DB12551', 'DB12553', 'DB12554', 'DB12555', 'DB12556', 'DB12557', 'DB12558', 'DB12559', 'DB12560', 'DB12561', 'DB12562', 'DB12563', 'DB12564', 'DB12565', 'DB12566', 'DB12567', 'DB12568', 'DB12569', 'DB12570', 'DB12571', 'DB12572', 'DB12573', 'DB12574', 'DB12575', 'DB12576', 'DB12577', 'DB12578', 'DB12579', 'DB12580', 'DB12581', 'DB12582', 'DB12583', 'DB12584', 'DB12585', 'DB12586', 'DB12587', 'DB12588', 'DB12589', 'DB12590', 'DB12591', 'DB12592', 'DB12593', 'DB12594', 'DB12595', 'DB12596', 'DB12597', 'DB12598', 'DB12601', 'DB12602', 'DB12604', 'DB12605', 'DB12606', 'DB12607', 'DB12608', 'DB12609', 'DB12610', 'DB12611', 'DB12612', 'DB12613', 'DB12614', 'DB12615', 'DB12616', 'DB12617', 'DB12618', 'DB12619', 'DB12620', 'DB12621', 'DB12622', 'DB12623', 'DB12624', 'DB12625', 'DB12626', 'DB12627', 'DB12628', 'DB12629', 'DB12630', 'DB12631', 'DB12632', 'DB12633', 'DB12634', 'DB12635', 'DB12636', 'DB12637', 'DB12638', 'DB12639', 'DB12640', 'DB12641', 'DB12642', 'DB12643', 'DB12644', 'DB12645', 'DB12647', 'DB12648', 'DB12649', 'DB12650', 'DB12651', 'DB12652', 'DB12654', 'DB12655', 'DB12656', 'DB12657', 'DB12658', 'DB12659', 'DB12660', 'DB12661', 'DB12662', 'DB12663', 'DB12664', 'DB12665', 'DB12666', 'DB12667', 'DB12668', 'DB12669', 'DB12670', 'DB12671', 'DB12672', 'DB12673', 'DB12674', 'DB12675', 'DB12676', 'DB12677', 'DB12678', 'DB12679', 'DB12680', 'DB12681', 'DB12682', 'DB12683', 'DB12684', 'DB12685', 'DB12686', 'DB12687', 'DB12688', 'DB12689', 'DB12690', 'DB12691', 'DB12692', 'DB12693', 'DB12694', 'DB12695', 'DB12696', 'DB12697', 'DB12698', 'DB12699', 'DB12700', 'DB12701', 'DB12702', 'DB12703', 'DB12704', 'DB12705', 'DB12706', 'DB12707', 'DB12708', 'DB12709', 'DB12710', 'DB12711', 'DB12712', 'DB12713', 'DB12714', 'DB12715', 'DB12716', 'DB12717', 'DB12718', 'DB12719', 'DB12720', 'DB12721', 'DB12722', 'DB12724', 'DB12725', 'DB12726', 'DB12727', 'DB12728', 'DB12729', 'DB12730', 'DB12731', 'DB12732', 'DB12733', 'DB12734', 'DB12736', 'DB12737', 'DB12738', 'DB12739', 'DB12740', 'DB12741', 'DB12742', 'DB12743', 'DB12744', 'DB12745', 'DB12746', 'DB12747', 'DB12748', 'DB12749', 'DB12750', 'DB12751', 'DB12752', 'DB12753', 'DB12754', 'DB12755', 'DB12756', 'DB12757', 'DB12758', 'DB12759', 'DB12760', 'DB12761', 'DB12762', 'DB12763', 'DB12764', 'DB12765', 'DB12766', 'DB12767', 'DB12768', 'DB12769', 'DB12770', 'DB12771', 'DB12773', 'DB12774', 'DB12775', 'DB12776', 'DB12777', 'DB12778', 'DB12779', 'DB12780', 'DB12781', 'DB12782', 'DB12783', 'DB12784', 'DB12785', 'DB12786', 'DB12787', 'DB12788', 'DB12789', 'DB12791', 'DB12792', 'DB12793', 'DB12794', 'DB12795', 'DB12796', 'DB12797', 'DB12798', 'DB12799', 'DB12800', 'DB12802', 'DB12803', 'DB12804', 'DB12805', 'DB12806', 'DB12807', 'DB12808', 'DB12809', 'DB12810', 'DB12812', 'DB12813', 'DB12814', 'DB12815', 'DB12816', 'DB12817', 'DB12818', 'DB12819', 'DB12820', 'DB12821', 'DB12822', 'DB12823', 'DB12824', 'DB12825', 'DB12826', 'DB12827', 'DB12829', 'DB12830', 'DB12831', 'DB12832', 'DB12833', 'DB12834', 'DB12835', 'DB12836', 'DB12837', 'DB12838', 'DB12839', 'DB12840', 'DB12841', 'DB12842', 'DB12843', 'DB12844', 'DB12845', 'DB12846', 'DB12847', 'DB12848', 'DB12849', 'DB12850', 'DB12851', 'DB12852', 'DB12853', 'DB12854', 'DB12855', 'DB12856', 'DB12857', 'DB12858', 'DB12859', 'DB12860', 'DB12861', 'DB12862', 'DB12863', 'DB12864', 'DB12865', 'DB12866', 'DB12867', 'DB12868', 'DB12869', 'DB12870', 'DB12871', 'DB12872', 'DB12873', 'DB12874', 'DB12875', 'DB12876', 'DB12877', 'DB12878', 'DB12879', 'DB12880', 'DB12881', 'DB12882', 'DB12883', 'DB12884', 'DB12885', 'DB12886', 'DB12887', 'DB12888', 'DB12889', 'DB12890', 'DB12891', 'DB12892', 'DB12893', 'DB12894', 'DB12895', 'DB12896', 'DB12897', 'DB12898', 'DB12899', 'DB12900', 'DB12901', 'DB12902', 'DB12903', 'DB12904', 'DB12905', 'DB12906', 'DB12907', 'DB12908', 'DB12909', 'DB12910', 'DB12911', 'DB12912', 'DB12914', 'DB12915', 'DB12916', 'DB12917', 'DB12919', 'DB12920', 'DB12921', 'DB12923', 'DB12924', 'DB12925', 'DB12926', 'DB12927', 'DB12928', 'DB12929', 'DB12930', 'DB12931', 'DB12932', 'DB12933', 'DB12934', 'DB12935', 'DB12937', 'DB12938', 'DB12939', 'DB12940', 'DB12941', 'DB12942', 'DB12943', 'DB12944', 'DB12945', 'DB12946', 'DB12947', 'DB12948', 'DB12949', 'DB12950', 'DB12951', 'DB12952', 'DB12953', 'DB12954', 'DB12955', 'DB12956', 'DB12957', 'DB12958', 'DB12959', 'DB12960', 'DB12961', 'DB12962', 'DB12963', 'DB12964', 'DB12965', 'DB12966', 'DB12967', 'DB12968', 'DB12969', 'DB12970', 'DB12971', 'DB12972', 'DB12973', 'DB12974', 'DB12975', 'DB12976', 'DB12977', 'DB12978', 'DB12979', 'DB12980', 'DB12981', 'DB12982', 'DB12983', 'DB12984', 'DB12985', 'DB12986', 'DB12987', 'DB12988', 'DB12989', 'DB12990', 'DB12991', 'DB12992', 'DB12993', 'DB12994', 'DB12996', 'DB12997', 'DB12998', 'DB12999', 'DB13000', 'DB13001', 'DB13002', 'DB13003', 'DB13004', 'DB13005', 'DB13006', 'DB13007', 'DB13008', 'DB13009', 'DB13010', 'DB13011', 'DB13012', 'DB13013', 'DB13014', 'DB13016', 'DB13017', 'DB13018', 'DB13019', 'DB13020', 'DB13021', 'DB13022', 'DB13023', 'DB13024', 'DB13025', 'DB13026', 'DB13027', 'DB13028', 'DB13029', 'DB13030', 'DB13031', 'DB13032', 'DB13033', 'DB13034', 'DB13035', 'DB13036', 'DB13037', 'DB13038', 'DB13039', 'DB13040', 'DB13041', 'DB13042', 'DB13044', 'DB13045', 'DB13046', 'DB13047', 'DB13048', 'DB13049', 'DB13050', 'DB13051', 'DB13052', 'DB13053', 'DB13054', 'DB13055', 'DB13056', 'DB13057', 'DB13058', 'DB13059', 'DB13060', 'DB13061', 'DB13062', 'DB13063', 'DB13064', 'DB13065', 'DB13066', 'DB13067', 'DB13068', 'DB13069', 'DB13070', 'DB13071', 'DB13072', 'DB13073', 'DB13074', 'DB13075', 'DB13076', 'DB13077', 'DB13078', 'DB13080', 'DB13082', 'DB13083', 'DB13084', 'DB13085', 'DB13086', 'DB13087', 'DB13088', 'DB13089', 'DB13090', 'DB13091', 'DB13092', 'DB13093', 'DB13094', 'DB13095', 'DB13096', 'DB13097', 'DB13098', 'DB13099', 'DB13100', 'DB13101', 'DB13102', 'DB13103', 'DB13104', 'DB13105', 'DB13106', 'DB13107', 'DB13108', 'DB13109', 'DB13110', 'DB13111', 'DB13112', 'DB13113', 'DB13114', 'DB13115', 'DB13116', 'DB13117', 'DB13118', 'DB13119', 'DB13120', 'DB13121', 'DB13122', 'DB13123', 'DB13124', 'DB13125', 'DB13126', 'DB13127', 'DB13128', 'DB13129', 'DB13131', 'DB13132', 'DB13133', 'DB13134', 'DB13135', 'DB13136', 'DB13137', 'DB13138', 'DB13139', 'DB13140', 'DB13141', 'DB13142', 'DB13143', 'DB13144', 'DB13145', 'DB13146', 'DB13147', 'DB13148', 'DB13149', 'DB13150', 'DB13151', 'DB13152', 'DB13153', 'DB13154', 'DB13155', 'DB13156', 'DB13157', 'DB13158', 'DB13160', 'DB13161', 'DB13163', 'DB13164', 'DB13165', 'DB13166', 'DB13167', 'DB13168', 'DB13169', 'DB13170', 'DB13171', 'DB13172', 'DB13173', 'DB13174', 'DB13175', 'DB13177', 'DB13178', 'DB13179', 'DB13180', 'DB13181', 'DB13182', 'DB13183', 'DB13185', 'DB13189', 'DB13190', 'DB13191', 'DB13192', 'DB13193', 'DB13194', 'DB13195', 'DB13196', 'DB13197', 'DB13198', 'DB13199', 'DB13200', 'DB13201', 'DB13202', 'DB13203', 'DB13204', 'DB13205', 'DB13206', 'DB13207', 'DB13208', 'DB13209', 'DB13210', 'DB13211', 'DB13212', 'DB13213', 'DB13214', 'DB13215', 'DB13216', 'DB13217', 'DB13218', 'DB13219', 'DB13220', 'DB13221', 'DB13222', 'DB13223', 'DB13224', 'DB13225', 'DB13226', 'DB13227', 'DB13228', 'DB13229', 'DB13230', 'DB13231', 'DB13232', 'DB13233', 'DB13234', 'DB13235', 'DB13236', 'DB13237', 'DB13238', 'DB13239', 'DB13240', 'DB13241', 'DB13242', 'DB13243', 'DB13244', 'DB13245', 'DB13246', 'DB13247', 'DB13248', 'DB13249', 'DB13250', 'DB13251', 'DB13252', 'DB13253', 'DB13254', 'DB13255', 'DB13256', 'DB13257', 'DB13258', 'DB13259', 'DB13260', 'DB13261', 'DB13262', 'DB13263', 'DB13264', 'DB13265', 'DB13266', 'DB13267', 'DB13268', 'DB13269', 'DB13270', 'DB13271', 'DB13272', 'DB13273', 'DB13274', 'DB13275', 'DB13276', 'DB13277', 'DB13278', 'DB13279', 'DB13280', 'DB13281', 'DB13282', 'DB13283', 'DB13284', 'DB13285', 'DB13286', 'DB13287', 'DB13288', 'DB13289', 'DB13290', 'DB13291', 'DB13292', 'DB13293', 'DB13294', 'DB13295', 'DB13296', 'DB13297', 'DB13298', 'DB13299', 'DB13300', 'DB13302', 'DB13303', 'DB13304', 'DB13305', 'DB13306', 'DB13307', 'DB13308', 'DB13309', 'DB13310', 'DB13311', 'DB13312', 'DB13313', 'DB13314', 'DB13315', 'DB13316', 'DB13317', 'DB13318', 'DB13319', 'DB13320', 'DB13321', 'DB13322', 'DB13323', 'DB13324', 'DB13325', 'DB13326', 'DB13327', 'DB13328', 'DB13329', 'DB13330', 'DB13331', 'DB13332', 'DB13333', 'DB13334', 'DB13335', 'DB13336', 'DB13337', 'DB13338', 'DB13339', 'DB13340', 'DB13341', 'DB13342', 'DB13343', 'DB13344', 'DB13345', 'DB13346', 'DB13347', 'DB13348', 'DB13349', 'DB13350', 'DB13351', 'DB13352', 'DB13353', 'DB13354', 'DB13355', 'DB13356', 'DB13357', 'DB13358', 'DB13359', 'DB13360', 'DB13361', 'DB13362', 'DB13363', 'DB13364', 'DB13365', 'DB13366', 'DB13367', 'DB13368', 'DB13369', 'DB13370', 'DB13371', 'DB13372', 'DB13373', 'DB13374', 'DB13375', 'DB13376', 'DB13377', 'DB13378', 'DB13379', 'DB13380', 'DB13381', 'DB13382', 'DB13383', 'DB13384', 'DB13385', 'DB13386', 'DB13387', 'DB13388', 'DB13389', 'DB13391', 'DB13392', 'DB13393', 'DB13394', 'DB13395', 'DB13396', 'DB13397', 'DB13398', 'DB13399', 'DB13400', 'DB13401', 'DB13402', 'DB13403', 'DB13404', 'DB13405', 'DB13406', 'DB13407', 'DB13408', 'DB13409', 'DB13410', 'DB13411', 'DB13412', 'DB13413', 'DB13414', 'DB13415', 'DB13416', 'DB13417', 'DB13418', 'DB13419', 'DB13420', 'DB13421', 'DB13422', 'DB13423', 'DB13424', 'DB13425', 'DB13427', 'DB13428', 'DB13429', 'DB13430', 'DB13431', 'DB13432', 'DB13433', 'DB13434', 'DB13435', 'DB13436', 'DB13437', 'DB13438', 'DB13439', 'DB13441', 'DB13442', 'DB13443', 'DB13444', 'DB13445', 'DB13446', 'DB13447', 'DB13448', 'DB13449', 'DB13451', 'DB13452', 'DB13453', 'DB13454', 'DB13455', 'DB13456', 'DB13457', 'DB13458', 'DB13459', 'DB13460', 'DB13461', 'DB13462', 'DB13463', 'DB13464', 'DB13465', 'DB13466', 'DB13467', 'DB13468', 'DB13469', 'DB13470', 'DB13471', 'DB13472', 'DB13473', 'DB13474', 'DB13475', 'DB13476', 'DB13477', 'DB13478', 'DB13479', 'DB13480', 'DB13481', 'DB13482', 'DB13483', 'DB13484', 'DB13485', 'DB13486', 'DB13487', 'DB13488', 'DB13489', 'DB13490', 'DB13491', 'DB13492', 'DB13493', 'DB13494', 'DB13495', 'DB13496', 'DB13497', 'DB13499', 'DB13500', 'DB13501', 'DB13502', 'DB13503', 'DB13504', 'DB13505', 'DB13506', 'DB13507', 'DB13508', 'DB13509', 'DB13510', 'DB13511', 'DB13512', 'DB13513', 'DB13514', 'DB13515', 'DB13516', 'DB13517', 'DB13518', 'DB13519', 'DB13520', 'DB13521', 'DB13522', 'DB13523', 'DB13524', 'DB13525', 'DB13526', 'DB13527', 'DB13528', 'DB13529', 'DB13530', 'DB13531', 'DB13532', 'DB13533', 'DB13534', 'DB13535', 'DB13536', 'DB13537', 'DB13538', 'DB13539', 'DB13540', 'DB13541', 'DB13542', 'DB13543', 'DB13544', 'DB13545', 'DB13546', 'DB13547', 'DB13548', 'DB13549', 'DB13550', 'DB13551', 'DB13552', 'DB13553', 'DB13554', 'DB13555', 'DB13556', 'DB13557', 'DB13558', 'DB13559', 'DB13560', 'DB13561', 'DB13563', 'DB13564', 'DB13565', 'DB13566', 'DB13567', 'DB13568', 'DB13569', 'DB13570', 'DB13571', 'DB13572', 'DB13573', 'DB13574', 'DB13575', 'DB13576', 'DB13577', 'DB13578', 'DB13579', 'DB13580', 'DB13581', 'DB13582', 'DB13583', 'DB13584', 'DB13585', 'DB13586', 'DB13587', 'DB13588', 'DB13590', 'DB13591', 'DB13592', 'DB13593', 'DB13595', 'DB13596', 'DB13597', 'DB13598', 'DB13599', 'DB13600', 'DB13601', 'DB13602', 'DB13603', 'DB13604', 'DB13605', 'DB13606', 'DB13607', 'DB13608', 'DB13609', 'DB13610', 'DB13611', 'DB13612', 'DB13613', 'DB13614', 'DB13615', 'DB13616', 'DB13617', 'DB13618', 'DB13619', 'DB13620', 'DB13621', 'DB13622', 'DB13623', 'DB13624', 'DB13625', 'DB13626', 'DB13627', 'DB13628', 'DB13629', 'DB13630', 'DB13631', 'DB13632', 'DB13633', 'DB13634', 'DB13635', 'DB13636', 'DB13637', 'DB13638', 'DB13639', 'DB13640', 'DB13641', 'DB13642', 'DB13643', 'DB13644', 'DB13645', 'DB13646', 'DB13647', 'DB13648', 'DB13649', 'DB13650', 'DB13651', 'DB13652', 'DB13653', 'DB13654', 'DB13655', 'DB13656', 'DB13657', 'DB13658', 'DB13659', 'DB13660', 'DB13661', 'DB13662', 'DB13663', 'DB13664', 'DB13665', 'DB13666', 'DB13667', 'DB13668', 'DB13669', 'DB13670', 'DB13671', 'DB13672', 'DB13673', 'DB13674', 'DB13675', 'DB13676', 'DB13677', 'DB13678', 'DB13679', 'DB13680', 'DB13681', 'DB13682', 'DB13683', 'DB13684', 'DB13685', 'DB13686', 'DB13687', 'DB13688', 'DB13689', 'DB13690', 'DB13691', 'DB13692', 'DB13693', 'DB13694', 'DB13695', 'DB13696', 'DB13697', 'DB13698', 'DB13699', 'DB13700', 'DB13701', 'DB13702', 'DB13703', 'DB13704', 'DB13705', 'DB13706', 'DB13707', 'DB13708', 'DB13709', 'DB13710', 'DB13711', 'DB13712', 'DB13713', 'DB13714', 'DB13715', 'DB13716', 'DB13717', 'DB13718', 'DB13719', 'DB13720', 'DB13721', 'DB13722', 'DB13723', 'DB13724', 'DB13725', 'DB13726', 'DB13727', 'DB13728', 'DB13729', 'DB13730', 'DB13731', 'DB13732', 'DB13733', 'DB13734', 'DB13735', 'DB13736', 'DB13737', 'DB13738', 'DB13739', 'DB13740', 'DB13741', 'DB13742', 'DB13743', 'DB13744', 'DB13745', 'DB13746', 'DB13747', 'DB13748', 'DB13749', 'DB13750', 'DB13751', 'DB13752', 'DB13753', 'DB13754', 'DB13755', 'DB13756', 'DB13757', 'DB13758', 'DB13759', 'DB13760', 'DB13761', 'DB13762', 'DB13763', 'DB13764', 'DB13765', 'DB13766', 'DB13767', 'DB13768', 'DB13769', 'DB13770', 'DB13771', 'DB13772', 'DB13773', 'DB13774', 'DB13775', 'DB13776', 'DB13777', 'DB13778', 'DB13779', 'DB13780', 'DB13781', 'DB13782', 'DB13783', 'DB13784', 'DB13785', 'DB13786', 'DB13787', 'DB13788', 'DB13789', 'DB13790', 'DB13791', 'DB13792', 'DB13793', 'DB13794', 'DB13795', 'DB13796', 'DB13797', 'DB13798', 'DB13799', 'DB13800', 'DB13801', 'DB13802', 'DB13803', 'DB13804', 'DB13805', 'DB13806', 'DB13807', 'DB13808', 'DB13809', 'DB13810', 'DB13811', 'DB13812', 'DB13813', 'DB13814', 'DB13815', 'DB13816', 'DB13817', 'DB13818', 'DB13819', 'DB13820', 'DB13821', 'DB13822', 'DB13823', 'DB13824', 'DB13825', 'DB13826', 'DB13827', 'DB13828', 'DB13829', 'DB13830', 'DB13831', 'DB13832', 'DB13833', 'DB13834', 'DB13835', 'DB13836', 'DB13837', 'DB13838', 'DB13839', 'DB13840', 'DB13841', 'DB13842', 'DB13843', 'DB13844', 'DB13845', 'DB13846', 'DB13847', 'DB13848', 'DB13849', 'DB13850', 'DB13851', 'DB13852', 'DB13853', 'DB13854', 'DB13855', 'DB13856', 'DB13857', 'DB13858', 'DB13860', 'DB13861', 'DB13862', 'DB13863', 'DB13864', 'DB13865', 'DB13866', 'DB13867', 'DB13868', 'DB13869', 'DB13871', 'DB13872', 'DB13873', 'DB13874', 'DB13875', 'DB13876', 'DB13877', 'DB13878', 'DB13879', 'DB13881', 'DB13882', 'DB13883', 'DB13884', 'DB13885', 'DB13886', 'DB13887', 'DB13888', 'DB13889', 'DB13890', 'DB13891', 'DB13892', 'DB13893', 'DB13894', 'DB13895', 'DB13896', 'DB13897', 'DB13898', 'DB13899', 'DB13900', 'DB13901', 'DB13902', 'DB13903', 'DB13904', 'DB13905', 'DB13906', 'DB13907', 'DB13908', 'DB13909', 'DB13910', 'DB13911', 'DB13912', 'DB13913', 'DB13914', 'DB13915', 'DB13916', 'DB13917', 'DB13918', 'DB13919', 'DB13920', 'DB13921', 'DB13923', 'DB13924', 'DB13925', 'DB13926', 'DB13927', 'DB13928', 'DB13929', 'DB13930', 'DB13931', 'DB13932', 'DB13933', 'DB13934', 'DB13935', 'DB13936', 'DB13937', 'DB13938', 'DB13939', 'DB13940', 'DB13941', 'DB13943', 'DB13944', 'DB13946', 'DB13947', 'DB13948', 'DB13949', 'DB13950', 'DB13951', 'DB13952', 'DB13953', 'DB13954', 'DB13955', 'DB13956', 'DB13957', 'DB13958', 'DB13959', 'DB13960', 'DB13961', 'DB13962', 'DB13963', 'DB13964', 'DB13965', 'DB13966', 'DB13967', 'DB13968', 'DB13969', 'DB13970', 'DB13971', 'DB13972', 'DB13973', 'DB13974', 'DB13975', 'DB13976', 'DB13977', 'DB13978', 'DB13979', 'DB13980', 'DB13981', 'DB13982', 'DB13983', 'DB13984', 'DB13985', 'DB13987', 'DB13988', 'DB13989', 'DB13990', 'DB13991', 'DB13992', 'DB13993', 'DB13994', 'DB13995', 'DB13996', 'DB13997', 'DB13998', 'DB13999', 'DB14000', 'DB14001', 'DB14002', 'DB14003', 'DB14004', 'DB14005', 'DB14006', 'DB14007', 'DB14008', 'DB14009', 'DB14010', 'DB14011', 'DB14012', 'DB14013', 'DB14014', 'DB14015', 'DB14016', 'DB14017', 'DB14018', 'DB14019', 'DB14020', 'DB14022', 'DB14025', 'DB14026', 'DB14027', 'DB14028', 'DB14029', 'DB14030', 'DB14031', 'DB14033', 'DB14034', 'DB14035', 'DB14037', 'DB14038', 'DB14039', 'DB14040', 'DB14041', 'DB14042', 'DB14043', 'DB14044', 'DB14045', 'DB14046', 'DB14048', 'DB14049', 'DB14050', 'DB14051', 'DB14052', 'DB14054', 'DB14055', 'DB14056', 'DB14057', 'DB14058', 'DB14059', 'DB14060', 'DB14061', 'DB14062', 'DB14063', 'DB14064', 'DB14065', 'DB14066', 'DB14067', 'DB14068', 'DB14069', 'DB14070', 'DB14071', 'DB14072', 'DB14073', 'DB14074', 'DB14075', 'DB14076', 'DB14077', 'DB14078', 'DB14079', 'DB14080', 'DB14081', 'DB14082', 'DB14083', 'DB14084', 'DB14085', 'DB14086', 'DB14087', 'DB14088', 'DB14089', 'DB14090', 'DB14091', 'DB14092', 'DB14093', 'DB14094', 'DB14096', 'DB14097', 'DB14098', 'DB14099', 'DB14100', 'DB14101', 'DB14102', 'DB14103', 'DB14104', 'DB14105', 'DB14106', 'DB14107', 'DB14108', 'DB14109', 'DB14110', 'DB14111', 'DB14112', 'DB14113', 'DB14114', 'DB14115', 'DB14116', 'DB14117', 'DB14119', 'DB14120', 'DB14121', 'DB14122', 'DB14123', 'DB14124', 'DB14125', 'DB14126', 'DB14127', 'DB14128', 'DB14129', 'DB14130', 'DB14131', 'DB14132', 'DB14134', 'DB14135', 'DB14136', 'DB14137', 'DB14138', 'DB14139', 'DB14140', 'DB14141', 'DB14142', 'DB14143', 'DB14144', 'DB14145', 'DB14146', 'DB14148', 'DB14149', 'DB14150', 'DB14151', 'DB14152', 'DB14153', 'DB14154', 'DB14155', 'DB14156', 'DB14157', 'DB14158', 'DB14159', 'DB14160', 'DB14161', 'DB14162', 'DB14163', 'DB14164', 'DB14165', 'DB14166', 'DB14167', 'DB14168', 'DB14169', 'DB14170', 'DB14171', 'DB14172', 'DB14173', 'DB14174', 'DB14175', 'DB14176', 'DB14177', 'DB14178', 'DB14179', 'DB14180', 'DB14181', 'DB14182', 'DB14183', 'DB14184', 'DB14185', 'DB14186', 'DB14187', 'DB14188', 'DB14189', 'DB14190', 'DB14191', 'DB14192', 'DB14193', 'DB14194', 'DB14195', 'DB14196', 'DB14197', 'DB14198', 'DB14199', 'DB14200', 'DB14201', 'DB14202', 'DB14203', 'DB14204', 'DB14205', 'DB14206', 'DB14207', 'DB14208', 'DB14209', 'DB14210', 'DB14211', 'DB14212', 'DB14213', 'DB14214', 'DB14217', 'DB14218', 'DB14219', 'DB14221', 'DB14222', 'DB14223', 'DB14224', 'DB14225', 'DB14226', 'DB14227', 'DB14228', 'DB14229', 'DB14230', 'DB14231', 'DB14232', 'DB14233', 'DB14234', 'DB14235', 'DB14236', 'DB14237', 'DB14238', 'DB14239', 'DB14240', 'DB14241', 'DB14242', 'DB14243', 'DB14244', 'DB14245', 'DB14246', 'DB14247', 'DB14248', 'DB14249', 'DB14250', 'DB14251', 'DB14252', 'DB14253', 'DB14254', 'DB14255', 'DB14256', 'DB14257', 'DB14258', 'DB14259', 'DB14260', 'DB14261', 'DB14262', 'DB14263', 'DB14264', 'DB14265', 'DB14266', 'DB14267', 'DB14268', 'DB14269', 'DB14270', 'DB14271', 'DB14272', 'DB14273', 'DB14274', 'DB14275', 'DB14276', 'DB14277', 'DB14278', 'DB14279', 'DB14280', 'DB14281', 'DB14282', 'DB14283', 'DB14284', 'DB14285', 'DB14286', 'DB14287', 'DB14288', 'DB14289', 'DB14290', 'DB14291', 'DB14292', 'DB14293', 'DB14294', 'DB14295', 'DB14296', 'DB14297', 'DB14298', 'DB14299', 'DB14300', 'DB14301', 'DB14302', 'DB14303', 'DB14304', 'DB14305', 'DB14306', 'DB14307', 'DB14308', 'DB14309', 'DB14310', 'DB14311', 'DB14312', 'DB14313', 'DB14314', 'DB14315', 'DB14316', 'DB14317', 'DB14318', 'DB14319', 'DB14320', 'DB14321', 'DB14322', 'DB14323', 'DB14324', 'DB14325', 'DB14326', 'DB14327', 'DB14328', 'DB14329', 'DB14330', 'DB14331', 'DB14332', 'DB14333', 'DB14334', 'DB14335', 'DB14336', 'DB14337', 'DB14338', 'DB14339', 'DB14340', 'DB14341', 'DB14342', 'DB14343', 'DB14344', 'DB14345', 'DB14346', 'DB14347', 'DB14348', 'DB14349', 'DB14350', 'DB14351', 'DB14352', 'DB14353', 'DB14354', 'DB14355', 'DB14356', 'DB14357', 'DB14358', 'DB14359', 'DB14360', 'DB14361', 'DB14362', 'DB14363', 'DB14364', 'DB14365', 'DB14366', 'DB14367', 'DB14368', 'DB14369', 'DB14370', 'DB14371', 'DB14372', 'DB14373', 'DB14374', 'DB14375', 'DB14376', 'DB14377', 'DB14378', 'DB14379', 'DB14382', 'DB14383', 'DB14384', 'DB14385', 'DB14386', 'DB14387', 'DB14388', 'DB14389', 'DB14390', 'DB14391', 'DB14392', 'DB14393', 'DB14394', 'DB14395', 'DB14396', 'DB14397', 'DB14398', 'DB14399', 'DB14400', 'DB14401', 'DB14402', 'DB14403', 'DB14404', 'DB14405', 'DB14406', 'DB14407', 'DB14408', 'DB14409', 'DB14410', 'DB14411', 'DB14412', 'DB14413', 'DB14414', 'DB14415', 'DB14416', 'DB14417', 'DB14418', 'DB14419', 'DB14420', 'DB14421', 'DB14422', 'DB14423', 'DB14424', 'DB14425', 'DB14426', 'DB14427', 'DB14428', 'DB14429', 'DB14430', 'DB14431', 'DB14432', 'DB14433', 'DB14434', 'DB14435', 'DB14436', 'DB14437', 'DB14438', 'DB14439', 'DB14440', 'DB14441', 'DB14442', 'DB14443', 'DB14444', 'DB14445', 'DB14446', 'DB14447', 'DB14449', 'DB14450', 'DB14451', 'DB14452', 'DB14453', 'DB14454', 'DB14455', 'DB14456', 'DB14457', 'DB14458', 'DB14459', 'DB14460', 'DB14461', 'DB14462', 'DB14463', 'DB14464', 'DB14465', 'DB14466', 'DB14467', 'DB14468', 'DB14469', 'DB14470', 'DB14471', 'DB14472', 'DB14473', 'DB14474', 'DB14475', 'DB14476', 'DB14477', 'DB14478', 'DB14479', 'DB14480', 'DB14481', 'DB14482', 'DB14483', 'DB14484', 'DB14485', 'DB14486', 'DB14487', 'DB14488', 'DB14489', 'DB14490', 'DB14491', 'DB14492', 'DB14493', 'DB14494', 'DB14495', 'DB14496', 'DB14497', 'DB14498', 'DB14499', 'DB14500', 'DB14501', 'DB14502', 'DB14503', 'DB14504', 'DB14505', 'DB14506', 'DB14507', 'DB14508', 'DB14509', 'DB14510', 'DB14511', 'DB14512', 'DB14513', 'DB14514', 'DB14515', 'DB14516', 'DB14517', 'DB14518', 'DB14519', 'DB14520', 'DB14521', 'DB14522', 'DB14523', 'DB14524', 'DB14525', 'DB14526', 'DB14527', 'DB14528', 'DB14529', 'DB14530', 'DB14531', 'DB14532', 'DB14533', 'DB14534', 'DB14535', 'DB14536', 'DB14537', 'DB14538', 'DB14539', 'DB14540', 'DB14541', 'DB14542', 'DB14543', 'DB14544', 'DB14545', 'DB14546', 'DB14547', 'DB14548', 'DB14549', 'DB14550', 'DB14551', 'DB14552', 'DB14553', 'DB14554', 'DB14555', 'DB14556', 'DB14557', 'DB14558', 'DB14559', 'DB14560', 'DB14561', 'DB14562', 'DB14563', 'DB14564', 'DB14565', 'DB14566', 'DB14567', 'DB14568', 'DB14569', 'DB14570', 'DB14571', 'DB14572', 'DB14573', 'DB14574', 'DB14575', 'DB14576', 'DB14577', 'DB14578', 'DB14579', 'DB14580', 'DB14581', 'DB14582', 'DB14583', 'DB14584', 'DB14585', 'DB14586', 'DB14587', 'DB14588', 'DB14589', 'DB14590', 'DB14591', 'DB14592', 'DB14593', 'DB14594', 'DB14595', 'DB00873', 'DB14597', 'DB14598', 'DB14599', 'DB14600', 'DB14601', 'DB14602', 'DB14603', 'DB14604', 'DB14605', 'DB14606', 'DB14607', 'DB14608', 'DB14609', 'DB14610', 'DB14611', 'DB14612', 'DB14613', 'DB14614', 'DB14615', 'DB14616', 'DB14617', 'DB14618', 'DB14619', 'DB14620', 'DB14622', 'DB14623', 'DB14624', 'DB14625', 'DB14626', 'DB14627', 'DB14628', 'DB14629', 'DB14630', 'DB14631', 'DB14632', 'DB14633', 'DB14634', 'DB14635', 'DB14636', 'DB14637', 'DB14638', 'DB14639', 'DB14640', 'DB14641', 'DB14642', 'DB14643', 'DB14644', 'DB14645', 'DB14646', 'DB14647', 'DB14648', 'DB14649', 'DB14650', 'DB14651', 'DB14652', 'DB14653', 'DB14654', 'DB14655', 'DB14656', 'DB14657', 'DB14658', 'DB14659', 'DB14660', 'DB14661', 'DB14662', 'DB14663', 'DB14664', 'DB14665', 'DB14666', 'DB14667', 'DB14668', 'DB14669', 'DB14670', 'DB14671', 'DB14672', 'DB14673', 'DB14674', 'DB14675', 'DB14676', 'DB14677', 'DB14678', 'DB14679', 'DB14680', 'DB14681', 'DB14682', 'DB14683', 'DB14684', 'DB14685', 'DB14686', 'DB14687', 'DB14688', 'DB14689', 'DB14690', 'DB14691', 'DB14692', 'DB14693', 'DB14694', 'DB14695', 'DB14696', 'DB14697', 'DB14698', 'DB14699', 'DB14700', 'DB14701', 'DB14702', 'DB14703', 'DB14704', 'DB14705', 'DB14706', 'DB14707', 'DB14708', 'DB14709', 'DB14710', 'DB14711', 'DB14712', 'DB14713', 'DB14714', 'DB14715', 'DB14716', 'DB14717', 'DB14718', 'DB14719', 'DB14720', 'DB14721', 'DB14722', 'DB14723', 'DB14724', 'DB14725', 'DB14726', 'DB14727', 'DB14728', 'DB14729', 'DB14730', 'DB14731', 'DB14732', 'DB14733', 'DB14734', 'DB14735', 'DB14736', 'DB14737', 'DB14738', 'DB14739', 'DB14740', 'DB14741', 'DB00781', 'DB14743', 'DB14744', 'DB14745', 'DB14746', 'DB14747', 'DB14748', 'DB14749', 'DB14750', 'DB14751', 'DB14752', 'DB14753', 'DB14754', 'DB14755', 'DB14756', 'DB14757', 'DB14758', 'DB14759', 'DB14760', 'DB14761', 'DB14762', 'DB14763', 'DB14764', 'DB14765', 'DB14766', 'DB14767', 'DB14768', 'DB14769', 'DB14770', 'DB14771', 'DB14772', 'DB14773', 'DB14774', 'DB14775', 'DB14776', 'DB14777', 'DB14778', 'DB14779', 'DB14780', 'DB14781', 'DB14782', 'DB14783', 'DB14784', 'DB14785', 'DB14786', 'DB14787', 'DB14788', 'DB14789', 'DB14790', 'DB14791', 'DB14792', 'DB14793', 'DB14794', 'DB14795', 'DB14796', 'DB14797', 'DB14798', 'DB14799', 'DB14800', 'DB14801', 'DB14802', 'DB14803', 'DB14804', 'DB14805', 'DB14806', 'DB14807', 'DB14808', 'DB14809', 'DB14810', 'DB14811', 'DB14812', 'DB14813', 'DB14814', 'DB14815', 'DB14816', 'DB14817', 'DB14818', 'DB14819', 'DB14820', 'DB14821', 'DB14822', 'DB14823', 'DB14824', 'DB14825', 'DB14826', 'DB14827', 'DB14828', 'DB14829', 'DB14830', 'DB14831', 'DB14832', 'DB14833', 'DB14834', 'DB14835', 'DB14836', 'DB14838', 'DB14839', 'DB14840', 'DB14841', 'DB14843', 'DB14844', 'DB14845', 'DB14846', 'DB14847', 'DB14848', 'DB14849', 'DB14850', 'DB14851', 'DB14852', 'DB14853', 'DB14854', 'DB14855', 'DB14856', 'DB14857', 'DB14858', 'DB14859', 'DB14860', 'DB14862', 'DB14864', 'DB14865', 'DB14866', 'DB14867', 'DB14868', 'DB14869', 'DB14870', 'DB14871', 'DB14872', 'DB14873', 'DB14874', 'DB14875', 'DB14876', 'DB14877', 'DB14878', 'DB14879', 'DB14880', 'DB14881', 'DB14882', 'DB14883', 'DB14884', 'DB14885', 'DB14886', 'DB14887', 'DB14888', 'DB14889', 'DB14890', 'DB14891', 'DB14892', 'DB14894', 'DB14895', 'DB14896', 'DB14897', 'DB14898', 'DB14899', 'DB14900', 'DB14901', 'DB14902', 'DB14903', 'DB14904', 'DB14905', 'DB14906', 'DB14907', 'DB14908', 'DB14909', 'DB14910', 'DB14911', 'DB14912', 'DB14913', 'DB14914', 'DB14915', 'DB14916', 'DB14917', 'DB14918', 'DB14919', 'DB14920', 'DB14921', 'DB14922', 'DB14923', 'DB14924', 'DB14925', 'DB14926', 'DB14927', 'DB14928', 'DB14929', 'DB14930', 'DB14931', 'DB14932', 'DB14933', 'DB14934', 'DB14935', 'DB14936', 'DB14937', 'DB14938', 'DB14939', 'DB14940', 'DB14941', 'DB14942', 'DB14943', 'DB14944', 'DB14945', 'DB14946', 'DB14947', 'DB14948', 'DB14949', 'DB14950', 'DB14951', 'DB14952', 'DB14953', 'DB14954', 'DB14955', 'DB14956', 'DB14957', 'DB14958', 'DB14959', 'DB14960', 'DB14961', 'DB14962', 'DB14963', 'DB14964', 'DB14965', 'DB14966', 'DB14967', 'DB14968', 'DB14969', 'DB14970', 'DB14971', 'DB14972', 'DB14973', 'DB14974', 'DB14975', 'DB14976', 'DB14977', 'DB14978', 'DB14979', 'DB14980', 'DB14981', 'DB14982', 'DB14983', 'DB14984', 'DB14985', 'DB14986', 'DB14987', 'DB14988', 'DB14989', 'DB14990', 'DB14991', 'DB14992', 'DB14993', 'DB14995', 'DB14996', 'DB14997', 'DB14998', 'DB14999', 'DB15000', 'DB15001', 'DB15002', 'DB15003', 'DB15004', 'DB15005', 'DB15006', 'DB15007', 'DB15008', 'DB15009', 'DB15010', 'DB15011', 'DB15012', 'DB15013', 'DB15014', 'DB15015', 'DB15016', 'DB15017', 'DB15018', 'DB15019', 'DB15020', 'DB15021', 'DB15022', 'DB15023', 'DB15024', 'DB15025', 'DB15026', 'DB15027', 'DB15028', 'DB15029', 'DB15030', 'DB15031', 'DB15032', 'DB15033', 'DB15034', 'DB15035', 'DB15036', 'DB15037', 'DB15038', 'DB15039', 'DB15040', 'DB15041', 'DB15042', 'DB15043', 'DB15044', 'DB15045', 'DB15046', 'DB15047', 'DB15048', 'DB15049', 'DB15050', 'DB15051', 'DB15052', 'DB15053', 'DB15054', 'DB15055', 'DB15056', 'DB15057', 'DB15058', 'DB15059', 'DB15061', 'DB15062', 'DB15063', 'DB15064', 'DB15065', 'DB15066', 'DB15067', 'DB15068', 'DB15069', 'DB15070', 'DB15071', 'DB15072', 'DB15073', 'DB15074', 'DB15075', 'DB15076', 'DB15077', 'DB15078', 'DB15079', 'DB15080', 'DB15081', 'DB15082', 'DB15083', 'DB15084', 'DB15085', 'DB15086', 'DB15087', 'DB15088', 'DB15089', 'DB15090', 'DB15091', 'DB15092', 'DB15093', 'DB15094', 'DB15095', 'DB15096', 'DB15097', 'DB15098', 'DB15099', 'DB15100', 'DB15101', 'DB15102', 'DB15104', 'DB15105', 'DB15106', 'DB15107', 'DB15108', 'DB15109', 'DB15110', 'DB15111', 'DB15112', 'DB15113', 'DB15114', 'DB15115', 'DB15116', 'DB15117', 'DB15118', 'DB15119', 'DB15120', 'DB15121', 'DB15122', 'DB15123', 'DB15124', 'DB15125', 'DB15126', 'DB15127', 'DB15128', 'DB15129', 'DB15130', 'DB15131', 'DB15132', 'DB15133', 'DB15134', 'DB15135', 'DB15136', 'DB15137', 'DB15138', 'DB15139', 'DB15140', 'DB15141', 'DB15143', 'DB15144', 'DB15145', 'DB15146', 'DB15147', 'DB15148', 'DB15149', 'DB15150', 'DB15151', 'DB15152', 'DB15153', 'DB15154', 'DB15155', 'DB15156', 'DB15157', 'DB15158', 'DB15159', 'DB15160', 'DB15161', 'DB15162', 'DB15163', 'DB15164', 'DB15165', 'DB15166', 'DB15167', 'DB15168', 'DB15169', 'DB15170', 'DB15171', 'DB15172', 'DB15173', 'DB15175', 'DB15176', 'DB15177', 'DB15178', 'DB15182', 'DB15183', 'DB15185', 'DB15186', 'DB15187', 'DB15188', 'DB15189', 'DB15190', 'DB15191', 'DB15192', 'DB15193', 'DB15194', 'DB15195', 'DB15197', 'DB15198', 'DB15199', 'DB15200', 'DB15201', 'DB15202', 'DB15203', 'DB15204', 'DB15205', 'DB15206', 'DB15207', 'DB15208', 'DB15209', 'DB15210', 'DB15211', 'DB15212', 'DB15213', 'DB15214', 'DB15215', 'DB15216', 'DB15217', 'DB15218', 'DB15219', 'DB15220', 'DB15221', 'DB15222', 'DB15223', 'DB15224', 'DB15225', 'DB15226', 'DB15227', 'DB15228', 'DB15229', 'DB15230', 'DB15231', 'DB15232', 'DB15233', 'DB15234', 'DB15235', 'DB15236', 'DB15237', 'DB15238', 'DB15239', 'DB15240', 'DB15241', 'DB15242', 'DB15243', 'DB15244', 'DB15245', 'DB15246', 'DB15247', 'DB15248', 'DB15249', 'DB15250', 'DB15251', 'DB15252', 'DB15253', 'DB15254', 'DB15256', 'DB15257', 'DB15258', 'DB15259', 'DB15260', 'DB15261', 'DB15262', 'DB15263', 'DB15264', 'DB15265', 'DB15266', 'DB15267', 'DB15268', 'DB15269', 'DB15270', 'DB15271', 'DB15272', 'DB15273', 'DB15274', 'DB15275', 'DB15276', 'DB15277', 'DB15278', 'DB15279', 'DB15280', 'DB15281', 'DB15282', 'DB15283', 'DB15284', 'DB15285', 'DB15286', 'DB15287', 'DB15288', 'DB15289', 'DB15290', 'DB15291', 'DB15292', 'DB15293', 'DB15294', 'DB15295', 'DB15296', 'DB15297', 'DB15298', 'DB15299', 'DB15300', 'DB15301', 'DB15302', 'DB15303', 'DB15304', 'DB15305', 'DB15306', 'DB15307', 'DB15308', 'DB15310', 'DB15311', 'DB15312', 'DB15313', 'DB15314', 'DB15315', 'DB15316', 'DB15317', 'DB15318', 'DB15319', 'DB15321', 'DB15322', 'DB15323', 'DB15324', 'DB15325', 'DB15326', 'DB15327', 'DB15328', 'DB15329', 'DB15330', 'DB15331', 'DB15332', 'DB15333', 'DB15334', 'DB15335', 'DB15336', 'DB15338', 'DB15339', 'DB15340', 'DB15341', 'DB15342', 'DB15343', 'DB15344', 'DB15345', 'DB15346', 'DB15347', 'DB15348', 'DB15349', 'DB15350', 'DB15352', 'DB15353', 'DB15354', 'DB15355', 'DB15356', 'DB15357', 'DB15358', 'DB15359', 'DB15360', 'DB15361', 'DB15362', 'DB15363', 'DB15365', 'DB15366', 'DB15367', 'DB15368', 'DB15369', 'DB15370', 'DB15371', 'DB15372', 'DB15373', 'DB15374', 'DB15375', 'DB15376', 'DB15377', 'DB15378', 'DB15379', 'DB15380', 'DB15381', 'DB15382', 'DB15383', 'DB15384', 'DB15385', 'DB15386', 'DB15387', 'DB15388', 'DB15389', 'DB15390', 'DB15391', 'DB15392', 'DB15393', 'DB15394', 'DB15395', 'DB15396', 'DB15397', 'DB15398', 'DB15399', 'DB15400', 'DB15401', 'DB15402', 'DB15403', 'DB15404', 'DB15405', 'DB15406', 'DB15407', 'DB15408', 'DB15409', 'DB15410', 'DB15411', 'DB15412', 'DB15413', 'DB15414', 'DB15415', 'DB15416', 'DB15417', 'DB15418', 'DB15419', 'DB15420', 'DB15421', 'DB15422', 'DB15423', 'DB15424', 'DB15425', 'DB15426', 'DB15427', 'DB15428', 'DB15429', 'DB15430', 'DB15431', 'DB15432', 'DB15433', 'DB15434', 'DB15435', 'DB15436', 'DB15437', 'DB15438', 'DB15439', 'DB15440', 'DB15441', 'DB15442', 'DB15443', 'DB15444', 'DB15445', 'DB15446', 'DB15447', 'DB15448', 'DB15449', 'DB15450', 'DB15451', 'DB15452', 'DB15453', 'DB15455', 'DB15456', 'DB15457', 'DB15458', 'DB15460', 'DB15461', 'DB15462', 'DB15463', 'DB15464', 'DB15465', 'DB15466', 'DB15467', 'DB15468', 'DB15469', 'DB15470', 'DB15471', 'DB15472', 'DB15473', 'DB15474', 'DB15475', 'DB15476', 'DB15477', 'DB15478', 'DB15479', 'DB15480', 'DB15481', 'DB15482', 'DB15483', 'DB15484', 'DB15485', 'DB15486', 'DB15487', 'DB15488', 'DB15489', 'DB15490', 'DB15491', 'DB15492', 'DB15493', 'DB15494', 'DB15495', 'DB15496', 'DB15497', 'DB15498', 'DB15499', 'DB15500', 'DB15501', 'DB15502', 'DB15503', 'DB15504', 'DB15505', 'DB15506', 'DB15507', 'DB15508', 'DB15509', 'DB15510', 'DB15511', 'DB15512', 'DB15513', 'DB15514', 'DB15515', 'DB15516', 'DB15517', 'DB15518', 'DB15519', 'DB15520', 'DB15521', 'DB15522', 'DB15523', 'DB15524', 'DB15525', 'DB15526', 'DB15527', 'DB15528', 'DB15529', 'DB15530', 'DB15531', 'DB15532', 'DB15533', 'DB15534', 'DB15535', 'DB15536', 'DB15537', 'DB15538', 'DB15539', 'DB15540', 'DB15541', 'DB15542', 'DB15543', 'DB15544', 'DB15545', 'DB15546', 'DB15547', 'DB15548', 'DB15549', 'DB15550', 'DB15551', 'DB15552', 'DB15553', 'DB15554', 'DB15555', 'DB15556', 'DB15557', 'DB15558', 'DB15559', 'DB15560', 'DB15561', 'DB15562', 'DB15563', 'DB15564', 'DB15565', 'DB15566', 'DB15567', 'DB15568', 'DB15569', 'DB15570', 'DB15571', 'DB15572', 'DB15573', 'DB15574', 'DB15575', 'DB15576', 'DB15578', 'DB15579', 'DB15580', 'DB15581', 'DB15582', 'DB15583', 'DB15584', 'DB15585', 'DB15586', 'DB15587', 'DB15588', 'DB15589', 'DB15590', 'DB15591', 'DB15592', 'DB15593', 'DB15594', 'DB15595', 'DB15596', 'DB15597', 'DB15598', 'DB15599', 'DB15601', 'DB15602', 'DB15603', 'DB15604', 'DB15605', 'DB15606', 'DB15607', 'DB15608', 'DB15609', 'DB15610', 'DB15611', 'DB15612', 'DB15613', 'DB15614', 'DB15615', 'DB15616', 'DB15617', 'DB15618', 'DB15619', 'DB15620', 'DB15621', 'DB15622', 'DB15623', 'DB15624', 'DB15626', 'DB15627', 'DB15628', 'DB15629', 'DB15630', 'DB15631', 'DB15632', 'DB15633', 'DB15634', 'DB15635', 'DB15636', 'DB15637', 'DB15638', 'DB15639', 'DB15640', 'DB15641', 'DB15642', 'DB15643', 'DB15644', 'DB15645', 'DB15646', 'DB15647', 'DB15648', 'DB15649', 'DB15650', 'DB15651', 'DB15652', 'DB15653', 'DB15654', 'DB15655', 'DB15656', 'DB15657', 'DB15658', 'DB15659', 'DB15660', 'DB15661', 'DB15662', 'DB15663', 'DB15664', 'DB15665', 'DB15666', 'DB15667', 'DB15668', 'DB15669', 'DB15670', 'DB15671', 'DB15672', 'DB15673', 'DB15674', 'DB15675', 'DB15676', 'DB15677', 'DB15678', 'DB15679', 'DB15680', 'DB15681', 'DB15682', 'DB15683', 'DB15684', 'DB15685', 'DB15686', 'DB15687', 'DB15688', 'DB15689', 'DB15690', 'DB15691', 'DB15692', 'DB15693', 'DB15694', 'DB15695', 'DB15696', 'DB15697', 'DB15698', 'DB15699', 'DB15700', 'DB15701', 'DB15702', 'DB15703', 'DB15704', 'DB15705', 'DB15706', 'DB15707', 'DB15708', 'DB15709', 'DB15710', 'DB15711', 'DB15712', 'DB15713', 'DB15714', 'DB15715', 'DB15716', 'DB15717', 'DB15718', 'DB15719', 'DB15720', 'DB15721', 'DB15722', 'DB15723', 'DB15724', 'DB15725', 'DB15726', 'DB15727', 'DB15728', 'DB15729', 'DB15730', 'DB15731', 'DB15732', 'DB15733', 'DB15734', 'DB15735', 'DB15736', 'DB15737', 'DB15738', 'DB15739', 'DB15740', 'DB15741', 'DB15742', 'DB15743', 'DB15744', 'DB15745', 'DB15746', 'DB15747', 'DB15748', 'DB15749', 'DB15750', 'DB15751', 'DB15752', 'DB15753', 'DB15756', 'DB15757', 'DB15758', 'DB15759', 'DB15760', 'DB15761', 'DB15762', 'DB15763', 'DB15764', 'DB15765', 'DB15766', 'DB15767', 'DB15768', 'DB15769', 'DB15770', 'DB15771', 'DB15772', 'DB15773', 'DB15774', 'DB15775', 'DB15776', 'DB15777', 'DB15778', 'DB15779', 'DB15780', 'DB15781', 'DB15782', 'DB15783', 'DB15784', 'DB15785', 'DB15786', 'DB15787', 'DB15788', 'DB15789', 'DB15790', 'DB15791', 'DB15793', 'DB15794', 'DB15795', 'DB15796', 'DB15797', 'DB15798', 'DB15799', 'DB15800', 'DB15801', 'DB15802', 'DB15803', 'DB15804', 'DB15805', 'DB15806', 'DB15807', 'DB15808', 'DB15809', 'DB15810', 'DB15811', 'DB15812', 'DB15813', 'DB15814', 'DB15815', 'DB15816', 'DB15817', 'DB15818', 'DB15819', 'DB15820', 'DB15821', 'DB15822', 'DB15823', 'DB15824', 'DB15825', 'DB15826', 'DB15827', 'DB15830', 'DB15831', 'DB15832', 'DB15833', 'DB15834', 'DB15835', 'DB15836', 'DB15838', 'DB15839', 'DB15840', 'DB15841', 'DB15842', 'DB15843', 'DB15844', 'DB15845', 'DB15846', 'DB15847', 'DB15848', 'DB15849', 'DB15850', 'DB15851', 'DB15852', 'DB15853', 'DB15854', 'DB15855', 'DB15856', 'DB15857', 'DB15858', 'DB15859', 'DB15860', 'DB15861', 'DB15862', 'DB15863', 'DB15864', 'DB15865', 'DB15866', 'DB15867', 'DB15868', 'DB15869', 'DB15870', 'DB15871', 'DB15872', 'DB15873', 'DB15874', 'DB15875', 'DB15876', 'DB15877', 'DB15878', 'DB15879', 'DB15880', 'DB15881', 'DB15882', 'DB15883', 'DB15884', 'DB15885', 'DB15886', 'DB15887', 'DB15888', 'DB15889', 'DB15890', 'DB15891', 'DB15892', 'DB15893', 'DB15894', 'DB15895', 'DB15897', 'DB15898', 'DB15899', 'DB15900', 'DB15901', 'DB15902', 'DB15903', 'DB15904', 'DB15905', 'DB15906', 'DB15907', 'DB15908', 'DB15909', 'DB15910', 'DB15911', 'DB15912', 'DB15914', 'DB15915', 'DB15916', 'DB15917', 'DB15918', 'DB15919', 'DB15920', 'DB15921', 'DB15922', 'DB15923', 'DB15924', 'DB15925', 'DB15926', 'DB15927', 'DB15928', 'DB15929', 'DB15930', 'DB15931', 'DB15932', 'DB15933', 'DB15934', 'DB15935', 'DB15936', 'DB15937', 'DB15938', 'DB15939', 'DB15940', 'DB15941', 'DB15942', 'DB15943', 'DB15944', 'DB15945', 'DB15946', 'DB15947', 'DB15948', 'DB15949', 'DB15950', 'DB15951', 'DB15952', 'DB15953', 'DB15954', 'DB15955', 'DB15956', 'DB15957', 'DB15958', 'DB15959', 'DB15960', 'DB15961', 'DB15962', 'DB15963', 'DB15964', 'DB15965', 'DB15966', 'DB15967', 'DB15968', 'DB15969', 'DB15970', 'DB15971', 'DB15972', 'DB15973', 'DB15974', 'DB15975', 'DB15976', 'DB15977', 'DB15978', 'DB15979', 'DB15980', 'DB15981', 'DB15982', 'DB15983', 'DB15984', 'DB15985', 'DB15986', 'DB15987', 'DB15988', 'DB15989', 'DB15990', 'DB15991', 'DB15992', 'DB15993', 'DB15994', 'DB15995', 'DB15996', 'DB15997', 'DB15998', 'DB15999', 'DB16000', 'DB16001', 'DB16002', 'DB16003', 'DB16004', 'DB16005', 'DB16006', 'DB16007', 'DB16008', 'DB16009', 'DB16010', 'DB16011', 'DB16012', 'DB16013', 'DB16014', 'DB16015', 'DB16016', 'DB16017', 'DB16018', 'DB16019', 'DB16020', 'DB16021', 'DB16022', 'DB16023', 'DB16024', 'DB16025', 'DB16026', 'DB16027', 'DB16028', 'DB16029', 'DB16030', 'DB16031', 'DB16032', 'DB16033', 'DB16034', 'DB16035', 'DB16036', 'DB16037', 'DB16038', 'DB16039', 'DB16040', 'DB16041', 'DB16042', 'DB16043', 'DB16044', 'DB16045', 'DB16046', 'DB16047', 'DB16048', 'DB16049', 'DB16050', 'DB16051', 'DB16052', 'DB16053', 'DB16054', 'DB16055', 'DB16056', 'DB16057', 'DB16058', 'DB16059', 'DB16060', 'DB16061', 'DB16062', 'DB16063', 'DB16064', 'DB16065', 'DB16066', 'DB16067', 'DB16068', 'DB16069', 'DB16070', 'DB16071', 'DB16072', 'DB16073', 'DB16074', 'DB16075', 'DB16076', 'DB16077', 'DB16078', 'DB16079', 'DB16080', 'DB16081', 'DB16082', 'DB16083', 'DB16084', 'DB16085', 'DB16086', 'DB16087', 'DB16088', 'DB16089', 'DB16090', 'DB16091', 'DB16092', 'DB16093', 'DB16094', 'DB16095', 'DB16096', 'DB16097', 'DB16098', 'DB16099', 'DB16100', 'DB16101', 'DB16102', 'DB16103', 'DB16104', 'DB16105', 'DB16106', 'DB16107', 'DB16108', 'DB16109', 'DB16110', 'DB16111', 'DB16112', 'DB16113', 'DB16114', 'DB16115', 'DB16116', 'DB16117', 'DB16118', 'DB16119', 'DB16120', 'DB16121', 'DB16122', 'DB16123', 'DB16124', 'DB16125', 'DB16126', 'DB16127', 'DB16128', 'DB16129', 'DB16130', 'DB16131', 'DB16132', 'DB16133', 'DB16134', 'DB16135', 'DB16136', 'DB16137', 'DB16138', 'DB16139', 'DB16140', 'DB16141', 'DB16142', 'DB16143', 'DB16144', 'DB16145', 'DB16146', 'DB16147', 'DB16148', 'DB16149', 'DB16150', 'DB16151', 'DB16152', 'DB16153', 'DB16154', 'DB16155', 'DB16156', 'DB16157', 'DB16158', 'DB16159', 'DB16160', 'DB16161', 'DB16162', 'DB16163', 'DB16164', 'DB16165', 'DB16166', 'DB16167', 'DB16168', 'DB16169', 'DB16170', 'DB16171', 'DB16172', 'DB16173', 'DB16174', 'DB16175', 'DB16176', 'DB16177', 'DB16178', 'DB16179', 'DB16180', 'DB16181', 'DB16182', 'DB16183', 'DB16184', 'DB16185', 'DB16186', 'DB16187', 'DB16188', 'DB16189', 'DB16190', 'DB16191', 'DB16192', 'DB16193', 'DB16194', 'DB16195', 'DB16196', 'DB16197', 'DB16198', 'DB16199', 'DB16200', 'DB16201', 'DB16202', 'DB16203', 'DB16204', 'DB16205', 'DB16206', 'DB16207', 'DB16208', 'DB16209', 'DB16210', 'DB16211', 'DB16212', 'DB16213', 'DB16214', 'DB16215', 'DB16216', 'DB16217', 'DB16218', 'DB16219', 'DB16220', 'DB16221', 'DB16222', 'DB16223', 'DB16224', 'DB16225', 'DB16226', 'DB16227', 'DB16228', 'DB16229', 'DB16230', 'DB16231', 'DB16232', 'DB16233', 'DB16234', 'DB16235', 'DB16236', 'DB16237', 'DB16238', 'DB16239', 'DB16240', 'DB16241', 'DB16242', 'DB16243', 'DB16244', 'DB16245', 'DB16246', 'DB16247', 'DB16248', 'DB16249', 'DB16250', 'DB16251', 'DB16252', 'DB16253', 'DB16254', 'DB16255', 'DB16256', 'DB16257', 'DB16258', 'DB16259', 'DB16260', 'DB16261', 'DB16262', 'DB16263', 'DB16264', 'DB16265', 'DB16266', 'DB16267', 'DB16268', 'DB16269', 'DB16270', 'DB16271', 'DB16272', 'DB16273', 'DB16274', 'DB16275', 'DB16276', 'DB16277', 'DB16278', 'DB16279', 'DB16280', 'DB16281', 'DB16282', 'DB16283', 'DB16284', 'DB16285', 'DB16286', 'DB16287', 'DB16288', 'DB16289', 'DB16290', 'DB16291', 'DB16292', 'DB16293', 'DB16294', 'DB16295', 'DB16296', 'DB16297', 'DB16298', 'DB16299', 'DB16300', 'DB16301', 'DB16302', 'DB16303', 'DB16304', 'DB16305', 'DB16306', 'DB16307', 'DB16308', 'DB16309', 'DB16310', 'DB16311', 'DB16312', 'DB16313', 'DB16314', 'DB16315', 'DB16316', 'DB16317', 'DB16318', 'DB16319', 'DB16320', 'DB16321', 'DB16322', 'DB16323', 'DB16324', 'DB16325', 'DB16326', 'DB16327', 'DB16328', 'DB16329', 'DB16330', 'DB16331', 'DB16332', 'DB16333', 'DB16334', 'DB16335', 'DB16336', 'DB16337', 'DB16338', 'DB16339', 'DB16340', 'DB16341', 'DB16342', 'DB16343', 'DB16344', 'DB16345', 'DB16346', 'DB16347', 'DB16348', 'DB16349', 'DB16350', 'DB16351', 'DB16352', 'DB16353', 'DB16354', 'DB16355', 'DB16356', 'DB16357', 'DB16358', 'DB16359', 'DB16360', 'DB16361', 'DB16362', 'DB16363', 'DB16364', 'DB16365', 'DB16366', 'DB16367', 'DB16368', 'DB16369', 'DB16370', 'DB16371', 'DB16372', 'DB16373', 'DB16374', 'DB16375', 'DB16376', 'DB16377', 'DB16378', 'DB16379', 'DB16380', 'DB16381', 'DB16383', 'DB16384', 'DB16385', 'DB16386', 'DB16387', 'DB16388', 'DB16389', 'DB16390', 'DB16391', 'DB16392', 'DB16393', 'DB16394', 'DB16395', 'DB16396', 'DB16397', 'DB16398', 'DB16399', 'DB16400', 'DB16401', 'DB16402', 'DB16403', 'DB16404', 'DB16405', 'DB16406', 'DB16407', 'DB16408', 'DB16409', 'DB16410', 'DB16411', 'DB16412', 'DB16413', 'DB16414', 'DB16415', 'DB16416', 'DB16417', 'DB16418', 'DB16419', 'DB16420', 'DB16421', 'DB16422', 'DB16423', 'DB16424'])"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary.keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f4b26c30",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "14315"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(dictionary.keys())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "658d38d8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['drugbank_id', 'name', 'description', 'indication', 'pharmacodynamics', 'toxicity', 'metabolism', 'absorption', 'half_life', 'market_start', 'affected_organism', 'market_end', 'mechanism_of_action', 'route_of_elimination', 'volume_of_distribution', 'classification', 'carriers', 'targets', 'transporters', 'enzymes', 'atc_code', 'identifiers', 'categories', 'atc_hierarchy', 'food_interactions', 'ddi', 'pathways'])"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001'].keys()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "e5d6bed3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Lepirudin'"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001']['name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "3f05b437",
   "metadata": {},
   "outputs": [],
   "source": [
    "name_drugs = {k : dictionary[k]['name'].lower() for k in dictionary.keys()}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "6144a2c1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "re.findall(r\"increase\", 'The risk or severity of neutropenia and thrombocytopenia can be decreased when  is combined with .',)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "fc66d76b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'DB06605': {'name': 'Apixaban',\n",
       "  'description': 'Apixaban may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB06695': {'name': 'Dabigatran etexilate',\n",
       "  'description': 'Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01254': {'name': 'Dasatinib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.'},\n",
       " 'DB01609': {'name': 'Deferasirox',\n",
       "  'description': 'The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.'},\n",
       " 'DB01586': {'name': 'Ursodeoxycholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.'},\n",
       " 'DB02123': {'name': 'Glycochenodeoxycholic Acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid.'},\n",
       " 'DB02659': {'name': 'Cholic Acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid.'},\n",
       " 'DB02691': {'name': 'Glycocholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid.'},\n",
       " 'DB03619': {'name': 'Deoxycholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.'},\n",
       " 'DB04348': {'name': 'Taurocholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.'},\n",
       " 'DB05990': {'name': 'Obeticholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid.'},\n",
       " 'DB06777': {'name': 'Chenodeoxycholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.'},\n",
       " 'DB08833': {'name': 'Taurochenodeoxycholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid.'},\n",
       " 'DB08834': {'name': 'Tauroursodeoxycholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.'},\n",
       " 'DB08857': {'name': 'Bamet-UD2',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2.'},\n",
       " 'DB11622': {'name': 'Dehydrocholic acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.'},\n",
       " 'DB11789': {'name': 'Hyodeoxycholic Acid',\n",
       "  'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid.'},\n",
       " 'DB09075': {'name': 'Edoxaban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.'},\n",
       " 'DB09053': {'name': 'Ibrutinib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.'},\n",
       " 'DB08935': {'name': 'Obinutuzumab',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.'},\n",
       " 'DB06228': {'name': 'Rivaroxaban',\n",
       "  'description': 'Lepirudin may increase the anticoagulant activities of Rivaroxaban.'},\n",
       " 'DB06206': {'name': 'Sugammadex',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.'},\n",
       " 'DB09070': {'name': 'Tibolone',\n",
       "  'description': 'Tibolone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00932': {'name': 'Tipranavir',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.'},\n",
       " 'DB00013': {'name': 'Urokinase',\n",
       "  'description': 'Urokinase may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00163': {'name': 'Vitamin E',\n",
       "  'description': 'Vitamin E may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09030': {'name': 'Vorapaxar',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.'},\n",
       " 'DB01381': {'name': 'Ginkgo biloba',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Ginkgo biloba.'},\n",
       " 'DB01181': {'name': 'Ifosfamide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.'},\n",
       " 'DB00468': {'name': 'Quinine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.'},\n",
       " 'DB00908': {'name': 'Quinidine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.'},\n",
       " 'DB00675': {'name': 'Tamoxifen',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.'},\n",
       " 'DB00539': {'name': 'Toremifene',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.'},\n",
       " 'DB00806': {'name': 'Pentoxifylline',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.'},\n",
       " 'DB00686': {'name': 'Pentosan polysulfate',\n",
       "  'description': 'Pentosan polysulfate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00583': {'name': 'Levocarnitine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.'},\n",
       " 'DB00255': {'name': 'Diethylstilbestrol',\n",
       "  'description': 'Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00269': {'name': 'Chlorotrianisene',\n",
       "  'description': 'Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00286': {'name': 'Conjugated estrogens',\n",
       "  'description': 'Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00783': {'name': 'Estradiol',\n",
       "  'description': 'Estradiol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00977': {'name': 'Ethinylestradiol',\n",
       "  'description': 'Ethinylestradiol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01357': {'name': 'Mestranol',\n",
       "  'description': 'Mestranol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB04574': {'name': 'Estrone sulfate',\n",
       "  'description': 'Estrone sulfate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB04575': {'name': 'Quinestrol',\n",
       "  'description': 'Quinestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB07931': {'name': 'Hexestrol',\n",
       "  'description': 'Hexestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09317': {'name': 'Synthetic Conjugated Estrogens, A',\n",
       "  'description': 'Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09318': {'name': 'Synthetic Conjugated Estrogens, B',\n",
       "  'description': 'Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09369': {'name': 'Polyestradiol phosphate',\n",
       "  'description': 'Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09381': {'name': 'Esterified estrogens',\n",
       "  'description': 'Esterified estrogens may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11478': {'name': 'Zeranol',\n",
       "  'description': 'Zeranol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11674': {'name': 'Equol',\n",
       "  'description': 'Equol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13143': {'name': 'Methallenestril',\n",
       "  'description': 'Methallenestril may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13386': {'name': 'Epimestrol',\n",
       "  'description': 'Epimestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13418': {'name': 'Moxestrol',\n",
       "  'description': 'Moxestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13952': {'name': 'Estradiol acetate',\n",
       "  'description': 'Estradiol acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13953': {'name': 'Estradiol benzoate',\n",
       "  'description': 'Estradiol benzoate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13954': {'name': 'Estradiol cypionate',\n",
       "  'description': 'Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13956': {'name': 'Estradiol valerate',\n",
       "  'description': 'Estradiol valerate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB15334': {'name': 'Biochanin A',\n",
       "  'description': 'Biochanin A may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB15335': {'name': 'Formononetin',\n",
       "  'description': 'Formononetin may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00655': {'name': 'Estrone',\n",
       "  'description': 'Estrone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB04573': {'name': 'Estriol',\n",
       "  'description': 'Estriol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09211': {'name': 'Limaprost',\n",
       "  'description': 'The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.'},\n",
       " 'DB00159': {'name': 'Icosapent',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.'},\n",
       " 'DB00244': {'name': 'Mesalazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.'},\n",
       " 'DB00328': {'name': 'Indomethacin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.'},\n",
       " 'DB00461': {'name': 'Nabumetone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.'},\n",
       " 'DB00465': {'name': 'Ketorolac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.'},\n",
       " 'DB00469': {'name': 'Tenoxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.'},\n",
       " 'DB00482': {'name': 'Celecoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.'},\n",
       " 'DB00500': {'name': 'Tolmetin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.'},\n",
       " 'DB00533': {'name': 'Rofecoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.'},\n",
       " 'DB00554': {'name': 'Piroxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.'},\n",
       " 'DB00573': {'name': 'Fenoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.'},\n",
       " 'DB00580': {'name': 'Valdecoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.'},\n",
       " 'DB00586': {'name': 'Diclofenac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.'},\n",
       " 'DB00605': {'name': 'Sulindac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.'},\n",
       " 'DB00712': {'name': 'Flurbiprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.'},\n",
       " 'DB00749': {'name': 'Etodolac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.'},\n",
       " 'DB00784': {'name': 'Mefenamic acid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.'},\n",
       " 'DB00788': {'name': 'Naproxen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.'},\n",
       " 'DB00795': {'name': 'Sulfasalazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin.'},\n",
       " 'DB00812': {'name': 'Phenylbutazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.'},\n",
       " 'DB00814': {'name': 'Meloxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.'},\n",
       " 'DB00821': {'name': 'Carprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.'},\n",
       " 'DB00861': {'name': 'Diflunisal',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin.'},\n",
       " 'DB00936': {'name': 'Salicylic acid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin.'},\n",
       " 'DB00939': {'name': 'Meclofenamic acid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.'},\n",
       " 'DB00991': {'name': 'Oxaprozin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.'},\n",
       " 'DB01009': {'name': 'Ketoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.'},\n",
       " 'DB01014': {'name': 'Balsalazide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin.'},\n",
       " 'DB01250': {'name': 'Olsalazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Lepirudin.'},\n",
       " 'DB01283': {'name': 'Lumiracoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.'},\n",
       " 'DB01397': {'name': 'Magnesium salicylate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.'},\n",
       " 'DB01399': {'name': 'Salsalate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.'},\n",
       " 'DB01401': {'name': 'Choline magnesium trisalicylate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.'},\n",
       " 'DB01419': {'name': 'Antrafenine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.'},\n",
       " 'DB01424': {'name': 'Aminophenazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.'},\n",
       " 'DB01435': {'name': 'Antipyrine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.'},\n",
       " 'DB01600': {'name': 'Tiaprofenic acid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.'},\n",
       " 'DB01628': {'name': 'Etoricoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.'},\n",
       " 'DB02224': {'name': 'Taxifolin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.'},\n",
       " 'DB03585': {'name': 'Oxyphenbutazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.'},\n",
       " 'DB04725': {'name': 'Licofelone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin.'},\n",
       " 'DB04812': {'name': 'Benoxaprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.'},\n",
       " 'DB04817': {'name': 'Metamizole',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Lepirudin.'},\n",
       " 'DB04828': {'name': 'Zomepirac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.'},\n",
       " 'DB05095': {'name': 'Cimicoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.'},\n",
       " 'DB06725': {'name': 'Lornoxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.'},\n",
       " 'DB06736': {'name': 'Aceclofenac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.'},\n",
       " 'DB06737': {'name': 'Zaltoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.'},\n",
       " 'DB07402': {'name': 'Azapropazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.'},\n",
       " 'DB08439': {'name': 'Parecoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.'},\n",
       " 'DB08797': {'name': 'Salicylamide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.'},\n",
       " 'DB08940': {'name': 'Kebuzone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.'},\n",
       " 'DB08942': {'name': 'Isoxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.'},\n",
       " 'DB08951': {'name': 'Indoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.'},\n",
       " 'DB08955': {'name': 'Ibuproxam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.'},\n",
       " 'DB08976': {'name': 'Floctafenine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.'},\n",
       " 'DB08981': {'name': 'Fenbufen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.'},\n",
       " 'DB08984': {'name': 'Etofenamate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.'},\n",
       " 'DB08991': {'name': 'Epirizole',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.'},\n",
       " 'DB09084': {'name': 'Benzydamine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.'},\n",
       " 'DB09214': {'name': 'Dexketoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.'},\n",
       " 'DB09215': {'name': 'Droxicam',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.'},\n",
       " 'DB09216': {'name': 'Tolfenamic acid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin.'},\n",
       " 'DB09217': {'name': 'Firocoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.'},\n",
       " 'DB09218': {'name': 'Clonixin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.'},\n",
       " 'DB09285': {'name': 'Morniflumate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.'},\n",
       " 'DB09288': {'name': 'Propacetamol',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.'},\n",
       " 'DB09295': {'name': 'Talniflumate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.'},\n",
       " 'DB11455': {'name': 'Robenacoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.'},\n",
       " 'DB11466': {'name': 'Tepoxalin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.'},\n",
       " 'DB11518': {'name': 'Flunixin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.'},\n",
       " 'DB12399': {'name': 'Polmacoxib',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin.'},\n",
       " 'DB12610': {'name': 'Ebselen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.'},\n",
       " 'DB13001': {'name': 'Tinoridine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.'},\n",
       " 'DB13167': {'name': 'Alclofenac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.'},\n",
       " 'DB13217': {'name': 'Fentiazac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.'},\n",
       " 'DB13232': {'name': 'Suxibuzone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.'},\n",
       " 'DB13286': {'name': 'Bumadizone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.'},\n",
       " 'DB13314': {'name': 'Alminoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.'},\n",
       " 'DB13371': {'name': 'Difenpiramide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.'},\n",
       " 'DB13407': {'name': 'Nifenazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.'},\n",
       " 'DB13432': {'name': 'Lonazolac',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.'},\n",
       " 'DB13481': {'name': 'Tenidap',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.'},\n",
       " 'DB13524': {'name': 'Propyphenazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.'},\n",
       " 'DB13527': {'name': 'Proglumetacin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.'},\n",
       " 'DB13538': {'name': 'Guacetisal',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin.'},\n",
       " 'DB13544': {'name': 'Ethenzamide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.'},\n",
       " 'DB13612': {'name': 'Carbaspirin calcium',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin.'},\n",
       " 'DB13629': {'name': 'Mofebutazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.'},\n",
       " 'DB13649': {'name': 'Proquazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.'},\n",
       " 'DB13657': {'name': 'Benorilate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.'},\n",
       " 'DB13722': {'name': 'Pirprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.'},\n",
       " 'DB13860': {'name': 'Imidazole salicylate',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.'},\n",
       " 'DB14059': {'name': 'SC-236',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.'},\n",
       " 'DB14060': {'name': 'NS-398',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.'},\n",
       " 'DB14938': {'name': 'Flurbiprofen axetil',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin.'},\n",
       " 'DB09212': {'name': 'Loxoprofen',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.'},\n",
       " 'DB04865': {'name': 'Omacetaxine mepesuccinate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.'},\n",
       " 'DB11133': {'name': 'Omega-3 fatty acids',\n",
       "  'description': 'Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00081': {'name': 'Tositumomab',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.'},\n",
       " 'DB00048': {'name': 'Collagenase clostridium histolyticum',\n",
       "  'description': 'The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.'},\n",
       " 'DB00389': {'name': 'Carbimazole',\n",
       "  'description': 'Carbimazole may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00550': {'name': 'Propylthiouracil',\n",
       "  'description': 'Propylthiouracil may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00763': {'name': 'Methimazole',\n",
       "  'description': 'Methimazole may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB03374': {'name': '3,5-Diiodotyrosine',\n",
       "  'description': '3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB06715': {'name': 'Potassium Iodide',\n",
       "  'description': 'Potassium Iodide may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB07637': {'name': 'Dibromotyrosine',\n",
       "  'description': 'Dibromotyrosine may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09418': {'name': 'Potassium perchlorate',\n",
       "  'description': 'Potassium perchlorate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13644': {'name': 'Methylthiouracil',\n",
       "  'description': 'Methylthiouracil may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13804': {'name': 'Benzylthiouracil',\n",
       "  'description': 'Benzylthiouracil may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00834': {'name': 'Mifepristone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mifepristone.'},\n",
       " 'DB04066': {'name': 'p-Coumaric acid',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with p-Coumaric acid.'},\n",
       " 'DB04682': {'name': 'Octylphenoxy polyethoxyethanol',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.'},\n",
       " 'DB05830': {'name': 'Trestolone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone.'},\n",
       " 'DB06266': {'name': 'Lonidamine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lonidamine.'},\n",
       " 'DB08867': {'name': 'Ulipristal',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal.'},\n",
       " 'DB09401': {'name': 'Isosorbide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Isosorbide.'},\n",
       " 'DB11507': {'name': 'Cloprostenol',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol.'},\n",
       " 'DB12025': {'name': 'Triptolide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triptolide.'},\n",
       " 'DB13044': {'name': 'Gossypol',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol.'},\n",
       " 'DB13310': {'name': 'Ormeloxifene',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ormeloxifene.'},\n",
       " 'DB00294': {'name': 'Etonogestrel',\n",
       "  'description': 'Etonogestrel may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00304': {'name': 'Desogestrel',\n",
       "  'description': 'Desogestrel may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00351': {'name': 'Megestrol acetate',\n",
       "  'description': 'Megestrol acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00367': {'name': 'Levonorgestrel',\n",
       "  'description': 'Levonorgestrel may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00378': {'name': 'Dydrogesterone',\n",
       "  'description': 'Dydrogesterone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00396': {'name': 'Progesterone',\n",
       "  'description': 'Progesterone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00603': {'name': 'Medroxyprogesterone acetate',\n",
       "  'description': 'Medroxyprogesterone acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00717': {'name': 'Norethisterone',\n",
       "  'description': 'Norethisterone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00823': {'name': 'Ethynodiol diacetate',\n",
       "  'description': 'Ethynodiol diacetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00957': {'name': 'Norgestimate',\n",
       "  'description': 'Norgestimate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01395': {'name': 'Drospirenone',\n",
       "  'description': 'Drospirenone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01431': {'name': 'Allylestrenol',\n",
       "  'description': 'Allylestrenol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB04839': {'name': 'Cyproterone acetate',\n",
       "  'description': 'Cyproterone acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB06713': {'name': 'Norelgestromin',\n",
       "  'description': 'Norelgestromin may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB06730': {'name': 'Gestodene',\n",
       "  'description': 'Gestodene may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB06789': {'name': 'Hydroxyprogesterone caproate',\n",
       "  'description': 'Hydroxyprogesterone caproate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09123': {'name': 'Dienogest',\n",
       "  'description': 'Dienogest may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09124': {'name': 'Medrogestone',\n",
       "  'description': 'Medrogestone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09371': {'name': 'Norethynodrel',\n",
       "  'description': 'Norethynodrel may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB09389': {'name': 'Norgestrel',\n",
       "  'description': 'Norgestrel may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11372': {'name': 'Altrenogest',\n",
       "  'description': 'Altrenogest may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11619': {'name': 'Gestrinone',\n",
       "  'description': 'Gestrinone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11636': {'name': 'Nomegestrol',\n",
       "  'description': 'Nomegestrol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB12474': {'name': 'Lynestrenol',\n",
       "  'description': 'Lynestrenol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13230': {'name': 'Gestonorone',\n",
       "  'description': 'Gestonorone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13528': {'name': 'Chlormadinone',\n",
       "  'description': 'Chlormadinone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13533': {'name': 'Methylestrenolone',\n",
       "  'description': 'Methylestrenolone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13563': {'name': 'Norgestrienone',\n",
       "  'description': 'Norgestrienone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13602': {'name': 'Promegestone',\n",
       "  'description': 'Promegestone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13685': {'name': 'Quingestanol',\n",
       "  'description': 'Quingestanol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13857': {'name': 'Demegestone',\n",
       "  'description': 'Demegestone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13866': {'name': 'Etynodiol',\n",
       "  'description': 'Etynodiol may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13981': {'name': 'Nomegestrol acetate',\n",
       "  'description': 'Nomegestrol acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB14570': {'name': 'Hydroxyprogesterone',\n",
       "  'description': 'Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB14678': {'name': 'Norethindrone enanthate',\n",
       "  'description': 'Norethindrone enanthate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB14679': {'name': 'Quingestanol acetate',\n",
       "  'description': 'Quingestanol acetate may decrease the anticoagulant activities of Lepirudin.'},\n",
       " 'DB00233': {'name': 'Aminosalicylic acid',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.'},\n",
       " 'DB01294': {'name': 'Bismuth subsalicylate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Lepirudin.'},\n",
       " 'DB06251': {'name': 'Dersalazine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin.'},\n",
       " 'DB06807': {'name': 'Phenyl aminosalicylate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin.'},\n",
       " 'DB09543': {'name': 'Methyl salicylate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.'},\n",
       " 'DB11079': {'name': 'Trolamine salicylate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.'},\n",
       " 'DB13509': {'name': 'Aloxiprin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin.'},\n",
       " 'DB14006': {'name': 'Choline salicylate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin.'},\n",
       " 'DB14026': {'name': 'Thiosalicylic acid',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin.'},\n",
       " 'DB00054': {'name': 'Abciximab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin.'},\n",
       " 'DB00063': {'name': 'Eptifibatide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.'},\n",
       " 'DB00208': {'name': 'Ticlopidine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.'},\n",
       " 'DB00261': {'name': 'Anagrelide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin.'},\n",
       " 'DB00758': {'name': 'Clopidogrel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin.'},\n",
       " 'DB00775': {'name': 'Tirofiban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.'},\n",
       " 'DB00975': {'name': 'Dipyridamole',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.'},\n",
       " 'DB01088': {'name': 'Iloprost',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Iloprost is combined with Lepirudin.'},\n",
       " 'DB01138': {'name': 'Sulfinpyrazone',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.'},\n",
       " 'DB01166': {'name': 'Cilostazol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin.'},\n",
       " 'DB01207': {'name': 'Ridogrel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin.'},\n",
       " 'DB01236': {'name': 'Sevoflurane',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sevoflurane is combined with Lepirudin.'},\n",
       " 'DB01240': {'name': 'Epoprostenol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.'},\n",
       " 'DB02709': {'name': 'Resveratrol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin.'},\n",
       " 'DB04743': {'name': 'Nimesulide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Nimesulide is combined with Lepirudin.'},\n",
       " 'DB04905': {'name': 'Tesmilifene',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.'},\n",
       " 'DB04932': {'name': 'Defibrotide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin.'},\n",
       " 'DB05229': {'name': 'Beraprost',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin.'},\n",
       " 'DB05266': {'name': 'Ibudilast',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin.'},\n",
       " 'DB05767': {'name': 'Andrographolide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin.'},\n",
       " 'DB06081': {'name': 'Caplacizumab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin.'},\n",
       " 'DB06209': {'name': 'Prasugrel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin.'},\n",
       " 'DB06441': {'name': 'Cangrelor',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin.'},\n",
       " 'DB07615': {'name': 'Tranilast',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.'},\n",
       " 'DB08814': {'name': 'Triflusal',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin.'},\n",
       " 'DB08816': {'name': 'Ticagrelor',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.'},\n",
       " 'DB08887': {'name': 'Icosapent ethyl',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin.'},\n",
       " 'DB09283': {'name': 'Trapidil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.'},\n",
       " 'DB12092': {'name': 'Naftopidil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.'},\n",
       " 'DB12163': {'name': 'Sarpogrelate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin.'},\n",
       " 'DB12321': {'name': 'Ifetroban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin.'},\n",
       " 'DB12445': {'name': 'Nitroaspirin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin.'},\n",
       " 'DB12465': {'name': 'Ketanserin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ketanserin is combined with Lepirudin.'},\n",
       " 'DB12545': {'name': 'Indobufen',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Indobufen is combined with Lepirudin.'},\n",
       " 'DB12749': {'name': 'Butylphthalide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin.'},\n",
       " 'DB12771': {'name': 'Hydroxytyrosol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.'},\n",
       " 'DB13036': {'name': 'Ramatroban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin.'},\n",
       " 'DB13327': {'name': 'Picotamide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin.'},\n",
       " 'DB13367': {'name': 'Cloricromen',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin.'},\n",
       " 'DB13400': {'name': 'Linsidomine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin.'},\n",
       " 'DB13510': {'name': 'Buflomedil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin.'},\n",
       " 'DB13929': {'name': 'Relcovaptan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin.'},\n",
       " 'DB00374': {'name': 'Treprostinil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin.'},\n",
       " 'DB03404': {'name': 'Hemin',\n",
       "  'description': 'Hemin may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13783': {'name': 'Acemetacin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Lepirudin.'},\n",
       " 'DB00624': {'name': 'Testosterone',\n",
       "  'description': 'Testosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01420': {'name': 'Testosterone propionate',\n",
       "  'description': 'Testosterone propionate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01481': {'name': '1-Testosterone',\n",
       "  'description': '1-Testosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01485': {'name': '4-Hydroxytestosterone',\n",
       "  'description': '4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01510': {'name': 'Dehydrochloromethyltestosterone',\n",
       "  'description': 'Dehydrochloromethyltestosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01541': {'name': 'Boldenone',\n",
       "  'description': 'Boldenone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01543': {'name': '18-methyl-19-nortestosterone',\n",
       "  'description': '18-methyl-19-nortestosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01564': {'name': 'Calusterone',\n",
       "  'description': 'Calusterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01569': {'name': 'Formebolone',\n",
       "  'description': 'Formebolone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01572': {'name': 'Methyl-1-testosterone',\n",
       "  'description': 'Methyl-1-testosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB07447': {'name': '5beta-dihydrotestosterone',\n",
       "  'description': '5beta-dihydrotestosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB08619': {'name': 'Testosterone succinate',\n",
       "  'description': 'Testosterone succinate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11429': {'name': 'Mibolerone',\n",
       "  'description': 'Mibolerone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13943': {'name': 'Testosterone cypionate',\n",
       "  'description': 'Testosterone cypionate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13944': {'name': 'Testosterone enanthate',\n",
       "  'description': 'Testosterone enanthate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13946': {'name': 'Testosterone undecanoate',\n",
       "  'description': 'Testosterone undecanoate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13947': {'name': 'Testosterone enantate benzilic acid hydrazone',\n",
       "  'description': 'Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13951': {'name': 'Stanolone acetate',\n",
       "  'description': 'Stanolone acetate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB13958': {'name': 'Trestolone acetate',\n",
       "  'description': 'Trestolone acetate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB14093': {'name': '(1,2,6,7-3H)Testosterone',\n",
       "  'description': '(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB14655': {'name': 'Drostanolone propionate',\n",
       "  'description': 'Drostanolone propionate may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB11051': {'name': 'Azficel-T',\n",
       "  'description': 'The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.'},\n",
       " 'DB09568': {'name': 'Omega-3-carboxylic acids',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.'},\n",
       " 'DB00025': {'name': 'Antihemophilic factor, human recombinant',\n",
       "  'description': 'The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB00036': {'name': 'Coagulation factor VIIa Recombinant Human',\n",
       "  'description': 'The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB00100': {'name': 'Coagulation Factor IX (Recombinant)',\n",
       "  'description': 'The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB00258': {'name': 'Calcium acetate',\n",
       "  'description': 'The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB01164': {'name': 'Calcium chloride',\n",
       "  'description': 'The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB01373': {'name': 'Calcium',\n",
       "  'description': 'The therapeutic efficacy of Calcium can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB01783': {'name': 'Pantothenic acid',\n",
       "  'description': 'The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB01942': {'name': 'Formic acid',\n",
       "  'description': 'The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB02261': {'name': 'Platelet Activating Factor',\n",
       "  'description': 'The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB06724': {'name': 'Calcium carbonate',\n",
       "  'description': 'The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB09109': {'name': 'Turoctocog alfa',\n",
       "  'description': 'The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB09222': {'name': 'Fibrinogen human',\n",
       "  'description': 'The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB09310': {'name': 'Catridecacog',\n",
       "  'description': 'The therapeutic efficacy of Catridecacog can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB09329': {'name': 'Antihemophilic Factor (Recombinant), PEGylated',\n",
       "  'description': 'The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11093': {'name': 'Calcium citrate',\n",
       "  'description': 'The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11126': {'name': 'Calcium gluconate',\n",
       "  'description': 'The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11168': {'name': 'Calcium threonate',\n",
       "  'description': 'The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11311': {'name': 'Prothrombin',\n",
       "  'description': 'The therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11330': {'name': 'Factor IX Complex (Human)',\n",
       "  'description': 'The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11348': {'name': 'Calcium Phosphate',\n",
       "  'description': 'The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11606': {'name': 'Susoctocog alfa',\n",
       "  'description': 'The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11608': {'name': 'Eftrenonacog alfa',\n",
       "  'description': 'The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB11668': {'name': 'Rusalatide acetate',\n",
       "  'description': 'The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB12409': {'name': 'Vatreptacog alfa',\n",
       "  'description': 'The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB12909': {'name': 'Factor XIII (human)',\n",
       "  'description': 'The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13133': {'name': 'Von Willebrand Factor Human',\n",
       "  'description': 'The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13148': {'name': 'Coagulation factor X human',\n",
       "  'description': 'The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13150': {'name': 'Coagulation factor VII human',\n",
       "  'description': 'The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13151': {'name': 'Anti-inhibitor coagulant complex',\n",
       "  'description': 'The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13152': {'name': 'Coagulation Factor IX Human',\n",
       "  'description': 'The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13192': {'name': 'Antihemophilic factor human',\n",
       "  'description': 'The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13197': {'name': 'Kallidinogenase',\n",
       "  'description': 'The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13201': {'name': 'Trenonacog alfa',\n",
       "  'description': 'The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13884': {'name': 'Albutrepenonacog alfa',\n",
       "  'description': 'The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13923': {'name': 'Emicizumab',\n",
       "  'description': 'The therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13933': {'name': 'Nonacog beta pegol',\n",
       "  'description': 'The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB13999': {'name': 'Moroctocog alfa',\n",
       "  'description': 'The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB14473': {'name': 'Beroctocog alfa',\n",
       "  'description': 'The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB14562': {'name': 'Andexanet alfa',\n",
       "  'description': 'The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB14577': {'name': 'Calcium cation',\n",
       "  'description': 'The therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB14700': {'name': 'Damoctocog alfa pegol',\n",
       "  'description': 'The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB14738': {'name': 'Turoctocog alfa pegol',\n",
       "  'description': 'The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Lepirudin.'},\n",
       " 'DB00176': {'name': 'Fluvoxamine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin.'},\n",
       " 'DB00215': {'name': 'Citalopram',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Citalopram is combined with Lepirudin.'},\n",
       " 'DB00472': {'name': 'Fluoxetine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.'},\n",
       " 'DB00715': {'name': 'Paroxetine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.'},\n",
       " 'DB01149': {'name': 'Nefazodone',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin.'},\n",
       " 'DB04832': {'name': 'Zimelidine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin.'},\n",
       " 'DB04884': {'name': 'Dapoxetine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin.'},\n",
       " 'DB06731': {'name': 'Seproxetine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin.'},\n",
       " 'DB08953': {'name': 'Indalpine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin.'},\n",
       " 'DB12693': {'name': 'Ritanserin',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin.'},\n",
       " 'DB13233': {'name': 'Alaproclate',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin.'},\n",
       " 'DB00476': {'name': 'Duloxetine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.'},\n",
       " 'DB01105': {'name': 'Sibutramine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.'},\n",
       " 'DB04896': {'name': 'Milnacipran',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Milnacipran is combined with Lepirudin.'},\n",
       " 'DB06700': {'name': 'Desvenlafaxine',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Lepirudin.'},\n",
       " 'DB08918': {'name': 'Levomilnacipran',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Lepirudin.'},\n",
       " 'DB00285': {'name': 'Venlafaxine',\n",
       "  'description': 'Venlafaxine may increase the antiplatelet activities of Lepirudin.'},\n",
       " 'DB00182': {'name': 'Amphetamine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Lepirudin.'},\n",
       " 'DB00601': {'name': 'Linezolid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin.'},\n",
       " 'DB00614': {'name': 'Furazolidone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin.'},\n",
       " 'DB00721': {'name': 'Procaine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Lepirudin.'},\n",
       " 'DB00752': {'name': 'Tranylcypromine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.'},\n",
       " 'DB00780': {'name': 'Phenelzine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin.'},\n",
       " 'DB00805': {'name': 'Minaprine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin.'},\n",
       " 'DB01037': {'name': 'Selegiline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin.'},\n",
       " 'DB01168': {'name': 'Procarbazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin.'},\n",
       " 'DB01171': {'name': 'Moclobemide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin.'},\n",
       " 'DB01247': {'name': 'Isocarboxazid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin.'},\n",
       " 'DB01367': {'name': 'Rasagiline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.'},\n",
       " 'DB01626': {'name': 'Pargyline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin.'},\n",
       " 'DB04017': {'name': 'Clorgiline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin.'},\n",
       " 'DB04818': {'name': 'Iproniazid',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin.'},\n",
       " 'DB04820': {'name': 'Nialamide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin.'},\n",
       " 'DB06654': {'name': 'Safinamide',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin.'},\n",
       " 'DB08550': {'name': '7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lepirudin.'},\n",
       " 'DB09241': {'name': 'Methylene blue',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin.'},\n",
       " 'DB09243': {'name': 'Hydracarbazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin.'},\n",
       " 'DB09244': {'name': 'Pirlindole',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin.'},\n",
       " 'DB09245': {'name': 'Toloxatone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin.'},\n",
       " 'DB09246': {'name': 'Benmoxin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin.'},\n",
       " 'DB09248': {'name': 'Mebanazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin.'},\n",
       " 'DB09249': {'name': 'Octamoxin',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin.'},\n",
       " 'DB09250': {'name': 'Pheniprazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin.'},\n",
       " 'DB09251': {'name': 'Phenoxypropazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin.'},\n",
       " 'DB09252': {'name': 'Pivhydrazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin.'},\n",
       " 'DB09253': {'name': 'Safrazine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin.'},\n",
       " 'DB09254': {'name': 'Caroxazone',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin.'},\n",
       " 'DB13875': {'name': 'Harmaline',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin.'},\n",
       " 'DB13876': {'name': 'Brofaromine',\n",
       "  'description': 'The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Lepirudin.'},\n",
       " 'DB00006': {'name': 'Bivalirudin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Bivalirudin is combined with Lepirudin.'},\n",
       " 'DB00266': {'name': 'Dicoumarol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin.'},\n",
       " 'DB00278': {'name': 'Argatroban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Argatroban is combined with Lepirudin.'},\n",
       " 'DB00407': {'name': 'Ardeparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ardeparin is combined with Lepirudin.'},\n",
       " 'DB00498': {'name': 'Phenindione',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Phenindione is combined with Lepirudin.'},\n",
       " 'DB00569': {'name': 'Fondaparinux',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Fondaparinux is combined with Lepirudin.'},\n",
       " 'DB00682': {'name': 'Warfarin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin.'},\n",
       " 'DB00946': {'name': 'Phenprocoumon',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin.'},\n",
       " 'DB00974': {'name': 'Edetic acid',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Edetic acid is combined with Lepirudin.'},\n",
       " 'DB01109': {'name': 'Heparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Heparin is combined with Lepirudin.'},\n",
       " 'DB01225': {'name': 'Enoxaparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Enoxaparin is combined with Lepirudin.'},\n",
       " 'DB01418': {'name': 'Acenocoumarol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.'},\n",
       " 'DB04898': {'name': 'Ximelagatran',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ximelagatran is combined with Lepirudin.'},\n",
       " 'DB05099': {'name': 'Ancrod',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin.'},\n",
       " 'DB06271': {'name': 'Sulodexide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin.'},\n",
       " 'DB06406': {'name': 'Idraparinux',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Idraparinux is combined with Lepirudin.'},\n",
       " 'DB06635': {'name': 'Otamixaban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Otamixaban is combined with Lepirudin.'},\n",
       " 'DB06754': {'name': 'Danaparoid',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Danaparoid is combined with Lepirudin.'},\n",
       " 'DB06779': {'name': 'Dalteparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Dalteparin is combined with Lepirudin.'},\n",
       " 'DB07767': {'name': 'Ferulic acid',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ferulic acid is combined with Lepirudin.'},\n",
       " 'DB08794': {'name': 'Ethyl biscoumacetate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin.'},\n",
       " 'DB08813': {'name': 'Nadroparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Nadroparin is combined with Lepirudin.'},\n",
       " 'DB09255': {'name': 'Dextran',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Dextran is combined with Lepirudin.'},\n",
       " 'DB11095': {'name': 'Desirudin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Desirudin is combined with Lepirudin.'},\n",
       " 'DB11268': {'name': 'Protocatechualdehyde',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Lepirudin.'},\n",
       " 'DB11312': {'name': 'Protein C',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Protein C is combined with Lepirudin.'},\n",
       " 'DB11598': {'name': 'Antithrombin III human',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Antithrombin III human is combined with Lepirudin.'},\n",
       " 'DB11984': {'name': 'Letaxaban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Letaxaban is combined with Lepirudin.'},\n",
       " 'DB12289': {'name': 'Darexaban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Darexaban is combined with Lepirudin.'},\n",
       " 'DB12598': {'name': 'Nafamostat',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Nafamostat is combined with Lepirudin.'},\n",
       " 'DB12831': {'name': 'Gabexate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Gabexate is combined with Lepirudin.'},\n",
       " 'DB13124': {'name': 'Troxerutin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Troxerutin is combined with Lepirudin.'},\n",
       " 'DB13136': {'name': 'Fluindione',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Fluindione is combined with Lepirudin.'},\n",
       " 'DB13149': {'name': 'Protein S human',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Protein S human is combined with Lepirudin.'},\n",
       " 'DB13616': {'name': 'Melagatran',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Melagatran is combined with Lepirudin.'},\n",
       " 'DB09125': {'name': 'Potassium citrate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Potassium citrate is combined with Lepirudin.'},\n",
       " 'DB09154': {'name': 'Sodium citrate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sodium citrate is combined with Lepirudin.'},\n",
       " 'DB00031': {'name': 'Tenecteplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.'},\n",
       " 'DB00055': {'name': 'Drotrecogin alfa',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.'},\n",
       " 'DB06822': {'name': 'Tinzaparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tinzaparin is combined with Lepirudin.'},\n",
       " 'DB13199': {'name': 'Brinase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Brinase is combined with Lepirudin.'},\n",
       " 'DB13646': {'name': 'Saruplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin.'},\n",
       " 'DB00086': {'name': 'Streptokinase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.'},\n",
       " 'DB04925': {'name': 'Desmoteplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin.'},\n",
       " 'DB05254': {'name': 'Fibrinolysin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Fibrinolysin is combined with Lepirudin.'},\n",
       " 'DB06543': {'name': 'Astaxanthin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin.'},\n",
       " 'DB08994': {'name': 'Ditazole',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Ditazole is combined with Lepirudin.'},\n",
       " 'DB09258': {'name': 'Bemiparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Bemiparin is combined with Lepirudin.'},\n",
       " 'DB09260': {'name': 'Parnaparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Parnaparin is combined with Lepirudin.'},\n",
       " 'DB13275': {'name': 'Clorindione',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Clorindione is combined with Lepirudin.'},\n",
       " 'DB13347': {'name': 'Diphenadione',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Diphenadione is combined with Lepirudin.'},\n",
       " 'DB13451': {'name': 'Tioclomarol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tioclomarol is combined with Lepirudin.'},\n",
       " 'DB00009': {'name': 'Alteplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Alteplase.'},\n",
       " 'DB00015': {'name': 'Reteplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.'},\n",
       " 'DB00029': {'name': 'Anistreplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Anistreplase.'},\n",
       " 'DB14094': {'name': 'Tocopherylquinone',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone.'},\n",
       " 'DB06679': {'name': 'Amediplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Amediplase.'},\n",
       " 'DB03410': {'name': '4-hydroxycoumarin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with 4-hydroxycoumarin.'},\n",
       " 'DB08496': {'name': '(R)-warfarin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin.'},\n",
       " 'DB14055': {'name': '(S)-Warfarin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin.'},\n",
       " 'DB12364': {'name': 'Betrixaban',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban.'},\n",
       " 'DB14598': {'name': 'Edetate calcium disodium anhydrous',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Edetate calcium disodium anhydrous.'},\n",
       " 'DB11154': {'name': 'Zinc citrate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Zinc citrate.'},\n",
       " 'DB11166': {'name': 'Antithrombin Alfa',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.'},\n",
       " 'DB04665': {'name': 'Coumarin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin.'},\n",
       " 'DB14726': {'name': 'Dabigatran',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.'},\n",
       " 'DB06294': {'name': 'Semuloparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Semuloparin.'},\n",
       " 'DB12726': {'name': 'Monteplase',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Monteplase.'},\n",
       " 'DB09259': {'name': 'Reviparin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Reviparin.'},\n",
       " 'DB00203': {'name': 'Sildenafil',\n",
       "  'description': 'The risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil.'},\n",
       " 'DB00008': {'name': 'Peginterferon alfa-2a',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.'},\n",
       " 'DB00011': {'name': 'Interferon alfa-n1',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.'},\n",
       " 'DB00018': {'name': 'Interferon alfa-n3',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.'},\n",
       " 'DB00022': {'name': 'Peginterferon alfa-2b',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.'},\n",
       " 'DB00033': {'name': 'Interferon gamma-1b',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.'},\n",
       " 'DB00034': {'name': 'Interferon alfa-2a, Recombinant',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a, Recombinant.'},\n",
       " 'DB00041': {'name': 'Aldesleukin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.'},\n",
       " 'DB00056': {'name': 'Gemtuzumab ozogamicin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.'},\n",
       " 'DB00068': {'name': 'Interferon beta-1b',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.'},\n",
       " 'DB00069': {'name': 'Interferon alfacon-1',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.'},\n",
       " 'DB00073': {'name': 'Rituximab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.'},\n",
       " 'DB00078': {'name': 'Ibritumomab tiuxetan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.'},\n",
       " 'DB00087': {'name': 'Alemtuzumab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.'},\n",
       " 'DB00105': {'name': 'Interferon alfa-2b',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.'},\n",
       " 'DB00120': {'name': 'Phenylalanine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Phenylalanine.'},\n",
       " 'DB00188': {'name': 'Bortezomib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.'},\n",
       " 'DB00242': {'name': 'Cladribine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.'},\n",
       " 'DB00262': {'name': 'Carmustine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine.'},\n",
       " 'DB00276': {'name': 'Amsacrine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine.'},\n",
       " 'DB00291': {'name': 'Chlorambucil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil.'},\n",
       " 'DB00293': {'name': 'Raltitrexed',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed.'},\n",
       " 'DB00305': {'name': 'Mitomycin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin.'},\n",
       " 'DB00307': {'name': 'Bexarotene',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.'},\n",
       " 'DB00309': {'name': 'Vindesine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine.'},\n",
       " 'DB00322': {'name': 'Floxuridine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine.'},\n",
       " 'DB00352': {'name': 'Tioguanine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine.'},\n",
       " 'DB00361': {'name': 'Vinorelbine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine.'},\n",
       " 'DB00380': {'name': 'Dexrazoxane',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.'},\n",
       " 'DB00398': {'name': 'Sorafenib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib.'},\n",
       " 'DB00428': {'name': 'Streptozocin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin.'},\n",
       " 'DB00441': {'name': 'Gemcitabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine.'},\n",
       " 'DB00444': {'name': 'Teniposide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide.'},\n",
       " 'DB00445': {'name': 'Epirubicin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin.'},\n",
       " 'DB00446': {'name': 'Chloramphenicol',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol.'},\n",
       " 'DB00480': {'name': 'Lenalidomide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide.'},\n",
       " 'DB00488': {'name': 'Altretamine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine.'},\n",
       " 'DB00495': {'name': 'Zidovudine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine.'},\n",
       " 'DB00515': {'name': 'Cisplatin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.'},\n",
       " 'DB00526': {'name': 'Oxaliplatin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.'},\n",
       " 'DB00531': {'name': 'Cyclophosphamide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.'},\n",
       " 'DB00544': {'name': 'Fluorouracil',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.'},\n",
       " 'DB00552': {'name': 'Pentostatin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin.'},\n",
       " 'DB00563': {'name': 'Methotrexate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate.'},\n",
       " 'DB00564': {'name': 'Carbamazepine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine.'},\n",
       " 'DB00570': {'name': 'Vinblastine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine.'},\n",
       " 'DB00619': {'name': 'Imatinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.'},\n",
       " 'DB00631': {'name': 'Clofarabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine.'},\n",
       " 'DB00642': {'name': 'Pemetrexed',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed.'},\n",
       " 'DB00694': {'name': 'Daunorubicin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.'},\n",
       " 'DB00762': {'name': 'Irinotecan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.'},\n",
       " 'DB00773': {'name': 'Etoposide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide.'},\n",
       " 'DB00851': {'name': 'Dacarbazine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine.'},\n",
       " 'DB00853': {'name': 'Temozolomide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide.'},\n",
       " 'DB00859': {'name': 'Penicillamine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine.'},\n",
       " 'DB00864': {'name': 'Tacrolimus',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.'},\n",
       " 'DB00877': {'name': 'Sirolimus',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus.'},\n",
       " 'DB00888': {'name': 'Mechlorethamine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine.'},\n",
       " 'DB00928': {'name': 'Azacitidine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine.'},\n",
       " 'DB00958': {'name': 'Carboplatin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.'},\n",
       " 'DB00970': {'name': 'Dactinomycin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin.'},\n",
       " 'DB00987': {'name': 'Cytarabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.'},\n",
       " 'DB00997': {'name': 'Doxorubicin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin.'},\n",
       " 'DB01005': {'name': 'Hydroxyurea',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea.'},\n",
       " 'DB01008': {'name': 'Busulfan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan.'},\n",
       " 'DB01030': {'name': 'Topotecan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.'},\n",
       " 'DB01033': {'name': 'Mercaptopurine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine.'},\n",
       " 'DB01041': {'name': 'Thalidomide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.'},\n",
       " 'DB01042': {'name': 'Melphalan',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan.'},\n",
       " 'DB01073': {'name': 'Fludarabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine.'},\n",
       " 'DB01099': {'name': 'Flucytosine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.'},\n",
       " 'DB01101': {'name': 'Capecitabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine.'},\n",
       " 'DB01169': {'name': 'Arsenic trioxide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.'},\n",
       " 'DB01177': {'name': 'Idarubicin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin.'},\n",
       " 'DB01204': {'name': 'Mitoxantrone',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.'},\n",
       " 'DB01206': {'name': 'Lomustine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine.'},\n",
       " 'DB01229': {'name': 'Paclitaxel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.'},\n",
       " 'DB01248': {'name': 'Docetaxel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel.'},\n",
       " 'DB01262': {'name': 'Decitabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine.'},\n",
       " 'DB01280': {'name': 'Nelarabine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine.'},\n",
       " 'DB01590': {'name': 'Everolimus',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus.'},\n",
       " 'DB02546': {'name': 'Vorinostat',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat.'},\n",
       " 'DB04572': {'name': 'Thiotepa',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa.'},\n",
       " 'DB04845': {'name': 'Ixabepilone',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone.'},\n",
       " 'DB04868': {'name': 'Nilotinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib.'},\n",
       " 'DB05015': {'name': 'Belinostat',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.'},\n",
       " 'DB05109': {'name': 'Trabectedin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin.'},\n",
       " 'DB05258': {'name': 'Interferon alfa',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa.'},\n",
       " 'DB05472': {'name': 'Human interferon omega-1',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Human interferon omega-1.'},\n",
       " 'DB05773': {'name': 'Trastuzumab emtansine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine.'},\n",
       " 'DB06287': {'name': 'Temsirolimus',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus.'},\n",
       " 'DB06616': {'name': 'Bosutinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib.'},\n",
       " 'DB06769': {'name': 'Bendamustine',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.'},\n",
       " 'DB06772': {'name': 'Cabazitaxel',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel.'},\n",
       " 'DB08871': {'name': 'Eribulin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin.'},\n",
       " 'DB08877': {'name': 'Ruxolitinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.'},\n",
       " 'DB08889': {'name': 'Carfilzomib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib.'},\n",
       " 'DB08895': {'name': 'Tofacitinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.'},\n",
       " 'DB08901': {'name': 'Ponatinib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib.'},\n",
       " 'DB08910': {'name': 'Pomalidomide',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.'},\n",
       " 'DB09042': {'name': 'Tedizolid phosphate',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate.'},\n",
       " 'DB09052': {'name': 'Blinatumomab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.'},\n",
       " 'DB09073': {'name': 'Palbociclib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib.'},\n",
       " 'DB09074': {'name': 'Olaparib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.'},\n",
       " 'DB09077': {'name': 'Dinutuximab',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.'},\n",
       " 'DB09122': {'name': 'Peginterferon beta-1a',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a.'},\n",
       " 'DB12814': {'name': 'Cepeginterferon alfa-2B',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B.'},\n",
       " 'DB00229': {'name': 'Cefotiam',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam.'},\n",
       " 'DB00267': {'name': 'Cefmenoxime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime.'},\n",
       " 'DB00274': {'name': 'Cefmetazole',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole.'},\n",
       " 'DB00430': {'name': 'Cefpiramide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide.'},\n",
       " 'DB00438': {'name': 'Ceftazidime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.'},\n",
       " 'DB00447': {'name': 'Loracarbef',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef.'},\n",
       " 'DB00456': {'name': 'Cefalotin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin.'},\n",
       " 'DB00493': {'name': 'Cefotaxime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.'},\n",
       " 'DB00535': {'name': 'Cefdinir',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir.'},\n",
       " 'DB00567': {'name': 'Cephalexin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin.'},\n",
       " 'DB00671': {'name': 'Cefixime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.'},\n",
       " 'DB00689': {'name': 'Cephaloglycin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin.'},\n",
       " 'DB00833': {'name': 'Cefaclor',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor.'},\n",
       " 'DB00923': {'name': 'Ceforanide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide.'},\n",
       " 'DB01066': {'name': 'Cefditoren',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren.'},\n",
       " 'DB01112': {'name': 'Cefuroxime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime.'},\n",
       " 'DB01139': {'name': 'Cefapirin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin.'},\n",
       " 'DB01140': {'name': 'Cefadroxil',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil.'},\n",
       " 'DB01150': {'name': 'Cefprozil',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil.'},\n",
       " 'DB01212': {'name': 'Ceftriaxone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone.'},\n",
       " 'DB01326': {'name': 'Cefamandole',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole.'},\n",
       " 'DB01327': {'name': 'Cefazolin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin.'},\n",
       " 'DB01328': {'name': 'Cefonicid',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid.'},\n",
       " 'DB01329': {'name': 'Cefoperazone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone.'},\n",
       " 'DB01330': {'name': 'Cefotetan',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan.'},\n",
       " 'DB01331': {'name': 'Cefoxitin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin.'},\n",
       " 'DB01332': {'name': 'Ceftizoxime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime.'},\n",
       " 'DB01333': {'name': 'Cefradine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine.'},\n",
       " 'DB01413': {'name': 'Cefepime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime.'},\n",
       " 'DB01414': {'name': 'Cefacetrile',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile.'},\n",
       " 'DB01415': {'name': 'Ceftibuten',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten.'},\n",
       " 'DB01416': {'name': 'Cefpodoxime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime.'},\n",
       " 'DB04570': {'name': 'Latamoxef',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef.'},\n",
       " 'DB04918': {'name': 'Ceftobiprole',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole.'},\n",
       " 'DB06590': {'name': 'Ceftaroline fosamil',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil.'},\n",
       " 'DB09008': {'name': 'Cefaloridine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine.'},\n",
       " 'DB09050': {'name': 'Ceftolozane',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane.'},\n",
       " 'DB09062': {'name': 'Cefminox',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox.'},\n",
       " 'DB11367': {'name': 'Cefroxadine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine.'},\n",
       " 'DB11935': {'name': 'Flomoxef',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef.'},\n",
       " 'DB13266': {'name': 'Cefatrizine',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine.'},\n",
       " 'DB13461': {'name': 'Cefcapene',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene.'},\n",
       " 'DB13470': {'name': 'Cefodizime',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime.'},\n",
       " 'DB13499': {'name': 'Cefsulodin',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin.'},\n",
       " 'DB13504': {'name': 'Cefetamet',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet.'},\n",
       " 'DB13638': {'name': 'Cefbuperazone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone.'},\n",
       " 'DB13667': {'name': 'Cefozopran',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran.'},\n",
       " 'DB13682': {'name': 'Cefpirome',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome.'},\n",
       " 'DB13778': {'name': 'Cefazedone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone.'},\n",
       " 'DB13821': {'name': 'Ceftezole',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole.'},\n",
       " 'DB14725': {'name': 'Cefamandole nafate',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate.'},\n",
       " 'DB00254': {'name': 'Doxycycline',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Doxycycline is combined with Lepirudin.'},\n",
       " 'DB00207': {'name': 'Azithromycin',\n",
       "  'description': 'The risk or severity of adverse effects can be increased when Azithromycin is combined with Lepirudin.'},\n",
       " 'DB09539': {'name': 'Omega-3-acid ethyl esters',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.'},\n",
       " 'DB00945': {'name': 'Acetylsalicylic acid',\n",
       "  'description': 'Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.'},\n",
       " 'DB01606': {'name': 'Tazobactam',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Tazobactam is combined with Lepirudin.'},\n",
       " 'DB00199': {'name': 'Erythromycin',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.'},\n",
       " 'DB00656': {'name': 'Trazodone',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.'},\n",
       " 'DB00620': {'name': 'Triamcinolone',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triamcinolone.'},\n",
       " 'DB09079': {'name': 'Nintedanib',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Nintedanib.'},\n",
       " 'DB01175': {'name': 'Escitalopram',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Escitalopram is combined with Lepirudin.'},\n",
       " 'DB01104': {'name': 'Sertraline',\n",
       "  'description': 'The risk or severity of bleeding can be increased when Sertraline is combined with Lepirudin.'},\n",
       " 'DB00232': {'name': 'Methyclothiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide.'},\n",
       " 'DB00436': {'name': 'Bendroflumethiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.'},\n",
       " 'DB00562': {'name': 'Benzthiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Benzthiazide.'},\n",
       " 'DB00606': {'name': 'Cyclothiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclothiazide.'},\n",
       " 'DB00774': {'name': 'Hydroflumethiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroflumethiazide.'},\n",
       " 'DB00880': {'name': 'Chlorothiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlorothiazide.'},\n",
       " 'DB00999': {'name': 'Hydrochlorothiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydrochlorothiazide.'},\n",
       " 'DB01021': {'name': 'Trichlormethiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trichlormethiazide.'},\n",
       " 'DB01324': {'name': 'Polythiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Polythiazide.'},\n",
       " 'DB13430': {'name': 'Mebutizide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mebutizide.'},\n",
       " 'DB13532': {'name': 'Cyclopenthiazide',\n",
       "  'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclopenthiazide.'}}"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001']['ddi']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "a223309b",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'seen_interactions' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Input \u001b[0;32mIn [34]\u001b[0m, in \u001b[0;36m<cell line: 3>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      1\u001b[0m side \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m      2\u001b[0m no_go_words \u001b[38;5;241m=\u001b[39m [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m-uracil\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m 400\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mI-131\u001b[39m\u001b[38;5;124m\"\u001b[39m]\n\u001b[0;32m----> 3\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m s \u001b[38;5;129;01min\u001b[39;00m \u001b[43mseen_interactions\u001b[49m:\n\u001b[1;32m      4\u001b[0m     increase \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m      5\u001b[0m     side_effect \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'seen_interactions' is not defined"
     ]
    }
   ],
   "source": [
    "side = []\n",
    "no_go_words = [\"-uracil\", \" 400\", \"I-131\"]\n",
    "for s in seen_interactions:\n",
    "    increase = 0\n",
    "    side_effect = \"\"\n",
    "    s = s.replace(\", an active metabolite of ,\", \"\")\n",
    "    for w in no_go_words:\n",
    "        s = s.replace(w, \"\")\n",
    "    if len(re.findall(r\"reduction in efficacy\", s))>0 or len(re.findall(r\"reduced efficacy\", s))>0 or len(re.findall(r\"decreased efficacy\", s))>0 or len(re.findall(r\"decrease in efficacy\", s))>0:\n",
    "        increase = -1\n",
    "        side_effect = \"reduction in efficacy\"\n",
    "    elif len(re.findall(r\"may decrease effectiveness\", s))>0 or len(re.findall(r\"loss in efficacy\",s))>0:\n",
    "        increase = -1\n",
    "        side_effect = \"reduction in efficacy\"\n",
    "    elif len(re.findall(r\"increase\", s))>0 or len(re.findall(r\"augment\", s))>0:\n",
    "        increase = 1\n",
    "        if len(re.findall(r\"The risk or severity of\", s))>0:\n",
    "            side_effect = re.findall(r'The risk or severity of (.*?) can be increased', s)[0]\n",
    "        if len(re.findall(r\" may increase\", s))>0:\n",
    "            side_effect = re.findall(r' may increase\\ (.*?) of .', s)[0]\n",
    "        if len(re.findall(r\"of  can be increased\", s))>0:\n",
    "            side_effect = re.findall(r'The (.*?) of  can be increased', s)[0]\n",
    "        elif len(re.findall(r\"can be increased\", s))>0:\n",
    "            side_effect = re.findall(r'The (.*?) can be increased', s)[0]\n",
    "        if len(re.findall(r\"to  is increased\", s))>0:\n",
    "            side_effect = re.findall(r'The risk of (.*?) to  is increased', s)[0]\n",
    "        elif len(re.findall(r\"is increased\", s))>0:\n",
    "            side_effect = re.findall(r'The (.*?) to  is increased', s)[0]\n",
    "        \n",
    "    elif len(re.findall(r\"decrease\", s))>0 or len(re.findall(r\"reduce\", s))>0:\n",
    "        increase = -1\n",
    "        if len(re.findall(r\"serum concentration\", s))>0:\n",
    "            side_effect = 'serum concentration'\n",
    "        if len(re.findall(r\"can cause a decrease in \", s))>0:         \n",
    "            side_effect = re.findall(r'can cause a decrease in \\ (.*?).', s)[0]\n",
    "        if len(re.findall(r\"may decrease the \", s))>0:         \n",
    "            side_effect = re.findall(r'may decrease the\\ (.*?) of .', s)[0]\n",
    "        if len(re.findall(r\"of  can be decreased\", s))>0:         \n",
    "            side_effect = re.findall(r'The\\ (.*?) of  can be decreased', s)[0]\n",
    "        elif len(re.findall(r\"can be decreased\", s))>0:         \n",
    "            side_effect = re.findall(r'The (.*?) can be decreased', s)[0]\n",
    "    else:\n",
    "        print(s)\n",
    "    if len(side_effect) == 0:\n",
    "        if s == ' can cause an increase in the absorption of  resulting in an increased serum concentration and potentially a worsening of adverse effects.':\n",
    "            side_effect = 'adverse effects'\n",
    "            increase = 1\n",
    "        else:\n",
    "            print(s)\n",
    "    if re.findall(r\"metabolism\", s):\n",
    "        side_effect = \"metabolism\"\n",
    "    if re.findall(r\"serum concentration\", side_effect):\n",
    "        print(s)\n",
    "        \n",
    "        if re.findall(r\"serum concentration of  \", s):\n",
    "            side_effect = \"serum concentration drug\"\n",
    "        \n",
    "            \n",
    "    append = \"increased \" if increase == 1 else \"decreased \"    \n",
    "    se = side_effect.lower().replace(\"the \", \"\").replace(\"risk or severity of\", \"\")       \n",
    "        \n",
    "    side += [[increase, se, append + se ]]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "fe50d49c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'=\"biotech\" created=\"2005-06-13\" updated=\"2020-11-02\">   <drugbank-id primary=\"true\">DB00001</drugbank-id>   <drugbank-id>BTD00024</drugbank-id>   <drugbank-id>BIOD00024</drugbank-id>   <name>Lepirudin</name>   <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</description>   <cas-number>138068-37-8</cas-number>   <unii>Y43GF64R34</unii>   <state>liquid</state>   <groups>     <group>approved</group>   </groups>   <general-references>     <articles>       <article>         <ref-id>A1</ref-id>         <pubmed-id>16244762</pubmed-id>         <citation>Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.</citation>       </article>       <article>         <ref-id>A2</ref-id>         <pubmed-id>16690967</pubmed-id>         <citation>Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.</citation>       </article>       <article>         <ref-id>A3</ref-id>         <pubmed-id>16241940</pubmed-id>         <citation>Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.</citation>       </article>     </articles>     <textbooks/>     <links>       <link>         <ref-id>L48</ref-id>         <title>Google books</title>         <url>http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440</url>       </link>     </links>     <attachments/>   </general-references>   <synthesis-reference/>   <indication>For the treatment of heparin-induced thrombocytopenia</indication>   <pharmacodynamics>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacodynamics>   <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>   <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>   <metabolism>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</metabolism>   <absorption>Bioavailability is 100% following injection.</absorption>   <half-life>Approximately 1.3 hours</half-life>   <protein-binding/>   <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>   <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#13; * 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#13; * 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#13; * 32.1 L [HIT patients (n = 73)]</volume-of-distribution>   <clearance>* 164 ml/min [Healthy 18-60 yrs]&#13; * 139 ml/min [Healthy 65-80 yrs]&#13; * 61 ml/min [renal impaired]&#13; * 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>   <classification>     <description/>     <direct-parent>Peptides</direct-parent>     <kingdom>Organic Compounds</kingdom>     <superclass>Organic Acids</superclass>     <class>Carboxylic Acids and Derivatives</class>     <subclass>Amino Acids, Peptides, and Analogues</subclass>   </classification>   <salts/>   <synonyms>     <synonym language=\"english\" coder=\"\">Hirudin variant-1</synonym>     <synonym language=\"english\" coder=\"\">Lepirudin recombinant</synonym>   </synonyms>   <products>     <product>       <name>Refludan</name>       <labeller>Celgene Europe Limited</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id/>       <ema-product-code>EMEA/H/C/000122</ema-product-code>       <ema-ma-number>EU/1/97/035/001</ema-ma-number>       <started-marketing-on>1997-03-13</started-marketing-on>       <ended-marketing-on>2012-07-27</ended-marketing-on>       <dosage-form>Injection, solution, concentrate</dosage-form>       <strength>50 mg</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>false</approved>       <country>EU</country>       <source>EMA</source>     </product>     <product>       <name>Refludan</name>       <labeller>Celgene Europe Limited</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id/>       <ema-product-code>EMEA/H/C/000122</ema-product-code>       <ema-ma-number>EU/1/97/035/002</ema-ma-number>       <started-marketing-on>1997-03-13</started-marketing-on>       <ended-marketing-on>2012-07-27</ended-marketing-on>       <dosage-form>Injection, solution, concentrate</dosage-form>       <strength>50 mg</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>false</approved>       <country>EU</country>       <source>EMA</source>     </product>     <product>       <name>Refludan</name>       <labeller>Celgene Europe Limited</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id/>       <ema-product-code>EMEA/H/C/000122</ema-product-code>       <ema-ma-number>EU/1/97/035/003</ema-ma-number>       <started-marketing-on>1997-03-13</started-marketing-on>       <ended-marketing-on>2012-07-27</ended-marketing-on>       <dosage-form>Injection, solution, concentrate</dosage-form>       <strength>20 mg</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>false</approved>       <country>EU</country>       <source>EMA</source>     </product>     <product>       <name>Refludan</name>       <labeller>Celgene Europe Limited</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id/>       <ema-product-code>EMEA/H/C/000122</ema-product-code>       <ema-ma-number>EU/1/97/035/004</ema-ma-number>       <started-marketing-on>1997-03-13</started-marketing-on>       <ended-marketing-on>2012-07-27</ended-marketing-on>       <dosage-form>Injection, solution, concentrate</dosage-form>       <strength>20 mg</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>false</approved>       <country>EU</country>       <source>EMA</source>     </product>     <product>       <name>Refludan</name>       <labeller>Bayer</labeller>       <ndc-id/>       <ndc-product-code>50419-150</ndc-product-code>       <dpd-id/>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>1998-03-06</started-marketing-on>       <ended-marketing-on>2013-06-30</ended-marketing-on>       <dosage-form>Powder</dosage-form>       <strength>50 mg/1mL</strength>       <route>Intravenous</route>       <fda-application-number>NDA020807</fda-application-number>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>US</country>       <source>FDA NDC</source>     </product>     <product>       <name>Refludan</name>       <labeller>Bayer</labeller>       <ndc-id/>       <ndc-product-code/>       <dpd-id>02240996</dpd-id>       <ema-product-code/>       <ema-ma-number/>       <started-marketing-on>2000-01-31</started-marketing-on>       <ended-marketing-on>2013-07-26</ended-marketing-on>       <dosage-form>Powder, for solution</dosage-form>       <strength>50 mg</strength>       <route>Intravenous</route>       <fda-application-number/>       <generic>false</generic>       <over-the-counter>false</over-the-counter>       <approved>true</approved>       <country>Canada</country>       <source>DPD</source>     </product>   </products>   <international-brands/>   <mixtures>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>     <mixture>       <name>Refludan</name>       <ingredients>Lepirudin</ingredients>     </mixture>   </mixtures>   <packagers>     <packager>       <name>Bayer Healthcare</name>       <url>http://www.bayerhealthcare.com</url>     </packager>     <packager>       <name>Berlex Labs</name>       <url>http://www.berlex.com</url>     </packager>   </packagers>   <manufacturers>     <manufacturer generic=\"false\" url=\"\">Bayer healthcare pharmaceuticals inc</manufacturer>   </manufacturers>   <prices>     <price>       <description>Refludan 50 mg vial</description>       <cost currency=\"USD\">273.19</cost>       <unit>vial</unit>     </price>   </prices>   <categories>     <category>       <category>Amino Acids, Peptides, and Proteins</category>       <mesh-id>D000602</mesh-id>     </category>     <category>       <category>Anticoagulants</category>       <mesh-id>D000925</mesh-id>     </category>     <category>       <category>Antithrombin Proteins</category>       <mesh-id>D058833</mesh-id>     </category>     <category>       <category>Antithrombins</category>       <mesh-id>D000991</mesh-id>     </category>     <category>       <category>Blood and Blood Forming Organs</category>       <mesh-id/>     </category>     <category>       <category>Cardiovascular Agents</category>       <mesh-id>D002317</mesh-id>     </category>     <category>       <category>Enzyme Inhibitors</category>       <mesh-id>D004791</mesh-id>     </category>     <category>       <category>Fibrin Modulating Agents</category>       <mesh-id>D050299</mesh-id>     </category>     <category>       <category>Hematologic Agents</category>       <mesh-id>D006401</mesh-id>     </category>     <category>       <category>Peptides</category>       <mesh-id>D010455</mesh-id>     </category>     <category>       <category>Protease Inhibitors</category>       <mesh-id>D011480</mesh-id>     </category>     <category>       <category>Proteins</category>       <mesh-id>D011506</mesh-id>     </category>     <category>       <category>Serine Protease Inhibitors</category>       <mesh-id>D015842</mesh-id>     </category>     <category>       <category>Serpins</category>       <mesh-id>D015843</mesh-id>     </category>     <category>       <category>Thrombin Inhibitors</category>       <mesh-id/>     </category>   </categories>   <affected-organisms>     <affected-organism>Humans and other mammals</affected-organism>   </affected-organisms>   <dosages>     <dosage>       <form>Injection, solution, concentrate</form>       <route>Intravenous</route>       <strength>20 mg</strength>     </dosage>     <dosage>       <form>Injection, solution, concentrate</form>       <route>Intravenous</route>       <strength>50 mg</strength>     </dosage>     <dosage>       <form>Powder</form>       <route>Intravenous</route>       <strength>50 MG</strength>     </dosage>     <dosage>       <form>Powder</form>       <route>Intravenous</route>       <strength>50 mg/1mL</strength>     </dosage>     <dosage>       <form>Powder, for solution</form>       <route>Intravenous</route>       <strength>50 mg</strength>     </dosage>   </dosages>   <atc-codes>     <atc-code code=\"B01AE02\">       <level code=\"B01AE\">Direct thrombin inhibitors</level>       <level code=\"B01A\">ANTITHROMBOTIC AGENTS</level>       <level code=\"B01\">ANTITHROMBOTIC AGENTS</level>       <level code=\"B\">BLOOD AND BLOOD FORMING ORGANS</level>     </atc-code>   </atc-codes>   <ahfs-codes/>   <pdb-entries/>   <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00001.pdf?1265924858</fda-label>   <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00001.pdf?1368416245</msds>   <patents>     <patent>       <number>5180668</number>       <country>United States</country>       <approved>1993-01-19</approved>       <expires>2010-01-19</expires>       <pediatric-extension>false</pediatric-extension>     </patent>   </patents>   <food-interactions>     <food-interaction>Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.</food-interaction>   </food-interactions>   <drug-interactions>     <drug-interaction>       <drugbank-id>DB06605</drugbank-id>       <name>Apixaban</name>       <description>Apixaban may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06695</drugbank-id>       <name>Dabigatran etexilate</name>       <description>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01254</drugbank-id>       <name>Dasatinib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01609</drugbank-id>       <name>Deferasirox</name>       <description>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01586</drugbank-id>       <name>Ursodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02123</drugbank-id>       <name>Glycochenodeoxycholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02659</drugbank-id>       <name>Cholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02691</drugbank-id>       <name>Glycocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03619</drugbank-id>       <name>Deoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04348</drugbank-id>       <name>Taurocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05990</drugbank-id>       <name>Obeticholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06777</drugbank-id>       <name>Chenodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08833</drugbank-id>       <name>Taurochenodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08834</drugbank-id>       <name>Tauroursodeoxycholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08857</drugbank-id>       <name>Bamet-UD2</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11622</drugbank-id>       <name>Dehydrocholic acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11789</drugbank-id>       <name>Hyodeoxycholic Acid</name>       <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09075</drugbank-id>       <name>Edoxaban</name>       <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09053</drugbank-id>       <name>Ibrutinib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08935</drugbank-id>       <name>Obinutuzumab</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06228</drugbank-id>       <name>Rivaroxaban</name>       <description>Lepirudin may increase the anticoagulant activities of Rivaroxaban.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06206</drugbank-id>       <name>Sugammadex</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09070</drugbank-id>       <name>Tibolone</name>       <description>Tibolone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00932</drugbank-id>       <name>Tipranavir</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00013</drugbank-id>       <name>Urokinase</name>       <description>Urokinase may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00163</drugbank-id>       <name>Vitamin E</name>       <description>Vitamin E may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09030</drugbank-id>       <name>Vorapaxar</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01381</drugbank-id>       <name>Ginkgo biloba</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Ginkgo biloba.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01181</drugbank-id>       <name>Ifosfamide</name>       <description>The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00468</drugbank-id>       <name>Quinine</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00908</drugbank-id>       <name>Quinidine</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00675</drugbank-id>       <name>Tamoxifen</name>       <description>The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00539</drugbank-id>       <name>Toremifene</name>       <description>The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00806</drugbank-id>       <name>Pentoxifylline</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00686</drugbank-id>       <name>Pentosan polysulfate</name>       <description>Pentosan polysulfate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00583</drugbank-id>       <name>Levocarnitine</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00255</drugbank-id>       <name>Diethylstilbestrol</name>       <description>Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00269</drugbank-id>       <name>Chlorotrianisene</name>       <description>Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00286</drugbank-id>       <name>Conjugated estrogens</name>       <description>Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00783</drugbank-id>       <name>Estradiol</name>       <description>Estradiol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00977</drugbank-id>       <name>Ethinylestradiol</name>       <description>Ethinylestradiol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01357</drugbank-id>       <name>Mestranol</name>       <description>Mestranol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04574</drugbank-id>       <name>Estrone sulfate</name>       <description>Estrone sulfate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04575</drugbank-id>       <name>Quinestrol</name>       <description>Quinestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07931</drugbank-id>       <name>Hexestrol</name>       <description>Hexestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09317</drugbank-id>       <name>Synthetic Conjugated Estrogens, A</name>       <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09318</drugbank-id>       <name>Synthetic Conjugated Estrogens, B</name>       <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09369</drugbank-id>       <name>Polyestradiol phosphate</name>       <description>Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09381</drugbank-id>       <name>Esterified estrogens</name>       <description>Esterified estrogens may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11478</drugbank-id>       <name>Zeranol</name>       <description>Zeranol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11674</drugbank-id>       <name>Equol</name>       <description>Equol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13143</drugbank-id>       <name>Methallenestril</name>       <description>Methallenestril may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13386</drugbank-id>       <name>Epimestrol</name>       <description>Epimestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13418</drugbank-id>       <name>Moxestrol</name>       <description>Moxestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13952</drugbank-id>       <name>Estradiol acetate</name>       <description>Estradiol acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13953</drugbank-id>       <name>Estradiol benzoate</name>       <description>Estradiol benzoate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13954</drugbank-id>       <name>Estradiol cypionate</name>       <description>Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13956</drugbank-id>       <name>Estradiol valerate</name>       <description>Estradiol valerate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB15334</drugbank-id>       <name>Biochanin A</name>       <description>Biochanin A may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB15335</drugbank-id>       <name>Formononetin</name>       <description>Formononetin may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00655</drugbank-id>       <name>Estrone</name>       <description>Estrone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04573</drugbank-id>       <name>Estriol</name>       <description>Estriol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09211</drugbank-id>       <name>Limaprost</name>       <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00159</drugbank-id>       <name>Icosapent</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00244</drugbank-id>       <name>Mesalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00328</drugbank-id>       <name>Indomethacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00461</drugbank-id>       <name>Nabumetone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00465</drugbank-id>       <name>Ketorolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00469</drugbank-id>       <name>Tenoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00482</drugbank-id>       <name>Celecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00500</drugbank-id>       <name>Tolmetin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00533</drugbank-id>       <name>Rofecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00554</drugbank-id>       <name>Piroxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00573</drugbank-id>       <name>Fenoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00580</drugbank-id>       <name>Valdecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00586</drugbank-id>       <name>Diclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00605</drugbank-id>       <name>Sulindac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00712</drugbank-id>       <name>Flurbiprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00749</drugbank-id>       <name>Etodolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00784</drugbank-id>       <name>Mefenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00788</drugbank-id>       <name>Naproxen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00795</drugbank-id>       <name>Sulfasalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00812</drugbank-id>       <name>Phenylbutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00814</drugbank-id>       <name>Meloxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00821</drugbank-id>       <name>Carprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00861</drugbank-id>       <name>Diflunisal</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00936</drugbank-id>       <name>Salicylic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00939</drugbank-id>       <name>Meclofenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00991</drugbank-id>       <name>Oxaprozin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01009</drugbank-id>       <name>Ketoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01014</drugbank-id>       <name>Balsalazide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01250</drugbank-id>       <name>Olsalazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01283</drugbank-id>       <name>Lumiracoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01397</drugbank-id>       <name>Magnesium salicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01399</drugbank-id>       <name>Salsalate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01401</drugbank-id>       <name>Choline magnesium trisalicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01419</drugbank-id>       <name>Antrafenine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01424</drugbank-id>       <name>Aminophenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01435</drugbank-id>       <name>Antipyrine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01600</drugbank-id>       <name>Tiaprofenic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01628</drugbank-id>       <name>Etoricoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02224</drugbank-id>       <name>Taxifolin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03585</drugbank-id>       <name>Oxyphenbutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04725</drugbank-id>       <name>Licofelone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04812</drugbank-id>       <name>Benoxaprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04817</drugbank-id>       <name>Metamizole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04828</drugbank-id>       <name>Zomepirac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05095</drugbank-id>       <name>Cimicoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06725</drugbank-id>       <name>Lornoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06736</drugbank-id>       <name>Aceclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06737</drugbank-id>       <name>Zaltoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07402</drugbank-id>       <name>Azapropazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08439</drugbank-id>       <name>Parecoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08797</drugbank-id>       <name>Salicylamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08940</drugbank-id>       <name>Kebuzone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08942</drugbank-id>       <name>Isoxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08951</drugbank-id>       <name>Indoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08955</drugbank-id>       <name>Ibuproxam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08976</drugbank-id>       <name>Floctafenine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08981</drugbank-id>       <name>Fenbufen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08984</drugbank-id>       <name>Etofenamate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08991</drugbank-id>       <name>Epirizole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09084</drugbank-id>       <name>Benzydamine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09214</drugbank-id>       <name>Dexketoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09215</drugbank-id>       <name>Droxicam</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09216</drugbank-id>       <name>Tolfenamic acid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09217</drugbank-id>       <name>Firocoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09218</drugbank-id>       <name>Clonixin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09285</drugbank-id>       <name>Morniflumate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09288</drugbank-id>       <name>Propacetamol</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09295</drugbank-id>       <name>Talniflumate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11455</drugbank-id>       <name>Robenacoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11466</drugbank-id>       <name>Tepoxalin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11518</drugbank-id>       <name>Flunixin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12399</drugbank-id>       <name>Polmacoxib</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12610</drugbank-id>       <name>Ebselen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13001</drugbank-id>       <name>Tinoridine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13167</drugbank-id>       <name>Alclofenac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13217</drugbank-id>       <name>Fentiazac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13232</drugbank-id>       <name>Suxibuzone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13286</drugbank-id>       <name>Bumadizone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13314</drugbank-id>       <name>Alminoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13371</drugbank-id>       <name>Difenpiramide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13407</drugbank-id>       <name>Nifenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13432</drugbank-id>       <name>Lonazolac</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13481</drugbank-id>       <name>Tenidap</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13524</drugbank-id>       <name>Propyphenazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13527</drugbank-id>       <name>Proglumetacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13538</drugbank-id>       <name>Guacetisal</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13544</drugbank-id>       <name>Ethenzamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13612</drugbank-id>       <name>Carbaspirin calcium</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13629</drugbank-id>       <name>Mofebutazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13649</drugbank-id>       <name>Proquazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13657</drugbank-id>       <name>Benorilate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13722</drugbank-id>       <name>Pirprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13860</drugbank-id>       <name>Imidazole salicylate</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14059</drugbank-id>       <name>SC-236</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14060</drugbank-id>       <name>NS-398</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14938</drugbank-id>       <name>Flurbiprofen axetil</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09212</drugbank-id>       <name>Loxoprofen</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04865</drugbank-id>       <name>Omacetaxine mepesuccinate</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11133</drugbank-id>       <name>Omega-3 fatty acids</name>       <description>Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00081</drugbank-id>       <name>Tositumomab</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00048</drugbank-id>       <name>Collagenase clostridium histolyticum</name>       <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00389</drugbank-id>       <name>Carbimazole</name>       <description>Carbimazole may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00550</drugbank-id>       <name>Propylthiouracil</name>       <description>Propylthiouracil may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00763</drugbank-id>       <name>Methimazole</name>       <description>Methimazole may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03374</drugbank-id>       <name>3,5-Diiodotyrosine</name>       <description>3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06715</drugbank-id>       <name>Potassium Iodide</name>       <description>Potassium Iodide may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07637</drugbank-id>       <name>Dibromotyrosine</name>       <description>Dibromotyrosine may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09418</drugbank-id>       <name>Potassium perchlorate</name>       <description>Potassium perchlorate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13644</drugbank-id>       <name>Methylthiouracil</name>       <description>Methylthiouracil may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13804</drugbank-id>       <name>Benzylthiouracil</name>       <description>Benzylthiouracil may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00834</drugbank-id>       <name>Mifepristone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mifepristone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04066</drugbank-id>       <name>p-Coumaric acid</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with p-Coumaric acid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04682</drugbank-id>       <name>Octylphenoxy polyethoxyethanol</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05830</drugbank-id>       <name>Trestolone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06266</drugbank-id>       <name>Lonidamine</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lonidamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08867</drugbank-id>       <name>Ulipristal</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09401</drugbank-id>       <name>Isosorbide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Isosorbide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11507</drugbank-id>       <name>Cloprostenol</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12025</drugbank-id>       <name>Triptolide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triptolide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13044</drugbank-id>       <name>Gossypol</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13310</drugbank-id>       <name>Ormeloxifene</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ormeloxifene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00294</drugbank-id>       <name>Etonogestrel</name>       <description>Etonogestrel may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00304</drugbank-id>       <name>Desogestrel</name>       <description>Desogestrel may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00351</drugbank-id>       <name>Megestrol acetate</name>       <description>Megestrol acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00367</drugbank-id>       <name>Levonorgestrel</name>       <description>Levonorgestrel may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00378</drugbank-id>       <name>Dydrogesterone</name>       <description>Dydrogesterone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00396</drugbank-id>       <name>Progesterone</name>       <description>Progesterone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00603</drugbank-id>       <name>Medroxyprogesterone acetate</name>       <description>Medroxyprogesterone acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00717</drugbank-id>       <name>Norethisterone</name>       <description>Norethisterone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00823</drugbank-id>       <name>Ethynodiol diacetate</name>       <description>Ethynodiol diacetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00957</drugbank-id>       <name>Norgestimate</name>       <description>Norgestimate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01395</drugbank-id>       <name>Drospirenone</name>       <description>Drospirenone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01431</drugbank-id>       <name>Allylestrenol</name>       <description>Allylestrenol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04839</drugbank-id>       <name>Cyproterone acetate</name>       <description>Cyproterone acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06713</drugbank-id>       <name>Norelgestromin</name>       <description>Norelgestromin may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06730</drugbank-id>       <name>Gestodene</name>       <description>Gestodene may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06789</drugbank-id>       <name>Hydroxyprogesterone caproate</name>       <description>Hydroxyprogesterone caproate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09123</drugbank-id>       <name>Dienogest</name>       <description>Dienogest may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09124</drugbank-id>       <name>Medrogestone</name>       <description>Medrogestone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09371</drugbank-id>       <name>Norethynodrel</name>       <description>Norethynodrel may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09389</drugbank-id>       <name>Norgestrel</name>       <description>Norgestrel may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11372</drugbank-id>       <name>Altrenogest</name>       <description>Altrenogest may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11619</drugbank-id>       <name>Gestrinone</name>       <description>Gestrinone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11636</drugbank-id>       <name>Nomegestrol</name>       <description>Nomegestrol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12474</drugbank-id>       <name>Lynestrenol</name>       <description>Lynestrenol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13230</drugbank-id>       <name>Gestonorone</name>       <description>Gestonorone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13528</drugbank-id>       <name>Chlormadinone</name>       <description>Chlormadinone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13533</drugbank-id>       <name>Methylestrenolone</name>       <description>Methylestrenolone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13563</drugbank-id>       <name>Norgestrienone</name>       <description>Norgestrienone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13602</drugbank-id>       <name>Promegestone</name>       <description>Promegestone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13685</drugbank-id>       <name>Quingestanol</name>       <description>Quingestanol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13857</drugbank-id>       <name>Demegestone</name>       <description>Demegestone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13866</drugbank-id>       <name>Etynodiol</name>       <description>Etynodiol may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13981</drugbank-id>       <name>Nomegestrol acetate</name>       <description>Nomegestrol acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14570</drugbank-id>       <name>Hydroxyprogesterone</name>       <description>Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14678</drugbank-id>       <name>Norethindrone enanthate</name>       <description>Norethindrone enanthate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14679</drugbank-id>       <name>Quingestanol acetate</name>       <description>Quingestanol acetate may decrease the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00233</drugbank-id>       <name>Aminosalicylic acid</name>       <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01294</drugbank-id>       <name>Bismuth subsalicylate</name>       <description>The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06251</drugbank-id>       <name>Dersalazine</name>       <description>The risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06807</drugbank-id>       <name>Phenyl aminosalicylate</name>       <description>The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09543</drugbank-id>       <name>Methyl salicylate</name>       <description>The risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11079</drugbank-id>       <name>Trolamine salicylate</name>       <description>The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13509</drugbank-id>       <name>Aloxiprin</name>       <description>The risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14006</drugbank-id>       <name>Choline salicylate</name>       <description>The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14026</drugbank-id>       <name>Thiosalicylic acid</name>       <description>The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00054</drugbank-id>       <name>Abciximab</name>       <description>The risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00063</drugbank-id>       <name>Eptifibatide</name>       <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00208</drugbank-id>       <name>Ticlopidine</name>       <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00261</drugbank-id>       <name>Anagrelide</name>       <description>The risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00758</drugbank-id>       <name>Clopidogrel</name>       <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00775</drugbank-id>       <name>Tirofiban</name>       <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00975</drugbank-id>       <name>Dipyridamole</name>       <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01088</drugbank-id>       <name>Iloprost</name>       <description>The risk or severity of bleeding can be increased when Iloprost is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01138</drugbank-id>       <name>Sulfinpyrazone</name>       <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01166</drugbank-id>       <name>Cilostazol</name>       <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01207</drugbank-id>       <name>Ridogrel</name>       <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01236</drugbank-id>       <name>Sevoflurane</name>       <description>The risk or severity of bleeding can be increased when Sevoflurane is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01240</drugbank-id>       <name>Epoprostenol</name>       <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02709</drugbank-id>       <name>Resveratrol</name>       <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04743</drugbank-id>       <name>Nimesulide</name>       <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04905</drugbank-id>       <name>Tesmilifene</name>       <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04932</drugbank-id>       <name>Defibrotide</name>       <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05229</drugbank-id>       <name>Beraprost</name>       <description>The risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05266</drugbank-id>       <name>Ibudilast</name>       <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05767</drugbank-id>       <name>Andrographolide</name>       <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06081</drugbank-id>       <name>Caplacizumab</name>       <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06209</drugbank-id>       <name>Prasugrel</name>       <description>The risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06441</drugbank-id>       <name>Cangrelor</name>       <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07615</drugbank-id>       <name>Tranilast</name>       <description>The risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08814</drugbank-id>       <name>Triflusal</name>       <description>The risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08816</drugbank-id>       <name>Ticagrelor</name>       <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08887</drugbank-id>       <name>Icosapent ethyl</name>       <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09283</drugbank-id>       <name>Trapidil</name>       <description>The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12092</drugbank-id>       <name>Naftopidil</name>       <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12163</drugbank-id>       <name>Sarpogrelate</name>       <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12321</drugbank-id>       <name>Ifetroban</name>       <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12445</drugbank-id>       <name>Nitroaspirin</name>       <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12465</drugbank-id>       <name>Ketanserin</name>       <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12545</drugbank-id>       <name>Indobufen</name>       <description>The risk or severity of bleeding can be increased when Indobufen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12749</drugbank-id>       <name>Butylphthalide</name>       <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12771</drugbank-id>       <name>Hydroxytyrosol</name>       <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13036</drugbank-id>       <name>Ramatroban</name>       <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13327</drugbank-id>       <name>Picotamide</name>       <description>The risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13367</drugbank-id>       <name>Cloricromen</name>       <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13400</drugbank-id>       <name>Linsidomine</name>       <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13510</drugbank-id>       <name>Buflomedil</name>       <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13929</drugbank-id>       <name>Relcovaptan</name>       <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00374</drugbank-id>       <name>Treprostinil</name>       <description>The risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03404</drugbank-id>       <name>Hemin</name>       <description>Hemin may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13783</drugbank-id>       <name>Acemetacin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00624</drugbank-id>       <name>Testosterone</name>       <description>Testosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01420</drugbank-id>       <name>Testosterone propionate</name>       <description>Testosterone propionate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01481</drugbank-id>       <name>1-Testosterone</name>       <description>1-Testosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01485</drugbank-id>       <name>4-Hydroxytestosterone</name>       <description>4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01510</drugbank-id>       <name>Dehydrochloromethyltestosterone</name>       <description>Dehydrochloromethyltestosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01541</drugbank-id>       <name>Boldenone</name>       <description>Boldenone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01543</drugbank-id>       <name>18-methyl-19-nortestosterone</name>       <description>18-methyl-19-nortestosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01564</drugbank-id>       <name>Calusterone</name>       <description>Calusterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01569</drugbank-id>       <name>Formebolone</name>       <description>Formebolone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01572</drugbank-id>       <name>Methyl-1-testosterone</name>       <description>Methyl-1-testosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07447</drugbank-id>       <name>5beta-dihydrotestosterone</name>       <description>5beta-dihydrotestosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08619</drugbank-id>       <name>Testosterone succinate</name>       <description>Testosterone succinate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11429</drugbank-id>       <name>Mibolerone</name>       <description>Mibolerone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13943</drugbank-id>       <name>Testosterone cypionate</name>       <description>Testosterone cypionate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13944</drugbank-id>       <name>Testosterone enanthate</name>       <description>Testosterone enanthate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13946</drugbank-id>       <name>Testosterone undecanoate</name>       <description>Testosterone undecanoate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13947</drugbank-id>       <name>Testosterone enantate benzilic acid hydrazone</name>       <description>Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13951</drugbank-id>       <name>Stanolone acetate</name>       <description>Stanolone acetate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13958</drugbank-id>       <name>Trestolone acetate</name>       <description>Trestolone acetate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14093</drugbank-id>       <name>(1,2,6,7-3H)Testosterone</name>       <description>(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14655</drugbank-id>       <name>Drostanolone propionate</name>       <description>Drostanolone propionate may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11051</drugbank-id>       <name>Azficel-T</name>       <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09568</drugbank-id>       <name>Omega-3-carboxylic acids</name>       <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00025</drugbank-id>       <name>Antihemophilic factor, human recombinant</name>       <description>The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00036</drugbank-id>       <name>Coagulation factor VIIa Recombinant Human</name>       <description>The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00100</drugbank-id>       <name>Coagulation Factor IX (Recombinant)</name>       <description>The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00258</drugbank-id>       <name>Calcium acetate</name>       <description>The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01164</drugbank-id>       <name>Calcium chloride</name>       <description>The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01373</drugbank-id>       <name>Calcium</name>       <description>The therapeutic efficacy of Calcium can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01783</drugbank-id>       <name>Pantothenic acid</name>       <description>The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01942</drugbank-id>       <name>Formic acid</name>       <description>The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02261</drugbank-id>       <name>Platelet Activating Factor</name>       <description>The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06724</drugbank-id>       <name>Calcium carbonate</name>       <description>The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09109</drugbank-id>       <name>Turoctocog alfa</name>       <description>The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09222</drugbank-id>       <name>Fibrinogen human</name>       <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09310</drugbank-id>       <name>Catridecacog</name>       <description>The therapeutic efficacy of Catridecacog can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09329</drugbank-id>       <name>Antihemophilic Factor (Recombinant), PEGylated</name>       <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11093</drugbank-id>       <name>Calcium citrate</name>       <description>The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11126</drugbank-id>       <name>Calcium gluconate</name>       <description>The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11168</drugbank-id>       <name>Calcium threonate</name>       <description>The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11311</drugbank-id>       <name>Prothrombin</name>       <description>The therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11330</drugbank-id>       <name>Factor IX Complex (Human)</name>       <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11348</drugbank-id>       <name>Calcium Phosphate</name>       <description>The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11606</drugbank-id>       <name>Susoctocog alfa</name>       <description>The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11608</drugbank-id>       <name>Eftrenonacog alfa</name>       <description>The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11668</drugbank-id>       <name>Rusalatide acetate</name>       <description>The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12409</drugbank-id>       <name>Vatreptacog alfa</name>       <description>The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12909</drugbank-id>       <name>Factor XIII (human)</name>       <description>The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13133</drugbank-id>       <name>Von Willebrand Factor Human</name>       <description>The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13148</drugbank-id>       <name>Coagulation factor X human</name>       <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13150</drugbank-id>       <name>Coagulation factor VII human</name>       <description>The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13151</drugbank-id>       <name>Anti-inhibitor coagulant complex</name>       <description>The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13152</drugbank-id>       <name>Coagulation Factor IX Human</name>       <description>The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13192</drugbank-id>       <name>Antihemophilic factor human</name>       <description>The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13197</drugbank-id>       <name>Kallidinogenase</name>       <description>The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13201</drugbank-id>       <name>Trenonacog alfa</name>       <description>The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13884</drugbank-id>       <name>Albutrepenonacog alfa</name>       <description>The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13923</drugbank-id>       <name>Emicizumab</name>       <description>The therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13933</drugbank-id>       <name>Nonacog beta pegol</name>       <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13999</drugbank-id>       <name>Moroctocog alfa</name>       <description>The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14473</drugbank-id>       <name>Beroctocog alfa</name>       <description>The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14562</drugbank-id>       <name>Andexanet alfa</name>       <description>The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14577</drugbank-id>       <name>Calcium cation</name>       <description>The therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14700</drugbank-id>       <name>Damoctocog alfa pegol</name>       <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14738</drugbank-id>       <name>Turoctocog alfa pegol</name>       <description>The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00176</drugbank-id>       <name>Fluvoxamine</name>       <description>The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00215</drugbank-id>       <name>Citalopram</name>       <description>The risk or severity of hemorrhage can be increased when Citalopram is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00472</drugbank-id>       <name>Fluoxetine</name>       <description>The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00715</drugbank-id>       <name>Paroxetine</name>       <description>The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01149</drugbank-id>       <name>Nefazodone</name>       <description>The risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04832</drugbank-id>       <name>Zimelidine</name>       <description>The risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04884</drugbank-id>       <name>Dapoxetine</name>       <description>The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06731</drugbank-id>       <name>Seproxetine</name>       <description>The risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08953</drugbank-id>       <name>Indalpine</name>       <description>The risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12693</drugbank-id>       <name>Ritanserin</name>       <description>The risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13233</drugbank-id>       <name>Alaproclate</name>       <description>The risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00476</drugbank-id>       <name>Duloxetine</name>       <description>The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01105</drugbank-id>       <name>Sibutramine</name>       <description>The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04896</drugbank-id>       <name>Milnacipran</name>       <description>The risk or severity of hemorrhage can be increased when Milnacipran is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06700</drugbank-id>       <name>Desvenlafaxine</name>       <description>The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08918</drugbank-id>       <name>Levomilnacipran</name>       <description>The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00285</drugbank-id>       <name>Venlafaxine</name>       <description>Venlafaxine may increase the antiplatelet activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00182</drugbank-id>       <name>Amphetamine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00601</drugbank-id>       <name>Linezolid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00614</drugbank-id>       <name>Furazolidone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00721</drugbank-id>       <name>Procaine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00752</drugbank-id>       <name>Tranylcypromine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00780</drugbank-id>       <name>Phenelzine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00805</drugbank-id>       <name>Minaprine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01037</drugbank-id>       <name>Selegiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01168</drugbank-id>       <name>Procarbazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01171</drugbank-id>       <name>Moclobemide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01247</drugbank-id>       <name>Isocarboxazid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01367</drugbank-id>       <name>Rasagiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01626</drugbank-id>       <name>Pargyline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04017</drugbank-id>       <name>Clorgiline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04818</drugbank-id>       <name>Iproniazid</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04820</drugbank-id>       <name>Nialamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06654</drugbank-id>       <name>Safinamide</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08550</drugbank-id>       <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09241</drugbank-id>       <name>Methylene blue</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09243</drugbank-id>       <name>Hydracarbazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09244</drugbank-id>       <name>Pirlindole</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09245</drugbank-id>       <name>Toloxatone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09246</drugbank-id>       <name>Benmoxin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09248</drugbank-id>       <name>Mebanazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09249</drugbank-id>       <name>Octamoxin</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09250</drugbank-id>       <name>Pheniprazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09251</drugbank-id>       <name>Phenoxypropazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09252</drugbank-id>       <name>Pivhydrazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09253</drugbank-id>       <name>Safrazine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09254</drugbank-id>       <name>Caroxazone</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13875</drugbank-id>       <name>Harmaline</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13876</drugbank-id>       <name>Brofaromine</name>       <description>The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00006</drugbank-id>       <name>Bivalirudin</name>       <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00266</drugbank-id>       <name>Dicoumarol</name>       <description>The risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00278</drugbank-id>       <name>Argatroban</name>       <description>The risk or severity of bleeding can be increased when Argatroban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00407</drugbank-id>       <name>Ardeparin</name>       <description>The risk or severity of bleeding can be increased when Ardeparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00498</drugbank-id>       <name>Phenindione</name>       <description>The risk or severity of bleeding can be increased when Phenindione is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00569</drugbank-id>       <name>Fondaparinux</name>       <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00682</drugbank-id>       <name>Warfarin</name>       <description>The risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00946</drugbank-id>       <name>Phenprocoumon</name>       <description>The risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00974</drugbank-id>       <name>Edetic acid</name>       <description>The risk or severity of bleeding can be increased when Edetic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01109</drugbank-id>       <name>Heparin</name>       <description>The risk or severity of bleeding can be increased when Heparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01225</drugbank-id>       <name>Enoxaparin</name>       <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01418</drugbank-id>       <name>Acenocoumarol</name>       <description>The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04898</drugbank-id>       <name>Ximelagatran</name>       <description>The risk or severity of bleeding can be increased when Ximelagatran is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05099</drugbank-id>       <name>Ancrod</name>       <description>The risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06271</drugbank-id>       <name>Sulodexide</name>       <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06406</drugbank-id>       <name>Idraparinux</name>       <description>The risk or severity of bleeding can be increased when Idraparinux is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06635</drugbank-id>       <name>Otamixaban</name>       <description>The risk or severity of bleeding can be increased when Otamixaban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06754</drugbank-id>       <name>Danaparoid</name>       <description>The risk or severity of bleeding can be increased when Danaparoid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06779</drugbank-id>       <name>Dalteparin</name>       <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB07767</drugbank-id>       <name>Ferulic acid</name>       <description>The risk or severity of bleeding can be increased when Ferulic acid is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08794</drugbank-id>       <name>Ethyl biscoumacetate</name>       <description>The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08813</drugbank-id>       <name>Nadroparin</name>       <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09255</drugbank-id>       <name>Dextran</name>       <description>The risk or severity of bleeding can be increased when Dextran is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11095</drugbank-id>       <name>Desirudin</name>       <description>The risk or severity of bleeding can be increased when Desirudin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11268</drugbank-id>       <name>Protocatechualdehyde</name>       <description>The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11312</drugbank-id>       <name>Protein C</name>       <description>The risk or severity of bleeding can be increased when Protein C is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11598</drugbank-id>       <name>Antithrombin III human</name>       <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11984</drugbank-id>       <name>Letaxaban</name>       <description>The risk or severity of bleeding can be increased when Letaxaban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12289</drugbank-id>       <name>Darexaban</name>       <description>The risk or severity of bleeding can be increased when Darexaban is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12598</drugbank-id>       <name>Nafamostat</name>       <description>The risk or severity of bleeding can be increased when Nafamostat is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12831</drugbank-id>       <name>Gabexate</name>       <description>The risk or severity of bleeding can be increased when Gabexate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13124</drugbank-id>       <name>Troxerutin</name>       <description>The risk or severity of bleeding can be increased when Troxerutin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13136</drugbank-id>       <name>Fluindione</name>       <description>The risk or severity of bleeding can be increased when Fluindione is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13149</drugbank-id>       <name>Protein S human</name>       <description>The risk or severity of bleeding can be increased when Protein S human is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13616</drugbank-id>       <name>Melagatran</name>       <description>The risk or severity of bleeding can be increased when Melagatran is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09125</drugbank-id>       <name>Potassium citrate</name>       <description>The risk or severity of bleeding can be increased when Potassium citrate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09154</drugbank-id>       <name>Sodium citrate</name>       <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00031</drugbank-id>       <name>Tenecteplase</name>       <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00055</drugbank-id>       <name>Drotrecogin alfa</name>       <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06822</drugbank-id>       <name>Tinzaparin</name>       <description>The risk or severity of bleeding can be increased when Tinzaparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13199</drugbank-id>       <name>Brinase</name>       <description>The risk or severity of bleeding can be increased when Brinase is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13646</drugbank-id>       <name>Saruplase</name>       <description>The risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00086</drugbank-id>       <name>Streptokinase</name>       <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04925</drugbank-id>       <name>Desmoteplase</name>       <description>The risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05254</drugbank-id>       <name>Fibrinolysin</name>       <description>The risk or severity of bleeding can be increased when Fibrinolysin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06543</drugbank-id>       <name>Astaxanthin</name>       <description>The risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08994</drugbank-id>       <name>Ditazole</name>       <description>The risk or severity of bleeding can be increased when Ditazole is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09258</drugbank-id>       <name>Bemiparin</name>       <description>The risk or severity of bleeding can be increased when Bemiparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09260</drugbank-id>       <name>Parnaparin</name>       <description>The risk or severity of bleeding can be increased when Parnaparin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13275</drugbank-id>       <name>Clorindione</name>       <description>The risk or severity of bleeding can be increased when Clorindione is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13347</drugbank-id>       <name>Diphenadione</name>       <description>The risk or severity of bleeding can be increased when Diphenadione is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13451</drugbank-id>       <name>Tioclomarol</name>       <description>The risk or severity of bleeding can be increased when Tioclomarol is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00009</drugbank-id>       <name>Alteplase</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Alteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00015</drugbank-id>       <name>Reteplase</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00029</drugbank-id>       <name>Anistreplase</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Anistreplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14094</drugbank-id>       <name>Tocopherylquinone</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06679</drugbank-id>       <name>Amediplase</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Amediplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB03410</drugbank-id>       <name>4-hydroxycoumarin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with 4-hydroxycoumarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08496</drugbank-id>       <name>(R)-warfarin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14055</drugbank-id>       <name>(S)-Warfarin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12364</drugbank-id>       <name>Betrixaban</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14598</drugbank-id>       <name>Edetate calcium disodium anhydrous</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Edetate calcium disodium anhydrous.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11154</drugbank-id>       <name>Zinc citrate</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Zinc citrate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11166</drugbank-id>       <name>Antithrombin Alfa</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04665</drugbank-id>       <name>Coumarin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14726</drugbank-id>       <name>Dabigatran</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06294</drugbank-id>       <name>Semuloparin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Semuloparin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12726</drugbank-id>       <name>Monteplase</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Monteplase.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09259</drugbank-id>       <name>Reviparin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Reviparin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00203</drugbank-id>       <name>Sildenafil</name>       <description>The risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00008</drugbank-id>       <name>Peginterferon alfa-2a</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00011</drugbank-id>       <name>Interferon alfa-n1</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00018</drugbank-id>       <name>Interferon alfa-n3</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00022</drugbank-id>       <name>Peginterferon alfa-2b</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00033</drugbank-id>       <name>Interferon gamma-1b</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00034</drugbank-id>       <name>Interferon alfa-2a, Recombinant</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a, Recombinant.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00041</drugbank-id>       <name>Aldesleukin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00056</drugbank-id>       <name>Gemtuzumab ozogamicin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00068</drugbank-id>       <name>Interferon beta-1b</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00069</drugbank-id>       <name>Interferon alfacon-1</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00073</drugbank-id>       <name>Rituximab</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00078</drugbank-id>       <name>Ibritumomab tiuxetan</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00087</drugbank-id>       <name>Alemtuzumab</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00105</drugbank-id>       <name>Interferon alfa-2b</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00120</drugbank-id>       <name>Phenylalanine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Phenylalanine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00188</drugbank-id>       <name>Bortezomib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00242</drugbank-id>       <name>Cladribine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00262</drugbank-id>       <name>Carmustine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00276</drugbank-id>       <name>Amsacrine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00291</drugbank-id>       <name>Chlorambucil</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00293</drugbank-id>       <name>Raltitrexed</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00305</drugbank-id>       <name>Mitomycin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00307</drugbank-id>       <name>Bexarotene</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00309</drugbank-id>       <name>Vindesine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00322</drugbank-id>       <name>Floxuridine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00352</drugbank-id>       <name>Tioguanine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00361</drugbank-id>       <name>Vinorelbine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00380</drugbank-id>       <name>Dexrazoxane</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00398</drugbank-id>       <name>Sorafenib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00428</drugbank-id>       <name>Streptozocin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00441</drugbank-id>       <name>Gemcitabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00444</drugbank-id>       <name>Teniposide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00445</drugbank-id>       <name>Epirubicin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00446</drugbank-id>       <name>Chloramphenicol</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00480</drugbank-id>       <name>Lenalidomide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00488</drugbank-id>       <name>Altretamine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00495</drugbank-id>       <name>Zidovudine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00515</drugbank-id>       <name>Cisplatin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00526</drugbank-id>       <name>Oxaliplatin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00531</drugbank-id>       <name>Cyclophosphamide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00544</drugbank-id>       <name>Fluorouracil</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00552</drugbank-id>       <name>Pentostatin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00563</drugbank-id>       <name>Methotrexate</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00564</drugbank-id>       <name>Carbamazepine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00570</drugbank-id>       <name>Vinblastine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00619</drugbank-id>       <name>Imatinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00631</drugbank-id>       <name>Clofarabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00642</drugbank-id>       <name>Pemetrexed</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00694</drugbank-id>       <name>Daunorubicin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00762</drugbank-id>       <name>Irinotecan</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00773</drugbank-id>       <name>Etoposide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00851</drugbank-id>       <name>Dacarbazine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00853</drugbank-id>       <name>Temozolomide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00859</drugbank-id>       <name>Penicillamine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00864</drugbank-id>       <name>Tacrolimus</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00877</drugbank-id>       <name>Sirolimus</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00888</drugbank-id>       <name>Mechlorethamine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00928</drugbank-id>       <name>Azacitidine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00958</drugbank-id>       <name>Carboplatin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00970</drugbank-id>       <name>Dactinomycin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00987</drugbank-id>       <name>Cytarabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00997</drugbank-id>       <name>Doxorubicin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01005</drugbank-id>       <name>Hydroxyurea</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01008</drugbank-id>       <name>Busulfan</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01030</drugbank-id>       <name>Topotecan</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01033</drugbank-id>       <name>Mercaptopurine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01041</drugbank-id>       <name>Thalidomide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01042</drugbank-id>       <name>Melphalan</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01073</drugbank-id>       <name>Fludarabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01099</drugbank-id>       <name>Flucytosine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01101</drugbank-id>       <name>Capecitabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01169</drugbank-id>       <name>Arsenic trioxide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01177</drugbank-id>       <name>Idarubicin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01204</drugbank-id>       <name>Mitoxantrone</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01206</drugbank-id>       <name>Lomustine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01229</drugbank-id>       <name>Paclitaxel</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01248</drugbank-id>       <name>Docetaxel</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01262</drugbank-id>       <name>Decitabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01280</drugbank-id>       <name>Nelarabine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01590</drugbank-id>       <name>Everolimus</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB02546</drugbank-id>       <name>Vorinostat</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04572</drugbank-id>       <name>Thiotepa</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04845</drugbank-id>       <name>Ixabepilone</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04868</drugbank-id>       <name>Nilotinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05015</drugbank-id>       <name>Belinostat</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05109</drugbank-id>       <name>Trabectedin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05258</drugbank-id>       <name>Interferon alfa</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05472</drugbank-id>       <name>Human interferon omega-1</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Human interferon omega-1.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB05773</drugbank-id>       <name>Trastuzumab emtansine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06287</drugbank-id>       <name>Temsirolimus</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06616</drugbank-id>       <name>Bosutinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06769</drugbank-id>       <name>Bendamustine</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06772</drugbank-id>       <name>Cabazitaxel</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08871</drugbank-id>       <name>Eribulin</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08877</drugbank-id>       <name>Ruxolitinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08889</drugbank-id>       <name>Carfilzomib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08895</drugbank-id>       <name>Tofacitinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08901</drugbank-id>       <name>Ponatinib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB08910</drugbank-id>       <name>Pomalidomide</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09042</drugbank-id>       <name>Tedizolid phosphate</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09052</drugbank-id>       <name>Blinatumomab</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09073</drugbank-id>       <name>Palbociclib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09074</drugbank-id>       <name>Olaparib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09077</drugbank-id>       <name>Dinutuximab</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09122</drugbank-id>       <name>Peginterferon beta-1a</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB12814</drugbank-id>       <name>Cepeginterferon alfa-2B</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00229</drugbank-id>       <name>Cefotiam</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00267</drugbank-id>       <name>Cefmenoxime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00274</drugbank-id>       <name>Cefmetazole</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00430</drugbank-id>       <name>Cefpiramide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00438</drugbank-id>       <name>Ceftazidime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00447</drugbank-id>       <name>Loracarbef</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00456</drugbank-id>       <name>Cefalotin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00493</drugbank-id>       <name>Cefotaxime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00535</drugbank-id>       <name>Cefdinir</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00567</drugbank-id>       <name>Cephalexin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00671</drugbank-id>       <name>Cefixime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00689</drugbank-id>       <name>Cephaloglycin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00833</drugbank-id>       <name>Cefaclor</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00923</drugbank-id>       <name>Ceforanide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01066</drugbank-id>       <name>Cefditoren</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01112</drugbank-id>       <name>Cefuroxime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01139</drugbank-id>       <name>Cefapirin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01140</drugbank-id>       <name>Cefadroxil</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01150</drugbank-id>       <name>Cefprozil</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01212</drugbank-id>       <name>Ceftriaxone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01326</drugbank-id>       <name>Cefamandole</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01327</drugbank-id>       <name>Cefazolin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01328</drugbank-id>       <name>Cefonicid</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01329</drugbank-id>       <name>Cefoperazone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01330</drugbank-id>       <name>Cefotetan</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01331</drugbank-id>       <name>Cefoxitin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01332</drugbank-id>       <name>Ceftizoxime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01333</drugbank-id>       <name>Cefradine</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01413</drugbank-id>       <name>Cefepime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01414</drugbank-id>       <name>Cefacetrile</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01415</drugbank-id>       <name>Ceftibuten</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01416</drugbank-id>       <name>Cefpodoxime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04570</drugbank-id>       <name>Latamoxef</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB04918</drugbank-id>       <name>Ceftobiprole</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB06590</drugbank-id>       <name>Ceftaroline fosamil</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09008</drugbank-id>       <name>Cefaloridine</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09050</drugbank-id>       <name>Ceftolozane</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09062</drugbank-id>       <name>Cefminox</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11367</drugbank-id>       <name>Cefroxadine</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB11935</drugbank-id>       <name>Flomoxef</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13266</drugbank-id>       <name>Cefatrizine</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13461</drugbank-id>       <name>Cefcapene</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13470</drugbank-id>       <name>Cefodizime</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13499</drugbank-id>       <name>Cefsulodin</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13504</drugbank-id>       <name>Cefetamet</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13638</drugbank-id>       <name>Cefbuperazone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13667</drugbank-id>       <name>Cefozopran</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13682</drugbank-id>       <name>Cefpirome</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13778</drugbank-id>       <name>Cefazedone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13821</drugbank-id>       <name>Ceftezole</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB14725</drugbank-id>       <name>Cefamandole nafate</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00254</drugbank-id>       <name>Doxycycline</name>       <description>The risk or severity of bleeding can be increased when Doxycycline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00207</drugbank-id>       <name>Azithromycin</name>       <description>The risk or severity of adverse effects can be increased when Azithromycin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09539</drugbank-id>       <name>Omega-3-acid ethyl esters</name>       <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00945</drugbank-id>       <name>Acetylsalicylic acid</name>       <description>Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01606</drugbank-id>       <name>Tazobactam</name>       <description>The risk or severity of bleeding can be increased when Tazobactam is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00199</drugbank-id>       <name>Erythromycin</name>       <description>The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00656</drugbank-id>       <name>Trazodone</name>       <description>The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00620</drugbank-id>       <name>Triamcinolone</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triamcinolone.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB09079</drugbank-id>       <name>Nintedanib</name>       <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nintedanib.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01175</drugbank-id>       <name>Escitalopram</name>       <description>The risk or severity of bleeding can be increased when Escitalopram is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01104</drugbank-id>       <name>Sertraline</name>       <description>The risk or severity of bleeding can be increased when Sertraline is combined with Lepirudin.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00232</drugbank-id>       <name>Methyclothiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00436</drugbank-id>       <name>Bendroflumethiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00562</drugbank-id>       <name>Benzthiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Benzthiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00606</drugbank-id>       <name>Cyclothiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00774</drugbank-id>       <name>Hydroflumethiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroflumethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00880</drugbank-id>       <name>Chlorothiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlorothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB00999</drugbank-id>       <name>Hydrochlorothiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydrochlorothiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01021</drugbank-id>       <name>Trichlormethiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trichlormethiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB01324</drugbank-id>       <name>Polythiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Polythiazide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13430</drugbank-id>       <name>Mebutizide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mebutizide.</description>     </drug-interaction>     <drug-interaction>       <drugbank-id>DB13532</drugbank-id>       <name>Cyclopenthiazide</name>       <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclopenthiazide.</description>     </drug-interaction>   </drug-interactions>   <sequences>     <sequence format=\"FASTA\">&gt;DB00001 sequence LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP EEYLQ</sequence>   </sequences>   <experimental-properties>     <property>       <kind>Melting Point</kind>       <value>65 C</value>       <source>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</source>     </property>     <property>       <kind>Hydrophobicity</kind>       <value>-0.777</value>       <source/>     </property>     <property>       <kind>Isoelectric Point</kind>       <value>4.04</value>       <source/>     </property>     <property>       <kind>Molecular Weight</kind>       <value>6963.425</value>       <source/>     </property>     <property>       <kind>Molecular Formula</kind>       <value>C287H440N80O110S6</value>       <source/>     </property>   </experimental-properties>   <external-identifiers>     <external-identifier>       <resource>Drugs Product Database (DPD)</resource>       <identifier>11916</identifier>     </external-identifier>     <external-identifier>       <resource>PubChem Substance</resource>       <identifier>46507011</identifier>     </external-identifier>     <external-identifier>       <resource>KEGG Drug</resource>       <identifier>D06880</identifier>     </external-identifier>     <external-identifier>       <resource>PharmGKB</resource>       <identifier>PA450195</identifier>     </external-identifier>     <external-identifier>       <resource>UniProtKB</resource>       <identifier>P01050</identifier>     </external-identifier>     <external-identifier>       <resource>Therapeutic Targets Database</resource>       <identifier>DAP000541</identifier>     </external-identifier>     <external-identifier>       <resource>Wikipedia</resource>       <identifier>Lepirudin</identifier>     </external-identifier>     <external-identifier>       <resource>ChEMBL</resource>       <identifier>CHEMBL1201666</identifier>     </external-identifier>     <external-identifier>       <resource>RxCUI</resource>       <identifier>237057</identifier>     </external-identifier>   </external-identifiers>   <external-links>     <external-link>       <resource>RxList</resource>       <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>     </external-link>     <external-link>       <resource>Drugs.com</resource>       <url>http://www.drugs.com/cdi/lepirudin.html</url>     </external-link>   </external-links>   <pathways>     <pathway>       <smpdb-id>SMP0000278</smpdb-id>       <name>Lepirudin Action Pathway</name>       <category>drug_action</category>       <drugs>         <drug>           <drugbank-id>DB00001</drugbank-id>           <name>Lepirudin</name>         </drug>         <drug>           <drugbank-id>DB01022</drugbank-id>           <name>Phylloquinone</name>         </drug>         <drug>           <drugbank-id>DB01373</drugbank-id>           <name>Calcium</name>         </drug>       </drugs>       <enzymes>         <uniprot-id>P00734</uniprot-id>         <uniprot-id>P00748</uniprot-id>         <uniprot-id>P02452</uniprot-id>         <uniprot-id>P03952</uniprot-id>         <uniprot-id>P03951</uniprot-id>         <uniprot-id>P00740</uniprot-id>         <uniprot-id>P00451</uniprot-id>         <uniprot-id>P12259</uniprot-id>         <uniprot-id>P00742</uniprot-id>         <uniprot-id>P02671</uniprot-id>         <uniprot-id>P02675</uniprot-id>         <uniprot-id>P02679</uniprot-id>         <uniprot-id>P00488</uniprot-id>         <uniprot-id>P05160</uniprot-id>         <uniprot-id>P00747</uniprot-id>         <uniprot-id>P00750</uniprot-id>         <uniprot-id>P08709</uniprot-id>         <uniprot-id>P13726</uniprot-id>         <uniprot-id>Q9BQB6</uniprot-id>         <uniprot-id>P38435</uniprot-id>       </enzymes>     </pathway>   </pathways>   <reactions/>   <snp-effects/>   <snp-adverse-drug-reactions/>   <targets>     <target>       <id>BE0000048</id>       <name>Prothrombin</name>       <organism>Humans</organism>       <actions>         <action>inhibitor</action>       </actions>       <references>         <articles>           <article>             <ref-id>A1703</ref-id>             <pubmed-id>10505536</pubmed-id>             <citation>Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.</citation>           </article>           <article>             <ref-id>A1705</ref-id>             <pubmed-id>10912644</pubmed-id>             <citation>Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.</citation>           </article>           <article>             <ref-id>A1707</ref-id>             <pubmed-id>11055889</pubmed-id>             <citation>Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.</citation>           </article>           <article>             <ref-id>A1709</ref-id>             <pubmed-id>11467439</pubmed-id>             <citation>Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.</citation>           </article>           <article>             <ref-id>A1711</ref-id>             <pubmed-id>11807012</pubmed-id>             <citation>Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.</citation>           </article>           <article>             <ref-id>A9</ref-id>             <pubmed-id>11752352</pubmed-id>             <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>           </article>         </articles>         <textbooks/>         <links/>         <attachments/>       </references>       <known-action>yes</known-action>       <polypeptide id=\"P00734\" source=\"Swiss-Prot\">         <name>Prothrombin</name>         <general-function>Thrombospondin receptor activity</general-function>         <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>         <gene-name>F2</gene-name>         <locus>11p11-q12</locus>         <cellular-location>Secreted</cellular-location>         <transmembrane-regions/>         <signal-regions>1-24</signal-regions>         <theoretical-pi>5.7</theoretical-pi>         <molecular-weight>70036.295</molecular-weight>         <chromosome-location>11</chromosome-location>         <organism ncbi-taxonomy-id=\"9606\">Humans</organism>         <external-identifiers>           <external-identifier>             <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>             <identifier>HGNC:3535</identifier>           </external-identifier>           <external-identifier>             <resource>GenAtlas</resource>             <identifier>F2</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Gene Database</resource>             <identifier>M17262</identifier>           </external-identifier>           <external-identifier>             <resource>GenBank Protein Database</resource>             <identifier>339641</identifier>           </external-identifier>           <external-identifier>             <resource>Guide to Pharmacology</resource>             <identifier>2362</identifier>           </external-identifier>           <external-identifier>             <resource>UniProtKB</resource>             <identifier>P00734</identifier>           </external-identifier>           <external-identifier>             <resource>UniProt Accession</resource>             <identifier>THRB_HUMAN</identifier>           </external-identifier>         </external-identifiers>         <synonyms>           <synonym>3.4.21.5</synonym>           <synonym>Coagulation factor II</synonym>         </synonyms>         <amino-acid-sequence format=\"FASTA\">&gt;lcl|BSEQ0016004|Prothrombin MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>         <gene-sequence format=\"FASTA\">&gt;lcl|BSEQ0016005|Prothrombin (F2) ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT GGAGAGTAG</gene-sequence>         <pfams>           <pfam>             <identifier>PF00594</identifier>             <name>Gla</name>           </pfam>           <pfam>             <identifier>PF00051</identifier>             <name>Kringle</name>           </pfam>           <pfam>             <identifier>PF00089</identifier>             <name>Trypsin</name>           </pfam>           <pfam>             <identifier>PF09396</identifier>             <name>Thrombin_light</name>           </pfam>         </pfams>         <go-classifiers>           <go-classifier>             <category>component</category>             <description>blood microparticle</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>cytosol</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>endoplasmic reticulum lumen</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular exosome</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular matrix</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular region</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>extracellular space</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>Golgi lumen</description>           </go-classifier>           <go-classifier>             <category>component</category>             <description>plasma membrane</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>calcium ion binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>growth factor activity</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>receptor binding</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>serine-type endopeptidase activity</description>           </go-classifier>           <go-classifier>             <category>function</category>             <description>thrombospondin receptor activity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>acute-phase response</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>blood coagulation, intrinsic pathway</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cell surface receptor signaling pathway</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular protein metabolic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cellular response to mechanical stimulus</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>cytosolic calcium ion homeostasis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>leukocyte migration</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>multicellular organismal development</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of astrocyte differentiation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of fibrinolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of platelet activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>negative regulation of proteolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>peptidyl-glutamic acid carboxylation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>platelet activation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of cell growth</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of cell proliferation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of collagen biosynthetic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of protein phosphorylation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of reactive oxygen species metabolic process</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>positive regulation of release of sequestered calcium ion into cytosol</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>post-translational protein modification</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>proteolysis</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>regulation of blood coagulation</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>regulation of cell shape</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>regulation of gene expression</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to inactivity</description>           </go-classifier>           <go-classifier>             <category>process</category>             <description>response to wounding</description>           </go-classifier>         </go-classifiers>       </polypeptide>     </target>   </targets>   <enzymes/>   <carriers/>   <transporters/> </drug> <'"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list1[1]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "589e74a4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s = seen_interactions[-3]\n",
    "len(re.findall(r\"reduction in efficacy\", s))>0 or len(re.findall(r\"reduced efficacy\", s))>0 or len(re.findall(r\"decreased efficacy\", s))>0 or len(re.findall(r\"decrease in efficacy\", s))>0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "id": "46af5aef",
   "metadata": {},
   "outputs": [],
   "source": [
    "no_go_words = ['emtansine', 'zirconium Zr-89.', \"(S)-\", \"busulfan\", \"acetate\", \"dienanthate\",\n",
    "               \"acetate\", \"enanthate\", \"enacarbil\", \"trevatide\", \"poliglumex\", \"isonicotinate\",\n",
    "               \"lauroxil\", \", C-11\", \"govitecan\", \"-n1\", \"-n3\", \"-2a, Recombinant\", \"con-1\", \"-2b\",\n",
    "               \"-uracil\", \"400\", \", unspecified form\"\n",
    "              ] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 227,
   "id": "901dd26a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB00001\n",
      "DB00002\n",
      "DB00003\n",
      "DB00004\n",
      "DB00005\n",
      "DB00006\n",
      "DB00007\n",
      "DB00008\n",
      "DB00009\n",
      "DB00010\n",
      "DB00011\n",
      "DB00012\n",
      "DB00013\n",
      "DB00014\n",
      "DB00015\n",
      "DB00016\n",
      "DB00017\n",
      "DB00018\n",
      "DB00019\n",
      "DB00020\n",
      "DB00022\n",
      "DB00023\n",
      "DB00024\n",
      "DB00025\n",
      "DB00026\n",
      "DB00027\n",
      "DB00028\n",
      "DB00029\n",
      "DB00030\n",
      "DB00031\n",
      "DB00032\n",
      "DB00033\n",
      "DB00034\n",
      "DB00035\n",
      "DB00036\n",
      "DB00038\n",
      "DB00039\n",
      "DB00040\n",
      "DB00041\n",
      "DB00042\n",
      "DB00043\n",
      "DB00044\n",
      "DB00045\n",
      "DB00046\n",
      "DB00047\n",
      "DB00048\n",
      "DB00049\n",
      "DB00050\n",
      "DB00051\n",
      "DB00052\n",
      "DB00053\n",
      "DB00054\n",
      "DB00055\n",
      "DB00056\n",
      "DB00057\n",
      "DB00058\n",
      "DB00059\n",
      "DB00060\n",
      "DB00061\n",
      "DB00062\n",
      "DB00063\n",
      "DB00065\n",
      "DB00066\n",
      "DB00067\n",
      "DB00068\n",
      "DB00069\n",
      "DB00070\n",
      "DB00071\n",
      "DB00072\n",
      "DB00073\n",
      "DB00074\n",
      "DB00075\n",
      "DB00076\n",
      "DB00078\n",
      "DB00080\n",
      "DB00081\n",
      "DB00082\n",
      "DB00083\n",
      "DB00085\n",
      "DB00086\n",
      "DB00087\n",
      "DB00088\n",
      "DB00089\n",
      "DB00090\n",
      "DB00091\n",
      "DB00092\n",
      "DB00093\n",
      "DB00094\n",
      "DB00095\n",
      "DB00097\n",
      "DB00098\n",
      "DB00099\n",
      "DB00100\n",
      "DB00102\n",
      "DB00103\n",
      "DB00104\n",
      "DB00105\n",
      "DB00106\n",
      "DB00107\n",
      "DB00108\n",
      "DB00109\n",
      "DB00110\n",
      "DB00111\n",
      "DB00112\n",
      "DB00113\n",
      "DB00114\n",
      "DB00115\n",
      "DB00116\n",
      "DB00117\n",
      "DB00118\n",
      "DB00119\n",
      "DB00120\n",
      "DB00121\n",
      "DB00122\n",
      "DB00123\n",
      "DB00125\n",
      "DB00126\n",
      "DB00127\n",
      "DB00128\n",
      "DB00129\n",
      "DB00130\n",
      "DB00131\n",
      "DB00132\n",
      "DB00133\n",
      "DB00134\n",
      "DB00135\n",
      "DB00136\n",
      "DB00137\n",
      "DB00138\n",
      "DB00139\n",
      "DB00140\n",
      "DB00141\n",
      "DB00142\n",
      "DB00143\n",
      "DB00144\n",
      "DB00145\n",
      "DB00146\n",
      "DB00147\n",
      "DB00148\n",
      "DB00149\n",
      "DB00150\n",
      "DB00151\n",
      "DB00152\n",
      "DB00153\n",
      "DB00154\n",
      "DB00155\n",
      "DB00156\n",
      "DB00157\n",
      "DB00158\n",
      "DB00159\n",
      "DB00160\n",
      "DB00161\n",
      "DB00162\n",
      "DB00163\n",
      "DB00165\n",
      "DB00166\n",
      "DB00167\n",
      "DB00168\n",
      "DB00169\n",
      "DB00170\n",
      "DB00171\n",
      "DB00172\n",
      "DB00173\n",
      "DB00174\n",
      "DB00175\n",
      "DB00176\n",
      "DB00177\n",
      "DB00178\n",
      "DB00179\n",
      "DB00180\n",
      "DB00181\n",
      "DB00182\n",
      "DB00183\n",
      "DB00184\n",
      "DB00185\n",
      "DB00186\n",
      "DB00187\n",
      "DB00188\n",
      "DB00189\n",
      "DB00190\n",
      "DB00191\n",
      "DB00192\n",
      "DB00193\n",
      "DB00194\n",
      "DB00195\n",
      "DB00196\n",
      "DB00197\n",
      "DB00198\n",
      "DB00199\n",
      "DB00200\n",
      "DB00201\n",
      "DB00202\n",
      "DB00203\n",
      "DB00204\n",
      "DB00205\n",
      "DB00206\n",
      "DB00207\n",
      "DB00208\n",
      "DB00209\n",
      "DB00210\n",
      "DB00211\n",
      "DB00212\n",
      "DB00213\n",
      "DB00214\n",
      "DB00215\n",
      "DB00216\n",
      "DB00217\n",
      "DB00218\n",
      "DB00219\n",
      "DB00220\n",
      "DB00221\n",
      "DB00222\n",
      "DB00223\n",
      "DB00224\n",
      "DB00225\n",
      "DB00226\n",
      "DB00227\n",
      "DB00228\n",
      "DB00229\n",
      "DB00230\n",
      "DB00231\n",
      "DB00232\n",
      "DB00233\n",
      "DB00234\n",
      "DB00235\n",
      "DB00236\n",
      "DB00237\n",
      "DB00238\n",
      "DB00239\n",
      "DB00240\n",
      "DB00241\n",
      "DB00242\n",
      "DB00243\n",
      "DB00244\n",
      "DB00245\n",
      "DB00246\n",
      "DB00247\n",
      "DB00248\n",
      "DB00249\n",
      "DB00250\n",
      "DB00251\n",
      "DB00252\n",
      "DB00253\n",
      "DB00254\n",
      "DB00255\n",
      "DB00256\n",
      "DB00257\n",
      "DB00258\n",
      "DB00259\n",
      "DB00260\n",
      "DB00261\n",
      "DB00262\n",
      "DB00263\n",
      "DB00264\n",
      "DB00265\n",
      "DB00266\n",
      "DB00267\n",
      "DB00268\n",
      "DB00269\n",
      "DB00270\n",
      "DB00271\n",
      "DB00272\n",
      "DB00273\n",
      "DB00274\n",
      "DB00275\n",
      "DB00276\n",
      "DB00277\n",
      "DB00278\n",
      "DB00279\n",
      "DB00280\n",
      "DB00281\n",
      "DB00282\n",
      "DB00283\n",
      "DB00284\n",
      "DB00285\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Input \u001b[0;32mIn [227]\u001b[0m, in \u001b[0;36m<cell line: 9>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     21\u001b[0m     type_interaction \u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m new_int\u001b[38;5;241m.\u001b[39mlower()\n\u001b[1;32m     22\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m---> 23\u001b[0m     j \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39mwhere([new_int \u001b[38;5;241m==\u001b[39m s \u001b[38;5;28;01mfor\u001b[39;00m s \u001b[38;5;129;01min\u001b[39;00m seen_interactions])[\u001b[38;5;241m0\u001b[39m][\u001b[38;5;241m0\u001b[39m]\n\u001b[1;32m     24\u001b[0m     clusters \u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m [j]\n\u001b[1;32m     26\u001b[0m it\u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m0\u001b[39m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "### Create the labels:\n",
    "type_interaction = \"\"\n",
    "seen_interactions = []\n",
    "clusters = []\n",
    "edges = []\n",
    "#### Need to create a cluster analysis\n",
    "it = 0\n",
    "new_it = 0\n",
    "for k in dictionary.keys():\n",
    "    print(k)\n",
    "    old_int = \"\"\n",
    "    if len(dictionary[k]['ddi']) > 0:\n",
    "        for key2 in dictionary[k]['ddi'].keys():\n",
    "            new_int = dictionary[k]['ddi'][key2]['description'].replace(dictionary[k]['name'], \"\")\n",
    "            new_int = new_int.replace(dictionary[k]['ddi'][key2]['name'], \"\")\n",
    "            edges += [[k, key2]]\n",
    "            if new_int not in seen_interactions:\n",
    "                seen_interactions += [new_int]\n",
    "                clusters += [new_it]\n",
    "                new_it += 1\n",
    "                type_interaction += new_int.lower()\n",
    "            else:\n",
    "                j = np.where([new_int == s for s in seen_interactions])[0][0]\n",
    "                clusters += [j]\n",
    "                \n",
    "            it+=0\n",
    "                \n",
    "#### Usef            \n",
    "type_interaction = re.split('\\W+', type_interaction.lower())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "818420cc",
   "metadata": {},
   "outputs": [],
   "source": [
    "clusters = np.array(clusters)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "6f94dc5c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(array([      2,      18,      19, ..., 2647487, 2647488, 2647489]),)"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.where(np.array(clusters) == 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "f01ab258",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[0,\n",
       " 0,\n",
       " 1,\n",
       " 2,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 3,\n",
       " 4,\n",
       " 1,\n",
       " 1,\n",
       " 0,\n",
       " 1,\n",
       " 0,\n",
       " 1,\n",
       " 0,\n",
       " 0,\n",
       " 1,\n",
       " 5,\n",
       " 4,\n",
       " 5,\n",
       " 5,\n",
       " 4,\n",
       " 4,\n",
       " 5,\n",
       " 0,\n",
       " 5,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 6,\n",
       " 7,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1,\n",
       " 1]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "representants = []\n",
    "for u in np.unique(clusters):\n",
    "    candidate = np.where(clusters == u)[0][0]\n",
    "    k, key2 = edges[candidate]\n",
    "    representants += [dictionary[k]['ddi'][key2]['description'].replace(dictionary[k]['name'], \"\")]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "76efb628",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "383"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(seen_interactions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "da12619d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "from collections import Counter\n",
    "dictionary_interactions = Counter([i for i in type_interaction if i not in stop_words and len(i)>2])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 264,
   "id": "88267a31",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 265,
   "id": "5e61da31",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>anticoagulant</th>\n",
       "      <th>activities</th>\n",
       "      <th>bleeding</th>\n",
       "      <th>hemorrhage</th>\n",
       "      <th>gastrointestinal</th>\n",
       "      <th>bruising</th>\n",
       "      <th>therapeutic</th>\n",
       "      <th>efficacy</th>\n",
       "      <th>adverse</th>\n",
       "      <th>effects</th>\n",
       "      <th>...</th>\n",
       "      <th>neuroleptic</th>\n",
       "      <th>malignant</th>\n",
       "      <th>dihydroartemisinin</th>\n",
       "      <th>mucosal</th>\n",
       "      <th>ischemic</th>\n",
       "      <th>colitis</th>\n",
       "      <th>hypothyroid</th>\n",
       "      <th>monomethyl</th>\n",
       "      <th>fumarate</th>\n",
       "      <th>hypercoagulability</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>322</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>353</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>383 rows  284 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     anticoagulant  activities  bleeding  hemorrhage  gastrointestinal  \\\n",
       "0              1.0         1.0       0.0         0.0               0.0   \n",
       "6              1.0         1.0       0.0         0.0               0.0   \n",
       "382            1.0         1.0       0.0         0.0               0.0   \n",
       "10             0.0         1.0       0.0         0.0               0.0   \n",
       "12             0.0         1.0       0.0         0.0               0.0   \n",
       "..             ...         ...       ...         ...               ...   \n",
       "273            0.0         0.0       0.0         0.0               0.0   \n",
       "257            0.0         0.0       0.0         0.0               0.0   \n",
       "266            0.0         0.0       0.0         0.0               0.0   \n",
       "322            0.0         0.0       0.0         0.0               0.0   \n",
       "353            0.0         0.0       0.0         0.0               0.0   \n",
       "\n",
       "     bruising  therapeutic  efficacy  adverse  effects  ...  neuroleptic  \\\n",
       "0         0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "6         0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "382       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "10        0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "12        0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "..        ...          ...       ...      ...      ...  ...          ...   \n",
       "273       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "257       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "266       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "322       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "353       0.0          0.0       0.0      0.0      0.0  ...          0.0   \n",
       "\n",
       "     malignant  dihydroartemisinin  mucosal  ischemic  colitis  hypothyroid  \\\n",
       "0          0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "6          0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "382        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "10         0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "12         0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "..         ...                 ...      ...       ...      ...          ...   \n",
       "273        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "257        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "266        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "322        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "353        0.0                 0.0      0.0       0.0      0.0          0.0   \n",
       "\n",
       "     monomethyl  fumarate  hypercoagulability  \n",
       "0           0.0       0.0                 0.0  \n",
       "6           0.0       0.0                 0.0  \n",
       "382         0.0       0.0                 0.0  \n",
       "10          0.0       0.0                 0.0  \n",
       "12          0.0       0.0                 0.0  \n",
       "..          ...       ...                 ...  \n",
       "273         0.0       0.0                 0.0  \n",
       "257         0.0       0.0                 0.0  \n",
       "266         0.0       0.0                 0.0  \n",
       "322         0.0       0.0                 0.0  \n",
       "353         0.0       0.0                 1.0  \n",
       "\n",
       "[383 rows x 284 columns]"
      ]
     },
     "execution_count": 265,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Y "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "id": "1a9e350b",
   "metadata": {},
   "outputs": [],
   "source": [
    "Y = pd.DataFrame.from_dict(all_int, orient= 'index').fillna(0)\n",
    "Y.values[np.where(Y.values>1)] = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "id": "e924f7d3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/5d/vnx7yths3n3f_d7862mdryz80000gn/T/ipykernel_1938/2408577597.py:1: UserWarning: Pandas doesn't allow columns to be created via a new attribute name - see https://pandas.pydata.org/pandas-docs/stable/indexing.html#attribute-access\n",
      "  Y.values = new_Y\n"
     ]
    },
    {
     "ename": "AttributeError",
     "evalue": "can't set attribute",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "File \u001b[0;32m~/anaconda3/envs/myenv/lib/python3.9/site-packages/pandas/core/generic.py:5606\u001b[0m, in \u001b[0;36mNDFrame.__setattr__\u001b[0;34m(self, name, value)\u001b[0m\n\u001b[1;32m   5605\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 5606\u001b[0m         \u001b[38;5;28;43mobject\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__setattr__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mname\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mvalue\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   5607\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m (\u001b[38;5;167;01mAttributeError\u001b[39;00m, \u001b[38;5;167;01mTypeError\u001b[39;00m):\n",
      "\u001b[0;31mAttributeError\u001b[0m: can't set attribute",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Input \u001b[0;32mIn [271]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0m Y\u001b[38;5;241m.\u001b[39mvalues \u001b[38;5;241m=\u001b[39m new_Y\n",
      "File \u001b[0;32m~/anaconda3/envs/myenv/lib/python3.9/site-packages/pandas/core/generic.py:5616\u001b[0m, in \u001b[0;36mNDFrame.__setattr__\u001b[0;34m(self, name, value)\u001b[0m\n\u001b[1;32m   5608\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(\u001b[38;5;28mself\u001b[39m, ABCDataFrame) \u001b[38;5;129;01mand\u001b[39;00m (is_list_like(value)):\n\u001b[1;32m   5609\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[1;32m   5610\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPandas doesn\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mt allow columns to be \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   5611\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcreated via a new attribute name - see \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   5614\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39mfind_stack_level(),\n\u001b[1;32m   5615\u001b[0m     )\n\u001b[0;32m-> 5616\u001b[0m \u001b[38;5;28;43mobject\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[38;5;21;43m__setattr__\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mname\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mvalue\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[0;31mAttributeError\u001b[0m: can't set attribute"
     ]
    }
   ],
   "source": [
    "Y.values = new_Y"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6d394c3f",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "len(side)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 232,
   "id": "0487c413",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(383, 284)"
      ]
     },
     "execution_count": 232,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_Y.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 233,
   "id": "40703387",
   "metadata": {},
   "outputs": [],
   "source": [
    "import scipy as sc\n",
    "distance = sc.spatial.distance.pdist(new_Y, metric='jaccard')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 327,
   "id": "2bfc72ff",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.9650704418510686"
      ]
     },
     "execution_count": 327,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import scipy as sc\n",
    "distance = sc.spatial.distance.pdist(new_Y, metric='jaccard')\n",
    "distance2 = sc.spatial.distance.squareform(distance)\n",
    "distance2.mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 235,
   "id": "b2af6066",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/cdonnat/anaconda3/envs/myenv/lib/python3.9/site-packages/seaborn/matrix.py:654: UserWarning: Clustering large matrix with scipy. Installing `fastcluster` may give better performance.\n",
      "  warnings.warn(msg)\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x720 with 4 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sb\n",
    "g = sb.clustermap(new_Y, metric='jaccard')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 295,
   "id": "23197bb2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['bleeding', 'hemorrhage']\n",
      "['bleeding', 'bruising']\n",
      "['infection', 'neutropenia']\n",
      "['myopathy', 'rhabdomyolysis', 'myoglobinuria']\n",
      "['neutropenia', 'thrombocytopenia']\n",
      "['confusion', 'irritability', 'sleep disorders']\n",
      "['hyponatremia', 'water intoxication']\n",
      "['hypertension', 'hyponatremia', 'water intoxication']\n",
      "['orthostatic hypotension', 'syncope']\n",
      "['hypotension', 'orthostatic hypotension']\n",
      "['hypotension', 'sedation', 'death', 'somnolence', 'respiratory depression']\n",
      "['renal failure', 'hypertension']\n",
      "['nephrotoxicity', 'hypocalcemia']\n",
      "['jaw osteonecrosis', 'anti-angiogenesis']\n",
      "['ventricular arrhythmias', 'cardiac arrhythmia']\n",
      "['serotonin syndrome', 'hypomania']\n",
      "['gastrointestinal bleeding', 'peptic ulcer']\n",
      "['renal failure', 'hyperkalemia', 'hypertension']\n",
      "['pseudotumor cerebri', 'elevated intracranial pressure']\n",
      "['rhabdomyolysis', 'myoglobinuria', 'elevated creatine kinase (cpk)']\n",
      "['myopathy', 'rhabdomyolysis']\n",
      "['myopathy', 'rhabdomyolysis']\n",
      "['hypotension', 'hyperkalemia', 'reduced intravascular volume']\n",
      "['renal failure', 'hypotension', 'hyperkalemia']\n",
      "['renal failure', 'hypotension']\n",
      "['hypotension', 'hyperkalemia', 'nephrotoxicity']\n",
      "['myelosuppression', 'anemia', 'severe leukopenia']\n",
      "['hypotension', 'nitritoid reactions', 'facial flushing', 'nausea', 'vomiting']\n",
      "['gastrointestinal ulceration', 'gastrointestinal irritation']\n",
      "['myopathy', 'weakness']\n",
      "['cns depression', 'hypotonia']\n",
      "['serotonin syndrome', 'opioid toxicity']\n",
      "['qtc prolongation', 'torsade de pointes', 'cardiotoxicity']\n",
      "['serotonergic', 'central nervous system depressant (cns depressant) activities']\n",
      "['serotonin syndrome', 'seizure']\n",
      "['sedative', 'stimulatory activities']\n",
      "['atrioventricular blocking (av block)', 'tachycardic activities']\n",
      "['sedation', 'somnolence']\n",
      "['congestive heart failure', 'hypotension']\n",
      "['hypertension', 'tardive dyskinesia']\n",
      "['hyperthermia', 'oligohydrosis']\n",
      "['qtc prolongation', 'serotonin syndrome']\n",
      "['qtc-prolonging', 'arrhythmogenic activities']\n",
      "['weight gain', 'edema formation']\n",
      "['ventricular arrhythmias', 'torsade de pointes']\n",
      "['qtc prolongation', 'ventricular arrhythmias']\n",
      "['qtc prolongation', 'hypotension']\n",
      "['hypotension', 'priapism']\n",
      "['hypotension', 'dyspepsia', 'headache']\n",
      "['qtc prolongation', 'torsade de pointes', 'hypokalemia', 'hypomagnesemia', 'cardiac arrest']\n",
      "['drowsiness', 'cns depression']\n",
      "['tachycardia', 'drowsiness']\n",
      "['urinary retention', 'reduced gastrointestinal motility', 'constipation']\n",
      "['bradycardic', 'atrioventricular blocking (av block)', 'arrhythmogenic activities']\n",
      "['hypertensive', 'vasoconstricting activities']\n",
      "['ototoxicity', 'nephrotoxicity']\n",
      "['hypotensive', 'electrolyte disturbance activities']\n",
      "['hypotension', 'hyperglycemia', 'hyperuricemia']\n",
      "['bleeding', 'gastrointestinal bleeding']\n",
      "['bleeding', 'nephrotoxicity', 'gastrointestinal bleeding']\n",
      "['congestive heart failure', 'bleeding', 'hypotension', 'tachycardia']\n",
      "['hypotensive', 'central nervous system depressant (cns depressant) activities']\n",
      "['orthostatic hypotensive', 'hypotensive', 'antihypertensive activities']\n",
      "['arrhythmogenic', 'cardiotoxic activities']\n",
      "['hypertension', 'tachycardia']\n",
      "['generalized seizure', 'bradycardia']\n",
      "['gastrointestinal bleeding', 'gastrointestinal ulceration']\n"
     ]
    }
   ],
   "source": [
    "all_sides  = []\n",
    "for s in side:\n",
    "    ss = s[1]\n",
    "    if \",\" in ss or \"and\" in ss:\n",
    "        d = [uu.strip()  for u in ss.split(\",\") for uu in u.split(\"and\") if len(uu.strip())>1]\n",
    "        print(d)\n",
    "        all_sides += d\n",
    "        \n",
    "    else:\n",
    "        d = ss.strip()\n",
    "        if d == 'therapeutic efficacy of':\n",
    "            d = 'therapeutic efficacy'\n",
    "        all_sides += [d]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 332,
   "id": "ecb17f9a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['anticoagulant activities',\n",
       " 'bleeding',\n",
       " 'hemorrhage',\n",
       " 'gastrointestinal bleeding',\n",
       " 'bleeding',\n",
       " 'bruising',\n",
       " 'bleeding',\n",
       " 'therapeutic efficacy',\n",
       " 'anticoagulant activities',\n",
       " 'adverse effects',\n",
       " 'therapeutic efficacy',\n",
       " 'hemorrhage',\n",
       " 'antiplatelet activities',\n",
       " 'thrombosis',\n",
       " 'thrombogenic activities',\n",
       " 'infection',\n",
       " 'infection',\n",
       " 'neutropenia',\n",
       " 'immunosuppressive activities',\n",
       " 'myelosuppression',\n",
       " 'neutropenic activities',\n",
       " 'neutropenia',\n",
       " 'metabolism',\n",
       " 'serum concentration drug',\n",
       " 'serum concentration drug',\n",
       " 'qtc-prolonging activities',\n",
       " 'reduction in efficacy',\n",
       " 'qtc prolongation',\n",
       " 'excretion rate',\n",
       " 'reduction in efficacy',\n",
       " 'myopathy',\n",
       " 'rhabdomyolysis',\n",
       " 'myoglobinuria',\n",
       " 'metabolism',\n",
       " 'cardiotoxic activities',\n",
       " 'cardiotoxicity',\n",
       " 'myelosuppressive activities',\n",
       " 'neutropenia',\n",
       " 'thrombocytopenia',\n",
       " 'hepatotoxic activities',\n",
       " 'angioedema',\n",
       " 'pulmonary toxicity',\n",
       " 'peripheral neuropathy',\n",
       " 'hypocalcemia',\n",
       " 'cardiac arrhythmia',\n",
       " 'anemia',\n",
       " 'liver damage',\n",
       " 'reduction in efficacy',\n",
       " 'confusion',\n",
       " 'irritability',\n",
       " 'sleep disorders',\n",
       " 'vasoconstricting activities',\n",
       " 'hypoglycemic activities',\n",
       " 'hypoglycemic activities',\n",
       " 'hypoglycemia',\n",
       " 'congestive heart failure',\n",
       " 'hyperglycemia',\n",
       " 'hyponatremia',\n",
       " 'antihypertensive activities',\n",
       " 'hypertension',\n",
       " 'hyponatremia',\n",
       " 'water intoxication',\n",
       " 'hypertension',\n",
       " 'hyponatremia',\n",
       " 'water intoxication',\n",
       " 'hypertensive activities',\n",
       " 'gastrointestinal motility reducing activities',\n",
       " 'orthostatic hypotension',\n",
       " 'syncope',\n",
       " 'hypotension',\n",
       " 'orthostatic hypotension',\n",
       " 'hypotensive activities',\n",
       " 'a hypersensitivity reaction',\n",
       " 'orthostatic hypotensive activities',\n",
       " 'hypotension',\n",
       " 'central nervous system depressant (cns depressant) activities',\n",
       " 'sedative activities',\n",
       " 'respiratory depression',\n",
       " 'cns depression',\n",
       " 'sedation',\n",
       " 'hypotension',\n",
       " 'sedation',\n",
       " 'death',\n",
       " 'somnolence',\n",
       " 'respiratory depression',\n",
       " 'reduction in efficacy',\n",
       " 'water intoxication',\n",
       " 'adverse effects',\n",
       " 'neutropenic activities',\n",
       " 'adverse effects',\n",
       " 'nephrotoxic activities',\n",
       " 'myopathy',\n",
       " 'increased transaminases',\n",
       " 'neuromuscular blocking activities',\n",
       " 'bradycardic activities',\n",
       " 'neuromuscular blocking activities',\n",
       " 'excretion',\n",
       " 'neurotoxic activities',\n",
       " 'nephrotoxicity',\n",
       " 'renal failure',\n",
       " 'hypertrichosis',\n",
       " 'bioavailability',\n",
       " 'hyperkalemia',\n",
       " 'renal failure',\n",
       " 'hypertension',\n",
       " 'neuromuscular blockade',\n",
       " 'nephrotoxicity',\n",
       " 'hypocalcemia',\n",
       " 'hyperkalemic activities',\n",
       " 'excretion',\n",
       " 'seizure',\n",
       " 'gouty arthritis',\n",
       " 'bioavailability',\n",
       " 'serum concentration of active metabolites',\n",
       " 'uterotonic activities',\n",
       " 'jaw osteonecrosis',\n",
       " 'anti-angiogenesis',\n",
       " 'adverse effects',\n",
       " 'serum concentration drug',\n",
       " 'cardiovascular impairment',\n",
       " 'hypercalcemic activities',\n",
       " 'ventricular arrhythmias',\n",
       " 'cardiac arrhythmia',\n",
       " 'hypercalcemia',\n",
       " 'hypokalemia',\n",
       " 'photosensitizing activities',\n",
       " 'serotonin syndrome',\n",
       " 'serotonergic activities',\n",
       " 'serotonin syndrome',\n",
       " 'hypomania',\n",
       " 'gastrointestinal bleeding',\n",
       " 'peptic ulcer',\n",
       " 'renal failure',\n",
       " 'hyperkalemia',\n",
       " 'hypertension',\n",
       " 'neuroexcitatory activities',\n",
       " 'gastrointestinal irritation',\n",
       " 'protein binding',\n",
       " 'bleeding',\n",
       " 'pseudotumor cerebri activities',\n",
       " 'pseudotumor cerebri',\n",
       " 'elevated intracranial pressure',\n",
       " 'pseudotumor cerebri',\n",
       " 'cytotoxicity',\n",
       " 'myopathic rhabdomyolysis activities',\n",
       " 'rhabdomyolysis',\n",
       " 'myoglobinuria',\n",
       " 'elevated creatine kinase (cpk)',\n",
       " 'myopathy',\n",
       " 'rhabdomyolysis',\n",
       " 'increased glucose',\n",
       " 'rhabdomyolysis',\n",
       " 'absorption',\n",
       " 'myopathy',\n",
       " 'rhabdomyolysis',\n",
       " 'hypolipidaemic activities',\n",
       " 'extrapyramidal symptoms',\n",
       " 'hypotension',\n",
       " 'hyperkalemia',\n",
       " 'reduced intravascular volume',\n",
       " 'antihypertensive activities',\n",
       " 'renal failure',\n",
       " 'hypotension',\n",
       " 'hyperkalemia',\n",
       " 'renal failure',\n",
       " 'hypotension',\n",
       " 'hypotension',\n",
       " 'hyperkalemia',\n",
       " 'nephrotoxicity',\n",
       " 'myelosuppression',\n",
       " 'anemia',\n",
       " 'severe leukopenia',\n",
       " 'hypotension',\n",
       " 'nitritoid reactions',\n",
       " 'facial flushing',\n",
       " 'nausea',\n",
       " 'vomiting',\n",
       " 'vasodilatory activities',\n",
       " 'adverse effects',\n",
       " 'angioedema',\n",
       " 'lactic acidosis',\n",
       " 'gastrointestinal ulceration',\n",
       " 'gastrointestinal irritation',\n",
       " 'ulceration',\n",
       " 'tendinopathy',\n",
       " 'hypokalemic activities',\n",
       " 'fluid retention',\n",
       " 'myopathy',\n",
       " 'weakness',\n",
       " 'edema formation',\n",
       " 'electrolyte imbalance',\n",
       " 'cns depression',\n",
       " 'hypotonia',\n",
       " 'hyperkinetic symptoms',\n",
       " 'alpha-adrenergic activities',\n",
       " 'serotonin syndrome',\n",
       " 'opioid toxicity',\n",
       " 'anticholinergic activities',\n",
       " 'qtc prolongation',\n",
       " 'torsade de pointes',\n",
       " 'cardiotoxicity',\n",
       " 'serotonergic',\n",
       " 'central nervous system depressant (cns depressant) activities',\n",
       " 'sympathomimetic activities',\n",
       " 'hypotensive activities',\n",
       " 'serotonin syndrome',\n",
       " 'seizure',\n",
       " 'analgesic activities',\n",
       " 'sedative',\n",
       " 'stimulatory activities',\n",
       " 'stimulatory activities',\n",
       " 'tachycardia',\n",
       " 'atrioventricular blocking (av block)',\n",
       " 'tachycardic activities',\n",
       " 'anticholinergic activities',\n",
       " 'sedative activities',\n",
       " 'sedation',\n",
       " 'somnolence',\n",
       " 'change in thyroid function activities',\n",
       " 'hypertension',\n",
       " 'bronchoconstrictory activities',\n",
       " 'congestive heart failure',\n",
       " 'hypotension',\n",
       " 'arrhythmogenic activities',\n",
       " 'bradycardia',\n",
       " 'qtc prolongation',\n",
       " 'hypersensitivity reaction',\n",
       " 'cardiodepressant activities',\n",
       " 'serum concentration of norepinephrine',\n",
       " 'hypertension',\n",
       " 'tardive dyskinesia',\n",
       " 'urinary retention',\n",
       " 'gastrointestinal ulceration',\n",
       " 'reduced gastrointestinal motility',\n",
       " 'hyperthermia',\n",
       " 'oligohydrosis',\n",
       " 'constipation',\n",
       " 'qtc prolongation',\n",
       " 'serotonin syndrome',\n",
       " 'serum concentration of e3174',\n",
       " 'qtc-prolonging',\n",
       " 'arrhythmogenic activities',\n",
       " 'weight gain',\n",
       " 'edema formation',\n",
       " 'ventricular arrhythmias',\n",
       " 'torsade de pointes',\n",
       " 'qtc prolongation',\n",
       " 'ventricular arrhythmias',\n",
       " 'qtc prolongation',\n",
       " 'hypotension',\n",
       " 'diuretic activities',\n",
       " 'skeletal muscle relaxing activities',\n",
       " 'hypotension',\n",
       " 'priapism',\n",
       " 'orthostatic hypotension',\n",
       " 'hypotension',\n",
       " 'dyspepsia',\n",
       " 'headache',\n",
       " 'qtc prolongation',\n",
       " 'torsade de pointes',\n",
       " 'hypokalemia',\n",
       " 'hypomagnesemia',\n",
       " 'cardiac arrest',\n",
       " 'torsade de pointes',\n",
       " 'antipsychotic activities',\n",
       " 'drowsiness',\n",
       " 'cns depression',\n",
       " 'tachycardia',\n",
       " 'drowsiness',\n",
       " 'urinary retention',\n",
       " 'reduced gastrointestinal motility',\n",
       " 'constipation',\n",
       " 'smooth muscle relaxing activities',\n",
       " 'bradycardic',\n",
       " 'atrioventricular blocking (av block)',\n",
       " 'arrhythmogenic activities',\n",
       " 'vasopressor activities',\n",
       " 'hypertensive',\n",
       " 'vasoconstricting activities',\n",
       " 'tachycardic activities',\n",
       " 'ototoxicity',\n",
       " 'nephrotoxicity',\n",
       " 'ototoxicity',\n",
       " 'diuretic activities',\n",
       " 'vasospastic reactions',\n",
       " 'bronchodilatory activities',\n",
       " 'hyperbilirubinemia',\n",
       " 'myocardial depression',\n",
       " 'hypotensive',\n",
       " 'electrolyte disturbance activities',\n",
       " 'granulocytopenia',\n",
       " 'hypotension',\n",
       " 'hyperglycemia',\n",
       " 'hyperuricemia',\n",
       " 'bleeding',\n",
       " 'gastrointestinal bleeding',\n",
       " 'bleeding',\n",
       " 'nephrotoxicity',\n",
       " 'gastrointestinal bleeding',\n",
       " 'metabolic acidosis',\n",
       " 'congestive heart failure',\n",
       " 'bleeding',\n",
       " 'hypotension',\n",
       " 'tachycardia',\n",
       " 'hypotensive',\n",
       " 'central nervous system depressant (cns depressant) activities',\n",
       " 'methemoglobinemia',\n",
       " 'orthostatic hypotensive',\n",
       " 'hypotensive',\n",
       " 'antihypertensive activities',\n",
       " 'hypertensive activities',\n",
       " 'anticonvulsant toxicity',\n",
       " 'osteomalacia',\n",
       " 'serum concentration of aripiprazole',\n",
       " 'serum concentration of active metabolites',\n",
       " 'liver enzyme elevations',\n",
       " 'arrhythmogenic',\n",
       " 'cardiotoxic activities',\n",
       " 'nephrotoxic activities',\n",
       " 'atrioventricular blocking (av block) activities',\n",
       " 'therapeutic efficacy',\n",
       " 'hypertension',\n",
       " 'tachycardia',\n",
       " 'sinus node depression',\n",
       " 'generalized seizure',\n",
       " 'bradycardia',\n",
       " 'gastrointestinal bleeding',\n",
       " 'gastrointestinal ulceration']"
      ]
     },
     "execution_count": 332,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_sides"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 299,
   "id": "4b6126bc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "184"
      ]
     },
     "execution_count": 299,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### Gigantic cluster assignment matrix to be determined.\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 328,
   "id": "d2bd7f11",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.manifold import MDS\n",
    "mds =  MDS(n_components=2, metric=True, \n",
    "           n_init=4, max_iter=300, verbose=0, eps=0.001, n_jobs=None, \n",
    "           random_state=None, dissimilarity='precomputed')\n",
    "embeds = mds.fit_transform(distance2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 329,
   "id": "3523f9ba",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['a hypersensitivity reaction', 'absorption', 'adverse effects',\n",
       "       'alpha-adrenergic activities', 'analgesic activities', 'anemia',\n",
       "       'angioedema', 'anti-angiogenesis', 'anticholinergic activities',\n",
       "       'anticoagulant activities', 'anticonvulsant toxicity',\n",
       "       'antihypertensive activities', 'antiplatelet activities',\n",
       "       'antipsychotic activities', 'arrhythmogenic',\n",
       "       'arrhythmogenic activities',\n",
       "       'atrioventricular blocking (av block)',\n",
       "       'atrioventricular blocking (av block) activities',\n",
       "       'bioavailability', 'bleeding', 'bradycardia', 'bradycardic',\n",
       "       'bradycardic activities', 'bronchoconstrictory activities',\n",
       "       'bronchodilatory activities', 'bruising', 'cardiac arrest',\n",
       "       'cardiac arrhythmia', 'cardiodepressant activities',\n",
       "       'cardiotoxic activities', 'cardiotoxicity',\n",
       "       'cardiovascular impairment',\n",
       "       'central nervous system depressant (cns depressant) activities',\n",
       "       'change in thyroid function activities', 'cns depression',\n",
       "       'confusion', 'congestive heart failure', 'constipation',\n",
       "       'cytotoxicity', 'death', 'diuretic activities', 'drowsiness',\n",
       "       'dyspepsia', 'edema formation',\n",
       "       'electrolyte disturbance activities', 'electrolyte imbalance',\n",
       "       'elevated creatine kinase (cpk)', 'elevated intracranial pressure',\n",
       "       'excretion', 'excretion rate', 'extrapyramidal symptoms',\n",
       "       'facial flushing', 'fluid retention', 'gastrointestinal bleeding',\n",
       "       'gastrointestinal irritation',\n",
       "       'gastrointestinal motility reducing activities',\n",
       "       'gastrointestinal ulceration', 'generalized seizure',\n",
       "       'gouty arthritis', 'granulocytopenia', 'headache', 'hemorrhage',\n",
       "       'hepatotoxic activities', 'hyperbilirubinemia', 'hypercalcemia',\n",
       "       'hypercalcemic activities', 'hyperglycemia', 'hyperkalemia',\n",
       "       'hyperkalemic activities', 'hyperkinetic symptoms',\n",
       "       'hypersensitivity reaction', 'hypertension', 'hypertensive',\n",
       "       'hypertensive activities', 'hyperthermia', 'hypertrichosis',\n",
       "       'hyperuricemia', 'hypocalcemia', 'hypoglycemia',\n",
       "       'hypoglycemic activities', 'hypokalemia', 'hypokalemic activities',\n",
       "       'hypolipidaemic activities', 'hypomagnesemia', 'hypomania',\n",
       "       'hyponatremia', 'hypotension', 'hypotensive',\n",
       "       'hypotensive activities', 'hypotonia',\n",
       "       'immunosuppressive activities', 'increased glucose',\n",
       "       'increased transaminases', 'infection', 'irritability',\n",
       "       'jaw osteonecrosis', 'lactic acidosis', 'liver damage',\n",
       "       'liver enzyme elevations', 'metabolic acidosis', 'metabolism',\n",
       "       'methemoglobinemia', 'myelosuppression',\n",
       "       'myelosuppressive activities', 'myocardial depression',\n",
       "       'myoglobinuria', 'myopathic rhabdomyolysis activities', 'myopathy',\n",
       "       'nausea', 'nephrotoxic activities', 'nephrotoxicity',\n",
       "       'neuroexcitatory activities', 'neuromuscular blockade',\n",
       "       'neuromuscular blocking activities', 'neurotoxic activities',\n",
       "       'neutropenia', 'neutropenic activities', 'nitritoid reactions',\n",
       "       'oligohydrosis', 'opioid toxicity', 'orthostatic hypotension',\n",
       "       'orthostatic hypotensive', 'orthostatic hypotensive activities',\n",
       "       'osteomalacia', 'ototoxicity', 'peptic ulcer',\n",
       "       'peripheral neuropathy', 'photosensitizing activities', 'priapism',\n",
       "       'protein binding', 'pseudotumor cerebri',\n",
       "       'pseudotumor cerebri activities', 'pulmonary toxicity',\n",
       "       'qtc prolongation', 'qtc-prolonging', 'qtc-prolonging activities',\n",
       "       'reduced gastrointestinal motility',\n",
       "       'reduced intravascular volume', 'reduction in efficacy',\n",
       "       'renal failure', 'respiratory depression', 'rhabdomyolysis',\n",
       "       'sedation', 'sedative', 'sedative activities', 'seizure',\n",
       "       'serotonergic', 'serotonergic activities', 'serotonin syndrome',\n",
       "       'serum concentration drug',\n",
       "       'serum concentration of active metabolites',\n",
       "       'serum concentration of aripiprazole',\n",
       "       'serum concentration of e3174',\n",
       "       'serum concentration of norepinephrine', 'severe leukopenia',\n",
       "       'sinus node depression', 'skeletal muscle relaxing activities',\n",
       "       'sleep disorders', 'smooth muscle relaxing activities',\n",
       "       'somnolence', 'stimulatory activities',\n",
       "       'sympathomimetic activities', 'syncope', 'tachycardia',\n",
       "       'tachycardic activities', 'tardive dyskinesia', 'tendinopathy',\n",
       "       'therapeutic efficacy', 'thrombocytopenia',\n",
       "       'thrombogenic activities', 'thrombosis', 'torsade de pointes',\n",
       "       'ulceration', 'urinary retention', 'uterotonic activities',\n",
       "       'vasoconstricting activities', 'vasodilatory activities',\n",
       "       'vasopressor activities', 'vasospastic reactions',\n",
       "       'ventricular arrhythmias', 'vomiting', 'water intoxication',\n",
       "       'weakness', 'weight gain'], dtype='<U61')"
      ]
     },
     "execution_count": 329,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "(np.unique([all_sides]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 330,
   "id": "1d5d1fc6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1, ' bleeding and hemorrhage', 'increased  bleeding and hemorrhage']"
      ]
     },
     "execution_count": 330,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "side[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 331,
   "id": "af12a8d0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x720 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "fig, ax = plt.subplots( figsize=(10,10))\n",
    "ax.scatter(embeds[:,0], embeds[:,1])\n",
    "index= np.random.choice(range(len(side)), 100)\n",
    "for i in range(len(side)):\n",
    "    if i in index:\n",
    "        ax.annotate(side[i][1], (embeds[i,0]+ np.random.normal(0, 0.05), embeds[i,1]+ np.random.normal(0, 0.05)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "id": "977c0d36",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.cluster import AgglomerativeClustering\n",
    "ac =AgglomerativeClustering(n_clusters=None, affinity='precomputed', memory=None, \n",
    "                            connectivity=None, compute_full_tree='auto', linkage='complete', \n",
    "                            distance_threshold=0.9, compute_distances=False)\n",
    "res = ac.fit_predict(distance2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "11f5d099",
   "metadata": {},
   "outputs": [],
   "source": [
    "res[g.dendrogram_row.reordered_ind][430:700]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3fc5683b",
   "metadata": {},
   "outputs": [],
   "source": [
    "res[g.dendrogram_row.reordered_ind][490:700]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "17805f66",
   "metadata": {},
   "outputs": [],
   "source": [
    "res[g.dendrogram_row.reordered_ind][497:700]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dad6c135",
   "metadata": {},
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "plt.plot(distance2[g.dendrogram_row.reordered_ind[500], :][g.dendrogram_row.reordered_ind])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "53bea6cd",
   "metadata": {},
   "outputs": [],
   "source": [
    "np.where(Y.iloc[85714,:]>0)[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f691451b",
   "metadata": {},
   "outputs": [],
   "source": [
    "j = g.dendrogram_row.reordered_ind[498]\n",
    "Y.iloc[j,np.where(Y.iloc[j,:]>0)[0]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4bbb7027",
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary['DB00191']['ddi']['DB00344']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e5a20263",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_Y[index[g.dendrogram_row.reordered_ind],:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "463288dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "import seaborn as sb\n",
    "sb.heatmap(distance2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c6b066a2",
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "from collections import Counter\n",
    "dictionary_interactions = Counter([i for i in type_interaction if i not in stop_words and len(i)>2])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a7c5fc6b",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "b5f92057",
   "metadata": {},
   "source": [
    "## Indication analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "bcc78453",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "eb5c5eeb",
   "metadata": {
    "id": "1k_v5fbz8tdE"
   },
   "outputs": [],
   "source": [
    "from collections import Counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a4311741",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "627d2c7d",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'parse_indication' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-11-3066b93bce67>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     15\u001b[0m             \u001b[0ms\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdictionary\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'indication'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreplace\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdictionary\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'name'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"drug\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     16\u001b[0m             \u001b[0ms\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0ms\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreplace\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdictionary\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'name'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"drug\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 17\u001b[0;31m             \u001b[0mindications\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mk\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mparse_indication\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ms\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     18\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     19\u001b[0m \u001b[0;31m#             if new_int not in seen_indications:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'parse_indication' is not defined"
     ]
    }
   ],
   "source": [
    "dictionary['DB00005']['indication']\n",
    "indication = []\n",
    "#### Need to create a cluster analysis\n",
    "it = 0\n",
    "new_it = 0\n",
    "clusters_indication = []\n",
    "seen_indications =[]\n",
    "indications = {}\n",
    "pg = []\n",
    "for k in dictionary.keys():\n",
    "    #print(k)\n",
    "    old_int = \"\"\n",
    "    if len(dictionary[k]['indication']) > 0:\n",
    "            new_int = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\")\n",
    "            s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\").lower()\n",
    "            s = s.replace(dictionary[k]['name'].lower(), \"drug\").lower()\n",
    "            indications[k] = parse_indication(s)\n",
    "\n",
    "#             if new_int not in seen_indications:\n",
    "#                 seen_indications += [new_int]\n",
    "#                 clusters_indication += [new_it]\n",
    "#                 new_it += 1\n",
    "#                 type_interaction += new_int.lower()\n",
    "#             else:\n",
    "#                 j = np.where([new_int == s for s in seen_indications])[0][0]\n",
    "#                 clusters_indication += [j]\n",
    "                \n",
    "            it+=1\n",
    "            if len(indications[k])==0: \n",
    "                print(k)\n",
    "                pg += [k]\n",
    "\n",
    "                \n",
    "#### Usef            \n",
    "#type_interaction = re.split('\\W+', type_interaction.lower())   \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 751,
   "id": "d4b7cb40",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>anticoagulant</th>\n",
       "      <th>activities</th>\n",
       "      <th>bleeding</th>\n",
       "      <th>hemorrhage</th>\n",
       "      <th>gastrointestinal</th>\n",
       "      <th>bruising</th>\n",
       "      <th>therapeutic</th>\n",
       "      <th>efficacy</th>\n",
       "      <th>adverse</th>\n",
       "      <th>effects</th>\n",
       "      <th>...</th>\n",
       "      <th>metabolic</th>\n",
       "      <th>methemoglobinemia</th>\n",
       "      <th>anticonvulsant</th>\n",
       "      <th>osteomalacia</th>\n",
       "      <th>aripiprazole</th>\n",
       "      <th>enzyme</th>\n",
       "      <th>elevations</th>\n",
       "      <th>sinus</th>\n",
       "      <th>node</th>\n",
       "      <th>generalized</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>204</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>211</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>218</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>234 rows  227 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     anticoagulant  activities  bleeding  hemorrhage  gastrointestinal  \\\n",
       "0              1.0         1.0       0.0         0.0               0.0   \n",
       "6              1.0         1.0       0.0         0.0               0.0   \n",
       "10             0.0         1.0       0.0         0.0               0.0   \n",
       "12             0.0         1.0       0.0         0.0               0.0   \n",
       "15             0.0         1.0       0.0         0.0               0.0   \n",
       "..             ...         ...       ...         ...               ...   \n",
       "204            0.0         0.0       0.0         0.0               0.0   \n",
       "208            0.0         0.0       0.0         0.0               0.0   \n",
       "211            0.0         0.0       0.0         0.0               0.0   \n",
       "218            0.0         0.0       0.0         0.0               0.0   \n",
       "222            0.0         0.0       0.0         0.0               0.0   \n",
       "\n",
       "     bruising  therapeutic  efficacy  adverse  effects  ...  metabolic  \\\n",
       "0         0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "6         0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "10        0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "12        0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "15        0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "..        ...          ...       ...      ...      ...  ...        ...   \n",
       "204       0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "208       0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "211       0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "218       0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "222       0.0          0.0       0.0      0.0      0.0  ...        0.0   \n",
       "\n",
       "     methemoglobinemia  anticonvulsant  osteomalacia  aripiprazole  enzyme  \\\n",
       "0                  0.0             0.0           0.0           0.0     0.0   \n",
       "6                  0.0             0.0           0.0           0.0     0.0   \n",
       "10                 0.0             0.0           0.0           0.0     0.0   \n",
       "12                 0.0             0.0           0.0           0.0     0.0   \n",
       "15                 0.0             0.0           0.0           0.0     0.0   \n",
       "..                 ...             ...           ...           ...     ...   \n",
       "204                0.0             0.0           0.0           0.0     0.0   \n",
       "208                0.0             0.0           0.0           0.0     0.0   \n",
       "211                0.0             0.0           0.0           0.0     0.0   \n",
       "218                1.0             0.0           0.0           0.0     0.0   \n",
       "222                0.0             0.0           1.0           0.0     0.0   \n",
       "\n",
       "     elevations  sinus  node  generalized  \n",
       "0           0.0    0.0   0.0          0.0  \n",
       "6           0.0    0.0   0.0          0.0  \n",
       "10          0.0    0.0   0.0          0.0  \n",
       "12          0.0    0.0   0.0          0.0  \n",
       "15          0.0    0.0   0.0          0.0  \n",
       "..          ...    ...   ...          ...  \n",
       "204         0.0    0.0   0.0          0.0  \n",
       "208         0.0    0.0   0.0          0.0  \n",
       "211         0.0    0.0   0.0          0.0  \n",
       "218         0.0    0.0   0.0          0.0  \n",
       "222         0.0    0.0   0.0          0.0  \n",
       "\n",
       "[234 rows x 227 columns]"
      ]
     },
     "execution_count": 751,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame.from_dict(all_int, orient= 'index').fillna(0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 752,
   "id": "070dc3cb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'DB00001': ['the treatment of heparin-induced thrombocytopenia'],\n",
       " 'DB00002': ['egfr-expressing, metastatic colorectal carcinoma',\n",
       "  'the treatment of egfr-expressing, metastatic colorectal carcinoma',\n",
       "  'combination with irinotecan, is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy.',\n",
       "  'egfr-expressing, metastatic colorectal carcinoma',\n",
       "  'the treatment of egfr-expressing, metastatic colorectal carcinoma'],\n",
       " 'DB00003': ['cystic fibrosis.',\n",
       "  'adjunct therapy for the treatment of cystic fibrosis.'],\n",
       " 'DB00004': ['the treatment of cutaneous t-cell lymphoma'],\n",
       " 'DB00005': ['moderately to severely active rheumatoid arthritis',\n",
       "  'chronic moderate to severe plaque psoriasis',\n",
       "  'the treatment of moderately to severely active rheumatoid arthritis',\n",
       "  'chronic moderate to severe plaque psoriasis',\n",
       "  'polyarticular idiopathic arthritis',\n",
       "  'manage signs and symptoms of polyarticular idiopathic arthritis',\n",
       "  'psoriatic arthritis and ankylosing spondylitis.',\n",
       "  'manage symptoms of psoriatic arthritis and ankylosing spondylitis.'],\n",
       " 'DB00006': ['the treatment of heparin-induced thrombocytopenia .',\n",
       "  'thrombosis.',\n",
       "  'use',\n",
       "  'use in patients undergoing percutaneous coronary intervention (pci), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-st segment elevation in whom a pci is planned.',\n",
       "  'patients undergoing percutaneous coronary intervention (pci), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-st segment elevation in whom a pci is planned.'],\n",
       " 'DB00007': ['advanced prostate cancer.',\n",
       "  'the treatment of advanced prostate cancer.',\n",
       "  'patients with central precocious puberty (cpp).',\n",
       "  'central precocious puberty (cpp).',\n",
       "  'symptoms of endometriosis.',\n",
       "  'the treatment of symptoms of endometriosis.',\n",
       "  'the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).',\n",
       "  'the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).'],\n",
       " 'DB00008': ['drug is indicated as a monotherapy for adult patients with hbeag positive and hbeag negative chronic hepatitis b infection who have compensated liver disease and evidence of viral replication and liver inflammation ',\n",
       "  'hcv in combination with other antiviral drugs',\n",
       "  'the treatment of hcv in combination with other antiviral drugs',\n",
       "  'a monotherapy in patients with contraindications to or significant'],\n",
       " 'DB00009': ['management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli'],\n",
       " 'DB00010': ['the treatment of dwarfism, prevention of hiv-induced weight loss'],\n",
       " 'DB00011': ['the treatment of venereal or genital warts caused by the human papiloma virus'],\n",
       " 'DB00012': ['the treatment of anemia (from renal transplants or certain hiv treatment)'],\n",
       " 'DB00013': ['lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.',\n",
       "  'lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.'],\n",
       " 'DB00014': [' for the treatment of advanced carcinoma of the prostate',\n",
       "  ' - use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding',\n",
       "  'advanced carcinoma of the prostate&#13; for the management of endometriosis&#13; - use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding&#13; - use in the treatment of advanced breast cancer in pre- and perimenopausal women',\n",
       "  'locally confined carcinoma of the prostate&#13; for the treatment of advanced carcinoma of the prostate&#13; for the management of endometriosis&#13; - use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding&#13; - use in the treatment of advanced breast cancer in pre- and perimenopausal women'],\n",
       " 'DB00015': ['lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.'],\n",
       " 'DB00016': [' for the treatment of anemia due to zidovudine in patients with hiv-infection. ',\n",
       "  'anemia due to chronic kidney disease (ckd)',\n",
       "  'anemia due to zidovudine',\n",
       "  'anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.',\n",
       "  'allogeneic rbc transfusions in patients undergoing elective, noncardiac, nonvascular surgery.'],\n",
       " 'DB00017': [\"symptomatic paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments.\",\n",
       "  \"the treatment of symptomatic paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments.\",\n",
       "  'emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified.',\n",
       "  'patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves.',\n",
       "  'post-menopausal osteoporosis in women more than 5 years post-menopause.'],\n",
       " 'DB00018': ['the intralesional treatment of refractory or recurring external condylomata acuminata.'],\n",
       " 'DB00019': ['it is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)',\n",
       "  'decrease the incidence of infection, as manifested by febrile neutropenia,',\n",
       "  'the incidence of infection, as manifested by febrile neutropenia, in patients with non\\xad myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia',\n",
       "  'increase survival',\n",
       "  'survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)'],\n",
       " 'DB00020': ['the treatment of cancer and bone marrow transplant'],\n",
       " 'DB00022': ['hcv in combination with .',\n",
       "  'the treatment of hcv in combination with .',\n",
       "  'a monotherapy in patients with contraindications to or significant'],\n",
       " 'DB00023': ['patients with acute lymphoblastic leukemia (all) .',\n",
       "  'acute lymphoblastic leukemia (all) .'],\n",
       " 'DB00024': ['detection of residueal or recurrent thyroid cancer'],\n",
       " 'DB00025': ['the treatment of hemophilia a, von willebrand disease and factor xiii deficiency.'],\n",
       " 'DB00026': ['the treatment of adult rheumatoid arthritis and treatment of neonatal-onset multisystem inflammatory disease (nomid).'],\n",
       " 'DB00027': ['the treatment of skin lesions, surface wounds and eye infections.'],\n",
       " 'DB00028': ['immunodeficiencies, as well as autoimmune and inflammatory disorders.',\n",
       "  'the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.'],\n",
       " 'DB00029': ['lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction'],\n",
       " 'DB00030': ['improve glycemic control',\n",
       "  'glycemic control in adults and patients with diabetes mellitus'],\n",
       " 'DB00031': ['the treatment of myocardial infarction and lysis of intracoronary emboli'],\n",
       " 'DB00032': ['the treatment of female infertility'],\n",
       " 'DB00033': ['chronic granulomatous disease and osteopetrosis.',\n",
       "  'the treatment of chronic granulomatous disease and osteopetrosis.'],\n",
       " 'DB00034': [\"the treatment of chronic hepatitis c, hairy cell leukemia, aids-related kaposi's sarcoma, and chronic myelogenous leukemia.\",\n",
       "  'oral warts arising from hiv infection.'],\n",
       " 'DB00035': ['- indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral)',\n",
       "  \"- indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% or mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral)\",\n",
       "  'nocturia due to nocturnal polyuria',\n",
       "  'the treatment of nocturia due to nocturnal polyuria',\n",
       "  'central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).',\n",
       "  \"patients with hemophilia a with factor viii coagulant activity levels greater than 5% or mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).\"],\n",
       " 'DB00036': ['the treatment of hemorrhagic complications in hemophilia a and b.'],\n",
       " 'DB00038': ['the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy',\n",
       "  'severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.'],\n",
       " 'DB00039': ['the treatment of oral mucositis associated with chemotherapy and radiation therapy.'],\n",
       " 'DB00040': ['severe hypoglycemia.',\n",
       "  'the movement of the gastrointestinal tract',\n",
       "  'the movement of the gastrointestinal tract and to treat severe hypoglycemia'],\n",
       " 'DB00041': ['the treatment of adults with metastatic renal cell carcinoma.'],\n",
       " 'DB00042': ['the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.'],\n",
       " 'DB00043': [' with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids .fda label]'],\n",
       " 'DB00044': ['the treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound lh deficiency (lh &lt;1.'],\n",
       " 'DB00045': ['prophylactic treatment of lyme disease'],\n",
       " 'DB00046': ['improve glycemic control',\n",
       "  'glycemic control in adults and children with diabetes mellitus'],\n",
       " 'DB00047': ['improve glycemic control',\n",
       "  'glycemic control in adults and patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus'],\n",
       " 'DB00048': [\"adults with dupuytren's contracture with a palpable cord.\",\n",
       "  \"the treatment of adults with dupuytren's contracture with a palpable cord.\",\n",
       "  \"dupuytren's contracture with a palpable cord.\",\n",
       "  \"men with peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques.\",\n",
       "  \"treat men with peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy\",\n",
       "  'the tissue debridement of chronic dermal ulcers and severely burned tissues.',\n",
       "  'moderate to severe cellulite in the buttocks of adult women.',\n",
       "  'the treatment of moderate to severe cellulite in the buttocks of adult women.'],\n",
       " 'DB00049': ['the treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)'],\n",
       " 'DB00050': ['the inhibition of premature lh surges in women undergoing controlled ovarian stimulation'],\n",
       " 'DB00051': ['rheumatoid arthritis (moderate to severe)',\n",
       "  'psoriatic arthritis (active)',\n",
       "  'crohns disease (moderately to severely active)',\n",
       "  'plaque psoriasis (moderate to severe chronic)',\n",
       "  'hidradenitis suppurativa (moderate to severe)'],\n",
       " 'DB00052': ['the treatment of dwarfism, acromegaly and prevention of hiv-induced weight loss'],\n",
       " 'DB00053': [\"the treatment of gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00054': ['cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.'],\n",
       " 'DB00055': ['reduction of mortality in patients with severe sepsis.'],\n",
       " 'DB00056': ['patients with cd33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy.',\n",
       "  'the treatment of patients with cd33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy.',\n",
       "  'cd33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy.',\n",
       "  'patients aged 2 years and older with cd33-positive aml who have experienced a relapse or who have not responded to treatment (refractory).',\n",
       "  'the treatment of patients aged 2 years and older with cd33-positive aml who have experienced a relapse or who have not responded to treatment (refractory).'],\n",
       " 'DB00057': ['diagnosis of extrahepatic malignant cancers'],\n",
       " 'DB00058': ['chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (a1-pi) deficiency and clinical evidence of emphysema.'],\n",
       " 'DB00059': ['the treatment of acute lymphoblastic leukemia'],\n",
       " 'DB00060': ['the treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum'],\n",
       " 'DB00061': ['the treatment of adenosine deaminase deficiency'],\n",
       " 'DB00062': ['adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass .'],\n",
       " 'DB00063': ['the treatment of myocardial infarction and acute coronary syndrome.'],\n",
       " 'DB00065': [' * indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **crohns disease**. ',\n",
       "  ' * indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**. ',\n",
       "  ' * indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**. ',\n",
       "  'reducing signs and symptoms and inducing and maintaining clinical remission',\n",
       "  'reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure',\n",
       "  'signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ( 6 years of age) patients with moderately to severely active **crohns disease** who have had an inadequate response to conventional therapy&#13; * indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **crohns disease**',\n",
       "  'reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use',\n",
       "  'signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric ( 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy',\n",
       "  'reducing signs and symptoms',\n",
       "  'signs and symptoms in patients with active **ankylosing spondylitis**',\n",
       "  'reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function',\n",
       "  'signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**',\n",
       "  'adult patients with chronic severe (i.',\n",
       "  'the treatment of adult patients with chronic severe (i.'],\n",
       " 'DB00066': ['in ovulation and fertility',\n",
       "  'in ovulation and fertility',\n",
       "  'combination with human chorionic gonadotropin (hcg) to assist in ovulation and fertility.',\n",
       "  'spermatogenesis',\n",
       "  'induce spermatogenesis.',\n",
       "  'the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or in vitro fertilization (ivf)',\n",
       "  'the ovary to produce several follicles',\n",
       "  'cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or',\n",
       "  'gamete intrafallopian transfer (gift) or in vitro fertilization (ivf).'],\n",
       " 'DB00067': ['the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding'],\n",
       " 'DB00068': ['relapsing/remitting multiple sclerosis.',\n",
       "  'the treatment of relapsing/remitting multiple sclerosis.',\n",
       "  'the frequency of attacks'],\n",
       " 'DB00069': [\"the treatment of hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma\"],\n",
       " 'DB00070': ['increase of absorption and distribution of other injected drugs and for rehydration.'],\n",
       " 'DB00071': ['the treatment of type i and ii diabetes mellitus.'],\n",
       " 'DB00072': ['drug is indicated as a first-line treatment, in combination with paclitaxel, for metastatic her2-overexpressing breast cancer, and as monotherapy in patients who have previously received one or more chemotherapy regimens in the metastatic setting',\n",
       "  'drug is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease',\n",
       "  'drug is indicated for subcutaneous administration - in combination with either ',\n",
       "  'the adjuvant treatment of her2-overexpressing breast cancer, drug is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based therapy.',\n",
       "  'patients with her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.',\n",
       "  'her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.',\n",
       "  'subcutaneous administration - in combination with either .',\n",
       "  'subcutaneous administration - in combination with either .',\n",
       "  'adults with her-2 positive breast cancers.',\n",
       "  'her-2 positive breast cancers.'],\n",
       " 'DB00073': ['nonhodgkins lymphoma (nhl)',\n",
       "  'rheumatoid arthritis (ra) in combination with methotrexate in adult patients with moderately-to severely-active ra',\n",
       "  'moderate to severe pemphigus vulgaris (pv) in adult patients',\n",
       "  'in september 2019, the drug injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis (gpa) in addition to microscopic polyangiitis (mpa) in children of at least 2 years of age ',\n",
       "  'adult patients with cd20-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy .',\n",
       "  'the treatment of adult patients with cd20-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy .',\n",
       "  'a single agent or'],\n",
       " 'DB00074': ['prophylactic treatment of kidney transplant rejection'],\n",
       " 'DB00075': ['the treatment of organ transplant recipients, prevention of organ rejection'],\n",
       " 'DB00076': ['the treatment of digitoxin overdose or digitalis glycoside toxicity.'],\n",
       " 'DB00078': [\"the treatment of non-hodgkin's lymphoma\"],\n",
       " 'DB00080': ['the treatment of complicated skin and skin structure infections caused by susceptible strains of gram-positive microorganisms.'],\n",
       " 'DB00081': [\"the treatment of non-hodgkin's lymphoma (cd20 positive, follicular)\"],\n",
       " 'DB00082': ['acromegaly.', 'the treatment of acromegaly.'],\n",
       " 'DB00083': ['the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.',\n",
       "  'severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or vii nerve disorders',\n",
       "  'the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or vii nerve disorders',\n",
       "  'excessive underarm sweating.',\n",
       "  'the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating'],\n",
       " 'DB00085': ['pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.',\n",
       "  'the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.'],\n",
       " 'DB00086': ['the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae'],\n",
       " 'DB00087': ['b-cell chronic lymphocytic leukemia.',\n",
       "  'the treatment of b-cell chronic lymphocytic leukemia.'],\n",
       " 'DB00088': [\"the treatment of gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00089': ['diagnosis of prostate cancer and detection of intra-pelvic metastases.'],\n",
       " 'DB00090': ['the treatment of mucopolysaccharidosis'],\n",
       " 'DB00091': ['secondly, drug is used for the treatment of patients with severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone',\n",
       "  'off-label, drug is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura',\n",
       "  'bone marrow transplant rejection.',\n",
       "  'prevent bone marrow transplant rejection.',\n",
       "  'conjunction with azathioprine and corticosteroids.',\n",
       "  'patients who have chronic transplant rejection and have received previous immunosuppressive therapy.',\n",
       "  'or treat graft-versus-host disease (gvhd).',\n",
       "  'patients with severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone.',\n",
       "  'the treatment of patients with severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone.',\n",
       "  'severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone.',\n",
       "  'adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.',\n",
       "  'the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.',\n",
       "  'increase tear production',\n",
       "  'tear production in patients suffering from keratoconjunctivitis sicca',\n",
       "  'steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.',\n",
       "  'various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.',\n",
       "  'the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.'],\n",
       " 'DB00092': ['moderate to severe chronic plaque psoriasis',\n",
       "  'the treatment of moderate to severe chronic plaque psoriasis'],\n",
       " 'DB00093': ['use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.'],\n",
       " 'DB00094': ['the treatment of female infertility'],\n",
       " 'DB00095': ['the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.'],\n",
       " 'DB00097': ['the treatment of female infertility'],\n",
       " 'DB00098': ['prevention of renal transplant rejection'],\n",
       " 'DB00099': [' in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever .fda label]. ',\n",
       "  ' reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia (aml) .fda label]',\n",
       "  ' reduce the duration of neutropenia and neutropenia-related clinical sequelae e.g. febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (bmt) .fda label]',\n",
       "  ' mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis .fda label]',\n",
       "  ' reduce the incidence and duration of sequelae of severe neutropenia (e.g. fever infections oropharyngeal ulcers) in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia .fda label].',\n",
       "  'patients with radiation-induced myelosuppression following a radiological/nuclear incident .',\n",
       "  'radiation-induced myelosuppression following a radiological/nuclear incident .'],\n",
       " 'DB00100': ['the treatment of hemophilia (christmas disease).'],\n",
       " 'DB00102': ['topical treatment of skin ulcers (from diabetes)'],\n",
       " 'DB00103': ['fabry disease.', 'the treatment of fabry disease.'],\n",
       " 'DB00104': ['acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (vipoma) tumors.',\n",
       "  'the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (vipoma) tumors.',\n",
       "  'the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable drug and .'],\n",
       " 'DB00105': [\"the treatment of hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma.\"],\n",
       " 'DB00106': ['treatment of advanced prostate cancer.'],\n",
       " 'DB00107': ['labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability.'],\n",
       " 'DB00108': ['the treatment of multiple sclerosis.'],\n",
       " 'DB00109': ['hiv-1/aids.',\n",
       "  'combination therapy for the treatment of hiv-1/aids.'],\n",
       " 'DB00110': ['prophylaxis of respiratory diseases casued by respiratory syncytial virus.'],\n",
       " 'DB00111': ['prevention of renal transplant rejection'],\n",
       " 'DB00112': ['interestingly, drug is currently under investigation for the treatment of covid-19 complications including acute respiratory distress syndrome (ards) and acute lung injury (ali)',\n",
       "  'metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; and fallopian tube cancer.',\n",
       "  'several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; and fallopian tube cancer.',\n",
       "  'recurrent glioblastoma.',\n",
       "  'treat recurrent glioblastoma.',\n",
       "  'covid-19 complications including acute respiratory distress syndrome (ards) and acute lung injury (ali).'],\n",
       " 'DB00113': ['imaging colorectal tumors'],\n",
       " 'DB00114': ['nutritional supplementation and for treating dietary shortage or imbalance.'],\n",
       " 'DB00115': [' **nasal spray**',\n",
       "  ' the drug nasal spray is indicated for the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy in patients with deficiency of this vitamin who have no nervous system involvement .fda label].',\n",
       "  ' note:  calomist .fda label], the nasal spray form, has not been evaluated for the treatment of newly diagnosed vitamin b12 deficiency.',\n",
       "  ' **injection forms (subcutaneous, intramuscular)**',\n",
       "  ' these forms are indicated for vitamin b12 deficiencies due to various causes, with or without neurologic manifestations .f3736].  vitamin b12 deficiency is frequently caused by malabsorption, which is often associated with the following conditions .l5545]:',\n",
       "  ' addisonian (pernicious) anemia',\n",
       "  ' gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy',\n",
       "  ' fish tapeworm infestation',\n",
       "  ' malignancy of the pancreas or bowel',\n",
       "  ' folic acid deficiency',\n",
       "  'the maintenance of vitamin b12 concentrations after normalization with intramuscular vitamin b12 therapy',\n",
       "  'newly diagnosed vitamin b12 deficiency.',\n",
       "  'vitamin b12 deficiencies due to various causes, with or without neurologic manifestations .'],\n",
       " 'DB00116': ['nutritional supplementation, also for treating dietary shortage or imbalance.'],\n",
       " 'DB00117': ['some immunomodulatory as well as antioxidant',\n",
       "  'use in some with rheumatoid arthritis.',\n",
       "  'some with rheumatoid arthritis.',\n",
       "  'anemia or uremia or for lowering serum cholesterol.',\n",
       "  'the treatment of anemia or uremia or for lowering serum cholesterol.'],\n",
       " 'DB00118': ['depression, liver disorders, fibromyalgia, and osteoarthritis.',\n",
       "  'a drug'],\n",
       " 'DB00119': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00120': ['vitiligo.'],\n",
       " 'DB00121': ['nutritional supplementation, also for treating dietary shortage or imbalance.'],\n",
       " 'DB00122': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00123': ['putative anti-herpes simplex virus', 'some anti-osteoporotic'],\n",
       " 'DB00125': ['nutritional supplementation, also for treating dietary shortage or imbalance.',\n",
       "  'dietary shortage or imbalance'],\n",
       " 'DB00126': ['vitamin c deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant.',\n",
       "  'treat vitamin c deficiency, scurvy, delayed wound and bone healing, urine acidification, and'],\n",
       " 'DB00127': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00128': 'None',\n",
       " 'DB00129': ['nutritional supplementation, also for treating dietary shortage or imbalance.',\n",
       "  'dietary shortage or imbalance'],\n",
       " 'DB00130': ['used to reduce the acute complications of sickle cell disease in adult and patients 5 years of age and older ',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance.',\n",
       "  'dietary shortage or imbalance',\n",
       "  'the acute complications of sickle cell disease in adult and patients 5 years of age and older ',\n",
       "  'reduce the acute complications of sickle cell disease'],\n",
       " 'DB00131': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00132': ['nutritional supplementation and for treating dietary shortage or imbalance.'],\n",
       " 'DB00133': ['a natural moisturizing agent'],\n",
       " 'DB00134': ['protein synthesis including the formation of same, l-homocysteine, l-cysteine, taurine, and sulfate.'],\n",
       " 'DB00135': ['an effective antidepressant',\n",
       "  'stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies'],\n",
       " 'DB00136': ['hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis.',\n",
       "  'vitamin d deficiency or insufficiency, refractory rickets (vitamin d resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis.',\n",
       "  'treat vitamin d deficiency or insufficiency, refractory rickets (vitamin d resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy',\n",
       "  'conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.'],\n",
       " 'DB00137': ['dietary shortage or imbalance'],\n",
       " 'DB00138': ['any of these conditions.'],\n",
       " 'DB00139': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00140': ['the treatment of adrugosis (vitamin b2 deficiency).'],\n",
       " 'DB00141': ['the treatment and prevention of osteoarthritis, by itself or in combination with chondroitin sulfate.'],\n",
       " 'DB00142': [],\n",
       " 'DB00143': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00144': [\"cognitive impairment, including alzheimer's disease, age-associated memory impairment and some non-alzheimer's dementias\",\n",
       "  'immune enhancement or for reduction of exercise stress.'],\n",
       " 'DB00145': ['antispastic', 'antipsychotic'],\n",
       " 'DB00146': ['hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis.',\n",
       "  'vitamin d deficiency or insufficiency, refractory rickets (vitamin d resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis.',\n",
       "  'treat vitamin d deficiency or insufficiency, refractory rickets (vitamin d resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy',\n",
       "  'conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.'],\n",
       " 'DB00147': ['nutritional supplementation and for treating dietary shortage or imbalances.',\n",
       "  'dietary shortage or imbalances'],\n",
       " 'DB00148': ['nutritional supplementation, also for treating dietary shortage or imbalance.'],\n",
       " 'DB00149': ['assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress.',\n",
       "  'in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress',\n",
       "  'in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress'],\n",
       " 'DB00150': ['serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight'],\n",
       " 'DB00151': ['the prevention of liver damage and kidney damage associated with overdoses of acetaminophen'],\n",
       " 'DB00152': [\"the treatment of drug and niacin deficiency states, korsakov's alcoholic psychosis, wernicke-korsakov syndrome, delirium, and peripheral neuritis.\"],\n",
       " 'DB00153': ['hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands',\n",
       "  'rickets is a condition produced due to a deficiency in vitamin d, calcium or phosphorus',\n",
       "  'familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin d metabolism in the kidneys',\n",
       "  'hypoparathyroidism, refractory rickets, and familial hypophosphatemia.',\n",
       "  'the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.'],\n",
       " 'DB00154': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00155': ['nutritional supplementation, also for treating dietary shortage or imbalance.',\n",
       "  'dietary shortage or imbalance'],\n",
       " 'DB00156': [],\n",
       " 'DB00157': [\"parkinson's disease, chronic fatigue syndrome, alzheimer's disease and cardiovascular disease\"],\n",
       " 'DB00158': ['drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.',\n",
       "  'the treatment of drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.'],\n",
       " 'DB00159': ['lowering elevated triglycerides in those who are hyperglyceridemic.'],\n",
       " 'DB00160': ['protein synthesis.'],\n",
       " 'DB00161': [],\n",
       " 'DB00162': ['the treatment of drug deficiency.'],\n",
       " 'DB00163': ['drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet.',\n",
       "  'the treatment of drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet.'],\n",
       " 'DB00165': ['vitamin b6 deficiency and for the prophylaxis of .',\n",
       "  'the treatment of vitamin b6 deficiency and for the prophylaxis of .',\n",
       "  'nausea and vomiting in pregnancy in a combination product with .'],\n",
       " 'DB00166': ['nutritional supplementation, also for treating dietary shortage or imbalance.'],\n",
       " 'DB00167': ['antihepatic encephalopathy',\n",
       "  'anticatabolic and antitardive dyskinesia'],\n",
       " 'DB00168': ['a diet supplement and sugar substitute.'],\n",
       " 'DB00169': ['concurrently, as one of the most commonly utilized forms of vitamin d, drug is very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others ',\n",
       "  'specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia .',\n",
       "  'the treatment of specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia .',\n",
       "  'vitamin d deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others .',\n",
       "  'a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin d deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d'],\n",
       " 'DB00170': ['in the normal clotting of blood, but it may also play a role in normal bone calcification',\n",
       "  'in the normal clotting of blood, but it may also play a role in normal bone calcification'],\n",
       " 'DB00171': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00172': [],\n",
       " 'DB00173': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00174': ['nutritional supplementation, also for treating dietary shortage or imbalance.',\n",
       "  'dietary shortage or imbalance'],\n",
       " 'DB00175': [' - patients with elevated serum triglycerides including type iv hyperlipidemia.',\n",
       "  'primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease.',\n",
       "  'primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease.',\n",
       "  'a secondary prevention agent for cardiovascular events',\n",
       "  'patients with primary dysbetalipoproteinemia (type iii hyperlipidemia).',\n",
       "  'treat patients with primary dysbetalipoproteinemia (type iii hyperlipidemia).'],\n",
       " 'DB00176': ['depression and for obsessive compulsive disorder (ocd) .',\n",
       "  'bulimia nervosa .',\n",
       "  'the management of bulimia nervosa .'],\n",
       " 'DB00177': ['hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.',\n",
       "  'the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.',\n",
       "  'the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions',\n",
       "  'heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate.',\n",
       "  'the treatment of heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate.'],\n",
       " 'DB00178': ['mild to severe hypertension.',\n",
       "  'cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction',\n",
       "  'reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial',\n",
       "  'the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events',\n",
       "  'slow the progression of renal disease in'],\n",
       " 'DB00179': ['actinic keratoses (precancerous skin growths that can become malignant if left untreated).',\n",
       "  'the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).'],\n",
       " 'DB00180': ['the maintenance treatment of asthma as a prophylactic therapy.'],\n",
       " 'DB00181': ['patients receiving this drug should have reversible spasticity for drug to promote the restoration of residual function',\n",
       "  'the restoration of residual function',\n",
       "  'skeletal muscle spasm caused by rheumatic disorders.',\n",
       "  'the treatment of skeletal muscle spasm caused by rheumatic disorders.'],\n",
       " 'DB00182': ['adhd is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome',\n",
       "  'on the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness',\n",
       "  'drug is being used nowadays off-label for the treatment of obesity, depression and chronic pain',\n",
       "  'attention-deficit/hyperactivity disorders (adhd) as well as for the treatment of central nervous system disorders such as narcolepsy.',\n",
       "  'the treatment of attention-deficit/hyperactivity disorders (adhd) as well as for the treatment of central nervous system disorders such as narcolepsy.',\n",
       "  'obesity, depression and chronic pain.'],\n",
       " 'DB00183': ['a diagnostic aid for evaluation of gastric acid secretory function'],\n",
       " 'DB00184': ['the relief of drug withdrawal symptoms and as an aid to smoking cessation.'],\n",
       " 'DB00185': [\"the treatment of symptoms of dry mouth in patients with sj&amp;ouml;gren's syndrome.\"],\n",
       " 'DB00186': ['some off-label indications of drug include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia',\n",
       "  'status epilepticus.',\n",
       "  'anxiety or to produce sedation/amnesia and for the treatment of status epilepticus',\n",
       "  'an anesthesia premedication'],\n",
       " 'DB00187': ['the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable.',\n",
       "  'noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.'],\n",
       " 'DB00188': ['adult patients with multiple myeloma or mantle cell lymphoma.',\n",
       "  'the treatment of adult patients with multiple myeloma or mantle cell lymphoma.'],\n",
       " 'DB00189': ['short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.',\n",
       "  'insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.'],\n",
       " 'DB00190': ['the combination therapy is administered for the reduction of ',\n",
       "  'the product of drug should be used in patients where the combination therapy of drug/',\n",
       "  'as well drug can be used in patients where the dosages of drug and ',\n",
       "  'symptoms of idiopathic parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.',\n",
       "  'patients where the combination therapy of drug/.',\n",
       "  'patients where the dosages of drug and .'],\n",
       " 'DB00191': ['exogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants',\n",
       "  'exogenous obesity for patients with an initial body mass index (bmi) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia.'],\n",
       " 'DB00192': ['the treatment of life-threatening dysrhythmias and sustained ventricular tachycardia.'],\n",
       " 'DB00193': ['drug is used off-label for the treatment of premature ejaculation',\n",
       "  'moderate to severe pain in adults.',\n",
       "  'premature ejaculation.'],\n",
       " 'DB00194': ['the treatment of chickenpox - varicella, herpes zoster and herpes simplex'],\n",
       " 'DB00195': ['hypertension.'],\n",
       " 'DB00196': ['  2) systemic candida infections',\n",
       "  '  4) cryptococcal meningitis',\n",
       "  '  6) peritonitis (inflammation of the peritoneum) caused by candida',\n",
       "  ' **a note on fungal infection prophylaxis**',\n",
       "  ' patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive drug as prophylactic therapy..l11043]',\n",
       "  ' **a note on laboratory testing**',\n",
       "  ' obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting drug therapy in order to isolate the organisms to be eliminated through treatment. it is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary..l11043]',\n",
       "  'the following fungal infections.'],\n",
       " 'DB00197': ['the treatment of type ii diabetes mellitus.'],\n",
       " 'DB00198': ['drug is indicated for the prophylaxis of influenza in patients one year and older ',\n",
       "  'acute, uncomplicated illness due to influenza a and b infection',\n",
       "  'the treatment of acute, uncomplicated illness due to influenza a and b infection',\n",
       "  'the prophylaxis of influenza',\n",
       "  'the prophylaxis of influenza in patients one year and older .',\n",
       "  'post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak.'],\n",
       " 'DB00199': [' drug is indicated for the treatment of infections caused by susceptible strains of various bacteria..l7261] the indications for drug have been summarized by body system below:',\n",
       "  ' **respiratory infections**',\n",
       "  ' mild to moderate upper respiratory tract infections caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with drug..l7261] mild to moderate lower-respiratory tract infections due to susceptible strains of streptococcus pneumoniae or streptococcus pyogenes may also be treated. drug treats listeriosis caused by listeria monocytogenes may also be treated with drug..l7261]',\n",
       "  ' **skin infections**',\n",
       "  ' mild to moderate skin or skin structure infections caused by streptococcus pyogenes or staphylococcus aureus may be treated with drug, however, resistant staphylococcal organisms may emerge..l7261] drug can also be used to treat erythrasma, an infectious condition caused by corynebacterium minutissimum..l7261]',\n",
       "  ' **genital infections/stis**',\n",
       "  ' drug can be used as an alternative drug in treating acute pelvic inflammatory disease caused by n. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin..l7261] syphilis, caused by treponema pallidum, can be treated with drug.  it serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. drug can also be used in the primary stage of primary syphilis..l7261] another approved indication of drug is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. it is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by chlamydia trachomatis..l7261] drug can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. finally, drug is indicated to treat nongonococcal urethritis due to ureaplasma urealyticum..l7261]',\n",
       "  'infections caused by susceptible strains of various bacteria.',\n",
       "  'the treatment of infections caused by susceptible strains of various bacteria.',\n",
       "  'treat pertussis (whooping cough) caused by bordetella pertussis.',\n",
       "  'pertussis (whooping cough) caused by bordetella pertussis.',\n",
       "  'treat diphtheria and other infections due to corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers.',\n",
       "  'carrier status and to eradicate the organism in existing carriers.',\n",
       "  'diphtheria and other infections due to corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers.',\n",
       "  'rheumatic fever in penicillin intolerant patients.',\n",
       "  'prevent rheumatic fever in penicillin',\n",
       "  'erythrasma, an infectious condition caused by corynebacterium minutissimum.',\n",
       "  'treat erythrasma, an',\n",
       "  'acute pelvic inflammatory disease caused by n',\n",
       "  'an alternative drug in treating acute pelvic',\n",
       "  'the primary stage of primary syphilis.',\n",
       "  'chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy.',\n",
       "  'uncomplicated rectal, urethral and endocervical infections',\n",
       "  'nongonococcal urethritis can be used when tetracyclines cannot be administered.',\n",
       "  'treat nongonococcal urethritis due to ureaplasma urealyticum.',\n",
       "  'nongonococcal urethritis due to ureaplasma urealyticum.'],\n",
       " 'DB00200': ['the treatment of pernicious anemia and the prevention and treatment of vitamin b12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets.',\n",
       "  'known or suspected cyanide poisoning.'],\n",
       " 'DB00201': ['the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth.',\n",
       "  'the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth.',\n",
       "  'respiratory depression resulting from an overdose with cns depressant drugs.'],\n",
       " 'DB00202': ['surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ect)'],\n",
       " 'DB00203': [' a) the us fda specifically indicates drug for the treatment of pulmonary arterial hypertension (pah) (who group i) in adults to improve exercise ability and delay clinical worsening .f3850]. the delay in clinical worsening was demonstrated when drug was added to background epoprostenol therapy .f3850]. studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with new york heart association (nyha) functional class ii-iii symptoms and idiopathic etiology (71%) or associated with connective tissue disease (ctd) (25%) .f3850];',\n",
       "  ' b) the canadian product monograph specifically indicates drug for the treatment of primary pulmonary arterial hypertension (pph) or pulmonary hypertension secondary to connective tissue disease (ctd) in adult patients with who functional class ii or iii who have not responded to conventional therapy .f3859]. in addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy .f3859]; and',\n",
       "  'pulmonary arterial hypertension (pah) (who group i)',\n",
       "  'exercise ability and delay clinical worsening ',\n",
       "  'primary pulmonary arterial hypertension (pph) or pulmonary hypertension secondary to connective tissue disease (ctd)',\n",
       "  'adult patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity .',\n",
       "  'exercise capacity ',\n",
       "  'patients aged 1 year to 17 years old with pulmonary arterial hypertension .'],\n",
       " 'DB00204': ['the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter .'],\n",
       " 'DB00205': ['the treatment of toxoplasmosis and acute malaria; for the prevention of malaria in areas non-resistant to drug'],\n",
       " 'DB00206': ['the treatment of hypertension'],\n",
       " 'DB00207': [' uncomplicated skin and skin structure infections due to _staphylococcus aureus_, _streptococcus pyogenes_, or _streptococcus agalactiae_. abscesses usually require surgical drainage.',\n",
       "  ' urethritis and cervicitis due to _chlamydia trachomatis_ or _neisseria gonorrhoeae_.',\n",
       "  ' genital ulcer disease in men due to _haemophilus ducreyi_ (chancroid). due to the small number of women included in clinical trials, the efficacy of drug for the treatment of chancroid in women has not been established.',\n",
       "  ' **patients**',\n",
       "  ' acute otitis media caused by _haemophilus influenzae_, _moraxella catarrhalis_ or _streptococcus pneumoniae_',\n",
       "  ' community-acquired pneumonia due to _chlamydophila pneumoniae_, _haemophilus influenzae_, _mycoplasma pneumoniae_ or _streptococcus pneumoniae_ in patients appropriate for oral therapy.',\n",
       "  'the development antimicrobial resistance and maintain the efficacy of drug .',\n",
       "  'or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of drug .',\n",
       "  'patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below.',\n",
       "  'the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below.',\n",
       "  'mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below.',\n",
       "  'chancroid in women has not been established.'],\n",
       " 'DB00208': ['another thrombotic stroke.',\n",
       "  'patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.'],\n",
       " 'DB00209': ['the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.'],\n",
       " 'DB00210': ['the topical treatment of acne vulgaris',\n",
       "  'the topical treatment of acne vulgaris in patients aged 12 and over.'],\n",
       " 'DB00211': ['the treatment of symptomatic orthostatic hypotension (oh).'],\n",
       " 'DB00212': ['the treatment of hypertension and heart failure'],\n",
       " 'DB00213': [' **drug injection**:',\n",
       "  ' **treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**',\n",
       "  ' drug for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (gerd) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking drug delayed-release tablets. _safety and efficacy of drug injection as the treatment of patients having gerd with a history of erosive esophagitis have not been demonstrated at this time_..fda label]',\n",
       "  ' **pathological hypersecretion associated with zollinger-ellison syndrome**',\n",
       "  ' drug for injection is indicated for the treatment of pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions..fda label]',\n",
       "  ' **drug delayed-release oral suspension**:',\n",
       "  ' **short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd)**',\n",
       "  ' indicated in adults and patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of drug may be considered. safety of treatment beyond 8 weeks in patients has not been determined..f3202]',\n",
       "  ' **maintenance of healing of erosive esophagitis**',\n",
       "  ' indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd..f3202]',\n",
       "  ' **pathological hypersecretory conditions including zollinger-ellison syndrome**',\n",
       "  'short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (gerd) with a history of erosive esophagitis, as an alternative to oral medication',\n",
       "  'pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions.',\n",
       "  'the treatment of pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions.',\n",
       "  'maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms',\n",
       "  'the long-term treatment of the above conditions.'],\n",
       " 'DB00214': ['edema is considered when swelling is observed due to the trap of fluid in the body tissue',\n",
       "  'as well, drug is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives',\n",
       "  'hypertension is defined by the presence of high blood pressure',\n",
       "  'edema associated with congestive heart failure, renal or hepatic diseases.',\n",
       "  'the treatment of edema associated with congestive heart failure, renal or hepatic diseases.',\n",
       "  'an antihypertensive agent either alone or'],\n",
       " 'DB00215': ['the treatment of depression, as indicated by the fda label .'],\n",
       " 'DB00216': ['the acute treatment of migraine with or without aura in adults.'],\n",
       " 'DB00217': ['the treatment of hypertension.'],\n",
       " 'DB00218': ['the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis.',\n",
       "  'bacterial conjunctivitis (pinkeye).'],\n",
       " 'DB00219': ['the treatment of visceral spasms'],\n",
       " 'DB00220': ['hiv in both adults and children.',\n",
       "  'combination with other antiviral drugs for the treatment of hiv in both adults and children.'],\n",
       " 'DB00221': ['the treatment of asthma, wheezing, and chronic asthmatic bronchitis.'],\n",
       " 'DB00222': ['it may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone',\n",
       "  'the management of type 2 diabetes',\n",
       "  'the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.',\n",
       "  'type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.',\n",
       "  'glycemic control as monotherapy',\n",
       "  'use in combination with metformin or insulin to lower blood glucose',\n",
       "  'lower blood sugar levels) agent alone.',\n",
       "  'combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone.'],\n",
       " 'DB00223': ['relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.'],\n",
       " 'DB00224': ['hiv infection.'],\n",
       " 'DB00225': ['intravenous use in mri to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.'],\n",
       " 'DB00226': ['and control hypertension.', 'treat and control hypertension.'],\n",
       " 'DB00227': ['therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia',\n",
       "  'drug is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target levels',\n",
       "  'drug is indicated as an adjunct to diet to reduce total-c, ldl-c and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh) who are at least one year post-menarche, 10 to 17 years of age, with hefh if after an adequate trial of diet therapy the following findings are present: ldl-c remains greater than 189 mg/dl or ldl-c remains greater than 160 mg/dl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patient',\n",
       "  'before administering drug, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed',\n",
       "  'prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd',\n",
       "  'reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c.',\n",
       "  'the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c',\n",
       "  'slow the progression of coronary atherosclerosis',\n",
       "  'total-c, ldl-c and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh) who are at least one year post-menarche, 10 to 17 years of age, with hefh if after an adequate trial of diet therapy the following findings are present: ldl-c remains greater than 189 mg/dl or ldl-c remains greater than 160 mg/dl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the adolescent patient'],\n",
       " 'DB00228': ['both the induction and maintenance of general anesthesia.',\n",
       "  'analgesia for vaginal delivery',\n",
       "  'induce analgesia for vaginal delivery.',\n",
       "  'an adjunct to general anesthetic drugs during delivery by cesarean section.'],\n",
       " 'DB00229': ['the treatment of severe infections caused by susceptible bacteria.'],\n",
       " 'DB00230': ['partial-onset seizures',\n",
       "  'the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures',\n",
       "  'neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.'],\n",
       " 'DB00231': ['some regional prescribing information also notes that drug may be used for premedication prior to minor surgery or other related procedures ',\n",
       "  'insomnia .',\n",
       "  'premedication prior to minor surgery or other related procedures .'],\n",
       " 'DB00232': ['use in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.',\n",
       "  'adjunctive therapy'],\n",
       " 'DB00233': ['the treatment of tuberculosis'],\n",
       " 'DB00234': ['the treatment of clinical depression.'],\n",
       " 'DB00235': ['congestive heart failure.',\n",
       "  'the treatment of congestive heart failure.'],\n",
       " 'DB00236': ['the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.'],\n",
       " 'DB00237': ['use as a sedative or hypnotic.',\n",
       "  'use as a sedative or hypnotic.',\n",
       "  'insomnia for longer than 2 weeks.',\n",
       "  'treat'],\n",
       " 'DB00238': ['use in combination with other antiretroviral drugs in the ongoing treatment of hiv-1 infection.'],\n",
       " 'DB00239': ['the treatment of dermal fungal infection.'],\n",
       " 'DB00240': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.'],\n",
       " 'DB00241': ['the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine .',\n",
       "  'the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine .'],\n",
       " 'DB00242': ['the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.',\n",
       "  \"chronic lymphocytic leukemia (cll), low-grade non-hodgkin's lymphoma, and cutaneous t-cell lymphoma.\",\n",
       "  \"an alternative agent for the treatment of chronic lymphocytic leukemia (cll), low-grade non-hodgkin's lymphoma, and cutaneous t-cell lymphoma.\"],\n",
       " 'DB00243': ['drug has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly  supported by scientific evidence',\n",
       "  'chronic angina.',\n",
       "  'the treatment of chronic angina.',\n",
       "  'certain arrhythmias, including ventricular tachycardia, however, this use is not strongly  supported by scientific evidence.',\n",
       "  'acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.'],\n",
       " 'DB00244': ['the induction of remission',\n",
       "  'the induction of remission in patients with active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis .'],\n",
       " 'DB00245': ['the extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia',\n",
       "  \"parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to parkinson's disease such as tremors, slow movement, and stiffness\",\n",
       "  'be used as an adjunct in the therapy of all forms of parkinsonism.',\n",
       "  'an adjunct',\n",
       "  'the control of extrapyramidal disorders due to neuroleptic drugs.'],\n",
       " 'DB00246': ['schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar i disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar i disorder.',\n",
       "  'acute agitation in schizophrenia.'],\n",
       " 'DB00247': ['the treatment of vascular headache'],\n",
       " 'DB00248': ['the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas).',\n",
       "  'parkinsonian syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.',\n",
       "  'manage symptoms of parkinsonian syndrome as monotherapy during'],\n",
       " 'DB00249': ['use in keratoconjunctivitis and keratitis caused by herpes simplex virus.'],\n",
       " 'DB00250': ['the treatment and management of leprosy and dermatitis herpetiformis.'],\n",
       " 'DB00251': ['the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.'],\n",
       " 'DB00252': ['treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery.',\n",
       "  'and treat seizures during or following neurosurgery.',\n",
       "  'grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery.',\n",
       "  'treat tonic-clonic status epilepticus, .',\n",
       "  'tonic-clonic status epilepticus, .'],\n",
       " 'DB00253': ['the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.'],\n",
       " 'DB00254': ['the following are some of the major infections that may be treated with drug ',\n",
       "  'rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae',\n",
       "  'lymphogranuloma venereum caused by chlamydia trachomatis',\n",
       "  'trachoma caused by chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence',\n",
       "  'uncomplicated urethral, endocervical or rectal infections in adults caused by chlamydia trachomatis',\n",
       "  'relapsing fever due to borrelia recurrentis',\n",
       "  'it is important to note that drug is not the drug of choice for the treatment of any type of staphylococcal infection',\n",
       "  'various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria.',\n",
       "  'the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria.',\n",
       "  'any type of staphylococcal infection.',\n",
       "  'streptococcal infections unless the microorganism has been demonstrated to be susceptible .',\n",
       "  'treat streptococcal'],\n",
       " 'DB00255': ['prostate cancer.',\n",
       "  'the treatment of prostate cancer.',\n",
       "  'the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.'],\n",
       " 'DB00256': ['acne in addition to other susceptible infections; propionibacterium is often the cause of acne.',\n",
       "  'the treatment of acne in addition to other susceptible infections; propionibacterium is often the cause of acne.'],\n",
       " 'DB00257': [' in some preparations, drug may be combined with betamethasone dipropionate, a corticosteroid .f3121]. ',\n",
       "  ' **oral preparations**',\n",
       "  'the topical treatment of the following dermal infections .',\n",
       "  'the local treatment of oropharyngeal candidiasis .',\n",
       "  'leukemia, solid tumors, or renal transplantation .',\n",
       "  'the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized for the treatment of leukemia, solid tumors, or renal transplantation ',\n",
       "  'any systemic mycoses .',\n",
       "  'the treatment of any systemic mycoses .'],\n",
       " 'DB00258': ['hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.',\n",
       "  'treat hyperphosphatemia (too much phosphate in the blood)'],\n",
       " 'DB00259': ['the treatment of vulvovaginitis caused by &lt;i&gt;candida albicans&lt;/i&gt;.'],\n",
       " 'DB00260': ['tuberculosis (tb).',\n",
       "  'treat tuberculosis (tb).',\n",
       "  'combination with up to 5 other drugs as a treatment for mycobacterium avium complex (mac) and is used to treat tuberculosis (tb).'],\n",
       " 'DB00261': ['thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis.',\n",
       "  'the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis.',\n",
       "  'platelet count and the associated risk of thrombosis'],\n",
       " 'DB00262': [\"the treatment of brain tumors, multiple myeloma, hodgkin's disease and non-hodgkin's lymphomas.\"],\n",
       " 'DB00263': ['the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.'],\n",
       " 'DB00264': ['some off-label uses of drug include supraventricular tachycardia and thyroid storm',\n",
       "  'all the indications of drug are part of cardiovascular diseases',\n",
       "  'angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.',\n",
       "  'the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.'],\n",
       " 'DB00265': ['eradication of scabies (&lt;i&gt;sarcoptes scabiei&lt;/i&gt;) and for symptomatic treatment of pruritic skin.'],\n",
       " 'DB00266': ['decreasing blood clotting.', 'deep vein thrombosis.'],\n",
       " 'DB00267': ['female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria.',\n",
       "  'treat female gynecologic and obstetric'],\n",
       " 'DB00268': [\"the treatment of signs and symptoms of parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .\"],\n",
       " 'DB00269': ['symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer.',\n",
       "  'treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and',\n",
       "  'breast engorgement following childbirth.',\n",
       "  'prevent breast engorgement following childbirth.'],\n",
       " 'DB00270': ['mild to moderate essential hypertension.'],\n",
       " 'DB00271': ['imaging the gastrointestinal tract in patients allergic to barium.'],\n",
       " 'DB00272': ['use clinically to test gastric secretory function.'],\n",
       " 'DB00273': ['drug is used off-label as an adjunct therapy for weight management'],\n",
       " 'DB00274': ['the treatment of infections caused by susceptible organisms.'],\n",
       " 'DB00275': ['drug is used off-label for the management type 2 diabetes-associated nephropathy, heart failure, and post-myocardial infarction, particularly in patients who are unable to tolerate ace inhibitors',\n",
       "  'hypertension either alone or in combination with other antihypertensive agents.',\n",
       "  'the treatment of hypertension either alone or in combination with other antihypertensive agents.',\n",
       "  'cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization'],\n",
       " 'DB00276': ['the treatment of acute myeloid leukaemia.'],\n",
       " 'DB00277': ['the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.'],\n",
       " 'DB00278': ['prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (hit).',\n",
       "  'prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (hit).',\n",
       "  'use',\n",
       "  'patients with, or at risk for, hit who are undergoing percutaneous coronary intervention.'],\n",
       " 'DB00279': ['- replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism',\n",
       "  '- as an adjunct therapy to surgery and radioiodine in the management of thyroid cancer',\n",
       "  '- as a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy',\n",
       "  'in general terms, exogenous drug is used to replace insufficient hormonal production and restore t3 plasma levels',\n",
       "  'the lack of drug can be presented as a pale and puffy face, coarse,  brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy',\n",
       "  'drug should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor for the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis',\n",
       "  'thyroid cancer.',\n",
       "  'replace',\n",
       "  'hyperthyroidism during the recovery phase of subacute thyroiditis.',\n",
       "  'the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor for the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.'],\n",
       " 'DB00280': ['the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.'],\n",
       " 'DB00281': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks .'],\n",
       " 'DB00282': [\"treat moderate to severe hypercalcemia of malignancy, moderate to severe paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.\",\n",
       "  \"moderate to severe hypercalcemia of malignancy, moderate to severe paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.\"],\n",
       " 'DB00283': ['the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation.',\n",
       "  'mild, uncomplicated allergic skin manifestations of urticaria and angioedema.',\n",
       "  'self-medication for temporary relief of symptoms associated with the common cold.'],\n",
       " 'DB00284': ['the treatment and management of diabetes type ii (used in combination therapy as a second or third line agent)'],\n",
       " 'DB00285': ['major depressive disorder (mdd), generalized anxiety disorder (gad), social anxiety disorder (social phobia), and panic disorder with or without agoraphobia.',\n",
       "  'neuropathic pain (although there is only minimal evidence of efficacy for this condition) .',\n",
       "  'obsessive-compulsive disorder (ocd) .'],\n",
       " 'DB00286': [' for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.',\n",
       "  ' for the treatment of breast cancer in appropriately selected patients with metastatic disease.',\n",
       "  'moderate to severe vasomotor symptoms due to menopause.',\n",
       "  'several different conditions including:&#13; &#13; for the treatment of moderate to severe vasomotor symptoms due to menopause.',\n",
       "  'moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.',\n",
       "  'hypoestrogenism due to hypogonadism, castration or primary ovarian failure.',\n",
       "  'breast cancer in appropriately selected patients with metastatic disease.',\n",
       "  'androgen-dependent carcinoma of the prostate.'],\n",
       " 'DB00287': ['drug is currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to &lt; 18 years with ocular hypertension or paediatric glaucoma ',\n",
       "  'the reduction of elevated intraocular pressure',\n",
       "  'the decrease of elevated intraocular pressure in paediatric patients aged 2 months to &lt; 18 years with ocular hypertension or paediatric glaucoma .'],\n",
       " 'DB00288': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.'],\n",
       " 'DB00289': ['attention deficit hyperactivity disorder (adhd) in children and adults.',\n",
       "  'the treatment of attention deficit hyperactivity disorder (adhd) in children and adults.'],\n",
       " 'DB00290': ['treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.'],\n",
       " 'DB00291': [\"the treatment of chronic lymphatic (lymphocytic) leukemia,  childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, hodgkin's disease,  non-hodgkin's lymphomas, and waldenstrms macroglobulinemia.\"],\n",
       " 'DB00292': ['the induction of general anesthesia.'],\n",
       " 'DB00293': ['the treatment of malignant neoplasm of colon and rectum'],\n",
       " 'DB00294': ['drug is part of the long-acting contraceptive implants that prevent pregnancy'],\n",
       " 'DB00295': ['opiods, including drug, are effective for the short term management of pain',\n",
       "  'the management of chronic, moderate to severe pain.',\n",
       "  'chronic, moderate to severe pain.',\n",
       "  'pain.'],\n",
       " 'DB00296': ['obstetric anesthesia and regional anesthesia for surgery.'],\n",
       " 'DB00297': ['the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.'],\n",
       " 'DB00298': ['iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.',\n",
       "  'the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.',\n",
       "  'certain eye examinations.'],\n",
       " 'DB00299': ['recurrent cold sores on the lips and face from various herpesvirus invections.',\n",
       "  'treat recurrent cold sores on the lips and face from various herpesvirus'],\n",
       " 'DB00300': ['safety and effectiveness of drug in patients younger than 2 years of age has not been established to this date ',\n",
       "  'hiv-1 infection in adults and patients 2 years of age and older.',\n",
       "  'chronic hepatitis b',\n",
       "  'the treatment of chronic hepatitis b',\n",
       "  'the management of hiv-1 infection .',\n",
       "  'hiv-1 infection .'],\n",
       " 'DB00301': ['bacterial infection by susceptible microorganisms.',\n",
       "  'treat bacterial'],\n",
       " 'DB00302': ['use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.',\n",
       "  'excessive bleeding in menstruation, surgery, or trauma cases.'],\n",
       " 'DB00303': ['the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;clostridium clostridioforme&lt;/i&gt;, &lt;i&gt;eubacterium lentum&lt;/i&gt;, &lt;i&gt;peptostreptococcus&lt;/i&gt; species, &lt;i&gt;bacteroides fragilis&lt;/i&gt;, &lt;i&gt;bacteroides distasonis&lt;/i&gt;, &lt;i&gt;bacteroides ovatus&lt;/i&gt;, &lt;i&gt;bacteroides thetaiotaomicron&lt;/i&gt;, or &lt;i&gt;bacteroides uniformis&lt;/i&gt;, (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to &lt;i&gt;staphylococcus aureus&lt;/i&gt; (methicillin susceptible isolates only), &lt;i&gt;streptococcus agalactiae&lt;/i&gt;, &lt;i&gt;streptococcus pyogenes&lt;/i&gt;, &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;klebsiella pneumoniae&lt;/i&gt;, &lt;i&gt;proteus mirabilis&lt;/i&gt;, &lt;i&gt;bacteroides fragilis&lt;/i&gt;, &lt;i&gt;peptostreptococcus&lt;/i&gt; species, &lt;i&gt;porphyromonas asaccharolytica&lt;/i&gt;, or &lt;i&gt;prevotella bivia&lt;/i&gt;, (3) community acquired pneumonia due to &lt;i&gt;streptococcus pneumoniae&lt;/i&gt; (penicillin susceptible isolates only) including cases with concurrent bacteremia, &lt;i&gt;haemophilus influenzae&lt;/i&gt; (beta-lactamase negative isolates only), or &lt;i&gt;moraxella catarrhalis&lt;/i&gt;, (4) complicated urinary tract infections including pyelonephritis due to &lt;i&gt;escherichia coli&lt;/i&gt;, including cases with concurrent bacteremia, or &lt;i&gt;klebsiella pneumoniae&lt;/i&gt;, (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to &lt;i&gt;streptococcus agalactiae&lt;/i&gt;, &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;bacteroides fragilis&lt;/i&gt;, &lt;i&gt;porphyromonas asaccharolytica&lt;/i&gt;, &lt;i&gt;peptostreptococcus&lt;/i&gt; species, or &lt;i&gt;prevotella bivia&lt;/i&gt;.'],\n",
       " 'DB00304': ['drug is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation',\n",
       "  'combination with .',\n",
       "  'pregnancy.',\n",
       "  'ovulation.'],\n",
       " 'DB00305': ['the treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder.',\n",
       "  'an adjunct to ab externo glaucoma surgery.',\n",
       "  'adults with low-grade upper tract urothelial cancer (lg-utuc).',\n",
       "  'low-grade upper tract urothelial cancer (lg-utuc).'],\n",
       " 'DB00306': ['use as a sedative and hypnotic.'],\n",
       " 'DB00307': ['skin manifestations of cutaneous t-cell lymphoma (ctcl)',\n",
       "  'skin lesions in early (stage ia and ib) ctcl'],\n",
       " 'DB00308': ['the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.'],\n",
       " 'DB00309': [\"the treatment of acute leukaemia, malignant lymphoma, hodgkin's disease, acute erythraemia and acute panmyelosis\"],\n",
       " 'DB00310': ['drug is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy',\n",
       "  'drug has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure',\n",
       "  'hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.'],\n",
       " 'DB00311': ['use for the treatment of duodenal ulcers, as a diuretic, and for the treatment of glaucoma, and may also be useful for the treatment of seizures associated with epilepsy.'],\n",
       " 'DB00312': ['the short-term treatment of insomnia.'],\n",
       " 'DB00313': [' **off-label** uses include:',\n",
       "  ' 1) maintenance therapy for bipolar disorder..a177919]',\n",
       "  ' 2) treatment for acute bipolar depression..a177928,a177931,a177934]',\n",
       "  'complex partial seizures and simple or complex absence seizures.',\n",
       "  'multiple seizure types that include absence seizures.',\n",
       "  'mania associated with bipolar disorder.'],\n",
       " 'DB00314': ['tuberculosis in combination with other drugs.',\n",
       "  'the treatment of tuberculosis in combination with other drugs.'],\n",
       " 'DB00315': ['the acute treatment of migraine with or without auras',\n",
       "  'the acute treatment of migraine with or without auras in patients aged 18 and over.'],\n",
       " 'DB00316': ['drug _injection_ is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever',\n",
       "  'because of its low risk of causing allergic reactions, this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies, including bronchial asthmatics',\n",
       "  'mild to moderate pain and reduction of fever.',\n",
       "  'the treatment of mild to moderate pain and reduction of fever.',\n",
       "  'the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.',\n",
       "  'mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.'],\n",
       " 'DB00317': ['the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.'],\n",
       " 'DB00318': ['the solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above ',\n",
       "  'the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate .',\n",
       "  'a cough suppressant'],\n",
       " 'DB00319': ['the treatment of polymicrobial infections.'],\n",
       " 'DB00320': ['the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.'],\n",
       " 'DB00321': ['major depressive disorder in adults',\n",
       "  'prophylactic treatment of chronic tension-type headache (ctth) in adults',\n",
       "  'treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products',\n",
       "  'the following conditions .',\n",
       "  'neuropathic pain in adults&#13; &#13; prophylactic treatment of chronic tension-type headache (ctth) in adults&#13; &#13; prophylactic treatment of migraine in adults&#13; &#13; treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.',\n",
       "  'persistent enuresis .'],\n",
       " 'DB00322': ['palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means.',\n",
       "  'liver cancer (usually administered by hepatic intra-arterial infusion).'],\n",
       " 'DB00323': [\"an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of parkinson's disease.\"],\n",
       " 'DB00324': ['the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.'],\n",
       " 'DB00325': ['immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure'],\n",
       " 'DB00326': ['the treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin d deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, for the treatment of intestinal malabsorption, and to replenish electrolytes.'],\n",
       " 'DB00327': ['the who has proposed a three-step ladder for the management of pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as drug along with the existing regimen for cases of severe pain',\n",
       "  'off-label, drug can be administered for the suppression of refractory cough',\n",
       "  'the management of moderate to severe acute pain and severe chronic pain.',\n",
       "  'the management of moderate to severe acute pain and severe chronic pain.',\n",
       "  'moderate to severe acute pain and severe chronic pain.',\n",
       "  'pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as drug along with the existing regimen for cases of severe pain.'],\n",
       " 'DB00328': ['symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.',\n",
       "  'moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.',\n",
       "  'induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.',\n",
       "  'closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e'],\n",
       " 'DB00330': ['use, as an adjunct, for the treatment of pulmonary tuberculosis.'],\n",
       " 'DB00331': ['**drug extended-release tablet (xr)**',\n",
       "  'an extended-release combination product containing empagliflozin, linagliptin, and drug was approved by the fda in january 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise',\n",
       "  'glycemic control in _adults and patients_ 10 years of age and older diagnosed with type 2 diabetes mellitus',\n",
       "  'glycemic control in only _adults_ with type 2 diabetes mellitus'],\n",
       " 'DB00332': ['asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow',\n",
       "  'as a single agent, drug was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older',\n",
       "  'rhinorrhea refers to recurrent or chronic watery nasal discharge',\n",
       "  'additionally, drug is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema',\n",
       "  'the chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness',\n",
       "  'drug has also been studied to be used for the treatment of sialorrhea',\n",
       "  'sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivation',\n",
       "  'severe exacerbations of asthma flares requiring treatment.',\n",
       "  'the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older.',\n",
       "  'sialorrhea.',\n",
       "  'the treatment of sialorrhea.'],\n",
       " 'DB00333': ['drug is indicated for detoxification treatment of opioid addiction (heroin or other morphine-like drugs), and for maintenance substitution treatment for opioid dependence in adults in conjunction with appropriate social and medical services',\n",
       "  'the management of pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate.',\n",
       "  'the management of pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate.',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate.',\n",
       "  'pain.',\n",
       "  'patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.',\n",
       "  'detoxification treatment of opioid addiction (heroin or other morphine-like drugs), and for maintenance substitution treatment for opioid dependence',\n",
       "  'detoxification treatment of opioid addiction (heroin or other morphine-like drugs), and for maintenance substitution treatment for opioid dependence in adults in conjunction with appropriate social and medical services.'],\n",
       " 'DB00334': ['drug is indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults',\n",
       "  'as well, drug is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old',\n",
       "  'drug is approved for the management of psychomotor agitation associated with schizophrenia and bipolar i mania',\n",
       "  \"schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality\",\n",
       "  'bipolar disorder is a mental health condition defined by periods of extreme mood disturbances',\n",
       "  'episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression',\n",
       "  'psychomotor agitation associated with schizophrenia and bipolar i mania.'],\n",
       " 'DB00335': ['1) management of hypertension alone and in combination with other antihypertensives',\n",
       "  '2) management of angina pectoris associated with coronary atherosclerosis',\n",
       "  '3) management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmhg',\n",
       "  '**off-label** uses include:',\n",
       "  '2) management of heart failure',\n",
       "  '3) management of atrial fibrillation',\n",
       "  '4) management of supraventricular tachycardia',\n",
       "  '5) management of ventricular arrythmias such as congenital long-qt and arrhythmogenic right ventricular cardiomyopathy',\n",
       "  '6) management of symptomatic thyrotoxicosis in combination with ',\n",
       "  '7) prophylaxis of migraine headaches',\n",
       "  '8) management of alcohol withdrawal',\n",
       "  'hypertension alone and in combination with other antihypertensives.',\n",
       "  'angina pectoris associated with coronary atherosclerosis.',\n",
       "  'acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmhg.',\n",
       "  'heart failure.',\n",
       "  'atrial fibrillation.',\n",
       "  'supraventricular tachycardia.',\n",
       "  'ventricular arrythmias such as congenital long-qt and arrhythmogenic right ventricular cardiomyopathy.',\n",
       "  'symptomatic thyrotoxicosis in combination with .',\n",
       "  'alcohol withdrawal.'],\n",
       " 'DB00336': ['the treatment of bacterial skin infections including pyodermas, infected dermatoses and infections of cuts, wounds, burns and ulcers due to susceptible organisms.'],\n",
       " 'DB00337': ['the treatment of mild to moderate atopic dermatitis.'],\n",
       " 'DB00338': [' recurrence in adults ',\n",
       "  '  treatment of active benign gastric ulcer in adults ',\n",
       "  '  treatment of symptomatic gastroesophageal reflux disease (gerd) in',\n",
       "  ' patients 1 month of age and older ',\n",
       "  '  maintenance of healing of ee due to acid-mediated gerd in patients 1',\n",
       "  'the following purposes:&#13; &#13;  treatment of active duodenal ulcer in adults &#13; &#13;  eradication of helicobacter pylori to reduce the risk of duodenal ulcer&#13; recurrence in adults &#13; &#13;  treatment of active benign gastric ulcer in adults &#13; &#13;  treatment of symptomatic gastroesophageal reflux disease (gerd) in&#13; patients 1 year of age and older &#13; &#13;  treatment of erosive esophagitis (ee) due to acid-mediated gerd in&#13; patients 1 month of age and older &#13; &#13;  maintenance of healing of ee due to acid-mediated gerd in patients 1&#13; year of age and older &#13; &#13;  pathologic hypersecretory conditions in adults',\n",
       "  'the risk of duodenal ulcer&#13; recurrence in adults &#13; &#13;  treatment of active benign gastric ulcer in adults &#13; &#13;  treatment of symptomatic gastroesophageal reflux disease (gerd) in&#13; patients 1 year of age and older &#13; &#13;  treatment of erosive esophagitis (ee) due to acid-mediated gerd in&#13; patients 1 month of age and older &#13; &#13;  maintenance of healing of ee due to acid-mediated gerd in patients 1&#13; year of age and older &#13; &#13;  pathologic hypersecretory conditions in adult'],\n",
       " 'DB00339': ['the treatment of active tuberculosis in adults and children when combined with other antituberculous agents.'],\n",
       " 'DB00340': ['the symptomatic treatment of parkinsonism.'],\n",
       " 'DB00341': ['**perennial allergic rhinitis**: this drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older',\n",
       "  '**chronic urticaria**: drug is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older',\n",
       "  'the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens',\n",
       "  'the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds',\n",
       "  'the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older.',\n",
       "  'the uncomplicated skin manifestations of chronic idiopathic urticaria',\n",
       "  'the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria'],\n",
       " 'DB00342': ['the treatment of allergic rhinitis, hay fever, and allergic skin disorders.'],\n",
       " 'DB00343': ['indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents',\n",
       "  'indicated for use to improve exercise tolerance in patients with chronic stable angina',\n",
       "  \"indicated for the management of variant angina (prinzmetal's angina)\",\n",
       "  '**intravenous**',\n",
       "  'indicated for the rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm',\n",
       "  '**off-label**',\n",
       "  'the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.',\n",
       "  'hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.',\n",
       "  'use to improve exercise tolerance',\n",
       "  'exercise tolerance in patients with chronic stable angina',\n",
       "  \"the management of variant angina (prinzmetal's angina).\",\n",
       "  \"variant angina (prinzmetal's angina).\",\n",
       "  'the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.',\n",
       "  'atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.',\n",
       "  'the rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm.',\n",
       "  'off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,.'],\n",
       " 'DB00344': ['the treatment of depression.'],\n",
       " 'DB00345': ['measure effective renal plasma flow (erpf) and to determine the functional capacity of the tubular excretory mechanism.'],\n",
       " 'DB00346': ['the reduction of urinary obstruction and relief of associated manifestations (eg.'],\n",
       " 'DB00347': ['the control of absence (petit mal) seizures that are refractory to treatment with other medications.'],\n",
       " 'DB00348': ['hereditary tyrosinemia type 1.',\n",
       "  'an adjunct to dietary restriction of tyrosine and phenylalanine for the treatment of hereditary tyrosinemia type 1.'],\n",
       " 'DB00349': ['the treatment and management of epilepsy and seizures associated with lennox-gastaut syndrome, a difficult-to-treat form of childhood epilepsy.'],\n",
       " 'DB00350': ['the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.'],\n",
       " 'DB00351': ['the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids).',\n",
       "  'the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in canada and some other countries.',\n",
       "  'recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in canada and some other countries.'],\n",
       " 'DB00352': ['remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.'],\n",
       " 'DB00353': ['the prevention and control of excessive bleeding following vaginal childbirth'],\n",
       " 'DB00354': ['prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).'],\n",
       " 'DB00355': ['the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.'],\n",
       " 'DB00356': ['the relief of discomfort associated with acute painful musculoskeletal conditions.'],\n",
       " 'DB00357': [\"the suppression of adrenal function in selected patients with cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.\"],\n",
       " 'DB00358': ['the treatment of mild to moderate acute malaria caused by druguine-susceptible strains of &lt;i&gt;plasmodium falciparum&lt;/i&gt; (both chloroquine-susceptible and resistant strains) or by &lt;i&gt;plasmodium vivax&lt;/i&gt;.'],\n",
       " 'DB00359': ['the treatment of rheumatic fever and meningococcal meningitis'],\n",
       " 'DB00360': ['the treatment of tetrahydrobiopterin (bh4) deficiency.'],\n",
       " 'DB00361': ['  drug tartrate is indicated for adults for the treatment of advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs .l1998].',\n",
       "  ' used in relapsed or refractory hodgkin lymphoma, in combination with other chemotherapy agents .l2011].',\n",
       "  ' for the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .l2011].',\n",
       "  ' for the treatment of recurrent or metastatic squamous cell head and neck cancer .l2011].',\n",
       "  ' for the treatment of recurrent ovarian cancer .l2011].',\n",
       "  ' for the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .l2011].',\n",
       "  ' for the treatment of her2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .l2011].',\n",
       "  'advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs .',\n",
       "  'adults for the treatment of advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs .',\n",
       "  'relapsed or refractory hodgkin lymphoma, in combination with other chemotherapy agents .',\n",
       "  'desmoid tumor or aggressive fibromatosis, in combination with methotrexate .',\n",
       "  'recurrent or metastatic squamous cell head and neck cancer .',\n",
       "  'recurrent ovarian cancer .',\n",
       "  'metastatic breast cancer,',\n",
       "  'her2-positive, trastuzumab-resistant, advanced breast cancer'],\n",
       " 'DB00362': ['use for the treatment of the following fungal infections: candidemia and other forms of &lt;i&gt;candida&lt;/i&gt; infections (intra-abdominal abscess, and peritonitis), aspergillus infections, and esophageal candidiasis.'],\n",
       " 'DB00363': ['use in patients with treatment-resistant schizophrenia.'],\n",
       " 'DB00364': ['drug is used in the prevention and/or treatment of gastro-esophageal reflux disease (gerd), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia ',\n",
       "  'active duodenal ulcer for up to 8 weeks.',\n",
       "  'the treatment of active duodenal ulcer for up to 8 weeks.',\n",
       "  'the prevention and/or treatment of gastro-esophageal reflux disease (gerd), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia .'],\n",
       " 'DB00365': ['the treatment of adults with mild to moderate infections caused by susceptible strains of &lt;i&gt;haemophilus influenzae&lt;/i&gt;, &lt;i&gt;streptococcus pneumoniae&lt;/i&gt;, or &lt;i&gt;moraxella catarrhalis&lt;/i&gt;.'],\n",
       " 'DB00366': ['morning sickness in pregnant women.',\n",
       "  'combination with vitamin b6 (pyridoxine) to prevent morning sickness in pregnant women.'],\n",
       " 'DB00367': ['drug, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse',\n",
       "  '**long-term contraception or nonemergency contraception**',\n",
       "  '**hormone therapy and off-label uses**',\n",
       "  'the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse.',\n",
       "  'pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse.',\n",
       "  'regular contraception and must be taken as soon as possible within 72 hours after intercourse.',\n",
       "  'various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years.',\n",
       "  'pregnancy for up to 5 years.',\n",
       "  'osteoporosis.',\n",
       "  'menorrhagia, endometrial hyperplasia, and endometriosis.',\n",
       "  'treat menorrhagia, endometrial hyperplasia, and endometriosis.'],\n",
       " 'DB00368': ['patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine.',\n",
       "  'treat patients',\n",
       "  'a vasopressor medication for patients with critical hypotension.'],\n",
       " 'DB00369': ['the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids)'],\n",
       " 'DB00370': ['drug has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (ptsd), sleep disorders, substance abuse disorders, and sexual disorders, among others',\n",
       "  'major depressive disorder and its associated symptoms.',\n",
       "  'the treatment of major depressive disorder and its associated symptoms.'],\n",
       " 'DB00371': ['anxiety disorders or for the short-term relief of symptoms of anxiety.'],\n",
       " 'DB00372': ['the treatment or relief of nausea and vomiting.'],\n",
       " 'DB00373': ['increased intraocular pressure',\n",
       "  'the treatment of increased intraocular pressure',\n",
       "  'high blood pressure.',\n",
       "  'treat high blood pressure.',\n",
       "  'the prevention of migraine headaches.'],\n",
       " 'DB00374': ['use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with nyha class ii-iv symptoms to diminish symptoms associated with exercise.'],\n",
       " 'DB00375': ['therapy with lipid-altering agents like drug should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia ',\n",
       "  \"although drug is effective in all types of hypercholesterolemia, some regional prescribing information note in particular that it is medically most appropriate in patients with fredrickson's type ii hyperlipoproteinemia \",\n",
       "  'elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern '],\n",
       " 'DB00376': [\"parkinson's disease and extrapyramidal reactions caused by drugs.\",\n",
       "  \"the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.\"],\n",
       " 'DB00377': ['the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy.',\n",
       "  'the prevention of postoperative nausea and vomiting for up to 24 hours post operation.',\n",
       "  'postoperative nausea and vomiting for up to 24 hours post operation.'],\n",
       " 'DB00378': ['irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency.',\n",
       "  'treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency.',\n",
       "  'natural abortion in patients who have a history of habitual abortions.',\n",
       "  'prevent natural abortion'],\n",
       " 'DB00379': ['the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.'],\n",
       " 'DB00380': ['reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy.',\n",
       "  'extravasation from intravenous anthracyclines.'],\n",
       " 'DB00381': [' hypertension ',\n",
       "  ' chronic stable angina',\n",
       "  'the following conditions .'],\n",
       " 'DB00382': [\"the treatment of mild to moderate dementia of the alzheimer's type.\"],\n",
       " 'DB00383': ['the treatment of peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders.'],\n",
       " 'DB00384': ['drug in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked',\n",
       "  'edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.',\n",
       "  'the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.',\n",
       "  'the managment of hypertension or treatment of edema'],\n",
       " 'DB00385': ['the treatment of cancer of the bladder.'],\n",
       " 'DB00387': [\"the treatment of all forms of parkinson's disease, as well as control of extrapyramidal reactions induced by antipsychotic agents.\"],\n",
       " 'DB00388': ['treat hypotension caused by shock or anesthesia,.',\n",
       "  'hypotension caused by shock or anesthesia,.',\n",
       "  'dilate pupils.',\n",
       "  'congestion, and a topical formulation is used to treat hemorrhoids.',\n",
       "  'treat congestion, and a topical formulation is used to treat hemorrhoids.'],\n",
       " 'DB00389': ['the treatment of hyperthyroidism and thyrotoxicosis.',\n",
       "  'prepare patients for thyroidectomy.'],\n",
       " 'DB00390': ['in adults with heart failure, when it is clinically possible, drug should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ace) inhibitor for optimum effects',\n",
       "  'mild to moderate heart failure',\n",
       "  'myocardial contraction in children diagnosed with heart failure'],\n",
       " 'DB00391': ['schizophrenia.', 'the treatment of schizophrenia.'],\n",
       " 'DB00392': [\"use for the treatment of parkinson's disease and also used to control severe reactions to certain medicines such as reserpine.\"],\n",
       " 'DB00393': ['use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.'],\n",
       " 'DB00394': ['indicated for intranasal use to relieve symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal',\n",
       "  'indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older',\n",
       "  'oral inhalation use in the maintenance treatment of asthma as prophylactic therapy',\n",
       "  'the relief of acute bronchospasm.',\n",
       "  'intranasal use to relieve symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.',\n",
       "  'symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal',\n",
       "  'the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00395': [' **important limitations of use** .fda label]:',\n",
       "  '  should only be used for acute treatment periods up to two or three weeks ',\n",
       "  '  adequate evidence of effectiveness for more prolonged use has not been established ',\n",
       "  'the relief of discomfort related to acute, painful musculoskeletal conditions .',\n",
       "  'the relief of discomfort related to acute, painful musculoskeletal conditions .',\n",
       "  'acute treatment periods up to two or three weeks &#13; &#13;  adequate evidence of effectiveness for more prolonged use has not been established &#13; &#13;  not recommended in patients less than 16 years of age'],\n",
       " 'DB00396': ['the gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets',\n",
       "  '**vaginal gel**',\n",
       "  '**vaginal insert**',\n",
       "  '**injection (intramuscular)**',\n",
       "  '**tablets, contraceptive**',\n",
       "  'use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets.',\n",
       "  'the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets.',\n",
       "  'use in secondary amenorrhea .',\n",
       "  'secondary amenorrhea .',\n",
       "  'secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .',\n",
       "  'the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .',\n",
       "  'support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women .',\n",
       "  'the prevention of pregnancy .',\n",
       "  'pregnancy .'],\n",
       " 'DB00397': ['the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.'],\n",
       " 'DB00398': ['unresectable hepatocellular carcinoma and advanced renal cell carcinoma.',\n",
       "  'the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.'],\n",
       " 'DB00399': [\"treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and paget's disease of bone in men and women.\",\n",
       "  \"hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and paget's disease of bone in men and women.\",\n",
       "  'the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.',\n",
       "  'the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.',\n",
       "  'osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.'],\n",
       " 'DB00400': ['the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by &lt;i&gt;trichophyton&lt;/i&gt; or &lt;i&gt;microsporum&lt;/i&gt; fungi.'],\n",
       " 'DB00401': ['the treatment of hypertension.'],\n",
       " 'DB00402': ['insomnia.', 'the treatment of insomnia.'],\n",
       " 'DB00403': ['paralytic ileus and as diagnostic aid in pancreatic malfunction.',\n",
       "  'the treatment of paralytic ileus and as diagnostic aid in pancreatic malfunction.'],\n",
       " 'DB00404': ['the management of anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.',\n",
       "  'the management of anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.',\n",
       "  'anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.'],\n",
       " 'DB00405': ['the treatment and relief of symptoms of allergies, hay fever, and colds'],\n",
       " 'DB00406': [\"the treatment of bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of chagas' disease (as a blood additive).\"],\n",
       " 'DB00407': ['prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.'],\n",
       " 'DB00408': ['the manifestations of psychotic disorders such as schizophrenia'],\n",
       " 'DB00409': ['schizophrenia.', 'the treatment of schizophrenia.'],\n",
       " 'DB00410': ['impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_.',\n",
       "  'the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_.'],\n",
       " 'DB00411': ['glaucoma, but is used during ophthalmic surgery.',\n",
       "  'the treatment of glaucoma, but is used during ophthalmic surgery.'],\n",
       " 'DB00412': ['glycemic control in adults with type 2 diabetes mellitus'],\n",
       " 'DB00413': ['the symptomatic treatment of parkinsons disease .',\n",
       "  'the symptomatic treatment of parkinsons disease .',\n",
       "  'symptomatic treatment of moderate to severe primary restless legs syndrome (rls) .'],\n",
       " 'DB00414': ['diabetes mellitus type 2 (adult-onset).',\n",
       "  'the management of diabetes mellitus type 2 (adult-onset).'],\n",
       " 'DB00415': ['the treatment of infection (respiratory, gi, uti and meningitis) due to e.'],\n",
       " 'DB00416': ['use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.'],\n",
       " 'DB00417': [' - mild to moderately severe infections of the respiratory tract caused by pneumococcus',\n",
       "  ' - mild to moderately severe infections of the oropharynx caused by fusospirochetosis, including vincents gingivitis and pharyngitis, usually respond to oral penicillin therapy',\n",
       "  ' **off-label**',\n",
       "  'mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response.',\n",
       "  'the treatment of mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response.',\n",
       "  'use as prophylaxis against bacterial endocarditis',\n",
       "  'the treatment of: &#13; &#13; - mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas caused by streptococcus without bacteremia&#13; - mild to moderately severe infections of the respiratory tract caused by pneumococcus&#13; - mild infections of the skin and soft tissues caused by penicillin g-sensitive staphylococcus&#13; - mild to moderately severe infections of the oropharynx caused by fusospirochetosis, including vincents gingivitis and pharyngitis, usually respond to oral penicillin therapy&#13; &#13; **off-label**&#13; &#13; indicated for use as prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract.'],\n",
       " 'DB00418': ['the short-term treatment of intractable insomnia for patients habituated to barbiturates'],\n",
       " 'DB00419': [\"the treatment of adult patients with mild to moderate type 1 (nonneuropathic) gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e.\",\n",
       "  'progressive neurological symptoms'],\n",
       " 'DB00420': ['an adjunct for short term treatment of moderate and severe psychomotor agitation.',\n",
       "  'agitation or restlessness in the elderly.',\n",
       "  'treat agitation or restlessness'],\n",
       " 'DB00421': ['drug has antiandrogenic activity which leads to many of its off label uses',\n",
       "  'drug is frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth',\n",
       "  'new york heart association class iii-iv heart failure, management of edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term',\n",
       "  'the treatment of new york heart association class iii-iv heart failure, management of edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term',\n",
       "  'edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micro/macronodular adrenal hyperplasia, as an add-on therapy in hypertension, and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequate.',\n",
       "  'antiandrogenic',\n",
       "  'hirsutism, female pattern hair loss, and adult acne vulgaris.',\n",
       "  'its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth.'],\n",
       " 'DB00422': ['attention deficit hyperactivity disorder (adhd)',\n",
       "  'the treatment of attention deficit hyperactivity disorder (adhd)'],\n",
       " 'DB00423': ['in canada, drug containing oral formulations are sold over the counter for pain associated with muscle spasm'],\n",
       " 'DB00424': ['the treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis.',\n",
       "  \"certain heart conditions, to control symptoms of parkinson's disease and rhinitis.\",\n",
       "  \"treat certain heart conditions, to control symptoms of parkinson's disease and rhinitis.\"],\n",
       " 'DB00425': ['the short-term treatment of insomnia',\n",
       "  'the short-term treatment of insomnia in adults characterized by difficulties with sleep initiation .'],\n",
       " 'DB00426': ['the treatment of acute herpes zoster (shingles).'],\n",
       " 'DB00427': ['the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema.',\n",
       "  'combination with other agents for the symptomatic relief of symptoms associated with the common cold.'],\n",
       " 'DB00428': ['the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).'],\n",
       " 'DB00429': ['aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1.',\n",
       "  'postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.'],\n",
       " 'DB00430': ['the treatment of severe infections caused by susceptible bacteria such as p.'],\n",
       " 'DB00431': ['the treatment of patients infested with sarcoptes scabiei or pediculosis capitis who have either failed to respond to adequate doses, or are intolerant of other approved therapies.'],\n",
       " 'DB00432': ['drug, in combination with tipiracil as oral tablets, is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy ',\n",
       "  'primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2 in ophthalmic solutions.',\n",
       "  'the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2 in ophthalmic solutions.',\n",
       "  'adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy .',\n",
       "  'the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy .'],\n",
       " 'DB00433': ['indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety',\n",
       "  'off-label uses include use in emergency settings for adult and pediatric migraines',\n",
       "  'the symptomatic treatment of severe nausea and vomiting.',\n",
       "  'the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety.',\n",
       "  'manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety.',\n",
       "  'generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.',\n",
       "  'combination with dopamine antagonist.'],\n",
       " 'DB00434': ['the treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine.'],\n",
       " 'DB00435': ['the treatment of term and near-term (&amp;gt;34 weeks) neonates with hypoxic respiratory failure'],\n",
       " 'DB00436': ['the treatment of high blood pressure and management of edema related to heart failure.'],\n",
       " 'DB00437': ['1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy)',\n",
       "  '2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels',\n",
       "  '3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients',\n",
       "  'patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).',\n",
       "  'patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.',\n",
       "  'patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients.'],\n",
       " 'DB00438': ['the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).'],\n",
       " 'DB00439': ['an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson types iia and iib) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been'],\n",
       " 'DB00440': ['drug is available as an ophthalmic solution in combination with ',\n",
       "  'acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e.',\n",
       "  'the treatment of acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e.',\n",
       "  'the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media',\n",
       "  \"the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _shigella_, prophylaxis and treatment of _pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _e.\",\n",
       "  'acute bacterial conjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible bacteria.'],\n",
       " 'DB00441': ['advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (stage iiia or iiib), or metastatic (stage iv) non-small cell lung cancer; and locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas.',\n",
       "  'the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (stage iiia or iiib), or metastatic (stage iv) non-small cell lung cancer; and locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas.'],\n",
       " 'DB00442': ['the treatment of chronic hepatitis b virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease.'],\n",
       " 'DB00443': ['several inflammatory conditions.',\n",
       "  'the treatment of several inflammatory conditions.',\n",
       "  'relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.',\n",
       "  'pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses',\n",
       "  'plaque psoriasis.',\n",
       "  'manage a range of inflammatory conditions'],\n",
       " 'DB00444': ['refractory acute lymphoblastic leukaemia',\n",
       "  'the treatment of refractory acute lymphoblastic leukaemia'],\n",
       " 'DB00445': ['use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.'],\n",
       " 'DB00446': ['cholera, as it destroys the vibrios and decreases the diarrhea.',\n",
       "  'the treatment of cholera, as it destroys the vibrios and decreases the diarrhea.',\n",
       "  'bacterial conjunctivitis.',\n",
       "  'eye drops or ointment to treat bacterial conjunctivitis.'],\n",
       " 'DB00447': ['upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis and tonsillitis, skin absceses, urinary tract infections and pyelonephritis caused by &lt;i&gt;e.',\n",
       "  'treat upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis and tonsillitis, skin absceses, urinary tract'],\n",
       " 'DB00448': ['gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid) induced gastric and duodenal ulcers',\n",
       "  'reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid)',\n",
       "  'the maintenance and healing of several gastric conditions including duodenal ulcers, nsaid related gastric ulcers, and erosive esophagitis.',\n",
       "  'hypersecretory conditions including zollinger-ellison syndrome.',\n",
       "  'conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).'],\n",
       " 'DB00449': ['initial therapy for the control of intraocular pressure'],\n",
       " 'DB00450': ['the incidence of nausea and vomiting in surgical and diagnostic procedures'],\n",
       " 'DB00451': ['thyrotropin-dependent well-differentiated thyroid cancer.'],\n",
       " 'DB00452': ['the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis.'],\n",
       " 'DB00453': ['the treatment and management of brucellosis, mycoplasma infection, acne vulgaris, chlamydial infection;chronic bronchitis'],\n",
       " 'DB00454': ['control moderate to severe pain.'],\n",
       " 'DB00455': ['allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.',\n",
       "  'manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.'],\n",
       " 'DB00456': ['infection during surgery and to treat many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract.',\n",
       "  'many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract.',\n",
       "  'prevent infection during surgery and to treat many kinds of'],\n",
       " 'DB00457': ['drug does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (copd)',\n",
       "  'hypertension (high blood pressure).',\n",
       "  'the treatment of hypertension (high blood pressure).',\n",
       "  'manage hypertension'],\n",
       " 'DB00458': ['may also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for adhd in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy ',\n",
       "  'the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older .',\n",
       "  'acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy .',\n",
       "  'acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy .'],\n",
       " 'DB00459': ['the treatment of severe psoriasis in adults.'],\n",
       " 'DB00460': ['the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome.',\n",
       "  'destroy tumors.'],\n",
       " 'DB00461': ['1) symptomatic relief in rheumatoid arthritis',\n",
       "  '2) symptomatic relief in osteoarthritis'],\n",
       " 'DB00462': ['peptic ulcer.',\n",
       "  'adjunctive therapy for the treatment of peptic ulcer.',\n",
       "  'nausea and vomiting due to motion sickness.',\n",
       "  'treat nausea and vomiting due to motion sickness.'],\n",
       " 'DB00463': ['epilepsy.', 'the treatment of epilepsy.'],\n",
       " 'DB00464': ['the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.'],\n",
       " 'DB00465': ['short term management of acute pain that requires the caliber of pain management offered by opioids.',\n",
       "  'acute pain that requires the caliber of pain management offered by opioids.'],\n",
       " 'DB00466': ['respiratory distress'],\n",
       " 'DB00467': ['the treatment of adults (&amp;ge;18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to &lt;i&gt;neisseria gonorrhoeae&lt;/i&gt;, (2) uncomplicated urinary tract infections (cystitis) due to &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;staphylococcus epidermidis&lt;/i&gt;, or &lt;i&gt;staphylococcus saprophyticus&lt;/i&gt;, and (3) complicated urinary tract infections due to &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;klebsiella pneumoniae&lt;/i&gt;, &lt;i&gt;proteus mirabilis&lt;/i&gt;, &lt;i&gt;pseudomonas aeruginosa&lt;/i&gt;, &lt;i&gt;staphylococcus epidermidis&lt;/i&gt;, or &lt;i&gt;enterobacter cloacae&lt;/i&gt;.'],\n",
       " 'DB00468': ['the treatment of malaria and leg cramps'],\n",
       " 'DB00469': ['the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.'],\n",
       " 'DB00470': ['the treatment of anorexia associated with weight loss in patients with aids, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments'],\n",
       " 'DB00471': ['(a) the prophylaxis and chronic treatment of asthma in adults and patients who are 12 months of age and older',\n",
       "  '(b) the prevention of exercise-induced bronchoconstriction (eib) in patients who are 6 years of age and older',\n",
       "  '(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older',\n",
       "  'furthermore, some formulations like chewable drug tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and patients aged 2 and older',\n",
       "  'moreover, when employed for such indications drug is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma',\n",
       "  \"additionally, in patients who continue to experience asthma symptoms, drug can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist\",\n",
       "  'the maintenance treatment of chronic asthma.',\n",
       "  'the necessary inhaled corticosteroid dose while still maintaining clinical stability'],\n",
       " 'DB00472': ['both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.',\n",
       "  'both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.',\n",
       "  'depression related to bipolar i disorder, and treatment resistant depression.',\n",
       "  'combination with olanzapine to treat depression related to bipolar i disorder, and treatment resistant depression.'],\n",
       " 'DB00473': ['a local anesthetic for surface application,'],\n",
       " 'DB00474': ['use as an intravenous anaesthetic.',\n",
       "  'use as an intravenous anaesthetic.',\n",
       "  'deep sedation',\n",
       "  'induce deep sedation.'],\n",
       " 'DB00475': ['anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.'],\n",
       " 'DB00476': ['1) management of major depressive disorder',\n",
       "  '2) management of generalized anxiety disorder',\n",
       "  '3) management of diabetic peripheral neuropathy',\n",
       "  '4) management of fibromyalgia',\n",
       "  '5) management of chronic musculoskeletal pain',\n",
       "  '6) management of osteoarthritis of the knee in adults',\n",
       "  '7) management of chronic lower back pain in adults',\n",
       "  '8) management of stress urinary incontinence in adult women',\n",
       "  '**off-label** uses include:',\n",
       "  '2) management of stress urinary incontinence in adult men after prostatectomy until recovery is complete',\n",
       "  'major depressive disorder.',\n",
       "  'generalized anxiety disorder.',\n",
       "  'diabetic peripheral neuropathy.',\n",
       "  'fibromyalgia.',\n",
       "  'chronic musculoskeletal pain.',\n",
       "  'osteoarthritis of the knee in adults.',\n",
       "  'chronic lower back pain in adults.',\n",
       "  'stress urinary incontinence in adult women.',\n",
       "  'chemotherapy-induced peripheral neuropathy.',\n",
       "  'stress urinary incontinence in adult men after prostatectomy until recovery is complete.'],\n",
       " 'DB00477': ['the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct for the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.'],\n",
       " 'DB00478': ['the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults.'],\n",
       " 'DB00479': [' the use of drug for the treatment of staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics..f1949]',\n",
       "  'lung disease caused by a group of bacteria, mycobacterium avium complex (mac) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).',\n",
       "  'staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics.',\n",
       "  'initial therapy in suspected gram-negative infections and therapy may be'],\n",
       " 'DB00480': ['multiple myeloma in combination with dexamethasone.',\n",
       "  'the treatment of multiple myeloma in combination with dexamethasone.',\n",
       "  'patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.',\n",
       "  'the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.',\n",
       "  'transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.'],\n",
       " 'DB00481': ['indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer',\n",
       "  'the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.',\n",
       "  'the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.'],\n",
       " 'DB00482': ['it may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea',\n",
       "  'symptomatic treatment of adult osteoarthritis (oa) and adult rheumatoid arthritis (ra).',\n",
       "  'symptomatic treatment of adult osteoarthritis (oa) and adult rheumatoid arthritis (ra).',\n",
       "  'acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.',\n",
       "  'treat acute pain from various sources, juvenile rheumatoid arthritis'],\n",
       " 'DB00483': ['use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation'],\n",
       " 'DB00484': ['indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension ',\n",
       "  '**topical**',\n",
       "  'lowering intraocular pressure (iop)',\n",
       "  'persistent (non-transient) facial erythema of rosacea',\n",
       "  'the treatment of persistent (non-transient) facial erythema of rosacea'],\n",
       " 'DB00485': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.',\n",
       "  'treat'],\n",
       " 'DB00486': ['the nausea and vomiting associated with cancer chemotherapy',\n",
       "  'the treatment of the nausea and vomiting associated with cancer chemotherapy'],\n",
       " 'DB00487': ['the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract.'],\n",
       " 'DB00488': ['use as a single agent in the treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.'],\n",
       " 'DB00489': ['treat life threatening ventricular arrhytmias and maintain normal sinus rhythm',\n",
       "  'life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.',\n",
       "  'patients requiring drug, but for whom a tablet would not be appropriate.'],\n",
       " 'DB00490': ['the management of anxiety disorders or the short-term relief of symptoms of anxiety.',\n",
       "  'anxiety disorders or the short-term relief of symptoms of anxiety.'],\n",
       " 'DB00491': ['use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (niddm) whose hyperglycemia cannot be managed with diet alone.'],\n",
       " 'DB00492': ['treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.'],\n",
       " 'DB00493': ['gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system.',\n",
       "  'treat gonorrhoea, meningitis, and severe infections including',\n",
       "  'infection after surgery.'],\n",
       " 'DB00494': ['an adjunct to levodopa / carbidopa'],\n",
       " 'DB00495': ['human immunovirus (hiv) infections.',\n",
       "  'combination with other antiretroviral agents for the treatment of human immunovirus (hiv) infections.'],\n",
       " 'DB00496': ['the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.'],\n",
       " 'DB00497': ['moderate to severe pain.',\n",
       "  'the treatment of moderate to severe pain.',\n",
       "  'chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.'],\n",
       " 'DB00498': ['the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili.',\n",
       "  'anticoagulant prophylaxis.'],\n",
       " 'DB00499': ['locally confined stage b2-c and stage d2 metastatic carcinoma of the prostate'],\n",
       " 'DB00500': ['the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management.',\n",
       "  'juvenile rheumatoid arthritis.'],\n",
       " 'DB00501': ['the treatment and the management of acid-reflux disorders (gerd), peptic ulcer disease, heartburn, and acid indigestion.'],\n",
       " 'DB00502': ['schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of tourettes disorder in children and adults, for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation).',\n",
       "  'a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of tourettes disorder in children and adults, for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation).'],\n",
       " 'DB00503': ['hiv-1 infection.'],\n",
       " 'DB00504': ['the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids.'],\n",
       " 'DB00505': ['peptic ulcer disease and in acquired nystagmus',\n",
       "  'an adjunct for the treatment of peptic ulcer disease and'],\n",
       " 'DB00507': ['drug has not been shown to be superior to placebo medication for the management of diarrhea caused by cryptosporidium parvum in patients with hiv/immunodeficiency ',\n",
       "  'the treatment of diarrhea in adults and children caused by the protozoa &lt;i&gt;giardia lamblia&lt;/i&gt;,  and for the treatment of diarrhea in children caused by the protozoan,  &lt;i&gt;cryptosporidium parvum&lt;/i&gt; .',\n",
       "  'diarrhea caused by cryptosporidium parvum in patients with hiv/immunodeficiency .'],\n",
       " 'DB00508': ['psychoses.', 'control nausea and vomiting.'],\n",
       " 'DB00509': ['lower high cholesterol levels'],\n",
       " 'DB00511': ['fast digitalization in congestive heart failure.'],\n",
       " 'DB00512': ['additionally, a unique fda approved oral liquid treatment is available and indicated for the treatment of clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains ',\n",
       "  'serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci .',\n",
       "  'clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains .',\n",
       "  'the treatment of clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains .'],\n",
       " 'DB00513': ['use for the treatment of excessive postoperative bleeding.'],\n",
       " 'DB00514': ['coughs and upper respiratory symptoms associated with allergies or the common cold.',\n",
       "  'combination with .',\n",
       "  'a cough',\n",
       "  'pseudobulbar affect.',\n",
       "  'the treatment of pseudobulbar affect.'],\n",
       " 'DB00515': ['the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.'],\n",
       " 'DB00516': ['or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac.',\n",
       "  'prevent or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac.'],\n",
       " 'DB00517': ['use in conjunction with antacids or histamine h&lt;sub&gt;2&lt;/sub&gt;-receptor antagonists for the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying.'],\n",
       " 'DB00518': ['the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, &lt;i&gt;taenia solium&lt;/i&gt; and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, &lt;i&gt;echinococcus granulosus&lt;/i&gt;.'],\n",
       " 'DB00519': ['the treatment of mild to moderate hypertension, as an adjunct for the treatment of congestive heart failure (chf), to improve survival following myocardial infarction (mi) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of chf within a few days following acute mi, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.'],\n",
       " 'DB00520': ['the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.'],\n",
       " 'DB00521': ['the treatment of intraocular hypertension and chronic open-angle glaucoma'],\n",
       " 'DB00522': [],\n",
       " 'DB00523': [\"topical treatment of cutaneous lesions in patients with aids-related kaposi's sarcoma.\"],\n",
       " 'DB00524': ['the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.'],\n",
       " 'DB00525': [\"skin infections such as athlete's foot, jock itch, and ringworm infections.\",\n",
       "  \"treat skin infections such as athlete's foot, jock itch, and ringworm\",\n",
       "  'infections of the nails, scalp, palms, and soles of the feet.',\n",
       "  \"athlete's foot.\",\n",
       "  \"prevent athlete's foot.\"],\n",
       " 'DB00526': ['advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients who have undergone complete resection of the primary tumor.',\n",
       "  'the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients who have undergone complete resection of the primary tumor.',\n",
       "  'combination with infusional 5-fu/lv, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients who have undergone complete resection of the primary tumor.'],\n",
       " 'DB00527': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.'],\n",
       " 'DB00528': [\"the treatment of hypertension, management of angina pectoris and raynaud's syndrome\"],\n",
       " 'DB00529': ['the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) and for the treatment of acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients.'],\n",
       " 'DB00530': ['for the treatment of metastatic non-small cell lung cancer (nsclc) with tumors showing epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations ',\n",
       "  '- in combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer ',\n",
       "  'the safety and efficacy of drug have not been established for patients with nsclc whose tumors show other egfr mutations',\n",
       "  'metastatic non-small cell lung cancer (nsclc) with tumors showing epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations .',\n",
       "  'combination with platinum-based chemotherapy.'],\n",
       " 'DB00531': ['malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast.',\n",
       "  'the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast.',\n",
       "  'biopsy-proven minimal change nephrotic syndrome',\n",
       "  'the treatment of biopsy-proven minimal change nephrotic syndrome'],\n",
       " 'DB00532': ['the treatment of refractory partial epilepsy.'],\n",
       " 'DB00533': ['the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.'],\n",
       " 'DB00534': ['a diuretic.', 'a diagnostic and research tool.'],\n",
       " 'DB00535': [' acute bacterial exacerbations of chronic bronchitis caused by haemophilus influenzae, haemophilus parainfluenzae, streptococcus pneumoniae (penicillin-susceptible only), and moraxella catarrhalis',\n",
       "  ' community-acquired pneumonia caused by haemophilus influenzae, haemophilus parainfluenzae, streptococcus pneumoniae (penicillin-susceptible only), and moraxella catarrhalis',\n",
       "  ' **ear, nose, and throat** ',\n",
       "  'treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (ca) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.',\n",
       "  'acute bacterial otitis media, acute maxillary sinusitis, community-acquired (ca) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.'],\n",
       " 'DB00536': ['the reduction of symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of eaton-lambert.',\n",
       "  'treating myasthenia gravis.',\n",
       "  'myasthenia gravis'],\n",
       " 'DB00537': ['drug immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis',\n",
       "  'a drug otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa',\n",
       "  'a drug eye drop is indicated for bacterial corneal ulcers and conjunctivitis',\n",
       "  'a drug extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis',\n",
       "  'skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.',\n",
       "  'the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections',\n",
       "  'acute otitis externa.',\n",
       "  'acute otitis media',\n",
       "  'patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or patients 6 months or older with acute otitis externa.',\n",
       "  'bacterial corneal ulcers and conjunctivitis.',\n",
       "  'bacterial conjunctivitis.',\n",
       "  'uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.'],\n",
       " 'DB00538': ['mri diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.'],\n",
       " 'DB00539': ['the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors.'],\n",
       " 'DB00540': ['the relief of symptoms of major depressive disorder (mdd).',\n",
       "  'the relief of symptoms of major depressive disorder (mdd).'],\n",
       " 'DB00541': ['relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all).',\n",
       "  'the treatment of relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all).'],\n",
       " 'DB00542': ['hypertension.', 'the treatment of hypertension.'],\n",
       " 'DB00543': ['the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions.',\n",
       "  'depression accompanied by anxiety or agitation.',\n",
       "  'treat depression accompanied by anxiety or agitation.'],\n",
       " 'DB00544': ['the topical treatment of multiple actinic or solar keratoses.',\n",
       "  'superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.',\n",
       "  'some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.'],\n",
       " 'DB00545': ['the treatment of myasthenia gravis.'],\n",
       " 'DB00546': ['the treatment of anxiety and status epilepticus.'],\n",
       " 'DB00547': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.'],\n",
       " 'DB00548': ['the topical treatment of mild-to-moderate inflammatory acne vulgaris.'],\n",
       " 'DB00549': ['the prophylaxis and chronic treatment of asthma.'],\n",
       " 'DB00550': [\"manage hyperthyroidism which is due to an overactive thyroid gland (grave's disease).\"],\n",
       " 'DB00551': ['chronic urea-splitting urinary infections.'],\n",
       " 'DB00552': ['the treatment of hairy cell leukaemia refractory to alpha interferon.'],\n",
       " 'DB00553': ['the treatment of psoriasis and vitiligo'],\n",
       " 'DB00554': ['the treatment of osteoarthritis and rheumatoid arthritis.'],\n",
       " 'DB00555': ['it is indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently  are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed)',\n",
       "  'in addition to the above, drug is indicated for the maintenance treatment of bipolar i disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been  treated for acute mood symptoms with standard therapy',\n",
       "  'limitations of use',\n",
       "  'the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently  are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed).',\n",
       "  'the maintenance treatment of bipolar i disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes)',\n",
       "  'the maintenance treatment of bipolar i disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been  treated for acute mood symptoms with standard therapy.',\n",
       "  'acute mood episodes, as efficacy has not been established in this context.',\n",
       "  'the treatment of acute mood episodes, as efficacy has not been established in this context.'],\n",
       " 'DB00556': ['an ultrasound contrast imaging'],\n",
       " 'DB00557': ['canadian labeling states that drug is indicated in adults and children as a premedication prior to medical procedures, such as dental surgery',\n",
       "  'the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested.',\n",
       "  'the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested.',\n",
       "  'histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.',\n",
       "  'the treatment of histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.',\n",
       "  'the control of nausea and vomiting, excluding nausea and vomiting of pregnancy.'],\n",
       " 'DB00558': ['the prevention and treatment of influenza a and b.'],\n",
       " 'DB00559': ['pulmonary arterial hypertension (pah), to improve exercise ability and to decrease the rate of clinical worsening (in patients with who class iii or iv symptoms).',\n",
       "  'the treatment of pulmonary arterial hypertension (pah), to improve exercise ability and to decrease the rate of clinical worsening (in patients with who class iii or iv symptoms).',\n",
       "  'exercise ability and to decrease the rate of clinical worsening (in patients with who class iii or iv symptoms)'],\n",
       " 'DB00560': ['the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: complicated skin and skin structure infections caused by &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;enterococcus faecalis&lt;/i&gt; (vancomycin-susceptible isolates only), &lt;i&gt;staphylococcus aureus&lt;/i&gt; (methicillin-susceptible and -resistant isolates), &lt;i&gt;streptococcus agalactiae&lt;/i&gt;, &lt;i&gt;streptococcus anginosus&lt;/i&gt; grp.'],\n",
       " 'DB00561': ['use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.'],\n",
       " 'DB00562': ['the treatment of high blood pressure and management of edema.'],\n",
       " 'DB00563': [\"other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-hodgkin's lymphoma\",\n",
       "  'pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.',\n",
       "  'severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.',\n",
       "  \"treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-hodgkin's lymphoma.\",\n",
       "  \"gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-hodgkin's lymphoma.\",\n",
       "  'the maintenance of acute lymphocytic leukemia.'],\n",
       " 'DB00564': ['epilepsy and pain associated with true trigeminal neuralgia.',\n",
       "  'the treatment of epilepsy and pain associated with true trigeminal neuralgia.',\n",
       "  'mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures',\n",
       "  'manic episodes and mixed manic-depressive episodes caused by bipolar i disorder.',\n",
       "  'the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar i disorder.'],\n",
       " 'DB00565': ['inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the icu.'],\n",
       " 'DB00566': ['the treatment of lead poisoning in patients with blood lead levels above 45 &amp;micro;g/dl.',\n",
       "  'mercury or arsenic poisoning.',\n",
       "  'treat mercury or arsenic poisoning.'],\n",
       " 'DB00567': ['certain infections caused by susceptible bacteria.',\n",
       "  'the treatment of certain infections caused by susceptible bacteria.'],\n",
       " 'DB00568': [\"the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.\"],\n",
       " 'DB00569': ['ua and nstemi for the prevention of death and subsequent myocardial infarction (mi); and (5) management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy.',\n",
       "  'death and subsequent myocardial infarction (mi); and (5) management of stemi for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy.',\n",
       "  'the sole anticoagulant during percutaneous coronary intervention (pci) due to an'],\n",
       " 'DB00570': [\"the treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, hodgkin's and non-hodgkin's lymphomas, mycosis fungoides, histiocytosis, and kaposi's sarcoma.\"],\n",
       " 'DB00571': ['treat hypertension.',\n",
       "  'hypertension.',\n",
       "  'treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.',\n",
       "  'angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.'],\n",
       " 'DB00572': ['the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.'],\n",
       " 'DB00573': ['relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.'],\n",
       " 'DB00574': ['seizures in dravet syndrome patients aged two years and older.',\n",
       "  'the treatment of seizures in dravet syndrome patients aged two years and older.'],\n",
       " 'DB00575': ['drug is used for the diagnosis of pheochromocytoma,',\n",
       "  'hypertension alone or in combination with other medications.',\n",
       "  'the treatment of hypertension alone or in combination with other medications.',\n",
       "  'severe cancer pain where opiates alone are insufficient.',\n",
       "  'use with opiates for the treatment of severe cancer pain where opiates alone are insufficient.',\n",
       "  'adhd either alone or in combination with other medications.',\n",
       "  'the treatment of adhd either alone or in combination with other medications.',\n",
       "  'the diagnosis of pheochromocytoma,.'],\n",
       " 'DB00576': ['the treatment of urinary tract infection'],\n",
       " 'DB00577': ['**adults**',\n",
       "  ' genital herpes',\n",
       "  ' suppression of genital herpes lesions in immunocompetent or hiv-infected patients',\n",
       "  ' herpes zoster',\n",
       "  ' cold sores (herpes labialis)',\n",
       "  'the efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in hiv-infected patients',\n",
       "  '.'],\n",
       " 'DB00578': ['the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.'],\n",
       " 'DB00579': ['short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m&lt;sup&gt;2&lt;/sup&gt;) or in patients with a body mass index of 27 kg/m&lt;sup&gt;2&lt;/sup&gt; in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.'],\n",
       " 'DB00580': ['the treatment of osteoarthritis and dysmenorrhoea'],\n",
       " 'DB00581': ['additionally, drug is employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portal-systemic encephalopathy (pse), including both the hepatic pre-coma and coma variations',\n",
       "  'moreover, there have also been studies demonstrating the capacity for drug to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions ',\n",
       "  'chronic constipation',\n",
       "  'use as a laxative for the treatment of chronic constipation'],\n",
       " 'DB00582': ['the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by &lt;i&gt;scedosporium apiospermum&lt;/i&gt; and &lt;i&gt;fusarium&lt;/i&gt; spp.'],\n",
       " 'DB00583': ['the treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of drug from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylcoa dehydrogenase deficiency.',\n",
       "  'hyperlipoproteinemias.',\n",
       "  'the prevention and treatment of carnitine deficiency',\n",
       "  'the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.'],\n",
       " 'DB00584': ['indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis',\n",
       "  'indicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of  to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure',\n",
       "  'the management of essential or renovascular hypertension .',\n",
       "  'essential or renovascular hypertension .',\n",
       "  'symptomatic congestive heart failure, usually in combination with diuretics and digitalis.',\n",
       "  'the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.',\n",
       "  'the management of asymptomatic left ventricular dysfunction',\n",
       "  'asymptomatic left ventricular dysfunction in patients with an ejection fraction of  to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure.',\n",
       "  'the rate of development of overt heart failure and the incidence of hospitalization for heart failure'],\n",
       " 'DB00585': ['the treatment of acid-reflux disorders (gerd), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.'],\n",
       " 'DB00586': ['pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma.',\n",
       "  'use for the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma.',\n",
       "  'combination with .'],\n",
       " 'DB00587': ['protection against second- phase inflamation in exercise-induced bronchoconstriction and asthma.'],\n",
       " 'DB00588': ['asthma by prophylaxis.',\n",
       "  'managing allergic and nonallergic rhinitis.'],\n",
       " 'DB00589': [\"parkinson's disease\"],\n",
       " 'DB00590': ['treat symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms.',\n",
       "  'symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms.',\n",
       "  'hypertension.'],\n",
       " 'DB00591': ['-in dermatology, it is extensively used for the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis',\n",
       "  '-it has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalp',\n",
       "  '-in ear drops, it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and patients 2 years and older',\n",
       "  '-as an intravitreal implant, it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure',\n",
       "  '-drug was announced on october 15, 2018 to be fda approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye',\n",
       "  '-some reports have indicated the use of drug as a vasoprotective agent and for its use for the treatment of first-degree hemorrhoids',\n",
       "  'the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis.',\n",
       "  'seborrheic dermatitis of the scalp.',\n",
       "  'shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalp.',\n",
       "  'chronic eczematous external otitis',\n",
       "  'a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis',\n",
       "  'diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure.',\n",
       "  'the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure.',\n",
       "  'chronic non-infectious uveitis affecting the posterior segment of the eye.',\n",
       "  'first-degree hemorrhoids.'],\n",
       " 'DB00592': ['alternative treatment for ascariasis caused by &lt;i&gt;ascaris lumbricoides&lt;/i&gt; (roundworm) and enterobiasis (oxyuriasis) caused by &lt;i&gt;enterobius vermicularis&lt;/i&gt; (pinworm).',\n",
       "  'partial intestinal obstruction by the common roundworm, a condition primarily occurring in children.',\n",
       "  'treat partial intestinal obstruction by the common roundworm, a condition primarily occurring'],\n",
       " 'DB00593': ['the treatment of petit mal epilepsy.'],\n",
       " 'DB00594': ['use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.'],\n",
       " 'DB00595': ['infections caused by a variety of gram positive and gram negative microorganisms including &lt;i&gt;mycoplasma pneumoniae, pasteurella pestis, escherichia coli, haemophilus influenzae&lt;/i&gt; (respiratory infections), and &lt;i&gt;diplococcus pneumoniae&lt;/i&gt;.',\n",
       "  'the treatment of infections caused by a variety of gram positive and gram negative microorganisms including &lt;i&gt;mycoplasma pneumoniae, pasteurella pestis, escherichia coli, haemophilus influenzae&lt;/i&gt; (respiratory infections), and &lt;i&gt;diplococcus pneumoniae&lt;/i&gt;.'],\n",
       " 'DB00596': ['inflammatory and pruritic corticosteroid responsive dermatoses.',\n",
       "  'the treatment of inflammatory and pruritic corticosteroid responsive dermatoses.',\n",
       "  'plaque psoriasis.',\n",
       "  'the treatment of plaque psoriasis.'],\n",
       " 'DB00597': ['contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced mri) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier.',\n",
       "  'a disruption of the normal blood brain barrier',\n",
       "  'whole body contrast enhanced mri including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.'],\n",
       " 'DB00598': ['control blood pressure in severe hypertension.'],\n",
       " 'DB00599': ['use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.'],\n",
       " 'DB00600': ['the loss of skin color (vitiligo).'],\n",
       " 'DB00601': ['the treatment of bacterial infections caused by susceptible strains of vancomycin resistant &lt;i&gt;enterococcus faecium&lt;/i&gt;, &lt;i&gt;staphylococcal aureus&lt;/i&gt; (methicillin resistant and susceptible strains), &lt;i&gt;streptococcus pneumoniae&lt;/i&gt;, &lt;i&gt;streptococcus pyogenes&lt;/i&gt;, &lt;i&gt;streptococcus agalactiae&lt;/i&gt;.'],\n",
       " 'DB00602': ['the treatment of intestinal (i.',\n",
       "  'onchocerciasis (river blindness) due to the nematode parasite &lt;i&gt;onchocerca volvulus&lt;/i&gt;.',\n",
       "  'scabies caused by &lt;i&gt;sarcoptes scabiei&lt;/i&gt;.',\n",
       "  'treat scabies caused by &lt;i&gt;sarcoptes scabiei&lt;/i&gt;.'],\n",
       " 'DB00603': ['treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology.',\n",
       "  'secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology.',\n",
       "  'prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.',\n",
       "  'postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.',\n",
       "  'moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.',\n",
       "  'prevent pregnancy and manage pain associated with endometriosis.',\n",
       "  'pregnancy and manage pain associated with endometriosis.',\n",
       "  'prevent pregnancy,.',\n",
       "  'pregnancy,.'],\n",
       " 'DB00604': ['the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.'],\n",
       " 'DB00605': ['acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.'],\n",
       " 'DB00606': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.'],\n",
       " 'DB00607': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.',\n",
       "  'the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.'],\n",
       " 'DB00608': ['drug is used off label for the treatment of rheumatic diseases,',\n",
       "  'treat infections of _p.',\n",
       "  'infections of _p.',\n",
       "  'extraintestinal amebiasis.',\n",
       "  'treat extraintestinal amebiasis.',\n",
       "  'rheumatic diseases,.',\n",
       "  'covid-19.'],\n",
       " 'DB00609': ['use for the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.'],\n",
       " 'DB00610': ['the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage'],\n",
       " 'DB00611': ['the relief of moderate to severe pain.'],\n",
       " 'DB00612': ['mild to moderate hypertension.',\n",
       "  'the treatment of mild to moderate hypertension.',\n",
       "  'heart failure, atrial fibrillation, and angina pectoris.'],\n",
       " 'DB00613': ['the treatment of acute malarial attacks in non-immune subjects.'],\n",
       " 'DB00614': ['the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.'],\n",
       " 'DB00615': ['the prevention of disseminated &lt;i&gt;mycobacterium avium&lt;/i&gt; complex (mac) disease in patients with advanced hiv infection.'],\n",
       " 'DB00617': ['the control of absence (petit mal) seizures that are refractory to treatment with other medications.'],\n",
       " 'DB00618': ['lyme disease, acne, and bronchitis.',\n",
       "  'urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia.'],\n",
       " 'DB00619': ['the treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+ cml), ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (cel), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (gist).'],\n",
       " 'DB00620': ['drug acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses',\n",
       "  'intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum.',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.',\n",
       "  'inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.',\n",
       "  'the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon.',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.',\n",
       "  'leukemia and lymphoma; induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosus.',\n",
       "  'sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions.',\n",
       "  'the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions.',\n",
       "  'visualization during vitrectomy.',\n",
       "  'pain in osteoarthritis of the knee.'],\n",
       " 'DB00621': ['weight gain after weight loss following extensive surgery'],\n",
       " 'DB00622': ['hypertension.',\n",
       "  'the management of patients with chronic stable angina and for the treatment of hypertension.',\n",
       "  'patients with chronic stable angina and for the treatment of hypertension.'],\n",
       " 'DB00623': ['management of manifestations of psychotic disorders.'],\n",
       " 'DB00624': ['treat primary hypogonadism and hypogonadotropic hypogonadism.',\n",
       "  'primary hypogonadism and hypogonadotropic hypogonadism.'],\n",
       " 'DB00625': ['use in combination treatment of hiv infection (aids)'],\n",
       " 'DB00626': ['corticosteroid responsive dermatoses with secondary infection.',\n",
       "  'the treatment of corticosteroid responsive dermatoses with secondary infection.'],\n",
       " 'DB00627': ['prevent vitamin deficiencies',\n",
       "  'vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.',\n",
       "  'primary hyperlipidemia and mixed dyslipidemia.',\n",
       "  'the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia',\n",
       "  'reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial',\n",
       "  'atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.',\n",
       "  'treat severe hypertriglyceridemia.',\n",
       "  'severe hypertriglyceridemia.'],\n",
       " 'DB00628': ['anxiety disorders or for the short-term relief of symptoms of anxiety.',\n",
       "  'partial seizures and for the symptomatic relief of acute alcohol withdrawal.',\n",
       "  'adjunctive therapy'],\n",
       " 'DB00629': ['management of high blood pressure'],\n",
       " 'DB00630': [\"the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and paget's disease of bone.\",\n",
       "  \"the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and paget's disease of bone.\",\n",
       "  'use',\n",
       "  'pediatric populations or patients with a creatinine clearance &lt;35ml/min.'],\n",
       " 'DB00631': ['the treatment of patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens.'],\n",
       " 'DB00632': ['the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).'],\n",
       " 'DB00633': ['sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia'],\n",
       " 'DB00634': ['the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.'],\n",
       " 'DB00635': [],\n",
       " 'DB00636': ['primary dysbetalipoproteinemia (type iii hyperlipidemia) that does not respond adequately to diet.'],\n",
       " 'DB00637': ['use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis.',\n",
       "  'the relieving allergy symptoms, particularly rhinitis and conjunctivitis.'],\n",
       " 'DB00638': ['an important medical test of renal function, specifically a measure of glomerular filtration rate.',\n",
       "  'help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia.'],\n",
       " 'DB00639': ['the local treatment of vulvovaginal candidiasis (infections caused by candida)'],\n",
       " 'DB00640': ['an treatment for the termination of paroxysmal supraventricular tachycardia (pvst),',\n",
       "  'an adjunct to thallous chloride ti 201 myocardial perfusion scintigraphy (thallium stress test)'],\n",
       " 'DB00641': ['this includes the treatment of primary hyperlipidemia (fredrickson type iia, heterozygous familial and nonfamilial), mixed dyslipidemia (fredrickson type iib), hypertriglyceridemia (fredrickson type iv hyperlipidemia), primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia), homozygous familial hypercholesterolemia (hofh) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with heterozygous familial hypercholesterolemia (hefh)',\n",
       "  'drug is indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures',\n",
       "  'prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of cvd',\n",
       "  'hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg), and to increase high-density lipoprotein cholesterol (hdl-c).',\n",
       "  'the treatment of hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg), and to increase high-density lipoprotein cholesterol (hdl-c).',\n",
       "  'elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg), and to increase high-density lipoprotein cholesterol (hdl-c)',\n",
       "  'reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures.',\n",
       "  'the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures',\n",
       "  'patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.'],\n",
       " 'DB00642': ['malignant pleural mesothelioma',\n",
       "  'combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery.',\n",
       "  'locally advanced or metastatic non-small cell lung cancer (nsclc) after prior chemotherapy',\n",
       "  'a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (nsclc) after prior chemotherapy'],\n",
       " 'DB00643': ['the treatment of &lt;i&gt;enterobius vermicularis&lt;/i&gt; (pinworm), &lt;i&gt;trichuris trichiura&lt;/i&gt; (whipworm), &lt;i&gt;ascaris lumbricoides&lt;/i&gt; (common roundworm), &lt;i&gt;ancylostoma duodenale&lt;/i&gt; (common hookworm), &lt;i&gt;necator americanus&lt;/i&gt; (american hookworm) in single or mixed infections.'],\n",
       " 'DB00644': ['evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.'],\n",
       " 'DB00645': ['provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures',\n",
       "  'suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or',\n",
       "  'relief of canker sores, cold sores or fever blister.'],\n",
       " 'DB00646': ['drug is sometimes used off-label for the prevention of invasive candidiasis in low birth weight neonates,',\n",
       "  'vulvovaginal candidiasis and other cutaneous candida infections.',\n",
       "  'corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.',\n",
       "  'the treatment of corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.',\n",
       "  'mixed infections due to _trichomonas vaginalis_ and _candida albicans_.',\n",
       "  'invasive candidiasis in low birth weight neonates,.'],\n",
       " 'DB00647': ['the relief of mild to moderate pain.'],\n",
       " 'DB00648': [\"the treatment of inoperable adrenocortical tumours; cushing's syndrome\"],\n",
       " 'DB00649': ['the treatment of human immunovirus (hiv) infections.'],\n",
       " 'DB00650': ['the treatment of osteosarcoma (after high dose methotrexate therapy).',\n",
       "  'megaloblastic anemias due to folic acid deficiency.',\n",
       "  'diminish the toxicity and counteract the effects of impaired methotrexate elimination and of',\n",
       "  'patients with advanced colorectal cancer.',\n",
       "  'combination with 5-fluorouracil to prolong survival in the treatment of patients with advanced colorectal cancer.'],\n",
       " 'DB00651': ['relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.'],\n",
       " 'DB00652': ['the relief of moderate to severe pain.'],\n",
       " 'DB00653': ['severe toxemias (pre-eclampsia and eclampsia) of pregnancy and for the treatment of acute nephritis in children.',\n",
       "  'immediate control of life-threatening convulsions for the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and for the treatment of acute nephritis in children.',\n",
       "  'replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia.',\n",
       "  'uterine tetany as a myometriat relaxant.'],\n",
       " 'DB00654': ['the reduction of elevated intraocular pressure',\n",
       "  'the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.',\n",
       "  'elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.'],\n",
       " 'DB00655': ['management of perimenopausal and postmenopausal symptoms.'],\n",
       " 'DB00656': ['major depressive disorder (mdd).',\n",
       "  'the treatment of major depressive disorder (mdd).',\n",
       "  'anxiety and insomnia.',\n",
       "  'symptoms of dementia, alzheimers disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors.'],\n",
       " 'DB00657': ['the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension'],\n",
       " 'DB00658': ['the control of serum phosphorus in patients with chronic kidney disease (ckd) on hemodialysis.'],\n",
       " 'DB00659': ['the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation'],\n",
       " 'DB00660': ['the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.'],\n",
       " 'DB00661': ['drug is commonly used off-label for prophylaxis of cluster headaches',\n",
       "  'vasopastic (i.',\n",
       "  'the treatment of vasopastic (i.',\n",
       "  'treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate',\n",
       "  'combination with digoxin to control ventricular rate',\n",
       "  'hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter.',\n",
       "  'various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm',\n",
       "  'temporary control of ventricular rate',\n",
       "  'the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm'],\n",
       " 'DB00662': ['the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.'],\n",
       " 'DB00663': ['the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions'],\n",
       " 'DB00664': ['the treatment of urinary tract infection and chronic bronchitis.'],\n",
       " 'DB00665': ['use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (stage d2).'],\n",
       " 'DB00666': ['the treatment of central precocious puberty (true precocious puberty, gnrh-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.'],\n",
       " 'DB00668': [\"drug's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock \",\n",
       "  'drug is used as a hemostatic agent',\n",
       "  'in addition to the above, drug is used as an over the counter (otc) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath ',\n",
       "  'cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock .',\n",
       "  'a hemostatic agent.',\n",
       "  'uterine contractions.',\n",
       "  'bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions',\n",
       "  'mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions',\n",
       "  'treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions.',\n",
       "  'an over the counter (otc) agent for the',\n",
       "  'the maintenance of mydriasis during intraocular surgery .'],\n",
       " 'DB00669': ['migraines with or without auras',\n",
       "  'the treatment of migraines with or without auras',\n",
       "  'treat migraines with or without auras',\n",
       "  'migraines with or without auras in adults.',\n",
       "  'treat cluster headaches',\n",
       "  'cluster headaches in adults.'],\n",
       " 'DB00670': ['the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.'],\n",
       " 'DB00671': ['use for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by &lt;i&gt;escherichia coli&lt;/i&gt; and &lt;i&gt;proteus mirabilis&lt;/i&gt;, (2) otitis media caused by &lt;i&gt;haemophilus influenzae&lt;/i&gt; (beta-lactamase positive and negative strains), &lt;i&gt;moraxella catarrhalis&lt;/i&gt; (most of which are beta-lactamase positive), and &lt;i&gt;s.'],\n",
       " 'DB00672': ['the treatment of niddm in conjunction with diet and exercise.'],\n",
       " 'DB00673': ['the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).'],\n",
       " 'DB00674': ['mild to moderate dementia of the alzheimers type.',\n",
       "  'the treatment of mild to moderate dementia of the alzheimers type.'],\n",
       " 'DB00675': ['early stage estrogen receptor positive breast cancer',\n",
       "  'treat estrogen receptor positive metastatic breast cancer',\n",
       "  'estrogen receptor positive metastatic breast cancer in adults, as an adjuvant for the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.',\n",
       "  'the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ'],\n",
       " 'DB00676': ['kill lice and the mites responsible for the skin condition scabies.'],\n",
       " 'DB00677': ['use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.'],\n",
       " 'DB00678': ['treat hypertension',\n",
       "  'hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.',\n",
       "  'treat hypertension and to reduce the risk of stroke',\n",
       "  'hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage).',\n",
       "  'the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage)'],\n",
       " 'DB00679': ['the treatment of schizophrenia and generalized anxiety disorder.'],\n",
       " 'DB00680': ['irregular heartbeats (arrhythmias) and maintain a normal heart rate.',\n",
       "  'treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.'],\n",
       " 'DB00681': ['potentially life threatening fungal infections.',\n",
       "  'treat potentially life threatening fungal'],\n",
       " 'DB00682': ['1) prophylaxis and treatment of venous thromboembolism and related pulmonary embolism',\n",
       "  '2) prophylaxis and treatment of thromboembolism associated with atrial fibrillation',\n",
       "  '3) prophylaxis and treatment of thromboembolism associated with cardiac valve replacement',\n",
       "  '4) use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction',\n",
       "  '**off-label** uses include:',\n",
       "  'mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction'],\n",
       " 'DB00683': ['indicated for promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  '**intramuscular** ',\n",
       "  '**nasal** ',\n",
       "  'promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia.',\n",
       "  'preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  'status epilepticus',\n",
       "  'the treatment of status epilepticus',\n",
       "  'the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.'],\n",
       " 'DB00684': ['the treatment of pseudomonas aeruginosa lung infections.',\n",
       "  'sinus infections.'],\n",
       " 'DB00685': ['the treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by &lt;i&gt;neisseria gonorrhoeae&lt;/i&gt; as well as non gonoccocal urethritis and cervicitis due to &lt;i&gt;chlamydia trachomatis&lt;/i&gt;.'],\n",
       " 'DB00686': ['the relief of bladder pain or discomfort associated with interstitial cystitis.'],\n",
       " 'DB00687': ['salt-losing androgenital syndrome.',\n",
       "  'the treatment of salt-losing androgenital syndrome.'],\n",
       " 'DB00688': ['the prophylaxis of organ rejection',\n",
       "  'the prophylaxis of organ rejection in patients undergoing allogeneic renal, hepatic, or cardiac transplants.'],\n",
       " 'DB00689': ['the treatment of severe infections caused by susceptible bacteria.'],\n",
       " 'DB00690': ['short-term and intermittent use in patients with recurring insomnia and poor sleeping habits'],\n",
       " 'DB00691': ['the treatment of hypertension.'],\n",
       " 'DB00692': ['or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor.',\n",
       "  'an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor.',\n",
       "  'hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking mao inhibitors, or by clonidine withdrawal syndrome.',\n",
       "  'treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking mao',\n",
       "  'cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.'],\n",
       " 'DB00693': ['diagnostic imaging.'],\n",
       " 'DB00694': ['remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.'],\n",
       " 'DB00695': ['oral drug is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications',\n",
       "  'intravenous drug is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired',\n",
       "  'edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome,',\n",
       "  'the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome,',\n",
       "  'mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.'],\n",
       " 'DB00696': ['use as therapy to abort or prevent vascular headache, e.'],\n",
       " 'DB00697': ['the relief of muscle spasticity, which can interfere with daily activities.',\n",
       "  'the relief of muscle spasticity, which can interfere with daily activities.'],\n",
       " 'DB00698': ['treat acute uncomplicated urinary tract infections.',\n",
       "  'acute uncomplicated urinary tract infections.'],\n",
       " 'DB00699': ['the treatment of senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration.'],\n",
       " 'DB00700': ['improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction &lt;40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.'],\n",
       " 'DB00701': ['the treatment of hiv-1 infection in combination with other antiretroviral agents.'],\n",
       " 'DB00702': ['continuous ambulatory peritoneal dialysis (capd) of diabetic patients or automated peritoneal dialysis (apd) for the management of end-stage renal disease.',\n",
       "  'end-stage renal disease.'],\n",
       " 'DB00703': ['the treatment of chronic open-angle glaucoma and acute angle-closure glaucoma'],\n",
       " 'DB00704': ['an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in',\n",
       "  'the management of alcohol dependence in conjunction with a behavioural modification program.',\n",
       "  'alcohol dependence in conjunction with a behavioural modification program.'],\n",
       " 'DB00705': ['the treatment of hiv-1 infection in combination with appropriate antiretroviral agents when therapy is warranted'],\n",
       " 'DB00706': ['drug is used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction',\n",
       "  'signs and symptoms of benign prostatic hyperplasia.',\n",
       "  'the treatment of signs and symptoms of benign prostatic hyperplasia.',\n",
       "  'ureteral stones, prostatitis, and female voiding dysfunction.'],\n",
       " 'DB00707': ['esophageal cancer.', 'the treatment of esophageal cancer.'],\n",
       " 'DB00708': ['the management of acute pain',\n",
       "  'acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments.'],\n",
       " 'DB00709': ['the treatment of hiv infection and chronic hepatitis b (hbv).'],\n",
       " 'DB00710': ['the treatment and prevention of osteoporosis in postmenopausal women.'],\n",
       " 'DB00711': ['certain filarial diseases, including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with &lt;i&gt;wuchereria bancrofti&lt;/i&gt;, &lt;i&gt;brugia malayi&lt;/i&gt;, or &lt;i&gt;brugia timori&lt;/i&gt;.',\n",
       "  'the treatment of certain filarial diseases, including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with &lt;i&gt;wuchereria bancrofti&lt;/i&gt;, &lt;i&gt;brugia malayi&lt;/i&gt;, or &lt;i&gt;brugia timori&lt;/i&gt;.'],\n",
       " 'DB00712': ['the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis.',\n",
       "  'pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.',\n",
       "  'treat pain associated with dysmenorrhea and mild to moderate pain accompanied by',\n",
       "  'intraoperative miosis.'],\n",
       " 'DB00713': ['resistant staphylococci infections.',\n",
       "  'the treatment of resistant staphylococci infections.'],\n",
       " 'DB00714': [\"treat acute, intermittent treatment of hypomobility, off episodes associated with advanced parkinson's disease.\",\n",
       "  \"acute, intermittent treatment of hypomobility, off episodes associated with advanced parkinson's disease.\"],\n",
       " 'DB00715': ['the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.',\n",
       "  'the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.',\n",
       "  'depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.',\n",
       "  'manage mild to moderate vasomotor symptoms of menopause.',\n",
       "  'premature ejaculation or irritable bowel syndrome (ibs).',\n",
       "  'the treatment of premature ejaculation or irritable bowel syndrome (ibs).'],\n",
       " 'DB00716': ['the treatment of mild to moderate asthma'],\n",
       " 'DB00717': ['drug, taken in combination with intramuscular ',\n",
       "  'postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause.',\n",
       "  'hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.',\n",
       "  'the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.',\n",
       "  'the symptomatic treatment of endometriosis-related pain.'],\n",
       " 'DB00718': ['chronic hepatitis b', 'the treatment of chronic hepatitis b'],\n",
       " 'DB00719': ['the relief of symptoms of upper respiratory mucosal congestion in perennial and allergic rhinitis, and for the relief of nasal congestion and eustachian t.'],\n",
       " 'DB00720': ['osteolysis from bone metastases of malignant tumors and for management of hypercalcemia of malignancy.'],\n",
       " 'DB00721': ['a local anesthetic primarily'],\n",
       " 'DB00722': ['acute myocardial infarction, hypertension',\n",
       "  'the treatment of acute myocardial infarction, hypertension',\n",
       "  'hypertension.',\n",
       "  'the treatment of hypertension.'],\n",
       " 'DB00723': ['the treatment and management of hypotension.', 'hypotension.'],\n",
       " 'DB00724': ['the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.',\n",
       "  'external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.',\n",
       "  'the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.'],\n",
       " 'DB00725': ['peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.',\n",
       "  'further gastric acid secretion and delay gastric emptying',\n",
       "  'conjunction with antacids or histamine h2-receptor antagonists for the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.'],\n",
       " 'DB00726': ['the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance'],\n",
       " 'DB00727': ['the intravenous form is used off-label in emergency settings and is commonly used to treat acute coronary spasm caused by cocaine, hypertensive emergencies, as well as acute congestive heart failure exacerbations',\n",
       "  'various purposes.',\n",
       "  'various purposes.',\n",
       "  'prevent and treat angina or chest pain due to cardiovascular disease, as well as to treat peri-operative hypertension or induce intra-operative hypotension.',\n",
       "  'and treat angina or chest pain due to cardiovascular disease, as well as to treat peri-operative hypertension or induce intra-operative hypotension.',\n",
       "  'peri-operative hypertension or induce intra-operative hypotension.',\n",
       "  'treat acute heart failure',\n",
       "  'acute heart failure in patients with myocardial infarction.',\n",
       "  'treat pain caused by anal fissures.',\n",
       "  'pain caused by anal fissures.',\n",
       "  'acute anginal attacks.',\n",
       "  'acute coronary spasm caused by cocaine, hypertensive emergencies, as well as acute congestive heart failure exacerbations.',\n",
       "  'treat acute coronary spasm caused by cocaine, hypertensive emergencies, as well as acute congestive heart failure exacerbations.',\n",
       "  'variceal hemorrhage.',\n",
       "  'esophageal spasticity.'],\n",
       " 'DB00728': ['inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.'],\n",
       " 'DB00730': ['the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.'],\n",
       " 'DB00731': ['the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.'],\n",
       " 'DB00732': ['use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.'],\n",
       " 'DB00733': ['the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used for the treatment of myasthenia gravis.'],\n",
       " 'DB00734': ['drug is additionally indicated in canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the alzheimer type unresponsive to nonpharmacological approaches',\n",
       "  'drug is used off-label for a number of conditions including as an adjunct to antidepressants for the treatment-resistant depression',\n",
       "  'schizophrenia and irritability associated with autistic disorder.',\n",
       "  'the treatment of schizophrenia and irritability associated with autistic disorder.',\n",
       "  'acute mania or mixed episodes associated with bipolar i disorder.',\n",
       "  'aggression or psychotic symptoms in patients with severe dementia of the alzheimer type unresponsive to nonpharmacological approaches.'],\n",
       " 'DB00735': ['the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms &lt;i&gt;trichophyton rubrum&lt;/i&gt;, &lt;i&gt;trichophyton mentagrophytes&lt;/i&gt;, &lt;i&gt;trichophyton tonsurans&lt;/i&gt; and &lt;i&gt;epidermophyton floccosum&lt;/i&gt;.'],\n",
       " 'DB00736': ['acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h.',\n",
       "  'the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h.'],\n",
       " 'DB00737': ['the symptomatic treatment of nausea, vomiting, and dizziness associated with motion sickness,.',\n",
       "  'vertigo due to various causes, including radiation sickness, menieres syndrome, labyrinthitis and other vestibular disturbances.'],\n",
       " 'DB00738': ['the treatment of pneumonia due to &lt;i&gt;pneumocystis carinii&lt;/i&gt;.'],\n",
       " 'DB00739': ['bacterial infections.', 'treat bacterial'],\n",
       " 'DB00740': [\"the treatment of amyotrophic lateral sclerosis (als, lou gehrig's disease)\"],\n",
       " 'DB00741': ['infections of the external auditory canal caused by susceptible organisms and with inflammation.',\n",
       "  'certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions.',\n",
       "  'ulcerative colitis,.',\n",
       "  'corticosteroid responsive dermatoses with infections,.',\n",
       "  'treat cold sores.',\n",
       "  'cold sores.',\n",
       "  'a replacement therapy for adrenocortical insufficiency (ai)'],\n",
       " 'DB00742': ['drug is indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the bronchitol tolerance test (btt)',\n",
       "  'the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.'],\n",
       " 'DB00743': ['mri of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.'],\n",
       " 'DB00744': ['the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.'],\n",
       " 'DB00745': ['wakefulness in patients with excessive daytime sleepiness (eds) associated with narcolepsy'],\n",
       " 'DB00746': ['acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients.',\n",
       "  'treat acute iron or aluminum toxicity (an excess of aluminum in the body)',\n",
       "  'certain patients with anemia who must receive many blood transfusions.'],\n",
       " 'DB00747': ['the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.'],\n",
       " 'DB00748': ['symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens.',\n",
       "  'mild, uncomplicated allergic skin manifestations of urticaria and angioedema.'],\n",
       " 'DB00749': ['pain.'],\n",
       " 'DB00750': ['a local anaesthetic and is often used', 'dentistry.'],\n",
       " 'DB00751': ['the prevention of itching associated with allergic conjunctivitis.'],\n",
       " 'DB00752': ['the treatment of major depressive episode without melancholia.'],\n",
       " 'DB00753': ['induction and maintenance of general anesthesia.'],\n",
       " 'DB00754': ['the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.'],\n",
       " 'DB00755': [\"the the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant); for the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (darier's disease), and basal cell carcinomas.\",\n",
       "  'fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage'],\n",
       " 'DB00756': ['use as a surgical scrub and a bacteriostatic skin cleanser.',\n",
       "  'control an outbreak of gram-positive infection where other'],\n",
       " 'DB00757': ['the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy.',\n",
       "  'the prevention of postoperative nausea and vomiting.',\n",
       "  'postoperative nausea and vomiting.',\n",
       "  'postoperative nausea and vomiting.'],\n",
       " 'DB00758': ['reduce the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and in recent mi, stroke, or established peripheral arterial disease,.',\n",
       "  'the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and in recent mi, stroke, or established peripheral arterial disease,'],\n",
       " 'DB00759': ['bacterial infections such as rocky mountain spotted fever, typhus fever, tick fevers, q fever, rickettsialpox and brill-zinsser disease.',\n",
       "  'treat bacterial',\n",
       "  'infections caused by chlamydiae spp.',\n",
       "  'treat',\n",
       "  'acne.',\n",
       "  'treat acne.'],\n",
       " 'DB00760': ['use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: &lt;b&gt;complicated skin and skin structure infections&lt;/b&gt; due to &lt;i&gt;staphylococcus aureus&lt;/i&gt; (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), &lt;i&gt;streptococcus pyogenes&lt;/i&gt;, &lt;i&gt;streptococcus agalactiae&lt;/i&gt;, viridans group streptococci, &lt;i&gt;enterococcus faecalis&lt;/i&gt; (excluding vancomycin-resistant isolates), &lt;i&gt;pseudomonas aeruginosa&lt;/i&gt;, &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;proteus mirabilis&lt;/i&gt;, &lt;i&gt;bacteroides fragilis&lt;/i&gt; and &lt;i&gt;peptostreptococcus&lt;/i&gt; species; &lt;b&gt;complicated appendicitis and peritonitis&lt;/b&gt; caused by viridans group streptococci, &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;klebsiella pneumoniae&lt;/i&gt;, &lt;i&gt;pseudomonas aeruginosa&lt;/i&gt;, &lt;i&gt;bacteroides fragilis&lt;/i&gt;, &lt;i&gt;b.',\n",
       "  'bacterial meningitis caused by &lt;i&gt;streptococcus pneumoniae&lt;/i&gt;, &lt;i&gt;haemophilus influenzae&lt;/i&gt; (b-lactamase and non-b-lactamase-producing isolates), and &lt;i&gt;neisseria meningitidis&lt;/i&gt;.'],\n",
       " 'DB00761': ['use as an electrolyte replenisher and for the treatment of hypokalemia.'],\n",
       " 'DB00762': ['the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).',\n",
       "  'extensive small cell lung cancer.',\n",
       "  'combination with cisplatin for the treatment of extensive small cell lung cancer.',\n",
       "  'metastatic or recurrent cervical cancer.',\n",
       "  'patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.',\n",
       "  'metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.',\n",
       "  'combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.'],\n",
       " 'DB00763': ['in canada, drug carries the above indications and is indicated for the medical treatment of hyperthyroidism regardless of other available treatment options',\n",
       "  'hyperthyroidism',\n",
       "  'the treatment of hyperthyroidism',\n",
       "  'the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.',\n",
       "  'the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.',\n",
       "  'the medical treatment of hyperthyroidism regardless of other available treatment options.'],\n",
       " 'DB00764': ['the maintenance treatment of asthma as prophylactic therapy.',\n",
       "  'the nasal symptoms of seasonal allergic and perennial allergic rhinitis.',\n",
       "  'the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.'],\n",
       " 'DB00765': ['use for the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.'],\n",
       " 'DB00766': ['the following conditions, when they produced beta-lactamases, have been treated with a combination of amoxicillin and drug or ticarcillin and drug',\n",
       "  'acute otitis media caused by  h',\n",
       "  'sinusitis due to h',\n",
       "  'lower respiratory tract infections due to haemophilus influenzae, s',\n",
       "  'skin and skin structure infections caused by staphylococcus aureus, escherichia coli, and klebsiella species',\n",
       "  'gynecologic infections due to a variety of bacteria, including p',\n",
       "  'septicemia due to a variety of bacteria, including klebsiella species, e',\n",
       "  'bone and joint infections due to s',\n",
       "  'intraabdominal infections due to e',\n",
       "  '**a note on susceptibility**',\n",
       "  'prevent the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.',\n",
       "  'the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects.',\n",
       "  'selecting whether this antibiotic is prescribed.',\n",
       "  'determine the appropriateness of using drug.',\n",
       "  'infections where a regimen of several drugs may normally be used.'],\n",
       " 'DB00767': ['and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously.',\n",
       "  'prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or'],\n",
       " 'DB00768': ['in nasal spray, drug is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older',\n",
       "  'the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution.',\n",
       "  'the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution.',\n",
       "  'the symptomatic relief of seasonal allergic rhinitis',\n",
       "  'the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older.'],\n",
       " 'DB00769': ['steroid-responsive dermatoses'],\n",
       " 'DB00770': ['palliative, not definitive, therapy to maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival.',\n",
       "  'erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.'],\n",
       " 'DB00771': ['the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.'],\n",
       " 'DB00772': ['patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.'],\n",
       " 'DB00773': ['use in combination with other chemotherapeutic agents for the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer.',\n",
       "  'other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.',\n",
       "  'treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.'],\n",
       " 'DB00774': ['adjunctive therapy',\n",
       "  'hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.',\n",
       "  'the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.'],\n",
       " 'DB00775': ['the treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy.'],\n",
       " 'DB00776': ['partial-onset seizures',\n",
       "  'partial-onset seizures',\n",
       "  'partial-onset seizures',\n",
       "  'use as monotherapy or adjunctive therapy for the treatment of partial-onset seizures'],\n",
       " 'DB00777': ['its antihistamininc sleep inducing effects in treating insomnia.',\n",
       "  'insomnia'],\n",
       " 'DB00778': ['respiratory tract, urinary and soft tissue infections.',\n",
       "  'treat respiratory tract, urinary and soft tissue'],\n",
       " 'DB00779': ['the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of &lt;i&gt;e.'],\n",
       " 'DB00780': ['atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior',\n",
       "  'neurotic depression is a depression of an emotionally unstable person',\n",
       "  'a nonendogenous depression is characterized by a disturbance in mood and general outlook',\n",
       "  'nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.',\n",
       "  'the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.'],\n",
       " 'DB00782': ['the treatment of enuresis.',\n",
       "  'hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.'],\n",
       " 'DB00783': ['**a note on duration of treatment**',\n",
       "  'following extensive critique of the whi results, hormone replacement therapy (hrt) is now recommended to be used only for a short period (for 3-5 years postmenopause) in low doses, and in women without a history of breast cancer or increased risk of cardiovascular or thromboembolic disease',\n",
       "  'moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, .',\n",
       "  'postmenopausal osteoporosis.',\n",
       "  'breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for the treatment of androgen-dependent prostate cancer (only for palliation therapy).',\n",
       "  'the treatment of breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for the treatment of androgen-dependent prostate cancer (only for palliation therapy).',\n",
       "  'combination with other hormones as a component of oral contraceptive pills for preventing pregnancy (most commonly as .',\n",
       "  \"menopausal symptoms changed drastically following the release of results and early termination of the women's health initiative (whi) studies in 2002 as concerns were raised regarding estrogen use.\",\n",
       "  'the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer over the long-term'],\n",
       " 'DB00784': ['the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.'],\n",
       " 'DB00785': ['the treatment of hypertension.'],\n",
       " 'DB00786': ['the treatment of various cancers'],\n",
       " 'DB00787': ['treat recurrent herpes labialis in immunocompetent patients 12 years and older.',\n",
       "  'recurrent herpes labialis in immunocompetent patients 12 years and older.',\n",
       "  'treat herpes zoster, genital herpes, and chickenpox.',\n",
       "  'herpes zoster, genital herpes, and chickenpox.',\n",
       "  'treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients.',\n",
       "  'initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients.',\n",
       "  'treat recurrent herpes labialis, and shortening lesion healing time',\n",
       "  'recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older.',\n",
       "  'recurrent herpes labialis.',\n",
       "  'the treatment of recurrent herpes labialis.',\n",
       "  'treat acute herpetic keratitis.',\n",
       "  'acute herpetic keratitis.'],\n",
       " 'DB00788': ['the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.',\n",
       "  'the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.',\n",
       "  'rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.'],\n",
       " 'DB00789': ['use with magnetic resonance imaging (mri) in adults, and patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck.',\n",
       "  'facilitate the visualization of lesions with abnormal vascularity'],\n",
       " 'DB00790': ['the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.'],\n",
       " 'DB00791': ['its antineoplastic properties.'],\n",
       " 'DB00792': ['the symptomatic relief of hypersensitivity reactions, coughs, and the common cold.'],\n",
       " 'DB00793': [\"fungal (tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor.\",\n",
       "  'treat fungal (tinea) skin'],\n",
       " 'DB00794': ['the management of grand mal, psychomotor, and focal epileptic seizures.',\n",
       "  'grand mal, psychomotor, and focal epileptic seizures.',\n",
       "  'essential tremor.'],\n",
       " 'DB00795': [\"the treatment of crohn's disease and rheumatoid arthritis as a second-line agent.\"],\n",
       " 'DB00796': ['uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy.',\n",
       "  'a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy.',\n",
       "  'a first line agent to delay progression of diabetic nephropathy.',\n",
       "  'congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace inhibitors.',\n",
       "  'a second line agent for the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace'],\n",
       " 'DB00797': ['the treatment of pulmonary artery anomalies'],\n",
       " 'DB00798': ['the treatment of serious infections caused by susceptible strains of the following microorganisms: &lt;i&gt;p.'],\n",
       " 'DB00799': ['psoriasis, acne and sun damaged skin (photodamage).',\n",
       "  'treat psoriasis, acne and sun damaged skin (photodamage).'],\n",
       " 'DB00800': ['the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.'],\n",
       " 'DB00801': ['anxiety, nervousness, and tension associated with anxiety disorders',\n",
       "  'relieve anxiety, nervousness, and tension associated with anxiety disorders.'],\n",
       " 'DB00802': ['postoperative pain and the maintenance of general anesthesia.'],\n",
       " 'DB00803': ['the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly &lt;i&gt;pseudomonas aeruginosa&lt;/i&gt;.'],\n",
       " 'DB00804': ['functional bowel disorder and irritable bowel syndrome.',\n",
       "  'the treatment of functional bowel disorder and irritable bowel syndrome.'],\n",
       " 'DB00805': ['the treatment of depression'],\n",
       " 'DB00806': ['the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.'],\n",
       " 'DB00807': ['a local (ophthalmic) anesthetic.'],\n",
       " 'DB00808': ['use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension.',\n",
       "  'hypertension.',\n",
       "  'fluid and salt retention associated with congestive heart failure.',\n",
       "  'treat fluid and salt retention associated with congestive heart failure.'],\n",
       " 'DB00809': ['induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye.',\n",
       "  'mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye'],\n",
       " 'DB00810': ['use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.'],\n",
       " 'DB00811': ['the addition of drug in technivie therapy indicated for treating hcv genotype 1a and 4 infections is recommended in patients with or without cirrhosis',\n",
       "  'resistance: viral genetic determinants resulting in variable response to drug therapy has not been yet determined',\n",
       "  'chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr).',\n",
       "  'the treatment of chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr).',\n",
       "  'svr and reduce relapse rates ',\n",
       "  'treating hcv genotype 1a and 4 infections is recommended',\n",
       "  'hcv genotype 1a and 4 infections is recommended in patients with or without cirrhosis'],\n",
       " 'DB00812': ['the treatment of backache and ankylosing spondylitis'],\n",
       " 'DB00813': ['drug sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management',\n",
       "  'short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.',\n",
       "  'the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.',\n",
       "  'breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.'],\n",
       " 'DB00814': ['the symptomatic treatment of arthritis and osteoarthritis.',\n",
       "  'the symptomatic treatment of arthritis and osteoarthritis.',\n",
       "  'the pauciarticular and polyarticular course of juvenile rheumatoid arthritis (jra)',\n",
       "  'neuropathic pain.'],\n",
       " 'DB00815': ['a surfactant', 'microbicidal'],\n",
       " 'DB00816': ['the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.'],\n",
       " 'DB00817': ['the treatment of bacterial infection of respiratory tract, urinary tract, gi, cns and immuno compromised patients.'],\n",
       " 'DB00818': ['induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.',\n",
       "  'refractory status epilepticus.'],\n",
       " 'DB00819': ['adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma'],\n",
       " 'DB00820': ['erectile dysfunction.',\n",
       "  'the treatment of erectile dysfunction.'],\n",
       " 'DB00821': ['use as a pain reliever for the treatment of joint pain and post-surgical pain.'],\n",
       " 'DB00822': ['the treatment and management of chronic alcoholism'],\n",
       " 'DB00823': ['the prevention of pregnancy in women who elect to use this product as a method of contraception.'],\n",
       " 'DB00824': ['symptoms of asthma.',\n",
       "  'the management of symptoms of asthma.',\n",
       "  'peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.',\n",
       "  'the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.',\n",
       "  'cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.'],\n",
       " 'DB00825': ['occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.',\n",
       "  'treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or'],\n",
       " 'DB00826': ['the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including &lt;i&gt;fusarium solani&lt;/i&gt; keratitis.'],\n",
       " 'DB00827': ['the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: &lt;i&gt;escherichia coli&lt;/i&gt;, &lt;i&gt;proteus mirabilis&lt;/i&gt;, &lt;i&gt;proteus vulgaris&lt;/i&gt;, &lt;i&gt;klebsiella&lt;/i&gt; species (including &lt;i&gt;k.'],\n",
       " 'DB00828': ['the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of &lt;i&gt;escherichia coli&lt;/i&gt; and &lt;i&gt;enterococcus faecalis&lt;/i&gt;.'],\n",
       " 'DB00829': ['moreover, in acute alcoholic withdrawal, drug may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens',\n",
       "  'furthermore, drug is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare \"stiff man syndrome\"',\n",
       "  'particular label information from the united kingdom also lists particular age-specific indications, including for adults: (1) the short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg',\n",
       "  'in the same uk label information, drug is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication',\n",
       "  \"a drug nasal spray is indicated in patients 6 years and older to treat intermittent, stereotypic episodes of frequent seizure activity that are different than the patient's usual seizure pattern\",\n",
       "  'mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression.',\n",
       "  \"intermittent, stereotypic episodes of frequent seizure activity that are different than the patient's usual seizure pattern.\"],\n",
       " 'DB00830': ['obesity.', 'an anorectic for the treatment of obesity.'],\n",
       " 'DB00831': ['the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.'],\n",
       " 'DB00832': ['the treatment of epilepsy.'],\n",
       " 'DB00833': ['the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.'],\n",
       " 'DB00834': [\"the medical termination of intrauterine pregnancy through 49 days' pregnancy.\",\n",
       "  'control hyperglycemia secondary to hypercortisolism'],\n",
       " 'DB00835': ['the treatment of symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.'],\n",
       " 'DB00836': ['the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis.',\n",
       "  'reducing the volume of discharge from ileostomies.',\n",
       "  'the volume of discharge from ileostomies'],\n",
       " 'DB00837': ['epilepsy.', 'the treatment of epilepsy.'],\n",
       " 'DB00838': ['short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.'],\n",
       " 'DB00839': ['use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (type ii) whose hyperglycemia cannot be satisfactorily controlled by diet alone.'],\n",
       " 'DB00840': ['dryness and irritation caused by reduced tear flow that occurs in certain eye diseases (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes',\n",
       "  'relieve dryness and irritation caused by reduced tear flow that occurs'],\n",
       " 'DB00841': [],\n",
       " 'DB00842': ['the management of anxiety disorders and for the short-term relief of symptoms of anxiety.',\n",
       "  'the management of anxiety disorders and for the short-term relief of symptoms of anxiety.',\n",
       "  'anxiety disorders and for the short-term relief of symptoms of anxiety.',\n",
       "  'alcohol withdrawal symptoms.',\n",
       "  'the management of alcohol withdrawal symptoms.'],\n",
       " 'DB00843': ['the management of mild to moderate alzheimers disease at doses of 5 mg or 10 mg.',\n",
       "  'the management of mild to moderate alzheimers disease at doses of 5 mg or 10 mg.',\n",
       "  'mild to moderate alzheimers disease at doses of 5 mg or 10 mg.',\n",
       "  'the management of moderate to severe alzheimers disease in a higher dose of 10 mg or 23 mg administered once daily.',\n",
       "  'moderate to severe alzheimers disease in a higher dose of 10 mg or 23 mg administered once daily.',\n",
       "  \"vascular dementia, parkinson's disease-associated dementia, and lewy body dementia, among others.\",\n",
       "  'treat symptoms of moderate to severe dementia.',\n",
       "  'symptoms of moderate to severe dementia.'],\n",
       " 'DB00844': ['the relief of moderate to severe pain.'],\n",
       " 'DB00845': ['lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.',\n",
       "  'the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.',\n",
       "  'the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments.'],\n",
       " 'DB00846': ['relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions'],\n",
       " 'DB00847': ['the oral treatment of nephropathic cystinosis and cystinuria in children 6 years old and above, and adults.',\n",
       "  'corneal cystine crystal accumulation',\n",
       "  'the treatment of corneal cystine crystal accumulation',\n",
       "  'eye drop preparations, is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.'],\n",
       " 'DB00848': [\"adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes' stage c colon cancer.\",\n",
       "  'malignant melanoma and head/neck cancer.',\n",
       "  'treat malignant melanoma and head/neck cancer.'],\n",
       " 'DB00849': ['the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.'],\n",
       " 'DB00850': ['use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.'],\n",
       " 'DB00851': ['the treatment of metastatic malignant melanoma.',\n",
       "  \"hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.\",\n",
       "  \"hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.\",\n",
       "  'combination with other antineoplastic agents.'],\n",
       " 'DB00852': ['its decongestant activity.'],\n",
       " 'DB00853': ['the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.',\n",
       "  'maintenance therapy for glioblastoma multiforme.'],\n",
       " 'DB00854': ['moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate.'],\n",
       " 'DB00855': ['minimally to moderately thick actinic keratoses of the face or scalp.',\n",
       "  'the treatment of minimally to moderately thick actinic keratoses of the face or scalp.'],\n",
       " 'DB00856': ['injuries and other painful muscular conditions.',\n",
       "  'trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain.'],\n",
       " 'DB00857': ['treat fungal skin and nail infections caused by _trichophyton_ species, _microsporum canis_, _epidermophyton floccosum_,.',\n",
       "  'fungal skin and nail infections caused by _trichophyton_ species, _microsporum canis_, _epidermophyton floccosum_,.'],\n",
       " 'DB00859': [\"the treatment of wilson's disease, cystinuria and active rheumatoid arthritis.\"],\n",
       " 'DB00860': ['treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.',\n",
       "  'endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.'],\n",
       " 'DB00861': ['symptomatic treatment of mild to moderate pain accompanied by inflammation (e.'],\n",
       " 'DB00862': ['erectile dysfunction', 'the treatment of erectile dysfunction'],\n",
       " 'DB00863': ['the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose.',\n",
       "  'gerd symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.',\n",
       "  'the treatment of gerd symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.'],\n",
       " 'DB00864': [\"use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection.\",\n",
       "  'liver transplantation.',\n",
       "  'severe atopic dermatitis.',\n",
       "  'a topical preparation for the treatment of severe atopic dermatitis.'],\n",
       " 'DB00865': ['exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction'],\n",
       " 'DB00866': ['the treatment of hypertension, angina, and arrhythmia'],\n",
       " 'DB00867': ['the treatment and prophylaxis of premature labour'],\n",
       " 'DB00868': ['the symptomatic relief of cough.',\n",
       "  'the symptomatic relief of cough.'],\n",
       " 'DB00869': ['its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy',\n",
       "  'the management of elevated intraocular pressure',\n",
       "  'the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.',\n",
       "  'elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.',\n",
       "  'combination with .',\n",
       "  'elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.'],\n",
       " 'DB00870': ['the miosis (pupil constriction) that may occur during ocular surgery.',\n",
       "  'the miosis (pupil constriction) that may occur during ocular surgery',\n",
       "  'eye drops to'],\n",
       " 'DB00871': ['the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema.',\n",
       "  'uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.',\n",
       "  'uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial'],\n",
       " 'DB00872': ['the treatment of euvolemic or hypervolemic hyponatremia (e.'],\n",
       " 'DB14596': ['post-operative inflammation and pain following ocular surgery .',\n",
       "  'the treatment of post-operative inflammation and pain following ocular surgery .'],\n",
       " 'DB00874': ['providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses .'],\n",
       " 'DB00875': ['use for the treatment of schizophrenia and depression'],\n",
       " 'DB00876': ['hypertension alone or in combination with other classes of antihypertensive agents.',\n",
       "  'diabetic nephropathy, as well as a second-line agent for the treatment of congestive heart failure (only in those intolerant of ace inhibitors).',\n",
       "  'a first-line agent for the treatment of diabetic nephropathy, as well as a second-line agent for the treatment of congestive heart failure (only in those intolerant of ace'],\n",
       " 'DB00877': ['the prophylaxis of organ rejection in patients receiving renal transplants.'],\n",
       " 'DB00878': ['gingivitis.',\n",
       "  'the treatment of gingivitis.',\n",
       "  'the reduction of pocket depth'],\n",
       " 'DB00879': ['hiv-1 infections;.'],\n",
       " 'DB00880': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.'],\n",
       " 'DB00881': ['hypertension and as an adjunct therapy for the treatment of heart failure.',\n",
       "  'the treatment of hypertension and as an adjunct therapy for the treatment of heart failure.',\n",
       "  'hypertension.',\n",
       "  'the treatment of hypertension.'],\n",
       " 'DB00882': ['ovulation'],\n",
       " 'DB00883': ['the prevention of angina pectoris due to coronary artery disease.'],\n",
       " 'DB00884': [\"osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.\",\n",
       "  \"the treatment of osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.\"],\n",
       " 'DB00885': ['the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis'],\n",
       " 'DB00886': ['the treatment of hypertension.'],\n",
       " 'DB00887': ['the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.'],\n",
       " 'DB00888': [\"the treatment of hodgkin's disease (stages iii and iv), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma.\",\n",
       "  'metastatic carcinoma resulting in effusion.'],\n",
       " 'DB00889': ['the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).'],\n",
       " 'DB00890': ['use for the treatment of atrophic vaginitis and kraurosis vulvae.'],\n",
       " 'DB00891': ['the treatment of dermatitis herpetiformis, benign mucous membrane pemphigoid and pyoderma gangrenosum'],\n",
       " 'DB00892': ['numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.'],\n",
       " 'DB00893': ['the treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible.',\n",
       "  'replenish body iron stores in non-dialysis dependent-chronic kidney disease (ndd-ckd) patients receiving or not receiving erythropoietin and'],\n",
       " 'DB00894': ['treatment of advanced breast cancer in postmenopausal women.'],\n",
       " 'DB00895': ['use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin g).'],\n",
       " 'DB00896': ['the treatment of postoperative inflammation following ocular surgery and for the treatment of anterior uveitis.'],\n",
       " 'DB00897': ['the short-term treatment of insomnia.'],\n",
       " 'DB00898': ['therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.'],\n",
       " 'DB00899': ['use during the induction and maintenance of general anesthesia.'],\n",
       " 'DB00900': ['use, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in adults.'],\n",
       " 'DB00901': ['dilate air passages in the lungs that have become narrowed as a result of disease or',\n",
       "  'asthma and chronic obstructive pulmonary disease (copd).',\n",
       "  'the treatment of asthma and chronic obstructive pulmonary disease (copd).'],\n",
       " 'DB00902': ['the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders'],\n",
       " 'DB00903': ['the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.'],\n",
       " 'DB00904': [' i) orally administered drug tablets and orally disintegrating tablets (odt) are indicated for:',\n",
       "  ' - the prevention and treatment of postoperative nausea and vomiting',\n",
       "  ' ii) intravenously administered drug injection formulations are indicated for:',\n",
       "  ' - the prevention and treatment of postoperative nausea and vomiting',\n",
       "  ' in the pediatric (4-18 years of age) patient population:',\n",
       "  ' ii) drug tablets, drug odt, drug injection are not indicated for the treatment of children 3 years of age or younger,',\n",
       "  ' iv) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting',\n",
       "  ' in the geriatric (&gt;65 years of age) patient population:',\n",
       "  'post-chemotherapy induced nausea and vomiting,&#13; ii) drug tablets, drug odt, drug injection are not indicated for the treatment of children 3 years of age or younger,&#13; iii) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and&#13; iv) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting&#13; &#13; in the geriatric (&gt;65 years of age) patient population:&#13; i) efficacy and tolerance of drug were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and&#13; ii) clinical experience in the use of drug in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population ',\n",
       "  'the treatment of children 3 years of age or younger,&#13; iii) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and&#13; iv) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting&#13; &#13; in the geriatric (&gt;65 years of age) patient population:&#13; i) efficacy and tolerance of drug were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and&#13; ii) clinical experience in the use of drug in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population ',\n",
       "  'any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and&#13; iv) drug tablets, drug odt, drug injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting&#13; &#13; in the geriatric (&gt;65 years of age) patient population:&#13; i) efficacy and tolerance of drug were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and&#13; ii) clinical experience in the use of drug in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population '],\n",
       " 'DB00905': [' these patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments..l6877]',\n",
       "  'the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.',\n",
       "  'treat eyelash hypotrichosis.',\n",
       "  'eyelash hypotrichosis.'],\n",
       " 'DB00906': ['the treatment of partial seizures'],\n",
       " 'DB00907': ['the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.'],\n",
       " 'DB00908': ['the treatment of ventricular pre-excitation and cardiac dysrhythmias'],\n",
       " 'DB00909': ['use as adjunctive treatment of partial seizures in adults with epilepsy.'],\n",
       " 'DB00910': ['the treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 3 and 4'],\n",
       " 'DB00911': ['the treatment of trichomoniasis caused by &lt;i&gt;t.',\n",
       "  'giardiasis caused by &lt;i&gt;g.',\n",
       "  'intestinal amebiasis and amebic liver abscess caused by &lt;i&gt;e.'],\n",
       " 'DB00912': ['glycemic control in adults with type 2 diabetes mellitus'],\n",
       " 'DB00913': ['the treatment and management of pain (systemic) and for use as an anesthesia adjunct.'],\n",
       " 'DB00914': ['the reatment of type ii diabetes mellitus.'],\n",
       " 'DB00915': ['the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza a virus.',\n",
       "  'parkinsonism and drug-induced extrapyramidal reactions.'],\n",
       " 'DB00916': [\"it is used off-label for the treatment of crohn's disease and rosacea, as a prophylactic agent after surgery\",\n",
       "  \"confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis.\",\n",
       "  \"the treatment of confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis.\",\n",
       "  \"crohn's disease and rosacea, as a prophylactic agent after surgery.\",\n",
       "  'helicobacter pylori infection.',\n",
       "  'periodontal disease.'],\n",
       " 'DB00917': ['the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period.',\n",
       "  'nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).',\n",
       "  'the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).',\n",
       "  'postpartum hemorrhage.'],\n",
       " 'DB00918': ['the treatment of acute migraine headache in adults'],\n",
       " 'DB00919': ['use for the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of &lt;i&gt;neisseria gonorrhoeae&lt;/i&gt;.'],\n",
       " 'DB00920': ['self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic).'],\n",
       " 'DB00921': ['the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.',\n",
       "  'the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.',\n",
       "  'combination with .',\n",
       "  'moderate to severe opioid use disorder.'],\n",
       " 'DB00922': ['short term treatment of acutely decompensated severe chronic heart failure (chf).',\n",
       "  'heart disease.'],\n",
       " 'DB00923': ['the treatment of infections caused by susceptible organisms.'],\n",
       " 'DB00924': ['spasticity originating from cerebral or spinal cord disease, or spasticity in children with cerebral palsy.',\n",
       "  'pain and sleep disturbances in patients with fibromyalgia'],\n",
       " 'DB00925': ['the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.'],\n",
       " 'DB00926': ['the treatment of severe psoriasis in adults.'],\n",
       " 'DB00927': ['it is indicated in adult patients for the treatment of pathological hypersecretory conditions (e',\n",
       "  'the intravenous formulation of drug is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication',\n",
       "  'over-the-counter drug is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults',\n",
       "  'active duodenal ulcer (du), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (gerd), and erosive esophagitis due to gerd, diagnosed by biopsy.',\n",
       "  'pathological hypersecretory conditions (e.',\n",
       "  'the management and prevention of heartburn caused by gastroesophageal reflux in children and adults.'],\n",
       " 'DB00928': ['the treatment of patients with the following french-american-british myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.'],\n",
       " 'DB00929': ['the risk of nsaid induced gastric ulcers but not duodenal ulcers in high risk patients',\n",
       "  'symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers.',\n",
       "  'miscarriages, prevention of post partum hemorrhage, and is used alone or in combination with mifepristone in other countries for first trimester abortions.'],\n",
       " 'DB00930': ['use, alone or in combination with an hmg-coa reductase inhibitor, as adjunctive therapy to diet and exercise for the reduction of elevated ldl cholesterol in patients with primary hypercholesterolemia (fredrickson type iia).'],\n",
       " 'DB00931': ['the treatment of acute bacterial exacerbations of chronic bronchitis'],\n",
       " 'DB00932': ['combination antiretroviral treatment of hiv-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have hiv-1 strains resistant to multiple protease inhibitors.'],\n",
       " 'DB00933': ['schizophrenia, organic brain disorders, alcoholism and psychoneuroses.',\n",
       "  'the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.'],\n",
       " 'DB00934': ['the treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.'],\n",
       " 'DB00935': ['drug in the ophthalmic formulation is indicated for the treatment of acquired blepharoptosis in adults',\n",
       "  'when used in combination with tetracaine intranasally, drug is indicated for the for regional anesthesia when performing a restorative procedure on teeth 4-13 and a-j in adults and children who weigh 40 kg or more',\n",
       "  'the topical treatment of persistent facial erythema associated with rosacea',\n",
       "  'the topical treatment of persistent facial erythema associated with rosacea in adults.',\n",
       "  'acquired blepharoptosis',\n",
       "  'the treatment of acquired blepharoptosis',\n",
       "  'the for regional anesthesia when performing a restorative procedure on teeth 4-13 and a-j',\n",
       "  'the for regional anesthesia when performing a restorative procedure on teeth 4-13 and a-j in adults and children who weigh 40 kg or more.',\n",
       "  'combination with tetracaine intranasally, drug is indicated for the for regional anesthesia when performing a restorative procedure on teeth 4-13 and a-j in adults and children who weigh 40 kg or more.'],\n",
       " 'DB00936': ['acne, psoriasis, callouses, corns, keratosis pilaris and warts.'],\n",
       " 'DB00937': ['exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.',\n",
       "  'the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.'],\n",
       " 'DB00938': ['asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease.',\n",
       "  'the treatment of asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease.'],\n",
       " 'DB00939': ['the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss.'],\n",
       " 'DB00940': ['the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.'],\n",
       " 'DB00941': ['succinylcholine-induced muscle fasciculations.',\n",
       "  'an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.'],\n",
       " 'DB00942': [\"the treatment and management of parkinson's disease.\"],\n",
       " 'DB00943': ['the treatment of human immunovirus (hiv) infections in conjunction with other antivirals.'],\n",
       " 'DB00944': ['the topical treatment of chronic open-angle glaucoma.'],\n",
       " 'DB00945': ['drug (asa), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries',\n",
       "  'the _extra strength_ formulation of drug is indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)',\n",
       "  '**other indications**',\n",
       "  'reducing the risk of cardiovascular death in suspected cases of myocardial infarction (mi) ',\n",
       "  'reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction ',\n",
       "  'for reducing the risk of transient ischemic attacks (tia) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) ',\n",
       "  'for the prevention of thromboembolism after hip replacement surgery ',\n",
       "  'for decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (tia) ',\n",
       "  'used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site ',\n",
       "  '**important note regarding use of the extended-release formulation ',\n",
       "  'in the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of drug should not be used',\n",
       "  'relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries.',\n",
       "  'pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries',\n",
       "  'symptomatic pain relief after surgical and dental procedures .',\n",
       "  'the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).',\n",
       "  'the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).',\n",
       "  'various other purposes, due to its ability to inhibit platelet aggregation.',\n",
       "  'platelet aggregation.',\n",
       "  'platelet aggregation',\n",
       "  'the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction ',\n",
       "  'atherothrombotic cerebral infarction (in conjunction with other treatments) .',\n",
       "  'the risk of transient ischemic attacks (tia) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) ',\n",
       "  'thromboembolism after hip replacement surgery .',\n",
       "  'platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (tia) ',\n",
       "  'patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .',\n",
       "  'thrombosis at the insertion site .',\n",
       "  'the incidence of mortality and myocardial infarction (mi) for individuals diagnosed with chronic coronary artery disease (cad), including patients with previous myocardial infarction (mi) or unstable angina or with chronic stable angina',\n",
       "  'the risk of death and recurrent episodes of stroke in patients with a history of stroke or tia ',\n",
       "  'decrease the risk of death and recurrent episodes of stroke'],\n",
       " 'DB00946': ['the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (af).',\n",
       "  'ischemic stroke in patients with atrial fibrillation (af).'],\n",
       " 'DB00947': ['the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.'],\n",
       " 'DB00948': ['serious gram&amp;ndash;negative infections of the lungs, urinary tract, and skin.',\n",
       "  'treat serious gram&amp;ndash;negative'],\n",
       " 'DB00949': ['use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.'],\n",
       " 'DB00950': ['the symptomatic treatment of allergic rhinitis',\n",
       "  'the symptomatic treatment of allergic rhinitis in patients 2 years old and chronic idiopathic urticaria in patients 6 months old.'],\n",
       " 'DB00951': ['the treatment of all forms of tuberculosis in which organisms are susceptible.'],\n",
       " 'DB00952': ['the acute treatment of migraine attacks with or without aura in adults.'],\n",
       " 'DB00953': ['the treatment of acute migraine attacks with or without aura.'],\n",
       " 'DB00954': ['the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.'],\n",
       " 'DB00955': ['the treatment of bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains.'],\n",
       " 'DB00956': ['the management of acute pain, sometimes in combination with .',\n",
       "  'the management of acute pain, sometimes in combination with .',\n",
       "  'acute pain, sometimes in combination with .'],\n",
       " 'DB00957': [],\n",
       " 'DB00958': ['the treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.',\n",
       "  'patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.',\n",
       "  'the treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.',\n",
       "  'ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.'],\n",
       " 'DB00959': ['a number of endocrine,  rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.',\n",
       "  'short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.'],\n",
       " 'DB00960': ['hypertension, edema, ventricular tachycardias, and atrial fibrillation.'],\n",
       " 'DB00961': ['production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.'],\n",
       " 'DB00962': ['the treatment of short-term treatment of insomnia in adults.'],\n",
       " 'DB00963': ['the treatment of postoperative inflammation in patients who have undergone cataract extraction.'],\n",
       " 'DB00964': ['prevention or reduction of intraoperative and postoperative increases in intraocular pressure (iop) before and after ocular laser surgery when used prophylactically.',\n",
       "  'a short-term adjunctive therapy'],\n",
       " 'DB00965': ['use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-i.',\n",
       "  'follow-up imaging for chemoembolization.'],\n",
       " 'DB00966': ['hypertension.',\n",
       "  'diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only',\n",
       "  'the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ace inhibitors).'],\n",
       " 'DB00967': ['the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis.',\n",
       "  'the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.'],\n",
       " 'DB00968': ['use for the treatment of hypertension.'],\n",
       " 'DB00969': ['symptoms of severe diarrhea-predominant irritable bowel syndrome (ibs) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical gi abnormalities and have not responded to conventional therapy.'],\n",
       " 'DB00970': [\"the treatment of wilms' tumor, childhood rhabdomyosarcoma, ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen\"],\n",
       " 'DB00971': ['the treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.'],\n",
       " 'DB00972': ['the symptomatic treatment of seasonal allergic rhinitis',\n",
       "  'the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and older.',\n",
       "  'itchy eyes associated with allergic conjunctivitis.',\n",
       "  'the treatment of itchy eyes associated with allergic conjunctivitis.'],\n",
       " 'DB00973': ['reduce elevated total-c, ldl-c, apo b, and non-hdl-c',\n",
       "  'elevated total-c, ldl-c, apo b, and non-hdl-c in patients with primary hyperlipidemia, alone or in combination with an hmg-coa reductase inhibitor (statin)',\n",
       "  'reduce elevated total-c, ldl-c, apo b, and non-hdl-c',\n",
       "  'elevated total-c, ldl-c, apo b, and non-hdl-c in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia (hofh), in combination with atorvastatin or simvastatin',\n",
       "  'elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia)',\n",
       "  'reduce elevated sitosterol and campesterol'],\n",
       " 'DB00974': ['the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.'],\n",
       " 'DB00975': ['as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.'],\n",
       " 'DB00976': ['the treatment of &lt;i&gt;pneumococcal&lt;/i&gt; infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia.'],\n",
       " 'DB00977': [],\n",
       " 'DB00978': ['the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: &lt;i&gt;s.'],\n",
       " 'DB00979': [],\n",
       " 'DB00980': ['the treatment of insomnia characterized by difficulty with sleep onset.'],\n",
       " 'DB00981': ['the treatment of glaucoma, and for the treatment of severe anticholinergic toxicity.'],\n",
       " 'DB00982': ['treat severe recalcitrant nodular acne and patients 12 years enrolled in the ipledge program.',\n",
       "  'severe recalcitrant nodular acne and patients 12 years enrolled in the ipledge program.'],\n",
       " 'DB00983': ['asthma and copd.',\n",
       "  'copd, drug is available as a single-entity inhalation solution,.',\n",
       "  'asthma, drug is available in combination with .'],\n",
       " 'DB00984': [\"the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin iii deficiency, fibrinogen excess, growth failure and turner's syndrome.\"],\n",
       " 'DB00985': ['the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.',\n",
       "  'the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.'],\n",
       " 'DB00986': ['use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation.',\n",
       "  'chronic obstructive pulmonary disease (copd).',\n",
       "  'treat chronic obstructive pulmonary disease (copd).'],\n",
       " 'DB00987': ['the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.'],\n",
       " 'DB00988': ['the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure'],\n",
       " 'DB00989': [\"the treatment of mild to moderate dementia associated with parkinson's disease or of the alzheimer's type.\"],\n",
       " 'DB00990': ['the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.'],\n",
       " 'DB00991': ['the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis',\n",
       "  'relieve the'],\n",
       " 'DB00992': ['topical use, in combination with 570 to 670 nm wavelength red light illumination, for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).'],\n",
       " 'DB00993': ['treat rheumatoid arthritis and prevent renal transplant rejection.',\n",
       "  'rheumatoid arthritis and prevent renal transplant rejection.'],\n",
       " 'DB00994': ['drug, in combination with polymyxin b sulfates and hydrocortisone in otic suspensions, is used for the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics',\n",
       "  'the ophthalmic solution containing drug in combination with polymyxin b sulfates and dexamethasone is used to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists',\n",
       "  'the risk of the development of drug-resistant bacteria',\n",
       "  'infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria.',\n",
       "  'superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics.',\n",
       "  'the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics.',\n",
       "  'infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.',\n",
       "  'the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.',\n",
       "  'steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.',\n",
       "  'treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial'],\n",
       " 'DB00995': ['active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.',\n",
       "  'the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.'],\n",
       " 'DB00996': ['postherpetic neuralgia',\n",
       "  'the adjunctive treatment of partial-onset seizures, with or without secondary generalization,',\n",
       "  'the treatment of postherpetic neuralgia',\n",
       "  'partial-onset seizures, with or without secondary generalization,',\n",
       "  'adjunctive therapy for the treatment of partial-onset seizures, with or without secondary generalization,',\n",
       "  'various types of peripheral neuropathic pain, such as painful diabetic neuropathy.',\n",
       "  'adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.'],\n",
       " 'DB00997': ['produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkins disease, malignant lymphoma and bronchogenic carcinoma',\n",
       "  'use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.',\n",
       "  'use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.'],\n",
       " 'DB00998': ['the acute treatment of migraine attacks with or without aura in adults.'],\n",
       " 'DB00999': ['edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy.',\n",
       "  'hypertension.'],\n",
       " 'DB01000': ['the treatment of bacterial infections caused by susceptible organisms.'],\n",
       " 'DB01001': ['(i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.',\n",
       "  '(i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.',\n",
       "  'bronchospasm'],\n",
       " 'DB01002': ['the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management'],\n",
       " 'DB01003': ['patients with bronchial asthma.',\n",
       "  'vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.',\n",
       "  'the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.'],\n",
       " 'DB01004': ['induction and maintenance for the treatment of cytomegalovirus (cmv) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (aids).',\n",
       "  'severe cytomegalovirus (cmv) disease, including cmv pneumonia, cmv gastrointestinal disease, and disseminated cmv infections, in immunocompromised patients.',\n",
       "  'the treatment of severe cytomegalovirus (cmv) disease, including cmv pneumonia, cmv gastrointestinal disease, and disseminated cmv infections, in immunocompromised patients.'],\n",
       " 'DB01005': ['management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and sickle-cell anemia.'],\n",
       " 'DB01006': ['treat postmenopausal women with hormone receptor (hr) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with hr+ or unknown advanced breast cancer.',\n",
       "  'postmenopausal women with hormone receptor (hr) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with hr+ or unknown advanced breast cancer.',\n",
       "  'treat pre, peri, and postmenopausal women with hr+ and human epidermal growth factor 2 (her2) negative advanced or metastatic breast cancer.',\n",
       "  'pre, peri, and postmenopausal women with hr+ and human epidermal growth factor 2 (her2) negative advanced or metastatic breast cancer.'],\n",
       " 'DB01007': ['the local treatment of vulvovaginal candidiasis (moniliasis).'],\n",
       " 'DB01008': ['use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  (myeloid, myelocytic, granulocytic) leukemia (fda has designated drug as an orphan drug for this use).',\n",
       "  'a component of pretransplant conditioning regimens'],\n",
       " 'DB01009': ['symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.'],\n",
       " 'DB01010': ['the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease.',\n",
       "  'evaluating emergency treatment in myasthenic crises.'],\n",
       " 'DB01011': ['a diagnostic drug for testing hypothalamic-pituitary acth function.',\n",
       "  \"cushing's syndrome.\"],\n",
       " 'DB01012': ['the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on hemodialysis or peritoneal dialysis.',\n",
       "  'hypercalcemia'],\n",
       " 'DB01013': ['treat moderate to severe plaque psoriasis.',\n",
       "  'moderate to severe plaque psoriasis.'],\n",
       " 'DB01014': ['the treatment of mildly to moderately active ulcerative colitis.'],\n",
       " 'DB01015': ['in canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with '],\n",
       " 'DB01016': ['glycemic control in adults with type 2 diabetes mellitus'],\n",
       " 'DB01017': ['treat inflammatory lesions of acne vulgaris.',\n",
       "  'inflammatory lesions of acne vulgaris.',\n",
       "  'treat infections of susceptible microorganisms.',\n",
       "  'infections of susceptible microorganisms.'],\n",
       " 'DB01018': ['adhd.'],\n",
       " 'DB01019': ['the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.'],\n",
       " ...}"
      ]
     },
     "execution_count": 752,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 390,
   "id": "e91bc125",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['heparin-induced thrombocytopenia', '']]"
      ]
     },
     "execution_count": 390,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parse_indication(new_int.lower())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 564,
   "id": "b2859bc8",
   "metadata": {},
   "outputs": [],
   "source": [
    "s = dictionary[k]['indication']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 569,
   "id": "f2965574",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].&#13; &#13; Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and \"Indications\" section of this drug entry for detailed information [FDA label]. &#13; &#13; **Adults**:&#13; &#13; Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_&#13; &#13; Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_&#13; &#13; Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy&#13; &#13; Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.&#13; Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.&#13; &#13; Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.&#13; &#13; Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.&#13; &#13; **Pediatric Patients**&#13; &#13; Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_&#13; &#13; Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.&#13; &#13; Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.'"
      ]
     },
     "execution_count": 569,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary[k]['indication']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1262,
   "id": "1ec4933c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['drugbank_id', 'name', 'description', 'indication', 'pharmacodynamics', 'toxicity', 'metabolism', 'absorption', 'half_life', 'market_start', 'affected_organism', 'market_end', 'mechanism_of_action', 'route_of_elimination', 'volume_of_distribution', 'classification', 'carriers', 'targets', 'transporters', 'enzymes', 'go_classifiers', 'food_interactions', 'ddi', 'pathways'])"
      ]
     },
     "execution_count": 1262,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001'].keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1264,
   "id": "56ad6603",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Pulmonary Toxicity&#13; &#13; Interstitial lung disease (ILD) was reported in 3 of 633 (&lt;0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmonary edema resulting in death was reported in one case. Two patients had pre-existing fibrotic lung disease and experienced an acute exacerbation of their disease while receiving cetuximab in combination with irinotecan. In the clinical investigational program, an additional case of interstitial pneumonitis was reported in a patient with head and neck cancer treated with cetuximab and cisplatin. The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases.'"
      ]
     },
     "execution_count": 1264,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00002']['toxicity']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "20166e54",
   "metadata": {},
   "source": [
    "#### Alternative parsing strategy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "98960399",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "drug, used in combination with irinotecan, is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. drug administered as a single agent is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.\n",
      "['egfr-expressing, metastatic colorectal carcinoma', 'the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy.', 'combination with irinotecan, is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy.', 'egfr-expressing, metastatic colorectal carcinoma', 'the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.']\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['egfr',\n",
       " 'expressing',\n",
       " 'metastatic colorectal carcinoma',\n",
       " 'egfr',\n",
       " 'expressing',\n",
       " 'metastatic colorectal carcinoma in patients who are refractory to irinotecan',\n",
       " 'based chemotherapy',\n",
       " 'combination with irinotecan',\n",
       " 'is indicated for egfr',\n",
       " 'expressing',\n",
       " 'metastatic colorectal carcinoma in patients who are refractory to irinotecan',\n",
       " 'based chemotherapy',\n",
       " 'egfr',\n",
       " 'expressing',\n",
       " 'metastatic colorectal carcinoma',\n",
       " 'egfr',\n",
       " 'expressing',\n",
       " 'metastatic colorectal carcinoma in patients who are intolerant to irinotecan',\n",
       " 'based chemotherapy']"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "k= 'DB00002'\n",
    "s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\").lower()\n",
    "s = s.replace(dictionary[k]['name'].lower(), \"drug\").lower()\n",
    "\n",
    "print(s)\n",
    "#### Start by looking for breaks:\n",
    "def parse_indication(s):\n",
    "    new_s = \"\"\n",
    "    for ss in re.split(\"\\[l\\d+]\", s):\n",
    "        if len(ss) > 2:\n",
    "            new_s += ss\n",
    "            \n",
    "    s = new_s\n",
    "    \n",
    "    s = s.replace(\"twice daily treatment\", \"treatment\")\n",
    "    s = s.replace(\"topical treatment\", \"treatment\")\n",
    "    s = s.replace(\"for treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"symptomatic treatment\", \"treatment\")\n",
    "    s = s.replace(\"in treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"in the treatment of\", \"for the treatment of\")\n",
    "    s = s.replace(\"the symptoms\", \"symptoms\")\n",
    "    s = s.replace(\"use/treatment\", \"use\")\n",
    "    s = s.replace(\"important for\", \"used for\")\n",
    "    s = s.replace(\"the prevention and treatment\", \"the treatment\")\n",
    "    s = s.replace(\"treatment/use\", \"use\")\n",
    "    s = s.replace(\"use this compound as\", \"used as\")\n",
    "    s = s.replace(\"the signs\", \"signs\")\n",
    "    s = s.replace(\"people\", \"patients\")\n",
    "    s = s.replace(\"in those aged\", \"in patients aged\")\n",
    "    s = s.replace(\"and for the prevention\", \". and for the treatment\")\n",
    "    s = s.replace(\"palliative treatment\", \"treatment\")\n",
    "    s = s.replace(\"palliative management\", \"management\")\n",
    "    s = s.replace(\"initial treatment\", \"treatment\")\n",
    "    s = s.replace(\"[\", \"...\")\n",
    "    s = s.replace(\"pediatric patients\", \"patients\")\n",
    "    s = s.replace(\"- treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"- the treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"- management\", \"for the management\")\n",
    "    s = s.replace(\"- the management\", \"for the management\")\n",
    "    s = s.replace(\"- reduction\", \"for the management\")\n",
    "    s = s.replace(\"is also\", \"is\")\n",
    "    s = s.replace(\"to temporarily\", \"to\")\n",
    "    s = s.replace(\"a minority of patients\", \"patients\")\n",
    "    s = s.replace(\"helps control\", \"helps to control\")\n",
    "    \n",
    "    indication = [ e for e in re.findall(r'&#13;(.*?)&#13;', s) if (len(e)>2) ]\n",
    "    if len(indication)==0:\n",
    "        indication = [ e for e,ee in re.findall(r'&#13; &#13; (.*?)(\\.|&#13)', s) if (len(e)>2) ]\n",
    "    many_s = [u for u in s.replace(\".\", \".##############\").split(\"##############\") if len(u)>0]\n",
    "    many_ss = []\n",
    "    #print(many_s)\n",
    "    \n",
    "        \n",
    "    for ss in many_s:\n",
    "        #print(\"beg\", indication)\n",
    "        #print(\"beg\", ss)\n",
    "        if ss=='`code text here`':\n",
    "            return(\"None\")\n",
    "\n",
    "        if len(re.findall(\"no (fda|ema)\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"there is no support\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"unsubstantiated\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"(no approved indication|no approved therapeutic indication|has no indication)\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(ss)>1 and len(re.findall(r'cannot be used',ss))==0:\n",
    "            #print(ss)\n",
    "            ##### split if patients or adults are there\n",
    "            if ss[:3]== \"for\" and len(re.findall(r'for (the management of)|(the treatment of)', ss))==0:\n",
    "                indication += re.findall(r'for (.*?)(?=$)', ss)\n",
    "            else:\n",
    "                if len(re.findall(r'for the treatment of\\ (.*?)\\ in (adult|adults|patients)', ss))>0:\n",
    "                    #print(\"here 1\")\n",
    "                    indication +=  [ e for e, ee in re.findall(r'for the treatment of\\ (.*?)\\ in (adult|adults|patients)', ss)]\n",
    "                    #print(indication, len(indication))\n",
    "                    indication += [ ee for e, ee, eee in re.findall(r'and (in|for)\\ (.*?)\\ in (adult|pediatric|adults|patients)', ss)]\n",
    "                    #indication += [[ind, patients]]\n",
    "                elif len(re.findall(r'(for|in) the treatment of\\ (.*?)(?=$)', ss)):\n",
    "                    indication +=  [ee for e, ee in re.findall(r'(for|in) the treatment of\\ (.*?)(?=$)', ss)]\n",
    "                else:\n",
    "                    indication +=  [ee for e, ee in re.findall(r'treatment (of|for|to)\\ (.*?)(?=$)', ss)]\n",
    "                    #print(re.findall(r'(?<=for the treatment of\\ )(.*?)(?=$)', ss))\n",
    "                    #print(indication)\n",
    "                    #indication += [[ind, patients]]\n",
    "                indication +=   re.findall(r'detection of (.*?)(?=$)', s)\n",
    "                indication +=   re.findall(r'for use as (.*?)(?=$)', s)\n",
    "                \n",
    "                if len(re.findall(r'indicated (to|for) (.*?)\\ in (adult|pediatric|adults|patients)', ss))>0 and len(re.findall(r'(to treat|to prevent|in prevention of|for the treatment of) (.*?)', ss))==0:\n",
    "                    #print(\"here 1\")\n",
    "                    indication +=  [ee for e, ee, eee in re.findall(r'indicated (to|for) (.*?)\\ in (adult|pediatric|adults|patients)', ss)]\n",
    "                    #print(indication, len(indication))\n",
    "                    indication += [ e for e, ee in re.findall(r'and in\\ (.*?)\\ in (adult|pediatric|adults|patients)', ss)]\n",
    "                elif len(re.findall(r'indicated (to|for)', ss))>0:\n",
    "                    #print(\"here 1\")\n",
    "                    indication +=  [ee for e, ee in re.findall(r'indicated (to|for)\\ (.*?)(?=$)', ss)]\n",
    "                if len(re.findall(r'used for', ss))>0:\n",
    "                    #print(\"here 1\")\n",
    "                    indication +=  re.findall(r'used for\\ (.*?)(?=$)', ss)\n",
    "    \n",
    "                if len(re.findall(r'for the treatment of (adults |patients )with (.*?)(?=$)', ss))>0:\n",
    "                    indication += [ee for e, ee in re.findall(r'for the treatment of (adults|patients) with (.*?)(?=$)', ss)]\n",
    "                if len(re.findall(r'to manage (signs and symptoms of |symptoms of |signs of )', ss))>0:\n",
    "                    #print(\"here 3\")\n",
    "                    #print(ss, re.findall(r'to manage (signs and symptoms of |symptoms of |signs of )(.*?)', ss))\n",
    "                    indication += [ ee for e, ee in re.findall(r'to manage (signs and symptoms of |symptoms of |signs of )(.*?) in patients', ss)]\n",
    "                    if len(re.findall(r'patients', ss))==0:\n",
    "                        indication += [ ee for e, ee in re.findall(r'to manage (signs and symptoms of |symptoms of |signs of )(.*$)', ss)]\n",
    "#                 if len(re.findall('drug is indicated for', ss))>0 and (len(re.findall(r\"for the treatment of\", ss)) == 0):\n",
    "#                     #print(\"here 2\")\n",
    "#                     indication +=  re.findall('(?<=drug is indicated for\\ )(.*?)(?=$)', ss)\n",
    "                if len(re.findall(r'for the management of', ss))>0:\n",
    "                    indication += re.findall(r'for the management of (.*?)(?=$)', ss)\n",
    "                elif len(re.findall(r'management of', ss))>0:\n",
    "                    indication += re.findall(r'management of (.*?)(?=$)', ss)\n",
    "                if len(re.findall(r'to prevent', ss))>0:\n",
    "                    indication += re.findall(r'to prevent (.*?)(?=$)', ss)\n",
    "                if len(re.findall(r'for the prevention of', ss))>0:\n",
    "                    indication += re.findall(r'for the prevention of (.*?)(?=$)', ss)\n",
    "                if len(re.findall(r'to treat', ss))>0:\n",
    "                    if len(re.findall(r'to treat (.*)  and to', ss)) > 0:\n",
    "                        indication += re.findall(r'to treat (.*)  and to', ss)\n",
    "                    else:\n",
    "                        indication += re.findall(r'to treat (.*)', ss)\n",
    "                if len(re.findall(r'inhibit', ss))>0:\n",
    "                    if len(re.findall(r'inhibit (.*) and to', ss)) > 0:\n",
    "                        indication += re.findall(r'inhibit (.*) and to', ss)\n",
    "                    else:\n",
    "                        indication += re.findall(r'inhibit (.*)', ss)\n",
    "                indication += re.findall(r'to assist (.*).', ss)\n",
    "                indication += re.findall(r'to induce (.*).', ss)\n",
    "                indication += re.findall(r'to function as (.*).', ss)\n",
    "                indication +=  re.findall(r'promotes(.*).', ss)\n",
    "#                 if len(re.findall(r'to (relieve|reduce|assist|cause|inhibit|decrease|augment|increase) (.*),', ss))>0:\n",
    "#                     indication += [ee for e, ee in re.findall(r'to (relieve|reduce|assist|cause|inhibit|decrease|augment|increase) (.*),', ss)]\n",
    "                if len(re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve) (.*).', ss))>0:\n",
    "                    indication += [ee for e, ee in re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve) (.*).', ss)]\n",
    "                if len(re.findall(r'for (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*).', ss))>0:\n",
    "                    indication += [ee for e, ee in re.findall(r'for (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*).', ss)]\n",
    "                if len(re.findall(r'in (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*).', ss))>0:\n",
    "                    indication += [ee for e, ee in re.findall(r'in (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*).', ss)]\n",
    "                indication += re.findall(r'to cause (.*),', ss)\n",
    "                if len(re.findall(r'used (as|to) (.*) in', ss))>0:\n",
    "                    indication += [ee for e, ee in re.findall(r'used (as|to) (.*) in', ss)]\n",
    "                else:\n",
    "                    indication += [ee for e, ee in re.findall(r'used (as|to) (.*)', ss)]\n",
    "                indication += re.findall(r'act as (.*),', ss)\n",
    "                indication += [ee for e, ee in re.findall(r'(for\\ use|used) in (.*?)(?=$)', ss)]\n",
    "                indication +=  re.findall(r'drug is a (.*?)(?=$)', ss)\n",
    "                indication +=  re.findall(r'is a (.*?) drug', ss)\n",
    "                indication +=  re.findall(r'prevents (.*?) in patients', ss)\n",
    "                indication +=  re.findall(r'in conditions like (.*?),', ss)\n",
    "                indication +=  re.findall(r'drug of choice (.*?)(?=$)', ss)\n",
    "                indication +=  re.findall(r'be of use in patients with (.*?)(?=$)',ss)\n",
    "                if len(re.findall(r'(has|have) (.*?) (activity|activities)', ss))>0:\n",
    "                    indication +=  [ee for e, ee, eee in re.findall(r'(has|have) (.*?) (activity|activities)', ss)]\n",
    "                    \n",
    "\n",
    "\n",
    "#             if len(re.findall(r'for the treatment of\\ (.*?)', ss))>0 and (len(re.findall(r\"adults\", ss)) == 0) and (len(re.findall(r\"patients\", ss)) == 0):\n",
    "#                 print(\"here4\")\n",
    "#                 indication += re.findall(r'(?<=for the treatment of\\ ).*?(?=$)', ss)[0]\n",
    "    if len(indication) == 0:\n",
    "        indication = [s]\n",
    "    out = []\n",
    "    print(indication)\n",
    "    for m in indication:\n",
    "        m = m.replace(\"the treatment of \", \"\")\n",
    "        m = m.replace(\"the management of \", \"\")\n",
    "        m = m.replace(\"management of \", \"\")\n",
    "        out+= [ u.strip() for u in re.split(',|\\.|and|-', m) if len(u)>1]\n",
    "        \n",
    "    \n",
    "              \n",
    "    return(out)\n",
    "parse_indication(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "a77edbe0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "drug is indication to a number of conditions including treat allergic states, dermatologic diseases, edematous states, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system, ophthalmic diseases, respiratory diseases, rheumatic disorders.[l9437,l9440]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['allergic states, dermatologic diseases, edematous states, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system, ophthalmic diseases, respiratory diseases, rheumatic disorders']"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "k= 'DB14631'\n",
    "s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\").lower()\n",
    "s = s.replace(dictionary[k]['name'].lower(), \"drug\").lower()\n",
    "print(s)\n",
    "#### Start by looking for breaks:\n",
    "\n",
    "def parse_indication2(s):\n",
    "    s = re.sub(\"f\\d+\", '', s)\n",
    "    s = re.sub(\"a\\d+\", '', s)\n",
    "    s = re.sub(\"l\\d+\", '', s)\n",
    "    s = re.sub(\"t\\d+\", '', s)\n",
    "    s = re.sub(\"\\d+\", '', s)\n",
    "    \n",
    "    s = re.sub(\"\\[fda label\\]\", '', s)\n",
    "    s = re.sub(\"\\]\", '', s)\n",
    "    s = re.sub(\"\\[\", '', s)\n",
    "    s = s.replace('as adjunctive therapy', '')\n",
    "    #s = re.sub(\",\", '', s)\n",
    "    s = s.replace(\"fro the treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"inflamatory\", \"inflammatory\")\n",
    "    s = s.replace(\"however\", \".\")\n",
    "    s = s.replace(\"as well as\", \"and\")\n",
    "    s = s.replace(\"including treat\", \"and to treat\")\n",
    "    s = s.replace(\"individuals\", \"patients\")\n",
    "    s = s.replace(\"as well used\", \"used\")\n",
    "    s = s.replace(\"twice daily treatment\", \"treatment\")\n",
    "    s = s.replace(\"topical treatment\", \"treatment\")\n",
    "    s = s.replace(\"acute treatment\", \"treatment\")\n",
    "    s = s.replace(\"for treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"symptomatic treatment\", \"treatment\")\n",
    "    s = s.replace(\"in treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"in the treatment of\", \"for the treatment of\")\n",
    "    s = s.replace(\"the symptoms\", \"symptoms\")\n",
    "    s = s.replace(\"use/treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"important for\", \"used for\")\n",
    "    s = s.replace(\"the prevention and treatment\", \"the treatment\")\n",
    "    s = s.replace(\"treatment/use\", \"use\")\n",
    "    s = s.replace(\"use this compound as\", \"used as\")\n",
    "    s = s.replace(\"the signs\", \"signs\")\n",
    "    s = s.replace(\"people\", \"patients\")\n",
    "    s = s.replace(\"in conjunction\", \"along with\")\n",
    "    s = s.replace(\"in those aged\", \"in patients aged\")\n",
    "    s = s.replace(\"and for the prevention\", \". and for the treatment\")\n",
    "    s = s.replace(\"palliative treatment\", \"treatment\")\n",
    "    s = s.replace(\"palliative management\", \"management\")\n",
    "    s = s.replace(\"initial treatment\", \"treatment\")\n",
    "    s = re.sub('[0-9]* years of age and older', '', s)\n",
    "    s = s.replace(\"pediatric patients\", \"patients\")\n",
    "    s = s.replace(\"adult patients\", \"patients\")\n",
    "    s = s.replace(\"- treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"- the treatment\", \"for the treatment\")\n",
    "    s = s.replace(\"- management\", \"for the management\")\n",
    "    s = s.replace(\"- the management\", \"for the management\")\n",
    "    s = s.replace(\"- reduction\", \"for the management\")\n",
    "    s = s.replace(\"is also\", \"is\")\n",
    "    s = s.replace(\" speed \", \" \")\n",
    "    s = s.replace(\"and to\", \".to\")\n",
    "    s = s.replace(\"to temporarily\", \"to\")\n",
    "    s = s.replace(\"to manage symptoms of\", \"for the treatment of\")\n",
    "    s = s.replace(\"a minority of patients\", \"patients\")\n",
    "    s = s.replace(\"helps control\", \"helps to control\")\n",
    "    #s = s.replace(\"is indicated for\", \"is indicated for the treatment of\")\n",
    "    s = s.replace(\"for management\", \"for the management\")\n",
    "\n",
    "    indication  = []\n",
    "    many_s  = []\n",
    "    #indication = [ e for e in re.findall(r'&#13;(.*?)&#13;', s) if (len(e)>2) and len(re.findall(\"drug is indicated as\",e))==0  and len(e.split(\" \"))<5 ]\n",
    "    #if len(indication)==0:\n",
    "    #    indication = [ e for e, ee in re.findall(r'&#13; &#13; (.*?)(\\.|&#13)', s) if (len(e)>2) ]\n",
    "    if len(re.findall(\"&#13; &#13;\", s))>0:\n",
    "        if len(re.findall(r'&#13; &#13; (.*?)&#13; &#13;', s))>0:\n",
    "            many_s += [ ee  for e in re.findall(r'(.*?)&#13; &#13;', s) for ee in re.split('\\.|;', e) if len(ee)>0]\n",
    "            for e in re.findall(r'&#13; &#13; (.*?)&#13; &#13;', s):\n",
    "                if len(re.findall(\" is \", e))>0:\n",
    "                    many_s += re.split('\\.|;', e)\n",
    "                else:\n",
    "                    indication +=[e]\n",
    "            many_s += [ ee  for e in re.findall(r'&#13; &#13;(.*?)', s) for ee in re.split('\\.|;', u)if len(ee)>0]\n",
    "        else:\n",
    "            many_s = [uu for u in s.split(\"&#13; &#13;\") for uu in re.split('\\.|;', u)  if len(uu)>0]\n",
    "    else:\n",
    "        #print(\"h here\")\n",
    "        many_s += [u for u in re.split('\\.|;', s) if len(u)>0] \n",
    "    \n",
    "    #print(\"may s\", many_s)\n",
    "    \n",
    "        \n",
    "    for ss in many_s:\n",
    "        #print(\"beg\", indication)\n",
    "        #print(\"beg\", ss)\n",
    "        if ss=='`code text here`':\n",
    "            return(\"None\")\n",
    "\n",
    "        if len(re.findall(\"no (fda|ema)\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"there is no support\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"unsubstantiated\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(re.findall(\"(no approved indication|no approved therapeutic indication|has no indication)\",ss))>0:\n",
    "            indication += [\"no approved indication\"]\n",
    "        if len(ss)>1 and len(re.findall(r'cannot be used',ss))==0:\n",
    "            #print(ss)\n",
    "            ##### split if patients or adults are there\n",
    "            if ss[:3]== \"for\" and len(re.findall(r'for (the management of)|(the treatment of)', ss))==0:\n",
    "                indication += re.findall(r'for (.*?)(?=$)', ss)\n",
    "            else:\n",
    "                \n",
    "                if len(re.findall(r'in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss)):\n",
    "                    if len(re.findall(r'for the (management|treatment) of (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss))>0:\n",
    "                         indication += [e for _,e, ee in re.findall(r'for the (management|treatment) of (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss)]\n",
    "                    elif len(re.findall(r'of (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss)):\n",
    "                        indication += [ee for e, ee in re.findall(r'for the treatment of (patients|adults|pediatric patients|children|teenagers|women|pregnant women) (.*?)(?=$)', ss)]\n",
    "                    elif len(re.findall(r'for (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with', ss)):\n",
    "                        #print(\"yes\", ss, re.findall(r'for (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*?)(?=$)', ss))\n",
    "                        indication += [ee for e, ee in re.findall(r'for (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*?)(?=$)', ss)]\n",
    "                    elif len(re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*) receiving\", ss))>0:\n",
    "                        #print(\"usted\")\n",
    "                        #print(re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*) receiving\", ss))\n",
    "                        indication += [ee + \" \"+ eeee for e, ee, eee, eeee in re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*) receiving\", ss)]\n",
    "                    elif len(re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*)\", ss))>0:\n",
    "                        indication += [ee + \" \"+ eeee for e, ee, eee, eeee in re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*?)(?=$)\", ss)]\n",
    "                    elif len(re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) (.*)\", ss))>0:\n",
    "                        indication += [ee + \" \"+ eeee for e, ee, eee, eeee in re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) (.*?)(?=$)\", ss)]\n",
    "                    elif len(re.findall(r'(patients|adults|pediatric patients|children|teenagers|women|pregnant women) with', ss)):\n",
    "                        indication += [ee  for e, ee  in re.findall(r'(patients|adults|pediatric patients|children|teenagers|women|pregnant women) with (.*?)(?=$)', ss)]\n",
    "                    elif len(re.findall(\"indicated for the relief of symptoms (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)\", ss))>0:\n",
    "                        indication += [e for e, _ in re.findall(\"indicated for the relief of symptoms (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)\", ss)]\n",
    "                    elif len(re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss))>0:\n",
    "                        indication += [ee for e, ee, _ in re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent|treat) (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss)]\n",
    "                    elif  len(re.findall(r'is (approved|indicated|fda-approved) (.*) for (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss))>0:\n",
    "                        indication += [e for _,_,e, ee in re.findall(r'is (approved|indicated|fda-approved) (.*) for (.*) in (patients|adults|pediatric patients|children|teenagers|women|pregnant women)', ss)]\n",
    "                    elif len(re.findall(r'in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) (.*) used to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent|treat) (.*?)(?=$)', ss))>0:\n",
    "                        indication += [e for _, _, _, e in re.findall(r'in (patients|adults|pediatric patients|children|teenagers|women|pregnant women) (.*) used to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent|treat) (.*?)(?=$)', ss)]\n",
    "                    else:\n",
    "                        print(\"here\")\n",
    "                else:\n",
    "                    #print(\"no\")\n",
    "                    if len(re.findall(r'is (approved|indicated|fda-approved) for', ss))>0:\n",
    "                        indication += [ee for e, ee in re.findall(r'is (approved|indicated|fda-approved) for (.*?)(?=$)', ss)]\n",
    "                    elif len(re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve)\", ss))>0:\n",
    "                        indication += [ee for e, ee in re.findall(\"indicated to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve) (.*?)(?=$)\", ss)]\n",
    "                    elif len(re.findall(\"(approved|indicated) for\", ss))>0:\n",
    "                        indication += [ee for e, ee in re.findall(r'(approved|indicated|fda-approved) for (.*?)(?=$)', ss)]\n",
    "                    if len(re.findall(r'(for|in) the (treatment|management|prevention) of', ss))>0:\n",
    "                        indication += [ee for _, e, ee in re.findall(r'(for|in) the (treatment|management|prevention) of (.*?)(?=$)', ss)]\n",
    "                    elif len(re.findall(r'(for|in|) the (treatment|management|prevention) in', ss))>0:\n",
    "                        indication += [ee for _, e, ee in re.findall(r'(for|in) the (treatment|management|prevention) in (.*?)(?=$)', ss)]\n",
    "                    \n",
    "                    elif len(re.findall(r'to treat', ss))>0:\n",
    "                        if len(re.findall(r'to treat (.*)  and to', ss)) > 0:\n",
    "                            indication += re.findall(r'to treat (.*)  and to', ss)\n",
    "                        else:\n",
    "                            indication += re.findall(r'to treat (.*)', ss)\n",
    "                    else:\n",
    "                        indication += re.findall(r'to assist (.*)', ss)\n",
    "                        indication += re.findall(r'to induce (.*)', ss)\n",
    "                        indication += re.findall(r'to function as (.*)', ss)\n",
    "                        indication +=  re.findall(r'promotes(.*)', ss)\n",
    "                        if len(re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent) (.*) in', ss))>0:\n",
    "                            indication += [ee for e, ee in re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent) (.*) in', ss)]\n",
    "                        elif len(re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent) (.*)', ss))>0:\n",
    "                            indication += [ee for e, ee in re.findall(r'to (produce|elicit|control|promote|relieve|reduce|assist|cause|inhibit|decrease|augment|increase|improve|prevent) (.*)', ss)]\n",
    "                        if len(re.findall(r'for (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*)', ss))>0:\n",
    "                            indication += [ee for e, ee in re.findall(r'for (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*)', ss)]\n",
    "                        if len(re.findall(r'in (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*)', ss))>0:\n",
    "                            indication += [ee for e, ee in re.findall(r'in (controlling|promoting|relieving|reducing|treating|assisting|causing|inhibiting|decreasing|augmenting|increasing) (.*)', ss)]\n",
    "                        indication += re.findall(r'to cause (.*),', ss)\n",
    "                        indication += [ee for e, ee in re.findall(r'used (as|to|for) (.*?)(?=$)', ss)]\n",
    "                        indication += re.findall(r'to act as(.*)', ss)\n",
    "                        #print(re.findall(r'to act as(.*)', ss), ss)\n",
    "                        indication += [ee for e, ee in re.findall(r'(for\\ use|used) in (.*?)(?=$)', ss)]\n",
    "                        indication +=  re.findall(r'drug is a (.*?)(?=$)', ss)\n",
    "                        indication +=  re.findall(r'is a (.*?) drug', ss)\n",
    "                        indication +=  re.findall(r'has ((?:(?!has).)*?) properties', ss)\n",
    "                        indication +=  re.findall(r'prevents (.*?) in patients', ss)\n",
    "                        indication +=  re.findall(r'protect against (.*?)(?=$),', ss)\n",
    "                        indication +=  re.findall(r'helpful in (.*?)(?=$)', ss)\n",
    "                        indication +=  re.findall(r'healing of (.*?)(?=$)', ss)\n",
    "                        indication +=  [ee for _,ee in re.findall(r'(aids|helps) (.*?)(?=$)', ss)]\n",
    "                        indication +=  re.findall(r'in conditions like (.*?)', ss)\n",
    "                        indication +=  re.findall(r'drug of choice (.*?)(?=$)', ss)\n",
    "                        indication +=  re.findall(r'be of use in patients with (.*?)(?=$)',ss)\n",
    "                        indication += re.findall(r'is being studied for its activity against (.*?)(?=$)', ss)\n",
    "                        if len(re.findall(r'(has|have) (.*?) (activity|activities)', ss))>0:\n",
    "                            indication +=  [ee for e, ee, eee in re.findall(r'(has|have) (.*?) (activity|activities)', ss)]\n",
    "\n",
    "\n",
    "                #print(indication)\n",
    "#             if len(re.findall(r'for the treatment of\\ (.*?)', ss))>0 and (len(re.findall(r\"adults\", ss)) == 0) and (len(re.findall(r\"patients\", ss)) == 0):\n",
    "#                 print(\"here4\")\n",
    "#                 indication += re.findall(r'(?<=for the treatment of\\ ).*?(?=$)', ss)[0]\n",
    "#     if len(indication) == 0:\n",
    "#         indication = [s]\n",
    "    out = []\n",
    "#     print(\"many_s\")\n",
    "#     print(many_s)\n",
    "    #print(indication)\n",
    "    for m in indication:\n",
    "        m = m.replace(\"the treatment of \", \"\")\n",
    "        m = m.replace(\"the management of \", \"\")\n",
    "        m = m.replace(\"management of \", \"\")\n",
    "        m = m.replace(\"symptoms of \", \"\")\n",
    "        m = m.replace(\"in combination with other antiviral drugs\", \"\")\n",
    "        m = m.replace(\"who have \", \"\")\n",
    "        m = m.replace(\"#\", \"\")\n",
    "        m = m.replace(\"&\", \"\")\n",
    "        m = m.replace(\"*\", \"\")\n",
    "        out+= [ u.strip() for u in re.split('\\.', m) if len(u)>1]\n",
    "        \n",
    "              \n",
    "    return(out)\n",
    "parse_indication2(s)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "28dff955",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00043\n",
      "DB00051\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00208\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00271\n",
      "here\n",
      "DB00294\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00335\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00347\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00423\n",
      "here\n",
      "DB00425\n",
      "DB00437\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00461\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00476\n",
      "DB00522\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00617\n",
      "DB00635\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00688\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00743\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00841\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB00934\n",
      "here\n",
      "here\n",
      "DB00957\n",
      "DB00977\n",
      "here\n",
      "here\n",
      "DB01047\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB01118\n",
      "DB01123\n",
      "here\n",
      "here\n",
      "here\n",
      "DB01173\n",
      "here\n",
      "here\n",
      "DB01207\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB01256\n",
      "here\n",
      "here\n",
      "here\n",
      "DB01354\n",
      "DB01373\n",
      "DB01392\n",
      "here\n",
      "here\n",
      "here\n",
      "DB01422\n",
      "DB01454\n",
      "DB01497\n",
      "DB01546\n",
      "DB01564\n",
      "here\n",
      "here\n",
      "DB01586\n",
      "here\n",
      "DB01593\n",
      "DB01604\n",
      "DB01645\n",
      "here\n",
      "here\n",
      "DB02659\n",
      "DB03783\n",
      "DB03843\n",
      "DB04335\n",
      "DB04844\n",
      "DB04872\n",
      "DB04900\n",
      "DB04919\n",
      "DB04946\n",
      "DB04953\n",
      "DB05198\n",
      "DB05199\n",
      "DB05200\n",
      "DB05201\n",
      "DB05202\n",
      "DB05204\n",
      "DB05205\n",
      "DB05207\n",
      "DB05249\n",
      "DB05252\n",
      "DB05255\n",
      "DB05263\n",
      "DB05264\n",
      "DB05268\n",
      "DB05282\n",
      "DB05285\n",
      "DB05292\n",
      "DB05332\n",
      "DB05381\n",
      "here\n",
      "DB05541\n",
      "here\n",
      "DB06168\n",
      "here\n",
      "DB06206\n",
      "DB06207\n",
      "here\n",
      "DB06210\n",
      "DB06212\n",
      "DB06213\n",
      "here\n",
      "DB06237\n",
      "here\n",
      "DB06404\n",
      "here\n",
      "here\n",
      "DB06589\n",
      "here\n",
      "DB06605\n",
      "here\n",
      "here\n",
      "here\n",
      "DB06616\n",
      "DB06654\n",
      "DB06693\n",
      "here\n",
      "here\n",
      "here\n",
      "DB06698\n",
      "DB06704\n",
      "here\n",
      "here\n",
      "here\n",
      "DB06754\n",
      "DB06771\n",
      "here\n",
      "here\n",
      "DB06784\n",
      "here\n",
      "DB06789\n",
      "DB06800\n",
      "DB06813\n",
      "here\n",
      "here\n",
      "DB08805\n",
      "DB08815\n",
      "here\n",
      "here\n",
      "DB08822\n",
      "here\n",
      "DB08828\n",
      "DB08833\n",
      "DB08838\n",
      "here\n",
      "here\n",
      "DB08870\n",
      "DB08877\n",
      "DB08879\n",
      "here\n",
      "DB08883\n",
      "DB08890\n",
      "DB08891\n",
      "here\n",
      "here\n",
      "DB08898\n",
      "here\n",
      "DB08900\n",
      "here\n",
      "DB08903\n",
      "here\n",
      "DB08913\n",
      "DB08928\n",
      "here\n",
      "here\n",
      "DB08933\n",
      "here\n",
      "DB08964\n",
      "DB09001\n",
      "here\n",
      "DB09020\n",
      "here\n",
      "here\n",
      "DB09039\n",
      "here\n",
      "here\n",
      "here\n",
      "DB09087\n",
      "DB09088\n",
      "here\n",
      "here\n",
      "DB09108\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB09137\n",
      "here\n",
      "DB09153\n",
      "DB09164\n",
      "here\n",
      "DB09209\n",
      "here\n",
      "DB09210\n",
      "here\n",
      "DB09216\n",
      "DB09221\n",
      "here\n",
      "DB09225\n",
      "here\n",
      "here\n",
      "DB09268\n",
      "DB09282\n",
      "DB09286\n",
      "here\n",
      "here\n",
      "DB09291\n",
      "DB09298\n",
      "here\n",
      "DB09313\n",
      "here\n",
      "here\n",
      "DB09314\n",
      "DB09315\n",
      "here\n",
      "DB09328\n",
      "DB09332\n",
      "DB09338\n",
      "DB09352\n",
      "DB09375\n",
      "DB09379\n",
      "here\n",
      "DB09389\n",
      "DB09418\n",
      "DB09459\n",
      "DB09460\n",
      "DB09495\n",
      "here\n",
      "here\n",
      "DB09517\n",
      "DB09534\n",
      "DB09535\n",
      "DB09543\n",
      "DB09571\n",
      "here\n",
      "DB10400\n",
      "here\n",
      "DB10401\n",
      "here\n",
      "DB10989\n",
      "here\n",
      "DB10990\n",
      "DB10997\n",
      "here\n",
      "DB11051\n",
      "DB11057\n",
      "DB11062\n",
      "DB11064\n",
      "DB11065\n",
      "DB11066\n",
      "DB11071\n",
      "DB11082\n",
      "DB11085\n",
      "DB11095\n",
      "DB11125\n",
      "DB11129\n",
      "DB11133\n",
      "here\n",
      "here\n",
      "DB11182\n",
      "DB11201\n",
      "DB11204\n",
      "DB11206\n",
      "DB11207\n",
      "DB11226\n",
      "DB11273\n",
      "DB11274\n",
      "DB11275\n",
      "DB11284\n",
      "here\n",
      "DB11323\n",
      "DB11327\n",
      "DB11332\n",
      "DB11338\n",
      "DB11571\n",
      "here\n",
      "DB11572\n",
      "DB11587\n",
      "here\n",
      "DB11608\n",
      "here\n",
      "DB11619\n",
      "here\n",
      "DB11637\n",
      "here\n",
      "DB11700\n",
      "DB11755\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB11820\n",
      "DB11855\n",
      "DB11963\n",
      "DB11967\n",
      "here\n",
      "here\n",
      "DB12023\n",
      "here\n",
      "DB12364\n",
      "here\n",
      "DB12404\n",
      "DB12442\n",
      "here\n",
      "here\n",
      "here\n",
      "DB12872\n",
      "DB12909\n",
      "here\n",
      "DB13140\n",
      "here\n",
      "DB13146\n",
      "DB13147\n",
      "here\n",
      "DB13157\n",
      "DB13168\n",
      "DB13170\n",
      "here\n",
      "DB13173\n",
      "here\n",
      "DB13200\n",
      "here\n",
      "DB13615\n",
      "DB13800\n",
      "here\n",
      "DB13854\n",
      "here\n",
      "DB13897\n",
      "here\n",
      "DB13898\n",
      "here\n",
      "DB13899\n",
      "here\n",
      "DB13900\n",
      "here\n",
      "DB13901\n",
      "here\n",
      "DB13902\n",
      "here\n",
      "DB13903\n",
      "DB13908\n",
      "DB13913\n",
      "here\n",
      "DB13924\n",
      "here\n",
      "DB13953\n",
      "DB13955\n",
      "DB13960\n",
      "here\n",
      "here\n",
      "DB13975\n",
      "DB14003\n",
      "DB14004\n",
      "here\n",
      "DB14006\n",
      "here\n",
      "DB14019\n",
      "here\n",
      "DB14039\n",
      "here\n",
      "DB14040\n",
      "here\n",
      "DB14041\n",
      "here\n",
      "DB14042\n",
      "DB14051\n",
      "DB14052\n",
      "here\n",
      "DB14100\n",
      "here\n",
      "here\n",
      "DB14112\n",
      "DB14126\n",
      "here\n",
      "DB14443\n",
      "here\n",
      "DB14487\n",
      "here\n",
      "here\n",
      "here\n",
      "here\n",
      "DB14512\n",
      "DB14548\n",
      "here\n",
      "DB14738\n",
      "here\n",
      "here\n",
      "DB14914\n",
      "DB15465\n",
      "DB15566\n",
      "DB15622\n",
      "here\n",
      "here\n",
      "DB15873\n",
      "here\n",
      "here\n",
      "here\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'DB00001': ['heparin-induced thrombocytopenia'],\n",
       " 'DB00002': ['egfr-expressing, metastatic colorectal carcinoma',\n",
       "  'egfr-expressing, metastatic colorectal carcinoma'],\n",
       " 'DB00003': ['cystic fibrosis'],\n",
       " 'DB00004': ['cutaneous t-cell lymphoma'],\n",
       " 'DB00005': ['moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis',\n",
       "  'psoriatic arthritis and ankylosing spondylitis'],\n",
       " 'DB00006': ['heparin-induced thrombocytopenia', 'thrombosis'],\n",
       " 'DB00007': ['advanced prostate cancer,  and for patients with central precocious puberty (cpp)',\n",
       "  'advanced prostate cancer,  and for patients with central precocious puberty (cpp)',\n",
       "  'endometriosis',\n",
       "  'endometriosis',\n",
       "  'the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids)'],\n",
       " 'DB00008': ['hcv',\n",
       "  'contraindications to or significant intolerance to other anti-viral therapies'],\n",
       " 'DB00009': ['acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli'],\n",
       " 'DB00010': ['dwarfism, prevention of hiv-induced weight loss'],\n",
       " 'DB00011': ['venereal or genital warts caused by the human papiloma virus'],\n",
       " 'DB00012': ['anemia (from renal transplants or certain hiv treatment)'],\n",
       " 'DB00013': ['lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters'],\n",
       " 'DB00014': ['locally confined carcinoma of the prostate',\n",
       "  'advanced carcinoma of the prostate',\n",
       "  'endometriosis',\n",
       "  'advanced breast cancer in pre- and perimenopausal women'],\n",
       " 'DB00015': ['lysis of acute pulmonary emboli, intracoronary emboli, and myocardial infarction'],\n",
       " 'DB00016': ['anemia due to chronic kidney disease (ckd)',\n",
       "  'anemia due to zidovudine',\n",
       "  'anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy',\n",
       "  'allogeneic rbc transfusions'],\n",
       " 'DB00017': [\"symptomatic paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments\",\n",
       "  'emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified',\n",
       "  'azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves',\n",
       "  'post-menopausal osteoporosis'],\n",
       " 'DB00018': ['the intralesional treatment of refractory or recurring external condylomata acuminata'],\n",
       " 'DB00019': ['the incidence of infection, as manifested by febrile neutropenia, non\\xad myeloid malignancies',\n",
       "  'survival acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)'],\n",
       " 'DB00020': ['cancer and bone marrow transplant'],\n",
       " 'DB00022': ['hcv in combination with db and a ns/a protease inhibitor for genotype  or without a ns/a protease inhibitor for genotypes -',\n",
       "  'hcv in combination with db and a ns/a protease inhibitor for genotype  or without a ns/a protease inhibitor for genotypes -',\n",
       "  'contraindications to or significant intolerance to other anti-viral therapies'],\n",
       " 'DB00023': ['patients with acute lymphoblastic leukemia (all)'],\n",
       " 'DB00024': ['detection of residueal or recurrent thyroid cancer'],\n",
       " 'DB00025': ['hemophilia a, von willebrand disease and factor xiii deficiency'],\n",
       " 'DB00026': ['adult rheumatoid arthritis and treatment of neonatal-onset multisystem inflammatory disease (nomid)'],\n",
       " 'DB00027': ['skin lesions, surface wounds and eye infections'],\n",
       " 'DB00028': ['immunodeficiencies, and autoimmune and inflammatory disorders'],\n",
       " 'DB00029': ['lysis of acute pulmonary emboli, intracoronary emboli and myocardial infarction'],\n",
       " 'DB00030': ['glycemic control and patients with diabetes mellitus'],\n",
       " 'DB00031': ['myocardial infarction and lysis of intracoronary emboli'],\n",
       " 'DB00032': ['female infertility'],\n",
       " 'DB00033': ['chronic granulomatous disease and osteopetrosis'],\n",
       " 'DB00034': [\"chronic hepatitis c, hairy cell leukemia, aids-related kaposi's sarcoma, and chronic myelogenous leukemia\",\n",
       "  'oral warts arising from hiv infection'],\n",
       " 'DB00035': ['nocturia due to nocturnal polyuria',\n",
       "  'central cranial diabetes insipidus and for the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral)',\n",
       "  \"patients with hemophilia a with factor viii coagulant activity levels greater than % or mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than % during surgical procedures and postoperatively to maintain hemostasis (parenteral)\"],\n",
       " 'DB00036': ['hemorrhagic complications in hemophilia a and b'],\n",
       " 'DB00038': ['nonmyeloid malignancies who are at high risk of severe thrombocytopenia'],\n",
       " 'DB00039': ['oral mucositis associated with chemotherapy and radiation therapy'],\n",
       " 'DB00040': ['the movement of the gastrointestinal tract',\n",
       "  'severe hypoglycemia'],\n",
       " 'DB00041': ['adults with metastatic renal cell carcinoma'],\n",
       " 'DB00042': ['patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia'],\n",
       " 'DB00043': [],\n",
       " 'DB00044': ['infertility'],\n",
       " 'DB00045': ['prophylactic treatment of lyme disease'],\n",
       " 'DB00046': ['glycemic control and children with diabetes mellitus'],\n",
       " 'DB00047': ['glycemic control in adults and patients with type  diabetes mellitus and type  diabetes mellitus'],\n",
       " 'DB00048': [\"adults with dupuytren's contracture with a palpable cord\",\n",
       "  \"adults with dupuytren's contracture with a palpable cord\",\n",
       "  \"men with peyronie's disease diagnosed with a penile curvature deformity of at least a -degree angle at the beginning of therapy in addition to palpable plaques\",\n",
       "  'the tissue debridement of chronic dermal ulcers and severely burned tissues',\n",
       "  'moderate to severe cellulite in the buttocks of adult women'],\n",
       " 'DB00049': ['hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)'],\n",
       " 'DB00050': ['the inhibition of premature lh surges in women undergoing controlled ovarian stimulation'],\n",
       " 'DB00051': [],\n",
       " 'DB00052': ['dwarfism, acromegaly and prevention of hiv-induced weight loss'],\n",
       " 'DB00053': [\"gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00054': ['unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within  hours'],\n",
       " 'DB00055': ['reduction of mortality in patients with severe sepsis'],\n",
       " 'DB00056': ['patients with cd positive acute myeloid leukemia in first relapse who are  years of age or older and who are not considered candidates for other cytotoxic chemotherapy',\n",
       "  'patients with cd positive acute myeloid leukemia in first relapse who are  years of age or older and who are not considered candidates for other cytotoxic chemotherapy',\n",
       "  'patients aged  years and older with cd-positive aml experienced a relapse or not responded to treatment (refractory)',\n",
       "  'patients aged  years and older with cd-positive aml experienced a relapse or not responded to treatment (refractory)'],\n",
       " 'DB00057': ['diagnosis of extrahepatic malignant cancers'],\n",
       " 'DB00058': ['chronic augmentation and maintenance therapy in patients with alph-proteinase inhibitor (-pi) deficiency and clinical evidence of emphysema'],\n",
       " 'DB00059': ['acute lymphoblastic leukemia'],\n",
       " 'DB00060': ['relapsing/remitting multiple sclerosis, also for condyloma acuminatum'],\n",
       " 'DB00061': ['adenosine deaminase deficiency'],\n",
       " 'DB00062': ['adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass'],\n",
       " 'DB00063': ['myocardial infarction and acute coronary syndrome'],\n",
       " 'DB00065': ['reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (  years of age) patients with moderately to severely active crohns disease had an inadequate response to conventional therapy',\n",
       "  'signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (  years of age) patients with moderately to severely active crohns disease had an inadequate response to conventional therapy',\n",
       "  'fistulizing crohns disease',\n",
       "  'reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (  years of age) patients with moderately to severely active ulcerative colitis had an inadequate response to conventional therapy',\n",
       "  'signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (  years of age) patients with moderately to severely active ulcerative colitis had an inadequate response to conventional therapy',\n",
       "  'moderately to severely active rheumatoid arthritis',\n",
       "  'active ankylosing spondylitis',\n",
       "  'psoriatic arthritis',\n",
       "  'patients with chronic severe (i',\n",
       "  'patients with chronic severe (i'],\n",
       " 'DB00066': ['spermatogenesis',\n",
       "  'induce spermatogenesis',\n",
       "  'the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or',\n",
       "  'the ovary to produce several follicles',\n",
       "  'cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or in vitro fertilization (ivf)',\n",
       "  'gamete intrafallopian transfer (gift) or in vitro fertilization (ivf)'],\n",
       " 'DB00067': ['enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding'],\n",
       " 'DB00068': ['relapsing/remitting multiple sclerosis',\n",
       "  'the frequency of attacks'],\n",
       " 'DB00069': [\"hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma\"],\n",
       " 'DB00070': ['increase of absorption and distribution of other injected drugs and for rehydration'],\n",
       " 'DB00071': ['type i and ii diabetes mellitus'],\n",
       " 'DB00072': ['the adjuvant treatment of her-overexpressing breast cancer, drug is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel',\n",
       "  'metastatic her-overexpressing breast cancer, and as monotherapy',\n",
       "  'patients with her-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma not received prior treatment for metastatic disease',\n",
       "  'subcutaneous administration - in combination with either hyaluronidase or both hyaluronidase and pertuzumab - for adults with her- positive breast cancers',\n",
       "  'adults with her- positive breast cancers'],\n",
       " 'DB00073': ['moderately-to severely-active ra',\n",
       "  'patients with cd-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy',\n",
       "  'patients with cd-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy'],\n",
       " 'DB00074': ['prophylactic treatment of kidney transplant rejection'],\n",
       " 'DB00075': ['organ transplant recipients, prevention of organ rejection'],\n",
       " 'DB00076': ['digitoxin overdose or digitalis glycoside toxicity'],\n",
       " 'DB00078': [\"non-hodgkin's lymphoma\"],\n",
       " 'DB00080': ['complicated skin and skin structure infections caused by susceptible strains of gram-positive microorganisms'],\n",
       " 'DB00081': [\"non-hodgkin's lymphoma (cd positive, follicular)\"],\n",
       " 'DB00082': ['acromegaly'],\n",
       " 'DB00083': ['cervical dystonia',\n",
       "  'severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or vii nerve disorders',\n",
       "  'excessive underarm sweating'],\n",
       " 'DB00085': ['pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it',\n",
       "  'pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it'],\n",
       " 'DB00086': ['acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae'],\n",
       " 'DB00087': ['b-cell chronic lymphocytic leukemia'],\n",
       " 'DB00088': [\"gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00089': ['diagnosis of prostate cancer and detection of intra-pelvic metastases'],\n",
       " 'DB00090': ['mucopolysaccharidosis'],\n",
       " 'DB00091': ['a variety of conditions',\n",
       "  'the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants',\n",
       "  'bone marrow transplant rejection',\n",
       "  'prevent bone marrow transplant rejection',\n",
       "  'or treat graft-versus-host disease (gvhd)',\n",
       "  'patients with severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone',\n",
       "  'adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated',\n",
       "  'tear production suffering from keratoconjunctivitis sicca',\n",
       "  'steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis',\n",
       "  'steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis',\n",
       "  'various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, and idiopathic thrombocytopenic purpura'],\n",
       " 'DB00092': ['moderate to severe chronic plaque psoriasis'],\n",
       " 'DB00093': ['use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential'],\n",
       " 'DB00094': ['female infertility'],\n",
       " 'DB00095': ['patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy'],\n",
       " 'DB00097': ['female infertility'],\n",
       " 'DB00098': ['prevention of renal transplant rejection'],\n",
       " 'DB00099': ['leucocyte growth factor  indicated to:',\n",
       "  'nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever',\n",
       "  'acute myeloid leukemia (aml)',\n",
       "  'nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (bmt)',\n",
       "  'patients with radiation-induced myelosuppression following a radiological/nuclear incident',\n",
       "  'patients with radiation-induced myelosuppression following a radiological/nuclear incident'],\n",
       " 'DB00100': ['hemophilia (christmas disease)'],\n",
       " 'DB00102': ['skin ulcers (from diabetes)'],\n",
       " 'DB00103': ['fabry disease', 'fabry disease'],\n",
       " 'DB00104': ['acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (vipoma) tumors'],\n",
       " 'DB00105': [\"hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma\"],\n",
       " 'DB00106': ['treatment of advanced prostate cancer'],\n",
       " 'DB00107': ['labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability'],\n",
       " 'DB00108': ['multiple sclerosis'],\n",
       " 'DB00109': ['hiv-/aids'],\n",
       " 'DB00110': ['prophylaxis of respiratory diseases casued by respiratory syncytial virus'],\n",
       " 'DB00111': ['prevention of renal transplant rejection'],\n",
       " 'DB00112': ['metastatic colorectal cancer',\n",
       "  'recurrent glioblastoma',\n",
       "  'covid- complications including acute respiratory distress syndrome (ards) and acute lung injury (ali)'],\n",
       " 'DB00113': ['imaging colorectal tumors'],\n",
       " 'DB00114': ['nutritional supplementation and for treating dietary shortage or imbalance'],\n",
       " 'DB00115': ['deficiency of this vitamin no nervous system involvement',\n",
       "  'newly diagnosed vitamin b deficiency',\n",
       "  'vitamin b deficiencies due to various causes, with or without neurologic manifestations',\n",
       "  'malabsorption, as these forms are primarily absorbed in the gastrointestinal tract'],\n",
       " 'DB00116': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00117': ['some immunomodulatory and antioxidant',\n",
       "  'use in some with rheumatoid arthritis',\n",
       "  'some with rheumatoid arthritis',\n",
       "  'anemia or uremia or for lowering serum cholesterol',\n",
       "  'anemia or uremia or for lowering serum cholesterol'],\n",
       " 'DB00118': ['depression, liver disorders, fibromyalgia, and osteoarthritis'],\n",
       " 'DB00119': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00120': ['some with depression', 'vitiligo'],\n",
       " 'DB00121': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00122': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00123': ['putative anti-herpes simplex virus', 'some anti-osteoporotic'],\n",
       " 'DB00125': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00126': ['vitamin c deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant'],\n",
       " 'DB00127': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00128': ['no approved indication'],\n",
       " 'DB00129': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00130': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance',\n",
       "  'the acute complications of sickle cell disease',\n",
       "  'reduce the acute complications of sickle cell disease in adult and patients'],\n",
       " 'DB00131': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00132': ['nutritional supplementation and for treating dietary shortage or imbalance'],\n",
       " 'DB00133': ['a natural moisturizing agent in some cosmetics and skin care products'],\n",
       " 'DB00134': ['protein synthesis including the formation of same, l-homocysteine, l-cysteine, taurine, and sulfate'],\n",
       " 'DB00135': ['an effective antidepressant,',\n",
       "  'stress and combat narcolepsy and chronic fatigue,'],\n",
       " 'DB00136': ['chronic renal failure undergoing dialysis'],\n",
       " 'DB00137': ['dietary shortage or imbalance'],\n",
       " 'DB00138': ['anti-inflammatory',\n",
       "  'osteoarthritis and rheumatoid arthritis',\n",
       "  'any of these conditions'],\n",
       " 'DB00139': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00140': ['adrugosis (vitamin b deficiency)'],\n",
       " 'DB00141': ['the treatment and prevention of osteoarthritis, by itself or in combination with chondroitin sulfate'],\n",
       " 'DB00142': ['ulcers',\n",
       "  'the healing of ulcers',\n",
       "  'alcoholism, schizophrenia and the craving for sugar',\n",
       "  'to control alcoholism, schizophrenia and the craving for sugar'],\n",
       " 'DB00143': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00144': [\"cognitive impairment, including alzheimer's disease, age-associated memory impairment and some non-alzheimer's dementias\",\n",
       "  'immune enhancement or for reduction of exercise stress'],\n",
       " 'DB00145': ['antispastic', 'antipsychotic'],\n",
       " 'DB00146': ['chronic renal failure undergoing dialysis'],\n",
       " 'DB00147': ['dietary shortage or imbalances',\n",
       "  'nutritional supplementation and for treating dietary shortage or imbalances'],\n",
       " 'DB00148': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00149': ['in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress',\n",
       "  'the breakdown of muscle proteins that sometimes occur after trauma or severe stress'],\n",
       " 'DB00150': ['serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight'],\n",
       " 'DB00151': ['the prevention of liver damage and kidney damage associated with overdoses of acetaminophen'],\n",
       " 'DB00152': [\"drug and niacin deficiency states, korsakov's alcoholic psychosis, wernicke-korsakov syndrome, delirium, and peripheral neuritis\"],\n",
       " 'DB00153': ['hypoparathyroidism, refractory rickets, and familial hypophosphatemia',\n",
       "  'hypoparathyroidism, refractory rickets, and familial hypophosphatemia'],\n",
       " 'DB00154': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00155': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00156': ['proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation'],\n",
       " 'DB00157': [\"parkinson's disease, chronic fatigue syndrome, alzheimer's disease and cardiovascular disease\"],\n",
       " 'DB00158': ['drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood',\n",
       "  'drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood'],\n",
       " 'DB00159': ['lowering elevated triglycerides in those who are hyperglyceridemic',\n",
       "  'cystic fibrosis by reducing disease severity and may play a similar role in type  diabetics in slowing the progression of diabetic nephropathy'],\n",
       " 'DB00160': ['protein synthesis'],\n",
       " 'DB00161': ['mental vigor, muscle coordination, and calm emotions',\n",
       "  'hepatic encephalopathy and in some with phenylketonuria'],\n",
       " 'DB00162': ['drug deficiency'],\n",
       " 'DB00163': ['drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet,',\n",
       "  'drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet,'],\n",
       " 'DB00165': ['vitamin b deficiency and for the prophylaxis of db-induced peripheral neuropathy',\n",
       "  'vitamin b deficiency and for the prophylaxis of db-induced peripheral neuropathy',\n",
       "  'nausea and vomiting in pregnancy in a combination product with db (as the commercially available product diclectin)'],\n",
       " 'DB00166': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00167': ['antihepatic encephalopathy',\n",
       "  'anticatabolic and antitardive dyskinesia'],\n",
       " 'DB00168': ['a diet supplement and sugar substitute'],\n",
       " 'DB00169': ['specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia ,',\n",
       "  'specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia ,'],\n",
       " 'DB00170': ['in the normal clotting of blood, but it may also play a role in normal bone calcification',\n",
       "  'in the normal clotting of blood, but it may also play a role'],\n",
       " 'DB00171': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00172': ['the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles',\n",
       "  'maintain and strengthen heart muscles'],\n",
       " 'DB00173': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00174': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00175': ['primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease',\n",
       "  'clinically evident coronary heart disease',\n",
       "  'heterozygous familial hypercholesterolemia in patients over  years of age with low-density lipoprotein (ldl) cholesterol higher than  mg/dl after diet modifications or ldl levels higher than  mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors',\n",
       "  'primary dysbetalipoproteinemia (type iii hyperlipidemia)'],\n",
       " 'DB00176': ['depression and for obsessive compulsive disorder (ocd)',\n",
       "  'bulimia nervosa'],\n",
       " 'DB00177': ['hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions',\n",
       "  'hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions',\n",
       "  'heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate',\n",
       "  'heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate'],\n",
       " 'DB00178': ['mild to severe hypertension',\n",
       "  'cardiovascular mortality following myocardial infarction in hemodynamically stable patients who develop clinical signs of congestive heart failure within a few days following myocardial',\n",
       "  'reduce cardiovascular mortality following myocardial infarction in hemodynamically stable patients who develop clinical signs of congestive heart failure within a few days following myocardial infarction',\n",
       "  'the rate of death, myocardial infarction and stroke',\n",
       "  'hypertension, diabetes mellitus and microalubinuria or overt nephropathy'],\n",
       " 'DB00179': ['actinic keratoses (precancerous skin growths that can become malignant if left untreated)'],\n",
       " 'DB00180': ['the maintenance treatment of asthma as a prophylactic therapy'],\n",
       " 'DB00181': ['the restoration of residual function',\n",
       "  'skeletal muscle spasm caused by rheumatic disorders',\n",
       "  'skeletal muscle spasm caused by rheumatic disorders'],\n",
       " 'DB00182': ['attention-deficit/hyperactivity disorders (adhd) and for central nervous system disorders such as narcolepsy',\n",
       "  'attention-deficit/hyperactivity disorders (adhd) and for central nervous system disorders such as narcolepsy',\n",
       "  'obesity, depression and chronic pain'],\n",
       " 'DB00183': ['a diagnostic aid for evaluation of gastric acid secretory function'],\n",
       " 'DB00184': ['the relief of drug withdrawal symptoms and as an aid to smoking cessation'],\n",
       " 'DB00185': ['dry mouth'],\n",
       " 'DB00186': ['the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia'],\n",
       " 'DB00187': ['the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable',\n",
       "  'noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention'],\n",
       " 'DB00188': ['patients with multiple myeloma or mantle cell lymphoma',\n",
       "  'patients with multiple myeloma or mantle cell lymphoma'],\n",
       " 'DB00189': ['insomnia for periods of up to one week in duration'],\n",
       " 'DB00190': ['idiopathic parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication'],\n",
       " 'DB00191': ['exogenous obesity for patients with an initial body mass index (bmi) greater than  kg/m or greater than  kg/m in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia'],\n",
       " 'DB00192': ['life-threatening dysrhythmias and sustained ventricular tachycardia'],\n",
       " 'DB00193': ['moderate to severe pain', 'premature ejaculation'],\n",
       " 'DB00194': ['chickenpox - varicella, herpes zoster and herpes simplex'],\n",
       " 'DB00195': ['hypertension'],\n",
       " 'DB00196': ['the following fungal infections:'],\n",
       " 'DB00197': ['type ii diabetes mellitus'],\n",
       " 'DB00198': ['acute, uncomplicated illness due to influenza a and b infection',\n",
       "  'post-exposure prevention of influenza in infants less than  year of age during a pandemic influenza outbreak'],\n",
       " 'DB00199': ['infections caused by susceptible strains of various bacteria',\n",
       "  'infections caused by susceptible strains of various bacteria',\n",
       "  'pertussis (whooping cough) caused by bordetella pertussis',\n",
       "  'pertussis infection for patients been exposed to the bacteria',\n",
       "  'diphtheria and other infections due to corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status',\n",
       "  'rheumatic fever in penicillin',\n",
       "  'prevent rheumatic fever in penicillin intolerant patients',\n",
       "  'erythrasma, an infectious condition caused by corynebacterium minutissimum',\n",
       "  'acute pelvic inflammatory disease caused by n',\n",
       "  'an alternative drug in treating acute pelvic inflammatory disease caused by n',\n",
       "  'the primary stage of primary syphilis',\n",
       "  'chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy',\n",
       "  'uncomplicated rectal, urethral and endocervical infections',\n",
       "  'nongonococcal urethritis can be used when tetracyclines cannot be administered',\n",
       "  'nongonococcal urethritis due to ureaplasma urealyticum'],\n",
       " 'DB00200': ['pernicious anemia and vitamin b deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets',\n",
       "  'known or suspected cyanide poisoning'],\n",
       " 'DB00201': ['the short term treatment of apnea of prematurity in infants and off label for bronchopulmonary dysplasia caused by premature birth',\n",
       "  'bronchopulmonary dysplasia caused by premature birth',\n",
       "  'respiratory depression resulting from an overdose with cns depressant drugs'],\n",
       " 'DB00202': ['surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ect)'],\n",
       " 'DB00203': ['phosphodiesterase- (pde) inhibitor that is predominantly employed for two primary indications:',\n",
       "  'pulmonary arterial hypertension (pah) (who group i)',\n",
       "  'primary pulmonary arterial hypertension (pph) or pulmonary hypertension secondary to connective tissue disease (ctd)',\n",
       "  'patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity',\n",
       "  'patients aged  year to  years old with pulmonary arterial hypertension'],\n",
       " 'DB00204': ['the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter af/afl) in patients with atrial fibrillation/atrial flutter of greater than one week duration been converted to normal sinus rhythm'],\n",
       " 'DB00205': ['toxoplasmosis and acute malaria',\n",
       "  'malaria in areas non-resistant to drug'],\n",
       " 'DB00206': ['hypertension'],\n",
       " 'DB00207': ['or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of drug',\n",
       "  'patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below',\n",
       "  'patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below',\n",
       "  'chancroid'],\n",
       " 'DB00208': [],\n",
       " 'DB00209': ['overactive bladder with urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition'],\n",
       " 'DB00210': ['acne vulgaris'],\n",
       " 'DB00211': ['symptomatic orthostatic hypotension (oh)'],\n",
       " 'DB00212': ['hypertension and heart failure'],\n",
       " 'DB00213': ['pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions',\n",
       "  'pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions',\n",
       "  'erosive esophagitis',\n",
       "  'gerd',\n",
       "  'the long-term treatment of the above conditions'],\n",
       " 'DB00214': ['edema associated with congestive heart failure, renal or hepatic diseases',\n",
       "  'edema associated with congestive heart failure, renal or hepatic diseases',\n",
       "  'an antihypertensive agent either alone or in combination with other antihypertensives'],\n",
       " 'DB00215': ['depression, as indicated by the fda label'],\n",
       " 'DB00216': ['migraine with or without aura'],\n",
       " 'DB00217': ['hypertension'],\n",
       " 'DB00218': ['sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis',\n",
       "  'bacterial conjunctivitis (pinkeye)'],\n",
       " 'DB00219': ['visceral spasms'],\n",
       " 'DB00220': ['hiv in both adults and children'],\n",
       " 'DB00221': ['asthma, wheezing, and chronic asthmatic bronchitis'],\n",
       " 'DB00222': ['type  diabetes',\n",
       "  'type  diabetes whose high blood sugar levels cannot be controlled by diet and exercise along with with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone'],\n",
       " 'DB00223': ['relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses'],\n",
       " 'DB00224': ['hiv infection'],\n",
       " 'DB00225': ['intravenous use in mri to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues'],\n",
       " 'DB00226': ['and control hypertension'],\n",
       " 'DB00227': ['the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c',\n",
       "  'primary hypercholesterolemia (types iia and iib), when the response to diet restricted in saturated fat and cholesterol',\n",
       "  'coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target levels',\n",
       "  'total-c, ldl-c and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh) who are at least one year post-menarche,  to  years of age, with hefh if after an adequate trial of diet therapy the following findings are present: ldl-c remains greater than  mg/dl or ldl-c remains greater than  mg/dl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present'],\n",
       " 'DB00228': ['both the induction and maintenance of general anesthesia',\n",
       "  'analgesia for vaginal delivery',\n",
       "  'induce analgesia for vaginal delivery',\n",
       "  'an adjunct to general anesthetic drugs during delivery by cesarean section'],\n",
       " 'DB00229': ['severe infections caused by susceptible bacteria'],\n",
       " 'DB00230': ['neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and  for partial-onset seizures'],\n",
       " 'DB00231': ['premedication prior to minor surgery or other related procedures'],\n",
       " 'DB00232': ['use in hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00233': ['tuberculosis'],\n",
       " 'DB00234': ['clinical depression'],\n",
       " 'DB00235': ['congestive heart failure', 'congestive heart failure'],\n",
       " 'DB00236': ['polycythaemia vera and refractory chronic myeloid leukaemia'],\n",
       " 'DB00237': ['use as a sedative or hypnotic',\n",
       "  'insomnia for longer than  weeks'],\n",
       " 'DB00238': ['use in combination with other antiretroviral drugs in the ongoing treatment of hiv- infection'],\n",
       " 'DB00239': ['dermal fungal infection'],\n",
       " 'DB00240': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00241': ['the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine',\n",
       "  'the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine'],\n",
       " 'DB00242': ['active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms',\n",
       "  \"chronic lymphocytic leukemia (cll), low-grade non-hodgkin's lymphoma, and cutaneous t-cell lymphoma\"],\n",
       " 'DB00243': ['chronic angina',\n",
       "  'chronic angina',\n",
       "  'certain arrhythmias, including ventricular tachycardia,',\n",
       "  'acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications'],\n",
       " 'DB00244': ['active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis ,'],\n",
       " 'DB00245': ['an adjunct in the therapy of all forms of parkinsonism',\n",
       "  'the control of extrapyramidal disorders due to neuroleptic drugs'],\n",
       " 'DB00246': ['schizophrenia, as monotherapy for manic or mixed episodes related to bipolar i disorder, and  to lithium or valproate for maintenance treatment of bipolar i disorder',\n",
       "  'schizophrenia, as monotherapy for manic or mixed episodes related to bipolar i disorder, and  to lithium or valproate for maintenance treatment of bipolar i disorder',\n",
       "  'acute agitation in schizophrenia'],\n",
       " 'DB00247': ['vascular headache'],\n",
       " 'DB00248': ['hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas)',\n",
       "  'parkinsonian syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease'],\n",
       " 'DB00249': ['use in keratoconjunctivitis and keratitis caused by herpes simplex virus'],\n",
       " 'DB00250': ['the treatment and leprosy and dermatitis herpetiformis'],\n",
       " 'DB00251': ['candidiasis (a yeast-like fungal infection) of the vulva and vagina'],\n",
       " 'DB00252': ['grand mal seizures, complex partial seizures,',\n",
       "  'and treat seizures during or following neurosurgery',\n",
       "  'seizures occurring during neurosurgery'],\n",
       " 'DB00253': ['allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity'],\n",
       " 'DB00254': ['various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria',\n",
       "  'various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria',\n",
       "  'any type of staphylococcal infection',\n",
       "  'streptococcal infections unless the microorganism has been demonstrated to be susceptible'],\n",
       " 'DB00255': ['prostate cancer'],\n",
       " 'DB00256': ['acne in addition to other susceptible infections'],\n",
       " 'DB00257': ['the following dermal infections , :',\n",
       "  'the following dermal infections , :',\n",
       "  'the local treatment of oropharyngeal candidiasis',\n",
       "  'the incidence of oropharyngeal candidiasis',\n",
       "  'any systemic mycoses',\n",
       "  'any systemic mycoses'],\n",
       " 'DB00258': ['kidney disease'],\n",
       " 'DB00259': ['vulvovaginitis caused by lt'],\n",
       " 'DB00260': ['tuberculosis (tb)'],\n",
       " 'DB00261': ['thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis',\n",
       "  'thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis'],\n",
       " 'DB00262': [\"brain tumors, multiple myeloma, hodgkin's disease and non-hodgkin's lymphomas\"],\n",
       " 'DB00263': ['severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections'],\n",
       " 'DB00264': ['angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension',\n",
       "  'angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension'],\n",
       " 'DB00265': ['eradication of scabies (lt'],\n",
       " 'DB00266': ['decreasing blood clotting', 'deep vein thrombosis'],\n",
       " 'DB00267': ['female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria'],\n",
       " 'DB00268': [\"signs and parkinson's disease and for primary moderate-severe restless legs syndrome\"],\n",
       " 'DB00269': ['menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer',\n",
       "  'breast engorgement following childbirth',\n",
       "  'prevent breast engorgement following childbirth'],\n",
       " 'DB00270': ['mild to moderate essential hypertension'],\n",
       " 'DB00271': [],\n",
       " 'DB00272': ['use clinically to test gastric secretory function'],\n",
       " 'DB00273': ['seizures associated with lennox-gastaut syndrome in patients above  years of age )prophylaxis of migraine'],\n",
       " 'DB00274': ['infections caused by susceptible organisms'],\n",
       " 'DB00275': ['hypertension either alone or in combination with other antihypertensive agents',\n",
       "  'hypertension either alone or in combination with other antihypertensive agents',\n",
       "  'cardiovascular outcomes including reducing risk of myocardial'],\n",
       " 'DB00276': ['acute myeloid leukaemia'],\n",
       " 'DB00277': ['symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis'],\n",
       " 'DB00278': ['prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (hit)'],\n",
       " 'DB00279': ['the following indications:',\n",
       "  'thyroid cancer',\n",
       "  'replace insufficient hormonal production and restore  plasma levels',\n",
       "  'hyperthyroidism during the recovery phase of subacute thyroiditis'],\n",
       " 'DB00280': ['documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias',\n",
       "  'class ia antiarrhythmic'],\n",
       " 'DB00281': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks ,'],\n",
       " 'DB00282': [\"moderate to severe hypercalcemia of malignancy, moderate to severe paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma\"],\n",
       " 'DB00283': ['the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation',\n",
       "  'mild, uncomplicated allergic skin manifestations of urticaria and angioedema',\n",
       "  'self-medication for temporary relief of symptoms associated with the common cold'],\n",
       " 'DB00284': ['the treatment and diabetes type ii (used in combination therapy as a second or third line agent)'],\n",
       " 'DB00285': ['major depressive disorder (mdd), generalized anxiety disorder (gad), social anxiety disorder (social phobia), and panic disorder with or without agoraphobia',\n",
       "  'neuropathic pain (although there is only minimal evidence of efficacy for this condition)',\n",
       "  'obsessive-compulsive disorder (ocd) ,'],\n",
       " 'DB00286': ['several different conditions including:',\n",
       "  'moderate to severe vasomotor symptoms due to menopause',\n",
       "  'moderate to severe vulvar and vaginal atrophy due to menopause',\n",
       "  'hypoestrogenism due to hypogonadism, castration or primary ovarian failure',\n",
       "  'breast cancer in appropriately selected patients with metastatic disease',\n",
       "  'androgen-dependent carcinoma of the prostate'],\n",
       " 'DB00287': ['open-angle glaucoma or ocular hypertension , ,',\n",
       "  'the decrease of elevated intraocular pressure in paediatric patients aged  months to lt'],\n",
       " 'DB00288': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00289': ['attention deficit hyperactivity disorder (adhd)'],\n",
       " 'DB00290': ['treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas'],\n",
       " 'DB00291': [\"chronic lymphatic (lymphocytic) leukemia,  childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, hodgkin's disease,  non-hodgkin's lymphomas, and waldenstrms macroglobulinemia\"],\n",
       " 'DB00292': ['the induction of general anesthesia'],\n",
       " 'DB00293': ['malignant neoplasm of colon and rectum'],\n",
       " 'DB00294': [],\n",
       " 'DB00295': ['chronic, moderate to severe pain'],\n",
       " 'DB00296': ['obstetric anesthesia and regional anesthesia for surgery'],\n",
       " 'DB00297': ['the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures'],\n",
       " 'DB00298': ['iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations'],\n",
       " 'DB00299': ['recurrent cold sores on the lips and face from various herpesvirus invections'],\n",
       " 'DB00300': ['hiv- infection', 'chronic hepatitis b', 'hiv- infection ,'],\n",
       " 'DB00301': ['bacterial infection by susceptible microorganisms'],\n",
       " 'DB00302': ['use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction',\n",
       "  'excessive bleeding in menstruation, surgery, or trauma cases'],\n",
       " 'DB00303': ['the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: () complicated intra-abdominal infections due to lt'],\n",
       " 'DB00304': ['pregnancy'],\n",
       " 'DB00305': ['malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder',\n",
       "  'an adjunct to ab externo glaucoma surgery',\n",
       "  'adults with low-grade upper tract urothelial cancer (lg-utuc)'],\n",
       " 'DB00306': ['use as a sedative and hypnotic'],\n",
       " 'DB00307': ['skin manifestations of cutaneous t-cell lymphoma (ctcl)',\n",
       "  'skin lesions in early (stage ia and ib) ctcl'],\n",
       " 'DB00308': ['the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm'],\n",
       " 'DB00309': [\"acute leukaemia, malignant lymphoma, hodgkin's disease, acute erythraemia and acute panmyelosis\"],\n",
       " 'DB00310': ['hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00311': ['duodenal ulcers, as a diuretic, and for glaucoma, and may also be useful for seizures associated with epilepsy'],\n",
       " 'DB00312': ['the short-term treatment of insomnia'],\n",
       " 'DB00313': ['complex partial seizures and simple or complex absence seizures',\n",
       "  'multiple seizure types that include absence seizures'],\n",
       " 'DB00314': ['tuberculosis in combination with other drugs'],\n",
       " 'DB00315': ['migraine with or without auras'],\n",
       " 'DB00316': ['mild to moderate pain and reduction of fever',\n",
       "  'mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever',\n",
       "  'mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever'],\n",
       " 'DB00317': ['the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies'],\n",
       " 'DB00318': ['form of this',\n",
       "  'the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate'],\n",
       " 'DB00319': ['polymicrobial infections'],\n",
       " 'DB00320': ['migraine headaches with or without aura and cluster headache episodes'],\n",
       " 'DB00321': ['the following conditions :', 'persistent enuresis'],\n",
       " 'DB00322': ['gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means',\n",
       "  'liver cancer (usually administered by hepatic intra-arterial infusion)'],\n",
       " 'DB00323': [\"parkinson's disease\"],\n",
       " 'DB00324': ['the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe'],\n",
       " 'DB00325': ['acute congestive heart failure'],\n",
       " 'DB00326': ['mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin d deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, for intestinal malabsorption,'],\n",
       " 'DB00327': ['moderate to severe acute pain and severe chronic pain',\n",
       "  'moderate to severe acute pain and severe chronic pain',\n",
       "  'pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as drug along with the existing regimen for cases of severe pain'],\n",
       " 'DB00328': ['symptomatic moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis',\n",
       "  'closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between  and  g when after  hours usual medical management (e'],\n",
       " 'DB00330': ['pulmonary tuberculosis'],\n",
       " 'DB00331': ['glycemic control',\n",
       "  'glycemic control',\n",
       "  'type  diabetes mellitus when used adjunctively with diet and exercise'],\n",
       " 'DB00332': ['severe exacerbations of asthma flares requiring treatment',\n",
       "  'the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients  years or older',\n",
       "  'sialorrhea'],\n",
       " 'DB00333': ['pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate',\n",
       "  'opioid dependence'],\n",
       " 'DB00334': ['episodes of depression associated with bipolar disorder type  and treatment-resistant depression',\n",
       "  'psychomotor agitation associated with schizophrenia and bipolar i mania',\n",
       "  'psychomotor agitation associated with schizophrenia and bipolar i mania'],\n",
       " 'DB00335': [],\n",
       " 'DB00336': ['bacterial skin infections including pyodermas, infected dermatoses and infections of cuts, wounds, burns and ulcers due to susceptible organisms'],\n",
       " 'DB00337': ['mild to moderate atopic dermatitis'],\n",
       " 'DB00338': ['the following purposes:', 'the risk of duodenal ulcer'],\n",
       " 'DB00339': ['active tuberculosis'],\n",
       " 'DB00340': ['parkinsonism'],\n",
       " 'DB00341': ['associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens',\n",
       "  'associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds',\n",
       "  'the uncomplicated skin manifestations of chronic idiopathic urticaria'],\n",
       " 'DB00342': ['allergic rhinitis, hay fever, and allergic skin disorders'],\n",
       " 'DB00343': ['hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents',\n",
       "  'hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents',\n",
       "  'chronic stable angina',\n",
       "  \"variant angina (prinzmetal's angina)\",\n",
       "  \"variant angina (prinzmetal's angina)\",\n",
       "  'the short-term atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate',\n",
       "  'the rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm',\n",
       "  'off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy'],\n",
       " 'DB00344': ['depression'],\n",
       " 'DB00345': ['measure effective renal plasma flow (erpf)'],\n",
       " 'DB00346': ['the reduction of urinary obstruction and relief of associated manifestations (eg',\n",
       "  'symptomatic beningn prostatic hyperplasia'],\n",
       " 'DB00347': [],\n",
       " 'DB00348': ['hereditary tyrosinemia type'],\n",
       " 'DB00349': ['the treatment and epilepsy and seizures associated with lennox-gastaut syndrome, a difficult-to-treat form of childhood epilepsy'],\n",
       " 'DB00350': ['severe hypertension and in the treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss'],\n",
       " 'DB00351': ['anorexia, cachexia, or an unexplained, significant weight loss',\n",
       "  'recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in canada and some other countries'],\n",
       " 'DB00352': ['remission induction and remission consolidation treatment of acute nonlymphocytic leukemias'],\n",
       " 'DB00353': ['the prevention and control of excessive bleeding following vaginal childbirth'],\n",
       " 'DB00354': ['prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems)'],\n",
       " 'DB00355': ['the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections'],\n",
       " 'DB00356': ['the relief of discomfort associated with acute painful musculoskeletal conditions'],\n",
       " 'DB00357': [\"the suppression of adrenal function in selected patients with cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast\"],\n",
       " 'DB00358': ['mild to moderate acute malaria caused by druguine-susceptible strains of lt'],\n",
       " 'DB00359': ['rheumatic fever and meningococcal meningitis'],\n",
       " 'DB00360': ['tetrahydrobiopterin (bh) deficiency'],\n",
       " 'DB00361': ['adults for advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs',\n",
       "  'advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs',\n",
       "  'relapsed or refractory hodgkin lymphoma, in combination with other chemotherapy agents',\n",
       "  'desmoid tumor or aggressive fibromatosis, in combination with methotrexate',\n",
       "  'recurrent or metastatic squamous cell head and neck cancer',\n",
       "  'recurrent ovarian cancer',\n",
       "  'metastatic breast cancer,',\n",
       "  'her-positive, trastuzumab-resistant, advanced breast cancer'],\n",
       " 'DB00362': ['the following fungal infections: candidemia and other forms of lt'],\n",
       " 'DB00363': ['use in patients with treatment-resistant schizophrenia'],\n",
       " 'DB00364': ['active duodenal ulcer for up to  weeks',\n",
       "  'the prevention and/or treatment of gastro-esophageal reflux disease (gerd), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia ,'],\n",
       " 'DB00365': ['adults with mild to moderate infections caused by susceptible strains of lt'],\n",
       " 'DB00366': ['morning sickness'],\n",
       " 'DB00367': ['the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse',\n",
       "  'pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse',\n",
       "  'regular contraception and must be taken as soon as possible within  hours after intercourse',\n",
       "  'various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of - years',\n",
       "  'pregnancy for up to  years',\n",
       "  'osteoporosis',\n",
       "  'menorrhagia, endometrial hyperplasia, and endometriosis'],\n",
       " 'DB00368': ['patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine',\n",
       "  'a vasopressor medication for patients with critical hypotension'],\n",
       " 'DB00369': ['cmv retinitis'],\n",
       " 'DB00370': ['major depressive disorder and its associated symptoms',\n",
       "  'major depressive disorder and its associated symptoms'],\n",
       " 'DB00371': ['anxiety disorders or for the short-term relief of anxiety'],\n",
       " 'DB00372': ['the treatment or relief of nausea and vomiting'],\n",
       " 'DB00373': ['increased intraocular pressure',\n",
       "  'high blood pressure',\n",
       "  'migraine headaches'],\n",
       " 'DB00374': ['pulmonary arterial hypertension'],\n",
       " 'DB00375': ['primary hypercholesterolemia (a condition that features elevated ldl-c) who do not respond adequately to dietary changes',\n",
       "  'severe elevations of ldl-c or with definite coronary heart disease fda label,',\n",
       "  \"fredrickson's type ii hyperlipoproteinemia\",\n",
       "  'combined hypercholesterolemia and hypertriglyceridemia, although drug may be helpful in reducing elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern'],\n",
       " 'DB00376': [\"parkinson's disease and extrapyramidal reactions caused by drugs\",\n",
       "  \"parkinson's disease and extrapyramidal reactions caused by drugs\"],\n",
       " 'DB00377': ['the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy',\n",
       "  'postoperative nausea and vomiting for up to  hours post operation'],\n",
       " 'DB00378': ['irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency',\n",
       "  'natural abortion'],\n",
       " 'DB00379': ['ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation'],\n",
       " 'DB00380': ['reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer received a cumulative doxorubicin hydrochloride dose of  mg/m^ and would benefit from continued doxorubicin therapy',\n",
       "  'extravasation from intravenous anthracyclines',\n",
       "  'extravasation from intravenous anthracyclines'],\n",
       " 'DB00381': ['the following conditions :'],\n",
       " 'DB00382': [\"mild to moderate dementia of the alzheimer's type\"],\n",
       " 'DB00383': ['peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders'],\n",
       " 'DB00384': ['edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome',\n",
       "  'edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome'],\n",
       " 'DB00385': ['cancer of the bladder'],\n",
       " 'DB00387': [\"all forms of parkinson's disease, and control of extrapyramidal reactions induced by antipsychotic agents\"],\n",
       " 'DB00388': ['hypotension caused by shock or anesthesia,,  an ophthalmic formulation is indicated to dilate pupils and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids'],\n",
       " 'DB00389': ['hyperthyroidism and thyrotoxicosis',\n",
       "  'prepare patients for thyroidectomy'],\n",
       " 'DB00390': ['mild to moderate heart failure',\n",
       "  'myocardial contraction',\n",
       "  'heart failure, when it is clinically possible, drug should be administered along with with a diuretic and an angiotensin-converting enzyme (ace) inhibitor for optimum effects'],\n",
       " 'DB00391': ['schizophrenia', 'schizophrenia'],\n",
       " 'DB00392': [\"parkinson's disease and also used to control severe reactions to certain medicines such as reserpine\"],\n",
       " 'DB00393': ['use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits'],\n",
       " 'DB00394': ['the relief of acute bronchospasm',\n",
       "  'intranasal use to relieve seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal',\n",
       "  'seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal'],\n",
       " 'DB00395': ['the relief of discomfort related to acute, painful musculoskeletal conditions',\n",
       "  'the treatment periods up to two or three weeks'],\n",
       " 'DB00396': ['use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets',\n",
       "  'endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets',\n",
       "  'use in secondary amenorrhea',\n",
       "  'secondary amenorrhea',\n",
       "  'secondary amenorrhea, with the use of the % concentration if there is no therapeutic response to the % gel',\n",
       "  'the prevention of pregnancy',\n",
       "  'pregnancy'],\n",
       " 'DB00397': ['nasal congestion, control of urinary incontinence, priapism and obesity'],\n",
       " 'DB00398': ['unresectable hepatocellular carcinoma and advanced renal cell carcinoma',\n",
       "  'unresectable hepatocellular carcinoma and advanced renal cell carcinoma'],\n",
       " 'DB00399': [\"hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and paget's disease of bone in men and women\",\n",
       "  'the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis',\n",
       "  'osteoporosis in post menopausal women and glucocorticoid induced osteoporosis'],\n",
       " 'DB00400': ['ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by lt'],\n",
       " 'DB00401': ['hypertension'],\n",
       " 'DB00402': ['insomnia', 'insomnia'],\n",
       " 'DB00403': ['paralytic ileus and as diagnostic aid in pancreatic malfunction'],\n",
       " 'DB00404': ['anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia',\n",
       "  'anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia'],\n",
       " 'DB00405': ['the treatment and relief of allergies, hay fever, and colds'],\n",
       " 'DB00406': [\"bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of chagas' disease (as a blood additive)\"],\n",
       " 'DB00407': ['prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery'],\n",
       " 'DB00408': ['the manifestations of psychotic disorders such as schizophrenia'],\n",
       " 'DB00409': ['schizophrenia'],\n",
       " 'DB00410': ['impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_',\n",
       "  'impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_'],\n",
       " 'DB00411': ['glaucoma, but is used during ophthalmic surgery'],\n",
       " 'DB00412': ['type  diabetes mellitus'],\n",
       " 'DB00413': ['parkinsons disease',\n",
       "  'parkinsons disease',\n",
       "  'treatment of moderate to severe primary restless legs syndrome (rls)'],\n",
       " 'DB00414': ['diabetes mellitus type  (adult-onset)'],\n",
       " 'DB00415': ['infection (respiratory, gi, uti and meningitis) due to e'],\n",
       " 'DB00416': ['use as an anesthesia adjunct to induce skeletal muscle relaxation',\n",
       "  'the intensity of muscle contractions'],\n",
       " 'DB00417': ['mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response',\n",
       "  'mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response',\n",
       "  'congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract'],\n",
       " 'DB00418': ['the short-term treatment of intractable insomnia for patients habituated to barbiturates'],\n",
       " 'DB00419': [\"patients with mild to moderate type  (nonneuropathic) gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e\",\n",
       "  'progressive neurological symptoms in adult and patients with niemann-pick disease type c (np-c)'],\n",
       " 'DB00420': ['an adjunct for short term treatment of moderate and severe psychomotor agitation',\n",
       "  'agitation or restlessness in the elderly'],\n",
       " 'DB00421': ['new york heart association class iii-iv heart failure, edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term',\n",
       "  'antiandrogenic',\n",
       "  'hirsutism, female pattern hair loss, and adult acne vulgaris',\n",
       "  'its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth'],\n",
       " 'DB00422': ['attention deficit hyperactivity disorder (adhd)'],\n",
       " 'DB00423': [],\n",
       " 'DB00424': ['bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis',\n",
       "  \"certain heart conditions, to control parkinson's disease and rhinitis\"],\n",
       " 'DB00425': [],\n",
       " 'DB00426': ['acute herpes zoster (shingles)'],\n",
       " 'DB00427': ['the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis',\n",
       "  'combination with other agents for the symptomatic relief of symptoms associated with the common cold'],\n",
       " 'DB00428': ['malignant neoplasms of pancreas (metastatic islet cell carcinoma)'],\n",
       " 'DB00429': ['aborting pregnancy between the th and th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion:',\n",
       "  'postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management'],\n",
       " 'DB00430': ['severe infections caused by susceptible bacteria such as p'],\n",
       " 'DB00431': ['patients infested with sarcoptes scabiei or pediculosis capitis either failed to respond to adequate doses, or are intolerant of other approved therapies'],\n",
       " 'DB00432': ['primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types  and  in ophthalmic solutions',\n",
       "  'patients with metastatic colorectal cancer been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy',\n",
       "  'patients with metastatic colorectal cancer been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy'],\n",
       " 'DB00433': ['severe nausea and vomiting',\n",
       "  'severe nausea and vomiting',\n",
       "  'manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety',\n",
       "  'manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety',\n",
       "  'generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than  mg per day or for shorter than  weeks',\n",
       "  'combination with dopamine antagonist'],\n",
       " 'DB00434': ['perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine'],\n",
       " 'DB00435': ['term and near-term (amp'],\n",
       " 'DB00436': ['high blood pressure and edema related to heart failure'],\n",
       " 'DB00437': [],\n",
       " 'DB00438': ['patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis)'],\n",
       " 'DB00439': ['primary hypercholesterolemia and mixed dyslipidemia (fredrickson types iia and iib) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate'],\n",
       " 'DB00440': ['acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e',\n",
       "  'acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e',\n",
       "  'acute bacterial conjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible bacteria'],\n",
       " 'DB00441': ['advanced ovarian cancer that has relapsed at least  months after completion of platinum-based therapy',\n",
       "  'advanced ovarian cancer that has relapsed at least  months after completion of platinum-based therapy'],\n",
       " 'DB00442': ['chronic hepatitis b virus infection'],\n",
       " 'DB00443': ['several inflammatory conditions',\n",
       "  'several inflammatory conditions',\n",
       "  'pruritic and inflammatory corticosteroid-responsive-dermatoses',\n",
       "  'pruritic and',\n",
       "  'plaque psoriasis',\n",
       "  'manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions'],\n",
       " 'DB00444': ['refractory acute lymphoblastic leukaemia'],\n",
       " 'DB00445': ['use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer'],\n",
       " 'DB00446': ['cholera, as it destroys the vibrios and decreases the diarrhea',\n",
       "  'bacterial conjunctivitis'],\n",
       " 'DB00447': ['upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis'],\n",
       " 'DB00448': ['short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid) induced gastric and duodenal ulcers',\n",
       "  'gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid)',\n",
       "  'reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid) induced gastric and duodenal ulcers',\n",
       "  'the maintenance and healing of several gastric conditions including duodenal ulcers, nsaid related gastric ulcers, and erosive esophagitis',\n",
       "  'several gastric conditions including duodenal ulcers, nsaid related gastric ulcers, and erosive esophagitis',\n",
       "  'hypersecretory conditions including zollinger-ellison syndrome'],\n",
       " 'DB00449': ['initial therapy for the control of intraocular pressure in chronic open-angle glaucoma',\n",
       "  'prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma'],\n",
       " 'DB00450': ['tranquilization', 'the incidence of nausea and vomiting'],\n",
       " 'DB00451': ['thyrotropin-dependent well-differentiated thyroid cancer'],\n",
       " 'DB00452': ['bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis'],\n",
       " 'DB00453': ['the treatment and brucellosis, mycoplasma infection, acne vulgaris, chlamydial infection'],\n",
       " 'DB00454': ['moderate to severe pain', 'control moderate to severe pain'],\n",
       " 'DB00455': ['allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions'],\n",
       " 'DB00456': ['infection during surgery',\n",
       "  'prevent infection during surgery',\n",
       "  'many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract'],\n",
       " 'DB00457': ['hypertension (high blood pressure)',\n",
       "  'hypertension (high blood pressure)',\n",
       "  'chronic obstructive lung disease (copd)'],\n",
       " 'DB00458': ['the relief of depression and as temporary adjunctive therapy in reducing enuresis in children aged  years and older'],\n",
       " 'DB00459': ['severe psoriasis'],\n",
       " 'DB00460': ['patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome',\n",
       "  'destroy tumors'],\n",
       " 'DB00461': [],\n",
       " 'DB00462': ['peptic ulcer', 'nausea and vomiting due to motion sickness'],\n",
       " 'DB00463': ['epilepsy'],\n",
       " 'DB00464': ['small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves'],\n",
       " 'DB00465': ['non-steroidal anti-inflammatory drug (nsaid) and has antipyretic, analgesic and anti-inflammatory properties',\n",
       "  'non-steroidal anti-inflammatory',\n",
       "  'antipyretic, analgesic and anti-inflammatory',\n",
       "  'short term acute pain that requires the caliber of pain management offered by opioids'],\n",
       " 'DB00466': ['respiratory distress'],\n",
       " 'DB00467': ['adults (amp'],\n",
       " 'DB00468': ['malaria and leg cramps'],\n",
       " 'DB00469': ['rheumatoid arthritis, osteoarthritis, backache, and pain'],\n",
       " 'DB00470': ['anorexia associated with weight loss in patients with aids, and nausea and vomiting associated with cancer chemotherapy'],\n",
       " 'DB00471': ['the maintenance treatment of chronic asthma',\n",
       "  'asthma or to decrease the necessary'],\n",
       " 'DB00472': ['both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa',\n",
       "  'panic disorder independent of whether agoraphobia is present',\n",
       "  'panic disorder independent of whether agoraphobia is present',\n",
       "  'depression related to bipolar i disorder, and treatment resistant depression'],\n",
       " 'DB00473': ['a local anesthetic for surface application, infiltration or nerve block'],\n",
       " 'DB00474': ['use as an intravenous anaesthetic',\n",
       "  'deep sedation',\n",
       "  'induce deep sedation'],\n",
       " 'DB00475': ['anxiety disorders or for the short-term relief of anxiety, withdrawal acute alcoholism, and preoperative apprehension and anxiety'],\n",
       " 'DB00476': [],\n",
       " 'DB00477': ['schizophrenia',\n",
       "  'nausea and vomiting',\n",
       "  'tetanus',\n",
       "  'the manifestations of the manic type of manic-depressive illness',\n",
       "  'severe behavioral problems'],\n",
       " 'DB00478': ['the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults'],\n",
       " 'DB00479': ['this drug',\n",
       "  'lung disease caused by a group of bacteria, mycobacterium avium complex (mac) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease)',\n",
       "  'lung disease caused by a group of bacteria, mycobacterium avium complex (mac) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease)',\n",
       "  'staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species failed to show sensitivity to other available antibiotics',\n",
       "  'initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing'],\n",
       " 'DB00480': ['multiple myeloma in combination with dexamethasone',\n",
       "  'multiple myeloma in combination with dexamethasone',\n",
       "  'patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities',\n",
       "  'patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities'],\n",
       " 'DB00481': ['osteoporosis in postmenopausal women, and prevention and treatment of corticosteroid-induced bone loss',\n",
       "  'osteoporosis in postmenopausal women, and prevention and treatment of corticosteroid-induced bone loss',\n",
       "  'the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer'],\n",
       " 'DB00482': ['treatment of adult osteoarthritis (oa) and adult rheumatoid arthritis (ra)',\n",
       "  'acute pain from various sources, juvenile rheumatoid arthritis'],\n",
       " 'DB00483': ['use as adjuncts to anesthesia to induce skeletal muscle relaxation'],\n",
       " 'DB00484': ['open-angle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamide',\n",
       "  'persistent (non-transient) facial erythema of rosacea'],\n",
       " 'DB00485': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug'],\n",
       " 'DB00486': ['the nausea and vomiting associated with cancer chemotherapy'],\n",
       " 'DB00487': ['uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract'],\n",
       " 'DB00488': ['patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination'],\n",
       " 'DB00489': ['life threatening ventricular arrhytmias and maintain normal sinus rhythm atrial fibrillation or flutter',\n",
       "  'patients requiring drug, but for whom a tablet would not be appropriate'],\n",
       " 'DB00490': ['anxiety disorders or the short-term relief of anxiety',\n",
       "  'anxiety disorders or the short-term relief of anxiety'],\n",
       " 'DB00491': ['use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (niddm) whose hyperglycemia cannot be managed with diet alone'],\n",
       " 'DB00492': ['treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy'],\n",
       " 'DB00493': ['gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system',\n",
       "  'infection after surgery'],\n",
       " 'DB00494': ['patients with idiopathic parkinson\\'s disease who experience signs and end-of-dose \"wearing-off\"'],\n",
       " 'DB00495': ['human immunovirus (hiv) infections'],\n",
       " 'DB00496': ['overactive bladder with urge urinary incontinence, urgency and frequency'],\n",
       " 'DB00497': ['moderate to severe pain',\n",
       "  'moderate to severe pain',\n",
       "  'chronic moderate to severe pain requiring continuous opioid analgesics for an extended period'],\n",
       " 'DB00498': ['pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili',\n",
       "  'anticoagulant prophylaxis'],\n",
       " 'DB00499': ['locally confined stage b-c and stage d metastatic carcinoma of the prostate'],\n",
       " 'DB00500': ['juvenile rheumatoid arthritis'],\n",
       " 'DB00501': ['the treatment and acid-reflux disorders (gerd), peptic ulcer disease, heartburn, and acid indigestion'],\n",
       " 'DB00502': ['schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of tourettes disorder in children and adults, for severe behavior problems'],\n",
       " 'DB00503': ['hiv- infection'],\n",
       " 'DB00504': ['the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids'],\n",
       " 'DB00505': ['peptic ulcer disease and in acquired nystagmus'],\n",
       " 'DB00507': ['diarrhea',\n",
       "  'diarrhea',\n",
       "  'diarrhea caused by cryptosporidium parvum'],\n",
       " 'DB00508': ['psychoses',\n",
       "  'nausea and vomiting',\n",
       "  'control nausea and vomiting'],\n",
       " 'DB00509': ['lower high cholesterol levels in the blood'],\n",
       " 'DB00511': ['fast digitalization in congestive heart failure'],\n",
       " 'DB00512': ['serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci',\n",
       "  'clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains',\n",
       "  'clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains'],\n",
       " 'DB00513': ['excessive postoperative bleeding'],\n",
       " 'DB00514': ['coughs and upper respiratory symptoms associated with allergies or the common cold',\n",
       "  'a cough',\n",
       "  'combination with guaifenesin as an over the counter product to relieve a cough',\n",
       "  'pseudobulbar affect',\n",
       "  'pseudobulbar affect'],\n",
       " 'DB00515': ['metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer'],\n",
       " 'DB00516': ['or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac',\n",
       "  'prevent or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac'],\n",
       " 'DB00517': ['use along with with antacids or histamine hlt',\n",
       "  'peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying'],\n",
       " 'DB00518': ['parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, lt',\n",
       "  'cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, lt'],\n",
       " 'DB00519': ['mild to moderate hypertension, as an adjunct for congestive heart failure (chf), to improve survival following myocardial infarction (mi)'],\n",
       " 'DB00520': ['esophageal candidiasis and invasive aspergillosis'],\n",
       " 'DB00521': ['intraocular hypertension and chronic open-angle glaucoma'],\n",
       " 'DB00522': [],\n",
       " 'DB00523': ['cutaneous lesions'],\n",
       " 'DB00524': ['hypertension, alone or in combination with other antihypertensive drugs of a different class'],\n",
       " 'DB00525': [\"skin infections such as athlete's foot, jock itch, and ringworm infections\",\n",
       "  'infections of the nails, scalp, palms, and soles of the feet',\n",
       "  \"athlete's foot\",\n",
       "  \"prevent athlete's foot\"],\n",
       " 'DB00526': ['advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients undergone complete resection of the primary tumor',\n",
       "  'advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients undergone complete resection of the primary tumor'],\n",
       " 'DB00527': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks'],\n",
       " 'DB00528': [\"hypertension, angina pectoris and raynaud's syndrome\"],\n",
       " 'DB00529': ['cmv retinitis'],\n",
       " 'DB00530': ['metastatic non-small cell lung cancer (nsclc) with tumors showing epidermal growth factor receptor (egfr) exon  deletions or exon  (r) substitution mutations',\n",
       "  'combination with platinum-based chemotherapy'],\n",
       " 'DB00531': ['malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast',\n",
       "  'malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast',\n",
       "  'biopsy-proven minimal change nephrotic syndrome'],\n",
       " 'DB00532': ['refractory partial epilepsy'],\n",
       " 'DB00533': ['osteoarthritis, rheumatoid arthritis, acute pain'],\n",
       " 'DB00534': ['a diuretic', 'a diagnostic and research tool'],\n",
       " 'DB00535': ['acute bacterial otitis media, acute maxillary sinusitis, community-acquired (ca) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections and adults'],\n",
       " 'DB00536': ['the reduction of muscle weakness and easy fatigability associated with the myasthenic syndrome of eaton-lambert',\n",
       "  'treating myasthenia gravis',\n",
       "  'myasthenia gravis'],\n",
       " 'DB00537': ['skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis',\n",
       "  'skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis',\n",
       "  'acute otitis externa',\n",
       "  'tympanostomy tubes or acute otitis externa',\n",
       "  'patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or patients  months or older with acute otitis externa',\n",
       "  'bacterial corneal ulcers and conjunctivitis',\n",
       "  'bacterial conjunctivitis',\n",
       "  'uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis'],\n",
       " 'DB00538': ['mri diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors'],\n",
       " 'DB00539': ['metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors'],\n",
       " 'DB00540': ['the relief of major depressive disorder (mdd)'],\n",
       " 'DB00541': ['relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all)',\n",
       "  'relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all)'],\n",
       " 'DB00542': ['hypertension', 'hypertension'],\n",
       " 'DB00543': ['the relief of depression in patients with neurotic or reactive depressive disorders and endogenous and psychotic depressions',\n",
       "  'depression accompanied by anxiety or agitation'],\n",
       " 'DB00544': ['multiple actinic or solar keratoses',\n",
       "  'superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites',\n",
       "  'some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid'],\n",
       " 'DB00545': ['myasthenia gravis'],\n",
       " 'DB00546': ['anxiety and status epilepticus'],\n",
       " 'DB00547': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00548': ['mild-to-moderate inflammatory acne vulgaris'],\n",
       " 'DB00549': ['the prophylaxis and chronic treatment of asthma'],\n",
       " 'DB00550': [\"manage hyperthyroidism which is due to an overactive thyroid gland (grave's disease)\"],\n",
       " 'DB00551': ['chronic urea-splitting urinary infections'],\n",
       " 'DB00552': ['hairy cell leukaemia refractory to alpha interferon'],\n",
       " 'DB00553': ['psoriasis and vitiligo'],\n",
       " 'DB00554': ['osteoarthritis and rheumatoid arthritis'],\n",
       " 'DB00555': ['the following seizure types',\n",
       "  'the process of conversion to drug monotherapy for those at least  years of age or older with partial seizures and currently  are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed)',\n",
       "  'acute mood episodes, as efficacy has not been established in this context'],\n",
       " 'DB00556': ['an ultrasound contrast imaging in cardiology and radiology'],\n",
       " 'DB00557': ['the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested',\n",
       "  'histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria',\n",
       "  'histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria',\n",
       "  'the control of nausea and vomiting, excluding nausea and vomiting of pregnancy'],\n",
       " 'DB00558': ['influenza a and b'],\n",
       " 'DB00559': ['pulmonary arterial hypertension (pah), to improve exercise ability',\n",
       "  'who class iii or iv symptoms)'],\n",
       " 'DB00560': ['infections caused by susceptible strains of the designated microorganisms in the following conditions: complicated skin and skin structure infections caused by lt'],\n",
       " 'DB00561': ['use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease'],\n",
       " 'DB00562': ['high blood pressure and edema'],\n",
       " 'DB00563': ['pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis',\n",
       "  'severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis',\n",
       "  \"gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-hodgkin's lymphoma\",\n",
       "  'the maintenance of acute lymphocytic leukemia'],\n",
       " 'DB00564': ['epilepsy and pain associated with true trigeminal neuralgia',\n",
       "  'epilepsy and pain associated with true trigeminal neuralgia',\n",
       "  'mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures',\n",
       "  'manic episodes and mixed manic-depressive episodes caused by bipolar i disorder',\n",
       "  'manic episodes and mixed manic-depressive episodes caused by bipolar i disorder'],\n",
       " 'DB00565': ['inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation,'],\n",
       " 'DB00566': ['lead poisoning', 'mercury or arsenic poisoning'],\n",
       " 'DB00567': ['certain infections caused by susceptible bacteria',\n",
       "  'certain infections caused by susceptible bacteria'],\n",
       " 'DB00568': [\"vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular other origins\"],\n",
       " 'DB00569': ['death and subsequent myocardial infarction (mi)',\n",
       "  'the sole anticoagulant during percutaneous coronary intervention (pci) due to an increased risk of guiding catheter thrombosis'],\n",
       " 'DB00570': [\"breast cancer, testicular cancer, lymphomas, neuroblastoma, hodgkin's and non-hodgkin's lymphomas, mycosis fungoides, histiocytosis, and kaposi's sarcoma\"],\n",
       " 'DB00571': ['hypertension',\n",
       "  'angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma'],\n",
       " 'DB00572': ['poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) and organophosphorous or carbamate insecticides'],\n",
       " 'DB00573': ['relief of signs and rheumatoid arthritis and osteoarthritis'],\n",
       " 'DB00574': ['seizures in dravet syndrome patients aged two years and older',\n",
       "  'seizures in dravet syndrome patients aged two years and older'],\n",
       " 'DB00575': ['hypertension alone or in combination with other medications',\n",
       "  'hypertension alone or in combination with other medications',\n",
       "  'use with opiates for severe cancer pain where opiates alone are insufficient',\n",
       "  'severe cancer pain where opiates alone are insufficient',\n",
       "  'adhd either alone or in combination with other medications',\n",
       "  'adhd either alone or in combination with other medications',\n",
       "  'the diagnosis of pheochromocytoma, treatment of nicotine dependance, and opiate withdrawal'],\n",
       " 'DB00576': ['urinary tract infection'],\n",
       " 'DB00577': [':'],\n",
       " 'DB00578': ['acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria'],\n",
       " 'DB00579': ['a body mass index of  kg of body weight per height in meters squared (kg/mlt',\n",
       "  'a body mass index of  kg/mlt'],\n",
       " 'DB00580': ['osteoarthritis and dysmenorrhoea'],\n",
       " 'DB00581': ['chronic constipation',\n",
       "  'portal-systemic encephalopathy (pse), including both the hepatic pre-coma and coma variations'],\n",
       " 'DB00582': ['esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by lt'],\n",
       " 'DB00583': ['primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of drug from dietary sources, or for secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylcoa dehydrogenase deficiency',\n",
       "  'hyperlipoproteinemias',\n",
       "  'carnitine deficiency'],\n",
       " 'DB00584': ['essential or renovascular hypertension  as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect',\n",
       "  'essential or renovascular hypertension  as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect',\n",
       "  'symptomatic congestive heart failure, usually in combination with diuretics and digitalis',\n",
       "  'symptomatic congestive heart failure, usually in combination with diuretics and digitalis',\n",
       "  'asymptomatic left ventricular dysfunction'],\n",
       " 'DB00585': ['acid-reflux disorders (gerd), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer'],\n",
       " 'DB00586': ['use for pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, and injury-related inflammation due to surgery and physical trauma',\n",
       "  'pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, and injury-related inflammation due to surgery and physical trauma',\n",
       "  'high risk of developing nsaid-induced ulcers'],\n",
       " 'DB00587': ['protection against second- phase inflamation in exercise-induced bronchoconstriction and asthma'],\n",
       " 'DB00588': ['managing allergic and nonallergic rhinitis,'],\n",
       " 'DB00589': [\"parkinson's disease\"],\n",
       " 'DB00590': ['benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms',\n",
       "  'hypertension'],\n",
       " 'DB00591': ['the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis',\n",
       "  'seborrheic dermatitis of the scalp',\n",
       "  'chronic eczematous external otitis',\n",
       "  'diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure',\n",
       "  'diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure',\n",
       "  'chronic non-infectious uveitis affecting the posterior segment of the eye',\n",
       "  'chronic non-infectious uveitis affecting the posterior segment of the eye',\n",
       "  'first-degree hemorrhoids'],\n",
       " 'DB00592': ['alternative treatment for ascariasis caused by lt',\n",
       "  'partial intestinal obstruction by the common roundworm, a condition primarily occurring'],\n",
       " 'DB00593': ['petit mal epilepsy'],\n",
       " 'DB00594': ['use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension'],\n",
       " 'DB00595': ['infections caused by a variety of gram positive and gram negative microorganisms including lt',\n",
       "  'infections caused by a variety of gram positive and gram negative microorganisms including lt'],\n",
       " 'DB00596': ['inflammatory and pruritic corticosteroid responsive dermatoses',\n",
       "  'inflammatory and pruritic corticosteroid responsive dermatoses',\n",
       "  'plaque psoriasis',\n",
       "  'plaque psoriasis'],\n",
       " 'DB00597': ['a disruption of the normal blood brain barrier',\n",
       "  'contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced mri) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier',\n",
       "  'whole body contrast enhanced mri including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies'],\n",
       " 'DB00598': ['blood pressure in severe hypertension', 'blood pressure'],\n",
       " 'DB00599': ['use as the sole anesthetic agent for brief ( minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders'],\n",
       " 'DB00600': ['the loss of skin color (vitiligo)'],\n",
       " 'DB00601': ['bacterial infections caused by susceptible strains of vancomycin resistant lt'],\n",
       " 'DB00602': ['intestinal (i',\n",
       "  'onchocerciasis (river blindness) due to the nematode parasite lt',\n",
       "  'scabies caused by lt'],\n",
       " 'DB00603': ['secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women,',\n",
       "  'abnormal uterine bleeding due to hormonal imbalance, not organic pathology',\n",
       "  'postmenopausal osteoporosis',\n",
       "  'moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy',\n",
       "  'pregnancy and manage pain associated with endometriosis',\n",
       "  'pregnancy, and at higher concentrations for treatment of endometrial or renal carcinoma'],\n",
       " 'DB00604': ['patients with nocturnal heartburn due to gastroesophageal reflux disease'],\n",
       " 'DB00605': ['acute or long-term use in the relief of signs and osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis'],\n",
       " 'DB00606': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00607': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug',\n",
       "  'infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug'],\n",
       " 'DB00608': ['infections of _p',\n",
       "  'extraintestinal amebiasis',\n",
       "  'rheumatic diseases, and treatment and prophylaxis of zika virus',\n",
       "  'covid-'],\n",
       " 'DB00609': ['pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed'],\n",
       " 'DB00610': ['the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage'],\n",
       " 'DB00611': ['the relief of moderate to severe pain'],\n",
       " 'DB00612': ['mild to moderate hypertension',\n",
       "  'mild to moderate hypertension',\n",
       "  'heart failure, atrial fibrillation, and angina pectoris'],\n",
       " 'DB00613': ['acute malarial attacks in non-immune subjects'],\n",
       " 'DB00614': ['the specific and treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms'],\n",
       " 'DB00615': ['the prevention of disseminated lt', 'advanced hiv infection'],\n",
       " 'DB00617': [],\n",
       " 'DB00618': ['lyme disease, acne, and bronchitis',\n",
       "  'urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia'],\n",
       " 'DB00619': ['philadelphia chromosome positive chronic myeloid leukemia (ph+ cml), ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (cel), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (gist)'],\n",
       " 'DB00620': ['intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques',\n",
       "  'inflammatory and pruritic manifestations of corticosteroid responsive dermatoses',\n",
       "  'inflammatory and pruritic manifestations of corticosteroid responsive dermatoses',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques',\n",
       "  'severe allergic conditions such as asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis, serum sickness, and transfusion reactions',\n",
       "  'sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions',\n",
       "  'sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions',\n",
       "  'visualization during vitrectomy',\n",
       "  'pain in osteoarthritis of the knee'],\n",
       " 'DB00621': ['weight gain after weight loss following extensive surgery'],\n",
       " 'DB00622': ['patients with chronic stable angina and for hypertension'],\n",
       " 'DB00623': ['manifestations of psychotic disorders'],\n",
       " 'DB00624': ['primary hypogonadism and hypogonadotropic hypogonadism'],\n",
       " 'DB00625': ['use in combination treatment of hiv infection (aids)'],\n",
       " 'DB00626': ['corticosteroid responsive dermatoses with secondary infection',\n",
       "  'corticosteroid responsive dermatoses with secondary infection'],\n",
       " 'DB00627': ['vitamin deficiencies in pediatric and patients receiving parenteral nutrition as part of multivitamin intravenous',\n",
       "  'primary hyperlipidemia and mixed dyslipidemia',\n",
       "  'a history of myocardial infarction and hyperlipidemia',\n",
       "  'coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia',\n",
       "  'severe hypertriglyceridemia'],\n",
       " 'DB00628': ['anxiety disorders or for the short-term relief of anxiety',\n",
       "  'partial seizures and for the symptomatic relief of acute alcohol withdrawal'],\n",
       " 'DB00629': ['high blood pressure'],\n",
       " 'DB00630': [\"the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and paget's disease of bone,\",\n",
       "  'use in pediatric populations or patients with a creatinine clearance lt',\n",
       "  'pediatric populations or patients with a creatinine clearance lt'],\n",
       " 'DB00631': ['patients  to  years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens'],\n",
       " 'DB00632': ['recurrent oral-facial herpes simplex episodes (cold sores or fever blisters)'],\n",
       " 'DB00633': ['sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief'],\n",
       " 'DB00634': ['bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis'],\n",
       " 'DB00635': [],\n",
       " 'DB00636': ['primary dysbetalipoproteinemia (type iii hyperlipidemia) that does not respond adequately to diet',\n",
       "  'high cholesterol and high triglyceride levels',\n",
       "  'to control high cholesterol and high triglyceride levels'],\n",
       " 'DB00637': ['use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis',\n",
       "  'the relieving allergy symptoms, particularly rhinitis and conjunctivitis'],\n",
       " 'DB00638': ['an important medical test of renal function, specifically a measure of glomerular filtration rate',\n",
       "  'help relieve diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia'],\n",
       " 'DB00639': ['the local treatment of vulvovaginal candidiasis (infections caused by candida)'],\n",
       " 'DB00640': ['an treatment for the termination of paroxysmal supraventricular tachycardia (pvst), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (svt)',\n",
       "  'for terminating stable, narrow-complex supraventricular tachycardias (svt)'],\n",
       " 'DB00641': ['hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg),',\n",
       "  'hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg),',\n",
       "  'high-density lipoprotein cholesterol (hdl-c)',\n",
       "  'the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures',\n",
       "  'the risk of cardiovascular morbidity and mortality including myocardial'],\n",
       " 'DB00642': ['malignant pleural mesothelioma',\n",
       "  'locally advanced or metastatic non-small cell lung cancer (nsclc) after prior chemotherapy'],\n",
       " 'DB00643': ['lt'],\n",
       " 'DB00644': ['evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation'],\n",
       " 'DB00645': ['provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina',\n",
       "  'suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation',\n",
       "  'relief of canker sores, cold sores or fever blister'],\n",
       " 'DB00646': ['vulvovaginal candidiasis and other cutaneous candida infections',\n",
       "  'corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae',\n",
       "  'corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae',\n",
       "  'mixed infections due to _trichomonas vaginalis_ and _candida albicans_',\n",
       "  'invasive candidiasis in low birth weight neonates, though it is generally reserved as a second-line option after fluconazole'],\n",
       " 'DB00647': ['the relief of mild to moderate pain'],\n",
       " 'DB00648': ['inoperable adrenocortical tumours'],\n",
       " 'DB00649': ['human immunovirus (hiv) infections'],\n",
       " 'DB00650': ['osteosarcoma (after high dose methotrexate therapy)',\n",
       "  'diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists,',\n",
       "  'megaloblastic anemias due to folic acid deficiency',\n",
       "  'patients with advanced colorectal cancer'],\n",
       " 'DB00651': ['relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema'],\n",
       " 'DB00652': ['the relief of moderate to severe pain'],\n",
       " 'DB00653': ['severe toxemias (pre-eclampsia and eclampsia) of pregnancy and for acute nephritis',\n",
       "  'replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia',\n",
       "  'uterine tetany as a myometriat relaxant'],\n",
       " 'DB00654': ['elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty'],\n",
       " 'DB00655': ['perimenopausal and postmenopausal symptoms'],\n",
       " 'DB00656': ['major depressive disorder (mdd)',\n",
       "  'major depressive disorder (mdd)',\n",
       "  'anxiety and insomnia',\n",
       "  'dementia, alzheimers disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors'],\n",
       " 'DB00657': ['moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension'],\n",
       " 'DB00658': ['the control of serum phosphorus in patients with chronic kidney disease (ckd) on hemodialysis'],\n",
       " 'DB00659': ['the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation'],\n",
       " 'DB00660': ['painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes'],\n",
       " 'DB00661': ['vasopastic (i',\n",
       "  'vasopastic (i',\n",
       "  'hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate atrial fibrillation or atrial flutter',\n",
       "  'various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate'],\n",
       " 'DB00662': ['postoperative nausea and vomiting and for nausea associated with gastroenteritis'],\n",
       " 'DB00663': ['contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions'],\n",
       " 'DB00664': ['urinary tract infection and chronic bronchitis'],\n",
       " 'DB00665': ['metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (stage d)'],\n",
       " 'DB00666': ['central precocious puberty (true precocious puberty, gnrh-dependent precocious precocity, complete isosexual precocity)'],\n",
       " 'DB00668': ['a history of anaphylaxis',\n",
       "  'cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock',\n",
       "  'a hemostatic agent',\n",
       "  'mucosal congestion of hay fever, rhinitis, and acute sinusitis',\n",
       "  'treating mucosal congestion of hay fever, rhinitis, and acute sinusitis',\n",
       "  'bronchial asthmatic paroxysms',\n",
       "  'uterine contractions',\n",
       "  'an over the counter (otc) agent for the intermittent asthma, such as wheezing, tightness of chest and shortness of breath',\n",
       "  'the maintenance of mydriasis during intraocular surgery'],\n",
       " 'DB00669': ['migraines with or without auras',\n",
       "  'migraines with or without auras',\n",
       "  'cluster headaches'],\n",
       " 'DB00670': ['peptic ulcer, gastric ulcer, and duodenal ulcer'],\n",
       " 'DB00671': ['the following infections when caused by susceptible strains of the designated microorganisms: () uncomplicated urinary tract infections caused by lt'],\n",
       " 'DB00672': ['niddm along with with diet and exercise'],\n",
       " 'DB00673': ['the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents)'],\n",
       " 'DB00674': ['mild to moderate dementia of the alzheimers type',\n",
       "  'mild to moderate dementia of the alzheimers type'],\n",
       " 'DB00675': ['early stage estrogen receptor positive breast cancer'],\n",
       " 'DB00676': ['kill lice and the mites responsible for the skin condition scabies'],\n",
       " 'DB00677': ['use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia'],\n",
       " 'DB00678': ['hypertension in patients older than  years, reduce the risk of stroke hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage),',\n",
       "  'type  diabetes and hypertension',\n",
       "  'hypertension',\n",
       "  'hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage)'],\n",
       " 'DB00679': ['schizophrenia and generalized anxiety disorder'],\n",
       " 'DB00680': ['irregular heartbeats (arrhythmias) and maintain a normal heart rate'],\n",
       " 'DB00681': ['potentially life threatening fungal infections'],\n",
       " 'DB00682': ['mortality, recurrent myocardial infarction, and thromboembolic events post myocardial',\n",
       "  'rheumatic mitral valve disease but without atrial fibrillation'],\n",
       " 'DB00683': ['promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  'preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  'status epilepticus',\n",
       "  'intermittent, stereotypic episodes of frequent seizure activity (i',\n",
       "  'intermittent, stereotypic episodes of frequent seizure activity (i',\n",
       "  'epilepsy'],\n",
       " 'DB00684': ['pseudomonas aeruginosa lung infections', 'sinus infections'],\n",
       " 'DB00685': ['infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by lt'],\n",
       " 'DB00686': ['the relief of bladder pain or discomfort associated with interstitial cystitis'],\n",
       " 'DB00687': ['salt-losing androgenital syndrome',\n",
       "  'salt-losing androgenital syndrome'],\n",
       " 'DB00688': [],\n",
       " 'DB00689': ['severe infections caused by susceptible bacteria'],\n",
       " 'DB00690': ['short-term and intermittent use in patients with recurring insomnia and poor sleeping habits'],\n",
       " 'DB00691': ['hypertension'],\n",
       " 'DB00692': ['or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor',\n",
       "  'an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor',\n",
       "  'hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs',\n",
       "  'mi associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin'],\n",
       " 'DB00693': ['diagnostic imaging'],\n",
       " 'DB00694': ['remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults'],\n",
       " 'DB00695': ['edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome,',\n",
       "  'mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications'],\n",
       " 'DB00696': ['use as therapy to abort or prevent vascular headache, e'],\n",
       " 'DB00697': ['the relief of muscle spasticity, which can interfere with daily activities'],\n",
       " 'DB00698': ['acute uncomplicated urinary tract infections'],\n",
       " 'DB00699': ['senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration'],\n",
       " 'DB00700': ['improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction lt'],\n",
       " 'DB00701': ['hiv- infection in combination with other antiretroviral agents'],\n",
       " 'DB00702': ['end-stage renal disease'],\n",
       " 'DB00703': ['chronic open-angle glaucoma and acute angle-closure glaucoma'],\n",
       " 'DB00704': ['alcohol dependence along with with a behavioural modification program'],\n",
       " 'DB00705': ['hiv- infection in combination with appropriate antiretroviral agents when therapy is warranted'],\n",
       " 'DB00706': ['signs and benign prostatic hyperplasia',\n",
       "  'signs and benign prostatic hyperplasia',\n",
       "  'ureteral stones, prostatitis, and female voiding dysfunction'],\n",
       " 'DB00707': ['esophageal cancer', 'esophageal cancer'],\n",
       " 'DB00708': ['acute pain'],\n",
       " 'DB00709': ['hiv infection and chronic hepatitis b (hbv)'],\n",
       " 'DB00710': ['the treatment and prevention of osteoporosis in postmenopausal women'],\n",
       " 'DB00711': ['certain filarial diseases, including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with lt'],\n",
       " 'DB00712': ['the acute or long-term treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis',\n",
       "  'pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e',\n",
       "  'intraoperative miosis'],\n",
       " 'DB00713': ['resistant staphylococci infections'],\n",
       " 'DB00714': [\"acute, intermittent treatment of hypomobility, off episodes associated with advanced parkinson's disease\"],\n",
       " 'DB00715': ['depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder',\n",
       "  'depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder',\n",
       "  'manage mild to moderate vasomotor menopause',\n",
       "  'premature ejaculation or irritable bowel syndrome (ibs)'],\n",
       " 'DB00716': ['mild to moderate asthma'],\n",
       " 'DB00717': ['postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause',\n",
       "  'hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms',\n",
       "  'hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms',\n",
       "  'endometriosis-related pain',\n",
       "  'endometriosis-related pain'],\n",
       " 'DB00718': ['chronic hepatitis b',\n",
       "  'hbeag+ and hbeag- chronic hepatitis b with compensated liver function, and in patients with clinical evidence of lamivudine-resistant hepatitis b virus with either compensated or decompensated liver function'],\n",
       " 'DB00719': ['the relief of upper respiratory mucosal congestion in perennial and allergic rhinitis, and for the relief of nasal congestion and eustachian t'],\n",
       " 'DB00720': ['osteolysis from bone metastases of malignant tumors and for hypercalcemia of malignancy'],\n",
       " 'DB00721': ['a local anesthetic primarily in oral surgery'],\n",
       " 'DB00722': ['acute myocardial infarction, hypertension',\n",
       "  'hypertension',\n",
       "  'hypertension'],\n",
       " 'DB00723': ['the treatment and hypotension'],\n",
       " 'DB00724': ['clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults',\n",
       "  'external genital and perianal warts/condyloma acuminata'],\n",
       " 'DB00725': ['peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying'],\n",
       " 'DB00726': ['depression and depression accompanied by anxiety, agitation or sleep disturbance'],\n",
       " 'DB00727': ['various purposes',\n",
       "  'and treat angina or chest pain due to cardiovascular disease,',\n",
       "  'peri-operative hypertension or induce intra-operative hypotension',\n",
       "  'acute heart failure myocardial infarction',\n",
       "  'pain caused by anal fissures',\n",
       "  'acute anginal attacks',\n",
       "  'acute coronary spasm caused by cocaine, hypertensive emergencies, and acute congestive heart failure exacerbations'],\n",
       " 'DB00728': ['inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation,'],\n",
       " 'DB00730': ['strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis'],\n",
       " 'DB00731': ['non-insulin dependent-diabetes mellitus along with with diet and exercise'],\n",
       " 'DB00732': ['use, as an adjunct to general anesthesia, to facilitate endotracheal intubation'],\n",
       " 'DB00733': ['poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used for myasthenia gravis'],\n",
       " 'DB00734': ['schizophrenia and irritability associated with autistic disorder',\n",
       "  'schizophrenia and irritability associated with autistic disorder',\n",
       "  'acute mania or mixed episodes associated with bipolar i disorder',\n",
       "  'severe dementia of the alzheimer type unresponsive to nonpharmacological approaches'],\n",
       " 'DB00735': ['tinea pedis, tinea cruris, and tinea corporis caused by the organisms lt'],\n",
       " 'DB00736': ['acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h',\n",
       "  'acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h'],\n",
       " 'DB00737': ['nausea, vomiting, and dizziness associated with motion sickness, and vertigo due to various causes, including radiation sickness, menieres syndrome, labyrinthitis and other vestibular disturbances',\n",
       "  'nausea, vomiting, and dizziness associated with motion sickness, and vertigo due to various causes, including radiation sickness, menieres syndrome, labyrinthitis and other vestibular disturbances'],\n",
       " 'DB00738': ['pneumonia due to lt'],\n",
       " 'DB00739': ['bacterial infections'],\n",
       " 'DB00740': [\"amyotrophic lateral sclerosis (als, lou gehrig's disease)\"],\n",
       " 'DB00741': ['infections of the external auditory canal caused by susceptible organisms and with inflammation',\n",
       "  'certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions',\n",
       "  'ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores',\n",
       "  'cold sores'],\n",
       " 'DB00742': ['the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, cerebral edema, and the promotion of urinary excretion of toxic substances'],\n",
       " 'DB00743': [],\n",
       " 'DB00744': ['the prophylaxis and chronic treatment of asthma in adults and children'],\n",
       " 'DB00745': ['excessive daytime sleepiness (eds) associated with narcolepsy'],\n",
       " 'DB00746': ['anemia who must receive many blood transfusions'],\n",
       " 'DB00747': ['excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness'],\n",
       " 'DB00748': ['symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, and allergic conjunctivitis caused by foods and inhaled allergens'],\n",
       " 'DB00749': ['pain'],\n",
       " 'DB00750': ['a local anaesthetic and is often used in dentistry',\n",
       "  'dentistry'],\n",
       " 'DB00751': ['the prevention of itching associated with allergic conjunctivitis'],\n",
       " 'DB00752': ['major depressive episode without melancholia'],\n",
       " 'DB00753': ['induction and maintenance of general anesthesia'],\n",
       " 'DB00754': ['the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures'],\n",
       " 'DB00755': ['the the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m (including the m variant)',\n",
       "  \"acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (darier's disease), and basal cell carcinomas\",\n",
       "  'fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage'],\n",
       " 'DB00756': ['use as a surgical scrub and a bacteriostatic skin cleanser',\n",
       "  'an outbreak of gram-positive infection where other',\n",
       "  'control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful'],\n",
       " 'DB00757': ['the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting'],\n",
       " 'DB00758': ['the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and in recent mi, stroke, or established peripheral arterial disease,',\n",
       "  'the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and'],\n",
       " 'DB00759': ['bacterial infections such as rocky mountain spotted fever, typhus fever, tick fevers, q fever, rickettsialpox and brill-zinsser disease',\n",
       "  'infections caused by chlamydiae spp',\n",
       "  'acne'],\n",
       " 'DB00760': ['the following infections when caused by susceptible isolates of the designated microorganisms: lt',\n",
       "  'bacterial meningitis caused by lt'],\n",
       " 'DB00761': ['hypokalemia'],\n",
       " 'DB00762': ['metastatic colorectal cancer (first-line therapy when administered with -fluorouracil and leucovorin)',\n",
       "  'extensive small cell lung cancer',\n",
       "  'metastatic or recurrent cervical cancer',\n",
       "  'patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy'],\n",
       " 'DB00763': ['hyperthyroidism',\n",
       "  'the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy',\n",
       "  'the medical treatment of hyperthyroidism regardless of other available treatment options'],\n",
       " 'DB00764': ['the maintenance treatment of asthma as prophylactic therapy',\n",
       "  'the nasal seasonal allergic and perennial allergic rhinitis',\n",
       "  'the nasal seasonal allergic and perennial allergic rhinitis'],\n",
       " 'DB00765': ['patients with pheochromocytoma, for preoperative preparation of patients for surgery, patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma'],\n",
       " 'DB00766': ['their therapeutic antibacterial effects',\n",
       "  'the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects',\n",
       "  'selecting whether this antibiotic is prescribed',\n",
       "  'determine the appropriateness of using drug',\n",
       "  'infections where a regimen of several drugs may normally be used'],\n",
       " 'DB00767': ['and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or',\n",
       "  'prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously'],\n",
       " 'DB00768': ['ocular itching associated with allergic conjunctivitis as ophthalmic solution',\n",
       "  'ocular itching associated with allergic conjunctivitis as ophthalmic solution'],\n",
       " 'DB00769': ['steroid-responsive dermatoses'],\n",
       " 'DB00770': ['palliative, not definitive, therapy to maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates congenital heart defects and who depend upon the patent ductus for survival',\n",
       "  'erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology'],\n",
       " 'DB00771': ['peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome'],\n",
       " 'DB00772': ['patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair'],\n",
       " 'DB00773': ['refractory testicular tumors and as first line treatment',\n",
       "  'other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme'],\n",
       " 'DB00774': ['hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00775': ['the treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy'],\n",
       " 'DB00776': ['partial-onset seizures in patients , and  for partial-onset seizures',\n",
       "  'partial-onset seizures'],\n",
       " 'DB00777': ['insomnia',\n",
       "  'its antihistamininc sleep inducing effects in treating insomnia'],\n",
       " 'DB00778': ['respiratory tract, urinary and soft tissue infections'],\n",
       " 'DB00779': ['urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of lt'],\n",
       " 'DB00780': ['nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy',\n",
       "  'nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy',\n",
       "  'bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior',\n",
       "  'secondary condition to major personality disorder, neuroses and'],\n",
       " 'DB00782': ['enuresis',\n",
       "  'hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder'],\n",
       " 'DB00783': ['moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,',\n",
       "  'postmenopausal osteoporosis',\n",
       "  'breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for androgen-dependent prostate cancer (only for palliation therapy)',\n",
       "  'combination with other hormones as a component of oral contraceptive pills for preventing pregnancy (most commonly as db, a synthetic form of drug)',\n",
       "  \"menopausal symptoms changed drastically following the release of results and early termination of the women's health initiative (whi) studies in  as concerns were raised regarding estrogen use\",\n",
       "  'an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer over the long-term'],\n",
       " 'DB00784': ['rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever'],\n",
       " 'DB00785': ['hypertension'],\n",
       " 'DB00786': ['various cancers'],\n",
       " 'DB00787': ['recurrent herpes labialis in immunocompetent patients  years and older',\n",
       "  'herpes zoster, genital herpes, and chickenpox',\n",
       "  'initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients',\n",
       "  'recurrent herpes labialis, and shortening lesion healing time  years and older',\n",
       "  'recurrent herpes labialis',\n",
       "  'recurrent herpes labialis',\n",
       "  'acute herpetic keratitis'],\n",
       " 'DB00788': ['rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain',\n",
       "  'rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain'],\n",
       " 'DB00789': ['use with magnetic resonance imaging (mri) in adults, and patients () to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues and lesions with abnormal vascularity in the head and neck',\n",
       "  'facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart)'],\n",
       " 'DB00790': ['mild to moderate essential hypertension, mild to moderate congestive heart failure,',\n",
       "  'the cardiovascular risk of patients with hypertension or post-myocardial'],\n",
       " 'DB00791': ['its antineoplastic properties'],\n",
       " 'DB00792': ['the symptomatic relief of hypersensitivity reactions, coughs, and the common cold'],\n",
       " 'DB00793': [\"fungal (tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor\"],\n",
       " 'DB00794': ['grand mal, psychomotor, and focal epileptic seizures',\n",
       "  'grand mal, psychomotor, and focal epileptic seizures'],\n",
       " 'DB00795': [\"crohn's disease and rheumatoid arthritis as a second-line agent\"],\n",
       " 'DB00796': ['uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy',\n",
       "  'a first line agent to delay progression of diabetic nephropathy',\n",
       "  'congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace inhibitors'],\n",
       " 'DB00797': ['pulmonary artery anomalies'],\n",
       " 'DB00798': ['serious infections caused by susceptible strains of the following microorganisms: lt'],\n",
       " 'DB00799': ['psoriasis, acne and sun damaged skin (photodamage)'],\n",
       " 'DB00800': ['the in-hospital, short-term (up to  hours) severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function'],\n",
       " 'DB00801': ['anxiety, nervousness, and tension associated with anxiety disorders',\n",
       "  'relieve anxiety, nervousness, and tension associated with anxiety disorders'],\n",
       " 'DB00802': ['postoperative pain and the maintenance of general anesthesia'],\n",
       " 'DB00803': ['acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly lt'],\n",
       " 'DB00804': ['functional bowel disorder and irritable bowel syndrome',\n",
       "  'functional bowel disorder and irritable bowel syndrome'],\n",
       " 'DB00805': ['depression'],\n",
       " 'DB00806': ['patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs'],\n",
       " 'DB00807': ['a local (ophthalmic) anesthetic'],\n",
       " 'DB00808': ['use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension',\n",
       "  'hypertension',\n",
       "  'fluid and salt retention associated with congestive heart failure'],\n",
       " 'DB00809': ['mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye'],\n",
       " 'DB00810': ['use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy'],\n",
       " 'DB00811': ['chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr)',\n",
       "  'chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr)',\n",
       "  'svr and reduce relapse rates',\n",
       "  'or without cirrhosis'],\n",
       " 'DB00812': ['backache and ankylosing spondylitis'],\n",
       " 'DB00813': ['short term analgesia during induction, maintenance, and recovery from general or regional anesthesia',\n",
       "  'breakthrough pain in opioid tolerant cancer patients who require around the clock pain management',\n",
       "  'breakthrough pain in opioid tolerant cancer patients who require around the clock pain management'],\n",
       " 'DB00814': ['arthritis and osteoarthritis',\n",
       "  'arthritis and osteoarthritis',\n",
       "  'neuropathic pain'],\n",
       " 'DB00815': ['a surfactant in shampoos', 'this use', 'microbicidal'],\n",
       " 'DB00816': ['bronchospasm, chronic bronchitis, asthma, and emphysema'],\n",
       " 'DB00817': ['bacterial infection of respiratory tract, urinary tract, gi, cns and immuno compromised patients'],\n",
       " 'DB00818': ['refractory status epilepticus'],\n",
       " 'DB00819': ['adjunctive treatment of: edema due to congestive heart failure'],\n",
       " 'DB00820': ['erectile dysfunction'],\n",
       " 'DB00821': ['joint pain and post-surgical pain'],\n",
       " 'DB00822': ['the treatment and chronic alcoholism'],\n",
       " 'DB00823': ['the prevention of pregnancy in women who elect to use this product as a method of contraception'],\n",
       " 'DB00824': ['asthma',\n",
       "  'peripheral vascular diseases and in cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy'],\n",
       " 'DB00825': ['occasional minor irritation, pain, sore mouth, and sore throat and cough associated with a cold or inhaled irritants'],\n",
       " 'DB00826': ['fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including lt'],\n",
       " 'DB00827': ['initial and recurrent urinary tract infections'],\n",
       " 'DB00828': ['uncomplicated urinary tract infections (acute cystitis)'],\n",
       " 'DB00829': ['useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma'],\n",
       " 'DB00830': ['obesity'],\n",
       " 'DB00831': ['anxiety disorders, depressive symptoms secondary to anxiety and agitation'],\n",
       " 'DB00832': ['epilepsy'],\n",
       " 'DB00833': ['certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections'],\n",
       " 'DB00834': [\"the medical termination of intrauterine pregnancy through  days' pregnancy\",\n",
       "  \"hyperglycemia secondary to hypercortisolism endogenous cushing's syndrome type  diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery\"],\n",
       " 'DB00835': ['the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing'],\n",
       " 'DB00836': ['the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis',\n",
       "  'the volume of discharge from ileostomies',\n",
       "  'reducing the volume of discharge from ileostomies'],\n",
       " 'DB00837': ['epilepsy', 'epilepsy'],\n",
       " 'DB00838': ['short-term treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp'],\n",
       " 'DB00839': ['use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (type ii) whose hyperglycemia cannot be satisfactorily controlled by diet alone'],\n",
       " 'DB00840': ['dryness and irritation caused by reduced tear flow that occurs',\n",
       "  'relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes'],\n",
       " 'DB00841': [],\n",
       " 'DB00842': ['anxiety disorders and for the short-term relief of anxiety',\n",
       "  'anxiety disorders and for the short-term relief of anxiety',\n",
       "  'alcohol withdrawal symptoms'],\n",
       " 'DB00843': ['mild to moderate alzheimers disease at doses of  mg or  mg',\n",
       "  'mild to moderate alzheimers disease at doses of  mg or  mg',\n",
       "  'moderate to severe alzheimers disease in a higher dose of  mg or  mg administered once daily',\n",
       "  'moderate to severe alzheimers disease in a higher dose of  mg or  mg administered once daily',\n",
       "  'moderate to severe dementia'],\n",
       " 'DB00844': ['the relief of moderate to severe pain'],\n",
       " 'DB00845': ['lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum',\n",
       "  'lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum',\n",
       "  'the development of drug resistance, it should be used only'],\n",
       " 'DB00846': ['relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions'],\n",
       " 'DB00847': ['corneal cystine crystal accumulation'],\n",
       " 'DB00848': [\"adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes' stage c colon cancer\",\n",
       "  'malignant melanoma and head/neck cancer'],\n",
       " 'DB00849': ['epilepsy'],\n",
       " 'DB00850': ['use in the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults'],\n",
       " 'DB00851': ['metastatic malignant melanoma',\n",
       "  \"hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents\",\n",
       "  'combination with other antineoplastic agents'],\n",
       " 'DB00852': ['its decongestant activity',\n",
       "  'sympathomimetic amine used for its decongestant activity'],\n",
       " 'DB00853': ['patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, and concomitantly with radiation therapy for newly diagnosed glioblastoma multiforme',\n",
       "  'maintenance therapy for glioblastoma multiforme'],\n",
       " 'DB00854': ['moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate'],\n",
       " 'DB00855': ['minimally to moderately thick actinic keratoses of the face or scalp',\n",
       "  'minimally to moderately thick actinic keratoses of the face or scalp'],\n",
       " 'DB00856': ['injuries and other painful muscular conditions',\n",
       "  'trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain'],\n",
       " 'DB00857': ['fungal skin and nail infections caused by _trichophyton_ species, _microsporum canis_, _epidermophyton floccosum_, and _tinea_ species'],\n",
       " 'DB00859': [\"wilson's disease, cystinuria and active rheumatoid arthritis\"],\n",
       " 'DB00860': ['endocrine, rheumatic, and hematologic disorders'],\n",
       " 'DB00861': ['treatment of mild to moderate pain accompanied by inflammation (e'],\n",
       " 'DB00862': ['erectile dysfunction'],\n",
       " 'DB00863': ['the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose',\n",
       "  'gerd symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing'],\n",
       " 'DB00864': [\"use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection\",\n",
       "  'liver transplantation',\n",
       "  'severe atopic dermatitis'],\n",
       " 'DB00865': ['exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction'],\n",
       " 'DB00866': ['hypertension, angina, and arrhythmia'],\n",
       " 'DB00867': ['the treatment and prophylaxis of premature labour'],\n",
       " 'DB00868': ['the symptomatic relief of cough'],\n",
       " 'DB00869': ['elevated intraocular pressure', 'elevated'],\n",
       " 'DB00870': ['the miosis (pupil constriction) that may occur during ocular surgery',\n",
       "  'eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery'],\n",
       " 'DB00871': ['the prevention and reversal of bronchospasm in patients  with reversible, obstructive airway disease, and symptomatic reversible bronchospasm associated with bronchitis and emphysema',\n",
       "  'uterine contractions'],\n",
       " 'DB00872': ['euvolemic or hypervolemic hyponatremia (e'],\n",
       " 'DB14596': ['post-operative inflammation and pain following ocular surgery',\n",
       "  'post-operative inflammation and pain following ocular surgery'],\n",
       " 'DB00874': ['providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses fda label, ,'],\n",
       " 'DB00875': ['schizophrenia and depression'],\n",
       " 'DB00876': ['hypertension alone or in combination with other classes of antihypertensive agents',\n",
       "  'diabetic nephropathy, and a second-line agent for congestive heart failure (only in those intolerant of ace inhibitors)'],\n",
       " 'DB00877': ['the prophylaxis of organ rejection in patients receiving renal transplants'],\n",
       " 'DB00878': ['gingivitis and a slow-release \"chip\" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth'],\n",
       " 'DB00879': ['hiv- infections'],\n",
       " 'DB00880': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00881': ['hypertension and as an adjunct therapy for heart failure',\n",
       "  'hypertension and as an adjunct therapy for heart failure',\n",
       "  'hypertension',\n",
       "  'hypertension'],\n",
       " 'DB00882': ['ovulation'],\n",
       " 'DB00883': ['the prevention of angina pectoris due to coronary artery disease'],\n",
       " 'DB00884': [\"osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis\",\n",
       "  \"osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis\"],\n",
       " 'DB00885': ['the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis'],\n",
       " 'DB00886': ['hypertension'],\n",
       " 'DB00887': ['edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome'],\n",
       " 'DB00888': [\"hodgkin's disease (stages iii and iv), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma\",\n",
       "  'metastatic carcinoma resulting in effusion'],\n",
       " 'DB00889': ['the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation)'],\n",
       " 'DB00890': ['atrophic vaginitis and kraurosis vulvae'],\n",
       " 'DB00891': ['dermatitis herpetiformis, benign mucous membrane pemphigoid and pyoderma gangrenosum'],\n",
       " 'DB00892': ['numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed'],\n",
       " 'DB00893': ['patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible',\n",
       "  'replenish body iron stores in non-dialysis dependent-chronic kidney disease (ndd-ckd) patients receiving or not receiving erythropoietin and in hemodialysis dependent (hdd-ckd) and peritoneal dialysis dependent (pdd-ckd) - chronic kidney disease patients receiving an erythropoietin'],\n",
       " 'DB00894': ['treatment of advanced breast cancer in postmenopausal women'],\n",
       " 'DB00895': ['use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin g)'],\n",
       " 'DB00896': ['postoperative inflammation following ocular surgery and for anterior uveitis'],\n",
       " 'DB00897': ['the short-term treatment of insomnia'],\n",
       " 'DB00898': ['therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated'],\n",
       " 'DB00899': ['use during the induction and maintenance of general anesthesia'],\n",
       " 'DB00900': ['hiv- infection'],\n",
       " 'DB00901': ['dilate air passages in the lungs that have become narrowed as a result of disease or inflammation',\n",
       "  'asthma and chronic obstructive pulmonary disease (copd)'],\n",
       " 'DB00902': ['the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders'],\n",
       " 'DB00903': ['high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure'],\n",
       " 'DB00904': ['postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'post-chemotherapy induced nausea and vomiting,',\n",
       "  'children  years of age or younger,',\n",
       "  'children  years of age or younger,',\n",
       "  'use in any age group of the pediatric population for post-radiotherapy induced nausea and vomiting, and',\n",
       "  'post-radiotherapy induced nausea and vomiting, and',\n",
       "  'use in any age group of the pediatric population for postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'post-chemotherapy and radiotherapy-induced nausea and vomiting, and',\n",
       "  'use in the geriatric patient population',\n",
       "  'postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population'],\n",
       " 'DB00905': ['open-angle glaucoma or ocular hypertension',\n",
       "  'eyelash hypotrichosis'],\n",
       " 'DB00906': ['partial seizures'],\n",
       " 'DB00907': ['the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities'],\n",
       " 'DB00908': ['ventricular pre-excitation and cardiac dysrhythmias'],\n",
       " 'DB00909': ['use as adjunctive treatment of partial seizures in adults with epilepsy'],\n",
       " 'DB00910': ['secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage  and'],\n",
       " 'DB00911': ['trichomoniasis caused by lt',\n",
       "  'giardiasis caused by lt',\n",
       "  'intestinal amebiasis and amebic liver abscess caused by lt'],\n",
       " 'DB00912': ['type  diabetes mellitus'],\n",
       " 'DB00913': ['the treatment and pain (systemic) and for use as an anesthesia adjunct'],\n",
       " 'DB00914': ['the reatment of type ii diabetes mellitus'],\n",
       " 'DB00915': ['the chemoprophylaxis, prophylaxis, and treatment of signs and infection caused by various strains of influenza a virus',\n",
       "  'parkinsonism and drug-induced extrapyramidal reactions'],\n",
       " 'DB00916': [\"confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections\",\n",
       "  \"confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections\",\n",
       "  \"crohn's disease and rosacea, as a prophylactic agent after surgery, and for helicobacter pylori infection\",\n",
       "  'preterm births',\n",
       "  'periodontal disease'],\n",
       " 'DB00917': ['the termination of pregnancy during the second trimester (from the th through the th gestational week as calculated from the first day of the last normal menstrual period), and for evacuation of the uterine contents in missed abortion or intrauterine fetal death up to  weeks of gestational age as calculated from the first day of the last normal menstrual period',\n",
       "  'nonmetastatic gestational trophoblastic disease (benign hydatidiform mole)'],\n",
       " 'DB00918': ['acute migraine headache'],\n",
       " 'DB00919': ['acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of lt'],\n",
       " 'DB00920': ['self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic)'],\n",
       " 'DB00921': ['pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate',\n",
       "  'moderate to severe opioid use disorder'],\n",
       " 'DB00922': ['short term treatment of acutely decompensated severe chronic heart failure (chf)',\n",
       "  'heart disease'],\n",
       " 'DB00923': ['infections caused by susceptible organisms'],\n",
       " 'DB00924': ['spasticity originating from cerebral or spinal cord disease, or spasticity',\n",
       "  'fibromyalgia'],\n",
       " 'DB00925': ['phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension'],\n",
       " 'DB00926': ['severe psoriasis'],\n",
       " 'DB00927': ['active duodenal ulcer (du), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (gerd), and erosive esophagitis due to gerd, diagnosed by biopsy',\n",
       "  'pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication'],\n",
       " 'DB00928': ['patients with the following french-american-british myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia'],\n",
       " 'DB00929': ['the risk of nsaid induced gastric ulcers but not duodenal ulcers',\n",
       "  'a high risk of developing gastric ulcers',\n",
       "  'miscarriages, prevention of post partum hemorrhage, and is used alone or in combination with mifepristone in other countries for first trimester abortions'],\n",
       " 'DB00930': ['use, alone or in combination with an hmg-coa reductase inhibitor,  to diet and exercise for the reduction of elevated ldl cholesterol in patients with primary hypercholesterolemia (fredrickson type iia)'],\n",
       " 'DB00931': ['acute bacterial exacerbations of chronic bronchitis'],\n",
       " 'DB00932': ['combination antiretroviral treatment of hiv- infected patients with evidence of viral replication, who are highly treatment-experienced or have hiv- strains resistant to multiple protease inhibitors'],\n",
       " 'DB00933': ['schizophrenia, organic brain disorders, alcoholism and psychoneuroses'],\n",
       " 'DB00934': [],\n",
       " 'DB00935': ['persistent facial erythema associated with rosacea',\n",
       "  'acquired blepharoptosis',\n",
       "  'regional anesthesia when performing a restorative procedure on teeth - and a-j'],\n",
       " 'DB00936': ['acne, psoriasis, callouses, corns, keratosis pilaris and warts'],\n",
       " 'DB00937': ['exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction'],\n",
       " 'DB00938': ['asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease',\n",
       "  'asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease'],\n",
       " 'DB00939': ['primary dysmenorrhea and for idiopathic heavy menstrual blood loss'],\n",
       " 'DB00940': ['peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder'],\n",
       " 'DB00941': ['an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation',\n",
       "  'succinylcholine-induced muscle fasciculations'],\n",
       " 'DB00942': [\"the treatment and parkinson's disease\"],\n",
       " 'DB00943': ['human immunovirus (hiv) infections along with with other antivirals'],\n",
       " 'DB00944': ['chronic open-angle glaucoma'],\n",
       " 'DB00945': ['pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries',\n",
       "  'pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various',\n",
       "  'symptomatic pain relief after surgical and dental procedures',\n",
       "  'the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)',\n",
       "  'various other purposes, due to its ability to inhibit platelet aggregation',\n",
       "  'platelet aggregation',\n",
       "  'the risk of transient ischemic attacks (tia)',\n",
       "  'atherothrombotic cerebral',\n",
       "  'thromboembolism after hip replacement surgery',\n",
       "  'transient ischemic attacks (tia)',\n",
       "  'thrombosis at the',\n",
       "  'patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site',\n",
       "  'the incidence of mortality and myocardial infarction (mi) for patients diagnosed with chronic coronary artery disease (cad), including patients with previous myocardial',\n",
       "  'a history of stroke or tia'],\n",
       " 'DB00946': ['thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism',\n",
       "  'ischemic stroke'],\n",
       " 'DB00947': ['hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents'],\n",
       " 'DB00948': ['serious gramamp'],\n",
       " 'DB00949': ['use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use'],\n",
       " 'DB00950': ['allergic rhinitis in patients  years old and chronic idiopathic urticaria',\n",
       "  'season allergic rhinitis'],\n",
       " 'DB00951': ['all forms of tuberculosis in which organisms are susceptible'],\n",
       " 'DB00952': ['migraine attacks with or without aura'],\n",
       " 'DB00953': ['acute migraine attacks with or without aura'],\n",
       " 'DB00954': ['the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections'],\n",
       " 'DB00955': ['bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains'],\n",
       " 'DB00956': ['acute pain, sometimes in combination with acetaminophen or ibuprofen, and the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants',\n",
       "  'acute pain, sometimes in combination with acetaminophen or ibuprofen, and the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants'],\n",
       " 'DB00957': [],\n",
       " 'DB00958': ['advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents',\n",
       "  'patients with ovarian carcinoma recurrent after prior chemotherapy, including patients been previously treated with cisplatin',\n",
       "  'patients with ovarian carcinoma recurrent after prior chemotherapy, including patients been previously treated with cisplatin'],\n",
       " 'DB00959': ['a number of endocrine,  rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders',\n",
       "  'short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare'],\n",
       " 'DB00960': ['hypertension, edema, ventricular tachycardias, and atrial fibrillation'],\n",
       " 'DB00961': ['production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks'],\n",
       " 'DB00962': ['short-term treatment of insomnia'],\n",
       " 'DB00963': ['postoperative inflammation'],\n",
       " 'DB00964': ['prevention or reduction of intraoperative and postoperative increases in intraocular pressure (iop) before and after ocular laser surgery when used prophylactically',\n",
       "  'open-angle glaucoma who are on maximally tolerated medical therapy requiring additional iop reduction'],\n",
       " 'DB00965': ['use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is -i',\n",
       "  'follow-up imaging for chemoembolization'],\n",
       " 'DB00966': ['hypertension',\n",
       "  'diabetic nephropathy in hypertensive patients with type  diabetes mellitus, and congestive heart failure (only'],\n",
       " 'DB00967': ['the relief of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis',\n",
       "  'the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria'],\n",
       " 'DB00968': ['hypertension'],\n",
       " 'DB00969': ['severe diarrhea-predominant irritable bowel syndrome (ibs)'],\n",
       " 'DB00970': [\"wilms' tumor, childhood rhabdomyosarcoma, ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen\"],\n",
       " 'DB00971': ['tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp'],\n",
       " 'DB00972': ['seasonal allergic rhinitis in patients  years and older and for vasomotor rhinitis',\n",
       "  'itchy eyes associated with allergic conjunctivitis',\n",
       "  'itchy eyes associated with allergic conjunctivitis'],\n",
       " 'DB00973': ['elevated total-c, ldl-c, apo b, and non-hdl-c primary hyperlipidemia, alone or in combination with an hmg-coa reductase inhibitor (statin)',\n",
       "  'elevated total-c, ldl-c, apo b, and non-hdl-c mixed hyperlipidemia in combination with fenofibrate,',\n",
       "  'homozygous familial hypercholesterolemia (hofh), in combination with atorvastatin or simvastatin',\n",
       "  'homozygous sitosterolemia (phytosterolemia)'],\n",
       " 'DB00974': ['the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults'],\n",
       " 'DB00975': ['as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina'],\n",
       " 'DB00976': ['lt'],\n",
       " 'DB00977': [],\n",
       " 'DB00978': ['bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: lt'],\n",
       " 'DB00979': ['mydriasis and cycloplegia for diagnostic purposes'],\n",
       " 'DB00980': ['insomnia characterized by difficulty with sleep onset'],\n",
       " 'DB00981': ['glaucoma, and for severe anticholinergic toxicity'],\n",
       " 'DB00982': ['severe recalcitrant nodular acne and patients  years enrolled in the ipledge program'],\n",
       " 'DB00983': ['asthma and copd',\n",
       "  'copd, drug is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (lamas) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide',\n",
       "  'asthma, drug is available in combination with mometasone furoate for patients  years and older and with budesonide for patients  years and older'],\n",
       " 'DB00984': [\"refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin iii deficiency, fibrinogen excess, growth failure and turner's syndrome\"],\n",
       " 'DB00985': ['nausea, vomiting, or vertigo of motion sickness',\n",
       "  'nausea, vomiting, or vertigo of motion sickness'],\n",
       " 'DB00986': ['use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions',\n",
       "  'chronic obstructive pulmonary disease (copd)'],\n",
       " 'DB00987': ['acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia'],\n",
       " 'DB00988': ['the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure'],\n",
       " 'DB00989': [\"mild to moderate dementia associated with parkinson's disease or of the alzheimer's type\"],\n",
       " 'DB00990': ['advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy'],\n",
       " 'DB00991': ['the',\n",
       "  'relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis'],\n",
       " 'DB00992': ['non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used along with with lesion preparation (debridement using a sharp dermal curette)'],\n",
       " 'DB00993': ['rheumatoid arthritis and prevent renal transplant rejection'],\n",
       " 'DB00994': ['the risk of the development of drug-resistant bacteria',\n",
       "  'infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria',\n",
       "  'superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics',\n",
       "  'infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics',\n",
       "  'steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists'],\n",
       " 'DB00995': ['active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis'],\n",
       " 'DB00996': ['postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization,',\n",
       "  'partial-onset seizures, with or without secondary generalization, in patients  and as monotherapy'],\n",
       " 'DB00997': ['regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkins disease, malignant lymphoma and bronchogenic carcinoma',\n",
       "  'produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkins disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types',\n",
       "  'evidence of axillary lymph node involvement following resection of primary breast cancer'],\n",
       " 'DB00998': ['migraine attacks with or without aura'],\n",
       " 'DB00999': ['edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy',\n",
       "  'hypertension'],\n",
       " 'DB01000': ['bacterial infections caused by susceptible organisms'],\n",
       " 'DB01001': ['(i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm',\n",
       "  'bronchospasm'],\n",
       " 'DB01002': ['the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management'],\n",
       " 'DB01003': ['patients with bronchial asthma',\n",
       "  'vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis'],\n",
       " 'DB01004': ['cytomegalovirus (cmv) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (aids)',\n",
       "  'severe cytomegalovirus (cmv) disease, including cmv pneumonia, cmv gastrointestinal disease, and disseminated cmv infections, in immunocompromised patients'],\n",
       " 'DB01005': ['melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and sickle-cell anemia'],\n",
       " 'DB01006': ['postmenopausal women with hormone receptor (hr) positive early breast cancer, postmenopausal women with early breast cancer periviously been treated with tamoxifen, and postmenopausal women with hr+ or unknown advanced breast cancer',\n",
       "  'pre, peri, and postmenopausal women with hr+ and human epidermal growth factor  (her) negative advanced or metastatic breast cancer'],\n",
       " 'DB01007': ['the local treatment of vulvovaginal candidiasis (moniliasis)'],\n",
       " 'DB01008': ['use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  (myeloid, myelocytic, granulocytic) leukemia (fda has designated drug as an orphan drug for this use)'],\n",
       " 'DB01009': ['treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain'],\n",
       " 'DB01010': ['the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease',\n",
       "  'evaluating emergency treatment in myasthenic crises'],\n",
       " 'DB01011': ['a diagnostic drug for testing hypothalamic-pituitary acth function',\n",
       "  \"cushing's syndrome\"],\n",
       " 'DB01012': ['secondary hyperparathyroidism', 'hypercalcemia'],\n",
       " 'DB01013': ['moderate to severe plaque psoriasis,, and inflammatory and pruritic manifestations of corticosteroid responsive dermatoses'],\n",
       " 'DB01014': ['mildly to moderately active ulcerative colitis'],\n",
       " 'DB01015': ['the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in patients (when clinically indicated), acute exacerbations of chronic bronchitis'],\n",
       " 'DB01016': ['type  diabetes mellitus'],\n",
       " 'DB01017': ['inflammatory lesions of acne vulgaris',\n",
       "  'periodontitis',\n",
       "  'infections of susceptible microorganisms'],\n",
       " 'DB01018': ['adhd'],\n",
       " 'DB01019': ['acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention'],\n",
       " ...}"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication = []\n",
    "#### Need to create a cluster analysis\n",
    "it = 0\n",
    "new_it = 0\n",
    "clusters_indication = []\n",
    "seen_indications =[]\n",
    "indications = {}\n",
    "pg = []\n",
    "for k in dictionary.keys():\n",
    "    #print(k)\n",
    "    old_int = \"\"\n",
    "    if len(dictionary[k]['indication']) > 0:\n",
    "            new_int = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\")\n",
    "            s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"drug\").lower()\n",
    "            s = s.replace(dictionary[k]['name'].lower(), \"drug\").lower()\n",
    "            indications[k] = parse_indication2(s)\n",
    "\n",
    "#             if new_int not in seen_indications:\n",
    "#                 seen_indications += [new_int]\n",
    "#                 clusters_indication += [new_it]\n",
    "#                 new_it += 1\n",
    "#                 type_interaction += new_int.lower()\n",
    "#             else:\n",
    "#                 j = np.where([new_int == s for s in seen_indications])[0][0]\n",
    "#                 clusters_indication += [j]\n",
    "                \n",
    "            it+=1\n",
    "            if len(indications[k])==0: \n",
    "                print(k)\n",
    "                pg += [k]\n",
    "\n",
    "                \n",
    "#### Usef            \n",
    "#type_interaction = re.split('\\W+', type_interaction.lower())   \n",
    "indications   \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "82879c68",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'DB00001': ['heparin-induced thrombocytopenia'],\n",
       " 'DB00002': ['egfr-expressing, metastatic colorectal carcinoma',\n",
       "  'egfr-expressing, metastatic colorectal carcinoma'],\n",
       " 'DB00003': ['cystic fibrosis'],\n",
       " 'DB00004': ['cutaneous t-cell lymphoma'],\n",
       " 'DB00005': ['moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis',\n",
       "  'psoriatic arthritis and ankylosing spondylitis'],\n",
       " 'DB00006': ['heparin-induced thrombocytopenia', 'thrombosis'],\n",
       " 'DB00007': ['advanced prostate cancer,  and for patients with central precocious puberty (cpp)',\n",
       "  'advanced prostate cancer,  and for patients with central precocious puberty (cpp)',\n",
       "  'endometriosis',\n",
       "  'endometriosis',\n",
       "  'the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids)'],\n",
       " 'DB00008': ['hcv',\n",
       "  'contraindications to or significant intolerance to other anti-viral therapies'],\n",
       " 'DB00009': ['acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli'],\n",
       " 'DB00010': ['dwarfism, prevention of hiv-induced weight loss'],\n",
       " 'DB00011': ['venereal or genital warts caused by the human papiloma virus'],\n",
       " 'DB00012': ['anemia (from renal transplants or certain hiv treatment)'],\n",
       " 'DB00013': ['lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters'],\n",
       " 'DB00014': ['locally confined carcinoma of the prostate',\n",
       "  'advanced carcinoma of the prostate',\n",
       "  'endometriosis',\n",
       "  'advanced breast cancer in pre- and perimenopausal women'],\n",
       " 'DB00015': ['lysis of acute pulmonary emboli, intracoronary emboli, and myocardial infarction'],\n",
       " 'DB00016': ['anemia due to chronic kidney disease (ckd)',\n",
       "  'anemia due to zidovudine',\n",
       "  'anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy',\n",
       "  'allogeneic rbc transfusions'],\n",
       " 'DB00017': [\"symptomatic paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments\",\n",
       "  'emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified',\n",
       "  'azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves',\n",
       "  'post-menopausal osteoporosis'],\n",
       " 'DB00018': ['the intralesional treatment of refractory or recurring external condylomata acuminata'],\n",
       " 'DB00019': ['the incidence of infection, as manifested by febrile neutropenia, non\\xad myeloid malignancies',\n",
       "  'survival acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)'],\n",
       " 'DB00020': ['cancer and bone marrow transplant'],\n",
       " 'DB00022': ['hcv in combination with db and a ns/a protease inhibitor for genotype  or without a ns/a protease inhibitor for genotypes -',\n",
       "  'hcv in combination with db and a ns/a protease inhibitor for genotype  or without a ns/a protease inhibitor for genotypes -',\n",
       "  'contraindications to or significant intolerance to other anti-viral therapies'],\n",
       " 'DB00023': ['patients with acute lymphoblastic leukemia (all)'],\n",
       " 'DB00024': ['detection of residueal or recurrent thyroid cancer'],\n",
       " 'DB00025': ['hemophilia a, von willebrand disease and factor xiii deficiency'],\n",
       " 'DB00026': ['adult rheumatoid arthritis and treatment of neonatal-onset multisystem inflammatory disease (nomid)'],\n",
       " 'DB00027': ['skin lesions, surface wounds and eye infections'],\n",
       " 'DB00028': ['immunodeficiencies, and autoimmune and inflammatory disorders'],\n",
       " 'DB00029': ['lysis of acute pulmonary emboli, intracoronary emboli and myocardial infarction'],\n",
       " 'DB00030': ['glycemic control and patients with diabetes mellitus'],\n",
       " 'DB00031': ['myocardial infarction and lysis of intracoronary emboli'],\n",
       " 'DB00032': ['female infertility'],\n",
       " 'DB00033': ['chronic granulomatous disease and osteopetrosis'],\n",
       " 'DB00034': [\"chronic hepatitis c, hairy cell leukemia, aids-related kaposi's sarcoma, and chronic myelogenous leukemia\",\n",
       "  'oral warts arising from hiv infection'],\n",
       " 'DB00035': ['nocturia due to nocturnal polyuria',\n",
       "  'central cranial diabetes insipidus and for the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral)',\n",
       "  \"patients with hemophilia a with factor viii coagulant activity levels greater than % or mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than % during surgical procedures and postoperatively to maintain hemostasis (parenteral)\"],\n",
       " 'DB00036': ['hemorrhagic complications in hemophilia a and b'],\n",
       " 'DB00038': ['nonmyeloid malignancies who are at high risk of severe thrombocytopenia'],\n",
       " 'DB00039': ['oral mucositis associated with chemotherapy and radiation therapy'],\n",
       " 'DB00040': ['the movement of the gastrointestinal tract',\n",
       "  'severe hypoglycemia'],\n",
       " 'DB00041': ['adults with metastatic renal cell carcinoma'],\n",
       " 'DB00042': ['patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia'],\n",
       " 'DB00043': [],\n",
       " 'DB00044': ['infertility'],\n",
       " 'DB00045': ['prophylactic treatment of lyme disease'],\n",
       " 'DB00046': ['glycemic control and children with diabetes mellitus'],\n",
       " 'DB00047': ['glycemic control in adults and patients with type  diabetes mellitus and type  diabetes mellitus'],\n",
       " 'DB00048': [\"adults with dupuytren's contracture with a palpable cord\",\n",
       "  \"adults with dupuytren's contracture with a palpable cord\",\n",
       "  \"men with peyronie's disease diagnosed with a penile curvature deformity of at least a -degree angle at the beginning of therapy in addition to palpable plaques\",\n",
       "  'the tissue debridement of chronic dermal ulcers and severely burned tissues',\n",
       "  'moderate to severe cellulite in the buttocks of adult women'],\n",
       " 'DB00049': ['hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)'],\n",
       " 'DB00050': ['the inhibition of premature lh surges in women undergoing controlled ovarian stimulation'],\n",
       " 'DB00051': [],\n",
       " 'DB00052': ['dwarfism, acromegaly and prevention of hiv-induced weight loss'],\n",
       " 'DB00053': [\"gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00054': ['unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within  hours'],\n",
       " 'DB00055': ['reduction of mortality in patients with severe sepsis'],\n",
       " 'DB00056': ['patients with cd positive acute myeloid leukemia in first relapse who are  years of age or older and who are not considered candidates for other cytotoxic chemotherapy',\n",
       "  'patients with cd positive acute myeloid leukemia in first relapse who are  years of age or older and who are not considered candidates for other cytotoxic chemotherapy',\n",
       "  'patients aged  years and older with cd-positive aml experienced a relapse or not responded to treatment (refractory)',\n",
       "  'patients aged  years and older with cd-positive aml experienced a relapse or not responded to treatment (refractory)'],\n",
       " 'DB00057': ['diagnosis of extrahepatic malignant cancers'],\n",
       " 'DB00058': ['chronic augmentation and maintenance therapy in patients with alph-proteinase inhibitor (-pi) deficiency and clinical evidence of emphysema'],\n",
       " 'DB00059': ['acute lymphoblastic leukemia'],\n",
       " 'DB00060': ['relapsing/remitting multiple sclerosis, also for condyloma acuminatum'],\n",
       " 'DB00061': ['adenosine deaminase deficiency'],\n",
       " 'DB00062': ['adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass'],\n",
       " 'DB00063': ['myocardial infarction and acute coronary syndrome'],\n",
       " 'DB00065': ['reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (  years of age) patients with moderately to severely active crohns disease had an inadequate response to conventional therapy',\n",
       "  'signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (  years of age) patients with moderately to severely active crohns disease had an inadequate response to conventional therapy',\n",
       "  'fistulizing crohns disease',\n",
       "  'reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (  years of age) patients with moderately to severely active ulcerative colitis had an inadequate response to conventional therapy',\n",
       "  'signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (  years of age) patients with moderately to severely active ulcerative colitis had an inadequate response to conventional therapy',\n",
       "  'moderately to severely active rheumatoid arthritis',\n",
       "  'active ankylosing spondylitis',\n",
       "  'psoriatic arthritis',\n",
       "  'patients with chronic severe (i',\n",
       "  'patients with chronic severe (i'],\n",
       " 'DB00066': ['spermatogenesis',\n",
       "  'induce spermatogenesis',\n",
       "  'the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or',\n",
       "  'the ovary to produce several follicles',\n",
       "  'cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (gift) or in vitro fertilization (ivf)',\n",
       "  'gamete intrafallopian transfer (gift) or in vitro fertilization (ivf)'],\n",
       " 'DB00067': ['enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding'],\n",
       " 'DB00068': ['relapsing/remitting multiple sclerosis',\n",
       "  'the frequency of attacks'],\n",
       " 'DB00069': [\"hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma\"],\n",
       " 'DB00070': ['increase of absorption and distribution of other injected drugs and for rehydration'],\n",
       " 'DB00071': ['type i and ii diabetes mellitus'],\n",
       " 'DB00072': ['the adjuvant treatment of her-overexpressing breast cancer, drug is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel',\n",
       "  'metastatic her-overexpressing breast cancer, and as monotherapy',\n",
       "  'patients with her-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma not received prior treatment for metastatic disease',\n",
       "  'subcutaneous administration - in combination with either hyaluronidase or both hyaluronidase and pertuzumab - for adults with her- positive breast cancers',\n",
       "  'adults with her- positive breast cancers'],\n",
       " 'DB00073': ['moderately-to severely-active ra',\n",
       "  'patients with cd-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy',\n",
       "  'patients with cd-positive, b-cell non-hodgkins lymphoma (nhl) to be used as a single agent or in combination with chemotherapy'],\n",
       " 'DB00074': ['prophylactic treatment of kidney transplant rejection'],\n",
       " 'DB00075': ['organ transplant recipients, prevention of organ rejection'],\n",
       " 'DB00076': ['digitoxin overdose or digitalis glycoside toxicity'],\n",
       " 'DB00078': [\"non-hodgkin's lymphoma\"],\n",
       " 'DB00080': ['complicated skin and skin structure infections caused by susceptible strains of gram-positive microorganisms'],\n",
       " 'DB00081': [\"non-hodgkin's lymphoma (cd positive, follicular)\"],\n",
       " 'DB00082': ['acromegaly'],\n",
       " 'DB00083': ['cervical dystonia',\n",
       "  'severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or vii nerve disorders',\n",
       "  'excessive underarm sweating'],\n",
       " 'DB00085': ['pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it',\n",
       "  'pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it'],\n",
       " 'DB00086': ['acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae'],\n",
       " 'DB00087': ['b-cell chronic lymphocytic leukemia'],\n",
       " 'DB00088': [\"gaucher's disease (deficiency in glucocerebrosidase)\"],\n",
       " 'DB00089': ['diagnosis of prostate cancer and detection of intra-pelvic metastases'],\n",
       " 'DB00090': ['mucopolysaccharidosis'],\n",
       " 'DB00091': ['a variety of conditions',\n",
       "  'the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants',\n",
       "  'bone marrow transplant rejection',\n",
       "  'prevent bone marrow transplant rejection',\n",
       "  'or treat graft-versus-host disease (gvhd)',\n",
       "  'patients with severe active rheumatoid arthritis (ra) when they no longer respond to methotrexate alone',\n",
       "  'adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated',\n",
       "  'tear production suffering from keratoconjunctivitis sicca',\n",
       "  'steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis',\n",
       "  'steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis',\n",
       "  'various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, and idiopathic thrombocytopenic purpura'],\n",
       " 'DB00092': ['moderate to severe chronic plaque psoriasis'],\n",
       " 'DB00093': ['use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential'],\n",
       " 'DB00094': ['female infertility'],\n",
       " 'DB00095': ['patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy'],\n",
       " 'DB00097': ['female infertility'],\n",
       " 'DB00098': ['prevention of renal transplant rejection'],\n",
       " 'DB00099': ['leucocyte growth factor  indicated to:',\n",
       "  'nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever',\n",
       "  'acute myeloid leukemia (aml)',\n",
       "  'nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (bmt)',\n",
       "  'patients with radiation-induced myelosuppression following a radiological/nuclear incident',\n",
       "  'patients with radiation-induced myelosuppression following a radiological/nuclear incident'],\n",
       " 'DB00100': ['hemophilia (christmas disease)'],\n",
       " 'DB00102': ['skin ulcers (from diabetes)'],\n",
       " 'DB00103': ['fabry disease', 'fabry disease'],\n",
       " 'DB00104': ['acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (vipoma) tumors'],\n",
       " 'DB00105': [\"hairy cell leukemia, malignant melanoma, and aids-related kaposi's sarcoma\"],\n",
       " 'DB00106': ['treatment of advanced prostate cancer'],\n",
       " 'DB00107': ['labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability'],\n",
       " 'DB00108': ['multiple sclerosis'],\n",
       " 'DB00109': ['hiv-/aids'],\n",
       " 'DB00110': ['prophylaxis of respiratory diseases casued by respiratory syncytial virus'],\n",
       " 'DB00111': ['prevention of renal transplant rejection'],\n",
       " 'DB00112': ['metastatic colorectal cancer',\n",
       "  'recurrent glioblastoma',\n",
       "  'covid- complications including acute respiratory distress syndrome (ards) and acute lung injury (ali)'],\n",
       " 'DB00113': ['imaging colorectal tumors'],\n",
       " 'DB00114': ['nutritional supplementation and for treating dietary shortage or imbalance'],\n",
       " 'DB00115': ['deficiency of this vitamin no nervous system involvement',\n",
       "  'newly diagnosed vitamin b deficiency',\n",
       "  'vitamin b deficiencies due to various causes, with or without neurologic manifestations',\n",
       "  'malabsorption, as these forms are primarily absorbed in the gastrointestinal tract'],\n",
       " 'DB00116': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00117': ['some immunomodulatory and antioxidant',\n",
       "  'use in some with rheumatoid arthritis',\n",
       "  'some with rheumatoid arthritis',\n",
       "  'anemia or uremia or for lowering serum cholesterol',\n",
       "  'anemia or uremia or for lowering serum cholesterol'],\n",
       " 'DB00118': ['depression, liver disorders, fibromyalgia, and osteoarthritis'],\n",
       " 'DB00119': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00120': ['some with depression', 'vitiligo'],\n",
       " 'DB00121': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00122': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00123': ['putative anti-herpes simplex virus', 'some anti-osteoporotic'],\n",
       " 'DB00125': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00126': ['vitamin c deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant'],\n",
       " 'DB00127': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00128': ['no approved indication'],\n",
       " 'DB00129': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00130': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance',\n",
       "  'the acute complications of sickle cell disease',\n",
       "  'reduce the acute complications of sickle cell disease in adult and patients'],\n",
       " 'DB00131': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00132': ['nutritional supplementation and for treating dietary shortage or imbalance'],\n",
       " 'DB00133': ['a natural moisturizing agent in some cosmetics and skin care products'],\n",
       " 'DB00134': ['protein synthesis including the formation of same, l-homocysteine, l-cysteine, taurine, and sulfate'],\n",
       " 'DB00135': ['an effective antidepressant,',\n",
       "  'stress and combat narcolepsy and chronic fatigue,'],\n",
       " 'DB00136': ['chronic renal failure undergoing dialysis'],\n",
       " 'DB00137': ['dietary shortage or imbalance'],\n",
       " 'DB00138': ['anti-inflammatory',\n",
       "  'osteoarthritis and rheumatoid arthritis',\n",
       "  'any of these conditions'],\n",
       " 'DB00139': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00140': ['adrugosis (vitamin b deficiency)'],\n",
       " 'DB00141': ['the treatment and prevention of osteoarthritis, by itself or in combination with chondroitin sulfate'],\n",
       " 'DB00142': ['ulcers',\n",
       "  'the healing of ulcers',\n",
       "  'alcoholism, schizophrenia and the craving for sugar',\n",
       "  'to control alcoholism, schizophrenia and the craving for sugar'],\n",
       " 'DB00143': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00144': [\"cognitive impairment, including alzheimer's disease, age-associated memory impairment and some non-alzheimer's dementias\",\n",
       "  'immune enhancement or for reduction of exercise stress'],\n",
       " 'DB00145': ['antispastic', 'antipsychotic'],\n",
       " 'DB00146': ['chronic renal failure undergoing dialysis'],\n",
       " 'DB00147': ['dietary shortage or imbalances',\n",
       "  'nutritional supplementation and for treating dietary shortage or imbalances'],\n",
       " 'DB00148': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00149': ['in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress',\n",
       "  'the breakdown of muscle proteins that sometimes occur after trauma or severe stress'],\n",
       " 'DB00150': ['serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight'],\n",
       " 'DB00151': ['the prevention of liver damage and kidney damage associated with overdoses of acetaminophen'],\n",
       " 'DB00152': [\"drug and niacin deficiency states, korsakov's alcoholic psychosis, wernicke-korsakov syndrome, delirium, and peripheral neuritis\"],\n",
       " 'DB00153': ['hypoparathyroidism, refractory rickets, and familial hypophosphatemia',\n",
       "  'hypoparathyroidism, refractory rickets, and familial hypophosphatemia'],\n",
       " 'DB00154': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00155': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00156': ['proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation'],\n",
       " 'DB00157': [\"parkinson's disease, chronic fatigue syndrome, alzheimer's disease and cardiovascular disease\"],\n",
       " 'DB00158': ['drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood',\n",
       "  'drug deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood'],\n",
       " 'DB00159': ['lowering elevated triglycerides in those who are hyperglyceridemic',\n",
       "  'cystic fibrosis by reducing disease severity and may play a similar role in type  diabetics in slowing the progression of diabetic nephropathy'],\n",
       " 'DB00160': ['protein synthesis'],\n",
       " 'DB00161': ['mental vigor, muscle coordination, and calm emotions',\n",
       "  'hepatic encephalopathy and in some with phenylketonuria'],\n",
       " 'DB00162': ['drug deficiency'],\n",
       " 'DB00163': ['drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet,',\n",
       "  'drug deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet,'],\n",
       " 'DB00165': ['vitamin b deficiency and for the prophylaxis of db-induced peripheral neuropathy',\n",
       "  'vitamin b deficiency and for the prophylaxis of db-induced peripheral neuropathy',\n",
       "  'nausea and vomiting in pregnancy in a combination product with db (as the commercially available product diclectin)'],\n",
       " 'DB00166': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00167': ['antihepatic encephalopathy',\n",
       "  'anticatabolic and antitardive dyskinesia'],\n",
       " 'DB00168': ['a diet supplement and sugar substitute'],\n",
       " 'DB00169': ['specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia ,',\n",
       "  'specific medical conditions like refractory rickets (or vitamin d resistant rickets), hypoparathyroidism, and familial hypophosphatemia ,'],\n",
       " 'DB00170': ['in the normal clotting of blood, but it may also play a role in normal bone calcification',\n",
       "  'in the normal clotting of blood, but it may also play a role'],\n",
       " 'DB00171': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00172': ['the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles',\n",
       "  'maintain and strengthen heart muscles'],\n",
       " 'DB00173': ['nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00174': ['dietary shortage or imbalance',\n",
       "  'nutritional supplementation, also for treating dietary shortage or imbalance'],\n",
       " 'DB00175': ['primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease',\n",
       "  'clinically evident coronary heart disease',\n",
       "  'heterozygous familial hypercholesterolemia in patients over  years of age with low-density lipoprotein (ldl) cholesterol higher than  mg/dl after diet modifications or ldl levels higher than  mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors',\n",
       "  'primary dysbetalipoproteinemia (type iii hyperlipidemia)'],\n",
       " 'DB00176': ['depression and for obsessive compulsive disorder (ocd)',\n",
       "  'bulimia nervosa'],\n",
       " 'DB00177': ['hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions',\n",
       "  'hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions',\n",
       "  'heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate',\n",
       "  'heart failure (nyha class ii-iv) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (acei) is not appropriate'],\n",
       " 'DB00178': ['mild to severe hypertension',\n",
       "  'cardiovascular mortality following myocardial infarction in hemodynamically stable patients who develop clinical signs of congestive heart failure within a few days following myocardial',\n",
       "  'reduce cardiovascular mortality following myocardial infarction in hemodynamically stable patients who develop clinical signs of congestive heart failure within a few days following myocardial infarction',\n",
       "  'the rate of death, myocardial infarction and stroke',\n",
       "  'hypertension, diabetes mellitus and microalubinuria or overt nephropathy'],\n",
       " 'DB00179': ['actinic keratoses (precancerous skin growths that can become malignant if left untreated)'],\n",
       " 'DB00180': ['the maintenance treatment of asthma as a prophylactic therapy'],\n",
       " 'DB00181': ['the restoration of residual function',\n",
       "  'skeletal muscle spasm caused by rheumatic disorders',\n",
       "  'skeletal muscle spasm caused by rheumatic disorders'],\n",
       " 'DB00182': ['attention-deficit/hyperactivity disorders (adhd) and for central nervous system disorders such as narcolepsy',\n",
       "  'attention-deficit/hyperactivity disorders (adhd) and for central nervous system disorders such as narcolepsy',\n",
       "  'obesity, depression and chronic pain'],\n",
       " 'DB00183': ['a diagnostic aid for evaluation of gastric acid secretory function'],\n",
       " 'DB00184': ['the relief of drug withdrawal symptoms and as an aid to smoking cessation'],\n",
       " 'DB00185': ['dry mouth'],\n",
       " 'DB00186': ['the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia'],\n",
       " 'DB00187': ['the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable',\n",
       "  'noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention'],\n",
       " 'DB00188': ['patients with multiple myeloma or mantle cell lymphoma',\n",
       "  'patients with multiple myeloma or mantle cell lymphoma'],\n",
       " 'DB00189': ['insomnia for periods of up to one week in duration'],\n",
       " 'DB00190': ['idiopathic parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication'],\n",
       " 'DB00191': ['exogenous obesity for patients with an initial body mass index (bmi) greater than  kg/m or greater than  kg/m in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia'],\n",
       " 'DB00192': ['life-threatening dysrhythmias and sustained ventricular tachycardia'],\n",
       " 'DB00193': ['moderate to severe pain', 'premature ejaculation'],\n",
       " 'DB00194': ['chickenpox - varicella, herpes zoster and herpes simplex'],\n",
       " 'DB00195': ['hypertension'],\n",
       " 'DB00196': ['the following fungal infections:'],\n",
       " 'DB00197': ['type ii diabetes mellitus'],\n",
       " 'DB00198': ['acute, uncomplicated illness due to influenza a and b infection',\n",
       "  'post-exposure prevention of influenza in infants less than  year of age during a pandemic influenza outbreak'],\n",
       " 'DB00199': ['infections caused by susceptible strains of various bacteria',\n",
       "  'infections caused by susceptible strains of various bacteria',\n",
       "  'pertussis (whooping cough) caused by bordetella pertussis',\n",
       "  'pertussis infection for patients been exposed to the bacteria',\n",
       "  'diphtheria and other infections due to corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status',\n",
       "  'rheumatic fever in penicillin',\n",
       "  'prevent rheumatic fever in penicillin intolerant patients',\n",
       "  'erythrasma, an infectious condition caused by corynebacterium minutissimum',\n",
       "  'acute pelvic inflammatory disease caused by n',\n",
       "  'an alternative drug in treating acute pelvic inflammatory disease caused by n',\n",
       "  'the primary stage of primary syphilis',\n",
       "  'chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy',\n",
       "  'uncomplicated rectal, urethral and endocervical infections',\n",
       "  'nongonococcal urethritis can be used when tetracyclines cannot be administered',\n",
       "  'nongonococcal urethritis due to ureaplasma urealyticum'],\n",
       " 'DB00200': ['pernicious anemia and vitamin b deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets',\n",
       "  'known or suspected cyanide poisoning'],\n",
       " 'DB00201': ['the short term treatment of apnea of prematurity in infants and off label for bronchopulmonary dysplasia caused by premature birth',\n",
       "  'bronchopulmonary dysplasia caused by premature birth',\n",
       "  'respiratory depression resulting from an overdose with cns depressant drugs'],\n",
       " 'DB00202': ['surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ect)'],\n",
       " 'DB00203': ['phosphodiesterase- (pde) inhibitor that is predominantly employed for two primary indications:',\n",
       "  'pulmonary arterial hypertension (pah) (who group i)',\n",
       "  'primary pulmonary arterial hypertension (pph) or pulmonary hypertension secondary to connective tissue disease (ctd)',\n",
       "  'patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity',\n",
       "  'patients aged  year to  years old with pulmonary arterial hypertension'],\n",
       " 'DB00204': ['the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter af/afl) in patients with atrial fibrillation/atrial flutter of greater than one week duration been converted to normal sinus rhythm'],\n",
       " 'DB00205': ['toxoplasmosis and acute malaria',\n",
       "  'malaria in areas non-resistant to drug'],\n",
       " 'DB00206': ['hypertension'],\n",
       " 'DB00207': ['or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of drug',\n",
       "  'patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below',\n",
       "  'patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below',\n",
       "  'chancroid'],\n",
       " 'DB00208': [],\n",
       " 'DB00209': ['overactive bladder with urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition'],\n",
       " 'DB00210': ['acne vulgaris'],\n",
       " 'DB00211': ['symptomatic orthostatic hypotension (oh)'],\n",
       " 'DB00212': ['hypertension and heart failure'],\n",
       " 'DB00213': ['pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions',\n",
       "  'pathological hypersecretory conditions associated with zollinger-ellison syndrome or other neoplastic conditions',\n",
       "  'erosive esophagitis',\n",
       "  'gerd',\n",
       "  'the long-term treatment of the above conditions'],\n",
       " 'DB00214': ['edema associated with congestive heart failure, renal or hepatic diseases',\n",
       "  'edema associated with congestive heart failure, renal or hepatic diseases',\n",
       "  'an antihypertensive agent either alone or in combination with other antihypertensives'],\n",
       " 'DB00215': ['depression, as indicated by the fda label'],\n",
       " 'DB00216': ['migraine with or without aura'],\n",
       " 'DB00217': ['hypertension'],\n",
       " 'DB00218': ['sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis',\n",
       "  'bacterial conjunctivitis (pinkeye)'],\n",
       " 'DB00219': ['visceral spasms'],\n",
       " 'DB00220': ['hiv in both adults and children'],\n",
       " 'DB00221': ['asthma, wheezing, and chronic asthmatic bronchitis'],\n",
       " 'DB00222': ['type  diabetes',\n",
       "  'type  diabetes whose high blood sugar levels cannot be controlled by diet and exercise along with with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone'],\n",
       " 'DB00223': ['relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses'],\n",
       " 'DB00224': ['hiv infection'],\n",
       " 'DB00225': ['intravenous use in mri to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues'],\n",
       " 'DB00226': ['and control hypertension'],\n",
       " 'DB00227': ['the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c',\n",
       "  'primary hypercholesterolemia (types iia and iib), when the response to diet restricted in saturated fat and cholesterol',\n",
       "  'coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target levels',\n",
       "  'total-c, ldl-c and apolipoprotein b levels in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh) who are at least one year post-menarche,  to  years of age, with hefh if after an adequate trial of diet therapy the following findings are present: ldl-c remains greater than  mg/dl or ldl-c remains greater than  mg/dl and there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present'],\n",
       " 'DB00228': ['both the induction and maintenance of general anesthesia',\n",
       "  'analgesia for vaginal delivery',\n",
       "  'induce analgesia for vaginal delivery',\n",
       "  'an adjunct to general anesthetic drugs during delivery by cesarean section'],\n",
       " 'DB00229': ['severe infections caused by susceptible bacteria'],\n",
       " 'DB00230': ['neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and  for partial-onset seizures'],\n",
       " 'DB00231': ['premedication prior to minor surgery or other related procedures'],\n",
       " 'DB00232': ['use in hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00233': ['tuberculosis'],\n",
       " 'DB00234': ['clinical depression'],\n",
       " 'DB00235': ['congestive heart failure', 'congestive heart failure'],\n",
       " 'DB00236': ['polycythaemia vera and refractory chronic myeloid leukaemia'],\n",
       " 'DB00237': ['use as a sedative or hypnotic',\n",
       "  'insomnia for longer than  weeks'],\n",
       " 'DB00238': ['use in combination with other antiretroviral drugs in the ongoing treatment of hiv- infection'],\n",
       " 'DB00239': ['dermal fungal infection'],\n",
       " 'DB00240': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00241': ['the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine',\n",
       "  'the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesics and alternative treatments are inadequate, in various combinations with acetaminophen, aspirin, caffeine, and codeine'],\n",
       " 'DB00242': ['active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms',\n",
       "  \"chronic lymphocytic leukemia (cll), low-grade non-hodgkin's lymphoma, and cutaneous t-cell lymphoma\"],\n",
       " 'DB00243': ['chronic angina',\n",
       "  'chronic angina',\n",
       "  'certain arrhythmias, including ventricular tachycardia,',\n",
       "  'acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications'],\n",
       " 'DB00244': ['active or mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitis ,'],\n",
       " 'DB00245': ['an adjunct in the therapy of all forms of parkinsonism',\n",
       "  'the control of extrapyramidal disorders due to neuroleptic drugs'],\n",
       " 'DB00246': ['schizophrenia, as monotherapy for manic or mixed episodes related to bipolar i disorder, and  to lithium or valproate for maintenance treatment of bipolar i disorder',\n",
       "  'schizophrenia, as monotherapy for manic or mixed episodes related to bipolar i disorder, and  to lithium or valproate for maintenance treatment of bipolar i disorder',\n",
       "  'acute agitation in schizophrenia'],\n",
       " 'DB00247': ['vascular headache'],\n",
       " 'DB00248': ['hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas)',\n",
       "  'parkinsonian syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease'],\n",
       " 'DB00249': ['use in keratoconjunctivitis and keratitis caused by herpes simplex virus'],\n",
       " 'DB00250': ['the treatment and leprosy and dermatitis herpetiformis'],\n",
       " 'DB00251': ['candidiasis (a yeast-like fungal infection) of the vulva and vagina'],\n",
       " 'DB00252': ['grand mal seizures, complex partial seizures,',\n",
       "  'and treat seizures during or following neurosurgery',\n",
       "  'seizures occurring during neurosurgery'],\n",
       " 'DB00253': ['allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity'],\n",
       " 'DB00254': ['various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria',\n",
       "  'various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria',\n",
       "  'any type of staphylococcal infection',\n",
       "  'streptococcal infections unless the microorganism has been demonstrated to be susceptible'],\n",
       " 'DB00255': ['prostate cancer'],\n",
       " 'DB00256': ['acne in addition to other susceptible infections'],\n",
       " 'DB00257': ['the following dermal infections , :',\n",
       "  'the following dermal infections , :',\n",
       "  'the local treatment of oropharyngeal candidiasis',\n",
       "  'the incidence of oropharyngeal candidiasis',\n",
       "  'any systemic mycoses',\n",
       "  'any systemic mycoses'],\n",
       " 'DB00258': ['kidney disease'],\n",
       " 'DB00259': ['vulvovaginitis caused by lt'],\n",
       " 'DB00260': ['tuberculosis (tb)'],\n",
       " 'DB00261': ['thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis',\n",
       "  'thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis'],\n",
       " 'DB00262': [\"brain tumors, multiple myeloma, hodgkin's disease and non-hodgkin's lymphomas\"],\n",
       " 'DB00263': ['severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections'],\n",
       " 'DB00264': ['angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension',\n",
       "  'angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension'],\n",
       " 'DB00265': ['eradication of scabies (lt'],\n",
       " 'DB00266': ['decreasing blood clotting', 'deep vein thrombosis'],\n",
       " 'DB00267': ['female gynecologic and obstetric infections caused by susceptible aerobic (including the gonococcus) and anaerobic bacteria'],\n",
       " 'DB00268': [\"signs and parkinson's disease and for primary moderate-severe restless legs syndrome\"],\n",
       " 'DB00269': ['menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer',\n",
       "  'breast engorgement following childbirth',\n",
       "  'prevent breast engorgement following childbirth'],\n",
       " 'DB00270': ['mild to moderate essential hypertension'],\n",
       " 'DB00271': [],\n",
       " 'DB00272': ['use clinically to test gastric secretory function'],\n",
       " 'DB00273': ['seizures associated with lennox-gastaut syndrome in patients above  years of age )prophylaxis of migraine'],\n",
       " 'DB00274': ['infections caused by susceptible organisms'],\n",
       " 'DB00275': ['hypertension either alone or in combination with other antihypertensive agents',\n",
       "  'hypertension either alone or in combination with other antihypertensive agents',\n",
       "  'cardiovascular outcomes including reducing risk of myocardial'],\n",
       " 'DB00276': ['acute myeloid leukaemia'],\n",
       " 'DB00277': ['symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis'],\n",
       " 'DB00278': ['prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (hit)'],\n",
       " 'DB00279': ['the following indications:',\n",
       "  'thyroid cancer',\n",
       "  'replace insufficient hormonal production and restore  plasma levels',\n",
       "  'hyperthyroidism during the recovery phase of subacute thyroiditis'],\n",
       " 'DB00280': ['documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias',\n",
       "  'class ia antiarrhythmic'],\n",
       " 'DB00281': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks ,'],\n",
       " 'DB00282': [\"moderate to severe hypercalcemia of malignancy, moderate to severe paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma\"],\n",
       " 'DB00283': ['the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation',\n",
       "  'mild, uncomplicated allergic skin manifestations of urticaria and angioedema',\n",
       "  'self-medication for temporary relief of symptoms associated with the common cold'],\n",
       " 'DB00284': ['the treatment and diabetes type ii (used in combination therapy as a second or third line agent)'],\n",
       " 'DB00285': ['major depressive disorder (mdd), generalized anxiety disorder (gad), social anxiety disorder (social phobia), and panic disorder with or without agoraphobia',\n",
       "  'neuropathic pain (although there is only minimal evidence of efficacy for this condition)',\n",
       "  'obsessive-compulsive disorder (ocd) ,'],\n",
       " 'DB00286': ['several different conditions including:',\n",
       "  'moderate to severe vasomotor symptoms due to menopause',\n",
       "  'moderate to severe vulvar and vaginal atrophy due to menopause',\n",
       "  'hypoestrogenism due to hypogonadism, castration or primary ovarian failure',\n",
       "  'breast cancer in appropriately selected patients with metastatic disease',\n",
       "  'androgen-dependent carcinoma of the prostate'],\n",
       " 'DB00287': ['open-angle glaucoma or ocular hypertension , ,',\n",
       "  'the decrease of elevated intraocular pressure in paediatric patients aged  months to lt'],\n",
       " 'DB00288': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00289': ['attention deficit hyperactivity disorder (adhd)'],\n",
       " 'DB00290': ['treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas'],\n",
       " 'DB00291': [\"chronic lymphatic (lymphocytic) leukemia,  childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, hodgkin's disease,  non-hodgkin's lymphomas, and waldenstrms macroglobulinemia\"],\n",
       " 'DB00292': ['the induction of general anesthesia'],\n",
       " 'DB00293': ['malignant neoplasm of colon and rectum'],\n",
       " 'DB00294': [],\n",
       " 'DB00295': ['chronic, moderate to severe pain'],\n",
       " 'DB00296': ['obstetric anesthesia and regional anesthesia for surgery'],\n",
       " 'DB00297': ['the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures'],\n",
       " 'DB00298': ['iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations'],\n",
       " 'DB00299': ['recurrent cold sores on the lips and face from various herpesvirus invections'],\n",
       " 'DB00300': ['hiv- infection', 'chronic hepatitis b', 'hiv- infection ,'],\n",
       " 'DB00301': ['bacterial infection by susceptible microorganisms'],\n",
       " 'DB00302': ['use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction',\n",
       "  'excessive bleeding in menstruation, surgery, or trauma cases'],\n",
       " 'DB00303': ['the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: () complicated intra-abdominal infections due to lt'],\n",
       " 'DB00304': ['pregnancy'],\n",
       " 'DB00305': ['malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder',\n",
       "  'an adjunct to ab externo glaucoma surgery',\n",
       "  'adults with low-grade upper tract urothelial cancer (lg-utuc)'],\n",
       " 'DB00306': ['use as a sedative and hypnotic'],\n",
       " 'DB00307': ['skin manifestations of cutaneous t-cell lymphoma (ctcl)',\n",
       "  'skin lesions in early (stage ia and ib) ctcl'],\n",
       " 'DB00308': ['the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm'],\n",
       " 'DB00309': [\"acute leukaemia, malignant lymphoma, hodgkin's disease, acute erythraemia and acute panmyelosis\"],\n",
       " 'DB00310': ['hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00311': ['duodenal ulcers, as a diuretic, and for glaucoma, and may also be useful for seizures associated with epilepsy'],\n",
       " 'DB00312': ['the short-term treatment of insomnia'],\n",
       " 'DB00313': ['complex partial seizures and simple or complex absence seizures',\n",
       "  'multiple seizure types that include absence seizures'],\n",
       " 'DB00314': ['tuberculosis in combination with other drugs'],\n",
       " 'DB00315': ['migraine with or without auras'],\n",
       " 'DB00316': ['mild to moderate pain and reduction of fever',\n",
       "  'mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever',\n",
       "  'mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever'],\n",
       " 'DB00317': ['the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies'],\n",
       " 'DB00318': ['form of this',\n",
       "  'the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate'],\n",
       " 'DB00319': ['polymicrobial infections'],\n",
       " 'DB00320': ['migraine headaches with or without aura and cluster headache episodes'],\n",
       " 'DB00321': ['the following conditions :', 'persistent enuresis'],\n",
       " 'DB00322': ['gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means',\n",
       "  'liver cancer (usually administered by hepatic intra-arterial infusion)'],\n",
       " 'DB00323': [\"parkinson's disease\"],\n",
       " 'DB00324': ['the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe'],\n",
       " 'DB00325': ['acute congestive heart failure'],\n",
       " 'DB00326': ['mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin d deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, for intestinal malabsorption,'],\n",
       " 'DB00327': ['moderate to severe acute pain and severe chronic pain',\n",
       "  'moderate to severe acute pain and severe chronic pain',\n",
       "  'pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as drug along with the existing regimen for cases of severe pain'],\n",
       " 'DB00328': ['symptomatic moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis',\n",
       "  'closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between  and  g when after  hours usual medical management (e'],\n",
       " 'DB00330': ['pulmonary tuberculosis'],\n",
       " 'DB00331': ['glycemic control',\n",
       "  'glycemic control',\n",
       "  'type  diabetes mellitus when used adjunctively with diet and exercise'],\n",
       " 'DB00332': ['severe exacerbations of asthma flares requiring treatment',\n",
       "  'the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients  years or older',\n",
       "  'sialorrhea'],\n",
       " 'DB00333': ['pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate',\n",
       "  'opioid dependence'],\n",
       " 'DB00334': ['episodes of depression associated with bipolar disorder type  and treatment-resistant depression',\n",
       "  'psychomotor agitation associated with schizophrenia and bipolar i mania',\n",
       "  'psychomotor agitation associated with schizophrenia and bipolar i mania'],\n",
       " 'DB00335': [],\n",
       " 'DB00336': ['bacterial skin infections including pyodermas, infected dermatoses and infections of cuts, wounds, burns and ulcers due to susceptible organisms'],\n",
       " 'DB00337': ['mild to moderate atopic dermatitis'],\n",
       " 'DB00338': ['the following purposes:', 'the risk of duodenal ulcer'],\n",
       " 'DB00339': ['active tuberculosis'],\n",
       " 'DB00340': ['parkinsonism'],\n",
       " 'DB00341': ['associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens',\n",
       "  'associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds',\n",
       "  'the uncomplicated skin manifestations of chronic idiopathic urticaria'],\n",
       " 'DB00342': ['allergic rhinitis, hay fever, and allergic skin disorders'],\n",
       " 'DB00343': ['hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents',\n",
       "  'hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents',\n",
       "  'chronic stable angina',\n",
       "  \"variant angina (prinzmetal's angina)\",\n",
       "  \"variant angina (prinzmetal's angina)\",\n",
       "  'the short-term atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate',\n",
       "  'the rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm',\n",
       "  'off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy'],\n",
       " 'DB00344': ['depression'],\n",
       " 'DB00345': ['measure effective renal plasma flow (erpf)'],\n",
       " 'DB00346': ['the reduction of urinary obstruction and relief of associated manifestations (eg',\n",
       "  'symptomatic beningn prostatic hyperplasia'],\n",
       " 'DB00347': [],\n",
       " 'DB00348': ['hereditary tyrosinemia type'],\n",
       " 'DB00349': ['the treatment and epilepsy and seizures associated with lennox-gastaut syndrome, a difficult-to-treat form of childhood epilepsy'],\n",
       " 'DB00350': ['severe hypertension and in the treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss'],\n",
       " 'DB00351': ['anorexia, cachexia, or an unexplained, significant weight loss',\n",
       "  'recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in canada and some other countries'],\n",
       " 'DB00352': ['remission induction and remission consolidation treatment of acute nonlymphocytic leukemias'],\n",
       " 'DB00353': ['the prevention and control of excessive bleeding following vaginal childbirth'],\n",
       " 'DB00354': ['prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems)'],\n",
       " 'DB00355': ['the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections'],\n",
       " 'DB00356': ['the relief of discomfort associated with acute painful musculoskeletal conditions'],\n",
       " 'DB00357': [\"the suppression of adrenal function in selected patients with cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast\"],\n",
       " 'DB00358': ['mild to moderate acute malaria caused by druguine-susceptible strains of lt'],\n",
       " 'DB00359': ['rheumatic fever and meningococcal meningitis'],\n",
       " 'DB00360': ['tetrahydrobiopterin (bh) deficiency'],\n",
       " 'DB00361': ['adults for advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs',\n",
       "  'advanced non-small cell lung cancer (nsclc), as a single therapy or in combination with other chemotherapeutic drugs',\n",
       "  'relapsed or refractory hodgkin lymphoma, in combination with other chemotherapy agents',\n",
       "  'desmoid tumor or aggressive fibromatosis, in combination with methotrexate',\n",
       "  'recurrent or metastatic squamous cell head and neck cancer',\n",
       "  'recurrent ovarian cancer',\n",
       "  'metastatic breast cancer,',\n",
       "  'her-positive, trastuzumab-resistant, advanced breast cancer'],\n",
       " 'DB00362': ['the following fungal infections: candidemia and other forms of lt'],\n",
       " 'DB00363': ['use in patients with treatment-resistant schizophrenia'],\n",
       " 'DB00364': ['active duodenal ulcer for up to  weeks',\n",
       "  'the prevention and/or treatment of gastro-esophageal reflux disease (gerd), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia ,'],\n",
       " 'DB00365': ['adults with mild to moderate infections caused by susceptible strains of lt'],\n",
       " 'DB00366': ['morning sickness'],\n",
       " 'DB00367': ['the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse',\n",
       "  'pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse',\n",
       "  'regular contraception and must be taken as soon as possible within  hours after intercourse',\n",
       "  'various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of - years',\n",
       "  'pregnancy for up to  years',\n",
       "  'osteoporosis',\n",
       "  'menorrhagia, endometrial hyperplasia, and endometriosis'],\n",
       " 'DB00368': ['patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine',\n",
       "  'a vasopressor medication for patients with critical hypotension'],\n",
       " 'DB00369': ['cmv retinitis'],\n",
       " 'DB00370': ['major depressive disorder and its associated symptoms',\n",
       "  'major depressive disorder and its associated symptoms'],\n",
       " 'DB00371': ['anxiety disorders or for the short-term relief of anxiety'],\n",
       " 'DB00372': ['the treatment or relief of nausea and vomiting'],\n",
       " 'DB00373': ['increased intraocular pressure',\n",
       "  'high blood pressure',\n",
       "  'migraine headaches'],\n",
       " 'DB00374': ['pulmonary arterial hypertension'],\n",
       " 'DB00375': ['primary hypercholesterolemia (a condition that features elevated ldl-c) who do not respond adequately to dietary changes',\n",
       "  'severe elevations of ldl-c or with definite coronary heart disease fda label,',\n",
       "  \"fredrickson's type ii hyperlipoproteinemia\",\n",
       "  'combined hypercholesterolemia and hypertriglyceridemia, although drug may be helpful in reducing elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern'],\n",
       " 'DB00376': [\"parkinson's disease and extrapyramidal reactions caused by drugs\",\n",
       "  \"parkinson's disease and extrapyramidal reactions caused by drugs\"],\n",
       " 'DB00377': ['the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy',\n",
       "  'postoperative nausea and vomiting for up to  hours post operation'],\n",
       " 'DB00378': ['irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency',\n",
       "  'natural abortion'],\n",
       " 'DB00379': ['ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation'],\n",
       " 'DB00380': ['reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer received a cumulative doxorubicin hydrochloride dose of  mg/m^ and would benefit from continued doxorubicin therapy',\n",
       "  'extravasation from intravenous anthracyclines',\n",
       "  'extravasation from intravenous anthracyclines'],\n",
       " 'DB00381': ['the following conditions :'],\n",
       " 'DB00382': [\"mild to moderate dementia of the alzheimer's type\"],\n",
       " 'DB00383': ['peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders'],\n",
       " 'DB00384': ['edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome',\n",
       "  'edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome'],\n",
       " 'DB00385': ['cancer of the bladder'],\n",
       " 'DB00387': [\"all forms of parkinson's disease, and control of extrapyramidal reactions induced by antipsychotic agents\"],\n",
       " 'DB00388': ['hypotension caused by shock or anesthesia,,  an ophthalmic formulation is indicated to dilate pupils and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids'],\n",
       " 'DB00389': ['hyperthyroidism and thyrotoxicosis',\n",
       "  'prepare patients for thyroidectomy'],\n",
       " 'DB00390': ['mild to moderate heart failure',\n",
       "  'myocardial contraction',\n",
       "  'heart failure, when it is clinically possible, drug should be administered along with with a diuretic and an angiotensin-converting enzyme (ace) inhibitor for optimum effects'],\n",
       " 'DB00391': ['schizophrenia', 'schizophrenia'],\n",
       " 'DB00392': [\"parkinson's disease and also used to control severe reactions to certain medicines such as reserpine\"],\n",
       " 'DB00393': ['use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits'],\n",
       " 'DB00394': ['the relief of acute bronchospasm',\n",
       "  'intranasal use to relieve seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal',\n",
       "  'seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal'],\n",
       " 'DB00395': ['the relief of discomfort related to acute, painful musculoskeletal conditions',\n",
       "  'the treatment periods up to two or three weeks'],\n",
       " 'DB00396': ['use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets',\n",
       "  'endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets',\n",
       "  'use in secondary amenorrhea',\n",
       "  'secondary amenorrhea',\n",
       "  'secondary amenorrhea, with the use of the % concentration if there is no therapeutic response to the % gel',\n",
       "  'the prevention of pregnancy',\n",
       "  'pregnancy'],\n",
       " 'DB00397': ['nasal congestion, control of urinary incontinence, priapism and obesity'],\n",
       " 'DB00398': ['unresectable hepatocellular carcinoma and advanced renal cell carcinoma',\n",
       "  'unresectable hepatocellular carcinoma and advanced renal cell carcinoma'],\n",
       " 'DB00399': [\"hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and paget's disease of bone in men and women\",\n",
       "  'the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis',\n",
       "  'osteoporosis in post menopausal women and glucocorticoid induced osteoporosis'],\n",
       " 'DB00400': ['ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by lt'],\n",
       " 'DB00401': ['hypertension'],\n",
       " 'DB00402': ['insomnia', 'insomnia'],\n",
       " 'DB00403': ['paralytic ileus and as diagnostic aid in pancreatic malfunction'],\n",
       " 'DB00404': ['anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia',\n",
       "  'anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia'],\n",
       " 'DB00405': ['the treatment and relief of allergies, hay fever, and colds'],\n",
       " 'DB00406': [\"bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of chagas' disease (as a blood additive)\"],\n",
       " 'DB00407': ['prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery'],\n",
       " 'DB00408': ['the manifestations of psychotic disorders such as schizophrenia'],\n",
       " 'DB00409': ['schizophrenia'],\n",
       " 'DB00410': ['impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_',\n",
       "  'impetigo and secondary skin infections, leading to traumatic skin lesions, due to _staphylococcus aureus_ and _streptococcus pyogenes_'],\n",
       " 'DB00411': ['glaucoma, but is used during ophthalmic surgery'],\n",
       " 'DB00412': ['type  diabetes mellitus'],\n",
       " 'DB00413': ['parkinsons disease',\n",
       "  'parkinsons disease',\n",
       "  'treatment of moderate to severe primary restless legs syndrome (rls)'],\n",
       " 'DB00414': ['diabetes mellitus type  (adult-onset)'],\n",
       " 'DB00415': ['infection (respiratory, gi, uti and meningitis) due to e'],\n",
       " 'DB00416': ['use as an anesthesia adjunct to induce skeletal muscle relaxation',\n",
       "  'the intensity of muscle contractions'],\n",
       " 'DB00417': ['mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response',\n",
       "  'mild to moderately severe infections due to penicillin g\\xad-sensitive microorganisms, with the use of bacteriological studies (including sensitivity tests) and clinical response',\n",
       "  'congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract'],\n",
       " 'DB00418': ['the short-term treatment of intractable insomnia for patients habituated to barbiturates'],\n",
       " 'DB00419': [\"patients with mild to moderate type  (nonneuropathic) gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e\",\n",
       "  'progressive neurological symptoms in adult and patients with niemann-pick disease type c (np-c)'],\n",
       " 'DB00420': ['an adjunct for short term treatment of moderate and severe psychomotor agitation',\n",
       "  'agitation or restlessness in the elderly'],\n",
       " 'DB00421': ['new york heart association class iii-iv heart failure, edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term',\n",
       "  'antiandrogenic',\n",
       "  'hirsutism, female pattern hair loss, and adult acne vulgaris',\n",
       "  'its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth'],\n",
       " 'DB00422': ['attention deficit hyperactivity disorder (adhd)'],\n",
       " 'DB00423': [],\n",
       " 'DB00424': ['bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis',\n",
       "  \"certain heart conditions, to control parkinson's disease and rhinitis\"],\n",
       " 'DB00425': [],\n",
       " 'DB00426': ['acute herpes zoster (shingles)'],\n",
       " 'DB00427': ['the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis',\n",
       "  'combination with other agents for the symptomatic relief of symptoms associated with the common cold'],\n",
       " 'DB00428': ['malignant neoplasms of pancreas (metastatic islet cell carcinoma)'],\n",
       " 'DB00429': ['aborting pregnancy between the th and th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion:',\n",
       "  'postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management'],\n",
       " 'DB00430': ['severe infections caused by susceptible bacteria such as p'],\n",
       " 'DB00431': ['patients infested with sarcoptes scabiei or pediculosis capitis either failed to respond to adequate doses, or are intolerant of other approved therapies'],\n",
       " 'DB00432': ['primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types  and  in ophthalmic solutions',\n",
       "  'patients with metastatic colorectal cancer been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy',\n",
       "  'patients with metastatic colorectal cancer been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy'],\n",
       " 'DB00433': ['severe nausea and vomiting',\n",
       "  'severe nausea and vomiting',\n",
       "  'manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety',\n",
       "  'manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety',\n",
       "  'generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than  mg per day or for shorter than  weeks',\n",
       "  'combination with dopamine antagonist'],\n",
       " 'DB00434': ['perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine'],\n",
       " 'DB00435': ['term and near-term (amp'],\n",
       " 'DB00436': ['high blood pressure and edema related to heart failure'],\n",
       " 'DB00437': [],\n",
       " 'DB00438': ['patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis)'],\n",
       " 'DB00439': ['primary hypercholesterolemia and mixed dyslipidemia (fredrickson types iia and iib) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate'],\n",
       " 'DB00440': ['acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e',\n",
       "  'acute episodes of uncomplicated urinary tract infections caused by susceptible bacteria, including _e',\n",
       "  'acute bacterial conjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible bacteria'],\n",
       " 'DB00441': ['advanced ovarian cancer that has relapsed at least  months after completion of platinum-based therapy',\n",
       "  'advanced ovarian cancer that has relapsed at least  months after completion of platinum-based therapy'],\n",
       " 'DB00442': ['chronic hepatitis b virus infection'],\n",
       " 'DB00443': ['several inflammatory conditions',\n",
       "  'several inflammatory conditions',\n",
       "  'pruritic and inflammatory corticosteroid-responsive-dermatoses',\n",
       "  'pruritic and',\n",
       "  'plaque psoriasis',\n",
       "  'manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions'],\n",
       " 'DB00444': ['refractory acute lymphoblastic leukaemia'],\n",
       " 'DB00445': ['use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer'],\n",
       " 'DB00446': ['cholera, as it destroys the vibrios and decreases the diarrhea',\n",
       "  'bacterial conjunctivitis'],\n",
       " 'DB00447': ['upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis'],\n",
       " 'DB00448': ['short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid) induced gastric and duodenal ulcers',\n",
       "  'gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid)',\n",
       "  'reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (nsaid) induced gastric and duodenal ulcers',\n",
       "  'the maintenance and healing of several gastric conditions including duodenal ulcers, nsaid related gastric ulcers, and erosive esophagitis',\n",
       "  'several gastric conditions including duodenal ulcers, nsaid related gastric ulcers, and erosive esophagitis',\n",
       "  'hypersecretory conditions including zollinger-ellison syndrome'],\n",
       " 'DB00449': ['initial therapy for the control of intraocular pressure in chronic open-angle glaucoma',\n",
       "  'prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma'],\n",
       " 'DB00450': ['tranquilization', 'the incidence of nausea and vomiting'],\n",
       " 'DB00451': ['thyrotropin-dependent well-differentiated thyroid cancer'],\n",
       " 'DB00452': ['bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis'],\n",
       " 'DB00453': ['the treatment and brucellosis, mycoplasma infection, acne vulgaris, chlamydial infection'],\n",
       " 'DB00454': ['moderate to severe pain', 'control moderate to severe pain'],\n",
       " 'DB00455': ['allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions'],\n",
       " 'DB00456': ['infection during surgery',\n",
       "  'prevent infection during surgery',\n",
       "  'many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract'],\n",
       " 'DB00457': ['hypertension (high blood pressure)',\n",
       "  'hypertension (high blood pressure)',\n",
       "  'chronic obstructive lung disease (copd)'],\n",
       " 'DB00458': ['the relief of depression and as temporary adjunctive therapy in reducing enuresis in children aged  years and older'],\n",
       " 'DB00459': ['severe psoriasis'],\n",
       " 'DB00460': ['patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome',\n",
       "  'destroy tumors'],\n",
       " 'DB00461': [],\n",
       " 'DB00462': ['peptic ulcer', 'nausea and vomiting due to motion sickness'],\n",
       " 'DB00463': ['epilepsy'],\n",
       " 'DB00464': ['small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves'],\n",
       " 'DB00465': ['non-steroidal anti-inflammatory drug (nsaid) and has antipyretic, analgesic and anti-inflammatory properties',\n",
       "  'non-steroidal anti-inflammatory',\n",
       "  'antipyretic, analgesic and anti-inflammatory',\n",
       "  'short term acute pain that requires the caliber of pain management offered by opioids'],\n",
       " 'DB00466': ['respiratory distress'],\n",
       " 'DB00467': ['adults (amp'],\n",
       " 'DB00468': ['malaria and leg cramps'],\n",
       " 'DB00469': ['rheumatoid arthritis, osteoarthritis, backache, and pain'],\n",
       " 'DB00470': ['anorexia associated with weight loss in patients with aids, and nausea and vomiting associated with cancer chemotherapy'],\n",
       " 'DB00471': ['the maintenance treatment of chronic asthma',\n",
       "  'asthma or to decrease the necessary'],\n",
       " 'DB00472': ['both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa',\n",
       "  'panic disorder independent of whether agoraphobia is present',\n",
       "  'panic disorder independent of whether agoraphobia is present',\n",
       "  'depression related to bipolar i disorder, and treatment resistant depression'],\n",
       " 'DB00473': ['a local anesthetic for surface application, infiltration or nerve block'],\n",
       " 'DB00474': ['use as an intravenous anaesthetic',\n",
       "  'deep sedation',\n",
       "  'induce deep sedation'],\n",
       " 'DB00475': ['anxiety disorders or for the short-term relief of anxiety, withdrawal acute alcoholism, and preoperative apprehension and anxiety'],\n",
       " 'DB00476': [],\n",
       " 'DB00477': ['schizophrenia',\n",
       "  'nausea and vomiting',\n",
       "  'tetanus',\n",
       "  'the manifestations of the manic type of manic-depressive illness',\n",
       "  'severe behavioral problems'],\n",
       " 'DB00478': ['the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults'],\n",
       " 'DB00479': ['this drug',\n",
       "  'lung disease caused by a group of bacteria, mycobacterium avium complex (mac) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease)',\n",
       "  'lung disease caused by a group of bacteria, mycobacterium avium complex (mac) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease)',\n",
       "  'staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species failed to show sensitivity to other available antibiotics',\n",
       "  'initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing'],\n",
       " 'DB00480': ['multiple myeloma in combination with dexamethasone',\n",
       "  'multiple myeloma in combination with dexamethasone',\n",
       "  'patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities',\n",
       "  'patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (mds) associated with a deletion q cytogenetic abnormality with or without additional cytogenetic abnormalities'],\n",
       " 'DB00481': ['osteoporosis in postmenopausal women, and prevention and treatment of corticosteroid-induced bone loss',\n",
       "  'osteoporosis in postmenopausal women, and prevention and treatment of corticosteroid-induced bone loss',\n",
       "  'the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer'],\n",
       " 'DB00482': ['treatment of adult osteoarthritis (oa) and adult rheumatoid arthritis (ra)',\n",
       "  'acute pain from various sources, juvenile rheumatoid arthritis'],\n",
       " 'DB00483': ['use as adjuncts to anesthesia to induce skeletal muscle relaxation'],\n",
       " 'DB00484': ['open-angle glaucoma or ocular hypertension label as monotherapy or combination product with brinzolamide',\n",
       "  'persistent (non-transient) facial erythema of rosacea'],\n",
       " 'DB00485': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug'],\n",
       " 'DB00486': ['the nausea and vomiting associated with cancer chemotherapy'],\n",
       " 'DB00487': ['uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract'],\n",
       " 'DB00488': ['patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination'],\n",
       " 'DB00489': ['life threatening ventricular arrhytmias and maintain normal sinus rhythm atrial fibrillation or flutter',\n",
       "  'patients requiring drug, but for whom a tablet would not be appropriate'],\n",
       " 'DB00490': ['anxiety disorders or the short-term relief of anxiety',\n",
       "  'anxiety disorders or the short-term relief of anxiety'],\n",
       " 'DB00491': ['use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (niddm) whose hyperglycemia cannot be managed with diet alone'],\n",
       " 'DB00492': ['treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy'],\n",
       " 'DB00493': ['gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system',\n",
       "  'infection after surgery'],\n",
       " 'DB00494': ['patients with idiopathic parkinson\\'s disease who experience signs and end-of-dose \"wearing-off\"'],\n",
       " 'DB00495': ['human immunovirus (hiv) infections'],\n",
       " 'DB00496': ['overactive bladder with urge urinary incontinence, urgency and frequency'],\n",
       " 'DB00497': ['moderate to severe pain',\n",
       "  'moderate to severe pain',\n",
       "  'chronic moderate to severe pain requiring continuous opioid analgesics for an extended period'],\n",
       " 'DB00498': ['pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili',\n",
       "  'anticoagulant prophylaxis'],\n",
       " 'DB00499': ['locally confined stage b-c and stage d metastatic carcinoma of the prostate'],\n",
       " 'DB00500': ['juvenile rheumatoid arthritis'],\n",
       " 'DB00501': ['the treatment and acid-reflux disorders (gerd), peptic ulcer disease, heartburn, and acid indigestion'],\n",
       " 'DB00502': ['schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of tourettes disorder in children and adults, for severe behavior problems'],\n",
       " 'DB00503': ['hiv- infection'],\n",
       " 'DB00504': ['the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids'],\n",
       " 'DB00505': ['peptic ulcer disease and in acquired nystagmus'],\n",
       " 'DB00507': ['diarrhea',\n",
       "  'diarrhea',\n",
       "  'diarrhea caused by cryptosporidium parvum'],\n",
       " 'DB00508': ['psychoses',\n",
       "  'nausea and vomiting',\n",
       "  'control nausea and vomiting'],\n",
       " 'DB00509': ['lower high cholesterol levels in the blood'],\n",
       " 'DB00511': ['fast digitalization in congestive heart failure'],\n",
       " 'DB00512': ['serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci',\n",
       "  'clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains',\n",
       "  'clostridium difficile associated diarrhea and enterocolitis caused by _staphylococcus aureus_, including methicillin-resistant strains'],\n",
       " 'DB00513': ['excessive postoperative bleeding'],\n",
       " 'DB00514': ['coughs and upper respiratory symptoms associated with allergies or the common cold',\n",
       "  'a cough',\n",
       "  'combination with guaifenesin as an over the counter product to relieve a cough',\n",
       "  'pseudobulbar affect',\n",
       "  'pseudobulbar affect'],\n",
       " 'DB00515': ['metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer'],\n",
       " 'DB00516': ['or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac',\n",
       "  'prevent or reduce the severity of allergic contact dermatitis due to urushiol, the allergenic resin of poison ivy, poison oak, and poison sumac'],\n",
       " 'DB00517': ['use along with with antacids or histamine hlt',\n",
       "  'peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying'],\n",
       " 'DB00518': ['parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, lt',\n",
       "  'cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, lt'],\n",
       " 'DB00519': ['mild to moderate hypertension, as an adjunct for congestive heart failure (chf), to improve survival following myocardial infarction (mi)'],\n",
       " 'DB00520': ['esophageal candidiasis and invasive aspergillosis'],\n",
       " 'DB00521': ['intraocular hypertension and chronic open-angle glaucoma'],\n",
       " 'DB00522': [],\n",
       " 'DB00523': ['cutaneous lesions'],\n",
       " 'DB00524': ['hypertension, alone or in combination with other antihypertensive drugs of a different class'],\n",
       " 'DB00525': [\"skin infections such as athlete's foot, jock itch, and ringworm infections\",\n",
       "  'infections of the nails, scalp, palms, and soles of the feet',\n",
       "  \"athlete's foot\",\n",
       "  \"prevent athlete's foot\"],\n",
       " 'DB00526': ['advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients undergone complete resection of the primary tumor',\n",
       "  'advanced carcinoma of the colon or rectum and for adjuvant treatment of stage iii colon cancer patients undergone complete resection of the primary tumor'],\n",
       " 'DB00527': ['production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks'],\n",
       " 'DB00528': [\"hypertension, angina pectoris and raynaud's syndrome\"],\n",
       " 'DB00529': ['cmv retinitis'],\n",
       " 'DB00530': ['metastatic non-small cell lung cancer (nsclc) with tumors showing epidermal growth factor receptor (egfr) exon  deletions or exon  (r) substitution mutations',\n",
       "  'combination with platinum-based chemotherapy'],\n",
       " 'DB00531': ['malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast',\n",
       "  'malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast',\n",
       "  'biopsy-proven minimal change nephrotic syndrome'],\n",
       " 'DB00532': ['refractory partial epilepsy'],\n",
       " 'DB00533': ['osteoarthritis, rheumatoid arthritis, acute pain'],\n",
       " 'DB00534': ['a diuretic', 'a diagnostic and research tool'],\n",
       " 'DB00535': ['acute bacterial otitis media, acute maxillary sinusitis, community-acquired (ca) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections and adults'],\n",
       " 'DB00536': ['the reduction of muscle weakness and easy fatigability associated with the myasthenic syndrome of eaton-lambert',\n",
       "  'treating myasthenia gravis',\n",
       "  'myasthenia gravis'],\n",
       " 'DB00537': ['skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis',\n",
       "  'skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis',\n",
       "  'acute otitis externa',\n",
       "  'tympanostomy tubes or acute otitis externa',\n",
       "  'patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or patients  months or older with acute otitis externa',\n",
       "  'bacterial corneal ulcers and conjunctivitis',\n",
       "  'bacterial conjunctivitis',\n",
       "  'uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis'],\n",
       " 'DB00538': ['mri diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors'],\n",
       " 'DB00539': ['metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors'],\n",
       " 'DB00540': ['the relief of major depressive disorder (mdd)'],\n",
       " 'DB00541': ['relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all)',\n",
       "  'relapsed philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all)'],\n",
       " 'DB00542': ['hypertension', 'hypertension'],\n",
       " 'DB00543': ['the relief of depression in patients with neurotic or reactive depressive disorders and endogenous and psychotic depressions',\n",
       "  'depression accompanied by anxiety or agitation'],\n",
       " 'DB00544': ['multiple actinic or solar keratoses',\n",
       "  'superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites',\n",
       "  'some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid'],\n",
       " 'DB00545': ['myasthenia gravis'],\n",
       " 'DB00546': ['anxiety and status epilepticus'],\n",
       " 'DB00547': ['the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses'],\n",
       " 'DB00548': ['mild-to-moderate inflammatory acne vulgaris'],\n",
       " 'DB00549': ['the prophylaxis and chronic treatment of asthma'],\n",
       " 'DB00550': [\"manage hyperthyroidism which is due to an overactive thyroid gland (grave's disease)\"],\n",
       " 'DB00551': ['chronic urea-splitting urinary infections'],\n",
       " 'DB00552': ['hairy cell leukaemia refractory to alpha interferon'],\n",
       " 'DB00553': ['psoriasis and vitiligo'],\n",
       " 'DB00554': ['osteoarthritis and rheumatoid arthritis'],\n",
       " 'DB00555': ['the following seizure types',\n",
       "  'the process of conversion to drug monotherapy for those at least  years of age or older with partial seizures and currently  are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed)',\n",
       "  'acute mood episodes, as efficacy has not been established in this context'],\n",
       " 'DB00556': ['an ultrasound contrast imaging in cardiology and radiology'],\n",
       " 'DB00557': ['the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested',\n",
       "  'histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria',\n",
       "  'histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria',\n",
       "  'the control of nausea and vomiting, excluding nausea and vomiting of pregnancy'],\n",
       " 'DB00558': ['influenza a and b'],\n",
       " 'DB00559': ['pulmonary arterial hypertension (pah), to improve exercise ability',\n",
       "  'who class iii or iv symptoms)'],\n",
       " 'DB00560': ['infections caused by susceptible strains of the designated microorganisms in the following conditions: complicated skin and skin structure infections caused by lt'],\n",
       " 'DB00561': ['use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease'],\n",
       " 'DB00562': ['high blood pressure and edema'],\n",
       " 'DB00563': ['pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis',\n",
       "  'severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis',\n",
       "  \"gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-hodgkin's lymphoma\",\n",
       "  'the maintenance of acute lymphocytic leukemia'],\n",
       " 'DB00564': ['epilepsy and pain associated with true trigeminal neuralgia',\n",
       "  'epilepsy and pain associated with true trigeminal neuralgia',\n",
       "  'mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures',\n",
       "  'manic episodes and mixed manic-depressive episodes caused by bipolar i disorder',\n",
       "  'manic episodes and mixed manic-depressive episodes caused by bipolar i disorder'],\n",
       " 'DB00565': ['inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation,'],\n",
       " 'DB00566': ['lead poisoning', 'mercury or arsenic poisoning'],\n",
       " 'DB00567': ['certain infections caused by susceptible bacteria',\n",
       "  'certain infections caused by susceptible bacteria'],\n",
       " 'DB00568': [\"vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular other origins\"],\n",
       " 'DB00569': ['death and subsequent myocardial infarction (mi)',\n",
       "  'the sole anticoagulant during percutaneous coronary intervention (pci) due to an increased risk of guiding catheter thrombosis'],\n",
       " 'DB00570': [\"breast cancer, testicular cancer, lymphomas, neuroblastoma, hodgkin's and non-hodgkin's lymphomas, mycosis fungoides, histiocytosis, and kaposi's sarcoma\"],\n",
       " 'DB00571': ['hypertension',\n",
       "  'angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma'],\n",
       " 'DB00572': ['poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) and organophosphorous or carbamate insecticides'],\n",
       " 'DB00573': ['relief of signs and rheumatoid arthritis and osteoarthritis'],\n",
       " 'DB00574': ['seizures in dravet syndrome patients aged two years and older',\n",
       "  'seizures in dravet syndrome patients aged two years and older'],\n",
       " 'DB00575': ['hypertension alone or in combination with other medications',\n",
       "  'hypertension alone or in combination with other medications',\n",
       "  'use with opiates for severe cancer pain where opiates alone are insufficient',\n",
       "  'severe cancer pain where opiates alone are insufficient',\n",
       "  'adhd either alone or in combination with other medications',\n",
       "  'adhd either alone or in combination with other medications',\n",
       "  'the diagnosis of pheochromocytoma, treatment of nicotine dependance, and opiate withdrawal'],\n",
       " 'DB00576': ['urinary tract infection'],\n",
       " 'DB00577': [':'],\n",
       " 'DB00578': ['acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria'],\n",
       " 'DB00579': ['a body mass index of  kg of body weight per height in meters squared (kg/mlt',\n",
       "  'a body mass index of  kg/mlt'],\n",
       " 'DB00580': ['osteoarthritis and dysmenorrhoea'],\n",
       " 'DB00581': ['chronic constipation',\n",
       "  'portal-systemic encephalopathy (pse), including both the hepatic pre-coma and coma variations'],\n",
       " 'DB00582': ['esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by lt'],\n",
       " 'DB00583': ['primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of drug from dietary sources, or for secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria ii, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylcoa dehydrogenase deficiency',\n",
       "  'hyperlipoproteinemias',\n",
       "  'carnitine deficiency'],\n",
       " 'DB00584': ['essential or renovascular hypertension  as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect',\n",
       "  'essential or renovascular hypertension  as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect',\n",
       "  'symptomatic congestive heart failure, usually in combination with diuretics and digitalis',\n",
       "  'symptomatic congestive heart failure, usually in combination with diuretics and digitalis',\n",
       "  'asymptomatic left ventricular dysfunction'],\n",
       " 'DB00585': ['acid-reflux disorders (gerd), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer'],\n",
       " 'DB00586': ['use for pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, and injury-related inflammation due to surgery and physical trauma',\n",
       "  'pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, and injury-related inflammation due to surgery and physical trauma',\n",
       "  'high risk of developing nsaid-induced ulcers'],\n",
       " 'DB00587': ['protection against second- phase inflamation in exercise-induced bronchoconstriction and asthma'],\n",
       " 'DB00588': ['managing allergic and nonallergic rhinitis,'],\n",
       " 'DB00589': [\"parkinson's disease\"],\n",
       " 'DB00590': ['benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms',\n",
       "  'hypertension'],\n",
       " 'DB00591': ['the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis',\n",
       "  'seborrheic dermatitis of the scalp',\n",
       "  'chronic eczematous external otitis',\n",
       "  'diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure',\n",
       "  'diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure',\n",
       "  'chronic non-infectious uveitis affecting the posterior segment of the eye',\n",
       "  'chronic non-infectious uveitis affecting the posterior segment of the eye',\n",
       "  'first-degree hemorrhoids'],\n",
       " 'DB00592': ['alternative treatment for ascariasis caused by lt',\n",
       "  'partial intestinal obstruction by the common roundworm, a condition primarily occurring'],\n",
       " 'DB00593': ['petit mal epilepsy'],\n",
       " 'DB00594': ['use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension'],\n",
       " 'DB00595': ['infections caused by a variety of gram positive and gram negative microorganisms including lt',\n",
       "  'infections caused by a variety of gram positive and gram negative microorganisms including lt'],\n",
       " 'DB00596': ['inflammatory and pruritic corticosteroid responsive dermatoses',\n",
       "  'inflammatory and pruritic corticosteroid responsive dermatoses',\n",
       "  'plaque psoriasis',\n",
       "  'plaque psoriasis'],\n",
       " 'DB00597': ['a disruption of the normal blood brain barrier',\n",
       "  'contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced mri) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier',\n",
       "  'whole body contrast enhanced mri including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies'],\n",
       " 'DB00598': ['blood pressure in severe hypertension', 'blood pressure'],\n",
       " 'DB00599': ['use as the sole anesthetic agent for brief ( minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders'],\n",
       " 'DB00600': ['the loss of skin color (vitiligo)'],\n",
       " 'DB00601': ['bacterial infections caused by susceptible strains of vancomycin resistant lt'],\n",
       " 'DB00602': ['intestinal (i',\n",
       "  'onchocerciasis (river blindness) due to the nematode parasite lt',\n",
       "  'scabies caused by lt'],\n",
       " 'DB00603': ['secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women,',\n",
       "  'abnormal uterine bleeding due to hormonal imbalance, not organic pathology',\n",
       "  'postmenopausal osteoporosis',\n",
       "  'moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy',\n",
       "  'pregnancy and manage pain associated with endometriosis',\n",
       "  'pregnancy, and at higher concentrations for treatment of endometrial or renal carcinoma'],\n",
       " 'DB00604': ['patients with nocturnal heartburn due to gastroesophageal reflux disease'],\n",
       " 'DB00605': ['acute or long-term use in the relief of signs and osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis'],\n",
       " 'DB00606': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00607': ['infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug',\n",
       "  'infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug'],\n",
       " 'DB00608': ['infections of _p',\n",
       "  'extraintestinal amebiasis',\n",
       "  'rheumatic diseases, and treatment and prophylaxis of zika virus',\n",
       "  'covid-'],\n",
       " 'DB00609': ['pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed'],\n",
       " 'DB00610': ['the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage'],\n",
       " 'DB00611': ['the relief of moderate to severe pain'],\n",
       " 'DB00612': ['mild to moderate hypertension',\n",
       "  'mild to moderate hypertension',\n",
       "  'heart failure, atrial fibrillation, and angina pectoris'],\n",
       " 'DB00613': ['acute malarial attacks in non-immune subjects'],\n",
       " 'DB00614': ['the specific and treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms'],\n",
       " 'DB00615': ['the prevention of disseminated lt', 'advanced hiv infection'],\n",
       " 'DB00617': [],\n",
       " 'DB00618': ['lyme disease, acne, and bronchitis',\n",
       "  'urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia'],\n",
       " 'DB00619': ['philadelphia chromosome positive chronic myeloid leukemia (ph+ cml), ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (cel), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (gist)'],\n",
       " 'DB00620': ['intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques',\n",
       "  'inflammatory and pruritic manifestations of corticosteroid responsive dermatoses',\n",
       "  'inflammatory and pruritic manifestations of corticosteroid responsive dermatoses',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon',\n",
       "  'localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques',\n",
       "  'severe allergic conditions such as asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis, serum sickness, and transfusion reactions',\n",
       "  'sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions',\n",
       "  'sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions',\n",
       "  'visualization during vitrectomy',\n",
       "  'pain in osteoarthritis of the knee'],\n",
       " 'DB00621': ['weight gain after weight loss following extensive surgery'],\n",
       " 'DB00622': ['patients with chronic stable angina and for hypertension'],\n",
       " 'DB00623': ['manifestations of psychotic disorders'],\n",
       " 'DB00624': ['primary hypogonadism and hypogonadotropic hypogonadism'],\n",
       " 'DB00625': ['use in combination treatment of hiv infection (aids)'],\n",
       " 'DB00626': ['corticosteroid responsive dermatoses with secondary infection',\n",
       "  'corticosteroid responsive dermatoses with secondary infection'],\n",
       " 'DB00627': ['vitamin deficiencies in pediatric and patients receiving parenteral nutrition as part of multivitamin intravenous',\n",
       "  'primary hyperlipidemia and mixed dyslipidemia',\n",
       "  'a history of myocardial infarction and hyperlipidemia',\n",
       "  'coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia',\n",
       "  'severe hypertriglyceridemia'],\n",
       " 'DB00628': ['anxiety disorders or for the short-term relief of anxiety',\n",
       "  'partial seizures and for the symptomatic relief of acute alcohol withdrawal'],\n",
       " 'DB00629': ['high blood pressure'],\n",
       " 'DB00630': [\"the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and paget's disease of bone,\",\n",
       "  'use in pediatric populations or patients with a creatinine clearance lt',\n",
       "  'pediatric populations or patients with a creatinine clearance lt'],\n",
       " 'DB00631': ['patients  to  years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens'],\n",
       " 'DB00632': ['recurrent oral-facial herpes simplex episodes (cold sores or fever blisters)'],\n",
       " 'DB00633': ['sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief'],\n",
       " 'DB00634': ['bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis'],\n",
       " 'DB00635': [],\n",
       " 'DB00636': ['primary dysbetalipoproteinemia (type iii hyperlipidemia) that does not respond adequately to diet',\n",
       "  'high cholesterol and high triglyceride levels',\n",
       "  'to control high cholesterol and high triglyceride levels'],\n",
       " 'DB00637': ['use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis',\n",
       "  'the relieving allergy symptoms, particularly rhinitis and conjunctivitis'],\n",
       " 'DB00638': ['an important medical test of renal function, specifically a measure of glomerular filtration rate',\n",
       "  'help relieve diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia'],\n",
       " 'DB00639': ['the local treatment of vulvovaginal candidiasis (infections caused by candida)'],\n",
       " 'DB00640': ['an treatment for the termination of paroxysmal supraventricular tachycardia (pvst), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (svt)',\n",
       "  'for terminating stable, narrow-complex supraventricular tachycardias (svt)'],\n",
       " 'DB00641': ['hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg),',\n",
       "  'hyperlipidemia to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldlc), apolipoprotein b (apo b), and triglycerides (tg),',\n",
       "  'high-density lipoprotein cholesterol (hdl-c)',\n",
       "  'the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures',\n",
       "  'the risk of cardiovascular morbidity and mortality including myocardial'],\n",
       " 'DB00642': ['malignant pleural mesothelioma',\n",
       "  'locally advanced or metastatic non-small cell lung cancer (nsclc) after prior chemotherapy'],\n",
       " 'DB00643': ['lt'],\n",
       " 'DB00644': ['evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation'],\n",
       " 'DB00645': ['provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina',\n",
       "  'suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation',\n",
       "  'relief of canker sores, cold sores or fever blister'],\n",
       " 'DB00646': ['vulvovaginal candidiasis and other cutaneous candida infections',\n",
       "  'corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae',\n",
       "  'corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae',\n",
       "  'mixed infections due to _trichomonas vaginalis_ and _candida albicans_',\n",
       "  'invasive candidiasis in low birth weight neonates, though it is generally reserved as a second-line option after fluconazole'],\n",
       " 'DB00647': ['the relief of mild to moderate pain'],\n",
       " 'DB00648': ['inoperable adrenocortical tumours'],\n",
       " 'DB00649': ['human immunovirus (hiv) infections'],\n",
       " 'DB00650': ['osteosarcoma (after high dose methotrexate therapy)',\n",
       "  'diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists,',\n",
       "  'megaloblastic anemias due to folic acid deficiency',\n",
       "  'patients with advanced colorectal cancer'],\n",
       " 'DB00651': ['relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema'],\n",
       " 'DB00652': ['the relief of moderate to severe pain'],\n",
       " 'DB00653': ['severe toxemias (pre-eclampsia and eclampsia) of pregnancy and for acute nephritis',\n",
       "  'replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia',\n",
       "  'uterine tetany as a myometriat relaxant'],\n",
       " 'DB00654': ['elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty'],\n",
       " 'DB00655': ['perimenopausal and postmenopausal symptoms'],\n",
       " 'DB00656': ['major depressive disorder (mdd)',\n",
       "  'major depressive disorder (mdd)',\n",
       "  'anxiety and insomnia',\n",
       "  'dementia, alzheimers disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors'],\n",
       " 'DB00657': ['moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension'],\n",
       " 'DB00658': ['the control of serum phosphorus in patients with chronic kidney disease (ckd) on hemodialysis'],\n",
       " 'DB00659': ['the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation'],\n",
       " 'DB00660': ['painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes'],\n",
       " 'DB00661': ['vasopastic (i',\n",
       "  'vasopastic (i',\n",
       "  'hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate atrial fibrillation or atrial flutter',\n",
       "  'various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate'],\n",
       " 'DB00662': ['postoperative nausea and vomiting and for nausea associated with gastroenteritis'],\n",
       " 'DB00663': ['contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions'],\n",
       " 'DB00664': ['urinary tract infection and chronic bronchitis'],\n",
       " 'DB00665': ['metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (stage d)'],\n",
       " 'DB00666': ['central precocious puberty (true precocious puberty, gnrh-dependent precocious precocity, complete isosexual precocity)'],\n",
       " 'DB00668': ['a history of anaphylaxis',\n",
       "  'cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock',\n",
       "  'a hemostatic agent',\n",
       "  'mucosal congestion of hay fever, rhinitis, and acute sinusitis',\n",
       "  'treating mucosal congestion of hay fever, rhinitis, and acute sinusitis',\n",
       "  'bronchial asthmatic paroxysms',\n",
       "  'uterine contractions',\n",
       "  'an over the counter (otc) agent for the intermittent asthma, such as wheezing, tightness of chest and shortness of breath',\n",
       "  'the maintenance of mydriasis during intraocular surgery'],\n",
       " 'DB00669': ['migraines with or without auras',\n",
       "  'migraines with or without auras',\n",
       "  'cluster headaches'],\n",
       " 'DB00670': ['peptic ulcer, gastric ulcer, and duodenal ulcer'],\n",
       " 'DB00671': ['the following infections when caused by susceptible strains of the designated microorganisms: () uncomplicated urinary tract infections caused by lt'],\n",
       " 'DB00672': ['niddm along with with diet and exercise'],\n",
       " 'DB00673': ['the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents)'],\n",
       " 'DB00674': ['mild to moderate dementia of the alzheimers type',\n",
       "  'mild to moderate dementia of the alzheimers type'],\n",
       " 'DB00675': ['early stage estrogen receptor positive breast cancer'],\n",
       " 'DB00676': ['kill lice and the mites responsible for the skin condition scabies'],\n",
       " 'DB00677': ['use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia'],\n",
       " 'DB00678': ['hypertension in patients older than  years, reduce the risk of stroke hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage),',\n",
       "  'type  diabetes and hypertension',\n",
       "  'hypertension',\n",
       "  'hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with african heritage)'],\n",
       " 'DB00679': ['schizophrenia and generalized anxiety disorder'],\n",
       " 'DB00680': ['irregular heartbeats (arrhythmias) and maintain a normal heart rate'],\n",
       " 'DB00681': ['potentially life threatening fungal infections'],\n",
       " 'DB00682': ['mortality, recurrent myocardial infarction, and thromboembolic events post myocardial',\n",
       "  'rheumatic mitral valve disease but without atrial fibrillation'],\n",
       " 'DB00683': ['promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  'preoperative sedation, anxiolysis, anesthesia induction, or amnesia',\n",
       "  'status epilepticus',\n",
       "  'intermittent, stereotypic episodes of frequent seizure activity (i',\n",
       "  'intermittent, stereotypic episodes of frequent seizure activity (i',\n",
       "  'epilepsy'],\n",
       " 'DB00684': ['pseudomonas aeruginosa lung infections', 'sinus infections'],\n",
       " 'DB00685': ['infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by lt'],\n",
       " 'DB00686': ['the relief of bladder pain or discomfort associated with interstitial cystitis'],\n",
       " 'DB00687': ['salt-losing androgenital syndrome',\n",
       "  'salt-losing androgenital syndrome'],\n",
       " 'DB00688': [],\n",
       " 'DB00689': ['severe infections caused by susceptible bacteria'],\n",
       " 'DB00690': ['short-term and intermittent use in patients with recurring insomnia and poor sleeping habits'],\n",
       " 'DB00691': ['hypertension'],\n",
       " 'DB00692': ['or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor',\n",
       "  'an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor',\n",
       "  'hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs',\n",
       "  'mi associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin'],\n",
       " 'DB00693': ['diagnostic imaging'],\n",
       " 'DB00694': ['remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults'],\n",
       " 'DB00695': ['edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome,',\n",
       "  'mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications'],\n",
       " 'DB00696': ['use as therapy to abort or prevent vascular headache, e'],\n",
       " 'DB00697': ['the relief of muscle spasticity, which can interfere with daily activities'],\n",
       " 'DB00698': ['acute uncomplicated urinary tract infections'],\n",
       " 'DB00699': ['senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration'],\n",
       " 'DB00700': ['improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction lt'],\n",
       " 'DB00701': ['hiv- infection in combination with other antiretroviral agents'],\n",
       " 'DB00702': ['end-stage renal disease'],\n",
       " 'DB00703': ['chronic open-angle glaucoma and acute angle-closure glaucoma'],\n",
       " 'DB00704': ['alcohol dependence along with with a behavioural modification program'],\n",
       " 'DB00705': ['hiv- infection in combination with appropriate antiretroviral agents when therapy is warranted'],\n",
       " 'DB00706': ['signs and benign prostatic hyperplasia',\n",
       "  'signs and benign prostatic hyperplasia',\n",
       "  'ureteral stones, prostatitis, and female voiding dysfunction'],\n",
       " 'DB00707': ['esophageal cancer', 'esophageal cancer'],\n",
       " 'DB00708': ['acute pain'],\n",
       " 'DB00709': ['hiv infection and chronic hepatitis b (hbv)'],\n",
       " 'DB00710': ['the treatment and prevention of osteoporosis in postmenopausal women'],\n",
       " 'DB00711': ['certain filarial diseases, including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with lt'],\n",
       " 'DB00712': ['the acute or long-term treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis',\n",
       "  'pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e',\n",
       "  'intraoperative miosis'],\n",
       " 'DB00713': ['resistant staphylococci infections'],\n",
       " 'DB00714': [\"acute, intermittent treatment of hypomobility, off episodes associated with advanced parkinson's disease\"],\n",
       " 'DB00715': ['depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder',\n",
       "  'depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder',\n",
       "  'manage mild to moderate vasomotor menopause',\n",
       "  'premature ejaculation or irritable bowel syndrome (ibs)'],\n",
       " 'DB00716': ['mild to moderate asthma'],\n",
       " 'DB00717': ['postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause',\n",
       "  'hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms',\n",
       "  'hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms',\n",
       "  'endometriosis-related pain',\n",
       "  'endometriosis-related pain'],\n",
       " 'DB00718': ['chronic hepatitis b',\n",
       "  'hbeag+ and hbeag- chronic hepatitis b with compensated liver function, and in patients with clinical evidence of lamivudine-resistant hepatitis b virus with either compensated or decompensated liver function'],\n",
       " 'DB00719': ['the relief of upper respiratory mucosal congestion in perennial and allergic rhinitis, and for the relief of nasal congestion and eustachian t'],\n",
       " 'DB00720': ['osteolysis from bone metastases of malignant tumors and for hypercalcemia of malignancy'],\n",
       " 'DB00721': ['a local anesthetic primarily in oral surgery'],\n",
       " 'DB00722': ['acute myocardial infarction, hypertension',\n",
       "  'hypertension',\n",
       "  'hypertension'],\n",
       " 'DB00723': ['the treatment and hypotension'],\n",
       " 'DB00724': ['clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults',\n",
       "  'external genital and perianal warts/condyloma acuminata'],\n",
       " 'DB00725': ['peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying'],\n",
       " 'DB00726': ['depression and depression accompanied by anxiety, agitation or sleep disturbance'],\n",
       " 'DB00727': ['various purposes',\n",
       "  'and treat angina or chest pain due to cardiovascular disease,',\n",
       "  'peri-operative hypertension or induce intra-operative hypotension',\n",
       "  'acute heart failure myocardial infarction',\n",
       "  'pain caused by anal fissures',\n",
       "  'acute anginal attacks',\n",
       "  'acute coronary spasm caused by cocaine, hypertensive emergencies, and acute congestive heart failure exacerbations'],\n",
       " 'DB00728': ['inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation,'],\n",
       " 'DB00730': ['strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis'],\n",
       " 'DB00731': ['non-insulin dependent-diabetes mellitus along with with diet and exercise'],\n",
       " 'DB00732': ['use, as an adjunct to general anesthesia, to facilitate endotracheal intubation'],\n",
       " 'DB00733': ['poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used for myasthenia gravis'],\n",
       " 'DB00734': ['schizophrenia and irritability associated with autistic disorder',\n",
       "  'schizophrenia and irritability associated with autistic disorder',\n",
       "  'acute mania or mixed episodes associated with bipolar i disorder',\n",
       "  'severe dementia of the alzheimer type unresponsive to nonpharmacological approaches'],\n",
       " 'DB00735': ['tinea pedis, tinea cruris, and tinea corporis caused by the organisms lt'],\n",
       " 'DB00736': ['acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h',\n",
       "  'acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (gerd), peptic ulcer disease, h'],\n",
       " 'DB00737': ['nausea, vomiting, and dizziness associated with motion sickness, and vertigo due to various causes, including radiation sickness, menieres syndrome, labyrinthitis and other vestibular disturbances',\n",
       "  'nausea, vomiting, and dizziness associated with motion sickness, and vertigo due to various causes, including radiation sickness, menieres syndrome, labyrinthitis and other vestibular disturbances'],\n",
       " 'DB00738': ['pneumonia due to lt'],\n",
       " 'DB00739': ['bacterial infections'],\n",
       " 'DB00740': [\"amyotrophic lateral sclerosis (als, lou gehrig's disease)\"],\n",
       " 'DB00741': ['infections of the external auditory canal caused by susceptible organisms and with inflammation',\n",
       "  'certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions',\n",
       "  'ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores',\n",
       "  'cold sores'],\n",
       " 'DB00742': ['the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, cerebral edema, and the promotion of urinary excretion of toxic substances'],\n",
       " 'DB00743': [],\n",
       " 'DB00744': ['the prophylaxis and chronic treatment of asthma in adults and children'],\n",
       " 'DB00745': ['excessive daytime sleepiness (eds) associated with narcolepsy'],\n",
       " 'DB00746': ['anemia who must receive many blood transfusions'],\n",
       " 'DB00747': ['excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness'],\n",
       " 'DB00748': ['symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, and allergic conjunctivitis caused by foods and inhaled allergens'],\n",
       " 'DB00749': ['pain'],\n",
       " 'DB00750': ['a local anaesthetic and is often used in dentistry',\n",
       "  'dentistry'],\n",
       " 'DB00751': ['the prevention of itching associated with allergic conjunctivitis'],\n",
       " 'DB00752': ['major depressive episode without melancholia'],\n",
       " 'DB00753': ['induction and maintenance of general anesthesia'],\n",
       " 'DB00754': ['the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures'],\n",
       " 'DB00755': ['the the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m (including the m variant)',\n",
       "  \"acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (darier's disease), and basal cell carcinomas\",\n",
       "  'fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage'],\n",
       " 'DB00756': ['use as a surgical scrub and a bacteriostatic skin cleanser',\n",
       "  'an outbreak of gram-positive infection where other',\n",
       "  'control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful'],\n",
       " 'DB00757': ['the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting'],\n",
       " 'DB00758': ['the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and in recent mi, stroke, or established peripheral arterial disease,',\n",
       "  'the risk of myocardial infarction for patients with non-st elevated acute coronary syndrome (acs), patients with st-elevated myocardial infarction, and'],\n",
       " 'DB00759': ['bacterial infections such as rocky mountain spotted fever, typhus fever, tick fevers, q fever, rickettsialpox and brill-zinsser disease',\n",
       "  'infections caused by chlamydiae spp',\n",
       "  'acne'],\n",
       " 'DB00760': ['the following infections when caused by susceptible isolates of the designated microorganisms: lt',\n",
       "  'bacterial meningitis caused by lt'],\n",
       " 'DB00761': ['hypokalemia'],\n",
       " 'DB00762': ['metastatic colorectal cancer (first-line therapy when administered with -fluorouracil and leucovorin)',\n",
       "  'extensive small cell lung cancer',\n",
       "  'metastatic or recurrent cervical cancer',\n",
       "  'patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy'],\n",
       " 'DB00763': ['hyperthyroidism',\n",
       "  'the amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy',\n",
       "  'the medical treatment of hyperthyroidism regardless of other available treatment options'],\n",
       " 'DB00764': ['the maintenance treatment of asthma as prophylactic therapy',\n",
       "  'the nasal seasonal allergic and perennial allergic rhinitis',\n",
       "  'the nasal seasonal allergic and perennial allergic rhinitis'],\n",
       " 'DB00765': ['patients with pheochromocytoma, for preoperative preparation of patients for surgery, patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma'],\n",
       " 'DB00766': ['their therapeutic antibacterial effects',\n",
       "  'the development of drug-resistant strains of bacteria and promotes their therapeutic antibacterial effects',\n",
       "  'selecting whether this antibiotic is prescribed',\n",
       "  'determine the appropriateness of using drug',\n",
       "  'infections where a regimen of several drugs may normally be used'],\n",
       " 'DB00767': ['and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or',\n",
       "  'prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously'],\n",
       " 'DB00768': ['ocular itching associated with allergic conjunctivitis as ophthalmic solution',\n",
       "  'ocular itching associated with allergic conjunctivitis as ophthalmic solution'],\n",
       " 'DB00769': ['steroid-responsive dermatoses'],\n",
       " 'DB00770': ['palliative, not definitive, therapy to maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates congenital heart defects and who depend upon the patent ductus for survival',\n",
       "  'erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology'],\n",
       " 'DB00771': ['peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome'],\n",
       " 'DB00772': ['patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair'],\n",
       " 'DB00773': ['refractory testicular tumors and as first line treatment',\n",
       "  'other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme'],\n",
       " 'DB00774': ['hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00775': ['the treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy'],\n",
       " 'DB00776': ['partial-onset seizures in patients , and  for partial-onset seizures',\n",
       "  'partial-onset seizures'],\n",
       " 'DB00777': ['insomnia',\n",
       "  'its antihistamininc sleep inducing effects in treating insomnia'],\n",
       " 'DB00778': ['respiratory tract, urinary and soft tissue infections'],\n",
       " 'DB00779': ['urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of lt'],\n",
       " 'DB00780': ['nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy',\n",
       "  'nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy',\n",
       "  'bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior',\n",
       "  'secondary condition to major personality disorder, neuroses and'],\n",
       " 'DB00782': ['enuresis',\n",
       "  'hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder'],\n",
       " 'DB00783': ['moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,',\n",
       "  'postmenopausal osteoporosis',\n",
       "  'breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for androgen-dependent prostate cancer (only for palliation therapy)',\n",
       "  'combination with other hormones as a component of oral contraceptive pills for preventing pregnancy (most commonly as db, a synthetic form of drug)',\n",
       "  \"menopausal symptoms changed drastically following the release of results and early termination of the women's health initiative (whi) studies in  as concerns were raised regarding estrogen use\",\n",
       "  'an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer over the long-term'],\n",
       " 'DB00784': ['rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever'],\n",
       " 'DB00785': ['hypertension'],\n",
       " 'DB00786': ['various cancers'],\n",
       " 'DB00787': ['recurrent herpes labialis in immunocompetent patients  years and older',\n",
       "  'herpes zoster, genital herpes, and chickenpox',\n",
       "  'initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients',\n",
       "  'recurrent herpes labialis, and shortening lesion healing time  years and older',\n",
       "  'recurrent herpes labialis',\n",
       "  'recurrent herpes labialis',\n",
       "  'acute herpetic keratitis'],\n",
       " 'DB00788': ['rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain',\n",
       "  'rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain'],\n",
       " 'DB00789': ['use with magnetic resonance imaging (mri) in adults, and patients () to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues and lesions with abnormal vascularity in the head and neck',\n",
       "  'facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart)'],\n",
       " 'DB00790': ['mild to moderate essential hypertension, mild to moderate congestive heart failure,',\n",
       "  'the cardiovascular risk of patients with hypertension or post-myocardial'],\n",
       " 'DB00791': ['its antineoplastic properties'],\n",
       " 'DB00792': ['the symptomatic relief of hypersensitivity reactions, coughs, and the common cold'],\n",
       " 'DB00793': [\"fungal (tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor\"],\n",
       " 'DB00794': ['grand mal, psychomotor, and focal epileptic seizures',\n",
       "  'grand mal, psychomotor, and focal epileptic seizures'],\n",
       " 'DB00795': [\"crohn's disease and rheumatoid arthritis as a second-line agent\"],\n",
       " 'DB00796': ['uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy',\n",
       "  'a first line agent to delay progression of diabetic nephropathy',\n",
       "  'congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace inhibitors'],\n",
       " 'DB00797': ['pulmonary artery anomalies'],\n",
       " 'DB00798': ['serious infections caused by susceptible strains of the following microorganisms: lt'],\n",
       " 'DB00799': ['psoriasis, acne and sun damaged skin (photodamage)'],\n",
       " 'DB00800': ['the in-hospital, short-term (up to  hours) severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function'],\n",
       " 'DB00801': ['anxiety, nervousness, and tension associated with anxiety disorders',\n",
       "  'relieve anxiety, nervousness, and tension associated with anxiety disorders'],\n",
       " 'DB00802': ['postoperative pain and the maintenance of general anesthesia'],\n",
       " 'DB00803': ['acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly lt'],\n",
       " 'DB00804': ['functional bowel disorder and irritable bowel syndrome',\n",
       "  'functional bowel disorder and irritable bowel syndrome'],\n",
       " 'DB00805': ['depression'],\n",
       " 'DB00806': ['patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs'],\n",
       " 'DB00807': ['a local (ophthalmic) anesthetic'],\n",
       " 'DB00808': ['use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension',\n",
       "  'hypertension',\n",
       "  'fluid and salt retention associated with congestive heart failure'],\n",
       " 'DB00809': ['mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye'],\n",
       " 'DB00810': ['use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy'],\n",
       " 'DB00811': ['chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr)',\n",
       "  'chronic hepatitis c virus (hcv) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (svr)',\n",
       "  'svr and reduce relapse rates',\n",
       "  'or without cirrhosis'],\n",
       " 'DB00812': ['backache and ankylosing spondylitis'],\n",
       " 'DB00813': ['short term analgesia during induction, maintenance, and recovery from general or regional anesthesia',\n",
       "  'breakthrough pain in opioid tolerant cancer patients who require around the clock pain management',\n",
       "  'breakthrough pain in opioid tolerant cancer patients who require around the clock pain management'],\n",
       " 'DB00814': ['arthritis and osteoarthritis',\n",
       "  'arthritis and osteoarthritis',\n",
       "  'neuropathic pain'],\n",
       " 'DB00815': ['a surfactant in shampoos', 'this use', 'microbicidal'],\n",
       " 'DB00816': ['bronchospasm, chronic bronchitis, asthma, and emphysema'],\n",
       " 'DB00817': ['bacterial infection of respiratory tract, urinary tract, gi, cns and immuno compromised patients'],\n",
       " 'DB00818': ['refractory status epilepticus'],\n",
       " 'DB00819': ['adjunctive treatment of: edema due to congestive heart failure'],\n",
       " 'DB00820': ['erectile dysfunction'],\n",
       " 'DB00821': ['joint pain and post-surgical pain'],\n",
       " 'DB00822': ['the treatment and chronic alcoholism'],\n",
       " 'DB00823': ['the prevention of pregnancy in women who elect to use this product as a method of contraception'],\n",
       " 'DB00824': ['asthma',\n",
       "  'peripheral vascular diseases and in cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy'],\n",
       " 'DB00825': ['occasional minor irritation, pain, sore mouth, and sore throat and cough associated with a cold or inhaled irritants'],\n",
       " 'DB00826': ['fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including lt'],\n",
       " 'DB00827': ['initial and recurrent urinary tract infections'],\n",
       " 'DB00828': ['uncomplicated urinary tract infections (acute cystitis)'],\n",
       " 'DB00829': ['useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma'],\n",
       " 'DB00830': ['obesity'],\n",
       " 'DB00831': ['anxiety disorders, depressive symptoms secondary to anxiety and agitation'],\n",
       " 'DB00832': ['epilepsy'],\n",
       " 'DB00833': ['certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections'],\n",
       " 'DB00834': [\"the medical termination of intrauterine pregnancy through  days' pregnancy\",\n",
       "  \"hyperglycemia secondary to hypercortisolism endogenous cushing's syndrome type  diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery\"],\n",
       " 'DB00835': ['the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing'],\n",
       " 'DB00836': ['the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis',\n",
       "  'the volume of discharge from ileostomies',\n",
       "  'reducing the volume of discharge from ileostomies'],\n",
       " 'DB00837': ['epilepsy', 'epilepsy'],\n",
       " 'DB00838': ['short-term treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp'],\n",
       " 'DB00839': ['use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (type ii) whose hyperglycemia cannot be satisfactorily controlled by diet alone'],\n",
       " 'DB00840': ['dryness and irritation caused by reduced tear flow that occurs',\n",
       "  'relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes'],\n",
       " 'DB00841': [],\n",
       " 'DB00842': ['anxiety disorders and for the short-term relief of anxiety',\n",
       "  'anxiety disorders and for the short-term relief of anxiety',\n",
       "  'alcohol withdrawal symptoms'],\n",
       " 'DB00843': ['mild to moderate alzheimers disease at doses of  mg or  mg',\n",
       "  'mild to moderate alzheimers disease at doses of  mg or  mg',\n",
       "  'moderate to severe alzheimers disease in a higher dose of  mg or  mg administered once daily',\n",
       "  'moderate to severe alzheimers disease in a higher dose of  mg or  mg administered once daily',\n",
       "  'moderate to severe dementia'],\n",
       " 'DB00844': ['the relief of moderate to severe pain'],\n",
       " 'DB00845': ['lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum',\n",
       "  'lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum',\n",
       "  'the development of drug resistance, it should be used only'],\n",
       " 'DB00846': ['relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions'],\n",
       " 'DB00847': ['corneal cystine crystal accumulation'],\n",
       " 'DB00848': [\"adjuvant treatment in combination with fluorouracil after surgical resection in patients with dukes' stage c colon cancer\",\n",
       "  'malignant melanoma and head/neck cancer'],\n",
       " 'DB00849': ['epilepsy'],\n",
       " 'DB00850': ['use in the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults'],\n",
       " 'DB00851': ['metastatic malignant melanoma',\n",
       "  \"hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents\",\n",
       "  'combination with other antineoplastic agents'],\n",
       " 'DB00852': ['its decongestant activity',\n",
       "  'sympathomimetic amine used for its decongestant activity'],\n",
       " 'DB00853': ['patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, and concomitantly with radiation therapy for newly diagnosed glioblastoma multiforme',\n",
       "  'maintenance therapy for glioblastoma multiforme'],\n",
       " 'DB00854': ['moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate'],\n",
       " 'DB00855': ['minimally to moderately thick actinic keratoses of the face or scalp',\n",
       "  'minimally to moderately thick actinic keratoses of the face or scalp'],\n",
       " 'DB00856': ['injuries and other painful muscular conditions',\n",
       "  'trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain'],\n",
       " 'DB00857': ['fungal skin and nail infections caused by _trichophyton_ species, _microsporum canis_, _epidermophyton floccosum_, and _tinea_ species'],\n",
       " 'DB00859': [\"wilson's disease, cystinuria and active rheumatoid arthritis\"],\n",
       " 'DB00860': ['endocrine, rheumatic, and hematologic disorders'],\n",
       " 'DB00861': ['treatment of mild to moderate pain accompanied by inflammation (e'],\n",
       " 'DB00862': ['erectile dysfunction'],\n",
       " 'DB00863': ['the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose',\n",
       "  'gerd symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing'],\n",
       " 'DB00864': [\"use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection\",\n",
       "  'liver transplantation',\n",
       "  'severe atopic dermatitis'],\n",
       " 'DB00865': ['exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction'],\n",
       " 'DB00866': ['hypertension, angina, and arrhythmia'],\n",
       " 'DB00867': ['the treatment and prophylaxis of premature labour'],\n",
       " 'DB00868': ['the symptomatic relief of cough'],\n",
       " 'DB00869': ['elevated intraocular pressure', 'elevated'],\n",
       " 'DB00870': ['the miosis (pupil constriction) that may occur during ocular surgery',\n",
       "  'eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery'],\n",
       " 'DB00871': ['the prevention and reversal of bronchospasm in patients  with reversible, obstructive airway disease, and symptomatic reversible bronchospasm associated with bronchitis and emphysema',\n",
       "  'uterine contractions'],\n",
       " 'DB00872': ['euvolemic or hypervolemic hyponatremia (e'],\n",
       " 'DB14596': ['post-operative inflammation and pain following ocular surgery',\n",
       "  'post-operative inflammation and pain following ocular surgery'],\n",
       " 'DB00874': ['providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses fda label, ,'],\n",
       " 'DB00875': ['schizophrenia and depression'],\n",
       " 'DB00876': ['hypertension alone or in combination with other classes of antihypertensive agents',\n",
       "  'diabetic nephropathy, and a second-line agent for congestive heart failure (only in those intolerant of ace inhibitors)'],\n",
       " 'DB00877': ['the prophylaxis of organ rejection in patients receiving renal transplants'],\n",
       " 'DB00878': ['gingivitis and a slow-release \"chip\" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth'],\n",
       " 'DB00879': ['hiv- infections'],\n",
       " 'DB00880': ['hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension'],\n",
       " 'DB00881': ['hypertension and as an adjunct therapy for heart failure',\n",
       "  'hypertension and as an adjunct therapy for heart failure',\n",
       "  'hypertension',\n",
       "  'hypertension'],\n",
       " 'DB00882': ['ovulation'],\n",
       " 'DB00883': ['the prevention of angina pectoris due to coronary artery disease'],\n",
       " 'DB00884': [\"osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis\",\n",
       "  \"osteoperosis in men, treatment of paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis\"],\n",
       " 'DB00885': ['the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis'],\n",
       " 'DB00886': ['hypertension'],\n",
       " 'DB00887': ['edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome'],\n",
       " 'DB00888': [\"hodgkin's disease (stages iii and iv), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma\",\n",
       "  'metastatic carcinoma resulting in effusion'],\n",
       " 'DB00889': ['the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation)'],\n",
       " 'DB00890': ['atrophic vaginitis and kraurosis vulvae'],\n",
       " 'DB00891': ['dermatitis herpetiformis, benign mucous membrane pemphigoid and pyoderma gangrenosum'],\n",
       " 'DB00892': ['numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed'],\n",
       " 'DB00893': ['patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible',\n",
       "  'replenish body iron stores in non-dialysis dependent-chronic kidney disease (ndd-ckd) patients receiving or not receiving erythropoietin and in hemodialysis dependent (hdd-ckd) and peritoneal dialysis dependent (pdd-ckd) - chronic kidney disease patients receiving an erythropoietin'],\n",
       " 'DB00894': ['treatment of advanced breast cancer in postmenopausal women'],\n",
       " 'DB00895': ['use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin g)'],\n",
       " 'DB00896': ['postoperative inflammation following ocular surgery and for anterior uveitis'],\n",
       " 'DB00897': ['the short-term treatment of insomnia'],\n",
       " 'DB00898': ['therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated'],\n",
       " 'DB00899': ['use during the induction and maintenance of general anesthesia'],\n",
       " 'DB00900': ['hiv- infection'],\n",
       " 'DB00901': ['dilate air passages in the lungs that have become narrowed as a result of disease or inflammation',\n",
       "  'asthma and chronic obstructive pulmonary disease (copd)'],\n",
       " 'DB00902': ['the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders'],\n",
       " 'DB00903': ['high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure'],\n",
       " 'DB00904': ['postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'post-chemotherapy induced nausea and vomiting,',\n",
       "  'children  years of age or younger,',\n",
       "  'children  years of age or younger,',\n",
       "  'use in any age group of the pediatric population for post-radiotherapy induced nausea and vomiting, and',\n",
       "  'post-radiotherapy induced nausea and vomiting, and',\n",
       "  'use in any age group of the pediatric population for postoperative nausea and vomiting',\n",
       "  'postoperative nausea and vomiting',\n",
       "  'post-chemotherapy and radiotherapy-induced nausea and vomiting, and',\n",
       "  'use in the geriatric patient population',\n",
       "  'postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population'],\n",
       " 'DB00905': ['open-angle glaucoma or ocular hypertension',\n",
       "  'eyelash hypotrichosis'],\n",
       " 'DB00906': ['partial seizures'],\n",
       " 'DB00907': ['the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities'],\n",
       " 'DB00908': ['ventricular pre-excitation and cardiac dysrhythmias'],\n",
       " 'DB00909': ['use as adjunctive treatment of partial seizures in adults with epilepsy'],\n",
       " 'DB00910': ['secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage  and'],\n",
       " 'DB00911': ['trichomoniasis caused by lt',\n",
       "  'giardiasis caused by lt',\n",
       "  'intestinal amebiasis and amebic liver abscess caused by lt'],\n",
       " 'DB00912': ['type  diabetes mellitus'],\n",
       " 'DB00913': ['the treatment and pain (systemic) and for use as an anesthesia adjunct'],\n",
       " 'DB00914': ['the reatment of type ii diabetes mellitus'],\n",
       " 'DB00915': ['the chemoprophylaxis, prophylaxis, and treatment of signs and infection caused by various strains of influenza a virus',\n",
       "  'parkinsonism and drug-induced extrapyramidal reactions'],\n",
       " 'DB00916': [\"confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections\",\n",
       "  \"confirmed trichomoniasis caused by trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis, certain types of amebiasis, and various anaerobic infections\",\n",
       "  \"crohn's disease and rosacea, as a prophylactic agent after surgery, and for helicobacter pylori infection\",\n",
       "  'preterm births',\n",
       "  'periodontal disease'],\n",
       " 'DB00917': ['the termination of pregnancy during the second trimester (from the th through the th gestational week as calculated from the first day of the last normal menstrual period), and for evacuation of the uterine contents in missed abortion or intrauterine fetal death up to  weeks of gestational age as calculated from the first day of the last normal menstrual period',\n",
       "  'nonmetastatic gestational trophoblastic disease (benign hydatidiform mole)'],\n",
       " 'DB00918': ['acute migraine headache'],\n",
       " 'DB00919': ['acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of lt'],\n",
       " 'DB00920': ['self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic)'],\n",
       " 'DB00921': ['pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate',\n",
       "  'pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate',\n",
       "  'moderate to severe opioid use disorder'],\n",
       " 'DB00922': ['short term treatment of acutely decompensated severe chronic heart failure (chf)',\n",
       "  'heart disease'],\n",
       " 'DB00923': ['infections caused by susceptible organisms'],\n",
       " 'DB00924': ['spasticity originating from cerebral or spinal cord disease, or spasticity',\n",
       "  'fibromyalgia'],\n",
       " 'DB00925': ['phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension'],\n",
       " 'DB00926': ['severe psoriasis'],\n",
       " 'DB00927': ['active duodenal ulcer (du), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (gerd), and erosive esophagitis due to gerd, diagnosed by biopsy',\n",
       "  'pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication'],\n",
       " 'DB00928': ['patients with the following french-american-british myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia'],\n",
       " 'DB00929': ['the risk of nsaid induced gastric ulcers but not duodenal ulcers',\n",
       "  'a high risk of developing gastric ulcers',\n",
       "  'miscarriages, prevention of post partum hemorrhage, and is used alone or in combination with mifepristone in other countries for first trimester abortions'],\n",
       " 'DB00930': ['use, alone or in combination with an hmg-coa reductase inhibitor,  to diet and exercise for the reduction of elevated ldl cholesterol in patients with primary hypercholesterolemia (fredrickson type iia)'],\n",
       " 'DB00931': ['acute bacterial exacerbations of chronic bronchitis'],\n",
       " 'DB00932': ['combination antiretroviral treatment of hiv- infected patients with evidence of viral replication, who are highly treatment-experienced or have hiv- strains resistant to multiple protease inhibitors'],\n",
       " 'DB00933': ['schizophrenia, organic brain disorders, alcoholism and psychoneuroses'],\n",
       " 'DB00934': [],\n",
       " 'DB00935': ['persistent facial erythema associated with rosacea',\n",
       "  'acquired blepharoptosis',\n",
       "  'regional anesthesia when performing a restorative procedure on teeth - and a-j'],\n",
       " 'DB00936': ['acne, psoriasis, callouses, corns, keratosis pilaris and warts'],\n",
       " 'DB00937': ['exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction'],\n",
       " 'DB00938': ['asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease',\n",
       "  'asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease'],\n",
       " 'DB00939': ['primary dysmenorrhea and for idiopathic heavy menstrual blood loss'],\n",
       " 'DB00940': ['peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder'],\n",
       " 'DB00941': ['an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation',\n",
       "  'succinylcholine-induced muscle fasciculations'],\n",
       " 'DB00942': [\"the treatment and parkinson's disease\"],\n",
       " 'DB00943': ['human immunovirus (hiv) infections along with with other antivirals'],\n",
       " 'DB00944': ['chronic open-angle glaucoma'],\n",
       " 'DB00945': ['pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries',\n",
       "  'pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various',\n",
       "  'symptomatic pain relief after surgical and dental procedures',\n",
       "  'the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)',\n",
       "  'various other purposes, due to its ability to inhibit platelet aggregation',\n",
       "  'platelet aggregation',\n",
       "  'the risk of transient ischemic attacks (tia)',\n",
       "  'atherothrombotic cerebral',\n",
       "  'thromboembolism after hip replacement surgery',\n",
       "  'transient ischemic attacks (tia)',\n",
       "  'thrombosis at the',\n",
       "  'patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site',\n",
       "  'the incidence of mortality and myocardial infarction (mi) for patients diagnosed with chronic coronary artery disease (cad), including patients with previous myocardial',\n",
       "  'a history of stroke or tia'],\n",
       " 'DB00946': ['thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism',\n",
       "  'ischemic stroke'],\n",
       " 'DB00947': ['hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents'],\n",
       " 'DB00948': ['serious gramamp'],\n",
       " 'DB00949': ['use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use'],\n",
       " 'DB00950': ['allergic rhinitis in patients  years old and chronic idiopathic urticaria',\n",
       "  'season allergic rhinitis'],\n",
       " 'DB00951': ['all forms of tuberculosis in which organisms are susceptible'],\n",
       " 'DB00952': ['migraine attacks with or without aura'],\n",
       " 'DB00953': ['acute migraine attacks with or without aura'],\n",
       " 'DB00954': ['the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections'],\n",
       " 'DB00955': ['bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains'],\n",
       " 'DB00956': ['acute pain, sometimes in combination with acetaminophen or ibuprofen, and the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants',\n",
       "  'acute pain, sometimes in combination with acetaminophen or ibuprofen, and the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants'],\n",
       " 'DB00957': [],\n",
       " 'DB00958': ['advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents',\n",
       "  'patients with ovarian carcinoma recurrent after prior chemotherapy, including patients been previously treated with cisplatin',\n",
       "  'patients with ovarian carcinoma recurrent after prior chemotherapy, including patients been previously treated with cisplatin'],\n",
       " 'DB00959': ['a number of endocrine,  rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders',\n",
       "  'short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis',\n",
       "  'alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare'],\n",
       " 'DB00960': ['hypertension, edema, ventricular tachycardias, and atrial fibrillation'],\n",
       " 'DB00961': ['production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks'],\n",
       " 'DB00962': ['short-term treatment of insomnia'],\n",
       " 'DB00963': ['postoperative inflammation'],\n",
       " 'DB00964': ['prevention or reduction of intraoperative and postoperative increases in intraocular pressure (iop) before and after ocular laser surgery when used prophylactically',\n",
       "  'open-angle glaucoma who are on maximally tolerated medical therapy requiring additional iop reduction'],\n",
       " 'DB00965': ['use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is -i',\n",
       "  'follow-up imaging for chemoembolization'],\n",
       " 'DB00966': ['hypertension',\n",
       "  'diabetic nephropathy in hypertensive patients with type  diabetes mellitus, and congestive heart failure (only'],\n",
       " 'DB00967': ['the relief of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis',\n",
       "  'the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria'],\n",
       " 'DB00968': ['hypertension'],\n",
       " 'DB00969': ['severe diarrhea-predominant irritable bowel syndrome (ibs)'],\n",
       " 'DB00970': [\"wilms' tumor, childhood rhabdomyosarcoma, ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen\"],\n",
       " 'DB00971': ['tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp'],\n",
       " 'DB00972': ['seasonal allergic rhinitis in patients  years and older and for vasomotor rhinitis',\n",
       "  'itchy eyes associated with allergic conjunctivitis',\n",
       "  'itchy eyes associated with allergic conjunctivitis'],\n",
       " 'DB00973': ['elevated total-c, ldl-c, apo b, and non-hdl-c primary hyperlipidemia, alone or in combination with an hmg-coa reductase inhibitor (statin)',\n",
       "  'elevated total-c, ldl-c, apo b, and non-hdl-c mixed hyperlipidemia in combination with fenofibrate,',\n",
       "  'homozygous familial hypercholesterolemia (hofh), in combination with atorvastatin or simvastatin',\n",
       "  'homozygous sitosterolemia (phytosterolemia)'],\n",
       " 'DB00974': ['the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults'],\n",
       " 'DB00975': ['as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina'],\n",
       " 'DB00976': ['lt'],\n",
       " 'DB00977': [],\n",
       " 'DB00978': ['bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: lt'],\n",
       " 'DB00979': ['mydriasis and cycloplegia for diagnostic purposes'],\n",
       " 'DB00980': ['insomnia characterized by difficulty with sleep onset'],\n",
       " 'DB00981': ['glaucoma, and for severe anticholinergic toxicity'],\n",
       " 'DB00982': ['severe recalcitrant nodular acne and patients  years enrolled in the ipledge program'],\n",
       " 'DB00983': ['asthma and copd',\n",
       "  'copd, drug is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (lamas) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide',\n",
       "  'asthma, drug is available in combination with mometasone furoate for patients  years and older and with budesonide for patients  years and older'],\n",
       " 'DB00984': [\"refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin iii deficiency, fibrinogen excess, growth failure and turner's syndrome\"],\n",
       " 'DB00985': ['nausea, vomiting, or vertigo of motion sickness',\n",
       "  'nausea, vomiting, or vertigo of motion sickness'],\n",
       " 'DB00986': ['use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions',\n",
       "  'chronic obstructive pulmonary disease (copd)'],\n",
       " 'DB00987': ['acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia'],\n",
       " 'DB00988': ['the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure'],\n",
       " 'DB00989': [\"mild to moderate dementia associated with parkinson's disease or of the alzheimer's type\"],\n",
       " 'DB00990': ['advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy'],\n",
       " 'DB00991': ['the',\n",
       "  'relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis'],\n",
       " 'DB00992': ['non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used along with with lesion preparation (debridement using a sharp dermal curette)'],\n",
       " 'DB00993': ['rheumatoid arthritis and prevent renal transplant rejection'],\n",
       " 'DB00994': ['the risk of the development of drug-resistant bacteria',\n",
       "  'infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria',\n",
       "  'superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics',\n",
       "  'infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics',\n",
       "  'steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists'],\n",
       " 'DB00995': ['active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis'],\n",
       " 'DB00996': ['postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization,',\n",
       "  'partial-onset seizures, with or without secondary generalization, in patients  and as monotherapy'],\n",
       " 'DB00997': ['regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkins disease, malignant lymphoma and bronchogenic carcinoma',\n",
       "  'produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkins disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types',\n",
       "  'evidence of axillary lymph node involvement following resection of primary breast cancer'],\n",
       " 'DB00998': ['migraine attacks with or without aura'],\n",
       " 'DB00999': ['edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy',\n",
       "  'hypertension'],\n",
       " 'DB01000': ['bacterial infections caused by susceptible organisms'],\n",
       " 'DB01001': ['(i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm',\n",
       "  'bronchospasm'],\n",
       " 'DB01002': ['the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management'],\n",
       " 'DB01003': ['patients with bronchial asthma',\n",
       "  'vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis'],\n",
       " 'DB01004': ['cytomegalovirus (cmv) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (aids)',\n",
       "  'severe cytomegalovirus (cmv) disease, including cmv pneumonia, cmv gastrointestinal disease, and disseminated cmv infections, in immunocompromised patients'],\n",
       " 'DB01005': ['melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and sickle-cell anemia'],\n",
       " 'DB01006': ['postmenopausal women with hormone receptor (hr) positive early breast cancer, postmenopausal women with early breast cancer periviously been treated with tamoxifen, and postmenopausal women with hr+ or unknown advanced breast cancer',\n",
       "  'pre, peri, and postmenopausal women with hr+ and human epidermal growth factor  (her) negative advanced or metastatic breast cancer'],\n",
       " 'DB01007': ['the local treatment of vulvovaginal candidiasis (moniliasis)'],\n",
       " 'DB01008': ['use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  (myeloid, myelocytic, granulocytic) leukemia (fda has designated drug as an orphan drug for this use)'],\n",
       " 'DB01009': ['treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain'],\n",
       " 'DB01010': ['the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease',\n",
       "  'evaluating emergency treatment in myasthenic crises'],\n",
       " 'DB01011': ['a diagnostic drug for testing hypothalamic-pituitary acth function',\n",
       "  \"cushing's syndrome\"],\n",
       " 'DB01012': ['secondary hyperparathyroidism', 'hypercalcemia'],\n",
       " 'DB01013': ['moderate to severe plaque psoriasis,, and inflammatory and pruritic manifestations of corticosteroid responsive dermatoses'],\n",
       " 'DB01014': ['mildly to moderately active ulcerative colitis'],\n",
       " 'DB01015': ['the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in patients (when clinically indicated), acute exacerbations of chronic bronchitis'],\n",
       " 'DB01016': ['type  diabetes mellitus'],\n",
       " 'DB01017': ['inflammatory lesions of acne vulgaris',\n",
       "  'periodontitis',\n",
       "  'infections of susceptible microorganisms'],\n",
       " 'DB01018': ['adhd'],\n",
       " 'DB01019': ['acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention'],\n",
       " ...}"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indications\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "904ac04d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "245"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "a0671593",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['DB00043',\n",
       " 'DB00051',\n",
       " 'DB00208',\n",
       " 'DB00271',\n",
       " 'DB00294',\n",
       " 'DB00335',\n",
       " 'DB00347',\n",
       " 'DB00423',\n",
       " 'DB00425',\n",
       " 'DB00437',\n",
       " 'DB00461',\n",
       " 'DB00476',\n",
       " 'DB00522',\n",
       " 'DB00617',\n",
       " 'DB00635',\n",
       " 'DB00688',\n",
       " 'DB00743',\n",
       " 'DB00841',\n",
       " 'DB00934',\n",
       " 'DB00957',\n",
       " 'DB00977',\n",
       " 'DB01047',\n",
       " 'DB01118',\n",
       " 'DB01123',\n",
       " 'DB01173',\n",
       " 'DB01207',\n",
       " 'DB01256',\n",
       " 'DB01354',\n",
       " 'DB01373',\n",
       " 'DB01392',\n",
       " 'DB01422',\n",
       " 'DB01454',\n",
       " 'DB01497',\n",
       " 'DB01546',\n",
       " 'DB01564',\n",
       " 'DB01586',\n",
       " 'DB01593',\n",
       " 'DB01604',\n",
       " 'DB01645',\n",
       " 'DB02659',\n",
       " 'DB03783',\n",
       " 'DB03843',\n",
       " 'DB04335',\n",
       " 'DB04844',\n",
       " 'DB04872',\n",
       " 'DB04900',\n",
       " 'DB04919',\n",
       " 'DB04946',\n",
       " 'DB04953',\n",
       " 'DB05198',\n",
       " 'DB05199',\n",
       " 'DB05200',\n",
       " 'DB05201',\n",
       " 'DB05202',\n",
       " 'DB05204',\n",
       " 'DB05205',\n",
       " 'DB05207',\n",
       " 'DB05249',\n",
       " 'DB05252',\n",
       " 'DB05255',\n",
       " 'DB05263',\n",
       " 'DB05264',\n",
       " 'DB05268',\n",
       " 'DB05282',\n",
       " 'DB05285',\n",
       " 'DB05292',\n",
       " 'DB05332',\n",
       " 'DB05381',\n",
       " 'DB05541',\n",
       " 'DB06168',\n",
       " 'DB06206',\n",
       " 'DB06207',\n",
       " 'DB06210',\n",
       " 'DB06212',\n",
       " 'DB06213',\n",
       " 'DB06237',\n",
       " 'DB06404',\n",
       " 'DB06589',\n",
       " 'DB06605',\n",
       " 'DB06616',\n",
       " 'DB06654',\n",
       " 'DB06693',\n",
       " 'DB06698',\n",
       " 'DB06704',\n",
       " 'DB06754',\n",
       " 'DB06771',\n",
       " 'DB06784',\n",
       " 'DB06789',\n",
       " 'DB06800',\n",
       " 'DB06813',\n",
       " 'DB08805',\n",
       " 'DB08815',\n",
       " 'DB08822',\n",
       " 'DB08828',\n",
       " 'DB08833',\n",
       " 'DB08838',\n",
       " 'DB08870',\n",
       " 'DB08877',\n",
       " 'DB08879',\n",
       " 'DB08883',\n",
       " 'DB08890',\n",
       " 'DB08891',\n",
       " 'DB08898',\n",
       " 'DB08900',\n",
       " 'DB08903',\n",
       " 'DB08913',\n",
       " 'DB08928',\n",
       " 'DB08933',\n",
       " 'DB08964',\n",
       " 'DB09001',\n",
       " 'DB09020',\n",
       " 'DB09039',\n",
       " 'DB09087',\n",
       " 'DB09088',\n",
       " 'DB09108',\n",
       " 'DB09137',\n",
       " 'DB09153',\n",
       " 'DB09164',\n",
       " 'DB09209',\n",
       " 'DB09210',\n",
       " 'DB09216',\n",
       " 'DB09221',\n",
       " 'DB09225',\n",
       " 'DB09268',\n",
       " 'DB09282',\n",
       " 'DB09286',\n",
       " 'DB09291',\n",
       " 'DB09298',\n",
       " 'DB09313',\n",
       " 'DB09314',\n",
       " 'DB09315',\n",
       " 'DB09328',\n",
       " 'DB09332',\n",
       " 'DB09338',\n",
       " 'DB09352',\n",
       " 'DB09375',\n",
       " 'DB09379',\n",
       " 'DB09389',\n",
       " 'DB09418',\n",
       " 'DB09459',\n",
       " 'DB09460',\n",
       " 'DB09495',\n",
       " 'DB09517',\n",
       " 'DB09534',\n",
       " 'DB09535',\n",
       " 'DB09543',\n",
       " 'DB09571',\n",
       " 'DB10400',\n",
       " 'DB10401',\n",
       " 'DB10989',\n",
       " 'DB10990',\n",
       " 'DB10997',\n",
       " 'DB11051',\n",
       " 'DB11057',\n",
       " 'DB11062',\n",
       " 'DB11064',\n",
       " 'DB11065',\n",
       " 'DB11066',\n",
       " 'DB11071',\n",
       " 'DB11082',\n",
       " 'DB11085',\n",
       " 'DB11095',\n",
       " 'DB11125',\n",
       " 'DB11129',\n",
       " 'DB11133',\n",
       " 'DB11182',\n",
       " 'DB11201',\n",
       " 'DB11204',\n",
       " 'DB11206',\n",
       " 'DB11207',\n",
       " 'DB11226',\n",
       " 'DB11273',\n",
       " 'DB11274',\n",
       " 'DB11275',\n",
       " 'DB11284',\n",
       " 'DB11323',\n",
       " 'DB11327',\n",
       " 'DB11332',\n",
       " 'DB11338',\n",
       " 'DB11571',\n",
       " 'DB11572',\n",
       " 'DB11587',\n",
       " 'DB11608',\n",
       " 'DB11619',\n",
       " 'DB11637',\n",
       " 'DB11700',\n",
       " 'DB11755',\n",
       " 'DB11820',\n",
       " 'DB11855',\n",
       " 'DB11963',\n",
       " 'DB11967',\n",
       " 'DB12023',\n",
       " 'DB12364',\n",
       " 'DB12404',\n",
       " 'DB12442',\n",
       " 'DB12872',\n",
       " 'DB12909',\n",
       " 'DB13140',\n",
       " 'DB13146',\n",
       " 'DB13147',\n",
       " 'DB13157',\n",
       " 'DB13168',\n",
       " 'DB13170',\n",
       " 'DB13173',\n",
       " 'DB13200',\n",
       " 'DB13615',\n",
       " 'DB13800',\n",
       " 'DB13854',\n",
       " 'DB13897',\n",
       " 'DB13898',\n",
       " 'DB13899',\n",
       " 'DB13900',\n",
       " 'DB13901',\n",
       " 'DB13902',\n",
       " 'DB13903',\n",
       " 'DB13908',\n",
       " 'DB13913',\n",
       " 'DB13924',\n",
       " 'DB13953',\n",
       " 'DB13955',\n",
       " 'DB13960',\n",
       " 'DB13975',\n",
       " 'DB14003',\n",
       " 'DB14004',\n",
       " 'DB14006',\n",
       " 'DB14019',\n",
       " 'DB14039',\n",
       " 'DB14040',\n",
       " 'DB14041',\n",
       " 'DB14042',\n",
       " 'DB14051',\n",
       " 'DB14052',\n",
       " 'DB14100',\n",
       " 'DB14112',\n",
       " 'DB14126',\n",
       " 'DB14443',\n",
       " 'DB14487',\n",
       " 'DB14512',\n",
       " 'DB14548',\n",
       " 'DB14738',\n",
       " 'DB14914',\n",
       " 'DB15465',\n",
       " 'DB15566',\n",
       " 'DB15622',\n",
       " 'DB15873']"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "ac0aedbe",
   "metadata": {},
   "outputs": [],
   "source": [
    "it = 0\n",
    "\n",
    "indication_str = \"\"\n",
    "for k in dictionary.keys():\n",
    "    #print(k)\n",
    "    s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"\").lower()\n",
    "    s = s.replace(dictionary[k]['name'].lower(), \"\").lower()\n",
    "    indication_str += s"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "312ea5da",
   "metadata": {},
   "outputs": [],
   "source": [
    "it = 0\n",
    "\n",
    "indication_str = \"\"\n",
    "for k in dictionary.keys():\n",
    "    #print(k)\n",
    "    s = dictionary[k]['indication'].replace(dictionary[k]['name'], \"\").lower()\n",
    "    s = s.replace(dictionary[k]['name'].lower(), \"\").lower()\n",
    "    indication_str += s\n",
    "    \n",
    "indication_str = indication_str.replace(\"&#13;\", \"\")\n",
    "indication_str = re.sub(\"l\\d+\", \"\", indication_str )\n",
    "indication_str = re.sub(\"L\\d+\", \"\", indication_str )\n",
    "indication_str = re.sub(\"_\", \"\", indication_str )\n",
    "indication_str = re.sub(\"\\*\", \"\", indication_str )\n",
    "indication_str = re.sub(\"A\\d+\", \"\", indication_str )\n",
    "indication_str = re.sub(\"F\\d+\", \"\", indication_str )\n",
    "indication_str = re.sub(\"G\\d+\", \"\", indication_str )\n",
    "indication_str = re.sub(\"T\\d+\", \"\", indication_str )\n",
    "indication_str = indication_str.replace(\"&lt;/i&gt\", \"\")\n",
    "indication_str = indication_str.replace(\"&lt;i&gt\", \"\")\n",
    "indication_str = indication_str.replace(\"&lt;b&\", \"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "a01b27ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "indication_str = re.sub(r'[^\\w\\s]', ' ', indication_str).lower()\n",
    "all_indic_words =Counter(indication_str.split(\" \"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "cccc5149",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "18810e85",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "9483"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(all_indic_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "fcb112cb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('', 24127),\n",
       " ('of', 5722),\n",
       " ('the', 4873),\n",
       " ('for', 4869),\n",
       " ('and', 4823),\n",
       " ('in', 4648),\n",
       " ('treatment', 3374),\n",
       " ('is', 2564),\n",
       " ('to', 2408),\n",
       " ('with', 2096),\n",
       " ('or', 1729),\n",
       " ('as', 1623),\n",
       " ('indicated', 1577),\n",
       " ('use', 1569),\n",
       " ('a', 1347),\n",
       " ('used', 1294),\n",
       " ('patients', 1252),\n",
       " ('investigated', 1021),\n",
       " ('cancer', 767),\n",
       " ('disease', 732),\n",
       " ('an', 713),\n",
       " ('also', 669),\n",
       " ('by', 599),\n",
       " ('it', 596),\n",
       " ('be', 570),\n",
       " ('label', 506),\n",
       " ('infections', 476),\n",
       " ('fda', 473),\n",
       " ('are', 444),\n",
       " ('therapy', 443),\n",
       " ('combination', 415),\n",
       " ('acute', 407),\n",
       " ('s', 389),\n",
       " ('disorders', 379),\n",
       " ('who', 375),\n",
       " ('chronic', 372),\n",
       " ('other', 367),\n",
       " ('adults', 336),\n",
       " ('not', 331),\n",
       " ('treat', 330),\n",
       " ('that', 321),\n",
       " ('management', 309),\n",
       " ('caused', 290),\n",
       " ('have', 289),\n",
       " ('may', 278),\n",
       " ('associated', 276),\n",
       " ('pain', 266),\n",
       " ('severe', 263),\n",
       " ('this', 263),\n",
       " ('has', 262)]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_indic_words.most_common(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "f29a4fcf",
   "metadata": {},
   "outputs": [],
   "source": [
    "no_go_words = [e for e, ee in all_indic_words.most_common(60) if e not in [\"infections\", \"cancer\", \"fda\",  'adults', 'disease', 'infection', 'investigated', 'therapy', 'chronic', \n",
    "                                                              'disorders', 'pain', 'severe', 'symptoms', 'tumors', 'skin']] + ['when', '1','can', 'which', 'at', 'on','such','its', 'was']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "5c2c9523",
   "metadata": {},
   "outputs": [],
   "source": [
    "indication_str = indication_str.replace(\"vitamin e\", \"vitaminE\")\n",
    "indication_str = indication_str.replace(\"vitamin a\", \"vitaminA\")\n",
    "indication_str = indication_str.replace(\"vitamin c\", \"vitaminC\")\n",
    "indication_str = indication_str.replace(\"vitamin d\", \"vitaminD\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "c802239e",
   "metadata": {},
   "outputs": [],
   "source": [
    "for w in no_go_words:\n",
    "    indication_str = indication_str.replace(\" \"+ w + \" \", \" \")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "79120a73",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'for heparin induced thrombocytopenia irinotecan egfr expressing metastatic colorectal carcinoma refractory irinotecan based chemotherapy  administered single agent egfr expressing metastatic colorectal carcinoma intolerant irinotecan based chemotherapy adjunct therapy cystic fibrosis cutaneous t cell lymphoma moderately severely active rheumatoid arthritis adults chronic moderate severe plaque psoriasis 4 age older  manage signs symptoms polyarticular idiopathic arthritis those aged older  manage symptoms psoriatic arthritis ankylosing spondylitis heparin induced thrombocytopenia prevention thrombosis  undergoing percutaneous coronary intervention pci  moderate high risk coronary syndromes unstable angina non st segment elevation whom pci planned palliative advanced prostate cancer   well pediatric central precocious puberty cpp    oral norethisterone  known norethindrone  initial symptoms endometriosis  finally iron supplementation  preoperative hematological improvement anemic uterine leiomyomata uterine fibroids   hcv antiviral drugs over 5 age compensated liver disease fda  monotherapy contraindications significant intolerance anti viral therapies  monotherapy hbeag positive hbeag negative chronic hepatitis b infection compensated liver disease evidence viral replication liver inflammation fda myocardial infarction ischemic strok lysis pulmonary embolifor dwarfism prevention hiv induced weight lossfor venereal genital warts human papiloma virusfor anemia from renal transplants certain hiv canada  lysis massive pulmonary emboli thrombi obstructing coronary arteries occlusive thromboemboli peripheral arteries grafts restoration patency intravenous catheters    flutamide locally confined carcinoma prostate  palliative advanced carcinoma prostate  endometriosis  endometrial thinning agent prior endometrial ablation dysfunctional uterine bleeding  palliative advanced breast cancer pre perimenopausal womenfor lysis pulmonary emboli intracoronary emboli myocardial infarction paediatric   anemia chronic kidney disease ckd dialysis dialysis  anemia zidovudine hiv infection   anemia effects concomitant myelosuppressive chemotherapy upon initiation there minimum two additional months planned chemotherapy  reduction allogeneic rbc transfusions undergoing elective noncardiac nonvascular surgery symptomatic paget disease unresponsive alternate treatments intolerant treatments addition emergency situations serum calcium levels must decreased quickly until underlying condition identified added existing therapeutic regimens hypercalcemia intravenous fluids furosemide oral phosphate corticosteroids agents calcitonin azotemia cases where intravenous fluids would contraindicated limited cardiac reserves post menopausal osteoporosis women more than 5 post menopause  intralesional refractory recurring external condylomata acuminata decrease incidence infection manifested febrile neutropenia non myeloid malignancies receiving myelosuppressive anti cancer drugs clinically significant incidence febrile neutropenia   increase survival acutely exposed myelosuppressive doses radiation hematopoietic subsyndrome radiation syndrome  cancer bone marrow transplant hcv db00811 ns3 4a protease inhibitor genotype without ns3 4a protease inhibitor genotypes 6 fda  monotherapy contraindications significant intolerance anti viral therapies component multi agent chemotherapeutic regimen lymphoblastic leukemia all  fda detection residueal recurrent thyroid cancerfor hemophilia von willebrand disease factor xiii deficiency rheumatoid arthritis neonatal onset multisystem inflammatory disease nomid  skin lesions surface wounds eye infections ivig immunodeficiencies well autoimmune inflammatory disorders these indications includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complications guillain barr syndrome chronic inflammatory demyelinating polyneuropathy cidp  multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott aldrich syndrome inflammatory skin diseases lysis pulmonary emboli intracoronary emboli myocardial infarctionhuman insulin improve glycemic control adults pediatric diabetes mellitus myocardial infarction lysis intracoronary embolifor female infertility chronic granulomatous disease osteopetrosis chronic hepatitis c hairy cell leukemia aids related kaposi sarcoma chronic myelogenous leukemia oral warts arising from hiv infection  nocturia nocturnal polyuria adults awaken least times per night void intranasal    antidiuretic replacement therapy central cranial diabetes insipidus temporary polyuria polydipsia following head trauma surgery pituitary region intranasal parenteral   hemophilia factor viii coagulant activity levels greater than 5 mild moderate classic von willebrand disease type i factor viii levels greater than 5 during surgical procedures postoperatively maintain hemostasis parenteral hemorrhagic complications hemophilia b prevention severe thrombocytopenia reduction need platelet transfusions following myelosuppressive chemotherapy nonmyeloid malignancies high risk severe thrombocytopenia oral mucositis chemotherapy radiation therapy diagnostic aid radiologic exams temporarily inhibit movement gastrointestinal tract severe hypoglycemia    adults metastatic renal cell carcinoma cervical dystonia reduce severity abnormal head position neck pain cervical dystonia drug anti ige antibody  moderate severe persistent asthma 6 age older positive skin test vitro reactivity perennial aeroallergen symptoms inadequately controlled inhaled corticosteroids fda  chronic idiopathic urticaria adults adolescents 12 age older remain symptomatic despite h1 antihistamine fda infertility women hypothalamic pituitary insufficiency hypogonadotropic hypogonadism profound lh deficiency lh lt international units iu l prophylactic lyme disease improve glycemic control adults children diabetes mellitus  improve glycemic control adults pediatric type diabetes mellitus adults type diabetes mellitus adults dupuytren contracture palpable cord additionally men peyronie disease diagnosed penile curvature deformity least 30 degree angle beginning therapy addition palpable plaques  collagenase ointment tissue debridement chronic dermal ulcers severely burned tissues  collagenase product known qwo moderate severe cellulite buttocks women  hyperuricemia reduces elevated plasma uric acid levels from chemotherapy inhibition premature lh surges women undergoing controlled ovarian stimulationthe following conditions f2118  fda    a40001  a40002     rheumatoid arthritis moderate severe  juvenile idiopathic arthritis moderately severely active  psoriatic arthritis active  ankylosing spondylitis active  crohn disease moderately severely active  ulcerative colitis moderately severely active  plaque psoriasis moderate severe chronic  non infectious intermediate posterior panuveitis hidradenitis suppurativa moderate severe  pyoderma gangrenosum off dwarfism acromegaly prevention hiv induced weight lossfor gaucher disease deficiency glucocerebrosidase adjunct percutaneous coronary intervention prevention cardiac ischemic complications undergoing percutaneous coronary intervention unstable angina responding conventional medical therapy percutaneous coronary intervention planned within 24 hours  intended aspirin heparin studied only setting reduction mortality severe sepsis cd33 positive myeloid leukemia first relapse 60 age older considered candidates cytotoxic chemotherapy aged older cd33 positive aml experienced relapse responded initial refractory  diagnosis extrahepatic malignant cancersfor chronic augmentation maintenance therapy individuals alpha1 proteinase inhibitor a1 pi deficiency clinical evidence emphysema lymphoblastic leukemiafor relapsing remitting multiple sclerosis condyloma acuminatumfor adenosine deaminase deficiencyalbuminex solution adults children hypovolemia ascites hypoalbuminemia from burns nephrosis respiratory distress syndrome cardipulmonary bypass f229 myocardial infarction coronary syndrome reducing signs symptoms inducing maintaining clinical remission pediatric  6 age moderately severely active crohn disease had inadequate response conventional therapy reducing number draining enterocutaneous rectovaginal fistulas maintaining fistula closure fistulizing crohn disease  reducing signs symptoms inducing maintaining clinical remission mucosal healing eliminating corticosteroid pediatric  6 age moderately severely active ulcerative colitis had inadequate response conventional therapy  methotrexate reducing signs symptoms inhibiting progression structural damage improving physical function moderately severely active rheumatoid arthritis  reducing signs symptoms active ankylosing spondylitis  reducing signs symptoms active arthritis inhibiting progression structural damage improving physical function psoriatic arthritis  chronic severe i e  extensive disabling plaque psoriasis candidates systemic therapy systemic therapies medically less appropriate women having diagnosed primary ovarian failure human chorionic gonadotropin hcg assist ovulation fertility men hypogonadotrophic hypogonadism induce spermatogenesis  cause ovary produce several follicles then harvested gamete intrafallopian transfer gift vitro fertilization ivf enuresis polyuria diabetes insipidus polydipsia oesophageal varices bleeding drug relapsing remitting multiple sclerosis shown slow advance disease well decrease frequency attacks hairy cell leukemia malignant melanoma aids related kaposi sarcomafor increase absorption distribution injected drugs rehydration type i ii diabetes mellitus adjuvant her2 overexpressing breast cancer  several clinical settings part regimen consisting doxorubicin cyclophosphamide either paclitaxel docetaxel part regimen docetaxel carboplatin monotherapy following multi modality anthracycline based therapy   first line paclitaxel metastatic her2 overexpressing breast cancer monotherapy previously received one more chemotherapy regimens metastatic setting   cisplatin capecitabine 5 fluorouracil her2 overexpressing metastatic gastric gastroesophageal junction adenocarcinoma received prior metastatic disease   subcutaneous administration  either hyaluronidase  both hyaluronidase pertuzumab   adults her positive breast cancers following conditions fda  non hodgkin lymphoma nhl  chronic lymphocytic leukemia cll  rheumatoid arthritis ra methotrexate moderately severely active ra granulomatosis polyangiitis gpa  wegener granulomatosis microscopic polyangiitis mpa  moderate severe pemphigus vulgaris pv biosimilar approved november 2018  truxima cd20 positive b cell non hodgkin lymphoma nhl single agent chemotherapy   september 2019 injection approved along glucocorticoids manage granulomatosis polyangiitis gpa addition microscopic polyangiitis mpa children least age  prophylactic kidney transplant rejectionfor organ transplant recipients prevention organ rejectionfor digitoxin overdose digitalis glycoside toxicity non hodgkin lymphomafor complicated skin skin structure infections susceptible strains gram positive microorganisms non hodgkin lymphoma cd20 positive follicular growth hormone receptor antagonist acromegaly cervical dystonia adults decrease severity abnormal head position neck pain cervical dystonia severe primary axillary hyperhidrosis inadequately managed topical agents strabismus blepharospasm dystonia benign essential blepharospasm vii nerve disorders 12 age above cosmetically temporarily improve appearance moderate severe frown lines between eyebrows glabellar lines well excessive underarm sweating amylase part pancreatic enzyme replacement therapy therapy pancreatic insufficiency attributed cystic fibrosis chronic pancreatitis any medically defined pancreatic disease might require a32721 a32736 pancreatic diseases deterioration pancreatic parenchyma dual physiological functions pancreas once established pancreatic insufficiency results malnutrition weight loss steatorrhea a32723 evolving transmural myocardial infarction pulmonary embolism deep vein thrombosis arterial thrombosis emolism occlusion arteriovenous cannulae campath monoclonal antibody therapy b cell chronic lymphocytic leukemia gaucher disease deficiency glucocerebrosidase diagnosis prostate cancer detection intra pelvic metastases mucopolysaccharidosis approved variety conditions firstly approved prophylaxis organ rejection allogeneic kidney liver heart transplants prevent bone marrow transplant rejection above indications  conjunction azathioprine corticosteroids finally  chronic transplant rejection received previous immunosuppressive therapy  prevent graft versus host disease gvhd   secondly  severe active rheumatoid arthritis ra they no longer respond methotrexate alone  non immunocompromised severe recalcitrant plaque psoriasis failed respond least one systemic therapy systemic therapies tolerated contraindicated  ophthalmic solution increase tear production suffering from keratoconjunctivitis sicca  addition  approved steroid dependent steroid resistant nephrotic syndrome glomerular diseases include minimal change nephropathy focal segmental glomerulosclerosis membranous glomerulonephritis   off  commonly various autoimmune inflammatory conditions atopic dermatitis blistering disorders ulcerative colitis juvenile rheumatoid arthritis uveitis connective tissue diseases well idiopathic thrombocytopenic purpura a139 a174085 a189393 a189396 a189399 immunosuppressive drug  moderate severe chronic plaque psoriasisfor alternative adrenaline localising agent provided local ischaemia essential female infertilityfor moderate severe chronic plaque psoriasis candidates phototherapy systemic therapy female infertilityfor prevention renal transplant rejectionthis drug leucocyte growth factor fda  decrease incidence infection manifested febrile neutropenia nonmyeloid malignancies receiving myelosuppressive anti cancer drugs significant incidence severe neutropenia fever fda   reduce time neutrophil recovery duration fever following induction consolidation chemotherapy myeloid leukemia aml  fda  reduce duration neutropenia neutropenia related clinical sequelae e g  febrile neutropenia nonmyeloid malignancies undergoing myeloablative chemotherapy followed bone marrow transplantation bmt  fda  mobilize autologous hematopoietic progenitor cells into peripheral blood collection leukapheresis fda  reduce incidence duration sequelae severe neutropenia e g  fever infections oropharyngeal ulcers symptomatic congenital neutropenia cyclic neutropenia idiopathic neutropenia fda  neupogen approved radiation induced myelosuppression following radiological nuclear incident  hemophilia christmas disease topical skin ulcers from diabetes fabry disease  injection acromegaly reduction flushing diarrhea symptoms related carcinoid tumors vasoactive intestinal peptide vipoma tumors  delayed release oral formulation long term acromegaly tolerate respond adequately injectable lanreotide  hairy cell leukemia malignant melanoma aids related kaposi sarcoma palliative advanced prostate cancer labor induction augmentation labor postpartum abbreviation third stage labor postpartum control uterine bleeding termination pregnancy evaluation fetal respiratory capability  cannot elective induction labor there must clear medical requirement multiple sclerosis antiretroviral drug therapy hiv aids prophylaxis respiratory diseases casued respiratory syncytial virus zenapax humanized monoclonal antibody prevention renal transplant rejectionas vascular endothelial growth factor vegf inhibitor  several chemotherapy regimens metastatic colorectal cancer metastatic unresectable locally advanced recurrent non squamous non small cell lung cancer metastatic renal cell carcinoma metastatic persistent recurrent cervical cancer primary peritoneal cancer epithelial ovarian cancer fallopian tube cancer  recurrent glioblastoma   interestingly  currently under investigation covid 19 complications respiratory distress syndrome ards lung injury ali   imaging colorectal tumorsfor nutritional supplementation treating dietary shortage imbalance nasal spray nasal spray maintenance vitamin b12 concentrations after normalization intramuscular vitamin b12 therapy deficiency vitamin no nervous system involvement fda  note  calomist fda  nasal spray form evaluated newly diagnosed vitamin b12 deficiency  injection forms subcutaneous intramuscular  these forms vitamin b12 deficiencies various causes without neurologic manifestations f3736  vitamin b12 deficiency frequently malabsorption often following conditions   addisonian pernicious anemia gastrointestinal pathology dysfunction surgery gluten enteropathy sprue small bowel bacterial overgrowth total partial gastrectomy fish tapeworm infestation malignancy pancreas bowel folic acid deficiency  oral forms vitamin b12 supplements widely available require supplementation various reasons  dose requirements vitamin b12 higher than normal pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic renal disease usually achieved oral supplementation    oral products vitamin b12 recommended malabsorption these forms primarily absorbed gastrointestinal tract f3739  nutritional supplementation treating dietary shortage imbalance actions supplemental l entirely unclear some immunomodulatory well antioxidant activity l some rheumatoid arthritis anemia uremia lowering serum cholesterol adenosylmethionine same drug europe depression liver disorders fibromyalgia osteoarthritis introduced into united states market dietary supplement support bone joint health well mood emotional well being nutritional supplementation treating dietary shortage imbalancel helpful some depression useful vitiligo there some evidence l exacerbate tardive dyskinesia some schizophrenic some neuroleptic drugs nutritional supplementation treating dietary shortage imbalance nutritional supplementation treating dietary shortage imbalancesupplemental putative anti herpes simplex virus activity there preliminary research suggesting some anti osteoporotic activity nutritional supplementation treating dietary shortage imbalance vitaminC deficiency scurvy delayed wound bone healing urine acidification general antioxidant suggested effective antiviral agent nutritional supplementation treating dietary shortage imbalancethere no support claim aspartates exercise performance enhancers i e ergogenic aids nutritional supplementation treating dietary shortage imbalance claimed improves athletic performance anabolic effects wound healing effects immuno enhancing nutritional supplementation treating dietary shortage imbalance  reduce complications sickle cell disease pediatric 5 age older fda nutritional supplementation treating dietary shortage imbalancefor nutritional supplementation treating dietary shortage imbalance natural moisturizing agent some cosmetics skin care products protein synthesis formation same l homocysteine l cysteine taurine sulfate claimed act effective antidepressant however results mixed  claimed reduce stress combat narcolepsy chronic fatigue however these claims refuted some studies vitaminD deficiency insufficiency refractory rickets vitaminD resistant rickets  familial hypophosphatemia hypoparathyroidism hypocalcemia renal osteodystrophy chronic renal failure undergoing dialysis conjunction calcium prevention primary corticosteroid induced osteoporosis xanthophylls taken nutritional supplementation treating dietary shortage imbalance claimed l cysteine anti inflammatory properties protect against various toxins might helpful osteoarthritis rheumatoid arthritis more research will done before l cysteine any these conditions research date mostly animal models nutritional supplementation treating dietary shortage imbalancefor aosis vitamin b2 deficiency prevention osteoarthritis itself chondroitin sulfate considered nature brain food improving mental capacities helps speed healing ulcers gives lift from fatigue helps control alcoholism schizophrenia craving sugar nutritional supplementation treating dietary shortage imbalancephosphatidylserine demonstrated some usefulness treating cognitive impairment alzheimer disease age memory impairment some non alzheimer dementias more research needed before phosphatidylserine immune enhancement reduction exercise stress supplemental antispastic activity very early findings suggest antipsychotic activity well antioxidant anti inflammatory activities vitaminD deficiency insufficiency refractory rickets vitaminD resistant rickets  familial hypophosphatemia hypoparathyroidism hypocalcemia renal osteodystrophy chronic renal failure undergoing dialysis conjunction calcium prevention primary corticosteroid induced osteoporosis one natural forms available vitamin b6 therefore nutritional supplementation treating dietary shortage imbalances nutritional supplementation treating dietary shortage imbalance assist prevention breakdown muscle proteins sometimes occur after trauma severe stress useful increasing serotonin production promoting healthy sleep managing depression enhancing mental emotional well being managing pain tolerance managing weight prevention liver damage kidney damage overdoses acetaminophenfor niacin deficiency states korsakov alcoholic psychosis wernicke korsakov syndrome delirium peripheral neuritis hypoparathyroidism refractory rickets familial hypophosphatemia fda  hypoparathyroidism result inadequate parathyroid hormone production occurs presence damage removal parathyroid glands condition produces decreased calcium increased phosphorus levels   rickets condition produced deficiency vitaminD calcium phosphorus however condition related renal diseases characterized present weak soft bones a177664  familial hypophosphatemia characterized impaired transport phosphate altered vitaminD metabolism kidneys presence condition derive presence osteomalacia bone softening rickets  nutritional supplementation treating dietary shortage imbalanceused nutritional supplementation treating dietary shortage imbalance l makes up collagen elastin enamel protein aids proper fat metabolism liver helps digestive intestinal tracts function more smoothly assists metabolism assimilation some evidence suggests might useful treating parkinson disease chronic fatigue syndrome alzheimer disease cardiovascular disease deficiency megaloblastic anemia anemias nutritional origins pregnancy infancy childhood epa lowering elevated triglycerides those hyperglyceridemic addition epa play therapeutic role cystic fibrosis reducing disease severity play similar role type diabetics slowing progression diabetic nephropathy protein synthesis promotes mental vigor muscle coordination calm emotions minority hepatic encephalopathy some phenylketonuria deficiency supplementation deficiency occur cystic fibrosis cholestasis severe liver disease abetalipoproteinemia simply poor diet a176104  vitamin b6 deficiency prophylaxis db00951 induced peripheral neuropathy approved health canada nausea vomiting pregnancy product db00366  commercially available product diclectin nutritional supplementation treating dietary shortage imbalance branched chain amino acids antihepatic encephalopathy activity some they anticatabolic antitardive dyskinesia activity diet supplement sugar substitute specific medical conditions like refractory rickets vitaminD resistant rickets  hypoparathyroidism familial hypophosphatemia f4027 f4042  concurrently one most commonly utilized forms vitaminD  very frequently supplement individuals maintain sufficient vitaminD levels body vitaminD deficiency well various medical conditions directly indirectly vitaminD insufficiency like osteoporosis chronic kidney disease among others a176041 a176044 f4051 primary known function vitamin k assist normal clotting blood but play role normal bone calcification nutritional supplementation treating dietary shortage imbalancel extremely important proper functioning joints tendons helps maintain strengthen heart muscles nutritional supplementation treating dietary shortage imbalanceused nutritional supplementation treating dietary shortage imbalance primary prevention coronary events hypercholesterolemic without clinical evidence coronary heart disease includes reduction risk myocardial infarction undergoing myocardial revascularization procedures cardiovascular mortality t274  well  secondary prevention agent cardiovascular events clinically evident coronary heart disease indication includes reduction risk total mortality reducing coronary death myocardial infarction undergoing myocardial revascularization procedures stroke stroke transient ischemic attack well slow progression coronary atherosclerosis t274  term cardiovascular events correspond all incidents produce damage heart muscle interruption blood flow   adjunctive therapy diet    primary hypercholesterolemia mixed dyslipidemias hyperlipidemia type iia iib  elevated serum triglycerides type iv hyperlipidemia  heterozygous familial hypercholesterolemia over 8 age low density lipoprotein ldl cholesterol higher than 190 mg dl after diet modifications ldl levels higher than 160 mg dl familial history premature cardiovascular diseases least two cardiovascular risk factors t274  do respond adequately diet  primary dysbetalipoproteinemia type iii hyperlipidemia  t274  dyslipidemia defined elevation plasma cholesterol triglycerides both well presence low levels high density lipoprotein condition represents increased risk development atherosclerosis  predominantly depression obsessive compulsive disorder ocd  fda  bulimia nervosa a250  hypertension reduce risk fatal nonfatal cardiovascular events primarily strokes myocardial infarctions heart failure nyha class ii iv left ventricular dysfunction failure after myocardial infarction angiotensin converting enzyme inhibitor acei appropriate f4703 mild severe hypertension reduce cardiovascular mortality following myocardial infarction hemodynamically stable individuals develop clinical signs congestive heart failure within few days following myocardial infarction  fda reduce rate death myocardial infarction stroke individuals high risk cardiovascular events slow progression renal disease individuals hypertension diabetes mellitus microalubinuria overt nephropathy  t116 actinic keratoses precancerous skin growths become malignant if left untreated maintenance asthma prophylactic therapy administered relief signs symptoms spasticity resulting from multiple sclerosis particularly relief flexor spasms pain clonus addition muscular rigidity fda  receiving drug should reversible spasticity promote restoration residual function drug skeletal muscle spasm rheumatic disorders efficacy stroke cerebral palsy parkinson disease determined therefore  recommended these conditions fda  attention deficit hyperactivity disorders adhd well central nervous system disorders narcolepsy a18540  adhd complex disorder substantial heterogeneity etiology clinical presentation outcome adhd comes from complex interplay between interdependent genetic non genetic factors cause complex mental disorders children teenagers a174271  hand narcolepsy chronic sleep disorder typically resenting during adolescence characterized excessive daytime sleepiness a174274  being nowadays off obesity depression chronic pain a174268 a174283 diagnostic aid evaluation gastric acid secretory functionfor relief withdrawal symptoms aid smoking cessation symptoms dry mouth sj amp ouml gren syndrome fda approved short term relief anxiety symptoms related anxiety disorders anxiety depressive symptoms anxiety insomnia well anesthesia premedication adults relieve anxiety produce sedation amnesia status epilepticus t385  some off indications include rapid tranquilization agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasms insomnia panic disorder delirium chemotherapy anticipatory nausea vomiting psychogenic catatonia t385 rapid control ventricular rate atrial fibrillation atrial flutter perioperative postoperative emergent circumstances where short term control ventricular rate short acting agent desirable noncompensatory sinus tachycardia where rapid heart rate requires specific intervention multiple myeloma mantle cell lymphoma  short term hypnotic therapy insomnia periods up one week duration however medication generally replaced sedative hypnotic agents levodopa symptoms idiopathic parkinson disease postencephalitic parkinsonism symptomatic parkinsonism followed carbon monoxide manganese intoxication fda  therapy administered reduction levodopa driven nausea vomiting fda  product should where therapy  levodopa provide less than adequate daily dosage fda  well where dosages levodopa require individual titration fda alone topiramate short term adjunct pass few weeks regimen weight reduction based exercise behavioral modifications caloric restriction exogenous obesity initial body mass index bmi greater than 30 kg m2 greater than 27 kg m2 presence risk factors controller hypertension diabetes hyperlipidemia fda  exogenous obesity considered overweight consuming more food than person activity level warrants condition commonly causes increase fat storage epidemic condition united states where over two thirds adults overweight obese one three americans obese world incidence obesity nearly doubled a174391 life threatening dysrhythmias sustained ventricular tachycardia approved moderate severe pain adults  f4679  off premature ejaculation a173986 chickenpox  varicella herpes zoster herpes simplexfor hypertension administered following fungal infections   vaginal yeast infections candida systemic candida infections 3 both esophageal oropharyngeal candidiasis  4 cryptococcal meningitis 5 uti urinary tract infection candida 6 peritonitis inflammation peritoneum candida note fungal infection prophylaxis receiving bone marrow transplantation treated cytotoxic chemotherapy radiation therapy predisposed candida infections receive prophylactic therapy   note laboratory testing obtaining specimens fungal culture important laboratory studies serology pathology advised before starting therapy order isolate organisms eliminated through permissible start therapy before results available however adjusting therapy once laboratory results confirm causative organism necessary  type ii diabetes mellitus alone sulfonylurea metformin insulin adjunct diet exercise according fda prescribing information  uncomplicated illness influenza b infection weeks age older symptomatic no more than 48 hours f3094  particular agent adults children full term neonates present symptoms typical influenza influenza virus circulating community efficacy demonstrated initiated within two days first onset symptoms f3097  prophylaxis influenza one year older f3094  specifically post exposure prevention individuals one year age older following contact clinically diagnosed influenza case influenza virus circulating community qualifies prophylactic therapy  would only post exposure prevention influenza infants less than year age during pandemic influenza outbreak  f3097  infections susceptible strains various bacteria  indications summarized body system below  respiratory infections mild moderate upper respiratory tract infections streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae concomitantly appropriate doses sulfonamides treated   mild moderate lower respiratory tract infections susceptible strains streptococcus pneumoniae streptococcus pyogenes treated  treats listeriosis listeria monocytogenes treated   pertussis whooping cough bordetella pertussis effective eliminating causative organism from nasopharynx infected individuals rendering them noninfectious clinical studies suggest aid prevention pertussis infection individuals exposed bacteria  respiratory tract infections mycoplasma pneumoniae treated   despite fact no controlled clinical efficacy studies conducted date vitro certain preliminary clinical study results indicate effective legionnaires disease  finally  diphtheria infections corynebacterium diphtheriae adjunct antitoxin prevent carrier status eradicate organism existing carriers  addition prevention diphtheria  prevent rheumatic fever penicillin intolerant    skin infections mild moderate skin skin structure infections streptococcus pyogenes staphylococcus aureus treated  however resistant staphylococcal organisms emerge   erythrasma infectious condition corynebacterium minutissimum   gastrointestinal infections intestinal amebiasis entamoeba histolytica treated oral  extraenteric amebiasis warrants antimicrobial drugs   genital infections stis  alternative drug treating pelvic inflammatory disease n gonorrheae female demonstrated hypersensitivity intolerance penicillin  syphilis treponema pallidum treated  serves alternative primary syphilis demonstrated penicillin hypersensitivity  primary stage primary syphilis  another approved indication chlamydial infections cause conjunctivitis newborn pneumonia infancy urogenital infections occurring pregnancy alternative option tetracyclines uncomplicated rectal urethral endocervical infections adults chlamydia trachomatis   nongonococcal urethritis tetracyclines cannot administered finally  nongonococcal urethritis ureaplasma urealyticum  pernicious anemia prevention vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepatic biliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diets macrobiotic diets restrictive diets known suspected cyanide poisoning short term apnea prematurity infants off prevention bronchopulmonary dysplasia premature birth t716  addition sodium benzoate respiratory depression resulting from overdose cns depressant drugs   broad range over counter uses found energy supplements athletic enhancement products pain relief products well cosmetic products t716  surgical procedures where rapid onset brief duration muscle relaxation needed includes intubation endoscopies ect phosphodiesterase 5 pde5 inhibitor predominantly employed two primary indications  erectile dysfunction a175582  f3853 f3856 f3886   pulmonary hypertension where us fda specifically indicates pulmonary arterial hypertension pah  group i adults improve exercise ability delay clinical worsening f3850  delay clinical worsening demonstrated added background epoprostenol therapy f3850  studies establishing effectiveness were short term 12 16 weeks  included predominately new york heart association nyha functional class ii iii symptoms idiopathic etiology 71  connective tissue disease ctd  25  f3850  b canadian product monograph specifically indicates primary pulmonary arterial hypertension pph pulmonary hypertension secondary connective tissue disease ctd functional class ii iii responded conventional therapy f3859  addition improvement exercise ability delay clinical worsening demonstrated were already stabilized background epoprostenol therapy f3859  c ema product information specifically indicates pulmonary arterial hypertension classified functional class ii iii improve exercise capacity f3883  efficacy shown primary pulmonary hypertension pulmonary hypertension connective tissue disease f3883  ema indicates pediatric aged year 17 old pulmonary arterial hypertension f3883  efficacy terms improvement exercise capacity pulmonary hemodynamics shown primary pulmonary hypertension pulmonary hypertension congenital heart disease f3883 maintenance normal sinus rhythm delay time recurrence atrial fibrillation atrial flutter af afl  atrial fibrillation atrial flutter greater than one week duration converted normal sinus rhythmfor toxoplasmosis malaria prevention malaria areas non resistant hypertension should only prevent infections proven strongly suspected susceptible bacteria order prevent development antimicrobial resistance maintain efficacy  fda   mild moderate infections susceptible strains microorganisms listed specific conditions below recommended dosages duration therapy considerations various patient populations vary among these infections refer fda indications section drug entry detailed information fda   adults  bacterial exacerbations chronic obstructive pulmonary disease haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae bacterial sinusitis haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae community acquired pneumonia chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae appropriate oral therapy pharyngitis tonsillitis streptococcus pyogenes alternative first line therapy individuals cannot first line therapy uncomplicated skin skin structure infections staphylococcus aureus streptococcus pyogenes streptococcus agalactiae abscesses usually require surgical drainage  urethritis cervicitis chlamydia trachomatis neisseria gonorrhoeae  genital ulcer disease men haemophilus ducreyi chancroid  small number women included clinical trials efficacy chancroid women established  pediatric otitis media haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae community acquired pneumonia chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae appropriate oral therapy  pharyngitis tonsillitis streptococcus pyogenes alternative first line therapy individuals cannot first line therapy had stroke stroke precursors cannot take aspirin aspirin worked try prevent another thrombotic stroke overactive bladder symptoms urge urinary incontinence urgency urinary frequency detrusor instability frequency micturition topical acne vulgaris aged 12 over  symptomatic orthostatic hypotension oh hypertension heart failure injection  gastroesophageal reflux disease history erosive esophagitis  injection short term 7 10 days having gastroesophageal reflux disease gerd history erosive esophagitis alternative oral medication unable continue taking delayed release tablets safety efficacy injection initial having gerd history erosive esophagitis demonstrated time fda  pathological hypersecretion zollinger ellison syndrome  injection pathological hypersecretory conditions zollinger ellison syndrome neoplastic conditions fda  delayed release oral suspension  short term erosive esophagitis gastroesophageal reflux disease gerd  adults pediatric five age above short term up 8 weeks healing symptomatic relief erosive esophagitis healed after 8 weeks additional 8 week course considered safety beyond 8 weeks pediatric determined f3202  maintenance healing erosive esophagitis maintenance healing erosive esophagitis reduction relapse rates daytime nighttime heartburn symptoms gerd f3202  pathological hypersecretory conditions zollinger ellison syndrome long term above conditions f3202 edema congestive heart failure renal hepatic diseases from condition observed very effective cases kidney failure fda  edema considered swelling observed trap fluid body tissue mainly located feet ankles legs but extended parts face hands abdomen even whole body   well  approved antihypertensive agent either alone antihypertensives fda  hypertension defined presence high blood pressure increase amount blood pumped order produces narrowing arteries  depression fda fda  off indications include but limited sexual dysfunction post stroke behavioural changes ethanol abuse obsessive compulsive disorder ocd children diabetic neuropathy fda  a321  a322  a323  a324  a174406  a174409  a174412 migraine without aura adults hypertension sinus lung infections sinusitis pneumonia secondary infections chronic bronchitis bacterial conjunctivitis pinkeye visceral spasmsused antiviral drugs hiv both adults children asthma wheezing chronic asthmatic bronchitis type diabetes adults adjunct diet exercise improve glycemic control monotherapy  metformin insulin lower blood glucose type diabetes whose high blood sugar levels cannot controlled diet exercise conjunction oral hypoglycemic drug lower blood sugar levels agent alone  relief inflammatory pruritic manifestations corticosteroid responsive dermatoses antiretroviral drug hiv infection intravenous mri visualize lesions abnormal vascularity those thought cause abnormalities blood brain barrier brain intracranial lesions  spine tissues control hypertension reduce risk myocardial infarction unstable angina need coronary revascularization procedures individuals without symptomatic cardiovascular disease average moderately elevated total c ldl c below average hdl c intervention alternative individuals presenting dyslipidemia risk developing atherosclerotic vascular disease administration agent should accompanied implementation fat cholesterol restricted diet f4661  therapy lipid altering agents should component multiple risk factor intervention those individuals significantly increased risk atherosclerotic vascular disease hypercholesterolemia  adjunct diet reduction elevated total c ldl c levels primary hypercholesterolemia types iia iib2  response diet restricted saturated fat cholesterol nonpharmacological measures alone inadequate f4661 f4664  slow progression coronary atherosclerosis coronary heart disease part strategy lower total c ldl c target levels f4661  adjunct diet reduce total c ldl c apolipoprotein b levels adolescent boys girls heterozygous familial hypercholesterolemia hefh least one year post menarche 10 17 age hefh if after adequate trial diet therapy following findings present ldl c remains greater than 189 mg dl ldl c remains greater than 160 mg dl there positive family history premature cardiovascular disease two more cvd risk factors present adolescent patient  before administering  important rule out presence secondary causes hypercholesterolemia lipid profile should performed  prescribing statin medications considered standard practice following any cardiovascular events people moderate high risk development cvd statin conditions include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia  documented carotid disease peripheral artery disease claudication  abdominal aortic aneurysm chronic kidney disease severely elevated ldl c levels a181087 a181406 both induction maintenance general anesthesia induce analgesia vaginal delivery low concentrations adjunct general anesthetic drugs during delivery cesarean section  severe infections susceptible bacteria neuropathic pain diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain spinal cord injury adjunctive therapy partial onset seizures month age older  specifically only short term insomnia fda    furthermore generally predominantly symptomatic relief transient short term insomnia characterized difficulty falling asleep frequent nocturnal awakenings early morning awakenings f3718  particular official prescribing information typically specifies instructions issued dispensed prescriptions medication should indicate specifically only expected therapy short periods time  usually 7 10 days general fda f3718  subsequently should usually exceed 7 10 consecutive days nor should prescribed quantities exceeding one month supply f3718  some regional prescribing information notes premedication prior minor surgery related procedures  hypertension either sole therapeutic agent enhance effect antihypertensive drugs more severe forms hypertension adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy tuberculosisfor clinical depression congestive heart failure polycythaemia vera refractory chronic myeloid leukaemia sedative hypnotic   should insomnia longer than weeks  antiretroviral drugs ongoing hiv infection dermal fungal infection relief inflammatory pruritic manifestations corticosteroid responsive dermatoses symptom complex tension muscle contraction headache non opioid analgesics alternative treatments inadequate various combinations acetaminophen aspirin caffeine codeine  active hairy cell leukemia leukemic reticuloendotheliosis defined clinically significant anemia neutropenia thrombocytopenia disease related symptoms alternative agent chronic lymphocytic leukemia cll  low grade non hodgkin lymphoma cutaneous t cell lymphoma chronic angina alone conjunction nitrates beta blockers angiotensin receptor blockers anti platelet drugs calcium channel blockers lipid lowering drugs ace inhibitors   off certain arrhythmias ventricular tachycardia however strongly supported scientific evidence a174940  studied coronary syndrome microvascular coronary dysfunction arrhythmia glycemic control yet approved indications a174898  induction remission active mild moderate exacerbations ulcerative colitis maintenance remission ulcerative colitis fda    prescribing information uk indicates medication maintenance remission crohn ileo colitis  benztropine adjunct therapy all forms parkinsonism control extrapyramidal disorders neuroleptic drugs t203  extrapyramidal symptoms defined drug induced disorders include symptoms dystonia akathisia parkinsonism bradykinesia tremors dyskinesia a175120  parkinsonism general term refers group neurological disorders produce symptoms similar parkinson disease tremors slow movement stiffness parkinsonism includes large number disorders some them clearly defined  oral form  approved schizophrenia monotherapy manic mixed episodes related bipolar i disorder adjunctive therapy lithium valproate maintenance bipolar i disorder  injectable formulation approved only agitation schizophrenia  vascular headachefor hyperprolactinemic disorders either idiopathic prolactinoma prolactin secreting adenomas  manage symptoms parkinsonian syndrome monotherapy during initial symptomatic adjunct levodopa therapy during advanced stages disease keratoconjunctivitis keratitis herpes simplex virus leprosy dermatitis herpetiformis candidiasis yeast like fungal infection vulva vagina grand mal seizures complex partial seizures prevent seizures during following neurosurgery  injectable fos  phosphate ester prodrug formulation a188571  tonic clonic status epilepticus prevention seizures occurring during neurosurgery  allergic conjunctivitis vernal conjunctivitis episcleritis epinephrine sensitivity various infections gram positive gram negative bacteria aerobes anaerobes well types bacteria complete list organisms available fda indications section drug entry fda  following some major infections treated  fda  rocky mountain spotted fever typhus fever typhus group q fever rickettsialpox tick fevers rickettsiae respiratory tract infections mycoplasma pneumoniae lymphogranuloma venereum chlamydia trachomatis psittacosis ornithosis chlamydia psittaci trachoma chlamydia trachomatis although infectious agent always eliminated judged immunofluorescence inclusion conjunctivitis chlamydia trachomatis uncomplicated urethral endocervical rectal infections adults chlamydia trachomatis nongonococcal urethritis ureaplasma urealyticum relapsing fever borrelia recurrentis note regarding anti microbial resistance important note drug choice any type staphylococcal infection up 44 percent strains streptococcus pyogenes 74 percent streptococcus faecalis found resistant tetracyclines therefore tetracyclines should streptococcal infections unless microorganism demonstrated susceptible fda prostate cancer previously prevention miscarriage premature delivery pregnant women prone miscarriage premature delivery acne addition susceptible infections propionibacterium often cause acne   some infections treated include upper respiratory tract infections urinary tract infections bronchitis chlamydial infections rickettsial infections  topical preparations  topical cream topical following dermal infections f3088  f3121  tinea pedis tinea cruris tinea corporis trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum candidiasis candida albicans tinea versicolor malassezia furfur diaper rash infected candida albicans  some preparations  combined betamethasone dipropionate corticosteroid f3121   oral preparations oral troche preparation local oropharyngeal candidiasis fda  prophylactic drug reduce incidence oropharyngeal candidiasis immunocompromised conditions chemotherapy radiotherapy steroid therapy utilized leukemia solid tumors renal transplantation fda  troche preparations any systemic mycoses fda  one number calcium salts hyperphosphatemia too much phosphate blood kidney disease vulvovaginitis candida albicans up 5 drugs mycobacterium avium complex mac tuberculosis tb  thrombocythemia secondary malignant neoplasms reduce platelet count risk thrombosis beneficial amelioration thrombocythemia symptoms thrombo hemorrhagic events  brain tumors multiple myeloma hodgkin disease non hodgkin lymphomas severe repeated long lasting urinary tract infections meningococcal meningitis otitis media trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria bacterial infections angina heart failure myocardial infarction atrial fibrillation atrial flutter hypertension a175141  some off uses include supraventricular tachycardia thyroid storm a175141  all indications part cardiovascular diseases these conditions correspond number diseases involve function heart blood vessels underlying causes these conditions variable genetic disposition lifestyle decisions smoking obesity diet lack exercise comorbidity conditions diabetes cardiovascular diseases leading cause death global scale  eradication scabies  sarcoptes scabiei  symptomatic pruritic skin decreasing blood clotting often along heparin deep vein thrombosis female gynecologic obstetric infections susceptible aerobic gonococcus anaerobic bacteria signs symptoms parkinson disease primary moderate severe restless legs syndrome fda symptoms menopause deficiencies ovary function underdevelopment female sexual characteristics some types infertility  rare cases prostate cancer  prevent breast engorgement following childbirth mild moderate essential hypertension alone concurrently thiazide type diuretics alone wide variety diagnostic imaging methods angiography urography cholangiography computed tomography hysterosalpingography retrograde pyelography imaging gastrointestinal tract allergic barium clinically test gastric secretory function following conditions monotherapy partial onset primary generalized tonic clonic seizures age above adjunctive therapy partial onset seizures primary generalized tonic clonic seizures both pediatric above old 3 adjunctive therapy seizures lennox gastaut syndrome above age 4 prophylaxis migraine children 12 age older adults   off adjunct therapy weight  mood disorders a188312 infections susceptible organisms hypertension either alone antihypertensive agents f4709 f4712 a173869   off type diabetes nephropathy heart failure post myocardial infarction particularly unable tolerate ace inhibitors a178153 a185912 a185915 arbs shown number large scale clinical outcomes trials improve cardiovascular outcomes reducing risk myocardial infarction stroke progression heart failure hospitalization a174124 a178153 a173869 a185324 a185327 a185333 a185342 a185345 like arbs  blockade raas slows progression diabetic nephropathy renoprotective effects a185906 a185909 a185912 myeloid leukaemia symptoms reversible airflow obstruction chronic asthma chronic lung diseases emphysema chronic bronchitis prevention thrombosis heparin induced thrombocytopenia hit  risk hit undergoing percutaneous coronary intervention officially approved following indications   replacement therapy primary thyroidal  secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism   adjunct therapy surgery radioiodine thyroid cancer   diagnostic agent suppression tests mild hyperthyroidism thyroid gland autonomy fda  general terms exogenous replace insufficient hormonal production restore t3 plasma levels t457  lack presented pale puffy face coarse  brittle hair dry skin croaky voice constipation well irregular periods drowsiness lethargy t457  should never suppression benign nodules nontoxic diffuse goiter iodine sufficient nor hyperthyroidism during recovery phase subacute thyroiditis fda documented ventricular arrhythmias sustained ventricular tachycardia ventricular pre excitation cardiac dysrhythmias class ia antiarrhythmic drug anesthetic amide group production local regional anesthesia infiltration techniques percutaneous injection intravenous regional anesthesia peripheral nerve block techniques brachial plexus intercostal central neural techniques lumbar caudal epidural blocks f4349  pamidronate moderate severe hypercalcemia malignancy moderate severe paget disease bone osteolytic bone metastases breast cancer osteolytic lesions multiple myeloma  relief symptoms allergic rhinitis sneezing rhinorrhea pruritus acrimation mild uncomplicated allergic skin manifestations urticaria angioedema self medication temporary relief symptoms common cold diabetes type ii therapy second third line agent major depressive disorder mdd  generalized anxiety disorder gad  social anxiety disorder social phobia  panic disorder without agoraphobia  off prophylaxis migraine headaches a177229  reduction vasomotor symptoms menopause a177238  neuropathic pain although there only minimal evidence efficacy condition  a177232  considered second line option obsessive compulsive disorder ocd  a177226 a177235  several different conditions   moderate severe vasomotor symptoms menopause  moderate severe symptoms vulvar vaginal atrophy menopause  hypoestrogenism hypogonadism castration primary ovarian failure  palliative breast cancer appropriately selected metastatic disease  palliative androgen dependent carcinoma prostate  preventive therapy postmenopausal osteoporosis a38238  ophthalmic solution reduction elevated intraocular pressure open angle glaucoma ocular hypertension f3061 f3064    currently decrease elevated intraocular pressure paediatric aged months lt 18 ocular hypertension paediatric glaucoma  relief inflammatory pruritic manifestations corticosteroid responsive dermatoses attention deficit hyperactivity disorder adhd children adults palliative malignant neoplasm trachea bronchus lung  squamous cell carcinoma lymphomas chronic lymphatic lymphocytic leukemia  childhood minimal change nephrotic syndrome malignant lymphomas lymphosarcoma giant follicular lymphoma hodgkin disease  non hodgkin lymphomas waldenstrm macroglobulinemia induction general anesthesia malignant neoplasm colon rectum administered subdermal implants long acting reversible contraception known effective postpartum insertion breastfeeding women a175990  part long acting contraceptive implants prevent pregnancy implant effect remain 5  chronic moderate severe pain a176050  opiods  effective short term pain taking opioids long term need monitored development physical dependence addiction disorder drug abuse  obstetric anesthesia regional anesthesia surgery production local regional anesthesia analgesia surgery oral surgery procedures diagnostic therapeutic procedures obstetrical procedures iatrogenically induced mydriasis produced adrenergic phenylephrine parasympatholytic tropicamide agents certain eye examinations recurrent cold sores lips face from various herpesvirus invections tenofovir antiretroviral agents hiv infection adults pediatric age older chronic hepatitis b adults pediatric 12 age older fda  drug component multiple products hiv infection f3418  f3421   safety effectiveness pediatric younger than age established date fda bacterial infection susceptible microorganisms hemophilia short term two eight days reduce prevent hemorrhage reduce need replacement therapy during following tooth extraction excessive bleeding menstruation surgery trauma cases following moderate severe infections susceptible isolates designated microorganisms  complicated intra abdominal infections escherichia coli  clostridium clostridioforme  eubacterium lentum  peptostreptococcus species  bacteroides fragilis  bacteroides distasonis  bacteroides ovatus  bacteroides thetaiotaomicron  bacteroides uniformis  complicated skin skin structure infections diabetic foot infections without osteomyelitis staphylococcus aureus  methicillin susceptible isolates only  streptococcus agalactiae  streptococcus pyogenes  escherichia coli  klebsiella pneumoniae  proteus mirabilis  bacteroides fragilis  peptostreptococcus species  porphyromonas asaccharolytica  prevotella bivia  3 community acquired pneumonia streptococcus pneumoniae  penicillin susceptible isolates only cases concurrent bacteremia  haemophilus influenzae  beta lactamase negative isolates only  moraxella catarrhalis  4 complicated urinary tract infections pyelonephritis escherichia coli  cases concurrent bacteremia klebsiella pneumoniae  5 pelvic infections postpartum endomyometritis septic abortion post surgical gynecologic infections streptococcus agalactiae  escherichia coli  bacteroides fragilis  porphyromonas asaccharolytica  peptostreptococcus species prevotella bivia oral ethinylestradiol contraceptive agent prevention pregnancy fda  part combined oral contraceptives contain mix estrogen progestin inhibit ovulation  malignant neoplasm lip oral cavity pharynx digestive organs peritoneum female breast urinary bladder adjunct ab externo glaucoma surgery  pyelocalyceal solution adults low grade upper tract urothelial cancer lg utuc  sedative hypnotic orally skin manifestations cutaneous t cell lymphoma ctcl refractory least one prior systemic therapy topically skin lesions early stage ia ib ctcl experience refractory persistent disease therapies intolerant therapies rapid conversion atrial fibrillation atrial flutter recent onset sinus rhythm leukaemia malignant lymphoma hodgkin disease erythraemia panmyelosis hypertension either sole therapeutic agent enhance effect antihypertensive drugs more severe forms hypertension  adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy  found useful edema various forms renal dysfunction nephrotic syndrome glomerulonephritis chronic renal failure duodenal ulcers diuretic glaucoma useful seizures epilepsy short term insomnia  monotherapy adjunctive therapy complex partial seizures simple complex absence seizures  adjunctive therapy multiple seizure types include absence seizures  3 prophylaxis migraine headaches  4 mania bipolar disorder  off uses include  maintenance therapy bipolar disorder a177919  bipolar depression a177928 a177931 a177934  3 emergency status epilepticus a177955 tuberculosis drugs migraine without auras aged 18 over  general  mild moderate pain reduction fever f4124 available over counter various forms most common being oral forms  injection mild moderate pain moderate severe pain adjunctive opioid analgesics reduction fever  because low risk causing allergic reactions drug administered intolerant salicylates those allergic tendencies bronchial asthmatics f4124 specific dosing guidelines should followed administering children  continued locally advanced metastatic non small cell lung cancer after failure either platinum based docetaxel chemotherapies sulfate form drug commonly available tablet form fda relief mild moderately severe pain where opioid analgesic appropriate fda  solution form itself combined syrup drugs cough suppressant adults aged 18 above     polymicrobial infections migraine headaches without aura cluster headache episodes drug following conditions fda  major depressive disorder adults neuropathic pain adults prophylactic chronic tension type headache ctth adults prophylactic migraine adults nocturnal enuresis children aged 6 above organic pathology spina bifida related disorders excluded no response achieved all non drug drug treatments antispasmodics vasopressin related products product should only prescribed healthcare professional expertise persistent enuresis fda  off uses irritable bowel syndrome sleep disorders diabetic neuropathy agitation fibromyalgia insomnia palliative gastrointestinal adenocarcinoma metastatic liver given continuous regional intra arterial infusion carefully selected considered incurable surgery means palliative liver cancer usually administered hepatic intra arterial infusion adjunct levodopa carbidopa therapy symptomatic parkinson disease drug generally reserved parkinsonian syndrome receiving levodopa carbidopa experiencing symptom fluctuations responding adequately candidates adjunctive therapies ophthalmic corticosteroid responsive inflammation palpebral bulbar conjunctiva cornea anterior segment globe immediate reduction blood pressure hypertensive crises reduce bleeding during surgery congestive heart failurefor mild hypocalcemia neonatal tetany tetany parathyroid deficiency vitaminD deficiency alkalosis prophylaxis hypocalcemia during exchange transfusions intestinal malabsorption replenish electrolytes moderate severe pain severe chronic pain addictive potential overdose risk  only prescribed first line treatments failed a176468  proposed three step ladder pain suggested start non opioid medication followed addition weak opioids non opioid moderate pain finishing strong opioids along existing regimen cases severe pain a176471  off  administered suppression refractory cough a176468 oral indometacin symptomatic moderate severe rheumatoid arthritis flares chronic disease moderate severe ankylosing spondylitis moderate severe osteoarthritis painful shoulder bursitis tendinitis gouty arthritis a177871   intravenous indometacin induce closure hemodynamically significant patent ductus arteriosus premature infants weighing between 500 1750 g after 48 hours usual medical e g  fluid restriction diuretics digitalis respiratory support etc  ineffective  adjunct pulmonary tuberculosis tablet  adjunct diet exercise increase glycemic control adults pediatric 10 age older diagnosed type diabetes mellitus fda  extended release tablet xr  extended release form adjunct diet exercise improve glycemic control only adults type diabetes mellitus safety children determined date fda  extended release product containing empagliflozin linagliptin approved fda january 2020 improvement glycemic control adults type diabetes mellitus adjunctively diet exercise  inhaled inhaled beta agonist systemic corticosteroids severe exacerbations asthma flares requiring a176939  asthma exacerbations characterized progressive increase one more asthma symptoms accompanied decrease expiratory flow   single agent  symptomatic relief rhinorrhea common cold seasonal allergic rhinitis 5 older does alleviate nasal congestion nor sneezing fda  rhinorrhea refers recurrent chronic watery nasal discharge condition debilitating pathogenesis etiology complex very well understood presenting very substantial cost burden   additionally  bronchodilator maintenance bronchospasm chronic obstructive pulmonary disease chronic bronchitis emphysema fda  chronic obstructive pulmonary disease includes large number conditions characterized breathlessness includes several conditions etiology symptoms treatments diverse   studied sialorrhea a176942  sialorrhea common symptom accompanies different neurologic conditions characterized drooling excessive salivation a176963 pain severe enough require opioid analgesic alternative options inadequate recommended reserved whom alternative options eg nonopioid analgesics opioid products ineffective tolerated would otherwise inadequate provide sufficient pain f4688  detoxification opioid addiction heroin morphine like drugs  maintenance substitution opioid dependence adults conjunction appropriate social medical services f4685 f4691 initially orally intramuscularly chronic schizophrenia over 13 old psychiatric disorders bipolar i disorder mixed manic episodes a177014   lithium valproate short term manic mixed episodes bipolar i disorder adults fda  well  fluoxetine episodes depression bipolar disorder type resistant depression over 10 old a177014  approved psychomotor agitation schizophrenia bipolar i mania fda  schizophrenia complex biochemical brain disorder affects person ability differentiate reality usually observed presence delusions hallucinations social withdrawal disturbed thinking   bipolar disorder mental health condition defined periods extreme mood disturbances categorized different types from type known involve episodes severe mania often depression while type presents less severe forms mania   hypertension alone antihypertensives  angina pectoris coronary atherosclerosis  3 myocardial infarction hemodynamically stable heart rate greater than 50 beats per minutes systolic blood pressure above 100 mmhg  off uses include  secondary prevention myocardial infarction a178156  heart failure a178153  3 atrial fibrillation a178141  4 supraventricular tachycardia a178162  5 ventricular arrythmias congenital long qt arrhythmogenic right ventricular cardiomyopathy a178168  6 symptomatic thyrotoxicosis methimazole  a178147  7 prophylaxis migraine headaches a178171  8 alcohol withdrawal a178174 a178177 bacterial skin infections pyodermas infected dermatoses infections cuts wounds burns ulcers susceptible organisms mild moderate atopic dermatitis  according fda fda proton pump inhibitor ppi following purposes   active duodenal ulcer adults   eradication helicobacter pylori reduce risk duodenal ulcer recurrence adults   active benign gastric ulcer adults   symptomatic gastroesophageal reflux disease gerd year age older   erosive esophagitis ee acid mediated gerd month age older   maintenance healing ee acid mediated gerd year age older   pathologic hypersecretory conditions adultsfor initial active tuberculosis adults children combined antituberculous agents symptomatic parkinsonism seasonal allergic rhinitis relief symptoms seasonal allergic rhinitis allergens ragweed grass tree pollens adults children age above symptoms treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing redness eyes fda   perennial allergic rhinitis drug relief symptoms perennial allergic rhinitis allergens dust mites animal dander molds adults children 6 months age older symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus tearing fda   chronic urticaria  uncomplicated skin manifestations chronic idiopathic urticaria adults children 6 months age older markedly reduces occurrence severity duration hives significantly reduces pruritus fda allergic rhinitis hay fever allergic skin disorders oral hypertension lower blood pressure alone antihypertensive agents   improve exercise tolerance chronic stable angina   variant angina prinzmetal angina   intravenous short term atrial fibrillation atrial flutter temporary control rapid ventricular rate   rapid conversion paroxysmal supraventricular tachycardias psvt sinus rhythm includes av nodal reentrant tachycardias reciprocating tachycardias extranodal accessory pathway wpw syndrome short pr syndrome   off off uses anal fissures topical formulation  migraine prophylaxis cramps lower leg related rest pulmonary hypertension  idiopathic dilated cardiomyopathy proteinuria diabetic nephropathy  depression measure effective renal plasma flow erpf determine functional capacity tubular excretory mechanism reduction urinary obstruction relief manifestations eg sensation incomplete bladder emptying straining urgency interrupted weak stream symptomatic beningn prostatic hyperplasia control absence petit mal seizures refractory medications adjunct dietary restriction tyrosine phenylalanine hereditary tyrosinemia type epilepsy seizures lennox gastaut syndrome difficult form childhood epilepsy severe hypertension topical regrowth androgenic alopecia males females stabilisation hair loss androgenic alopecia anorexia cachexia unexplained significant weight loss diagnosis acquired immunodeficiency syndrome aids  palliative recurrent inoperable metastatic breast cancer endometrial cancer prostate cancer canada some countries remission induction remission consolidation nonlymphocytic leukemias prevention control excessive bleeding following vaginal childbirthfor prevention nausea vomiting dizziness motion sickness vertigo dizziness medical problems following infections susceptible gram negative microorganisms urinary tract infections lower respiratory tract infections septicemia skin skin structure infections intra abdominal infections gynecologic infections relief discomfort painful musculoskeletal conditions suppression adrenal function selected cushing syndrome malignant neoplasm female breast carcinoma situ breast mild moderate malaria uine susceptible strains plasmodium falciparum  both chloroquine susceptible resistant strains plasmodium vivax  prophylaxis plasmodium falciparum plasmodium vivax malaria infections prophylaxis chloroquine resistant strains plasmodium falciparum rheumatic fever meningococcal meningitisfor tetrahydrobiopterin bh4 deficiency  tartrate adults advanced non small cell lung cancer nsclc  single therapy chemotherapeutic drugs   relapsed refractory hodgkin lymphoma chemotherapy agents    desmoid tumor aggressive fibromatosis methotrexate   recurrent metastatic squamous cell head neck cancer   recurrent ovarian cancer   metastatic breast cancer previously treated anthracyline taxane therapy   her2 positive trastuzumab resistant advanced breast cancer previously treated taxane trastuzumab everolimus   following fungal infections candidemia forms candida infections intra abdominal abscess peritonitis  aspergillus infections esophageal candidiasis considered alternative oropharyngeal canaidiasis resistant schizophrenia suspension fda tablet f4534 active duodenal ulcer up 8 weeks  tablet form lower dose healed duodenal ulcers purpose maintaining healing preventing recurrence f4519 f4534   prevention gastro esophageal reflux disease gerd  gastritis peptic ulcer disease stress ulcer addition dyspepsia a177655 f4519 adults mild moderate infections susceptible strains haemophilus influenzae  streptococcus pneumoniae  moraxella catarrhalis alone short term sleep aid drugs night time cold allergy relief drug vitamin b6 pyridoxine prevent morning sickness pregnant women emergency contraception  single agent emergency contraceptive form prevention pregnancy after confirmed suspected failure contraception methods following unprotected intercourse distributed prescription under 17 over counter those above age  only form contraception regular contraception must taken soon possible within 72 hours after intercourse a181976  shown lower efficacy off within 96 hours t659  long term contraception nonemergency contraception addition above indication emergency contraception  combined contraceptives contraceptive formulations designed regular example ethinyl estradiol  various hormone releasing intrauterine devices long term contraception ranging duration 3 5   product labeling mirena specifically mentions recommended women had least child  subdermal implant available prevention pregnancy up 5   hormone therapy off uses  prescribed estradiol hormone therapy during menopause manage vasomotor symptoms prevent osteoporosis  off  menorrhagia endometrial hyperplasia endometriosis t659 mainly vasodilatory shock states septic shock neurogenic shock shown survival benefit over dopamine vasopressor medication critical hypotension cmv retinitis acquired immunodeficiency syndrome aids drug major depressive disorder symptoms fda  off variety conditions panic disorder generalized anxiety disorder dysthymia tension headaches hot flushes post traumatic stress disorder ptsd  sleep disorders substance abuse disorders sexual disorders among others a177811 a177946 anxiety disorders short term relief symptoms anxiety relief nausea vomiting ophthalmic increased intraocular pressure ocular hypertension open angle glaucoma oral form drug high blood pressure   certain cases  prevention migraine headaches a179530  continuous subcutaneous infusion intravenous infusion those able tolerate subcutaneous infusion pulmonary arterial hypertension nyha class ii iv symptoms diminish symptoms exercise adjunctive therapy diet reduction elevated serum total low density lipoprotein cholesterol ldl c primary hypercholesterolemia condition features elevated ldl c do respond adequately dietary changes  fda f4555  therapy lipid altering agents like should component multiple risk factor intervention those individuals significantly increased risk atherosclerotic vascular disease hypercholesterolemia fda  f4555  should begin continue dietary therapy fda  f4555  general minimum six months intensive dietary therapy counseling should carried out prior initiation drug therapy  fda f4555  shorter periods considered severe elevations ldl c definite coronary heart disease fda f4555  although effective all types hypercholesterolemia some regional prescribing information note particular medically most appropriate fredrickson type ii hyperlipoproteinemia   nevertheless combined hypercholesterolemia hypertriglyceridemia although helpful reducing elevated cholesterol formally where hypertriglyceridemia abnormality greatest concern f4567 parkinson disease extrapyramidal reactions drugs prevention delayed nausea vomiting initial repeat courses moderately emetogenic cancer chemotherapy well prevention nausea vomiting highly emetogenic cancer chemotherapy prevention postoperative nausea vomiting up 24 hours post operation irregular duration cycles irregular occurrence duration periods progesterone deficiency prevent natural abortion history habitual abortions ventricular tachycardia symptomatic premature ventricular beats prevention ventricular fibrillation reducing incidence severity cardiomyopathy doxorubicin administration women metastatic breast cancer received cumulative doxorubicin hydrochloride dose 300 mg m would benefit from continued doxorubicin therapy approved extravasation from intravenous anthracyclines alone antihypertensive antianginal agents following conditions fda   hypertension   coronary artery disease  chronic stable angina  vasospastic angina prinzmetal variant angina   angiographically documented coronary artery disease without heart failure ejection fraction lt 40 palliative mild moderate dementia alzheimer type peptic ulcer disease relief smooth muscle spasms gastrointestinal disorders edema congestive heart failure cirrhosis liver nephrotic syndrome steroid induced edema idiopathic edema edema secondary hyperaldosteronism   hydrochlorothiazide managment hypertension edema develop hypokalemia following hydrochlorothiazide monotherapy require thiazide diuretic whom development hypokalemia cannot risked   allows maintenance potassium balance given loop diuretics thiazides t28 cancer bladder all forms parkinson disease well control extrapyramidal reactions induced antipsychotic agents injections hypotension shock anesthesia   ophthalmic formulation dilate pupils  induce vasoconstriction intranasal formulation congestion topical formulation hemorrhoids a187370 off uses include situations require local blood flow restriction priapism a187370 hyperthyroidism thyrotoxicosis prepare thyroidectomy following conditions mild moderate heart failure  increase myocardial contraction children diagnosed heart failure  3 maintain control ventricular rate diagnosed chronic atrial fibrillation   adults heart failure clinically possible  should administered conjunction diuretic angiotensin converting enzyme ace inhibitor optimum effects   schizophrenia parkinson disease control severe reactions certain medicines reserpine adjunct improve neurologic outcome following subarachnoid hemorrhage sah from ruptured intracranial berry aneurysms reducing incidence severity ischemic deficits oral inhalation maintenance asthma prophylactic therapy 5 age older aerosol form beclomethasone diproprionate relief bronchospasm   intranasal relieve symptoms seasonal perennial allergic nonallergic vasomotor rhinitis prevent recurrence nasal polyps following surgical removal   relief inflammatory pruritic manifestations corticosteroid responsive dermatoses 13 age older  corticosteroid responsive dermatoses include psoriasis contact dermatitis dermatitis venenata  atopic dermatitis infantile eczema allergic dermatitis  neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis  intertrigo dyshidroses pompholyx  seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis anogenital senile pruritus  relief discomfort related painful musculoskeletal conditions fda   important limitations fda   should only periods up two three weeks   adequate evidence effectiveness more prolonged established   recommended pediatric less than 16 agegelatinized capsules gelatinized capsules prevention endometrial hyperplasia non hysterectomized postmenopausal women receiving conjugated estrogens tablets they secondary amenorrhea fda   vaginal gel  gel 8  supplementation replacement part assisted reproductive technology  art  infertile women deficiency  lower concentration gel 4  secondary amenorrhea 8 concentration if there no therapeutic response 4 gel f3898  vaginal insert form support embryo implantation early pregnancy supplementation corpus luteal function part assisted reproductive technology art program infertile women f3901  injection intramuscular  drug amenorrhea abnormal uterine bleeding hormonal imbalance absence organic pathology submucous fibroids uterine cancer f3907   tablets contraceptive tablet form contraceptive formulations prevention pregnancy f3904  nasal congestion control urinary incontinence priapism obesity unresectable hepatocellular carcinoma advanced renal cell carcinoma  hypercalcemia malignancy multiple myeloma bone metastases from solid tumors osteoporosis men postmenopausal women glucocorticoid induced osteoporosis paget disease bone men women    prevention osteoporosis post menopausal women glucocorticoid induced osteoporosis   ringworm infections skin hair nails namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap conditions trichophyton microsporum fungi hypertension alone antihypertensive agents insomnia  caerulein paralytic ileus diagnostic aid pancreatic malfunction anxiety disorder anxiety depression panic disorder panic disorder agoraphobia  prescribed off insomnia premenstrual syndrome depression a177973 relief symptoms allergies hay fever coldsfor bacterial fungal infections inside mouth thrush skin prevention transmission chagas disease blood additive prevention deep vein thrombosis result pulmonary embolism following knee surgery manifestations psychotic disorders schizophrenia atypical antipsychotic once schizophrenia a215532 impetigo secondary skin infections leading traumatic skin lesions staphylococcus aureus streptococcus pyogenes  primarily glaucoma but during ophthalmic surgery adjunct diet exercise improve glycemic control adults type diabetes mellitus drug symptomatic parkinson disease fda  drug administered monotherapy conjunction levodopa symptomatic moderate severe primary restless legs syndrome rls  fda  diabetes mellitus type onset infection respiratory gi uti meningitis e coli p mirabilis enterococci shigella typhosa salmonella nonpenicillinase producing n gononhoeae h influenzae staphylococci streptococci streptocfor anesthesia adjunct induce skeletal muscle relaxation reduce intensity muscle contractions convulsive therapy mild moderately severe infections penicillin g sensitive microorganisms bacteriological studies sensitivity tests clinical response     mild moderate infections upper respiratory tract scarlet fever mild erysipelas streptococcus without bacteremia  mild moderately severe infections respiratory tract pneumococcus  mild infections skin soft tissues penicillin g sensitive staphylococcus  mild moderately severe infections oropharynx fusospirochetosis vincent gingivitis pharyngitis usually respond oral penicillin therapy off prophylaxis against bacterial endocarditis congenital heart disease rheumatic acquired valvular heart disease they undergo dental procedures surgical procedures upper respiratory tract short term intractable insomnia habituated barbituratesfor mild moderate type nonneuropathic gaucher disease whom enzyme replacement therapy therapeutic option e g constraints allergy hypersensitivity poor venous access  now approved some countries progressive neurological symptoms pediatric niemann pick disease type c np c  adjunct short term moderate severe psychomotor agitation agitation restlessness elderly new york heart association class iii iv heart failure edema cirrhotic adults responsive fluid sodium restrictions primary hyperaldosteronism short term preoperatively primary hyperaldosteronism long term aldosterone producing adrenal adenomas candidates surgery bilarteral micro macronodular adrenal hyperplasia add therapy hypertension nephrotic syndrome disease well fluid sodium restriction diuretics inadequate  antiandrogenic activity leads many off uses  off hirsutism female pattern hair loss acne vulgaris a178135  frequently antiandrogenic effects transgender female low cost reducing male pattern hair growth a178138 attention deficit hyperactivity disorder adhd 6 age older narcolepsy tablets intramuscular injections united states adjunct rest physical therapy measures relief discomforts painful musculoskeletal conditions  oral america given up 1500mg 4 times daily 3 days a31312  canada  containing oral formulations sold over counter pain muscle spasm  however if these formulations include codeine they prescription only  bladder spasms peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis pancreatitis certain heart conditions control symptoms parkinson disease rhinitis drug short term insomnia adults characterized difficulties sleep initiation fda  herpes zoster shingles  suppression recurrent genital herpes immunocompetent recurrent mucocutaneous herpes simplex infections hiv infected symptomatic relief seasonal perennial allergic rhinitis nonallergic rhinitis allergic conjunctivitis mild uncomplicated allergic skin manifestations urticaria angioedema agents symptomatic relief symptoms common cold malignant neoplasms pancreas metastatic islet cell carcinoma aborting pregnancy between 13th 20th weeks gestation calculated from first day last normal menstrual period following conditions related second trimester abortion failure expulsion fetus during course another method premature rupture membranes intrauterine methods loss drug insufficient absent uterine activity 3 requirement repeat intrauterine instillation drug expulsion fetus 4 inadvertent spontaneous rupture membranes presence previable fetus absence adequate activity expulsion postpartum hemorrhage uterine atony responded conventional methods severe infections susceptible bacteria p aeruginosa infested sarcoptes scabiei pediculosis capitis either failed respond adequate doses intolerant approved therapies primay keratoconjunctivitis recurrent epithelial keratitis herpes simplex virus types ophthalmic solutions   tipiracil oral tablets metastatic colorectal cancer previously treated fluoropyrimidine  oxaliplatin irinotecan based chemotherapy anti vegf biological therapy if ras wild type anti egfr therapy fda symptomatic severe nausea vomiting  manifestations psychotic disorders schizophrenia generalized non psychotic anxiety generalized non psychotic anxiety typically first line therapy should limited doses less than 20 mg per day shorter than 12 weeks  off uses include emergency settings pediatric migraines american headache society recommends first line medication setting pediatric migraines non steroidal anti inflammatory agent often dopamine antagonist  perennial seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis inhalant allergens foods mild uncomplicated allergic skin manifestations urticaria angioedema amelioration allergic reactions blood plasma cold urticaria dermatographism therapy anaphylactic reactions adjunctive epinephrine term near term  amp gt 34 weeks neonates hypoxic respiratory failurefor high blood pressure edema related heart failure fda  signs symptoms primary secondary gout attacks tophi joint destruction uric acid lithiasis nephropathy  leukemia lymphoma malignancies receiving cancer therapy causes elevations serum urinary uric acid levels should discontinued potential overproduction uric acid no longer present  3 recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg day male 750 mg day female therapy should carefully assessed initially reassessed periodically determine each case beneficial benefits outweigh risks infections susceptible strains organisms following diseases lower respiratory tract infections skin skin structure infections urinary tract infections bacterial septicemia bone joint infections gynecologic infections intra abdominal infections peritonitis  central nervous system infections meningitis adjunct diet reduction elevated total ldl cholesterol levels primary hypercholesterolemia mixed dyslipidemia fredrickson types iia iib response dietary restriction saturated fat cholesterol non pharmacological measures alone inadequate monotherapy  episodes uncomplicated urinary tract infections susceptible bacteria e coli  k pneumoniae enterobacter spp  p mirabilis coagulase negative staphylococcus species   various formulations sulfamethoxazole  following infections bacteria documented susceptibility urinary tract infections otitis media pediatric clinically  exacerbations chronic bronchitis adults enteritis susceptible shigella prophylaxis pneumocystis jiroveci pneumonia travelers diarrhea enterotoxigenic e coli    available ophthalmic solution polymyxin b bacterial conjunctivitis blepharitis blepharoconjunctivitis susceptible bacteria  advanced ovarian cancer relapsed least 6 months after completion platinum based therapy metastatic ovarian cancer inoperable locally advanced stage iiia iiib  metastatic stage iv non small cell lung cancer locally advanced nonresectable stage ii stage iii metastatic stage iv adenocarcinoma pancreas chronic hepatitis b virus infection adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active disease member corticosteroid family  several inflammatory conditions topical monotherapy  relieve pruritic inflammatory symptoms corticosteroid responsive dermatoses    topically vitaminD analog calcipotriene plaque psoriasis  corticosteroid available injectable suspension manage range inflammatory conditions endocrine disorders gastrointestinal disorders rheumatic disorders among conditions   refractory lymphoblastic leukaemiafor component adjuvant therapy evidence axillary node tumor involvement following resection primary breast cancer cholera destroys vibrios decreases diarrhea effective against tetracycline resistant vibrios eye drops ointment bacterial conjunctivitis upper respiratory tract bacterial infections chronic bronchitis pneumonia sinusitis pharyntitis tonsillitis skin absceses urinary tract infections pyelonephritis e coli  pyogenes  aureus  saprphyticus  penumoniae  h influenzae m catarrhalis  reduce gastric acid secretion approved short term active gastric ulcers active duodenal ulcers erosive reflux oesophagitis symptomatic gastroesophageal reflux disease non steroidal anti inflammatory drug nsaid induced gastric duodenal ulcers  a4892 a177065 fda  maintenance healing several gastric conditions duodenal ulcers nsaid related gastric ulcers erosive esophagitis fda  prevents recurrence gastric ulcers documented history gastric ulcers nsaids chronically  fda  predictably useful hypersecretory conditions zollinger ellison syndrome  fda  effective eradicating h pylori conjunction amoxicillin clarithromycin triple therapy amoxicillin alone dual therapy  fda prodrug initial therapy control intraocular pressure chronic open angle glaucoma ssed produce tranquilization reduce incidence nausea vomiting surgical diagnostic procedures replacement therapy primary thyroidal  secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism adjunct surgery radioiodine therapy thyrotropin dependent well differentiated thyroid cancer bacterial blepharitis bacterial bonjunctivitis corneal injuries corneal ulcers meibomianitis prophylaxis ocular infections following foreign body removalfor brucellosis mycoplasma infection acne vulgaris chlamydial infection chronic bronchitisused control moderate severe pain 2nd generation antihistamine manage symptoms allergic rhinitis wheal formation urticaria allergic dermatologic conditions a176435 a176438  prevent infection during surgery many kinds infections blood bone joints respiratory tract skin urinary tract drug hypertension high blood pressure  given alone given blood pressure lowering drugs diuretics beta adrenergic blocking agents fda   does negatively impact lung function therefore manage hypertension asthmatic chronic obstructive lung disease copd a176630 relief symptoms depression temporary adjunctive therapy reducing enuresis children aged 6 older fda   off manage panic disorders without agoraphobia second line agent adhd children adolescents manage bulimia nervosa short term depressive episodes bipolar disorder schizophrenia stress disorder posttraumatic stress disorder symptomatic postherpetic neuralgia painful diabetic neuropathy  a31900  a31904  severe psoriasis adults predominantly classic subfoveal choroidal neovascularization age related macular degeneration pathologic myopia presumed ocular histoplasmosis syndrome  destroy tumors  symptomatic relief rheumatoid arthritis  symptomatic relief osteoarthritis adjunctive therapy peptic ulcer nausea vomiting motion sickness epilepsy small uncomplicated varicose veins lower extremities show simple dilation competent valves non steroidal anti inflammatory drug nsaid antipyretic analgesic anti inflammatory properties  a176131  short term pain requires caliber pain offered opioids   clinicians choose initiate manage post operative pain spinal soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorders headaches among ailments   regardless etiology pain should lowest possible dose avoid using extended period time ideally  5 days   benefit choosing over analgesics similar potency that there does appear risk dependence tolerance a176131   internally relieving respiratory distress antidote poisoning cns depressants especially barbiturates adults  amp ge 18 age following infections susceptible strains designated microorganisms  uncomplicated urethral cervical gonorrhea neisseria gonorrhoeae  uncomplicated urinary tract infections cystitis escherichia coli  staphylococcus epidermidis  staphylococcus saprophyticus  3 complicated urinary tract infections escherichia coli  klebsiella pneumoniae  proteus mirabilis  pseudomonas aeruginosa  staphylococcus epidermidis  enterobacter cloacae malaria leg crampsfor rheumatoid arthritis osteoarthritis backache pain anorexia weight loss aids nausea vomiting cancer chemotherapy failed respond adequately conventional antiemetic treatments  prophylaxis chronic asthma adults pediatric 12 months age older  although regional health authorities specifically note indication adults adolescents 15 older  include indications preventing day night time symptoms acetylsalicylic acid sensitive asthma   b prevention exercise induced bronchoconstriction eib 6 age older  although regional health authorities specifically note indication adults adolescents 15 older    c relief symptoms seasonal allergic rhinitis age older perennial allergic rhinitis 6 months age older  although regional health authorities specifically note relief seasonal allergic rhinitis symptoms adults adolescents 15 older   furthermore some formulations like chewable tablets specifically particular regulatory bodies prophylaxis chronic asthma prevention day night time symptoms acetylsalicylic acid based asthma prevention exercise induced bronchoconstriction pediatric aged older  between ages 5  between ages 6 14   moreover employed indications considered effective monotherapy combined medications maintenance chronic asthma   instance  inhaled corticosteroids concomitantly demonstrate additive effects control asthma decrease necessary inhaled corticosteroid dose while still maintaining clinical stability   additionally continue experience asthma symptoms  combined required short acting beta agonist inhaled corticosteroid inhaled corticosteroid paired long acting beta agonist   both maintenance major depressive disorder obsessive compulsive disorder bulimia nervosa however only panic disorder independent whether agoraphobia present   olanzapine depression related bipolar i disorder resistant depression  local anesthetic surface application infiltration nerve block intravenous anaesthetic commonly induce deep sedation anxiety disorders short term relief symptoms anxiety withdrawal symptoms alcoholism preoperative apprehension anxiety  major depressive disorder  generalized anxiety disorder  3 diabetic peripheral neuropathy  4 fibromyalgia  5 chronic musculoskeletal pain  6 osteoarthritis knee adults   7 chronic lower back pain adults   8 stress urinary incontinence women   off uses include  chemotherapy induced peripheral neuropathy a178603  stress urinary incontinence men after prostatectomy until recovery complete  schizophrenia control nausea vomiting relief restlessness apprehension before surgery intermittent porphyria adjunct tetanus control manifestations manic type manic depressive illness relief intractable hiccups severe behavioral problems children 12 age marked combativeness explosive hyperexcitable behavior out proportion immediate provocations  short term hyperactive children show excessive motor activity accompanying conduct disorders consisting some all following symptoms impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance prophylaxis illness various strains influenza virus adults sulfate injection short term serious bacterial infections susceptible strains gram negative bacteria pseudomonas species escherichia coli species indole positive indole negative proteus providencia species klebsiella enterobacter serratia species well acinetobacter mima herellea species f1954  clinical studies shown sulfate injection effective bacterial septicemia neonatal sepsis  serious infections respiratory tract bones joints central nervous system meningitis skin soft tissue intra abdominal infections peritonitis  burns postoperative infections post vascular surgery  f1954  clinical studies shown effective serious complicated recurrent urinary tract infections above organisms aminoglycosides  uncomplicated first time episodes urinary tract infections unless causative organisms susceptible antibiotics less toxic f1954  september 2018 new indication new dosage route approved drug  liposome inhalation suspension approved lung disease group bacteria mycobacterium avium complex mac limited population disease do respond conventional refractory disease   indication approved under accelerated approval based achieving sputum culture conversion defined 3 consecutive negative monthly sputum cultures month 6 clinical benefit yet established  important notes regarding staphylococcus sensitivity testing  staphylococcus aureus methicillin resistant strains principal gram positive organism sensitive  staphylococcal infections should restricted only second line therapy should limited only those suffering from severe infections susceptible strains staphylococcus species failed show sensitivity available antibiotics f1949  bacteriologic studies should performed identify causative organisms their susceptibilities  initial therapy suspected gram negative infections therapy initiated before obtaining results susceptibility testing f1949 f1954 multiple myeloma dexamethasone transfusion dependent anemia low intermediate risk myelodysplastic syndromes mds deletion 5q cytogenetic abnormality without additional cytogenetic abnormalities prevention osteoporosis postmenopausal women well prevention corticosteroid induced bone loss  reduction risk invasive breast cancer postmenopausal women osteoporosis postmenopausal women high risk invasive breast cancer symptomatic osteoarthritis oa rheumatoid arthritis ra   substitute aspirin cardiovascular event prophylaxis   be pain from various sources juvenile rheumatoid arthritis children over ankylosing spondylitis primary dysmenorrhea  adjuncts anesthesia induce skeletal muscle relaxation facilitate undergoing mechanical ventilationopthalmic lowering intraocular pressure iop open angle glaucoma ocular hypertension monotherapy product brinzolamide  topical persistent non transient facial erythema rosacea adults 18 age older  infections penicillinase producing staphylococci demonstrated susceptibility drug nausea vomiting cancer chemotherapy failed respond adequately conventional antiemetic treatments restriction required because substantial proportion any group treated expected experience disturbing psychotomimetic reactions observed antiemetic agents uncomplicated gonococcal urethritis males gram negative bacterial infections gastrointestinal system genitourinary tract single agent palliative persistent recurrent ovarian cancer following first line therapy cisplatin alkylating agent based life threatening ventricular arrhytmias maintain normal sinus rhythm atrial fibrillation flutter there oral solutions intravenous injections requiring  but whom tablet would appropriate  anxiety disorders short term relief symptoms anxiety  adjunct diet improve glycemic control non insulin dependent diabetes mellitus niddm whose hyperglycemia cannot managed diet alone treating mild moderate hypertension adjunct treating congestive heart failure slow rate progression renal disease hypertensive individuals diabetes mellitus microalbuminuria overt nephropathy gonorrhoea meningitis severe infections infections kidney pyelonephritis urinary system before operation prevent infection after surgery adjunct levodopa  carbidopa symptomatic idiopathic parkinson disease experience signs symptoms end dose wearing off antiretroviral agents human immunovirus hiv infections overactive bladder symptoms urge urinary incontinence urgency frequency moderate severe pain there extended release formulation chronic moderate severe pain requiring continuous opioid analgesics extended period pulmonary embolism cardiomyopathy atrial fibrillation flutter cerebral embolism mural thrombosis thrombophili anticoagulant prophylaxis locally confined stage b2 c stage d2 metastatic carcinoma prostatefor relief signs symptoms rheumatoid arthritis osteoarthritis flares long term juvenile rheumatoid arthritis acid reflux disorders gerd  peptic ulcer disease heartburn acid indigestion number conditions schizophrenia manifestations psychotic disorders control tics vocal utterances tourette disorder children adults severe behavior problems children combative explosive hyperexcitability cannot accounted immediate provocation  short term hyperactive children show excessive motor activity accompanying conduct disorders consisting some all following symptoms impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance  should reserved these two groups children only after failure respond psychotherapy medications than antipsychotics f4645 antiretroviral agents hiv infection complete partial reversal narcotic depression respiratory depression induced opioids adjunct peptic ulcer disease acquired nystagmusfor diarrhea adults children protozoa giardia lamblia  diarrhea children protozoan  cryptosporidium parvum  fda   shown superior placebo medication diarrhea cryptosporidium parvum hiv immunodeficiency fda a31973 a31976  mainly psychoses control nausea vomiting lower high cholesterol levels blood fast digitalization congestive heart failure variety dosage forms example oral injections etc  exist serious severe infections susceptible strains methicillin resistant beta lactam resistant staphylococci fda  additionally unique fda approved oral liquid available clostridium difficile diarrhea enterocolitis staphylococcus aureus methicillin resistant strains  excessive postoperative bleeding brompheniramine pseudoephedrine coughs upper respiratory symptoms allergies common cold   guaifenesin over counter product relieve cough  dextromethorpahn quinidine pseudobulbar affect  metastatic testicular tumors metastatic ovarian tumors advanced bladder cancer prevent reduce severity allergic contact dermatitis urushiol allergenic resin poison ivy poison oak poison sumac conjunction antacids histamine h lt sub gt lt sub gt receptor antagonists peptic ulcer reduce further gastric acid secretion delay gastric emptying parenchymal neurocysticercosis active lesions larval forms pork tapeworm  taenia solium cystic hydatid disease liver lung peritoneum larval form dog tapeworm  echinococcus granulosus mild moderate hypertension adjunct congestive heart failure chf  improve survival following myocardial infarction mi individuals hemodynamically stable demonstrate symptoms left ventricular systolic dysfunction signs chf within few days following mi slow progression renal disease hypertensive diabetes mellitus microalbuminuria overt nephropathy esophageal candidiasis invasive aspergillosis refractory intolerant therapies intraocular hypertension chronic open angle glaucomaindicated screening test exocrine pancreatic insufficiency monitor adequacy supplemental pancreatic therapy topical cutaneous lesions aids related kaposi sarcoma hypertension alone antihypertensive drugs different class topical skin infections athlete foot jock itch ringworm infections  along antifungals infections nails scalp palms soles feet powder powder aerosol prevent athlete foot infusional 5 fu lv advanced carcinoma colon rectum adjuvant stage iii colon cancer undergone complete resection primary tumor production local regional anesthesia infiltration techniques percutaneous injection intravenous regional anesthesia peripheral nerve block techniques brachial plexus intercostal central neural techniques lumbar caudal epidural blocks hypertension angina pectoris raynaud syndromefor cmv retinitis acquired immunodeficiency syndrome aids acyclovir resistant mucocutaneous hsv infections immunocompromised   metastatic non small cell lung cancer nsclc tumors showing epidermal growth factor receptor egfr exon 19 deletions exon 21 r substitution mutations fda    first line diagnosed locally advanced unresectable metastatic pancreatic cancer fda  safety efficacy established nsclc whose tumors show egfr mutations additionally recommended platinum based chemotherapy  fda malignant lymphomas multiple myeloma leukemias mycosis fungoides advanced disease  neuroblastoma disseminated disease  adenocarcinoma ovary retinoblastoma carcinoma breast biopsy proven minimal change nephrotic syndrome pediatric refractory partial epilepsy osteoarthritis rheumatoid arthritis pain adults primary dysmenorrhea well migraine attacks without auras previously diuretic radiolabeled form diagnostic research tool bacterial otitis media maxillary sinusitis community acquired ca pneumonia bacterial exacerbations chronic bronchitis pharyngitis tonsillitis uncomplicated skin skin structure infections children adults  a180739  organisms susceptible listed below addition their clinical condition treated   various beta lactamase producing organisms treated certain sections below  respiratory bacterial exacerbations chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin susceptible only  moraxella catarrhalis community acquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin susceptible only  moraxella catarrhalis ear nose throat bacterial otitis media haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae penicillin susceptible only  tonsillitis streptococcus pyogenes pharyngitis streptococcus pyogenes maxillary sinusitis haemophilus pneumoniae streptococcus pneumoniae penicillin susceptible only  moraxella catarrhalis skin skin structure infections uncomplicated skin skin structure infections staphylococcus aureus streptococcus pyogenesfor reduction symptoms muscle weakness easy fatigability myasthenic syndrome eaton lambert treating myasthenia gravis only infections susceptible bacteria       immediate release tablets oral suspensions intravenous injections skin skin structure infections bone joint infections complicated intra abdominal infections nosocomial pneumonia febrile neutropenia adults inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infections exacerbations chronic bronchitis urinary tract infections complicated urinary tract infections pediatrics complicated pyelonephritis pediatrics sinusitis   otic solution otic suspension hydrocortisone otitis externa   suspension dexamethasone otitis media pediatric tympanostomy tubes otitis externa  intratympanic injection pediatric bilateral otitis media effusion having tympanostomy tubes placed pediatric 6 months older otitis externa   eye drop bacterial corneal ulcers conjunctivitis  eye ointment bacterial conjunctivitis   extended release tablet uncomplicated urinary tract infections complicated urinary tract infections uncomplicated pyelonephritis  mri contrast agent mri diagnostic procedures provide increased enhancement visualization lesions brain spine liver tumors metastatic breast cancer postmenopausal women estrogen receptor positive receptor unknown tumors  currently under investigation preventative agent prostate cancer men high grade prostatic intraepithelial neoplasia no evidence prostate cancer relief symptoms major depressive disorder mdd   some off uses drug include chronic pain myofascial pain neuralgia irritable bowel syndrome a191083 lymphocytic leukemia all  hodgkin lymphoma non hodgkin lymphomas wilms tumor neuroblastoma rhabdomyosarcoma liposomal relapsed philadelphia chromosome negative ph  lymphoblastic leukemia all  hypertension a840  alone thiazide diuretics fda relief symptoms depression neurotic reactive depressive disorders well endogenous psychotic depressions depression accompanied anxiety agitation topical multiple actinic solar keratoses 5 strength useful superficial basal cell carcinomas conventional methods impractical multiple lesions difficult sites  injection palliative some types cancer colon esophageal gastric rectum breast biliary tract stomach head neck cervical pancreas renal cell carcinoid myasthenia gravis anxiety status epilepticus relief inflammatory pruritic manifestations corticosteroid responsive dermatoses topical mild moderate inflammatory acne vulgaris prophylaxis chronic asthma manage hyperthyroidism overactive thyroid gland grave disease addition antibiotics medical procedures chronic urea splitting urinary infections hairy cell leukaemia refractory alpha interferon psoriasis vitiligofor osteoarthritis rheumatoid arthritis adjunctive therapy following seizure types age partial seizures primary generalized tonic clonic seizures generalized seizures lennox gastaut syndrome   process conversion drug monotherapy those least 16 age older partial seizures currently receiving carbamazepine phenytoin phenobarbital primidone valproate single antiepileptic drug aed   addition above  maintenance bipolar i disorder delaying time mood episodes include mania hypomania depression mixed episodes adults least 18 older treated mood symptoms standard therapy   limitations important note lamotirigine should mood episodes efficacy established context  ultrasound contrast imaging cardiology radiology symptomatic relief anxiety tension psychoneuroses adjunct organic disease states anxiety manifested  histamine mediated pruritus pruritus allergic conditions chronic urticaria   canadian labeling states adults children premedication prior medical procedures dental surgery  control nausea vomiting excluding nausea vomiting pregnancy  prevention influenza b pulmonary arterial hypertension pah  improve exercise ability decrease rate clinical worsening class iii iv symptoms infections susceptible strains designated microorganisms following conditions complicated skin skin structure infections escherichia coli  enterococcus faecalis  vancomycin susceptible isolates only  staphylococcus aureus  methicillin susceptible resistant isolates  streptococcus agalactiae  streptococcus anginosus grp  includes anginosus  intermedius  constellatus   streptococcus pyogenes bacteroides fragilis  complicated intra abdominal infections citrobacter freundii  enterobacter cloacae  escherichia coli  klebsiella oxytoca  klebsiella pneumoniae  enterococcus faecalis  vancomycin susceptible isolates only  staphylococcus aureus  methicillin susceptible isolates only  streptococcus anginosus grp  includes anginosus  intermedius  constellatus   bacteroides fragilis  bacteroides thetaiotaomicron  bacteroides uniformis  bacteroides vulgatus  clostridium perfringens  peptostreptococcus micros temporary measure hospitalized respiratory insufficiency superimposed chronic obstructive pulmonary disease high blood pressure edema oral solution pediatric lymphoblastic leukemia pediatric polyarticular juvenile idiopathic arthritis   injections subcutaneous severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis severe recalcitrant disabling psoriasis    formulations gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer head neck advanced mycosis fungoides lung cancer advanced non hodgkin lymphoma  maintenance lymphocytic leukemia   given before leucovorin prolong relapse free survival following surgical removal tumour non metastatic osteosarcoma  epilepsy pain true trigeminal neuralgia  particular  shown efficacy treating mixed seizures partial seizures complex symptoms generalized tonic clonic seizures a180301  manic episodes mixed manic depressive episodes bipolar i disorder  some off unapproved uses include alcohol withdrawal syndrome restless leg syndrome a180415 a180421 inpatients outpatients adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation icu lead poisoning pediatric blood lead levels above 45 amp micro g dl mercury arsenic poisoning certain infections susceptible bacteria  these infections include respiratory tract infections otitis media skin skin structure infections bone infections genitourinary tract infections  vertigo meniere disease nausea vomiting motion sickness useful vestibular symptoms origins approved  prophylaxis vte up one month post surgery undergoing orthopedic surgery lower limbs hip fracture hip replacement knee surgery  prophylaxis vte undergoing abdominal surgery high risk thromboembolic complications e g undergoing abdominal cancer surgery  3 dvt pe  4 ua nstemi prevention death subsequent myocardial infarction mi  5 stemi prevention death myocardial reinfarction managed thrombolytics initially receive no form reperfusion therapy  should sole anticoagulant during percutaneous coronary intervention pci increased risk guiding catheter thrombosis breast cancer testicular cancer lymphomas neuroblastoma hodgkin non hodgkin lymphomas mycosis fungoides histiocytosis kaposi sarcoma hypertension   angina pectoris coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma proliferating infantile hemangioma  poisoning susceptible organophosphorous nerve agents having anti cholinesterase activity cholinesterase inhibitors well organophosphorous carbamate insecticides relief signs symptoms rheumatoid arthritis osteoarthritis relief mild moderate pain seizures dravet syndrome aged two older  tablets transdermal systems hypertension alone medications   injection opiates severe cancer pain where opiates alone insufficient  extended release tablet adhd either alone medications   diagnosis pheochromocytoma a180565 nicotine dependance a180568 opiate withdrawal a180571 urinary tract infectionvalacyclovir nucleoside analog dna polymerase inhibitor fda   adults  cold sores herpes labialis   genital herpes  genital herpes lesions immunocompetent initial recurrent episode   suppression genital herpes lesions immunocompetent hiv infected  reduction viral transmission  herpes zoster pediatric   cold sores herpes labialis   chickenpox   limitations fda  efficacy safety valacyclovir established immunocompromised than suppression genital herpes hiv infected chronic infections upper lower urinary tract asymptomatic bacteriuria susceptible strains bacteria short term few weeks exogenous obesity conjunction regimen weight reduction based caloric restriction exercise behavior modification body mass index 30 kg body weight per height meters squared kg m lt sup gt lt sup gt  body mass index 27 kg m lt sup gt lt sup gt presence risk factors hypertension diabetes hyperlipidemia osteoarthritis dysmenorrhoea laxative chronic constipation adults geriatric fda   additionally  employed adjunct protein restriction supportive therapy prevention portal systemic encephalopathy pse  both hepatic pre coma coma variations fda  particular  solution effective managing pse resulting from surgical portacaval shunts from chronic hepatic diseases like cirrhosis   moreover there studies demonstrating capacity minimize formation gallstones even some investigations regarding experimental agent developing novel anticancer agents owing ability bind galactin carbohydrates involved various tumor progressions  esophageal candidiasis invasive pulmonary aspergillosis serious fungal infections scedosporium apiospermum fusarium spp primary systemic carnitine deficiency genetic impairment normal biosynthesis utilization from dietary sources secondary carnitine deficiency resulting from inborn error metabolism glutaric aciduria ii methyl malonic aciduria propionic acidemia medium chain fatty acylcoa dehydrogenase deficiency therapeutically stimulate gastric pancreatic secretions hyperlipoproteinemias parenteral prevention carnitine deficiency end stage renal disease essential renovascular hypertension  monotherapy antihypertensive agents thiazide diuretics additive effect  symptomatic congestive heart failure usually diuretics digitalis  asymptomatic left ventricular dysfunction ejection fraction  35 percent decrease rate development overt heart failure incidence hospitalization heart failure acid reflux disorders gerd  peptic ulcer disease active benign gastric ulcer active duodenal ulcer pain inflammation from varying sources inflammatory conditions osteoarthritis rheumatoid arthritis akylosing spondylitis well injury related inflammation surgery physical trauma often misoprostol gastro protective agent high risk developing nsaid induced ulcers protection against second phase inflamation exercise induced bronchoconstriction asthma inhaler asthma prophylaxis fda well inflammatory pruritic dermatoses f4355  nasal spray managing allergic nonallergic rhinitis f4358 parkinson disease symptoms benign prostatic hypertrophy include urinary frequency urgency nocturia among symptoms addition  alone various antihypertensive agents hypertension  off uses include pediatric hypertension a180634 ureteric calculi a180637 extensively different medical areas  dermatology extensively relief inflammatory dermatosis dermatitis psoriasis hypertrophic tissues keloid tissues atopic dermatitis f1955  shampoo products low medium potency corticosteroid seborrheic dermatitis scalp   ear drops low medium potency corticosteroid chronic eczematous external otitis adults pediatric older   intravitreal implant diabetic macular edema previously treated course corticosteroids no clinically significant rise intraocular pressure    announced october 15 2018 fda approved chronic non infectious uveitis affecting posterior segment eye   some reports vasoprotective agent first degree hemorrhoids a39532 alternative ascariasis ascaris lumbricoides  roundworm enterobiasis oxyuriasis enterobius vermicularis  pinworm  partial intestinal obstruction common roundworm condition primarily occurring children petit mal epilepsy adjunctive thiazide diuretics kaliuretic diuretic agents congestive heart failure hypertension infections variety gram positive gram negative microorganisms mycoplasma pneumoniae pasteurella pestis escherichia coli haemophilus influenzae  respiratory infections  diplococcus pneumoniae  cream ointment inflammatory pruritic corticosteroid responsive dermatoses   lotion plaque psoriasis  mri contrast agent contrast enhancement brain spine surrounding tissues resulting improved visualization compared unenhanced mri lesions abnormal vascularity those thought cause disruption normal blood brain barrier  whole body contrast enhanced mri head neck liver breast musculoskeletal system soft tissue pathologies injections control blood pressure severe hypertension   tablets alone antihypertensives like thiazides loop diuretics manage hypertension  sole anesthetic agent brief 15 minute procedures induction anesthesia prior administration anesthetic agents supplement regional anesthesia provide hypnosis during balanced anesthesia agents analgesia muscle relaxation control convulsive states during following inhalation anesthesia local anesthesia neurosurgical increased intracranial pressure narcoanalysis narcosynthesis psychiatric disorders topically loss skin color vitiligo bacterial infections susceptible strains vancomycin resistant enterococcus faecium  staphylococcal aureus  methicillin resistant susceptible strains  streptococcus pneumoniae  streptococcus pyogenes  streptococcus agalactiae intestinal i e  nondisseminated strongyloidiasis nematode parasite strongyloides stercoralis  onchocerciasis river blindness nematode parasite onchocerca volvulus  scabies sarcoptes scabiei  mpa oral tablets secondary amenorrhea reduce incidence endometrial hyperplasia postmenopausal women abnormal uterine bleeding hormonal imbalance organic pathology  oral tablets containing mpa conjugated estrogens prevent postmenopausal osteoporosis moderate severe menopausal symptoms vasomotor symptoms vulvar atrophy vaginal atrophy  subcutaneous mpa prevent pregnancy manage pain endometriosis  intramuscular mpa prevent pregnancy  higher concentrations palliative endometrial renal carcinoma  symptomatic nocturnal heartburn gastroesophageal reflux disease long term relief signs symptoms osteoarthritis rheumatoid arthritis ankylosing spondylitis painful shoulder subacromial bursitis supraspinatus tendinitis  gouty arthritis adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effectiveness antihypertensive drugs more severe forms hypertension infections penicillinase producing staphylococci demonstrated susceptibility drug  infections p vivax p malariae p ovale susceptible strains p falciparum  extraintestinal amebiasis   off rheumatic diseases a191655 well prophylaxis zika virus a191649 a191652  currently undergoing clinical trials covid 19 a191631 pulmonary extrapulmonary tuberculosis antitubercular drugs failed prevention hypotension hemorrhage spinal anesthesia shock brain damagefor relief moderate severe pain mild moderate hypertension  off heart failure atrial fibrillation angina pectoris a180460 a180463 malarial attacks non immune subjects specific symptomatic bacterial protozoal diarrhea enteritis susceptible organisms prevention disseminated mycobacterium avium complex mac disease advanced hiv infection control absence petit mal seizures refractory medications primarily lyme disease acne bronchitis but rarely urinary tract infections gum disease malaria bacterial infections gonorrhea chlamydia one registered uses hyponatremia low blood sodium concentration syndrome inappropriate antidiuretic hormone siadh where fluid restriction alone ineffective philadelphia chromosome positive chronic myeloid leukemia ph cml  ph lymphoblastic leukaemia myelodysplastic myeloproliferative diseases aggressive systemic mastocytosis hypereosinophilic syndrome chronic eosinophilic leukemia cel  dermatofibrosarcoma protuberans malignant gastrointestinal stromal tumors gist  hexacetonide injections intralesional administration alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum  formulation localized hypertrophic infiltrated inflammatory lesions granuloma annulare lichen planus lichen simplex chronicus psoriatic plaques   acetonide spray cream inflammatory pruritic manifestations corticosteroid responsive dermatoses   acetonide 10mg ml 40mg ml injection intra articularly gouty arthritis subacute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis   same 10mg ml injection intralesional route alopecia areata discoid lupus erythematosus keloids necrobiosis lipoidica diabeticorum tumors aponeurosis tendon  formulation localized hypertrophic infiltrated inflammatory lesions granuloma annulare lichen planus lichen simplex chronicus psoriatic plaques  40mg ml injection intramuscularly controlling severe allergic conditions asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevens johnson syndrome congenital adrenal hyperplasia hypercalcemia cancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamond blackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis exacerbations multiple sclerosis cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonias symptomatic sarcoidosis dermatomyositis polymyositis systemic lupus erythematosus adjunct adrenocortical insufficiency regional enteritis ulcerative colitis fulminating disseminated pulmonary tuberculosis gouty arthritis rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative leukemia lymphoma induction diuresis remission proteinuria idiopathic nephrotic syndrome lupus erythematosus  intravitreal injection sympathetic ophthalmia temporal arteritis uveitis ocular inflammatory conditions  intravitreal injection visualization during vitrectomy  extended release suspension intra articularly pain osteoarthritis knee  promote weight gain after weight loss following extensive surgery chronic stable angina hypertension manifestations psychotic disorders primary hypogonadism hypogonadotropic hypogonadism     hiv infection aids topical formulations chronic localized skin infections a181997 occasionally intramuscularly infantile streptococcal pneumonia empyema a181997  formulated ointment neomycin polymyxin b over counter a181997  ointment formulated neomycin polymyxin b along hydrocortisone corticosteroid responsive dermatoses secondary infection  prevent vitaminDeficiencies pediatric receiving parenteral nutrition part multivitamin intravenous injections    oral tablets monotherapy simvastatin lovastatin primary hyperlipidemia mixed dyslipidemia   reduce risk nonfatal myocardial infarctions history myocardial infarction hyperlipidemia   bile acid binding resins atherosclerosis coronary artery disease hyperlipidemia primary hyperlipidemia   finally severe hypertriglyceridemia  anxiety disorders short term relief symptoms anxiety adjunctive therapy partial seizures symptomatic relief alcohol withdrawal high blood pressure prevention osteoporosis men postmenopausal women glucocorticoid induced osteoporosis paget disease bone fda a959 a176750  however  pediatric populations creatinine clearance lt 35ml min fda pediatric 21 old relapsed refractory lymphocytic lymphoblastic leukemia after least two prior regimens designated orphan drug fda topical recurrent oral facial herpes simplex episodes cold sores fever blisters sedation initially intubated mechanically ventilated during intensive care setting pain relief anxiety reduction analgesiafor bacterial vaginitis keratitis conjunctivitis blepharitis anti inflammatory immunosuppressive drug allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious endocrine neoplastic conditions well organ transplant  primary dysbetalipoproteinemia type iii hyperlipidemia does respond adequately diet helps control high cholesterol high triglyceride levels  relieving allergy symptoms particularly rhinitis conjunctivitis withdrawn from market however concerns arrhythmias historically important medical test renal function specifically measure glomerular filtration rate sometimes help relieve symptoms diabetes mellitus  condition characterised hyperglycemia hyperinsulinemia local vulvovaginal candidiasis infections candida initial termination paroxysmal supraventricular tachycardia pvst  accessory bypass tracts drug choice terminating stable narrow complex supraventricular tachycardias svt  adjunct thallous chloride ti 201 myocardial perfusion scintigraphy thallium stress test unable exercise adequately well adjunct vagal maneuvers clinical assessment establish specific diagnosis undefined stable narrow complex svt hyperlipidemia reduce elevated total cholesterol total c  low density lipoprotein cholesterol ldl c  apolipoprotein b apo b  triglycerides tg  increase high density lipoprotein cholesterol hdl c  f4655 f4658  includes primary hyperlipidemia fredrickson type iia heterozygous familial nonfamilial  mixed dyslipidemia fredrickson type iib  hypertriglyceridemia fredrickson type iv hyperlipidemia  primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia  homozygous familial hypercholesterolemia hofh adjunct lipid lowering treatments well adolescent heterozygous familial hypercholesterolemia hefh  f4655 f4658  reduce risk cardiovascular morbidity mortality myocardial infarction stroke need revascularization procedures primarily high risk coronary events because existing coronary heart disease diabetes peripheral vessel disease history stroke cerebrovascular disease f4655 f4658  prescribing statin medications considered standard practice following any cardiovascular events people moderate high risk development cvd statin conditions include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia  documented carotid disease peripheral artery disease claudication  abdominal aortic aneurysm chronic kidney disease severely elevated ldl c levels a181087 a181406 cisplatin malignant pleural mesothelioma adults whose disease unresectable otherwise candidates potentially curative surgery monotherapy locally advanced metastatic non small cell lung cancer nsclc after prior chemotherapyfor enterobius vermicularis  pinworm  trichuris trichiura  whipworm  ascaris lumbricoides  common roundworm  ancylostoma duodenale  common hookworm  necator americanus  american hookworm single mixed infections evaluating functional capacity response gonadotropes anterior pituitary evaluating residual gonadotropic function pituitary following removal pituitary tumor surgery irradiation provide topical anesthesia accessible mucous membranes prior examination endoscopy instrumentation procedures involving esophagus larynx mouth pharynx throat respiratory tract trachea urinary tract vagina suppress gag reflex laryngeal esophageal reflexes facilitate dental examination procedures oral surgery  endoscopy intubation relief canker sores cold sores fever blister available oral formulations prevention oral candidiasis k thrush  intestinal candidiasis anal candidiasis   topically vulvovaginal candidiasis cutaneous candida infections  product containing alongside neomycin  gramicidin d  triamcinolone  viaderm k c  corticosteroid responsive dermatoses bacterial candidal infections pruritus ani vulvae  available metronidazole mixed infections trichomonas vaginalis candida albicans   sometimes off prevention invasive candidiasis low birth weight neonates a188565 though generally reserved second line option after fluconazole relief mild moderate pain inoperable adrenocortical tumours cushing syndromefor human immunovirus hiv infections osteosarcoma after high dose methotrexate therapy  diminish toxicity counteract effects impaired methotrexate elimination inadvertent overdosages folic acid antagonists megaloblastic anemias folic acid deficiency 5 fluorouracil prolong survival palliative advanced colorectal cancer relief bronchial asthma reversible bronchospasm chronic bronchitis emphysema relief moderate severe pain immediate control life threatening convulsions severe toxemias pre eclampsia eclampsia pregnancy nephritis children replacement therapy magnesium deficiency especially hypomagnesemia accompanied signs tetany similar those hypocalcemia uterine tetany myometriat relaxant reduction elevated intraocular pressure diagnosed open angle glaucoma ocular hypertension   combined product netarsudil  rho kinase inhibitor same indications  addition above indications canadian monograph drug approves elevated intraocular pressure result angle closure glaucoma treated peripheral iridotomy laser iridoplasty  perimenopausal postmenopausal symptoms major depressive disorder mdd   off adjunct therapy alcohol dependence off anxiety insomnia  off symptoms dementia alzheimer disease schizophrenia eating disorders fibromyalgia effects various neurotransmitter receptors a31634 moderately severe severe essential hypertension uncomplicated cases malignant hypertensionfor control serum phosphorus chronic kidney disease ckd hemodialysis maintenance abstinence from alcohol alcohol dependence abstinent initiationfor painful peripheral musculoskeletal conditions spasticity from upper motor neuron syndromes vasopastic i e prinzmetal angina unstable angina chronic stable angina hypertension prophylaxis repetitive paroxysmal supraventricular tachycardia digoxin control ventricular rate atrial fibrillation atrial flutter  given intravenously various supraventricular tachyarrhythmias rapid conversion sinus rhythm supraventricular tachycardia temporary control ventricular rate atrial fibrillation atrial flutter   commonly off prophylaxis cluster headaches a13983 postoperative nausea vomiting nausea gastroenteritis contact dermatitis atopic dermatitis exczema psoriasis diaper rash skin conditionsfor urinary tract infection chronic bronchitis surgical castration metastatic prostate cancer involving distant lymph nodes bone visceral organs stage d2 central precocious puberty true precocious puberty gnrh dependent precocious precocity complete isosexual precocity children both sexes endometriosis injection emergency allergic reactions type i anaphylaxis stinging insects e g  order hymenoptera include bees wasps hornets yellow jackets fire ants biting insects e g  triatoma mosquitos  allergen immunotherapy foods drugs diagnostic testing substances e g  radiocontrast media allergens well idiopathic anaphylaxis exercise induced anaphylaxis injectable intended immediate urgent administration found increased risk anaphylaxis individuals history anaphylaxis selection appropriate dosage strength determined according body weight fda   cardiac effects restoring cardiac rhythm cardiac arrest various causes but cardiac failure hemorrhagic traumatic cardiogenic shock f1247   hemostatic agent treating mucosal congestion hay fever rhinitis sinusitis relieve bronchial asthmatic paroxysms syncope complete heart block carotid sinus hypersensitivity symptomatic relief serum sickness urticaria angioneurotic edema resuscitation cardiac arrest following anesthetic accidents simple open angle glaucoma relaxation uterine musculature inhibit uterine contractions  injection utilized prolong action local anesthetics f1247  addition above  over counter otc agent intermittent symptoms asthma wheezing tightness chest shortness breath f2131  maintenance mydriasis during intraocular surgery  naproxen tablet migraines without auras 12 age older   nasal powder nasal spray subcutaneous injection tablets migraines without auras adults    one subcutaneous formulations cluster headaches adults  while subcutaneous formulation  peptic ulcer gastric ulcer duodenal ulcer following infections susceptible strains designated microorganisms  uncomplicated urinary tract infections escherichia coli proteus mirabilis  otitis media haemophilus influenzae  beta lactamase positive negative strains  moraxella catarrhalis  most beta lactamase positive  pyogenes  3 pharyngitis tonsillitis pyogenes  4 bronchitis exacerbations chronic bronchitis streptococcus pneumoniae haemophilus influenzae  beta lactamase positive negative strains  5 uncomplicated gonorrhea cervical urethral neisseria gonorrhoeae  penicillinase non penicillinase producing strains niddm conjunction diet exercise prevention nausea vomiting highly emetogenic cancer chemotherapy high dose cisplatin antiemetic agents  mild moderate dementia alzheimer type  estrogen receptor positive metastatic breast cancer adults adjuvant early stage estrogen receptor positive breast cancer adults reduce risk invasive breast cancer after surgery radiation women ductal carcinoma situ  kill lice mites responsible skin condition scabies eye certain types glaucoma eye conditions accommodative esotropia hypertension older than 6 reduce risk stroke hypertension left ventricular hypertrophy though benefit extend african heritage  diabetic nephropathy elevated serum creatinine proteinuria type diabetes hypertension   hydrochlorothiazide hypertension reduce risk stroke hypertension left ventricular hypertrophy though benefit extend african heritage  schizophrenia generalized anxiety disorder irregular heartbeats arrhythmias maintain normal heart rate potentially life threatening fungal infections  prophylaxis venous thromboembolism related pulmonary embolism  prophylaxis thromboembolism atrial fibrillation  3 prophylaxis thromboembolism cardiac valve replacement  4 adjunct therapy reduce mortality recurrent myocardial infarction thromboembolic events post myocardial infarction  off uses include  secondary prevention stroke transient ischemic attacks rheumatic mitral valve disease but without atrial fibrillation a179182 intravenous  promoting preoperative sedation anxiolysis anesthesia induction amnesia f2434  intramuscular  status epilepticus adults fda  nasal  intermittent stereotypic episodes frequent seizure activity i e  seizure clusters repetitive seizures distinct from patient usual seizure pattern epilepsy 12 age older  pseudomonas aeruginosa lung infections being investigated sinus infections infections susceptible strains designated microorganisms uncomplicated urethral gonorrhea males endocervical rectal gonorrhea females neisseria gonorrhoeae well non gonoccocal urethritis cervicitis chlamydia trachomatis relief bladder pain discomfort interstitial cystitis partial replacement therapy primary secondary adrenocortical insufficiency addison disease salt losing androgenital syndrome  prophylaxis organ rejection undergoing allogeneic renal hepatic cardiac transplants should cyclosporine corticosteroids   off second line autoimmune hepatitis responded adequately first line therapy a180814 off uses drug include lupus nephritis dermatitis children a180817 severe infections susceptible bacteria short term intermittent recurring insomnia poor sleeping habitsfor hypertension aid diagnosis pheochromocytoma administered immediately prior during pheochromocytomectomy prevent control paroxysmal hypertension resulting from anesthesia stress operative manipulation tumor  hypertensive crisis sympathomimetic amines catecholamine excess certain foods drugs taking mao inhibitors clonidine withdrawal syndrome indications include prevention dermal necrosis sloughing following iv administration extravasation norepinephrine decrease impedance left ventricular ejection infarct size mi left ventricular failure erectile dysfunction through self injection small doses combined papaverine hydrochloride into corpus cavernosum adjunct cocaine overdose reverse coronary vasoconstriction following oxygen benzodiazepines nitroglycerin diagnostic imaging primarily diagnostic angiography angioscopy fundus iris vasculature remission induction nonlymphocytic leukemia myelogenous monocytic erythroid adults remission induction lymphocytic leukemia children adults edema congestive heart failure cirrhosis liver renal disease nephrotic syndrome adults pediatric   oral alone mild moderate hypertension severe hypertension antihypertensive medications   intravenous adjunctive therapy pulmonary edema rapid onset diuresis desired  therapy abort prevent vascular headache e g  migraine migraine variants so called histaminic cephalalgia  relief muscle spasticity interfere daily activities  general recommendation reserve periods time there particular need relief short duration action fda f4471  uncomplicated urinary tract infections   senile dementia migraines vascular origin transient ischemia platelet hyper aggregability macular degeneration improvement survival stable left ventricular systolic dysfunction ejection fraction lt 40  clinical evidence congestive heart failure after myocardial infarction hiv infection antiretroviral agents continuous ambulatory peritoneal dialysis capd diabetic automated peritoneal dialysis apd end stage renal disease chronic open angle glaucoma angle closure glaucomaused adjunct medically supervised behaviour modification program maintenance opiate cessation individuals were formerly physically dependent opiates successfully undergone detoxification alcohol dependence conjunction behavioural modification program hiv infection appropriate antiretroviral agents therapy warranted signs symptoms benign prostatic hyperplasia  off ureteral stones prostatitis female voiding dysfunction a178339 esophageal cancer indications drug follows  analgesic adjunct maintenance balanced general anesthesia intubated ventilated  primary anesthetic agent induction maintenance anesthesia 100 oxygen undergoing major surgical procedures intubated ventilated cardiovascular surgery neurosurgical procedures sitting position provide favorable myocardial cerebral oxygen balance extended postoperative ventilation anticipated  3 epidural administration analgesic combined low dose usually 12 5 mg per administration bupivacaine usually during labor vaginal delivery  4 sublingual form pain adults severe warrant opioid analgesic certified medically supervised healthcare settings hospitals surgical centers emergency departments  fda hiv infection chronic hepatitis b hbv prevention osteoporosis postmenopausal women  certain filarial diseases tropical pulmonary eosinophilia loiasis lymphatic filariasis infection wuchereria bancrofti  brugia malayi  brugia timori  tablets long term symptomatic rheumatoid arthritis osteorarthritis anklosing spondylitis pain dysmenorrhea mild moderate pain accompanied inflammation e g bursitis tendonitis soft tissue trauma  topical ophthalmic formulations pre operatively prevent intraoperative miosis resistant staphylococci infections intermittent hypomobility off episodes advanced parkinson disease   depression obsessive compulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorder  one form  commercially known brisdelle manage mild moderate vasomotor symptoms menopause  off  premature ejaculation irritable bowel syndrome ibs  a1093 a181754 a181904 mild moderate asthma oral contraceptive given monotherapy  estrogen component ethinylestradiol estradiol   estrogen component oral hormone replacement therapy postmenopausal osteoporosis moderate severe vasomotor symptoms arising from menopause  applied via transdermal patch estradiol hypoestrogenism vulvovaginal atrophy moderate severe vasomotor symptoms    taken intramuscular leuprolide  symptomatic endometriosis related pain  chronic hepatitis b evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active disease based histological virological biochemical serological responses hbeag hbeag chronic hepatitis b compensated liver function clinical evidence lamivudine resistant hepatitis b virus either compensated decompensated liver function relief symptoms upper respiratory mucosal congestion perennial allergic rhinitis relief nasal congestion eustachian t b congestion adjunct osteolysis from bone metastases malignant tumors hypercalcemia malignancy  local anesthetic primarily oral surgery myocardial infarction hypertension 6 adjunct therapy heart failure   product hydrochlorothiazide hypertension  hypotension topical clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses face scalp immunocompetent adults external genital perianal warts condyloma acuminata individuals 12 old above conjunction antacids histamine h2 receptor antagonists peptic ulcers gastric ulcers duodenal ulcers reduce further gastric acid secretion delay gastric emptying depression depression accompanied anxiety agitation sleep disturbance various purposes  prevent angina chest pain cardiovascular disease well peri operative hypertension induce intra operative hypotension   heart failure myocardial infarction  ointment form  pain anal fissures  transdermal form applied directly skin prevent anginal attacks   intravenous form off emergency settings commonly coronary spasm cocaine hypertensive emergencies well congestive heart failure exacerbations t628 some off uses include variceal hemorrhage a180280  esophageal spasticity a180283  induction uterine relaxation a180277 inpatients outpatients adjunct general anesthesia facilitate both rapid sequence routine tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation strongyloidiasis threadworm  cutaneous larva migrans creeping eruption  visceral larva migrans trichinosis non insulin dependent diabetes mellitus conjunction diet exercise adjunct general anesthesia facilitate endotracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation poisoning those pesticides chemicals organophosphate class anticholinesterase activity control overdosage anticholinesterase drugs myasthenia gravis schizophrenia irritability autistic disorder  monotherapy adjunctly lithium valproic acid mania mixed episodes bipolar i disorder   additionally canada short term symptomatic aggression psychotic symptoms severe dementia alzheimer type unresponsive nonpharmacological approaches   off number conditions adjunct antidepressants resistant depression a177226 topical tinea pedis tinea cruris tinea corporis organisms trichophyton rubrum  trichophyton mentagrophytes  trichophyton tonsurans epidermophyton floccosum  acid reflux disorders healing maintenance erosive esophagitis symptomatic gastroesophageal reflux disease gerd  peptic ulcer disease h pylori eradication prevention gastrointestinal bleeds nsaid long term pathological hypersecretory conditions zollinger ellison syndrome symptomatic nausea vomiting dizziness motion sickness  vertigo various causes radiation sickness meniere syndrome labyrinthitis vestibular disturbances  pneumonia pneumocystis carinii  beta lactam antibiotic prodrug bacterial infections body gets converted ampicillin amyotrophic lateral sclerosis als lou gehrig disease otic solutions infections external auditory canal susceptible organisms inflammation   tablets certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal conditions  enema ulcerative colitis  topical ointment antibiotics corticosteroid responsive dermatoses infections  topical cream acyclovir cold sores  oral granules replacement therapy adrenocortical insufficiency ai children under 17 age  promotion diuresis before irreversible renal failure becomes established reduction intracranial pressure cerebral edema promotion urinary excretion toxic substances  add maintenance therapy improving pulmonary function cystic fibrosis aged 18 over passed bronchitol tolerance test btt  recommended take orally inhaled short acting bronchodilator 5 15 minutes prior every inhaled dose  gadobenate dimeglumine mri contrast agent primarily mr imaging liver mri heart well central nervous system adults visualize lesions abnormal brain vascularity abnormalities blood brain barrier brain spine tissues prophylaxis chronic asthma adults children 12 age older improve wakefulness excessive daytime sleepiness eds narcolepsy iron aluminum toxicity excess aluminum body certain certain anemia must receive many blood transfusions excessive salivation colicky abdominal pain bradycardia sialorrhoea diverticulitis irritable bowel syndrome motion sickness symptomatic relief seasonal perennial allergic rhinitis vasomotor rhinitis well allergic conjunctivitis foods inhaled allergens relief allergic reactions blood plasma symptomatic mild uncomplicated allergic skin manifestations urticaria angioedema long term signs symptoms osteoarthritis rheumatoid arthritis well pain local anaesthetic often dentistry prevention itching allergic conjunctivitis major depressive episode without melancholia induction maintenance general anesthesia control tonic clonic grand mal complex partial psychomotor seizures the induction remission promyelocytic leukemia apl  french american british fab classification m3 m3 variant  topical acne vulgaris flat warts skin conditions psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedones senile keratosis keratosis follicularis darier disease  basal cell carcinomas  palliative therapy improve fine wrinkling mottled hyperpigmentation roughness photodamage surgical scrub bacteriostatic skin cleanser control outbreak gram positive infection where infection control procedures unsuccessful prevention nausea vomiting emetogenic cancer chemotherapy initial repeat courses chemotherapy prevention postoperative nausea vomiting drug intravenously postoperative nausea vomiting reduce risk myocardial infarction non st elevated coronary syndrome acs  st elevated myocardial infarction recent mi stroke established peripheral arterial disease  bacterial infections rocky mountain spotted fever typhus fever tick fevers q fever rickettsialpox brill zinsser disease infections chlamydiae spp  b burgdorferi lyme disease  upper respiratory infections typical pneumoniae h influenzae m catarrhalis atypical organisms c pneumoniae m pneumoniae l pneumophila  acne  alternative drug people allergic penicillin single agent therapy following infections susceptible isolates designated microorganisms gt complicated skin skin structure infections lt b gt staphylococcus aureus  b lactamase non b lactamase producing methicillin susceptible isolates only  streptococcus pyogenes  streptococcus agalactiae  viridans group streptococci  enterococcus faecalis  excluding vancomycin resistant isolates  pseudomonas aeruginosa  escherichia coli  proteus mirabilis  bacteroides fragilis peptostreptococcus species gt complicated appendicitis peritonitis lt b gt viridans group streptococci  escherichia coli  klebsiella pneumoniae  pseudomonas aeruginosa  bacteroides fragilis  b thetaiotaomicron  peptostreptococcus species bacterial meningitis streptococcus pneumoniae  haemophilus influenzae  b lactamase non b lactamase producing isolates  neisseria meningitidis electrolyte replenisher hypokalemia metastatic colorectal cancer first line therapy administered 5 fluorouracil leucovorin  cisplatin extensive small cell lung cancer  currently under investigation metastatic recurrent cervical cancer fluorouracil leucovorin metastatic adenocarcinoma pancreas after disease progression following gemcitabine based therapy united states  hyperthyroidism graves disease toxic multinodular goiter whom thyroidectomy radioactive iodine therapy appropriate options  amelioration hyperthyroid symptoms preparation thyroidectomy radioactive iodine therapy   canada  carries above indications medical hyperthyroidism regardless available options  inhaler maintenance asthma prophylactic therapy nasal spray nasal symptoms seasonal allergic perennial allergic rhinitis pheochromocytoma preoperative preparation surgery surgery contraindicated chronic malignant pheochromocytoma combined antibiotics prevent development drug resistant strains bacteria promotes their therapeutic antibacterial effects   following conditions they produced beta lactamases treated amoxicillin ticarcillin    otitis media h influenzae m catarrhalis sinusitis h influenzae m catarrhalis lower respiratory tract infections haemophilus influenzae aureus klebsiella species moraxella catarrhalis  skin skin structure infections staphylococcus aureus escherichia coli klebsiella species urinary tract infections e coli klebsiella species bacteria enterobacter species bacteria marcescens aureus gynecologic infections variety bacteria p melaninogenicus enterobacter species e coli species klebsiella species aureus epidermidis septicemia variety bacteria klebsiella species e coli species aureus pseudomonas species bone joint infections aureus intraabdominal infections e coli k pnemoniae b fragilis group note susceptibility should noted only administered infections confirmed highly likely susceptible bacteria culture susceptibility tests should performed if possible selecting whether antibiotic prescribed beta lactamase enzyme production detected during microbiological testing  should these tests available patterns local infection susceptibility determine appropriateness using   ticarcillin clavulanate shown particular efficacy mixed infections addition empiric therapy before determining susceptibility causative organisms ticarcillin prove effective single agent antibiotic therapy infections where regimen several drugs normally  prevent nausea vomiting anesthesia surgery administered intramuscularly intravenously symptomatic ocular itching allergic conjunctivitis ophthalmic solution   nasal spray  symptomatic relief seasonal allergic rhinitis 12 age older  topically antiinflammatory steroid responsive dermatosesfor palliative definitive therapy temporarily maintain patency ductus arteriosus until corrective palliative surgery performed neonates congenital heart defects depend upon patent ductus survival erectile dysfunction neurogenic vasculogenic psychogenic mixed etiology peptic ulcer disease help relieve abdominal stomach spasms cramps colicky abdominal pain diverticulitis irritable bowel syndrome infected pediculus humanus capitis head lice their ova scalp hair chemotherapeutic agents refractory testicular tumors first line small cell lung cancer malignancies lymphoma non lymphocytic leukemia glioblastoma multiforme adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effect antihypertensive drugs more severe forms hypertension heparin coronary syndrome managed medically those undergoing ptca atherectomy united states  monotherapy partial onset seizures 4 age older adjunctive therapy partial onset seizures age older  canada  monotherapy adjunctive therapy partial onset seizures 6 age older  largely antihistamininc sleep inducing effects treating insomnia respiratory tract urinary soft tissue infections urinary tract infections susceptible gram negative microorganisms majority e coli  enterobacter species  klebsiella species proteus species nonendogenous neurotic atypical depression do tolerate forms therapy   atypical depression high prevalence rate starts early life tends last longer more likely occur people bipolar disorder high comorbidity anxiety disorder carries more risk suicidal behavior important specify atypical feature predict clinical course depression hence generate best service featuring symptoms atypical feature include mood reactivity two more symptoms increased appetite increased sleep 3 leaden paralysis 4 interpersonal rejection sensitivity should melancholic catatonic features depression a31917  neurotic depression depression emotionally unstable person secondary condition major personality disorder neuroses drug disorders likewise primary depression family history depression spectrum disease would fit category a31922  nonendogenous depression characterized disturbance mood general outlook physical symptoms tend less severe often occurs response stressful life events keep occurring over large period time generating continuous stress daily living a31924 enuresis hyperhidrosis cramps spasms stomach intestines bladder various preparations moderate severe vasomotor symptoms vulvar vaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure prevention postmenopausal osteoporosis breast cancer only palliation therapy certain men women metastatic disease androgen dependent prostate cancer only palliation therapy    hormones component oral contraceptive pills preventing pregnancy most commonly db00977  synthetic form   note duration recommendations menopausal symptoms changed drastically following release results early termination women health initiative whi studies 2002 concerns were raised regarding estrogen a31626 specifically combined estrogen progestin group discontinued after about 5 follow up statistically significant increase invasive breast cancer cardiovascular events a31627  following extensive critique whi results hormone replacement therapy hrt now recommended only short period 3 5 postmenopause low doses women without history breast cancer increased risk cardiovascular thromboembolic disease a31628 estrogen postmenopausal symptoms should always given progestin component estrogen stimulatory effects endometrium women intact uterus unopposed estrogen shown promote growth endometrium lead endometrial hyperplasia possibly cancer over long term  rheumatoid arthritis osteoarthritis dysmenorrhea mild moderate pain inflammation fever hypertension various cancersan topical cream recurrent herpes labialis immunocompetent 12 older   oral tablets capsules suspensions herpes zoster genital herpes chickenpox  topical ointment initial genital herpes limited non life threatening mucocutaneous herpes simplex immunocompromised  cream hydrocortisone recurrent herpes labialis shortening lesion healing time 6 older  buccal tablet recurrent herpes labialis  ophthalmic ointment herpetic keratitis  rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis gout primary dysmenorrhea relief mild moderate pain   a178975 further first line therapy osteoarthritis gouty arthritis dysmenorrhea musculoskeletal inflammation pain a178975 magnetic resonance imaging mri adults pediatric age older visualize lesions abnormal vascularity brain intracranial lesions  spine tissues well lesions abnormal vascularity head neck facilitate visualization lesions abnormal vascularity body excluding heart mild moderate essential hypertension mild moderate congestive heart failure reduce cardiovascular risk individuals hypertension post myocardial infarction stable coronary disease antineoplastic properties symptomatic relief hypersensitivity reactions coughs common cold fungal tinea skin infections athlete foot jock itch ringworm tinea versicolor commonly grand mal psychomotor focal epileptic seizures   addition studied utilized effective essential tremor a39414 a39415 crohn disease rheumatoid arthritis second line agent first line agent uncomplicated hypertension isolated systolic hypertension left ventricular hypertrophy first line agent delay progression diabetic nephropathy candesartan second line agent congestive heart failure systolic dysfunction myocardial infarction coronary artery disease those intolerant ace inhibitors pulmonary artery anomaliesfor serious infections susceptible strains following microorganisms  p aeruginosa  proteus species indole positive indole negative  e coli  klebsiella enterobactor serratia species  citrobacter species staphylococcus species coagulase positive coagulase negative psoriasis acne sun damaged skin photodamage hospital short term up 48 hours severe hypertension rapid but quickly reversible emergency reduction blood pressure clinically malignant hypertension deteriorating end organ function relieve anxiety nervousness tension anxiety disorders postoperative pain maintenance general anesthesia chronic infections sensitive strains certain gram negative bacilli particularly pseudomonas aeruginosa  functional bowel disorder irritable bowel syndrome  depressionfor intermittent lameness immobility arising from chronic occlusive arterial disease limbs local ophthalmic anesthetic diuretic monotherapy blood pressure lowering agents hypertension  fluid salt retention congestive heart failure  induce mydriasis dilation pupil cycloplegia paralysis ciliary muscle eye diagnostic procedures measurement refractive errors examination fundus eye adjunct therapy all forms parkinsonism control extrapyramidal disorders secondary neuroleptic drug therapy chronic hepatitis c virus hcv infection antiviral agents intent cure achieve sustained virologic response svr  typically added improve svr reduce relapse rates a19644  addition technivie therapy treating hcv genotype 1a 4 infections recommended without cirrhosis  resistance viral genetic determinants resulting variable response therapy yet determined backache ankylosing spondylitis intravenous intramuscular injections short term analgesia during induction maintenance recovery from general regional anesthesia these injections neuroleptic premedication induction adjunct maintenance anesthesia finally  intravenous intramuscular injections oxygen anesthesia high risk  sublingual tablets transmucosal lozenges buccal tablets sublingual sprays transdermal systems nasal sprays breakthrough pain opioid tolerant cancer require around clock pain     symptomatic arthritis osteoarthritis  addition pauciarticular polyarticular course juvenile rheumatoid arthritis jra aged old above  off uses include dental post surgical pain addition above  studied neuropathic pain  a190189 sls surfactant shampoos toothpastes sls microbicidal activities against both enveloped herpes simplex viruses hiv semliki forest virus nonenveloped papillomaviruses reovirus rotavirus poliovirus viruses although approved bronchospasm chronic bronchitis asthma emphysema bacterial infection respiratory tract urinary tract gi cns immuno compromised induction maintenance anaesthesia refractory status epilepticus adjunctive edema congestive heart failure drug induced edema centrencephalic epilepsies chronic simple open angle glaucomaused erectile dysfunction pain reliever joint pain post surgical pain chronic alcoholismfor prevention pregnancy women elect product method contraception symptoms asthma peripheral vascular diseases cerebrovascular insufficiency sickle cell disease diabetic neuropathy occasional minor irritation pain sore mouth sore throat well cough cold inhaled irritants fungal blepharitis conjunctivitis keratitis susceptible organisms fusarium solani keratitis initial recurrent urinary tract infections adults following susceptible microorganisms  escherichia coli  proteus mirabilis  proteus vulgaris  klebsiella species k pneumoniae  enterobacter species uncomplicated urinary tract infections cystitis women susceptible strains escherichia coli enterococcus faecalis general  useful symptomatic mild moderate degrees anxiety conditions dominated tension excitation agitation fear aggressiveness occur psychoneurosis anxiety reactions stress conditions anxiety states somatic expression f3160  moreover alcoholic withdrawal  useful symptomatic relief agitation tremor impending delirium tremens f3160  furthermore  useful adjunct relief skeletal muscle spasm reflex spasm local pathologies inflammation muscle joints secondary trauma spasticity upper motor neuron disorders cerebral palsy paraplegia athetosis rare stiff man syndrome  f3160  particular information from united kingdom lists particular age specific indications adults  short term relief 4 weeks only anxiety severe disabling subjecting individual unacceptable distress occurring alone association insomnia short term psychosomatic organic psychotic illness  cerebral palsy  3 muscle spasm  4 adjunct certain types epilepsy eg myoclonus  5 symptomatic alcohol withdrawal  6 oral premedication nervous dental patient 7 premedication before surgery   same uk information  children  control tension irritability cerebral spasticity selected cases  adjunct control muscle spasm tetanus 3 oral premedication   nasal spray 6 older intermittent stereotypic episodes frequent seizure activity different than patient usual seizure pattern  anorectic obesity anxiety disorders depressive symptoms secondary anxiety agitation epilepsy certain infections bacteria pneumonia ear lung skin throat urinary tract infections medical termination intrauterine pregnancy through 49 days pregnancy control hyperglycemia secondary hypercortisolism endogenous cushing syndrome type diabetes mellitus glucose intolerance candidates surgery had unsuccessful surgery symptoms common cold allergic rhinitis runny nose itchy eyes watery eyes sneezing control symptomatic relief nonspecific diarrhea chronic diarrhea inflammatory bowel disease gastroenteritis reducing volume discharge from ileostomies epilepsy short term topical inflammatory pruritic manifestations moderate severe corticosteroid responsive dermatoses scalp adjunct diet lower blood glucose non insulin dependent diabetes mellitus type ii whose hyperglycemia cannot satisfactorily controlled diet alone relieve dryness irritation reduced tear flow occurs certain eye diseases keratoconjunctivitis sicca  recurrent corneal erosions decreased corneal sensitivity exposure neuroparalytic keratitis lubricant artificial eyes parenteral therapy necessary inotropic support short term cardiac decompensation depressed contractility resulting either from organic heart disease from cardiac surgical procedures anxiety disorders short term relief symptoms anxiety  alcohol withdrawal symptoms  mild moderate alzheimer disease doses 5 mg 10 mg  moderate severe alzheimer disease higher dose 10 mg 23 mg administered once daily  off uses include vascular dementia parkinson disease dementia lewy body dementia among others a182333 t668 combined memantine extended release form symptoms moderate severe dementia  relief moderate severe pain lepromatous leprosy dapsone resistant lepromatous leprosy lepromatous leprosy complicated erythema nodosum leprosum  prevent development drug resistance should only antimycobacterial leprosy treatments relief inflammatory pruritic manifestations corticosteroid responsive dermatoses particularly dry scaling localized lesionsthe bitartrate salt oral nephropathic cystinosis cystinuria children 6 old above adults  hydrochloride salt eye drop preparations corneal cystine crystal accumulation cystinosis   adjuvant fluorouracil after surgical resection dukes stage c colon cancer malignant melanoma head neck cancer relief anxiety tension apprehension anticonvulsant epilepsy manifestations psychotic disorders control severe nausea vomiting adults metastatic malignant melanoma addition  hodgkin disease secondary line therapy antineoplastic agents sympathomimetic amine decongestant activity     diagnosed anaplastic astrocytoma whose disease progressed after therapy nitrosourea procarbazine well concomitantly radiation therapy newly diagnosed glioblastoma multiforme maintenance therapy glioblastoma multiforme moderate severe pain preoperative medication where opioid analgesic appropriate plus blue light illumination using blue light photodynamic therapy illuminator minimally moderately thick actinic keratoses face scalp along rest physical therapy injuries painful muscular conditions investigated trigeminal neuralgia tic douloureux  neuropathic disorder characterized severe facial pain investigated modulator histamine release hydrochloride fungal skin nail infections trichophyton species microsporum canis epidermophyton floccosum  tinea species   hydrochloride treats yeast infections skin candida species malassezia furfur  wilson disease cystinuria active rheumatoid arthritis endocrine rheumatic hematologic disorders collagen dermatologic ophthalmic respiratory gastrointestinal diseases allergic edematous states conditions like tuberculous meningitis  symptomatic mild moderate pain accompanied inflammation e g musculoskeletal trauma post dental extraction post episiotomy  osteoarthritis rheumatoid arthritis erectile dysfunctionthis drug alone concomitant antacids following conditions short term active duodenal ulcer treating gastric acid hypersecretion zollinger ellison syndrome systemic mastocytosis conditions pathologically raise gastric acid levels short term active benign gastric ulcers maintenance therapy gastric ulcers reduced dose addition above  gerd symptoms erosive esophagitis endoscopically diagnosed maintenance gastric duodenal ulcer healing        after allogenic organ transplant reduce activity patient immune system so risk organ rejection given fda approval 1994 liver transplantation since then indication expanded kidney heart small bowel pancreas lung trachea skin cornea limb transplants topical preparation severe atopic dermatitis exogenous obesity short term adjunct few weeks regimen weight reduction based caloric restrictionfor hypertension angina arrhythmiafor prophylaxis premature labour symptomatic relief cough  elevated intraocular pressure ocular hypertension open angle glaucoma  timolol same indication insufficiently responsive ophthalmic beta blockers   pre operative investigated prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy a190183 eye drops inhibit miosis pupil constriction occur during ocular surgery prevention reversal bronchospasm 12 age older reversible obstructive airway disease well symptomatic reversible bronchospasm bronchitis emphysema iv sub q therapy selected women inhibit uterine contractions preterm labor tocolysis prolong gestation beneficial euvolemic hypervolemic hyponatremia e g syndrome inappropriate secretion antidiuretic hormone setting hypothyroidism adrenal insufficiency pulmonary disorders etc  hospitalized number prescription ophthalmic products specifically post operative inflammation pain following ocular surgery fda  expectorant providing temporary symptomatic relief from congested chests coughs cold bronchitis breathing illnesses fda f4510  schizophrenia depressionfor hypertension alone classes antihypertensive agents first line agent diabetic nephropathy well second line agent congestive heart failure only those intolerant ace inhibitors prophylaxis organ rejection receiving renal transplants available over counter various formulations e g solution sponge cloth swab topical antiseptic sanitize prior surgeries medical procedures    dental formulations available prescription only include oral rinse gingivitis  slow release chip inserted into periodontal pockets reduction pocket depth periodontitis adjunct therapy dental scaling root planing procedures  medications hiv infections   hiv infections pediatric 25 35kg hiv infections 35kg pre exposure prophylaxis hiv adolescent excluding those receptive vaginal sex   hiv infections pediatric 17kg pre exposure prophylaxis adolescents adults 35kg  hiv 12 35kg  hiv weighing 35kg   hiv weighing 25kg   hiv weighing 40kg  adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effectiveness antihypertensive drugs more severe forms hypertension hypertension adjunct therapy heart failure   hydrochlorothiazide hypertension  mainly female infertility anovulation e g polycystic ovary syndrome induce ovulation prevention angina pectoris coronary artery disease osteoperosis men paget disease prevention osteoperosis postmenopausal women prevention glucocorticoid induced osteoperosis fda prevention itching eyes allergies hay fever allergic conjunctivitisfor hypertension edema congestive heart failure hepatic renal disease nephrotic syndrome palliative hodgkin disease stages iii iv  lymphosarcoma chronic myelocytic chronic lymphocytic leukemia polycythemia vera mycosis fungoides bronchogenic carcinoma palliative metastatic carcinoma resulting effusion prevention nausea vomiting initial repeat courses emetogenic cancer therapy high dose cisplatin  postoperation radiation total body irradiation daily fractionated abdominal radiation atrophic vaginitis kraurosis vulvae dermatitis herpetiformis benign mucous membrane pemphigoid pyoderma gangrenosumused temporarily numb front surface eye so eye pressure measured foreign body removed documented iron deficiency whom oral administration unsatisfactory impossible replenish body iron stores non dialysis dependent chronic kidney disease ndd ckd receiving receiving erythropoietin hemodialysis dependent hdd ckd peritoneal dialysis dependent pdd ckd  chronic kidney disease receiving erythropoietin palliative advanced breast cancer postmenopausal women adjunct assessing risk administering penicillin benzylpenicillin penicillin g postoperative inflammation following ocular surgery anterior uveitis short term insomnia therapeutic neurolysis nerves ganglia relief intractable chronic pain conditions inoperable cancer trigeminal neuralgia tic douloureux  whom neurosurgical procedures contraindicated during induction maintenance general anesthesia antiretroviral agents hiv infection adults dilate air passages lungs become narrowed result disease inflammation asthma chronic obstructive pulmonary disease copd symptomatic relief hypersensitivity reactions particularly control pruritic skin disordersfor high blood pressure edema diseases like congestive heart failure liver failure kidney failure patient population i orally administered tablets orally disintegrating tablets odt  prevention nausea vomiting emetogenic cancer chemotherapy high dose ie greater than equal 50 mg m2 cisplatin therapy radiotherapy  prevention postoperative nausea vomiting ii intravenously administered injection formulations  prevention nausea vomiting emetogenic cancer chemotherapy high dose ie greater than equal 50 mg m2 cisplatin therapy  prevention postoperative nausea vomiting pediatric 4 18 age patient population i  effective well tolerated given children 4 12 age post chemotherapy induced nausea vomiting ii  tablets  odt  injection children 3 age younger iii  tablets  odt  injection any age group pediatric population post radiotherapy induced nausea vomiting iv  tablets  odt  injection any age group pediatric population postoperative nausea vomiting geriatric  gt 65 age patient population i efficacy tolerance were similar observed younger adults post chemotherapy radiotherapy induced nausea vomiting ii clinical experience prevention postoperative nausea vomiting limited geriatric patient population reduction elevated intraocular pressure open angle glaucoma ocular hypertension these must intolerant intraocular pressure lowering medications inadequately responsive treatments   eyelash hypotrichosis  partial seizuresfor introduction local topical anesthesia accessible mucous membranes oral laryngeal nasal cavities ventricular pre excitation cardiac dysrhythmiasfor adjunctive partial seizures adults epilepsy secondary hyperparathyroidism chronic kidney disease ckd stage 3 4for trichomoniasis t vaginalis both female male giardiasis g duodenalis both adults pediatric older than three age intestinal amebiasis amebic liver abscess e histolytica both adults pediatric older than three age adjunct diet exercise improve glycemic control adults type diabetes mellitus pain systemic anesthesia adjunct reatment type ii diabetes mellitus chemoprophylaxis prophylaxis signs symptoms infection various strains influenza virus parkinsonism drug induced extrapyramidal reactions confirmed trichomoniasis trichomonas vaginalis except first trimester pregnancy patient sexual partners bacterial vaginosis  certain types amebiasis various anaerobic infections a181057  above anaerobic infections occur skin skin structures abdomen heart reproductive organs central nervous system respiratory system some present bloodstream cases septicemia common infections treated bacteroides species infections clostridium infections fusobacterium infections well peptococcus peptostreptococcus infections   off crohn disease rosacea prophylactic agent after surgery a181039  helicobacter pylori infection a181045 studied prevention preterm births periodontal disease a1391 a181078 termination pregnancy during second trimester from 12th through 20th gestational week calculated from first day last normal menstrual period  well evacuation uterine contents missed abortion intrauterine fetal death up 28 weeks gestational age calculated from first day last normal menstrual period nonmetastatic gestational trophoblastic disease benign hydatidiform mole  indications include improving cervical inducibility cervical ripening  pregnant women near term medical obstetrical need labor induction postpartum hemorrhage migraine headache adultsfor gonorrheal urethritis proctitis male gonorrheal cervicitis proctitis female susceptible strains neisseria gonorrhoeae add prophylactic oral medication chronic mild atopic asthmatic children self medication temporary relief itching eye allergic conjunctivitis ophthalmic  pain severe enough require opioid analgesic alternative treatments inadequate  naloxone fixed dose product moderate severe opioid disorder f4715 f4718 short term acutely decompensated severe chronic heart failure chf  being investigated heart disease infections susceptible organisms short term 3 weeks adjunct therapy along rest physical therapy relief muscle spasm painful musculoskeletal conditions found effective spasticity originating from cerebral spinal cord disease spasticity children cerebral palsy   occasionally off reducing pain sleep disturbances fibromyalgia a184946 phaeochromocytoma malignant  benign prostatic hypertrophy malignant essential hypertension severe psoriasis adults pediatric bodyweight 40 kg above active duodenal ulcer du  active gastric ulcer symptomatic non erosive gastroesophageal reflux disease gerd  erosive esophagitis gerd diagnosed biopsy   pathological hypersecretory conditions e g  zollinger ellison syndrome multiple endocrine neoplasias reduction risk du recurrence   intravenous formulation available some hospitalized pathological hypersecretory conditions intractable ulcers alternative oral dosage form short term unable take oral medication   over counter prevention heartburn gastroesophageal reflux children adults off uses include reduction nsaids gastrointestinal effects refractory urticarial prevention stress ulcer critically ill symptomatic relief gastritis  following french american british myelodysplastic syndrome subtypes refractory anemia refractory anemia ringed sideroblasts if accompanied neutropenia thrombocytopenia requiring transfusions  refractory anemia excess blasts refractory anemia excess blasts transformation now classified myelogenous leukemia multilineage dysplasia  chronic myelomonocytic leukemia tablet reduce risk nsaid induced gastric ulcers but duodenal ulcers high risk   formulated diclofenac symptoms osteoarthritis rheumatoid arthritis high risk developing gastric ulcers   off miscarriages prevention post partum hemorrhage alone mifepristone countries first trimester abortions a181589 a181583 a181697 alone hmg coa reductase inhibitor adjunctive therapy diet exercise reduction elevated ldl cholesterol primary hypercholesterolemia fredrickson type iia bacterial exacerbations chronic bronchitisfor antiretroviral hiv infected evidence viral replication highly experienced hiv strains resistant multiple protease inhibitors schizophrenia organic brain disorders alcoholism psychoneuroses depression depressed phase bipolar depression psychotic depression involutional melancholia helpful treating certain suffering severe depressive neurosis topical persistent facial erythema rosacea adults   ophthalmic formulation acquired blepharoptosis adults   tetracaine intranasally  for regional anesthesia performing restorative procedure teeth 4 13 j adults children weigh 40 kg more  key additive many skin care products acne psoriasis callouses corns keratosis pilaris warts exogenous obesity short term adjunct few weeks regimen weight reduction based caloric restriction asthma inhaled corticosteroid prevention exercise induced bronchospasm maintenance airflow obstruction prevention exacerbations chronic obstructive pulmonary disease    relief mild moderate pain primary dysmenorrhea idiopathic heavy menstrual blood loss relief signs symptoms chronic rheumatoid arthritis osteoarthritis peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm reflex neurogenic bladder children adjunct succinylcholine suxamethonium chloride prolong muscle relaxation prevent succinylcholine induced muscle fasciculations parkinson disease human immunovirus hiv infections conjunction antivirals topical chronic open angle glaucoma pain fever inflammation  asa  regular tablet form immediate release  relieve pain fever inflammation many conditions flu common cold neck back pain dysmenorrhea headache tooth pain sprains fractures myositis neuralgia synovitis arthritis bursitis burns various injuries symptomatic pain relief after surgical dental procedures fda   extra strength formulation migraine pain photophobia sensitivity light phonophobia sensitivity sound fda  indications asa various purposes ability inhibit platelet aggregation these include  reducing risk cardiovascular death suspected cases myocardial infarction mi  fda   reducing risk first non fatal myocardial infarction reducing risk morbidity mortality cases unstable angina those had prior myocardial infarction fda  reducing risk transient ischemic attacks tia prevent atherothrombotic cerebral infarction conjunction treatments  fda  prevention thromboembolism after hip replacement surgery fda   decreasing platelet platelet adhesion following carotid endarterectomy aiding prevention transient ischemic attacks tia  fda  undergoing hemodialysis silicone rubber arteriovenous cannula inserted prevent thrombosis insertion site fda   important note regarding extended release formulation f4405  setting myocardial infarction before percutaneous interventions extended release form should immediate release formulations scenarios requiring rapid onset action f4405  extended release form taken decrease incidence mortality myocardial infarction mi individuals diagnosed chronic coronary artery disease cad  previous myocardial infarction mi unstable angina chronic stable angina additionally extended release form decrease risk death recurrent episodes stroke history stroke tia f4405   prevention thromboembolic disease venous thrombosis thromboembolism pulmonary embolism well prevention ischemic stroke atrial fibrillation af hormone receptor positive metastatic breast cancer postmenopausal women disease progression following anti estrogen therapy monotherapy antineoplastic agents serious gram amp ndash negative infections lungs urinary tract skin only those respond inadequately alternative treatments whose epilepsy so severe substantial risk aplastic anemia liver failure deemed acceptable light benefits conferred united states  symptomatic allergic rhinitis old chronic idiopathic urticaria 6 months old  canada  carries same indications but approved only 12 old   available pseudoephedrine symptomatic season allergic rhinitis 12 old  all forms tuberculosis organisms susceptible migraine attacks without aura adults migraine attacks without aura following mild moderate infections susceptible strains microorganisms bacterial exacerbations chronic bronchitis secondary bacterial infection bronchitis community acquired pneumonia pharyngitis tonsilitis uncomplicated skin skin structure infections bacteremia septicaemia respiratory tract infections skin soft tissue infection burns wounds peri operative infections susceptible strains pain sometimes acetaminophen ibuprofen  well symptomatic common cold allergic rhinitis decongestants antihistamines expectorants  formulated ethinylestradiol combined oral contraceptive   given low dose ethinylestradiol contraception well moderate acne vulgaris women 15 old  initial advanced ovarian carcinoma established approved chemotherapeutic agents one established regimen consists paraplatin cyclophosphamide palliative ovarian carcinoma recurrent after prior chemotherapy previously treated cisplatin oral intramuscular number endocrine  rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system disorders   intra articular soft tissue injections short term gouty arthritis subactute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis  intralesional injections alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus psoriatic plaques necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesions granuloma annulare  hypertension edema ventricular tachycardias atrial fibrillation production local regional analgesia anesthesia local infiltration peripheral nerve block techniques central neural techniques epidural caudal blocks short term insomnia adults postoperative inflammation undergone cataract extraction prevention reduction intraoperative postoperative increases intraocular pressure iop before after ocular laser surgery prophylactically short term adjunctive therapy open angle glaucoma maximally tolerated medical therapy requiring additional iop reduction radio opaque medium hysterosalpingography lymphography antineoplastic agent part iodine 131 i follow up imaging chemoembolization alone classes antihypertensives hypertension diabetic nephropathy hypertensive type diabetes mellitus well congestive heart failure only cannot tolerate ace inhibitors relief symptoms seasonal allergic rhinitis perennial non seasonal allergic rhinitis desloratidine sympomatic pruritus urticaria hives chronic idiopathic urticaria hypertension only symptoms severe diarrhea predominant irritable bowel syndrome ibs women chronic symptoms generally lasting greater than 6 months does present anatomic biochemical gi abnormalities responded conventional therapy wilms tumor childhood rhabdomyosarcoma ewing sarcoma metastatic nonseminomatous testicular cancer part chemotherapy multi modality regimenfor tinea versicolor tinea capitis dandruff seborrheic dermatitis scalp intranasal symptomatic seasonal allergic rhinitis 5 older symptomatic vasomotor rhinitis 12 older  ophthalmic solution itchy eyes allergic conjunctivitis  reduce elevated total c ldl c apo b non hdl c primary hyperlipidemia alone hmg coa reductase inhibitor statin    reduce elevated total c ldl c apo b non hdl c mixed hyperlipidemia fenofibrate reduce elevated total c ldl c homozygous familial hypercholesterolemia hofh  atorvastatin simvastatin   reduce elevated sitosterol campesterol homozygous sitosterolemia phytosterolemia  reduction blood levels depot stores lead lead poisoning chronic lead encephalopathy both pediatric populations adults adjunct coumarin anticoagulants prevention postoperative thromboembolic complications cardiac valve replacement prevention angina pneumococcal infection sinusitis bacterial tonsillitis bronchitis bronchiolitis lower respiratory tract infection lobar pneumococcal pneumonia combined drugs contraceptive premenstrual dysphoric disorder moderate acne moderate severe vasomotor symptoms menopause prevention postmenopausal osteoporosis       bacterial infections respiratory tract chronic bronchitis urinary tract pre operative prophylactic prevent urinary tract infection  pneumoniae  h influenzae  aureus  p aeruginosa  e cloacae  p mirabilis  c civersus  asprphyticus  e coli  k pneumoniae mainly produce mydriasis cycloplegia diagnostic purposes insomnia characterized difficulty sleep onset glaucoma severe anticholinergic toxicity severe recalcitrant nodular acne 12 enrolled ipledge program  various formulations asthma copd copd  available single entity inhalation solution  long acting muscarinic antagonists lamas  aclidinium  glycopyrronium   corticosteroid budesonide   asthma  available mometasone furoate 5 older  budesonide 6 older   needed basis prophylaxis against exercise induced bronchospasm  refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure turner syndrome prophylaxis hereditary angioedema prevention nausea vomiting vertigo motion sickness preoperative antimuscarinic reduce salivary tracheobronchial pharyngeal secretions reduce volume free acidity gastric secretions block cardiac vagal inhibitory reflexes during induction anesthesia intubation chronic obstructive pulmonary disease copd non lymphocytic leukemia lymphocytic leukemia blast phase chronic myelocytic leukemia correction hemodynamic imbalances present shock syndrome myocardial infarction trauma endotoxic septicemia open heart surgery renal failure chronic cardiac decompensation congestive failurefor mild moderate dementia parkinson disease alzheimer type advanced breast cancer postmenopausal women whose disease progressed following tamoxifen therapy relieve inflammation swelling stiffness joint pain rheumatoid arthritis osteoarthritis topical 570 670 nm wavelength red light illumination non hyperkeratotic actinic keratoses face scalp immunocompetent conjunction lesion preparation debridement using sharp dermal curette  rheumatoid arthritis prevent renal transplant rejection  oral sulfate adjunctive therapy hepatic coma portal system encephalopathy reducing ammonia forming bacteria intestinal tract strongly recommended oral only infections proven strongly suspected susceptible bacteria reduce risk development drug resistant bacteria    polymyxin b sulfates hydrocortisone otic suspensions superficial bacterial infections external auditory canal organisms susceptible antibiotics otic formulation infections mastoidectomy fenestration cavities organisms susceptible antibiotics   ophthalmic solution containing polymyxin b sulfates dexamethasone steroid responsive inflammatory ocular conditions corticosteroid where bacterial infection risk bacterial infection exists  active progressive destructive forms inflammatory arthritis rheumatoid arthritis united states  officially postherpetic neuralgia adults adjunctive partial onset seizures without secondary generalization 3 age older  europe  adjunctive therapy partial onset seizures without secondary generalization 6 age older monotherapy 12 age older adults various types peripheral neuropathic pain painful diabetic neuropathy  produce regression disseminated neoplastic conditions like lymphoblastic leukemia myeloblastic leukemia wilms tumor neuroblastoma soft tissue bone sarcomas breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin disease malignant lymphoma bronchogenic carcinoma small cell histologic type most responsive compared cell types  component adjuvant therapy women evidence axillary lymph node involvement following resection primary breast cancer migraine attacks without aura adults alone edema congestive heart failure hepatic cirrhosis nephrotic syndrome glomerulonephritis chronic renal failure corticosteroid estrogen therapy   alone hypertension a185138  bacterial infections susceptible organisms i symptomatic relief prevention bronchospasm bronchial asthma chronic bronchitis reversible obstructive airway disease chronic bronchopulmonary disorders bronchospasm complicating factor ii prophylaxis against exercise induced bronchospasm stimuli known induce bronchospasm f3265 f3268 production local regional anesthesia surgery obstetrics post operative pain managementfor bronchial asthma vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis induction maintenance cytomegalovirus cmv retinitis immunocompromised acquired immunodeficiency syndrome aids  severe cytomegalovirus cmv disease cmv pneumonia cmv gastrointestinal disease disseminated cmv infections immunocompromised melanoma resistant chronic myelocytic leukemia recurrent metastatic inoperable carcinoma ovary sickle cell anemia postmenopausal women hormone receptor hr positive early breast cancer postmenopausal women early breast cancer periviously treated tamoxifen postmenopausal women hr unknown advanced breast cancer   given ribociclib pre peri postmenopausal women hr human epidermal growth factor her2 negative advanced metastatic breast cancer  local vulvovaginal candidiasis moniliasis cyclophosphamide conditioning regimen prior allogeneic hematopoietic progenitor cell transplantation chronic myelogenous  myeloid myelocytic granulocytic leukemia fda designated orphan drug  component pretransplant conditioning regimens undergoing bone marrow transplantation myeloid leukemia nonmalignant diseases symptomatic chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea mild moderate pain musculotendinous trauma sprains strains  postoperative dental surgery postpartum pain differential diagnosis myasthenia gravis adjunct evaluation requirements disease evaluating emergency myasthenic crises diagnostic drug testing hypothalamic pituitary acth function occasionally cushing syndrome secondary hyperparathyroidism chronic kidney disease hemodialysis peritoneal dialysis hypercalcemia parathyroid carcinoma moderate severe plaque psoriasis   well inflammatory pruritic manifestations corticosteroid responsive dermatoses  mildly moderately active ulcerative colitis trimethoprim various formulations following infections bacteria documented susceptibility urinary tract infections otitis media pediatric clinically  exacerbations chronic bronchitis adults enteritis susceptible shigella prophylaxis pneumocystis jiroveci pneumonia travelers diarrhea enterotoxigenic e coli   canada additional indications include adjunctive cholera bacillary dysentery nocardiosis second line brucellosis gentamicin rifampicin   alone part product metformin adjunct diet exercise improve glycemic control adults type diabetes mellitus  oral topical inflammatory lesions acne vulgaris   subgingival microspheres adjunct reduction pocket depth adults periodontitis  oral intravenous formulations infections susceptible microorganisms   these include rickettsiae mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis ureaplasma urealyticum borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella species bartonella bacilliformis klebsiella granulomatis escherichia coli enterobacter aerogenes shigella species acinetobacter species haemophilus influenzae kelbsiella species  alone adjunct stimulants adhd  postoperative postpartum nonobstructive functional urinary retention neurogenic atony urinary bladder retention prevention angina pectoris coronary artery disease onset action oral sufficiently rapid useful aborting anginal episode  oedema heart failure hypertension haemorrhagic conditions infants antidote coumarin anticoagulants hypoprothrombinaemia mild moderate essential hypertension prophylaxis organ rejection receiving allogeneic renal transplants administered cyclosporine corticosteroids paste mouth aphthous ulcers canker sores  prevention fungal infections blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis paracoccidioidomycosis fda europe endogenous cushing syndrome  induction maintenance general anesthesia hypertension diabetic nephropathy hypertensive type diabetes elevated serum creatinine proteinuria  product hydrochlorothiazide hypertension uncontrolled hypertension monotherapy first line expected well controlled monotherapy  advanced ovarian cancer disease recurred progressed following therapy platinum based regimens second line therapy sensitive small cell lung cancer well cisplatin stage iv b recurrent persistent cervical cancer amenable curative surgery radiation therapy short term insomnia however generally replaced sedative hypnotic agents reduction serum uric acid concentrations chronic gouty arthritis tophaceous gout frequent disabling gout attacks effectively promote uric acid excretion hyperuricemia secondary administration thiazide related diuretics remission induction maintenance therapy lymphatic leukemia biochemical tool  shown cause dramatic weight loss animalsfor life threatening ventricular arrhythmias overactive bladder symptoms urinary frequency urgency urge incontinence monotherapy initial parkinson disease well adjunct therapy decreased response levodopa carbadopa palliative mild moderate alzheimer disease higher doses depression chronic schizophrenic reactions hospitalized adjunctive therapy diet reduce elevated ldl c total c triglycerides apo b increase hdl c adults primary hypercholesterolemia mixed dyslipidemia   adults severe hypertriglyceridemia  cutaneous manifestations moderate severe erythema nodosum leprosum enl  maintenance therapy prevention suppression cutaneous manifestations enl recurrence palliative multiple myeloma palliation non resectable epithelial carcinoma ovary alone part various chemotherapeutic regimens adjunct surgery breast cancer alone regimens palliative locally recurrent unresectable transit metastatic melanoma extremities well amyloidosis prednisone manage moderate severe alzheimer dementia fda   more recent systemic review meta analysis a177106 indicates beneficial first line drug alzheimer dementia  cholinesterase inhibitors added further beneficial effects behavioral symptoms symptoms dementia a177106 bronchitis sinusitis community acquired pneumonia skin infections abscesses wounds pneumoniae h influenzae aureus m pneumoniae c pneumoniae l pneumophila pyogenesfor tuberculosis tuberculosis related mycobacterial infections chronic idiopathic constipation population irritable bowel syndrome constipation women 18 age older topical anti inflammatory product relief inflammatory pruritic manifestations corticosteroid responsive dermatoses hiv infection antiretroviral agents labeled fda symptoms idiopathic decline mental capacity related potentially reversible condition a32913 well age related cognitive impairment a32926 prescription drug conditioned corroboration patient suffering from potentially reversible treatable condition especially delirium dementiform illness secondary systemic disease primary neurological disease primary mood disturbance  know more about individual components ergoloid mixture please visit db13345 db11274 most commonly prescribed nsaid very common over counter medication widely analgesic anti inflammatory antipyretic a39096  enantiomer db09213 racemic mix common mild moderate pain related dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis soft tissue disorder a39097  activity against prostaglandin thromboxane synthesis  attributed alteration platelet function prolongation gestation labor a39092  widely medication main therapeutic indications  patent ductus arteriosus  neonatal condition wherein ductus arteriosus blood vessel connects main pulmonary artery proximal descending aorta fails close after birth causing severe risk heart failure prostaglandin inhibition studied condition known prostaglandin e2 responsible keeping ductus arteriosus open a39100  rheumatoid osteo arthritis  very commonly symptomatic inflammatory musculoskeletal rheumatic disorders a39176  cystic fibrosis  high dosages proven decrease inflammation decreasing polymorphonuclear cell influx lungs a39177  orthostatic hypotension  induce sodium retention antagonize effect diuretics reported beneficial severe orthostatic hypotension a1651  dental pain  manage chronic orofacial pain a10901  minor pain  widely reduce minor aches pains well reduce fever manage dysmenorrhea very commonly relief indications fever tension headaches a39092  investigational uses  efforts put into developing prophylaxis alzheimer disease parkinson disease breast cancer a39092 infections staphylococci susceptible organismsfor severe infections penicillin g susceptible microorganisms rapid high penicillin levels required septicemia meningitis pericarditis endocarditis severe pneumonia mild moderate hypertensionfor documented ventricular arrhythmias sustained ventricular tachycardia judgment physician life threatening subacute chronic angle closure glaucoma after iridectomy where surgery refused contraindicated infections all species schistosoma urinary tract infection alone susceptible bacterial infections ear nose throat genitourinary tract skin skin structure lower respiratory tract   given calvulanic acid bacterial sinusitis community acquired pneumonia lower respiratory tract infections bacterial otitis media skin skin structure infections urinary tract infections    given omeprazole h pylori  infections pseudomonas aeruginosa  escherichia coli  haemophilus influenzae  symptomatic overactive bladder causes urge urinary incontinence frequency urgency  children aged 6 above symptomatic detrusor muscle overactivity found related neurological condition spina bifida example neurological condition control urinary symptoms  occasion  off relieve bladder spasms ureteral stents urinary catheters t689 disorganized psychotic thinking help false perceptions e g hallucinations delusions mild transient episodes heart block do require electric shock pacemaker therapy asthma chronic bronchitisused orally jet lag insomnia shift work disorder circadian rhythm disorders blind evidence efficacy  benzodiazepine nicotine withdrawal evidence indicates likely effective treating circadian rhythm sleep disorders blind children adults received fda orphan drug status oral medication number studies shown effective treating sleep wake cycle disturbances children adolescents mental retardation autism central nervous system disorders appears decrease time fall asleep children developmental disabilities cerebral palsy autism mental retardation improve secondary insomnia various sleep wake cycle disturbances possible uses there some evidence include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps  primary insomnia jet lag nicotine withdrawal preoperative anxiety sedation prostate cancer solid tumors combined il therapy certain cancers  sunburn prevention topical  tardive dyskinesia thrombocytopenia cancer chemotherapy disorders mild moderate infections adults adolescents 12 age older susceptible strains microorganisms bacterial exacerbation chronic bronchitis community acquired pneumonia pharyngitis tonsillitis uncomplicated skin skin structure infections adjunct diet exercise improve glycemic control adults type diabetes mellitus  monotherapy adjunct lennox gastaut syndrome petit mal variant  akinetic myoclonic seizures fda  f3787  furthermore  some value absence spells petit mal failed respond succinimides fda  f3787  additionally  panic disorder without agoraphobia defined dsm v fda  alternatively some regional prescribing information note all clinical forms epileptic disease seizures adults especially absence seizures petit mal atypical absence primary secondarily generalised tonic clonic grand mal  tonic clonic seizures partial focal seizures elementary complex symptomatology various forms myoclonic seizures myoclonus abnormal movements  f3796  regional data most types epilepsy infants children especially absences petit mal  myoclonic seizures tonic clonic fits whether primary generalized epilepsy secondary generalization partial epilepsy f3796                                                                                    tablets suppositories rhinitis allergic conjunctivitis allergic reactions blood plasma dermographism anaphylactic reactions sedation nausea vomiting pain motion sickness allergic skin reactions a189907  cough syrup phenylephrine codeine relieve cough upper respiratory symptoms nasal congestion allergy common cold  prevention rickets osteomalacia manage hypocalcemia hypoparathyroidism pseudohypoparathyroidism vitaminD dependent rickets rickets osteomalacia secondary long term high dose anticonvulsant therapy early renal osteodystrophy osteoporosis conjunction calcium  hypophosphatemia fanconi syndrome acidosis hay fever urticaria hives allergic rhinitisused antiretroviral agents hiv infection well postexposure prophylaxis hiv infection individuals had occupational nonoccupational exposure potentially infectious body fluids person known infected hiv exposure represents substantial risk hiv transmission b cell chronic lymphocytic leukemia cll responded whose disease progressed during least one standard alkylating agent containing regimenfor severe angina pectoris first generation histamine h1 receptor antagonist h1 antihistamine widely available non prescription over counter otc medication otc medication  typically formulated tablets creams treating sneezing runny nose itchy watery eyes itching nose throat insomnia pruritis urticaria insect bites stings allergic rashes nausea    f3379 a174541  additionally oral impractical there prescription only formulations injection products effective adults pediatric than premature infants neonates i amelioration allergic reactions blood plasma anaphylaxis adjunct epinephrine standard measures after allergic reaction symptoms controlled uncomplicated allergic conditions immediate type oral therapy impossible contraindicated f3352  ii active motion sickness f3352  iii parkinsonism oral therapy impossible contraindicated follows parkinsonism elderly unable tolerate more potent agents mild cases parkinsonism age groups cases parkinsonism centrally acting anticholinergic agents f3352  several types dyslipidemias primary hyperlipidemia mixed dyslipidemia adults hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia adolescent failed dietary modifications a177397  dyslipidemia describes elevation plasma cholesterol triglycerides both well presence low levels high density lipoprotein condition represents increased risk development atherosclerosis    dietary modifications prevent cardiovascular events cardiac risk factors abnormal lipid profiles a177397  preventive agent myocardial infarction stroke revascularization angina without coronary heart disease but multiple risk factors type diabetes without coronary heart disease but multiple risk factors a177397  preventive agent non fatal myocardial infarction fatal non fatal stroke revascularization procedures hospitalization congestive heart failure angina coronary heart disease a177397  prescribing statin medications considered standard practice following any cardiovascular events people moderate high risk development cvd statin conditions include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia  documented carotid disease peripheral artery disease claudication  abdominal aortic aneurysm chronic kidney disease severely elevated ldl c levels a181087 a181406 etidronate paget disease bone well prevention heterotropic ossification after total hip replacement spinal cord injury  congestive cardiac insufficiency arrhythmias heart failure serotonin 4 5 ht4 receptor agonist women less than 65 age irritable bowel syndrome constipation ibs c  f4223 f4229  safety effectiveness men ibs c established f4223 f4229  adjunctive therapy refractory complex partial seizures age older had inadequate responses multiple previous treatments i e first line therapy   monotherapy infantile spasms between month age whom potential benefits outweigh risk vision loss  adjunctive therapy diarrheafor tuberculosis drugs tularemia francisella tularensis  plague yersia pestis  severe m avium complex brucellosis enterococcal endocarditis e g e faecalis e faecium obesity weight loss weight maintenance conjunction reduced calorie diet reduce risk weight regain after prior weight loss pending revision reports liver related adverse events temporary relief signs symptoms allergic conjunctivitis radiation induced dry mouth xerostomia symptoms dry mouth sj amp ouml grens syndrome general lubricant topical anesthetic esophagus larynx mouth nasal cavity rectum respiratory tract trachea urinary tract vagina suppress gag reflex malaria pulmonary arterial hypertension hypertension produce controlled hypotension during surgical procedures hypertensive crises topical following dermatologic infections tinea pityriasis versicolor m furfur  interdigital tinea pedis athlete amp rsquo foot  tinea corporis ringworm tinea cruris jock itch e floccosum  t mentagrophytes  t rubrum  t tonsurans atrial fibrillation flutter heart failurefor symptomatic relief interstitial cystitis lowering cholesterol possibly otherwise favorably affecting lipids  vitro research suggests possibility might some anticancer effects might some anti aromatase activity well activity again adjunct dietary therapy prevent cardiovascular events secondary prevention coronary heart disease chd reduce risk requiring coronary revascularization procedures reducing progression coronary atherosclerosis hypercholesterolemic chd primary hypercholesterolemia mixed dyslidipidemia schistosomiasis schistosoma mansoni signs symptoms active rheumatoid arthritis ra improve physical function slow progression structural damage disease prevention chronic rejection recipients solid organ trasnplants designated fda orphan drug fda monograph states adjunct diet triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia  homozygous familial hypercholesterolemia f4649  health canada monograph further specifies reduction elevated total cholesterol total c  ldl c apob total c hdl c ratio triglycerides tg increasing hdl c hyperlipidemic dyslipidemic conditions response diet exercise alone inadequate prevention major cardiovascular events risk myocardial infarction nonfatal stroke coronary artery revascularization without documented history cardiovascular cerebrovascular events but least two conventional risk factors cardiovascular disease f4652  prescribing statin medications considered standard practice following any cardiovascular events people moderate high risk development cvd statin conditions include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia  documented carotid disease peripheral artery disease claudication  abdominal aortic aneurysm chronic kidney disease severely elevated ldl c levels a181087 a181406 amphotericin b serious infections susceptible strains candida septicemia endocarditis urinary system infections cryptococcus meningitis pulmonary infections suppression motor phonic tics tourette disorder failed respond satisfactorily standard treatment metastatic breast cancer resistant both paclitaxel anthracycline containing chemotherapy regimen docetaxel metastatic breast cancer failed respond recurred relasped during following anthracycline containing chemotherapy  alone adjuvant therapy following complete resection primary tumor stage iii colon cancer monotherapy fluroprymidine preferred regimens advanced gastric cancer currently being investigated elicit cardiovascular responses cardiac stumulant  similar those produced exercise order aid diagnosing presence absence coronary artery disease cad cannot exercise adequately giardiasis cutaneous leishmaniasis malignant effusions major depressive disorder mdd  post traumatic stress disorder ptsd  obsessive compulsive disorder ocd  panic disorder pd  premenstrual dysphoric disorder pmdd  social anxiety disorder sad   common off uses include prevention post stroke depression a187078  generalized anxiety disorder gad  fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy neurocardiogenic syncope  obesity ophthalmic temporary relief signs symptoms seasonal allergic conjunctivitis nasal spray allergic rhinitis insomnia cushing syndrome normally short term until permanent therapy possible unfractionated prophylaxis venous thrombosis extension prevention post operative deep venous thrombosis pulmonary embolism prevention clotting arterial cardiac surgery cardiology prevent embolisms atrial fibrillation adjunct antithrombin therapy unstable angina non q wave myocardial infarctions i e non st elevated coronary artery syndrome platelet glycoprotein iib iiia receptor inhibitors additionally prevent clotting during dialysis surgical procedures maintain patency intravenous injection devices prevent vitro coagulation blood transfusions blood samples drawn laboratory values local oropharyngeal candidiasis adjunctive diaper dermatitis complicated candidiasis immunocompetent aged four weeks older    available both suppository cream vaginal yeast infections relief vulvar itching irritation  lastly  cream effective treating athlete foot tinea pedis  jock itch tinea cruris  ringworm infections tinea corporis   pityriasis formerly tinea versicolor a203633 cutaneous candidiasis a203630 chronic infections sensitive strains certain gram negative bacilli particularly pseudomonas aeruginosa many different types bacterial infections bronchitis sinusitis tonsillitis ear infections skin infections gonorrhea urinary tract infections impotence vasospasms rhinitis urticaria allergy common cold asthma hay fever capsules vasospastic angina chronic stable angina  extended release tablets vasospastic angina chronic stable angina hypertension  controlled reduction blood pressure during surgery hypertensive emergencies prevention pneumocystis carinii pneumonia intolerant trimethoprim sulfamethoxazole tmp smx  oral mild moderate pcp intolerant tmp smx fda approved indications recurrent ventricular fibrillation vf recurrent hemodynamically unstable ventricular tachycardia vt  fda emphasizes drug should only given these conditions they clinically documented responded normal therapeutic doses antiarrhythmic agents drugs tolerated patient   off indications include atrial fibrillation supraventricular tachycardia a189666 a189720 a189723 parentally hypertensive emergencies hypoglycemia secondary insulinoma niddm conjunction diet exercise control certain seizures epilepsy muscle weakness muscle disease myasthenia gravis topical antiseptic mainly wound dressings niddm non insulin dependent diabetes mellitus conjunction diet exercise prophylaxis venous thrombosis extension atrial fibrillation embolization prophylaxis pulmonary embolism adjunct coronary occlusion symptomatic benign prostatic hyperplasia bph men enlarged prostate gland improve symptoms reduce risk urinary retention need bph related surgery alone tamsulosin  topical application tinea pedis tinea cruris tinea corporis trichophyton rubrum  trichophyton mentagrophytes  trichophyton tonsurans  microsporum canis  microsporum audouini  microsporum gypseum  epidermophyton floccosum  cutaneous candidiasis tinea versicolor together surgery lhrh analogue advanced prostatic cancer acid reflux disorders gerd  peptic ulcer disease h pylori eradication prevention gastroinetestinal bleeds nsaid relief inflammatory pruritic manifestations corticosteroid responsive dermatoses causal prevention suppression malaria susceptible strains p falciparum species plasmodium found some geographical areas world adjunct diet exercise improve glycemic control adults type diabetes mellitus  available metformin   glimepiride   alogliptin  same indication paget disease bone serum alkaline phosphatase levels times upper limit normal symptoms risk future complications  examined adrenocortical insufficiency especially multiple sclerosis congenital cerebral palsy polyarteritis nodosa rheumatoid arthritis currently only approved treating cats dogs addison disease provide skeletal muscle relaxation adjunct general anesthesia endotracheal intubation facilitate mechanical ventilation mild severe heart failure left ventricular dysfunction after myocardial infarction ventricular ejection fraction 40  hypertension  oral intravenous formulations  adults various infections susceptible bacteria infections upper respiratory tract lower respiratory tract skin skin structures urinary tract prostate   oral formulation both adults children 6 months age older post exposure inhalational anthrax bacillus anthracis prophylaxis plague yersinia pestis   ophthalmic formulation  bacterial conjunctivitis susceptible organisms  inhalational solution available canada cystic fibrosis aged 18 older chronic pulmonary pseudomonas aeruginosa infections  gout gouty arthritis infections susceptible bacteria following infections skin uti ent  pneumoniae h influenzae staphylococci pyogenes  group beta hemolytic streptococci  e coli p mirabilis klebsiella sp coagulase negative staphylococci streptococcus pyogenes candidemia disseminated candidiasis certain invasive candida infections well esophageal candidiasis prophylaxis candida infections undergoing hematopoietic stem cell transplantation  alternative oropharyngeal candidiases some success primary salvage therapy alone antifungals invasive aspergillosis  prophylaxis candida infections undergoing hematopoietic stem cell transplantation oral approved following indications   depression anxiety a177163  depression anxiety different conditions alcoholism organic disease manic depressive disorders t249  psychotic depressive disorders anxiety t249  involutional depression t249   manic depressive disorder t249  insomnia characterized difficulties sleep maintenance a177163  topical approved short term up 8 days moderate pruritus atopic dermatitis pruritus lichen simplex chronicus t249  off  topically neuropathic pain a177172  depression common medical illness causes feelings sadness loss interest prior enjoyable activities condition lead emotional physical disturbances decrease ability person function regular environment   anxiety normal reaction body towards normal danger anxious state exacerbated appears situations without danger defined anxiety disorder disorders appear different forms phobias panic obsessive compulsive disorder post traumatic stress disorder   insomnia sleep disorder directly affects quality life individual characterized complication either fall asleep stay asleep condition occasional chronic   pruritus defined unpleasant skin reaction provokes urge scratch localized generalized appear chronic manner   neuropathic pain occurs damage dysfunction peripheral central nervous system rather than stimulation pain receptors  reduction cumulative renal toxicity ovarian cancer using cisplatin moderate severe xerostomia undergoing post operative radiation head neck cancer adjunctive chronic simple open angle glaucoma secondary glaucoma preoperatively angle closure glaucoma where delay surgery desired order lower intraocular pressurefor leprosy dermatitis herpetiformisfor allergic rhinitis hay fever allergic skin disorders infections penicillinase producing staphylococci pneumococci group beta hemolytic streptococci penicillin g sensitive penicillin g resistant staphylococci symptomatic relief dysuria urgency nocturia suprapubic pain frequency incontinence occur cystitis prostatitis urethritis urethrocystitis urethrotrigonitis depression following infections respiratory skin soft tissue uti ent pneumoniae h influenzae staphylococci pyogenes group beta hemolytic streptococci  e coli p mirabilis klebsiella sp coagulase negative staphfor relief symptoms various depressive syndromes especially endogenous depression manage chronic peripheral neuropathic pain second line agent anxiety disorders e g panic disorder generalized anxiety disorder  second third line agent adhd topical vulvovaginal candidiasis topical interdigital tinea pedis immunocompetent 12 age older trichophyton rubrum  trichophyton mentagrophytes  epidermophyton floccosum production complete anaesthesia short duration induction general anaesthesia inducing hypnotic state bacterial infection susceptible strains pneumoniae  h influenzae  h parainfluenzae  m catarrhalis  pneumoniae  multi drug resistant strains mdrsp   m pneumoniae  c pneumoniae  k pneumoniae  major depressive disorder mdd  seasonal affective disorder sad  aid smoking cessation  naltrexone marketed product contrave  adjunct reduced calorie diet increased physical activity chronic weight adults initial body mass index bmi 30 kg m greater obese 27 kg m greater overweight presence least one weight related comorbid condition e g  hypertension type diabetes mellitus dyslipidemia   off first line adhd comorbid bipolar disorder adjunct mood stabilizers f4624 concurrent leucovorin administration leucovorin protection  alternative therapy moderate severe pneumocystis carinii pneumonia pcp immunocompromised acquired immunodeficiency syndrome aids  several types cancer colon cancer prophylaxis therapy ventricular fibrillation life threatening ventricular arrhythmias ventricular tachycardia failed respond adequate doses first line antiarrhythmic agent lidocaine induction maintenance general anesthesiaused aborting second trimester pregnancy between twelfth eighteenth week gestation incomplete abortion therapeutic abortion cases intrauterine fetal death congenital abnormalities incompatible life low doses medically induction labor term injected intra arterially vasodilator assist angiography production local anesthesia infiltration peripheral nerve block they lumbar caudal epidural anesthesia treating symptomatic benign prostatic hyperplasia hypertension fda urinary tract infections some strains e coli klebsiella enterobacter species mainly against gram negative organisms hypocalcemia those conditions requiring prompt increase blood plasma calcium levels magnesium intoxication overdosage magnesium sulfate combat deleterious effects hyperkalemia measured electrocardiographic ecg  pending correction increased potassium level extracellular fluid infections respiratory tract kidney skin soft tissue uti  urethral cervical gonorrhoea alleviation symptoms intermittent claudication pain legs occurs walking disappears rest following fungal infections immunocompromised non immunocompromised pulmonary extrapulmonary blastomycosis histoplasmosis aspergillosis onychomycosis anticancer drugs stage iii stage iv hodgkin disease induction remission consolidation promyelocytic leukemia apl  whose apl characterized presence t 15 17 translocation pml rar alpha gene expressionfor moderate severe hypertension either alone adjunct renal hypertension major depressive disorder bipolar disorder a31901 infections where one more following known suspected pathogens  e coli  proteus species both indole positive indole negative  e aerogenes k pneumoniae marcescens  acinetobacter species adjunct rest physical therapy measures relief discomfort painful musculo skeletal conditions all types seizures except absence seizures both maintenance major depressive disorder mdd generalized anxiety disorder gad   additionally symptomatic relief obsessive compulsive disorder ocd canada  prevention nausea vomiting dizziness motion sickness vertigo dizziness medical problems myeloid leukemia aml adults includes french american british fab classifications m1 through m7 anxiety muscle spasm external genital warts  condyloma acuminatum  hypertension component various chemotherapeutic regimens third line therapy recurrent refractory germ cell testicular cancer component various chemotherapeutic regimens cervical cancer well conjunction surgery radiation therapy various soft tissue sarcomas indications include osteosarcoma bladder cancer ovarian cancer small cell lung cancer non hodgkin lymphoma prolong time recurrence paroxysmal atrial fibrillation flutter paf disabling symptoms without structural heart disease life threatening documented ventricular arrhythmias sustained ventricular tachycardia complete partial reversal narcotic depression respiratory depression induced opioids natural synthetic narcotics propoxyphene methadone narcotic antagonist analgesics nalbuphine pentazocine butorphanol diagnosis suspected opioid overdose adjunctive agent increase blood pressure septic shock dyspepsia heartburn epigastric pain nausea vomiting males replacement therapy conditions symptoms deficiency absence endogenous testosterone females palliation androgenresponsive recurrent mammary cancer women more than one year but less than five postmenopausal adjunctive levodopa carbidopa signs symptoms parkinson disease withdrawn from us canadian markets 2007 increased risk cardiac valvulopathy  contrast agent locate spinal tumors topical immunocompetent mild moderate onychomycosis fingernails toenails without lunula involvement trichophyton rubrum inhalation agent induction maintenance anesthesia inpatient outpatient surgery adults oral parenteral formulations  serious infections susceptible anaerobic bacteria well susceptible staphylococci streptococci pneumococci   topically acne vulgaris   available benzoyl peroxide  tretinoin  purpose  vaginal cream  suppository  bacterial vaginosis non pregnant females  antimicrobial prophylaxis against viridans group streptococcal infections susceptible undergoing oral dental upper respiratory surgery prophylaxis against bacterial endocarditis penicillin allergic high risk these infections  obesity weight loss maintenance weight loss reduced calorie dietfor moderate severe pain hypertension ventricular premature beats adults elevated intraocular pressure ocular hypertension open angle glaucoma new zealand america  prevent supraventricular arrhythmias ventricular arrhythmias  united states prevent paroxysmal atrial fibrillation flutter a186886 palliative metastatic progressive carcinoma prostatefor essential renovascular hypertension usually administered drugs particularly thiazide diuretics  congestive heart failure drugs e g cardiac glycosides diuretics  amp beta adrenergic blockers  improve survival left ventricular dysfunction following myocardial infarction nephropathy diabetic nephropathy short term insomnia galactorrhea hyperprolactinemia prolactin dependent menstrual disorders infertility prolactin secreting adenomas prolactin dependent male hypogonadism adjunct therapy surgery radiotherapy acromegaly monotherapy special cases monotherapy early parksinsonian syndrome adjunct levodopa advanced cases motor complications  off restless legs syndrome neuroleptic malignant syndrome pulmonary tuberculosis adjunctive therapy partial onset seizures epileptic one month age older additionally adjunct myoclonic seizures juvenile myoclonic epilepsy 12 age older primary generalized tonic clonic seizures idiopathic generalized epilepsy 6 age older   available orally dissolvable tablet adjunct partial onset seizures epilepsy 4 age older weigh more than 20kg  angina pectoris hypertension  another product formulated bendroflumethiazide hypertension  secondary chronic progressive progressive relapsing worsening relapsing remitting multiple sclerosisfor complete partial reversal sedative effects benzodiazepines cases where general anesthesia induced maintained benzodiazepines where sedation produced benzodiazepines diagnostic therapeutic procedures benzodiazepine overdose adjunct appropriate supportive symptomatic measures primary metastatic brain tumors component chemotherapy addition appropriate surgical radiotherapeutic procedures agents secondary therapy refractory relapsed hodgkin disease adjunctive therapy induce thrombolysis suffering myocardial infarction adults following infections susceptible strains microorganisms community acquired pneumonia chlamydia pneumoniae  haemophilus influenzae  haemophilus parainfluenzae  moraxella catarrhalis  mycoplasma pneumoniae  streptococcus pneumoniae  bacterial exacerbations chronic bronchitis chlamydia pneumoniae  enterobacter cloacae  haemophilus influenzae  haemophilus parainfluenzae  klebsiella pneumoniae  moraxella catarrhalis  staphylococcus aureus  streptococcus pneumoniae  moderate severe pain lowering intraocular pressure iop chronic open angle glaucoma ocular hypertension alternative medication otitis media h influenzae m catarrhalis pneumoniae history type i penicillin hypersensitivity pharyngitis tonsillitis susceptible streptococcus pyogenes  well respiratory tract infections maxillary sinusitis bacterial exacerbations chronic bronchitis mild moderate community acquired pneuomia legionnaires disease pertussis indications include uncomplicated skin skin structure infections helicobacter pylori infection duodenal ulcer disease bartonella infections early lyme disease encephalitis toxoplasma gondii  hiv infected conjunction pyrimethamine  decrease incidence cryptosporidiosis prevent occurence  hemolytic viridans group streptococcal endocarditis well serve primary prevention mycobacterium avium complex mac bacteremia disseminated infections adults adolescents children advanced hiv infection  infections respiratory skin soft tissue uti ent susceptible organisms  organisms generally susceptible include pneumoniae pyogenes group beta hemolytic streptococci  coagulase negative staphylococci some enterobacter spp h influenzae n gonorrhoeae p mirabilis e coli klebsiella spp m catarrhalis b burgdorferi some oral anaerobes a215582 antizol antidote ethylene glycol antifreeze methanol poisoning suspected ethylene glycol methanol ingestion either alone hemodialysisindicated elevated intraocular pressure ocular hypertension open angle glaucoma short term insomnia characterized difficulty falling asleep frequent nocturnal awakenings early morning awakenings symptomatic benign prostatic hyperplasia bph men enlarged prostate improve symptoms reduce risk urinary retention reduce risk need surgery transurethral resection prostate turp prostatectomy   male pattern hair loss androgenetic alopecia hereditary alopecia common male baldness male  adjunct therapy hormone receptor positive early breast cancer postmenopausal women first line hormone receptor positive hormone receptor unknown locally advanced metastatic breast cancer postmenopausal women  advanced breast cancer postmenopausal women experience disease progression despite tamoxifen   severe malariafor along appropriate supportive measures fulminant hypermetabolism skeletal muscle characteristic malignant hyperthermia crises all ages preoperatively sometimes postoperatively prevent attenuate development clinical laboratory signs malignant hyperthermia individuals judged malignant hyperthermia susceptible multiple indications fda  12 age traveller diarrhea noninvasive strains escherichia coli reduction overt hepatic encephalopathy recurrence 18 age 2015 approved irritable bowel syndrome diarrhea ibs d men women  anesthetic agent recommended diagnostic surgical procedures if skeletal muscle relaxation needed should combined muscle relaxant if surgical procedure involves visceral pain should supplemented agent obtunds visceral pain  induction anesthesia prior general anesthetic agents supplement low potency agents  fda  reports potential therapeutic tool depression administered lower doses a31873 these reports increased interest area several clinical trials launched indication  a31874 extended release capsules maintenance mild moderate crohn disease   various inhaled products prophylactic therapy asthma   reducing exacerbations copd  nasal spray available over counter symptoms hay fever upper respiratory allergies  extended release capsules induce remission mild moderate ulcerative colitis  rectal foam mild moderate distal ulcerative colitis  bronchospasm asthma emphysema chronic bronchitis symptomatic schizophrenia  addition manic mixed episodes bipolar i disorder monotherapy combined drugs manage depressive episodes bipolar disorder addition above indications  antidepressant drugs major depression   some off uses drug include post traumatic stress disorder ptsd  generalized anxiety disorder psychosis parkinson disease a185438 a185447 t685 prophylaxis deep vein thrombosis lead pulmonary embolism prophylaxis ischemic complications unstable angina non q wave myocardial infarction concurrently administered aspirin inpatients outpatients adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation opiate dependence sometimes severe pain terminal class ic antiarrhythmic agent irregular heartbeats atrial fibrillation atrial flutter ventricular tachycardia ventricular fibrillation kaposi sarcoma cancer lung ovarian breast abraxane specfically metastatic breast cancer locally advanced metastatic non small cell lung cancer attention deficit hyperactivity disorder adhd prevention symptomatic peripheral labyrinthine vertigo nausea vomiting occur conditions meniere disease surgery middle inner ear control nausea vomiting postoperative states malignant neoplasms labyrinthine disturbances antineoplastic agent therapy radiation sickness infectious diseases ritonavir antiretroviral agents hiv infection 16 age older  oral tablet form symptomatic both recurrent diabetic gastroparesis addition gastroesophageal reflux disease gerd failed respond traditional therapy  nasal spray formulation adults recurrent diabetic gastroparesis   intravenous injection form above conditions well prevention vomiting follow emetogenic chemotherapy nausea vomiting after surgery intravenous facilitates intubation small bowel stimulates gastric emptying barium flow require radiological examination stomach small intestine  some cases delay gastrointestinal emptying interferes radiographic visualization gastrointestinal tract facilitate emptying these cases allowing adequate diagnostic visualization   some off uses include radiation induced nausea vomiting gastric bezoars intractable hiccups migraine pain a184961 a184964 a184967 a40105 ciprofloxacin otic suspension bacterial infections inflammation otitis media otitis externa  intramuscular intravenous injections number endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous conditions  oral tablets multiple myeloma  intravitreal implant some forms macular edema non infectious posterior uveitis affecting posterior eye  various ophthalmic formulations inflammatory conditions eye     own formulated oral inhalation powder intermittent off episodes parkinson already being treated carbidopa fda  most commonly formulated oral tablet peripheral dopa decarboxylase inhibitor parkinson disease post encephalitic parkinsonism symptomatic parkinsonism following carbon monoxide intoxication manganese intoxication f4579 induction maintenance general anesthesia pediatric inpatient outpatient surgery symptoms related hay fever types allergy help bring up phlegm thin secretions make cough productive manic mixed episodes bipolar i disorder irritability autism spectrum disorder schizophrenia tourette disorder adjunctive major depressive disorder  injectable formulation agitation schizophrenia bipolar mania psychotic disorders e g schizophrenia mania occuring part bipolar disorders long term intravenous primary pulmonary hypertension pulmonary hypertension scleroderma spectrum disease nyha class iii class iv do respond adequately conventional therapy types iv v hyperlipidemia elevated serum triglycerides usually above 2000mg dl  elevated vldl cholesterol fasting chylomicrons risk developing pancreatitis do adequately respond dietary restrictions   reduce risk developing coronary heart disease type iib hyperlipidemia without history symptoms coronary heart disease do adequately respond weight loss diet exercise medications low hdl raised ldl raised triglycerides  obsessive compulsive disorder disorders obsessive compulsive component e g depression schizophrenia tourette disorder  unlabeled indications include depression panic disorder chronic pain e g central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain  cataplexy narcolepsy limited evidence  autistic disorder limited evidence  trichotillomania limited evidence  onchophagia limited evidence  stuttering limited evidence  premature ejaculation premenstrual syndrome dandruff mild moderately severe seborrheic dermatitis scalp hypertension chronic stable angina classic effort angina skeletal muscle relaxantused prevent relieve allergic conditions cause pruritus itching urticaria some allergic skin reactions  enduring debilitating symptoms depression responded antidepressant drugs  depression common but serious mood disorder patient will present changes feelings thoughts ability handle everyday activities mood disorder considered depression symptoms should present least two weeks  locally advanced metastatic breast cancer after failure prior chemotherapy single agent locally advanced metastatic non small cell lung cancer after failure prior platinum based chemotherapy prednisone androgen independent hormone refractory metastatic prostate cancer furthermore  uses gastric adenocarinoma head neck cancer  contrast agent during coronary angiography inflammatory bowel disease ulcerative colitis diabetes mellitus type type diabetes postpartum haemorrhage postabortion haemorrhage uterine atony adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy adults philadelphia chromosome positive lymphoblastic leukemia resistance intolerance prior therapy attention deficit hyperactivity disorder adhd moderate severe binge eating disorder adults fda  a40246  drug weight loss sympathomimetic drugs weight loss serious cardiovascular effects safety effectiveness drug obesity yet determined fda  adults pediatric aged 9 months older topical impetigo up 100 cm lt sup gt lt sup gt total area adults total body surface area pediatric aged 9 months older staphylococcus aureus methicillin susceptible isolates only streptococcus pyogenes paroxysmal nocturnal hemoglobinuria pnh reduce hemolysis atypical hemolytic uremic syndrome inhibit complement mediated thrombotic microangiopathy a2246  neuromyelitis optica spectrum disorder nmosd  capecitabine advanced metastatic breast cancer whose tumors overexpress human epidermal receptor type her2 protein received prior therapy anthracycline taxane trastuzuma relief inflammatory pruritic manifestations corticosteroid responsive dermatose glycemic control type diabetes mellitus along diet exercise  myelodysplastic syndromes mds all french american british subtypes refractory anemia refractory anemia ringed sideroblasts refractory anemia excess blasts refractory anemia excess blasts transformation chronic myelomonocytic leukemia  well mds scored belonging intermediate intermediate high risk group international prognostic scoring system  prophylaxis invasive lt em gt aspergillus lt em gt lt em gt candida lt em gt infections 13 age older high risk developing these infections being severely immunocompromised result procedures hematopoietic stem cell transplant hsct recipients graft versus host disease gvhd  hematologic malignancies prolonged neutropenia from chemotherapy oropharyngeal candidiasis oropharyngeal candidiasis refractory itraconazole fluconazole  alternative invasive aspergillosis  lt em gt fusarium lt em gt infections zygomycosis intolerant whose disease refractory antifungals  co administered ritonavir antiretroviral agents human immunodeficiency virus hiv children age 3 above adults hiv infection  chronic hepatitis b adolescent 16 age evidence viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active disease topical external genital perianal warts condylomata acuminata immunocompetent 18 older schizophrenia advanced renal cell carcinoma well gastrointestinal stromal tumor after disease progression intolerance imatinib mesylate egfr expressing metastatic colorectal carcinoma refractory fluoropyrimidine  oxaliplatin  irinotecan containing chemotherapy regimens macular edema after retinal vein occlusion age related macular degeneration wet  diabetic macular edema hunter syndrome adults children ages 5 older pompe disease gaa deficiency infants pediatric aid smoking cessation bronchodilator long term symptomatic reversible bronchoconstriction chronic obstructive pulmonary disease copd  chronic bronchitis emphysema  alone adjunct standard therapy essential hypertension  product isosorbide dinitrate adjunct therapy heart failure  improving glycemic control adults type diabetes mellitus along diet exercise long term growth failure pediatric primary igfd gh gene deletion developed neutralizing antibodies gh a2322  secondary igfd resulting from gh deficiency malnutrition hypothyroidism causes substitute gh therapy type type diabetes mellitus adjunct preprandial insulin therapy without adequate glycemic control insulin therapy adults children mucopolysaccharidosis vi pediatric t cell lymphoblastic leukemia t cell lymphoblastic lymphoma whose disease responded relapsed following least two chemotherapy regimens signs symptoms moderate severe active rheumatoid arthritis inducing major clinical response slowing progression structural damage improving physical function both monotherapy continued regimen dmards tnf antagonists  signs symptoms moderately severely active polyarticular juvenile idiopathic arthritis children control postpartum hemorrhage bleeding after giving birth chronic signs symptoms osteoarthritis knee adults diagnostic agent screening presumed adrenocortical insufficiency diagnostic agent screening presumed adrenocortical insufficiency asthma diabetes mellitus type prevention reversal bronchospasm 12 age older reversible bronchospasm asthma nausea heartburn indigestion upset stomach diarrhea temporary discomforts stomach gastrointestinal tract angina pectoris hypertension usually osteoarthritis although efficacy still question emergency cardiac arrhythmias orally urinary tract infections pyrimethamine prevention malaria various infections livestock well  pyrimethamine plasmodium falciparum malaria those whom chloroquine resistance suspected  broad spectrum antibiotic cases needing high concentrations oral administration impractical symptoms asthma bronchitis copd emphysema improve glycemic control adults children diabetes mellitus improve glycemic control adults children diabetes mellitus improve glycemic control adults pediatric diabetes mellitus antiretroviral agents human immunodeficiency virus hiv infection well postexposure prophylaxis hiv infection individuals had occupational nonoccupational exposure potentially infectious body fluids person known infected hiv exposure represents substantial risk hiv transmission pending revision potential association between drug myocardial infarction dyslipidemia hiv infected adults generalized tonic clonic status epilepticus prevention seizures occurring during neurosurgery substituted short term oral phenytoin aged two older oral phenytoin administration possible  bacterial infections thiazide diuretic decrease edema decrease blood pressure hypertension serious infections susceptible strains microorganisms mainly bacterial infections skin moderately severe bacterial infections involving lung bone joint stomach blood heart valve urinary tract clinically effective against infections staphylococci streptococci species gram positive bacteria surgical prophylaxis if required metronidazole added cover b fragilis bacterial infections susceptible microorganisms following infections susceptible bacteria  respiratory tract infections pneumoniae h influenzae aureus penicillinase non penicillinase producing strains  pyogenes group beta hemolytic streptococci  p aeruginosa klebsiella pneumoniae e coli proteus mirabilis enterobacter species  peritonitis intra abdominal infections e coli p aeruginosa anaerobic gram negative bacilli bacteroides fragilis  3 bacterial septicemia pneumoniae agalactiae aureus pseudomonas aeruginosa e coli klebsiella spp  klebsiella pneumoniae proteus species indole positive indole negative  clostridium spp anaerobic gram positive cocci  4 infections skin skin structures aureus penicillinase non penicillinase producing strains  pyogenes p aeruginosa  5 pelvic inflammatory disease endometritis infections female genital tract n gonorrhoeae epidermidis agalactiae e coli clostridium spp  bacteroides species bacteroides fragilis  anaerobic gram positive cocci  6 urinary tract infections escherichia coli pseudomonas aeruginosa  7 enterococcal infections although shown clinically effective infections enterococci cases peritonitis intra abdominal infections infections skin skin structures pelvic inflammatory disease endometritis infections female genital tract urinary tract infections majority clinical isolates enterococci tested susceptible but fall just intermediate zone susceptibility moderately resistant  however vitro susceptibility testing correlate directly vivo results despite  therapy resulted clinical cures enterococcal infections chiefly polymicrobial infections  should enterococcal infections care doses achieve satisfactory serum levels prophylaxis bacterial infections serious infections susceptible strains microorganisms cetizoxime previously infections susceptible strains bacteria muscle relaxant muscle relaxant during anesthesia surgical procedures muscle relaxant during anesthesia surgical procedures muscle relaxing agent adjunct general anesthesia ace inhibtor class drug hypertension heart failure hypertension abnormally high potassium levels potassium regulate hypokalemia primary condition secondary medical conditions  hypertension heart failure ace inhibitor class drug hypertension infrequently hypertension heart failure insomnia mainly sedation hypnosis induction anesthesia prior general anesthetic agents induction anesthesia short surgical diagnostic therapeutic procedures minimal painful stimuli lithium salt forms mood stabilizer depression mania most frequently prescribed bipolar disorder one first oral contraceptives mild moderate arterial hypertension alone antihypertensive agents especially thiazide type diuretics contraindicated cardiogenic shock sinus bradycardia second third degree atrioventricular conduction block bronchial asthma those known hypersensitivity ia myelography arthrography nephroangiography arteriography radiographic procedures ephedra temporary relief shortness breath tightness chest wheezing bronchial asthma  temporary relief bronchial asthma over counter formulations  intravenous injections hypotension under anesthesia   injections multiple routes allergic conditions bronchial asthma   nasal spray otc medication decongestant  maintain blood pressure hypotensive states asthma chronic obstructive pulmonary disease copd signs symptoms idiopathic parkinsons disease initial monotherapy adjunct therapy levodopa bacterial infections usually dalfopristin  plays vital role anatomy physiology biochemistry organisms cell particularly signal transduction pathways vital cell signaling muscular contractions bone health signalling cascades over counter supplement cardiovascular neuromuscular health antacid relief acid indigestion upset stomach relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders appears effective alleviating age related memory impairment some elderly people mild moderate age related memory cognitive impairment improving cognitive function healthy young middle aged people improving symptoms alzheimer vascular mixed dementia improving damage visual field normal tension glaucoma decreasing number painful attacks raynaud syndrome improve symptoms vertigo dizziness some glycodiazine concomitantly insulin noninsulin dependent type diabetes mellitus all conditions corticosteroid therapy except adrenal deficiency states lack sodium retaining properties makes less suitable than hydrocortisone supplementary fludrocortisone angina high blood pressure metabolic acidosis occur severe renal disease uncontrolled diabetes circulatory insufficiency shock severe dehydration extracorporeal circulation blood cardiac arrest severe primary lactic acidosis severe diarrhea often accompanied significant loss bicarbonate further certain drug intoxications barbiturates where dissociation barbiturateprotein complex desired  poisoning salicylates methyl alcohol hemolytic reactions requiring alkalinization urine diminish nephrotoxicity blood pigments sympatholytic mydriatic impotence successfully treated male vascular diabetic origins psychogenic origins primary hyperlipidaemia types iia iib iii iv v fredrickson classification corresponding groups i ii iii european atherosclerosis society guidelines  diet alone improvements lifestyle increased exercise weight reduction do lead adequate response secondary hyperlipidaemias e g severe hypertriglyceridemias sufficient improvement does occur after correction underlying disorder e g diabetes mellitus  prophylaxis gout flares  familial mediterranean fever fmf children adults 4 age older important note medication pain reliever painful conditions consider analgesics purpose  some off uses include manifestations behcet syndrome pericarditis postpericardiotomy syndrome a183932 a183935  ethinyl estradiol oral contraceptive prevention pregnancy  addition contraceptive effects moderate acne vulgaris symptoms premenstrual dysphoric disorder   drug approved indications estrogens menopause symptoms vasomotor symptoms vulvovaginal atrophy  combined estrogen may aid prevention osteoporosis women post menopausal least year candidates therapies    sometimes found preparations containing estrogen folic acid folic acid replenishment during oral contraception   acne vulgaris  containing contraceptives should only women 14 age experienced menarche desire oral contraception do any contraindications oral contraceptives  off uses drug include menstrual irregularities dysmenorrhea hirsutism endometriosis a2439 a182576 congestive cardiac insufficiency arrhythmias heart failure common analgesic non steroidal anti inflammatory drug nsaid mild moderate muscular painfor relief signs symptoms rheumatoid arthritis osteoarthritis related rheumatic disorders symptomatic myasthenia gravis improving muscle tone reduce pain inflammation conditions arthritis medication fever adults psychosis particular those schizophrenia manic phases bipolar disorder lower respiratory tract infections genital urinary infections like prostatitis skin infections endometriosis fibrocystic breast disease unresponsive simple measures  prophylactic all types hereditary angioedema males females bronchodilator asthma prevention reversal bronchospasm 12 age older asthma reversible bronchospasm bronchitis emphysema powder inhalation maintenance bronchospasm copd prevent exacerbations copd  olodaterol metered inhalation spray maintenance copd  inhalation spray maintenance bronchospasm copd prevent exacerbations copd asthma 12 more old  metered inhalation spray maintenance bronchospasm copd prevent exacerbations copd asthma 6 more old  nasal symptoms seasonal perennial allergic rhinitis adults adolescents 12 age older adjunct standard therapy inhaled steroids inhaled long short acting beta agonists  vasodilator diuretic heart stimulant similar caffeine useful fatigue orthostatic hypotension pneumonia moderate severe streptococcus pneumoniae  cases concurrent bacteremia  pseudomonas aeruginosa  klebsiella pneumoniae  enterobacter species empiric febrile neutropenic uncomplicated complicated urinary tract infections pyelonephritis escherichia coli klebsiella pneumoniae  infection severe escherichia coli  klebsiella pneumoniae  proteus mirabilis  infection mild moderate cases concurrent bacteremia these microorganisms uncomplicated skin skin structure infections staphylococcus aureus  methicillin susceptible strains only streptococcus pyogenes complicated intra abdominal infections metronidazole escherichia coli  viridans group streptococci  pseudomonas aeruginosa  klebsiella pneumoniae  enterobacter species bacteroides fragilis  broad spectrum first generation cephalosporin antibiotic effective gram positive gram negative bacterial infections bacterial exacerbations chronic bronchitis abecb  bacterial otitis media pharyngitis tonsilitis mild moderate infections susceptible strains designated microorganisms prevention thromboembolic diseases more specifically prevention cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism infarction transient ischemic attacks deep vein thrombosis myocardial infarction anti inflammatory analgesic agent relief mild moderate pain often muscle mass building original medical indication androgen deficiency male adults either hypogonadism andropause  nowadays heifers order stimulate maximal growth  chronic intestinal amebiasis effective extraintestinal amebiasis  hepatic coma adjunctive therapy antibiotic agent strepronin mucolytic expectorant drug formerly widely antipyretic analgesic rheumatism neuritis common colds currently measure total body water nausea vomiting postoperative nausea vomiting antiarrhythmic agent congestive heart failure ingredient sunscreen cosmetics chronic obstructive pulmonary disease designed miscarriage prevention prevention premature labour investigated possible men benign prostatic hyperplasia adjunctive therapy diet reduction elevated serum cholesterol primary hypercholesterolemia elevated low density lipoprotein ldl cholesterol do respond adequately diet relief pruritus partial biliary obstruction mainly narcotic dependence claim supplemental anabolic effects unsubstantiated analgesic often test effects drugs liver enzymes  benzocaine otic solutions  symptomatic relief otitis media arising from various etiologies hypocalcemia secondary hyperparathyroidism osteodystrophy chronic renal failure insomnia hydrochloride relieve uncomfortable symptoms occur consequence mucosal irritation lower urinary tract adults  irritation result trauma surgery endoscopic procedures infection insertion instruments urinary catheters   antimicrobial therapy but antimicrobial agent contributes relief discomfort pain before antimicrobial therapy begins take effect  important note duration drug should last maximum days   available many countries over counter drug a182147 general anesthetic conditions insomnia clinical depression narcolepsy alcoholism improve athletic performance  recreational drug no current medical uses schedule i controlled substance usa present opioid analgesic previously moderate pain relief  prescription medication united kingdom severe pain surgical procedures myocardial infarction pain terminally ill relief dyspnoea pulmonary edema  clinical trials now testing therapeutic potential mdma post traumatic stress disorder ptsd anxiety terminal cancer mdma one four most widely illicit drugs u narcotic analgesic once severe chronic pain  a14383 the depressive fatigue convalescence debilitated states well depressive day time fatigue lack concentration lethargy analgesic pain relief decrease appetite some people compound psychedelic inducing agent placebo controlled studies suffering from anxiety depression  only available veterinary main usage related immobilization large mammals motofen r atropine anticholinergic drug  antidiarrheal drug many countries many second line opioid agonist antidiarrheal exists intermediate between loperamide paragoric   diarrhea result cyclic diarrhea predominant inflammatory bowel syndrome treated effectively  diphenoxylate loperamide diarrhea cramping does respond non centrally acting derivatives belladonna derivatives atropine often treated conservative doses codeine ulcerative colitis induction toxic megacolon possible thus motofen r cautioned   motofen r assigned pregnancy category c fda only potential benefits outweigh potential risk fetus safety during lactation unknown thus recommended mainly anti anxiety agent studies found more effective first 4 weeks than antidepressants however after 4 weeks antidepressants showed superior anti anxiety effects anti anxiety effects appear weaker elderly  effectiveness observed alcohol withdrawal delorazapam reported manageable drug did exhibit severe side effects did require further therapies control symptoms withdrawal because high affinity phencyclidine binding site nmda receptor 3h radiolabelled form widely research into nmda receptors similar but more potent opioid analgesic fentanyl tranquilizer large animals short term severe insomnias responsive hypnotics developed 1960 antidepressant before market withdrawal 1962  reverse effects powerful opioids etorphine carfentanil often tranquilizing large animals drug approved humans anesthetic properties induce sedative effect  appetite suppressant anti obesity agent  however substance abuse potential illicit substance many countries some countries brazil still prescribed  often form diet pills ie brazilian diet pills combine amphetamines benzodiazepines antidepressants diuretics laxatives  united states sale diet pills banned concerns over side effects risk potentially fatal overdose however internet sales illicit markets lead international availability found primary care physicians brazilian immigrant women utilized imported diet pills particularly high rates sometimes suffered from side effects requiring hospitalization experienced loss employment  3 moderate severe pain post operative dental pain  chronic pain  breathlessness coughing  heroin addicts  substitute drug doses up 2500mg day addiction  http  www ncbi nlm nih gov pmc articles pmc2014322  primarily anti anxiety agent typically short term given single dose up 100mcg kg reduce anxiety tension experienced prior surgery appetite suppressant short term insomnia short term anxiety panic attacks if benzodiazepine required alleviation symptoms alcohol opiate withdrawal anxiety disorders mainly hypnotic insomnia however only effective hypnotic short term routine sedative preoperatively decrease anxiety cause sedation sleep respiration depression cough reflex anabolic steroid theoretically aid restauration buildup certain tissues especially muscle similar synthetic testosterone still early investigation investigated metastatic breast cancer opioid analgesic moderate severe pain relief short term anxiety disorders no approved indications studied experimentally non pituitary growth retardation a14416 medicine physically binds acids toxic substances stomach digestive tract reason often antidiarrheal medications  adsorbent upset stomach diarrhea traditional medicine china south america africa  aids related diarrhea  based bandages under investigation  attention deficit hyperactivity disorder adhd attention deficit disorder hyperactivity adhd exogenous obesity lumbar thoracic cervical total columnar myelography determine presence abnormalities spinal column spinal canal central nervous system cns well cisternography direct injection using standard radiologic techniques visualize basal cistern brain computerized tomography ct intracranial subarachnoid spaces ventriculography direct injection using standard radiologic techniques visualize cerebral ventricles pediatric angiocardiography visualize lesions malformations heart obstructions anomalies major thoracic vessels peripheral arteriography visualize specific regions vascular system blood flow areas help diagnosis evaluation neoplasms known suspected vascular diseases congenital acquired cause changes normal vascular anatomy physiology  adults intravenous digital arteriography head neck exogenous obesity short term adjunct few weeks regimen weight reduction based caloric restriction hypertension angina pectoris arrhythmias anxiety sulfanilamide antibacterial agent bronchitis prostatitis urinary tract infections bacterial infections causing bronchitis prostatitis urinary tract infections primary secondary tertiary hypothyroidism suppress thyroid stimulating hormone tsh secretion simple nontoxic goiter subacute chronic lymphocytic thyroiditis multinodular goiter thyroid cancer conjunction antithyroid agents thyrotoxicosis prevent goitrogenesis hypothyroidism differential diagnosis suspected mild hyperthyroidism thyroid gland autonomy hypothyroidism deficiency production thyroid hormone drug decreases absorption cholesterol dissolve cholesterol gallstones alternative surgical procedure remove gallstones could anxiety approved countries anxiety tension irritability similar stress related symptoms anxiety disorders insomnia postmenopausal women advanced hormone receptor positive her2 negative breast cancer advanced hr bc exemestane after failure letrozole anastrozole progressive neuroendocrine tumors pancreatic origin pnet unresectable locally advanced metastatic disease advanced renal cell carcinoma rcc after failure sunitinib sorafenib renal angiomyolipoma tuberous sclerosis complex tsc  requiring immediate surgery pediatric tuberous sclerosis complex tsc subependymal giant cell astrocytoma sega requires therapeutic intervention but cannot curatively resected tablets overactive bladder urinary incontinence urgency frequency  preventing treating deficiency anemia prevention deficiency consequences stunted growth diarrhea children slowed wound healing utilized boosting immune system treating common cold recurrent ear infections well preventing lower respiratory tract infections    anxiety disorders short term relief symptoms anxiety anxiety depressive symptoms short term sleeping problems insomnia  difficulty falling asleep frequent awakenings during night early morning awakening imipenem without relebactam  bacterial infections respiratory skin bone gynecologic urinary tract intra abdominal well septicemia endocarditis   cilastatin without relebactam  bacterial infections respiratory skin bone gynecologic urinary tract intra abdominal well septicemia endocarditis  lower ldl hdl cholesterol pain especially arthritic pain product ritonavir marketed under brand name kaletra antiretrovirals hiv infection adults pediatric 14 days old  infections following sites upper lower respiratory tract skin soft tissue urinary tract uncomplicated gonococcal urethritis sensitive strains following organisms  gram positive streptococci faecalis pneumoniae  nonpenicillinase producing staphylococci gram negative  h influenzae  n gonorrhoeae  e coli  p mirabilis  salmonellae shigellae infections susceptible gram positive bacteria particularly beta lactamase producing organisms staphylococcus aureus would otherwise resistant most penicillins respiratory tract infections bronchitis exacerbations chronic bronchitis pneumonia  ear nose throat infections gynecological infections urinary tract infections uncomplicated gonococcal urethritis non penicillinase producing susceptible strains following organisms gram positive organisms e g  streptococci pneumococci staphylococci gram negative organisms e g  h influenzae n gonorrhoeae e coli p mirabilis infections mecillinam sensitive organisms urinary tract infections salmonellosis typhoid fever piperacillin ceftolozane broaden spectrum piperacillin antibacterial action treating susceptible infections any antibiotic  should only infections either proven strongly suspected susceptible containing drug  piperacillin combined piperacillin variety infections those aerobic facultative gram positive gram negative bacteria addition gram positive gram negative anaerobes some examples infections treated piperacillin include cellulitis diabetic foot infections appendicitis postpartum endometritis infections  certain gram negative bacilli infections beta lactamase producing organisms cannot treated piperacillin  gene mutation conferring antibiotic resistance a179266  ceftolozane  ceftolozane combined metronidazole complicated urinary tract infections uti complicated intra abdominal infections well ventilator bacterial pneumonia hospital acquired bacterial pneumonia fda  increases efficacy against infections gram negative bacilli a7657 bacterial infections adjunctive medication some psychotic pro pericyazine control residual prevailing hostility impulsiveness aggressiveness chronic iron overload blood transfusions transfusional hemosiderosis age older antiviral medication cytomegalovirus infections prophylaxis malaria where chloroquine resistance reported uncomplicated malaria p falciparum p malariae p ovale p vivax  chronic discoid lupus erythematosus systemic lupus erythematosus rheumatoid arthritis chronic rheumatoid arthritis  rapid relief angina pectoris prevention angina first humans 1950s antipsychotic agent now rarely humans  frequently animals sedative antiemetic principal value quietening calming anxious animals often meprobamate sleep disorders relieve cramps spasms stomach intestines useful treating irritable bowel syndrome ibs similar conditions help relieve period pain  citrate under investigation increase cytotoxic effects proteasome inhibitor mg132 breast cancer cells  manifestations psychotic disorders sneezing runny nose itching watery eyes hives rashes itching symptoms allergies common cold commonly over counter products seasonal allergies cold flu symptoms  maintenance chronic non agitated schizophrenic all types chronic schizophrenia those did respond usual neuroleptics manic syndromes schizophrenia psychoses mania schizophrenia however acetate psychiatric emergencies alternative standard treatments haloperidol clotiapine etc  should cautioned since well executed documented trials acetate yet conducted  acetate intended long term wide range gastrointestinal disorders conditions peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable spastic colon pyloroduodenal irritability pylorospasm nonspecific gastroenteritis biliary dyskinesia chronic cholelithiasis duodenitis gastrointestinal spasm genitourinary spasm moderate severe hypertension antibiotic staphylococcal streptococcal bacteroides fragilis infections rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain pain gout non stimulant laxative via oral suspension enema currently being studied clinical trials prostate cancer  reduce risk copd exacerbations severe copd chronic bronchitis history exacerbations  bronchodilator relief bronchospasm bacterial infections gout hyperurcemia japan dhea taken supplement variety unsubstantiated indications following indications shown promise backed up some scientific evidence schizophrenia dhea more effective women than men  improving appearance older people skin taking dhea mouth seems increase skin thickness moisture decrease facial age spots elderly men women  improving ability achieve erection men sexual dysfunction additionally dhea shown promise improving symptoms lupus sle  taking dhea mouth along conventional help reduce number times symptoms flare up allow reduction dose prescription drugs needed dhea help sle symptoms muscle ache mouth ulcers dhea seems strengthen bones sle being treated high dose steroids corticosteroids  dhea shows promise osteoporosis taking dhea mouth daily seems improve bone mineral density bmd older women men osteoporosis osteopenia pre osteoporosis  dhea increase bmd young women eating disorder called anorexia nervosa dhea often prescribed india induction ovulation improve chances pregnancy bacterial infections usually quinupristin studied many uses testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy investigated hypolipidemic effects cholesterol lowering agent investigated colorectal cancer lung cancer breast cancer solid tumors prostate cancer glucose pharmaceutical formulations oral tablets injections caloric supply carbohydrate supplementation case nutrient deprivation metabolic disorders hypoglycemia  diet supplements containing nutritional support infants young pediatric requiring total parenteral nutrition via central peripheral routes usage diet supplements containing prevents nitrogen weight loss negative nitrogen balance pediatric where alimentary tract cannot done through oral gastrostomy jejunostomy administration there impaired gastrointestinal absorption protein requirements substantially increased fda investigated neuropathy diabetic moderate severe vasomotor symptoms menopause atrophic vaginitis osteoporosis hypoestrogenism hypogonadism castration primary ovarian failure breast cancer palliation only  advanced androgen dependent carcinoma prostate palliation only moderate plaque psoriasis adults breast cancer inflammatory diseases rheumatoid arthritis pharmacological control certain diabetic complications cutaneous manifestations cutaneous t cell lymphoma progressive persistent recurrent disease following two systemic therapies commonly stop bleeding varices food pipe oesophagus oral bile acid synthesis disorders single enzyme defects adjunctive peroxisomal disorders zellweger spectrum disorders exhibit manifestations liver disease steatorrhea complications from decreased fat soluble vitaminAbsorption bacterial infections being investigated herpes labialis infections cold sores antidepressant appetite suppressant sleep aid investigated ovarian cancer lung cancer brain cancer breast cancer gastric cancer there currently no clinically approved marketed medicine relies upon active ingredient any formal therapeutic indication  although sold variety non prescription over counter dietary supplement products cognitive memory enhancement there many studies suggest products supplementation do elicit any kind cognitive benefit users a32981 a32982  fact general suggestion any product exercise caution their recommendation much more research necessary a32981   sodium however some extent skin hair conditioning agents owing their humectant characteristics f53 obtain miosis iris seconds after delivery lens cataract surgery penetrating keratoplasty iridectomy anterior segment surgery where rapid miosis required eye diseases vitamin b2 deficiency keratitis blepharitis infections ear canal adjunct antineoplastic therapy within product teysuno  adults advanced gastric stomach cancer given cisplatin primarily minor sore throat pain sore mouth minor mouth irritation pain canker sores additionally  focal spasticity under investigation alzheimer disease porphyria attacks particularly intermittent porphyria adjuvant therapy chronic myelonous leukemia lung cancer nasopharyngeal cancer hypercholesterolaemia investigated esophageal cancer leukemia lymphoid  lung cancer liver cancer lymphoma unspecified cancer 5 fluorouracil improvement appearance moderate severe fullness submental fat adults prevention correction metabolic acidosis high docosahexaenoic acid dha oral supplement  various direct sodium calcium salt formulations acid currently most commonly approved organizations like fda ema antibacterial food additive preservative animal feed food human consumption    similarly although any direct sodium calcium salt formulations excipient ingredients pharmaceuticals necessarily major role compound today sodium propionate some vaginal cream preparations cervicitis cervical tears postcauterization postcryosurgery postconization cervix t193  products sodium propionate primarily elicit preservative bacteriostatic  f50 effect while active ingredients combined formulation like urea benzalkonium chloride inositol methionine cystine amino acids facilitated debridement enhanced medication spread epithelialization promotion wound healing respectively  a32973  nevertheless great variety propionic acid derivatives exist separate pharmaceuticals each their own unique therapeutic categories pharmacodynamics pharmacokinetics principally analgesic drying skin before after surgical removal warts where dryness required investigated chronic obstructive pulmonary disease copd  lt ul gt  lt li gt 10 hydrate skin lt li gt  lt li gt 15 accelerate fibrin degradation lt li gt  lt li gt 20 30 antipruritic break down keratin decrease thickness stratum corneum scaling conditions ichthysosis lt li gt  lt li gt 40 proteolytic dissolve peel dystrophic nails lt li gt  lt ul gt  lt br gt patient self care 2010 lt br gt investigated chronic obstructive pulmonary disease copd effective local vaginal tablets infections fluor vaginalis bacterial vaginosis aerobic vaginitis vulvo vaginal candidiasis trichomoniasis topical antimicrobial agent primary popular claim made  enhances exercise athletic performance refuted available research data there some preliminary evidence some neurorestorative anti inflammatory immunomodulatory cardioprotective effects help relieve symptoms chronic obstructive pulmonary disorder copd bronchiectasis alkalinizing agent potential menstrual cycle related mastalgia fibrocystic breast disease breast disease gynecomastia keloid scarring rheumatoid arthritis oxacephem antibiotic usually grouped cephalosporins bacterial infections  primarily conditions like bone joint infection gi infections gynecological infections meningitis respiratory tract infections septicaemia skin infections soft tissue infections uti  pigmenting photosensitizing agent conjunction ultraviolet light vitiligo conditioning prior allogeneic autologous haematopoietic progenitor cell transplantation hpct haematological diseases paediatric high dose chemotherapy hpct support appropriate solid tumours paediatric test determine general health unborn fetus estropipate moderate severe vasomotor symptoms monopause moderate severe symptoms vulval vaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure prevent postmenopausal osteoporosis hormone replacement therapy treating symptoms menopause hot flashes breast prostate cancer broad spectrum antimicrobial fluoroquinolone bacterial infections animals investigated cancer contrast agent cholecystography intravenous cholangiography osteoarthritis pain symptomatic osteoarthritis primary dysmenorrhoea adolescents adults above 12 old human sleeping sickness onchocerciasis diseases trypanosomes worms various topical fungal infections athlete foot tinea pedis investigated prostate cancer psoriasis hyperparathyroidism topical antifungal past powerful painkiller fever reducer depression originally intended tuberculosis over century laxative mild severe pain hypertension depression insomnia sedative muscle relaxant anaesthesia aid enable endotracheal intubation experienced infected only ccr5 tropic hiv detectable evidence viral replication hiv strains resistant multiple antiretroviral agents depression dry cough various blood vessel diseases e g  claudication arteriosclerosis raynaud disease nighttime leg cramps palliative advanced prostatic carcinoma moderate severe hypertension either alone adjunct renal hypertension prophylaxis migraine occlusive peripheral vascular disease vertigo central peripheral origin adjuvant therapy epilepsy schizophrenia adjunctive therapy peptic ulcer shown effective contributing healing peptic ulcer decreasing rate recurrence preventing complications hyperkinetic movement disorders like chorea huntington disease hemiballismus senile chorea tourette syndrome tic disorders tardive dyskinesia investigated breast cancer head neck cancer melanoma lung cancer lymphoma non hodgkin  prostate cancer renal cell carcinoma cancer tumors unspecified  mild moderate hypertension effort induced angina pectoris clinical development anemia chronic inflammatory disease intended urinary incontinence liver cancer advanced non small cell lung cancer nsclc  advanced colorectal cancer crc solid tumors gram positive infections multiresistant strains administered intravenously  dicitrate cancer chemotherapy agents atherosclerosis cardiac pharmacologic stress spect imaging diagnose coronary artery disease hyperuricemia gout atrial fibrillation af sinus rhythm history paroxysmal persistent af reduce risk hospitalization  irritable bowel syndrome ibs gastroesophageal reflux disease gerd parkinson disease head neck cancer dementia subjects alzheimer disease hepatitis c hypertension a2762 a182579  hepatitis c virus hcv infection unstable angina investigated alzheimer disease intolerant resistant two more tyrosine kinase inhibitors accelerated chronic phase cml   scleroderma cancer restenosis pancreatic cancer appetite disorders potential various leukemias chronic myeloid leukemia cml migraine headaches obesity obesity adjunct reduced calorie diet increased physical activity potential therapy schizophrenia depression visceral pain atrial fibrillation irritable bowel syndrome ibs solid tumors rheumatoid arthritis ra reduce hyperglycemia type diabetes mellitus malaria under investigation modulation multidrug resistance cancer cells diabetes specifically lowering post prandial blood glucose levels thereby reducing risk macrovascular complications first second line chemotherapy metastatic colorectal cancer non small cell lung cancer nsclc congestive heart failure solid tumors clinical studies shown activity subjects colorectal cancer esophageal cancer solid tumors congestive heart failure hypertension premature ejaculation symptoms irritable bowel syndrome hiv infection aids hiv infection antiretroviral agents being evaluated schizophrenia psychosis parkinson disease pain symptomatic itchy eyes ige induced mast cell degranulation allergic conjunctivitis topical psoriasis psoriatic disorders alzheimer disease ad solid tumors esophageal variceal bleeding cirrhotic liver disease shown efficacy aids related diarrhea neovascular wet age related macular degeneration selective serotonin norepinephrine reuptake inhibitor snri fibromyalgia 18 old above f3925   while major depressive disorder mdd  only recommended 18 old above f3922 increased risk suicidal ideation thinking behavior children adolescents young adults taking antidepressants major depressive disorder mdd psychiatric disorders some regional prescribing information notes medication specifically short term symptomatic relief mdd f3919  nevertheless important note regulatory approval indications listed here may exist vary greatly between regions nations f3928 f3934 intended prevention respiratory distress syndrome rds premature infants high risk rds deep vein thrombosis intravenous acutely decompensated congestive heart failure dyspnea rest minimal activity adjuvant influenza vaccine elderly adjuvant both influenza hepatitis b vaccines chronic hemodialysis failed achieve adequate antibody titers from previous immunization investigated lymphoma non hodgkin  psoriasis psoriatic disorders bone metastases multiple myeloma prostate cancer rheumatoid arthritis potential panic anxiety disorders intended cervical dysplasia human papillomavirus hpv intended various forms cancer intended brain cancer hypoactive sexual desire disorder hsdd premenopausal women investigated infectious parasitic disease unspecified investigated infectious parasitic disease unspecified pediatric indications bacterial skin skin structure subcutaneous infection confirmed suspected infections designated susceptible gram positive organisms   antimicrobial susceptibility patterns geographically distinct local antibiograms should consulted ensure adequate coverage relevant pathogens prior investigated liver disease metabolic disease pediatric indications intended various forms cancer intended various forms cancer constipation predominant irritable bowel syndrome ibs c serious bacterial infections hospitalised being evaluated potential ischemic stroke catheter occlusion co peripheral arterial occlusion pao reduction blood pressure when oral antihypertensive therapy feasible desirable multiple sclerosis ms investigated blood blood forming organ disorders unspecified hemorrhage investigated gastrointestinal diseases disorders miscellaneous investigated cerebral ischemia strokes investigated alzheimer disease hearing loss pain chronic investigated menstrual disorders investigated heart disease myocardial infarction infestation sarcoptes scabiei  scabies  prevention phototoxicity erythropoietic protoporphyria epp  severe hepatic veno occlusive disease vod  known sinusoidal obstruction syndrome sos  renal pulmonary dysfunction following hematopoietic stem cell transplantation hsct  investigated sepsis septicemia investigated atherosclerosis bacterial infection peripheral vascular disease intended therapeutic adjunct type ii diabetes moderate dyspareunia symptom vulvar vaginal atrophy menopause symptomatic non infectious diarrhea hiv aids taking antiretroviral therapy investigated leukemia unspecified investigated eye disorders infections transplant rejection investigated cardiac reperfusion injury cardiovascular disorders coronary artery disease investigated blood blood forming organ disorders unspecified hemorrhage schizophrenia investigated attention deficit hyperactivity disorder adhd  parkinson disease pediatric indications mitigation symptoms withdrawal from opioids facilitation completion opioid discontinuation first non opioid medication symptomatic opioid discontinuation   opioid withdrawal syndrome debilitating manifestation opioid dependence a33085 condition extremely unpleasant lasting several days some main features being abdominal pain nausea diarrhea mydriasis lacrimation piloerection these symptoms often observed after abrupt reductions opioid dose resolved re administration opioid a33088 inflammation during cardiac surgery various forms cancer idiopathic pulmonary fibrosis ipf bacterial infections adjuvant partial onset seizures investigated arrhythmia atrial fibrillation investigated asthma lung injury surgical adhesions investigated sepsis septicemia investigated arrhythmia atrial fibrillation investigated leukemia lymphoid  lymphoma non hodgkin  systemic lupus erythematosus investigated anal dysplasia cervical dysplasia cancer genital warts hiv infection infectious parasitic disease unspecified  pediatric indications warts viral infection investigated colorectal cancer leukemia myeloid  pancreatic cancer solid tumors investigated leukemia myeloid investigated lymphoma non hodgkin investigated diabetes mellitus type investigated ovarian cancer intended radiation sensitizer brain cancer intended social phobia intended various forms cancer intended anxiety disorders diabetes mellitus type intended various forms cancer intended various forms cancer investigated bone marrow transplant graft versus host disease various forms cancer intended pain possibly various forms cancer intended various forms cancer intended carcinoma oesophagus intended benign prostatic hyperplasia prostrate disorders intended various forms cancer epilepsy inhaled cystic fibrosis late stage hormone refractory prostate cancer hrpc no effective therapy currently exists  various forms cancer potential cystic fibrosis bacterial infections intended various forms cancer production immunity salmonella typhi  cause typhoid fever diabetes clinically significant proteinuria various forms cancer investigated pain chronic investigated lung cancer prostate cancer solid tumors investigated asthma multiple sclerosis investigated cancer tumors unspecified  kidney cancer leukemia myeloid  pancreatic cancer investigated liver cancer investigated pain chronic investigated diabetes mellitus type investigated melanoma multiple myeloma ovarian cancer pancreatic cancer solid tumors investigated metabolic disease obesity investigated breast cancer prostate cancer investigated cardiovascular disorders inflammatory disorders unspecified investigated alzheimer disease attention deficit hyperactivity disorder adhd  memory loss schizophrenia schizoaffective disorders investigated cardiovascular disorders kidney disease chronic cancer pain  topical actinic keratosis investigated cancer tumors unspecified  lung cancer solid tumors relapsed refractory peripheral t cell lymphoma ptcl manageable safety profile potential alternative therapy did experience adequate response first line drugs ptcl baseline thrombocytopenia a19161  approved european medicines agency duchenne muscular dystrophy aged 5 older able walk more specifically  small group whose disease specific genetic defect called nonsense mutation  dystrophin gene investigated crohn disease psoriasis psoriatic disorders rheumatoid arthritis alpha galactosidase alpha gal pharmacological chaperone long term adults adolescents aged 16 older confirmed diagnosis fabry disease alpha galactosidase deficiency amenable galactosidase alpha gene gla mutation variant based upon vitro assay data fda f1107   indication approved us fda under accelerated approval based reduction kidney interstitial capillary cell globotriaosylceramide kic gl 3 substrate fda  continued approval us fda indication contingent upon verification description clinical benefit ongoing confirmatory trials fda investigated viral infection investigated hepatitis viral b investigated hepatitis viral c investigated breast cancer ovarian cancer prostate cancer investigated psoriasis psoriatic disorders investigated kidney disease psoriasis psoriatic disorders investigated amyotrophic lateral sclerosis als  diabetes mellitus type neurologic disorders neuropathy diabetic investigated peripheral vascular disease investigated cystic fibrosis eye disorders infections investigated allergic reaction allergic rhinitis cataracts investigated breast cancer investigated congestive heart failure investigated hyperlipidemia metabolic disease obesity investigated leukemia lymphoid solid tumors investigated traumatic brain injuries long term once daily dosing maintenance airflow obstruction chronic obstructive pulmonary disease copd  chronic bronchitis emphysema investigated viral infection investigated neurologic disorders schizophrenia schizoaffective disorders investigated asthma chronic obstructive pulmonary disease copd investigated diabetes mellitus type investigated obesity investigated pain chronic investigated attention deficit hyperactivity disorder adhd alzheimer disease investigated pain chronic investigated constipation gastroesophageal reflux disease gerd  gastrointestinal diseases disorders miscellaneous  irritable bowel syndrome ibs investigated pain chronic investigated breast cancer investigated hormone replacement therapy menopause menopause investigated diabetes mellitus type investigated acne atopic dermatitis pediatric indications psoriasis psoriatic disorders investigated bipolar disorders manic disorders investigated crohn disease hepatitis unspecified  liver disease fro chronic bronchitis adults investigated kidney disease investigated hepatitis viral c investigated cardiovascular disorders hyperlipidemia investigated hepatitis viral c parkinson disease investigated diabetes mellitus type diabetes prevention investigated diabetic foot ulcers wounds investigated macular degeneration investigated anxiety disorders gastroesophageal reflux disease gerd  migraine cluster headaches investigated diarrhea infectious parasitic disease unspecified investigated anxiety disorders irritable bowel syndrome ibs  urinary incontinence investigated macular degeneration investigated macular degeneration investigated obesity investigated asthma investigated insomnia investigated adverse effects drug  hyperlipidemia obesity investigated psoriasis psoriatic disorders skin infections disorders investigated growth hormone deficiencies abnormalities investigated postmenopausal osteoporosis reduce vertebral non vertebral fractures investigated schizophrenia schizoaffective disorders investigated pediatric indications seizure disorders investigated liver disease pulmonary fibrosis investigated prostate cancer investigated amyotrophic lateral sclerosis als parkinson disease vasopressin regulates renal water resorption through v2 receptor inhibition vasopressin effects v2 receptors enhances water excretion increases urinary output  vasopressin antagonis electrolyte sparing aquaretic causes much lower levels salt excretion investigated multiple sclerosis investigated cardiovascular disorders strokes investigated depression investigated psychosis schizophrenia schizoaffective disorders humanized monoclonal antibody cancer retrieved from http  en wikipedia org wiki investigated lipodystrophy obesity deep vein thrombosis dvt  central retinal branch vein thrombosis pripaism pulmonary hypertension embolic origin embolism after insertion prosthetic cardiac valves rethrombosis after thrombolytic therapy rethrombosis after vascular surgery prevention dvt after repair fractured neck femur investigated brain cancer lung cancer prostate cancer investigated cervical dysplasia cancer colorectal cancer gastric cancer lung cancer investigated viral infection investigated liver cancer lung cancer melanoma leukemia lymphoid investigated irritable bowel syndrome ibs investigated upper respiratory infection investigated multiple sclerosis investigated cystic fibrosis hiv infection hepatitis viral b  malaria investigated hepatitis viral b advanced soft tissue sarcoma refractory unsuitable receive anthracycline ifosfamide chemotherapy europe russia south korea approved orphan drug status u fda soft tissue sarcomas ovarian cancer investigated cancer tumors unspecified  gastric cancer ovarian cancer pediatric indications sarcoma solid tumors investigated hiv infection investigated crohn disease psoriasis psoriatic disorders investigated solid tumors investigated colorectal cancer investigated hepatitis viral c hepatocellular carcinoma investigated diabetes mellitus type investigated colorectal cancer investigated cancer tumors unspecified investigated depression investigated atherosclerosis cardiovascular disorders investigated diabetes mellitus type intended various forms cancer investigated rheumatoid arthritis investigated atherosclerosis cardiovascular disorders hyperlipidemia investigated blood blood forming organ disorders unspecified  cardiac surgery coronary artery disease investigated multiple sclerosis rheumatoid arthritis investigated amyotrophic lateral sclerosis als investigated hepatitis viral c investigated fungal infections investigated lymphoma non hodgkin investigated inflammatory disorders unspecified investigated blood blood forming organ disorders unspecified  cardiac surgery venous thromboembolism investigated depression investigated alzheimer disease inflammatory disorders unspecified investigated leukemia myeloid solid tumors investigated burns burn infections investigated breast cancer cancer tumors unspecified  hiv infection hepatitis viral c  solid tumors investigated addictions investigated macular degeneration investigated nephropathy investigated solid tumors investigated cancer tumors unspecified solid tumors investigated anxiety disorders depression investigated cancer tumors unspecified investigated malaria investigated diabetes mellitus type investigated solid tumors investigated solid tumors investigated bladder cancer investigated cancer tumors unspecified solid tumors investigated alzheimer disease investigated solid tumors investigated alzheimer disease schizophrenia schizoaffective disorders adults bedaquiline linezolid pulmonary forms nonresponsive multidrug resistant mdr  extensively drug resistant xdr  intolerant forms pulmonary tuberculosis tb   important note following conditions approved indications therapy according fda   drug sensitive ds tuberculosis latent tuberculosis m tuberculosis extra pulmonary tuberculosis m tuberculosis multidrug resistant tb intolerant nonresponsive conventional tb therapy investigated pain chronic investigated acne actinic keratosis cancer tumors unspecified  keratoses skin infections disorders investigated cardiovascular disorders inflammatory bowel disease inflammatory disorders unspecified  psoriasis psoriatic disorders rheumatoid arthritis investigated cancer tumors unspecified solid tumors investigated multiple sclerosis neurologic disorders investigated benign prostatic hyperplasia cancer tumors unspecified  prostate cancer prostate disorders solid tumors investigated inflammatory disorders unspecified investigated infertility investigated leukemia myeloid investigated cancer tumors unspecified solid tumors investigated diabetes mellitus type investigated hepatitis viral b investigated solid tumors investigated cancer tumors unspecified  leukemia myeloid  solid tumors investigated cancer tumors unspecified investigated alzheimer disease investigated pain chronic investigated cancer tumors unspecified solid tumors investigated skin infections disorders investigated myocardial infarction investigated parkinson disease investigated parkinson disease investigated alzheimer disease attention deficit hyperactivity disorder adhd  dementia neurologic disorders schizophrenia schizoaffective disorders investigated viral infection investigated kidney cancer melanoma investigated inflammatory disorders unspecified investigated leukemia lymphoid leukemia myeloid investigated neurologic disorders investigated bacterial infection infectious parasitic disease unspecified  tuberculosis investigated atherosclerosis diabetes mellitus type investigated metabolic disease obesity investigated cancer tumors unspecified investigated solid tumors investigated inflammatory disorders unspecified investigated hyperlipidemia investigated rheumatoid arthritis investigated asthma chronic obstructive pulmonary disease copd investigated affective disorders bipolar disorders psychosis investigated gastroenteritis ulcers advanced solid tumorsirritable bowel syndrome ibs gastrointestinal disorderspompe disease known glycogen storage disease type ii acid maltase deficiency relatively rare neuromuscular lysosomal storage disorder inherited genetic mutations key enzyme called  glucosidase gaa obesity related disorders cardiovascular disease type ii diabetesplatelet aggregation thrombosis coronary syndromesinvestigated hypertension canceranxiety disorders i depression icentral nervous system  neuropathic pain investigated thrombocytopenia various forms cancer inflammatory disease rheumatoid arthritis type diabetes pain intended solid tumors lymphomas intended auto immune diseases rheumatoid arthritis psoriasis crohn disease intended topical mild moderate atopic dermatitis age older various forms cancer infections multi drug resistant lt em gt pseudomonas aeruginosa lt em gt various forms cancer bacterial infections susceptible microorganisms  staphylococcus aureus  methicillin resistant aureus  mrsa  streptococcus pyogenes  asthma cardiovascular disease respiratory syncytial virus infections prophylaxis arterial thrombosis hiv infection appropriate antiretroviral agents therapy warranted pulmonary hypertension atherosclerosis conditions related obstruction blood vessels chronic breakthrough pain advanced cancer well opioid dependence female contraceptive prevention osteoporosis hypothyroidism stroke investigated immunodeficiency infectious parasitic disease unspecified unresectable metastatic melanoma braf v600e v600k mutation  vemurafenib braf inhibitor various forms cancer investigated hepatitis viral b various forms cancer non hodgkin lymphoma bone metastases paget disease osteoporosisindicated adjunct prevention wound sepsis second third degree burns control absence petit mal seizures refractory drugs b cell non hodgkin lymphomachronic angina coronary artery disease \\tfor uterine fibroids endometriosis assists healing minor burns superficial wounds ulcers surgical wounds superficial hematomas post menopausal women osteoporosisinvestigated pain chronic investigated hepatitis viral c  leukemia lymphoid  leukemia myeloid  leukemia unspecified  melanoma reduction frequency relapses relapsing remitting multiple sclerosis hypercalcemia intended non hodgkin lymphoma intended congestive heart failure hyperuricemia alzheimer diseaseatopic dermatitisfor reflux oesophagitis peptic ulcer disease multiple sclerosis asthma cerebrovascular disease various eye diseasesfor neurologic disorders parkinson disease well moderate severe primary restless legs syndrome investigated bone metastases multiple myeloma prostate cancer rheumatoid arthritis investigated hepatitis viral b  liver transplant surgery pediatric indications bladder cancerlung cancer melanoma\\tinvestigated glaucoma macular degeneration investigated alzheimer disease prostate cancer investigated cardiovascular disorders neuropathy diabetic ovarian cancerinvestigated bladder cancer currently approved alternative local therapies both unresectable disseminated disease because prolong q t interval contraindicated serious cardiac complications congenital long qt syndrome uncompensated heart failure investigated osteoporosis investigated brain cancer breast cancer cervical dysplasia cancer prostate cancer cancer tumors unspecified  coronary artery disease macular degeneration peripheral vascular disease investigated breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer skin cancer investigated ulcerative colitis investigated bladder cancer solid tumors investigated addictions osteoarthritis pain chronic investigated depression huntington disease investigated inflammatory disorders unspecified  knee replacement orthopedic surgery pain chronic investigated gall bladder cancer renal cell carcinoma investigated brain cancer investigated angina coronary artery disease heart disease investigated breast cancer colorectal cancer gall bladder cancer pancreatic cancer investigated bone fractures diabetic foot ulcers wounds investigated endometriosis symptomatic attacks hereditary angioedema hae 12 age older fda investigated autoimmune diseases rheumatoid arthritis investigated hemorrhage transfusion investigated coronary artery disease investigated neurologic disorders parkinson disease psychosis schizophrenia schizoaffective disorders sleep disorders investigated hyperlipidemia investigated bladder cancer head neck cancer investigated immunosuppressive transplant rejection investigated hyperuricemia investigated bladder cancer brain cancer breast cancer esophageal cancer head neck cancer lung cancer oral cavity cancer ovarian cancer prostate cancer investigated breast cancer head neck cancer lung cancer investigated gastrointestinal diseases disorders miscellaneous investigated neuropathy diabetic investigated hiv infection investigated melanoma investigated cystic fibrosis pancreatic disorders chronic immune thrombocytopenic purpura investigated attention deficit hyperactivity disorder adhd  neurologic disorders tourette syndrome investigated anthrax exposure bacterial infection crohn disease graft versus host disease investigated brain cancer investigated anxiety disorders depression insomnia neurologic disorders investigated inflammatory bowel disease ulcerative colitis investigated cerebral ischemia investigated eye disorders infections macular degeneration retinal disorders unspecified investigated insomnia investigated osteoarthritis pain chronic  healing all grades erosive esophagitis ee  maintaining healing ee relief heartburn treating heartburn symptomatic non erosive gastroesophageal reflux disease gerd  investigated amyloidosis investigated liver cancer investigated cardiovascular disorders thrombosis venous thromboembolism investigated thrombosis venous thromboembolism investigated bipolar disorders investigated pain chronic investigated cardiovascular disorders hypertension pulmonary hypertension investigated allergic reaction investigated pain chronic investigated huntington disease schizophrenia schizoaffective disorders investigated brain cancer investigated fungal infections investigated multiple myeloma phosphate diagnostic aid evaluation gastric acid secretory function investigated breast disorders unspecified pain chronic investigated diabetic kidney disease investigated contraception hiv prevention investigated hiv prevention prevention stdis vaginal infection investigated adverse effects chemotherapy bone marrow transplant investigated kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer psoriasis psoriatic disorders investigated acquired immune deficiency syndrome aids aids related infections cancer tumors unspecified  hiv infection inflammatory disorders unspecified investigated lung cancer investigated neuropathy diabetic peripheral vascular disease investigated breast cancer lung cancer ovarian cancer investigated brain cancer neurologic disorders investigated depression irritable bowel syndrome ibs  obesity investigated hepatitis viral c investigated contraception hiv infection prevention stdis investigated atherosclerosis coronary artery disease diabetes mellitus type stent restenosis investigated genital herpes hiv infection hepatitis viral b  influenza malaria melanoma viral infection investigated asthma parkinson disease investigated gastroesophageal reflux disease gerd investigated hepatitis viral b investigated prostate cancer solid tumors investigated congestive heart failure hypertension pulmonary hypertension investigated hepatitis viral c  liver disease transplantation organ tissue investigated pain chronic investigated atopic dermatitis investigated cancer tumors unspecified investigated pain chronic rheumatoid arthritis investigated acquired immune deficiency syndrome aids aids related infections hiv infection investigated breast cancer investigated crohn disease inflammatory bowel disease kidney cancer leukemia lymphoid  prostate cancer investigated hyperlipidemia investigated tobacco dependence investigated adverse effects chemotherapy  anxiety disorders depression gastrointestinal diseases disorders miscellaneous investigated sleep disorders smoking cessation substance abuse investigated bladder cancer lymphoma unspecified  multiple myeloma paget disease prostate cancer investigated asthma depression irritable bowel syndrome ibs investigated bulimia depression obsessive compulsive disorders investigated depression investigated breast cancer lung cancer investigated adverse effects chemotherapy  cancer tumors unspecified  diabetic foot ulcers lung cancer solid tumors ulcers investigated melanoma investigated brain cancer cancer tumors unspecified  lung cancer lymphoma non hodgkin investigated allergic rhinitis investigated peripheral vascular disease investigated asthma chronic obstructive pulmonary disease copd investigated addictions dementia parkinson disease schizophrenia schizoaffective disorders strokes investigated congestive heart failure diabetes mellitus type investigated lymphoma unspecified  melanoma solid tumors investigated colorectal cancer solid tumors investigated leukemia lymphoid investigated prostate cancer investigated asthma atopic dermatitis pediatric atopic dermatitis indications investigated asthma atopic dermatitis investigated asthma crohn disease investigated pain chronic rheumatoid arthritis trials being conducted relieving burn pain dermal itch investigated atherosclerosis vascular diseases cardioprotective agent suggested prevention early restenosis following vascular surgery balloon angioplasty investigated tobacco dependence investigated autoimmune diseases strokes thrombosis investigated adverse effects chemotherapy adverse effects drug investigated cancer tumors unspecified  gastric cancer pancreatic cancer investigated hyperlipidemia cancer tumors unspecified  monotherapy recommended people marginally high ldl cholesterol cannot prescribed statins drug interactions safety concerns therapy recommended if statin therapy alone either insufficient achieve guidelines set ncep there concern over side effects statin doses lowered without losing efficacy investigated alzheimer disease parkinson disease neurodegenerative diseases investigated cancer tumors unspecified  crohn disease inflammatory bowel disease osteoarthritis ulcerative colitis investigated anorexia conditions causing harmful weight loss manufacturer suggests could relevant weight loss symptoms  i e  lack energy decrease appetite physical wasting vulnerability toxicity sometimes reduced life expectancy  eating disorders advanced cancer aids experiencing loss appetite aging illness pregnancy investigated alzheimer disease parkinson disease investigated cardiovascular disorders syndrome inappropriate secretion anti diuretic hormone siadh hyponatremia  investigated atherosclerosis coronary artery disease vascular diseases investigated gastric cancer investigated alzheimer disease attention deficit hyperactivity disorder adhd  schizophrenia schizoaffective disorders investigated autoimmune diseases crohn disease multiple sclerosis psoriasis psoriatic disorders rheumatoid arthritis investigated myelodysplastic syndrome investigated peripheral vascular disease raynaud disease investigated various forms brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma  oligo astrocytoma  gliosarcomainvestigated colorectal cancer hepatitis viral b  lymphoma non hodgkin  iss 1018 currently being investigated hbsag vaccine prophylactic prevent hepatitis b adults investigated rituximab b cell non hodgkin lymphoma investigated diabetes mellitus type investigated leukemia myeloid investigated depression anxiety investigated emphysema investigated asthma investigated urinary incontinence investigated coronary artery disease inflammatory disorders unspecified  rheumatoid arthritis investigated autoimmune diseases cancer tumors unspecified  lymphoma non hodgkin  lymphoma unspecified investigated hepatitis viral c investigated saliva salivary gland dysfunction sialorrhea investigated inflammatory disorders rheumatoid arthritis inflammatory bowel disease psoriasis investigated hepatitis viral c  infectious parasitic disease unspecified  tuberculosis investigated solid tumors investigated cancer tumors unspecified ovarian cancer investigated prodrug hepsera treating hepatitis viral b investigated candidiasis vaginitis investigated adverse effects chemotherapy  anemia chemotherapy investigated alpha antitrypsin deficiency atopic dermatitis chronic obstructive pulmonary disease copd investigated colorectal cancer investigated acne herpes labialis infections cold sores  venereal disease investigated autoimmune diseases inflammatory disorders unspecified investigated breast cancer cancer tumors unspecified  melanoma ovarian cancer solid tumors investigated brain cancer breast cancer investigated infectious parasitic disease unspecified investigated ovarian cancer investigated diabetes mellitus type investigated brain cancer cancer tumors unspecified investigated neuropathy diabetic pain chronic investigated benign prostatic hyperplasia investigated leukemia unspecified melanoma investigated osteoarthritis investigated diabetes mellitus type pediatric indications psoriasis psoriatic disorders investigated urinary incontinence investigated neuropathy diabetic investigated cancer tumors unspecified  leukemia unspecified  lymphoma unspecified  multiple myeloma pancreatic cancer investigated hiv infection investigated leukemia myeloid investigated peripheral vascular disease investigated diabetes mellitus type investigated inflammatory disorders unspecified psoriasis psoriatic disorders investigated premature ejaculation investigated cancer tumors unspecified  eye disorders infections psoriasis psoriatic disorders rheumatoid arthritis fite biopharma reported targeting adenosine a3 receptor cf101 crohn disease serious gastrointestinal disorder investigated autoimmune diseases psoriasis psoriatic disorders rheumatoid arthritis investigated cancer tumors unspecified  multiple myeloma rheumatoid arthritis investigated cystic fibrosis investigated autoimmune diseases skin infections disorders investigated diabetes mellitus type investigated arrhythmia atrial fibrillation investigated alzheimer disease  db00811  db00008  db00022 chronic hcv genotype infection adults fda investigated colorectal cancer lung cancer investigated peripheral vascular disease homozygous familial hypercholesterolemia adjunct diet lipid lowering medications investigated hepatitis viral c viral infection investigated actinic keratosis breast cancer liver cancer melanoma psoriasis psoriatic disorders solid tumors investigated hiv infection investigated neuropathy diabetic investigated brain cancer cancer tumors unspecified adjunctive therapy partial onset seizures 16 age older investigated gastroesophageal reflux disease gerd gastroparesis investigated osteoarthritis rheumatoid arthritis investigated brain cancer cardiovascular disorders myocardial infarction investigated lymphoma unspecified investigated angioedema myocardial infarction investigated cardiac surgery coronary artery disease thrombosis transfusion investigated asthma investigated atopic dermatitis inflammatory disorders unspecified  skin infections disorders investigated myocardial infarction investigated anxiety disorders depression investigated alzheimer disease investigated solid tumors advanced gastric gastro esophageal junction adenocarcinoma single agent paclitaxel after prior fluoropyrimidine platinum containing chemotherapy investigated lymphoma unspecified rheumatoid arthritis investigated spinal cord injuries investigated brain cancer lung cancer melanoma solid tumors investigated alzheimer disease neurologic disorders schizophrenia schizoaffective disorders investigated asthma labor delivery investigated breast cancer investigated gastric cancer investigated ovarian cancer investigated alzheimer disease memory loss investigated coronary artery disease peripheral vascular disease investigated leukemia lymphoid investigated chronic obstructive pulmonary disease copd pulmonary hypertension investigated breast cancer leukemia unspecified  lung cancer solid tumors investigated crohn disease psoriasis psoriatic disorders investigated inflammatory disorders unspecified  psoriasis psoriatic disorders rheumatoid arthritis investigated hepatitis viral c investigated benign prostatic hyperplasia endometriosis prostate cancer investigated cancer tumors unspecified  lung cancer sarcoma investigated gastric cancer lung cancer multiple myeloma various types protozoal infection called leishmaniasis result from sandfly bites tropical temperate parts world investigated cancer tumors unspecified solid tumors investigated cardiovascular disorders diabetes mellitus type investigated neurologic disorders investigated infectious parasitic disease unspecified viral infection investigated alzheimer disease depression diarrhea gastrointestinal diseases disorders miscellaneous  irritable bowel syndrome ibs investigated cancer tumors unspecified  head neck cancer solid tumors investigated hiv infection investigated autoimmune diseases diabetes mellitus type gastrointestinal diseases disorders miscellaneous investigated strokes investigated cataracts eye disorders infections glaucoma macular degeneration investigated psoriasis psoriatic disorders investigated adverse effects chemotherapy blood blood forming organ disorders unspecified investigated lymphoma non hodgkin investigated bacterial infection bronchitis otitis media pediatric indications investigated hearing loss investigated eye disorders infections investigated diabetes mellitus type investigated cancer tumors unspecified  lymphoma unspecified  sarcoma investigated adverse effects chemotherapy investigated periodontal disease investigated cardiovascular disorders thrombosis treating active psoriatic arthritis adults treating active moderate severe psoriatic arthritis eligible phototherapy systemic  addition  now oral ulcers behcet disease adults  investigated hyperlipidemia moderate severe plaque psoriasis children aged 6 above adolescents adults candidates phototherapy systemic therapy   active psoriatic arthritis adults alone methotrexate   moderately severely active crohn disease adults were clinically unresponsive intolerant immunomodulator corticosteroid therapy but never failed tutor necrosis factor tnf blocker one more tnf blockers   moderately severely active ulcerative colitis adults  investigated actinic keratosis skin infections disorders investigated cardiac ischemia investigated cardiac reperfusion injury myocardial infarction investigated cervical dysplasia cancer genital warts skin cancer investigated schizophrenia schizoaffective disorders investigated periodontal disease rheumatoid arthritis investigated osteoporosis investigated pancreatic cancer investigated amyotrophic lateral sclerosis als investigated breast cancer cancer tumors unspecified investigated alzheimer disease schizophrenia schizoaffective disorders investigated anesthesia unspecified investigated thrombosis investigated thrombosis venous thromboembolism investigated thrombosis investigated adverse effects chemotherapy neutropenics investigated melanoma investigated insomnia investigated lymphoma unspecified  macular degeneration prostate cancer solid tumors investigated addictions alcohol dependence investigated pain chronic investigated rheumatoid arthritis investigated osteoporosis investigated bacterial infection skin infections disorders staph bacterial infections investigated osteoporosis investigated atherosclerosis coronary artery disease investigated atopic dermatitis investigated hypertension investigated multiple sclerosis neurologic disorders pain chronic investigated leukemia lymphoid investigated hiv infection investigated rheumatoid arthritis investigated glaucoma ocular hypertension investigated cervical dysplasia cancer viral infection investigated menstrual disorders investigated alzheimer disease obesity schizophrenia schizoaffective disorders investigated allergic reaction asthma investigated chronic obstructive pulmonary disease copd investigated sleep disorders investigated hepatitis viral c  leukemia myeloid  lymphoma non hodgkin investigated atopic dermatitis investigated candidiasis fungal infections saliva salivary gland dysfunction investigated ocular hypertension investigated psoriasis psoriatic disorders investigated actinic keratosis investigated schizophrenia schizoaffective disorders investigated ulcerative colitis investigated ulcerative colitis investigated hyperlipidemia investigated psoriasis psoriatic disorders investigated rheumatoid arthritis her2 positive metastatic breast cancer already taxane trastuzumab metastatic disease had their cancer recur within 6 months adjuvant  investigated diabetes mellitus type investigated hepatitis viral c investigated blood preservative blood blood forming organ disorders unspecified  sepsis septicemia thrombosis investigated skin infections disorders investigated hepatitis viral c investigated solid tumors investigated cancer tumors unspecified investigated brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indications prostate cancer sarcoma investigated colorectal cancer melanoma prostate cancer psoriasis psoriatic disorders rheumatoid arthritis solid tumors investigated cervical dysplasia cancer investigated asthma inflammatory bowel disease investigated cardiac surgery hemorrhage ileus investigated cancer tumors unspecified  immunosuppressive prostate cancer investigated acquired immune deficiency syndrome aids aids related infections hiv infection pediatric indications investigated cardiovascular disorders congestive heart failure infertility peripheral vascular disease scleroderma investigated congestive heart failure hypertension investigated allergic reaction investigated solid tumors investigated sepsis septicemia investigated blood blood forming organ disorders unspecified  lymphoma unspecified  multiple myeloma investigated breast cancer colorectal cancer leukemia myeloid  leukemia unspecified  myelodysplastic syndrome prostate cancer renal cell carcinoma solid tumors investigated hepatitis viral c investigated asthma burns burn infections investigated addictions attention deficit hyperactivity disorder adhd  depression investigated brain cancer lung cancer melanoma investigated hiv infection investigated hepatocellular carcinoma liver cancer melanoma multiple myeloma investigated cervical dysplasia cancer investigated myocardial infarction investigated genital herpes prednisone metastatic castration resistant prostate cancer investigated erectile dysfunction parkinson disease investigated prostate cancer investigated brain cancer cancer tumors unspecified  colorectal cancer leukemia lymphoid  leukemia myeloid  lung cancer myelodysplastic syndrome pediatric indications solid tumors investigated breast cancer colorectal cancer lung cancer investigated diabetes mellitus type pediatric indications investigated strokes traumatic brain injuries investigated bipolar disorders epilepsy migraine cluster headaches investigated migraine cluster headaches neuropathy diabetic  pain chronic investigated arthritis arthritic pain inflammatory bowel disease investigated infertility investigated brain cancer investigated psychosis schizophrenia schizoaffective disorders osteoporosis investigated contraception male hormonal deficiencies abnormalities investigated cancer tumors unspecified investigated alzheimer disease investigated adverse effects chemotherapy head neck cancer investigated anemia sickle cell cancer tumors unspecified investigated genital herpes investigated solid tumors investigated nocturia frequent nighttime urination urinary incontinence investigated cytomegalovirus cmv retinitis hiv infection influenza pneumonia investigated transplant rejection investigated asthma investigated breast cancer solid tumors investigated cardiovascular disorders hypertension investigated skin cancer skin infections disorders investigated alzheimer disease neurologic disorders parkinson disease retinal disorders unspecified investigated autoimmune diseases inflammatory disorders unspecified investigated asthma chronic obstructive pulmonary disease copd investigated adverse effects chemotherapy renal cell carcinoma investigated liver disease investigated diabetes mellitus type investigated ulcerative colitis investigated metabolic disease investigated acne investigated liver cancer investigated hepatitis viral c investigated prostate cancer investigated autoimmune diseases investigated lymphoma non hodgkin solid tumors investigated diabetic retinopathy scar tissue vitreous hemorrhage investigated hyperlipidemia investigated breast cancer investigated hepatitis viral c investigated burns burn infections cardiac surgery inflammatory disorders unspecified  ischemic reperfusion injury sepsis septicemia investigated colorectal cancer pancreatic cancer solid tumors investigated hiv infection investigated infectious parasitic disease unspecified viral infection investigated amyotrophic lateral sclerosis als investigated respiratory distress syndrome ards viral infection investigated rheumatoid arthritis investigated solid tumors investigated alzheimer disease neurologic disorders investigated osteoporosis investigated chronic renal failure parathyroid disorders investigated hepatitis viral c investigated epilepsy investigated solid tumors investigated transplant rejection investigated alzheimer disease depression memory loss neurologic disorders monotherapy adults relapsed refractory cd22 positive b cell precursor lymphoblastic leukaemia all  investigated cancer tumors unspecified solid tumors investigated pain chronic investigated obesity investigated solid tumors investigated macular degeneration investigated cancer tumors unspecified investigated alzheimer disease gene therapy investigated cancer tumors unspecified solid tumors investigated solid tumors investigated hepatitis viral c investigated constipation gastrointestinal diseases disorders miscellaneous  gastroparesis irritable bowel syndrome ibs investigated hiv infection investigated atherosclerosis investigated multiple sclerosis investigated solid tumors investigated muscular dystrophy investigated cancer tumors unspecified investigated macular degeneration investigated urinary incontinence investigated brain cancer investigated parkinson disease investigated multiple myeloma solid tumors investigated breast cancer kidney cancer leukemia myeloid  melanoma neuroblastoma ovarian cancer prostate cancer investigated thrombocytopenia investigated cancer tumors unspecified macular degeneration investigated solid tumors investigated adverse effects chemotherapy  blood blood forming organ disorders unspecified  cancer tumors unspecified  neutropenics vascular diseases investigated asthma investigated alzheimer disease investigated atherosclerosis currently being investigated number cancers a192858 hiv a3922  recently begun phase ii clinical trial severely ill covid 19  preliminary data shows reduction cytokine storm  particularly il 6 well normalization cd4 cd8 t cell ratio  these results mitigate immune mediate injury seen severely ill covid 19  investigated hepatitis viral c investigated sepsis septicemia investigated cancer tumors unspecified investigated anthrax exposure bacterial infection investigated pain chronic investigated alzheimer disease neurologic disorders pain chronic  parkinson disease investigated cancer tumors unspecified solid tumors investigated hiv infection investigated depression investigated breast cancer investigated cancer tumors unspecified liver cancer investigated cancer tumors unspecified solid tumors investigated cancer tumors unspecified  leukemia unspecified  lymphoma unspecified  multiple myeloma solid tumors investigated solid tumors investigated gastrointestinal diseases disorders miscellaneous  inflammatory bowel disease ulcerative colitis investigated cancer tumors unspecified  hemorrhage hypoxia respiratory failure strokes investigated lymphoma unspecified  multiple myeloma solid tumors investigated melanoma primary biliary cholangitis ursodeoxycholic acid udca adults inadequate response udca monotherapy adults pbc unable tolerate udca   currently being considered fda approval fibrosis non alcoholic liver steatohepatitis nash  likely approved indication 2020  investigated cancer tumors unspecified investigated alzheimer disease obesity schizophrenia schizoaffective disorders investigated melanoma investigated cardiovascular disorders coronary artery disease investigated diabetes mellitus type investigated solid tumors certain individuals duchenne muscular dystrophy dmd  limited those confirmed mutation dmd gene would benefit from exon 51 skipping  based clinical studies showing increased dystrophin production skeletal muscle some given drug above indication approved under accelerated approval  further confirmatory trials required demonstrate clinical benefit  atypical antipsychotic schizophrenia manic mixed episodes bipolar i disorder investigated cancer tumors unspecified investigated adverse effects chemotherapy neutropenics investigated hiv infection investigated cancer tumors unspecified investigated cancer tumors unspecified  doxorubicin advanced mestastatic soft tissue sarcoma sts histologic subtype anthracycline containing regimen appropriate amenable curative radiotherapy surgery investigated traumatic brain injuries investigated leukemia myeloid multiple myeloma investigated atrial fibrillation thrombosis investigated hepatitis viral c investigated cancer tumors unspecified investigated acromegaly cancer tumors unspecified investigated ischemic reperfusion injury investigated solid tumors investigated cancer tumors unspecified investigated cancer tumors unspecified investigated alzheimer disease investigated cancer tumors unspecified solid tumors approved schizophrenia adults  investigated leukemia myeloid  myelodysplastic syndrome solid tumors capacizumab approved adults experiencing episode acquired thrombotic thrombocytopenic purpura attp conjunction plasma exchange immunosuppression 18 older a174634   attp rare autoimmune condition presented disruption blood clotting order translated into systemic microvascular thrombosis leading profound thrombocytopenia hemolytic anemia organ ischemia production autoantibodies against adamts 13 protein charge cleaving von wilebrand factor lack process produces generation ultra large von wilebrand multimers bind platelets form microthrombi causing thromboembolic complications a174649  previously capacizumab under review prevention thrombosis high risk coronary syndrome undergoing percutaneous coronary intervention but indication withdrawn a174634 investigated cancer tumors unspecified investigated psoriasis psoriatic disorders investigated bacterial infection investigated epilepsy investigated neurologic disorders investigated solid tumors investigated neurologic disorders investigated cancer tumors unspecified investigated migraine cluster headaches investigated cancer tumors unspecified solid tumors investigated solid tumors investigated cancer tumors unspecified investigated autoimmune diseases psoriasis psoriatic disorders viral infection investigated dementia investigated schizophrenia schizoaffective disorders investigated diabetes mellitus type investigated asthma cystic fibrosis hiv infection investigated ulcerative colitis investigated parathyroid disorders partial onset seizures adults  investigated muscular dystrophy investigated diabetes mellitus type investigated cancer tumors unspecified lung cancer investigated lymphoma non hodgkin investigated acne alopecia investigated solid tumors topical actinic keratosis face scalp  investigated cancer tumors unspecified investigated neurologic disorders schizophrenia macrolide antibiotic various infections effective against wide range gram positive gram negative pathogenic microorganisms although no longer humans cattle depression bacterial infections susceptible microorganisms infections mainly mucolytic paracetamol acetaminophen overdose mainly conditions like arteriosclerosis cerebrovascular disease peripheral vascular disease raynaud disease thrombo angitis obliterans thrombophlebitis   sometimes peripheral vascular disorders addition premature labor however drug approved premature labor a32531 prophylactic migraines   angina pectoris  conjunction diet exercise body mass index greater than 30 kg m lt sup gt lt sup gt  wih bmi greater than 27 kg m lt sup gt lt sup gt risk factors type diabetes dyslipidaemia investigated alzheimer disease parkinson disease obesity investigated heart disease investigated pancreatic cancer leukemia unspecified  melanoma ovarian cancer cancer tumors unspecified investigated bacterial infection investigated crohn disease congenital anomaly unspecified  cardiovascular disorders pediatric indications burns burn infections investigated asthma leukemia lymphoid investigated pancreatic cancer solid tumors gastric cancer lung cancer colorectal cancer investigated hiv infection acquired immune deficiency syndrome aids aids related infections 4 age older familial cold autoinflammatory syndrome fcas muckle wells syndrome mws  both part cryopyrin periodic syndromes caps well age older systemic juvenile idiopathic arthritis sjia  investigated solid tumors investigated brain cancer investigated lymphoma non hodgkin  leukemia lymphoid  cancer tumors unspecified  multiple myeloma cutaneous t cell lymphoma ctcl peripheral t cell lymphoma ptcl received least one prior systemic therapy these indications based response rate clinical benefit improvement overall survival demonstrated investigated pancreatic cancer solid tumors breast cancer colorectal cancer brain cancer lung cancer ovarian cancer sarcoma investigated solid tumors lung cancer leukemia unspecified  leukemia lymphoid investigated blood blood forming organ disorders unspecified  cancer tumors unspecified  solid tumors multiple myeloma liver cancer investigated solid tumors melanoma investigated renal cell carcinoma solid tumors lung cancer investigated lymphoma non hodgkin  leukemia lymphoid  lung cancer melanoma pancreatic cancer investigated cancer tumors unspecified leukemia myeloid investigated lymphoma non hodgkin leukemia lymphoid  unresectable metastatic melanoma adjuvant cutaneous melanoma microsatellite high mismatch repair deficient metastatic colorectal cancer hepatocellular carcinoma   nivolumab advanced renal cell carcinoma  investigated hepatitis viral b investigated breast cancer lung cancer solid tumors renal cell carcinoma pediatric indications ovarian cancer head neck cancer investigated diabetes mellitus type irritable bowel syndrome ibs  urinary incontinence investigated leukemia myeloid myelodysplastic syndrome investigated head neck cancer brain cancer pediatric indications pancreatic cancer lung cancer colorectal cancer currently phase iii investigation relapsed refractory aggressive non hodgkin lymphoma failed two prior lines therapy presently no standard therapy exists relapsed refractory nhl  after first line therapy initiated most received their lifetime limit doxorubicin further anthracyclines potentially lead anthracycline induced congestive heart failure chf  attractive alternative second line agent lack cardiac toxicity   phase iii trial pix r ongoing will compare multidrug therapy equivalent regimen diffuse large b cell lymphoma most common type nhl  previous study results suggested possibility safe effective doxorubicin naive myocardial strips doxorubicin naive  taken up higher degree than myocardial strips doxorubicin exposed once absorbed exhibits redox inactivity  3   dimaleate investigated myelogenous leukemia diffuse large b cell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphomas general metastatic cancers   investigated benign prostatic hyperplasia urinary incontinence prostate disorders infertility investigated breast cancer lung cancer lymphoma unspecified  multiple myeloma leukemia lymphoid  cancer tumors unspecified approved attacks hereditary angioedema hae  investigated angioedema liver disease burns burn infections investigated asthma psoriasis psoriatic disorders atopic dermatitis inflammatory disorders unspecified  chronic obstructive pulmonary disease copd investigated hiv infection investigated prostate cancer cancer tumors unspecified investigated arrhythmia atrial fibrillation angina adjunct therapy seizures lennox gastaut syndrome  investigated postmenopausal osteoporosis reduce risk both vertebral novertebral fractures well address postmenopausal conditions reduction risk breast cancer vulvar vaginal atrophy vva adjunct diet exercise improve glycemic control adults type diabetes mellitus immediate release formulation relief moderate severe pain long acting formulation serves continuous around clock analgesic relief moderate severe chronic pain neuropathic pain diabetic peripheral neuropathy hyaluronidase subcutaneous fluid administration hydration increasing resorption radiopaque agents subcutaneous urography  hyaluronidase multiple routes increase dispersion injectable drugs  reversal neuromuscular blockade induced rocuronium bromide vecuronium bromide adults undergoing surgery symptomatic relief benign prostatic hyperplasia acetylsalicylic acid asa prevent atherothrombotic events coronary syndrome acs managed percutaneous coronary intervention pci  unstable angina ua  non st elevation myocardial infarction nstemi  st elevation myocardial infarction stemi managed pci  recommended 75 age greater those weigh lt 60kg history stroke transient ischemic attack increased risk fatal intracranial bleeding thrombopoietin receptor agonists pharmaceutical agents stimulate platelet production bone marrow they differ from previously discussed agents act attempting curtail platelet destruction  complicated intra abdominal infections complicated urinary tract infections pyelonephritis designated susceptible bacteria  symptomatic resistant fluid restriction euvolemic hypervolemic hyponatremia congestive heart failure siadh cirrhosis diagnostic agent radionuclide myocardial perfusion imaging mpi drug iron deficiency anemia experienced intolerance oral iron experienced unsatisfactory response oral iron chronic kidney disease ckd  fda psychosis schizophrenia schizoaffective disorders manic disorders bipolar disorders monotherapy rapid conversion recent onset atrial fibrillation sinus rhythm adults non surgery lasts less than 7 days duration post cardiac surgery atrial fibrillation lasting less than 3 days duration adjunctive therapy partial onset seizures epilepsy over 17 old injection short term oral therapy feasible  injection bacterial skin skin structure infections absssi  susceptible isolates following gram positive microorganisms staphylococcus aureus methicillin susceptible methicillin resistant strains  streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae streptococcus anginosus group streptococcus anginosus streptococcus intermedius streptococcus constellatus enterococcus faecalis vancomycin susceptible strains  fda f2356   active against gram negative bacteria therefore therapy clinically if absssi polymicrobial includes suspected documented gram negative pathogen f2356  reduce development drug resistant bacteria maintain effectiveness antibacterial drugs  should only infections proven strongly suspected susceptible bacteria fda f2356  culture susceptibility information available they should considered selecting modifying antibacterial therapy fda f2356  absence data local epidemiology susceptibility patterns contribute empiric selection therapy fda f2356   investigated crohn disease ulcerative colitis investigated asthma investigated prostate cancer breast cancer prevention venous thromboembolic events vte undergone total hips replacements total knee replacement surgery prevention stroke systemic embolism nonvalvular atrial fibrillation deep vein thrombosis dvt pulmonary embolism pe  reduce risk recurrent dvt pe  aspirin reducing risk major cardiovascular events chronic coronary artery disease peripheral artery disease lack safety studies recommended those under 18 old recommended those severe renal impairment  lt 30ml min  investigated schizophrenia schizoaffective disorders reduction alcohol consumption alcohol dependence high drinking risk level drl  without physical withdrawal symptoms do require immediate detoxification   complete partial reversal opioid drug effects respiratory depression  induced either natural synthetic opioids  known suspected opioid overdose fda investigated heart disease myocardial infarction investigated solid tumors sarcoma cancer tumors unspecified  endometrial cancer prostate cancer bone metastases investigated viral infection transplantation organ tissue  cytomegalovirus cmv retinitis retinal disorders unspecified investigated solid tumors lung cancer ovarian cancer prostate cancer investigated hepatitis viral b hiv infection erectile dysfunction males investigated cervical dysplasia cancer viral infection vulvar dysplasia carcinoma investigated ovarian cancer lung cancer breast cancer investigated rheumatoid arthritis facial hirsutism excessive hair growth investigated coronary artery disease peripheral vascular disease periodontal disease bone fractures entero related fistulae diabetic foot ulcers investigated myocardial infarction investigated adenomatous polyposis coli lung cancer prostate cancer colon polyps barrett esophagus disease pediatric indications investigated alzheimer disease memory loss autism neurologic disorders dementia schizophrenia schizoaffective disorders attention deficit hyperactivity disorder adhd  sleep disorders investigated asthma chronic obstructive pulmonary disease copd  cystic fibrosis rheumatoid arthritis investigated breast cancer osteoporosis endometrial cancer investigated psoriasis psoriatic disorders hyperlipidemia metabolic disease cancer tumors unspecified  obesity investigated inflammatory bowel disease investigated diabetes mellitus type neuropathy diabetic  vascular diseases incadronate investigated myeloma a14426 a14431 leukemia a14427 cancers a202769 investigated hypercalcemia malignancy a202862 investigated myocardial infarction red blood cell disorders anemia kidney transplant surgery transplant rejection  liver transplant surgery ischemic reperfusion injury investigated adverse effects chemotherapy  hyperlipidemia autoimmune diseases hepatitis viral b investigated neuropathy diabetic wounds cystoscopic detection non muscle invasive papillary cancer bladder among suspected known lesion basis prior cystoscopy neurogenic orthostatic hypotension noh various disorders multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension parkinson disease investigated neurologic disorders nephropathy blood blood forming organ disorders unspecified  dizzy fainting spells investigated lung cancer a4138 investigated neurologic disorders spinal cord injuries muscle spasm back pain multiple sclerosis investigated benign prostatic hyperplasia prostate disorders cancer tumors unspecified investigated erectile dysfunction hypertension investigated pulmonary hypertension connective tissue diseases hypertension congestive heart failure investigated hyperlipidemia clinically prophylaxis vascular diseases increased risk thrombosis intermittent claudication peripheral arterial occlusive disease post myocardial infarc tion investigated diabetic kidney disease diabetic neuropathy new anti inflammatory properties extended venous disease moderate severe rheumatoid arthritis giant cell arteritis polyarticular juvenile idiopathic arthritis systemic juvenile idiopathic arthritis cytokine release syndrome  accelerate time upper lower gastrointestinal recovery following partial large small bowel resection surgery primary anastomosis investigated pain chronic investigated pancreatic cancer lung cancer ovarian cancer osteoarthritis investigated anemia sickle cell asthma investigated peripheral vascular disease hyperlipidemia symptoms perennial allergic rhinitis uncomplicated skin manifestations chronic idiopathic urticaria  over counter variety mild allergy symptoms a181748 severe chronic pain refractory treatments whom intrathecal therapy warranted  osteoporosis men postmenopausal women high risk having fracture increase bone mass men primary hypogonadal osteoporosis high risk fracture renal cell carcinoma rcc  investigated breast cancer lymphoma unspecified  rheumatoid arthritis multiple myeloma investigated schizophrenia schizoaffective disorders mania bipolar disorder depression adults chronic hepatitis c virus hcv infection typically sofosbuvir hcv genotype without cirrhosis compensated cirrhosis peginterferon alfa peg ifn alfa ribavirin rbv hcv genotype 4 without cirrhosis compensated cirrhosis  resistance reduced susceptibility most commonly viral ns3 q80k polymorphism amino acid substitutions ns3 positions s122 r155 d168 shown reduce susceptibility genotype 1a b  improve glycemic control type diabetes mellitus along diet exercise a6757 a6758 investigated thrombosis coronary artery disease vascular diseases investigated thrombosis investigated seborrhea fungal infections skin infections disorders onychomycosis investigated rheumatoid arthritis inflammatory disorders unspecified  autoimmune diseases investigated liver disease investigated cancer tumors unspecified investigated inflammatory disorders unspecified investigated solid tumors investigated solid tumors investigated cancer tumors unspecified investigated cancer tumors unspecified investigated cancer tumors unspecified investigated viral infection pediatric indications investigated atherosclerosis investigated cancer tumors unspecified investigated solid tumors cancer tumors unspecified lenalidomide dexamethasone multiple myeloma received one three prior therapies investigated leukemia myeloid investigated autoimmune diseases investigated solid tumors investigated scar tissue investigated lymphoma unspecified lymphoma non hodgkin investigated macular degeneration eye disorders infections investigated gastrointestinal diseases disorders miscellaneous autoimmune diseases celiac disease investigated cancer tumors unspecified investigated solid tumors investigated obesity diabetes mellitus type investigated cancer tumors unspecified type diabetes mellitus improve glycemic control agents monotherapy investigated diarrhea adverse effects chemotherapy investigated lymphoma non hodgkin  thyroid eye disease  investigated hypertension investigated inflammatory disorders unspecified investigated solid tumors leukemia myeloid  myelodysplastic syndrome cancer tumors unspecified investigated cardiovascular disorders myocardial infarction investigated pain chronic migraine cluster headaches investigated cardiac ischemia cardiovascular disorders investigated solid tumors cancer tumors unspecified investigated bacterial infection skin infections disorders obesity liver disease kidney disease pneumonia investigated leukemia lymphoid  multiple myeloma lymphoma unspecified investigated prostate cancer investigated cancer tumors unspecified  liver cancer gastric cancer leukemia unspecified investigated solid tumors investigated solid tumors cutaneous t cell lymphoma myelodysplastic syndrome leukemia lymphoid  intravenous administration trastuzumab docetaxel her2 positive metastatic breast cancer received prior anti her2 therapy chemotherapy metastatic disease  trastuzumab chemotherapies neoadjuvant her2 positive locally advanced inflammatory early stage breast cancer part complete regimen  adjuvant her2 positive early stage breast cancer high risk recurrence   subcutaneous injection  trastuzumab hyaluronidase  her2 positive breast cancers adults  investigated osteoporosis bone metastases investigated hepatitis viral b investigated lung cancer investigated psoriasis psoriatic disorders transplant rejection  graft versus host disease lymphoma unspecified  leukemia unspecified  currently cryopyrin periodic syndrome 2012 advisory panel fda voted 11 0 against gout investigated menopause female hormonal deficiencies abnormalities investigated skin infections disorders investigated myocardial infarction heart disease asthma investigated amyotrophic lateral sclerosis als alzheimer disease investigated amputation limb peripheral vascular disease investigated fungal infections bacterial infection skin infections disorders onychomycosis investigated cerebrovascular disease unspecified investigated autoimmune diseases systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma non hodgkin  leukemia lymphoid investigated kidney cancer melanoma renal cell carcinoma lymphoma unspecified  colorectal cancer brain cancer following conditions alone conjugated estrogens women uterus   moderate severe vasomotor symptoms menopause  prevention postmenopausal osteoporosisfor complicated skin skin structure infections csssi gram positive bacteria like methicillin susceptible resistant staphylococcus aureus vancomycin susceptible enterococcus faecalis streptococcus pyogenes streptococcus agalactiae streptococcus anginosus group hospital acquired bacterial pneumonia hap ventilator bacterial pneumonia vap  known suspected susceptible isolates staphylococcus aureus methicillin susceptible methicillin resistant aureus  idiopathic  primary  pulmonary arterial hypertension ipah pulmonary arterial hypertension pah connective tissue disease functional class ii iii symptoms united states america  tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability c1 esterase inhibitors prophylaxis attacks hereditary angioedema least 6 old   investigated amyloidosis investigated thrombosis venous thromboembolism strokes heart disease atrial fibrillation investigated hepatitis viral c investigated pain chronic  secondary hyperparathyroidism chronic kidney disease dialysis well secondary hyperparathyroidism stage 3 stage 4 chronic kidney disease anemias deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis hypoplastic anemias administration myelotoxic drugs often respond  should replace supportive measures transfusion correction iron folic acid vitamin b12 pyridoxine deficiency antibacterial therapy appropriate corticosteroids investigated sleep disorders obstructive sleep apnea schizophrenia schizoaffective disorders depression bipolar disorders adjunct therapy hiv infections resistant therapy nnrtis antiretroviral agents  prophylaxis therapy prevent respiratory distress syndrome rds premature infants lt 29 weeks gestational age low lung surfactant high risk rds  therapy respiratory distress syndrome infants 72 hours less age rds confirmed clinical radiologic findings requiring endotracheal intubation currently no fda approved indications granted orphan drug designation prophylactic inhalation anthrax 2007 prophylactic both plague yersinia pestis tularemia francisella tularensis 2009  investigated breast cancer leukemia unspecified investigated colorectal cancer inflammatory bowel disease investigated gastroesophageal reflux disease gerd gastroparesis investigated cancer tumors unspecified  macular degeneration diabetic retinopathy investigated schizophrenia schizoaffective disorders irritable bowel syndrome ibs  chronic obstructive pulmonary disease copd investigated bacterial infection investigated colorectal cancer lung cancer leukemia unspecified  gastric cancer investigated bone marrow transplant ulcers inflammatory bowel disease investigated gastrointestinal diseases disorders miscellaneous investigated colorectal cancer lung cancer investigated sepsis septicemia pneumonia inhaled surfactant assists removing liquefying removing bronchopulmonary secretions mucus pus  administered either through nebulized solution stream oxygen investigated cystic fibrosis pediatric indications investigated fungal infections aspergillosis candidiasis onychomycosis adjunct percutaneous coronary intervention pci reducing risk periprocedural myocardial infarction mi  repeat coronary revascularization stent thrombosis st treated p2y12 platelet inhibitor being given glycoprotein iib iiia inhibitor investigated peripheral vascular disease investigated traumatic brain injuries neurologic disorders investigated renal cell carcinoma pancreatic cancer melanoma lung cancer investigated migraine cluster headaches investigated sepsis septicemia farnesyltransferase inhibitor aged 12 months older body surface area least 0 39 m lt sup gt lt sup gt reduce risk mortality hutchinson gilford progeria syndrome hgps  same population processing deficient progeroid laminopathies either involve heterozygous lmna mutation resulting accumulation progerin like protein homozygous compound heterozygous mutations zmpste24  investigated inflammatory disorders unspecified  crohn disease rheumatoid arthritis investigated lung cancer investigated breast cancer lung cancer ovarian cancer investigated schizophrenia schizoaffective disorders parkinson disease investigated colorectal cancer prostate cancer schizophrenia schizoaffective disorders psychosis depression lung cancer investigated allergic rhinitis investigated epilepsy huntington disease parkinson disease investigated congestive heart failure chronic obstructive pulmonary disease copd  benign prostatic hyperplasia investigated ovarian cancer lung cancer macular degeneration investigated lung cancer melanoma investigated psoriasis psoriatic disorders investigated rheumatoid arthritis investigated dementia alzheimer disease schizophrenia schizoaffective disorders memory loss investigated lymphoma non hodgkin  leukemia lymphoid  solid tumors investigated cardiac surgery investigated pancreatic cancer prostate cancer leukemia myeloid investigated strokes investigated congestive heart failure investigated angina investigated cancer tumors unspecified  colorectal cancer lung cancer investigated thrombocytopenia systemic lupus erythematosus transplant rejection  blood blood forming organ disorders unspecified  multiple sclerosis investigated parkinson disease investigated head neck cancer investigated alzheimer disease chronic idiopathic constipation cic adults   cic one most common chronic functional gastrointestinal disorders worldwide diagnosis agent very hard confirmed if patient experience least two following  straining during more than 25 bowel movements  lumpy hard stools 25 bowel movements  sensation incomplete evacuation more than 25 all bowel movements  sensation anorectal blockage obstruction more than 25 bowel movements  manual maneuvers required more than 25 bowel movements  fewer than 3 bowel movements per week  investigated immunosuppressive transplant rejection investigated pain chronic investigated cancer tumors unspecified investigated brain cancer lymphoma non hodgkin  lung cancer investigated parkinson disease investigated transplant rejection  kidney disease rheumatoid arthritis investigated adverse effects chemotherapy investigated endometriosis uterine fibroids investigated psoriasis psoriatic disorders crohn disease investigated hiv prevention investigated hiv infection investigated lung cancer investigated hepatitis viral c investigated coronary artery disease investigated alzheimer disease dementia investigated strokes cerebral ischemia depression investigated asthma allergic rhinitis investigated diabetes mellitus type investigated osteoporosis bone metastases investigated anxiety disorders investigated interstitial cystitis urinary incontinence investigated rheumatoid arthritis investigated diabetes mellitus type investigated diabetes mellitus type investigated hepatitis viral c investigated alzheimer disease investigated strokes alzheimer disease investigated anxiety disorders investigated genital herpes investigated pneumonia trypanosomiasis malaria hiv infection infectious parasitic disease unspecified investigated diabetes mellitus type investigated thrombocytopenia investigated parkinson disease investigated diabetes mellitus type investigated anxiety disorders depression investigated eye disorders infections cancer tumors unspecified  asthma investigated graft versus host disease investigated multiple myeloma breast cancer osteoporosis lung cancer investigated brain cancer pediatric indications investigated cancer tumors unspecified head neck cancer investigated thrombosis deep vein  angina coronary artery disease colorectal cancer investigated sleep disorders insomnia investigated anxiety disorders investigated cardiac surgery peripheral vascular disease kidney disease investigated glaucoma cataracts investigated congestive heart failure liver disease heart disease investigated fungal infections investigated asthma investigated adverse effects chemotherapy  reproductive health infertility investigated hiv infection investigated obesity investigated lung cancer prostate cancer investigated herpes zoster infections viral infection investigated rheumatoid arthritis investigated migraine cluster headaches investigated insomnia sleep disorders investigated hepatitis viral c investigated hiv infection investigated irritable bowel syndrome ibs investigated breast cancer renal cell carcinoma prostate cancer lung cancer investigated parkinson disease neurologic disorders investigated obesity investigated gastroparesis irritable bowel syndrome ibs investigated cancer tumors unspecified advanced renal cell cancer advanced soft tissue sarcoma previously treated chemotherapy  following infections susceptible isolates designated microorganisms investigated melanoma hepatocellular carcinoma major depressive episodes adults investigated high risk myeloid leukemia aml flt3 mutation positive agressive systemic mastocytosis asm  systemic mastocytosis hematological neoplasm sm ahn  mast cell leukemia mcl  investigated endometriosis investigated solid tumors investigated cancer tumors unspecified investigated bacterial infection pneumonia add maintenance severe asthma aged 18 older eosinophilic phenotype multiple myeloma dexamethasone bortezomib received previous regimens bortezomib immunomodulatory agent indication approved accelerated approval based progression free survival february 23 2015 investigated hypertension reducing risk stroke systemic embolism nonvalvular atrial fibrillation prophylaxis deep vein thrombosis dvt leading pulmonary embolism pe after hip knee replacement surgery dvt pe reduce risk recurrence a177565 a6897 investigated diabetes mellitus type malignant ascites tumours via intraperitoneal infusion where standard therapy available feasible fda  prevention relapse vivax malaria 16 older  vivax malaria a35671  malaria disease remains occur many tropical countries vivax malaria plasmodium vivax known less virulent seldom causes death however causes substantive illness related burden endemic areas known present dormant forms hepatocytes named hypnozoites remain dormant weeks even months dormant form produces ongoing relapses a35671 investigated atrial fibrillation cardiovascular disorders thrombosis venous thromboembolism investigated bacterial infection rosacea investigated rheumatoid arthritis anti il 5 igg1 kappa monoclonal antibody add maintenance aged six older severe eosinophilic asthma eosinophilic granulomatosis polyangiitis egpa  hypereosinophilic syndrome hes aged 12 older whom eosinophilia present least six months without identifiable non hematologic secondary cause  uncomplicated influenza 18 older symptomatic no more than two days chronic accelerated blast phase philadelphia chromosome positive ph  chronic myelogenous leukemia cml resistance intolerance prior therapy investigated strokes depression investigated hiv infection acquired immune deficiency syndrome aids aids related infections investigated parkinson disease neurologic disorders investigated alzheimer disease investigated fibromyalgia investigated obesity investigated parkinson disease kidney cell cancer investigated pancreatic thyroid cancer investigated prostate cancer investigated hyperlipidemia investigated eye disorders infections investigated urinary incontinence adverse effects chemotherapy investigated thrombosis invasive aspergillosis invasive mucormycosis neurofunctional modifier helps improve walking speed multiple sclerosis ms  investigated leukemia lymphoid investigated male hormonal deficiencies abnormalities investigated solid tumors multiple myeloma leukemia unspecified  lung cancer brain cancer investigated macular degeneration diabetic retinopathy prolia postmenopausal women osteoporosis high risk fracture reduces incidence vertebral nonvertebral hip fractures prolia increase bone mass women high risk fracture receiving adjuvant aromatase inhibitor therapy breast cancer men osteoporosis high risk fracture men receiving androgen deprivation therapy nonmetastatic prostate cancer increase bone mass xgeva prevention skeletal related events bone metastases from solid tumors investigated cachexia anorexia investigated solid tumors renal cell carcinoma melanoma pancreatic cancer lung cancer ovarian cancer investigated pain chronic  chlorambucil  previously untreated chronic lymphocytic leukemia cll whom fludarabine based therapy considered inappropriate   recurrent progressive cll  extended complete partial response after least two lines therapy recurrent progressive cll   cll refractory fludarabine alemtuzumab    relapsing forms multiple sclerosis active secondary progressive disease clinically isolated syndrome relapsing remitting disease  investigated diabetes mellitus type autoimmune diseases diabetes mellitus type investigated hiv infection viral infection add levodopa without medicines parkinson disease diet exercise improve glycemic control 10 older type diabetes mellitus  reduce risk major adverse cardiovascular events type diabetes mellitus well cardiovascular disease investigated solid tumors cancer tumors unspecified investigated epilepsy investigated macular degeneration investigated depression anxiety disorders investigated kidney disease systemic lupus erythematosus cushing disease specifically those whom pituitary surgery curative option investigated hyponatremia congestive heart failure investigated irritable bowel syndrome ibs diarrhea investigated osteoporosis a19388 investigated sleep disorders insomnia adults i adjunct methotrexate moderate severe active rheumatoid arthritis ra   ii old above active psoriatic arthritis psa   iii single agent active ankylosing spondylitis methotrexate  iv single agent moderate severe ulcerative colitis uc require chronic steroids experienced intolerance only partial response previous medications  v active polyarticular juvenile idiopathic arthritis pjia age older  investigated strokes investigated insomnia sleep disorders investigated myocardial infarction thrombosis investigated uterine fibroids prophylaxis organ rejection concomitantly basiliximumab induction therapy mycophenolate corticosteriods kidney transplant recepients seropositive epstein barr virus investigated pain chronic  inflammatory disorders unspecified  osteoarthritis arthritis arthritic pain investigated hepatitis viral b  approved major depressive disorder a38477 a177622 investigated multiple sclerosis autologous cellular immunotherapy asymptomatic minimally symptomatic metastatic castrate resistant hormone refractory prostate cancer esophageal varices recently bled prevent rebleeding allergic conditions symptomatic relief hypersensitivity reaction pruritic skin disorders prophylactic reduce perioperative blood loss need blood transfusion undergoing cardiopulmonary bypass course coronary artery bypass graft surgery increased risk blood loss blood transfusion therapeutically many side effects treating nasal congestion minor inflammation allergies colds dabigatran prevention venous thromboembolic events undergone elective hip knee replacement surgery based re novate re model re mobilize trials a177463 a6978 a6977  2010 approved us canada prevention stroke systemic embolism atrial fibrillation approval based re ly trial a177463  short term multi resistant bacterial infections methicillin resistant staphylococcus aureus  mrsa  lumefantrine therapy uncomplicated malaria plasmodium falciparum  malaria acquired chloroquine resistant areas uncomplicated malaria plasmodium species identified adults children greater than 5 kg  reduction recurrent vertigo episodes mnire disease 18 old above  degaralix advanced prostate cancer  major depressive disorder adults a6990 a6991  adhd ideally conjunction psychological educational behavioral forms a177187 overactive bladder symptoms urinary frequency urgency urge incontinence diagnostic only adults children age over contrast enhancement during cranial spinal mri contrast enhanced magnetic resonance angiography ce mra  particularly suited detection very small lesions visualization tumors do readily take up contrast media desired agent exclusion demonstration additional pathology influence choice therapy patient suitable perfusion studies diagnosis stroke detection focal cerebral ischemia studies tumor perfusion detection primary metastatic pheochromocytoma neuroblastoma contrast agent magnetic resonance angiography mra evaluate aortoiliac occlusive disease aiod adults known suspected peripheral vascular disease sympathomimetic drug causes vasoconstriction treating migraines tension headaches topical nasal decongestant vasoconstrictor dentistry artemether therapy uncomplicated malaria plasmodium falciparum  malaria acquired chloroquine resistant areas uncomplicated malaria plasmodium species identified adults children greater than 5 kg most commonly diagnosing bronchial hyperreactivity using bronchial challenge test anabolic steroid hormone men testosterone deficiency women breast cancer breast pain swelling pregnancy addition estrogen symptoms menopause otc eyedrops ocular vasoconstriction nasal preparation nasal congestion a176558  vasospastic angina chronic stable angina hypertension contraception menopausal hormonal therapy  potentially breast cancer inhibitory effect estrone sulfatase  they convert sulfated steroid precursors estrogen during pregnancy provide temporary symptomatic relief nasal congestion colds allergies allergic rhinitis oral antithyroid agent prevention radioactive iodine uptake into thyroid gland during nuclear radiation emergency  adjunct antithyroid agents hyperthyroidism thyrotoxicosis preoperatively induce thyroid involution monitored anaesthesia care sedation undergoing diagnostic procedures like bronchoscopy colonscopy minor surgical procedures like arthroscopy bunionectomy prevention nausea vomiting highly emetogenic cancer chemotherapy synthetic anabolic steroid therapeutic uses treating c1 inhibitor deficient hereditary angioedema c1 inhibitor protease inhibits complement system part innate immune system  biochemical chain reactions assists body removing pathogens from body  help control attacks hereditary angioedema  administered orally intramuscularly  hormone responsive cancers prostate cancer breast cancer estrogen dependent conditions endometriosis uterine fibroids  assisted reproduction hydrolytic lysosomal glucocerebroside specific enzyme long term enzyme replacement therapy pediatric type gaucher disease relief heartburn acid indigestion relief heartburn acid indigestion nutritional supplement hypocalcemia mild moderate pain well pain inflammation joints certain types rheumatic diseases bacterial infections relief pain inflammation osteoarthritis rheumatoid arthritis ankylosing spondylitis all types severe pain postoperative cancer kidney stones fractures secretolytic therapy bronchoplmonary diseaes abnormal mucus secretion transport allows mucus more easily cleared ease patient breathing functional bowel disorders alleviating pain renal colic development chemonucleolysis digestion nucleus pulposus disc herniation confirmed myelography a32687 disc herniation occurs outer portion spinal disc breaks down inner portion nucleus pulposus leaks out pressing surrounding nerves leading irradiating pain  chemonucleolysis non surgical involves injection enzyme dissolve nucleus pulposus  prophylaxis post operative deep venous thrombosis dvt  lead pulmonary embolism pe  undergoing elective hip replacement surgery fda beta carotene fda approved nutrient supplement even added infant formula source vitaminA  approved color additive food products  drugs only color additive   cosmetics   commonly reduction photosensitivity erythropoietic protoporphyria photosensitivity diseases a32485 betaine homocystinuria decrease elevated homocysteine blood levels included within category homocystinuria deficiencies defects cystathionine beta synthase cbs  5 10 methylenetetrahydrofolate reductase mthfr  3 cobalamin cofactor metabolism cbl  supplement intravenous solutions given total parenteral nutrition tpn  administration helps maintain plasma levels prevent depletion endogenous stores subsequent deficiency symptoms local cytomegalovirus cmv retinitis acquired immunodeficiency syndrome aids  therapy ineffective considered unsuitable fda  congenital sucrose isomaltase deficiency csid  prevention respiratory distress syndrome rds premature infants temporary relief discomfort redness eye minor eye irritations prevention itching allergic conjunctivitis expectorant cough syrups ammonium ion nh4  body plays important role maintenance acid base balance kidney uses ammonium nh4  place sodium na  combine fixed anions maintaining acid base balance especially homeostatic compensatory mechanism metabolic acidosis therapeutic effects depend upon ability kidney utilize ammonia excretion excess fixed anions conversion ammonia urea liver thereby liberating hydrogen h  chloride cl  ions into extracellular fluid  injection usp after dilution isotonic sodium chloride injection  hypochloremic states metabolic alkalosis dry scaly skin xerosis ichthyosis vulgaris temporary relief itching these conditions chronic lymphocytic leukemia cll indolent b cell non hodgkin lymphoma nhl progressed during within six months rituximab rituximab containing regimen ulesfia  lotion topical head lice infestation 6 months age older ulesfia lotion does ovicidal activity bacterial conjunctivitis bacterial isolates susceptible include cdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius hormone refractory metastatic prostate cancer previously treated docetaxel containing regimen paget disease cases where salmon calcitonin provoke generation high titer antibodies a32100 paget disease metabolic bone disorder characterized focal areas increased disorganized bone turnover coupled increased bone formation majority cases asymptomatic but some clinical manifestations include pain bone deformity some complications pathological fractures deafness a32105 increased activity bone rise serum level alkaline phosphatase increased urinary excretion hydroxyproline product bone breakdown a32099 8 patch neuropathic pain post herpetic neuralgia there multiple topical formulations available creams solutions temporary analgesia muscle join pain well neuropathic pain chronic hyperammonaemia n acetylglutamate synthase nags deficiency enzyme important component urea cycle prevent build up neurotoxic ammonium blood chenodiol radiolucent stones well opacifying gallbladders whom selective surgery would undertaken except presence increased surgical risk systemic disease age chenodiol will dissolve calcified radiopaque radiolucent bile pigment stones elemental copper deficiency   copper copper containing compounds broadly medical practice metallic copper already many dental fillings copper intrauterine devices iud reversible contraception ointments containing copper release copper ions absorbed skin cramps disturbances renal function peripheral venous hypostatic circulatory disturbances rheumatic disease swelling trauma there cosmetic facial creams containing copper their main active ingredient   prophylaxis deep vein thrombosis pulmonary embolisms undergoing general surgery e g  abdominal gynecologic urologic  medical conditions e g cancer bed rest heart failure severe lung disease  severely restricted mobility poses risk thromboembolic complications   concomitantly aspirin therapy e g  nitrates  adrenergic blockers clopidogrel platelet glycoprotein gp iib iiia receptor inhibitors reduce risk cardiac ischemic events undergo unstable angina non st segment elevation non q wave myocardial infarction i e  non st segment elevation coronary syndromes  prevention clotting during hemodialysis hemofiltration connection renal failure chronic renal insufficiency inflammation pain ocular surgery arsenic gold mercury poisoning lead poisoning concomitantly edetate calcium disodium db00974 known suspected internal contamination radioactive cesium radioactive non radioactive thallium increase their rates elimination gallium citrate ga 67 injection useful demonstrate presence extent hodgkin disease lymphoma bronchogenic carcinoma positive gallium ga 67 uptake absence prior symptoms warrants follow up indication potential disease state gallium citrate ga 67 injection useful aid detecting some inflammatory lesions inhibition premature lh surges women undergoing controlled ovarian hyperstimulation relief inflammatory pruritic manifestations corticosteroid responsive dermatoses world health organization classifies drug functional gastrointestinal disorders   like anti muscarinic agents  likely peptic ulcers diarrhea product supprelin la fda  children central precocious puberty cpp  product vantas fda  palliative advanced prostate cancer  prevention spontaneous preterm births singleton pregnancies women previously had spontaneous preterm birth   somatostatin analog approved neuroendocrine tumours acromegaly reduce serum phosphate end stage renal disease esrd  antitussive antitussive medication often recommended cough respiratory tract disorders a32160 enantiomer dextropropoxyphene presents analgesic effect a32161 ocular disorders referred terms vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis adjunctive topical antimicrobial agent control bacterial infection under moist dressings over meshed autografts excised burn wounds organ specific paramagnetic contrast agent developed imaging hepatobiliary system detecting lesions liver pancreas prophylactic suppressive frequently recurring urinary tract infections long term therapy considered necessary  drug infection should only after appropriate eradication infection antimicrobial agents opioids induced constipation palliative inadequately responding laxative therapy pain inflammation cataract surgery tapeworm intestinal fluke infections taenia saginata beef tapeworm  taenia solium pork tapeworm  diphyllobothrium latum fish tapeworm  fasciolopsis buski large intestinal fluke  molluscicide control schistosomiasis nonoxynol 9 surfactant spermicide contraception spermicidal creams jellies foams gel lubricants conjuction methods contraception condoms cervical caps diaphragms granulocyte colony stimulating factor g csf filgrastim mobilize hematopoietic stem cells peripheral blood collection subsequent autologous transplantation non hodgkin lymphoma nhl multiple myeloma mm testicular cancer well hypercalcemia hypercalciuria variety advanced forms cancer sclerosing agent uncomplicated spider veins uncomplicated reticular veins lower extremity topical application prevention infection wounds relapsed refractory peripheral t cell lymphoma dandruff seborrheic dermatitis a27133  once pinworm infestations t39 hiv infection conjunction antiretrovirals adjunctive therapy chronic urea cycle disorders deficiencies carbamylphosphate cps  ornithine transcarbamylase otc  argininosuccinic acid synthetase all neonatal onset efficiency presenting within first 28 days life late onset presenting after first month life history hyperammonemic encephalopathy  solution 0 tinea cruris tinea corporis trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum microsporum canis tinea versicolor effectiveness proven tinea pedis athlete foot  prevention postoperative venous thromboembolism undergoing orthopedic surgery undergoing general surgery high risk developing postoperative venous thromboembolism deep vein thrombosis pulmonary embolism preventing clot formation indwelling intravenous lines hemodialysis prevention kidney stone formation severe homozygous cystinuria consisting urinary cystine concentration greater than 500 mg day failed non pharmacological measures increased fluid intake decreased sodium protein intake urine alkalinization trientine copper chelator wilson disease alternative d penicillamine tends experiencing serious adverse effects from penicillamine therapy intolerance penicillamine  palliative advanced prostate cancer lowering intraocular pressure open angle glaucoma ocular hypertension intolerant intraocular pressure lowering medications insufficiently responsive failed achieve target iop determined after multiple measurements over time another intraocular pressure lowering medication essential component drug cocktail currently fight infections mycobacterium tuberculosis serious susceptible bacterial infections where less dangerous drugs ineffective contraindicated  bronchial asthma keloid hypertrophic scar allergic disorders asthma allergic rhinitis atopic dermatitis investigated leukemia unspecified  lymphoma unspecified  myelodysplastic syndrome solid tumors short term perioperative pain control investigated acquired immune deficiency syndrome aids aids related infections hiv infection variety common household products soaps mouthwashes dish detergents toothpastes deodorants hand sanitizers  health care settings surgical scrubs personnel hand washes investigated anemia kidney disease alone primary agent asymptomatic cyst passers intestinal amebiasis entamoeba histolytica  concurrently sequentially agents nitroimidazoles eg metronidazole invasive extraintestinal forms amebiasis infection respiratory gi uti meningitis e coli p mirabilis enterococci shigella typhosa salmonella nonpenicillinase producing n gononhoeae h influenzae staphylococci streptococci streptocfor cough bacterial infection relieve nasal congestion eye drops usually naphazoline relieve symptoms allergic conjunctivitis allergic conjunctivitis allergic rhinitis bronchial asthma atopic allergic conditions symptomatic allergic reactions urticaria allergies upper respiratory tract hey fever perennial rhinitis food drug allergies pruritus various origins except pruritus cholestasis insect bites dimethindene pruritus eruptive skin diseases chicken pox dimethindene adjuvant eczema pruriginous dermatoses allergic origin topical itching allergic reactions inflammation lining nose paranasal sinuses allergic inflammation nasopharyngeal refractory deficient red cell production anemias breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure turner syndrome prophylaxis hereditary angioedema potential acid reflux disorders gerd  peptic ulcer disease heartburn acid indigestion disorders upper gastro intestinal region excess hydrochloric acid gastric juice i e duodenal ulcers benign gastric ulcers prophylaxis recurrent gastric duodenal ulcersfor hypertension edema ventricular tachycardias atrial fibrillation manage hypertension tachycardia glaucoma gastrointestinal disorders motility disturbances like gastroesophageal reflux disease gerd  non ulcer dyspepsia delayed gastric emptying anxiety alcohol withdrawal prophylaxis thromboembolic disorders general surgery orthopedic surgery deep vein thrombosis prevention clotting during hemodialysis unstable angina non q wave myocardial infarction prophylaxis thromboembolic disorders  registered spain countries europe south america south korea prevention stroke myocardial infarction t93 schizophrenia  reduce risk cardiovascular death myocardial infarction stroke coronary syndrome history myocardial infarction   reduce risk first myocardial infarction stroke high risk coronary artery disease  knee pain joint inflammation osteoarthritis  usually responded treatments acetaminophen exercise physical therapy  plastic surgery reduce wrinkles face filler parts body ophthalmology assist extraction cataracts implantation intraocular lenses corneal transplants glaucoma filtration retinal attachment dry eyes finally  coat bladder lining treating interstitial cystitis reducing elevated intraocular pressure open angle glaucoma ocular hypertension monotherapy product kalydeco  cf age older mutation cftr gene responsive potentiation  received expanded approval 2017 following 33 cftr mutations e56k p67l r74w d110e d110h r117c r117h g178r e193k w r347h r352q a455e s549n s549r g551d g551s d579g s945l s977f f1052v k1060t a1067t g1069r r1070q r1070w f1074l d1152h g1244e s1251n s1255p d1270n g1349d   drug lumacaftor product orkambi  cf age 6 older shown homozygous f508del mutation cftr gene  tezacaftor product symdeko manage cf 12 older least one mutation cftr gene aged 12 older shown homozygous f508del mutation   tezacaftor elexacaftor product trikafta cystic fibrosis 12 age older least one f508del mutation cftr gene  hypertension alone adjunct  topical head lice children four old over adults spect single photon emission computerized tomography agent distinguish between parkinson syndrome tremors essential tremor  thalassemia syndromes first line chelation agents adequate transfusional iron overload homozygous familial hypercholesterolemia hofh reduce low density lipoprotein cholesterol ldl c  total cholesterol tc  apolipoprotein b apo b  non high density lipoprotein cholesterol non hdl c  treating locally advanced metastatic basal cell carcinoma whose carcinoma recurred after surgery candidates surgery radiation there no approved indication  but potential therapeutic certain viruses ischemic stroke july 2013 there no approved therapeutic indication  several potential indications adjunct chemotherapy radiotherapy solid tumors antiviral herpes simplex antiepileptic temporal lobe epilepsy likely choleretic cholagogue being investigated role inflammation cancer therapy cholesterol gallstones  being investigated several conditions primary biliary cirrhosis pbc  insulin resistance amyloidosis cystic fibrosis cholestasis amyotrophic lateral sclerosis allergic conjunctivitis ace inhibitor primarily hypertension congestive heart failure diabetic nephropathy improvement prognosis coronary artery diseases myocardial infarction  experimental drug no approved indication being studied experimentally several indications cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injuries epilepsy glaucoma neuropathic pain  psychiatric conditions depression anxiety schizophrenia cognition  investigational drug agamatine being studied non blinded prospective case study united states looking diagnosed small fiber peripheral neuropathy experimental drug no approved indication approved any indication united states canada but approved italy cerebrovascular disorders mental function disorders peripheral nerve disorders diabetic neuropathy nutritional supplementation portugal mental function disorders argentina cerebral vasculopathy nutritional supplementation peripheral neuropathy chile dementia philippines cerebrovascular disorders mental function disorders australia nutritional supplementation india nutritional supplementation increase sperm count  several potential therapeutic indications still being investigated norway  phase iv trial prophylactic migraines italy phase ii trial type diabetes mellitus phase iii trial alleviating fatigue chronic hepatitis c minimal hepatic encephalopathy united states phase ii trial neurodegenerative disorder progressive supranuclear palsy phase ii iii trial reducing peripheral neuropathy cancer adjunct chemotherapy phase i ii trial treating septic shock phase ii trial bipolar depression phase ii trial reduce oxidative stress sickle cell disease phase i ii trial chronic fatigue syndrome study preventing nerve damage hiv china phase iii trial reducing peripheral neuropathy cancer adjunct chemotherapy united kingdom being investigated preventing nerve damage hiv israel being studied male infertility   present august 2013  there no approved indication  potential therapeutic adjunct ischemic stroke   ketoglutarate approved any indication world but investigational drug united states potential indications  ketoglutarate metabolic disorder propionic acidemia trauma muscle loss  being investigated follicular lymphoma brain injury intrauterine growth restricted babies obese adolescents solar lentigines france product small superficial wounds there no approved indication  primary hyperlipidemia mixed dyslipidemia reduce elevated total cholesterol tc  low density lipoprotein cholesterol ldl c  apolipoprotein b apo b  triglycerides tg  increase high density lipoprotein cholesterol hdl c  pediatric aged 8 older heterozygous familial hypercholesterolemia hefh reduce elevated tc ldl c apo b f4667  prescribing statin medications considered standard practice following any cardiovascular events people moderate high risk development cvd statin conditions include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndromes stable angina documented coronary artery disease stroke trans ischemic attack tia  documented carotid disease peripheral artery disease claudication  abdominal aortic aneurysm chronic kidney disease severely elevated ldl c levels a181087 a181406 diagnostic aid evaluation gallbladder disorders  conjunction secretin pancreatic insufficiency   agents hiv infections antiretroviral naive hiv rna 100 000 copies ml cd4 cell count gt 200 cells mm3  fda therapy approval dolutegravir adults hiv infections whose virus currently suppressed  lt 50 copies ml stable regimen least six months without history failure no known substitutions resistance any two components therapy  locally advanced metastatic non small cell lung cancer nsclc anaplastic lymphoma kinase alk positive detected fda approved test product ella available canada us  emergency contraception after unprotected intercourse possible contraceptive failure administered within 120 hours 5 days after unprotected intercourse known suspected contraceptive failure product fibristal available canada  signs symptoms uterine fibroids women aged 10 above relapsing forms multiple sclerosis include clinically isolated syndrome relapsing remitting disease well active secondary progressive disease   drug being studied administration infected covid 19 high risk respiratory distress syndrome ards  april 3 2020 currently approved indication clinical trials underway  acetate synthetic analogue human hypothalamic growth hormone releasing factor hgrf induce maintain reduction excess abdominal fat hiv infected lipodystrophy seattle genetics announced fda approval adcetris   chemotherapy adults previously untreated stage iii iv classical hodgkin lymphoma march 2018     hodgkin lymphoma after failure autologous stem cell transplant asct after failure least two prior multi agent chemotherapy regimens asct candidates fda    systemic anaplastic large cell lymphoma after failure least one prior multi agent chemotherapy regimen fda metastatic breast cancer previously received least two chemotherapeutic regimens metastatic cancer restless legs syndrome rls postherpetic neuralgia phn  db00811  db00008  db00022 chronic hcv genotype infection adults fda  clostridioides formerly clostridium difficile diarrhea pediatric 6 months age older   should only proven strongly suspected c difficile infection reduce risk development drug resistant bacteria maximize therapeutic effectiveness antimicrobial agents  progressive metastatic medullary thyroid cancer  advanced renal cell carcinoma hepatocellular carcinoma previously treated sorafenib  type gaucher disease intermediate high risk myelofibrosis primary myelofibrosis post polycythemia vera post pv myelofibrosis post essential thrombocythemia post et myelofibrosis  lexicomp myeolofibrosis proliferation abnormal bone marrow stem cells cause fibrosis excessive formation connective tissue prior withdrawal  initially childhood leukemia specifically induce remissions later  off united states psoriasis yielding dramatic lesion clearing  later supplanted methotrexate treating cancer because better therapeutic index  well methotrexate explored abortifacient however their association severe congenital malformations teratogenic effects become known fetal syndrome adjunct auto antibody positive active systemic lupus erythematosus sle  intravenous injectable form only fda approved pediatric sle relapsing forms multiple sclerosis ms  approved since 2011 metastatic melanoma mutation braf valine located exon 15 codon 600 mutation denominated v600e a31270 v600e mutation substitution glutamic acid valine accounts 54 cases cutaneous melanoma a31271  approval extended 2017 erdheim chester disease whose cancer cells present braf v600 mutation  erdheim chester disease extremely rare histiocyte cell disorder affects large bones large vessels central nervous system well skin lungs reported association erdheim chester disease v600e mutation a31272 type ii diabetes addition diet exercise  should type i diabetes diabetic ketoacidosis  extended release product containing empagliflozin  metformin approved fda january 2020 improvement glycemic control adults type diabetes mellitus adjunctively diet exercise  over 12 old partial onset seizures may occur generalized seizures gadoxetate contrast medium magnetic resonance imaging mri detect characterize lesions liver opthalmic agent neovascular wet age related mascular degeneration amd macular edema following central retinal vein occulsion crvo  systemic injection known ziv  5 fluorouracil leucovorin irinotecan folfiri  metastatic colorectal cancer resistant progressed following oxaliplatin asparaginase erwinia chrysanthemi lymphoblastic leukemia all developed hypersensitivity e coli derivied asparaginase   component multi agent chemotherpeutic regimen  aforementioned disease considered second third line european american protocols a7464  adjunct therapy reduce triglyceride tg levels adults severe  gt 500 mg dl hypertriglyceridemia  proteolytic enzyme symptomatic vitreomacular adhesion  multiple myeloma received least two prior therapies bortezomib immunomodulatory agent demonstrated disease progression within 60 days completion last therapy approval based response rate irritable bowel syndrome ibs constipation chronic idiopathic constipation investigated clinical trials potential spasticity multiple sclerosis autism spectrum disorder social withdrawal fragile x syndrome investigated spasticity multiple sclerosis back spasms gerd  beta 3 adrenergic agonist overactive bladder oab symptoms urge urinary incontinence urgency urinary frequency anemia chronic kidney disease ckd dialysis moderate severe rheumatoid arthritis resistant intolerant methotrexate therapy adjunct methotrexate therapy non biologic disease modifying antirheumatic drugs dmards  methotrexate alone sufficient   investigated preventative therapy kidney transplant rejections psoriasis ulcerative colitis ankylosing spondylitis  initiated history chronic recurrent infections presence active infection even if localized reports serious sometimes fatal infections commonly pneumonia herpes zoster urinary tract infections  discouraged those likely exposed tb increased likelihood exposure encountered traveling certain areas addition  severe hepatic impairment low hemoglobin less than 9g dl  cautioned advised using risk gastrointestinal perforation elderly more susceptible infection   metastatic colorectal cancer crc previously treated fluoropyrimidine  oxaliplatin irinotecan based chemotherapy anti vegf therapy if kras wild type anti egfr therapy  locally advanced unresectable metastatic gastrointestinal stromal tumour gist previously treated imatinib mesylate sunitinib malate  hepatocellular carcinoma hcc previously treated sorafenib  bromide inhalation powder long term maintenance bronchospasm chronic obstructive pulmonary disease copd  chronic bronchitis emphysema methotrexate kidney dysfunction experiencing abnormally high plasma concentration methotrexate  gt micromole per liter  metastatic castration resistant prostate cancer previously received docetaxel short bowel syndrome sbs  malabsorption removal intestine adults dependent parenteral support  chronic phase accelerated phase blast phase chronic myeloid leukemia cml resistant intolerant prior tyrosine kinase inhibitor therapy philadelphia chromosome positive lymphoblastic leukemia ph all resistant intolerant prior tyrosine kinase inhibitor therapy pediatric inhalational anthrax bacillus anthracis appropriate antibacterial drugs prophylaxis inhalational anthrax alternative therapies available appropriate  part therapy adults  18 pulmonary multi drug resistant tuberculosis mdr tb  approved several different conditions listed below   symptomatic chron disease maintenance clinical response moderate severe disease inadequate response conventional therapy  moderate severely active rheumatoid arthritis  active psoriatic arthritis  active ankylosing spondylitis  moderate severe plaque psoriasis candidates systemic therapy phototherapy fda  active non radiographic axial spondyloarthritis objective signs inflammation   canada  additionally approved methotrexate symptomatic major clinical response reduction joint damage moderately severely active rheumatoid arthritis psoriatic arthritis   inflammation biological response against potential threat response normal but certain conditions immune system attack body normal cells tissues causes abnormal inflammation  tnf alpha identified key regulator inflammatory response signaling cascades inflammatory mediator produce wide range reactions cell death survival differentiation proliferation migration a176660 estrogen receptor positive breast cancer post menopausal women inhaler asthma prophylaxis fda f4364  nasal spray treating season perennial allergic rhinitis fda a177130 drug conjunction diet exercise increase glycemic control adults diagnosed type diabetes mellitus fda  another indication prevention major cardiovascular events myocardial infarction stroke death cardiovascular cause type diabetes well hospitalization heart failure type diabetes    addition above  lower risk end stage kidney disease major increases serum creatinine cardiovascular death type diabetes mellitus diabetic nephropathy albuminuria   important note drug type diabetes mellitus diabetic ketoacidosis fda  multiple sclerosis relapsing forms nitrogen binding agent chronic pediatric age urea cycle disorders ucds cannot managed dietary protein restriction amino acid supplementation alone  multiple myeloma received least two prior therapies lenalidomide bortezomib demonstrated disease progression within 60 days completion last therapy unresectable metastatic melanoma braf v600e v600k mutations detected fda approved test fda  2018 approved db08912 anaplastic thyroid cancer abnormal braf v600e gene  tafinlar kinase inhibitor initially single agent unresectable metastatic melanoma braf v600e mutation detected fda approved test fda  tafinlar db08911 unresectable metastatic melanoma braf v600e v600k mutations detected fda approved test based demonstration durable response rate improvement disease related symptoms overall survival demonstrated tafinlar trametinib fda  2018 tafinlar  mekinist  db08911  approved anaplastic thyroid cancer abnormal braf v600e gene  metastatic bone cancer symptomatic no visceral metastases prostate cancer castration resistant investigated type ii diabetes reduce their risks cardiovascular mortality morbidity kinase inhibitor monotherapy  first line fda epidermal growth factor receptor egfr tki tyrosine kinase inhibitor naive locally advanced metastatic non small cell lung cancer nsclc whose tumours non resistant egfr mutations detected fda approved test fda  b locally advanced metastatic nsclc squamous histology progressing after platinum based chemotherapy fda   recently january 2018 us fda approved supplemental new drug application boehringer ingelheim gilotrif  first line metastatic non small cell lung cancer nsclc whose tumors non resistant epidermal growth factor receptor egfr mutations detected fda approved test   new includes data three additional egfr mutations q g719x s768i   iron replacement product iron deficiency anemia intolerance oral iron had unsatisfactory response oral iron those non dialysis dependent chronic kidney disease  serotonin norepinephrine reuptake inhibitor major depressive disorder mdd  schizophrenia cases bipolar mania appetite suppressant relieve excessive sleepiness inattention elderly antiprotozoal agent effective against amoebiasis yaws antiretroviral agents hiv infection comply characteristics being adults children aged 12 older present least weight 40 kg a7520 fda therapy approval rilpivirine adults hiv infections whose virus currently suppressed  lt 50 copies ml stable regimen least six months without history failure no known substitutions resistance any two components therapy  adults persistent recurrent chronic thromboembolic pulmonary hypertension cteph  group 4 after surgical inoperable cteph improve exercise capacity functional class  adults pulmonary arterial hypertension pah  group  improve exercise capacity functional class delay clinical worsening efficacy shown monotherapy endothelin receptor antagonists prostanoids studies establishing effectiveness included predominately functional class ii iii etiologies idiopathic heritable pah 61  pah connective tissue diseases 25  pulmonary arterial hypertension adults aged 18 older topical fungal infections trichophyton rubrum epidermophyton floccosum specifically tinea pedis cruris corporis  therapy antiviral medications chronic hepatitis c virus hcv infected hcv genoptypes 6 hcv hiv co infected depending level cirrhosis decompensation therapy include either ribavirin alone ribavirin peg interferon alfa  db09027 product harvoni  following indications genotypes 4 5 6 infection without cirrhosis compensated cirrhosis db00811 genotype infection decompensated cirrhosis db00811 genotype 4 infection liver transplant recipients without cirrhosis compensated cirrhosis  db11613 product epclusa  chronic hepatitis c virus hcv genotypes 3 4 5 6 infection without cirrhosis compensated cirrhosis db00811 if decompensated cirrhosis  resistance reduced susceptibility ns5b substitution mutation s282t a19634  chlorambucil untreated chronic lymphocytic leukemia dietary supplement source niacin investigated potential beneficial effects serum lipids europe inositol hexanicotinate patented drug known hexopal therapeutically symptomatic relief severe intermittent claudication raynaud phenomenon softening dilatation cervix uteri prior transcervical intrauterine operative procedures first trimester pregnancy facilitating therapeutic termination pregnancy second trimester gestation created epilepsy intent creating antiepileptic less sedative properties than phenobarbital  no approved indications  defibrongenating agent observed reduce fibrinogen levels thus reduce clot risk intravenously epilepsy epilepsy related behavioural disorders  generalised tonic clonic seizures effective absence seizures  more recently focus shifted behavioural disorders mentally handicapped epileptic found decrease anxiety antisocial demanding behaviours impulsivity mood stabilizing effects were noted   additionally effects monoamines  potential place treating conditions tardive dyskinesia hyperkinetic syndromes  capillary parenchymal hemorrhage trauma tonsillectomy during surgery  intestinal bleeding thrombocytopenic purpura open angle glaucoma pmid 12480285  anxiety  4 weeks severe debilitating insomnia  nausea vomiting ponv post operative nausea vomiting  gastroesophageal reflux disease gerd gord  well endoscopy preparation radiographic studies gi tract  cleansing colon preparation colonoscopy adults  hypertension children above 6 adults  drug conjunction antihypertensives calcium channel blockers thiazides products form provide additional blood pressure control  antiviral medication sofosbuvir commercially available product harvoni  hcv genotypes 4 5 6 without ribavirin depending level liver damage cirrhosis fda  proven successful hcv co infected hiv a19627 smoking cessation moderate severe plaque psoriasis candidates systemic therapy phototherapy  reduction thrombotic cardiovascular events history myocardial infarction mi peripheral arterial disease pad  usually co administered acetylsalicylic acid asa clopidogrel should therefore administered addition these medications studied alone mucosal leishmania braziliensis  cutaneous l braziliensis l guyanensis l panamensis  visceral leishmaniasis l donovani  comparing leishmania drug susceptibility found l donovani most susceptible while l major least susceptible  off includes free living amebae fla infections unlabeled cdc 2013  moderately severely active uc cd had inadequate response lost response were intolerant tumor necrosis factor tnf blocker immunomodulator had inadequate response were intolerant demonstrated dependence corticosteroids  insomnia characterized difficulties sleep onset sleep maintenance unresectable metastatic melanoma adjuvant melanoma metastatic non small cell lung cancer small cell lung cancer advanced renal cell carcinoma classical hodgkin lymphoma squamous cell carcinoma head neck urothelial carcinoma microsatellite instability high mismatch repair deficient metastatic colorectal cancer hepatocellular carcinoma  multicentric castleman disease mcd human immunodeficiency virus hiv negative human herpesvirus 8 hhv 8 negative  did bind virally produced il 6 nonclinical study therefore studied mcd hiv hhv 8 positive  unresectable metastatic melanoma fda   single therapy  first line metastatic non small cell lung cancer whose tumors high pd expression  tumor proportion score tps  50  determined fda approved test no egfr alk genomic tumor aberrations f137  single therapy  first line metastatic non small cell lung cancer whose tumors express pd  tps  determined fda approved test disease progression after platinum containing chemotherapy egfr alk genomic tumor aberrations should disease progression fda approved therapy these aberrations prior f137  following indications present status accelerated approval based tumor response rate durability response thus approval indications contingent upon verification description clinical benefit confirmatory trials   recurrent metastatic cervical cancer disease progression after chemotherapy whose tumors express pd  cps gt determined fda approved test   pemetrexed carboplatin first line metastatic nonsquamous non small cell lung cancer f137  recurrent metastatic head neck squamous cell carcinoma disease progression after platinum containing chemotherapy f137  adults pediatric refractory classical hodgkin lymphoma relapsed after 3 more prior lines therapy f137  pediatric refractory primary mediastinal large b cell lymphoma relapsed after more prior lines therapy f137  locally advanced metastatic urothelial carcinoma eligible cisplatin containing chemotherapy f137  locally advanced metastatic urothelial carcinoma disease progression during following platinum containing chemotherapy f137  pediatric unresectable metastatic microsatellite instability high mismatch repair deficient solid tumors progressed following previous colorectal cancer progressed following fluoropyrimidine oxaliplatin irinotecan f137  recurrent locally advanced metastatic gastric gastroesophageal junction adenocarcinoma whose tumors express pd  cps gt determined fda approved test disease progression after two more prior lines therapy fluoropyrimidine platinum containing chemotherapy if appropriate her2 neu targeted therapy f137 adjunct diet exercise improve glycemic control type diabetes reduce risk cardiovascular death both type diabetes mellitus established cardiovascular disease   available product either metformin  linagliptin  adjunct diet exercise type diabetes mellitus adults  extended release product containing  metformin linagliptin approved fda january 2020 improvement glycemic control adults type diabetes mellitus adjunctively diet exercise   approved type diabetes long term type gaucher disease cyp2d6 extensive metabolizers ems  intermediate metabolizers ims  poor metabolizers pms detected fda cleared test fungal infection nail known onychomycosis onychomycosis fungal infection toenails trichophyton rubrum trichophyton mentagrophytes  tedizolid bacterial infections skin skin structure absssi  prevent drug resistance tedizolid should only infections susceptible bacteria  adjunct diet exercise improve glycemic control adults type diabetes mellitus adjunct diet exercise improve glycemic control adults type diabetes mellitus adjunct diet replacement therapy complications leptin deficiency congenital acquired generalized lipodystrophy otitis externa aoe without otowick susceptible strains pseudomonas aeruginosa staphylococcus aureus age year older  antiemitic drug approved fda october 2014 palonosetron prevention delayed vomiting nausea cancer chemotherapy highly emetogenic chemotherapy opioid induced constipation oic chronic non cancer pain drug administered tazobactam complicated intra abdominal infections metronidazole complicated urinary tract infections a179425  include pyelonephritis  tazobactam bacterial ventilator pneumonia bacterial hospital acquired pneumonia fda vimizim hydrolytic lysosomal glycosaminoglycan gag specific enzyme mucopolysaccharidosis type iva mps iva morquio syndrome  philadelphia chromosome negative relapsed refractory b cell precursor lymphoblastic leukemia all  acquired accelerated approval mantle cell lymphoma received least one prior therapy fda mantle cell lymphoma mcl b cell non hodgkin lymphoma develops outer edge lymph node mcl usually diagnosed late stages easily spread into bone marrow spleen liver gastrointestinal tract   chronic lymphocytic leukemia cll least one prior therapy fda cll type cancer overproduction lymphocytes bone marrow some symptoms include swollen lymph nodes tiredness   chronic lymphocytic leukemia cll 17p deletion fda cll 17p type leukemia deletion 17p disrupts tumor suppressor p53 deleting one allele tp53 gene remaining allele mainly inactivated thus type leukemia unresponsive p53 dependent treatments a32305  waldenstrom macroglobulinemia wm  fda wm called lymphoplasmacytic lymphoma type non hodgkin lymphoma cancer cells make large amounts macroglobulin macroglobulin monoclonal protein corresponds type igm antibodies unrestricted formation protein causes typical symptoms excessive bleeding effects vision nervous system  chronic lymphocytic leukemia cll  relapsed follicular b cell non hodgkin lymphoma fl  relapsed small lymphocytic lymphoma sll  relapsed cll currently second line agent rituximab whom rituximab alone would considered appropriate therapy co morbidities while fl sll intended received least two prior systemic therapies hyperlipidemias abnormally elevated levels any all lipids lipoproteins blood anthrax immune globulin inhalational anthrax pediatric appropriate antibacterial drugs delaying imminent pre term birth pregnant women   regular uterine contractions least 30 duration rate least 4 per 30 min  cervical dilation 3cm 0 3cm nulliparas effacement least 50  gestational age 24 33 weeks  normal fetal heart rateavycaz ceftazidime  metronidazole complicated intra abdominal infections following susceptible microorganisms escherichia coli klebsiella pneumoniae proteus mirabilis providencia stuartii enterobacter cloacae klebsiella oxytoca pseudomonas aeruginosa 18 older avycaz complicated urinary tract infections pyelonephritis following susceptible microorganisms escherichia coli klebsiella pneumoniae citrobacter koseri enterobacter aerogenes enterobacter cloacae citrobacter freundii proteus spp  pseudomonas aeruginosa 18 older delta 9 tetrahydrocannabinol product sativex  given standard marketing authorization ie notice compliance noc  health canada following indications  adjunctive symptomatic relief spasticity multiple sclerosis ms responded adequately therapy demonstrate meaningful improvement during initial trial therapy   need confirmatory studies verify clinical benefit coupled promising nature clinical evidence sativex given notice compliance conditions noc c health canada following indications  adjunctive symptomatic relief neuropathic pain multiple sclerosis  adjunctive analgesic advanced cancer experience moderate severe pain during highest tolerated dose strong opioid therapy persistent background pain   kinase inhibitor anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc progressed intolerant crizotinib indication approved under accelerated approval based tumor response rate duration response improvement survival disease related symptoms established continued approval indication contingent upon verification description clinical benefit confirmatory trials cyp3a inhibitor increase systemic exposure atazanavir darunavir once daily dosing regimen antiretroviral agents hiv infection interchangeable ritonavir increase systemic exposure darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir lack exposure data recommended darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir complex unknown mechanisms drug interactions preclude extrapolation ritonavir drug interactions certain interactions  ritonavir administered either atazanavir darunavir result different drug interactions concomitant medications controlled ovarian stimulation  cases women undergoing fertility stimulate development more than one mature egg simultaneously ovaries gonadotrophin releasing hormone gnrh antagonist type medicine fertility treatments  corticorelin differentiating pituitary ectopic production acth acth dependent cushing syndrome major depressive disorder mdd  angina pectoris relief post menopausal symptoms prevention osteoporosis   non 24 hour sleep wake disorder n24hswd cataplexy excessive daytime sleepiness eds narcolepsy letrozole initial endocrine based therapy human epidermal growth factor receptor type her2 negative hormone receptor hr positive tumors advanced metastatic breast cancer well approved fulvestrant disease progression prior endocrine therapy a176783  official labeling should accompanied either aromatase inhibition no restricted letrozole initial endocrine based therapy postmenopausal women man fda  breast cancer starts group cancer cells grow into destroy nearby breast tissue growth spread into parts body called metastasis according location cancer cells categorized ductal carcinoma lobular carcinoma however types breast cancer include inflammatory breast cancer paget disease breast triple negative breast cancer non hodgkin lymphoma soft tissue sarcoma  males breast cancer usually treated cases postmenopausal women almost all cases ductal carcinoma  poly adp ribose polymerase parp inhibitor  i ovarian cancer medication intended maintenance recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum based chemotherapy b deleterious suspected deleterious germline brca mutated gbrcam advanced ovarian cancer treated three more prior lines chemotherapy fda  select therapy based fda approved companion diagnostic  fda   ii breast cancer medication intended deleterious suspected deleterious gbrcam human epidermal growth factor receptor her2 negative metastatic breast cancer previously treated chemotherapy neoadjuvant adjuvant metastatic setting hormone receptor hr positive breast cancer should treated prior endocrine therapy considered inappropriate endocrine fda  select therapy based fda approved companion diagnostic  fda  reducing risk stroke systemic embolism se nonvalvular atrial fibrillation nvaf  however should creatinine clearance crcl  gt 95 ml min because increased risk ischemic stroke compared warfarin highest dose studied 60 mg  deep vein thrombosis dvt pulmonary embolism pe following 5 10 days initial therapy parenteral anticoagulant long term once daily maintenance airflow obstruction chronic obstructive pulmonary disease copd  granulocyte macrophage colony stimulating factor gm csf  interleukin il  13 cis retinoic acid ra  pediatric high risk neuroblastoma achieve least partial response prior first line multiagent multimodality therapy despite high clinical response seen after first line complete eradication neuroblastoma rarely achieved majority advanced disease suffer relapse current strategies include immunotherapy drugs target surviving neuroblastoma cells prevent relapse following conditions   locally recurrent metastatic progressive radioactive iodine refractory differentiated thyroid cancer   advanced renal cell carcinoma rcc everolimus following one prior antiangiogenic therapy   first line unresectable hepatocellular carcinoma hcc us  idiopathic pulmonary fibrosis ipf  slow declining pulmonary function systemic sclerosis interstitial lung disease  eu  docetaxel metastatic locally advanced locally recurrent non small cell lung cancer adenocarcinoma histology already tried first line therapy  chronic obstructive pulmonary disease copd  chronic bronchitis emphysema exacerbations copd asthma european medicines agency ema visual impairment adolescent leber hereditary optic neuropathy lhon  currently approved either food drug administration usa health canada   approved several products fluticasone furoate under tradename breo ellipta umeclidinium bromide anoro ellipta approved fda 2013 breo ellipta long term once daily maintenance airflow obstruction copd chronic bronchitis emphysema once daily maintenance asthma aged 18 older reversible obstructive airways disease fda reduce risk hospitalization worsening heart failure stable symptomatic chronic heart failure left ventricular ejection fraction 35  sinus rhythm resting heart rate 70 beats per minute either maximally tolerated doses beta blockers contraindication beta blocker stable symptomatic heart failure result dilated cardiomyopathy pediatric 6 months age more fda available predominantly liquid mouthwash oromucosal spray topical cream  most frequently employed locally acting analgesic anti inflammatory relief painful inflammatory conditions  formulated mouthwash spray  traumatic conditions like pharyngitis following tonsillectomy naso gastric tube inflammatory conditions like pharyngitis aphthous ulcers oral ulceration radiation therapy dentistry operations procedures more general conditions like sore throat sore tongue sore gums mouth ulcers discomfort dentures    topical cream  employed relieve symptoms painful inflammatory conditions muscolo skeletal system inflammatory disorders myalgia bursitis traumatic conditions like sprains strains bruises sore muscles stiff joints even after effects fractures   ophthalmic for procedures requiring rapid short acting topical ophthalmic anesthetic  lidocaine patch local dermal analgesia superficial dermatological procedures superficial venous access  lidocaine cream intended provide topical local analgesia superficial dermatological procedures currently available any fda approved drug products there number unapproved otc products advertise toothache  is commonly zinc oxide dental procedures cementation temporary prostheses temporary restoration teeth cavities considered safe fda homepathic otc products presence several different drugs main indications  constipation  cosmetic drug astringent helping shrinkage tissues dry secretions  oral health care drug  part formulation cleansing products skin care products mosturizers face powders deodorants  antiperspirant  antifungal most common indication usage spinal anesthesia a32277 symptomatic irritable bowel syndrome ibs postoperative paralytic ileus following abdominal surgery  symptomatic irritable bowel syndrome ibs functional disorders biliary tract rhinitis nasal suspension aerosol form lozenges pharyngitis form enemas rectal solution ulcerative colitis  orally suspension powder inflammatory conditions  substance screening contact allergies class steroids a31435 primarily diet supplements increase brain metabolism glucose obtain atp  agent reduced cholesterol vasodilator  action allows having elevated rate blood flow brain helps improve memory function concentration awareness  thus his actions  improve cerebrovascular peripheral vascular disorders well hyperlipidaemias  manufacuring medicated animal feeds fda 25  benzoin tincture removal soft genital venereal warts condylomata acuminata  topical symptoms inflammatory skin disorders like eczema seborrheic eczema lichen planus psoriasis all these disorders present common characteristic occurrence symptoms itching swelling redness scaling  mild moderate acne vulgaris rosacea combined agents more severe acne hyperprolactinemia idiopathic originating from prolactin secreting pituitary microadenoma macroadenoma  recombinant human growth hormone  paediatric growth failure growth hormone deficiency ghd  b paediatric growth failure idiopathic short stature iss   c paediatric growth failure turner syndrome ts  d paediatric growth failure chronic kidney disease ckd up time renal transplantation  e adults childhood onset ghd f adults onset ghd fda symptomatic bleeding from esophageal varices options long term condition considered if necessary once initial control established thyroid extract replacement therapy decreased absent thyroid function  hiv protease inhibitor coadministered ritonavir antiretroviral drug hiv infection antiretroviral experienced adults sofosbuvir without ribavirin chronic hcv genotype 1a b 3 infection dosing regimen 60mg 60 mg 400mg sofosbuvir once day recommended both genontypes  resistance reduced susceptibility polymorphisms ns5a amino acid positions m28 q30  y93 genotypes 1a 1b 3a ns5a resistance testing recommended hcv genotype 1a infected cirrhosis prior initiaition risk resistance development higher genotype 1a  filgrastim setting autologous peripheral blood progenitor cell transplantation risk poor peripheral blood progenitor cell mobilisation  filgrastim will generate sustained increase number peripheral blood progenitor cells capable engraftment mobilization progenitor cells from bone marrow peripheral blood withouth mobilizing chemotherapy harvested progenitor cells transplant following myelosuppressive myeloablative therapies  antacid laxative depending administered dose  antacid temporary relief heartburn upset stomach sour stomach acid indigestion  laxative relief occasional constipation promoting bowel movements 30 minutes up 6 hours perinatal infantile juvenile onset hypophosphatasia hpp  intravenous solution prevent shock following severe blood loss trauma surgery issues anaemia chronic kidney disease substitute rbc transfusion if immediate correction anemia required prophylaxis bleeding all ages haemophilia congenital factor viii deficiency  fda  prophylaxis bleedings presenting hemophilia  related control bleeding episodes perioperative  hemophilia a hereditary hemorrhagic disorder generated congenital deficit coagulation factor viii disease manifested excessive spontaneous trauma driven bleeding coagulation factor viii robust initiator thrombin later required generation fibrin form platelet plug gene expressed x chromosome a31505 mesna uroprotective agent prophylactically reduce ifosfamide cyclophosphamide induced hemorrhagic cystitis a18572 primary intended substitute older colloids albumin hetastarch plasma volume expansion sequential sodium thiosulfate cyanide poisoning judged life threatening fda  respiratory distress syndrome rds premature infants respiratory distress syndrome rds premature infants official referred intratracheal suspension prophylactic infants less than 1350 grams birth weight under risk developing rds infants birth weight greater than 1350 grams pulmonary immaturity rescue infants already developed rds  central feature rds surfactant deficiency lung immaturity lung condition more frequently presented risk factors like prematurity delayed lung maturation maternal diabetes male gender surfactant dysfuntion perinatal asphyxia pulmonary infection delivery without labor t70 amoebiasis approved fda but intended indication alcoholism t74 medication marketed canada united kingdom europe under trade name temposil sole alcoholism  historically sedative hypnotic a19735  seizures anticonvulsant a19736 conjunction clobazam valproate adjunctive therapy refractory generalized tonic clonic seizures severe myoclonic epilepsy infancy smei dravet syndrome whose seizures adequately controlled clobazam valproate adjunctive therapy partial onset seizures adequately controlled conventional therapy epileptic conjunction oral cox inhibitors nsaids relief severe pain osteoarthritis knee controlled oral cox inhibitors nsaids alone duration no more than three months  adjunctive early active juvenile type rheumatoid arthritis adequately controlled anti inflammatory agents conservative measures like salicylate glucocorticoids etc    chronic advanced cases rheumatoid arthritis gold therapy demonstrated valuable   antirheumatic measures salicylate anti inflammatory drugs both steroidal non steroidal continued after initiation gold therapy   after improvement commences these measures discontinued slowly symptoms permit  relapsing forms multiple sclerosis endometriosis alone contraceptive ethinylestradiol  adjunct endometial shedding menopausal women secondary amenorrhea induce menses dysfunctional uterine bleeding adolescent women t76 renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis uric acid lithiasis without calcium stones prepubertal cryptorchidism anatomical obstruction  selected cases hypogonadotropic hypogonadism hypogonadism secondary pituitary deficiency males induction ovulation pregnancy anovulatory infertile woman whom cause anovulation secondary primary ovarian failure appropriately pretreated human menotropins adjunctive major depressive disorder mdd schizophrenia supplement intravenous solutions given total parenteral nutrition tpn supplementation total parenteral nutrition contraception intrauterine devices fda   supplement intravenous solutions given total parenteral nutrition tpn  intravenous magnetic resonance imaging mri brain intracranial  spine tissues pediatric age older detect visualize areas disruption blood brain barrier bbb abnormal vascularity conray excretory urography cerebral angiography peripheral arteriography venography arthrography direct cholangiography endoscopic retrograde cholangiopancreatography contrast enhancement computed tomographic brain images cranial computerized angiotomography intravenous digital subtraction angiography arterial digital subtraction angiography conray enhancement computed tomographic scans performed detection evaluation lesions liver pancreas kidneys abdominal aorta mediastinum abdominal cavity retroperitoneal space optiray 350 adults peripheral coronary arteriography left ventriculography optiray 350 contrast enhanced computed tomographic imaging head body intravenous excretory urography intravenous digital subtraction angiography venography optiray 350 children angiocardiography optiray 320 adults angiography throughout cardiovascular system uses include cerebral coronary peripheral visceral renal arteriography venography aortography left ventriculography optiray 320 contrast enhanced computed tomographic imaging head body intravenous excretory urography optiray 320 children angiocardiography contrast enhanced computed tomographic imaging head body intravenous excretory urography optiray 300 cerebral angiography peripheral arteriography optiray 300 contrast enhanced computed tomographic imaging head body venography intravenous excretory urography optiray 240 cerebral angiography venography optiray 240 contrast enhanced computed tomographic imaging head body intravenous excretory urography administered intra arterially  following diagnostic tests cerebral arteriography 300 mgi ml  coronary arteriography left ventriculography 350 mgi ml  visceral angiography 350 mgi ml  aortography 350 mgi ml  peripheral arteriography 350 mgi ml  administered intravenously  excretory urography contrast enhanced computed tomographic cect imaging head body 300 350 mgi ml  synthetic visual lymphatic imaging agent  upon subcutaneous administration delineates lymphatic vessels draining region injection adjunct lymphography primary secondary lymphedema extremities chyluria chylous ascites chylothorax lymph node involvement primary secondary neoplasm lymph node response therapeutic modalities technetium tc 99m mebrofenin hepatobiliary imaging agent technetium tc 99m medronate bone imaging agent delineate areas altered osteogenesis pediatric skeletal imaging diagnosis areas present altered osteogenesis administered intravenously able generate clear image bones allows physician diagnose any bone problem  important point out drug manipulated only under service nuclear specialist  approved indications bone scan visualization tumor metastasis bone osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis 7 prosthetic joint evaluation from all major indications detection metastatic disease most common because presents 95 sensitivity lesion detection done 6 months earlier than x ray studies  therapy clinical settings across diverse specialties various types anoxia hypoxia dyspnea any disease states conditions reduce efficiency gas exchange consumption respiratory illnesses trauma poisonings drug overdoses  therapy tries achieve hyperoxia  reduce extent hypoxia induced tissue damage malfunction  counteracting reversing anticoagulant effect heparin necessary f3559 f3562    reversal example required often before surgery after renal hemodialysis post open heart surgery whenever excessive bleeding results from heparin heparin overdosage among similar related circumstances f3559 f3562   product kinevac fda  following indications stimulate gallbladder contraction assessed various methods diagnostic imaging obtain duodenal aspiration sample concentrated bile analysis cholesterol bile salts phospholipids crystals  stimulate pancreatic secretion especially conjunction secretin prior obtaining duodenal aspirate analysis enzyme activity composition cytology  3 accelerate transit barium meal through small bowel thereby decreasing time extent radiation fluoroscopy x ray examination intestinal tract approved us eu adults locally advanced basal cell carcinoma bcc recurred post surgery radiation therapy  approved bcc eligible surgery radiation therapy  marketed product xuriden fda  hereditary orotic aciduria  marketed product vistogard fda  emergency pediatric following situations following fluorouracil capecitabine overdose regardless presence symptoms exhibit early onset severe life threatening toxicity affecting cardiac central nervous system early onset unusually severe adverse reactions e g  gastrointestinal toxicity neutropenia within 96 hours following end fluorouracil capecitabine administration diluting dissolving drugs intravenous intramuscular subcutaneous injection according instructions manufacturer drug administered fda  elemental iron injection replenishes body iron stores iron deficiency intended iron loss iron deficiency formulation milder gastrointestinal effect    iron deficiency appears dietary intake does meet body requirement there chronic external blood loss during blood loss body iron stores sufficient accelerated erythropoiesis restoration iron homeostasis but altered homeostasis remains weeks months then some supplement needed some causes iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 florbetaben radioactive diagnostic agent positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad causes cognitive decline florbetapir 18f positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad causes cognitive decline flutemetamol f18 positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad causes cognitive decline liquid mainly cryogenic agent various benign malignant skin lesions intravenous solution adults pediatric source electrolytes water hydration designed diluent delivery system intermittent intravenous administration compatible drug additives anticoagulant during plasmophoresis well neutralizing agent upset stomach acidic urine fda    getting enough oxygen into their blood blockages lungs from pathological conditions injuries suggested potential benefit upper airway obstruction severe asthma exacerbations copd cold  place carbon monoxide during laparoscopic surgeries lowers risk developing respiratory acidosis selected  product iovist x ray contrast agent following procedures intra arterial digital subtraction angiography ia dsa  150 mg i ml  cerebral arteriography peripheral arteriography 300 mg i ml  coronary arteriography left ventriculography visceral angiography aortography 370 mg i ml  peripheral venography 240 mg i ml  excretory urography 300 mg i ml contrast computed tomography ct imaging head body 300 mg i ml 370 mg i ml  commonly insufflation gas minimal invasive surgery laparoscopy endoscopy arthroscopy enlarge stabilize body cavities provide better visibility surgical area cryotherapy respiratory stimulant before after anesthesia  could expansion blood vessels if required increase level after rapid breathing stimulate breathing after period nonbreathing trypan blue aid ophthalmic surgery staining epiretinal membranes during ophthalmic surgical vitrectomy procedures facilitating removal tissue technetium 99m tetrofosmin diagnosis heart abnormalities exercise myocardial scintigraphy exercise myocardial scintigraphy established method diagnosis severity coronary artery disease a31592 method allows distinguishing regions reversible myocardial ischemia presence absence infarcted myocardium following rest stress conditions  technetium 99m tetrofosmin mainly assess myocardial perfusion ischemia infarction  technetium tc 99m sestamibi detecting coronary artery disease localizing myocardial ischemia reversible defects infarction non reversible defects  evaluating myocardial function developing information patient decisions technetium tc99m exametazime scintigraphy without methylene blue stabilization useful adjunct detection altered regional cerebral perfusion stroke tc99m exametazime without methylene blue stabilization leukocyte labeled scintigraphy adjunct localization intra abdominal infection inflammatory bowel disease technetium tc99m disofenin hepatobiliary imaging agent hepatolite diagnosis cholecystitis well rule out occurrence cholecystitis suspected right upper quadrant pain fever jaundice right upper quadrant tenderness mass rebound tenderness but limited these signs symptoms skeletal imaging agent demonstrate areas altered osteogenesis cardiac imaging agent adjunct diagnosis myocardial infarction fda  image gated blood pools detect gastrointetinal bleeding generalized anxiety disorder depression panic disorder insomnia symptoms depressive illness especially where anti anxiety effect required investigated potential opioid analgesic but no longer purpose a182060 more often being recreational drug a182060  db09296  db09297  db00503  viekira pak hcv genotype 1a db00811 genotype 1b without db00811 those compensated cirrhosis fda clinical depression studied depression t47  tremors parkinson extrapyramidal symptoms  male impotence  certain if ever approved marketed but current status withdrawn 2016  classified chemical structure related drug like criteria global approved drugs antipsychotic anxiolytic  antipsychotic medication state delusion hallucination paranoia disordered thought hand anxiolytic medication severe chronic debilitating anxiety anxiety state defined unpleasant state tension apprehension uneasiness t77 anxiety neuroses approved ministry food drug safety south korea 2013 being monitored postmarketing surveillance until 2019  approved either food drug administration usa  health canada european medicines agency diabetes artinolol introduced antihypertensive agent since 1986 t88 studied functions like tremor control parkinson disease currently clinical trials control blood pressure heart rate   symptomatic sequelae cerebral infarction hemorrhage t91 cerebral infarction characterized blockage artery either formation thrombus embolus a31644  hand fda classified reversal phenylephrine induced mydriasis narrow anterior angles risk developing attack angle closure glaucoma   closed angle glaucoma contact between iris trabecular meshwork contact will damage aqueous outflow meshwork thus increasing eye pressure producing symptoms glaucoma a31645 mydriasis referred dilatation pupils standard body function known trigger factor development closed angle glaucoma risk explained generation pupillary block contact between pupillary margins lens thus preventing flow from aqueous humor anterior chamber followed increased pressure gradient    approved france first drug impotence a31647 chronic gout refractory conventional therapy cough suppressant temporary relief non productive dry cough stated present required indication temporary relief dry cough   cough respiratory movement occurs after irritation signal transmitted central nervous system further stimulates medulla oblongata stimulation causes motor output sent through motoneurons respiratory muscles non productive cough type cough characterized absence sputum large inspiration will cause continuous coughing suffering from myoclonus cortical origin irrespective aetiology should anti myoclonic therapies   improvement various ischemic symptoms ulcer pain feeling coldness thromboangiitis obliterans well improvement subjective symptoms pain numbness lower legs gait ability acquired lumbar spinal canal stenosis bilateral intermittent claudication showing normal slr test result  non steroidal anti inflammatory medication nsaid pain inflammation related musculoskeletal joint disorders  addition effects pain antipyretic anti inflammatory medication  more information refer ibuprofen short term mild moderate pain dysmenorrhoea musculoskeletal pain toothache   nsaid previously inflammation rheumatoid arthritis  information  stated drug being nsaid effective treating pain attack migraines adults  pain inflammation fever horses dogs chronic arthritic conditions certain soft tissue disorders pain inflammation constipation absence bowel obstruction surgical preparation colon  prevention chronic stable angina pectoris reduction risk coronary syndromes peptic ulcer disease dyspepsia  bleeding episodes congenital fibrinogen deficiency afibrinogenemia hypofibrinogenemia schizophrenia  schizophrenia sleep disorders agitation mentally confused states      like atypical antipsychotics considered first line newly diagnosed schizophrenia usually thought option choice managing schizophrenic episodes discussion patient possible  atypical antipsychotic suffering unacceptable side effects from conventional antipsychotics relapse were inadequately controlled t108  important consider indications stated above related atypical antipsychotics currently fda canada ema approved studies shown any additional benefit compared approved atypical antipsychotics a31857  schizophrenia chronic severe mental disorder affects how person thinks feels behaves usually marked loose reality perspective delineated hallucinations delusions thought movement disorders  investigated schizophrenia schizoaffective disorder mild moderate essential hypertension chronic stable angina attacks hereditary angioedema hae c1 esterase inhibitor deficiency adults many angina pectoris hypertension a31895 hypertension potent long lasting drug cardiovascular diseases hypertension renoparenchymal hypertension angina pectoris a31950 hypertension end organ protection  reported useful elderly those diabetes albuminuria  increasingly chronic kidney disease  hypertension term describe presence high blood pressure blood pressure generated force blood pumped from heart against blood vessels thus hypertension there too much pressure blood vessels effect damage blood vessel  hypertension hypertension either alone antihypertensive agents  adrenoceptor antagonists diuretics ace inhibitors   alone hypertension adults children  hypertension pediatric acquired methemoglobinemia  clinical applications include improvement hypotension various clinical states antiseptic urinary tract infections hypoxia hyperdynamic circulation cirrhosis liver severe hepatopulmonary syndrome ifofosamide induced neurotoxicity mild moderate essential primary hypertension   effective most first line antihypertensives monotherapy a27137 hypertension a19790 major depression  being studied fibromyalgia pain syndrome one study determined effect sensorimotor performance while driving motor vehicle shows many similarities placebo drug appears stimulate central nervous system rather than exhibit sedative effect like many antidepressants  because selective reversible inhibition monoamine oxidase mao short half life unpleasant cheese effects avoided refers effects consuming tyramine rich foods cheese while medicated monoamine oxidase inhibitors leading severe headaches hypertension   available evidence supports safe effective option depression fibromyalgia syndrome    major depressive disorder depression depression depression depression depression schizophrenia angina pectoris depression depression depression depression restoration blood mass during surgical interventions if there hypovolemia trauma dehydration well after presence hemorrhage cases blood loss level inferior 15 blood mass if compatibility test cannot completed blood lots need tested pathogen detection  prevention profound postoperative venous thrombosis   well presents ophthalmic applications solutions ointments temporary relief xerophthalmia minor ocular irritations  cancer usually biochemically modulating drugs  adults advanced gastric cancer given db00515    first line metastatic colorectal cancer db03419 calcium folinate   adjunct antineoplastic therapy within product teysuno  adults advanced gastric stomach cancer given cisplatin following cases prevent blood clots veins after general abdominal surgery moderate risk venous thromboembolism prevention thromboembolic disease non surgical prevention clotting extracorporeal circuit during hemodialysis prevent blood clots veins after major orthopedic surgery high risk venous thromboembolism secondary prevention venous thromboembolism recurrence deep vein thrombosis transient prevention deep vein thrombosis dvt   fda  deep vein lead pulmonary embolism pediatric long term deep vein thrombosis without pulmonary embolism pregnant  prevention venous thromboembolism deep vein thrombosis pulmonary embolism myocardial infarction prevention venous thromboembolism deep vein thrombosis pulmonary embolism myocardial infarction overactive bladder fda hyperkalemia treated dabigatran reversal anticoagulant effects dabigatran needed emergency surgery urgent procedures life threatening uncontrolled bleeding antihyperglycemic agent t2dm fda without scintigraphic imaging lymphatic mapping using handheld gamma counter locate lymph nodes draining primary tumor site solid tumors procedure component intraoperative fda  without scintigraphic imaging guiding sentinel lymph node biopsy using handheld gamma counter clinically node negative squamous cell carcinoma oral cavity breast cancer melanoma fda  therapeutically severe osteoperosis postmenopasual women b men high risk fractures whom medical products approved osteoperosis possible example contraindications intolerance   postmenopausal women  reduce risk vertebral hip fractures  cleansing colon preparation colonoscopy adults fda adjunctive therapy hyperammonemia encephalopathy deficiencies enzymes urea cycle diet supplements containing stated product assist individuals cardiovascular complaints congestive heart failure systolic hypertension product  increase cardiac input well prevention several diseases like parkinson fibromyalgia migraine periodontal disease diabetes based preclinical studies  important highlight these products fda approved recommended under discretion irritable bowel syndrome diarrhea ibs d chronic obstructive pulmonary disease copd  bronchial asthma pulmonary disease spastic bronchial component initial severe malaria pediatric  peptic ulcer gastro oesophageal reflux disease gord  inflammatory erosive ulcerous diseases gastric duodenal mucosa  gastritis ulcer disease stomach duodenum functional non ulcerous dyspepsia erosive duodenitis post operative inflammatory erosive changes  anastomositis peptic ulcer anastomosisa disease modifying antirheumatic drug dmard symptomatic arthritis choline c11 positron emission tomography pet imaging suspected prostate cancer recurrence non informative bone scintigraphy computerized tomography magnetic resonance imaging fda a32037 antidote poisonings following excessive oral ingestion certain medications poisons hypertension heart failure a20319 given db08820 fixed dose product orkambi  cystic fibrosis cf age 6 older homozygous f508del mutation cftr gene  fda peptic ulcers relieving indigestion heartburn indications include ischemic heart disease angina chronic heart failure pulmonary hypertension   chronic stable angina a19770  angina pectoris hydrochloride form local anesthetic t83  inflammatory conditions affecting airways ent system urogenital tract bone joint systems adults italy  pain ear nose throat ent gastrointestinal inflammatory conditions children  well established nsaid over three decades italy particularly upper respiratory tract infections children  france belgium austria switzerland spain portugal generally favorable tolerability profile chronic psychoses states aggressiveness various origins   over counter osmotic laxative relieve occasional constipation  sodium ascorbate sodium sulfate ascorbic acid sodium chloride potassium chloride cleansing colon preparation colonoscopy adults  paracetamol prodrug intravenous administration control fever pain perioperative period multimodal analgesia therapy  primarily major depressive disorder anxiety a31969  currently being studied fibromyalgia pain  nausea vomiting diarrhea predominant irritable bowel syndrome males drug adults antiemetics prevention delayed nausea vomiting emetogenic chemotherapy valsartan reduce risk cardiovascular events chronic heart failure nyha class ii iv reduced ejection fraction  usually administered conjunction heart failure therapies place ace inhibitor arb therapeutic solutions sodium iodide 131 hyperthyroidism thyroid carcinomas take up iodine  palliative effects observed advanced thyroid malignancy if metastatic lesions take up iodine  performance radioactive iodide rai uptake test evaluate thyroid function talnifumate phthalidyl ester nifumic acid potent analgesic anti inflammatory effects widely inflammatory disorders rheumatoid arthritis osteoarthritis   studied cystic fibrosis  db09297 db00503  fixed dose product technivie  db00811 genotype 4 chronic hepatitis c virus hcv infection without cirrhosis   db09297  db00503  db09183  fixed dose product viekira pak  hcv genotype 1b combined db00811  hcv genotype 1a fda within fixed dose product db09296  db09183  db00503 fda approved product viekira pak  hcv genotype 1b without cirrhosis compensated cirrhosis combined db00811 hcv genotype 1a without cirrhosis compensated cirrhosis  within fixed dose product db09296 db00503 fda health canada approved product technivie  db00811 genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis  within fixed dose product db09296  db09183  db00503 health canada approved commercially available product holkira pak  hcv genotype 1b without cirrhosis combined db00811 hcv genotype 1a without cirrhosis currently being tested severe intoxications hepatotoxic substances death cap amanita phalloides poisoning chronic hepatitis b compensated liver disease   emtricitabine antiretrovirals hiv infection adolescent weight higher than 35 kg  prevent hiv infections high risk adolescent excluding risk from receptive vaginal sex   combined antiretrovirals than protease inhibitors require cyp3a inhibitor pediatric weighing 25 35 kg   product emtricitabine bictegravir  considered complete regimen hiv infection naive patients virologically suppressed least 3 months no history failure   additionally product elvitegravir  cobicistat  emtricitabine and product emtricitabine  rilpivirine hiv infection older than 12 no previous antiretroviral therapy history virologically suppressed least 6 months no history failure   product darunavir  cobicistat emtricitabine hiv infection adults without prior antiretroviral therapy virologically suppressed 6 months no reported resistance darunavir tenofovir  abdmoninal cramping pain fda  glucosamine alleviate pain inflammation from primary osteoarthritis  supplement reported improve joint function slow disease progression  osteoarthritis characterized progressive structural metabolic changes joint tissues mainly cartilage degradation subchondral bone sclerosis inflammation synovial membrane a32066  studies proposed potential nutraceutical dietary supplements a32065  antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity  i reducing risk myocardial infarction stroke unstable angina requiring hospitalization adults established cardiovascular disease f4591   ii adjunct diet alone lipid lowering therapies statins ezetimibe example adults primary hyperlipidemia heterozygous familial hypercholesterolemia reduce low density lipoprotein cholesterol ldl c levels body f4591 heterozygous homozygous familial hypercholesterolemia clinical atherosclerotic cardiovascular disease maximum tolerated statin therapy requiring additional ldl cholesterol lowering depression a19792 investigated depression investigated depression investigated depression investigated community acquired pneumonia cap routine prophylaxis bleeding congenital factor xiii subunit deficiency constipation help maintain regular bowel movements prevention renal transplant rejection aplastic anemia medicinal product diagnostic only adults children low osmolality medium   a7924  sodium pertechnetate tc99m injection adults imaging following tissues thyroid salivary gland  urinary bladder detection vesico ureteral reflux  nasolacrimal drainage system dacryoscintigraphy  children imaging following tissues thyroid urinary bladder  inhalation xenon xe 133 gas proved valuable evaluation pulmonary function imaging lungs applied assessment cerebral flow diagnostic radiopharmaceutical help diagnose heart disease eg coronary artery disease heart attack  diagnosis parathyroid problems moderate severe vasomotor symptoms menopause moderate severe symptoms vulvar vaginal atrophy menopause moderate severe vasomotor symptoms menopause moderate severe vaginal dryness pain intercourse symptoms vulvar vaginal atrophy menopause chronic infections upper lower urinary tract asymptomatic bacteriuria susceptible strains escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter enterococci  prostatitis susceptible strains escherichia coli enterococcus faecalis  proteus mirabilis enterobacter sp  number bacterial infections syphilis anthrax mouth infections pneumonia diphtheria adjunctive diaper dermatitis minor skin irritations eg cuts burns scrapes poison ivy  ointments creams lotions protect against sunburn damage skin ultraviolet light medication mineral prevent low levels zinc alone together oral rehydration therapy ort  topical astringent  injection usp supplement intravenous solutions given tpn  currently available products ampicillin within formulation infections susceptible strains designated microorganisms conditions listed below skin skin structure infections beta lactamase producing strains staphylococcus aureus escherichia coli klebsiella spp  k pneumoniae  proteus mirabilis bacteroides fragilis enterobacter spp  acinetobacter calcoaceticus intra abdominal infections beta lactamase producing strains escherichia coli klebsiella spp  k pneumoniae  bacteroides spp  b fragilis  enterobacter spp gynecological infections beta lactamase producing strains escherichia coli bacteroides spp  b fragilis  oral topical form prevention control dental caries maintenance dental health a181652  fluoride supplements form tablets formulas prescribed prevent tooth decay high risk children aged 6 months 16 old whose drinking water source contains low fluoride concentrations  diagnostic positron emission tomography pet imaging myocardium under rest pharmacologic stress conditions evaluate myocardial perfusion suspected existing coronary artery disease first line metastatic colorectal cancer concomitant administration calcium folinate  colorectal cancer third most diagnosed cancer 30 cases present metastatic state a32077 adhd children  hypertriglyceridemia   hemophilia congenital factor viii deficiency  fda  a32064  medication human antihemophilic factor adolescent 12 older hemophilia congenital factor viii deficiency  demand control bleeding routine prophylaxis bleeding episodes von willebrand disease fda  metastatic epidermal growth factor receptor egfr t790m mutation positive non small cell lung cancer nsclc  detected fda approved test progressed after egfr tki therapy intravenous injection alone medications multiple myeloma  subcutaneous hyaluronidase alone multiple myeloma  anticoagulant induced prothrombin deficiency coumadin indanedione derivatives prophylaxis therapy hemorrhagic disease newborn hypoprothrombinemia antibacterial therapy hypoprothrombinemia secondary factors limiting absorption synthesis vitamin k example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis pancreas regional enteritis drug induced hypoprothrombinemia where definitely shown result interference vitamin k metabolism    available cholecystographic agent denomination indicates radiopaque substance visualize gallbladder biliary channels abdominal x ray  a32087 abdominal x ray uses minimal amount ionizing radiation produce pictures inside abdominal cavity commonly evaluate stomach liver intestines spleen   hyperthyroidism graves disease a32085 a32086 hyperthyroidism refers any condition where there too much thyroid hormone produced body overactive thyroid  overactivity involves entire thyroid gland known grave disease  tc 99m nm one technetium labeled antibodies detection small cell lung cancer  small cell lung cancer syndrome characterized abnormal uncontrolled cell growth characterized shorter doubling time higher growth fraction earlier development metastases  source clean air fda elevated blood pressure edema   cholecystography x ray diagnosis imaging gallstones glucose pharmaceutical formulations oral tablets injections caloric supply carbohydrate supplementation case nutrient deprivation metabolic disorders hypoglycemia local anesthetic medication  beginning 1950s during dental procedures   combined procaine accelerate onset action provide longer lasting anesthetic effect   produced amide local anesthetics were contraindicated allergy several amide anesthetics were unsuccessful   trifluridine refractory mestastatic colorectal cancer keep progressing despite standard chemotherapy biologics a31256 presents large variety uses therapeutically parenteral hyperalimentation t127 excipient known effect   approved food products humectant crystallization modifier liquid nutritive sweetener t128 temporary relief pain pruritus from minor lip skin irritations well temporary relief from pain burning itching discomfort hemorrhoids anorectal anogenital disorders contrast medium   indication contrast agent x ray some information indicates nephrotropic property one characteristics utilization  a32135 x ray imaging depends difference tissue density provided x ray attenuation between area interest surrounding tissue contrast agents will provoke contrast enhancement opacification will improve differentiation pathological processes from normal tissue t125 vaccines tissue grafts surgical instruments enzymes sterilant blood plasma water milk nutrient broth vapor phase disinfectant enclosed spaces sporicidal action against vegetative bacteria pathologic fungi viruses  no longer medical procedures food a32144 intrinsic factor currently available any fda health canada approved products however currently marketed but unapproved product hematogen cyanocobalamin synthetic vitamin b12  ferrous fumarate ascorbic acid anemias responsive oral iron therapy head pubic crab  body lice open angle glaucoma ocular hypertension fda mydriatic agent eye pupil dilatation diagnosis ophthalmic nerve lesions topically dandruff acne hayfever common cold scaly red skin patches seborrheic dermatitis  poison ivy sumac infections injection prophylactic immediately after major abdominal surgery minimize possibility paralytic ileus intestinal atony causing abdominal distention postoperative postpartum retention flatus postoperative delay resumption intestinal motility paralytic ileus  topical medication moisturizer prevent dry rough scaly itchy skin minor skin irritations e g  diaper rash skin burns from radiation therapy  rauwolfia alkaloids hypertension   rauwolfia alkaloids relief symptoms agitated psychotic states schizophrenia however antipsychotics sedatives replaced more effective safer agents   cold sores fever blisters diaper rash minor burn sunburn prickly heat vaginally  douche leukorrhea sore throat inflamed tonsils spongy receding gums dermatitis determining cardiac output hepatic function liver blood flow ophthalmic angiographyno therapeutic indications surfactant antistatic agent biocide cosmetic products a19426  form ointment biochemical debridement second third degree burns incisional traumatic pyrogenic wounds ulcers occurring peripheral vascular diseases t169 replace estrogen women ovarian failure conditions cause lack natural estrogen body symptoms breast cancer both men women men advanced prostate cancer menopausal symptoms  ethinyl estradiol prevention pregnancy women elect product method contraception dentistry orthodontics etching solution clean roughen surfaces teeth where dental appliances fillings will placed injection usp 40 meq source sodium addition large volume intravenous fluids prevent correct hyponatremia restricted no oral intake useful additive preparing specific intravenous fluid formulas needs patient cannot met standard electrolyte nutrient solutions  bicarbonate precursors alkalinising agents correct metabolic acidosis alkalinisation urine technetium 99m sulfur colloid diagnostic agent adults following tests localization lymph nodes draining primary tumor breast cancer malignant melanoma evaluation peritoneo venous leveen shunt patency both pediatric imaging areas functioning reticuloendothelial cells liver spleen bone marrow studies esophageal transit gastroesophageal reflux detection pulmonary aspiration gastric contents 18f bone imaging agent define areas altered osteogenic activity  back pain otherwise unexplained bone pain child abuse abnormal radiographic laboratory findings osteomyelitis trauma inflammatory degenerative arthritis avascular necrosis osteonecrosis mandible condylar hyperplasia metabolic bone disease among indications fluoride imaging prevention angina pectoris coronary artery disease onset action oral mononitrate sufficiently rapid product useful aborting anginal episode  several medical topical skin related applications  usp anhydrous uses electrolyte replenisher pharmaceutic necessity hemodialysis peritoneal dialysis fluids magnesium salf containing laxatives prevent constipation bring synergistic effect restore normal bowel function using aluminum salts induce bowel retention t28  source water electrolytes combined dextrose salts form intravenous infusions injection carbohydrate magnesium deficiency insulin hypoglycemia constipation hypertension during pregnancy buffers determination ph pharmaceutical production urinary acidifier paper processing baking powder food  nutrient solutions yeast foods special liquid fertilizers sonar systems electronic applications  nutritional supplement foods nonlinear optical material laser wastewater  imitation dairy creamers dry powder beverages mineral supplements starter cultures additive non dairy creamers prevent coagulation  make buffer solutions production trypticase soy agar make agar plates culturing bacteria no current fda ema approved therapeutic indications predominant everyday nutritional usage parent sugar alcohol from another sugar alcohol  xylitol derived from extremely common food additive sweetener place regular sugars lower calorie alternative   a32661  alternatively  involved procedure known d absorption test employed evaluate how well individual capable absorbing simple sugar like d from intestines   measuring amount d urine blood samples after individual ingested certain amount simple sugar dissolved some water test sought determine if nutrients were being properly absorbed patient gastrointestinal tract  administration sodium iodide i 123 capsules diagnostic procedure evaluating thyroid function morphology parenteral nutrition source calories essential fatty acids oral enteral nutrition possible insufficient contraindicated pentetate indium disodium 111 recommended radionuclide cisternography i 125 iodinated albumin determination total blood plasma volume  iodinated i 131 albumin determinations total blood plasma volumes cardiac output cardiac pulmonary blood volumes circulation times protein turnover studies heart great vessel delineation localization placenta localization cerebral neoplasms  no approved therapeutic indications constipation clean bowel before colonoscopy fda tartaric acid primarily conditions like antiscorbutic antiseptic topically dermatitides mouthwash vaginal douche veterinary emergency emetic occasionally dermatitides topically lotion medication vet  solution cleanse skin eczema soften scabs ringworm solvent emollient pharmaceutical agent sweetening agent bowel cleansing prior colonoscopy barium enema x ray examination indium 111 oxyquinoline radiolabeling autologous leukocytes injection hypertension oral therapy practical rubidium rb 82 chloride injection positron emission tomography pet imaging myocardium under rest pharmacologic stress conditions evaluate regional myocardial perfusion suspected existing coronary artery disease over counter antacid  sodium monofluorophosphate cavitiesfor relief symptoms seasonal allergic rhinitis sneezing rhinorrhea pruritus lacrimation nasal congestion radio labeling monoclonal antibodies preparations vivo diagnostic imaging procedures indiclor radiolabeling zevalin preparations radio immunotherapy procedureindicated blood pool imaging cardiac first pass gated equilibrium imaging detection sites gastrointestinal bleeding fda  no therapeutic indications medicinal products indirect additive food contact substances ingredient commercial cosmetic products sun protection factor added sunscreen products wide spectrum ultraviolet absorption properties active ingredient sunscreens lip balms protection against damaging effects sun rays strontium 89 chloride injection paliative relief bone pain skeletal metastases impotant confirm presence bone metastases prior beginning therapy a31264 sequential intravenous sodium nitrite cyanide poisoning judged life threatening uptake 18f fdg tissues marker tissue uptake glucose turn closely correlated certain types tissue metabolism fludeoxyglucose f 18 injection positron emission tomography pet imaging assessment abnormal glucose metabolism assist evaluation malignancy known suspected abnormalities found testing modalities existing diagnoses cancer urea 13c qualitative detection urease helicobacter pylori human stomach aid initial diagnosis post monitoring helicobacter pylori infection test monitoring if least four 4 weeks following completion therapy these purposes system utilizes infrared spectrophotometer measurement ratio 13co2 12co2 breath samples prevent recurrence malignant pleural effusions symptomatic during thoracoscopy open thoracotomy relieve pain discomfort excess gas intestine stomach cases flatulence post operative gaseous distention could prior endoscopy eliminate foam gas air from gastrointestinal tract reduce gas shadow will result better visualization  14c urea intended detection gastric urease aid diagnosis helicobacter pylori h pylori infection human stomach test utilizes liquid scintillation counter measurement 14co2 breath samples currently primarily available only active ingredient products combined tretinoin solar lentigines related hyperpigmented lesions resulting from chronic sun exposure fda replete total body content iron during iron deficiency anemia age 6 older chronic kidney disease receiving hemodialysis receiving supplemental epoetin therapy otc topical lightening agent disorders hyperpigmentation melasma post inflammatory hyperpigmention sunspots freckles stimulation   pancreatic secretions bicarbonate aid diagnosis pancreatic exocrine dysfunction fda   gastrin secretion aid diagnosis gastrinoma fda   pancreatic secretions facilitate identification ampulla vater accessory papilla during endoscopic retrograde cholangiopancreatography ercp  fda applied topically filter out uva rays us  evaluated fda considered safe up 10 formula similarly eu allows up 10 formula while health canada allows maximum level 12  most sunscreens block uva uvb rays similar zinc oxide antispetic germicidal agent patient preoperative skin preparation preparation skin prior surgery help reduce bacteria potentially cause skin infection capsules usp adjunct diet reduce triglyceride tg levels severe  500 mg dl hypertriglyceridemia htg fda a176687 ointments liniments containing applied topically counter irritant relief pain lumbago sciatica rheumatic conditions local analgesics human veterinary medicine diagnostic imaging adrenergically inervated tissues purposes detecting metastatic pheochromocytoma neuroblastoma fda  assess sympathetic inervation myocardium via determination heart mediastinum ratio radioactivity new york heart association class ii iii heart failure monocationic surfactant detergent help penetration active ingredients through cellular debris antibacterial action dexchlorpheniramine perennial seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis inhalant allergens foods mild uncomplicated allergic skin manifestations urticaria angioedema amelioration allergic reactions blood plasma dermographism approved cisplatin gemcitabine first line metastatic squamous non small cell lung cancer nsclc  non squamous nsclc  source phosphate total parenteral nutrition fda  amino acids dextrose lipid emulsions electrolytes choline c 11 injection positron emission tomography pet imaging suspected prostate cancer recurrence non informative bone scintigraphy computerized tomography ct   magnetic resonance imaging mri  these 11 c choline pet imaging help identify potential sites prostate cancer recurrence subsequent histologic confirmation suspected prostate recurrence based upon elevated blood prostate specific antigen psa levels following initial therapy  clinical studies imag  es w ere produced pet ct coregistration  improve glycemic control year age older diabetes mellitus adults source calories fatty acids total parenteral nutrition fda  sometimes additive cosmetic products om3 ca adjunct diet reduce triglycerides levels adults severe hypertriglyceridemia  gt 500 mg dl  involved should laced appropriate lipid lowering diet   hypertriglyceridemia defined elevated plasma triglyceride concentration usually correlated secondary conditions poor diet alcohol obesity metabolic syndrome type diabetes a32630 lenalidomide dexamethasone multiple myeloma received least one prior therapy over counter nasal congestion inactivated rabies virus antigen b pre post exposure prophylaxis against rabies  rotarix prevention rotavirus gastroenteritis g1 g3 g4 g9 types infants aged 6 24 weeks fda  rotateq prevention rotavirus gastroenteritis g1 g2 g3 g4 g9 types infants aged 6 32 weeks  zostavax vaccine prevention herpes zoster shingles immunocompetent adults aged 50 older  varivax vaccine active immunization prevention varicella individuals 12 months age older extract allergen extract immunotherapy house  dust  mite  hdm induced  allergic  rhinitis    without  conjunctivitis  confirmed    vitro testing   ige  antibodies   dermatophagoidesfarinae house dust mites  skin testing licensed house dust mite allergen extracts odactra approved adults 18 through 65 age allergen extract immunotherapy house dust mite hdm induced allergic rhinitis without conjunctivitis confirmed vitro testing ige antibodies house dust mites skin testing licensed house dust mite allergen extracts  approved adults 18 through 65 age pneumococcal pneumonia susceptible strains group beta hemolytic streptococcal infections upper respiratory tract device full thickness  diabetic foot ulcers greater than six weeks duration extends through dermis but without tendon muscle joint capsule bone exposure drug should conjunction standard wound care regimens adequate blood supply involved foot   wounds partial full thickness wounds pressure ulcers venous ulcers diabetic ulcers chronic vascular ulcers tunneled undermined wounds surgical wounds donor sites graft post moh dermatological surgery post laser surgery podiatric wound dehiscence  trauma wounds abrasions lacerations second degree burns skin tears draining wounds   gintuit allogeneic cultured keratinocytes fibroblasts bovine collagen allogeneic cellularized scaffold product topical non submerged application surgically created vascular wound bed mucogingival conditions adults uses bovine collagen matrix support growth keratinocytes fibroblasts wound healing   products using bovine type collagen include primatrix integra orcel matriderm   orcel bilayered cellular matrix normal human allogeneic skin cells both epidermal keratinocytes dermal fibroblasts cultured two separate layers into type i bovine collagen sponge venous leg ulcers diabetic foot type i bovine collagen acts matrix growth proliferation fibroblasts keratinocytes offering structure support   laboratory bovine collagen type i purified protein standard control sds page western blot elisa immunoprecipitation immunological assays  chronic leg ulcers diabetic foot    orcel standard therapeutic compression non infected partial full thickness skin ulcers venous insufficiency greater than month duration effectively responded conventional ulcer therapy orcel standard diabetic foot ulcer care full thickness neuropathic diabetic foot ulcers greater than 3 weeks duration effectively responded conventional ulcer therapy extend through dermis but without tendon muscle capsule bone involvement    intravesical prophylaxis carcinoma situ cis urinary bladder prophylaxis primary recurrent stage ta t1 papillary tumors following transurethral resection tur  active immunization prevention yellow fever persons 9 months age older following categories  persons living traveling endemic areas while actual risk contracting yellow fever during travel probably low variability itineraries behaviors seasonal incidence disease make difficult predict actual risk given individual living traveling known endemic epidemic area greater risk living traveling areas south america africa where yellow fever infection officially reported time travel traveling outside urban areas countries do officially report disease but lie yellow fever endemic zone  persons travelling internationally through countries yellow fever some countries require individual valid international certificate vaccination prophylaxis icvp if individual countries either known thought harbor yellow fever virus certificate becomes valid 10 days after vaccination  3 laboratory personnel laboratory personnel handle virulent yellow fever virus concentrated preparations virus strains risk exposure direct indirect contact aerosols immunization against hepatitis virus hav infection aged 12 months older first dose should administered least weeks before expected exposure hepatitis virus  active immunization pediatric 15 months through 4 age booster dose prevention invasive disease haemophilus influenzae type b cellular repair strategy symptomatic cartilage defects femoral condyle medial lateral trochlea trauma were previously unresponsive available surgical procedures improvement appearance moderate severe nasolabial fold wrinkles adults fda unrelated donor hematopoietic progenitor cell transplantation procedures conjunction appropriate preparative regimen hematopoietic immunologic reconstitution disorders affecting hematopoietic system inherited acquired result from myeloablative fda  component technetium 99m agents imaging skeleton areas altered osteogenesis detection infarcted heart tissue fda  considered active pharmacological ingredient pharmaceutical preparations so no official indication typically present topical formulations emollient occlusive agent t182 over counter skin protectant fda  commonly diaper rash chapped lips fda   symptomatic relief burning irritation discomfort eyes dryness exposure wind sun lubricant prevent further irritation relieve dryness eye   complex iodine inducing antisepsis prevention infection minor cuts scrapes burns ingredient sunscreens protection against damage effects sun light provides protection from sunburns aging skin cancer solubilizer antimicrobial preservative disinfectant  ingredient many sunscreen protection against sunburn skin aging skin cancer please refer db00085 please refer db00085 nutritional supplement pain fever  typically employed chloride salt compound commonly active ingredient various over counter mouthwashes toothpastes lozenges mouth sprays where generally antiseptic actions gingivitis plaque prevention well action prevention against some oropharyngeal bacterial infections a24813    colorless liquid both cosmetic therapeutic uses topical creams ointments help distribute active ingredients  anti foaming agent hair skin conditioner head lice anti bloating anti flatulence agent    ophthalmic protectant lubricant artificial tears diagnostic aid contact lens procedures gonioscopy  peg 400 temporary relief burning irritation dryness eye protection against further irritation desiccation      temporary relief aches pains muscles joints backache lumbago strains bruises sprains arthritic rheumatic pain pain tendons ligaments   control minor hemorrhage during dental restorative procedures  reduce underarm perspiration relieving itching irritation redness dryness scaling flaking skin psoriasis seborrhea eczema contemporary therapeutic uses primarily revolve around phenol derivative active ingredient topical antiseptics    f61 topical antibacterial skin products conditions like acne seborrheic dermatitis eczema others     f61 topical over counter skin products skin dryness reduction striae gravidarum stretch marks  constipation dry hard stools opioid induced constipation a176984  though recently pressure building end over concerns efficacy a176972 a176987  relief tooth sensitivity pesticide insecticide food additive rodenticide     disinfectant sterilizer relieve dental hypersensitivity increase enamel production prevent gingivitis cavities control periodontal infections over counter calcium supplement hypoparathyroidism refractory rickets known resistant rickets  familial hypophosphatemia fda prophylaxis deep vein thrombosis undergoing hip replacement surgery  active ingredient sunscreens sunblock factor different products fits under category broad spectrum absorbent agent these characteristics important consider fact kind ingredients either absorb reflect uv radiation important know type rays cover uva rays responsible causing sun damage reaching deeper layers skin while uvb only cause sunburn outer layer skin agent broad spectrum means agent capable acting both uva uvb rays  indications include needing high fibre regime perhaps  relief constipation constipation pregnancy maintenance regularity  b bowel function colostomy ileostomy hemorrhoids anal fissure chronic diarrhea diverticular disease irritable bowel syndrome ulcerative colitis   antacid electrolyte replenisher potassium supplement excipient drug formulations  antacid medication neutralize gastric acid short timeframe after ingestion effect soon overcome meal stimulated acid secretion a32214 commonly applied variety topical vehicles applications cosmetic creams toothpastes mouthwashes shampoos lipsticks anti acne products lotions a32213 purpose moisturizing skin enhancing smoothness skin stimulating healing wounds soothing irritated skin a32213 fda  several amino acids dextrose peripherally administered source nitrogen nutritional support adequate stores body fat whom short periods oral administration cannot tolerated undesirable inadequate fda  amino acids 5 10 dextrose fat emulsion  parenteral nutrition preserve protein reduce catabolism stress conditions where oral administration inadequate fda  administered amino acids concentrated dextrose central vein infusion prevent reverse negative nitrogen balance where alimentary tract oral gastrostomy jejestomy routes cannot should gastrointestinal absorption protein impaired metabolic requirements protein substantially increased morbidity mortality reduced replacing amino acids lost from tissue breakdown fda echocardiography  suboptimal echocardiograms opacify left ventricular chamber improve delineation left ventricularendocardial border  ultrasonography liver  ultrasound liver pediatric characterize focal liver lesions active ingredient products like antibacterial antiseptic disinfectant soaps topical sanitizers cleaning agents  primarily implemented salt form  chloride where often only active ingredient present primary purpose topical washing decrease bacteria skin   conversely implemented excipient ingredient variety multidose aqueous nose eye ear products  chloride being antimicrobial preservative choice facilitate effective bactericidal fungicidal actions help minimize growth unwanted organisms multidose containers fda  constipation  bowel preparations prior colonoscopy cathartic agent t215  over counter products relieve occasional constipation   one forms administration dietary supplements  skin protectant relieve dryness irritation skin     helps prevent diaper dermatitis  over counter laxative oral soothing agent topical skin hair active agent  relief symptoms catarrhal colds relief symptoms minor muscular sprains cramps  uv b absorbing molecule sunscreen formulations fungal infections salt form no therapeutic indications own  smelling salt prevent fainting   radiolabelled diagnostic pet imaging myocardium under rest pharmacologic stress conditions evaluate myocardial perfusion suspected existing coronary artery disease fda supplement intravenous solutions given total parenteral nutrition tpn    experimentally bath disseminated sclerosis sexual dysfunction studied antibacterial activity inhibition osteoclast activity  utilized experimental models inflammation induce systemic inflammatory immune response animals predominant medical applications formally therapeutic application skin cuts bites stings abrasions antiseptic hand cleaner  over counter disinfectant agent sodium form temporary relief mild symptoms intermittent asthma antiseptic agent no therapeutic indications clinical oral calcium salts dietary supplemental therapy person get enough calcium their regular diet  cardioprotective agent high blood potassium  antidote magnesium sulfate toxicity selenium injection supplement intravenous solutions given total parenteral nutrition tpn  administration tpn formulas helps maintain plasma selenium levels maintain endogenous stores prevent deficiency   selenium compounds selenium sulfide topically anti dandruff shampoos cases seborrhea    purpose brevity selenite will focus discussion more information about selenium obtained db11135 dental bleaching agent  oral wound healing agent oral mucosal injuries  aid removal hardened ear wax derivatives most commonly medications chronic pain  alkaloid derivatives tranquilizers antitussives diarrhea t138 direct common nowadays but some derivatives morphine codeine well tincture severe diarrhea seen medical practice t139  illegal registered both recreational medicinal purposes a32182 temporary relief minor aches pains muscles joints simple backache arthritis strains sprains provided daily supplements aa preparation omega 3 acid ethyl esters licensed uk prevention recurrent events after myocardial infarction addition hypertriglyceridaemia no fda ema approved therapeutic indications supplementation total parenteral nutrition prevent hyposelenemia fda supplement intravenous solutions given total parenteral nutrition tpn  maintain serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda  currently only available products prophylactic nutritional supplementation db06757  fda primary medical indications general include being bactericides pesticides disinfectants   certain isomers  like m  inactive ingredients purpose serving preservative some pharmaceuticals   biocidal component several over counter products these products marketed purposes inhibiting abnormal biological growth vagina restoring natural ph  chronic pain long duration effect a32663 surface anesthetic skin mucous membrane relief pain pruritus anorectal disorders   radiographic contrast agent computed tomography ct abdomen delineate gastrointestinal gi tract pediatric fda destroy kill nail matrix matrixectomies    medically microscopic examination  koh preparations utilized diagnosis fungal hyphae trichomonads   samples from hair skin nail tissue obtained scraping scalpel cotton tipped applicator inoculated directly onto koh solution   addition above  softener nail grooves   tcc  3 4 4 trichlorocarbanilide antibacterial agent bar liquid soaps body washes  enterobiasis roundworm ascariasis  pinworm enterobius hookworm strongyloides hookworm ancylostoma pamoate form    available various formulations humans dogs cats pamoate us pharmacopeia nomenclature embonate european pharmacopoeia nomenclature salt contains 34 7  base combined pamoic acid     a32283   pamoate embonate ingested orally effective removal control ascarid hookworm infections puppies dogs toxocara canis toxascaris leonina ancylostoma tubaeforme braziliense uncinaria stenocephala  cats toxocara cati toxa leonina caninum braziliense u stenocephala  horses ponies immature parascaris equorum strongylus vulgaris edentatus equinus cyathostomes triodontophorus spp  cyathostomum spp  cylicodontophorus spp  cylicocyclus spp  cylicostephanus spp  poteriostomum spp  oxyuris equi anoplocephala perfoliata  swine ascaris suum oesophagostomum dentatum  humans lumbricoides enterobius vermicularis duodenale necator americanus   stable plaque psoriasis skin scalp   topically psoriasis dermatoses alopecia areata  biomedical research effect egfr autophosphorylation   food gelling agent stabilizer medical drug obtained great interest potential source dietary fiber lipid cholesterol serum glucose insulin level lowering effect gastric emptying delay a32327 some recent studies researched possibility using formation nanoparticles delivery vehicle drugs a32331 primary therapeutic currently adjuvant therapy various products containing analgesic  either narcotic non narcotic  where expected potentiate pain relieving anti tussive etc effect analgesic component product  regard some these aforementioned products typically temporary relief minor aches pains like headache muscular aches backaches minor arthritis pain common cold toothaches menstrual cramps etc   perhaps exhausting non productive cough cold upper respiratory allergic condition does respond non narcotic antitussives  lubricant over counter ophthalmic solutions temporarily relieve redness burning irritation eyes complex technetium tc 99m single photon emission computerized tomography spect adjunct conventional ct mri localization stroke whom presence stroke already diagnosed assess functional viability brain tissue distinguish between stroke brain lesions   stroke defined condition blood stops flowing any part brain causing damage brain cells potential effect stroke depends part brain affected well extension damage  recombinant antithrombin prevention peri operative peri partum thromboembolic events hereditary deficiency antithrombin  no approved therapeutic indications  first dermatology part monsel solution solution antihemorrhagic agent skin mucosal biopsies dermatology under review corrosive injurious cause degenerative changes observed alternatives like collagen a32357  coagulative hemostatic agent mechanic hemostatic agent directly damaged tissue a32355  dentistry  pulpotomy medicament control pulpal bleeding antibacterial agent hemostatic reagent restorative dentistry postextraction hemorrhage periradicular endodontic surgery a32356  complex technetium tc 99m scintigraphic imaging myocardium following separate administrations under exercise resting conditions helps delineation regions reversible myocardial ischemia absence infarcted myocardium   complex scintigraphic imaging myocardium identify changes perfusion induced pharmacologic stress known suspected coronary artery disease   complex assessment left ventricular function evaluated heart disease  overdose rescuing agent hydrocodone antitussive fda  induction mydriasis ophthalmic solutions diagnostic agent routine ocular examinations superficial conjunctiva corneal tissue change suspected aid diagnosis keratoconjunctivitis sicca keratitis abrasions corrosions well detection foreign bodies sunscreening agents prevent sunburn actinic keratosis premature skin aging reduce incidence skin cancer  cough suppressant relieve cough common cold flu bronchitis sinusitis a32160  no fda approved therapeutic indications sugar substitute oral hygiene active ingredient over counter  symptomatic relief minor spasms gastrointestinal tract flatulence abdominal pain especially irritable bowel syndrome  temporary relief itching insect bites eczema minor burn sunburn minor skin irritations minor cuts scrapes atopic dermatitis skin disorders  temporary symptomatic relief mild joint muscle pain local topical analgesic  temporary relief tension type headache aluminum based antiperspirant preparations intended reduction normal underarm perspiration hyperhidrosis   temporary relief pain rheumatism arthritis neuralgia sprains strains joints muscles lumbago fibrositis f91 n alkyl c12 c14 dimethyl ethylbenzyl ammonium chloride added products function cleaning agent antimicrobial agents disinfecting cleaning products   containing racemic mixture dex levo currently available any fda approved products therefore does indication  please see db09357 fda approved uses dextrorotatory form  active sunscreen agent active sunscreen agent over counter epidermal hyperpigmentation various skin conditions melasma freckles senile lentigines topical help protect against infection minor cuts scrapes burns no fda approved therapeutic indications active sunscreen agent active sunscreen agent mild antisepsis skin cuts abrasions  employed photostabilizing agent various sunscreen products  solutions containing methyl cellulose substitute tears saliva if natural production these fluids disturbed constipation diverticulosis hemorrhoids irritable bowel syndrome manufacture capsules nutritional supplements edible nontoxic properties provide vegetarian alternative gelatin over counter antacid self heartburn sour stomach acid indigestion fda thozylamine symptomatic control allergic rhinitis upper respiratory allergic symptoms fda  typically part over counter products solutions containing 5 10  local applications ulcers arrest foul discharges from mucous surfaces  preparation aluminum acetate ear drops   often purchased over counter available solid stick powder form minor cuts abrasions after shaving     adjuvant vaccines   weight loss treating osteoarthritis rheumatoid arthritis brittle bones osteoporosis  some people strengthening bones joints fingernails  improving hair condition shorten recovery after exercise sports related injury   preparations foods cosmetics medicine   plasma volume expander hypovolaemic shock   haemostatic    based hydrogels being drug delivery tissue engineering because they able promote cell adhesion proliferation addition these hydrogels wound dressings because their attractive fluid absorbance properties manufacturing technologies ultraviolet stereolithography two photon polymerization prepare structures containing photosensitive based hydrogels   mainly conditions like zinc deficiency administered adjunctive therapy alternative drug choice diarrhea   dietary supplement deficit vitaminE mainly prescribed alpha form a32443 vitaminE deficiency rare primarily found premature babies very low birth weight fat malabsorption abetalipoproteinemia    antioxidant properties studied prevention different complex diseases cancer a32436 atherosclerosis cardiovascular diseases a32442 age related macular degeneration a32444 predominantly employed active ingredient lotions sprays lozenges a topical antiseptic help prevent skin infection minor cuts scrapes burns b antiseptic local anesthetic relief sore throat pain    addition  active ingredient various commercial cosmetic skincare products anti aging cream  while studies looked into whether compound could effectively anti inflammatory agent even anti cancer therapy  prevention folate deficiency antidote against folic acid antagonists contained oral contraceptives reduce risk neural tube defects arising from folic acid deficiency pregnant women conceived during shortly after discontinuation product being studied cardiovascular diseases a19273 adjunct therapy undergoing antidepressant pharmacotherapy a19271 a19272 sunscreen agent cosmetic products  found otc dental products toothpastes prevention dental caries otc products these do official indication  prescription products db01373 phosphate donor replacement supplementation insufficient db01373 phosphate symptomatic relief digestive disturbances feelings fullness slow digestion flatulence f114  sunscreen agent  uv filter cosmetic sunscreen products well cosmetic products like shampoos conditioners hairsprays etc  where confer photostability product   f89 know more about approved indications please visit db01049 alpha dihydroergocryptine studied early parkinson disease a32980 well migraine prophylaxis a32983 low blood pressure peripheral vascular disorder know more about ergoloid mesylate mixture uses please visit db01049 please refer db01049 know more about isomer please refer db11274 antitussive decongestant   deet active ingredient predominantly insect repellant repel biting pests like mosquitoes ticks   products containing deet currently available public variety liquids lotions sprays impregnated materials like towelettes roll ons   active pharmaceutical agent no indication considered active pharmacological ingredient pharmaceutical preparations so no official indications detect delayed type hypersensitivity coccidioides immitis individuals history pulmonary coccidioidomycosis  18 64 year old  positive result occurs if 48h after administration if diameter induration gt 5mm commonly cosmetic products skin hair a19503 bovine topical aid hemostasis whenever oozing blood minor bleeding from capillaries small venules accessible control bleeding standard surgical techniques like suture ligature cautery ineffective impractical fda  additionally topical bovine absorbable gelatin sponge usp fda antimicrobial agent preservative cosmetics      emergency reversal coagulation factor deficiency receiving vitamin k antagonist therapy  administered part cocktail containing several coagulation factors concentrate pediatric severe congenital deficiency prevention venous thrombosis purpura fulminans  found component some prothrombin complex concentrate i e  factor ix complex human  formulations kcentra  predominantly manufactured marketed population large general nutraceutical dietary supplement a27154 a33159   historically  often given children because vitaminD content oil had shown prevent vitaminD deficiency condition rickets a33159  over time common children growing up conferred upon identity healthy useful all purpose dietary supplement  however since composite several nutritional compounds omega 3 fatty acids eicosapentaenoic acid epa docosahexaenoic acid dha well vitaminA vitaminD a33159    presence varying amounts all these compounds once makes difficult recommend appropriate supplement confer any one particular health effect any one particular nutritional deficiency  regardless because does contain number important healthy nutritional compounds  sometimes recommended literature conferring health effects some these compounds potential supplements post heart attack secondary prophylaxis omega 3 fatty acids a33165 drug only recommended topical usages relief muscular rheumatic pain human animals   topical analgesic flavoring ingredient   a32884    no fda ema approved therapeutic indications own scalp dandruff  sotradecol sodium tetradecyl sulfate injection small uncomplicated varicose veins legs showing simple dilation competent valves   sodium tetradecyl sulfate designated orphan drug fda gastrointestinal bleeding esophageal varices    factor ix complex prevention control hemorrhagic episodes hemophilia b urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e g  warfarin therapy major bleeding require rapid reversal therapy palmitoyloleoyl phosphatidylglycerol component surfaxin prevention respiratory distress syndrome premature infants infant respiratory distress syndrome        reduce viscosity blood before transfusions  primarily conditions like colic flatulence toothache  temporary symptomatic relief minor aches pains muscles joints topical analgesics over counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda   part over counter dietary supplements   systemic inflammatory diseases women health conditions cyclical mastalgia these indications do sufficient evidence their effectiveness atopic dermatitis united kingdom but currently withdrawn lack evidence effectiveness a33131 medicinally expectorant antiseptic local anesthetic  traditional dental pulp sedation property inducing cell proliferation  potent scavenger reactive oxygen radicals radical scavenging activity effect cell proliferation  over counter products wounds ulcers bedsores shallow inflammatory processes thrombophlebitis erysipelas only externally over counter dermatologic combinations db11113   pulmonary arterial hypertension pah delay disease progression reduce risk hospitalization kinase inhibitor anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc progressed intolerant crizotinib indication approved under accelerated approval based tumor response rate duration response continued approval indication contingent upon verification description clinical benefit confirmatory trials immunostimulant therapy cell mediated immunosuppression respiratory urinary infections  over counter constipation fda   investigated a number cancers autoimmune conditions  well  researched adjuvant therapy after bone marrow transplantation cases leukemia bacterial infections no approved therapeutic indications own  river blindness called onchocerciasis aged 12 older river blindness parasitic worm onchocerca volvulus manifested severe itching disfiguring skin conditions visual impairment worm larvae   transmission onchocerca volvulus performed person person black flies breed fast flowing rivers sub saharan africa yemen south central america larvae released parasite invade skin eyes where they produce severe disease manifestations  reversal sedative analgesic effects dexmedetomidine medetomidine dogs found diverse cosmetics perfumes well flavoring agent cough syrups lozenges chewing gum candies f117  medical agent  local burns wounds antiseptic a27160 expectorant heart stimulant increase blood pressure parasiticide t221 reverse opioid overdose large animal sedative primarily horses removal ascarids toxocara canis toxascaris leonina hookworms ancylostoma caninum uncinaria stenocephala aid removing tapeworms taenia pisiformis dipylidium caninum echinococcus granulosus from dogs cats xanthine oxidase inhibitor hyperuricemia gout achieved target serum uric acid levels xanthine oxidase inhibitor alone hydrolytic lysosomal cholesteryl ester triacylglycerol specific enzyme diagnosis lysosomal acid lipase lal deficiency  code text here  adults moderate severe plaque psoriasis candidates systemic therapy phototherapy active uv b filter prevent photodamage aid hemostasis whenever oozing blood minor bleeding from capillaries small venules accessible control bleeding standard surgical techniques suture ligature cautery ineffective impractical fda aid hemostasis whenever oozing blood minor bleeding from capillaries small venules accessible control bleeding standard surgical techniques suture ligature cautery ineffective impractical adults pediatric populations greater than equal one month age fda  additionally  conjunction absorbable gelatin sponge usp fda antiperspirant  grazoprevir product zepatier without ribavirin chronic hcv genotypes 4 infection adults  db11574  fixed dose product zepatier without db00811 chronic hcv genotypes 1a 1b 4 infection adults drug initially kidney function test main application indigo carmine time localizing visualizing ureteral orifices during cystoscopy ureteral catheterization procedures   paroxysmal nocturnal hemoglobinuria pnh  fda bcl inhibitor chronic lymphocytic leukemia cll small lymphocytic lymphoma sll  without 17p deletion received least one prior therapy fda  skeletal muscle relaxant drug orthopedic traumatic rheumatologic disorders   adjuvant drug painful muscle contractures spinal pathology adults adolescents 16 age older   recent studies examined effect muscle tone stiffness contractures soreness experienced athletes during sporting competitions   surfactant germicide fungicide mildew preventive agents silicone based water repellents emulsifier disinfectant topical anti infective antiseptic antimicrobial pharmaceuticals chemical properties antiseptical characteristics  wide variety products part formulations determined active antiseptic ingredient over counter preparations t211 manage fatigue  depression   a32724      adjunct therapy obesity   active ingredient various sunscreens indication protecting skin absorbing damaging uv radiation sunlight a33069     f81 f82  agents chronic hepatitis c hepatitis c virus genotypes 4 compensated liver cirrhosis   hepatitis c liver disease hepatitis c virus chronic state condition accounts 60 80 cases from risk cirrhosis liver within 20 around 15 30   genotype most common type hepatitis c united states most difficult  conditions characterized bronchial congestion bronchospasm expectorant bronchodilator action required bronchitis episodes chronic bronchitis bronchial asthma    marker respiratory status spirometry tests   f4  food additive pigment fixation meat  diagnostic tracer gas pulmonary function tests preservative some cosmetics topical pharmaceuticals biological drug products includes vaccines    symptomatic relief nasal non nasal symptoms seasonal rhinitis 12 age older symptomatic relief chronic spontaneous urticaria 18 age older fda anti infective topical  infectious dental diseases conditions locally advanced metastatic urothelial carcinoma ineligible cicplatin containing chemotherapy tumors expressing pd  ineligible cisplatin containing chemotherapy irrespective pd  disease progression following platinum containing chemotherapy disease progression within 12 months neoadjuvant adjuvant chemotherapy   first line non small cell lung cancer bevacizumab paclitaxel carboplatin no egfr alk genomic abnormalities  disease progression during after platinum containing chemotherapy even if they egfr alk abnormalities   paclitaxel protein bound locally advanced metastatic triple negative breast cancer expressing pd   finally  carboplatin etoposide first line extensive stage small cell lung cancer  rescue therapy following high dose methotrexate osteosarcoma diminishing toxicity inadvertent overdosage folic acid antagonists  product fusilev fda dosed one half usual dose racemic d l leucovorin  additional indication chemotherapy 5 fluorouracil palliative advanced metastatic colorectal cancer although they should mixed same infusion precipitate form suppression rhesus rh isoimmunization nonsensitized rho d negative women rh incompatible pregnancy rho d negative individuals transfused rh0 d positive red blood cells rbcs blood components containing rh0 d positive rbcs rh0 d positive non splenectomized chronic immune thrombocytopenic purpura itp raise platelet counts human antithrombin hereditary antithrombin deficiency prevention thromboembolism prevention peri operative peri partum thromboembolism characterized several therapeutic properties great interest us thought particularly effective healing bruises inflammation burns recently interest researchers moved even antimicrobial properties although there still few studies literature focused only action  few studies showed antimicrobic effectiveness against overall staphylococcus aureus salmonella enterica candida albicans aspergillus niger sterile preparation white  hard paraffin isopropyl palmitate sterile surgical bone wax control bleeding from damaged bone during surgery should confused aseptic surgical wax bpc 1949  known horsley wax  contained yellow  olive oil phenol mercuric chloride solution control haemorrhage bone cranial surgery diagnostic agent mantoux test detect infection mycobacterium tuberculosis alleviating surface irritation topical ocular administrations artificial tear solutions  found topical formulations aid more efficient drug diffusion across membranes prophylaxis against rabies virus exposed virus immunocompromised previously recieved rabies vaccine fda prophylaxis against tetanus injured incomplete uncertain immunization statu fda  active tetanus fda approved only food historically indigestion ulcers colds cough asthma bronchial congestion arthritic pain cancer leprosy syphilis orally stimulant antispasmodic increase menstrual flow topically  mild inflammation oral pharyngeal mucosa aphthous ulcers gingivitis chapped lips hemorrhoids bedsores wounds abrasions furunculosis bad breath loose teeth foods beverages  flavoring component manufacturing  fragrance fixative cosmetics embalming incense bleeding episodes adults acquired hemophilia prophylaxis bleeding haemophilia congenital factor viii deficiency  fda prophylaxis bleeding all age haemophilia b congenital factor ix deficiency cough less potent treatments failed fda db11609 antitussive fda signs symptoms keratoconjunctivitis sicca dry eye syndrome  therapy antiviral medications chronic hepatitis c virus hcv infected hcv genoptypes 6 hcv hiv co infected depending level cirrhosis decompensation therapy include therapy db00811  db08934 product epclusa  chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis db00811 if decompensated cirrhosis fda symptomatic relief nasal non nasal symptoms seasonal allergic rhinitis perennial allergic rhinitis age older fda  symptomatic relief chronic spontaneous urticaria age older endometriosis without accompanying sterility limited single course 6 months duration per lifetime   preventing reducing severity chicken pox varicella zoster virus infections high risk individuals within 4 days exposure varicella zoster virus no approved therapeutic indications adults adjunct surgery subsequent removal tumour so prevent delay amputation palliative care irresectable soft tissue sarcoma limbs fda  melphalan via mild hyperthermic isolated limb perfusion active immunization against hepatitis b virus infection  vaccine will protect against infection hepatitis non non b hepatitis viruses hepatitis d delta agent does occur absence hepatitis b infection carrier state expected hepatitis d will prevented vaccination hepatitis b virus vaccine  vaccine administered any age from birth onwards start primary course vaccination booster dose complete primary course vaccination started plasma derived yeast derived vaccines booster dose subjects previously received primary course vaccination plasma derived yeast derived vaccines  areas low prevalence hepatitis b vaccination strongly recommended subjects increased risk infection these include following groups  health professionals physicians surgeons oral surgeons dentists nurses dental nurses dental hygienists podiatrists iv teams operating room personnel paramedical personnel close contact staff hemodialysis nephrology hepatology hematology oncology units laboratory personnel handling blood clinical specimens blood bank plasma fractionation workers pathologists morgue attendants cleaning staff handle waste hospitals emergency first aid workers ambulance staff dental medical nursing students  patients receiving frequent blood transfusion clotting factor concentrates those oncology units those thalassemia sickle cell anemia cirrhosis hemophilia etc  hemodialysis type diabetes  personnel residents institutions persons frequent close contacts high risk groups prisoners prison staff residents staff institutions developmentally challenged those contact aggressive biting residents being highest risk  persons increased risk their sexual practices males having sexual contact males others multiple sexual partners recent history sexually transmitted disease  persons injectable drugs illicitly  travellers areas high endemicity their close contacts  household contacts any above groups chronic hepatitis b infection  infants born hbsag positive mothers  chronic liver disease cld  subjects chronic liver disease subjects risk developing cld e g hepatitis c virus carriers persons abuse alcohol  others police fire fighters armed forces personnel morticians embalmers those through their work personal lifestyle exposed hepatitis b virus  areas both low high prevalence vaccination should offered all young children neonates risk well high risk groups advanced squamous cell carcinoma head neck failing standard therapies unsuitable radiotherapy surgery systemic chemotherapy fda  approved adjunctive therapy adults parkinson disease end dose motor fluctuations whose symptoms cannot stabilized levodopa dopa decarboxylase inhibitor combinations   18 age older invasive aspergillosis fda   18 age older invasive mucormycosis fda  where amphotericin b inappropriate   vitaminE deficiency digestive malabsorption pediatric congenital chronic cholestasis hereditary chronic cholestasis from birth full term newborns up 18 age  part appropriate regimen pulmonary multi drug resistant tuberculosis mdr tb effective regimen cannot otherwise composed reasons resistance tolerability  uncomplicated plasmodium falciparum infection adults children infants aged 6 months up weighing over 5 kg fda  db13941  tibia fractures adults adjunct standard care using open fracture reduction intramedullary unreamed nail fixation fda   single level lumbar interbody spine fusion substitute autogenous bone graft adults degenerative disc disease had least 6 months non operative condition   symptomatic lambert eaton myasthenic syndrome lems adults f272 aged 6 less than 17 age f4609  nevertheless important note current time only firdapse brand lems adults f272 ruzurgi brand lems aged 6 less than 17 f4609 monotherapy adults advanced transitional cell carcinoma urothelial tract after failure prior platinum containing therapy   narcolepsy without cataplexy  excessive daytime sleepiness narcolepsy  cardiomyopathy wild type hereditary transthyretin mediated amyloidosis adults a189708 a189711  trastuzumab capecitabine adults diagnosed advanced unresectable metastatic her2 positive breast cancer includes brain metastases those  received one more prior anti her2 based regimens metastatic setting   premenopausal women hypoactive sexual desire disorder medical psychiatric condition problems relationship effects medication drug  opthalmic solution reduction intraocular pressure open angle glaucoma ocular hypertension fda no approved therapeutic indications  medium chain triglyceride provide calories fatty acids long chain fatty acid oxidation disorders lc faods  although investigated several types cancer currently only neurofibromatosis type nf1 symptomatic inoperable plexiform neurofibromas pn  a193611  opioid induced constipation fda prevention nausea vomiting induced cytotoxic therapy postoperative  chronic weight 6 older obesity pro opiomelanocortin deficiency proprotein subtilisin kexin type deficiency leptin receptor deficiency  these conditions affect mc4r signalling pathway a224454 currently mantle cell lymphoma mcl received least one prior therapy  recently approved chronic lymphocytic leukemia small lymphocytic lymphoma  combined ivacaftor one product cystic fibrosis cf aged 12 older two copies f508del gene mutation least one mutation cftr gene responsive drug    ivacaftor elexacaftor product trikafta cf 12 age older least one f508del mutation cftr gene   locally advanced metastatic urothelial carcinoma disease progression during following platinum containing chemotherapy within 12 months neoadjuvant adjuvant platinum containing chemotherapy   unresectable stage iii non small cell lung cancer nsclc whose disease progressed following concurrent platinum based chemotherapy radiation therapy  approved extensive stage small cell lung cancer es sclc etoposide either carboplatin cisplatin first line therapy   monotherapy locally advanced unresectable non small cell lung cancer nsclc adults whose tumours express pd  tumour cells whose disease progressed following platinum based chemoradiation therapy  binimetinib metastatic melanoma braf v600e v600k mutation detected fda approved test  kisqali  selective cyclin dependent kinase inhibitor class drugs help slow progression cancer inhibiting two proteins called cyclin dependent kinase 4 6 cdk4 6  these proteins over activated enable cancer cells grow divide too quickly targeting cdk4 6 enhanced precision play role ensuring cancer cells do continue replicate uncontrollably no approved indication migraine without aura adults  there limited therapeutic uses formally some predominant indications include facilitate construction structurally immunologically effective attenuated vaccines t188   b role plays essential element formation lactulose  synthetic disaccharide constipation hepatic encephalopathy he  hepatic coma   nevertheless there many studies looking into variety possible uses  monosaccharide sugar accelerating senescence mice rats drosophila a32853 a32854  proposed association between consumed milk ovarian cancer a32855 a32856  possible role therapy focal segmental glomerulosclerosis a32858  among various others regardless none these proposed indications yet formally elucidated practical hydrochloride novel epidermal growth factor receptor egfr tyrosine kinase inhibitor exhibits encouraging efficacy tolerability advanced non small cell lung cancer nsclc failed previous chemotherapy travelers diarrhea noninvasive strains e coli status disease should complicated fever blood stool prevent drug resistant bacteria important mention indication should only done cases where infection proven strongly suspected bacteria   travallers diarrhea very common problem affecting 20 60 travellers defined increase frequency bowel movements three more loose stools per day during trip abroad condition rarely life threatening but severe cases produce dehydration sepsis most common cause travellers diarrhea pathogen from pathogens identified bacteria most common cause followed norovirus rotavirus similar viruses a39995 thcv does currently any fda health canada ema approved indications adjunct levodopa carbidopa parkinson disease  deleterious suspected deleterious germline brca mutated her2 negative locally advanced metastatic breast cancer adults fda  constipation predominant irritable bowel syndrome ibs c adults  currently being investigated hyperphosphatemia chronic kidney disease undergoing dialysis nct02081534 nct02675998  a185489 modere severe reactive ra irresponsive respond inadequately present intolerance disease modifying anti rheumatic drugs dmards tumor necrosis factor tnf antagonists methotrexate mtx monotherapy there intolerance mtx mtx administration inappropriate approved psoriasis vulgaris psoriatic arthritis pustular psoriasis psoriatic erythroderma  metastatic non small cell lung cancer nsclc whose tumors mutation leads mesenchymal epithelial transition met exon 14 skipping detected fda approved test  maintenance recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum based chemotherapy antiretrovirals multidrug resistant hiv infection heavily experienced adults failing their current antiretroviral therapy resistance intolerance safety concerns  hiv infection previously treated antiretroviral therapy  additionally  hiv infection virologically suppressed hiv rna lt 50 c ml regular antiretroviral regimen minimum three months without history failure no known factors resistance individual components medication  tenofovir emtricitabine   moderate severe active rheumatoid arthritis responded inadequately intolerant one more disease modifying anti rheumatic drugs monotherapy methotrexate pediatric under 18 weighing least 5 kg continued approval drug indication dependent upon confirmatory clinical trial results  drug conjunction oral antidepressant treatment resistant depression trd adults fda  note  approved anesthetic agent safety effectiveness anesthetic agent established date fda  monotherapy improve glycemic control type diabetes fda  metformin hydrochloride improve glycemic control diabetes type controlled regimen metformin already treated both metformin  administration sitagliptin improve glycemic control type diabetes sitagliptin appropriate  pointed out adjunct therapy diet exercise type diabetes mellitus characterized insulin resistance muscle liver results elevation glucose levels blood presence insulin deficiency insulin resistance related genetic factors obesity sedentary lifestyle aging increase blood glucose cause severe damage kidney eyes vascular system a31582 extended adjuvant early stage her2 overexpressed amplified breast cancer follow adjuvant trastuzumab based therapy fda adults moderate severe plaque psoriasis candidates systemic therapy phototherapy cushing disease whom pituitary surgery option curative  a191850 vasoconstrictor increasing blood pressure adults septic distributive shock fda  advanced prostate cancer  inhalation solution maintenance chronic obstructive pulmonary disease copd   copd growing disease being third leading cause death us disease characterized fully reversible airflow limitation  synthetic neuroactive steroid gamma aminobutyric acid gaba  receptor positive modulator postpartum depression ppd women fda a176080 a176083 f4063 f4066 f4072  osteoporosis post menopausal women high risk fractures osteoperosis intolerant treatments failed treatments  non metastatic castration resistant prostate cancer nm crpc  fda tardive dyskinesia adults fda  duchenne muscular dystrophy dmd age older fda context overall lice program topical head lice infestation 6 months age older  adjunct diet maximally tolerated statin therapy adults heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease warrants additional lowering ldl c   bempedoic ezetimibe diet maximally tolerated statin therapy elevated ldl c levels adults heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease require further lowering ldl c  relapsed refractory multiple myeloma dexamethasone must received least 4 prior therapies disease refractory least two proteasome inhibitors least two immunomodulatory agents anti cd38 monoclonal antibody bacterial skin skin structure infections gram positive organisms staphylococcus aureus methicillin resistant methicillin susceptible isolates  staphylococcus haemolyticus staphylococcus lugdunensis streptococcus agalactiae streptococcus anginosus group streptococcus anginosus streptococcus intermedius streptococcus constellatus  streptococcus pyogenes enterococcus faecalis well gram negative organisms escherichia coli enterobacter cloacae klebsiella pneumoniae pseudomonas aeruginosa fda adults pediatric 12 older metastatic merkel cell carcinoma mcc  insomnia characterized difficulties sleep onset sleep maintenance  relapsed refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll after least two prior therapies   cll cancer blood stem cells blood cells develop into different types cells leukemia there overproduction cells abnormal do mature into blood cells thus they just crowd out normal cells impair their normal function lymphocyte leukemia abnormal cell growth observed lymphoid cells type blood cells mature into lymphocytes cll type lymphocytic leukemia develops slowly over months  sll very similar disease cll these terms usually referred interchangeably only difference between these two diseases cll cells found mostly blood bone marrow while sll cells mainly found lymph nodes   well  obtained accelerated approval relapsed refractory follicular lymphoma after least two prior systemic therapies approval still under status continued approval restrained confirmatory trials   follicular lymphoma b cell lymphoma clusters lymph nodes tissues  first line metastatic non small cell lung cancer nsclc epidermal growth factor receptor egfr exon 19 deletion exon 21 r substitution mutations verified fda approved test   lung cancer leading cause cancer death nsclc accounts 85 lung cancer cases from cases nsclc approximately 75 present late diagnosis metastatic advanced disease produces survival rate 5  presence mutation egfr accounts more than 60 nsclc cases overexpression egfr frequent lymph node metastasis poor chemosensitivity a40018 a19201 june 27 2018 food drug administration approved encorafenib unresectable metastatic melanoma braf v600e v600k mutation detected fda approved test   cytarabine newly diagnosed myeloid leukemia over 75 old co morbidities preclude intensive induction chemotherapy   myeloid leukemia characterized abnormal production myeloblasts red cells platelets considered cancer blood bone marrow most common type leukemia adults  gonadotropin releasing hormone gnrh receptor antagonist moderate severe pain endometriosis fda  metastatic ros1 positive non small cell lung cancer adults   adults children over 12 old ntrk gene fusion positive solid tumors metastasized surgical resection likely result severe morbidity progressed previous therapies no comparable alternative therapies available relapsing primary progressive forms multiple sclerosis fda chagas disease children 12 age  osteoarthritis affecting hip knee  thrombocytopenia chronic liver disease scheduled undergo procedure fda  fulvestrant women hormone receptor hr positive human epidermal growth factor receptor her2 negative advanced metastatic breast cancer disease progression following endocrine therapy   inidicated monotherapy hr positive her2 negative advanced metastatic breast cancer disease progression following endocrine therapy prior chemotherapy metastatic setting over counter dietary supplement increasing bone density regulating blood fat  chronic immune thrombocytopenia itp had insufficient response previous therapy fda  fulvestrant postmenopausal women men advanced metastatic breast cancer cancer must hormone receptor hr positive human epidermal growth factor receptor her2 negative pik3ca mutated cancer must detected fda approved test following progression after endocrine based regimen smallpox infection administered children adults minimum body weight 13 kg  fda  inhibitor orthopoxvirus vp37 envelope wrapping protein fda  maintenance 12 older severe asthma eosinophilic phenotype  pathology severe asthma eosinophilic phenotype denotated th2 high phenotype phenotype characterized expression il 5 il 13 airway hyperresponsiveness responsiveness inhaled corticosteroids high serum ige eosinophilia blood airway th2 high phenotype il 5 presents central role responsible eosinophil differentiation survival activation migration lungs a31295 vosevi  db08934  db11613  approved genotypes 6 previously treated ns5a inhibitor genotypes 1a 3 infection previously treated hcv regimen containing db08934 without ns5a inhibitor   tetracycline class drug inflammatory lesions non nodular moderate severe acne vulgaris 9 age older fda prophylaxis cytomegalovirus cmv infection disease cmv seropositive recipients allogeneic hematopoietic stem cell transplant hsct  fda serotonin synthesis inhibitor telotristat etiprate potential reduce serotonin levels address key elements carcinoid syndrome meropenem 18 age older complicated urinary tract infections cuti pyelonephritis following susceptible microorganisms escherichia coli klebsiella pneumoniae enterobacter cloacae species complex fda initially formulated alzheimer progressive supranuclear palsy a31601 raising interest comes from significant upregulation gsk 3 brain alzheimer disease function degradant  catenin important prevents transcription cell survival genes all these factors directed current research towards kinase potential target a31603 alzheimer disease most prevalent form dementia most accepted hypothesis explain disease related presence amyloid  triggers cascade will alter tau protein provoke synaptic dysfunction neuronal death a31605  gsk 3 importance tissue repair pathway pointed out novel application  thus under research natural repair deep caries lesions a31602  third generation anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki   alk positive metastatic non small cell lung cancer nsclc whose disease progressed prior crizotinib least one alk inhibitor metastatic disease b prior alectinib first alk inhibitor therapy metastatic disease c prior certinib first alk inhibitor therapy metastatic disease  fda  trials studying diagnostic nerve trauma inflammation pain neuropathic arthritis rheumatoid coronary heart disease among others relapsed refractory myeloid leukemia flt3 mutation detected fda approved test indication expanded companion diagnostic include leukostrat cdx flt3 mutation assay   myeloid leukemia cancer impacts blood bone marrow rapid progression condition produces low numbers normal blood cells requirement continuous need transfusions   pan fibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda a177109 a177112 a177115 locally advanced metastatic urothelial carcinoma i susceptible fgfr3 fgfr2 genetic alterations fda  ii progressed during following least one line prior platinum containing chemotherapy within 12 months neoadjuvant adjuvant platinum containing chemotherapy fda  selection locally advanced metastatic urothelial carcinoma should based presence susceptible fgfr genetic alterations tumor specimens detected fda approved companion diagnostic like fda approved therascreen fgfr rgq rt pcr kit developed qiagen fda  above indication approved under accelerated approval us fda based tumor response rate fda  continued approval indication contingent upon verification description clinical benefit confirmatory trials fda  monotherapy topical corticosteroids aged 12 older moderate severe atopic dermatitis whose disease adequately controlled topical prescription therapies those therapies advisable   add maintenance moderate severe asthma aged 12 older eosinophilic phenotype oral corticosteroid dependent asthma relief bronchospasm status asthmaticus   nasal polyps accompanied inadequately controlled chronic rhinosinusitis  chorea huntington disease fda  medication adults relapsed refractory diffuse large b cell lymphoma bendamustine rituximab returned progressed after more previous therapies improving neurological symptoms damage from ischemic stroke delaying disease progression als drug fascioliasis aged 6 old above fda primary medical purpose  sb currently removal eschar adults deep partial full thickness thermal burns fda  besides official indication however believed sb several purposes well cardiovascular health osteoarthritis autoimmunity blood clotting diarrhea cancer surgery debridement  although specific mechanisms action these indications remain elucidated a27198 anaplastic lymphoma kinase positive metastatic non small cell lung cancer alk nsclc  represents only 3 5 nsclc cancer cases but alk mutation overexpression presence several oncogenic fusion proteins solid hematologic tumors pointed out importance well potential cancer therapy target a31311 alk related cases nsclc presence fusion gene em alk fused alk protein echinoderm microtubule protein like 4 whose original function correct formation microtubules a31313 presence aberrant fusion protein results abnormal signaling provokes increased cell growth proliferation survival a31316 crizotinib cases but presence alk kinase domain mutations confer resistance thus  alk nsclc intolerance crizotinib a31314 symptomatic urinary incontinence increased urinary frequency urgency overactive bladder oab    neurogenic bladder result spinal cord injury a32581  anemia adults beta thalassemia require regular red blood cell transfusions  antiretroviral agents hiv infection no prior antiretroviral history  replace current antiretroviral regimen those virologically suppressed hiv rna less than 50 copies per ml stable antiretroviral regimen no history failure no known substitutions resistance   different types cancer most notably philadelphia chromosome positive ph  chronic myeloid leukemia cml resistance intolerance bcr abl tyrosine kinase inhibitors resistant intolerant imatinib only therapeutic currently primarily active ingredient topical agents treating common warts verruca vulgaris  periungual warts plantar warts molluscum contagiosum a32891 a32892 f32   same time topical applications number off indications like callus removal cutaneous leishmaniasis herpes zoster acquired perforating dermatosis a32892  furthermore since most topical applications most commonly available 0 7 formulation more potent mixture 0 7 formulation most commonly common warts periungual warts molluscum contagiosum while more potent mixture typically limited only healthcare professionals clinical setting treating plantar warts more specialized off conditions a32891 a32892 f32  moreover there studies into whether could effective being inflammatory model cancer  either yet formally elucidate any results a32892 drug tetracycline class antibacterial complicated intra abdominal infections 18 age older fda monotherapy deleterious brca mutation germline somatic advanced ovarian cancer treated two more chemotherapies select therapy based fda approved companion diagnostic  prophylaxis venous thromboembolism vte conditions moderate severe restricted mobility qualify risk vte pediatric mucopolysaccharidosis vii mps vii sly syndrome drug relapsing forms multiple sclerosis ms  include clinically isolated syndrome relapsing remitting disease active secondary progressive disease adults fda  imipenem cilastatin complicated urinary tract infections pyelonephritis  complicated intra abdominal infections susceptible organisms adults induction maintenance procedural sedation adults undergoing procedures lasting 30 minutes less  investigated antineoplastic agent solid tumors advanced solid tumours myeloid leukaemia  community acquired bacterial pneumonia bacterial skin skin structure infections susceptible organisms adults fda migraine without aura adults  2014  approved japan cases influenza were unresponsive conventional a191721 given efficacy targetting several strains influenza investigated countries novel viruses ebola most recently covid 19 a191688 a191724 relapsed follicular lymphoma fl received least two prior systemic therapies intravenous relapsed refractory mycosis fungoides mf szary syndrome ss after least one prior systemic therapy approval provides new option mf first fda approval drug specifically szary syndrome fda  topical acne vulgaris 12 age older  adults primary secondary myelofibrosis either intermediate high risk  aquaporin 4 aqp4 immunoglobulin positive aqp4 igg neuromyelitis optica spectrum disorder nmosd  available over counter antacid alleviate pain gastritis peptic ulcer disease heartburn esophagitis hiatus hernia anorexia a33109 investigated lymphoma non hodgkin multiple myeloma anticoagulant disseminative blood vessel coagulation hemorrhagic lesions hemorrhagic tendencies prevents blood clot formation during extracorporeal circulation undergoing continuous renal replacement therapy extra corporeal membrane oxygenation  adults relapsing forms ms include relapsing remitting disease clinically isolated syndrome active secondary progressive ms  18 age older complicated urinary tract infections cuti pyelonephritis limited no alternative options should only infections proven strongly suspected susceptible microorganisms fda  bosnia relapsing remitting multiple sclerosis  metastatic small cell lung cancer sclc disease progression after platinum based chemotherapy  mxp relapsed refractory hairy cell leukemia hcl received least two prior systemic therapies purine nucleoside analog drug recommended severe renal impairment crcl lt 29 ml min   hcl uncommon type lymphocytic leukemia starts b cells b lymphocytes characterized accumulation abnormal b lymphocytes hcl called hairy produces hair like projections surface cancer cells usual symptom people having hcl presence splenomegaly less often hepatomegaly a38877 human immunodeficiency virus type hiv infection highly experienced adults multidrug resistant hiv infection failing their current antiretroviral regimen fda  approval trogarzo supported clinical trial 40 experienced adults mdr hiv infection persistently had elevated levels hiv rna their blood despite heavy antiretroviral therapy majority study had previously treated 10 antiretroviral medications   selective multi targeted tyrosine kinase inhibitor suppresses c met c ret mutant forms c kit pdgfr flt3  suppresses rad51 protein critical component double stranded dna repair cancer cells primary therapeutic currently therapy levadopa parkinson disease adults gt 25 age exception drug induced parkinsonism f2   certain doses product levodopa restless legs syndrome sometimes parkinson disease  t181  there some studies prompted european medicines agency confer orphan designation upon  hydrochloride potential therapy beta thalassaemia f3  although studies ongoing no evidence formally elucidated yet f3  topical acne vulgaris 9 age older  adults diagnosed community acquired bacterial pneumonia cabp susceptible bacteria should reserved confirmed susceptible organisms high probability infection susceptible organisms list susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillin susceptible  legionella pneumophila haemophilus influenza chlamydophila pneumoniae mycoplasma pneumoniae  no approved indication bacterial vaginosis women  effects investigated area analgesia anti inflammation effects reported about molecule a39816  molecule approved widely accepted veterinary pain reduction arthritis a39835 humans researched control pain inflammation osteoarthritis a39844 a39843  effect explained through function prostaglandin e2 pge2 key mediator swelling redness pain classic signs inflammation effect pge2 results from action through four receptor ep1 ep2 ep3 ep4 from ep4 primary mediator pge2 driven inflammation a39817 phenylketonuria pku uncontrolled blood phenylalanine concentrations greater than 600 micromol l existing  calcium sensing receptor agonist  secondary hyperparathyroidism hpt chronic kidney disease ckd hemodialysis demand control bleeding episodes adults previously diagnosed von willebrand disease   contains only vwf thus administration offers flexibility administer coagulation factor viii if needed von willebrand disease inherited disorder characterized deficiency misfunction von willebrand factor vwf  deficiency blood cannot clot properly present disease prone prolonged excessive bleeding there three types disease type 3 autosomal recessive inherited disorder marked very low absent levels vwf  pediatric 16 older metastatic locally advanced epithelioid sarcoma eligible complete resection  metastatic triple negative breast cancer mtnbc undergone two more prior therapies metastatic disease   indication approved under accelerated approval continued approval contingent demonstration clinical benefit confirmatory trials   available commercially available product corifact approved food drug administration routine prophylactic peri operative surgical bleeding pediatric congenital fxiii deficiency fda primary therapeutic currently active ingredient capsaicinoid nonivamide compound topical analgesic temporary relief pain rheumatism arthritis lumbago muscular aches sprains strains sporting injuries conditions where local warmth beneficial f11  nevertheless most available studies regarding nonivamide topical analgesics focus specifically their efficacy safety treating non specific low back pain typically finding analgesic effective safe well tolerated medication indication a32785 a32786  cream topical impetigo staphylococcus aureus streptococcus pyogenes aged months age older fda drug diagnosed non metastatic castrate resistant prostate cancer  chronic idiopathic constipation adults  acne topical dental caries dental  symptomatic tenosynovial giant cell tumor tgct severe morbidity functional limitations amenable improvement surgery  locally advanced metastatic urothelial cancer previously received programmed death receptor pd programmed death ligand pd  inhibitor platinum containing chemotherapy neoadjuvant adjuvant locally advanced metastatic setting  variety neurological psychiatric disorders dyskinesia alcohol withdrawal syndrome negative symptoms psychosis agitation aggression elderly diagnosis growth hormone deficiency aghd  fda currently under investigation topical ulcerative oral mucositis  thrombocytopenia adults chronic liver disease scheduled undergo medical dental procedure vwf factor viii complex prevention excessive bleeding during after minor major surgery pediatric von willebrand disease demand control bleeding episodes  von willebrand disease inherited disorder characterized deficiency misfunction von willebrand factor vwf  deficiency blood cannot clot properly present disease prone prolonged excessive bleeding there three types disease type 3 autosomal recessive inherited disorder marked very low absent levels vwf  copd chronic obstructive pulmonary disease known chronic obstructive lung disease asthma prevents recurrence clostridium difficile infection people 18 older either currently receiving c difficile infection high risk recurrence calcium glubionate conditions low calcium levels bone loss osteoporosis  weak bones osteomalacia rickets  decreased activity parathyroid gland hypoparathyroidism  certain muscle disease latent tetany  certain make sure they getting enough calcium e g  women pregnant nursing postmenopausal people taking certain medications phenytoin phenobarbital prednisone drug reduce risk life threatening infection neutropenia particularly after cytotoxic chemotherapy  reduce duration neutropenia severity infections non myeloid malignancy undergone autologous allogeneic bone marrow transplantation established cytotoxic chemotherapy addition reduce incidence infection established cytotoxic chemotherapy  mobilise peripheral blood progenitor cells pbpcs alone after myelosuppressive chemotherapy order accelerate haematopoietic recovery infusion cells after myelosuppressive myeloablative therapy  accelerate engraftment these cells after their reinfusion  granocyte severe chronic neutropenia congenital agranulocytosis kostmann syndrome non small cell lung cancer small cell lung cancer oesophygeal cancer head neck cancers a20300 fluciclovine detection agent positron emission tomography pet men suspected prostate cancer recurrence based elevated blood prostate specific antigen psa levels following prior a31388 overexpression l type amino acid transporters lat1 lat3 mediate uptake essential amino acids extensively reported tumoral mechanism cell growth a31389 please refer db00085 adults children aged 12 above hereditary factor x deficiency demand control bleeding episodes perioperative bleeding mild hereditary factor x deficiency fda  emergency reversal coagulation factor deficiency recieving vitamin k antagonist therapy fda  protein administered part cocktail containing several coagulation factors administered cases uncontrolled bleeding  factor vii alone congenital hemophilia b  acquired hemophilia congenital factor vii deficiency glanzmann thrombasthenia off refractory bleeding after cardiac surgery warfarin related intracerebral hemorrhage  brands human factor vii currently only vitamin k coagulation factors reverse vitamin k antagonist activity major bleeds urgent surgery invasive procedures control bleeding episodes perioperative routine prophylaxis against bleeding episodes hemophilia b inhibitors fda  absence factor viii ix inhibitors factor ix christmas disease factor ix deficiency treated injection factor ix produced from human plasma tranexamic acid value undergoing surgery inherited factor ix deficiency order reduce perioperative risk bleeding known elicit number potentially beneficial pharmacological effects anti irritant anti inflammatory anti microbial actions bisabolol demonstrated enhance percutaneous absorption certain moleculesused intermediate organic synthesis dyes drugs local antibacterial agent root canal therapy topical antiseptic ointments medication  sometimes vasoprotective agent  microbiology laboratory aid identification bacterial species especially enterococci listeria  all strains group d streptococci hydrolyze sculin 40 bile mucocutaneous infections herpes simplex virus type type ii genital warts adjunctive therapy podophyllin carbon dioxide laser  active pharmacological ingredient pharmaceutical preparations so no official indication dermatology topical clobestasone butyrate helps reduce itchiness erythema eczema dermatitis ophthalmology  butyrate 0 eye drops shown safe effective dry eyes sjgren syndrome spinal muscular atrophy sma pediatric  chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious inflammatory diseases upper respiratory tract metastatic t790m mutation positive non small cell lung cancer a19196  proven effective twice daily glaucoma ocular hypertension currently studies approved both diabetic retinopathy diabetic macular oedema  rheumatology particular rheumatoid arthritis ankylosing spondylitis analgesic painful arthritic pathologies there no current pharmacotherapeutic products based  stimulates intestinal fluid secretions gastrointestinal tract support regular bowel function  taken orally once daily works locally upper gi tract stimulate secretion intestinal fluid support regular bowel function late infantile neuronal ceroid lipofuscinosis type cln2 disease decelerate progressive motor function decline 3 age older cln2 disease form batten disease rare inherited neurodegenerative disorder seizures ataxia rapid loss language motor functions blindness early death   lack lysosomal enzyme tripeptidyl peptidase tpp1 subsequent accumulation lysosomal storage materials normally metabolized enzyme central nervous system no approved indication no approved indication food without any limitation drug  nutrient supplement special dietary foods infant formula  presents relevant role ensuring oocyte fertility  studied polycystic ovaries a32751  being researched diabetes a32766 prevention metabolic syndrome a32768 aid agent weight loss a32769 depression psychiatric disorder anxiety disorder a32770 prevention cancer a32771 bacterial infection part electrolyte supplementation total parenteral nutrition fda performance enhancing drug illicitly athletes  naturally occuring substance found predominantly skeletal muscles vertebrates primary utility within body serve maintanence recycling adenosine triphosphate atp muscular activity like contractions  given utility recycle atp most plausible therapeutic potentials involve conditions energy shortage increased energy requirements  ischemic stroke cerebrovascular diseases important note however relatively little clinical research done significantly further evidence any indications although administered intravenously cardiovascular conditions some countries  additionally because regulated controlled substance taken supplement some professional athletes means perhaps increase short bursts muscle strength energy professional athletics human antihemophilic factor cases hemophilia known classical hemophilia prevention control hemorrhagic episodes  if surgery needed hemophilia there need correction clotting abnormality cases human antihemophilic factor administered followed intermittent maintenance doses  hemophilia characterized deficiency coagulation factor viii results prolonged blood flow after injury surgery well recurrent bleeding t56 pancreatic enzyme replacement pancreatic insufficiency   intended mimic naturally produced human    powder prepared from gastric mucosa pigs cattle sheep   laboratory primarily unspecific hydrolysis proteins peptides acidic media addition provides limited hydrolysis native immunoglobulins yielding biologically active fragments   certain supplements  combined betaine hcl hydrochloric acid aid digestion various gastrointestinal conditions    reduction duration neutropenia incidence febrile neutropenia treated cytotoxic chemotherapy malignancy exception chronic myeloid leukaemia myelodysplastic syndromes   over counter antacid nutritional supplement industry sodium perborate disinfectant part ingredients detergents bleach powders personal care formulations cosmetic products  mainly salt oxidizing agent dyeing permanent waving f66  dentistry sodium perborate monohydrate aid removal phlegm mucus secretions occasional sore mouth cleansing minor wounds temporary cleanse canker sore removal foreign materials minor wounds   ophthalmic preparations sodium perborate preservative products dry eye approved compound rapidly degrades harmless byproducts t203 absorb moisture prevent caking improve feel product pharmaceutical companies dietary supplement part formulation ingredients drug production antacid antiulcer preparations component antiepileptic drugs antifungal topical agents acne facial moisturizer   complexed arginine  antiatherosclerotic agent promote bone cartilage formation mammals t186 ferrous sulfate prevention iron deficiency anemia adults children a190804   different diseases syphilis amoebiasis yaws trypanosomiasis malaria   commonly vaginitis trichomonas vaginalis candida albicans a32839 a32841 orally administered  intestinal amoebiasis form suppositories researched proctitis   protozoan infections parasitic diseases characterized organisms classified kingdom protozoa formed great diversity organisms  db13908 available over counter products symptomatic relief sore throat postoperative sore throat a27155 emetic agent induction vomiting poisoning victims ingested systemic poison order prevent absorption chemicals through gastrointestinal tract low doses  expectorant   reports suggested vastly eating disorders produce vomiting t49 historically topical antiseptic agent skin infections f4549 maintains european countries vaginal tablet promestriene vaginal infections f4552 some countries brasil single agent cerebral peripheric vascular events  know more about part ergoloid mesylate mixture please visit db01049 various skin conditions atopic eczema inflammatory dermatoses  europe form topical antiviral human herpes keratitis a32643 human herpes keratitis inflammation cornea eye herpes simplex virus infection infection cause significant morbidity whose incidence significantly increased presence recurrent infection even produce corneal blindness a32645  3 cream dermal herpes simplex virus a32643 virus produce infection ubiquitously highly contagious there two types herpes virus type mainly transmitted oral oral contact type sexually transmitted  ioxitalamate both available forms exploration digestive tract tomodensitometry regular gastroduodenal radiography restrained cases administration barium sulfate recommended contraindicated f55 intravascular administration ioxitalamate contraindicated present significant side effects f54 infections oral cavity upper lower respiratory tracts skin soft tissue infections alone mainly europe japan t207 prior withdrawal from various international regions concerns hepatotoxicity a39891 a39892 a39893  chemical had demonstrated potential usefulness predominantly prescription medication lysine indication managing level vision mild moderate cataracts facilitate delaying need surgical intervention a39863 a39869 a39890  elsewhere still available limited capacity non prescription topical cream product treating conditions like local pain inflammation dermatitis eczema pruritis hives insect bites burns erythema others   although products facing general discontinuation   over counter topical antibiotic gastric reflux reflux oesophagitis hiatus hernia heartburn heartburn pregnancy similar gastric distress f46  muscle spasticity diseases like parkinson multiple sclerosis antacid neutralization excess stomach acid f25  subsequently symptomatic diseases where necessary neutralize acid stomach example treating stomach duodenal ulcers heartburn stomach conditions excess stomach acid f25  currently licensed china russia prophylaxis influenza respiratory viral infections a191475 demonstrated activity against number viruses investigated flavivirus a191388 zika virus a191391 foot mouth disease a191394 lassa virus a191403 ebola virus a191403 herpes simplex a191409 addition shown vitro activity against hepatitis b c viruses chikungunya virus reovirus hantaan virus coxsackie virus b5 a191475 a191412  currently being investigated potential prophylactic agent prevention covid 19 sars cov infections a191385 a191550 children adolescents young adults high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection typically post operative multi agent chemotherapy  because potassium wide ranging roles body low intakes increase risk illness   potassium supplements prevent hypokalemia would particular risk if hypokalemia were develop e g  digitalis treated significant cardiac arrhythmias  potassium deficiency occurs rate loss through renal excretion loss from gastrointestinal tract higher than rate potassium intake addition serving preventative supplement  serves decreased potassium levels       acts emulsifier ph control agent food products     laboratory while performing karl fischer equation determine water content various substances f18   peptic ulcer gastric hyperacidity hypermotility gastritis pylorospasm hyperhidrosis excessive perspiration  mesylate japan chronic pancreatitis drug induced lung injury a193845 being investigated potential covid 19 a193800 lice scabies infestation pyrethroids now place  alkalizing agent surfactant counter ion cosmetic pharmaceutical formulations a27174  considered active pharmacological ingredient so no official indication mineral supplement prevent low levels magnesium magnesium very important normal physiologic functioning cells nerves muscles bones heart generally well balanced diet provides necessary amounts magnesium homeostasis however certain conditions causing chronic magnesium deficiency decrease levels magnesium these conditions include diuretics poor diet alcoholism medical conditions e g  severe diarrhea vomiting stomach intestinal absorption problems poorly controlled diabetes   widely applied foods natural sweetener therapeutic agent vast variety formulations reported anti inflammatory anti ulcer anti allergic antioxidant anti tumor anti diabetic hepatoprotective properties indications premenstrual syndrome viral infections anti lipidemic antihyperglycemic a33063 known remedy peptic ulcer stomach diseases t205 symptomatic lactose intolerance infants older requiring parenteral nutrition fluid diet   lactose intolerance occurs there existence inability break down lactose commonly found dairy products inability occurs lactase levels reduced thus there no via digest break down lactose undigested lactose moves into large intestine where normal flora bacteria interact cause bloating gas diarrhea a32592  fda canada ema approved but countries where marketed symptomatic pain swelling inflammation joints rheumathoid arthritis osteoarthritis low back pain post surgical pain  chronic inflammation joints presence rheumatoid arthritis ankylosing spondylitis irritation joints spinal column degenerative disorders inflammatory soft tissue rheumatism syndrome painful swelling inflammation injury   new application calcium intended food fortifier fortify foods like sauces condiments beer beverages soft drinks milk milk products soy milk soy products calcium nutrition   alone calcium lactate calcium chloride compounds either pharmaceutical tablets capsules injections preparation   essence  ultimately relatively new calcium supplementation option  no approved therapeutic indications fluorodopa f 18 positron emission tomography pet visualize dopaminergic nerve terminals striatum evaluation suspected parkinsonian syndromes ps  most typical uses anethol trithione currently includes increasing salivary secretion experiencing dry mouth being adjunctive therapy cholecystitis gallstone indigestion chronic hepatitis a32614 a32616   addition although some studies suggested anethol trithione possesses certain capacity inhibit tumorigenesis potential cancer therapy medication specific mechanism action effect remains elucidated a32619 certain national cancer institutes listing agent substance being studied cancer   dietary supplement over counter uses  esters inhalers asthma prophylaxis fda f4364 well inflammatory pruritic dermatoses f4355  db00588 nasal spray managing nonallergic rhinitis f4358 while db08906 nasal spray treating season perennial allergic rhinitis f4361 a177130 short term insomnia  adjunctive therapy diet  reduce triglyceride levels severe hypertriglyceridemia b reduce elevated total cholesterol low density lipoprotein ldl c  triglycerides apolipoprotein b increase high density lipoprotein hdl c primary hypercholesterolemia mixed dyslipidemia fredrickson types iia iib  fda relapsed refractory myeloid leukemia aml isocitrate dehydrogenase idh2 mutation chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis child pugh  mavyret hcv genotype infection previously treated regimen containing hcv ns5a inhibitor ns3 4a protease inhibitor pi  but both fda  chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis child pugh  mavyret hcv genotype infection previously treated regimen containing hcv ns5a inhibitor ns3 4a protease inhibitor pi  but both fda  up 25 age b cell precursor lymphoblastic leukemia all refractory second later relapse fda  temporary relief aches pains muscles tendons joints particular antivenin only envenomation bites from eastern coral snakes micrurus fulvius fulvius texas coral snakes micrurus fulvius tenere  fda   agent will neutralize venom arizona sonoran coral snakes micruroides euryxanthus south american species fda  under ema fda rix rfp hemophilia b  health canada rix frp prevent reduce bleeding episodes   hemophilia b second most common type hemophilia rare inherited bleeding disorder reduced absent levels factor ix fix  fix vitamin k dependent plasma protease activated involved blood coagulation cascade a32551 hemophilia b mutations fix gene cause different phenotypes severe form characterized presence spontaneous recurring bleeds into joints muscles excessive bleeding after trauma surgery a32552 prevent cytomegalovirus cmv disease after organ transplant   cytomegalovirus immune globulin intravenous human prophylaxis cytomegalovirus disease transplantation kidney lung liver pancreas heart fda   transplants these organs than kidney from cmv seropositive donors into seronegative recipients prophylactic cmv igiv should considered ganciclovir fda crofab pediatric north american crotalid envenomation term crotalid describe crotalinae subfamily formerly known crotalidae venomous snakes includes rattlesnakes copperheads cottonmouths water moccasins fda crofab pediatric north american crotalid envenomation term crotalid describe crotalinae subfamily formerly known crotalidae venomous snakes includes rattlesnakes copperheads cottonmouths water moccasins fda north american crotalid envenomation crotalinae rattlesnakes eg cottonmouths water moccasins copperheads rattlesnakes  fda   crofab sheep derived antivenin pediatric north american crotalid envenomation fda medication genetically modified oncolytic viral therapy local unresectable cutaneous subcutaneous nodal lesions melanoma recurrent after initial surgery fda  elsewhere ema notes agent adults unresectable melanoma regionally distantly metastatic stage iiib iiic ivm1a no bone brain lung visceral diseases   indicted documented suspected exposure botulinum toxin serotype e adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype c adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype g adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype f adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype d adults pediatric fda  indicted documented suspected exposure botulinum toxin serotype b adults pediatric fda clinical signs scorpion envenomation    topical agent soothe sensitive skin relieve symptoms various skin conditions contact atopic dermatitis eczema dermatitis acne urticata first second degree burns radiation dermatitis sunburn sore throat minor mouth throat infections     a32773 most common medical purpose currently formally non prescription internal deodorant product purpose deodorizing flatulence stools   a32566  additionally there various non prescription over counter  based wound healing products well ongoing studies into whether substance utilized legitimate hemostatic agent  usually soft tissue surgery otorhinolaryngology dermatologic settings a32567 a32568 a32569 a32570  moreover past seen some helicobacter pylori infection a32571  contrast contemporary first line therapies generally involve proton pump inhibitor antibiotic therapies generally achieve high rates pathogen eradication ease administration patient compliance dental disclosing products allowing highlighting bacterial placques no therapeutic indications  investigational drug approved any conditions relapsed refractory large b cell lymphoma after two more lines systemic therapy diffuse large b cell lymphoma dlbcl otherwise specified primary mediastinal large b cell lymphoma high grade b cell lymphoma dlbcl arising from follicular lymphoma main function prevention bleeding episodes thus  approved routine prophylaxis prevent reduce frequency bleeding episodes pediatric hemophilia without factor viii inhibitors   hemophilia a deficiency coagulation factor viii causes serious bleeding disorder standard done administration recombinant serum deriver factor viii induces formation anti factor viii alloantibodies factor viii inhibitors renders standard ineffective a31286 shingrix vaccine prevention herpes zoster shingles adults aged 50 older dotatate gallium 68 one most prominent radiopharmaceuticals imaging positron emission tomography binds somatostatin receptor usually overexpressed many neuroendocrine tumors both pediatric a31362 neuroendocrine tumors bening malignant tumors produced hormone producing cells neuroendocrine system   moderate persistent epithelial defect severe corneal ulcer neurotrophic keratitis adults fda f1502  improve glycemic control adults diagnosed type diabetes mellitus adjunct diet exercise    important note suitable first line drug diabetes controlled diet exercise addition studied pancreatitis  intended type diabetes diabetic ketoacidosis  reduction elevated intraocular pressure iop open angle glaucoma ocular hypertension fda vn rzyl children confirmed biallelic rpe65 mutation retinal dystrophy administration vn rzyl conditioned physician determination presence viable retinal cells fda rpe65 represents lca2 form leber congenital amaurosis lca  lca group inherited conditionts involves retinal degeneration severe vision loss early childhood leading total blindness 30 40 old lca2 form mutation interferes isomerohydrolase activity retinal pigment epithelium isomerohydrolase activity transforms trans retinyl esters 11 cis retinal natural ligand chromophore opsins rod cones photoreceptors presence rpe65 mutations opsins cannot capture light transduce into electrical responses initiate vision a31480 adults children hemophilia b control prevention bleeding episodes routine prophylaxis perioperative  ema approval demand bleeding episodes  hemophilia b characterized deficiency coagulation factor ix results prolonged oozing after injuries delayed recurring bleeding prior wound healing hemophilia b present more frequent bleeding episodes during childhood adolescence than adulthood t56 uncomplicated plasmodium falciparum infection adults children infants aged 6 months up weighing over 5 kg fda  db11638  males present conditions derived from deficiency absence endogenous testosterone these conditions primary hypogonadism defined testicular failure cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy hypogonadotropic hypogonadism characterized idiopathic gonadotropin lhrh deficiency pituitary hypothalamic injury from tumors trauma radiation  males replacement therapy conditions deficiency absence endogenous testosterone some treated conditions primary hypogonadism defined testicular failure cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy hypogonadotropic hypogonadism idiopathic gonadotropin luteinizing hormone releasing hormone deficiency pituitary hypothalamic injury from tumors trauma radiation case important accompany adrenal cortical thyroid hormone replacement therapy 3 stimulate puberty delayed puberty secondary pathological disorder if conditions occur prior puberty androgen replacement therapy will needed during adolescent development secondary sexual characteristics prolonged androgen might needed maintain sexual characteristics after puberty fda  females  secondarily presence advanced inoperable metastatic mammary cancer women from one five postmenopausal premenopausal women breast cancer benefited from oophorectomy considered hormone responsive tumor fda  injections currently formulated subcutaneous specifically only primary hypogonadism hypogonadotropic hypogonadism f1941  formulations limited because safety efficacy these subcutaneous products males late onset hypogonadism males less than 18 old yet established f1941  moreover subcutaneously administered only men hypogonadal conditions structural genetic etiologies considering medication could cause blood pressure increases raise risk major adverse cardiovascular events like non fatal myocardial infarction non fatal stroke cardiovascular death f1941  replacement therapy males conditions linked absence deficiency endogenous testosterone production  f4247 fda control serum phosphorus levels chronic kidney disease dialysis ferric citrate femring vasomotor urogenital symptoms menopause femring  shown improve symptoms atrophy vagina dryness burning pruritus dyspareunia lower urinary tract urinary urgency dysuria  currently available any fda health canada approved products depo estradiol intramuscular depot injection moderate severe vasomotor symptoms hypoestrogenism hypogonadism currently available any fda health canada approved products commercially available intramuscular injection product delestrogen moderate severe vasomotor symptoms vulvovaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure advanced androgen dependent carcinoma prostate palliation only   available db09123 commercially available product natazia prevention pregnancy heavy menstrual bleeding incorporated active ingredient active components like fish oils soya oil olive oil prescription medication smoflipid  medium chain triglycerides mcts constitute therapy supplying energy calories essential fatty acids part parenteral nutrition regimen oral enteral nutrition impossible insufficient contraindicated f126 f127  however given predominant indication mcts acting source calories essential fatty acids mcts alone component part various unique individual patient tailored composite regimen therapies mcts ultimately wide range health conditions involve energy deficiency malnutrition disturbances ordinary absorption dietary fats a33175 f128  conditions include crohn disease waldmann disease weight maintenance aids cachexia various disturbances patient bile secretion like cholestasis disturbances hepatic intestinal circulation bile acids intestinal dysbacteriosis  pancreatic lipase secretion like pancreatic failure course cystic fibrosis  a33175 f128  active ingredient registered commercial biocide preservative many industrial processes registered biocidal uses include pulp paper mills water cooling towers waste water evaporative condensers heat exchangers food pasteurizing plants metalworking fluids oilfield applications f2317  addition preservative uses include household products e g  dishwashing liquids laundry products  latex emulsions polymer lattices pigments leather milk samples analysis f2317  formulated into granular domestic end products form cat litter f2317 under fda approval  pharmaceuticals typically products consisting omega 3 fatty acids eicosapentaenoic acid epa docosahexaenoic acid dha primarily adjunct diet reduce triglyceride levels severe  gt 500 mg dl hypertriglyceridemia fda f36  under ema approval pharmaceuticals comprised virtually same fish derived omega 3 fatty acids epa dha specifically adjuvant secondary prevention after myocardial infarction addition standard therapy ie statins antiplatelet medicinal products beta blockers ace inhibitors  b supplement diet dietary measures alone insufficient produce adequate response particularly type iv hypertriglyceridemia monotherapy type iib iii statins control triglycerides insufficient   addition prescribing information ema approved pharmaceuticals adjunct diet reduce very high  gt 500 mg dl triglyceride levels much like similar fda approved indications f37 fda  widely food even component adulteration olive oil t41 over counter ear drops help lubricate ear wax f124 ingredient cleansing soaps emollient cream preparations laxatives  f125  usually solubilize drugs poor water solubility part oral formulation t224  orally administered  well researched prevent heart diseases lower cholesterol levels well aid weight loss decrease appetite  no approved therapeutic indications primary medical indication formally active ingredient patient care product non prescription pediculicide rinse a32330  marking lymphatic vessels arterial territories well sentinel lymph node prior biopsy operable breast cancer clinically negative lymph nodes radiotracer a32575  textile paper agriculture cosmetic industry a32574 ppfh replacement therapy complex deficiencies coagulation factors coagulopathy substitution therapy emergency cases factor deficiencies rapid reversal effects oral anticoagulants dangerous hemorrhages during fibrinolytic therapy ppfh therapeutic plasma exchange procedures thrombotic thrombocytopenic purpura   ppfh shock where there predominant loss plasma fluids red blood cells  graft versus host disease agvhd pediatric gvhd should refractory systemic corticosteroid therapy immunosuppressive agents  grades c d disease any organ  grade b agvhd involving any visceral organ gi tract liver but excluding skin  menopausal symptoms menstrual dysfunction   radiolabelled sodium pertechnetate tc99m solution develop technetium tc99m  solution solution adults scintigraphic imaging  conjunction appropriate imaging modalities possible  determining location inflammation infection peripheral bone adults suspected osteomyelitis fda  utilized medicinal product diagnostic only fda somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors gep nets  foregut midgut hindgut neuroendocrine tumors adults fda employed ingredient toothpaste formulations  predominantly treating teeth hypersensitivity a33167 a33168  f118  iron loss iron deficiency maintain hemoglobin reduce prescribed dose erythropoiesis stimulating agent esa required maintain desired hemoglobin levels   iron deficiency appears dietary intake does meet body requirement there chronic external blood loss during blood loss body iron stores sufficient accelerated erythropoiesis restoration iron homeostasis but altered homeostasis remains weeks months then some supplement needed some causes iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 influenza b virus infection    fda 12 older symptomatic no more than 48 hours  clinical trials drug did include subjects 65 age older determine whether they respond different way than younger subjects fda hemophilia von willebrand disease factor xiii deficiency approved health canada control prevention hemorrhagic episodes routine surgical prophylaxis hemophilia congenital factor viii deficiency classic hemophilia   approved european medicines agency prophylaxis bleeding haemophilia congenital factor viii deficiency primary health related formally dietary supplement demonstrate genuine vitaminE deficiency same time vitaminE deficiency generally quite rare but occur premature babies very low birth weight  lt 1500 grams  individuals fat malabsorption disorders fat required digestive tract absorb vitaminE  individuals abetalipoproteinemia  rare inherited disorder causes poor absorption dietary fat  require extremely large doses supplemental vitaminE daily around 100 mg kg 5 10 g day   all cases alpha tocopherol largely preferred form vitaminE administered  elsewhere vitaminE chemical profile fat soluble antioxidant capable neutralizing free radicals body continues generate ongoing interest study regarding how whether vitaminCan help prevent delay various chronic diseases free radicals potential biological effects vitaminE possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer more t166  none these ongoing studies yet elucidate any formally significant evidence however t166  similarly more effective clinical trials necessary confirm what only accrued preliminary data comes studies proposing demonstration capability act anti cancer therapy regulator inflammation  a32958 a32959 addition any following information owing closely related chemical nature alpha tocopherol acetate please refer drug information page alpha tocopherol acetate further data  vitaminE known antioxidant activities protective against cardiovascular disease some forms cancer demonstrated immune enhancing effects limited benefit some asthma rheumatoid arthritis helpful some neurological diseases alzheimer some eye disorders cataracts diabetes premenstrual syndrome help protect skin from ultraviolet irradiation although claims reverses skin aging enhances male fertility exercise performance poorly supported help relieve some muscle cramps primary health related formally dietary supplement demonstrate genuine vitaminE deficiency same time vitaminE deficiency generally quite rare but occur premature babies very low birth weight  lt 1500 grams  individuals fat malabsorption disorders fat required digestive tract absorb vitaminE  individuals abetalipoproteinemia  rare inherited disorder causes poor absorption dietary fat  require extremely large doses supplemental vitaminE daily around 100 mg kg 5 10 g day   all cases alpha tocopherol largely preferred form vitaminE administered  elsewhere vitaminE chemical profile fat soluble antioxidant capable neutralizing free radicals body continues generate ongoing interest study regarding how whether vitaminCan help prevent delay various chronic diseases free radicals potential biological effects vitaminE possesses like cardiovascular diseases diabetes ocular conditions immune illnesses cancer more t166  none these ongoing studies yet elucidate any formally significant evidence however t166 moderate severe plaque psoriasis   fda dimethicone approved transdermal drug delivery system  part simethicone element dow corning q7 2242 lva antifoam   some otc containing dimethicone relieve discomfort infant gas air swallowing certain formulas food  prevent help rash protect relieve chapped cracked skin  anti lice agent  oral gel relief pain discomfort common mouth ulcers cold sores denture sore spots infant teething mouth ulcers sore spots orthodontic devices children   dtpa widely industry medicine medical agent approved medical imaging decorporation internally deposited radionuclides a32501 fda approved individuals known suspected internal contamination plutonium americium curium increase rates elimination   pharmacokinetic elimination kidneys  conjugated technetium tc 99m being clinically estimate physiological parameters glomerular filtration rat effective renal plasma flow t168 canada sativex received notice compliance noc adjunctive symptomatic relief spasticity multiple sclerosis ms responded adequately therapy demonstrate meaningful improvement during initial trial therapy  sativex received notice compliance conditions noc c adjunctive symptomatic relief neuropathic pain multiple sclerosis ms adjunctive analgesic advanced cancer experience moderate severe pain during highest tolerated dose strong opioid therapy persistent background pain  marketing authorisations conditions reflect promising nature clinical evidence need confirmatory studies verify clinical benefit should advised conditional nature authorizations conditions drug x linked hypophosphatemia radiological evidence bone disease children year age older adolescents growing skeletons   diuretic db00316  relief temporary water weight gain bloating swelling full feeling premenstrual menstrual periods  palonosetron drug akynzeo dexamethasone adults prevention delayed nausea vomiting initial repeat courses cancer chemotherapy but limited highly emetogenic chemotherapy fda  following indications listed ema f29  prevention delayed nausea vomiting highly emetogenic cisplatin based cancer chemotherapy f29  prevention delayed nausea vomiting moderately emetogenic cancer chemotherapy f29 no approved therapeutic indications recurrent chronic urinary tract infections primarily pyelonephritis pyelitis cystitis susceptible organisms usually escherichia coli klebsiella enterobacter staphylococcus proteus mirabilis less frequently proteus vulgaris absence obstructive uropathy foreign bodies   meningococcal meningitis where organism demonstrated susceptible haemophilus influenzae meningitis adjunctive therapy parenteral streptomycin   meningococcal meningitis prophylaxis   otitis media haemophilus influenzae concomitantly adequate doses penicillin erythromycin see appropriate labeling prescribing information    trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis adjunctive therapy pyrimethamine malaria chloroquine resistant strains plasmodium falciparum adjunctive therapy   currently increasing frequency resistant organisms limitation usefulness antibacterial agents sulfonamides especially chronic recurrent urinary tract infections   preventative migraine adults fda  preventive migraine adults  preventative migraine adults  humanized monoclonal antibody migraine prophylaxis episodic cluster headaches adults binding endogenous human calcitonin gene related peptide cgrp  a33112 potassium binder hyperkalemia  f130 does currently any fda health canada approved indications however october 2017 cbdv given orphan designation european medicines agency rett syndrome  again february 2018 fragile x syndrome   being investigated antibiotic action potential antibacterial agent future a33312  being investigated antibiotic action potential antibacterial agent future a33312  repel insects mosquitoes biting flies ticks chiggers fleas via topical over clothing   repair single multiple symptomatic full thickness cartilage defects knee without bone involvement adults cnj 016 vaccinia immune globulin intravenous human vigiv modification  eczema vaccinatum  b progressive vaccinia  c severe generalized vaccinia  d vaccinia infections individuals skin conditions burns impetigo varicella zoster poison ivy individuals eczematous skin lesions because either activity extensiveness lesions e aberrant infections induced vaccinia virus include accidental implantation eyes except cases isolated keratitis  mouth areas where vaccinia infection would constitute special hazard fda  shown effective against hiv herpes simplex virus hepatitis b virus a178330  know more about specific product indications please visit information orally available forms   alafenamide  disoproxil  currently approved any fda health canada approved indications db01075 antiemetic db00985   prevention nausea vomiting vertigo motion sickness developed opioid analgesic low abuse potential treating chronic pain   application filed fda approval treating chronic lower back pain diagnostic skeletal imaging agent demonstrate areas altered osteogenesis pediatric  allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved fda within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older schizophrenia related psychotic disorders approved fda within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved fda within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved fda within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older approved within allergenic epicutaneous patch tests aid diagnosis allergic contact dermatitis acd persons 6 age older ingredient draximage maa kit preparation technetium tc99m injection assessment lung perfusion evaluation peritoneovenous leveen shunt patency  source calories requiring parenteral nutrition vibrio cholerae cvd 103 hgr strain live antigen active oral immunization against infection vibrio cholerae serogroup o1 between 18 64 age  prevention control bleeding hemophilia acquired factor viii fviii deficiency  surgical invasive procedures pediatric von willebrand disease desmopression either ineffective contraindicated  severe i e type 3 von willebrand disease whom undergoing major surgery  complex iodine inducing antisepsis prevention infection minor cuts scrapes burns over counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda   zinc prevention zinc deficiency consequences stunted growth diarrhea children slowed wound healing utilized boosting immune system treating common cold recurrent ear infections well preventing lower respiratory tract infections    preventing treating iron deficiency anemia preventing treating iron deficiency anemia preventing treating iron deficiency anemia preventing treating iron deficiency anemia potassium regulate hypokalemia primary condition secondary medical conditions potassium regulate hypokalemia primary condition secondary medical conditions general uses  variety conditions firstly replenish depleted conditions but limited malabsorption decreased intake excess sodium intake  causes deficiency numerous following indications comprehensive but include main indications nutrient various products preparations contain   chloride  chloride one main preparations clinical setting oral solution prevention hypokalemia presenting without metabolic alkalosis failed conservative rich foods diuretic dose titrations  injection form chloride replenish feasible candidates oral  highly concentrated intended deficiency fluid restricted individuals cannot tolerate fluid volumes normally injected solutions contain lower concentrations  finally extended release tablet preparation chloride hypokalemia without metabolic alkalosis digitalis intoxication manage hypokalemic familial periodic paralysis prevention hypokalemia those high risk negative clinical outcomes if hypokalemia occurs digitalis those cardiac arrhythmias would particular risk negative outcomes    chloride dextrose sodium chloride  liquid preparation is clinical setting source water calories electrolytes   acetate solution meant alternative chloride replenishing added large volume infusion fluids intravenous injection   citrate citrate preparation renal tubular acidosis rta calcium stones nephrolithiasis  calcium oxalate stones any cause uric acid nephrolithiasis without calcium stones  regimen includes adequate water intake leading urine out put l day more sodium restriction    preventing treating iron deficiency anemia constipation clean bowel before colonoscopy fda constipation clean bowel before colonoscopy fda no fda ema approved therapeutic indications own lithium mood stabilizer depression mania often bipolar disorder lithium mood stabilizer manic episodes maintenance bipolar disorder fda there 3 formulations various indications inhaler prophylaxis asthma 4 fda  nasal spray treating nasal symptoms allergic rhinitis treating symptoms nasal congestion from seasonal allergic rhinitis treating nasal polyps 18 prophylaxis seasonal allergic rhinitis 12 f4292  ointment symptomatic dermatitis pruritis f4295 healthy levels achieved through well balanced diet but if food sources insufficient  supplements prevent deficiencies   medicine various salts laxative antacid products a19349 example  citrate available over counter manage occasional constipation   sulfate own total parenteral nutrition hypomagnesemia   sulfate prevent seizures pregnant women pre eclampsia manage seizures eclampsia a188087  control serum phosphorous adults chronic kidney disease require dialysis   iron deficiency anemia adults chronic kidney disease dialysis  supplement intravenous solutions given total parenteral nutrition tpn  maintain chromium serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda supplement intravenous solutions given total parenteral nutrition tpn  maintain chromium serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda supplement intravenous solutions given total parenteral nutrition tpn  maintain chromium serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda supplement intravenous solutions given total parenteral nutrition tpn  maintain chromium serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda supplement intravenous solutions given total parenteral nutrition tpn  maintain chromium serum levels prevent depletion endogenous stores subsequent deficiency symptoms fda  injections total parenteral nutrition maintain zinc serum levels prevent deficiency syndromes  relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestations corticosteroid responsive dermatoses endocrine hormonal disorders adrenal insufficiency addisons disease  many immune allergic disorders arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease zinc sulfate common zinc supplement parenteral nutrition a216916 following complexation sodium citrate yield gallium citrate ga 67  demonstrate presence hodgkin disease lymphomas bronchogenic carcinomas some inflammatory lesions  treated rivaroxaban apixaban  reversal anticoagulation needed life threatening uncontrolled bleeding   andexxa shown effective bleeding related any factor xa inhibitors than apixaban rivaroxaban   approved relapsed refractory aml susceptible idh1 mutation detected fda approved test fda  bacterial infections skin skin structure absssi  prevent drug resistance  should only infections susceptible bacteria  t hereditary transthyretin mediated amyloidosis adults fda  administered pre medication reduce complications fda  these include intravenous corticosteroid equivalent 10 mg dexamethasone 500 mg oral acetaminophen intravenous histamine h1 blocker equivalent 50 mg diphenhydramine intravenous histamine h2 blocker equivalent 50 mg ranitidine ethinyl estradiol females reproductive potential prevent pregnancy hormonal contraceptive chc  induces contraception thirteen 28 day cycles year following vaginal administration vaginal system must remain place continuously 3 weeks 21 days followed week 7 day vaginal system free interval females body mass index gt 29 kg m adequately evaluated fda  prophylaxis prevent attacks 12 older hereditary angioedema   hereditary angioedema hea autosomal dominant disorder resulted from presence c1 deficiency some reports high prevalence cases result from spontaneous mutations inherited condition manifested attacks subcutaneous submucosal edema face larynx gi tract limbs genitalia from all types attacks most serious laryngeal compromise airway rest attacks accompanied pain considerable dysfunction a38679 edetate calcium disodium reduce blood levels depot stores lead chronic lead poisoning  edetate disodium emergency hypercalcemia digitalis toxicity ventricular arrhythmias  indication number conditions allergic states dermatologic diseases edematous states endocrine disorders gastrointestinal diseases hematologic disorders neoplastic diseases nervous system ophthalmic diseases respiratory diseases rheumatic disorders  no approved therapeutic indications diloxanide alone primary agent asymptomatic cyst passers intestinal amebiasis entamoeba histolytica diloxanide concurrently sequentially agents nitroimidazoles eg metronidazole invasive extraintestinal forms amebiasis females palliation androgenresponsive recurrent mammary cancer women more than one year but less than five postmenopausal intramuscularly allergic states dermatologic diseases endocrine disorders gastrointestinal diseases hematologic disorders neoplastic diseases nervous system conditions ophthalmic diseases renal diseases respiratory diseases rheumatic disorders trichinosis neurologic myocardial involvement tuberculous meningitis subarachnoid block impending block  intra articularly gouty arthritis subacute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis  intralesional betamethasone phospahte alopecia areata discoid lupus erythematosus keloids lichen planus lichen simplex chronicus psoriatic plaques necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesions granuloma annulare  commonly cosmetic products skin hair a19503 polycarbophil constipation help maintain regular bowel movements previously treated adults adolescents 12 age above hemophilia congenital factor viii deficiency  demand control bleeding episodes fda  perioperative bleeding fda  routine prophylaxis reduce frequency bleeding episodes fda drug programmed death receptor pd blocking antibody metastatic cutaneous squamous cell carcinoma cscc locally advanced cscc candidates curative surgery curative radiation fda a39201 live antigen new york city board health strain vaccinia within acam2000 formulation active immunization against smallpox disease determined high risk contracting smallpox infection  approved adenosine deaminase severe combined immune deficiency ada scid pediatric  condition previously treated bovine pegamedase part enzyme replacement therapy   ada scid genetically inherited disorder very rare characterized deficiency adenosine deaminase enzyme suffering from disease often present compromised immune system condition characterized very low levels white blood cells immunoglobulin levels results severe recurring infections  transthyretin directed antisense oligonucleotide polyneuropathy hereditary transthyretin mediated amyloidosis adults   tyrosine kinase inhibitor currently pediatric solid tumors either neurotrophic receptor tyrosine kinase ntrk gene fusion without known acquired resistance mutation b metastatic where surgical resection likely result severe morbidity c no satisfactory alternative treatments progressed following fda  moment these uses only approved under auspices accelerated approval us fda based overall response rate duration response continuation support these indications contingent upon verification description continued clinical benefit confirmatory trials fda  pediatric primary hemophagocytic lymphohistiocytosis hlh refractory recurrent progressive disease intolerance conventional hlh therapy   hlh condition hyperinflammatory status characterized overwhelming activation normal t lymphocytes macrophages lead disturbances hematology profile even death part condition profile there reports proving massive overexpression interferon gamma thought drive immune hyperactivation leading organ failure a38676 condition usually developed present symptomatic profile within first months life these symptoms consist fever enlarged liver spleen lower number blood cells  drug is asparagine specific enzyme component multi agent chemotherapeutic regimen lymphoblastic leukemia pediatric young age month 21 fda  pharmacokinetics were examined given multiagent chemotherapy 124 b cell lineage all   fda approval drug based achievement maintenance nadir serum asparaginase activity above level 0 u ml administering calaspargase 2500 u m2 intravenously 3 week intervals  blastic plasmacytoid dendritic cell neoplasm bpdcn adults pediatric over old allows alternative previous intense consisted intensive chemotherapy followed bone marrow transplantation   bpdcn rare hematologic malignancy derived from plasmacytoid dendritic cells characterized significantly increased expression cells expressing cd4 cd56 cd123 markers restricted plasmacytoid dendritic cells lack expression lymphoid natural killer myeloid lineage antigens a40274 key feature malignant cells overexpression cd123 known interleukin 3 receptor constant requirement il 3 survival  current going research suggests natural biochemical compound found endogenously human body plays essential role generation critical bodily chemicals tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipids others a173830 a173833 a173851  research subsequently proposes if could utilized pharmaceutic considered so called putative longevity vitamin age delaying prolonged survival functionality perhaps via maintaining ongoing generation aforementioned bodily chemicals human body a173830 a173833 a173851   n8 gp adults children all ages hemophilia congenital factor viii deficiency routine prophylaxis reducing frequency bleeding episodes demand control bleeding episodes perioperative bleeding f3649  subcutaneous fluid administration hydration increasing resorption radiopaque agents subcutaneous urography   multiple routes increase dispersion injectable drugs   infections urinary tract meninges blood stream susceptible strains pseudomonas aeruginosa fda  approved severe primary insulin like growth factor igf deficiency gh gene deletion developed antibodies growth hormone gh a176020  severe primary igf deficiency defined fda  height standard deviation sd score less than equal 3 sd below normal b basal igf sd score less than equal 3 sd below normal c normal above normal levels growth hormone 2007 insmed  manufacturer made agreement tercica mecasermin manufacturer mecasermin would no longer available indication but could developed non short stature conditions severe insulin resistance myotonic muscular dystrophy hiv adipose redistribution syndrome a176125 nonprogressive blastomycosis skin mycoses daytime sleepiness obstructive sleep apnea narcolepsy but underlying airway obstruction apnea fda a176534 a176744  pediatric aged 12 over weighing least 40 kg coronavirus disease 2019 covid 19 infection requiring hospitalization under indication  should only administered hospital healthcare setting capable providing care comparable inpatient hospital setting   originally granted fda emergency authorization eua  2020 adults children suspected confirmed covid 19 hospital setting spo2 94   following fda approval eua revised cover hospitalized pediatric between 3 5 40 kg well those under 12 age weigh least 3 5 kg suspected laboratory confirmed covid 19   under both eua indications needing invasive mechanical ventilation extracorporeal membrane oxygenation ecmo should treated 5 days loading dose day extended up 10 days if they do show improvement requiring invasive mechanical ventilation ecmo should treated 10 days   drug moderate severe plaque psoriasis adults eligible receive systemic therapy phototherapy based their disease process fda relapsing forms multiple sclerosis ms adults specifically active secondary progressive disease clinically isolated syndrome well relapsing remitting ms   pomalidomide dexamethasone multiple myeloma adults received least two prior therapies lenalidomide proteasome inhibitor  adults diagnosed advanced gastrointestinal stromal tumor gist had prior therapy least 3 kinase inhibitors imatinib  active moderate severe rheumatoid arthritis alone methotrexate   currently reserved unable tolerate responded adequately one more disease modifying anti rheumatic drugs dmards   monoclonal antibody neovascular age related macular degeneration a187208  complicated urinary tract infections without pyelonephritis fda pain adults severe enough require intravenous opioid analgesics whom no acceptable alternative treatments exist  overactive bladder oab symptoms urge urinary incontinence urgency urinary frequency adults  radioactive agent positron emission tomography pet imaging aggregated tau neurofibrillary tangles nfts under evaluation alzheimer disease  under evaluation chronic traumatic encephalopathy  her positive breast cancer unresectable metastatic previously treated least anti her2 based regimens while cancer metastatic   continued approval will depend results clinical trial results confirming clinical benefit  anti her2 monoclonal antibody chemotherapy metastatic her2 positive breast cancer received two more prior anti her2 regimens least one prior regimen metastatic disease  sickle cell disease both pediatric aged 12 above  drug relapsing forms multiple sclerosis ms adults includes clinically isolated syndrome relapsing remitting disease well active secondary progressive disease  duchenne muscular dystrophy confirmed dmd gene mutation amenable exon 53 skipping indication represents accelerated approval based observed efficacy continued approval indication contingent verification safety efficacy confirmatory trial  mantle cell lymphoma mcl received least one prior therapy  lenalidomide  relapsed refractory diffuse large b cell lymphoma dlbcl otherwise specified whom ineligible autologous stem cell transplant asct   adults hepatic porphyria  conditionally approved ema adjunct diet adults familial chylomicronemia high risk pancreatitis had inadequate response diet triglyceride lowering therapy  adults moderately severely active rheumatoid arthritis had inadequate response intolerance methotrexate   do responded well intolerant one more disease modifying anti rheumatic drugs dmards  monotherapy methotrexate mtx   replacement growth hormone growth hormone deficiency  unresectable locally advanced metastatic cholangiocarcinoma previously treated fibroblast growth factor receptor fgfr2 fusion rearrangement detected fda approved test  unresectable metastatic gastrointestinal stromal tumors platelet derived growth factor receptor alpha exon 18 mutation a189339  desensitization highly sensitized kidney transplant positive crossmatch against available deceased donor  reserved unlikely receive transplant under available kidney allocation system prioritization programs highly sensitized  reduce frequency vaso occlusive crisis sickle cell diseases 16 old  spinal muscular atrophy sma months age older  migraine without aura adults   ivacaftor tezacaftor product trikafta lt sup gt tm lt sup gt  cystic fibrosis cf 12 age older least one f508del mutation ctfr gene  benzyhydrocodone acetaminophen  short term pain requiring opioid therapy  being investigated treating tumors a182036 a182039 derivatives similar dna binding ability reduced myelotoxicity being investigated their antitumor activity a182039 anxiety without psychoneurotic conditions a184910 radioactive diagnostic compound positron emission tomography pet diagnose somatostatin receptor positive neuroendocrine tumors pediatrics adults  pediatric less than age neonatal infant spinal muscular atrophy sma bi allelic mutations survival motor neuron smn1 gene  anti inflammatory immunosuppressive agent allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious conditions   organ transplant well endocrine neoplastic conditions  experimental kras inhibitor being investigated kras g12c mutant lung colon adenocarcinomas a187559 being investigated kras g12c mutant non small cell lung cancer colorectal cancer appendix cancer a187547 duchenne muscular dystrophy dmd confirmed mutation dmd gene would benefit from exon 53 skipping continued fda approval drug contingent upon results clinical trials confirm benefit  drug selectively staining internal limiting membrane ilm  ebola zaire vaccine active immunization individuals 18 age older protect against ebola virus disease evd zaire ebolavirus  iron deficiency adults  drug iron deficiency anemia experienced intolerance oral iron preparations insufficient clinical response orally administered iron  ferric derisomaltase non hemodialysis dependent chronic kidney disease  australia united kingdom ferric derisomaltase cases rapid delivery iron required   developed russia potential influenza b infections a191706 experimental drug being researched cardiovascular disease sars cov infections a192426 authorized under emergency authorization eua active immunization prevent coronavirus disease 2019 covid 19 severe respiratory syndrome coronavirus sars cov individuals 18 age older administered two doses one month 28 days apart  prodrug eidd 2801 being studied activity against number viral infections influenza mers cov sars cov a193014 a193029 n4 hydroxycytidine prodrug being studied activity against number viral infections influenza mers cov sars cov a193014 a193029 ret fusion positive non small cell lung cancer  systemic advanced metastatic ret mutant medullary thyroid cancer systemic ret fusion positive radioactive iodine refractory thyroid cancer both pediatric aged 12 over   currently approved these indications under accelerated approval scheme continued approval contingent future confirmatory trials  radioactive diagnostic agent positron emission tomography pet imaging detection estrogen receptor positive lesions adjunct biopsy recurrent metastatic breast cancer   decitabine myelodysplastic syndromes mds  mds refractory anemia mds refractory anemia ringed sideroblasts mds refractory anemia excess blasts mds scoring intermediate intermediate high risk international prognostic scoring system ipss  chronic myelomonocytic leukemia cmml  tozinameran yet fully approved any country both uk canada tozinameran under interim authorization active immunization prevent covid 19 sars cov individuals aged 16 older    december 11 2020 u food drug administration granted emergency authorization eua tozinameran prevent covid 19 severe respiratory syndrome coronavirus sars cov aged 16 above  safety immune response information adolescents 12 15 age will follow studies further explore administration tozinameran pregnant women children under 12 age those special risk groups will evaluated future a225386  vaccine should only administered where appropriate medical immediate allergic reactions immediately available case anaphylactic reaction after vaccine administration  tozinameran administration should postponed any individual suffering from febrile illness should carefully considered immunocompromised individuals individuals bleeding disorder anticoagulant therapy appropriate medical should readily available case anaphylactic reaction following vaccine administration   modified autologous chimeric antigen receptor car t cell immunotherapy relapsed refractory mantle cell lymphoma mcl   granted accelerated approval based results from single arm open multicentre clinical trial continued approval contingent confirmatory trials  currently approved any indication fda   authorized under emergency authorization eua mild moderate covid 19 aged 12 older weighing least 40 kg high risk progressing severe covid 19 hospitalization covid 19 should confirmed covid 19 identification sars cov viral load approved test    under eua  authorized hospitalized covid 19 require oxygen covid 19 oxygen therapy non covid 19 related comorbidity require increased oxygen flow rate covid 19   adults relapsed refractory multiple myeloma received least 4 prior therapies anti cd38 monoclonal antibody proteasome inhibitor immunomodulatory agent  neuromyelitis optica spectrum disorder nmosd anti aquaporin 4 aqp4 antibody positive  canada adolescent same indication  metastatic non small cell lung cancer nsclc confirmed possess rearranged during transfection ret gene fusion determined fda approved test   currently approved indication under accelerated approval scheme continued approval contingent future confirmatory trials  copper cu 64 dotatate radiopharmaceutical positron emission tomography pet locate somatostatin receptor positive neuroendocrine tumors   fabry disease  odesivimab maftivimab zaire ebolavirus infection pediatric neonates born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any species within either ebolavirus marburgvirus genera special care should taken evaluate susceptibility circulating zaire ebolavirus strains before beginning possible emergence resistance should monitored  odesivimab atoltivimab zaire ebolavirus infection pediatric neonates born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any species within either ebolavirus marburgvirus genera special care should taken evaluate susceptibility circulating zaire ebolavirus strains before beginning possible emergence resistance should monitored  maftivimab atoltivimab zaire ebolavirus infection pediatric neonates born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any species within either ebolavirus marburgvirus genera special care should taken evaluate susceptibility circulating zaire ebolavirus strains before beginning possible emergence resistance should monitored  primary hyperoxaluria type  according emergency authorization eua fda indevimab only casirivimab mild moderate covid 19 from laboratory confirmed sars cov infection adults children aged 12 age older  weighing least 40 kg reserved high risk progressing require hospitalization severe covid 19   only administered intravenous infusion healthcare settings immediate access infusion reactions anaphylaxis ability activate emergency medical system ems  required   limitations  casirivimab currently hospitalized covid 19 requiring oxygen therapy covid 19 requiring increases baseline oxygen flow rate from covid 19 oxygen therapy non covid 19 related morbidity    according emergency authorization eua fda indevimab only mild moderate covid 19 from laboratory confirmed sars cov infection adults children aged 12 age older  weighing least 40 kg reserved high risk progressing require hospitalization severe covid 19   only administered intravenous infusion healthcare settings immediate access infusion reactions anaphylaxis ability activate emergency medical system ems  required   limitations imdevimab currently hospitalized covid 19 requiring oxygen therapy covid 19 requiring increases baseline oxygen flow rate from covid 19 oxygen therapy non covid 19 related morbidity    gqgk granulocyte macrophage colony stimulating factor gm csf  year age older relapsed refractory high risk neuroblastoma bone bone marrow demonstrated partial response minor response stable disease prior therapy  prophylaxis attacks hereditary angioedema hae adults pediatric 12 older hae attacks   gallium ga 68 psma 11 radioactive diagnostic agent positron emission tomography pet prostate specific membrane antigen psma positive lesions suspected prostate cancer metastasis candidates initial surgical radiation therapy suspected prostate cancer recurrence based elevated serum prostate specific antigen psa levels  '"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "e2900fdd",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_indic_words = Counter([u for u in indication_str.split(\" \") if u!=\"\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "f08507c2",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to /Users/cdonnat/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('punkt')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "ef6a6be1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "for heparin induced thrombocytopenia irinotecan egfr expressing metastatic colorectal carcinoma refractory irinotecan based chemotherapy administered single agent egfr expressing metastatic colorectal carcinoma intolerant irinotecan based chemotherapy adjunct therapy cystic fibrosis cutaneous t cell lymphoma moderately severely active rheumatoid arthritis adult chronic moderate severe plaque psoriasis 4 age older manage sign symptom polyarticular idiopathic arthritis those aged older manage symptom psoriatic arthritis ankylosing spondylitis heparin induced thrombocytopenia prevention thrombosis undergoing percutaneous coronary intervention pci moderate high risk coronary syndrome unstable angina non st segment elevation whom pci planned palliative advanced prostate cancer well pediatric central precocious puberty cpp oral norethisterone known norethindrone initial symptom endometriosis finally iron supplementation preoperative hematological improvement anemic uterine leiomyomata uterine fibroid hcv antiviral drug over 5 age compensated liver disease fda monotherapy contraindication significant intolerance anti viral therapy monotherapy hbeag positive hbeag negative chronic hepatitis b infection compensated liver disease evidence viral replication liver inflammation fda myocardial infarction ischemic strok lysis pulmonary embolifor dwarfism prevention hiv induced weight lossfor venereal genital wart human papiloma virusfor anemia from renal transplant certain hiv canada lysis massive pulmonary embolus thrombus obstructing coronary artery occlusive thromboemboli peripheral artery graft restoration patency intravenous catheter flutamide locally confined carcinoma prostate palliative advanced carcinoma prostate endometriosis endometrial thinning agent prior endometrial ablation dysfunctional uterine bleeding palliative advanced breast cancer pre perimenopausal womenfor lysis pulmonary embolus intracoronary embolus myocardial infarction paediatric anemia chronic kidney disease ckd dialysis dialysis anemia zidovudine hiv infection anemia effect concomitant myelosuppressive chemotherapy upon initiation there minimum two additional month planned chemotherapy reduction allogeneic rbc transfusion undergoing elective noncardiac nonvascular surgery symptomatic paget disease unresponsive alternate treatment intolerant treatment addition emergency situation serum calcium level must decreased quickly until underlying condition identified added existing therapeutic regimen hypercalcemia intravenous fluid furosemide oral phosphate corticosteroid agent calcitonin azotemia case where intravenous fluid would contraindicated limited cardiac reserve post menopausal osteoporosis woman more than 5 post menopause intralesional refractory recurring external condylomata acuminata decrease incidence infection manifested febrile neutropenia non myeloid malignancy receiving myelosuppressive anti cancer drug clinically significant incidence febrile neutropenia increase survival acutely exposed myelosuppressive dos radiation hematopoietic subsyndrome radiation syndrome cancer bone marrow transplant hcv db00811 ns3 4a protease inhibitor genotype without ns3 4a protease inhibitor genotype 6 fda monotherapy contraindication significant intolerance anti viral therapy component multi agent chemotherapeutic regimen lymphoblastic leukemia all fda detection residueal recurrent thyroid cancerfor hemophilia von willebrand disease factor xiii deficiency rheumatoid arthritis neonatal onset multisystem inflammatory disease nomid skin lesion surface wound eye infection ivig immunodeficiency well autoimmune inflammatory disorder these indication includes idiopathic thrombocytopenic purpura kawasaki disease hypogammaglobulinemia b cell chronic lymphocytic leukemia bone marrow transplant complication guillain barr syndrome chronic inflammatory demyelinating polyneuropathy cidp multiple sclerosis rheumatoid arthritis myesthenia gravis wiskott aldrich syndrome inflammatory skin disease lysis pulmonary embolus intracoronary embolus myocardial infarctionhuman insulin improve glycemic control adult pediatric diabetes mellitus myocardial infarction lysis intracoronary embolifor female infertility chronic granulomatous disease osteopetrosis chronic hepatitis c hairy cell leukemia aid related kaposi sarcoma chronic myelogenous leukemia oral wart arising from hiv infection nocturia nocturnal polyuria adult awaken least time per night void intranasal antidiuretic replacement therapy central cranial diabetes insipidus temporary polyuria polydipsia following head trauma surgery pituitary region intranasal parenteral hemophilia factor viii coagulant activity level greater than 5 mild moderate classic von willebrand disease type i factor viii level greater than 5 during surgical procedure postoperatively maintain hemostasis parenteral hemorrhagic complication hemophilia b prevention severe thrombocytopenia reduction need platelet transfusion following myelosuppressive chemotherapy nonmyeloid malignancy high risk severe thrombocytopenia oral mucositis chemotherapy radiation therapy diagnostic aid radiologic exam temporarily inhibit movement gastrointestinal tract severe hypoglycemia adult metastatic renal cell carcinoma cervical dystonia reduce severity abnormal head position neck pain cervical dystonia drug anti ige antibody moderate severe persistent asthma 6 age older positive skin test vitro reactivity perennial aeroallergen symptom inadequately controlled inhaled corticosteroid fda chronic idiopathic urticaria adult adolescent 12 age older remain symptomatic despite h1 antihistamine fda infertility woman hypothalamic pituitary insufficiency hypogonadotropic hypogonadism profound lh deficiency lh lt international unit iu l prophylactic lyme disease improve glycemic control adult child diabetes mellitus improve glycemic control adult pediatric type diabetes mellitus adult type diabetes mellitus adult dupuytren contracture palpable cord additionally men peyronie disease diagnosed penile curvature deformity least 30 degree angle beginning therapy addition palpable plaque collagenase ointment tissue debridement chronic dermal ulcer severely burned tissue collagenase product known qwo moderate severe cellulite buttock woman hyperuricemia reduces elevated plasma uric acid level from chemotherapy inhibition premature lh surge woman undergoing controlled ovarian stimulationthe following condition f2118 fda a40001 a40002 rheumatoid arthritis moderate severe juvenile idiopathic arthritis moderately severely active psoriatic arthritis active ankylosing spondylitis active crohn disease moderately severely active ulcerative colitis moderately severely active plaque psoriasis moderate severe chronic non infectious intermediate posterior panuveitis hidradenitis suppurativa moderate severe pyoderma gangrenosum off dwarfism acromegaly prevention hiv induced weight lossfor gaucher disease deficiency glucocerebrosidase adjunct percutaneous coronary intervention prevention cardiac ischemic complication undergoing percutaneous coronary intervention unstable angina responding conventional medical therapy percutaneous coronary intervention planned within 24 hour intended aspirin heparin studied only setting reduction mortality severe sepsis cd33 positive myeloid leukemia first relapse 60 age older considered candidate cytotoxic chemotherapy aged older cd33 positive aml experienced relapse responded initial refractory diagnosis extrahepatic malignant cancersfor chronic augmentation maintenance therapy individual alpha1 proteinase inhibitor a1 pi deficiency clinical evidence emphysema lymphoblastic leukemiafor relapsing remitting multiple sclerosis condyloma acuminatumfor adenosine deaminase deficiencyalbuminex solution adult child hypovolemia ascites hypoalbuminemia from burn nephrosis respiratory distress syndrome cardipulmonary bypass f229 myocardial infarction coronary syndrome reducing sign symptom inducing maintaining clinical remission pediatric 6 age moderately severely active crohn disease had inadequate response conventional therapy reducing number draining enterocutaneous rectovaginal fistula maintaining fistula closure fistulizing crohn disease reducing sign symptom inducing maintaining clinical remission mucosal healing eliminating corticosteroid pediatric 6 age moderately severely active ulcerative colitis had inadequate response conventional therapy methotrexate reducing sign symptom inhibiting progression structural damage improving physical function moderately severely active rheumatoid arthritis reducing sign symptom active ankylosing spondylitis reducing sign symptom active arthritis inhibiting progression structural damage improving physical function psoriatic arthritis chronic severe i e extensive disabling plaque psoriasis candidate systemic therapy systemic therapy medically le appropriate woman having diagnosed primary ovarian failure human chorionic gonadotropin hcg assist ovulation fertility men hypogonadotrophic hypogonadism induce spermatogenesis cause ovary produce several follicle then harvested gamete intrafallopian transfer gift vitro fertilization ivf enuresis polyuria diabetes insipidus polydipsia oesophageal varix bleeding drug relapsing remitting multiple sclerosis shown slow advance disease well decrease frequency attack hairy cell leukemia malignant melanoma aid related kaposi sarcomafor increase absorption distribution injected drug rehydration type i ii diabetes mellitus adjuvant her2 overexpressing breast cancer several clinical setting part regimen consisting doxorubicin cyclophosphamide either paclitaxel docetaxel part regimen docetaxel carboplatin monotherapy following multi modality anthracycline based therapy first line paclitaxel metastatic her2 overexpressing breast cancer monotherapy previously received one more chemotherapy regimen metastatic setting cisplatin capecitabine 5 fluorouracil her2 overexpressing metastatic gastric gastroesophageal junction adenocarcinoma received prior metastatic disease subcutaneous administration either hyaluronidase both hyaluronidase pertuzumab adult her positive breast cancer following condition fda non hodgkin lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra methotrexate moderately severely active ra granulomatosis polyangiitis gpa wegener granulomatosis microscopic polyangiitis mpa moderate severe pemphigus vulgaris pv biosimilar approved november 2018 truxima cd20 positive b cell non hodgkin lymphoma nhl single agent chemotherapy september 2019 injection approved along glucocorticoid manage granulomatosis polyangiitis gpa addition microscopic polyangiitis mpa child least age prophylactic kidney transplant rejectionfor organ transplant recipient prevention organ rejectionfor digitoxin overdose digitalis glycoside toxicity non hodgkin lymphomafor complicated skin skin structure infection susceptible strain gram positive microorganism non hodgkin lymphoma cd20 positive follicular growth hormone receptor antagonist acromegaly cervical dystonia adult decrease severity abnormal head position neck pain cervical dystonia severe primary axillary hyperhidrosis inadequately managed topical agent strabismus blepharospasm dystonia benign essential blepharospasm vii nerve disorder 12 age above cosmetically temporarily improve appearance moderate severe frown line between eyebrow glabellar line well excessive underarm sweating amylase part pancreatic enzyme replacement therapy therapy pancreatic insufficiency attributed cystic fibrosis chronic pancreatitis any medically defined pancreatic disease might require a32721 a32736 pancreatic disease deterioration pancreatic parenchyma dual physiological function pancreas once established pancreatic insufficiency result malnutrition weight loss steatorrhea a32723 evolving transmural myocardial infarction pulmonary embolism deep vein thrombosis arterial thrombosis emolism occlusion arteriovenous cannulae campath monoclonal antibody therapy b cell chronic lymphocytic leukemia gaucher disease deficiency glucocerebrosidase diagnosis prostate cancer detection intra pelvic metastasis mucopolysaccharidosis approved variety condition firstly approved prophylaxis organ rejection allogeneic kidney liver heart transplant prevent bone marrow transplant rejection above indication conjunction azathioprine corticosteroid finally chronic transplant rejection received previous immunosuppressive therapy prevent graft versus host disease gvhd secondly severe active rheumatoid arthritis ra they no longer respond methotrexate alone non immunocompromised severe recalcitrant plaque psoriasis failed respond least one systemic therapy systemic therapy tolerated contraindicated ophthalmic solution increase tear production suffering from keratoconjunctivitis sicca addition approved steroid dependent steroid resistant nephrotic syndrome glomerular disease include minimal change nephropathy focal segmental glomerulosclerosis membranous glomerulonephritis off commonly various autoimmune inflammatory condition atopic dermatitis blistering disorder ulcerative colitis juvenile rheumatoid arthritis uveitis connective tissue disease well idiopathic thrombocytopenic purpura a139 a174085 a189393 a189396 a189399 immunosuppressive drug moderate severe chronic plaque psoriasisfor alternative adrenaline localising agent provided local ischaemia essential female infertilityfor moderate severe chronic plaque psoriasis candidate phototherapy systemic therapy female infertilityfor prevention renal transplant rejectionthis drug leucocyte growth factor fda decrease incidence infection manifested febrile neutropenia nonmyeloid malignancy receiving myelosuppressive anti cancer drug significant incidence severe neutropenia fever fda reduce time neutrophil recovery duration fever following induction consolidation chemotherapy myeloid leukemia aml fda reduce duration neutropenia neutropenia related clinical sequela e g febrile neutropenia nonmyeloid malignancy undergoing myeloablative chemotherapy followed bone marrow transplantation bmt fda mobilize autologous hematopoietic progenitor cell into peripheral blood collection leukapheresis fda reduce incidence duration sequela severe neutropenia e g fever infection oropharyngeal ulcer symptomatic congenital neutropenia cyclic neutropenia idiopathic neutropenia fda neupogen approved radiation induced myelosuppression following radiological nuclear incident hemophilia christmas disease topical skin ulcer from diabetes fabry disease injection acromegaly reduction flushing diarrhea symptom related carcinoid tumor vasoactive intestinal peptide vipoma tumor delayed release oral formulation long term acromegaly tolerate respond adequately injectable lanreotide hairy cell leukemia malignant melanoma aid related kaposi sarcoma palliative advanced prostate cancer labor induction augmentation labor postpartum abbreviation third stage labor postpartum control uterine bleeding termination pregnancy evaluation fetal respiratory capability can not elective induction labor there must clear medical requirement multiple sclerosis antiretroviral drug therapy hiv aid prophylaxis respiratory disease casued respiratory syncytial virus zenapax humanized monoclonal antibody prevention renal transplant rejectionas vascular endothelial growth factor vegf inhibitor several chemotherapy regimen metastatic colorectal cancer metastatic unresectable locally advanced recurrent non squamous non small cell lung cancer metastatic renal cell carcinoma metastatic persistent recurrent cervical cancer primary peritoneal cancer epithelial ovarian cancer fallopian tube cancer recurrent glioblastoma interestingly currently under investigation covid 19 complication respiratory distress syndrome ards lung injury ali imaging colorectal tumorsfor nutritional supplementation treating dietary shortage imbalance nasal spray nasal spray maintenance vitamin b12 concentration after normalization intramuscular vitamin b12 therapy deficiency vitamin no nervous system involvement fda note calomist fda nasal spray form evaluated newly diagnosed vitamin b12 deficiency injection form subcutaneous intramuscular these form vitamin b12 deficiency various cause without neurologic manifestation f3736 vitamin b12 deficiency frequently malabsorption often following condition addisonian pernicious anemia gastrointestinal pathology dysfunction surgery gluten enteropathy sprue small bowel bacterial overgrowth total partial gastrectomy fish tapeworm infestation malignancy pancreas bowel folic acid deficiency oral form vitamin b12 supplement widely available require supplementation various reason dose requirement vitamin b12 higher than normal pregnancy thyrotoxicosis hemolytic anemia hemorrhage malignancy hepatic renal disease usually achieved oral supplementation oral product vitamin b12 recommended malabsorption these form primarily absorbed gastrointestinal tract f3739 nutritional supplementation treating dietary shortage imbalance action supplemental l entirely unclear some immunomodulatory well antioxidant activity l some rheumatoid arthritis anemia uremia lowering serum cholesterol adenosylmethionine same drug europe depression liver disorder fibromyalgia osteoarthritis introduced into united state market dietary supplement support bone joint health well mood emotional well being nutritional supplementation treating dietary shortage imbalancel helpful some depression useful vitiligo there some evidence l exacerbate tardive dyskinesia some schizophrenic some neuroleptic drug nutritional supplementation treating dietary shortage imbalance nutritional supplementation treating dietary shortage imbalancesupplemental putative anti herpes simplex virus activity there preliminary research suggesting some anti osteoporotic activity nutritional supplementation treating dietary shortage imbalance vitaminC deficiency scurvy delayed wound bone healing urine acidification general antioxidant suggested effective antiviral agent nutritional supplementation treating dietary shortage imbalancethere no support claim aspartates exercise performance enhancer i e ergogenic aid nutritional supplementation treating dietary shortage imbalance claimed improves athletic performance anabolic effect wound healing effect immuno enhancing nutritional supplementation treating dietary shortage imbalance reduce complication sickle cell disease pediatric 5 age older fda nutritional supplementation treating dietary shortage imbalancefor nutritional supplementation treating dietary shortage imbalance natural moisturizing agent some cosmetic skin care product protein synthesis formation same l homocysteine l cysteine taurine sulfate claimed act effective antidepressant however result mixed claimed reduce stress combat narcolepsy chronic fatigue however these claim refuted some study vitaminD deficiency insufficiency refractory rickets vitaminD resistant rickets familial hypophosphatemia hypoparathyroidism hypocalcemia renal osteodystrophy chronic renal failure undergoing dialysis conjunction calcium prevention primary corticosteroid induced osteoporosis xanthophyll taken nutritional supplementation treating dietary shortage imbalance claimed l cysteine anti inflammatory property protect against various toxin might helpful osteoarthritis rheumatoid arthritis more research will done before l cysteine any these condition research date mostly animal model nutritional supplementation treating dietary shortage imbalancefor aosis vitamin b2 deficiency prevention osteoarthritis itself chondroitin sulfate considered nature brain food improving mental capacity help speed healing ulcer give lift from fatigue help control alcoholism schizophrenia craving sugar nutritional supplementation treating dietary shortage imbalancephosphatidylserine demonstrated some usefulness treating cognitive impairment alzheimer disease age memory impairment some non alzheimer dementia more research needed before phosphatidylserine immune enhancement reduction exercise stress supplemental antispastic activity very early finding suggest antipsychotic activity well antioxidant anti inflammatory activity vitaminD deficiency insufficiency refractory rickets vitaminD resistant rickets familial hypophosphatemia hypoparathyroidism hypocalcemia renal osteodystrophy chronic renal failure undergoing dialysis conjunction calcium prevention primary corticosteroid induced osteoporosis one natural form available vitamin b6 therefore nutritional supplementation treating dietary shortage imbalance nutritional supplementation treating dietary shortage imbalance assist prevention breakdown muscle protein sometimes occur after trauma severe stress useful increasing serotonin production promoting healthy sleep managing depression enhancing mental emotional well being managing pain tolerance managing weight prevention liver damage kidney damage overdoses acetaminophenfor niacin deficiency state korsakov alcoholic psychosis wernicke korsakov syndrome delirium peripheral neuritis hypoparathyroidism refractory rickets familial hypophosphatemia fda hypoparathyroidism result inadequate parathyroid hormone production occurs presence damage removal parathyroid gland condition produce decreased calcium increased phosphorus level rickets condition produced deficiency vitaminD calcium phosphorus however condition related renal disease characterized present weak soft bone a177664 familial hypophosphatemia characterized impaired transport phosphate altered vitaminD metabolism kidney presence condition derive presence osteomalacia bone softening rickets nutritional supplementation treating dietary shortage imbalanceused nutritional supplementation treating dietary shortage imbalance l make up collagen elastin enamel protein aid proper fat metabolism liver help digestive intestinal tract function more smoothly assist metabolism assimilation some evidence suggests might useful treating parkinson disease chronic fatigue syndrome alzheimer disease cardiovascular disease deficiency megaloblastic anemia anemia nutritional origin pregnancy infancy childhood epa lowering elevated triglyceride those hyperglyceridemic addition epa play therapeutic role cystic fibrosis reducing disease severity play similar role type diabetic slowing progression diabetic nephropathy protein synthesis promotes mental vigor muscle coordination calm emotion minority hepatic encephalopathy some phenylketonuria deficiency supplementation deficiency occur cystic fibrosis cholestasis severe liver disease abetalipoproteinemia simply poor diet a176104 vitamin b6 deficiency prophylaxis db00951 induced peripheral neuropathy approved health canada nausea vomiting pregnancy product db00366 commercially available product diclectin nutritional supplementation treating dietary shortage imbalance branched chain amino acid antihepatic encephalopathy activity some they anticatabolic antitardive dyskinesia activity diet supplement sugar substitute specific medical condition like refractory rickets vitaminD resistant rickets hypoparathyroidism familial hypophosphatemia f4027 f4042 concurrently one most commonly utilized form vitaminD very frequently supplement individual maintain sufficient vitaminD level body vitaminD deficiency well various medical condition directly indirectly vitaminD insufficiency like osteoporosis chronic kidney disease among others a176041 a176044 f4051 primary known function vitamin k assist normal clotting blood but play role normal bone calcification nutritional supplementation treating dietary shortage imbalancel extremely important proper functioning joint tendon help maintain strengthen heart muscle nutritional supplementation treating dietary shortage imbalanceused nutritional supplementation treating dietary shortage imbalance primary prevention coronary event hypercholesterolemic without clinical evidence coronary heart disease includes reduction risk myocardial infarction undergoing myocardial revascularization procedure cardiovascular mortality t274 well secondary prevention agent cardiovascular event clinically evident coronary heart disease indication includes reduction risk total mortality reducing coronary death myocardial infarction undergoing myocardial revascularization procedure stroke stroke transient ischemic attack well slow progression coronary atherosclerosis t274 term cardiovascular event correspond all incident produce damage heart muscle interruption blood flow adjunctive therapy diet primary hypercholesterolemia mixed dyslipidemias hyperlipidemia type iia iib elevated serum triglyceride type iv hyperlipidemia heterozygous familial hypercholesterolemia over 8 age low density lipoprotein ldl cholesterol higher than 190 mg dl after diet modification ldl level higher than 160 mg dl familial history premature cardiovascular disease least two cardiovascular risk factor t274 do respond adequately diet primary dysbetalipoproteinemia type iii hyperlipidemia t274 dyslipidemia defined elevation plasma cholesterol triglyceride both well presence low level high density lipoprotein condition represents increased risk development atherosclerosis predominantly depression obsessive compulsive disorder ocd fda bulimia nervosa a250 hypertension reduce risk fatal nonfatal cardiovascular event primarily stroke myocardial infarction heart failure nyha class ii iv left ventricular dysfunction failure after myocardial infarction angiotensin converting enzyme inhibitor acei appropriate f4703 mild severe hypertension reduce cardiovascular mortality following myocardial infarction hemodynamically stable individual develop clinical sign congestive heart failure within few day following myocardial infarction fda reduce rate death myocardial infarction stroke individual high risk cardiovascular event slow progression renal disease individual hypertension diabetes mellitus microalubinuria overt nephropathy t116 actinic keratoses precancerous skin growth become malignant if left untreated maintenance asthma prophylactic therapy administered relief sign symptom spasticity resulting from multiple sclerosis particularly relief flexor spasm pain clonus addition muscular rigidity fda receiving drug should reversible spasticity promote restoration residual function drug skeletal muscle spasm rheumatic disorder efficacy stroke cerebral palsy parkinson disease determined therefore recommended these condition fda attention deficit hyperactivity disorder adhd well central nervous system disorder narcolepsy a18540 adhd complex disorder substantial heterogeneity etiology clinical presentation outcome adhd come from complex interplay between interdependent genetic non genetic factor cause complex mental disorder child teenager a174271 hand narcolepsy chronic sleep disorder typically resenting during adolescence characterized excessive daytime sleepiness a174274 being nowadays off obesity depression chronic pain a174268 a174283 diagnostic aid evaluation gastric acid secretory functionfor relief withdrawal symptom aid smoking cessation symptom dry mouth sj amp ouml gren syndrome fda approved short term relief anxiety symptom related anxiety disorder anxiety depressive symptom anxiety insomnia well anesthesia premedication adult relieve anxiety produce sedation amnesia status epilepticus t385 some off indication include rapid tranquilization agitated patient alcohol withdrawal delirium alcohol withdrawal syndrome muscle spasm insomnia panic disorder delirium chemotherapy anticipatory nausea vomiting psychogenic catatonia t385 rapid control ventricular rate atrial fibrillation atrial flutter perioperative postoperative emergent circumstance where short term control ventricular rate short acting agent desirable noncompensatory sinus tachycardia where rapid heart rate requires specific intervention multiple myeloma mantle cell lymphoma short term hypnotic therapy insomnia period up one week duration however medication generally replaced sedative hypnotic agent levodopa symptom idiopathic parkinson disease postencephalitic parkinsonism symptomatic parkinsonism followed carbon monoxide manganese intoxication fda therapy administered reduction levodopa driven nausea vomiting fda product should where therapy levodopa provide le than adequate daily dosage fda well where dosage levodopa require individual titration fda alone topiramate short term adjunct pas few week regimen weight reduction based exercise behavioral modification caloric restriction exogenous obesity initial body mass index bmi greater than 30 kg m2 greater than 27 kg m2 presence risk factor controller hypertension diabetes hyperlipidemia fda exogenous obesity considered overweight consuming more food than person activity level warrant condition commonly cause increase fat storage epidemic condition united state where over two third adult overweight obese one three american obese world incidence obesity nearly doubled a174391 life threatening dysrhythmias sustained ventricular tachycardia approved moderate severe pain adult f4679 off premature ejaculation a173986 chickenpox varicella herpes zoster herpes simplexfor hypertension administered following fungal infection vaginal yeast infection candida systemic candida infection 3 both esophageal oropharyngeal candidiasis 4 cryptococcal meningitis 5 uti urinary tract infection candida 6 peritonitis inflammation peritoneum candida note fungal infection prophylaxis receiving bone marrow transplantation treated cytotoxic chemotherapy radiation therapy predisposed candida infection receive prophylactic therapy note laboratory testing obtaining specimen fungal culture important laboratory study serology pathology advised before starting therapy order isolate organism eliminated through permissible start therapy before result available however adjusting therapy once laboratory result confirm causative organism necessary type ii diabetes mellitus alone sulfonylurea metformin insulin adjunct diet exercise according fda prescribing information uncomplicated illness influenza b infection week age older symptomatic no more than 48 hour f3094 particular agent adult child full term neonate present symptom typical influenza influenza virus circulating community efficacy demonstrated initiated within two day first onset symptom f3097 prophylaxis influenza one year older f3094 specifically post exposure prevention individual one year age older following contact clinically diagnosed influenza case influenza virus circulating community qualifies prophylactic therapy would only post exposure prevention influenza infant le than year age during pandemic influenza outbreak f3097 infection susceptible strain various bacteria indication summarized body system below respiratory infection mild moderate upper respiratory tract infection streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae concomitantly appropriate dos sulfonamide treated mild moderate lower respiratory tract infection susceptible strain streptococcus pneumoniae streptococcus pyogenes treated treat listeriosis listeria monocytogenes treated pertussis whooping cough bordetella pertussis effective eliminating causative organism from nasopharynx infected individual rendering them noninfectious clinical study suggest aid prevention pertussis infection individual exposed bacteria respiratory tract infection mycoplasma pneumoniae treated despite fact no controlled clinical efficacy study conducted date vitro certain preliminary clinical study result indicate effective legionnaire disease finally diphtheria infection corynebacterium diphtheriae adjunct antitoxin prevent carrier status eradicate organism existing carrier addition prevention diphtheria prevent rheumatic fever penicillin intolerant skin infection mild moderate skin skin structure infection streptococcus pyogenes staphylococcus aureus treated however resistant staphylococcal organism emerge erythrasma infectious condition corynebacterium minutissimum gastrointestinal infection intestinal amebiasis entamoeba histolytica treated oral extraenteric amebiasis warrant antimicrobial drug genital infection stis alternative drug treating pelvic inflammatory disease n gonorrheae female demonstrated hypersensitivity intolerance penicillin syphilis treponema pallidum treated serf alternative primary syphilis demonstrated penicillin hypersensitivity primary stage primary syphilis another approved indication chlamydial infection cause conjunctivitis newborn pneumonia infancy urogenital infection occurring pregnancy alternative option tetracycline uncomplicated rectal urethral endocervical infection adult chlamydia trachomatis nongonococcal urethritis tetracycline can not administered finally nongonococcal urethritis ureaplasma urealyticum pernicious anemia prevention vitamin b12 deficiency arising from alcoholism malabsorption tapeworm infestation celiac hyperthyroidism hepatic biliary tract disease persistent diarrhea ileal resection pancreatic cancer renal disease prolonged stress vegan diet macrobiotic diet restrictive diet known suspected cyanide poisoning short term apnea prematurity infant off prevention bronchopulmonary dysplasia premature birth t716 addition sodium benzoate respiratory depression resulting from overdose cns depressant drug broad range over counter us found energy supplement athletic enhancement product pain relief product well cosmetic product t716 surgical procedure where rapid onset brief duration muscle relaxation needed includes intubation endoscopy ect phosphodiesterase 5 pde5 inhibitor predominantly employed two primary indication erectile dysfunction a175582 f3853 f3856 f3886 pulmonary hypertension where u fda specifically indicates pulmonary arterial hypertension pah group i adult improve exercise ability delay clinical worsening f3850 delay clinical worsening demonstrated added background epoprostenol therapy f3850 study establishing effectiveness were short term 12 16 week included predominately new york heart association nyha functional class ii iii symptom idiopathic etiology 71 connective tissue disease ctd 25 f3850 b canadian product monograph specifically indicates primary pulmonary arterial hypertension pph pulmonary hypertension secondary connective tissue disease ctd functional class ii iii responded conventional therapy f3859 addition improvement exercise ability delay clinical worsening demonstrated were already stabilized background epoprostenol therapy f3859 c ema product information specifically indicates pulmonary arterial hypertension classified functional class ii iii improve exercise capacity f3883 efficacy shown primary pulmonary hypertension pulmonary hypertension connective tissue disease f3883 ema indicates pediatric aged year 17 old pulmonary arterial hypertension f3883 efficacy term improvement exercise capacity pulmonary hemodynamics shown primary pulmonary hypertension pulmonary hypertension congenital heart disease f3883 maintenance normal sinus rhythm delay time recurrence atrial fibrillation atrial flutter af afl atrial fibrillation atrial flutter greater than one week duration converted normal sinus rhythmfor toxoplasmosis malaria prevention malaria area non resistant hypertension should only prevent infection proven strongly suspected susceptible bacteria order prevent development antimicrobial resistance maintain efficacy fda mild moderate infection susceptible strain microorganism listed specific condition below recommended dosage duration therapy consideration various patient population vary among these infection refer fda indication section drug entry detailed information fda adult bacterial exacerbation chronic obstructive pulmonary disease haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae bacterial sinusitis haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae community acquired pneumonia chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae appropriate oral therapy pharyngitis tonsillitis streptococcus pyogenes alternative first line therapy individual can not first line therapy uncomplicated skin skin structure infection staphylococcus aureus streptococcus pyogenes streptococcus agalactiae abscess usually require surgical drainage urethritis cervicitis chlamydia trachomatis neisseria gonorrhoeae genital ulcer disease men haemophilus ducreyi chancroid small number woman included clinical trial efficacy chancroid woman established pediatric otitis medium haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae community acquired pneumonia chlamydophila pneumoniae haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae appropriate oral therapy pharyngitis tonsillitis streptococcus pyogenes alternative first line therapy individual can not first line therapy had stroke stroke precursor can not take aspirin aspirin worked try prevent another thrombotic stroke overactive bladder symptom urge urinary incontinence urgency urinary frequency detrusor instability frequency micturition topical acne vulgaris aged 12 over symptomatic orthostatic hypotension oh hypertension heart failure injection gastroesophageal reflux disease history erosive esophagitis injection short term 7 10 day having gastroesophageal reflux disease gerd history erosive esophagitis alternative oral medication unable continue taking delayed release tablet safety efficacy injection initial having gerd history erosive esophagitis demonstrated time fda pathological hypersecretion zollinger ellison syndrome injection pathological hypersecretory condition zollinger ellison syndrome neoplastic condition fda delayed release oral suspension short term erosive esophagitis gastroesophageal reflux disease gerd adult pediatric five age above short term up 8 week healing symptomatic relief erosive esophagitis healed after 8 week additional 8 week course considered safety beyond 8 week pediatric determined f3202 maintenance healing erosive esophagitis maintenance healing erosive esophagitis reduction relapse rate daytime nighttime heartburn symptom gerd f3202 pathological hypersecretory condition zollinger ellison syndrome long term above condition f3202 edema congestive heart failure renal hepatic disease from condition observed very effective case kidney failure fda edema considered swelling observed trap fluid body tissue mainly located foot ankle leg but extended part face hand abdomen even whole body well approved antihypertensive agent either alone antihypertensive fda hypertension defined presence high blood pressure increase amount blood pumped order produce narrowing artery depression fda fda off indication include but limited sexual dysfunction post stroke behavioural change ethanol abuse obsessive compulsive disorder ocd child diabetic neuropathy fda a321 a322 a323 a324 a174406 a174409 a174412 migraine without aura adult hypertension sinus lung infection sinusitis pneumonia secondary infection chronic bronchitis bacterial conjunctivitis pinkeye visceral spasmsused antiviral drug hiv both adult child asthma wheezing chronic asthmatic bronchitis type diabetes adult adjunct diet exercise improve glycemic control monotherapy metformin insulin lower blood glucose type diabetes whose high blood sugar level can not controlled diet exercise conjunction oral hypoglycemic drug lower blood sugar level agent alone relief inflammatory pruritic manifestation corticosteroid responsive dermatosis antiretroviral drug hiv infection intravenous mri visualize lesion abnormal vascularity those thought cause abnormality blood brain barrier brain intracranial lesion spine tissue control hypertension reduce risk myocardial infarction unstable angina need coronary revascularization procedure individual without symptomatic cardiovascular disease average moderately elevated total c ldl c below average hdl c intervention alternative individual presenting dyslipidemia risk developing atherosclerotic vascular disease administration agent should accompanied implementation fat cholesterol restricted diet f4661 therapy lipid altering agent should component multiple risk factor intervention those individual significantly increased risk atherosclerotic vascular disease hypercholesterolemia adjunct diet reduction elevated total c ldl c level primary hypercholesterolemia type iia iib2 response diet restricted saturated fat cholesterol nonpharmacological measure alone inadequate f4661 f4664 slow progression coronary atherosclerosis coronary heart disease part strategy lower total c ldl c target level f4661 adjunct diet reduce total c ldl c apolipoprotein b level adolescent boy girl heterozygous familial hypercholesterolemia hefh least one year post menarche 10 17 age hefh if after adequate trial diet therapy following finding present ldl c remains greater than 189 mg dl ldl c remains greater than 160 mg dl there positive family history premature cardiovascular disease two more cvd risk factor present adolescent patient before administering important rule out presence secondary cause hypercholesterolemia lipid profile should performed prescribing statin medication considered standard practice following any cardiovascular event people moderate high risk development cvd statin condition include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl c level a181087 a181406 both induction maintenance general anesthesia induce analgesia vaginal delivery low concentration adjunct general anesthetic drug during delivery cesarean section severe infection susceptible bacteria neuropathic pain diabetic peripheral neuropathy postherpetic neuralgia fibromyalgia neuropathic pain spinal cord injury adjunctive therapy partial onset seizure month age older specifically only short term insomnia fda furthermore generally predominantly symptomatic relief transient short term insomnia characterized difficulty falling asleep frequent nocturnal awakening early morning awakening f3718 particular official prescribing information typically specifies instruction issued dispensed prescription medication should indicate specifically only expected therapy short period time usually 7 10 day general fda f3718 subsequently should usually exceed 7 10 consecutive day nor should prescribed quantity exceeding one month supply f3718 some regional prescribing information note premedication prior minor surgery related procedure hypertension either sole therapeutic agent enhance effect antihypertensive drug more severe form hypertension adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy tuberculosisfor clinical depression congestive heart failure polycythaemia vera refractory chronic myeloid leukaemia sedative hypnotic should insomnia longer than week antiretroviral drug ongoing hiv infection dermal fungal infection relief inflammatory pruritic manifestation corticosteroid responsive dermatosis symptom complex tension muscle contraction headache non opioid analgesic alternative treatment inadequate various combination acetaminophen aspirin caffeine codeine active hairy cell leukemia leukemic reticuloendotheliosis defined clinically significant anemia neutropenia thrombocytopenia disease related symptom alternative agent chronic lymphocytic leukemia cll low grade non hodgkin lymphoma cutaneous t cell lymphoma chronic angina alone conjunction nitrate beta blocker angiotensin receptor blocker anti platelet drug calcium channel blocker lipid lowering drug ace inhibitor off certain arrhythmia ventricular tachycardia however strongly supported scientific evidence a174940 studied coronary syndrome microvascular coronary dysfunction arrhythmia glycemic control yet approved indication a174898 induction remission active mild moderate exacerbation ulcerative colitis maintenance remission ulcerative colitis fda prescribing information uk indicates medication maintenance remission crohn ileo colitis benztropine adjunct therapy all form parkinsonism control extrapyramidal disorder neuroleptic drug t203 extrapyramidal symptom defined drug induced disorder include symptom dystonia akathisia parkinsonism bradykinesia tremor dyskinesia a175120 parkinsonism general term refers group neurological disorder produce symptom similar parkinson disease tremor slow movement stiffness parkinsonism includes large number disorder some them clearly defined oral form approved schizophrenia monotherapy manic mixed episode related bipolar i disorder adjunctive therapy lithium valproate maintenance bipolar i disorder injectable formulation approved only agitation schizophrenia vascular headachefor hyperprolactinemic disorder either idiopathic prolactinoma prolactin secreting adenoma manage symptom parkinsonian syndrome monotherapy during initial symptomatic adjunct levodopa therapy during advanced stage disease keratoconjunctivitis keratitis herpes simplex virus leprosy dermatitis herpetiformis candidiasis yeast like fungal infection vulva vagina grand mal seizure complex partial seizure prevent seizure during following neurosurgery injectable fo phosphate ester prodrug formulation a188571 tonic clonic status epilepticus prevention seizure occurring during neurosurgery allergic conjunctivitis vernal conjunctivitis episcleritis epinephrine sensitivity various infection gram positive gram negative bacteria aerobe anaerobe well type bacteria complete list organism available fda indication section drug entry fda following some major infection treated fda rocky mountain spotted fever typhus fever typhus group q fever rickettsialpox tick fever rickettsia respiratory tract infection mycoplasma pneumoniae lymphogranuloma venereum chlamydia trachomatis psittacosis ornithosis chlamydia psittaci trachoma chlamydia trachomatis although infectious agent always eliminated judged immunofluorescence inclusion conjunctivitis chlamydia trachomatis uncomplicated urethral endocervical rectal infection adult chlamydia trachomatis nongonococcal urethritis ureaplasma urealyticum relapsing fever borrelia recurrentis note regarding anti microbial resistance important note drug choice any type staphylococcal infection up 44 percent strain streptococcus pyogenes 74 percent streptococcus faecalis found resistant tetracycline therefore tetracycline should streptococcal infection unless microorganism demonstrated susceptible fda prostate cancer previously prevention miscarriage premature delivery pregnant woman prone miscarriage premature delivery acne addition susceptible infection propionibacterium often cause acne some infection treated include upper respiratory tract infection urinary tract infection bronchitis chlamydial infection rickettsial infection topical preparation topical cream topical following dermal infection f3088 f3121 tinea pedis tinea cruris tinea corporis trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum candidiasis candida albicans tinea versicolor malassezia furfur diaper rash infected candida albicans some preparation combined betamethasone dipropionate corticosteroid f3121 oral preparation oral troche preparation local oropharyngeal candidiasis fda prophylactic drug reduce incidence oropharyngeal candidiasis immunocompromised condition chemotherapy radiotherapy steroid therapy utilized leukemia solid tumor renal transplantation fda troche preparation any systemic mycoses fda one number calcium salt hyperphosphatemia too much phosphate blood kidney disease vulvovaginitis candida albicans up 5 drug mycobacterium avium complex mac tuberculosis tb thrombocythemia secondary malignant neoplasm reduce platelet count risk thrombosis beneficial amelioration thrombocythemia symptom thrombo hemorrhagic event brain tumor multiple myeloma hodgkin disease non hodgkin lymphoma severe repeated long lasting urinary tract infection meningococcal meningitis otitis medium trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis malaria bacterial infection angina heart failure myocardial infarction atrial fibrillation atrial flutter hypertension a175141 some off us include supraventricular tachycardia thyroid storm a175141 all indication part cardiovascular disease these condition correspond number disease involve function heart blood vessel underlying cause these condition variable genetic disposition lifestyle decision smoking obesity diet lack exercise comorbidity condition diabetes cardiovascular disease leading cause death global scale eradication scabies sarcoptes scabiei symptomatic pruritic skin decreasing blood clotting often along heparin deep vein thrombosis female gynecologic obstetric infection susceptible aerobic gonococcus anaerobic bacteria sign symptom parkinson disease primary moderate severe restless leg syndrome fda symptom menopause deficiency ovary function underdevelopment female sexual characteristic some type infertility rare case prostate cancer prevent breast engorgement following childbirth mild moderate essential hypertension alone concurrently thiazide type diuretic alone wide variety diagnostic imaging method angiography urography cholangiography computed tomography hysterosalpingography retrograde pyelography imaging gastrointestinal tract allergic barium clinically test gastric secretory function following condition monotherapy partial onset primary generalized tonic clonic seizure age above adjunctive therapy partial onset seizure primary generalized tonic clonic seizure both pediatric above old 3 adjunctive therapy seizure lennox gastaut syndrome above age 4 prophylaxis migraine child 12 age older adult off adjunct therapy weight mood disorder a188312 infection susceptible organism hypertension either alone antihypertensive agent f4709 f4712 a173869 off type diabetes nephropathy heart failure post myocardial infarction particularly unable tolerate ace inhibitor a178153 a185912 a185915 arb shown number large scale clinical outcome trial improve cardiovascular outcome reducing risk myocardial infarction stroke progression heart failure hospitalization a174124 a178153 a173869 a185324 a185327 a185333 a185342 a185345 like arb blockade raas slows progression diabetic nephropathy renoprotective effect a185906 a185909 a185912 myeloid leukaemia symptom reversible airflow obstruction chronic asthma chronic lung disease emphysema chronic bronchitis prevention thrombosis heparin induced thrombocytopenia hit risk hit undergoing percutaneous coronary intervention officially approved following indication replacement therapy primary thyroidal secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism adjunct therapy surgery radioiodine thyroid cancer diagnostic agent suppression test mild hyperthyroidism thyroid gland autonomy fda general term exogenous replace insufficient hormonal production restore t3 plasma level t457 lack presented pale puffy face coarse brittle hair dry skin croaky voice constipation well irregular period drowsiness lethargy t457 should never suppression benign nodule nontoxic diffuse goiter iodine sufficient nor hyperthyroidism during recovery phase subacute thyroiditis fda documented ventricular arrhythmia sustained ventricular tachycardia ventricular pre excitation cardiac dysrhythmias class ia antiarrhythmic drug anesthetic amide group production local regional anesthesia infiltration technique percutaneous injection intravenous regional anesthesia peripheral nerve block technique brachial plexus intercostal central neural technique lumbar caudal epidural block f4349 pamidronate moderate severe hypercalcemia malignancy moderate severe paget disease bone osteolytic bone metastasis breast cancer osteolytic lesion multiple myeloma relief symptom allergic rhinitis sneezing rhinorrhea pruritus acrimation mild uncomplicated allergic skin manifestation urticaria angioedema self medication temporary relief symptom common cold diabetes type ii therapy second third line agent major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder social phobia panic disorder without agoraphobia off prophylaxis migraine headache a177229 reduction vasomotor symptom menopause a177238 neuropathic pain although there only minimal evidence efficacy condition a177232 considered second line option obsessive compulsive disorder ocd a177226 a177235 several different condition moderate severe vasomotor symptom menopause moderate severe symptom vulvar vaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure palliative breast cancer appropriately selected metastatic disease palliative androgen dependent carcinoma prostate preventive therapy postmenopausal osteoporosis a38238 ophthalmic solution reduction elevated intraocular pressure open angle glaucoma ocular hypertension f3061 f3064 currently decrease elevated intraocular pressure paediatric aged month lt 18 ocular hypertension paediatric glaucoma relief inflammatory pruritic manifestation corticosteroid responsive dermatosis attention deficit hyperactivity disorder adhd child adult palliative malignant neoplasm trachea bronchus lung squamous cell carcinoma lymphoma chronic lymphatic lymphocytic leukemia childhood minimal change nephrotic syndrome malignant lymphoma lymphosarcoma giant follicular lymphoma hodgkin disease non hodgkin lymphoma waldenstrm macroglobulinemia induction general anesthesia malignant neoplasm colon rectum administered subdermal implant long acting reversible contraception known effective postpartum insertion breastfeeding woman a175990 part long acting contraceptive implant prevent pregnancy implant effect remain 5 chronic moderate severe pain a176050 opiods effective short term pain taking opioids long term need monitored development physical dependence addiction disorder drug abuse obstetric anesthesia regional anesthesia surgery production local regional anesthesia analgesia surgery oral surgery procedure diagnostic therapeutic procedure obstetrical procedure iatrogenically induced mydriasis produced adrenergic phenylephrine parasympatholytic tropicamide agent certain eye examination recurrent cold sore lip face from various herpesvirus invections tenofovir antiretroviral agent hiv infection adult pediatric age older chronic hepatitis b adult pediatric 12 age older fda drug component multiple product hiv infection f3418 f3421 safety effectiveness pediatric younger than age established date fda bacterial infection susceptible microorganism hemophilia short term two eight day reduce prevent hemorrhage reduce need replacement therapy during following tooth extraction excessive bleeding menstruation surgery trauma case following moderate severe infection susceptible isolates designated microorganism complicated intra abdominal infection escherichia coli clostridium clostridioforme eubacterium lentum peptostreptococcus specie bacteroides fragilis bacteroides distasonis bacteroides ovatus bacteroides thetaiotaomicron bacteroides uniformis complicated skin skin structure infection diabetic foot infection without osteomyelitis staphylococcus aureus methicillin susceptible isolates only streptococcus agalactiae streptococcus pyogenes escherichia coli klebsiella pneumoniae proteus mirabilis bacteroides fragilis peptostreptococcus specie porphyromonas asaccharolytica prevotella bivia 3 community acquired pneumonia streptococcus pneumoniae penicillin susceptible isolates only case concurrent bacteremia haemophilus influenzae beta lactamase negative isolates only moraxella catarrhalis 4 complicated urinary tract infection pyelonephritis escherichia coli case concurrent bacteremia klebsiella pneumoniae 5 pelvic infection postpartum endomyometritis septic abortion post surgical gynecologic infection streptococcus agalactiae escherichia coli bacteroides fragilis porphyromonas asaccharolytica peptostreptococcus specie prevotella bivia oral ethinylestradiol contraceptive agent prevention pregnancy fda part combined oral contraceptive contain mix estrogen progestin inhibit ovulation malignant neoplasm lip oral cavity pharynx digestive organ peritoneum female breast urinary bladder adjunct ab externo glaucoma surgery pyelocalyceal solution adult low grade upper tract urothelial cancer lg utuc sedative hypnotic orally skin manifestation cutaneous t cell lymphoma ctcl refractory least one prior systemic therapy topically skin lesion early stage ia ib ctcl experience refractory persistent disease therapy intolerant therapy rapid conversion atrial fibrillation atrial flutter recent onset sinus rhythm leukaemia malignant lymphoma hodgkin disease erythraemia panmyelosis hypertension either sole therapeutic agent enhance effect antihypertensive drug more severe form hypertension adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy found useful edema various form renal dysfunction nephrotic syndrome glomerulonephritis chronic renal failure duodenal ulcer diuretic glaucoma useful seizure epilepsy short term insomnia monotherapy adjunctive therapy complex partial seizure simple complex absence seizure adjunctive therapy multiple seizure type include absence seizure 3 prophylaxis migraine headache 4 mania bipolar disorder off us include maintenance therapy bipolar disorder a177919 bipolar depression a177928 a177931 a177934 3 emergency status epilepticus a177955 tuberculosis drug migraine without aura aged 18 over general mild moderate pain reduction fever f4124 available over counter various form most common being oral form injection mild moderate pain moderate severe pain adjunctive opioid analgesic reduction fever because low risk causing allergic reaction drug administered intolerant salicylate those allergic tendency bronchial asthmatic f4124 specific dosing guideline should followed administering child continued locally advanced metastatic non small cell lung cancer after failure either platinum based docetaxel chemotherapy sulfate form drug commonly available tablet form fda relief mild moderately severe pain where opioid analgesic appropriate fda solution form itself combined syrup drug cough suppressant adult aged 18 above polymicrobial infection migraine headache without aura cluster headache episode drug following condition fda major depressive disorder adult neuropathic pain adult prophylactic chronic tension type headache ctth adult prophylactic migraine adult nocturnal enuresis child aged 6 above organic pathology spina bifida related disorder excluded no response achieved all non drug drug treatment antispasmodic vasopressin related product product should only prescribed healthcare professional expertise persistent enuresis fda off us irritable bowel syndrome sleep disorder diabetic neuropathy agitation fibromyalgia insomnia palliative gastrointestinal adenocarcinoma metastatic liver given continuous regional intra arterial infusion carefully selected considered incurable surgery mean palliative liver cancer usually administered hepatic intra arterial infusion adjunct levodopa carbidopa therapy symptomatic parkinson disease drug generally reserved parkinsonian syndrome receiving levodopa carbidopa experiencing symptom fluctuation responding adequately candidate adjunctive therapy ophthalmic corticosteroid responsive inflammation palpebral bulbar conjunctiva cornea anterior segment globe immediate reduction blood pressure hypertensive crisis reduce bleeding during surgery congestive heart failurefor mild hypocalcemia neonatal tetany tetany parathyroid deficiency vitaminD deficiency alkalosis prophylaxis hypocalcemia during exchange transfusion intestinal malabsorption replenish electrolyte moderate severe pain severe chronic pain addictive potential overdose risk only prescribed first line treatment failed a176468 proposed three step ladder pain suggested start non opioid medication followed addition weak opioids non opioid moderate pain finishing strong opioids along existing regimen case severe pain a176471 off administered suppression refractory cough a176468 oral indometacin symptomatic moderate severe rheumatoid arthritis flare chronic disease moderate severe ankylosing spondylitis moderate severe osteoarthritis painful shoulder bursitis tendinitis gouty arthritis a177871 intravenous indometacin induce closure hemodynamically significant patent ductus arteriosus premature infant weighing between 500 1750 g after 48 hour usual medical e g fluid restriction diuretic digitalis respiratory support etc ineffective adjunct pulmonary tuberculosis tablet adjunct diet exercise increase glycemic control adult pediatric 10 age older diagnosed type diabetes mellitus fda extended release tablet xr extended release form adjunct diet exercise improve glycemic control only adult type diabetes mellitus safety child determined date fda extended release product containing empagliflozin linagliptin approved fda january 2020 improvement glycemic control adult type diabetes mellitus adjunctively diet exercise inhaled inhaled beta agonist systemic corticosteroid severe exacerbation asthma flare requiring a176939 asthma exacerbation characterized progressive increase one more asthma symptom accompanied decrease expiratory flow single agent symptomatic relief rhinorrhea common cold seasonal allergic rhinitis 5 older doe alleviate nasal congestion nor sneezing fda rhinorrhea refers recurrent chronic watery nasal discharge condition debilitating pathogenesis etiology complex very well understood presenting very substantial cost burden additionally bronchodilator maintenance bronchospasm chronic obstructive pulmonary disease chronic bronchitis emphysema fda chronic obstructive pulmonary disease includes large number condition characterized breathlessness includes several condition etiology symptom treatment diverse studied sialorrhea a176942 sialorrhea common symptom accompanies different neurologic condition characterized drooling excessive salivation a176963 pain severe enough require opioid analgesic alternative option inadequate recommended reserved whom alternative option eg nonopioid analgesic opioid product ineffective tolerated would otherwise inadequate provide sufficient pain f4688 detoxification opioid addiction heroin morphine like drug maintenance substitution opioid dependence adult conjunction appropriate social medical service f4685 f4691 initially orally intramuscularly chronic schizophrenia over 13 old psychiatric disorder bipolar i disorder mixed manic episode a177014 lithium valproate short term manic mixed episode bipolar i disorder adult fda well fluoxetine episode depression bipolar disorder type resistant depression over 10 old a177014 approved psychomotor agitation schizophrenia bipolar i mania fda schizophrenia complex biochemical brain disorder affect person ability differentiate reality usually observed presence delusion hallucination social withdrawal disturbed thinking bipolar disorder mental health condition defined period extreme mood disturbance categorized different type from type known involve episode severe mania often depression while type present le severe form mania hypertension alone antihypertensive angina pectoris coronary atherosclerosis 3 myocardial infarction hemodynamically stable heart rate greater than 50 beat per minute systolic blood pressure above 100 mmhg off us include secondary prevention myocardial infarction a178156 heart failure a178153 3 atrial fibrillation a178141 4 supraventricular tachycardia a178162 5 ventricular arrythmias congenital long qt arrhythmogenic right ventricular cardiomyopathy a178168 6 symptomatic thyrotoxicosis methimazole a178147 7 prophylaxis migraine headache a178171 8 alcohol withdrawal a178174 a178177 bacterial skin infection pyodermas infected dermatosis infection cut wound burn ulcer susceptible organism mild moderate atopic dermatitis according fda fda proton pump inhibitor ppi following purpose active duodenal ulcer adult eradication helicobacter pylorus reduce risk duodenal ulcer recurrence adult active benign gastric ulcer adult symptomatic gastroesophageal reflux disease gerd year age older erosive esophagitis ee acid mediated gerd month age older maintenance healing ee acid mediated gerd year age older pathologic hypersecretory condition adultsfor initial active tuberculosis adult child combined antituberculous agent symptomatic parkinsonism seasonal allergic rhinitis relief symptom seasonal allergic rhinitis allergen ragweed grass tree pollen adult child age above symptom treated effectively include sneezing rhinorrhea nasal pruritus ocular pruritus tearing redness eye fda perennial allergic rhinitis drug relief symptom perennial allergic rhinitis allergen dust mite animal dander mold adult child 6 month age older symptom treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus tearing fda chronic urticaria uncomplicated skin manifestation chronic idiopathic urticaria adult child 6 month age older markedly reduces occurrence severity duration hive significantly reduces pruritus fda allergic rhinitis hay fever allergic skin disorder oral hypertension lower blood pressure alone antihypertensive agent improve exercise tolerance chronic stable angina variant angina prinzmetal angina intravenous short term atrial fibrillation atrial flutter temporary control rapid ventricular rate rapid conversion paroxysmal supraventricular tachycardia psvt sinus rhythm includes av nodal reentrant tachycardia reciprocating tachycardia extranodal accessory pathway wpw syndrome short pr syndrome off off us anal fissure topical formulation migraine prophylaxis cramp lower leg related rest pulmonary hypertension idiopathic dilated cardiomyopathy proteinuria diabetic nephropathy depression measure effective renal plasma flow erpf determine functional capacity tubular excretory mechanism reduction urinary obstruction relief manifestation eg sensation incomplete bladder emptying straining urgency interrupted weak stream symptomatic beningn prostatic hyperplasia control absence petit mal seizure refractory medication adjunct dietary restriction tyrosine phenylalanine hereditary tyrosinemia type epilepsy seizure lennox gastaut syndrome difficult form childhood epilepsy severe hypertension topical regrowth androgenic alopecia male female stabilisation hair loss androgenic alopecia anorexia cachexia unexplained significant weight loss diagnosis acquired immunodeficiency syndrome aid palliative recurrent inoperable metastatic breast cancer endometrial cancer prostate cancer canada some country remission induction remission consolidation nonlymphocytic leukemia prevention control excessive bleeding following vaginal childbirthfor prevention nausea vomiting dizziness motion sickness vertigo dizziness medical problem following infection susceptible gram negative microorganism urinary tract infection lower respiratory tract infection septicemia skin skin structure infection intra abdominal infection gynecologic infection relief discomfort painful musculoskeletal condition suppression adrenal function selected cushing syndrome malignant neoplasm female breast carcinoma situ breast mild moderate malaria uine susceptible strain plasmodium falciparum both chloroquine susceptible resistant strain plasmodium vivax prophylaxis plasmodium falciparum plasmodium vivax malaria infection prophylaxis chloroquine resistant strain plasmodium falciparum rheumatic fever meningococcal meningitisfor tetrahydrobiopterin bh4 deficiency tartrate adult advanced non small cell lung cancer nsclc single therapy chemotherapeutic drug relapsed refractory hodgkin lymphoma chemotherapy agent desmoid tumor aggressive fibromatosis methotrexate recurrent metastatic squamous cell head neck cancer recurrent ovarian cancer metastatic breast cancer previously treated anthracyline taxane therapy her2 positive trastuzumab resistant advanced breast cancer previously treated taxane trastuzumab everolimus following fungal infection candidemia form candida infection intra abdominal abscess peritonitis aspergillus infection esophageal candidiasis considered alternative oropharyngeal canaidiasis resistant schizophrenia suspension fda tablet f4534 active duodenal ulcer up 8 week tablet form lower dose healed duodenal ulcer purpose maintaining healing preventing recurrence f4519 f4534 prevention gastro esophageal reflux disease gerd gastritis peptic ulcer disease stress ulcer addition dyspepsia a177655 f4519 adult mild moderate infection susceptible strain haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis alone short term sleep aid drug night time cold allergy relief drug vitamin b6 pyridoxine prevent morning sickness pregnant woman emergency contraception single agent emergency contraceptive form prevention pregnancy after confirmed suspected failure contraception method following unprotected intercourse distributed prescription under 17 over counter those above age only form contraception regular contraception must taken soon possible within 72 hour after intercourse a181976 shown lower efficacy off within 96 hour t659 long term contraception nonemergency contraception addition above indication emergency contraception combined contraceptive contraceptive formulation designed regular example ethinyl estradiol various hormone releasing intrauterine device long term contraception ranging duration 3 5 product labeling mirena specifically mention recommended woman had least child subdermal implant available prevention pregnancy up 5 hormone therapy off us prescribed estradiol hormone therapy during menopause manage vasomotor symptom prevent osteoporosis off menorrhagia endometrial hyperplasia endometriosis t659 mainly vasodilatory shock state septic shock neurogenic shock shown survival benefit over dopamine vasopressor medication critical hypotension cmv retinitis acquired immunodeficiency syndrome aid drug major depressive disorder symptom fda off variety condition panic disorder generalized anxiety disorder dysthymia tension headache hot flush post traumatic stress disorder ptsd sleep disorder substance abuse disorder sexual disorder among others a177811 a177946 anxiety disorder short term relief symptom anxiety relief nausea vomiting ophthalmic increased intraocular pressure ocular hypertension open angle glaucoma oral form drug high blood pressure certain case prevention migraine headache a179530 continuous subcutaneous infusion intravenous infusion those able tolerate subcutaneous infusion pulmonary arterial hypertension nyha class ii iv symptom diminish symptom exercise adjunctive therapy diet reduction elevated serum total low density lipoprotein cholesterol ldl c primary hypercholesterolemia condition feature elevated ldl c do respond adequately dietary change fda f4555 therapy lipid altering agent like should component multiple risk factor intervention those individual significantly increased risk atherosclerotic vascular disease hypercholesterolemia fda f4555 should begin continue dietary therapy fda f4555 general minimum six month intensive dietary therapy counseling should carried out prior initiation drug therapy fda f4555 shorter period considered severe elevation ldl c definite coronary heart disease fda f4555 although effective all type hypercholesterolemia some regional prescribing information note particular medically most appropriate fredrickson type ii hyperlipoproteinemia nevertheless combined hypercholesterolemia hypertriglyceridemia although helpful reducing elevated cholesterol formally where hypertriglyceridemia abnormality greatest concern f4567 parkinson disease extrapyramidal reaction drug prevention delayed nausea vomiting initial repeat course moderately emetogenic cancer chemotherapy well prevention nausea vomiting highly emetogenic cancer chemotherapy prevention postoperative nausea vomiting up 24 hour post operation irregular duration cycle irregular occurrence duration period progesterone deficiency prevent natural abortion history habitual abortion ventricular tachycardia symptomatic premature ventricular beat prevention ventricular fibrillation reducing incidence severity cardiomyopathy doxorubicin administration woman metastatic breast cancer received cumulative doxorubicin hydrochloride dose 300 mg m would benefit from continued doxorubicin therapy approved extravasation from intravenous anthracyclines alone antihypertensive antianginal agent following condition fda hypertension coronary artery disease chronic stable angina vasospastic angina prinzmetal variant angina angiographically documented coronary artery disease without heart failure ejection fraction lt 40 palliative mild moderate dementia alzheimer type peptic ulcer disease relief smooth muscle spasm gastrointestinal disorder edema congestive heart failure cirrhosis liver nephrotic syndrome steroid induced edema idiopathic edema edema secondary hyperaldosteronism hydrochlorothiazide managment hypertension edema develop hypokalemia following hydrochlorothiazide monotherapy require thiazide diuretic whom development hypokalemia can not risked allows maintenance potassium balance given loop diuretic thiazide t28 cancer bladder all form parkinson disease well control extrapyramidal reaction induced antipsychotic agent injection hypotension shock anesthesia ophthalmic formulation dilate pupil induce vasoconstriction intranasal formulation congestion topical formulation hemorrhoid a187370 off us include situation require local blood flow restriction priapism a187370 hyperthyroidism thyrotoxicosis prepare thyroidectomy following condition mild moderate heart failure increase myocardial contraction child diagnosed heart failure 3 maintain control ventricular rate diagnosed chronic atrial fibrillation adult heart failure clinically possible should administered conjunction diuretic angiotensin converting enzyme ace inhibitor optimum effect schizophrenia parkinson disease control severe reaction certain medicine reserpine adjunct improve neurologic outcome following subarachnoid hemorrhage sah from ruptured intracranial berry aneurysm reducing incidence severity ischemic deficit oral inhalation maintenance asthma prophylactic therapy 5 age older aerosol form beclomethasone diproprionate relief bronchospasm intranasal relieve symptom seasonal perennial allergic nonallergic vasomotor rhinitis prevent recurrence nasal polyp following surgical removal relief inflammatory pruritic manifestation corticosteroid responsive dermatosis 13 age older corticosteroid responsive dermatosis include psoriasis contact dermatitis dermatitis venenata atopic dermatitis infantile eczema allergic dermatitis neurodermatitis lichen simplex chronicus lichen planus eczema eczematous dermatitis intertrigo dyshidroses pompholyx seborrheic dermatitis exfoliative dermatitis solar dermatitis stasis dermatitis anogenital senile pruritus relief discomfort related painful musculoskeletal condition fda important limitation fda should only period up two three week adequate evidence effectiveness more prolonged established recommended pediatric le than 16 agegelatinized capsule gelatinized capsule prevention endometrial hyperplasia non hysterectomized postmenopausal woman receiving conjugated estrogen tablet they secondary amenorrhea fda vaginal gel gel 8 supplementation replacement part assisted reproductive technology art infertile woman deficiency lower concentration gel 4 secondary amenorrhea 8 concentration if there no therapeutic response 4 gel f3898 vaginal insert form support embryo implantation early pregnancy supplementation corpus luteal function part assisted reproductive technology art program infertile woman f3901 injection intramuscular drug amenorrhea abnormal uterine bleeding hormonal imbalance absence organic pathology submucous fibroid uterine cancer f3907 tablet contraceptive tablet form contraceptive formulation prevention pregnancy f3904 nasal congestion control urinary incontinence priapism obesity unresectable hepatocellular carcinoma advanced renal cell carcinoma hypercalcemia malignancy multiple myeloma bone metastasis from solid tumor osteoporosis men postmenopausal woman glucocorticoid induced osteoporosis paget disease bone men woman prevention osteoporosis post menopausal woman glucocorticoid induced osteoporosis ringworm infection skin hair nail namely tinea corporis tinea pedis tinea cruris tinea barbae cradle cap condition trichophyton microsporum fungi hypertension alone antihypertensive agent insomnia caerulein paralytic ileus diagnostic aid pancreatic malfunction anxiety disorder anxiety depression panic disorder panic disorder agoraphobia prescribed off insomnia premenstrual syndrome depression a177973 relief symptom allergy hay fever coldsfor bacterial fungal infection inside mouth thrush skin prevention transmission chaga disease blood additive prevention deep vein thrombosis result pulmonary embolism following knee surgery manifestation psychotic disorder schizophrenia atypical antipsychotic once schizophrenia a215532 impetigo secondary skin infection leading traumatic skin lesion staphylococcus aureus streptococcus pyogenes primarily glaucoma but during ophthalmic surgery adjunct diet exercise improve glycemic control adult type diabetes mellitus drug symptomatic parkinson disease fda drug administered monotherapy conjunction levodopa symptomatic moderate severe primary restless leg syndrome rls fda diabetes mellitus type onset infection respiratory gi uti meningitis e coli p mirabilis enterococci shigella typhosa salmonella nonpenicillinase producing n gononhoeae h influenzae staphylococci streptococci streptocfor anesthesia adjunct induce skeletal muscle relaxation reduce intensity muscle contraction convulsive therapy mild moderately severe infection penicillin g sensitive microorganism bacteriological study sensitivity test clinical response mild moderate infection upper respiratory tract scarlet fever mild erysipelas streptococcus without bacteremia mild moderately severe infection respiratory tract pneumococcus mild infection skin soft tissue penicillin g sensitive staphylococcus mild moderately severe infection oropharynx fusospirochetosis vincent gingivitis pharyngitis usually respond oral penicillin therapy off prophylaxis against bacterial endocarditis congenital heart disease rheumatic acquired valvular heart disease they undergo dental procedure surgical procedure upper respiratory tract short term intractable insomnia habituated barbituratesfor mild moderate type nonneuropathic gaucher disease whom enzyme replacement therapy therapeutic option e g constraint allergy hypersensitivity poor venous access now approved some country progressive neurological symptom pediatric niemann pick disease type c np c adjunct short term moderate severe psychomotor agitation agitation restlessness elderly new york heart association class iii iv heart failure edema cirrhotic adult responsive fluid sodium restriction primary hyperaldosteronism short term preoperatively primary hyperaldosteronism long term aldosterone producing adrenal adenoma candidate surgery bilarteral micro macronodular adrenal hyperplasia add therapy hypertension nephrotic syndrome disease well fluid sodium restriction diuretic inadequate antiandrogenic activity lead many off us off hirsutism female pattern hair loss acne vulgaris a178135 frequently antiandrogenic effect transgender female low cost reducing male pattern hair growth a178138 attention deficit hyperactivity disorder adhd 6 age older narcolepsy tablet intramuscular injection united state adjunct rest physical therapy measure relief discomfort painful musculoskeletal condition oral america given up 1500mg 4 time daily 3 day a31312 canada containing oral formulation sold over counter pain muscle spasm however if these formulation include codeine they prescription only bladder spasm peptic ulcer disease diverticulitis colic irritable bowel syndrome cystitis pancreatitis certain heart condition control symptom parkinson disease rhinitis drug short term insomnia adult characterized difficulty sleep initiation fda herpes zoster shingle suppression recurrent genital herpes immunocompetent recurrent mucocutaneous herpes simplex infection hiv infected symptomatic relief seasonal perennial allergic rhinitis nonallergic rhinitis allergic conjunctivitis mild uncomplicated allergic skin manifestation urticaria angioedema agent symptomatic relief symptom common cold malignant neoplasm pancreas metastatic islet cell carcinoma aborting pregnancy between 13th 20th week gestation calculated from first day last normal menstrual period following condition related second trimester abortion failure expulsion fetus during course another method premature rupture membrane intrauterine method loss drug insufficient absent uterine activity 3 requirement repeat intrauterine instillation drug expulsion fetus 4 inadvertent spontaneous rupture membrane presence previable fetus absence adequate activity expulsion postpartum hemorrhage uterine atony responded conventional method severe infection susceptible bacteria p aeruginosa infested sarcoptes scabiei pediculosis capitis either failed respond adequate dos intolerant approved therapy primay keratoconjunctivitis recurrent epithelial keratitis herpes simplex virus type ophthalmic solution tipiracil oral tablet metastatic colorectal cancer previously treated fluoropyrimidine oxaliplatin irinotecan based chemotherapy anti vegf biological therapy if ra wild type anti egfr therapy fda symptomatic severe nausea vomiting manifestation psychotic disorder schizophrenia generalized non psychotic anxiety generalized non psychotic anxiety typically first line therapy should limited dos le than 20 mg per day shorter than 12 week off us include emergency setting pediatric migraine american headache society recommends first line medication setting pediatric migraine non steroidal anti inflammatory agent often dopamine antagonist perennial seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis inhalant allergen food mild uncomplicated allergic skin manifestation urticaria angioedema amelioration allergic reaction blood plasma cold urticaria dermatographism therapy anaphylactic reaction adjunctive epinephrine term near term amp gt 34 week neonate hypoxic respiratory failurefor high blood pressure edema related heart failure fda sign symptom primary secondary gout attack tophus joint destruction uric acid lithiasis nephropathy leukemia lymphoma malignancy receiving cancer therapy cause elevation serum urinary uric acid level should discontinued potential overproduction uric acid no longer present 3 recurrent calcium oxalate calculus whose daily uric acid excretion exceeds 800 mg day male 750 mg day female therapy should carefully assessed initially reassessed periodically determine each case beneficial benefit outweigh risk infection susceptible strain organism following disease lower respiratory tract infection skin skin structure infection urinary tract infection bacterial septicemia bone joint infection gynecologic infection intra abdominal infection peritonitis central nervous system infection meningitis adjunct diet reduction elevated total ldl cholesterol level primary hypercholesterolemia mixed dyslipidemia fredrickson type iia iib response dietary restriction saturated fat cholesterol non pharmacological measure alone inadequate monotherapy episode uncomplicated urinary tract infection susceptible bacteria e coli k pneumoniae enterobacter spp p mirabilis coagulase negative staphylococcus specie various formulation sulfamethoxazole following infection bacteria documented susceptibility urinary tract infection otitis medium pediatric clinically exacerbation chronic bronchitis adult enteritis susceptible shigella prophylaxis pneumocystis jiroveci pneumonia traveler diarrhea enterotoxigenic e coli available ophthalmic solution polymyxin b bacterial conjunctivitis blepharitis blepharoconjunctivitis susceptible bacteria advanced ovarian cancer relapsed least 6 month after completion platinum based therapy metastatic ovarian cancer inoperable locally advanced stage iiia iiib metastatic stage iv non small cell lung cancer locally advanced nonresectable stage ii stage iii metastatic stage iv adenocarcinoma pancreas chronic hepatitis b virus infection adult evidence active viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease member corticosteroid family several inflammatory condition topical monotherapy relieve pruritic inflammatory symptom corticosteroid responsive dermatosis topically vitaminD analog calcipotriene plaque psoriasis corticosteroid available injectable suspension manage range inflammatory condition endocrine disorder gastrointestinal disorder rheumatic disorder among condition refractory lymphoblastic leukaemiafor component adjuvant therapy evidence axillary node tumor involvement following resection primary breast cancer cholera destroys vibrio decrease diarrhea effective against tetracycline resistant vibrio eye drop ointment bacterial conjunctivitis upper respiratory tract bacterial infection chronic bronchitis pneumonia sinusitis pharyntitis tonsillitis skin absceses urinary tract infection pyelonephritis e coli pyogenes aureus saprphyticus penumoniae h influenzae m catarrhalis reduce gastric acid secretion approved short term active gastric ulcer active duodenal ulcer erosive reflux oesophagitis symptomatic gastroesophageal reflux disease non steroidal anti inflammatory drug nsaid induced gastric duodenal ulcer a4892 a177065 fda maintenance healing several gastric condition duodenal ulcer nsaid related gastric ulcer erosive esophagitis fda prevents recurrence gastric ulcer documented history gastric ulcer nsaid chronically fda predictably useful hypersecretory condition zollinger ellison syndrome fda effective eradicating h pylorus conjunction amoxicillin clarithromycin triple therapy amoxicillin alone dual therapy fda prodrug initial therapy control intraocular pressure chronic open angle glaucoma ssed produce tranquilization reduce incidence nausea vomiting surgical diagnostic procedure replacement therapy primary thyroidal secondary pituitary tertiary hypothalamic congenital acquired hypothyroidism adjunct surgery radioiodine therapy thyrotropin dependent well differentiated thyroid cancer bacterial blepharitis bacterial bonjunctivitis corneal injury corneal ulcer meibomianitis prophylaxis ocular infection following foreign body removalfor brucellosis mycoplasma infection acne vulgaris chlamydial infection chronic bronchitisused control moderate severe pain 2nd generation antihistamine manage symptom allergic rhinitis wheal formation urticaria allergic dermatologic condition a176435 a176438 prevent infection during surgery many kind infection blood bone joint respiratory tract skin urinary tract drug hypertension high blood pressure given alone given blood pressure lowering drug diuretic beta adrenergic blocking agent fda doe negatively impact lung function therefore manage hypertension asthmatic chronic obstructive lung disease copd a176630 relief symptom depression temporary adjunctive therapy reducing enuresis child aged 6 older fda off manage panic disorder without agoraphobia second line agent adhd child adolescent manage bulimia nervosa short term depressive episode bipolar disorder schizophrenia stress disorder posttraumatic stress disorder symptomatic postherpetic neuralgia painful diabetic neuropathy a31900 a31904 severe psoriasis adult predominantly classic subfoveal choroidal neovascularization age related macular degeneration pathologic myopia presumed ocular histoplasmosis syndrome destroy tumor symptomatic relief rheumatoid arthritis symptomatic relief osteoarthritis adjunctive therapy peptic ulcer nausea vomiting motion sickness epilepsy small uncomplicated varicose vein lower extremity show simple dilation competent valve non steroidal anti inflammatory drug nsaid antipyretic analgesic anti inflammatory property a176131 short term pain requires caliber pain offered opioids clinician choose initiate manage post operative pain spinal soft tissue pain rheumatoid arthritis osteoarthritis ankylosing spondylitis menstrual disorder headache among ailment regardless etiology pain should lowest possible dose avoid using extended period time ideally 5 day benefit choosing over analgesic similar potency that there doe appear risk dependence tolerance a176131 internally relieving respiratory distress antidote poisoning cns depressant especially barbiturate adult amp ge 18 age following infection susceptible strain designated microorganism uncomplicated urethral cervical gonorrhea neisseria gonorrhoeae uncomplicated urinary tract infection cystitis escherichia coli staphylococcus epidermidis staphylococcus saprophyticus 3 complicated urinary tract infection escherichia coli klebsiella pneumoniae proteus mirabilis pseudomonas aeruginosa staphylococcus epidermidis enterobacter cloaca malaria leg crampsfor rheumatoid arthritis osteoarthritis backache pain anorexia weight loss aid nausea vomiting cancer chemotherapy failed respond adequately conventional antiemetic treatment prophylaxis chronic asthma adult pediatric 12 month age older although regional health authority specifically note indication adult adolescent 15 older include indication preventing day night time symptom acetylsalicylic acid sensitive asthma b prevention exercise induced bronchoconstriction eib 6 age older although regional health authority specifically note indication adult adolescent 15 older c relief symptom seasonal allergic rhinitis age older perennial allergic rhinitis 6 month age older although regional health authority specifically note relief seasonal allergic rhinitis symptom adult adolescent 15 older furthermore some formulation like chewable tablet specifically particular regulatory body prophylaxis chronic asthma prevention day night time symptom acetylsalicylic acid based asthma prevention exercise induced bronchoconstriction pediatric aged older between age 5 between age 6 14 moreover employed indication considered effective monotherapy combined medication maintenance chronic asthma instance inhaled corticosteroid concomitantly demonstrate additive effect control asthma decrease necessary inhaled corticosteroid dose while still maintaining clinical stability additionally continue experience asthma symptom combined required short acting beta agonist inhaled corticosteroid inhaled corticosteroid paired long acting beta agonist both maintenance major depressive disorder obsessive compulsive disorder bulimia nervosa however only panic disorder independent whether agoraphobia present olanzapine depression related bipolar i disorder resistant depression local anesthetic surface application infiltration nerve block intravenous anaesthetic commonly induce deep sedation anxiety disorder short term relief symptom anxiety withdrawal symptom alcoholism preoperative apprehension anxiety major depressive disorder generalized anxiety disorder 3 diabetic peripheral neuropathy 4 fibromyalgia 5 chronic musculoskeletal pain 6 osteoarthritis knee adult 7 chronic lower back pain adult 8 stress urinary incontinence woman off us include chemotherapy induced peripheral neuropathy a178603 stress urinary incontinence men after prostatectomy until recovery complete schizophrenia control nausea vomiting relief restlessness apprehension before surgery intermittent porphyria adjunct tetanus control manifestation manic type manic depressive illness relief intractable hiccup severe behavioral problem child 12 age marked combativeness explosive hyperexcitable behavior out proportion immediate provocation short term hyperactive child show excessive motor activity accompanying conduct disorder consisting some all following symptom impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance prophylaxis illness various strain influenza virus adult sulfate injection short term serious bacterial infection susceptible strain gram negative bacteria pseudomonas specie escherichia coli specie indole positive indole negative proteus providencia specie klebsiella enterobacter serratia specie well acinetobacter mima herellea specie f1954 clinical study shown sulfate injection effective bacterial septicemia neonatal sepsis serious infection respiratory tract bone joint central nervous system meningitis skin soft tissue intra abdominal infection peritonitis burn postoperative infection post vascular surgery f1954 clinical study shown effective serious complicated recurrent urinary tract infection above organism aminoglycosides uncomplicated first time episode urinary tract infection unless causative organism susceptible antibiotic le toxic f1954 september 2018 new indication new dosage route approved drug liposome inhalation suspension approved lung disease group bacteria mycobacterium avium complex mac limited population disease do respond conventional refractory disease indication approved under accelerated approval based achieving sputum culture conversion defined 3 consecutive negative monthly sputum culture month 6 clinical benefit yet established important note regarding staphylococcus sensitivity testing staphylococcus aureus methicillin resistant strain principal gram positive organism sensitive staphylococcal infection should restricted only second line therapy should limited only those suffering from severe infection susceptible strain staphylococcus specie failed show sensitivity available antibiotic f1949 bacteriologic study should performed identify causative organism their susceptibility initial therapy suspected gram negative infection therapy initiated before obtaining result susceptibility testing f1949 f1954 multiple myeloma dexamethasone transfusion dependent anemia low intermediate risk myelodysplastic syndrome md deletion 5q cytogenetic abnormality without additional cytogenetic abnormality prevention osteoporosis postmenopausal woman well prevention corticosteroid induced bone loss reduction risk invasive breast cancer postmenopausal woman osteoporosis postmenopausal woman high risk invasive breast cancer symptomatic osteoarthritis oa rheumatoid arthritis ra substitute aspirin cardiovascular event prophylaxis be pain from various source juvenile rheumatoid arthritis child over ankylosing spondylitis primary dysmenorrhea adjunct anesthesia induce skeletal muscle relaxation facilitate undergoing mechanical ventilationopthalmic lowering intraocular pressure iop open angle glaucoma ocular hypertension monotherapy product brinzolamide topical persistent non transient facial erythema rosacea adult 18 age older infection penicillinase producing staphylococci demonstrated susceptibility drug nausea vomiting cancer chemotherapy failed respond adequately conventional antiemetic treatment restriction required because substantial proportion any group treated expected experience disturbing psychotomimetic reaction observed antiemetic agent uncomplicated gonococcal urethritis male gram negative bacterial infection gastrointestinal system genitourinary tract single agent palliative persistent recurrent ovarian cancer following first line therapy cisplatin alkylating agent based life threatening ventricular arrhytmias maintain normal sinus rhythm atrial fibrillation flutter there oral solution intravenous injection requiring but whom tablet would appropriate anxiety disorder short term relief symptom anxiety adjunct diet improve glycemic control non insulin dependent diabetes mellitus niddm whose hyperglycemia can not managed diet alone treating mild moderate hypertension adjunct treating congestive heart failure slow rate progression renal disease hypertensive individual diabetes mellitus microalbuminuria overt nephropathy gonorrhoea meningitis severe infection infection kidney pyelonephritis urinary system before operation prevent infection after surgery adjunct levodopa carbidopa symptomatic idiopathic parkinson disease experience sign symptom end dose wearing off antiretroviral agent human immunovirus hiv infection overactive bladder symptom urge urinary incontinence urgency frequency moderate severe pain there extended release formulation chronic moderate severe pain requiring continuous opioid analgesic extended period pulmonary embolism cardiomyopathy atrial fibrillation flutter cerebral embolism mural thrombosis thrombophili anticoagulant prophylaxis locally confined stage b2 c stage d2 metastatic carcinoma prostatefor relief sign symptom rheumatoid arthritis osteoarthritis flare long term juvenile rheumatoid arthritis acid reflux disorder gerd peptic ulcer disease heartburn acid indigestion number condition schizophrenia manifestation psychotic disorder control tic vocal utterance tourette disorder child adult severe behavior problem child combative explosive hyperexcitability can not accounted immediate provocation short term hyperactive child show excessive motor activity accompanying conduct disorder consisting some all following symptom impulsivity difficulty sustaining attention aggressivity mood lability poor frustration tolerance should reserved these two group child only after failure respond psychotherapy medication than antipsychotic f4645 antiretroviral agent hiv infection complete partial reversal narcotic depression respiratory depression induced opioids adjunct peptic ulcer disease acquired nystagmusfor diarrhea adult child protozoa giardia lamblia diarrhea child protozoan cryptosporidium parvum fda shown superior placebo medication diarrhea cryptosporidium parvum hiv immunodeficiency fda a31973 a31976 mainly psychosis control nausea vomiting lower high cholesterol level blood fast digitalization congestive heart failure variety dosage form example oral injection etc exist serious severe infection susceptible strain methicillin resistant beta lactam resistant staphylococci fda additionally unique fda approved oral liquid available clostridium difficile diarrhea enterocolitis staphylococcus aureus methicillin resistant strain excessive postoperative bleeding brompheniramine pseudoephedrine cough upper respiratory symptom allergy common cold guaifenesin over counter product relieve cough dextromethorpahn quinidine pseudobulbar affect metastatic testicular tumor metastatic ovarian tumor advanced bladder cancer prevent reduce severity allergic contact dermatitis urushiol allergenic resin poison ivy poison oak poison sumac conjunction antacid histamine h lt sub gt lt sub gt receptor antagonist peptic ulcer reduce further gastric acid secretion delay gastric emptying parenchymal neurocysticercosis active lesion larval form pork tapeworm taenia solium cystic hydatid disease liver lung peritoneum larval form dog tapeworm echinococcus granulosus mild moderate hypertension adjunct congestive heart failure chf improve survival following myocardial infarction mi individual hemodynamically stable demonstrate symptom left ventricular systolic dysfunction sign chf within few day following mi slow progression renal disease hypertensive diabetes mellitus microalbuminuria overt nephropathy esophageal candidiasis invasive aspergillosis refractory intolerant therapy intraocular hypertension chronic open angle glaucomaindicated screening test exocrine pancreatic insufficiency monitor adequacy supplemental pancreatic therapy topical cutaneous lesion aid related kaposi sarcoma hypertension alone antihypertensive drug different class topical skin infection athlete foot jock itch ringworm infection along antifungal infection nail scalp palm sol foot powder powder aerosol prevent athlete foot infusional 5 fu lv advanced carcinoma colon rectum adjuvant stage iii colon cancer undergone complete resection primary tumor production local regional anesthesia infiltration technique percutaneous injection intravenous regional anesthesia peripheral nerve block technique brachial plexus intercostal central neural technique lumbar caudal epidural block hypertension angina pectoris raynaud syndromefor cmv retinitis acquired immunodeficiency syndrome aid acyclovir resistant mucocutaneous hsv infection immunocompromised metastatic non small cell lung cancer nsclc tumor showing epidermal growth factor receptor egfr exon 19 deletion exon 21 r substitution mutation fda first line diagnosed locally advanced unresectable metastatic pancreatic cancer fda safety efficacy established nsclc whose tumor show egfr mutation additionally recommended platinum based chemotherapy fda malignant lymphoma multiple myeloma leukemia mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma ovary retinoblastoma carcinoma breast biopsy proven minimal change nephrotic syndrome pediatric refractory partial epilepsy osteoarthritis rheumatoid arthritis pain adult primary dysmenorrhea well migraine attack without aura previously diuretic radiolabeled form diagnostic research tool bacterial otitis medium maxillary sinusitis community acquired ca pneumonia bacterial exacerbation chronic bronchitis pharyngitis tonsillitis uncomplicated skin skin structure infection child adult a180739 organism susceptible listed below addition their clinical condition treated various beta lactamase producing organism treated certain section below respiratory bacterial exacerbation chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin susceptible only moraxella catarrhalis community acquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae penicillin susceptible only moraxella catarrhalis ear nose throat bacterial otitis medium haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae penicillin susceptible only tonsillitis streptococcus pyogenes pharyngitis streptococcus pyogenes maxillary sinusitis haemophilus pneumoniae streptococcus pneumoniae penicillin susceptible only moraxella catarrhalis skin skin structure infection uncomplicated skin skin structure infection staphylococcus aureus streptococcus pyogenesfor reduction symptom muscle weakness easy fatigability myasthenic syndrome eaton lambert treating myasthenia gravis only infection susceptible bacteria immediate release tablet oral suspension intravenous injection skin skin structure infection bone joint infection complicated intra abdominal infection nosocomial pneumonia febrile neutropenia adult inhaled anthrax plague chronic bacterial prostatitis lower respiratory tract infection exacerbation chronic bronchitis urinary tract infection complicated urinary tract infection pediatrics complicated pyelonephritis pediatrics sinusitis otic solution otic suspension hydrocortisone otitis externa suspension dexamethasone otitis medium pediatric tympanostomy tube otitis externa intratympanic injection pediatric bilateral otitis medium effusion having tympanostomy tube placed pediatric 6 month older otitis externa eye drop bacterial corneal ulcer conjunctivitis eye ointment bacterial conjunctivitis extended release tablet uncomplicated urinary tract infection complicated urinary tract infection uncomplicated pyelonephritis mri contrast agent mri diagnostic procedure provide increased enhancement visualization lesion brain spine liver tumor metastatic breast cancer postmenopausal woman estrogen receptor positive receptor unknown tumor currently under investigation preventative agent prostate cancer men high grade prostatic intraepithelial neoplasia no evidence prostate cancer relief symptom major depressive disorder mdd some off us drug include chronic pain myofascial pain neuralgia irritable bowel syndrome a191083 lymphocytic leukemia all hodgkin lymphoma non hodgkin lymphoma wilms tumor neuroblastoma rhabdomyosarcoma liposomal relapsed philadelphia chromosome negative ph lymphoblastic leukemia all hypertension a840 alone thiazide diuretic fda relief symptom depression neurotic reactive depressive disorder well endogenous psychotic depression depression accompanied anxiety agitation topical multiple actinic solar keratoses 5 strength useful superficial basal cell carcinoma conventional method impractical multiple lesion difficult site injection palliative some type cancer colon esophageal gastric rectum breast biliary tract stomach head neck cervical pancreas renal cell carcinoid myasthenia gravis anxiety status epilepticus relief inflammatory pruritic manifestation corticosteroid responsive dermatosis topical mild moderate inflammatory acne vulgaris prophylaxis chronic asthma manage hyperthyroidism overactive thyroid gland grave disease addition antibiotic medical procedure chronic urea splitting urinary infection hairy cell leukaemia refractory alpha interferon psoriasis vitiligofor osteoarthritis rheumatoid arthritis adjunctive therapy following seizure type age partial seizure primary generalized tonic clonic seizure generalized seizure lennox gastaut syndrome process conversion drug monotherapy those least 16 age older partial seizure currently receiving carbamazepine phenytoin phenobarbital primidone valproate single antiepileptic drug aed addition above maintenance bipolar i disorder delaying time mood episode include mania hypomania depression mixed episode adult least 18 older treated mood symptom standard therapy limitation important note lamotirigine should mood episode efficacy established context ultrasound contrast imaging cardiology radiology symptomatic relief anxiety tension psychoneurosis adjunct organic disease state anxiety manifested histamine mediated pruritus pruritus allergic condition chronic urticaria canadian labeling state adult child premedication prior medical procedure dental surgery control nausea vomiting excluding nausea vomiting pregnancy prevention influenza b pulmonary arterial hypertension pah improve exercise ability decrease rate clinical worsening class iii iv symptom infection susceptible strain designated microorganism following condition complicated skin skin structure infection escherichia coli enterococcus faecalis vancomycin susceptible isolates only staphylococcus aureus methicillin susceptible resistant isolates streptococcus agalactiae streptococcus anginosus grp includes anginosus intermedius constellatus streptococcus pyogenes bacteroides fragilis complicated intra abdominal infection citrobacter freundii enterobacter cloaca escherichia coli klebsiella oxytoca klebsiella pneumoniae enterococcus faecalis vancomycin susceptible isolates only staphylococcus aureus methicillin susceptible isolates only streptococcus anginosus grp includes anginosus intermedius constellatus bacteroides fragilis bacteroides thetaiotaomicron bacteroides uniformis bacteroides vulgatus clostridium perfringens peptostreptococcus micros temporary measure hospitalized respiratory insufficiency superimposed chronic obstructive pulmonary disease high blood pressure edema oral solution pediatric lymphoblastic leukemia pediatric polyarticular juvenile idiopathic arthritis injection subcutaneous severe active rheumatoid arthritis polyarticular juvenile idiopathic arthritis severe recalcitrant disabling psoriasis formulation gestational choriocarcinoma chorioadenoma destruens hydatiform mole breast cancer epidermoid cancer head neck advanced mycosis fungoides lung cancer advanced non hodgkin lymphoma maintenance lymphocytic leukemia given before leucovorin prolong relapse free survival following surgical removal tumour non metastatic osteosarcoma epilepsy pain true trigeminal neuralgia particular shown efficacy treating mixed seizure partial seizure complex symptom generalized tonic clonic seizure a180301 manic episode mixed manic depressive episode bipolar i disorder some off unapproved us include alcohol withdrawal syndrome restless leg syndrome a180415 a180421 inpatient outpatient adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation icu lead poisoning pediatric blood lead level above 45 amp micro g dl mercury arsenic poisoning certain infection susceptible bacteria these infection include respiratory tract infection otitis medium skin skin structure infection bone infection genitourinary tract infection vertigo meniere disease nausea vomiting motion sickness useful vestibular symptom origin approved prophylaxis vte up one month post surgery undergoing orthopedic surgery lower limb hip fracture hip replacement knee surgery prophylaxis vte undergoing abdominal surgery high risk thromboembolic complication e g undergoing abdominal cancer surgery 3 dvt pe 4 ua nstemi prevention death subsequent myocardial infarction mi 5 stemi prevention death myocardial reinfarction managed thrombolytic initially receive no form reperfusion therapy should sole anticoagulant during percutaneous coronary intervention pci increased risk guiding catheter thrombosis breast cancer testicular cancer lymphoma neuroblastoma hodgkin non hodgkin lymphoma mycosis fungoides histiocytosis kaposi sarcoma hypertension angina pectoris coronary atherosclerosis atrial fibrillation myocardial infarction migraine essential tremor hypertrophic subaortic stenosis pheochromocytoma proliferating infantile hemangioma poisoning susceptible organophosphorous nerve agent having anti cholinesterase activity cholinesterase inhibitor well organophosphorous carbamate insecticide relief sign symptom rheumatoid arthritis osteoarthritis relief mild moderate pain seizure dravet syndrome aged two older tablet transdermal system hypertension alone medication injection opiate severe cancer pain where opiate alone insufficient extended release tablet adhd either alone medication diagnosis pheochromocytoma a180565 nicotine dependance a180568 opiate withdrawal a180571 urinary tract infectionvalacyclovir nucleoside analog dna polymerase inhibitor fda adult cold sore herpes labialis genital herpes genital herpes lesion immunocompetent initial recurrent episode suppression genital herpes lesion immunocompetent hiv infected reduction viral transmission herpes zoster pediatric cold sore herpes labialis chickenpox limitation fda efficacy safety valacyclovir established immunocompromised than suppression genital herpes hiv infected chronic infection upper lower urinary tract asymptomatic bacteriuria susceptible strain bacteria short term few week exogenous obesity conjunction regimen weight reduction based caloric restriction exercise behavior modification body mass index 30 kg body weight per height meter squared kg m lt sup gt lt sup gt body mass index 27 kg m lt sup gt lt sup gt presence risk factor hypertension diabetes hyperlipidemia osteoarthritis dysmenorrhoea laxative chronic constipation adult geriatric fda additionally employed adjunct protein restriction supportive therapy prevention portal systemic encephalopathy pse both hepatic pre coma coma variation fda particular solution effective managing pse resulting from surgical portacaval shunt from chronic hepatic disease like cirrhosis moreover there study demonstrating capacity minimize formation gallstone even some investigation regarding experimental agent developing novel anticancer agent owing ability bind galactin carbohydrate involved various tumor progression esophageal candidiasis invasive pulmonary aspergillosis serious fungal infection scedosporium apiospermum fusarium spp primary systemic carnitine deficiency genetic impairment normal biosynthesis utilization from dietary source secondary carnitine deficiency resulting from inborn error metabolism glutaric aciduria ii methyl malonic aciduria propionic acidemia medium chain fatty acylcoa dehydrogenase deficiency therapeutically stimulate gastric pancreatic secretion hyperlipoproteinemia parenteral prevention carnitine deficiency end stage renal disease essential renovascular hypertension monotherapy antihypertensive agent thiazide diuretic additive effect symptomatic congestive heart failure usually diuretic digitalis asymptomatic left ventricular dysfunction ejection fraction 35 percent decrease rate development overt heart failure incidence hospitalization heart failure acid reflux disorder gerd peptic ulcer disease active benign gastric ulcer active duodenal ulcer pain inflammation from varying source inflammatory condition osteoarthritis rheumatoid arthritis akylosing spondylitis well injury related inflammation surgery physical trauma often misoprostol gastro protective agent high risk developing nsaid induced ulcer protection against second phase inflamation exercise induced bronchoconstriction asthma inhaler asthma prophylaxis fda well inflammatory pruritic dermatosis f4355 nasal spray managing allergic nonallergic rhinitis f4358 parkinson disease symptom benign prostatic hypertrophy include urinary frequency urgency nocturia among symptom addition alone various antihypertensive agent hypertension off us include pediatric hypertension a180634 ureteric calculus a180637 extensively different medical area dermatology extensively relief inflammatory dermatosis dermatitis psoriasis hypertrophic tissue keloid tissue atopic dermatitis f1955 shampoo product low medium potency corticosteroid seborrheic dermatitis scalp ear drop low medium potency corticosteroid chronic eczematous external otitis adult pediatric older intravitreal implant diabetic macular edema previously treated course corticosteroid no clinically significant rise intraocular pressure announced october 15 2018 fda approved chronic non infectious uveitis affecting posterior segment eye some report vasoprotective agent first degree hemorrhoid a39532 alternative ascariasis ascaris lumbricoides roundworm enterobiasis oxyuriasis enterobius vermicularis pinworm partial intestinal obstruction common roundworm condition primarily occurring child petit mal epilepsy adjunctive thiazide diuretic kaliuretic diuretic agent congestive heart failure hypertension infection variety gram positive gram negative microorganism mycoplasma pneumoniae pasteurella pestis escherichia coli haemophilus influenzae respiratory infection diplococcus pneumoniae cream ointment inflammatory pruritic corticosteroid responsive dermatosis lotion plaque psoriasis mri contrast agent contrast enhancement brain spine surrounding tissue resulting improved visualization compared unenhanced mri lesion abnormal vascularity those thought cause disruption normal blood brain barrier whole body contrast enhanced mri head neck liver breast musculoskeletal system soft tissue pathology injection control blood pressure severe hypertension tablet alone antihypertensive like thiazide loop diuretic manage hypertension sole anesthetic agent brief 15 minute procedure induction anesthesia prior administration anesthetic agent supplement regional anesthesia provide hypnosis during balanced anesthesia agent analgesia muscle relaxation control convulsive state during following inhalation anesthesia local anesthesia neurosurgical increased intracranial pressure narcoanalysis narcosynthesis psychiatric disorder topically loss skin color vitiligo bacterial infection susceptible strain vancomycin resistant enterococcus faecium staphylococcal aureus methicillin resistant susceptible strain streptococcus pneumoniae streptococcus pyogenes streptococcus agalactiae intestinal i e nondisseminated strongyloidiasis nematode parasite strongyloides stercoralis onchocerciasis river blindness nematode parasite onchocerca volvulus scabies sarcoptes scabiei mpa oral tablet secondary amenorrhea reduce incidence endometrial hyperplasia postmenopausal woman abnormal uterine bleeding hormonal imbalance organic pathology oral tablet containing mpa conjugated estrogen prevent postmenopausal osteoporosis moderate severe menopausal symptom vasomotor symptom vulvar atrophy vaginal atrophy subcutaneous mpa prevent pregnancy manage pain endometriosis intramuscular mpa prevent pregnancy higher concentration palliative endometrial renal carcinoma symptomatic nocturnal heartburn gastroesophageal reflux disease long term relief sign symptom osteoarthritis rheumatoid arthritis ankylosing spondylitis painful shoulder subacromial bursitis supraspinatus tendinitis gouty arthritis adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effectiveness antihypertensive drug more severe form hypertension infection penicillinase producing staphylococci demonstrated susceptibility drug infection p vivax p malariae p ovale susceptible strain p falciparum extraintestinal amebiasis off rheumatic disease a191655 well prophylaxis zika virus a191649 a191652 currently undergoing clinical trial covid 19 a191631 pulmonary extrapulmonary tuberculosis antitubercular drug failed prevention hypotension hemorrhage spinal anesthesia shock brain damagefor relief moderate severe pain mild moderate hypertension off heart failure atrial fibrillation angina pectoris a180460 a180463 malarial attack non immune subject specific symptomatic bacterial protozoal diarrhea enteritis susceptible organism prevention disseminated mycobacterium avium complex mac disease advanced hiv infection control absence petit mal seizure refractory medication primarily lyme disease acne bronchitis but rarely urinary tract infection gum disease malaria bacterial infection gonorrhea chlamydia one registered us hyponatremia low blood sodium concentration syndrome inappropriate antidiuretic hormone siadh where fluid restriction alone ineffective philadelphia chromosome positive chronic myeloid leukemia ph cml ph lymphoblastic leukaemia myelodysplastic myeloproliferative disease aggressive systemic mastocytosis hypereosinophilic syndrome chronic eosinophilic leukemia cel dermatofibrosarcoma protuberans malignant gastrointestinal stromal tumor gist hexacetonide injection intralesional administration alopecia areata discoid lupus erythematosus keloid necrobiosis lipoidica diabeticorum formulation localized hypertrophic infiltrated inflammatory lesion granuloma annulare lichen planus lichen simplex chronicus psoriatic plaque acetonide spray cream inflammatory pruritic manifestation corticosteroid responsive dermatosis acetonide 10mg ml 40mg ml injection intra articularly gouty arthritis subacute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis same 10mg ml injection intralesional route alopecia areata discoid lupus erythematosus keloid necrobiosis lipoidica diabeticorum tumor aponeurosis tendon formulation localized hypertrophic infiltrated inflammatory lesion granuloma annulare lichen planus lichen simplex chronicus psoriatic plaque 40mg ml injection intramuscularly controlling severe allergic condition asthma atopic dermatitis contact dermatitis drug hypersensitivity perennial seasonal allergic rhinitis serum sickness transfusion reaction bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus stevens johnson syndrome congenital adrenal hyperplasia hypercalcemia cancer nonsuppurative thyroiditis autoimmune hemolytic anemia diamond blackfan anemia pure red cell aplasia secondary thrombocytopenia trichinosis tuberculous meningitis exacerbation multiple sclerosis cerebral edema sympathetic ophthalmia temporal arteritis uveitis ocular inflammation berylliosis idiopathic eosinophilic pneumonia symptomatic sarcoidosis dermatomyositis polymyositis systemic lupus erythematosus adjunct adrenocortical insufficiency regional enteritis ulcerative colitis fulminating disseminated pulmonary tuberculosis gouty arthritis rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis palliative leukemia lymphoma induction diuresis remission proteinuria idiopathic nephrotic syndrome lupus erythematosus intravitreal injection sympathetic ophthalmia temporal arteritis uveitis ocular inflammatory condition intravitreal injection visualization during vitrectomy extended release suspension intra articularly pain osteoarthritis knee promote weight gain after weight loss following extensive surgery chronic stable angina hypertension manifestation psychotic disorder primary hypogonadism hypogonadotropic hypogonadism hiv infection aid topical formulation chronic localized skin infection a181997 occasionally intramuscularly infantile streptococcal pneumonia empyema a181997 formulated ointment neomycin polymyxin b over counter a181997 ointment formulated neomycin polymyxin b along hydrocortisone corticosteroid responsive dermatosis secondary infection prevent vitaminDeficiencies pediatric receiving parenteral nutrition part multivitamin intravenous injection oral tablet monotherapy simvastatin lovastatin primary hyperlipidemia mixed dyslipidemia reduce risk nonfatal myocardial infarction history myocardial infarction hyperlipidemia bile acid binding resin atherosclerosis coronary artery disease hyperlipidemia primary hyperlipidemia finally severe hypertriglyceridemia anxiety disorder short term relief symptom anxiety adjunctive therapy partial seizure symptomatic relief alcohol withdrawal high blood pressure prevention osteoporosis men postmenopausal woman glucocorticoid induced osteoporosis paget disease bone fda a959 a176750 however pediatric population creatinine clearance lt 35ml min fda pediatric 21 old relapsed refractory lymphocytic lymphoblastic leukemia after least two prior regimen designated orphan drug fda topical recurrent oral facial herpes simplex episode cold sore fever blister sedation initially intubated mechanically ventilated during intensive care setting pain relief anxiety reduction analgesiafor bacterial vaginitis keratitis conjunctivitis blepharitis anti inflammatory immunosuppressive drug allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious endocrine neoplastic condition well organ transplant primary dysbetalipoproteinemia type iii hyperlipidemia doe respond adequately diet help control high cholesterol high triglyceride level relieving allergy symptom particularly rhinitis conjunctivitis withdrawn from market however concern arrhythmia historically important medical test renal function specifically measure glomerular filtration rate sometimes help relieve symptom diabetes mellitus condition characterised hyperglycemia hyperinsulinemia local vulvovaginal candidiasis infection candida initial termination paroxysmal supraventricular tachycardia pvst accessory bypass tract drug choice terminating stable narrow complex supraventricular tachycardia svt adjunct thallous chloride ti 201 myocardial perfusion scintigraphy thallium stress test unable exercise adequately well adjunct vagal maneuver clinical assessment establish specific diagnosis undefined stable narrow complex svt hyperlipidemia reduce elevated total cholesterol total c low density lipoprotein cholesterol ldl c apolipoprotein b apo b triglyceride tg increase high density lipoprotein cholesterol hdl c f4655 f4658 includes primary hyperlipidemia fredrickson type iia heterozygous familial nonfamilial mixed dyslipidemia fredrickson type iib hypertriglyceridemia fredrickson type iv hyperlipidemia primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia homozygous familial hypercholesterolemia hofh adjunct lipid lowering treatment well adolescent heterozygous familial hypercholesterolemia hefh f4655 f4658 reduce risk cardiovascular morbidity mortality myocardial infarction stroke need revascularization procedure primarily high risk coronary event because existing coronary heart disease diabetes peripheral vessel disease history stroke cerebrovascular disease f4655 f4658 prescribing statin medication considered standard practice following any cardiovascular event people moderate high risk development cvd statin condition include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl c level a181087 a181406 cisplatin malignant pleural mesothelioma adult whose disease unresectable otherwise candidate potentially curative surgery monotherapy locally advanced metastatic non small cell lung cancer nsclc after prior chemotherapyfor enterobius vermicularis pinworm trichuris trichiura whipworm ascaris lumbricoides common roundworm ancylostoma duodenale common hookworm necator americanus american hookworm single mixed infection evaluating functional capacity response gonadotropes anterior pituitary evaluating residual gonadotropic function pituitary following removal pituitary tumor surgery irradiation provide topical anesthesia accessible mucous membrane prior examination endoscopy instrumentation procedure involving esophagus larynx mouth pharynx throat respiratory tract trachea urinary tract vagina suppress gag reflex laryngeal esophageal reflex facilitate dental examination procedure oral surgery endoscopy intubation relief canker sore cold sore fever blister available oral formulation prevention oral candidiasis k thrush intestinal candidiasis anal candidiasis topically vulvovaginal candidiasis cutaneous candida infection product containing alongside neomycin gramicidin d triamcinolone viaderm k c corticosteroid responsive dermatosis bacterial candidal infection pruritus ani vulva available metronidazole mixed infection trichomonas vaginalis candida albicans sometimes off prevention invasive candidiasis low birth weight neonate a188565 though generally reserved second line option after fluconazole relief mild moderate pain inoperable adrenocortical tumour cushing syndromefor human immunovirus hiv infection osteosarcoma after high dose methotrexate therapy diminish toxicity counteract effect impaired methotrexate elimination inadvertent overdosages folic acid antagonist megaloblastic anemia folic acid deficiency 5 fluorouracil prolong survival palliative advanced colorectal cancer relief bronchial asthma reversible bronchospasm chronic bronchitis emphysema relief moderate severe pain immediate control life threatening convulsion severe toxemia pre eclampsia eclampsia pregnancy nephritis child replacement therapy magnesium deficiency especially hypomagnesemia accompanied sign tetany similar those hypocalcemia uterine tetany myometriat relaxant reduction elevated intraocular pressure diagnosed open angle glaucoma ocular hypertension combined product netarsudil rho kinase inhibitor same indication addition above indication canadian monograph drug approves elevated intraocular pressure result angle closure glaucoma treated peripheral iridotomy laser iridoplasty perimenopausal postmenopausal symptom major depressive disorder mdd off adjunct therapy alcohol dependence off anxiety insomnia off symptom dementia alzheimer disease schizophrenia eating disorder fibromyalgia effect various neurotransmitter receptor a31634 moderately severe severe essential hypertension uncomplicated case malignant hypertensionfor control serum phosphorus chronic kidney disease ckd hemodialysis maintenance abstinence from alcohol alcohol dependence abstinent initiationfor painful peripheral musculoskeletal condition spasticity from upper motor neuron syndrome vasopastic i e prinzmetal angina unstable angina chronic stable angina hypertension prophylaxis repetitive paroxysmal supraventricular tachycardia digoxin control ventricular rate atrial fibrillation atrial flutter given intravenously various supraventricular tachyarrhythmias rapid conversion sinus rhythm supraventricular tachycardia temporary control ventricular rate atrial fibrillation atrial flutter commonly off prophylaxis cluster headache a13983 postoperative nausea vomiting nausea gastroenteritis contact dermatitis atopic dermatitis exczema psoriasis diaper rash skin conditionsfor urinary tract infection chronic bronchitis surgical castration metastatic prostate cancer involving distant lymph node bone visceral organ stage d2 central precocious puberty true precocious puberty gnrh dependent precocious precocity complete isosexual precocity child both sex endometriosis injection emergency allergic reaction type i anaphylaxis stinging insect e g order hymenoptera include bee wasp hornet yellow jacket fire ant biting insect e g triatoma mosquito allergen immunotherapy food drug diagnostic testing substance e g radiocontrast medium allergen well idiopathic anaphylaxis exercise induced anaphylaxis injectable intended immediate urgent administration found increased risk anaphylaxis individual history anaphylaxis selection appropriate dosage strength determined according body weight fda cardiac effect restoring cardiac rhythm cardiac arrest various cause but cardiac failure hemorrhagic traumatic cardiogenic shock f1247 hemostatic agent treating mucosal congestion hay fever rhinitis sinusitis relieve bronchial asthmatic paroxysm syncope complete heart block carotid sinus hypersensitivity symptomatic relief serum sickness urticaria angioneurotic edema resuscitation cardiac arrest following anesthetic accident simple open angle glaucoma relaxation uterine musculature inhibit uterine contraction injection utilized prolong action local anesthetic f1247 addition above over counter otc agent intermittent symptom asthma wheezing tightness chest shortness breath f2131 maintenance mydriasis during intraocular surgery naproxen tablet migraine without aura 12 age older nasal powder nasal spray subcutaneous injection tablet migraine without aura adult one subcutaneous formulation cluster headache adult while subcutaneous formulation peptic ulcer gastric ulcer duodenal ulcer following infection susceptible strain designated microorganism uncomplicated urinary tract infection escherichia coli proteus mirabilis otitis medium haemophilus influenzae beta lactamase positive negative strain moraxella catarrhalis most beta lactamase positive pyogenes 3 pharyngitis tonsillitis pyogenes 4 bronchitis exacerbation chronic bronchitis streptococcus pneumoniae haemophilus influenzae beta lactamase positive negative strain 5 uncomplicated gonorrhea cervical urethral neisseria gonorrhoeae penicillinase non penicillinase producing strain niddm conjunction diet exercise prevention nausea vomiting highly emetogenic cancer chemotherapy high dose cisplatin antiemetic agent mild moderate dementia alzheimer type estrogen receptor positive metastatic breast cancer adult adjuvant early stage estrogen receptor positive breast cancer adult reduce risk invasive breast cancer after surgery radiation woman ductal carcinoma situ kill louse mite responsible skin condition scabies eye certain type glaucoma eye condition accommodative esotropia hypertension older than 6 reduce risk stroke hypertension left ventricular hypertrophy though benefit extend african heritage diabetic nephropathy elevated serum creatinine proteinuria type diabetes hypertension hydrochlorothiazide hypertension reduce risk stroke hypertension left ventricular hypertrophy though benefit extend african heritage schizophrenia generalized anxiety disorder irregular heartbeat arrhythmia maintain normal heart rate potentially life threatening fungal infection prophylaxis venous thromboembolism related pulmonary embolism prophylaxis thromboembolism atrial fibrillation 3 prophylaxis thromboembolism cardiac valve replacement 4 adjunct therapy reduce mortality recurrent myocardial infarction thromboembolic event post myocardial infarction off us include secondary prevention stroke transient ischemic attack rheumatic mitral valve disease but without atrial fibrillation a179182 intravenous promoting preoperative sedation anxiolysis anesthesia induction amnesia f2434 intramuscular status epilepticus adult fda nasal intermittent stereotypic episode frequent seizure activity i e seizure cluster repetitive seizure distinct from patient usual seizure pattern epilepsy 12 age older pseudomonas aeruginosa lung infection being investigated sinus infection infection susceptible strain designated microorganism uncomplicated urethral gonorrhea male endocervical rectal gonorrhea female neisseria gonorrhoeae well non gonoccocal urethritis cervicitis chlamydia trachomatis relief bladder pain discomfort interstitial cystitis partial replacement therapy primary secondary adrenocortical insufficiency addison disease salt losing androgenital syndrome prophylaxis organ rejection undergoing allogeneic renal hepatic cardiac transplant should cyclosporine corticosteroid off second line autoimmune hepatitis responded adequately first line therapy a180814 off us drug include lupus nephritis dermatitis child a180817 severe infection susceptible bacteria short term intermittent recurring insomnia poor sleeping habitsfor hypertension aid diagnosis pheochromocytoma administered immediately prior during pheochromocytomectomy prevent control paroxysmal hypertension resulting from anesthesia stress operative manipulation tumor hypertensive crisis sympathomimetic amine catecholamine excess certain food drug taking mao inhibitor clonidine withdrawal syndrome indication include prevention dermal necrosis sloughing following iv administration extravasation norepinephrine decrease impedance left ventricular ejection infarct size mi left ventricular failure erectile dysfunction through self injection small dos combined papaverine hydrochloride into corpus cavernosum adjunct cocaine overdose reverse coronary vasoconstriction following oxygen benzodiazepine nitroglycerin diagnostic imaging primarily diagnostic angiography angioscopy fundus iris vasculature remission induction nonlymphocytic leukemia myelogenous monocytic erythroid adult remission induction lymphocytic leukemia child adult edema congestive heart failure cirrhosis liver renal disease nephrotic syndrome adult pediatric oral alone mild moderate hypertension severe hypertension antihypertensive medication intravenous adjunctive therapy pulmonary edema rapid onset diuresis desired therapy abort prevent vascular headache e g migraine migraine variant so called histaminic cephalalgia relief muscle spasticity interfere daily activity general recommendation reserve period time there particular need relief short duration action fda f4471 uncomplicated urinary tract infection senile dementia migraine vascular origin transient ischemia platelet hyper aggregability macular degeneration improvement survival stable left ventricular systolic dysfunction ejection fraction lt 40 clinical evidence congestive heart failure after myocardial infarction hiv infection antiretroviral agent continuous ambulatory peritoneal dialysis capd diabetic automated peritoneal dialysis apd end stage renal disease chronic open angle glaucoma angle closure glaucomaused adjunct medically supervised behaviour modification program maintenance opiate cessation individual were formerly physically dependent opiate successfully undergone detoxification alcohol dependence conjunction behavioural modification program hiv infection appropriate antiretroviral agent therapy warranted sign symptom benign prostatic hyperplasia off ureteral stone prostatitis female voiding dysfunction a178339 esophageal cancer indication drug follows analgesic adjunct maintenance balanced general anesthesia intubated ventilated primary anesthetic agent induction maintenance anesthesia 100 oxygen undergoing major surgical procedure intubated ventilated cardiovascular surgery neurosurgical procedure sitting position provide favorable myocardial cerebral oxygen balance extended postoperative ventilation anticipated 3 epidural administration analgesic combined low dose usually 12 5 mg per administration bupivacaine usually during labor vaginal delivery 4 sublingual form pain adult severe warrant opioid analgesic certified medically supervised healthcare setting hospital surgical center emergency department fda hiv infection chronic hepatitis b hbv prevention osteoporosis postmenopausal woman certain filarial disease tropical pulmonary eosinophilia loiasis lymphatic filariasis infection wuchereria bancrofti brugia malayi brugia timori tablet long term symptomatic rheumatoid arthritis osteorarthritis anklosing spondylitis pain dysmenorrhea mild moderate pain accompanied inflammation e g bursitis tendonitis soft tissue trauma topical ophthalmic formulation pre operatively prevent intraoperative miosis resistant staphylococci infection intermittent hypomobility off episode advanced parkinson disease depression obsessive compulsive disorder panic disorder social anxiety disorder generalized anxiety disorder posttraumatic stress disorder one form commercially known brisdelle manage mild moderate vasomotor symptom menopause off premature ejaculation irritable bowel syndrome ibs a1093 a181754 a181904 mild moderate asthma oral contraceptive given monotherapy estrogen component ethinylestradiol estradiol estrogen component oral hormone replacement therapy postmenopausal osteoporosis moderate severe vasomotor symptom arising from menopause applied via transdermal patch estradiol hypoestrogenism vulvovaginal atrophy moderate severe vasomotor symptom taken intramuscular leuprolide symptomatic endometriosis related pain chronic hepatitis b evidence active viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease based histological virological biochemical serological response hbeag hbeag chronic hepatitis b compensated liver function clinical evidence lamivudine resistant hepatitis b virus either compensated decompensated liver function relief symptom upper respiratory mucosal congestion perennial allergic rhinitis relief nasal congestion eustachian t b congestion adjunct osteolysis from bone metastasis malignant tumor hypercalcemia malignancy local anesthetic primarily oral surgery myocardial infarction hypertension 6 adjunct therapy heart failure product hydrochlorothiazide hypertension hypotension topical clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses face scalp immunocompetent adult external genital perianal wart condyloma acuminata individual 12 old above conjunction antacid histamine h2 receptor antagonist peptic ulcer gastric ulcer duodenal ulcer reduce further gastric acid secretion delay gastric emptying depression depression accompanied anxiety agitation sleep disturbance various purpose prevent angina chest pain cardiovascular disease well peri operative hypertension induce intra operative hypotension heart failure myocardial infarction ointment form pain anal fissure transdermal form applied directly skin prevent anginal attack intravenous form off emergency setting commonly coronary spasm cocaine hypertensive emergency well congestive heart failure exacerbation t628 some off us include variceal hemorrhage a180280 esophageal spasticity a180283 induction uterine relaxation a180277 inpatient outpatient adjunct general anesthesia facilitate both rapid sequence routine tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation strongyloidiasis threadworm cutaneous larva migrans creeping eruption visceral larva migrans trichinosis non insulin dependent diabetes mellitus conjunction diet exercise adjunct general anesthesia facilitate endotracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation poisoning those pesticide chemical organophosphate class anticholinesterase activity control overdosage anticholinesterase drug myasthenia gravis schizophrenia irritability autistic disorder monotherapy adjunctly lithium valproic acid mania mixed episode bipolar i disorder additionally canada short term symptomatic aggression psychotic symptom severe dementia alzheimer type unresponsive nonpharmacological approach off number condition adjunct antidepressant resistant depression a177226 topical tinea pedis tinea cruris tinea corporis organism trichophyton rubrum trichophyton mentagrophytes trichophyton tonsurans epidermophyton floccosum acid reflux disorder healing maintenance erosive esophagitis symptomatic gastroesophageal reflux disease gerd peptic ulcer disease h pylorus eradication prevention gastrointestinal bleeds nsaid long term pathological hypersecretory condition zollinger ellison syndrome symptomatic nausea vomiting dizziness motion sickness vertigo various cause radiation sickness meniere syndrome labyrinthitis vestibular disturbance pneumonia pneumocystis carinii beta lactam antibiotic prodrug bacterial infection body get converted ampicillin amyotrophic lateral sclerosis al lou gehrig disease otic solution infection external auditory canal susceptible organism inflammation tablet certain endocrine rheumatic collagen allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal condition enema ulcerative colitis topical ointment antibiotic corticosteroid responsive dermatosis infection topical cream acyclovir cold sore oral granule replacement therapy adrenocortical insufficiency ai child under 17 age promotion diuresis before irreversible renal failure becomes established reduction intracranial pressure cerebral edema promotion urinary excretion toxic substance add maintenance therapy improving pulmonary function cystic fibrosis aged 18 over passed bronchitol tolerance test btt recommended take orally inhaled short acting bronchodilator 5 15 minute prior every inhaled dose gadobenate dimeglumine mri contrast agent primarily mr imaging liver mri heart well central nervous system adult visualize lesion abnormal brain vascularity abnormality blood brain barrier brain spine tissue prophylaxis chronic asthma adult child 12 age older improve wakefulness excessive daytime sleepiness ed narcolepsy iron aluminum toxicity excess aluminum body certain certain anemia must receive many blood transfusion excessive salivation colicky abdominal pain bradycardia sialorrhoea diverticulitis irritable bowel syndrome motion sickness symptomatic relief seasonal perennial allergic rhinitis vasomotor rhinitis well allergic conjunctivitis food inhaled allergen relief allergic reaction blood plasma symptomatic mild uncomplicated allergic skin manifestation urticaria angioedema long term sign symptom osteoarthritis rheumatoid arthritis well pain local anaesthetic often dentistry prevention itching allergic conjunctivitis major depressive episode without melancholia induction maintenance general anesthesia control tonic clonic grand mal complex partial psychomotor seizure the induction remission promyelocytic leukemia apl french american british fab classification m3 m3 variant topical acne vulgaris flat wart skin condition psoriasis ichthyosis congenita icthyosis vulgaris lamellar icthyosis keratosis palmaris et plantaris epidermolytic hyperkeratosis senile comedo senile keratosis keratosis follicularis darier disease basal cell carcinoma palliative therapy improve fine wrinkling mottled hyperpigmentation roughness photodamage surgical scrub bacteriostatic skin cleanser control outbreak gram positive infection where infection control procedure unsuccessful prevention nausea vomiting emetogenic cancer chemotherapy initial repeat course chemotherapy prevention postoperative nausea vomiting drug intravenously postoperative nausea vomiting reduce risk myocardial infarction non st elevated coronary syndrome ac st elevated myocardial infarction recent mi stroke established peripheral arterial disease bacterial infection rocky mountain spotted fever typhus fever tick fever q fever rickettsialpox brill zinsser disease infection chlamydiae spp b burgdorferi lyme disease upper respiratory infection typical pneumoniae h influenzae m catarrhalis atypical organism c pneumoniae m pneumoniae l pneumophila acne alternative drug people allergic penicillin single agent therapy following infection susceptible isolates designated microorganism gt complicated skin skin structure infection lt b gt staphylococcus aureus b lactamase non b lactamase producing methicillin susceptible isolates only streptococcus pyogenes streptococcus agalactiae viridans group streptococci enterococcus faecalis excluding vancomycin resistant isolates pseudomonas aeruginosa escherichia coli proteus mirabilis bacteroides fragilis peptostreptococcus specie gt complicated appendicitis peritonitis lt b gt viridans group streptococci escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides fragilis b thetaiotaomicron peptostreptococcus specie bacterial meningitis streptococcus pneumoniae haemophilus influenzae b lactamase non b lactamase producing isolates neisseria meningitidis electrolyte replenisher hypokalemia metastatic colorectal cancer first line therapy administered 5 fluorouracil leucovorin cisplatin extensive small cell lung cancer currently under investigation metastatic recurrent cervical cancer fluorouracil leucovorin metastatic adenocarcinoma pancreas after disease progression following gemcitabine based therapy united state hyperthyroidism graf disease toxic multinodular goiter whom thyroidectomy radioactive iodine therapy appropriate option amelioration hyperthyroid symptom preparation thyroidectomy radioactive iodine therapy canada carry above indication medical hyperthyroidism regardless available option inhaler maintenance asthma prophylactic therapy nasal spray nasal symptom seasonal allergic perennial allergic rhinitis pheochromocytoma preoperative preparation surgery surgery contraindicated chronic malignant pheochromocytoma combined antibiotic prevent development drug resistant strain bacteria promotes their therapeutic antibacterial effect following condition they produced beta lactamases treated amoxicillin ticarcillin otitis medium h influenzae m catarrhalis sinusitis h influenzae m catarrhalis lower respiratory tract infection haemophilus influenzae aureus klebsiella specie moraxella catarrhalis skin skin structure infection staphylococcus aureus escherichia coli klebsiella specie urinary tract infection e coli klebsiella specie bacteria enterobacter specie bacteria marcescens aureus gynecologic infection variety bacteria p melaninogenicus enterobacter specie e coli specie klebsiella specie aureus epidermidis septicemia variety bacteria klebsiella specie e coli specie aureus pseudomonas specie bone joint infection aureus intraabdominal infection e coli k pnemoniae b fragilis group note susceptibility should noted only administered infection confirmed highly likely susceptible bacteria culture susceptibility test should performed if possible selecting whether antibiotic prescribed beta lactamase enzyme production detected during microbiological testing should these test available pattern local infection susceptibility determine appropriateness using ticarcillin clavulanate shown particular efficacy mixed infection addition empiric therapy before determining susceptibility causative organism ticarcillin prove effective single agent antibiotic therapy infection where regimen several drug normally prevent nausea vomiting anesthesia surgery administered intramuscularly intravenously symptomatic ocular itching allergic conjunctivitis ophthalmic solution nasal spray symptomatic relief seasonal allergic rhinitis 12 age older topically antiinflammatory steroid responsive dermatosesfor palliative definitive therapy temporarily maintain patency ductus arteriosus until corrective palliative surgery performed neonate congenital heart defect depend upon patent ductus survival erectile dysfunction neurogenic vasculogenic psychogenic mixed etiology peptic ulcer disease help relieve abdominal stomach spasm cramp colicky abdominal pain diverticulitis irritable bowel syndrome infected pediculus humanus capitis head louse their ovum scalp hair chemotherapeutic agent refractory testicular tumor first line small cell lung cancer malignancy lymphoma non lymphocytic leukemia glioblastoma multiforme adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effect antihypertensive drug more severe form hypertension heparin coronary syndrome managed medically those undergoing ptca atherectomy united state monotherapy partial onset seizure 4 age older adjunctive therapy partial onset seizure age older canada monotherapy adjunctive therapy partial onset seizure 6 age older largely antihistamininc sleep inducing effect treating insomnia respiratory tract urinary soft tissue infection urinary tract infection susceptible gram negative microorganism majority e coli enterobacter specie klebsiella specie proteus specie nonendogenous neurotic atypical depression do tolerate form therapy atypical depression high prevalence rate start early life tends last longer more likely occur people bipolar disorder high comorbidity anxiety disorder carry more risk suicidal behavior important specify atypical feature predict clinical course depression hence generate best service featuring symptom atypical feature include mood reactivity two more symptom increased appetite increased sleep 3 leaden paralysis 4 interpersonal rejection sensitivity should melancholic catatonic feature depression a31917 neurotic depression depression emotionally unstable person secondary condition major personality disorder neurosis drug disorder likewise primary depression family history depression spectrum disease would fit category a31922 nonendogenous depression characterized disturbance mood general outlook physical symptom tend le severe often occurs response stressful life event keep occurring over large period time generating continuous stress daily living a31924 enuresis hyperhidrosis cramp spasm stomach intestine bladder various preparation moderate severe vasomotor symptom vulvar vaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure prevention postmenopausal osteoporosis breast cancer only palliation therapy certain men woman metastatic disease androgen dependent prostate cancer only palliation therapy hormone component oral contraceptive pill preventing pregnancy most commonly db00977 synthetic form note duration recommendation menopausal symptom changed drastically following release result early termination woman health initiative whi study 2002 concern were raised regarding estrogen a31626 specifically combined estrogen progestin group discontinued after about 5 follow up statistically significant increase invasive breast cancer cardiovascular event a31627 following extensive critique whi result hormone replacement therapy hrt now recommended only short period 3 5 postmenopause low dos woman without history breast cancer increased risk cardiovascular thromboembolic disease a31628 estrogen postmenopausal symptom should always given progestin component estrogen stimulatory effect endometrium woman intact uterus unopposed estrogen shown promote growth endometrium lead endometrial hyperplasia possibly cancer over long term rheumatoid arthritis osteoarthritis dysmenorrhea mild moderate pain inflammation fever hypertension various cancersan topical cream recurrent herpes labialis immunocompetent 12 older oral tablet capsule suspension herpes zoster genital herpes chickenpox topical ointment initial genital herpes limited non life threatening mucocutaneous herpes simplex immunocompromised cream hydrocortisone recurrent herpes labialis shortening lesion healing time 6 older buccal tablet recurrent herpes labialis ophthalmic ointment herpetic keratitis rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendinitis bursitis gout primary dysmenorrhea relief mild moderate pain a178975 further first line therapy osteoarthritis gouty arthritis dysmenorrhea musculoskeletal inflammation pain a178975 magnetic resonance imaging mri adult pediatric age older visualize lesion abnormal vascularity brain intracranial lesion spine tissue well lesion abnormal vascularity head neck facilitate visualization lesion abnormal vascularity body excluding heart mild moderate essential hypertension mild moderate congestive heart failure reduce cardiovascular risk individual hypertension post myocardial infarction stable coronary disease antineoplastic property symptomatic relief hypersensitivity reaction cough common cold fungal tinea skin infection athlete foot jock itch ringworm tinea versicolor commonly grand mal psychomotor focal epileptic seizure addition studied utilized effective essential tremor a39414 a39415 crohn disease rheumatoid arthritis second line agent first line agent uncomplicated hypertension isolated systolic hypertension left ventricular hypertrophy first line agent delay progression diabetic nephropathy candesartan second line agent congestive heart failure systolic dysfunction myocardial infarction coronary artery disease those intolerant ace inhibitor pulmonary artery anomaliesfor serious infection susceptible strain following microorganism p aeruginosa proteus specie indole positive indole negative e coli klebsiella enterobactor serratia specie citrobacter specie staphylococcus specie coagulase positive coagulase negative psoriasis acne sun damaged skin photodamage hospital short term up 48 hour severe hypertension rapid but quickly reversible emergency reduction blood pressure clinically malignant hypertension deteriorating end organ function relieve anxiety nervousness tension anxiety disorder postoperative pain maintenance general anesthesia chronic infection sensitive strain certain gram negative bacillus particularly pseudomonas aeruginosa functional bowel disorder irritable bowel syndrome depressionfor intermittent lameness immobility arising from chronic occlusive arterial disease limb local ophthalmic anesthetic diuretic monotherapy blood pressure lowering agent hypertension fluid salt retention congestive heart failure induce mydriasis dilation pupil cycloplegia paralysis ciliary muscle eye diagnostic procedure measurement refractive error examination fundus eye adjunct therapy all form parkinsonism control extrapyramidal disorder secondary neuroleptic drug therapy chronic hepatitis c virus hcv infection antiviral agent intent cure achieve sustained virologic response svr typically added improve svr reduce relapse rate a19644 addition technivie therapy treating hcv genotype 1a 4 infection recommended without cirrhosis resistance viral genetic determinant resulting variable response therapy yet determined backache ankylosing spondylitis intravenous intramuscular injection short term analgesia during induction maintenance recovery from general regional anesthesia these injection neuroleptic premedication induction adjunct maintenance anesthesia finally intravenous intramuscular injection oxygen anesthesia high risk sublingual tablet transmucosal lozenge buccal tablet sublingual spray transdermal system nasal spray breakthrough pain opioid tolerant cancer require around clock pain symptomatic arthritis osteoarthritis addition pauciarticular polyarticular course juvenile rheumatoid arthritis jra aged old above off us include dental post surgical pain addition above studied neuropathic pain a190189 sl surfactant shampoo toothpaste sl microbicidal activity against both enveloped herpes simplex virus hiv semliki forest virus nonenveloped papillomaviruses reovirus rotavirus poliovirus virus although approved bronchospasm chronic bronchitis asthma emphysema bacterial infection respiratory tract urinary tract gi cns immuno compromised induction maintenance anaesthesia refractory status epilepticus adjunctive edema congestive heart failure drug induced edema centrencephalic epilepsy chronic simple open angle glaucomaused erectile dysfunction pain reliever joint pain post surgical pain chronic alcoholismfor prevention pregnancy woman elect product method contraception symptom asthma peripheral vascular disease cerebrovascular insufficiency sickle cell disease diabetic neuropathy occasional minor irritation pain sore mouth sore throat well cough cold inhaled irritant fungal blepharitis conjunctivitis keratitis susceptible organism fusarium solani keratitis initial recurrent urinary tract infection adult following susceptible microorganism escherichia coli proteus mirabilis proteus vulgaris klebsiella specie k pneumoniae enterobacter specie uncomplicated urinary tract infection cystitis woman susceptible strain escherichia coli enterococcus faecalis general useful symptomatic mild moderate degree anxiety condition dominated tension excitation agitation fear aggressiveness occur psychoneurosis anxiety reaction stress condition anxiety state somatic expression f3160 moreover alcoholic withdrawal useful symptomatic relief agitation tremor impending delirium tremens f3160 furthermore useful adjunct relief skeletal muscle spasm reflex spasm local pathology inflammation muscle joint secondary trauma spasticity upper motor neuron disorder cerebral palsy paraplegia athetosis rare stiff man syndrome f3160 particular information from united kingdom list particular age specific indication adult short term relief 4 week only anxiety severe disabling subjecting individual unacceptable distress occurring alone association insomnia short term psychosomatic organic psychotic illness cerebral palsy 3 muscle spasm 4 adjunct certain type epilepsy eg myoclonus 5 symptomatic alcohol withdrawal 6 oral premedication nervous dental patient 7 premedication before surgery same uk information child control tension irritability cerebral spasticity selected case adjunct control muscle spasm tetanus 3 oral premedication nasal spray 6 older intermittent stereotypic episode frequent seizure activity different than patient usual seizure pattern anorectic obesity anxiety disorder depressive symptom secondary anxiety agitation epilepsy certain infection bacteria pneumonia ear lung skin throat urinary tract infection medical termination intrauterine pregnancy through 49 day pregnancy control hyperglycemia secondary hypercortisolism endogenous cushing syndrome type diabetes mellitus glucose intolerance candidate surgery had unsuccessful surgery symptom common cold allergic rhinitis runny nose itchy eye watery eye sneezing control symptomatic relief nonspecific diarrhea chronic diarrhea inflammatory bowel disease gastroenteritis reducing volume discharge from ileostomy epilepsy short term topical inflammatory pruritic manifestation moderate severe corticosteroid responsive dermatosis scalp adjunct diet lower blood glucose non insulin dependent diabetes mellitus type ii whose hyperglycemia can not satisfactorily controlled diet alone relieve dryness irritation reduced tear flow occurs certain eye disease keratoconjunctivitis sicca recurrent corneal erosion decreased corneal sensitivity exposure neuroparalytic keratitis lubricant artificial eye parenteral therapy necessary inotropic support short term cardiac decompensation depressed contractility resulting either from organic heart disease from cardiac surgical procedure anxiety disorder short term relief symptom anxiety alcohol withdrawal symptom mild moderate alzheimer disease dos 5 mg 10 mg moderate severe alzheimer disease higher dose 10 mg 23 mg administered once daily off us include vascular dementia parkinson disease dementia lewy body dementia among others a182333 t668 combined memantine extended release form symptom moderate severe dementia relief moderate severe pain lepromatous leprosy dapsone resistant lepromatous leprosy lepromatous leprosy complicated erythema nodosum leprosum prevent development drug resistance should only antimycobacterial leprosy treatment relief inflammatory pruritic manifestation corticosteroid responsive dermatosis particularly dry scaling localized lesionsthe bitartrate salt oral nephropathic cystinosis cystinuria child 6 old above adult hydrochloride salt eye drop preparation corneal cystine crystal accumulation cystinosis adjuvant fluorouracil after surgical resection duke stage c colon cancer malignant melanoma head neck cancer relief anxiety tension apprehension anticonvulsant epilepsy manifestation psychotic disorder control severe nausea vomiting adult metastatic malignant melanoma addition hodgkin disease secondary line therapy antineoplastic agent sympathomimetic amine decongestant activity diagnosed anaplastic astrocytoma whose disease progressed after therapy nitrosourea procarbazine well concomitantly radiation therapy newly diagnosed glioblastoma multiforme maintenance therapy glioblastoma multiforme moderate severe pain preoperative medication where opioid analgesic appropriate plus blue light illumination using blue light photodynamic therapy illuminator minimally moderately thick actinic keratoses face scalp along rest physical therapy injury painful muscular condition investigated trigeminal neuralgia tic douloureux neuropathic disorder characterized severe facial pain investigated modulator histamine release hydrochloride fungal skin nail infection trichophyton specie microsporum canis epidermophyton floccosum tinea specie hydrochloride treat yeast infection skin candida specie malassezia furfur wilson disease cystinuria active rheumatoid arthritis endocrine rheumatic hematologic disorder collagen dermatologic ophthalmic respiratory gastrointestinal disease allergic edematous state condition like tuberculous meningitis symptomatic mild moderate pain accompanied inflammation e g musculoskeletal trauma post dental extraction post episiotomy osteoarthritis rheumatoid arthritis erectile dysfunctionthis drug alone concomitant antacid following condition short term active duodenal ulcer treating gastric acid hypersecretion zollinger ellison syndrome systemic mastocytosis condition pathologically raise gastric acid level short term active benign gastric ulcer maintenance therapy gastric ulcer reduced dose addition above gerd symptom erosive esophagitis endoscopically diagnosed maintenance gastric duodenal ulcer healing after allogenic organ transplant reduce activity patient immune system so risk organ rejection given fda approval 1994 liver transplantation since then indication expanded kidney heart small bowel pancreas lung trachea skin cornea limb transplant topical preparation severe atopic dermatitis exogenous obesity short term adjunct few week regimen weight reduction based caloric restrictionfor hypertension angina arrhythmiafor prophylaxis premature labour symptomatic relief cough elevated intraocular pressure ocular hypertension open angle glaucoma timolol same indication insufficiently responsive ophthalmic beta blocker pre operative investigated prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy a190183 eye drop inhibit miosis pupil constriction occur during ocular surgery prevention reversal bronchospasm 12 age older reversible obstructive airway disease well symptomatic reversible bronchospasm bronchitis emphysema iv sub q therapy selected woman inhibit uterine contraction preterm labor tocolysis prolong gestation beneficial euvolemic hypervolemic hyponatremia e g syndrome inappropriate secretion antidiuretic hormone setting hypothyroidism adrenal insufficiency pulmonary disorder etc hospitalized number prescription ophthalmic product specifically post operative inflammation pain following ocular surgery fda expectorant providing temporary symptomatic relief from congested chest cough cold bronchitis breathing illness fda f4510 schizophrenia depressionfor hypertension alone class antihypertensive agent first line agent diabetic nephropathy well second line agent congestive heart failure only those intolerant ace inhibitor prophylaxis organ rejection receiving renal transplant available over counter various formulation e g solution sponge cloth swab topical antiseptic sanitize prior surgery medical procedure dental formulation available prescription only include oral rinse gingivitis slow release chip inserted into periodontal pocket reduction pocket depth periodontitis adjunct therapy dental scaling root planing procedure medication hiv infection hiv infection pediatric 25 35kg hiv infection 35kg pre exposure prophylaxis hiv adolescent excluding those receptive vaginal sex hiv infection pediatric 17kg pre exposure prophylaxis adolescent adult 35kg hiv 12 35kg hiv weighing 35kg hiv weighing 25kg hiv weighing 40kg adjunctive therapy edema congestive heart failure hepatic cirrhosis corticosteroid estrogen therapy hypertension either sole therapeutic agent enhance effectiveness antihypertensive drug more severe form hypertension hypertension adjunct therapy heart failure hydrochlorothiazide hypertension mainly female infertility anovulation e g polycystic ovary syndrome induce ovulation prevention angina pectoris coronary artery disease osteoperosis men paget disease prevention osteoperosis postmenopausal woman prevention glucocorticoid induced osteoperosis fda prevention itching eye allergy hay fever allergic conjunctivitisfor hypertension edema congestive heart failure hepatic renal disease nephrotic syndrome palliative hodgkin disease stage iii iv lymphosarcoma chronic myelocytic chronic lymphocytic leukemia polycythemia vera mycosis fungoides bronchogenic carcinoma palliative metastatic carcinoma resulting effusion prevention nausea vomiting initial repeat course emetogenic cancer therapy high dose cisplatin postoperation radiation total body irradiation daily fractionated abdominal radiation atrophic vaginitis kraurosis vulva dermatitis herpetiformis benign mucous membrane pemphigoid pyoderma gangrenosumused temporarily numb front surface eye so eye pressure measured foreign body removed documented iron deficiency whom oral administration unsatisfactory impossible replenish body iron store non dialysis dependent chronic kidney disease ndd ckd receiving receiving erythropoietin hemodialysis dependent hdd ckd peritoneal dialysis dependent pdd ckd chronic kidney disease receiving erythropoietin palliative advanced breast cancer postmenopausal woman adjunct assessing risk administering penicillin benzylpenicillin penicillin g postoperative inflammation following ocular surgery anterior uveitis short term insomnia therapeutic neurolysis nerve ganglion relief intractable chronic pain condition inoperable cancer trigeminal neuralgia tic douloureux whom neurosurgical procedure contraindicated during induction maintenance general anesthesia antiretroviral agent hiv infection adult dilate air passage lung become narrowed result disease inflammation asthma chronic obstructive pulmonary disease copd symptomatic relief hypersensitivity reaction particularly control pruritic skin disordersfor high blood pressure edema disease like congestive heart failure liver failure kidney failure patient population i orally administered tablet orally disintegrating tablet odt prevention nausea vomiting emetogenic cancer chemotherapy high dose ie greater than equal 50 mg m2 cisplatin therapy radiotherapy prevention postoperative nausea vomiting ii intravenously administered injection formulation prevention nausea vomiting emetogenic cancer chemotherapy high dose ie greater than equal 50 mg m2 cisplatin therapy prevention postoperative nausea vomiting pediatric 4 18 age patient population i effective well tolerated given child 4 12 age post chemotherapy induced nausea vomiting ii tablet odt injection child 3 age younger iii tablet odt injection any age group pediatric population post radiotherapy induced nausea vomiting iv tablet odt injection any age group pediatric population postoperative nausea vomiting geriatric gt 65 age patient population i efficacy tolerance were similar observed younger adult post chemotherapy radiotherapy induced nausea vomiting ii clinical experience prevention postoperative nausea vomiting limited geriatric patient population reduction elevated intraocular pressure open angle glaucoma ocular hypertension these must intolerant intraocular pressure lowering medication inadequately responsive treatment eyelash hypotrichosis partial seizuresfor introduction local topical anesthesia accessible mucous membrane oral laryngeal nasal cavity ventricular pre excitation cardiac dysrhythmiasfor adjunctive partial seizure adult epilepsy secondary hyperparathyroidism chronic kidney disease ckd stage 3 4for trichomoniasis t vaginalis both female male giardiasis g duodenalis both adult pediatric older than three age intestinal amebiasis amebic liver abscess e histolytica both adult pediatric older than three age adjunct diet exercise improve glycemic control adult type diabetes mellitus pain systemic anesthesia adjunct reatment type ii diabetes mellitus chemoprophylaxis prophylaxis sign symptom infection various strain influenza virus parkinsonism drug induced extrapyramidal reaction confirmed trichomoniasis trichomonas vaginalis except first trimester pregnancy patient sexual partner bacterial vaginosis certain type amebiasis various anaerobic infection a181057 above anaerobic infection occur skin skin structure abdomen heart reproductive organ central nervous system respiratory system some present bloodstream case septicemia common infection treated bacteroides specie infection clostridium infection fusobacterium infection well peptococcus peptostreptococcus infection off crohn disease rosacea prophylactic agent after surgery a181039 helicobacter pylorus infection a181045 studied prevention preterm birth periodontal disease a1391 a181078 termination pregnancy during second trimester from 12th through 20th gestational week calculated from first day last normal menstrual period well evacuation uterine content missed abortion intrauterine fetal death up 28 week gestational age calculated from first day last normal menstrual period nonmetastatic gestational trophoblastic disease benign hydatidiform mole indication include improving cervical inducibility cervical ripening pregnant woman near term medical obstetrical need labor induction postpartum hemorrhage migraine headache adultsfor gonorrheal urethritis proctitis male gonorrheal cervicitis proctitis female susceptible strain neisseria gonorrhoeae add prophylactic oral medication chronic mild atopic asthmatic child self medication temporary relief itching eye allergic conjunctivitis ophthalmic pain severe enough require opioid analgesic alternative treatment inadequate naloxone fixed dose product moderate severe opioid disorder f4715 f4718 short term acutely decompensated severe chronic heart failure chf being investigated heart disease infection susceptible organism short term 3 week adjunct therapy along rest physical therapy relief muscle spasm painful musculoskeletal condition found effective spasticity originating from cerebral spinal cord disease spasticity child cerebral palsy occasionally off reducing pain sleep disturbance fibromyalgia a184946 phaeochromocytoma malignant benign prostatic hypertrophy malignant essential hypertension severe psoriasis adult pediatric bodyweight 40 kg above active duodenal ulcer du active gastric ulcer symptomatic non erosive gastroesophageal reflux disease gerd erosive esophagitis gerd diagnosed biopsy pathological hypersecretory condition e g zollinger ellison syndrome multiple endocrine neoplasia reduction risk du recurrence intravenous formulation available some hospitalized pathological hypersecretory condition intractable ulcer alternative oral dosage form short term unable take oral medication over counter prevention heartburn gastroesophageal reflux child adult off us include reduction nsaid gastrointestinal effect refractory urticarial prevention stress ulcer critically ill symptomatic relief gastritis following french american british myelodysplastic syndrome subtypes refractory anemia refractory anemia ringed sideroblast if accompanied neutropenia thrombocytopenia requiring transfusion refractory anemia excess blast refractory anemia excess blast transformation now classified myelogenous leukemia multilineage dysplasia chronic myelomonocytic leukemia tablet reduce risk nsaid induced gastric ulcer but duodenal ulcer high risk formulated diclofenac symptom osteoarthritis rheumatoid arthritis high risk developing gastric ulcer off miscarriage prevention post partum hemorrhage alone mifepristone country first trimester abortion a181589 a181583 a181697 alone hmg coa reductase inhibitor adjunctive therapy diet exercise reduction elevated ldl cholesterol primary hypercholesterolemia fredrickson type iia bacterial exacerbation chronic bronchitisfor antiretroviral hiv infected evidence viral replication highly experienced hiv strain resistant multiple protease inhibitor schizophrenia organic brain disorder alcoholism psychoneurosis depression depressed phase bipolar depression psychotic depression involutional melancholia helpful treating certain suffering severe depressive neurosis topical persistent facial erythema rosacea adult ophthalmic formulation acquired blepharoptosis adult tetracaine intranasally for regional anesthesia performing restorative procedure teeth 4 13 j adult child weigh 40 kg more key additive many skin care product acne psoriasis callouses corn keratosis pilaris wart exogenous obesity short term adjunct few week regimen weight reduction based caloric restriction asthma inhaled corticosteroid prevention exercise induced bronchospasm maintenance airflow obstruction prevention exacerbation chronic obstructive pulmonary disease relief mild moderate pain primary dysmenorrhea idiopathic heavy menstrual blood loss relief sign symptom chronic rheumatoid arthritis osteoarthritis peptic ulcer disease irritable bowel syndrome pancreatitis gastritis biliary dyskinesia pylorosplasm reflex neurogenic bladder child adjunct succinylcholine suxamethonium chloride prolong muscle relaxation prevent succinylcholine induced muscle fasciculation parkinson disease human immunovirus hiv infection conjunction antiviral topical chronic open angle glaucoma pain fever inflammation asa regular tablet form immediate release relieve pain fever inflammation many condition flu common cold neck back pain dysmenorrhea headache tooth pain sprain fracture myositis neuralgia synovitis arthritis bursitis burn various injury symptomatic pain relief after surgical dental procedure fda extra strength formulation migraine pain photophobia sensitivity light phonophobia sensitivity sound fda indication asa various purpose ability inhibit platelet aggregation these include reducing risk cardiovascular death suspected case myocardial infarction mi fda reducing risk first non fatal myocardial infarction reducing risk morbidity mortality case unstable angina those had prior myocardial infarction fda reducing risk transient ischemic attack tia prevent atherothrombotic cerebral infarction conjunction treatment fda prevention thromboembolism after hip replacement surgery fda decreasing platelet platelet adhesion following carotid endarterectomy aiding prevention transient ischemic attack tia fda undergoing hemodialysis silicone rubber arteriovenous cannula inserted prevent thrombosis insertion site fda important note regarding extended release formulation f4405 setting myocardial infarction before percutaneous intervention extended release form should immediate release formulation scenario requiring rapid onset action f4405 extended release form taken decrease incidence mortality myocardial infarction mi individual diagnosed chronic coronary artery disease cad previous myocardial infarction mi unstable angina chronic stable angina additionally extended release form decrease risk death recurrent episode stroke history stroke tia f4405 prevention thromboembolic disease venous thrombosis thromboembolism pulmonary embolism well prevention ischemic stroke atrial fibrillation af hormone receptor positive metastatic breast cancer postmenopausal woman disease progression following anti estrogen therapy monotherapy antineoplastic agent serious gram amp ndash negative infection lung urinary tract skin only those respond inadequately alternative treatment whose epilepsy so severe substantial risk aplastic anemia liver failure deemed acceptable light benefit conferred united state symptomatic allergic rhinitis old chronic idiopathic urticaria 6 month old canada carry same indication but approved only 12 old available pseudoephedrine symptomatic season allergic rhinitis 12 old all form tuberculosis organism susceptible migraine attack without aura adult migraine attack without aura following mild moderate infection susceptible strain microorganism bacterial exacerbation chronic bronchitis secondary bacterial infection bronchitis community acquired pneumonia pharyngitis tonsilitis uncomplicated skin skin structure infection bacteremia septicaemia respiratory tract infection skin soft tissue infection burn wound peri operative infection susceptible strain pain sometimes acetaminophen ibuprofen well symptomatic common cold allergic rhinitis decongestant antihistamine expectorant formulated ethinylestradiol combined oral contraceptive given low dose ethinylestradiol contraception well moderate acne vulgaris woman 15 old initial advanced ovarian carcinoma established approved chemotherapeutic agent one established regimen consists paraplatin cyclophosphamide palliative ovarian carcinoma recurrent after prior chemotherapy previously treated cisplatin oral intramuscular number endocrine rheumatic collagen dermatologic allergic ophthalmic respiratory hematologic neoplastic edematous gastrointestinal nervous system disorder intra articular soft tissue injection short term gouty arthritis subactute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis intralesional injection alopecia areata discoid lupus erythematosus keloid lichen planus lichen simplex chronicus psoriatic plaque necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesion granuloma annulare hypertension edema ventricular tachycardia atrial fibrillation production local regional analgesia anesthesia local infiltration peripheral nerve block technique central neural technique epidural caudal block short term insomnia adult postoperative inflammation undergone cataract extraction prevention reduction intraoperative postoperative increase intraocular pressure iop before after ocular laser surgery prophylactically short term adjunctive therapy open angle glaucoma maximally tolerated medical therapy requiring additional iop reduction radio opaque medium hysterosalpingography lymphography antineoplastic agent part iodine 131 i follow up imaging chemoembolization alone class antihypertensive hypertension diabetic nephropathy hypertensive type diabetes mellitus well congestive heart failure only can not tolerate ace inhibitor relief symptom seasonal allergic rhinitis perennial non seasonal allergic rhinitis desloratidine sympomatic pruritus urticaria hive chronic idiopathic urticaria hypertension only symptom severe diarrhea predominant irritable bowel syndrome ibs woman chronic symptom generally lasting greater than 6 month doe present anatomic biochemical gi abnormality responded conventional therapy wilms tumor childhood rhabdomyosarcoma ewing sarcoma metastatic nonseminomatous testicular cancer part chemotherapy multi modality regimenfor tinea versicolor tinea capitis dandruff seborrheic dermatitis scalp intranasal symptomatic seasonal allergic rhinitis 5 older symptomatic vasomotor rhinitis 12 older ophthalmic solution itchy eye allergic conjunctivitis reduce elevated total c ldl c apo b non hdl c primary hyperlipidemia alone hmg coa reductase inhibitor statin reduce elevated total c ldl c apo b non hdl c mixed hyperlipidemia fenofibrate reduce elevated total c ldl c homozygous familial hypercholesterolemia hofh atorvastatin simvastatin reduce elevated sitosterol campesterol homozygous sitosterolemia phytosterolemia reduction blood level depot store lead lead poisoning chronic lead encephalopathy both pediatric population adult adjunct coumarin anticoagulant prevention postoperative thromboembolic complication cardiac valve replacement prevention angina pneumococcal infection sinusitis bacterial tonsillitis bronchitis bronchiolitis lower respiratory tract infection lobar pneumococcal pneumonia combined drug contraceptive premenstrual dysphoric disorder moderate acne moderate severe vasomotor symptom menopause prevention postmenopausal osteoporosis bacterial infection respiratory tract chronic bronchitis urinary tract pre operative prophylactic prevent urinary tract infection pneumoniae h influenzae aureus p aeruginosa e cloaca p mirabilis c civersus asprphyticus e coli k pneumoniae mainly produce mydriasis cycloplegia diagnostic purpose insomnia characterized difficulty sleep onset glaucoma severe anticholinergic toxicity severe recalcitrant nodular acne 12 enrolled ipledge program various formulation asthma copd copd available single entity inhalation solution long acting muscarinic antagonist lama aclidinium glycopyrronium corticosteroid budesonide asthma available mometasone furoate 5 older budesonide 6 older needed basis prophylaxis against exercise induced bronchospasm refractory deficient red cell production anemia breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure turner syndrome prophylaxis hereditary angioedema prevention nausea vomiting vertigo motion sickness preoperative antimuscarinic reduce salivary tracheobronchial pharyngeal secretion reduce volume free acidity gastric secretion block cardiac vagal inhibitory reflex during induction anesthesia intubation chronic obstructive pulmonary disease copd non lymphocytic leukemia lymphocytic leukemia blast phase chronic myelocytic leukemia correction hemodynamic imbalance present shock syndrome myocardial infarction trauma endotoxic septicemia open heart surgery renal failure chronic cardiac decompensation congestive failurefor mild moderate dementia parkinson disease alzheimer type advanced breast cancer postmenopausal woman whose disease progressed following tamoxifen therapy relieve inflammation swelling stiffness joint pain rheumatoid arthritis osteoarthritis topical 570 670 nm wavelength red light illumination non hyperkeratotic actinic keratoses face scalp immunocompetent conjunction lesion preparation debridement using sharp dermal curette rheumatoid arthritis prevent renal transplant rejection oral sulfate adjunctive therapy hepatic coma portal system encephalopathy reducing ammonia forming bacteria intestinal tract strongly recommended oral only infection proven strongly suspected susceptible bacteria reduce risk development drug resistant bacteria polymyxin b sulfate hydrocortisone otic suspension superficial bacterial infection external auditory canal organism susceptible antibiotic otic formulation infection mastoidectomy fenestration cavity organism susceptible antibiotic ophthalmic solution containing polymyxin b sulfate dexamethasone steroid responsive inflammatory ocular condition corticosteroid where bacterial infection risk bacterial infection exists active progressive destructive form inflammatory arthritis rheumatoid arthritis united state officially postherpetic neuralgia adult adjunctive partial onset seizure without secondary generalization 3 age older europe adjunctive therapy partial onset seizure without secondary generalization 6 age older monotherapy 12 age older adult various type peripheral neuropathic pain painful diabetic neuropathy produce regression disseminated neoplastic condition like lymphoblastic leukemia myeloblastic leukemia wilms tumor neuroblastoma soft tissue bone sarcoma breast carcinoma ovarian carcinoma transitional cell bladder carcinoma thyroid carcinoma gastric carcinoma hodgkin disease malignant lymphoma bronchogenic carcinoma small cell histologic type most responsive compared cell type component adjuvant therapy woman evidence axillary lymph node involvement following resection primary breast cancer migraine attack without aura adult alone edema congestive heart failure hepatic cirrhosis nephrotic syndrome glomerulonephritis chronic renal failure corticosteroid estrogen therapy alone hypertension a185138 bacterial infection susceptible organism i symptomatic relief prevention bronchospasm bronchial asthma chronic bronchitis reversible obstructive airway disease chronic bronchopulmonary disorder bronchospasm complicating factor ii prophylaxis against exercise induced bronchospasm stimulus known induce bronchospasm f3265 f3268 production local regional anesthesia surgery obstetrics post operative pain managementfor bronchial asthma vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis induction maintenance cytomegalovirus cmv retinitis immunocompromised acquired immunodeficiency syndrome aid severe cytomegalovirus cmv disease cmv pneumonia cmv gastrointestinal disease disseminated cmv infection immunocompromised melanoma resistant chronic myelocytic leukemia recurrent metastatic inoperable carcinoma ovary sickle cell anemia postmenopausal woman hormone receptor hr positive early breast cancer postmenopausal woman early breast cancer periviously treated tamoxifen postmenopausal woman hr unknown advanced breast cancer given ribociclib pre peri postmenopausal woman hr human epidermal growth factor her2 negative advanced metastatic breast cancer local vulvovaginal candidiasis moniliasis cyclophosphamide conditioning regimen prior allogeneic hematopoietic progenitor cell transplantation chronic myelogenous myeloid myelocytic granulocytic leukemia fda designated orphan drug component pretransplant conditioning regimen undergoing bone marrow transplantation myeloid leukemia nonmalignant disease symptomatic chronic rheumatoid arthritis osteoarthritis ankylosing spondylitis primary dysmenorrhea mild moderate pain musculotendinous trauma sprain strain postoperative dental surgery postpartum pain differential diagnosis myasthenia gravis adjunct evaluation requirement disease evaluating emergency myasthenic crisis diagnostic drug testing hypothalamic pituitary acth function occasionally cushing syndrome secondary hyperparathyroidism chronic kidney disease hemodialysis peritoneal dialysis hypercalcemia parathyroid carcinoma moderate severe plaque psoriasis well inflammatory pruritic manifestation corticosteroid responsive dermatosis mildly moderately active ulcerative colitis trimethoprim various formulation following infection bacteria documented susceptibility urinary tract infection otitis medium pediatric clinically exacerbation chronic bronchitis adult enteritis susceptible shigella prophylaxis pneumocystis jiroveci pneumonia traveler diarrhea enterotoxigenic e coli canada additional indication include adjunctive cholera bacillary dysentery nocardiosis second line brucellosis gentamicin rifampicin alone part product metformin adjunct diet exercise improve glycemic control adult type diabetes mellitus oral topical inflammatory lesion acne vulgaris subgingival microspheres adjunct reduction pocket depth adult periodontitis oral intravenous formulation infection susceptible microorganism these include rickettsia mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis ureaplasma urealyticum borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella specie bartonella bacilliformis klebsiella granulomatis escherichia coli enterobacter aerogenes shigella specie acinetobacter specie haemophilus influenzae kelbsiella specie alone adjunct stimulant adhd postoperative postpartum nonobstructive functional urinary retention neurogenic atony urinary bladder retention prevention angina pectoris coronary artery disease onset action oral sufficiently rapid useful aborting anginal episode oedema heart failure hypertension haemorrhagic condition infant antidote coumarin anticoagulant hypoprothrombinaemia mild moderate essential hypertension prophylaxis organ rejection receiving allogeneic renal transplant administered cyclosporine corticosteroid paste mouth aphthous ulcer canker sore prevention fungal infection blastomycosis candidiasis coccidioidomycosis histoplasmosis chromomycosis paracoccidioidomycosis fda europe endogenous cushing syndrome induction maintenance general anesthesia hypertension diabetic nephropathy hypertensive type diabetes elevated serum creatinine proteinuria product hydrochlorothiazide hypertension uncontrolled hypertension monotherapy first line expected well controlled monotherapy advanced ovarian cancer disease recurred progressed following therapy platinum based regimen second line therapy sensitive small cell lung cancer well cisplatin stage iv b recurrent persistent cervical cancer amenable curative surgery radiation therapy short term insomnia however generally replaced sedative hypnotic agent reduction serum uric acid concentration chronic gouty arthritis tophaceous gout frequent disabling gout attack effectively promote uric acid excretion hyperuricemia secondary administration thiazide related diuretic remission induction maintenance therapy lymphatic leukemia biochemical tool shown cause dramatic weight loss animalsfor life threatening ventricular arrhythmia overactive bladder symptom urinary frequency urgency urge incontinence monotherapy initial parkinson disease well adjunct therapy decreased response levodopa carbadopa palliative mild moderate alzheimer disease higher dos depression chronic schizophrenic reaction hospitalized adjunctive therapy diet reduce elevated ldl c total c triglyceride apo b increase hdl c adult primary hypercholesterolemia mixed dyslipidemia adult severe hypertriglyceridemia cutaneous manifestation moderate severe erythema nodosum leprosum enl maintenance therapy prevention suppression cutaneous manifestation enl recurrence palliative multiple myeloma palliation non resectable epithelial carcinoma ovary alone part various chemotherapeutic regimen adjunct surgery breast cancer alone regimen palliative locally recurrent unresectable transit metastatic melanoma extremity well amyloidosis prednisone manage moderate severe alzheimer dementia fda more recent systemic review meta analysis a177106 indicates beneficial first line drug alzheimer dementia cholinesterase inhibitor added further beneficial effect behavioral symptom symptom dementia a177106 bronchitis sinusitis community acquired pneumonia skin infection abscess wound pneumoniae h influenzae aureus m pneumoniae c pneumoniae l pneumophila pyogenesfor tuberculosis tuberculosis related mycobacterial infection chronic idiopathic constipation population irritable bowel syndrome constipation woman 18 age older topical anti inflammatory product relief inflammatory pruritic manifestation corticosteroid responsive dermatosis hiv infection antiretroviral agent labeled fda symptom idiopathic decline mental capacity related potentially reversible condition a32913 well age related cognitive impairment a32926 prescription drug conditioned corroboration patient suffering from potentially reversible treatable condition especially delirium dementiform illness secondary systemic disease primary neurological disease primary mood disturbance know more about individual component ergoloid mixture please visit db13345 db11274 most commonly prescribed nsaid very common over counter medication widely analgesic anti inflammatory antipyretic a39096 enantiomer db09213 racemic mix common mild moderate pain related dysmenorrhea headache migraine postoperative dental pain spondylitis osteoarthritis rheumatoid arthritis soft tissue disorder a39097 activity against prostaglandin thromboxane synthesis attributed alteration platelet function prolongation gestation labor a39092 widely medication main therapeutic indication patent ductus arteriosus neonatal condition wherein ductus arteriosus blood vessel connects main pulmonary artery proximal descending aorta fails close after birth causing severe risk heart failure prostaglandin inhibition studied condition known prostaglandin e2 responsible keeping ductus arteriosus open a39100 rheumatoid osteo arthritis very commonly symptomatic inflammatory musculoskeletal rheumatic disorder a39176 cystic fibrosis high dosage proven decrease inflammation decreasing polymorphonuclear cell influx lung a39177 orthostatic hypotension induce sodium retention antagonize effect diuretic reported beneficial severe orthostatic hypotension a1651 dental pain manage chronic orofacial pain a10901 minor pain widely reduce minor ache pain well reduce fever manage dysmenorrhea very commonly relief indication fever tension headache a39092 investigational us effort put into developing prophylaxis alzheimer disease parkinson disease breast cancer a39092 infection staphylococci susceptible organismsfor severe infection penicillin g susceptible microorganism rapid high penicillin level required septicemia meningitis pericarditis endocarditis severe pneumonia mild moderate hypertensionfor documented ventricular arrhythmia sustained ventricular tachycardia judgment physician life threatening subacute chronic angle closure glaucoma after iridectomy where surgery refused contraindicated infection all specie schistosoma urinary tract infection alone susceptible bacterial infection ear nose throat genitourinary tract skin skin structure lower respiratory tract given calvulanic acid bacterial sinusitis community acquired pneumonia lower respiratory tract infection bacterial otitis medium skin skin structure infection urinary tract infection given omeprazole h pylorus infection pseudomonas aeruginosa escherichia coli haemophilus influenzae symptomatic overactive bladder cause urge urinary incontinence frequency urgency child aged 6 above symptomatic detrusor muscle overactivity found related neurological condition spina bifida example neurological condition control urinary symptom occasion off relieve bladder spasm ureteral stent urinary catheter t689 disorganized psychotic thinking help false perception e g hallucination delusion mild transient episode heart block do require electric shock pacemaker therapy asthma chronic bronchitisused orally jet lag insomnia shift work disorder circadian rhythm disorder blind evidence efficacy benzodiazepine nicotine withdrawal evidence indicates likely effective treating circadian rhythm sleep disorder blind child adult received fda orphan drug status oral medication number study shown effective treating sleep wake cycle disturbance child adolescent mental retardation autism central nervous system disorder appears decrease time fall asleep child developmental disability cerebral palsy autism mental retardation improve secondary insomnia various sleep wake cycle disturbance possible us there some evidence include benzodiazepine withdrawal cluster headache delayed sleep phase syndrome dsps primary insomnia jet lag nicotine withdrawal preoperative anxiety sedation prostate cancer solid tumor combined il therapy certain cancer sunburn prevention topical tardive dyskinesia thrombocytopenia cancer chemotherapy disorder mild moderate infection adult adolescent 12 age older susceptible strain microorganism bacterial exacerbation chronic bronchitis community acquired pneumonia pharyngitis tonsillitis uncomplicated skin skin structure infection adjunct diet exercise improve glycemic control adult type diabetes mellitus monotherapy adjunct lennox gastaut syndrome petit mal variant akinetic myoclonic seizure fda f3787 furthermore some value absence spell petit mal failed respond succinimides fda f3787 additionally panic disorder without agoraphobia defined dsm v fda alternatively some regional prescribing information note all clinical form epileptic disease seizure adult especially absence seizure petit mal atypical absence primary secondarily generalised tonic clonic grand mal tonic clonic seizure partial focal seizure elementary complex symptomatology various form myoclonic seizure myoclonus abnormal movement f3796 regional data most type epilepsy infant child especially absence petit mal myoclonic seizure tonic clonic fit whether primary generalized epilepsy secondary generalization partial epilepsy f3796 tablet suppository rhinitis allergic conjunctivitis allergic reaction blood plasma dermographism anaphylactic reaction sedation nausea vomiting pain motion sickness allergic skin reaction a189907 cough syrup phenylephrine codeine relieve cough upper respiratory symptom nasal congestion allergy common cold prevention rickets osteomalacia manage hypocalcemia hypoparathyroidism pseudohypoparathyroidism vitaminD dependent rickets rickets osteomalacia secondary long term high dose anticonvulsant therapy early renal osteodystrophy osteoporosis conjunction calcium hypophosphatemia fanconi syndrome acidosis hay fever urticaria hive allergic rhinitisused antiretroviral agent hiv infection well postexposure prophylaxis hiv infection individual had occupational nonoccupational exposure potentially infectious body fluid person known infected hiv exposure represents substantial risk hiv transmission b cell chronic lymphocytic leukemia cll responded whose disease progressed during least one standard alkylating agent containing regimenfor severe angina pectoris first generation histamine h1 receptor antagonist h1 antihistamine widely available non prescription over counter otc medication otc medication typically formulated tablet cream treating sneezing runny nose itchy watery eye itching nose throat insomnia pruritis urticaria insect bite sting allergic rash nausea f3379 a174541 additionally oral impractical there prescription only formulation injection product effective adult pediatric than premature infant neonate i amelioration allergic reaction blood plasma anaphylaxis adjunct epinephrine standard measure after allergic reaction symptom controlled uncomplicated allergic condition immediate type oral therapy impossible contraindicated f3352 ii active motion sickness f3352 iii parkinsonism oral therapy impossible contraindicated follows parkinsonism elderly unable tolerate more potent agent mild case parkinsonism age group case parkinsonism centrally acting anticholinergic agent f3352 several type dyslipidemias primary hyperlipidemia mixed dyslipidemia adult hypertriglyceridemia primary dysbetalipoproteinemia homozygous familial hypercholesterolemia heterozygous familial hypercholesterolemia adolescent failed dietary modification a177397 dyslipidemia describes elevation plasma cholesterol triglyceride both well presence low level high density lipoprotein condition represents increased risk development atherosclerosis dietary modification prevent cardiovascular event cardiac risk factor abnormal lipid profile a177397 preventive agent myocardial infarction stroke revascularization angina without coronary heart disease but multiple risk factor type diabetes without coronary heart disease but multiple risk factor a177397 preventive agent non fatal myocardial infarction fatal non fatal stroke revascularization procedure hospitalization congestive heart failure angina coronary heart disease a177397 prescribing statin medication considered standard practice following any cardiovascular event people moderate high risk development cvd statin condition include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl c level a181087 a181406 etidronate paget disease bone well prevention heterotropic ossification after total hip replacement spinal cord injury congestive cardiac insufficiency arrhythmia heart failure serotonin 4 5 ht4 receptor agonist woman le than 65 age irritable bowel syndrome constipation ibs c f4223 f4229 safety effectiveness men ibs c established f4223 f4229 adjunctive therapy refractory complex partial seizure age older had inadequate response multiple previous treatment i e first line therapy monotherapy infantile spasm between month age whom potential benefit outweigh risk vision loss adjunctive therapy diarrheafor tuberculosis drug tularemia francisella tularensis plague yersia pestis severe m avium complex brucellosis enterococcal endocarditis e g e faecalis e faecium obesity weight loss weight maintenance conjunction reduced calorie diet reduce risk weight regain after prior weight loss pending revision report liver related adverse event temporary relief sign symptom allergic conjunctivitis radiation induced dry mouth xerostomia symptom dry mouth sj amp ouml grens syndrome general lubricant topical anesthetic esophagus larynx mouth nasal cavity rectum respiratory tract trachea urinary tract vagina suppress gag reflex malaria pulmonary arterial hypertension hypertension produce controlled hypotension during surgical procedure hypertensive crisis topical following dermatologic infection tinea pityriasis versicolor m furfur interdigital tinea pedis athlete amp rsquo foot tinea corporis ringworm tinea cruris jock itch e floccosum t mentagrophytes t rubrum t tonsurans atrial fibrillation flutter heart failurefor symptomatic relief interstitial cystitis lowering cholesterol possibly otherwise favorably affecting lipid vitro research suggests possibility might some anticancer effect might some anti aromatase activity well activity again adjunct dietary therapy prevent cardiovascular event secondary prevention coronary heart disease chd reduce risk requiring coronary revascularization procedure reducing progression coronary atherosclerosis hypercholesterolemic chd primary hypercholesterolemia mixed dyslidipidemia schistosomiasis schistosoma mansoni sign symptom active rheumatoid arthritis ra improve physical function slow progression structural damage disease prevention chronic rejection recipient solid organ trasnplants designated fda orphan drug fda monograph state adjunct diet triglyceridemia primary dysbetalipoproteinemia type iii hyperlipoproteinemia homozygous familial hypercholesterolemia f4649 health canada monograph further specifies reduction elevated total cholesterol total c ldl c apob total c hdl c ratio triglyceride tg increasing hdl c hyperlipidemic dyslipidemic condition response diet exercise alone inadequate prevention major cardiovascular event risk myocardial infarction nonfatal stroke coronary artery revascularization without documented history cardiovascular cerebrovascular event but least two conventional risk factor cardiovascular disease f4652 prescribing statin medication considered standard practice following any cardiovascular event people moderate high risk development cvd statin condition include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl c level a181087 a181406 amphotericin b serious infection susceptible strain candida septicemia endocarditis urinary system infection cryptococcus meningitis pulmonary infection suppression motor phonic tic tourette disorder failed respond satisfactorily standard treatment metastatic breast cancer resistant both paclitaxel anthracycline containing chemotherapy regimen docetaxel metastatic breast cancer failed respond recurred relasped during following anthracycline containing chemotherapy alone adjuvant therapy following complete resection primary tumor stage iii colon cancer monotherapy fluroprymidine preferred regimen advanced gastric cancer currently being investigated elicit cardiovascular response cardiac stumulant similar those produced exercise order aid diagnosing presence absence coronary artery disease cad can not exercise adequately giardiasis cutaneous leishmaniasis malignant effusion major depressive disorder mdd post traumatic stress disorder ptsd obsessive compulsive disorder ocd panic disorder pd premenstrual dysphoric disorder pmdd social anxiety disorder sad common off us include prevention post stroke depression a187078 generalized anxiety disorder gad fibromyalgia premature ejaculation migraine prophylaxis diabetic neuropathy neurocardiogenic syncope obesity ophthalmic temporary relief sign symptom seasonal allergic conjunctivitis nasal spray allergic rhinitis insomnia cushing syndrome normally short term until permanent therapy possible unfractionated prophylaxis venous thrombosis extension prevention post operative deep venous thrombosis pulmonary embolism prevention clotting arterial cardiac surgery cardiology prevent embolism atrial fibrillation adjunct antithrombin therapy unstable angina non q wave myocardial infarction i e non st elevated coronary artery syndrome platelet glycoprotein iib iiia receptor inhibitor additionally prevent clotting during dialysis surgical procedure maintain patency intravenous injection device prevent vitro coagulation blood transfusion blood sample drawn laboratory value local oropharyngeal candidiasis adjunctive diaper dermatitis complicated candidiasis immunocompetent aged four week older available both suppository cream vaginal yeast infection relief vulvar itching irritation lastly cream effective treating athlete foot tinea pedis jock itch tinea cruris ringworm infection tinea corporis pityriasis formerly tinea versicolor a203633 cutaneous candidiasis a203630 chronic infection sensitive strain certain gram negative bacillus particularly pseudomonas aeruginosa many different type bacterial infection bronchitis sinusitis tonsillitis ear infection skin infection gonorrhea urinary tract infection impotence vasospasms rhinitis urticaria allergy common cold asthma hay fever capsule vasospastic angina chronic stable angina extended release tablet vasospastic angina chronic stable angina hypertension controlled reduction blood pressure during surgery hypertensive emergency prevention pneumocystis carinii pneumonia intolerant trimethoprim sulfamethoxazole tmp smx oral mild moderate pcp intolerant tmp smx fda approved indication recurrent ventricular fibrillation vf recurrent hemodynamically unstable ventricular tachycardia vt fda emphasizes drug should only given these condition they clinically documented responded normal therapeutic dos antiarrhythmic agent drug tolerated patient off indication include atrial fibrillation supraventricular tachycardia a189666 a189720 a189723 parentally hypertensive emergency hypoglycemia secondary insulinoma niddm conjunction diet exercise control certain seizure epilepsy muscle weakness muscle disease myasthenia gravis topical antiseptic mainly wound dressing niddm non insulin dependent diabetes mellitus conjunction diet exercise prophylaxis venous thrombosis extension atrial fibrillation embolization prophylaxis pulmonary embolism adjunct coronary occlusion symptomatic benign prostatic hyperplasia bph men enlarged prostate gland improve symptom reduce risk urinary retention need bph related surgery alone tamsulosin topical application tinea pedis tinea cruris tinea corporis trichophyton rubrum trichophyton mentagrophytes trichophyton tonsurans microsporum canis microsporum audouini microsporum gypseum epidermophyton floccosum cutaneous candidiasis tinea versicolor together surgery lhrh analogue advanced prostatic cancer acid reflux disorder gerd peptic ulcer disease h pylorus eradication prevention gastroinetestinal bleeds nsaid relief inflammatory pruritic manifestation corticosteroid responsive dermatosis causal prevention suppression malaria susceptible strain p falciparum specie plasmodium found some geographical area world adjunct diet exercise improve glycemic control adult type diabetes mellitus available metformin glimepiride alogliptin same indication paget disease bone serum alkaline phosphatase level time upper limit normal symptom risk future complication examined adrenocortical insufficiency especially multiple sclerosis congenital cerebral palsy polyarteritis nodosa rheumatoid arthritis currently only approved treating cat dog addison disease provide skeletal muscle relaxation adjunct general anesthesia endotracheal intubation facilitate mechanical ventilation mild severe heart failure left ventricular dysfunction after myocardial infarction ventricular ejection fraction 40 hypertension oral intravenous formulation adult various infection susceptible bacteria infection upper respiratory tract lower respiratory tract skin skin structure urinary tract prostate oral formulation both adult child 6 month age older post exposure inhalational anthrax bacillus anthracis prophylaxis plague yersinia pestis ophthalmic formulation bacterial conjunctivitis susceptible organism inhalational solution available canada cystic fibrosis aged 18 older chronic pulmonary pseudomonas aeruginosa infection gout gouty arthritis infection susceptible bacteria following infection skin uti ent pneumoniae h influenzae staphylococci pyogenes group beta hemolytic streptococci e coli p mirabilis klebsiella sp coagulase negative staphylococci streptococcus pyogenes candidemia disseminated candidiasis certain invasive candida infection well esophageal candidiasis prophylaxis candida infection undergoing hematopoietic stem cell transplantation alternative oropharyngeal candidiases some success primary salvage therapy alone antifungal invasive aspergillosis prophylaxis candida infection undergoing hematopoietic stem cell transplantation oral approved following indication depression anxiety a177163 depression anxiety different condition alcoholism organic disease manic depressive disorder t249 psychotic depressive disorder anxiety t249 involutional depression t249 manic depressive disorder t249 insomnia characterized difficulty sleep maintenance a177163 topical approved short term up 8 day moderate pruritus atopic dermatitis pruritus lichen simplex chronicus t249 off topically neuropathic pain a177172 depression common medical illness cause feeling sadness loss interest prior enjoyable activity condition lead emotional physical disturbance decrease ability person function regular environment anxiety normal reaction body towards normal danger anxious state exacerbated appears situation without danger defined anxiety disorder disorder appear different form phobia panic obsessive compulsive disorder post traumatic stress disorder insomnia sleep disorder directly affect quality life individual characterized complication either fall asleep stay asleep condition occasional chronic pruritus defined unpleasant skin reaction provokes urge scratch localized generalized appear chronic manner neuropathic pain occurs damage dysfunction peripheral central nervous system rather than stimulation pain receptor reduction cumulative renal toxicity ovarian cancer using cisplatin moderate severe xerostomia undergoing post operative radiation head neck cancer adjunctive chronic simple open angle glaucoma secondary glaucoma preoperatively angle closure glaucoma where delay surgery desired order lower intraocular pressurefor leprosy dermatitis herpetiformisfor allergic rhinitis hay fever allergic skin disorder infection penicillinase producing staphylococci pneumococcus group beta hemolytic streptococci penicillin g sensitive penicillin g resistant staphylococci symptomatic relief dysuria urgency nocturia suprapubic pain frequency incontinence occur cystitis prostatitis urethritis urethrocystitis urethrotrigonitis depression following infection respiratory skin soft tissue uti ent pneumoniae h influenzae staphylococci pyogenes group beta hemolytic streptococci e coli p mirabilis klebsiella sp coagulase negative staphfor relief symptom various depressive syndrome especially endogenous depression manage chronic peripheral neuropathic pain second line agent anxiety disorder e g panic disorder generalized anxiety disorder second third line agent adhd topical vulvovaginal candidiasis topical interdigital tinea pedis immunocompetent 12 age older trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum production complete anaesthesia short duration induction general anaesthesia inducing hypnotic state bacterial infection susceptible strain pneumoniae h influenzae h parainfluenzae m catarrhalis pneumoniae multi drug resistant strain mdrsp m pneumoniae c pneumoniae k pneumoniae major depressive disorder mdd seasonal affective disorder sad aid smoking cessation naltrexone marketed product contrave adjunct reduced calorie diet increased physical activity chronic weight adult initial body mass index bmi 30 kg m greater obese 27 kg m greater overweight presence least one weight related comorbid condition e g hypertension type diabetes mellitus dyslipidemia off first line adhd comorbid bipolar disorder adjunct mood stabilizer f4624 concurrent leucovorin administration leucovorin protection alternative therapy moderate severe pneumocystis carinii pneumonia pcp immunocompromised acquired immunodeficiency syndrome aid several type cancer colon cancer prophylaxis therapy ventricular fibrillation life threatening ventricular arrhythmia ventricular tachycardia failed respond adequate dos first line antiarrhythmic agent lidocaine induction maintenance general anesthesiaused aborting second trimester pregnancy between twelfth eighteenth week gestation incomplete abortion therapeutic abortion case intrauterine fetal death congenital abnormality incompatible life low dos medically induction labor term injected intra arterially vasodilator assist angiography production local anesthesia infiltration peripheral nerve block they lumbar caudal epidural anesthesia treating symptomatic benign prostatic hyperplasia hypertension fda urinary tract infection some strain e coli klebsiella enterobacter specie mainly against gram negative organism hypocalcemia those condition requiring prompt increase blood plasma calcium level magnesium intoxication overdosage magnesium sulfate combat deleterious effect hyperkalemia measured electrocardiographic ecg pending correction increased potassium level extracellular fluid infection respiratory tract kidney skin soft tissue uti urethral cervical gonorrhoea alleviation symptom intermittent claudication pain leg occurs walking disappears rest following fungal infection immunocompromised non immunocompromised pulmonary extrapulmonary blastomycosis histoplasmosis aspergillosis onychomycosis anticancer drug stage iii stage iv hodgkin disease induction remission consolidation promyelocytic leukemia apl whose apl characterized presence t 15 17 translocation pml rar alpha gene expressionfor moderate severe hypertension either alone adjunct renal hypertension major depressive disorder bipolar disorder a31901 infection where one more following known suspected pathogen e coli proteus specie both indole positive indole negative e aerogenes k pneumoniae marcescens acinetobacter specie adjunct rest physical therapy measure relief discomfort painful musculo skeletal condition all type seizure except absence seizure both maintenance major depressive disorder mdd generalized anxiety disorder gad additionally symptomatic relief obsessive compulsive disorder ocd canada prevention nausea vomiting dizziness motion sickness vertigo dizziness medical problem myeloid leukemia aml adult includes french american british fab classification m1 through m7 anxiety muscle spasm external genital wart condyloma acuminatum hypertension component various chemotherapeutic regimen third line therapy recurrent refractory germ cell testicular cancer component various chemotherapeutic regimen cervical cancer well conjunction surgery radiation therapy various soft tissue sarcoma indication include osteosarcoma bladder cancer ovarian cancer small cell lung cancer non hodgkin lymphoma prolong time recurrence paroxysmal atrial fibrillation flutter paf disabling symptom without structural heart disease life threatening documented ventricular arrhythmia sustained ventricular tachycardia complete partial reversal narcotic depression respiratory depression induced opioids natural synthetic narcotic propoxyphene methadone narcotic antagonist analgesic nalbuphine pentazocine butorphanol diagnosis suspected opioid overdose adjunctive agent increase blood pressure septic shock dyspepsia heartburn epigastric pain nausea vomiting male replacement therapy condition symptom deficiency absence endogenous testosterone female palliation androgenresponsive recurrent mammary cancer woman more than one year but le than five postmenopausal adjunctive levodopa carbidopa sign symptom parkinson disease withdrawn from u canadian market 2007 increased risk cardiac valvulopathy contrast agent locate spinal tumor topical immunocompetent mild moderate onychomycosis fingernail toenail without lunula involvement trichophyton rubrum inhalation agent induction maintenance anesthesia inpatient outpatient surgery adult oral parenteral formulation serious infection susceptible anaerobic bacteria well susceptible staphylococci streptococci pneumococcus topically acne vulgaris available benzoyl peroxide tretinoin purpose vaginal cream suppository bacterial vaginosis non pregnant female antimicrobial prophylaxis against viridans group streptococcal infection susceptible undergoing oral dental upper respiratory surgery prophylaxis against bacterial endocarditis penicillin allergic high risk these infection obesity weight loss maintenance weight loss reduced calorie dietfor moderate severe pain hypertension ventricular premature beat adult elevated intraocular pressure ocular hypertension open angle glaucoma new zealand america prevent supraventricular arrhythmia ventricular arrhythmia united state prevent paroxysmal atrial fibrillation flutter a186886 palliative metastatic progressive carcinoma prostatefor essential renovascular hypertension usually administered drug particularly thiazide diuretic congestive heart failure drug e g cardiac glycoside diuretic amp beta adrenergic blocker improve survival left ventricular dysfunction following myocardial infarction nephropathy diabetic nephropathy short term insomnia galactorrhea hyperprolactinemia prolactin dependent menstrual disorder infertility prolactin secreting adenoma prolactin dependent male hypogonadism adjunct therapy surgery radiotherapy acromegaly monotherapy special case monotherapy early parksinsonian syndrome adjunct levodopa advanced case motor complication off restless leg syndrome neuroleptic malignant syndrome pulmonary tuberculosis adjunctive therapy partial onset seizure epileptic one month age older additionally adjunct myoclonic seizure juvenile myoclonic epilepsy 12 age older primary generalized tonic clonic seizure idiopathic generalized epilepsy 6 age older available orally dissolvable tablet adjunct partial onset seizure epilepsy 4 age older weigh more than 20kg angina pectoris hypertension another product formulated bendroflumethiazide hypertension secondary chronic progressive progressive relapsing worsening relapsing remitting multiple sclerosisfor complete partial reversal sedative effect benzodiazepine case where general anesthesia induced maintained benzodiazepine where sedation produced benzodiazepine diagnostic therapeutic procedure benzodiazepine overdose adjunct appropriate supportive symptomatic measure primary metastatic brain tumor component chemotherapy addition appropriate surgical radiotherapeutic procedure agent secondary therapy refractory relapsed hodgkin disease adjunctive therapy induce thrombolysis suffering myocardial infarction adult following infection susceptible strain microorganism community acquired pneumonia chlamydia pneumoniae haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis mycoplasma pneumoniae streptococcus pneumoniae bacterial exacerbation chronic bronchitis chlamydia pneumoniae enterobacter cloaca haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae moraxella catarrhalis staphylococcus aureus streptococcus pneumoniae moderate severe pain lowering intraocular pressure iop chronic open angle glaucoma ocular hypertension alternative medication otitis medium h influenzae m catarrhalis pneumoniae history type i penicillin hypersensitivity pharyngitis tonsillitis susceptible streptococcus pyogenes well respiratory tract infection maxillary sinusitis bacterial exacerbation chronic bronchitis mild moderate community acquired pneuomia legionnaire disease pertussis indication include uncomplicated skin skin structure infection helicobacter pylorus infection duodenal ulcer disease bartonella infection early lyme disease encephalitis toxoplasma gondii hiv infected conjunction pyrimethamine decrease incidence cryptosporidiosis prevent occurence  hemolytic viridans group streptococcal endocarditis well serve primary prevention mycobacterium avium complex mac bacteremia disseminated infection adult adolescent child advanced hiv infection infection respiratory skin soft tissue uti ent susceptible organism organism generally susceptible include pneumoniae pyogenes group beta hemolytic streptococci coagulase negative staphylococci some enterobacter spp h influenzae n gonorrhoeae p mirabilis e coli klebsiella spp m catarrhalis b burgdorferi some oral anaerobe a215582 antizol antidote ethylene glycol antifreeze methanol poisoning suspected ethylene glycol methanol ingestion either alone hemodialysisindicated elevated intraocular pressure ocular hypertension open angle glaucoma short term insomnia characterized difficulty falling asleep frequent nocturnal awakening early morning awakening symptomatic benign prostatic hyperplasia bph men enlarged prostate improve symptom reduce risk urinary retention reduce risk need surgery transurethral resection prostate turp prostatectomy male pattern hair loss androgenetic alopecia hereditary alopecia common male baldness male adjunct therapy hormone receptor positive early breast cancer postmenopausal woman first line hormone receptor positive hormone receptor unknown locally advanced metastatic breast cancer postmenopausal woman advanced breast cancer postmenopausal woman experience disease progression despite tamoxifen severe malariafor along appropriate supportive measure fulminant hypermetabolism skeletal muscle characteristic malignant hyperthermia crisis all age preoperatively sometimes postoperatively prevent attenuate development clinical laboratory sign malignant hyperthermia individual judged malignant hyperthermia susceptible multiple indication fda 12 age traveller diarrhea noninvasive strain escherichia coli reduction overt hepatic encephalopathy recurrence 18 age 2015 approved irritable bowel syndrome diarrhea ibs d men woman anesthetic agent recommended diagnostic surgical procedure if skeletal muscle relaxation needed should combined muscle relaxant if surgical procedure involves visceral pain should supplemented agent obtunds visceral pain induction anesthesia prior general anesthetic agent supplement low potency agent fda report potential therapeutic tool depression administered lower dos a31873 these report increased interest area several clinical trial launched indication a31874 extended release capsule maintenance mild moderate crohn disease various inhaled product prophylactic therapy asthma reducing exacerbation copd nasal spray available over counter symptom hay fever upper respiratory allergy extended release capsule induce remission mild moderate ulcerative colitis rectal foam mild moderate distal ulcerative colitis bronchospasm asthma emphysema chronic bronchitis symptomatic schizophrenia addition manic mixed episode bipolar i disorder monotherapy combined drug manage depressive episode bipolar disorder addition above indication antidepressant drug major depression some off us drug include post traumatic stress disorder ptsd generalized anxiety disorder psychosis parkinson disease a185438 a185447 t685 prophylaxis deep vein thrombosis lead pulmonary embolism prophylaxis ischemic complication unstable angina non q wave myocardial infarction concurrently administered aspirin inpatient outpatient adjunct general anesthesia facilitate tracheal intubation provide skeletal muscle relaxation during surgery mechanical ventilation opiate dependence sometimes severe pain terminal class ic antiarrhythmic agent irregular heartbeat atrial fibrillation atrial flutter ventricular tachycardia ventricular fibrillation kaposi sarcoma cancer lung ovarian breast abraxane specfically metastatic breast cancer locally advanced metastatic non small cell lung cancer attention deficit hyperactivity disorder adhd prevention symptomatic peripheral labyrinthine vertigo nausea vomiting occur condition meniere disease surgery middle inner ear control nausea vomiting postoperative state malignant neoplasm labyrinthine disturbance antineoplastic agent therapy radiation sickness infectious disease ritonavir antiretroviral agent hiv infection 16 age older oral tablet form symptomatic both recurrent diabetic gastroparesis addition gastroesophageal reflux disease gerd failed respond traditional therapy nasal spray formulation adult recurrent diabetic gastroparesis intravenous injection form above condition well prevention vomiting follow emetogenic chemotherapy nausea vomiting after surgery intravenous facilitates intubation small bowel stimulates gastric emptying barium flow require radiological examination stomach small intestine some case delay gastrointestinal emptying interferes radiographic visualization gastrointestinal tract facilitate emptying these case allowing adequate diagnostic visualization some off us include radiation induced nausea vomiting gastric bezoars intractable hiccup migraine pain a184961 a184964 a184967 a40105 ciprofloxacin otic suspension bacterial infection inflammation otitis medium otitis externa intramuscular intravenous injection number endocrine rheumatic collagen dermatologic allergic ophthalmic gastrointestinal respiratory hematologic neoplastic edematous condition oral tablet multiple myeloma intravitreal implant some form macular edema non infectious posterior uveitis affecting posterior eye various ophthalmic formulation inflammatory condition eye own formulated oral inhalation powder intermittent off episode parkinson already being treated carbidopa fda most commonly formulated oral tablet peripheral dopa decarboxylase inhibitor parkinson disease post encephalitic parkinsonism symptomatic parkinsonism following carbon monoxide intoxication manganese intoxication f4579 induction maintenance general anesthesia pediatric inpatient outpatient surgery symptom related hay fever type allergy help bring up phlegm thin secretion make cough productive manic mixed episode bipolar i disorder irritability autism spectrum disorder schizophrenia tourette disorder adjunctive major depressive disorder injectable formulation agitation schizophrenia bipolar mania psychotic disorder e g schizophrenia mania occuring part bipolar disorder long term intravenous primary pulmonary hypertension pulmonary hypertension scleroderma spectrum disease nyha class iii class iv do respond adequately conventional therapy type iv v hyperlipidemia elevated serum triglyceride usually above 2000mg dl elevated vldl cholesterol fasting chylomicron risk developing pancreatitis do adequately respond dietary restriction reduce risk developing coronary heart disease type iib hyperlipidemia without history symptom coronary heart disease do adequately respond weight loss diet exercise medication low hdl raised ldl raised triglyceride obsessive compulsive disorder disorder obsessive compulsive component e g depression schizophrenia tourette disorder unlabeled indication include depression panic disorder chronic pain e g central pain idiopathic pain disorder tension headache diabetic peripheral neuropathy neuropathic pain cataplexy narcolepsy limited evidence autistic disorder limited evidence trichotillomania limited evidence onchophagia limited evidence stuttering limited evidence premature ejaculation premenstrual syndrome dandruff mild moderately severe seborrheic dermatitis scalp hypertension chronic stable angina classic effort angina skeletal muscle relaxantused prevent relieve allergic condition cause pruritus itching urticaria some allergic skin reaction enduring debilitating symptom depression responded antidepressant drug depression common but serious mood disorder patient will present change feeling thought ability handle everyday activity mood disorder considered depression symptom should present least two week locally advanced metastatic breast cancer after failure prior chemotherapy single agent locally advanced metastatic non small cell lung cancer after failure prior platinum based chemotherapy prednisone androgen independent hormone refractory metastatic prostate cancer furthermore us gastric adenocarinoma head neck cancer contrast agent during coronary angiography inflammatory bowel disease ulcerative colitis diabetes mellitus type type diabetes postpartum haemorrhage postabortion haemorrhage uterine atony adult chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy adult philadelphia chromosome positive lymphoblastic leukemia resistance intolerance prior therapy attention deficit hyperactivity disorder adhd moderate severe binge eating disorder adult fda a40246 drug weight loss sympathomimetic drug weight loss serious cardiovascular effect safety effectiveness drug obesity yet determined fda adult pediatric aged 9 month older topical impetigo up 100 cm lt sup gt lt sup gt total area adult total body surface area pediatric aged 9 month older staphylococcus aureus methicillin susceptible isolates only streptococcus pyogenes paroxysmal nocturnal hemoglobinuria pnh reduce hemolysis atypical hemolytic uremic syndrome inhibit complement mediated thrombotic microangiopathy a2246 neuromyelitis optica spectrum disorder nmosd capecitabine advanced metastatic breast cancer whose tumor overexpress human epidermal receptor type her2 protein received prior therapy anthracycline taxane trastuzuma relief inflammatory pruritic manifestation corticosteroid responsive dermatose glycemic control type diabetes mellitus along diet exercise myelodysplastic syndrome md all french american british subtypes refractory anemia refractory anemia ringed sideroblast refractory anemia excess blast refractory anemia excess blast transformation chronic myelomonocytic leukemia well md scored belonging intermediate intermediate high risk group international prognostic scoring system prophylaxis invasive lt em gt aspergillus lt em gt lt em gt candida lt em gt infection 13 age older high risk developing these infection being severely immunocompromised result procedure hematopoietic stem cell transplant hsct recipient graft versus host disease gvhd hematologic malignancy prolonged neutropenia from chemotherapy oropharyngeal candidiasis oropharyngeal candidiasis refractory itraconazole fluconazole alternative invasive aspergillosis lt em gt fusarium lt em gt infection zygomycosis intolerant whose disease refractory antifungal co administered ritonavir antiretroviral agent human immunodeficiency virus hiv child age 3 above adult hiv infection chronic hepatitis b adolescent 16 age evidence viral replication either evidence persistent elevation serum aminotransferase alt ast histologically active disease topical external genital perianal wart condylomata acuminata immunocompetent 18 older schizophrenia advanced renal cell carcinoma well gastrointestinal stromal tumor after disease progression intolerance imatinib mesylate egfr expressing metastatic colorectal carcinoma refractory fluoropyrimidine oxaliplatin irinotecan containing chemotherapy regimen macular edema after retinal vein occlusion age related macular degeneration wet diabetic macular edema hunter syndrome adult child age 5 older pompe disease gaa deficiency infant pediatric aid smoking cessation bronchodilator long term symptomatic reversible bronchoconstriction chronic obstructive pulmonary disease copd chronic bronchitis emphysema alone adjunct standard therapy essential hypertension product isosorbide dinitrate adjunct therapy heart failure improving glycemic control adult type diabetes mellitus along diet exercise long term growth failure pediatric primary igfd gh gene deletion developed neutralizing antibody gh a2322 secondary igfd resulting from gh deficiency malnutrition hypothyroidism cause substitute gh therapy type type diabetes mellitus adjunct preprandial insulin therapy without adequate glycemic control insulin therapy adult child mucopolysaccharidosis vi pediatric t cell lymphoblastic leukemia t cell lymphoblastic lymphoma whose disease responded relapsed following least two chemotherapy regimen sign symptom moderate severe active rheumatoid arthritis inducing major clinical response slowing progression structural damage improving physical function both monotherapy continued regimen dmards tnf antagonist sign symptom moderately severely active polyarticular juvenile idiopathic arthritis child control postpartum hemorrhage bleeding after giving birth chronic sign symptom osteoarthritis knee adult diagnostic agent screening presumed adrenocortical insufficiency diagnostic agent screening presumed adrenocortical insufficiency asthma diabetes mellitus type prevention reversal bronchospasm 12 age older reversible bronchospasm asthma nausea heartburn indigestion upset stomach diarrhea temporary discomfort stomach gastrointestinal tract angina pectoris hypertension usually osteoarthritis although efficacy still question emergency cardiac arrhythmia orally urinary tract infection pyrimethamine prevention malaria various infection livestock well pyrimethamine plasmodium falciparum malaria those whom chloroquine resistance suspected broad spectrum antibiotic case needing high concentration oral administration impractical symptom asthma bronchitis copd emphysema improve glycemic control adult child diabetes mellitus improve glycemic control adult child diabetes mellitus improve glycemic control adult pediatric diabetes mellitus antiretroviral agent human immunodeficiency virus hiv infection well postexposure prophylaxis hiv infection individual had occupational nonoccupational exposure potentially infectious body fluid person known infected hiv exposure represents substantial risk hiv transmission pending revision potential association between drug myocardial infarction dyslipidemia hiv infected adult generalized tonic clonic status epilepticus prevention seizure occurring during neurosurgery substituted short term oral phenytoin aged two older oral phenytoin administration possible bacterial infection thiazide diuretic decrease edema decrease blood pressure hypertension serious infection susceptible strain microorganism mainly bacterial infection skin moderately severe bacterial infection involving lung bone joint stomach blood heart valve urinary tract clinically effective against infection staphylococci streptococci specie gram positive bacteria surgical prophylaxis if required metronidazole added cover b fragilis bacterial infection susceptible microorganism following infection susceptible bacteria respiratory tract infection pneumoniae h influenzae aureus penicillinase non penicillinase producing strain pyogenes group beta hemolytic streptococci p aeruginosa klebsiella pneumoniae e coli proteus mirabilis enterobacter specie peritonitis intra abdominal infection e coli p aeruginosa anaerobic gram negative bacillus bacteroides fragilis 3 bacterial septicemia pneumoniae agalactiae aureus pseudomonas aeruginosa e coli klebsiella spp klebsiella pneumoniae proteus specie indole positive indole negative clostridium spp anaerobic gram positive cocci 4 infection skin skin structure aureus penicillinase non penicillinase producing strain pyogenes p aeruginosa 5 pelvic inflammatory disease endometritis infection female genital tract n gonorrhoeae epidermidis agalactiae e coli clostridium spp bacteroides specie bacteroides fragilis anaerobic gram positive cocci 6 urinary tract infection escherichia coli pseudomonas aeruginosa 7 enterococcal infection although shown clinically effective infection enterococci case peritonitis intra abdominal infection infection skin skin structure pelvic inflammatory disease endometritis infection female genital tract urinary tract infection majority clinical isolates enterococci tested susceptible but fall just intermediate zone susceptibility moderately resistant however vitro susceptibility testing correlate directly vivo result despite therapy resulted clinical cure enterococcal infection chiefly polymicrobial infection should enterococcal infection care dos achieve satisfactory serum level prophylaxis bacterial infection serious infection susceptible strain microorganism cetizoxime previously infection susceptible strain bacteria muscle relaxant muscle relaxant during anesthesia surgical procedure muscle relaxant during anesthesia surgical procedure muscle relaxing agent adjunct general anesthesia ace inhibtor class drug hypertension heart failure hypertension abnormally high potassium level potassium regulate hypokalemia primary condition secondary medical condition hypertension heart failure ace inhibitor class drug hypertension infrequently hypertension heart failure insomnia mainly sedation hypnosis induction anesthesia prior general anesthetic agent induction anesthesia short surgical diagnostic therapeutic procedure minimal painful stimulus lithium salt form mood stabilizer depression mania most frequently prescribed bipolar disorder one first oral contraceptive mild moderate arterial hypertension alone antihypertensive agent especially thiazide type diuretic contraindicated cardiogenic shock sinus bradycardia second third degree atrioventricular conduction block bronchial asthma those known hypersensitivity ia myelography arthrography nephroangiography arteriography radiographic procedure ephedra temporary relief shortness breath tightness chest wheezing bronchial asthma temporary relief bronchial asthma over counter formulation intravenous injection hypotension under anesthesia injection multiple route allergic condition bronchial asthma nasal spray otc medication decongestant maintain blood pressure hypotensive state asthma chronic obstructive pulmonary disease copd sign symptom idiopathic parkinson disease initial monotherapy adjunct therapy levodopa bacterial infection usually dalfopristin play vital role anatomy physiology biochemistry organism cell particularly signal transduction pathway vital cell signaling muscular contraction bone health signalling cascade over counter supplement cardiovascular neuromuscular health antacid relief acid indigestion upset stomach relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder appears effective alleviating age related memory impairment some elderly people mild moderate age related memory cognitive impairment improving cognitive function healthy young middle aged people improving symptom alzheimer vascular mixed dementia improving damage visual field normal tension glaucoma decreasing number painful attack raynaud syndrome improve symptom vertigo dizziness some glycodiazine concomitantly insulin noninsulin dependent type diabetes mellitus all condition corticosteroid therapy except adrenal deficiency state lack sodium retaining property make le suitable than hydrocortisone supplementary fludrocortisone angina high blood pressure metabolic acidosis occur severe renal disease uncontrolled diabetes circulatory insufficiency shock severe dehydration extracorporeal circulation blood cardiac arrest severe primary lactic acidosis severe diarrhea often accompanied significant loss bicarbonate further certain drug intoxication barbiturate where dissociation barbiturateprotein complex desired poisoning salicylate methyl alcohol hemolytic reaction requiring alkalinization urine diminish nephrotoxicity blood pigment sympatholytic mydriatic impotence successfully treated male vascular diabetic origin psychogenic origin primary hyperlipidaemia type iia iib iii iv v fredrickson classification corresponding group i ii iii european atherosclerosis society guideline diet alone improvement lifestyle increased exercise weight reduction do lead adequate response secondary hyperlipidaemia e g severe hypertriglyceridemias sufficient improvement doe occur after correction underlying disorder e g diabetes mellitus prophylaxis gout flare familial mediterranean fever fmf child adult 4 age older important note medication pain reliever painful condition consider analgesic purpose some off us include manifestation behcet syndrome pericarditis postpericardiotomy syndrome a183932 a183935 ethinyl estradiol oral contraceptive prevention pregnancy addition contraceptive effect moderate acne vulgaris symptom premenstrual dysphoric disorder drug approved indication estrogen menopause symptom vasomotor symptom vulvovaginal atrophy combined estrogen may aid prevention osteoporosis woman post menopausal least year candidate therapy sometimes found preparation containing estrogen folic acid folic acid replenishment during oral contraception acne vulgaris containing contraceptive should only woman 14 age experienced menarche desire oral contraception do any contraindication oral contraceptive off us drug include menstrual irregularity dysmenorrhea hirsutism endometriosis a2439 a182576 congestive cardiac insufficiency arrhythmia heart failure common analgesic non steroidal anti inflammatory drug nsaid mild moderate muscular painfor relief sign symptom rheumatoid arthritis osteoarthritis related rheumatic disorder symptomatic myasthenia gravis improving muscle tone reduce pain inflammation condition arthritis medication fever adult psychosis particular those schizophrenia manic phase bipolar disorder lower respiratory tract infection genital urinary infection like prostatitis skin infection endometriosis fibrocystic breast disease unresponsive simple measure prophylactic all type hereditary angioedema male female bronchodilator asthma prevention reversal bronchospasm 12 age older asthma reversible bronchospasm bronchitis emphysema powder inhalation maintenance bronchospasm copd prevent exacerbation copd olodaterol metered inhalation spray maintenance copd inhalation spray maintenance bronchospasm copd prevent exacerbation copd asthma 12 more old metered inhalation spray maintenance bronchospasm copd prevent exacerbation copd asthma 6 more old nasal symptom seasonal perennial allergic rhinitis adult adolescent 12 age older adjunct standard therapy inhaled steroid inhaled long short acting beta agonist vasodilator diuretic heart stimulant similar caffeine useful fatigue orthostatic hypotension pneumonia moderate severe streptococcus pneumoniae case concurrent bacteremia pseudomonas aeruginosa klebsiella pneumoniae enterobacter specie empiric febrile neutropenic uncomplicated complicated urinary tract infection pyelonephritis escherichia coli klebsiella pneumoniae infection severe escherichia coli klebsiella pneumoniae proteus mirabilis infection mild moderate case concurrent bacteremia these microorganism uncomplicated skin skin structure infection staphylococcus aureus methicillin susceptible strain only streptococcus pyogenes complicated intra abdominal infection metronidazole escherichia coli viridans group streptococci pseudomonas aeruginosa klebsiella pneumoniae enterobacter specie bacteroides fragilis broad spectrum first generation cephalosporin antibiotic effective gram positive gram negative bacterial infection bacterial exacerbation chronic bronchitis abecb bacterial otitis medium pharyngitis tonsilitis mild moderate infection susceptible strain designated microorganism prevention thromboembolic disease more specifically prevention cerebral embolism deep vein thrombosis pulmonary embolism thromboembolism infarction transient ischemic attack deep vein thrombosis myocardial infarction anti inflammatory analgesic agent relief mild moderate pain often muscle mass building original medical indication androgen deficiency male adult either hypogonadism andropause nowadays heifer order stimulate maximal growth chronic intestinal amebiasis effective extraintestinal amebiasis hepatic coma adjunctive therapy antibiotic agent strepronin mucolytic expectorant drug formerly widely antipyretic analgesic rheumatism neuritis common cold currently measure total body water nausea vomiting postoperative nausea vomiting antiarrhythmic agent congestive heart failure ingredient sunscreen cosmetic chronic obstructive pulmonary disease designed miscarriage prevention prevention premature labour investigated possible men benign prostatic hyperplasia adjunctive therapy diet reduction elevated serum cholesterol primary hypercholesterolemia elevated low density lipoprotein ldl cholesterol do respond adequately diet relief pruritus partial biliary obstruction mainly narcotic dependence claim supplemental anabolic effect unsubstantiated analgesic often test effect drug liver enzyme benzocaine otic solution symptomatic relief otitis medium arising from various etiology hypocalcemia secondary hyperparathyroidism osteodystrophy chronic renal failure insomnia hydrochloride relieve uncomfortable symptom occur consequence mucosal irritation lower urinary tract adult irritation result trauma surgery endoscopic procedure infection insertion instrument urinary catheter antimicrobial therapy but antimicrobial agent contributes relief discomfort pain before antimicrobial therapy begin take effect important note duration drug should last maximum day available many country over counter drug a182147 general anesthetic condition insomnia clinical depression narcolepsy alcoholism improve athletic performance recreational drug no current medical us schedule i controlled substance usa present opioid analgesic previously moderate pain relief prescription medication united kingdom severe pain surgical procedure myocardial infarction pain terminally ill relief dyspnoea pulmonary edema clinical trial now testing therapeutic potential mdma post traumatic stress disorder ptsd anxiety terminal cancer mdma one four most widely illicit drug u narcotic analgesic once severe chronic pain a14383 the depressive fatigue convalescence debilitated state well depressive day time fatigue lack concentration lethargy analgesic pain relief decrease appetite some people compound psychedelic inducing agent placebo controlled study suffering from anxiety depression only available veterinary main usage related immobilization large mammal motofen r atropine anticholinergic drug antidiarrheal drug many country many second line opioid agonist antidiarrheal exists intermediate between loperamide paragoric diarrhea result cyclic diarrhea predominant inflammatory bowel syndrome treated effectively diphenoxylate loperamide diarrhea cramping doe respond non centrally acting derivative belladonna derivative atropine often treated conservative dos codeine ulcerative colitis induction toxic megacolon possible thus motofen r cautioned motofen r assigned pregnancy category c fda only potential benefit outweigh potential risk fetus safety during lactation unknown thus recommended mainly anti anxiety agent study found more effective first 4 week than antidepressant however after 4 week antidepressant showed superior anti anxiety effect anti anxiety effect appear weaker elderly effectiveness observed alcohol withdrawal delorazapam reported manageable drug did exhibit severe side effect did require further therapy control symptom withdrawal because high affinity phencyclidine binding site nmda receptor 3h radiolabelled form widely research into nmda receptor similar but more potent opioid analgesic fentanyl tranquilizer large animal short term severe insomnia responsive hypnotic developed 1960 antidepressant before market withdrawal 1962 reverse effect powerful opioids etorphine carfentanil often tranquilizing large animal drug approved human anesthetic property induce sedative effect appetite suppressant anti obesity agent however substance abuse potential illicit substance many country some country brazil still prescribed often form diet pill ie brazilian diet pill combine amphetamine benzodiazepine antidepressant diuretic laxative united state sale diet pill banned concern over side effect risk potentially fatal overdose however internet sale illicit market lead international availability found primary care physician brazilian immigrant woman utilized imported diet pill particularly high rate sometimes suffered from side effect requiring hospitalization experienced loss employment 3 moderate severe pain post operative dental pain chronic pain breathlessness coughing heroin addict substitute drug dos up 2500mg day addiction http www ncbi nlm nih gov pmc article pmc2014322 primarily anti anxiety agent typically short term given single dose up 100mcg kg reduce anxiety tension experienced prior surgery appetite suppressant short term insomnia short term anxiety panic attack if benzodiazepine required alleviation symptom alcohol opiate withdrawal anxiety disorder mainly hypnotic insomnia however only effective hypnotic short term routine sedative preoperatively decrease anxiety cause sedation sleep respiration depression cough reflex anabolic steroid theoretically aid restauration buildup certain tissue especially muscle similar synthetic testosterone still early investigation investigated metastatic breast cancer opioid analgesic moderate severe pain relief short term anxiety disorder no approved indication studied experimentally non pituitary growth retardation a14416 medicine physically bind acid toxic substance stomach digestive tract reason often antidiarrheal medication adsorbent upset stomach diarrhea traditional medicine china south america africa aid related diarrhea based bandage under investigation attention deficit hyperactivity disorder adhd attention deficit disorder hyperactivity adhd exogenous obesity lumbar thoracic cervical total columnar myelography determine presence abnormality spinal column spinal canal central nervous system cns well cisternography direct injection using standard radiologic technique visualize basal cistern brain computerized tomography ct intracranial subarachnoid space ventriculography direct injection using standard radiologic technique visualize cerebral ventricle pediatric angiocardiography visualize lesion malformation heart obstruction anomaly major thoracic vessel peripheral arteriography visualize specific region vascular system blood flow area help diagnosis evaluation neoplasm known suspected vascular disease congenital acquired cause change normal vascular anatomy physiology adult intravenous digital arteriography head neck exogenous obesity short term adjunct few week regimen weight reduction based caloric restriction hypertension angina pectoris arrhythmia anxiety sulfanilamide antibacterial agent bronchitis prostatitis urinary tract infection bacterial infection causing bronchitis prostatitis urinary tract infection primary secondary tertiary hypothyroidism suppress thyroid stimulating hormone tsh secretion simple nontoxic goiter subacute chronic lymphocytic thyroiditis multinodular goiter thyroid cancer conjunction antithyroid agent thyrotoxicosis prevent goitrogenesis hypothyroidism differential diagnosis suspected mild hyperthyroidism thyroid gland autonomy hypothyroidism deficiency production thyroid hormone drug decrease absorption cholesterol dissolve cholesterol gallstone alternative surgical procedure remove gallstone could anxiety approved country anxiety tension irritability similar stress related symptom anxiety disorder insomnia postmenopausal woman advanced hormone receptor positive her2 negative breast cancer advanced hr bc exemestane after failure letrozole anastrozole progressive neuroendocrine tumor pancreatic origin pnet unresectable locally advanced metastatic disease advanced renal cell carcinoma rcc after failure sunitinib sorafenib renal angiomyolipoma tuberous sclerosis complex tsc requiring immediate surgery pediatric tuberous sclerosis complex tsc subependymal giant cell astrocytoma sega requires therapeutic intervention but can not curatively resected tablet overactive bladder urinary incontinence urgency frequency preventing treating deficiency anemia prevention deficiency consequence stunted growth diarrhea child slowed wound healing utilized boosting immune system treating common cold recurrent ear infection well preventing lower respiratory tract infection anxiety disorder short term relief symptom anxiety anxiety depressive symptom short term sleeping problem insomnia difficulty falling asleep frequent awakening during night early morning awakening imipenem without relebactam bacterial infection respiratory skin bone gynecologic urinary tract intra abdominal well septicemia endocarditis cilastatin without relebactam bacterial infection respiratory skin bone gynecologic urinary tract intra abdominal well septicemia endocarditis lower ldl hdl cholesterol pain especially arthritic pain product ritonavir marketed under brand name kaletra antiretrovirals hiv infection adult pediatric 14 day old infection following site upper lower respiratory tract skin soft tissue urinary tract uncomplicated gonococcal urethritis sensitive strain following organism gram positive streptococci faecalis pneumoniae nonpenicillinase producing staphylococci gram negative h influenzae n gonorrhoeae e coli p mirabilis salmonella shigellae infection susceptible gram positive bacteria particularly beta lactamase producing organism staphylococcus aureus would otherwise resistant most penicillin respiratory tract infection bronchitis exacerbation chronic bronchitis pneumonia ear nose throat infection gynecological infection urinary tract infection uncomplicated gonococcal urethritis non penicillinase producing susceptible strain following organism gram positive organism e g streptococci pneumococcus staphylococci gram negative organism e g h influenzae n gonorrhoeae e coli p mirabilis infection mecillinam sensitive organism urinary tract infection salmonellosis typhoid fever piperacillin ceftolozane broaden spectrum piperacillin antibacterial action treating susceptible infection any antibiotic should only infection either proven strongly suspected susceptible containing drug piperacillin combined piperacillin variety infection those aerobic facultative gram positive gram negative bacteria addition gram positive gram negative anaerobe some example infection treated piperacillin include cellulitis diabetic foot infection appendicitis postpartum endometritis infection certain gram negative bacillus infection beta lactamase producing organism can not treated piperacillin gene mutation conferring antibiotic resistance a179266 ceftolozane ceftolozane combined metronidazole complicated urinary tract infection uti complicated intra abdominal infection well ventilator bacterial pneumonia hospital acquired bacterial pneumonia fda increase efficacy against infection gram negative bacillus a7657 bacterial infection adjunctive medication some psychotic pro pericyazine control residual prevailing hostility impulsiveness aggressiveness chronic iron overload blood transfusion transfusional hemosiderosis age older antiviral medication cytomegalovirus infection prophylaxis malaria where chloroquine resistance reported uncomplicated malaria p falciparum p malariae p ovale p vivax chronic discoid lupus erythematosus systemic lupus erythematosus rheumatoid arthritis chronic rheumatoid arthritis rapid relief angina pectoris prevention angina first human 1950s antipsychotic agent now rarely human frequently animal sedative antiemetic principal value quietening calming anxious animal often meprobamate sleep disorder relieve cramp spasm stomach intestine useful treating irritable bowel syndrome ibs similar condition help relieve period pain citrate under investigation increase cytotoxic effect proteasome inhibitor mg132 breast cancer cell manifestation psychotic disorder sneezing runny nose itching watery eye hive rash itching symptom allergy common cold commonly over counter product seasonal allergy cold flu symptom maintenance chronic non agitated schizophrenic all type chronic schizophrenia those did respond usual neuroleptic manic syndrome schizophrenia psychosis mania schizophrenia however acetate psychiatric emergency alternative standard treatment haloperidol clotiapine etc should cautioned since well executed documented trial acetate yet conducted acetate intended long term wide range gastrointestinal disorder condition peptic ulcer gastritis hyperchlorhydria functional diarrhea irritable spastic colon pyloroduodenal irritability pylorospasm nonspecific gastroenteritis biliary dyskinesia chronic cholelithiasis duodenitis gastrointestinal spasm genitourinary spasm moderate severe hypertension antibiotic staphylococcal streptococcal bacteroides fragilis infection rheumatoid arthritis osteoarthritis ankylosing spondylitis chronic low back pain pain gout non stimulant laxative via oral suspension enema currently being studied clinical trial prostate cancer reduce risk copd exacerbation severe copd chronic bronchitis history exacerbation bronchodilator relief bronchospasm bacterial infection gout hyperurcemia japan dhea taken supplement variety unsubstantiated indication following indication shown promise backed up some scientific evidence schizophrenia dhea more effective woman than men improving appearance older people skin taking dhea mouth seems increase skin thickness moisture decrease facial age spot elderly men woman improving ability achieve erection men sexual dysfunction additionally dhea shown promise improving symptom lupus sle taking dhea mouth along conventional help reduce number time symptom flare up allow reduction dose prescription drug needed dhea help sle symptom muscle ache mouth ulcer dhea seems strengthen bone sle being treated high dose steroid corticosteroid dhea show promise osteoporosis taking dhea mouth daily seems improve bone mineral density bmd older woman men osteoporosis osteopenia pre osteoporosis dhea increase bmd young woman eating disorder called anorexia nervosa dhea often prescribed india induction ovulation improve chance pregnancy bacterial infection usually quinupristin studied many us testicular torsion diabetic ulceration wound healing acne obesity diabetic peripheral polyneuropathy investigated hypolipidemic effect cholesterol lowering agent investigated colorectal cancer lung cancer breast cancer solid tumor prostate cancer glucose pharmaceutical formulation oral tablet injection caloric supply carbohydrate supplementation case nutrient deprivation metabolic disorder hypoglycemia diet supplement containing nutritional support infant young pediatric requiring total parenteral nutrition via central peripheral route usage diet supplement containing prevents nitrogen weight loss negative nitrogen balance pediatric where alimentary tract can not done through oral gastrostomy jejunostomy administration there impaired gastrointestinal absorption protein requirement substantially increased fda investigated neuropathy diabetic moderate severe vasomotor symptom menopause atrophic vaginitis osteoporosis hypoestrogenism hypogonadism castration primary ovarian failure breast cancer palliation only advanced androgen dependent carcinoma prostate palliation only moderate plaque psoriasis adult breast cancer inflammatory disease rheumatoid arthritis pharmacological control certain diabetic complication cutaneous manifestation cutaneous t cell lymphoma progressive persistent recurrent disease following two systemic therapy commonly stop bleeding varix food pipe oesophagus oral bile acid synthesis disorder single enzyme defect adjunctive peroxisomal disorder zellweger spectrum disorder exhibit manifestation liver disease steatorrhea complication from decreased fat soluble vitaminAbsorption bacterial infection being investigated herpes labialis infection cold sore antidepressant appetite suppressant sleep aid investigated ovarian cancer lung cancer brain cancer breast cancer gastric cancer there currently no clinically approved marketed medicine relies upon active ingredient any formal therapeutic indication although sold variety non prescription over counter dietary supplement product cognitive memory enhancement there many study suggest product supplementation do elicit any kind cognitive benefit user a32981 a32982 fact general suggestion any product exercise caution their recommendation much more research necessary a32981 sodium however some extent skin hair conditioning agent owing their humectant characteristic f53 obtain miosis iris second after delivery lens cataract surgery penetrating keratoplasty iridectomy anterior segment surgery where rapid miosis required eye disease vitamin b2 deficiency keratitis blepharitis infection ear canal adjunct antineoplastic therapy within product teysuno adult advanced gastric stomach cancer given cisplatin primarily minor sore throat pain sore mouth minor mouth irritation pain canker sore additionally focal spasticity under investigation alzheimer disease porphyria attack particularly intermittent porphyria adjuvant therapy chronic myelonous leukemia lung cancer nasopharyngeal cancer hypercholesterolaemia investigated esophageal cancer leukemia lymphoid lung cancer liver cancer lymphoma unspecified cancer 5 fluorouracil improvement appearance moderate severe fullness submental fat adult prevention correction metabolic acidosis high docosahexaenoic acid dha oral supplement various direct sodium calcium salt formulation acid currently most commonly approved organization like fda ema antibacterial food additive preservative animal feed food human consumption similarly although any direct sodium calcium salt formulation excipient ingredient pharmaceutical necessarily major role compound today sodium propionate some vaginal cream preparation cervicitis cervical tear postcauterization postcryosurgery postconization cervix t193 product sodium propionate primarily elicit preservative bacteriostatic f50 effect while active ingredient combined formulation like urea benzalkonium chloride inositol methionine cystine amino acid facilitated debridement enhanced medication spread epithelialization promotion wound healing respectively a32973 nevertheless great variety propionic acid derivative exist separate pharmaceutical each their own unique therapeutic category pharmacodynamics pharmacokinetics principally analgesic drying skin before after surgical removal wart where dryness required investigated chronic obstructive pulmonary disease copd lt ul gt lt li gt 10 hydrate skin lt li gt lt li gt 15 accelerate fibrin degradation lt li gt lt li gt 20 30 antipruritic break down keratin decrease thickness stratum corneum scaling condition ichthysosis lt li gt lt li gt 40 proteolytic dissolve peel dystrophic nail lt li gt lt ul gt lt br gt patient self care 2010 lt br gt investigated chronic obstructive pulmonary disease copd effective local vaginal tablet infection fluor vaginalis bacterial vaginosis aerobic vaginitis vulvo vaginal candidiasis trichomoniasis topical antimicrobial agent primary popular claim made enhances exercise athletic performance refuted available research data there some preliminary evidence some neurorestorative anti inflammatory immunomodulatory cardioprotective effect help relieve symptom chronic obstructive pulmonary disorder copd bronchiectasis alkalinizing agent potential menstrual cycle related mastalgia fibrocystic breast disease breast disease gynecomastia keloid scarring rheumatoid arthritis oxacephem antibiotic usually grouped cephalosporin bacterial infection primarily condition like bone joint infection gi infection gynecological infection meningitis respiratory tract infection septicaemia skin infection soft tissue infection uti pigmenting photosensitizing agent conjunction ultraviolet light vitiligo conditioning prior allogeneic autologous haematopoietic progenitor cell transplantation hpct haematological disease paediatric high dose chemotherapy hpct support appropriate solid tumour paediatric test determine general health unborn fetus estropipate moderate severe vasomotor symptom monopause moderate severe symptom vulval vaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure prevent postmenopausal osteoporosis hormone replacement therapy treating symptom menopause hot flash breast prostate cancer broad spectrum antimicrobial fluoroquinolone bacterial infection animal investigated cancer contrast agent cholecystography intravenous cholangiography osteoarthritis pain symptomatic osteoarthritis primary dysmenorrhoea adolescent adult above 12 old human sleeping sickness onchocerciasis disease trypanosomes worm various topical fungal infection athlete foot tinea pedis investigated prostate cancer psoriasis hyperparathyroidism topical antifungal past powerful painkiller fever reducer depression originally intended tuberculosis over century laxative mild severe pain hypertension depression insomnia sedative muscle relaxant anaesthesia aid enable endotracheal intubation experienced infected only ccr5 tropic hiv detectable evidence viral replication hiv strain resistant multiple antiretroviral agent depression dry cough various blood vessel disease e g claudication arteriosclerosis raynaud disease nighttime leg cramp palliative advanced prostatic carcinoma moderate severe hypertension either alone adjunct renal hypertension prophylaxis migraine occlusive peripheral vascular disease vertigo central peripheral origin adjuvant therapy epilepsy schizophrenia adjunctive therapy peptic ulcer shown effective contributing healing peptic ulcer decreasing rate recurrence preventing complication hyperkinetic movement disorder like chorea huntington disease hemiballismus senile chorea tourette syndrome tic disorder tardive dyskinesia investigated breast cancer head neck cancer melanoma lung cancer lymphoma non hodgkin prostate cancer renal cell carcinoma cancer tumor unspecified mild moderate hypertension effort induced angina pectoris clinical development anemia chronic inflammatory disease intended urinary incontinence liver cancer advanced non small cell lung cancer nsclc advanced colorectal cancer crc solid tumor gram positive infection multiresistant strain administered intravenously dicitrate cancer chemotherapy agent atherosclerosis cardiac pharmacologic stress spect imaging diagnose coronary artery disease hyperuricemia gout atrial fibrillation af sinus rhythm history paroxysmal persistent af reduce risk hospitalization irritable bowel syndrome ibs gastroesophageal reflux disease gerd parkinson disease head neck cancer dementia subject alzheimer disease hepatitis c hypertension a2762 a182579 hepatitis c virus hcv infection unstable angina investigated alzheimer disease intolerant resistant two more tyrosine kinase inhibitor accelerated chronic phase cml scleroderma cancer restenosis pancreatic cancer appetite disorder potential various leukemia chronic myeloid leukemia cml migraine headache obesity obesity adjunct reduced calorie diet increased physical activity potential therapy schizophrenia depression visceral pain atrial fibrillation irritable bowel syndrome ibs solid tumor rheumatoid arthritis ra reduce hyperglycemia type diabetes mellitus malaria under investigation modulation multidrug resistance cancer cell diabetes specifically lowering post prandial blood glucose level thereby reducing risk macrovascular complication first second line chemotherapy metastatic colorectal cancer non small cell lung cancer nsclc congestive heart failure solid tumor clinical study shown activity subject colorectal cancer esophageal cancer solid tumor congestive heart failure hypertension premature ejaculation symptom irritable bowel syndrome hiv infection aid hiv infection antiretroviral agent being evaluated schizophrenia psychosis parkinson disease pain symptomatic itchy eye ige induced mast cell degranulation allergic conjunctivitis topical psoriasis psoriatic disorder alzheimer disease ad solid tumor esophageal variceal bleeding cirrhotic liver disease shown efficacy aid related diarrhea neovascular wet age related macular degeneration selective serotonin norepinephrine reuptake inhibitor snri fibromyalgia 18 old above f3925 while major depressive disorder mdd only recommended 18 old above f3922 increased risk suicidal ideation thinking behavior child adolescent young adult taking antidepressant major depressive disorder mdd psychiatric disorder some regional prescribing information note medication specifically short term symptomatic relief mdd f3919 nevertheless important note regulatory approval indication listed here may exist vary greatly between region nation f3928 f3934 intended prevention respiratory distress syndrome rds premature infant high risk rds deep vein thrombosis intravenous acutely decompensated congestive heart failure dyspnea rest minimal activity adjuvant influenza vaccine elderly adjuvant both influenza hepatitis b vaccine chronic hemodialysis failed achieve adequate antibody titer from previous immunization investigated lymphoma non hodgkin psoriasis psoriatic disorder bone metastasis multiple myeloma prostate cancer rheumatoid arthritis potential panic anxiety disorder intended cervical dysplasia human papillomavirus hpv intended various form cancer intended brain cancer hypoactive sexual desire disorder hsdd premenopausal woman investigated infectious parasitic disease unspecified investigated infectious parasitic disease unspecified pediatric indication bacterial skin skin structure subcutaneous infection confirmed suspected infection designated susceptible gram positive organism antimicrobial susceptibility pattern geographically distinct local antibiograms should consulted ensure adequate coverage relevant pathogen prior investigated liver disease metabolic disease pediatric indication intended various form cancer intended various form cancer constipation predominant irritable bowel syndrome ibs c serious bacterial infection hospitalised being evaluated potential ischemic stroke catheter occlusion co peripheral arterial occlusion pao reduction blood pressure when oral antihypertensive therapy feasible desirable multiple sclerosis m investigated blood blood forming organ disorder unspecified hemorrhage investigated gastrointestinal disease disorder miscellaneous investigated cerebral ischemia stroke investigated alzheimer disease hearing loss pain chronic investigated menstrual disorder investigated heart disease myocardial infarction infestation sarcoptes scabiei scabies prevention phototoxicity erythropoietic protoporphyria epp severe hepatic veno occlusive disease vod known sinusoidal obstruction syndrome so renal pulmonary dysfunction following hematopoietic stem cell transplantation hsct investigated sepsis septicemia investigated atherosclerosis bacterial infection peripheral vascular disease intended therapeutic adjunct type ii diabetes moderate dyspareunia symptom vulvar vaginal atrophy menopause symptomatic non infectious diarrhea hiv aid taking antiretroviral therapy investigated leukemia unspecified investigated eye disorder infection transplant rejection investigated cardiac reperfusion injury cardiovascular disorder coronary artery disease investigated blood blood forming organ disorder unspecified hemorrhage schizophrenia investigated attention deficit hyperactivity disorder adhd parkinson disease pediatric indication mitigation symptom withdrawal from opioids facilitation completion opioid discontinuation first non opioid medication symptomatic opioid discontinuation opioid withdrawal syndrome debilitating manifestation opioid dependence a33085 condition extremely unpleasant lasting several day some main feature being abdominal pain nausea diarrhea mydriasis lacrimation piloerection these symptom often observed after abrupt reduction opioid dose resolved re administration opioid a33088 inflammation during cardiac surgery various form cancer idiopathic pulmonary fibrosis ipf bacterial infection adjuvant partial onset seizure investigated arrhythmia atrial fibrillation investigated asthma lung injury surgical adhesion investigated sepsis septicemia investigated arrhythmia atrial fibrillation investigated leukemia lymphoid lymphoma non hodgkin systemic lupus erythematosus investigated anal dysplasia cervical dysplasia cancer genital wart hiv infection infectious parasitic disease unspecified pediatric indication wart viral infection investigated colorectal cancer leukemia myeloid pancreatic cancer solid tumor investigated leukemia myeloid investigated lymphoma non hodgkin investigated diabetes mellitus type investigated ovarian cancer intended radiation sensitizer brain cancer intended social phobia intended various form cancer intended anxiety disorder diabetes mellitus type intended various form cancer intended various form cancer investigated bone marrow transplant graft versus host disease various form cancer intended pain possibly various form cancer intended various form cancer intended carcinoma oesophagus intended benign prostatic hyperplasia prostrate disorder intended various form cancer epilepsy inhaled cystic fibrosis late stage hormone refractory prostate cancer hrpc no effective therapy currently exists various form cancer potential cystic fibrosis bacterial infection intended various form cancer production immunity salmonella typhi cause typhoid fever diabetes clinically significant proteinuria various form cancer investigated pain chronic investigated lung cancer prostate cancer solid tumor investigated asthma multiple sclerosis investigated cancer tumor unspecified kidney cancer leukemia myeloid pancreatic cancer investigated liver cancer investigated pain chronic investigated diabetes mellitus type investigated melanoma multiple myeloma ovarian cancer pancreatic cancer solid tumor investigated metabolic disease obesity investigated breast cancer prostate cancer investigated cardiovascular disorder inflammatory disorder unspecified investigated alzheimer disease attention deficit hyperactivity disorder adhd memory loss schizophrenia schizoaffective disorder investigated cardiovascular disorder kidney disease chronic cancer pain topical actinic keratosis investigated cancer tumor unspecified lung cancer solid tumor relapsed refractory peripheral t cell lymphoma ptcl manageable safety profile potential alternative therapy did experience adequate response first line drug ptcl baseline thrombocytopenia a19161 approved european medicine agency duchenne muscular dystrophy aged 5 older able walk more specifically small group whose disease specific genetic defect called nonsense mutation dystrophin gene investigated crohn disease psoriasis psoriatic disorder rheumatoid arthritis alpha galactosidase alpha gal pharmacological chaperone long term adult adolescent aged 16 older confirmed diagnosis fabry disease alpha galactosidase deficiency amenable galactosidase alpha gene gla mutation variant based upon vitro assay data fda f1107 indication approved u fda under accelerated approval based reduction kidney interstitial capillary cell globotriaosylceramide kic gl 3 substrate fda continued approval u fda indication contingent upon verification description clinical benefit ongoing confirmatory trial fda investigated viral infection investigated hepatitis viral b investigated hepatitis viral c investigated breast cancer ovarian cancer prostate cancer investigated psoriasis psoriatic disorder investigated kidney disease psoriasis psoriatic disorder investigated amyotrophic lateral sclerosis al diabetes mellitus type neurologic disorder neuropathy diabetic investigated peripheral vascular disease investigated cystic fibrosis eye disorder infection investigated allergic reaction allergic rhinitis cataract investigated breast cancer investigated congestive heart failure investigated hyperlipidemia metabolic disease obesity investigated leukemia lymphoid solid tumor investigated traumatic brain injury long term once daily dosing maintenance airflow obstruction chronic obstructive pulmonary disease copd chronic bronchitis emphysema investigated viral infection investigated neurologic disorder schizophrenia schizoaffective disorder investigated asthma chronic obstructive pulmonary disease copd investigated diabetes mellitus type investigated obesity investigated pain chronic investigated attention deficit hyperactivity disorder adhd alzheimer disease investigated pain chronic investigated constipation gastroesophageal reflux disease gerd gastrointestinal disease disorder miscellaneous irritable bowel syndrome ibs investigated pain chronic investigated breast cancer investigated hormone replacement therapy menopause menopause investigated diabetes mellitus type investigated acne atopic dermatitis pediatric indication psoriasis psoriatic disorder investigated bipolar disorder manic disorder investigated crohn disease hepatitis unspecified liver disease fro chronic bronchitis adult investigated kidney disease investigated hepatitis viral c investigated cardiovascular disorder hyperlipidemia investigated hepatitis viral c parkinson disease investigated diabetes mellitus type diabetes prevention investigated diabetic foot ulcer wound investigated macular degeneration investigated anxiety disorder gastroesophageal reflux disease gerd migraine cluster headache investigated diarrhea infectious parasitic disease unspecified investigated anxiety disorder irritable bowel syndrome ibs urinary incontinence investigated macular degeneration investigated macular degeneration investigated obesity investigated asthma investigated insomnia investigated adverse effect drug hyperlipidemia obesity investigated psoriasis psoriatic disorder skin infection disorder investigated growth hormone deficiency abnormality investigated postmenopausal osteoporosis reduce vertebral non vertebral fracture investigated schizophrenia schizoaffective disorder investigated pediatric indication seizure disorder investigated liver disease pulmonary fibrosis investigated prostate cancer investigated amyotrophic lateral sclerosis al parkinson disease vasopressin regulates renal water resorption through v2 receptor inhibition vasopressin effect v2 receptor enhances water excretion increase urinary output vasopressin antagonis electrolyte sparing aquaretic cause much lower level salt excretion investigated multiple sclerosis investigated cardiovascular disorder stroke investigated depression investigated psychosis schizophrenia schizoaffective disorder humanized monoclonal antibody cancer retrieved from http en wikipedia org wiki investigated lipodystrophy obesity deep vein thrombosis dvt central retinal branch vein thrombosis pripaism pulmonary hypertension embolic origin embolism after insertion prosthetic cardiac valve rethrombosis after thrombolytic therapy rethrombosis after vascular surgery prevention dvt after repair fractured neck femur investigated brain cancer lung cancer prostate cancer investigated cervical dysplasia cancer colorectal cancer gastric cancer lung cancer investigated viral infection investigated liver cancer lung cancer melanoma leukemia lymphoid investigated irritable bowel syndrome ibs investigated upper respiratory infection investigated multiple sclerosis investigated cystic fibrosis hiv infection hepatitis viral b malaria investigated hepatitis viral b advanced soft tissue sarcoma refractory unsuitable receive anthracycline ifosfamide chemotherapy europe russia south korea approved orphan drug status u fda soft tissue sarcoma ovarian cancer investigated cancer tumor unspecified gastric cancer ovarian cancer pediatric indication sarcoma solid tumor investigated hiv infection investigated crohn disease psoriasis psoriatic disorder investigated solid tumor investigated colorectal cancer investigated hepatitis viral c hepatocellular carcinoma investigated diabetes mellitus type investigated colorectal cancer investigated cancer tumor unspecified investigated depression investigated atherosclerosis cardiovascular disorder investigated diabetes mellitus type intended various form cancer investigated rheumatoid arthritis investigated atherosclerosis cardiovascular disorder hyperlipidemia investigated blood blood forming organ disorder unspecified cardiac surgery coronary artery disease investigated multiple sclerosis rheumatoid arthritis investigated amyotrophic lateral sclerosis al investigated hepatitis viral c investigated fungal infection investigated lymphoma non hodgkin investigated inflammatory disorder unspecified investigated blood blood forming organ disorder unspecified cardiac surgery venous thromboembolism investigated depression investigated alzheimer disease inflammatory disorder unspecified investigated leukemia myeloid solid tumor investigated burn burn infection investigated breast cancer cancer tumor unspecified hiv infection hepatitis viral c solid tumor investigated addiction investigated macular degeneration investigated nephropathy investigated solid tumor investigated cancer tumor unspecified solid tumor investigated anxiety disorder depression investigated cancer tumor unspecified investigated malaria investigated diabetes mellitus type investigated solid tumor investigated solid tumor investigated bladder cancer investigated cancer tumor unspecified solid tumor investigated alzheimer disease investigated solid tumor investigated alzheimer disease schizophrenia schizoaffective disorder adult bedaquiline linezolid pulmonary form nonresponsive multidrug resistant mdr extensively drug resistant xdr intolerant form pulmonary tuberculosis tb important note following condition approved indication therapy according fda drug sensitive d tuberculosis latent tuberculosis m tuberculosis extra pulmonary tuberculosis m tuberculosis multidrug resistant tb intolerant nonresponsive conventional tb therapy investigated pain chronic investigated acne actinic keratosis cancer tumor unspecified keratoses skin infection disorder investigated cardiovascular disorder inflammatory bowel disease inflammatory disorder unspecified psoriasis psoriatic disorder rheumatoid arthritis investigated cancer tumor unspecified solid tumor investigated multiple sclerosis neurologic disorder investigated benign prostatic hyperplasia cancer tumor unspecified prostate cancer prostate disorder solid tumor investigated inflammatory disorder unspecified investigated infertility investigated leukemia myeloid investigated cancer tumor unspecified solid tumor investigated diabetes mellitus type investigated hepatitis viral b investigated solid tumor investigated cancer tumor unspecified leukemia myeloid solid tumor investigated cancer tumor unspecified investigated alzheimer disease investigated pain chronic investigated cancer tumor unspecified solid tumor investigated skin infection disorder investigated myocardial infarction investigated parkinson disease investigated parkinson disease investigated alzheimer disease attention deficit hyperactivity disorder adhd dementia neurologic disorder schizophrenia schizoaffective disorder investigated viral infection investigated kidney cancer melanoma investigated inflammatory disorder unspecified investigated leukemia lymphoid leukemia myeloid investigated neurologic disorder investigated bacterial infection infectious parasitic disease unspecified tuberculosis investigated atherosclerosis diabetes mellitus type investigated metabolic disease obesity investigated cancer tumor unspecified investigated solid tumor investigated inflammatory disorder unspecified investigated hyperlipidemia investigated rheumatoid arthritis investigated asthma chronic obstructive pulmonary disease copd investigated affective disorder bipolar disorder psychosis investigated gastroenteritis ulcer advanced solid tumorsirritable bowel syndrome ibs gastrointestinal disorderspompe disease known glycogen storage disease type ii acid maltase deficiency relatively rare neuromuscular lysosomal storage disorder inherited genetic mutation key enzyme called  glucosidase gaa obesity related disorder cardiovascular disease type ii diabetesplatelet aggregation thrombosis coronary syndromesinvestigated hypertension canceranxiety disorder i depression icentral nervous system neuropathic pain investigated thrombocytopenia various form cancer inflammatory disease rheumatoid arthritis type diabetes pain intended solid tumor lymphoma intended auto immune disease rheumatoid arthritis psoriasis crohn disease intended topical mild moderate atopic dermatitis age older various form cancer infection multi drug resistant lt em gt pseudomonas aeruginosa lt em gt various form cancer bacterial infection susceptible microorganism staphylococcus aureus methicillin resistant aureus mrsa streptococcus pyogenes asthma cardiovascular disease respiratory syncytial virus infection prophylaxis arterial thrombosis hiv infection appropriate antiretroviral agent therapy warranted pulmonary hypertension atherosclerosis condition related obstruction blood vessel chronic breakthrough pain advanced cancer well opioid dependence female contraceptive prevention osteoporosis hypothyroidism stroke investigated immunodeficiency infectious parasitic disease unspecified unresectable metastatic melanoma braf v600e v600k mutation vemurafenib braf inhibitor various form cancer investigated hepatitis viral b various form cancer non hodgkin lymphoma bone metastasis paget disease osteoporosisindicated adjunct prevention wound sepsis second third degree burn control absence petit mal seizure refractory drug b cell non hodgkin lymphomachronic angina coronary artery disease for uterine fibroid endometriosis assist healing minor burn superficial wound ulcer surgical wound superficial hematoma post menopausal woman osteoporosisinvestigated pain chronic investigated hepatitis viral c leukemia lymphoid leukemia myeloid leukemia unspecified melanoma reduction frequency relapse relapsing remitting multiple sclerosis hypercalcemia intended non hodgkin lymphoma intended congestive heart failure hyperuricemia alzheimer diseaseatopic dermatitisfor reflux oesophagitis peptic ulcer disease multiple sclerosis asthma cerebrovascular disease various eye diseasesfor neurologic disorder parkinson disease well moderate severe primary restless leg syndrome investigated bone metastasis multiple myeloma prostate cancer rheumatoid arthritis investigated hepatitis viral b liver transplant surgery pediatric indication bladder cancerlung cancer melanoma investigated glaucoma macular degeneration investigated alzheimer disease prostate cancer investigated cardiovascular disorder neuropathy diabetic ovarian cancerinvestigated bladder cancer currently approved alternative local therapy both unresectable disseminated disease because prolong q t interval contraindicated serious cardiac complication congenital long qt syndrome uncompensated heart failure investigated osteoporosis investigated brain cancer breast cancer cervical dysplasia cancer prostate cancer cancer tumor unspecified coronary artery disease macular degeneration peripheral vascular disease investigated breast cancer colorectal cancer gastric cancer kidney cancer lung cancer pancreatic cancer prostate cancer skin cancer investigated ulcerative colitis investigated bladder cancer solid tumor investigated addiction osteoarthritis pain chronic investigated depression huntington disease investigated inflammatory disorder unspecified knee replacement orthopedic surgery pain chronic investigated gall bladder cancer renal cell carcinoma investigated brain cancer investigated angina coronary artery disease heart disease investigated breast cancer colorectal cancer gall bladder cancer pancreatic cancer investigated bone fracture diabetic foot ulcer wound investigated endometriosis symptomatic attack hereditary angioedema hae 12 age older fda investigated autoimmune disease rheumatoid arthritis investigated hemorrhage transfusion investigated coronary artery disease investigated neurologic disorder parkinson disease psychosis schizophrenia schizoaffective disorder sleep disorder investigated hyperlipidemia investigated bladder cancer head neck cancer investigated immunosuppressive transplant rejection investigated hyperuricemia investigated bladder cancer brain cancer breast cancer esophageal cancer head neck cancer lung cancer oral cavity cancer ovarian cancer prostate cancer investigated breast cancer head neck cancer lung cancer investigated gastrointestinal disease disorder miscellaneous investigated neuropathy diabetic investigated hiv infection investigated melanoma investigated cystic fibrosis pancreatic disorder chronic immune thrombocytopenic purpura investigated attention deficit hyperactivity disorder adhd neurologic disorder tourette syndrome investigated anthrax exposure bacterial infection crohn disease graft versus host disease investigated brain cancer investigated anxiety disorder depression insomnia neurologic disorder investigated inflammatory bowel disease ulcerative colitis investigated cerebral ischemia investigated eye disorder infection macular degeneration retinal disorder unspecified investigated insomnia investigated osteoarthritis pain chronic healing all grade erosive esophagitis ee maintaining healing ee relief heartburn treating heartburn symptomatic non erosive gastroesophageal reflux disease gerd investigated amyloidosis investigated liver cancer investigated cardiovascular disorder thrombosis venous thromboembolism investigated thrombosis venous thromboembolism investigated bipolar disorder investigated pain chronic investigated cardiovascular disorder hypertension pulmonary hypertension investigated allergic reaction investigated pain chronic investigated huntington disease schizophrenia schizoaffective disorder investigated brain cancer investigated fungal infection investigated multiple myeloma phosphate diagnostic aid evaluation gastric acid secretory function investigated breast disorder unspecified pain chronic investigated diabetic kidney disease investigated contraception hiv prevention investigated hiv prevention prevention stdis vaginal infection investigated adverse effect chemotherapy bone marrow transplant investigated kidney cancer lung cancer macular degeneration multiple myeloma prostate cancer psoriasis psoriatic disorder investigated acquired immune deficiency syndrome aid aid related infection cancer tumor unspecified hiv infection inflammatory disorder unspecified investigated lung cancer investigated neuropathy diabetic peripheral vascular disease investigated breast cancer lung cancer ovarian cancer investigated brain cancer neurologic disorder investigated depression irritable bowel syndrome ibs obesity investigated hepatitis viral c investigated contraception hiv infection prevention stdis investigated atherosclerosis coronary artery disease diabetes mellitus type stent restenosis investigated genital herpes hiv infection hepatitis viral b influenza malaria melanoma viral infection investigated asthma parkinson disease investigated gastroesophageal reflux disease gerd investigated hepatitis viral b investigated prostate cancer solid tumor investigated congestive heart failure hypertension pulmonary hypertension investigated hepatitis viral c liver disease transplantation organ tissue investigated pain chronic investigated atopic dermatitis investigated cancer tumor unspecified investigated pain chronic rheumatoid arthritis investigated acquired immune deficiency syndrome aid aid related infection hiv infection investigated breast cancer investigated crohn disease inflammatory bowel disease kidney cancer leukemia lymphoid prostate cancer investigated hyperlipidemia investigated tobacco dependence investigated adverse effect chemotherapy anxiety disorder depression gastrointestinal disease disorder miscellaneous investigated sleep disorder smoking cessation substance abuse investigated bladder cancer lymphoma unspecified multiple myeloma paget disease prostate cancer investigated asthma depression irritable bowel syndrome ibs investigated bulimia depression obsessive compulsive disorder investigated depression investigated breast cancer lung cancer investigated adverse effect chemotherapy cancer tumor unspecified diabetic foot ulcer lung cancer solid tumor ulcer investigated melanoma investigated brain cancer cancer tumor unspecified lung cancer lymphoma non hodgkin investigated allergic rhinitis investigated peripheral vascular disease investigated asthma chronic obstructive pulmonary disease copd investigated addiction dementia parkinson disease schizophrenia schizoaffective disorder stroke investigated congestive heart failure diabetes mellitus type investigated lymphoma unspecified melanoma solid tumor investigated colorectal cancer solid tumor investigated leukemia lymphoid investigated prostate cancer investigated asthma atopic dermatitis pediatric atopic dermatitis indication investigated asthma atopic dermatitis investigated asthma crohn disease investigated pain chronic rheumatoid arthritis trial being conducted relieving burn pain dermal itch investigated atherosclerosis vascular disease cardioprotective agent suggested prevention early restenosis following vascular surgery balloon angioplasty investigated tobacco dependence investigated autoimmune disease stroke thrombosis investigated adverse effect chemotherapy adverse effect drug investigated cancer tumor unspecified gastric cancer pancreatic cancer investigated hyperlipidemia cancer tumor unspecified monotherapy recommended people marginally high ldl cholesterol can not prescribed statin drug interaction safety concern therapy recommended if statin therapy alone either insufficient achieve guideline set ncep there concern over side effect statin dos lowered without losing efficacy investigated alzheimer disease parkinson disease neurodegenerative disease investigated cancer tumor unspecified crohn disease inflammatory bowel disease osteoarthritis ulcerative colitis investigated anorexia condition causing harmful weight loss manufacturer suggests could relevant weight loss symptom i e lack energy decrease appetite physical wasting vulnerability toxicity sometimes reduced life expectancy eating disorder advanced cancer aid experiencing loss appetite aging illness pregnancy investigated alzheimer disease parkinson disease investigated cardiovascular disorder syndrome inappropriate secretion anti diuretic hormone siadh hyponatremia investigated atherosclerosis coronary artery disease vascular disease investigated gastric cancer investigated alzheimer disease attention deficit hyperactivity disorder adhd schizophrenia schizoaffective disorder investigated autoimmune disease crohn disease multiple sclerosis psoriasis psoriatic disorder rheumatoid arthritis investigated myelodysplastic syndrome investigated peripheral vascular disease raynaud disease investigated various form brain cancer malignant glioma glioblastoma multiforme gbm anaplastic astrocytoma oligo astrocytoma gliosarcomainvestigated colorectal cancer hepatitis viral b lymphoma non hodgkin i 1018 currently being investigated hbsag vaccine prophylactic prevent hepatitis b adult investigated rituximab b cell non hodgkin lymphoma investigated diabetes mellitus type investigated leukemia myeloid investigated depression anxiety investigated emphysema investigated asthma investigated urinary incontinence investigated coronary artery disease inflammatory disorder unspecified rheumatoid arthritis investigated autoimmune disease cancer tumor unspecified lymphoma non hodgkin lymphoma unspecified investigated hepatitis viral c investigated saliva salivary gland dysfunction sialorrhea investigated inflammatory disorder rheumatoid arthritis inflammatory bowel disease psoriasis investigated hepatitis viral c infectious parasitic disease unspecified tuberculosis investigated solid tumor investigated cancer tumor unspecified ovarian cancer investigated prodrug hepsera treating hepatitis viral b investigated candidiasis vaginitis investigated adverse effect chemotherapy anemia chemotherapy investigated alpha antitrypsin deficiency atopic dermatitis chronic obstructive pulmonary disease copd investigated colorectal cancer investigated acne herpes labialis infection cold sore venereal disease investigated autoimmune disease inflammatory disorder unspecified investigated breast cancer cancer tumor unspecified melanoma ovarian cancer solid tumor investigated brain cancer breast cancer investigated infectious parasitic disease unspecified investigated ovarian cancer investigated diabetes mellitus type investigated brain cancer cancer tumor unspecified investigated neuropathy diabetic pain chronic investigated benign prostatic hyperplasia investigated leukemia unspecified melanoma investigated osteoarthritis investigated diabetes mellitus type pediatric indication psoriasis psoriatic disorder investigated urinary incontinence investigated neuropathy diabetic investigated cancer tumor unspecified leukemia unspecified lymphoma unspecified multiple myeloma pancreatic cancer investigated hiv infection investigated leukemia myeloid investigated peripheral vascular disease investigated diabetes mellitus type investigated inflammatory disorder unspecified psoriasis psoriatic disorder investigated premature ejaculation investigated cancer tumor unspecified eye disorder infection psoriasis psoriatic disorder rheumatoid arthritis fite biopharma reported targeting adenosine a3 receptor cf101 crohn disease serious gastrointestinal disorder investigated autoimmune disease psoriasis psoriatic disorder rheumatoid arthritis investigated cancer tumor unspecified multiple myeloma rheumatoid arthritis investigated cystic fibrosis investigated autoimmune disease skin infection disorder investigated diabetes mellitus type investigated arrhythmia atrial fibrillation investigated alzheimer disease db00811 db00008 db00022 chronic hcv genotype infection adult fda investigated colorectal cancer lung cancer investigated peripheral vascular disease homozygous familial hypercholesterolemia adjunct diet lipid lowering medication investigated hepatitis viral c viral infection investigated actinic keratosis breast cancer liver cancer melanoma psoriasis psoriatic disorder solid tumor investigated hiv infection investigated neuropathy diabetic investigated brain cancer cancer tumor unspecified adjunctive therapy partial onset seizure 16 age older investigated gastroesophageal reflux disease gerd gastroparesis investigated osteoarthritis rheumatoid arthritis investigated brain cancer cardiovascular disorder myocardial infarction investigated lymphoma unspecified investigated angioedema myocardial infarction investigated cardiac surgery coronary artery disease thrombosis transfusion investigated asthma investigated atopic dermatitis inflammatory disorder unspecified skin infection disorder investigated myocardial infarction investigated anxiety disorder depression investigated alzheimer disease investigated solid tumor advanced gastric gastro esophageal junction adenocarcinoma single agent paclitaxel after prior fluoropyrimidine platinum containing chemotherapy investigated lymphoma unspecified rheumatoid arthritis investigated spinal cord injury investigated brain cancer lung cancer melanoma solid tumor investigated alzheimer disease neurologic disorder schizophrenia schizoaffective disorder investigated asthma labor delivery investigated breast cancer investigated gastric cancer investigated ovarian cancer investigated alzheimer disease memory loss investigated coronary artery disease peripheral vascular disease investigated leukemia lymphoid investigated chronic obstructive pulmonary disease copd pulmonary hypertension investigated breast cancer leukemia unspecified lung cancer solid tumor investigated crohn disease psoriasis psoriatic disorder investigated inflammatory disorder unspecified psoriasis psoriatic disorder rheumatoid arthritis investigated hepatitis viral c investigated benign prostatic hyperplasia endometriosis prostate cancer investigated cancer tumor unspecified lung cancer sarcoma investigated gastric cancer lung cancer multiple myeloma various type protozoal infection called leishmaniasis result from sandfly bite tropical temperate part world investigated cancer tumor unspecified solid tumor investigated cardiovascular disorder diabetes mellitus type investigated neurologic disorder investigated infectious parasitic disease unspecified viral infection investigated alzheimer disease depression diarrhea gastrointestinal disease disorder miscellaneous irritable bowel syndrome ibs investigated cancer tumor unspecified head neck cancer solid tumor investigated hiv infection investigated autoimmune disease diabetes mellitus type gastrointestinal disease disorder miscellaneous investigated stroke investigated cataract eye disorder infection glaucoma macular degeneration investigated psoriasis psoriatic disorder investigated adverse effect chemotherapy blood blood forming organ disorder unspecified investigated lymphoma non hodgkin investigated bacterial infection bronchitis otitis medium pediatric indication investigated hearing loss investigated eye disorder infection investigated diabetes mellitus type investigated cancer tumor unspecified lymphoma unspecified sarcoma investigated adverse effect chemotherapy investigated periodontal disease investigated cardiovascular disorder thrombosis treating active psoriatic arthritis adult treating active moderate severe psoriatic arthritis eligible phototherapy systemic addition now oral ulcer behcet disease adult investigated hyperlipidemia moderate severe plaque psoriasis child aged 6 above adolescent adult candidate phototherapy systemic therapy active psoriatic arthritis adult alone methotrexate moderately severely active crohn disease adult were clinically unresponsive intolerant immunomodulator corticosteroid therapy but never failed tutor necrosis factor tnf blocker one more tnf blocker moderately severely active ulcerative colitis adult investigated actinic keratosis skin infection disorder investigated cardiac ischemia investigated cardiac reperfusion injury myocardial infarction investigated cervical dysplasia cancer genital wart skin cancer investigated schizophrenia schizoaffective disorder investigated periodontal disease rheumatoid arthritis investigated osteoporosis investigated pancreatic cancer investigated amyotrophic lateral sclerosis al investigated breast cancer cancer tumor unspecified investigated alzheimer disease schizophrenia schizoaffective disorder investigated anesthesia unspecified investigated thrombosis investigated thrombosis venous thromboembolism investigated thrombosis investigated adverse effect chemotherapy neutropenics investigated melanoma investigated insomnia investigated lymphoma unspecified macular degeneration prostate cancer solid tumor investigated addiction alcohol dependence investigated pain chronic investigated rheumatoid arthritis investigated osteoporosis investigated bacterial infection skin infection disorder staph bacterial infection investigated osteoporosis investigated atherosclerosis coronary artery disease investigated atopic dermatitis investigated hypertension investigated multiple sclerosis neurologic disorder pain chronic investigated leukemia lymphoid investigated hiv infection investigated rheumatoid arthritis investigated glaucoma ocular hypertension investigated cervical dysplasia cancer viral infection investigated menstrual disorder investigated alzheimer disease obesity schizophrenia schizoaffective disorder investigated allergic reaction asthma investigated chronic obstructive pulmonary disease copd investigated sleep disorder investigated hepatitis viral c leukemia myeloid lymphoma non hodgkin investigated atopic dermatitis investigated candidiasis fungal infection saliva salivary gland dysfunction investigated ocular hypertension investigated psoriasis psoriatic disorder investigated actinic keratosis investigated schizophrenia schizoaffective disorder investigated ulcerative colitis investigated ulcerative colitis investigated hyperlipidemia investigated psoriasis psoriatic disorder investigated rheumatoid arthritis her2 positive metastatic breast cancer already taxane trastuzumab metastatic disease had their cancer recur within 6 month adjuvant investigated diabetes mellitus type investigated hepatitis viral c investigated blood preservative blood blood forming organ disorder unspecified sepsis septicemia thrombosis investigated skin infection disorder investigated hepatitis viral c investigated solid tumor investigated cancer tumor unspecified investigated brain cancer breast cancer endometrial cancer liver cancer lung cancer ovarian cancer pancreatic cancer pediatric indication prostate cancer sarcoma investigated colorectal cancer melanoma prostate cancer psoriasis psoriatic disorder rheumatoid arthritis solid tumor investigated cervical dysplasia cancer investigated asthma inflammatory bowel disease investigated cardiac surgery hemorrhage ileus investigated cancer tumor unspecified immunosuppressive prostate cancer investigated acquired immune deficiency syndrome aid aid related infection hiv infection pediatric indication investigated cardiovascular disorder congestive heart failure infertility peripheral vascular disease scleroderma investigated congestive heart failure hypertension investigated allergic reaction investigated solid tumor investigated sepsis septicemia investigated blood blood forming organ disorder unspecified lymphoma unspecified multiple myeloma investigated breast cancer colorectal cancer leukemia myeloid leukemia unspecified myelodysplastic syndrome prostate cancer renal cell carcinoma solid tumor investigated hepatitis viral c investigated asthma burn burn infection investigated addiction attention deficit hyperactivity disorder adhd depression investigated brain cancer lung cancer melanoma investigated hiv infection investigated hepatocellular carcinoma liver cancer melanoma multiple myeloma investigated cervical dysplasia cancer investigated myocardial infarction investigated genital herpes prednisone metastatic castration resistant prostate cancer investigated erectile dysfunction parkinson disease investigated prostate cancer investigated brain cancer cancer tumor unspecified colorectal cancer leukemia lymphoid leukemia myeloid lung cancer myelodysplastic syndrome pediatric indication solid tumor investigated breast cancer colorectal cancer lung cancer investigated diabetes mellitus type pediatric indication investigated stroke traumatic brain injury investigated bipolar disorder epilepsy migraine cluster headache investigated migraine cluster headache neuropathy diabetic pain chronic investigated arthritis arthritic pain inflammatory bowel disease investigated infertility investigated brain cancer investigated psychosis schizophrenia schizoaffective disorder osteoporosis investigated contraception male hormonal deficiency abnormality investigated cancer tumor unspecified investigated alzheimer disease investigated adverse effect chemotherapy head neck cancer investigated anemia sickle cell cancer tumor unspecified investigated genital herpes investigated solid tumor investigated nocturia frequent nighttime urination urinary incontinence investigated cytomegalovirus cmv retinitis hiv infection influenza pneumonia investigated transplant rejection investigated asthma investigated breast cancer solid tumor investigated cardiovascular disorder hypertension investigated skin cancer skin infection disorder investigated alzheimer disease neurologic disorder parkinson disease retinal disorder unspecified investigated autoimmune disease inflammatory disorder unspecified investigated asthma chronic obstructive pulmonary disease copd investigated adverse effect chemotherapy renal cell carcinoma investigated liver disease investigated diabetes mellitus type investigated ulcerative colitis investigated metabolic disease investigated acne investigated liver cancer investigated hepatitis viral c investigated prostate cancer investigated autoimmune disease investigated lymphoma non hodgkin solid tumor investigated diabetic retinopathy scar tissue vitreous hemorrhage investigated hyperlipidemia investigated breast cancer investigated hepatitis viral c investigated burn burn infection cardiac surgery inflammatory disorder unspecified ischemic reperfusion injury sepsis septicemia investigated colorectal cancer pancreatic cancer solid tumor investigated hiv infection investigated infectious parasitic disease unspecified viral infection investigated amyotrophic lateral sclerosis al investigated respiratory distress syndrome ards viral infection investigated rheumatoid arthritis investigated solid tumor investigated alzheimer disease neurologic disorder investigated osteoporosis investigated chronic renal failure parathyroid disorder investigated hepatitis viral c investigated epilepsy investigated solid tumor investigated transplant rejection investigated alzheimer disease depression memory loss neurologic disorder monotherapy adult relapsed refractory cd22 positive b cell precursor lymphoblastic leukaemia all investigated cancer tumor unspecified solid tumor investigated pain chronic investigated obesity investigated solid tumor investigated macular degeneration investigated cancer tumor unspecified investigated alzheimer disease gene therapy investigated cancer tumor unspecified solid tumor investigated solid tumor investigated hepatitis viral c investigated constipation gastrointestinal disease disorder miscellaneous gastroparesis irritable bowel syndrome ibs investigated hiv infection investigated atherosclerosis investigated multiple sclerosis investigated solid tumor investigated muscular dystrophy investigated cancer tumor unspecified investigated macular degeneration investigated urinary incontinence investigated brain cancer investigated parkinson disease investigated multiple myeloma solid tumor investigated breast cancer kidney cancer leukemia myeloid melanoma neuroblastoma ovarian cancer prostate cancer investigated thrombocytopenia investigated cancer tumor unspecified macular degeneration investigated solid tumor investigated adverse effect chemotherapy blood blood forming organ disorder unspecified cancer tumor unspecified neutropenics vascular disease investigated asthma investigated alzheimer disease investigated atherosclerosis currently being investigated number cancer a192858 hiv a3922 recently begun phase ii clinical trial severely ill covid 19 preliminary data show reduction cytokine storm particularly il 6 well normalization cd4 cd8 t cell ratio these result mitigate immune mediate injury seen severely ill covid 19 investigated hepatitis viral c investigated sepsis septicemia investigated cancer tumor unspecified investigated anthrax exposure bacterial infection investigated pain chronic investigated alzheimer disease neurologic disorder pain chronic parkinson disease investigated cancer tumor unspecified solid tumor investigated hiv infection investigated depression investigated breast cancer investigated cancer tumor unspecified liver cancer investigated cancer tumor unspecified solid tumor investigated cancer tumor unspecified leukemia unspecified lymphoma unspecified multiple myeloma solid tumor investigated solid tumor investigated gastrointestinal disease disorder miscellaneous inflammatory bowel disease ulcerative colitis investigated cancer tumor unspecified hemorrhage hypoxia respiratory failure stroke investigated lymphoma unspecified multiple myeloma solid tumor investigated melanoma primary biliary cholangitis ursodeoxycholic acid udca adult inadequate response udca monotherapy adult pbc unable tolerate udca currently being considered fda approval fibrosis non alcoholic liver steatohepatitis nash likely approved indication 2020 investigated cancer tumor unspecified investigated alzheimer disease obesity schizophrenia schizoaffective disorder investigated melanoma investigated cardiovascular disorder coronary artery disease investigated diabetes mellitus type investigated solid tumor certain individual duchenne muscular dystrophy dmd limited those confirmed mutation dmd gene would benefit from exon 51 skipping based clinical study showing increased dystrophin production skeletal muscle some given drug above indication approved under accelerated approval further confirmatory trial required demonstrate clinical benefit atypical antipsychotic schizophrenia manic mixed episode bipolar i disorder investigated cancer tumor unspecified investigated adverse effect chemotherapy neutropenics investigated hiv infection investigated cancer tumor unspecified investigated cancer tumor unspecified doxorubicin advanced mestastatic soft tissue sarcoma sts histologic subtype anthracycline containing regimen appropriate amenable curative radiotherapy surgery investigated traumatic brain injury investigated leukemia myeloid multiple myeloma investigated atrial fibrillation thrombosis investigated hepatitis viral c investigated cancer tumor unspecified investigated acromegaly cancer tumor unspecified investigated ischemic reperfusion injury investigated solid tumor investigated cancer tumor unspecified investigated cancer tumor unspecified investigated alzheimer disease investigated cancer tumor unspecified solid tumor approved schizophrenia adult investigated leukemia myeloid myelodysplastic syndrome solid tumor capacizumab approved adult experiencing episode acquired thrombotic thrombocytopenic purpura attp conjunction plasma exchange immunosuppression 18 older a174634 attp rare autoimmune condition presented disruption blood clotting order translated into systemic microvascular thrombosis leading profound thrombocytopenia hemolytic anemia organ ischemia production autoantibody against adamts 13 protein charge cleaving von wilebrand factor lack process produce generation ultra large von wilebrand multimers bind platelet form microthrombi causing thromboembolic complication a174649 previously capacizumab under review prevention thrombosis high risk coronary syndrome undergoing percutaneous coronary intervention but indication withdrawn a174634 investigated cancer tumor unspecified investigated psoriasis psoriatic disorder investigated bacterial infection investigated epilepsy investigated neurologic disorder investigated solid tumor investigated neurologic disorder investigated cancer tumor unspecified investigated migraine cluster headache investigated cancer tumor unspecified solid tumor investigated solid tumor investigated cancer tumor unspecified investigated autoimmune disease psoriasis psoriatic disorder viral infection investigated dementia investigated schizophrenia schizoaffective disorder investigated diabetes mellitus type investigated asthma cystic fibrosis hiv infection investigated ulcerative colitis investigated parathyroid disorder partial onset seizure adult investigated muscular dystrophy investigated diabetes mellitus type investigated cancer tumor unspecified lung cancer investigated lymphoma non hodgkin investigated acne alopecia investigated solid tumor topical actinic keratosis face scalp investigated cancer tumor unspecified investigated neurologic disorder schizophrenia macrolide antibiotic various infection effective against wide range gram positive gram negative pathogenic microorganism although no longer human cattle depression bacterial infection susceptible microorganism infection mainly mucolytic paracetamol acetaminophen overdose mainly condition like arteriosclerosis cerebrovascular disease peripheral vascular disease raynaud disease thrombo angitis obliterans thrombophlebitis sometimes peripheral vascular disorder addition premature labor however drug approved premature labor a32531 prophylactic migraine angina pectoris conjunction diet exercise body mass index greater than 30 kg m lt sup gt lt sup gt wih bmi greater than 27 kg m lt sup gt lt sup gt risk factor type diabetes dyslipidaemia investigated alzheimer disease parkinson disease obesity investigated heart disease investigated pancreatic cancer leukemia unspecified melanoma ovarian cancer cancer tumor unspecified investigated bacterial infection investigated crohn disease congenital anomaly unspecified cardiovascular disorder pediatric indication burn burn infection investigated asthma leukemia lymphoid investigated pancreatic cancer solid tumor gastric cancer lung cancer colorectal cancer investigated hiv infection acquired immune deficiency syndrome aid aid related infection 4 age older familial cold autoinflammatory syndrome fcas muckle well syndrome mws both part cryopyrin periodic syndrome cap well age older systemic juvenile idiopathic arthritis sjia investigated solid tumor investigated brain cancer investigated lymphoma non hodgkin leukemia lymphoid cancer tumor unspecified multiple myeloma cutaneous t cell lymphoma ctcl peripheral t cell lymphoma ptcl received least one prior systemic therapy these indication based response rate clinical benefit improvement overall survival demonstrated investigated pancreatic cancer solid tumor breast cancer colorectal cancer brain cancer lung cancer ovarian cancer sarcoma investigated solid tumor lung cancer leukemia unspecified leukemia lymphoid investigated blood blood forming organ disorder unspecified cancer tumor unspecified solid tumor multiple myeloma liver cancer investigated solid tumor melanoma investigated renal cell carcinoma solid tumor lung cancer investigated lymphoma non hodgkin leukemia lymphoid lung cancer melanoma pancreatic cancer investigated cancer tumor unspecified leukemia myeloid investigated lymphoma non hodgkin leukemia lymphoid unresectable metastatic melanoma adjuvant cutaneous melanoma microsatellite high mismatch repair deficient metastatic colorectal cancer hepatocellular carcinoma nivolumab advanced renal cell carcinoma investigated hepatitis viral b investigated breast cancer lung cancer solid tumor renal cell carcinoma pediatric indication ovarian cancer head neck cancer investigated diabetes mellitus type irritable bowel syndrome ibs urinary incontinence investigated leukemia myeloid myelodysplastic syndrome investigated head neck cancer brain cancer pediatric indication pancreatic cancer lung cancer colorectal cancer currently phase iii investigation relapsed refractory aggressive non hodgkin lymphoma failed two prior line therapy presently no standard therapy exists relapsed refractory nhl after first line therapy initiated most received their lifetime limit doxorubicin further anthracyclines potentially lead anthracycline induced congestive heart failure chf attractive alternative second line agent lack cardiac toxicity phase iii trial pix r ongoing will compare multidrug therapy equivalent regimen diffuse large b cell lymphoma most common type nhl previous study result suggested possibility safe effective doxorubicin naive myocardial strip doxorubicin naive taken up higher degree than myocardial strip doxorubicin exposed once absorbed exhibit redox inactivity 3 dimaleate investigated myelogenous leukemia diffuse large b cell lymphoma follicular lymphoma metastatic breast cancer low grade small lymphocytic lymphoma general metastatic cancer investigated benign prostatic hyperplasia urinary incontinence prostate disorder infertility investigated breast cancer lung cancer lymphoma unspecified multiple myeloma leukemia lymphoid cancer tumor unspecified approved attack hereditary angioedema hae investigated angioedema liver disease burn burn infection investigated asthma psoriasis psoriatic disorder atopic dermatitis inflammatory disorder unspecified chronic obstructive pulmonary disease copd investigated hiv infection investigated prostate cancer cancer tumor unspecified investigated arrhythmia atrial fibrillation angina adjunct therapy seizure lennox gastaut syndrome investigated postmenopausal osteoporosis reduce risk both vertebral novertebral fracture well address postmenopausal condition reduction risk breast cancer vulvar vaginal atrophy vva adjunct diet exercise improve glycemic control adult type diabetes mellitus immediate release formulation relief moderate severe pain long acting formulation serf continuous around clock analgesic relief moderate severe chronic pain neuropathic pain diabetic peripheral neuropathy hyaluronidase subcutaneous fluid administration hydration increasing resorption radiopaque agent subcutaneous urography hyaluronidase multiple route increase dispersion injectable drug reversal neuromuscular blockade induced rocuronium bromide vecuronium bromide adult undergoing surgery symptomatic relief benign prostatic hyperplasia acetylsalicylic acid asa prevent atherothrombotic event coronary syndrome ac managed percutaneous coronary intervention pci unstable angina ua non st elevation myocardial infarction nstemi st elevation myocardial infarction stemi managed pci recommended 75 age greater those weigh lt 60kg history stroke transient ischemic attack increased risk fatal intracranial bleeding thrombopoietin receptor agonist pharmaceutical agent stimulate platelet production bone marrow they differ from previously discussed agent act attempting curtail platelet destruction complicated intra abdominal infection complicated urinary tract infection pyelonephritis designated susceptible bacteria symptomatic resistant fluid restriction euvolemic hypervolemic hyponatremia congestive heart failure siadh cirrhosis diagnostic agent radionuclide myocardial perfusion imaging mpi drug iron deficiency anemia experienced intolerance oral iron experienced unsatisfactory response oral iron chronic kidney disease ckd fda psychosis schizophrenia schizoaffective disorder manic disorder bipolar disorder monotherapy rapid conversion recent onset atrial fibrillation sinus rhythm adult non surgery last le than 7 day duration post cardiac surgery atrial fibrillation lasting le than 3 day duration adjunctive therapy partial onset seizure epilepsy over 17 old injection short term oral therapy feasible injection bacterial skin skin structure infection absssi susceptible isolates following gram positive microorganism staphylococcus aureus methicillin susceptible methicillin resistant strain streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae streptococcus anginosus group streptococcus anginosus streptococcus intermedius streptococcus constellatus enterococcus faecalis vancomycin susceptible strain fda f2356 active against gram negative bacteria therefore therapy clinically if absssi polymicrobial includes suspected documented gram negative pathogen f2356 reduce development drug resistant bacteria maintain effectiveness antibacterial drug should only infection proven strongly suspected susceptible bacteria fda f2356 culture susceptibility information available they should considered selecting modifying antibacterial therapy fda f2356 absence data local epidemiology susceptibility pattern contribute empiric selection therapy fda f2356 investigated crohn disease ulcerative colitis investigated asthma investigated prostate cancer breast cancer prevention venous thromboembolic event vte undergone total hip replacement total knee replacement surgery prevention stroke systemic embolism nonvalvular atrial fibrillation deep vein thrombosis dvt pulmonary embolism pe reduce risk recurrent dvt pe aspirin reducing risk major cardiovascular event chronic coronary artery disease peripheral artery disease lack safety study recommended those under 18 old recommended those severe renal impairment lt 30ml min investigated schizophrenia schizoaffective disorder reduction alcohol consumption alcohol dependence high drinking risk level drl without physical withdrawal symptom do require immediate detoxification complete partial reversal opioid drug effect respiratory depression induced either natural synthetic opioids known suspected opioid overdose fda investigated heart disease myocardial infarction investigated solid tumor sarcoma cancer tumor unspecified endometrial cancer prostate cancer bone metastasis investigated viral infection transplantation organ tissue cytomegalovirus cmv retinitis retinal disorder unspecified investigated solid tumor lung cancer ovarian cancer prostate cancer investigated hepatitis viral b hiv infection erectile dysfunction male investigated cervical dysplasia cancer viral infection vulvar dysplasia carcinoma investigated ovarian cancer lung cancer breast cancer investigated rheumatoid arthritis facial hirsutism excessive hair growth investigated coronary artery disease peripheral vascular disease periodontal disease bone fracture entero related fistula diabetic foot ulcer investigated myocardial infarction investigated adenomatous polyposis coli lung cancer prostate cancer colon polyp barrett esophagus disease pediatric indication investigated alzheimer disease memory loss autism neurologic disorder dementia schizophrenia schizoaffective disorder attention deficit hyperactivity disorder adhd sleep disorder investigated asthma chronic obstructive pulmonary disease copd cystic fibrosis rheumatoid arthritis investigated breast cancer osteoporosis endometrial cancer investigated psoriasis psoriatic disorder hyperlipidemia metabolic disease cancer tumor unspecified obesity investigated inflammatory bowel disease investigated diabetes mellitus type neuropathy diabetic vascular disease incadronate investigated myeloma a14426 a14431 leukemia a14427 cancer a202769 investigated hypercalcemia malignancy a202862 investigated myocardial infarction red blood cell disorder anemia kidney transplant surgery transplant rejection liver transplant surgery ischemic reperfusion injury investigated adverse effect chemotherapy hyperlipidemia autoimmune disease hepatitis viral b investigated neuropathy diabetic wound cystoscopic detection non muscle invasive papillary cancer bladder among suspected known lesion basis prior cystoscopy neurogenic orthostatic hypotension noh various disorder multiple system atrophy familial amyloid polyneuropathy hemodialysis induced hypotension parkinson disease investigated neurologic disorder nephropathy blood blood forming organ disorder unspecified dizzy fainting spell investigated lung cancer a4138 investigated neurologic disorder spinal cord injury muscle spasm back pain multiple sclerosis investigated benign prostatic hyperplasia prostate disorder cancer tumor unspecified investigated erectile dysfunction hypertension investigated pulmonary hypertension connective tissue disease hypertension congestive heart failure investigated hyperlipidemia clinically prophylaxis vascular disease increased risk thrombosis intermittent claudication peripheral arterial occlusive disease post myocardial infarc tion investigated diabetic kidney disease diabetic neuropathy new anti inflammatory property extended venous disease moderate severe rheumatoid arthritis giant cell arteritis polyarticular juvenile idiopathic arthritis systemic juvenile idiopathic arthritis cytokine release syndrome accelerate time upper lower gastrointestinal recovery following partial large small bowel resection surgery primary anastomosis investigated pain chronic investigated pancreatic cancer lung cancer ovarian cancer osteoarthritis investigated anemia sickle cell asthma investigated peripheral vascular disease hyperlipidemia symptom perennial allergic rhinitis uncomplicated skin manifestation chronic idiopathic urticaria over counter variety mild allergy symptom a181748 severe chronic pain refractory treatment whom intrathecal therapy warranted osteoporosis men postmenopausal woman high risk having fracture increase bone mass men primary hypogonadal osteoporosis high risk fracture renal cell carcinoma rcc investigated breast cancer lymphoma unspecified rheumatoid arthritis multiple myeloma investigated schizophrenia schizoaffective disorder mania bipolar disorder depression adult chronic hepatitis c virus hcv infection typically sofosbuvir hcv genotype without cirrhosis compensated cirrhosis peginterferon alfa peg ifn alfa ribavirin rbv hcv genotype 4 without cirrhosis compensated cirrhosis resistance reduced susceptibility most commonly viral ns3 q80k polymorphism amino acid substitution ns3 position s122 r155 d168 shown reduce susceptibility genotype 1a b improve glycemic control type diabetes mellitus along diet exercise a6757 a6758 investigated thrombosis coronary artery disease vascular disease investigated thrombosis investigated seborrhea fungal infection skin infection disorder onychomycosis investigated rheumatoid arthritis inflammatory disorder unspecified autoimmune disease investigated liver disease investigated cancer tumor unspecified investigated inflammatory disorder unspecified investigated solid tumor investigated solid tumor investigated cancer tumor unspecified investigated cancer tumor unspecified investigated cancer tumor unspecified investigated viral infection pediatric indication investigated atherosclerosis investigated cancer tumor unspecified investigated solid tumor cancer tumor unspecified lenalidomide dexamethasone multiple myeloma received one three prior therapy investigated leukemia myeloid investigated autoimmune disease investigated solid tumor investigated scar tissue investigated lymphoma unspecified lymphoma non hodgkin investigated macular degeneration eye disorder infection investigated gastrointestinal disease disorder miscellaneous autoimmune disease celiac disease investigated cancer tumor unspecified investigated solid tumor investigated obesity diabetes mellitus type investigated cancer tumor unspecified type diabetes mellitus improve glycemic control agent monotherapy investigated diarrhea adverse effect chemotherapy investigated lymphoma non hodgkin thyroid eye disease investigated hypertension investigated inflammatory disorder unspecified investigated solid tumor leukemia myeloid myelodysplastic syndrome cancer tumor unspecified investigated cardiovascular disorder myocardial infarction investigated pain chronic migraine cluster headache investigated cardiac ischemia cardiovascular disorder investigated solid tumor cancer tumor unspecified investigated bacterial infection skin infection disorder obesity liver disease kidney disease pneumonia investigated leukemia lymphoid multiple myeloma lymphoma unspecified investigated prostate cancer investigated cancer tumor unspecified liver cancer gastric cancer leukemia unspecified investigated solid tumor investigated solid tumor cutaneous t cell lymphoma myelodysplastic syndrome leukemia lymphoid intravenous administration trastuzumab docetaxel her2 positive metastatic breast cancer received prior anti her2 therapy chemotherapy metastatic disease trastuzumab chemotherapy neoadjuvant her2 positive locally advanced inflammatory early stage breast cancer part complete regimen adjuvant her2 positive early stage breast cancer high risk recurrence subcutaneous injection trastuzumab hyaluronidase her2 positive breast cancer adult investigated osteoporosis bone metastasis investigated hepatitis viral b investigated lung cancer investigated psoriasis psoriatic disorder transplant rejection graft versus host disease lymphoma unspecified leukemia unspecified currently cryopyrin periodic syndrome 2012 advisory panel fda voted 11 0 against gout investigated menopause female hormonal deficiency abnormality investigated skin infection disorder investigated myocardial infarction heart disease asthma investigated amyotrophic lateral sclerosis al alzheimer disease investigated amputation limb peripheral vascular disease investigated fungal infection bacterial infection skin infection disorder onychomycosis investigated cerebrovascular disease unspecified investigated autoimmune disease systemic lupus erythematosus rheumatoid arthritis multiple myeloma lymphoma non hodgkin leukemia lymphoid investigated kidney cancer melanoma renal cell carcinoma lymphoma unspecified colorectal cancer brain cancer following condition alone conjugated estrogen woman uterus moderate severe vasomotor symptom menopause prevention postmenopausal osteoporosisfor complicated skin skin structure infection csssi gram positive bacteria like methicillin susceptible resistant staphylococcus aureus vancomycin susceptible enterococcus faecalis streptococcus pyogenes streptococcus agalactiae streptococcus anginosus group hospital acquired bacterial pneumonia hap ventilator bacterial pneumonia vap known suspected susceptible isolates staphylococcus aureus methicillin susceptible methicillin resistant aureus idiopathic primary pulmonary arterial hypertension ipah pulmonary arterial hypertension pah connective tissue disease functional class ii iii symptom united state america tadalafil reduce risk disease progression hospitalization worsening pah improve exercise ability c1 esterase inhibitor prophylaxis attack hereditary angioedema least 6 old investigated amyloidosis investigated thrombosis venous thromboembolism stroke heart disease atrial fibrillation investigated hepatitis viral c investigated pain chronic secondary hyperparathyroidism chronic kidney disease dialysis well secondary hyperparathyroidism stage 3 stage 4 chronic kidney disease anemia deficient red cell production acquired aplastic anemia congenital aplastic anemia myelofibrosis hypoplastic anemia administration myelotoxic drug often respond should replace supportive measure transfusion correction iron folic acid vitamin b12 pyridoxine deficiency antibacterial therapy appropriate corticosteroid investigated sleep disorder obstructive sleep apnea schizophrenia schizoaffective disorder depression bipolar disorder adjunct therapy hiv infection resistant therapy nnrti antiretroviral agent prophylaxis therapy prevent respiratory distress syndrome rds premature infant lt 29 week gestational age low lung surfactant high risk rds therapy respiratory distress syndrome infant 72 hour le age rds confirmed clinical radiologic finding requiring endotracheal intubation currently no fda approved indication granted orphan drug designation prophylactic inhalation anthrax 2007 prophylactic both plague yersinia pestis tularemia francisella tularensis 2009 investigated breast cancer leukemia unspecified investigated colorectal cancer inflammatory bowel disease investigated gastroesophageal reflux disease gerd gastroparesis investigated cancer tumor unspecified macular degeneration diabetic retinopathy investigated schizophrenia schizoaffective disorder irritable bowel syndrome ibs chronic obstructive pulmonary disease copd investigated bacterial infection investigated colorectal cancer lung cancer leukemia unspecified gastric cancer investigated bone marrow transplant ulcer inflammatory bowel disease investigated gastrointestinal disease disorder miscellaneous investigated colorectal cancer lung cancer investigated sepsis septicemia pneumonia inhaled surfactant assist removing liquefying removing bronchopulmonary secretion mucus pu administered either through nebulized solution stream oxygen investigated cystic fibrosis pediatric indication investigated fungal infection aspergillosis candidiasis onychomycosis adjunct percutaneous coronary intervention pci reducing risk periprocedural myocardial infarction mi repeat coronary revascularization stent thrombosis st treated p2y12 platelet inhibitor being given glycoprotein iib iiia inhibitor investigated peripheral vascular disease investigated traumatic brain injury neurologic disorder investigated renal cell carcinoma pancreatic cancer melanoma lung cancer investigated migraine cluster headache investigated sepsis septicemia farnesyltransferase inhibitor aged 12 month older body surface area least 0 39 m lt sup gt lt sup gt reduce risk mortality hutchinson gilford progeria syndrome hgps same population processing deficient progeroid laminopathies either involve heterozygous lmna mutation resulting accumulation progerin like protein homozygous compound heterozygous mutation zmpste24 investigated inflammatory disorder unspecified crohn disease rheumatoid arthritis investigated lung cancer investigated breast cancer lung cancer ovarian cancer investigated schizophrenia schizoaffective disorder parkinson disease investigated colorectal cancer prostate cancer schizophrenia schizoaffective disorder psychosis depression lung cancer investigated allergic rhinitis investigated epilepsy huntington disease parkinson disease investigated congestive heart failure chronic obstructive pulmonary disease copd benign prostatic hyperplasia investigated ovarian cancer lung cancer macular degeneration investigated lung cancer melanoma investigated psoriasis psoriatic disorder investigated rheumatoid arthritis investigated dementia alzheimer disease schizophrenia schizoaffective disorder memory loss investigated lymphoma non hodgkin leukemia lymphoid solid tumor investigated cardiac surgery investigated pancreatic cancer prostate cancer leukemia myeloid investigated stroke investigated congestive heart failure investigated angina investigated cancer tumor unspecified colorectal cancer lung cancer investigated thrombocytopenia systemic lupus erythematosus transplant rejection blood blood forming organ disorder unspecified multiple sclerosis investigated parkinson disease investigated head neck cancer investigated alzheimer disease chronic idiopathic constipation cic adult cic one most common chronic functional gastrointestinal disorder worldwide diagnosis agent very hard confirmed if patient experience least two following straining during more than 25 bowel movement lumpy hard stool 25 bowel movement sensation incomplete evacuation more than 25 all bowel movement sensation anorectal blockage obstruction more than 25 bowel movement manual maneuver required more than 25 bowel movement fewer than 3 bowel movement per week investigated immunosuppressive transplant rejection investigated pain chronic investigated cancer tumor unspecified investigated brain cancer lymphoma non hodgkin lung cancer investigated parkinson disease investigated transplant rejection kidney disease rheumatoid arthritis investigated adverse effect chemotherapy investigated endometriosis uterine fibroid investigated psoriasis psoriatic disorder crohn disease investigated hiv prevention investigated hiv infection investigated lung cancer investigated hepatitis viral c investigated coronary artery disease investigated alzheimer disease dementia investigated stroke cerebral ischemia depression investigated asthma allergic rhinitis investigated diabetes mellitus type investigated osteoporosis bone metastasis investigated anxiety disorder investigated interstitial cystitis urinary incontinence investigated rheumatoid arthritis investigated diabetes mellitus type investigated diabetes mellitus type investigated hepatitis viral c investigated alzheimer disease investigated stroke alzheimer disease investigated anxiety disorder investigated genital herpes investigated pneumonia trypanosomiasis malaria hiv infection infectious parasitic disease unspecified investigated diabetes mellitus type investigated thrombocytopenia investigated parkinson disease investigated diabetes mellitus type investigated anxiety disorder depression investigated eye disorder infection cancer tumor unspecified asthma investigated graft versus host disease investigated multiple myeloma breast cancer osteoporosis lung cancer investigated brain cancer pediatric indication investigated cancer tumor unspecified head neck cancer investigated thrombosis deep vein angina coronary artery disease colorectal cancer investigated sleep disorder insomnia investigated anxiety disorder investigated cardiac surgery peripheral vascular disease kidney disease investigated glaucoma cataract investigated congestive heart failure liver disease heart disease investigated fungal infection investigated asthma investigated adverse effect chemotherapy reproductive health infertility investigated hiv infection investigated obesity investigated lung cancer prostate cancer investigated herpes zoster infection viral infection investigated rheumatoid arthritis investigated migraine cluster headache investigated insomnia sleep disorder investigated hepatitis viral c investigated hiv infection investigated irritable bowel syndrome ibs investigated breast cancer renal cell carcinoma prostate cancer lung cancer investigated parkinson disease neurologic disorder investigated obesity investigated gastroparesis irritable bowel syndrome ibs investigated cancer tumor unspecified advanced renal cell cancer advanced soft tissue sarcoma previously treated chemotherapy following infection susceptible isolates designated microorganism investigated melanoma hepatocellular carcinoma major depressive episode adult investigated high risk myeloid leukemia aml flt3 mutation positive agressive systemic mastocytosis asm systemic mastocytosis hematological neoplasm sm ahn mast cell leukemia mcl investigated endometriosis investigated solid tumor investigated cancer tumor unspecified investigated bacterial infection pneumonia add maintenance severe asthma aged 18 older eosinophilic phenotype multiple myeloma dexamethasone bortezomib received previous regimen bortezomib immunomodulatory agent indication approved accelerated approval based progression free survival february 23 2015 investigated hypertension reducing risk stroke systemic embolism nonvalvular atrial fibrillation prophylaxis deep vein thrombosis dvt leading pulmonary embolism pe after hip knee replacement surgery dvt pe reduce risk recurrence a177565 a6897 investigated diabetes mellitus type malignant ascites tumour via intraperitoneal infusion where standard therapy available feasible fda prevention relapse vivax malaria 16 older vivax malaria a35671 malaria disease remains occur many tropical country vivax malaria plasmodium vivax known le virulent seldom cause death however cause substantive illness related burden endemic area known present dormant form hepatocytes named hypnozoites remain dormant week even month dormant form produce ongoing relapse a35671 investigated atrial fibrillation cardiovascular disorder thrombosis venous thromboembolism investigated bacterial infection rosacea investigated rheumatoid arthritis anti il 5 igg1 kappa monoclonal antibody add maintenance aged six older severe eosinophilic asthma eosinophilic granulomatosis polyangiitis egpa hypereosinophilic syndrome he aged 12 older whom eosinophilia present least six month without identifiable non hematologic secondary cause uncomplicated influenza 18 older symptomatic no more than two day chronic accelerated blast phase philadelphia chromosome positive ph chronic myelogenous leukemia cml resistance intolerance prior therapy investigated stroke depression investigated hiv infection acquired immune deficiency syndrome aid aid related infection investigated parkinson disease neurologic disorder investigated alzheimer disease investigated fibromyalgia investigated obesity investigated parkinson disease kidney cell cancer investigated pancreatic thyroid cancer investigated prostate cancer investigated hyperlipidemia investigated eye disorder infection investigated urinary incontinence adverse effect chemotherapy investigated thrombosis invasive aspergillosis invasive mucormycosis neurofunctional modifier help improve walking speed multiple sclerosis m investigated leukemia lymphoid investigated male hormonal deficiency abnormality investigated solid tumor multiple myeloma leukemia unspecified lung cancer brain cancer investigated macular degeneration diabetic retinopathy prolia postmenopausal woman osteoporosis high risk fracture reduces incidence vertebral nonvertebral hip fracture prolia increase bone mass woman high risk fracture receiving adjuvant aromatase inhibitor therapy breast cancer men osteoporosis high risk fracture men receiving androgen deprivation therapy nonmetastatic prostate cancer increase bone mass xgeva prevention skeletal related event bone metastasis from solid tumor investigated cachexia anorexia investigated solid tumor renal cell carcinoma melanoma pancreatic cancer lung cancer ovarian cancer investigated pain chronic chlorambucil previously untreated chronic lymphocytic leukemia cll whom fludarabine based therapy considered inappropriate recurrent progressive cll extended complete partial response after least two line therapy recurrent progressive cll cll refractory fludarabine alemtuzumab relapsing form multiple sclerosis active secondary progressive disease clinically isolated syndrome relapsing remitting disease investigated diabetes mellitus type autoimmune disease diabetes mellitus type investigated hiv infection viral infection add levodopa without medicine parkinson disease diet exercise improve glycemic control 10 older type diabetes mellitus reduce risk major adverse cardiovascular event type diabetes mellitus well cardiovascular disease investigated solid tumor cancer tumor unspecified investigated epilepsy investigated macular degeneration investigated depression anxiety disorder investigated kidney disease systemic lupus erythematosus cushing disease specifically those whom pituitary surgery curative option investigated hyponatremia congestive heart failure investigated irritable bowel syndrome ibs diarrhea investigated osteoporosis a19388 investigated sleep disorder insomnia adult i adjunct methotrexate moderate severe active rheumatoid arthritis ra ii old above active psoriatic arthritis psa iii single agent active ankylosing spondylitis methotrexate iv single agent moderate severe ulcerative colitis uc require chronic steroid experienced intolerance only partial response previous medication v active polyarticular juvenile idiopathic arthritis pjia age older investigated stroke investigated insomnia sleep disorder investigated myocardial infarction thrombosis investigated uterine fibroid prophylaxis organ rejection concomitantly basiliximumab induction therapy mycophenolate corticosteriods kidney transplant recepients seropositive epstein barr virus investigated pain chronic inflammatory disorder unspecified osteoarthritis arthritis arthritic pain investigated hepatitis viral b approved major depressive disorder a38477 a177622 investigated multiple sclerosis autologous cellular immunotherapy asymptomatic minimally symptomatic metastatic castrate resistant hormone refractory prostate cancer esophageal varix recently bled prevent rebleeding allergic condition symptomatic relief hypersensitivity reaction pruritic skin disorder prophylactic reduce perioperative blood loss need blood transfusion undergoing cardiopulmonary bypass course coronary artery bypass graft surgery increased risk blood loss blood transfusion therapeutically many side effect treating nasal congestion minor inflammation allergy cold dabigatran prevention venous thromboembolic event undergone elective hip knee replacement surgery based re novate re model re mobilize trial a177463 a6978 a6977 2010 approved u canada prevention stroke systemic embolism atrial fibrillation approval based re ly trial a177463 short term multi resistant bacterial infection methicillin resistant staphylococcus aureus mrsa lumefantrine therapy uncomplicated malaria plasmodium falciparum malaria acquired chloroquine resistant area uncomplicated malaria plasmodium specie identified adult child greater than 5 kg reduction recurrent vertigo episode mnire disease 18 old above degaralix advanced prostate cancer major depressive disorder adult a6990 a6991 adhd ideally conjunction psychological educational behavioral form a177187 overactive bladder symptom urinary frequency urgency urge incontinence diagnostic only adult child age over contrast enhancement during cranial spinal mri contrast enhanced magnetic resonance angiography ce mra particularly suited detection very small lesion visualization tumor do readily take up contrast medium desired agent exclusion demonstration additional pathology influence choice therapy patient suitable perfusion study diagnosis stroke detection focal cerebral ischemia study tumor perfusion detection primary metastatic pheochromocytoma neuroblastoma contrast agent magnetic resonance angiography mra evaluate aortoiliac occlusive disease aiod adult known suspected peripheral vascular disease sympathomimetic drug cause vasoconstriction treating migraine tension headache topical nasal decongestant vasoconstrictor dentistry artemether therapy uncomplicated malaria plasmodium falciparum malaria acquired chloroquine resistant area uncomplicated malaria plasmodium specie identified adult child greater than 5 kg most commonly diagnosing bronchial hyperreactivity using bronchial challenge test anabolic steroid hormone men testosterone deficiency woman breast cancer breast pain swelling pregnancy addition estrogen symptom menopause otc eyedrop ocular vasoconstriction nasal preparation nasal congestion a176558 vasospastic angina chronic stable angina hypertension contraception menopausal hormonal therapy potentially breast cancer inhibitory effect estrone sulfatase they convert sulfated steroid precursor estrogen during pregnancy provide temporary symptomatic relief nasal congestion cold allergy allergic rhinitis oral antithyroid agent prevention radioactive iodine uptake into thyroid gland during nuclear radiation emergency adjunct antithyroid agent hyperthyroidism thyrotoxicosis preoperatively induce thyroid involution monitored anaesthesia care sedation undergoing diagnostic procedure like bronchoscopy colonscopy minor surgical procedure like arthroscopy bunionectomy prevention nausea vomiting highly emetogenic cancer chemotherapy synthetic anabolic steroid therapeutic us treating c1 inhibitor deficient hereditary angioedema c1 inhibitor protease inhibits complement system part innate immune system biochemical chain reaction assist body removing pathogen from body help control attack hereditary angioedema administered orally intramuscularly hormone responsive cancer prostate cancer breast cancer estrogen dependent condition endometriosis uterine fibroid assisted reproduction hydrolytic lysosomal glucocerebroside specific enzyme long term enzyme replacement therapy pediatric type gaucher disease relief heartburn acid indigestion relief heartburn acid indigestion nutritional supplement hypocalcemia mild moderate pain well pain inflammation joint certain type rheumatic disease bacterial infection relief pain inflammation osteoarthritis rheumatoid arthritis ankylosing spondylitis all type severe pain postoperative cancer kidney stone fracture secretolytic therapy bronchoplmonary diseaes abnormal mucus secretion transport allows mucus more easily cleared ease patient breathing functional bowel disorder alleviating pain renal colic development chemonucleolysis digestion nucleus pulposus disc herniation confirmed myelography a32687 disc herniation occurs outer portion spinal disc break down inner portion nucleus pulposus leak out pressing surrounding nerve leading irradiating pain chemonucleolysis non surgical involves injection enzyme dissolve nucleus pulposus prophylaxis post operative deep venous thrombosis dvt lead pulmonary embolism pe undergoing elective hip replacement surgery fda beta carotene fda approved nutrient supplement even added infant formula source vitaminA approved color additive food product drug only color additive cosmetic commonly reduction photosensitivity erythropoietic protoporphyria photosensitivity disease a32485 betaine homocystinuria decrease elevated homocysteine blood level included within category homocystinuria deficiency defect cystathionine beta synthase cbs 5 10 methylenetetrahydrofolate reductase mthfr 3 cobalamin cofactor metabolism cbl supplement intravenous solution given total parenteral nutrition tpn administration help maintain plasma level prevent depletion endogenous store subsequent deficiency symptom local cytomegalovirus cmv retinitis acquired immunodeficiency syndrome aid therapy ineffective considered unsuitable fda congenital sucrose isomaltase deficiency csid prevention respiratory distress syndrome rds premature infant temporary relief discomfort redness eye minor eye irritation prevention itching allergic conjunctivitis expectorant cough syrup ammonium ion nh4 body play important role maintenance acid base balance kidney us ammonium nh4 place sodium na combine fixed anion maintaining acid base balance especially homeostatic compensatory mechanism metabolic acidosis therapeutic effect depend upon ability kidney utilize ammonia excretion excess fixed anion conversion ammonia urea liver thereby liberating hydrogen h chloride cl ion into extracellular fluid injection usp after dilution isotonic sodium chloride injection hypochloremic state metabolic alkalosis dry scaly skin xerosis ichthyosis vulgaris temporary relief itching these condition chronic lymphocytic leukemia cll indolent b cell non hodgkin lymphoma nhl progressed during within six month rituximab rituximab containing regimen ulesfia lotion topical head louse infestation 6 month age older ulesfia lotion doe ovicidal activity bacterial conjunctivitis bacterial isolates susceptible include cdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius hormone refractory metastatic prostate cancer previously treated docetaxel containing regimen paget disease case where salmon calcitonin provoke generation high titer antibody a32100 paget disease metabolic bone disorder characterized focal area increased disorganized bone turnover coupled increased bone formation majority case asymptomatic but some clinical manifestation include pain bone deformity some complication pathological fracture deafness a32105 increased activity bone rise serum level alkaline phosphatase increased urinary excretion hydroxyproline product bone breakdown a32099 8 patch neuropathic pain post herpetic neuralgia there multiple topical formulation available cream solution temporary analgesia muscle join pain well neuropathic pain chronic hyperammonaemia n acetylglutamate synthase nag deficiency enzyme important component urea cycle prevent build up neurotoxic ammonium blood chenodiol radiolucent stone well opacifying gallbladder whom selective surgery would undertaken except presence increased surgical risk systemic disease age chenodiol will dissolve calcified radiopaque radiolucent bile pigment stone elemental copper deficiency copper copper containing compound broadly medical practice metallic copper already many dental filling copper intrauterine device iud reversible contraception ointment containing copper release copper ion absorbed skin cramp disturbance renal function peripheral venous hypostatic circulatory disturbance rheumatic disease swelling trauma there cosmetic facial cream containing copper their main active ingredient prophylaxis deep vein thrombosis pulmonary embolism undergoing general surgery e g abdominal gynecologic urologic medical condition e g cancer bed rest heart failure severe lung disease severely restricted mobility pose risk thromboembolic complication concomitantly aspirin therapy e g nitrate  adrenergic blocker clopidogrel platelet glycoprotein gp iib iiia receptor inhibitor reduce risk cardiac ischemic event undergo unstable angina non st segment elevation non q wave myocardial infarction i e non st segment elevation coronary syndrome prevention clotting during hemodialysis hemofiltration connection renal failure chronic renal insufficiency inflammation pain ocular surgery arsenic gold mercury poisoning lead poisoning concomitantly edetate calcium disodium db00974 known suspected internal contamination radioactive cesium radioactive non radioactive thallium increase their rate elimination gallium citrate ga 67 injection useful demonstrate presence extent hodgkin disease lymphoma bronchogenic carcinoma positive gallium ga 67 uptake absence prior symptom warrant follow up indication potential disease state gallium citrate ga 67 injection useful aid detecting some inflammatory lesion inhibition premature lh surge woman undergoing controlled ovarian hyperstimulation relief inflammatory pruritic manifestation corticosteroid responsive dermatosis world health organization classifies drug functional gastrointestinal disorder like anti muscarinic agent likely peptic ulcer diarrhea product supprelin la fda child central precocious puberty cpp product vantas fda palliative advanced prostate cancer prevention spontaneous preterm birth singleton pregnancy woman previously had spontaneous preterm birth somatostatin analog approved neuroendocrine tumour acromegaly reduce serum phosphate end stage renal disease esrd antitussive antitussive medication often recommended cough respiratory tract disorder a32160 enantiomer dextropropoxyphene present analgesic effect a32161 ocular disorder referred term vernal keratoconjunctivitis vernal conjunctivitis vernal keratitis adjunctive topical antimicrobial agent control bacterial infection under moist dressing over meshed autograft excised burn wound organ specific paramagnetic contrast agent developed imaging hepatobiliary system detecting lesion liver pancreas prophylactic suppressive frequently recurring urinary tract infection long term therapy considered necessary drug infection should only after appropriate eradication infection antimicrobial agent opioids induced constipation palliative inadequately responding laxative therapy pain inflammation cataract surgery tapeworm intestinal fluke infection taenia saginata beef tapeworm taenia solium pork tapeworm diphyllobothrium latum fish tapeworm fasciolopsis buski large intestinal fluke molluscicide control schistosomiasis nonoxynol 9 surfactant spermicide contraception spermicidal cream jelly foam gel lubricant conjuction method contraception condom cervical cap diaphragm granulocyte colony stimulating factor g csf filgrastim mobilize hematopoietic stem cell peripheral blood collection subsequent autologous transplantation non hodgkin lymphoma nhl multiple myeloma mm testicular cancer well hypercalcemia hypercalciuria variety advanced form cancer sclerosing agent uncomplicated spider vein uncomplicated reticular vein lower extremity topical application prevention infection wound relapsed refractory peripheral t cell lymphoma dandruff seborrheic dermatitis a27133 once pinworm infestation t39 hiv infection conjunction antiretrovirals adjunctive therapy chronic urea cycle disorder deficiency carbamylphosphate cps ornithine transcarbamylase otc argininosuccinic acid synthetase all neonatal onset efficiency presenting within first 28 day life late onset presenting after first month life history hyperammonemic encephalopathy solution 0 tinea cruris tinea corporis trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum microsporum canis tinea versicolor effectiveness proven tinea pedis athlete foot prevention postoperative venous thromboembolism undergoing orthopedic surgery undergoing general surgery high risk developing postoperative venous thromboembolism deep vein thrombosis pulmonary embolism preventing clot formation indwelling intravenous line hemodialysis prevention kidney stone formation severe homozygous cystinuria consisting urinary cystine concentration greater than 500 mg day failed non pharmacological measure increased fluid intake decreased sodium protein intake urine alkalinization trientine copper chelator wilson disease alternative d penicillamine tends experiencing serious adverse effect from penicillamine therapy intolerance penicillamine palliative advanced prostate cancer lowering intraocular pressure open angle glaucoma ocular hypertension intolerant intraocular pressure lowering medication insufficiently responsive failed achieve target iop determined after multiple measurement over time another intraocular pressure lowering medication essential component drug cocktail currently fight infection mycobacterium tuberculosis serious susceptible bacterial infection where le dangerous drug ineffective contraindicated bronchial asthma keloid hypertrophic scar allergic disorder asthma allergic rhinitis atopic dermatitis investigated leukemia unspecified lymphoma unspecified myelodysplastic syndrome solid tumor short term perioperative pain control investigated acquired immune deficiency syndrome aid aid related infection hiv infection variety common household product soap mouthwash dish detergent toothpaste deodorant hand sanitizers health care setting surgical scrub personnel hand wash investigated anemia kidney disease alone primary agent asymptomatic cyst passer intestinal amebiasis entamoeba histolytica concurrently sequentially agent nitroimidazoles eg metronidazole invasive extraintestinal form amebiasis infection respiratory gi uti meningitis e coli p mirabilis enterococci shigella typhosa salmonella nonpenicillinase producing n gononhoeae h influenzae staphylococci streptococci streptocfor cough bacterial infection relieve nasal congestion eye drop usually naphazoline relieve symptom allergic conjunctivitis allergic conjunctivitis allergic rhinitis bronchial asthma atopic allergic condition symptomatic allergic reaction urticaria allergy upper respiratory tract hey fever perennial rhinitis food drug allergy pruritus various origin except pruritus cholestasis insect bite dimethindene pruritus eruptive skin disease chicken pox dimethindene adjuvant eczema pruriginous dermatosis allergic origin topical itching allergic reaction inflammation lining nose paranasal sinus allergic inflammation nasopharyngeal refractory deficient red cell production anemia breast carcinoma hereditary angioedema antithrombin iii deficiency fibrinogen excess growth failure turner syndrome prophylaxis hereditary angioedema potential acid reflux disorder gerd peptic ulcer disease heartburn acid indigestion disorder upper gastro intestinal region excess hydrochloric acid gastric juice i e duodenal ulcer benign gastric ulcer prophylaxis recurrent gastric duodenal ulcersfor hypertension edema ventricular tachycardia atrial fibrillation manage hypertension tachycardia glaucoma gastrointestinal disorder motility disturbance like gastroesophageal reflux disease gerd non ulcer dyspepsia delayed gastric emptying anxiety alcohol withdrawal prophylaxis thromboembolic disorder general surgery orthopedic surgery deep vein thrombosis prevention clotting during hemodialysis unstable angina non q wave myocardial infarction prophylaxis thromboembolic disorder registered spain country europe south america south korea prevention stroke myocardial infarction t93 schizophrenia reduce risk cardiovascular death myocardial infarction stroke coronary syndrome history myocardial infarction reduce risk first myocardial infarction stroke high risk coronary artery disease knee pain joint inflammation osteoarthritis usually responded treatment acetaminophen exercise physical therapy plastic surgery reduce wrinkle face filler part body ophthalmology assist extraction cataract implantation intraocular lens corneal transplant glaucoma filtration retinal attachment dry eye finally coat bladder lining treating interstitial cystitis reducing elevated intraocular pressure open angle glaucoma ocular hypertension monotherapy product kalydeco cf age older mutation cftr gene responsive potentiation received expanded approval 2017 following 33 cftr mutation e56k p67l r74w d110e d110h r117c r117h g178r e193k w r347h r352q a455e s549n s549r g551d g551s d579g s945l s977f f1052v k1060t a1067t g1069r r1070q r1070w f1074l d1152h g1244e s1251n s1255p d1270n g1349d drug lumacaftor product orkambi cf age 6 older shown homozygous f508del mutation cftr gene tezacaftor product symdeko manage cf 12 older least one mutation cftr gene aged 12 older shown homozygous f508del mutation tezacaftor elexacaftor product trikafta cystic fibrosis 12 age older least one f508del mutation cftr gene hypertension alone adjunct topical head louse child four old over adult spect single photon emission computerized tomography agent distinguish between parkinson syndrome tremor essential tremor thalassemia syndrome first line chelation agent adequate transfusional iron overload homozygous familial hypercholesterolemia hofh reduce low density lipoprotein cholesterol ldl c total cholesterol tc apolipoprotein b apo b non high density lipoprotein cholesterol non hdl c treating locally advanced metastatic basal cell carcinoma whose carcinoma recurred after surgery candidate surgery radiation there no approved indication but potential therapeutic certain virus ischemic stroke july 2013 there no approved therapeutic indication several potential indication adjunct chemotherapy radiotherapy solid tumor antiviral herpes simplex antiepileptic temporal lobe epilepsy likely choleretic cholagogue being investigated role inflammation cancer therapy cholesterol gallstone being investigated several condition primary biliary cirrhosis pbc insulin resistance amyloidosis cystic fibrosis cholestasis amyotrophic lateral sclerosis allergic conjunctivitis ace inhibitor primarily hypertension congestive heart failure diabetic nephropathy improvement prognosis coronary artery disease myocardial infarction experimental drug no approved indication being studied experimentally several indication cardioprotection diabetes decreased kidney function neuroprotection stroke severe cns injury epilepsy glaucoma neuropathic pain psychiatric condition depression anxiety schizophrenia cognition investigational drug agamatine being studied non blinded prospective case study united state looking diagnosed small fiber peripheral neuropathy experimental drug no approved indication approved any indication united state canada but approved italy cerebrovascular disorder mental function disorder peripheral nerve disorder diabetic neuropathy nutritional supplementation portugal mental function disorder argentina cerebral vasculopathy nutritional supplementation peripheral neuropathy chile dementia philippine cerebrovascular disorder mental function disorder australia nutritional supplementation india nutritional supplementation increase sperm count several potential therapeutic indication still being investigated norway phase iv trial prophylactic migraine italy phase ii trial type diabetes mellitus phase iii trial alleviating fatigue chronic hepatitis c minimal hepatic encephalopathy united state phase ii trial neurodegenerative disorder progressive supranuclear palsy phase ii iii trial reducing peripheral neuropathy cancer adjunct chemotherapy phase i ii trial treating septic shock phase ii trial bipolar depression phase ii trial reduce oxidative stress sickle cell disease phase i ii trial chronic fatigue syndrome study preventing nerve damage hiv china phase iii trial reducing peripheral neuropathy cancer adjunct chemotherapy united kingdom being investigated preventing nerve damage hiv israel being studied male infertility present august 2013 there no approved indication potential therapeutic adjunct ischemic stroke   ketoglutarate approved any indication world but investigational drug united state potential indication  ketoglutarate metabolic disorder propionic acidemia trauma muscle loss being investigated follicular lymphoma brain injury intrauterine growth restricted baby obese adolescent solar lentigo france product small superficial wound there no approved indication primary hyperlipidemia mixed dyslipidemia reduce elevated total cholesterol tc low density lipoprotein cholesterol ldl c apolipoprotein b apo b triglyceride tg increase high density lipoprotein cholesterol hdl c pediatric aged 8 older heterozygous familial hypercholesterolemia hefh reduce elevated tc ldl c apo b f4667 prescribing statin medication considered standard practice following any cardiovascular event people moderate high risk development cvd statin condition include diabetes mellitus clinical atherosclerosis myocardial infarction coronary syndrome stable angina documented coronary artery disease stroke trans ischemic attack tia documented carotid disease peripheral artery disease claudication abdominal aortic aneurysm chronic kidney disease severely elevated ldl c level a181087 a181406 diagnostic aid evaluation gallbladder disorder conjunction secretin pancreatic insufficiency agent hiv infection antiretroviral naive hiv rna 100 000 copy ml cd4 cell count gt 200 cell mm3 fda therapy approval dolutegravir adult hiv infection whose virus currently suppressed lt 50 copy ml stable regimen least six month without history failure no known substitution resistance any two component therapy locally advanced metastatic non small cell lung cancer nsclc anaplastic lymphoma kinase alk positive detected fda approved test product ella available canada u emergency contraception after unprotected intercourse possible contraceptive failure administered within 120 hour 5 day after unprotected intercourse known suspected contraceptive failure product fibristal available canada sign symptom uterine fibroid woman aged 10 above relapsing form multiple sclerosis include clinically isolated syndrome relapsing remitting disease well active secondary progressive disease drug being studied administration infected covid 19 high risk respiratory distress syndrome ards april 3 2020 currently approved indication clinical trial underway acetate synthetic analogue human hypothalamic growth hormone releasing factor hgrf induce maintain reduction excess abdominal fat hiv infected lipodystrophy seattle genetics announced fda approval adcetris chemotherapy adult previously untreated stage iii iv classical hodgkin lymphoma march 2018 hodgkin lymphoma after failure autologous stem cell transplant asct after failure least two prior multi agent chemotherapy regimen asct candidate fda systemic anaplastic large cell lymphoma after failure least one prior multi agent chemotherapy regimen fda metastatic breast cancer previously received least two chemotherapeutic regimen metastatic cancer restless leg syndrome rls postherpetic neuralgia phn db00811 db00008 db00022 chronic hcv genotype infection adult fda clostridioides formerly clostridium difficile diarrhea pediatric 6 month age older should only proven strongly suspected c difficile infection reduce risk development drug resistant bacteria maximize therapeutic effectiveness antimicrobial agent progressive metastatic medullary thyroid cancer advanced renal cell carcinoma hepatocellular carcinoma previously treated sorafenib type gaucher disease intermediate high risk myelofibrosis primary myelofibrosis post polycythemia vera post pv myelofibrosis post essential thrombocythemia post et myelofibrosis lexicomp myeolofibrosis proliferation abnormal bone marrow stem cell cause fibrosis excessive formation connective tissue prior withdrawal initially childhood leukemia specifically induce remission later off united state psoriasis yielding dramatic lesion clearing later supplanted methotrexate treating cancer because better therapeutic index well methotrexate explored abortifacient however their association severe congenital malformation teratogenic effect become known fetal syndrome adjunct auto antibody positive active systemic lupus erythematosus sle intravenous injectable form only fda approved pediatric sle relapsing form multiple sclerosis m approved since 2011 metastatic melanoma mutation braf valine located exon 15 codon 600 mutation denominated v600e a31270 v600e mutation substitution glutamic acid valine account 54 case cutaneous melanoma a31271 approval extended 2017 erdheim chester disease whose cancer cell present braf v600 mutation erdheim chester disease extremely rare histiocyte cell disorder affect large bone large vessel central nervous system well skin lung reported association erdheim chester disease v600e mutation a31272 type ii diabetes addition diet exercise should type i diabetes diabetic ketoacidosis extended release product containing empagliflozin metformin approved fda january 2020 improvement glycemic control adult type diabetes mellitus adjunctively diet exercise over 12 old partial onset seizure may occur generalized seizure gadoxetate contrast medium magnetic resonance imaging mri detect characterize lesion liver opthalmic agent neovascular wet age related mascular degeneration amd macular edema following central retinal vein occulsion crvo systemic injection known ziv 5 fluorouracil leucovorin irinotecan folfiri metastatic colorectal cancer resistant progressed following oxaliplatin asparaginase erwinia chrysanthemi lymphoblastic leukemia all developed hypersensitivity e coli derivied asparaginase component multi agent chemotherpeutic regimen aforementioned disease considered second third line european american protocol a7464 adjunct therapy reduce triglyceride tg level adult severe gt 500 mg dl hypertriglyceridemia proteolytic enzyme symptomatic vitreomacular adhesion multiple myeloma received least two prior therapy bortezomib immunomodulatory agent demonstrated disease progression within 60 day completion last therapy approval based response rate irritable bowel syndrome ibs constipation chronic idiopathic constipation investigated clinical trial potential spasticity multiple sclerosis autism spectrum disorder social withdrawal fragile x syndrome investigated spasticity multiple sclerosis back spasm gerd beta 3 adrenergic agonist overactive bladder oab symptom urge urinary incontinence urgency urinary frequency anemia chronic kidney disease ckd dialysis moderate severe rheumatoid arthritis resistant intolerant methotrexate therapy adjunct methotrexate therapy non biologic disease modifying antirheumatic drug dmards methotrexate alone sufficient investigated preventative therapy kidney transplant rejection psoriasis ulcerative colitis ankylosing spondylitis initiated history chronic recurrent infection presence active infection even if localized report serious sometimes fatal infection commonly pneumonia herpes zoster urinary tract infection discouraged those likely exposed tb increased likelihood exposure encountered traveling certain area addition severe hepatic impairment low hemoglobin le than 9g dl cautioned advised using risk gastrointestinal perforation elderly more susceptible infection metastatic colorectal cancer crc previously treated fluoropyrimidine oxaliplatin irinotecan based chemotherapy anti vegf therapy if kras wild type anti egfr therapy locally advanced unresectable metastatic gastrointestinal stromal tumour gist previously treated imatinib mesylate sunitinib malate hepatocellular carcinoma hcc previously treated sorafenib bromide inhalation powder long term maintenance bronchospasm chronic obstructive pulmonary disease copd chronic bronchitis emphysema methotrexate kidney dysfunction experiencing abnormally high plasma concentration methotrexate gt micromole per liter metastatic castration resistant prostate cancer previously received docetaxel short bowel syndrome sb malabsorption removal intestine adult dependent parenteral support chronic phase accelerated phase blast phase chronic myeloid leukemia cml resistant intolerant prior tyrosine kinase inhibitor therapy philadelphia chromosome positive lymphoblastic leukemia ph all resistant intolerant prior tyrosine kinase inhibitor therapy pediatric inhalational anthrax bacillus anthracis appropriate antibacterial drug prophylaxis inhalational anthrax alternative therapy available appropriate part therapy adult 18 pulmonary multi drug resistant tuberculosis mdr tb approved several different condition listed below symptomatic chron disease maintenance clinical response moderate severe disease inadequate response conventional therapy moderate severely active rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderate severe plaque psoriasis candidate systemic therapy phototherapy fda active non radiographic axial spondyloarthritis objective sign inflammation canada additionally approved methotrexate symptomatic major clinical response reduction joint damage moderately severely active rheumatoid arthritis psoriatic arthritis inflammation biological response against potential threat response normal but certain condition immune system attack body normal cell tissue cause abnormal inflammation tnf alpha identified key regulator inflammatory response signaling cascade inflammatory mediator produce wide range reaction cell death survival differentiation proliferation migration a176660 estrogen receptor positive breast cancer post menopausal woman inhaler asthma prophylaxis fda f4364 nasal spray treating season perennial allergic rhinitis fda a177130 drug conjunction diet exercise increase glycemic control adult diagnosed type diabetes mellitus fda another indication prevention major cardiovascular event myocardial infarction stroke death cardiovascular cause type diabetes well hospitalization heart failure type diabetes addition above lower risk end stage kidney disease major increase serum creatinine cardiovascular death type diabetes mellitus diabetic nephropathy albuminuria important note drug type diabetes mellitus diabetic ketoacidosis fda multiple sclerosis relapsing form nitrogen binding agent chronic pediatric age urea cycle disorder ucds can not managed dietary protein restriction amino acid supplementation alone multiple myeloma received least two prior therapy lenalidomide bortezomib demonstrated disease progression within 60 day completion last therapy unresectable metastatic melanoma braf v600e v600k mutation detected fda approved test fda 2018 approved db08912 anaplastic thyroid cancer abnormal braf v600e gene tafinlar kinase inhibitor initially single agent unresectable metastatic melanoma braf v600e mutation detected fda approved test fda tafinlar db08911 unresectable metastatic melanoma braf v600e v600k mutation detected fda approved test based demonstration durable response rate improvement disease related symptom overall survival demonstrated tafinlar trametinib fda 2018 tafinlar mekinist db08911 approved anaplastic thyroid cancer abnormal braf v600e gene metastatic bone cancer symptomatic no visceral metastasis prostate cancer castration resistant investigated type ii diabetes reduce their risk cardiovascular mortality morbidity kinase inhibitor monotherapy first line fda epidermal growth factor receptor egfr tki tyrosine kinase inhibitor naive locally advanced metastatic non small cell lung cancer nsclc whose tumour non resistant egfr mutation detected fda approved test fda b locally advanced metastatic nsclc squamous histology progressing after platinum based chemotherapy fda recently january 2018 u fda approved supplemental new drug application boehringer ingelheim gilotrif first line metastatic non small cell lung cancer nsclc whose tumor non resistant epidermal growth factor receptor egfr mutation detected fda approved test new includes data three additional egfr mutation q g719x s768i iron replacement product iron deficiency anemia intolerance oral iron had unsatisfactory response oral iron those non dialysis dependent chronic kidney disease serotonin norepinephrine reuptake inhibitor major depressive disorder mdd schizophrenia case bipolar mania appetite suppressant relieve excessive sleepiness inattention elderly antiprotozoal agent effective against amoebiasis yaw antiretroviral agent hiv infection comply characteristic being adult child aged 12 older present least weight 40 kg a7520 fda therapy approval rilpivirine adult hiv infection whose virus currently suppressed lt 50 copy ml stable regimen least six month without history failure no known substitution resistance any two component therapy adult persistent recurrent chronic thromboembolic pulmonary hypertension cteph group 4 after surgical inoperable cteph improve exercise capacity functional class adult pulmonary arterial hypertension pah group improve exercise capacity functional class delay clinical worsening efficacy shown monotherapy endothelin receptor antagonist prostanoids study establishing effectiveness included predominately functional class ii iii etiology idiopathic heritable pah 61 pah connective tissue disease 25 pulmonary arterial hypertension adult aged 18 older topical fungal infection trichophyton rubrum epidermophyton floccosum specifically tinea pedis cruris corporis therapy antiviral medication chronic hepatitis c virus hcv infected hcv genoptypes 6 hcv hiv co infected depending level cirrhosis decompensation therapy include either ribavirin alone ribavirin peg interferon alfa db09027 product harvoni following indication genotype 4 5 6 infection without cirrhosis compensated cirrhosis db00811 genotype infection decompensated cirrhosis db00811 genotype 4 infection liver transplant recipient without cirrhosis compensated cirrhosis db11613 product epclusa chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis db00811 if decompensated cirrhosis resistance reduced susceptibility ns5b substitution mutation s282t a19634 chlorambucil untreated chronic lymphocytic leukemia dietary supplement source niacin investigated potential beneficial effect serum lipid europe inositol hexanicotinate patented drug known hexopal therapeutically symptomatic relief severe intermittent claudication raynaud phenomenon softening dilatation cervix uterus prior transcervical intrauterine operative procedure first trimester pregnancy facilitating therapeutic termination pregnancy second trimester gestation created epilepsy intent creating antiepileptic le sedative property than phenobarbital no approved indication defibrongenating agent observed reduce fibrinogen level thus reduce clot risk intravenously epilepsy epilepsy related behavioural disorder generalised tonic clonic seizure effective absence seizure more recently focus shifted behavioural disorder mentally handicapped epileptic found decrease anxiety antisocial demanding behaviour impulsivity mood stabilizing effect were noted additionally effect monoamine potential place treating condition tardive dyskinesia hyperkinetic syndrome capillary parenchymal hemorrhage trauma tonsillectomy during surgery intestinal bleeding thrombocytopenic purpura open angle glaucoma pmid 12480285 anxiety 4 week severe debilitating insomnia nausea vomiting ponv post operative nausea vomiting gastroesophageal reflux disease gerd gord well endoscopy preparation radiographic study gi tract cleansing colon preparation colonoscopy adult hypertension child above 6 adult drug conjunction antihypertensive calcium channel blocker thiazide product form provide additional blood pressure control antiviral medication sofosbuvir commercially available product harvoni hcv genotype 4 5 6 without ribavirin depending level liver damage cirrhosis fda proven successful hcv co infected hiv a19627 smoking cessation moderate severe plaque psoriasis candidate systemic therapy phototherapy reduction thrombotic cardiovascular event history myocardial infarction mi peripheral arterial disease pad usually co administered acetylsalicylic acid asa clopidogrel should therefore administered addition these medication studied alone mucosal leishmania braziliensis cutaneous l braziliensis l guyanensis l panamensis visceral leishmaniasis l donovani comparing leishmania drug susceptibility found l donovani most susceptible while l major least susceptible off includes free living ameba fla infection unlabeled cdc 2013 moderately severely active uc cd had inadequate response lost response were intolerant tumor necrosis factor tnf blocker immunomodulator had inadequate response were intolerant demonstrated dependence corticosteroid insomnia characterized difficulty sleep onset sleep maintenance unresectable metastatic melanoma adjuvant melanoma metastatic non small cell lung cancer small cell lung cancer advanced renal cell carcinoma classical hodgkin lymphoma squamous cell carcinoma head neck urothelial carcinoma microsatellite instability high mismatch repair deficient metastatic colorectal cancer hepatocellular carcinoma multicentric castleman disease mcd human immunodeficiency virus hiv negative human herpesvirus 8 hhv 8 negative did bind virally produced il 6 nonclinical study therefore studied mcd hiv hhv 8 positive unresectable metastatic melanoma fda single therapy first line metastatic non small cell lung cancer whose tumor high pd expression tumor proportion score tps 50 determined fda approved test no egfr alk genomic tumor aberration f137 single therapy first line metastatic non small cell lung cancer whose tumor express pd tps determined fda approved test disease progression after platinum containing chemotherapy egfr alk genomic tumor aberration should disease progression fda approved therapy these aberration prior f137 following indication present status accelerated approval based tumor response rate durability response thus approval indication contingent upon verification description clinical benefit confirmatory trial recurrent metastatic cervical cancer disease progression after chemotherapy whose tumor express pd cps gt determined fda approved test pemetrexed carboplatin first line metastatic nonsquamous non small cell lung cancer f137 recurrent metastatic head neck squamous cell carcinoma disease progression after platinum containing chemotherapy f137 adult pediatric refractory classical hodgkin lymphoma relapsed after 3 more prior line therapy f137 pediatric refractory primary mediastinal large b cell lymphoma relapsed after more prior line therapy f137 locally advanced metastatic urothelial carcinoma eligible cisplatin containing chemotherapy f137 locally advanced metastatic urothelial carcinoma disease progression during following platinum containing chemotherapy f137 pediatric unresectable metastatic microsatellite instability high mismatch repair deficient solid tumor progressed following previous colorectal cancer progressed following fluoropyrimidine oxaliplatin irinotecan f137 recurrent locally advanced metastatic gastric gastroesophageal junction adenocarcinoma whose tumor express pd cps gt determined fda approved test disease progression after two more prior line therapy fluoropyrimidine platinum containing chemotherapy if appropriate her2 neu targeted therapy f137 adjunct diet exercise improve glycemic control type diabetes reduce risk cardiovascular death both type diabetes mellitus established cardiovascular disease available product either metformin linagliptin adjunct diet exercise type diabetes mellitus adult extended release product containing metformin linagliptin approved fda january 2020 improvement glycemic control adult type diabetes mellitus adjunctively diet exercise approved type diabetes long term type gaucher disease cyp2d6 extensive metabolizers em intermediate metabolizers ims poor metabolizers pm detected fda cleared test fungal infection nail known onychomycosis onychomycosis fungal infection toenail trichophyton rubrum trichophyton mentagrophytes tedizolid bacterial infection skin skin structure absssi prevent drug resistance tedizolid should only infection susceptible bacteria adjunct diet exercise improve glycemic control adult type diabetes mellitus adjunct diet exercise improve glycemic control adult type diabetes mellitus adjunct diet replacement therapy complication leptin deficiency congenital acquired generalized lipodystrophy otitis externa aoe without otowick susceptible strain pseudomonas aeruginosa staphylococcus aureus age year older antiemitic drug approved fda october 2014 palonosetron prevention delayed vomiting nausea cancer chemotherapy highly emetogenic chemotherapy opioid induced constipation oic chronic non cancer pain drug administered tazobactam complicated intra abdominal infection metronidazole complicated urinary tract infection a179425 include pyelonephritis tazobactam bacterial ventilator pneumonia bacterial hospital acquired pneumonia fda vimizim hydrolytic lysosomal glycosaminoglycan gag specific enzyme mucopolysaccharidosis type iva mp iva morquio syndrome philadelphia chromosome negative relapsed refractory b cell precursor lymphoblastic leukemia all acquired accelerated approval mantle cell lymphoma received least one prior therapy fda mantle cell lymphoma mcl b cell non hodgkin lymphoma develops outer edge lymph node mcl usually diagnosed late stage easily spread into bone marrow spleen liver gastrointestinal tract chronic lymphocytic leukemia cll least one prior therapy fda cll type cancer overproduction lymphocyte bone marrow some symptom include swollen lymph node tiredness chronic lymphocytic leukemia cll 17p deletion fda cll 17p type leukemia deletion 17p disrupts tumor suppressor p53 deleting one allele tp53 gene remaining allele mainly inactivated thus type leukemia unresponsive p53 dependent treatment a32305 waldenstrom macroglobulinemia wm fda wm called lymphoplasmacytic lymphoma type non hodgkin lymphoma cancer cell make large amount macroglobulin macroglobulin monoclonal protein corresponds type igm antibody unrestricted formation protein cause typical symptom excessive bleeding effect vision nervous system chronic lymphocytic leukemia cll relapsed follicular b cell non hodgkin lymphoma fl relapsed small lymphocytic lymphoma sll relapsed cll currently second line agent rituximab whom rituximab alone would considered appropriate therapy co morbidity while fl sll intended received least two prior systemic therapy hyperlipidemia abnormally elevated level any all lipid lipoprotein blood anthrax immune globulin inhalational anthrax pediatric appropriate antibacterial drug delaying imminent pre term birth pregnant woman regular uterine contraction least 30 duration rate least 4 per 30 min cervical dilation 3cm 0 3cm nullipara effacement least 50 gestational age 24 33 week normal fetal heart rateavycaz ceftazidime metronidazole complicated intra abdominal infection following susceptible microorganism escherichia coli klebsiella pneumoniae proteus mirabilis providencia stuartii enterobacter cloaca klebsiella oxytoca pseudomonas aeruginosa 18 older avycaz complicated urinary tract infection pyelonephritis following susceptible microorganism escherichia coli klebsiella pneumoniae citrobacter koseri enterobacter aerogenes enterobacter cloaca citrobacter freundii proteus spp pseudomonas aeruginosa 18 older delta 9 tetrahydrocannabinol product sativex given standard marketing authorization ie notice compliance noc health canada following indication adjunctive symptomatic relief spasticity multiple sclerosis m responded adequately therapy demonstrate meaningful improvement during initial trial therapy need confirmatory study verify clinical benefit coupled promising nature clinical evidence sativex given notice compliance condition noc c health canada following indication adjunctive symptomatic relief neuropathic pain multiple sclerosis adjunctive analgesic advanced cancer experience moderate severe pain during highest tolerated dose strong opioid therapy persistent background pain kinase inhibitor anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc progressed intolerant crizotinib indication approved under accelerated approval based tumor response rate duration response improvement survival disease related symptom established continued approval indication contingent upon verification description clinical benefit confirmatory trial cyp3a inhibitor increase systemic exposure atazanavir darunavir once daily dosing regimen antiretroviral agent hiv infection interchangeable ritonavir increase systemic exposure darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir lack exposure data recommended darunavir 600 mg twice daily fosamprenavir saquinavir tipranavir complex unknown mechanism drug interaction preclude extrapolation ritonavir drug interaction certain interaction ritonavir administered either atazanavir darunavir result different drug interaction concomitant medication controlled ovarian stimulation case woman undergoing fertility stimulate development more than one mature egg simultaneously ovary gonadotrophin releasing hormone gnrh antagonist type medicine fertility treatment corticorelin differentiating pituitary ectopic production acth acth dependent cushing syndrome major depressive disorder mdd angina pectoris relief post menopausal symptom prevention osteoporosis non 24 hour sleep wake disorder n24hswd cataplexy excessive daytime sleepiness ed narcolepsy letrozole initial endocrine based therapy human epidermal growth factor receptor type her2 negative hormone receptor hr positive tumor advanced metastatic breast cancer well approved fulvestrant disease progression prior endocrine therapy a176783 official labeling should accompanied either aromatase inhibition no restricted letrozole initial endocrine based therapy postmenopausal woman man fda breast cancer start group cancer cell grow into destroy nearby breast tissue growth spread into part body called metastasis according location cancer cell categorized ductal carcinoma lobular carcinoma however type breast cancer include inflammatory breast cancer paget disease breast triple negative breast cancer non hodgkin lymphoma soft tissue sarcoma male breast cancer usually treated case postmenopausal woman almost all case ductal carcinoma poly adp ribose polymerase parp inhibitor i ovarian cancer medication intended maintenance recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum based chemotherapy b deleterious suspected deleterious germline brca mutated gbrcam advanced ovarian cancer treated three more prior line chemotherapy fda select therapy based fda approved companion diagnostic fda ii breast cancer medication intended deleterious suspected deleterious gbrcam human epidermal growth factor receptor her2 negative metastatic breast cancer previously treated chemotherapy neoadjuvant adjuvant metastatic setting hormone receptor hr positive breast cancer should treated prior endocrine therapy considered inappropriate endocrine fda select therapy based fda approved companion diagnostic fda reducing risk stroke systemic embolism se nonvalvular atrial fibrillation nvaf however should creatinine clearance crcl gt 95 ml min because increased risk ischemic stroke compared warfarin highest dose studied 60 mg deep vein thrombosis dvt pulmonary embolism pe following 5 10 day initial therapy parenteral anticoagulant long term once daily maintenance airflow obstruction chronic obstructive pulmonary disease copd granulocyte macrophage colony stimulating factor gm csf interleukin il 13 ci retinoic acid ra pediatric high risk neuroblastoma achieve least partial response prior first line multiagent multimodality therapy despite high clinical response seen after first line complete eradication neuroblastoma rarely achieved majority advanced disease suffer relapse current strategy include immunotherapy drug target surviving neuroblastoma cell prevent relapse following condition locally recurrent metastatic progressive radioactive iodine refractory differentiated thyroid cancer advanced renal cell carcinoma rcc everolimus following one prior antiangiogenic therapy first line unresectable hepatocellular carcinoma hcc u idiopathic pulmonary fibrosis ipf slow declining pulmonary function systemic sclerosis interstitial lung disease eu docetaxel metastatic locally advanced locally recurrent non small cell lung cancer adenocarcinoma histology already tried first line therapy chronic obstructive pulmonary disease copd chronic bronchitis emphysema exacerbation copd asthma european medicine agency ema visual impairment adolescent leber hereditary optic neuropathy lhon currently approved either food drug administration usa health canada approved several product fluticasone furoate under tradename breo ellipta umeclidinium bromide anoro ellipta approved fda 2013 breo ellipta long term once daily maintenance airflow obstruction copd chronic bronchitis emphysema once daily maintenance asthma aged 18 older reversible obstructive airway disease fda reduce risk hospitalization worsening heart failure stable symptomatic chronic heart failure left ventricular ejection fraction 35 sinus rhythm resting heart rate 70 beat per minute either maximally tolerated dos beta blocker contraindication beta blocker stable symptomatic heart failure result dilated cardiomyopathy pediatric 6 month age more fda available predominantly liquid mouthwash oromucosal spray topical cream most frequently employed locally acting analgesic anti inflammatory relief painful inflammatory condition formulated mouthwash spray traumatic condition like pharyngitis following tonsillectomy naso gastric tube inflammatory condition like pharyngitis aphthous ulcer oral ulceration radiation therapy dentistry operation procedure more general condition like sore throat sore tongue sore gum mouth ulcer discomfort denture topical cream employed relieve symptom painful inflammatory condition muscolo skeletal system inflammatory disorder myalgia bursitis traumatic condition like sprain strain bruise sore muscle stiff joint even after effect fracture ophthalmic for procedure requiring rapid short acting topical ophthalmic anesthetic lidocaine patch local dermal analgesia superficial dermatological procedure superficial venous access lidocaine cream intended provide topical local analgesia superficial dermatological procedure currently available any fda approved drug product there number unapproved otc product advertise toothache is commonly zinc oxide dental procedure cementation temporary prosthesis temporary restoration teeth cavity considered safe fda homepathic otc product presence several different drug main indication constipation cosmetic drug astringent helping shrinkage tissue dry secretion oral health care drug part formulation cleansing product skin care product mosturizers face powder deodorant antiperspirant antifungal most common indication usage spinal anesthesia a32277 symptomatic irritable bowel syndrome ibs postoperative paralytic ileus following abdominal surgery symptomatic irritable bowel syndrome ibs functional disorder biliary tract rhinitis nasal suspension aerosol form lozenge pharyngitis form enema rectal solution ulcerative colitis orally suspension powder inflammatory condition substance screening contact allergy class steroid a31435 primarily diet supplement increase brain metabolism glucose obtain atp agent reduced cholesterol vasodilator action allows having elevated rate blood flow brain help improve memory function concentration awareness thus his action improve cerebrovascular peripheral vascular disorder well hyperlipidaemia manufacuring medicated animal feed fda 25 benzoin tincture removal soft genital venereal wart condylomata acuminata topical symptom inflammatory skin disorder like eczema seborrheic eczema lichen planus psoriasis all these disorder present common characteristic occurrence symptom itching swelling redness scaling mild moderate acne vulgaris rosacea combined agent more severe acne hyperprolactinemia idiopathic originating from prolactin secreting pituitary microadenoma macroadenoma recombinant human growth hormone paediatric growth failure growth hormone deficiency ghd b paediatric growth failure idiopathic short stature i c paediatric growth failure turner syndrome t d paediatric growth failure chronic kidney disease ckd up time renal transplantation e adult childhood onset ghd f adult onset ghd fda symptomatic bleeding from esophageal varix option long term condition considered if necessary once initial control established thyroid extract replacement therapy decreased absent thyroid function hiv protease inhibitor coadministered ritonavir antiretroviral drug hiv infection antiretroviral experienced adult sofosbuvir without ribavirin chronic hcv genotype 1a b 3 infection dosing regimen 60mg 60 mg 400mg sofosbuvir once day recommended both genontypes resistance reduced susceptibility polymorphism ns5a amino acid position m28 q30 y93 genotype 1a 1b 3a ns5a resistance testing recommended hcv genotype 1a infected cirrhosis prior initiaition risk resistance development higher genotype 1a filgrastim setting autologous peripheral blood progenitor cell transplantation risk poor peripheral blood progenitor cell mobilisation filgrastim will generate sustained increase number peripheral blood progenitor cell capable engraftment mobilization progenitor cell from bone marrow peripheral blood withouth mobilizing chemotherapy harvested progenitor cell transplant following myelosuppressive myeloablative therapy antacid laxative depending administered dose antacid temporary relief heartburn upset stomach sour stomach acid indigestion laxative relief occasional constipation promoting bowel movement 30 minute up 6 hour perinatal infantile juvenile onset hypophosphatasia hpp intravenous solution prevent shock following severe blood loss trauma surgery issue anaemia chronic kidney disease substitute rbc transfusion if immediate correction anemia required prophylaxis bleeding all age haemophilia congenital factor viii deficiency fda prophylaxis bleeding presenting hemophilia related control bleeding episode perioperative hemophilia a hereditary hemorrhagic disorder generated congenital deficit coagulation factor viii disease manifested excessive spontaneous trauma driven bleeding coagulation factor viii robust initiator thrombin later required generation fibrin form platelet plug gene expressed x chromosome a31505 mesna uroprotective agent prophylactically reduce ifosfamide cyclophosphamide induced hemorrhagic cystitis a18572 primary intended substitute older colloid albumin hetastarch plasma volume expansion sequential sodium thiosulfate cyanide poisoning judged life threatening fda respiratory distress syndrome rds premature infant respiratory distress syndrome rds premature infant official referred intratracheal suspension prophylactic infant le than 1350 gram birth weight under risk developing rds infant birth weight greater than 1350 gram pulmonary immaturity rescue infant already developed rds central feature rds surfactant deficiency lung immaturity lung condition more frequently presented risk factor like prematurity delayed lung maturation maternal diabetes male gender surfactant dysfuntion perinatal asphyxia pulmonary infection delivery without labor t70 amoebiasis approved fda but intended indication alcoholism t74 medication marketed canada united kingdom europe under trade name temposil sole alcoholism historically sedative hypnotic a19735 seizure anticonvulsant a19736 conjunction clobazam valproate adjunctive therapy refractory generalized tonic clonic seizure severe myoclonic epilepsy infancy smei dravet syndrome whose seizure adequately controlled clobazam valproate adjunctive therapy partial onset seizure adequately controlled conventional therapy epileptic conjunction oral cox inhibitor nsaid relief severe pain osteoarthritis knee controlled oral cox inhibitor nsaid alone duration no more than three month adjunctive early active juvenile type rheumatoid arthritis adequately controlled anti inflammatory agent conservative measure like salicylate glucocorticoid etc chronic advanced case rheumatoid arthritis gold therapy demonstrated valuable antirheumatic measure salicylate anti inflammatory drug both steroidal non steroidal continued after initiation gold therapy after improvement commences these measure discontinued slowly symptom permit relapsing form multiple sclerosis endometriosis alone contraceptive ethinylestradiol adjunct endometial shedding menopausal woman secondary amenorrhea induce menses dysfunctional uterine bleeding adolescent woman t76 renal tubular acidosis hypocitraturic calcium oxalate nephrolithiasis uric acid lithiasis without calcium stone prepubertal cryptorchidism anatomical obstruction selected case hypogonadotropic hypogonadism hypogonadism secondary pituitary deficiency male induction ovulation pregnancy anovulatory infertile woman whom cause anovulation secondary primary ovarian failure appropriately pretreated human menotropins adjunctive major depressive disorder mdd schizophrenia supplement intravenous solution given total parenteral nutrition tpn supplementation total parenteral nutrition contraception intrauterine device fda supplement intravenous solution given total parenteral nutrition tpn intravenous magnetic resonance imaging mri brain intracranial spine tissue pediatric age older detect visualize area disruption blood brain barrier bbb abnormal vascularity conray excretory urography cerebral angiography peripheral arteriography venography arthrography direct cholangiography endoscopic retrograde cholangiopancreatography contrast enhancement computed tomographic brain image cranial computerized angiotomography intravenous digital subtraction angiography arterial digital subtraction angiography conray enhancement computed tomographic scan performed detection evaluation lesion liver pancreas kidney abdominal aorta mediastinum abdominal cavity retroperitoneal space optiray 350 adult peripheral coronary arteriography left ventriculography optiray 350 contrast enhanced computed tomographic imaging head body intravenous excretory urography intravenous digital subtraction angiography venography optiray 350 child angiocardiography optiray 320 adult angiography throughout cardiovascular system us include cerebral coronary peripheral visceral renal arteriography venography aortography left ventriculography optiray 320 contrast enhanced computed tomographic imaging head body intravenous excretory urography optiray 320 child angiocardiography contrast enhanced computed tomographic imaging head body intravenous excretory urography optiray 300 cerebral angiography peripheral arteriography optiray 300 contrast enhanced computed tomographic imaging head body venography intravenous excretory urography optiray 240 cerebral angiography venography optiray 240 contrast enhanced computed tomographic imaging head body intravenous excretory urography administered intra arterially following diagnostic test cerebral arteriography 300 mgi ml coronary arteriography left ventriculography 350 mgi ml visceral angiography 350 mgi ml aortography 350 mgi ml peripheral arteriography 350 mgi ml administered intravenously excretory urography contrast enhanced computed tomographic cect imaging head body 300 350 mgi ml synthetic visual lymphatic imaging agent upon subcutaneous administration delineates lymphatic vessel draining region injection adjunct lymphography primary secondary lymphedema extremity chyluria chylous ascites chylothorax lymph node involvement primary secondary neoplasm lymph node response therapeutic modality technetium tc 99m mebrofenin hepatobiliary imaging agent technetium tc 99m medronate bone imaging agent delineate area altered osteogenesis pediatric skeletal imaging diagnosis area present altered osteogenesis administered intravenously able generate clear image bone allows physician diagnose any bone problem important point out drug manipulated only under service nuclear specialist approved indication bone scan visualization tumor metastasis bone osteomyelitis 3 fracture 4 stress fracture 5 avascular necrosis 6 osteoporosis 7 prosthetic joint evaluation from all major indication detection metastatic disease most common because present 95 sensitivity lesion detection done 6 month earlier than x ray study therapy clinical setting across diverse specialty various type anoxia hypoxia dyspnea any disease state condition reduce efficiency gas exchange consumption respiratory illness trauma poisoning drug overdoses therapy try achieve hyperoxia reduce extent hypoxia induced tissue damage malfunction counteracting reversing anticoagulant effect heparin necessary f3559 f3562 reversal example required often before surgery after renal hemodialysis post open heart surgery whenever excessive bleeding result from heparin heparin overdosage among similar related circumstance f3559 f3562 product kinevac fda following indication stimulate gallbladder contraction assessed various method diagnostic imaging obtain duodenal aspiration sample concentrated bile analysis cholesterol bile salt phospholipid crystal stimulate pancreatic secretion especially conjunction secretin prior obtaining duodenal aspirate analysis enzyme activity composition cytology 3 accelerate transit barium meal through small bowel thereby decreasing time extent radiation fluoroscopy x ray examination intestinal tract approved u eu adult locally advanced basal cell carcinoma bcc recurred post surgery radiation therapy approved bcc eligible surgery radiation therapy marketed product xuriden fda hereditary orotic aciduria marketed product vistogard fda emergency pediatric following situation following fluorouracil capecitabine overdose regardless presence symptom exhibit early onset severe life threatening toxicity affecting cardiac central nervous system early onset unusually severe adverse reaction e g gastrointestinal toxicity neutropenia within 96 hour following end fluorouracil capecitabine administration diluting dissolving drug intravenous intramuscular subcutaneous injection according instruction manufacturer drug administered fda elemental iron injection replenishes body iron store iron deficiency intended iron loss iron deficiency formulation milder gastrointestinal effect iron deficiency appears dietary intake doe meet body requirement there chronic external blood loss during blood loss body iron store sufficient accelerated erythropoiesis restoration iron homeostasis but altered homeostasis remains week month then some supplement needed some cause iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 florbetaben radioactive diagnostic agent positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad cause cognitive decline florbetapir 18f positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad cause cognitive decline flutemetamol f18 positron emission tomography pet imaging brain estimate  amyloid neuritic plaque density cognitive impairment being evaluated alzheimer disease ad cause cognitive decline liquid mainly cryogenic agent various benign malignant skin lesion intravenous solution adult pediatric source electrolyte water hydration designed diluent delivery system intermittent intravenous administration compatible drug additive anticoagulant during plasmophoresis well neutralizing agent upset stomach acidic urine fda getting enough oxygen into their blood blockage lung from pathological condition injury suggested potential benefit upper airway obstruction severe asthma exacerbation copd cold place carbon monoxide during laparoscopic surgery lower risk developing respiratory acidosis selected product iovist x ray contrast agent following procedure intra arterial digital subtraction angiography ia dsa 150 mg i ml cerebral arteriography peripheral arteriography 300 mg i ml coronary arteriography left ventriculography visceral angiography aortography 370 mg i ml peripheral venography 240 mg i ml excretory urography 300 mg i ml contrast computed tomography ct imaging head body 300 mg i ml 370 mg i ml commonly insufflation gas minimal invasive surgery laparoscopy endoscopy arthroscopy enlarge stabilize body cavity provide better visibility surgical area cryotherapy respiratory stimulant before after anesthesia could expansion blood vessel if required increase level after rapid breathing stimulate breathing after period nonbreathing trypan blue aid ophthalmic surgery staining epiretinal membrane during ophthalmic surgical vitrectomy procedure facilitating removal tissue technetium 99m tetrofosmin diagnosis heart abnormality exercise myocardial scintigraphy exercise myocardial scintigraphy established method diagnosis severity coronary artery disease a31592 method allows distinguishing region reversible myocardial ischemia presence absence infarcted myocardium following rest stress condition technetium 99m tetrofosmin mainly ass myocardial perfusion ischemia infarction technetium tc 99m sestamibi detecting coronary artery disease localizing myocardial ischemia reversible defect infarction non reversible defect evaluating myocardial function developing information patient decision technetium tc99m exametazime scintigraphy without methylene blue stabilization useful adjunct detection altered regional cerebral perfusion stroke tc99m exametazime without methylene blue stabilization leukocyte labeled scintigraphy adjunct localization intra abdominal infection inflammatory bowel disease technetium tc99m disofenin hepatobiliary imaging agent hepatolite diagnosis cholecystitis well rule out occurrence cholecystitis suspected right upper quadrant pain fever jaundice right upper quadrant tenderness mass rebound tenderness but limited these sign symptom skeletal imaging agent demonstrate area altered osteogenesis cardiac imaging agent adjunct diagnosis myocardial infarction fda image gated blood pool detect gastrointetinal bleeding generalized anxiety disorder depression panic disorder insomnia symptom depressive illness especially where anti anxiety effect required investigated potential opioid analgesic but no longer purpose a182060 more often being recreational drug a182060 db09296 db09297 db00503 viekira pak hcv genotype 1a db00811 genotype 1b without db00811 those compensated cirrhosis fda clinical depression studied depression t47 tremor parkinson extrapyramidal symptom male impotence certain if ever approved marketed but current status withdrawn 2016 classified chemical structure related drug like criterion global approved drug antipsychotic anxiolytic antipsychotic medication state delusion hallucination paranoia disordered thought hand anxiolytic medication severe chronic debilitating anxiety anxiety state defined unpleasant state tension apprehension uneasiness t77 anxiety neurosis approved ministry food drug safety south korea 2013 being monitored postmarketing surveillance until 2019 approved either food drug administration usa health canada european medicine agency diabetes artinolol introduced antihypertensive agent since 1986 t88 studied function like tremor control parkinson disease currently clinical trial control blood pressure heart rate symptomatic sequela cerebral infarction hemorrhage t91 cerebral infarction characterized blockage artery either formation thrombus embolus a31644 hand fda classified reversal phenylephrine induced mydriasis narrow anterior angle risk developing attack angle closure glaucoma closed angle glaucoma contact between iris trabecular meshwork contact will damage aqueous outflow meshwork thus increasing eye pressure producing symptom glaucoma a31645 mydriasis referred dilatation pupil standard body function known trigger factor development closed angle glaucoma risk explained generation pupillary block contact between pupillary margin lens thus preventing flow from aqueous humor anterior chamber followed increased pressure gradient approved france first drug impotence a31647 chronic gout refractory conventional therapy cough suppressant temporary relief non productive dry cough stated present required indication temporary relief dry cough cough respiratory movement occurs after irritation signal transmitted central nervous system further stimulates medulla oblongata stimulation cause motor output sent through motoneuron respiratory muscle non productive cough type cough characterized absence sputum large inspiration will cause continuous coughing suffering from myoclonus cortical origin irrespective aetiology should anti myoclonic therapy improvement various ischemic symptom ulcer pain feeling coldness thromboangiitis obliterans well improvement subjective symptom pain numbness lower leg gait ability acquired lumbar spinal canal stenosis bilateral intermittent claudication showing normal slr test result non steroidal anti inflammatory medication nsaid pain inflammation related musculoskeletal joint disorder addition effect pain antipyretic anti inflammatory medication more information refer ibuprofen short term mild moderate pain dysmenorrhoea musculoskeletal pain toothache nsaid previously inflammation rheumatoid arthritis information stated drug being nsaid effective treating pain attack migraine adult pain inflammation fever horse dog chronic arthritic condition certain soft tissue disorder pain inflammation constipation absence bowel obstruction surgical preparation colon prevention chronic stable angina pectoris reduction risk coronary syndrome peptic ulcer disease dyspepsia bleeding episode congenital fibrinogen deficiency afibrinogenemia hypofibrinogenemia schizophrenia schizophrenia sleep disorder agitation mentally confused state like atypical antipsychotic considered first line newly diagnosed schizophrenia usually thought option choice managing schizophrenic episode discussion patient possible atypical antipsychotic suffering unacceptable side effect from conventional antipsychotic relapse were inadequately controlled t108 important consider indication stated above related atypical antipsychotic currently fda canada ema approved study shown any additional benefit compared approved atypical antipsychotic a31857 schizophrenia chronic severe mental disorder affect how person think feel behaves usually marked loose reality perspective delineated hallucination delusion thought movement disorder investigated schizophrenia schizoaffective disorder mild moderate essential hypertension chronic stable angina attack hereditary angioedema hae c1 esterase inhibitor deficiency adult many angina pectoris hypertension a31895 hypertension potent long lasting drug cardiovascular disease hypertension renoparenchymal hypertension angina pectoris a31950 hypertension end organ protection reported useful elderly those diabetes albuminuria increasingly chronic kidney disease hypertension term describe presence high blood pressure blood pressure generated force blood pumped from heart against blood vessel thus hypertension there too much pressure blood vessel effect damage blood vessel hypertension hypertension either alone antihypertensive agent  adrenoceptor antagonist diuretic ace inhibitor alone hypertension adult child hypertension pediatric acquired methemoglobinemia clinical application include improvement hypotension various clinical state antiseptic urinary tract infection hypoxia hyperdynamic circulation cirrhosis liver severe hepatopulmonary syndrome ifofosamide induced neurotoxicity mild moderate essential primary hypertension effective most first line antihypertensive monotherapy a27137 hypertension a19790 major depression being studied fibromyalgia pain syndrome one study determined effect sensorimotor performance while driving motor vehicle show many similarity placebo drug appears stimulate central nervous system rather than exhibit sedative effect like many antidepressant because selective reversible inhibition monoamine oxidase mao short half life unpleasant cheese effect avoided refers effect consuming tyramine rich food cheese while medicated monoamine oxidase inhibitor leading severe headache hypertension available evidence support safe effective option depression fibromyalgia syndrome major depressive disorder depression depression depression depression depression schizophrenia angina pectoris depression depression depression depression restoration blood mass during surgical intervention if there hypovolemia trauma dehydration well after presence hemorrhage case blood loss level inferior 15 blood mass if compatibility test can not completed blood lot need tested pathogen detection prevention profound postoperative venous thrombosis well present ophthalmic application solution ointment temporary relief xerophthalmia minor ocular irritation cancer usually biochemically modulating drug adult advanced gastric cancer given db00515 first line metastatic colorectal cancer db03419 calcium folinate adjunct antineoplastic therapy within product teysuno adult advanced gastric stomach cancer given cisplatin following case prevent blood clot vein after general abdominal surgery moderate risk venous thromboembolism prevention thromboembolic disease non surgical prevention clotting extracorporeal circuit during hemodialysis prevent blood clot vein after major orthopedic surgery high risk venous thromboembolism secondary prevention venous thromboembolism recurrence deep vein thrombosis transient prevention deep vein thrombosis dvt fda deep vein lead pulmonary embolism pediatric long term deep vein thrombosis without pulmonary embolism pregnant prevention venous thromboembolism deep vein thrombosis pulmonary embolism myocardial infarction prevention venous thromboembolism deep vein thrombosis pulmonary embolism myocardial infarction overactive bladder fda hyperkalemia treated dabigatran reversal anticoagulant effect dabigatran needed emergency surgery urgent procedure life threatening uncontrolled bleeding antihyperglycemic agent t2dm fda without scintigraphic imaging lymphatic mapping using handheld gamma counter locate lymph node draining primary tumor site solid tumor procedure component intraoperative fda without scintigraphic imaging guiding sentinel lymph node biopsy using handheld gamma counter clinically node negative squamous cell carcinoma oral cavity breast cancer melanoma fda therapeutically severe osteoperosis postmenopasual woman b men high risk fracture whom medical product approved osteoperosis possible example contraindication intolerance postmenopausal woman reduce risk vertebral hip fracture cleansing colon preparation colonoscopy adult fda adjunctive therapy hyperammonemia encephalopathy deficiency enzyme urea cycle diet supplement containing stated product assist individual cardiovascular complaint congestive heart failure systolic hypertension product increase cardiac input well prevention several disease like parkinson fibromyalgia migraine periodontal disease diabetes based preclinical study important highlight these product fda approved recommended under discretion irritable bowel syndrome diarrhea ibs d chronic obstructive pulmonary disease copd bronchial asthma pulmonary disease spastic bronchial component initial severe malaria pediatric peptic ulcer gastro oesophageal reflux disease gord inflammatory erosive ulcerous disease gastric duodenal mucosa gastritis ulcer disease stomach duodenum functional non ulcerous dyspepsia erosive duodenitis post operative inflammatory erosive change anastomositis peptic ulcer anastomosisa disease modifying antirheumatic drug dmard symptomatic arthritis choline c11 positron emission tomography pet imaging suspected prostate cancer recurrence non informative bone scintigraphy computerized tomography magnetic resonance imaging fda a32037 antidote poisoning following excessive oral ingestion certain medication poison hypertension heart failure a20319 given db08820 fixed dose product orkambi cystic fibrosis cf age 6 older homozygous f508del mutation cftr gene fda peptic ulcer relieving indigestion heartburn indication include ischemic heart disease angina chronic heart failure pulmonary hypertension chronic stable angina a19770 angina pectoris hydrochloride form local anesthetic t83 inflammatory condition affecting airway ent system urogenital tract bone joint system adult italy pain ear nose throat ent gastrointestinal inflammatory condition child well established nsaid over three decade italy particularly upper respiratory tract infection child france belgium austria switzerland spain portugal generally favorable tolerability profile chronic psychosis state aggressiveness various origin over counter osmotic laxative relieve occasional constipation sodium ascorbate sodium sulfate ascorbic acid sodium chloride potassium chloride cleansing colon preparation colonoscopy adult paracetamol prodrug intravenous administration control fever pain perioperative period multimodal analgesia therapy primarily major depressive disorder anxiety a31969 currently being studied fibromyalgia pain nausea vomiting diarrhea predominant irritable bowel syndrome male drug adult antiemetic prevention delayed nausea vomiting emetogenic chemotherapy valsartan reduce risk cardiovascular event chronic heart failure nyha class ii iv reduced ejection fraction usually administered conjunction heart failure therapy place ace inhibitor arb therapeutic solution sodium iodide 131 hyperthyroidism thyroid carcinoma take up iodine palliative effect observed advanced thyroid malignancy if metastatic lesion take up iodine performance radioactive iodide rai uptake test evaluate thyroid function talnifumate phthalidyl ester nifumic acid potent analgesic anti inflammatory effect widely inflammatory disorder rheumatoid arthritis osteoarthritis studied cystic fibrosis db09297 db00503 fixed dose product technivie db00811 genotype 4 chronic hepatitis c virus hcv infection without cirrhosis db09297 db00503 db09183 fixed dose product viekira pak hcv genotype 1b combined db00811 hcv genotype 1a fda within fixed dose product db09296 db09183 db00503 fda approved product viekira pak hcv genotype 1b without cirrhosis compensated cirrhosis combined db00811 hcv genotype 1a without cirrhosis compensated cirrhosis within fixed dose product db09296 db00503 fda health canada approved product technivie db00811 genotype 4 chronic hepatitis c virus hcv infection without cirrhosis compensated cirrhosis within fixed dose product db09296 db09183 db00503 health canada approved commercially available product holkira pak hcv genotype 1b without cirrhosis combined db00811 hcv genotype 1a without cirrhosis currently being tested severe intoxication hepatotoxic substance death cap amanita phalloides poisoning chronic hepatitis b compensated liver disease emtricitabine antiretrovirals hiv infection adolescent weight higher than 35 kg prevent hiv infection high risk adolescent excluding risk from receptive vaginal sex combined antiretrovirals than protease inhibitor require cyp3a inhibitor pediatric weighing 25 35 kg product emtricitabine bictegravir considered complete regimen hiv infection naive patient virologically suppressed least 3 month no history failure additionally product elvitegravir cobicistat emtricitabine and product emtricitabine rilpivirine hiv infection older than 12 no previous antiretroviral therapy history virologically suppressed least 6 month no history failure product darunavir cobicistat emtricitabine hiv infection adult without prior antiretroviral therapy virologically suppressed 6 month no reported resistance darunavir tenofovir abdmoninal cramping pain fda glucosamine alleviate pain inflammation from primary osteoarthritis supplement reported improve joint function slow disease progression osteoarthritis characterized progressive structural metabolic change joint tissue mainly cartilage degradation subchondral bone sclerosis inflammation synovial membrane a32066 study proposed potential nutraceutical dietary supplement a32065 antibody eliciting proprotein convertase subtilisin kexin type 9 pcsk9 inhibitor activity i reducing risk myocardial infarction stroke unstable angina requiring hospitalization adult established cardiovascular disease f4591 ii adjunct diet alone lipid lowering therapy statin ezetimibe example adult primary hyperlipidemia heterozygous familial hypercholesterolemia reduce low density lipoprotein cholesterol ldl c level body f4591 heterozygous homozygous familial hypercholesterolemia clinical atherosclerotic cardiovascular disease maximum tolerated statin therapy requiring additional ldl cholesterol lowering depression a19792 investigated depression investigated depression investigated depression investigated community acquired pneumonia cap routine prophylaxis bleeding congenital factor xiii subunit deficiency constipation help maintain regular bowel movement prevention renal transplant rejection aplastic anemia medicinal product diagnostic only adult child low osmolality medium a7924 sodium pertechnetate tc99m injection adult imaging following tissue thyroid salivary gland urinary bladder detection vesico ureteral reflux nasolacrimal drainage system dacryoscintigraphy child imaging following tissue thyroid urinary bladder inhalation xenon xe 133 gas proved valuable evaluation pulmonary function imaging lung applied assessment cerebral flow diagnostic radiopharmaceutical help diagnose heart disease eg coronary artery disease heart attack diagnosis parathyroid problem moderate severe vasomotor symptom menopause moderate severe symptom vulvar vaginal atrophy menopause moderate severe vasomotor symptom menopause moderate severe vaginal dryness pain intercourse symptom vulvar vaginal atrophy menopause chronic infection upper lower urinary tract asymptomatic bacteriuria susceptible strain escherichia coli proteus mirabilis morganella morganii providencia rettgeri proteus vulgaris pseudomonas enterobacter enterococci prostatitis susceptible strain escherichia coli enterococcus faecalis proteus mirabilis enterobacter sp number bacterial infection syphilis anthrax mouth infection pneumonia diphtheria adjunctive diaper dermatitis minor skin irritation eg cut burn scrape poison ivy ointment cream lotion protect against sunburn damage skin ultraviolet light medication mineral prevent low level zinc alone together oral rehydration therapy ort topical astringent injection usp supplement intravenous solution given tpn currently available product ampicillin within formulation infection susceptible strain designated microorganism condition listed below skin skin structure infection beta lactamase producing strain staphylococcus aureus escherichia coli klebsiella spp k pneumoniae proteus mirabilis bacteroides fragilis enterobacter spp acinetobacter calcoaceticus intra abdominal infection beta lactamase producing strain escherichia coli klebsiella spp k pneumoniae bacteroides spp b fragilis enterobacter spp gynecological infection beta lactamase producing strain escherichia coli bacteroides spp b fragilis oral topical form prevention control dental caries maintenance dental health a181652 fluoride supplement form tablet formula prescribed prevent tooth decay high risk child aged 6 month 16 old whose drinking water source contains low fluoride concentration diagnostic positron emission tomography pet imaging myocardium under rest pharmacologic stress condition evaluate myocardial perfusion suspected existing coronary artery disease first line metastatic colorectal cancer concomitant administration calcium folinate colorectal cancer third most diagnosed cancer 30 case present metastatic state a32077 adhd child hypertriglyceridemia hemophilia congenital factor viii deficiency fda a32064 medication human antihemophilic factor adolescent 12 older hemophilia congenital factor viii deficiency demand control bleeding routine prophylaxis bleeding episode von willebrand disease fda metastatic epidermal growth factor receptor egfr t790m mutation positive non small cell lung cancer nsclc detected fda approved test progressed after egfr tki therapy intravenous injection alone medication multiple myeloma subcutaneous hyaluronidase alone multiple myeloma anticoagulant induced prothrombin deficiency coumadin indanedione derivative prophylaxis therapy hemorrhagic disease newborn hypoprothrombinemia antibacterial therapy hypoprothrombinemia secondary factor limiting absorption synthesis vitamin k example obstructive jaundice biliary fistula sprue ulcerative colitis celiac disease intestinal resection cystic fibrosis pancreas regional enteritis drug induced hypoprothrombinemia where definitely shown result interference vitamin k metabolism available cholecystographic agent denomination indicates radiopaque substance visualize gallbladder biliary channel abdominal x ray a32087 abdominal x ray us minimal amount ionizing radiation produce picture inside abdominal cavity commonly evaluate stomach liver intestine spleen hyperthyroidism graf disease a32085 a32086 hyperthyroidism refers any condition where there too much thyroid hormone produced body overactive thyroid overactivity involves entire thyroid gland known grave disease tc 99m nm one technetium labeled antibody detection small cell lung cancer small cell lung cancer syndrome characterized abnormal uncontrolled cell growth characterized shorter doubling time higher growth fraction earlier development metastasis source clean air fda elevated blood pressure edema cholecystography x ray diagnosis imaging gallstone glucose pharmaceutical formulation oral tablet injection caloric supply carbohydrate supplementation case nutrient deprivation metabolic disorder hypoglycemia local anesthetic medication beginning 1950s during dental procedure combined procaine accelerate onset action provide longer lasting anesthetic effect produced amide local anesthetic were contraindicated allergy several amide anesthetic were unsuccessful trifluridine refractory mestastatic colorectal cancer keep progressing despite standard chemotherapy biologics a31256 present large variety us therapeutically parenteral hyperalimentation t127 excipient known effect approved food product humectant crystallization modifier liquid nutritive sweetener t128 temporary relief pain pruritus from minor lip skin irritation well temporary relief from pain burning itching discomfort hemorrhoid anorectal anogenital disorder contrast medium indication contrast agent x ray some information indicates nephrotropic property one characteristic utilization a32135 x ray imaging depends difference tissue density provided x ray attenuation between area interest surrounding tissue contrast agent will provoke contrast enhancement opacification will improve differentiation pathological process from normal tissue t125 vaccine tissue graft surgical instrument enzyme sterilant blood plasma water milk nutrient broth vapor phase disinfectant enclosed space sporicidal action against vegetative bacteria pathologic fungi virus no longer medical procedure food a32144 intrinsic factor currently available any fda health canada approved product however currently marketed but unapproved product hematogen cyanocobalamin synthetic vitamin b12 ferrous fumarate ascorbic acid anemia responsive oral iron therapy head pubic crab body louse open angle glaucoma ocular hypertension fda mydriatic agent eye pupil dilatation diagnosis ophthalmic nerve lesion topically dandruff acne hayfever common cold scaly red skin patch seborrheic dermatitis poison ivy sumac infection injection prophylactic immediately after major abdominal surgery minimize possibility paralytic ileus intestinal atony causing abdominal distention postoperative postpartum retention flatus postoperative delay resumption intestinal motility paralytic ileus topical medication moisturizer prevent dry rough scaly itchy skin minor skin irritation e g diaper rash skin burn from radiation therapy rauwolfia alkaloid hypertension rauwolfia alkaloid relief symptom agitated psychotic state schizophrenia however antipsychotic sedative replaced more effective safer agent cold sore fever blister diaper rash minor burn sunburn prickly heat vaginally douche leukorrhea sore throat inflamed tonsil spongy receding gum dermatitis determining cardiac output hepatic function liver blood flow ophthalmic angiographyno therapeutic indication surfactant antistatic agent biocide cosmetic product a19426 form ointment biochemical debridement second third degree burn incisional traumatic pyrogenic wound ulcer occurring peripheral vascular disease t169 replace estrogen woman ovarian failure condition cause lack natural estrogen body symptom breast cancer both men woman men advanced prostate cancer menopausal symptom ethinyl estradiol prevention pregnancy woman elect product method contraception dentistry orthodontics etching solution clean roughen surface teeth where dental appliance filling will placed injection usp 40 meq source sodium addition large volume intravenous fluid prevent correct hyponatremia restricted no oral intake useful additive preparing specific intravenous fluid formula need patient can not met standard electrolyte nutrient solution bicarbonate precursor alkalinising agent correct metabolic acidosis alkalinisation urine technetium 99m sulfur colloid diagnostic agent adult following test localization lymph node draining primary tumor breast cancer malignant melanoma evaluation peritoneo venous leveen shunt patency both pediatric imaging area functioning reticuloendothelial cell liver spleen bone marrow study esophageal transit gastroesophageal reflux detection pulmonary aspiration gastric content 18f bone imaging agent define area altered osteogenic activity back pain otherwise unexplained bone pain child abuse abnormal radiographic laboratory finding osteomyelitis trauma inflammatory degenerative arthritis avascular necrosis osteonecrosis mandible condylar hyperplasia metabolic bone disease among indication fluoride imaging prevention angina pectoris coronary artery disease onset action oral mononitrate sufficiently rapid product useful aborting anginal episode several medical topical skin related application usp anhydrous us electrolyte replenisher pharmaceutic necessity hemodialysis peritoneal dialysis fluid magnesium salf containing laxative prevent constipation bring synergistic effect restore normal bowel function using aluminum salt induce bowel retention t28 source water electrolyte combined dextrose salt form intravenous infusion injection carbohydrate magnesium deficiency insulin hypoglycemia constipation hypertension during pregnancy buffer determination ph pharmaceutical production urinary acidifier paper processing baking powder food nutrient solution yeast food special liquid fertilizer sonar system electronic application nutritional supplement food nonlinear optical material laser wastewater imitation dairy creamer dry powder beverage mineral supplement starter culture additive non dairy creamer prevent coagulation make buffer solution production trypticase soy agar make agar plate culturing bacteria no current fda ema approved therapeutic indication predominant everyday nutritional usage parent sugar alcohol from another sugar alcohol xylitol derived from extremely common food additive sweetener place regular sugar lower calorie alternative a32661 alternatively involved procedure known d absorption test employed evaluate how well individual capable absorbing simple sugar like d from intestine measuring amount d urine blood sample after individual ingested certain amount simple sugar dissolved some water test sought determine if nutrient were being properly absorbed patient gastrointestinal tract administration sodium iodide i 123 capsule diagnostic procedure evaluating thyroid function morphology parenteral nutrition source calorie essential fatty acid oral enteral nutrition possible insufficient contraindicated pentetate indium disodium 111 recommended radionuclide cisternography i 125 iodinated albumin determination total blood plasma volume iodinated i 131 albumin determination total blood plasma volume cardiac output cardiac pulmonary blood volume circulation time protein turnover study heart great vessel delineation localization placenta localization cerebral neoplasm no approved therapeutic indication constipation clean bowel before colonoscopy fda tartaric acid primarily condition like antiscorbutic antiseptic topically dermatitides mouthwash vaginal douche veterinary emergency emetic occasionally dermatitides topically lotion medication vet solution cleanse skin eczema soften scab ringworm solvent emollient pharmaceutical agent sweetening agent bowel cleansing prior colonoscopy barium enema x ray examination indium 111 oxyquinoline radiolabeling autologous leukocyte injection hypertension oral therapy practical rubidium rb 82 chloride injection positron emission tomography pet imaging myocardium under rest pharmacologic stress condition evaluate regional myocardial perfusion suspected existing coronary artery disease over counter antacid sodium monofluorophosphate cavitiesfor relief symptom seasonal allergic rhinitis sneezing rhinorrhea pruritus lacrimation nasal congestion radio labeling monoclonal antibody preparation vivo diagnostic imaging procedure indiclor radiolabeling zevalin preparation radio immunotherapy procedureindicated blood pool imaging cardiac first pas gated equilibrium imaging detection site gastrointestinal bleeding fda no therapeutic indication medicinal product indirect additive food contact substance ingredient commercial cosmetic product sun protection factor added sunscreen product wide spectrum ultraviolet absorption property active ingredient sunscreen lip balm protection against damaging effect sun ray strontium 89 chloride injection paliative relief bone pain skeletal metastasis impotant confirm presence bone metastasis prior beginning therapy a31264 sequential intravenous sodium nitrite cyanide poisoning judged life threatening uptake 18f fdg tissue marker tissue uptake glucose turn closely correlated certain type tissue metabolism fludeoxyglucose f 18 injection positron emission tomography pet imaging assessment abnormal glucose metabolism assist evaluation malignancy known suspected abnormality found testing modality existing diagnosis cancer urea 13c qualitative detection urease helicobacter pylorus human stomach aid initial diagnosis post monitoring helicobacter pylorus infection test monitoring if least four 4 week following completion therapy these purpose system utilizes infrared spectrophotometer measurement ratio 13co2 12co2 breath sample prevent recurrence malignant pleural effusion symptomatic during thoracoscopy open thoracotomy relieve pain discomfort excess gas intestine stomach case flatulence post operative gaseous distention could prior endoscopy eliminate foam gas air from gastrointestinal tract reduce gas shadow will result better visualization 14c urea intended detection gastric urease aid diagnosis helicobacter pylorus h pylorus infection human stomach test utilizes liquid scintillation counter measurement 14co2 breath sample currently primarily available only active ingredient product combined tretinoin solar lentigo related hyperpigmented lesion resulting from chronic sun exposure fda replete total body content iron during iron deficiency anemia age 6 older chronic kidney disease receiving hemodialysis receiving supplemental epoetin therapy otc topical lightening agent disorder hyperpigmentation melasma post inflammatory hyperpigmention sunspot freckle stimulation pancreatic secretion bicarbonate aid diagnosis pancreatic exocrine dysfunction fda gastrin secretion aid diagnosis gastrinoma fda pancreatic secretion facilitate identification ampulla vater accessory papilla during endoscopic retrograde cholangiopancreatography ercp fda applied topically filter out uva ray u evaluated fda considered safe up 10 formula similarly eu allows up 10 formula while health canada allows maximum level 12 most sunscreen block uva uvb ray similar zinc oxide antispetic germicidal agent patient preoperative skin preparation preparation skin prior surgery help reduce bacteria potentially cause skin infection capsule usp adjunct diet reduce triglyceride tg level severe 500 mg dl hypertriglyceridemia htg fda a176687 ointment liniment containing applied topically counter irritant relief pain lumbago sciatica rheumatic condition local analgesic human veterinary medicine diagnostic imaging adrenergically inervated tissue purpose detecting metastatic pheochromocytoma neuroblastoma fda ass sympathetic inervation myocardium via determination heart mediastinum ratio radioactivity new york heart association class ii iii heart failure monocationic surfactant detergent help penetration active ingredient through cellular debris antibacterial action dexchlorpheniramine perennial seasonal allergic rhinitis vasomotor rhiniti allergic conjunctivitis inhalant allergen food mild uncomplicated allergic skin manifestation urticaria angioedema amelioration allergic reaction blood plasma dermographism approved cisplatin gemcitabine first line metastatic squamous non small cell lung cancer nsclc non squamous nsclc source phosphate total parenteral nutrition fda amino acid dextrose lipid emulsion electrolyte choline c 11 injection positron emission tomography pet imaging suspected prostate cancer recurrence non informative bone scintigraphy computerized tomography ct magnetic resonance imaging mri these 11 c choline pet imaging help identify potential site prostate cancer recurrence subsequent histologic confirmation suspected prostate recurrence based upon elevated blood prostate specific antigen psa level following initial therapy clinical study imag e w ere produced pet ct coregistration improve glycemic control year age older diabetes mellitus adult source calorie fatty acid total parenteral nutrition fda sometimes additive cosmetic product om3 ca adjunct diet reduce triglyceride level adult severe hypertriglyceridemia gt 500 mg dl involved should laced appropriate lipid lowering diet hypertriglyceridemia defined elevated plasma triglyceride concentration usually correlated secondary condition poor diet alcohol obesity metabolic syndrome type diabetes a32630 lenalidomide dexamethasone multiple myeloma received least one prior therapy over counter nasal congestion inactivated rabies virus antigen b pre post exposure prophylaxis against rabies rotarix prevention rotavirus gastroenteritis g1 g3 g4 g9 type infant aged 6 24 week fda rotateq prevention rotavirus gastroenteritis g1 g2 g3 g4 g9 type infant aged 6 32 week zostavax vaccine prevention herpes zoster shingle immunocompetent adult aged 50 older varivax vaccine active immunization prevention varicella individual 12 month age older extract allergen extract immunotherapy house dust mite hdm induced allergic rhinitis without conjunctivitis confirmed vitro testing ige antibody dermatophagoidesfarinae house dust mite skin testing licensed house dust mite allergen extract odactra approved adult 18 through 65 age allergen extract immunotherapy house dust mite hdm induced allergic rhinitis without conjunctivitis confirmed vitro testing ige antibody house dust mite skin testing licensed house dust mite allergen extract approved adult 18 through 65 age pneumococcal pneumonia susceptible strain group beta hemolytic streptococcal infection upper respiratory tract device full thickness diabetic foot ulcer greater than six week duration extends through dermis but without tendon muscle joint capsule bone exposure drug should conjunction standard wound care regimen adequate blood supply involved foot wound partial full thickness wound pressure ulcer venous ulcer diabetic ulcer chronic vascular ulcer tunneled undermined wound surgical wound donor site graft post moh dermatological surgery post laser surgery podiatric wound dehiscence trauma wound abrasion laceration second degree burn skin tear draining wound gintuit allogeneic cultured keratinocytes fibroblast bovine collagen allogeneic cellularized scaffold product topical non submerged application surgically created vascular wound bed mucogingival condition adult us bovine collagen matrix support growth keratinocytes fibroblast wound healing product using bovine type collagen include primatrix integra orcel matriderm orcel bilayered cellular matrix normal human allogeneic skin cell both epidermal keratinocytes dermal fibroblast cultured two separate layer into type i bovine collagen sponge venous leg ulcer diabetic foot type i bovine collagen act matrix growth proliferation fibroblast keratinocytes offering structure support laboratory bovine collagen type i purified protein standard control sd page western blot elisa immunoprecipitation immunological assay chronic leg ulcer diabetic foot orcel standard therapeutic compression non infected partial full thickness skin ulcer venous insufficiency greater than month duration effectively responded conventional ulcer therapy orcel standard diabetic foot ulcer care full thickness neuropathic diabetic foot ulcer greater than 3 week duration effectively responded conventional ulcer therapy extend through dermis but without tendon muscle capsule bone involvement intravesical prophylaxis carcinoma situ ci urinary bladder prophylaxis primary recurrent stage ta t1 papillary tumor following transurethral resection tur active immunization prevention yellow fever person 9 month age older following category person living traveling endemic area while actual risk contracting yellow fever during travel probably low variability itinerary behavior seasonal incidence disease make difficult predict actual risk given individual living traveling known endemic epidemic area greater risk living traveling area south america africa where yellow fever infection officially reported time travel traveling outside urban area country do officially report disease but lie yellow fever endemic zone person travelling internationally through country yellow fever some country require individual valid international certificate vaccination prophylaxis icvp if individual country either known thought harbor yellow fever virus certificate becomes valid 10 day after vaccination 3 laboratory personnel laboratory personnel handle virulent yellow fever virus concentrated preparation virus strain risk exposure direct indirect contact aerosol immunization against hepatitis virus hav infection aged 12 month older first dose should administered least week before expected exposure hepatitis virus active immunization pediatric 15 month through 4 age booster dose prevention invasive disease haemophilus influenzae type b cellular repair strategy symptomatic cartilage defect femoral condyle medial lateral trochlea trauma were previously unresponsive available surgical procedure improvement appearance moderate severe nasolabial fold wrinkle adult fda unrelated donor hematopoietic progenitor cell transplantation procedure conjunction appropriate preparative regimen hematopoietic immunologic reconstitution disorder affecting hematopoietic system inherited acquired result from myeloablative fda component technetium 99m agent imaging skeleton area altered osteogenesis detection infarcted heart tissue fda considered active pharmacological ingredient pharmaceutical preparation so no official indication typically present topical formulation emollient occlusive agent t182 over counter skin protectant fda commonly diaper rash chapped lip fda symptomatic relief burning irritation discomfort eye dryness exposure wind sun lubricant prevent further irritation relieve dryness eye complex iodine inducing antisepsis prevention infection minor cut scrape burn ingredient sunscreen protection against damage effect sun light provides protection from sunburn aging skin cancer solubilizer antimicrobial preservative disinfectant ingredient many sunscreen protection against sunburn skin aging skin cancer please refer db00085 please refer db00085 nutritional supplement pain fever typically employed chloride salt compound commonly active ingredient various over counter mouthwash toothpaste lozenge mouth spray where generally antiseptic action gingivitis plaque prevention well action prevention against some oropharyngeal bacterial infection a24813 colorless liquid both cosmetic therapeutic us topical cream ointment help distribute active ingredient anti foaming agent hair skin conditioner head louse anti bloating anti flatulence agent ophthalmic protectant lubricant artificial tear diagnostic aid contact lens procedure gonioscopy peg 400 temporary relief burning irritation dryness eye protection against further irritation desiccation temporary relief ache pain muscle joint backache lumbago strain bruise sprain arthritic rheumatic pain pain tendon ligament control minor hemorrhage during dental restorative procedure reduce underarm perspiration relieving itching irritation redness dryness scaling flaking skin psoriasis seborrhea eczema contemporary therapeutic us primarily revolve around phenol derivative active ingredient topical antiseptic f61 topical antibacterial skin product condition like acne seborrheic dermatitis eczema others f61 topical over counter skin product skin dryness reduction stria gravidarum stretch mark constipation dry hard stool opioid induced constipation a176984 though recently pressure building end over concern efficacy a176972 a176987 relief tooth sensitivity pesticide insecticide food additive rodenticide disinfectant sterilizer relieve dental hypersensitivity increase enamel production prevent gingivitis cavity control periodontal infection over counter calcium supplement hypoparathyroidism refractory rickets known resistant rickets familial hypophosphatemia fda prophylaxis deep vein thrombosis undergoing hip replacement surgery active ingredient sunscreen sunblock factor different product fit under category broad spectrum absorbent agent these characteristic important consider fact kind ingredient either absorb reflect uv radiation important know type ray cover uva ray responsible causing sun damage reaching deeper layer skin while uvb only cause sunburn outer layer skin agent broad spectrum mean agent capable acting both uva uvb ray indication include needing high fibre regime perhaps relief constipation constipation pregnancy maintenance regularity b bowel function colostomy ileostomy hemorrhoid anal fissure chronic diarrhea diverticular disease irritable bowel syndrome ulcerative colitis antacid electrolyte replenisher potassium supplement excipient drug formulation antacid medication neutralize gastric acid short timeframe after ingestion effect soon overcome meal stimulated acid secretion a32214 commonly applied variety topical vehicle application cosmetic cream toothpaste mouthwash shampoo lipstick anti acne product lotion a32213 purpose moisturizing skin enhancing smoothness skin stimulating healing wound soothing irritated skin a32213 fda several amino acid dextrose peripherally administered source nitrogen nutritional support adequate store body fat whom short period oral administration can not tolerated undesirable inadequate fda amino acid 5 10 dextrose fat emulsion parenteral nutrition preserve protein reduce catabolism stress condition where oral administration inadequate fda administered amino acid concentrated dextrose central vein infusion prevent reverse negative nitrogen balance where alimentary tract oral gastrostomy jejestomy route can not should gastrointestinal absorption protein impaired metabolic requirement protein substantially increased morbidity mortality reduced replacing amino acid lost from tissue breakdown fda echocardiography suboptimal echocardiogram opacify left ventricular chamber improve delineation left ventricularendocardial border ultrasonography liver ultrasound liver pediatric characterize focal liver lesion active ingredient product like antibacterial antiseptic disinfectant soap topical sanitizers cleaning agent primarily implemented salt form chloride where often only active ingredient present primary purpose topical washing decrease bacteria skin conversely implemented excipient ingredient variety multidose aqueous nose eye ear product chloride being antimicrobial preservative choice facilitate effective bactericidal fungicidal action help minimize growth unwanted organism multidose container fda constipation bowel preparation prior colonoscopy cathartic agent t215 over counter product relieve occasional constipation one form administration dietary supplement skin protectant relieve dryness irritation skin help prevent diaper dermatitis over counter laxative oral soothing agent topical skin hair active agent relief symptom catarrhal cold relief symptom minor muscular sprain cramp uv b absorbing molecule sunscreen formulation fungal infection salt form no therapeutic indication own smelling salt prevent fainting radiolabelled diagnostic pet imaging myocardium under rest pharmacologic stress condition evaluate myocardial perfusion suspected existing coronary artery disease fda supplement intravenous solution given total parenteral nutrition tpn experimentally bath disseminated sclerosis sexual dysfunction studied antibacterial activity inhibition osteoclast activity utilized experimental model inflammation induce systemic inflammatory immune response animal predominant medical application formally therapeutic application skin cut bite sting abrasion antiseptic hand cleaner over counter disinfectant agent sodium form temporary relief mild symptom intermittent asthma antiseptic agent no therapeutic indication clinical oral calcium salt dietary supplemental therapy person get enough calcium their regular diet cardioprotective agent high blood potassium antidote magnesium sulfate toxicity selenium injection supplement intravenous solution given total parenteral nutrition tpn administration tpn formula help maintain plasma selenium level maintain endogenous store prevent deficiency selenium compound selenium sulfide topically anti dandruff shampoo case seborrhea purpose brevity selenite will focus discussion more information about selenium obtained db11135 dental bleaching agent oral wound healing agent oral mucosal injury aid removal hardened ear wax derivative most commonly medication chronic pain alkaloid derivative tranquilizer antitussive diarrhea t138 direct common nowadays but some derivative morphine codeine well tincture severe diarrhea seen medical practice t139 illegal registered both recreational medicinal purpose a32182 temporary relief minor ache pain muscle joint simple backache arthritis strain sprain provided daily supplement aa preparation omega 3 acid ethyl ester licensed uk prevention recurrent event after myocardial infarction addition hypertriglyceridaemia no fda ema approved therapeutic indication supplementation total parenteral nutrition prevent hyposelenemia fda supplement intravenous solution given total parenteral nutrition tpn maintain serum level prevent depletion endogenous store subsequent deficiency symptom fda currently only available product prophylactic nutritional supplementation db06757 fda primary medical indication general include being bactericide pesticide disinfectant certain isomer like m inactive ingredient purpose serving preservative some pharmaceutical biocidal component several over counter product these product marketed purpose inhibiting abnormal biological growth vagina restoring natural ph chronic pain long duration effect a32663 surface anesthetic skin mucous membrane relief pain pruritus anorectal disorder radiographic contrast agent computed tomography ct abdomen delineate gastrointestinal gi tract pediatric fda destroy kill nail matrix matrixectomies medically microscopic examination koh preparation utilized diagnosis fungal hypha trichomonad sample from hair skin nail tissue obtained scraping scalpel cotton tipped applicator inoculated directly onto koh solution addition above softener nail groove tcc 3 4 4 trichlorocarbanilide antibacterial agent bar liquid soap body wash enterobiasis roundworm ascariasis pinworm enterobius hookworm strongyloides hookworm ancylostoma pamoate form available various formulation human dog cat pamoate u pharmacopeia nomenclature embonate european pharmacopoeia nomenclature salt contains 34 7 base combined pamoic acid a32283 pamoate embonate ingested orally effective removal control ascarid hookworm infection puppy dog toxocara canis toxascaris leonina ancylostoma tubaeforme braziliense uncinaria stenocephala cat toxocara cati toxa leonina caninum braziliense u stenocephala horse pony immature parascaris equorum strongylus vulgaris edentatus equinus cyathostomes triodontophorus spp cyathostomum spp cylicodontophorus spp cylicocyclus spp cylicostephanus spp poteriostomum spp oxyuris equi anoplocephala perfoliata swine ascaris suum oesophagostomum dentatum human lumbricoides enterobius vermicularis duodenale necator americanus stable plaque psoriasis skin scalp topically psoriasis dermatosis alopecia areata biomedical research effect egfr autophosphorylation food gelling agent stabilizer medical drug obtained great interest potential source dietary fiber lipid cholesterol serum glucose insulin level lowering effect gastric emptying delay a32327 some recent study researched possibility using formation nanoparticles delivery vehicle drug a32331 primary therapeutic currently adjuvant therapy various product containing analgesic either narcotic non narcotic where expected potentiate pain relieving anti tussive etc effect analgesic component product regard some these aforementioned product typically temporary relief minor ache pain like headache muscular ache backache minor arthritis pain common cold toothache menstrual cramp etc perhaps exhausting non productive cough cold upper respiratory allergic condition doe respond non narcotic antitussive lubricant over counter ophthalmic solution temporarily relieve redness burning irritation eye complex technetium tc 99m single photon emission computerized tomography spect adjunct conventional ct mri localization stroke whom presence stroke already diagnosed ass functional viability brain tissue distinguish between stroke brain lesion stroke defined condition blood stop flowing any part brain causing damage brain cell potential effect stroke depends part brain affected well extension damage recombinant antithrombin prevention peri operative peri partum thromboembolic event hereditary deficiency antithrombin no approved therapeutic indication first dermatology part monsel solution solution antihemorrhagic agent skin mucosal biopsy dermatology under review corrosive injurious cause degenerative change observed alternative like collagen a32357 coagulative hemostatic agent mechanic hemostatic agent directly damaged tissue a32355 dentistry pulpotomy medicament control pulpal bleeding antibacterial agent hemostatic reagent restorative dentistry postextraction hemorrhage periradicular endodontic surgery a32356 complex technetium tc 99m scintigraphic imaging myocardium following separate administration under exercise resting condition help delineation region reversible myocardial ischemia absence infarcted myocardium complex scintigraphic imaging myocardium identify change perfusion induced pharmacologic stress known suspected coronary artery disease complex assessment left ventricular function evaluated heart disease overdose rescuing agent hydrocodone antitussive fda induction mydriasis ophthalmic solution diagnostic agent routine ocular examination superficial conjunctiva corneal tissue change suspected aid diagnosis keratoconjunctivitis sicca keratitis abrasion corrosion well detection foreign body sunscreening agent prevent sunburn actinic keratosis premature skin aging reduce incidence skin cancer cough suppressant relieve cough common cold flu bronchitis sinusitis a32160 no fda approved therapeutic indication sugar substitute oral hygiene active ingredient over counter symptomatic relief minor spasm gastrointestinal tract flatulence abdominal pain especially irritable bowel syndrome temporary relief itching insect bite eczema minor burn sunburn minor skin irritation minor cut scrape atopic dermatitis skin disorder temporary symptomatic relief mild joint muscle pain local topical analgesic temporary relief tension type headache aluminum based antiperspirant preparation intended reduction normal underarm perspiration hyperhidrosis temporary relief pain rheumatism arthritis neuralgia sprain strain joint muscle lumbago fibrositis f91 n alkyl c12 c14 dimethyl ethylbenzyl ammonium chloride added product function cleaning agent antimicrobial agent disinfecting cleaning product containing racemic mixture dex levo currently available any fda approved product therefore doe indication please see db09357 fda approved us dextrorotatory form active sunscreen agent active sunscreen agent over counter epidermal hyperpigmentation various skin condition melasma freckle senile lentigo topical help protect against infection minor cut scrape burn no fda approved therapeutic indication active sunscreen agent active sunscreen agent mild antisepsis skin cut abrasion employed photostabilizing agent various sunscreen product solution containing methyl cellulose substitute tear saliva if natural production these fluid disturbed constipation diverticulosis hemorrhoid irritable bowel syndrome manufacture capsule nutritional supplement edible nontoxic property provide vegetarian alternative gelatin over counter antacid self heartburn sour stomach acid indigestion fda thozylamine symptomatic control allergic rhinitis upper respiratory allergic symptom fda typically part over counter product solution containing 5 10 local application ulcer arrest foul discharge from mucous surface preparation aluminum acetate ear drop often purchased over counter available solid stick powder form minor cut abrasion after shaving adjuvant vaccine weight loss treating osteoarthritis rheumatoid arthritis brittle bone osteoporosis some people strengthening bone joint fingernail improving hair condition shorten recovery after exercise sport related injury preparation food cosmetic medicine plasma volume expander hypovolaemic shock haemostatic based hydrogel being drug delivery tissue engineering because they able promote cell adhesion proliferation addition these hydrogel wound dressing because their attractive fluid absorbance property manufacturing technology ultraviolet stereolithography two photon polymerization prepare structure containing photosensitive based hydrogel mainly condition like zinc deficiency administered adjunctive therapy alternative drug choice diarrhea dietary supplement deficit vitaminE mainly prescribed alpha form a32443 vitaminE deficiency rare primarily found premature baby very low birth weight fat malabsorption abetalipoproteinemia antioxidant property studied prevention different complex disease cancer a32436 atherosclerosis cardiovascular disease a32442 age related macular degeneration a32444 predominantly employed active ingredient lotion spray lozenge a topical antiseptic help prevent skin infection minor cut scrape burn b antiseptic local anesthetic relief sore throat pain addition active ingredient various commercial cosmetic skincare product anti aging cream while study looked into whether compound could effectively anti inflammatory agent even anti cancer therapy prevention folate deficiency antidote against folic acid antagonist contained oral contraceptive reduce risk neural tube defect arising from folic acid deficiency pregnant woman conceived during shortly after discontinuation product being studied cardiovascular disease a19273 adjunct therapy undergoing antidepressant pharmacotherapy a19271 a19272 sunscreen agent cosmetic product found otc dental product toothpaste prevention dental caries otc product these do official indication prescription product db01373 phosphate donor replacement supplementation insufficient db01373 phosphate symptomatic relief digestive disturbance feeling fullness slow digestion flatulence f114 sunscreen agent uv filter cosmetic sunscreen product well cosmetic product like shampoo conditioner hairsprays etc where confer photostability product f89 know more about approved indication please visit db01049 alpha dihydroergocryptine studied early parkinson disease a32980 well migraine prophylaxis a32983 low blood pressure peripheral vascular disorder know more about ergoloid mesylate mixture us please visit db01049 please refer db01049 know more about isomer please refer db11274 antitussive decongestant deet active ingredient predominantly insect repellant repel biting pest like mosquito tick product containing deet currently available public variety liquid lotion spray impregnated material like towelettes roll ons active pharmaceutical agent no indication considered active pharmacological ingredient pharmaceutical preparation so no official indication detect delayed type hypersensitivity coccidioides immitis individual history pulmonary coccidioidomycosis 18 64 year old positive result occurs if 48h after administration if diameter induration gt 5mm commonly cosmetic product skin hair a19503 bovine topical aid hemostasis whenever oozing blood minor bleeding from capillary small venule accessible control bleeding standard surgical technique like suture ligature cautery ineffective impractical fda additionally topical bovine absorbable gelatin sponge usp fda antimicrobial agent preservative cosmetic emergency reversal coagulation factor deficiency receiving vitamin k antagonist therapy administered part cocktail containing several coagulation factor concentrate pediatric severe congenital deficiency prevention venous thrombosis purpura fulminans found component some prothrombin complex concentrate i e factor ix complex human formulation kcentra predominantly manufactured marketed population large general nutraceutical dietary supplement a27154 a33159 historically often given child because vitaminD content oil had shown prevent vitaminD deficiency condition rickets a33159 over time common child growing up conferred upon identity healthy useful all purpose dietary supplement however since composite several nutritional compound omega 3 fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha well vitaminA vitaminD a33159 presence varying amount all these compound once make difficult recommend appropriate supplement confer any one particular health effect any one particular nutritional deficiency regardless because doe contain number important healthy nutritional compound sometimes recommended literature conferring health effect some these compound potential supplement post heart attack secondary prophylaxis omega 3 fatty acid a33165 drug only recommended topical usage relief muscular rheumatic pain human animal topical analgesic flavoring ingredient a32884 no fda ema approved therapeutic indication own scalp dandruff sotradecol sodium tetradecyl sulfate injection small uncomplicated varicose vein leg showing simple dilation competent valve sodium tetradecyl sulfate designated orphan drug fda gastrointestinal bleeding esophageal varix factor ix complex prevention control hemorrhagic episode hemophilia b urgent reversal acquired coagulation factor deficiency induced vitamin k antagonist vka e g warfarin therapy major bleeding require rapid reversal therapy palmitoyloleoyl phosphatidylglycerol component surfaxin prevention respiratory distress syndrome premature infant infant respiratory distress syndrome reduce viscosity blood before transfusion primarily condition like colic flatulence toothache temporary symptomatic relief minor ache pain muscle joint topical analgesic over counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda part over counter dietary supplement systemic inflammatory disease woman health condition cyclical mastalgia these indication do sufficient evidence their effectiveness atopic dermatitis united kingdom but currently withdrawn lack evidence effectiveness a33131 medicinally expectorant antiseptic local anesthetic traditional dental pulp sedation property inducing cell proliferation potent scavenger reactive oxygen radical radical scavenging activity effect cell proliferation over counter product wound ulcer bedsore shallow inflammatory process thrombophlebitis erysipelas only externally over counter dermatologic combination db11113 pulmonary arterial hypertension pah delay disease progression reduce risk hospitalization kinase inhibitor anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc progressed intolerant crizotinib indication approved under accelerated approval based tumor response rate duration response continued approval indication contingent upon verification description clinical benefit confirmatory trial immunostimulant therapy cell mediated immunosuppression respiratory urinary infection over counter constipation fda investigated a number cancer autoimmune condition well researched adjuvant therapy after bone marrow transplantation case leukemia bacterial infection no approved therapeutic indication own river blindness called onchocerciasis aged 12 older river blindness parasitic worm onchocerca volvulus manifested severe itching disfiguring skin condition visual impairment worm larva transmission onchocerca volvulus performed person person black fly breed fast flowing river sub saharan africa yemen south central america larva released parasite invade skin eye where they produce severe disease manifestation reversal sedative analgesic effect dexmedetomidine medetomidine dog found diverse cosmetic perfume well flavoring agent cough syrup lozenge chewing gum candy f117 medical agent local burn wound antiseptic a27160 expectorant heart stimulant increase blood pressure parasiticide t221 reverse opioid overdose large animal sedative primarily horse removal ascarids toxocara canis toxascaris leonina hookworm ancylostoma caninum uncinaria stenocephala aid removing tapeworm taenia pisiformis dipylidium caninum echinococcus granulosus from dog cat xanthine oxidase inhibitor hyperuricemia gout achieved target serum uric acid level xanthine oxidase inhibitor alone hydrolytic lysosomal cholesteryl ester triacylglycerol specific enzyme diagnosis lysosomal acid lipase lal deficiency code text here adult moderate severe plaque psoriasis candidate systemic therapy phototherapy active uv b filter prevent photodamage aid hemostasis whenever oozing blood minor bleeding from capillary small venule accessible control bleeding standard surgical technique suture ligature cautery ineffective impractical fda aid hemostasis whenever oozing blood minor bleeding from capillary small venule accessible control bleeding standard surgical technique suture ligature cautery ineffective impractical adult pediatric population greater than equal one month age fda additionally conjunction absorbable gelatin sponge usp fda antiperspirant grazoprevir product zepatier without ribavirin chronic hcv genotype 4 infection adult db11574 fixed dose product zepatier without db00811 chronic hcv genotype 1a 1b 4 infection adult drug initially kidney function test main application indigo carmine time localizing visualizing ureteral orifice during cystoscopy ureteral catheterization procedure paroxysmal nocturnal hemoglobinuria pnh fda bcl inhibitor chronic lymphocytic leukemia cll small lymphocytic lymphoma sll without 17p deletion received least one prior therapy fda skeletal muscle relaxant drug orthopedic traumatic rheumatologic disorder adjuvant drug painful muscle contracture spinal pathology adult adolescent 16 age older recent study examined effect muscle tone stiffness contracture soreness experienced athlete during sporting competition surfactant germicide fungicide mildew preventive agent silicone based water repellent emulsifier disinfectant topical anti infective antiseptic antimicrobial pharmaceutical chemical property antiseptical characteristic wide variety product part formulation determined active antiseptic ingredient over counter preparation t211 manage fatigue depression a32724 adjunct therapy obesity active ingredient various sunscreen indication protecting skin absorbing damaging uv radiation sunlight a33069 f81 f82 agent chronic hepatitis c hepatitis c virus genotype 4 compensated liver cirrhosis hepatitis c liver disease hepatitis c virus chronic state condition account 60 80 case from risk cirrhosis liver within 20 around 15 30 genotype most common type hepatitis c united state most difficult condition characterized bronchial congestion bronchospasm expectorant bronchodilator action required bronchitis episode chronic bronchitis bronchial asthma marker respiratory status spirometry test f4 food additive pigment fixation meat diagnostic tracer gas pulmonary function test preservative some cosmetic topical pharmaceutical biological drug product includes vaccine symptomatic relief nasal non nasal symptom seasonal rhinitis 12 age older symptomatic relief chronic spontaneous urticaria 18 age older fda anti infective topical infectious dental disease condition locally advanced metastatic urothelial carcinoma ineligible cicplatin containing chemotherapy tumor expressing pd ineligible cisplatin containing chemotherapy irrespective pd disease progression following platinum containing chemotherapy disease progression within 12 month neoadjuvant adjuvant chemotherapy first line non small cell lung cancer bevacizumab paclitaxel carboplatin no egfr alk genomic abnormality disease progression during after platinum containing chemotherapy even if they egfr alk abnormality paclitaxel protein bound locally advanced metastatic triple negative breast cancer expressing pd finally carboplatin etoposide first line extensive stage small cell lung cancer rescue therapy following high dose methotrexate osteosarcoma diminishing toxicity inadvertent overdosage folic acid antagonist product fusilev fda dosed one half usual dose racemic d l leucovorin additional indication chemotherapy 5 fluorouracil palliative advanced metastatic colorectal cancer although they should mixed same infusion precipitate form suppression rhesus rh isoimmunization nonsensitized rho d negative woman rh incompatible pregnancy rho d negative individual transfused rh0 d positive red blood cell rbc blood component containing rh0 d positive rbc rh0 d positive non splenectomized chronic immune thrombocytopenic purpura itp raise platelet count human antithrombin hereditary antithrombin deficiency prevention thromboembolism prevention peri operative peri partum thromboembolism characterized several therapeutic property great interest u thought particularly effective healing bruise inflammation burn recently interest researcher moved even antimicrobial property although there still few study literature focused only action few study showed antimicrobic effectiveness against overall staphylococcus aureus salmonella enterica candida albicans aspergillus niger sterile preparation white hard paraffin isopropyl palmitate sterile surgical bone wax control bleeding from damaged bone during surgery should confused aseptic surgical wax bpc 1949 known horsley wax contained yellow olive oil phenol mercuric chloride solution control haemorrhage bone cranial surgery diagnostic agent mantoux test detect infection mycobacterium tuberculosis alleviating surface irritation topical ocular administration artificial tear solution found topical formulation aid more efficient drug diffusion across membrane prophylaxis against rabies virus exposed virus immunocompromised previously recieved rabies vaccine fda prophylaxis against tetanus injured incomplete uncertain immunization statu fda active tetanus fda approved only food historically indigestion ulcer cold cough asthma bronchial congestion arthritic pain cancer leprosy syphilis orally stimulant antispasmodic increase menstrual flow topically mild inflammation oral pharyngeal mucosa aphthous ulcer gingivitis chapped lip hemorrhoid bedsore wound abrasion furunculosis bad breath loose teeth food beverage flavoring component manufacturing fragrance fixative cosmetic embalming incense bleeding episode adult acquired hemophilia prophylaxis bleeding haemophilia congenital factor viii deficiency fda prophylaxis bleeding all age haemophilia b congenital factor ix deficiency cough le potent treatment failed fda db11609 antitussive fda sign symptom keratoconjunctivitis sicca dry eye syndrome therapy antiviral medication chronic hepatitis c virus hcv infected hcv genoptypes 6 hcv hiv co infected depending level cirrhosis decompensation therapy include therapy db00811 db08934 product epclusa chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis db00811 if decompensated cirrhosis fda symptomatic relief nasal non nasal symptom seasonal allergic rhinitis perennial allergic rhinitis age older fda symptomatic relief chronic spontaneous urticaria age older endometriosis without accompanying sterility limited single course 6 month duration per lifetime preventing reducing severity chicken pox varicella zoster virus infection high risk individual within 4 day exposure varicella zoster virus no approved therapeutic indication adult adjunct surgery subsequent removal tumour so prevent delay amputation palliative care irresectable soft tissue sarcoma limb fda melphalan via mild hyperthermic isolated limb perfusion active immunization against hepatitis b virus infection vaccine will protect against infection hepatitis non non b hepatitis virus hepatitis d delta agent doe occur absence hepatitis b infection carrier state expected hepatitis d will prevented vaccination hepatitis b virus vaccine vaccine administered any age from birth onwards start primary course vaccination booster dose complete primary course vaccination started plasma derived yeast derived vaccine booster dose subject previously received primary course vaccination plasma derived yeast derived vaccine area low prevalence hepatitis b vaccination strongly recommended subject increased risk infection these include following group health professional physician surgeon oral surgeon dentist nurse dental nurse dental hygienist podiatrist iv team operating room personnel paramedical personnel close contact staff hemodialysis nephrology hepatology hematology oncology unit laboratory personnel handling blood clinical specimen blood bank plasma fractionation worker pathologist morgue attendant cleaning staff handle waste hospital emergency first aid worker ambulance staff dental medical nursing student patient receiving frequent blood transfusion clotting factor concentrate those oncology unit those thalassemia sickle cell anemia cirrhosis hemophilia etc hemodialysis type diabetes personnel resident institution person frequent close contact high risk group prisoner prison staff resident staff institution developmentally challenged those contact aggressive biting resident being highest risk person increased risk their sexual practice male having sexual contact male others multiple sexual partner recent history sexually transmitted disease person injectable drug illicitly traveller area high endemicity their close contact household contact any above group chronic hepatitis b infection infant born hbsag positive mother chronic liver disease cld subject chronic liver disease subject risk developing cld e g hepatitis c virus carrier person abuse alcohol others police fire fighter armed force personnel mortician embalmer those through their work personal lifestyle exposed hepatitis b virus area both low high prevalence vaccination should offered all young child neonate risk well high risk group advanced squamous cell carcinoma head neck failing standard therapy unsuitable radiotherapy surgery systemic chemotherapy fda approved adjunctive therapy adult parkinson disease end dose motor fluctuation whose symptom can not stabilized levodopa dopa decarboxylase inhibitor combination 18 age older invasive aspergillosis fda 18 age older invasive mucormycosis fda where amphotericin b inappropriate vitaminE deficiency digestive malabsorption pediatric congenital chronic cholestasis hereditary chronic cholestasis from birth full term newborn up 18 age part appropriate regimen pulmonary multi drug resistant tuberculosis mdr tb effective regimen can not otherwise composed reason resistance tolerability uncomplicated plasmodium falciparum infection adult child infant aged 6 month up weighing over 5 kg fda db13941 tibia fracture adult adjunct standard care using open fracture reduction intramedullary unreamed nail fixation fda single level lumbar interbody spine fusion substitute autogenous bone graft adult degenerative disc disease had least 6 month non operative condition symptomatic lambert eaton myasthenic syndrome lem adult f272 aged 6 le than 17 age f4609 nevertheless important note current time only firdapse brand lem adult f272 ruzurgi brand lem aged 6 le than 17 f4609 monotherapy adult advanced transitional cell carcinoma urothelial tract after failure prior platinum containing therapy narcolepsy without cataplexy excessive daytime sleepiness narcolepsy cardiomyopathy wild type hereditary transthyretin mediated amyloidosis adult a189708 a189711 trastuzumab capecitabine adult diagnosed advanced unresectable metastatic her2 positive breast cancer includes brain metastasis those received one more prior anti her2 based regimen metastatic setting premenopausal woman hypoactive sexual desire disorder medical psychiatric condition problem relationship effect medication drug opthalmic solution reduction intraocular pressure open angle glaucoma ocular hypertension fda no approved therapeutic indication medium chain triglyceride provide calorie fatty acid long chain fatty acid oxidation disorder lc faods although investigated several type cancer currently only neurofibromatosis type nf1 symptomatic inoperable plexiform neurofibroma pn a193611 opioid induced constipation fda prevention nausea vomiting induced cytotoxic therapy postoperative chronic weight 6 older obesity pro opiomelanocortin deficiency proprotein subtilisin kexin type deficiency leptin receptor deficiency these condition affect mc4r signalling pathway a224454 currently mantle cell lymphoma mcl received least one prior therapy recently approved chronic lymphocytic leukemia small lymphocytic lymphoma combined ivacaftor one product cystic fibrosis cf aged 12 older two copy f508del gene mutation least one mutation cftr gene responsive drug ivacaftor elexacaftor product trikafta cf 12 age older least one f508del mutation cftr gene locally advanced metastatic urothelial carcinoma disease progression during following platinum containing chemotherapy within 12 month neoadjuvant adjuvant platinum containing chemotherapy unresectable stage iii non small cell lung cancer nsclc whose disease progressed following concurrent platinum based chemotherapy radiation therapy approved extensive stage small cell lung cancer e sclc etoposide either carboplatin cisplatin first line therapy monotherapy locally advanced unresectable non small cell lung cancer nsclc adult whose tumour express pd tumour cell whose disease progressed following platinum based chemoradiation therapy binimetinib metastatic melanoma braf v600e v600k mutation detected fda approved test kisqali selective cyclin dependent kinase inhibitor class drug help slow progression cancer inhibiting two protein called cyclin dependent kinase 4 6 cdk4 6 these protein over activated enable cancer cell grow divide too quickly targeting cdk4 6 enhanced precision play role ensuring cancer cell do continue replicate uncontrollably no approved indication migraine without aura adult there limited therapeutic us formally some predominant indication include facilitate construction structurally immunologically effective attenuated vaccine t188 b role play essential element formation lactulose synthetic disaccharide constipation hepatic encephalopathy he hepatic coma nevertheless there many study looking into variety possible us monosaccharide sugar accelerating senescence mouse rat drosophila a32853 a32854 proposed association between consumed milk ovarian cancer a32855 a32856 possible role therapy focal segmental glomerulosclerosis a32858 among various others regardless none these proposed indication yet formally elucidated practical hydrochloride novel epidermal growth factor receptor egfr tyrosine kinase inhibitor exhibit encouraging efficacy tolerability advanced non small cell lung cancer nsclc failed previous chemotherapy traveler diarrhea noninvasive strain e coli status disease should complicated fever blood stool prevent drug resistant bacteria important mention indication should only done case where infection proven strongly suspected bacteria travallers diarrhea very common problem affecting 20 60 traveller defined increase frequency bowel movement three more loose stool per day during trip abroad condition rarely life threatening but severe case produce dehydration sepsis most common cause traveller diarrhea pathogen from pathogen identified bacteria most common cause followed norovirus rotavirus similar virus a39995 thcv doe currently any fda health canada ema approved indication adjunct levodopa carbidopa parkinson disease deleterious suspected deleterious germline brca mutated her2 negative locally advanced metastatic breast cancer adult fda constipation predominant irritable bowel syndrome ibs c adult currently being investigated hyperphosphatemia chronic kidney disease undergoing dialysis nct02081534 nct02675998 a185489 modere severe reactive ra irresponsive respond inadequately present intolerance disease modifying anti rheumatic drug dmards tumor necrosis factor tnf antagonist methotrexate mtx monotherapy there intolerance mtx mtx administration inappropriate approved psoriasis vulgaris psoriatic arthritis pustular psoriasis psoriatic erythroderma metastatic non small cell lung cancer nsclc whose tumor mutation lead mesenchymal epithelial transition met exon 14 skipping detected fda approved test maintenance recurrent epithelial ovarian fallopian tube primary peritoneal cancer complete partial response platinum based chemotherapy antiretrovirals multidrug resistant hiv infection heavily experienced adult failing their current antiretroviral therapy resistance intolerance safety concern hiv infection previously treated antiretroviral therapy additionally hiv infection virologically suppressed hiv rna lt 50 c ml regular antiretroviral regimen minimum three month without history failure no known factor resistance individual component medication tenofovir emtricitabine moderate severe active rheumatoid arthritis responded inadequately intolerant one more disease modifying anti rheumatic drug monotherapy methotrexate pediatric under 18 weighing least 5 kg continued approval drug indication dependent upon confirmatory clinical trial result drug conjunction oral antidepressant treatment resistant depression trd adult fda note approved anesthetic agent safety effectiveness anesthetic agent established date fda monotherapy improve glycemic control type diabetes fda metformin hydrochloride improve glycemic control diabetes type controlled regimen metformin already treated both metformin administration sitagliptin improve glycemic control type diabetes sitagliptin appropriate pointed out adjunct therapy diet exercise type diabetes mellitus characterized insulin resistance muscle liver result elevation glucose level blood presence insulin deficiency insulin resistance related genetic factor obesity sedentary lifestyle aging increase blood glucose cause severe damage kidney eye vascular system a31582 extended adjuvant early stage her2 overexpressed amplified breast cancer follow adjuvant trastuzumab based therapy fda adult moderate severe plaque psoriasis candidate systemic therapy phototherapy cushing disease whom pituitary surgery option curative a191850 vasoconstrictor increasing blood pressure adult septic distributive shock fda advanced prostate cancer inhalation solution maintenance chronic obstructive pulmonary disease copd copd growing disease being third leading cause death u disease characterized fully reversible airflow limitation synthetic neuroactive steroid gamma aminobutyric acid gaba receptor positive modulator postpartum depression ppd woman fda a176080 a176083 f4063 f4066 f4072 osteoporosis post menopausal woman high risk fracture osteoperosis intolerant treatment failed treatment non metastatic castration resistant prostate cancer nm crpc fda tardive dyskinesia adult fda duchenne muscular dystrophy dmd age older fda context overall louse program topical head louse infestation 6 month age older adjunct diet maximally tolerated statin therapy adult heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease warrant additional lowering ldl c bempedoic ezetimibe diet maximally tolerated statin therapy elevated ldl c level adult heterozygous familial hypercholesterolemia existing atherosclerotic cardiovascular disease require further lowering ldl c relapsed refractory multiple myeloma dexamethasone must received least 4 prior therapy disease refractory least two proteasome inhibitor least two immunomodulatory agent anti cd38 monoclonal antibody bacterial skin skin structure infection gram positive organism staphylococcus aureus methicillin resistant methicillin susceptible isolates staphylococcus haemolyticus staphylococcus lugdunensis streptococcus agalactiae streptococcus anginosus group streptococcus anginosus streptococcus intermedius streptococcus constellatus streptococcus pyogenes enterococcus faecalis well gram negative organism escherichia coli enterobacter cloaca klebsiella pneumoniae pseudomonas aeruginosa fda adult pediatric 12 older metastatic merkel cell carcinoma mcc insomnia characterized difficulty sleep onset sleep maintenance relapsed refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll after least two prior therapy cll cancer blood stem cell blood cell develop into different type cell leukemia there overproduction cell abnormal do mature into blood cell thus they just crowd out normal cell impair their normal function lymphocyte leukemia abnormal cell growth observed lymphoid cell type blood cell mature into lymphocyte cll type lymphocytic leukemia develops slowly over month sll very similar disease cll these term usually referred interchangeably only difference between these two disease cll cell found mostly blood bone marrow while sll cell mainly found lymph node well obtained accelerated approval relapsed refractory follicular lymphoma after least two prior systemic therapy approval still under status continued approval restrained confirmatory trial follicular lymphoma b cell lymphoma cluster lymph node tissue first line metastatic non small cell lung cancer nsclc epidermal growth factor receptor egfr exon 19 deletion exon 21 r substitution mutation verified fda approved test lung cancer leading cause cancer death nsclc account 85 lung cancer case from case nsclc approximately 75 present late diagnosis metastatic advanced disease produce survival rate 5 presence mutation egfr account more than 60 nsclc case overexpression egfr frequent lymph node metastasis poor chemosensitivity a40018 a19201 june 27 2018 food drug administration approved encorafenib unresectable metastatic melanoma braf v600e v600k mutation detected fda approved test cytarabine newly diagnosed myeloid leukemia over 75 old co morbidity preclude intensive induction chemotherapy myeloid leukemia characterized abnormal production myeloblast red cell platelet considered cancer blood bone marrow most common type leukemia adult gonadotropin releasing hormone gnrh receptor antagonist moderate severe pain endometriosis fda metastatic ros1 positive non small cell lung cancer adult adult child over 12 old ntrk gene fusion positive solid tumor metastasized surgical resection likely result severe morbidity progressed previous therapy no comparable alternative therapy available relapsing primary progressive form multiple sclerosis fda chaga disease child 12 age osteoarthritis affecting hip knee thrombocytopenia chronic liver disease scheduled undergo procedure fda fulvestrant woman hormone receptor hr positive human epidermal growth factor receptor her2 negative advanced metastatic breast cancer disease progression following endocrine therapy inidicated monotherapy hr positive her2 negative advanced metastatic breast cancer disease progression following endocrine therapy prior chemotherapy metastatic setting over counter dietary supplement increasing bone density regulating blood fat chronic immune thrombocytopenia itp had insufficient response previous therapy fda fulvestrant postmenopausal woman men advanced metastatic breast cancer cancer must hormone receptor hr positive human epidermal growth factor receptor her2 negative pik3ca mutated cancer must detected fda approved test following progression after endocrine based regimen smallpox infection administered child adult minimum body weight 13 kg fda inhibitor orthopoxvirus vp37 envelope wrapping protein fda maintenance 12 older severe asthma eosinophilic phenotype pathology severe asthma eosinophilic phenotype denotated th2 high phenotype phenotype characterized expression il 5 il 13 airway hyperresponsiveness responsiveness inhaled corticosteroid high serum ige eosinophilia blood airway th2 high phenotype il 5 present central role responsible eosinophil differentiation survival activation migration lung a31295 vosevi db08934 db11613 approved genotype 6 previously treated ns5a inhibitor genotype 1a 3 infection previously treated hcv regimen containing db08934 without ns5a inhibitor tetracycline class drug inflammatory lesion non nodular moderate severe acne vulgaris 9 age older fda prophylaxis cytomegalovirus cmv infection disease cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct fda serotonin synthesis inhibitor telotristat etiprate potential reduce serotonin level address key element carcinoid syndrome meropenem 18 age older complicated urinary tract infection cuti pyelonephritis following susceptible microorganism escherichia coli klebsiella pneumoniae enterobacter cloaca specie complex fda initially formulated alzheimer progressive supranuclear palsy a31601 raising interest come from significant upregulation gsk 3 brain alzheimer disease function degradant  catenin important prevents transcription cell survival gene all these factor directed current research towards kinase potential target a31603 alzheimer disease most prevalent form dementia most accepted hypothesis explain disease related presence amyloid  trigger cascade will alter tau protein provoke synaptic dysfunction neuronal death a31605 gsk 3 importance tissue repair pathway pointed out novel application thus under research natural repair deep caries lesion a31602 third generation anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki alk positive metastatic non small cell lung cancer nsclc whose disease progressed prior crizotinib least one alk inhibitor metastatic disease b prior alectinib first alk inhibitor therapy metastatic disease c prior certinib first alk inhibitor therapy metastatic disease fda trial studying diagnostic nerve trauma inflammation pain neuropathic arthritis rheumatoid coronary heart disease among others relapsed refractory myeloid leukemia flt3 mutation detected fda approved test indication expanded companion diagnostic include leukostrat cdx flt3 mutation assay myeloid leukemia cancer impact blood bone marrow rapid progression condition produce low number normal blood cell requirement continuous need transfusion pan fibroblast growth factor receptor fgfr tyrosine kinase inhibitor fda a177109 a177112 a177115 locally advanced metastatic urothelial carcinoma i susceptible fgfr3 fgfr2 genetic alteration fda ii progressed during following least one line prior platinum containing chemotherapy within 12 month neoadjuvant adjuvant platinum containing chemotherapy fda selection locally advanced metastatic urothelial carcinoma should based presence susceptible fgfr genetic alteration tumor specimen detected fda approved companion diagnostic like fda approved therascreen fgfr rgq rt pcr kit developed qiagen fda above indication approved under accelerated approval u fda based tumor response rate fda continued approval indication contingent upon verification description clinical benefit confirmatory trial fda monotherapy topical corticosteroid aged 12 older moderate severe atopic dermatitis whose disease adequately controlled topical prescription therapy those therapy advisable add maintenance moderate severe asthma aged 12 older eosinophilic phenotype oral corticosteroid dependent asthma relief bronchospasm status asthmaticus nasal polyp accompanied inadequately controlled chronic rhinosinusitis chorea huntington disease fda medication adult relapsed refractory diffuse large b cell lymphoma bendamustine rituximab returned progressed after more previous therapy improving neurological symptom damage from ischemic stroke delaying disease progression al drug fascioliasis aged 6 old above fda primary medical purpose sb currently removal eschar adult deep partial full thickness thermal burn fda besides official indication however believed sb several purpose well cardiovascular health osteoarthritis autoimmunity blood clotting diarrhea cancer surgery debridement although specific mechanism action these indication remain elucidated a27198 anaplastic lymphoma kinase positive metastatic non small cell lung cancer alk nsclc represents only 3 5 nsclc cancer case but alk mutation overexpression presence several oncogenic fusion protein solid hematologic tumor pointed out importance well potential cancer therapy target a31311 alk related case nsclc presence fusion gene em alk fused alk protein echinoderm microtubule protein like 4 whose original function correct formation microtubule a31313 presence aberrant fusion protein result abnormal signaling provokes increased cell growth proliferation survival a31316 crizotinib case but presence alk kinase domain mutation confer resistance thus alk nsclc intolerance crizotinib a31314 symptomatic urinary incontinence increased urinary frequency urgency overactive bladder oab neurogenic bladder result spinal cord injury a32581 anemia adult beta thalassemia require regular red blood cell transfusion antiretroviral agent hiv infection no prior antiretroviral history replace current antiretroviral regimen those virologically suppressed hiv rna le than 50 copy per ml stable antiretroviral regimen no history failure no known substitution resistance different type cancer most notably philadelphia chromosome positive ph chronic myeloid leukemia cml resistance intolerance bcr abl tyrosine kinase inhibitor resistant intolerant imatinib only therapeutic currently primarily active ingredient topical agent treating common wart verruca vulgaris periungual wart plantar wart molluscum contagiosum a32891 a32892 f32 same time topical application number off indication like callus removal cutaneous leishmaniasis herpes zoster acquired perforating dermatosis a32892 furthermore since most topical application most commonly available 0 7 formulation more potent mixture 0 7 formulation most commonly common wart periungual wart molluscum contagiosum while more potent mixture typically limited only healthcare professional clinical setting treating plantar wart more specialized off condition a32891 a32892 f32 moreover there study into whether could effective being inflammatory model cancer either yet formally elucidate any result a32892 drug tetracycline class antibacterial complicated intra abdominal infection 18 age older fda monotherapy deleterious brca mutation germline somatic advanced ovarian cancer treated two more chemotherapy select therapy based fda approved companion diagnostic prophylaxis venous thromboembolism vte condition moderate severe restricted mobility qualify risk vte pediatric mucopolysaccharidosis vii mp vii sly syndrome drug relapsing form multiple sclerosis m include clinically isolated syndrome relapsing remitting disease active secondary progressive disease adult fda imipenem cilastatin complicated urinary tract infection pyelonephritis complicated intra abdominal infection susceptible organism adult induction maintenance procedural sedation adult undergoing procedure lasting 30 minute le investigated antineoplastic agent solid tumor advanced solid tumour myeloid leukaemia community acquired bacterial pneumonia bacterial skin skin structure infection susceptible organism adult fda migraine without aura adult 2014 approved japan case influenza were unresponsive conventional a191721 given efficacy targetting several strain influenza investigated country novel virus ebola most recently covid 19 a191688 a191724 relapsed follicular lymphoma fl received least two prior systemic therapy intravenous relapsed refractory mycosis fungoides mf szary syndrome s after least one prior systemic therapy approval provides new option mf first fda approval drug specifically szary syndrome fda topical acne vulgaris 12 age older adult primary secondary myelofibrosis either intermediate high risk aquaporin 4 aqp4 immunoglobulin positive aqp4 igg neuromyelitis optica spectrum disorder nmosd available over counter antacid alleviate pain gastritis peptic ulcer disease heartburn esophagitis hiatus hernia anorexia a33109 investigated lymphoma non hodgkin multiple myeloma anticoagulant disseminative blood vessel coagulation hemorrhagic lesion hemorrhagic tendency prevents blood clot formation during extracorporeal circulation undergoing continuous renal replacement therapy extra corporeal membrane oxygenation adult relapsing form m include relapsing remitting disease clinically isolated syndrome active secondary progressive m 18 age older complicated urinary tract infection cuti pyelonephritis limited no alternative option should only infection proven strongly suspected susceptible microorganism fda bosnia relapsing remitting multiple sclerosis metastatic small cell lung cancer sclc disease progression after platinum based chemotherapy mxp relapsed refractory hairy cell leukemia hcl received least two prior systemic therapy purine nucleoside analog drug recommended severe renal impairment crcl lt 29 ml min hcl uncommon type lymphocytic leukemia start b cell b lymphocyte characterized accumulation abnormal b lymphocyte hcl called hairy produce hair like projection surface cancer cell usual symptom people having hcl presence splenomegaly le often hepatomegaly a38877 human immunodeficiency virus type hiv infection highly experienced adult multidrug resistant hiv infection failing their current antiretroviral regimen fda approval trogarzo supported clinical trial 40 experienced adult mdr hiv infection persistently had elevated level hiv rna their blood despite heavy antiretroviral therapy majority study had previously treated 10 antiretroviral medication selective multi targeted tyrosine kinase inhibitor suppresses c met c ret mutant form c kit pdgfr flt3 suppresses rad51 protein critical component double stranded dna repair cancer cell primary therapeutic currently therapy levadopa parkinson disease adult gt 25 age exception drug induced parkinsonism f2 certain dos product levodopa restless leg syndrome sometimes parkinson disease t181 there some study prompted european medicine agency confer orphan designation upon hydrochloride potential therapy beta thalassaemia f3 although study ongoing no evidence formally elucidated yet f3 topical acne vulgaris 9 age older adult diagnosed community acquired bacterial pneumonia cabp susceptible bacteria should reserved confirmed susceptible organism high probability infection susceptible organism list susceptible bacteria includes streptococcus pneumoniae staphylococcus aureus methicillin susceptible legionella pneumophila haemophilus influenza chlamydophila pneumoniae mycoplasma pneumoniae no approved indication bacterial vaginosis woman effect investigated area analgesia anti inflammation effect reported about molecule a39816 molecule approved widely accepted veterinary pain reduction arthritis a39835 human researched control pain inflammation osteoarthritis a39844 a39843 effect explained through function prostaglandin e2 pge2 key mediator swelling redness pain classic sign inflammation effect pge2 result from action through four receptor ep1 ep2 ep3 ep4 from ep4 primary mediator pge2 driven inflammation a39817 phenylketonuria pku uncontrolled blood phenylalanine concentration greater than 600 micromol l existing calcium sensing receptor agonist secondary hyperparathyroidism hpt chronic kidney disease ckd hemodialysis demand control bleeding episode adult previously diagnosed von willebrand disease contains only vwf thus administration offer flexibility administer coagulation factor viii if needed von willebrand disease inherited disorder characterized deficiency misfunction von willebrand factor vwf deficiency blood can not clot properly present disease prone prolonged excessive bleeding there three type disease type 3 autosomal recessive inherited disorder marked very low absent level vwf pediatric 16 older metastatic locally advanced epithelioid sarcoma eligible complete resection metastatic triple negative breast cancer mtnbc undergone two more prior therapy metastatic disease indication approved under accelerated approval continued approval contingent demonstration clinical benefit confirmatory trial available commercially available product corifact approved food drug administration routine prophylactic peri operative surgical bleeding pediatric congenital fxiii deficiency fda primary therapeutic currently active ingredient capsaicinoid nonivamide compound topical analgesic temporary relief pain rheumatism arthritis lumbago muscular ache sprain strain sporting injury condition where local warmth beneficial f11 nevertheless most available study regarding nonivamide topical analgesic focus specifically their efficacy safety treating non specific low back pain typically finding analgesic effective safe well tolerated medication indication a32785 a32786 cream topical impetigo staphylococcus aureus streptococcus pyogenes aged month age older fda drug diagnosed non metastatic castrate resistant prostate cancer chronic idiopathic constipation adult acne topical dental caries dental symptomatic tenosynovial giant cell tumor tgct severe morbidity functional limitation amenable improvement surgery locally advanced metastatic urothelial cancer previously received programmed death receptor pd programmed death ligand pd inhibitor platinum containing chemotherapy neoadjuvant adjuvant locally advanced metastatic setting variety neurological psychiatric disorder dyskinesia alcohol withdrawal syndrome negative symptom psychosis agitation aggression elderly diagnosis growth hormone deficiency aghd fda currently under investigation topical ulcerative oral mucositis thrombocytopenia adult chronic liver disease scheduled undergo medical dental procedure vwf factor viii complex prevention excessive bleeding during after minor major surgery pediatric von willebrand disease demand control bleeding episode von willebrand disease inherited disorder characterized deficiency misfunction von willebrand factor vwf deficiency blood can not clot properly present disease prone prolonged excessive bleeding there three type disease type 3 autosomal recessive inherited disorder marked very low absent level vwf copd chronic obstructive pulmonary disease known chronic obstructive lung disease asthma prevents recurrence clostridium difficile infection people 18 older either currently receiving c difficile infection high risk recurrence calcium glubionate condition low calcium level bone loss osteoporosis weak bone osteomalacia rickets decreased activity parathyroid gland hypoparathyroidism certain muscle disease latent tetany certain make sure they getting enough calcium e g woman pregnant nursing postmenopausal people taking certain medication phenytoin phenobarbital prednisone drug reduce risk life threatening infection neutropenia particularly after cytotoxic chemotherapy reduce duration neutropenia severity infection non myeloid malignancy undergone autologous allogeneic bone marrow transplantation established cytotoxic chemotherapy addition reduce incidence infection established cytotoxic chemotherapy mobilise peripheral blood progenitor cell pbpcs alone after myelosuppressive chemotherapy order accelerate haematopoietic recovery infusion cell after myelosuppressive myeloablative therapy accelerate engraftment these cell after their reinfusion granocyte severe chronic neutropenia congenital agranulocytosis kostmann syndrome non small cell lung cancer small cell lung cancer oesophygeal cancer head neck cancer a20300 fluciclovine detection agent positron emission tomography pet men suspected prostate cancer recurrence based elevated blood prostate specific antigen psa level following prior a31388 overexpression l type amino acid transporter lat1 lat3 mediate uptake essential amino acid extensively reported tumoral mechanism cell growth a31389 please refer db00085 adult child aged 12 above hereditary factor x deficiency demand control bleeding episode perioperative bleeding mild hereditary factor x deficiency fda emergency reversal coagulation factor deficiency recieving vitamin k antagonist therapy fda protein administered part cocktail containing several coagulation factor administered case uncontrolled bleeding factor vii alone congenital hemophilia b acquired hemophilia congenital factor vii deficiency glanzmann thrombasthenia off refractory bleeding after cardiac surgery warfarin related intracerebral hemorrhage brand human factor vii currently only vitamin k coagulation factor reverse vitamin k antagonist activity major bleeds urgent surgery invasive procedure control bleeding episode perioperative routine prophylaxis against bleeding episode hemophilia b inhibitor fda absence factor viii ix inhibitor factor ix christmas disease factor ix deficiency treated injection factor ix produced from human plasma tranexamic acid value undergoing surgery inherited factor ix deficiency order reduce perioperative risk bleeding known elicit number potentially beneficial pharmacological effect anti irritant anti inflammatory anti microbial action bisabolol demonstrated enhance percutaneous absorption certain moleculesused intermediate organic synthesis dye drug local antibacterial agent root canal therapy topical antiseptic ointment medication sometimes vasoprotective agent microbiology laboratory aid identification bacterial specie especially enterococci listeria all strain group d streptococci hydrolyze sculin 40 bile mucocutaneous infection herpes simplex virus type type ii genital wart adjunctive therapy podophyllin carbon dioxide laser active pharmacological ingredient pharmaceutical preparation so no official indication dermatology topical clobestasone butyrate help reduce itchiness erythema eczema dermatitis ophthalmology butyrate 0 eye drop shown safe effective dry eye sjgren syndrome spinal muscular atrophy sma pediatric chronic bronchitis pneumonia bronchiectasis chronic obstructive pulmonary disease infectious inflammatory disease upper respiratory tract metastatic t790m mutation positive non small cell lung cancer a19196 proven effective twice daily glaucoma ocular hypertension currently study approved both diabetic retinopathy diabetic macular oedema rheumatology particular rheumatoid arthritis ankylosing spondylitis analgesic painful arthritic pathology there no current pharmacotherapeutic product based stimulates intestinal fluid secretion gastrointestinal tract support regular bowel function taken orally once daily work locally upper gi tract stimulate secretion intestinal fluid support regular bowel function late infantile neuronal ceroid lipofuscinosis type cln2 disease decelerate progressive motor function decline 3 age older cln2 disease form batten disease rare inherited neurodegenerative disorder seizure ataxia rapid loss language motor function blindness early death lack lysosomal enzyme tripeptidyl peptidase tpp1 subsequent accumulation lysosomal storage material normally metabolized enzyme central nervous system no approved indication no approved indication food without any limitation drug nutrient supplement special dietary food infant formula present relevant role ensuring oocyte fertility studied polycystic ovary a32751 being researched diabetes a32766 prevention metabolic syndrome a32768 aid agent weight loss a32769 depression psychiatric disorder anxiety disorder a32770 prevention cancer a32771 bacterial infection part electrolyte supplementation total parenteral nutrition fda performance enhancing drug illicitly athlete naturally occuring substance found predominantly skeletal muscle vertebrate primary utility within body serve maintanence recycling adenosine triphosphate atp muscular activity like contraction given utility recycle atp most plausible therapeutic potential involve condition energy shortage increased energy requirement ischemic stroke cerebrovascular disease important note however relatively little clinical research done significantly further evidence any indication although administered intravenously cardiovascular condition some country additionally because regulated controlled substance taken supplement some professional athlete mean perhaps increase short burst muscle strength energy professional athletics human antihemophilic factor case hemophilia known classical hemophilia prevention control hemorrhagic episode if surgery needed hemophilia there need correction clotting abnormality case human antihemophilic factor administered followed intermittent maintenance dos hemophilia characterized deficiency coagulation factor viii result prolonged blood flow after injury surgery well recurrent bleeding t56 pancreatic enzyme replacement pancreatic insufficiency intended mimic naturally produced human powder prepared from gastric mucosa pig cattle sheep laboratory primarily unspecific hydrolysis protein peptide acidic medium addition provides limited hydrolysis native immunoglobulin yielding biologically active fragment certain supplement combined betaine hcl hydrochloric acid aid digestion various gastrointestinal condition reduction duration neutropenia incidence febrile neutropenia treated cytotoxic chemotherapy malignancy exception chronic myeloid leukaemia myelodysplastic syndrome over counter antacid nutritional supplement industry sodium perborate disinfectant part ingredient detergent bleach powder personal care formulation cosmetic product mainly salt oxidizing agent dyeing permanent waving f66 dentistry sodium perborate monohydrate aid removal phlegm mucus secretion occasional sore mouth cleansing minor wound temporary cleanse canker sore removal foreign material minor wound ophthalmic preparation sodium perborate preservative product dry eye approved compound rapidly degrades harmless byproduct t203 absorb moisture prevent caking improve feel product pharmaceutical company dietary supplement part formulation ingredient drug production antacid antiulcer preparation component antiepileptic drug antifungal topical agent acne facial moisturizer complexed arginine antiatherosclerotic agent promote bone cartilage formation mammal t186 ferrous sulfate prevention iron deficiency anemia adult child a190804 different disease syphilis amoebiasis yaw trypanosomiasis malaria commonly vaginitis trichomonas vaginalis candida albicans a32839 a32841 orally administered intestinal amoebiasis form suppository researched proctitis protozoan infection parasitic disease characterized organism classified kingdom protozoa formed great diversity organism db13908 available over counter product symptomatic relief sore throat postoperative sore throat a27155 emetic agent induction vomiting poisoning victim ingested systemic poison order prevent absorption chemical through gastrointestinal tract low dos expectorant report suggested vastly eating disorder produce vomiting t49 historically topical antiseptic agent skin infection f4549 maintains european country vaginal tablet promestriene vaginal infection f4552 some country brasil single agent cerebral peripheric vascular event know more about part ergoloid mesylate mixture please visit db01049 various skin condition atopic eczema inflammatory dermatosis europe form topical antiviral human herpes keratitis a32643 human herpes keratitis inflammation cornea eye herpes simplex virus infection infection cause significant morbidity whose incidence significantly increased presence recurrent infection even produce corneal blindness a32645 3 cream dermal herpes simplex virus a32643 virus produce infection ubiquitously highly contagious there two type herpes virus type mainly transmitted oral oral contact type sexually transmitted ioxitalamate both available form exploration digestive tract tomodensitometry regular gastroduodenal radiography restrained case administration barium sulfate recommended contraindicated f55 intravascular administration ioxitalamate contraindicated present significant side effect f54 infection oral cavity upper lower respiratory tract skin soft tissue infection alone mainly europe japan t207 prior withdrawal from various international region concern hepatotoxicity a39891 a39892 a39893 chemical had demonstrated potential usefulness predominantly prescription medication lysine indication managing level vision mild moderate cataract facilitate delaying need surgical intervention a39863 a39869 a39890 elsewhere still available limited capacity non prescription topical cream product treating condition like local pain inflammation dermatitis eczema pruritis hive insect bite burn erythema others although product facing general discontinuation over counter topical antibiotic gastric reflux reflux oesophagitis hiatus hernia heartburn heartburn pregnancy similar gastric distress f46 muscle spasticity disease like parkinson multiple sclerosis antacid neutralization excess stomach acid f25 subsequently symptomatic disease where necessary neutralize acid stomach example treating stomach duodenal ulcer heartburn stomach condition excess stomach acid f25 currently licensed china russia prophylaxis influenza respiratory viral infection a191475 demonstrated activity against number virus investigated flavivirus a191388 zika virus a191391 foot mouth disease a191394 lassa virus a191403 ebola virus a191403 herpes simplex a191409 addition shown vitro activity against hepatitis b c virus chikungunya virus reovirus hantaan virus coxsackie virus b5 a191475 a191412 currently being investigated potential prophylactic agent prevention covid 19 sars cov infection a191385 a191550 child adolescent young adult high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection typically post operative multi agent chemotherapy because potassium wide ranging role body low intake increase risk illness potassium supplement prevent hypokalemia would particular risk if hypokalemia were develop e g digitalis treated significant cardiac arrhythmia potassium deficiency occurs rate loss through renal excretion loss from gastrointestinal tract higher than rate potassium intake addition serving preventative supplement serf decreased potassium level act emulsifier ph control agent food product laboratory while performing karl fischer equation determine water content various substance f18 peptic ulcer gastric hyperacidity hypermotility gastritis pylorospasm hyperhidrosis excessive perspiration mesylate japan chronic pancreatitis drug induced lung injury a193845 being investigated potential covid 19 a193800 louse scabies infestation pyrethroids now place alkalizing agent surfactant counter ion cosmetic pharmaceutical formulation a27174 considered active pharmacological ingredient so no official indication mineral supplement prevent low level magnesium magnesium very important normal physiologic functioning cell nerve muscle bone heart generally well balanced diet provides necessary amount magnesium homeostasis however certain condition causing chronic magnesium deficiency decrease level magnesium these condition include diuretic poor diet alcoholism medical condition e g severe diarrhea vomiting stomach intestinal absorption problem poorly controlled diabetes widely applied food natural sweetener therapeutic agent vast variety formulation reported anti inflammatory anti ulcer anti allergic antioxidant anti tumor anti diabetic hepatoprotective property indication premenstrual syndrome viral infection anti lipidemic antihyperglycemic a33063 known remedy peptic ulcer stomach disease t205 symptomatic lactose intolerance infant older requiring parenteral nutrition fluid diet lactose intolerance occurs there existence inability break down lactose commonly found dairy product inability occurs lactase level reduced thus there no via digest break down lactose undigested lactose move into large intestine where normal flora bacteria interact cause bloating gas diarrhea a32592 fda canada ema approved but country where marketed symptomatic pain swelling inflammation joint rheumathoid arthritis osteoarthritis low back pain post surgical pain chronic inflammation joint presence rheumatoid arthritis ankylosing spondylitis irritation joint spinal column degenerative disorder inflammatory soft tissue rheumatism syndrome painful swelling inflammation injury new application calcium intended food fortifier fortify food like sauce condiment beer beverage soft drink milk milk product soy milk soy product calcium nutrition alone calcium lactate calcium chloride compound either pharmaceutical tablet capsule injection preparation essence ultimately relatively new calcium supplementation option no approved therapeutic indication fluorodopa f 18 positron emission tomography pet visualize dopaminergic nerve terminal striatum evaluation suspected parkinsonian syndrome p most typical us anethol trithione currently includes increasing salivary secretion experiencing dry mouth being adjunctive therapy cholecystitis gallstone indigestion chronic hepatitis a32614 a32616 addition although some study suggested anethol trithione posse certain capacity inhibit tumorigenesis potential cancer therapy medication specific mechanism action effect remains elucidated a32619 certain national cancer institute listing agent substance being studied cancer dietary supplement over counter us ester inhaler asthma prophylaxis fda f4364 well inflammatory pruritic dermatosis f4355 db00588 nasal spray managing nonallergic rhinitis f4358 while db08906 nasal spray treating season perennial allergic rhinitis f4361 a177130 short term insomnia adjunctive therapy diet reduce triglyceride level severe hypertriglyceridemia b reduce elevated total cholesterol low density lipoprotein ldl c triglyceride apolipoprotein b increase high density lipoprotein hdl c primary hypercholesterolemia mixed dyslipidemia fredrickson type iia iib fda relapsed refractory myeloid leukemia aml isocitrate dehydrogenase idh2 mutation chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis child pugh mavyret hcv genotype infection previously treated regimen containing hcv ns5a inhibitor ns3 4a protease inhibitor pi but both fda chronic hepatitis c virus hcv genotype 3 4 5 6 infection without cirrhosis compensated cirrhosis child pugh mavyret hcv genotype infection previously treated regimen containing hcv ns5a inhibitor ns3 4a protease inhibitor pi but both fda up 25 age b cell precursor lymphoblastic leukemia all refractory second later relapse fda temporary relief ache pain muscle tendon joint particular antivenin only envenomation bite from eastern coral snake micrurus fulvius fulvius texas coral snake micrurus fulvius tenere fda agent will neutralize venom arizona sonoran coral snake micruroides euryxanthus south american specie fda under ema fda rix rfp hemophilia b health canada rix frp prevent reduce bleeding episode hemophilia b second most common type hemophilia rare inherited bleeding disorder reduced absent level factor ix fix fix vitamin k dependent plasma protease activated involved blood coagulation cascade a32551 hemophilia b mutation fix gene cause different phenotype severe form characterized presence spontaneous recurring bleeds into joint muscle excessive bleeding after trauma surgery a32552 prevent cytomegalovirus cmv disease after organ transplant cytomegalovirus immune globulin intravenous human prophylaxis cytomegalovirus disease transplantation kidney lung liver pancreas heart fda transplant these organ than kidney from cmv seropositive donor into seronegative recipient prophylactic cmv igiv should considered ganciclovir fda crofab pediatric north american crotalid envenomation term crotalid describe crotalinae subfamily formerly known crotalidae venomous snake includes rattlesnake copperhead cottonmouth water moccasin fda crofab pediatric north american crotalid envenomation term crotalid describe crotalinae subfamily formerly known crotalidae venomous snake includes rattlesnake copperhead cottonmouth water moccasin fda north american crotalid envenomation crotalinae rattlesnake eg cottonmouth water moccasin copperhead rattlesnake fda crofab sheep derived antivenin pediatric north american crotalid envenomation fda medication genetically modified oncolytic viral therapy local unresectable cutaneous subcutaneous nodal lesion melanoma recurrent after initial surgery fda elsewhere ema note agent adult unresectable melanoma regionally distantly metastatic stage iiib iiic ivm1a no bone brain lung visceral disease indicted documented suspected exposure botulinum toxin serotype e adult pediatric fda indicted documented suspected exposure botulinum toxin serotype c adult pediatric fda indicted documented suspected exposure botulinum toxin serotype g adult pediatric fda indicted documented suspected exposure botulinum toxin serotype adult pediatric fda indicted documented suspected exposure botulinum toxin serotype f adult pediatric fda indicted documented suspected exposure botulinum toxin serotype d adult pediatric fda indicted documented suspected exposure botulinum toxin serotype b adult pediatric fda clinical sign scorpion envenomation topical agent soothe sensitive skin relieve symptom various skin condition contact atopic dermatitis eczema dermatitis acne urticata first second degree burn radiation dermatitis sunburn sore throat minor mouth throat infection a32773 most common medical purpose currently formally non prescription internal deodorant product purpose deodorizing flatulence stool a32566 additionally there various non prescription over counter based wound healing product well ongoing study into whether substance utilized legitimate hemostatic agent usually soft tissue surgery otorhinolaryngology dermatologic setting a32567 a32568 a32569 a32570 moreover past seen some helicobacter pylorus infection a32571 contrast contemporary first line therapy generally involve proton pump inhibitor antibiotic therapy generally achieve high rate pathogen eradication ease administration patient compliance dental disclosing product allowing highlighting bacterial placques no therapeutic indication investigational drug approved any condition relapsed refractory large b cell lymphoma after two more line systemic therapy diffuse large b cell lymphoma dlbcl otherwise specified primary mediastinal large b cell lymphoma high grade b cell lymphoma dlbcl arising from follicular lymphoma main function prevention bleeding episode thus approved routine prophylaxis prevent reduce frequency bleeding episode pediatric hemophilia without factor viii inhibitor hemophilia a deficiency coagulation factor viii cause serious bleeding disorder standard done administration recombinant serum deriver factor viii induces formation anti factor viii alloantibody factor viii inhibitor render standard ineffective a31286 shingrix vaccine prevention herpes zoster shingle adult aged 50 older dotatate gallium 68 one most prominent radiopharmaceutical imaging positron emission tomography bind somatostatin receptor usually overexpressed many neuroendocrine tumor both pediatric a31362 neuroendocrine tumor bening malignant tumor produced hormone producing cell neuroendocrine system moderate persistent epithelial defect severe corneal ulcer neurotrophic keratitis adult fda f1502 improve glycemic control adult diagnosed type diabetes mellitus adjunct diet exercise important note suitable first line drug diabetes controlled diet exercise addition studied pancreatitis intended type diabetes diabetic ketoacidosis reduction elevated intraocular pressure iop open angle glaucoma ocular hypertension fda vn rzyl child confirmed biallelic rpe65 mutation retinal dystrophy administration vn rzyl conditioned physician determination presence viable retinal cell fda rpe65 represents lca2 form leber congenital amaurosis lca lca group inherited conditionts involves retinal degeneration severe vision loss early childhood leading total blindness 30 40 old lca2 form mutation interferes isomerohydrolase activity retinal pigment epithelium isomerohydrolase activity transforms trans retinyl ester 11 ci retinal natural ligand chromophore opsin rod cone photoreceptors presence rpe65 mutation opsin can not capture light transduce into electrical response initiate vision a31480 adult child hemophilia b control prevention bleeding episode routine prophylaxis perioperative ema approval demand bleeding episode hemophilia b characterized deficiency coagulation factor ix result prolonged oozing after injury delayed recurring bleeding prior wound healing hemophilia b present more frequent bleeding episode during childhood adolescence than adulthood t56 uncomplicated plasmodium falciparum infection adult child infant aged 6 month up weighing over 5 kg fda db11638 male present condition derived from deficiency absence endogenous testosterone these condition primary hypogonadism defined testicular failure cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy hypogonadotropic hypogonadism characterized idiopathic gonadotropin lhrh deficiency pituitary hypothalamic injury from tumor trauma radiation male replacement therapy condition deficiency absence endogenous testosterone some treated condition primary hypogonadism defined testicular failure cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchidectomy hypogonadotropic hypogonadism idiopathic gonadotropin luteinizing hormone releasing hormone deficiency pituitary hypothalamic injury from tumor trauma radiation case important accompany adrenal cortical thyroid hormone replacement therapy 3 stimulate puberty delayed puberty secondary pathological disorder if condition occur prior puberty androgen replacement therapy will needed during adolescent development secondary sexual characteristic prolonged androgen might needed maintain sexual characteristic after puberty fda female secondarily presence advanced inoperable metastatic mammary cancer woman from one five postmenopausal premenopausal woman breast cancer benefited from oophorectomy considered hormone responsive tumor fda injection currently formulated subcutaneous specifically only primary hypogonadism hypogonadotropic hypogonadism f1941 formulation limited because safety efficacy these subcutaneous product male late onset hypogonadism male le than 18 old yet established f1941 moreover subcutaneously administered only men hypogonadal condition structural genetic etiology considering medication could cause blood pressure increase raise risk major adverse cardiovascular event like non fatal myocardial infarction non fatal stroke cardiovascular death f1941 replacement therapy male condition linked absence deficiency endogenous testosterone production f4247 fda control serum phosphorus level chronic kidney disease dialysis ferric citrate femring vasomotor urogenital symptom menopause femring shown improve symptom atrophy vagina dryness burning pruritus dyspareunia lower urinary tract urinary urgency dysuria currently available any fda health canada approved product depo estradiol intramuscular depot injection moderate severe vasomotor symptom hypoestrogenism hypogonadism currently available any fda health canada approved product commercially available intramuscular injection product delestrogen moderate severe vasomotor symptom vulvovaginal atrophy menopause hypoestrogenism hypogonadism castration primary ovarian failure advanced androgen dependent carcinoma prostate palliation only available db09123 commercially available product natazia prevention pregnancy heavy menstrual bleeding incorporated active ingredient active component like fish oil soya oil olive oil prescription medication smoflipid medium chain triglyceride mcts constitute therapy supplying energy calorie essential fatty acid part parenteral nutrition regimen oral enteral nutrition impossible insufficient contraindicated f126 f127 however given predominant indication mcts acting source calorie essential fatty acid mcts alone component part various unique individual patient tailored composite regimen therapy mcts ultimately wide range health condition involve energy deficiency malnutrition disturbance ordinary absorption dietary fat a33175 f128 condition include crohn disease waldmann disease weight maintenance aid cachexia various disturbance patient bile secretion like cholestasis disturbance hepatic intestinal circulation bile acid intestinal dysbacteriosis pancreatic lipase secretion like pancreatic failure course cystic fibrosis a33175 f128 active ingredient registered commercial biocide preservative many industrial process registered biocidal us include pulp paper mill water cooling tower waste water evaporative condenser heat exchanger food pasteurizing plant metalworking fluid oilfield application f2317 addition preservative us include household product e g dishwashing liquid laundry product latex emulsion polymer lattice pigment leather milk sample analysis f2317 formulated into granular domestic end product form cat litter f2317 under fda approval pharmaceutical typically product consisting omega 3 fatty acid eicosapentaenoic acid epa docosahexaenoic acid dha primarily adjunct diet reduce triglyceride level severe gt 500 mg dl hypertriglyceridemia fda f36 under ema approval pharmaceutical comprised virtually same fish derived omega 3 fatty acid epa dha specifically adjuvant secondary prevention after myocardial infarction addition standard therapy ie statin antiplatelet medicinal product beta blocker ace inhibitor b supplement diet dietary measure alone insufficient produce adequate response particularly type iv hypertriglyceridemia monotherapy type iib iii statin control triglyceride insufficient addition prescribing information ema approved pharmaceutical adjunct diet reduce very high gt 500 mg dl triglyceride level much like similar fda approved indication f37 fda widely food even component adulteration olive oil t41 over counter ear drop help lubricate ear wax f124 ingredient cleansing soap emollient cream preparation laxative f125 usually solubilize drug poor water solubility part oral formulation t224 orally administered well researched prevent heart disease lower cholesterol level well aid weight loss decrease appetite no approved therapeutic indication primary medical indication formally active ingredient patient care product non prescription pediculicide rinse a32330 marking lymphatic vessel arterial territory well sentinel lymph node prior biopsy operable breast cancer clinically negative lymph node radiotracer a32575 textile paper agriculture cosmetic industry a32574 ppfh replacement therapy complex deficiency coagulation factor coagulopathy substitution therapy emergency case factor deficiency rapid reversal effect oral anticoagulant dangerous hemorrhage during fibrinolytic therapy ppfh therapeutic plasma exchange procedure thrombotic thrombocytopenic purpura ppfh shock where there predominant loss plasma fluid red blood cell graft versus host disease agvhd pediatric gvhd should refractory systemic corticosteroid therapy immunosuppressive agent grade c d disease any organ grade b agvhd involving any visceral organ gi tract liver but excluding skin menopausal symptom menstrual dysfunction radiolabelled sodium pertechnetate tc99m solution develop technetium tc99m solution solution adult scintigraphic imaging conjunction appropriate imaging modality possible determining location inflammation infection peripheral bone adult suspected osteomyelitis fda utilized medicinal product diagnostic only fda somatostatin receptor positive gastroenteropancreatic neuroendocrine tumor gep net foregut midgut hindgut neuroendocrine tumor adult fda employed ingredient toothpaste formulation predominantly treating teeth hypersensitivity a33167 a33168 f118 iron loss iron deficiency maintain hemoglobin reduce prescribed dose erythropoiesis stimulating agent esa required maintain desired hemoglobin level iron deficiency appears dietary intake doe meet body requirement there chronic external blood loss during blood loss body iron store sufficient accelerated erythropoiesis restoration iron homeostasis but altered homeostasis remains week month then some supplement needed some cause iron deficiency include ectoparasitism endoparasitism hematuria epistaxis hemorrhagic skin coagulopathy thrombocytopenia thrombocytopathia gastrointestinal hemorrhage a31984 influenza b virus infection fda 12 older symptomatic no more than 48 hour clinical trial drug did include subject 65 age older determine whether they respond different way than younger subject fda hemophilia von willebrand disease factor xiii deficiency approved health canada control prevention hemorrhagic episode routine surgical prophylaxis hemophilia congenital factor viii deficiency classic hemophilia approved european medicine agency prophylaxis bleeding haemophilia congenital factor viii deficiency primary health related formally dietary supplement demonstrate genuine vitaminE deficiency same time vitaminE deficiency generally quite rare but occur premature baby very low birth weight lt 1500 gram individual fat malabsorption disorder fat required digestive tract absorb vitaminE individual abetalipoproteinemia rare inherited disorder cause poor absorption dietary fat require extremely large dos supplemental vitaminE daily around 100 mg kg 5 10 g day all case alpha tocopherol largely preferred form vitaminE administered elsewhere vitaminE chemical profile fat soluble antioxidant capable neutralizing free radical body continues generate ongoing interest study regarding how whether vitaminCan help prevent delay various chronic disease free radical potential biological effect vitaminE posse like cardiovascular disease diabetes ocular condition immune illness cancer more t166 none these ongoing study yet elucidate any formally significant evidence however t166 similarly more effective clinical trial necessary confirm what only accrued preliminary data come study proposing demonstration capability act anti cancer therapy regulator inflammation a32958 a32959 addition any following information owing closely related chemical nature alpha tocopherol acetate please refer drug information page alpha tocopherol acetate further data vitaminE known antioxidant activity protective against cardiovascular disease some form cancer demonstrated immune enhancing effect limited benefit some asthma rheumatoid arthritis helpful some neurological disease alzheimer some eye disorder cataract diabetes premenstrual syndrome help protect skin from ultraviolet irradiation although claim revers skin aging enhances male fertility exercise performance poorly supported help relieve some muscle cramp primary health related formally dietary supplement demonstrate genuine vitaminE deficiency same time vitaminE deficiency generally quite rare but occur premature baby very low birth weight lt 1500 gram individual fat malabsorption disorder fat required digestive tract absorb vitaminE individual abetalipoproteinemia rare inherited disorder cause poor absorption dietary fat require extremely large dos supplemental vitaminE daily around 100 mg kg 5 10 g day all case alpha tocopherol largely preferred form vitaminE administered elsewhere vitaminE chemical profile fat soluble antioxidant capable neutralizing free radical body continues generate ongoing interest study regarding how whether vitaminCan help prevent delay various chronic disease free radical potential biological effect vitaminE posse like cardiovascular disease diabetes ocular condition immune illness cancer more t166 none these ongoing study yet elucidate any formally significant evidence however t166 moderate severe plaque psoriasis fda dimethicone approved transdermal drug delivery system part simethicone element dow corning q7 2242 lva antifoam some otc containing dimethicone relieve discomfort infant gas air swallowing certain formula food prevent help rash protect relieve chapped cracked skin anti louse agent oral gel relief pain discomfort common mouth ulcer cold sore denture sore spot infant teething mouth ulcer sore spot orthodontic device child dtpa widely industry medicine medical agent approved medical imaging decorporation internally deposited radionuclides a32501 fda approved individual known suspected internal contamination plutonium americium curium increase rate elimination pharmacokinetic elimination kidney conjugated technetium tc 99m being clinically estimate physiological parameter glomerular filtration rat effective renal plasma flow t168 canada sativex received notice compliance noc adjunctive symptomatic relief spasticity multiple sclerosis m responded adequately therapy demonstrate meaningful improvement during initial trial therapy sativex received notice compliance condition noc c adjunctive symptomatic relief neuropathic pain multiple sclerosis m adjunctive analgesic advanced cancer experience moderate severe pain during highest tolerated dose strong opioid therapy persistent background pain marketing authorisation condition reflect promising nature clinical evidence need confirmatory study verify clinical benefit should advised conditional nature authorization condition drug x linked hypophosphatemia radiological evidence bone disease child year age older adolescent growing skeleton diuretic db00316 relief temporary water weight gain bloating swelling full feeling premenstrual menstrual period palonosetron drug akynzeo dexamethasone adult prevention delayed nausea vomiting initial repeat course cancer chemotherapy but limited highly emetogenic chemotherapy fda following indication listed ema f29 prevention delayed nausea vomiting highly emetogenic cisplatin based cancer chemotherapy f29 prevention delayed nausea vomiting moderately emetogenic cancer chemotherapy f29 no approved therapeutic indication recurrent chronic urinary tract infection primarily pyelonephritis pyelitis cystitis susceptible organism usually escherichia coli klebsiella enterobacter staphylococcus proteus mirabilis le frequently proteus vulgaris absence obstructive uropathy foreign body meningococcal meningitis where organism demonstrated susceptible haemophilus influenzae meningitis adjunctive therapy parenteral streptomycin meningococcal meningitis prophylaxis otitis medium haemophilus influenzae concomitantly adequate dos penicillin erythromycin see appropriate labeling prescribing information trachoma inclusion conjunctivitis nocardiosis chancroid toxoplasmosis adjunctive therapy pyrimethamine malaria chloroquine resistant strain plasmodium falciparum adjunctive therapy currently increasing frequency resistant organism limitation usefulness antibacterial agent sulfonamide especially chronic recurrent urinary tract infection preventative migraine adult fda preventive migraine adult preventative migraine adult humanized monoclonal antibody migraine prophylaxis episodic cluster headache adult binding endogenous human calcitonin gene related peptide cgrp a33112 potassium binder hyperkalemia f130 doe currently any fda health canada approved indication however october 2017 cbdv given orphan designation european medicine agency rett syndrome again february 2018 fragile x syndrome being investigated antibiotic action potential antibacterial agent future a33312 being investigated antibiotic action potential antibacterial agent future a33312 repel insect mosquito biting fly tick chigger flea via topical over clothing repair single multiple symptomatic full thickness cartilage defect knee without bone involvement adult cnj 016 vaccinia immune globulin intravenous human vigiv modification eczema vaccinatum b progressive vaccinia c severe generalized vaccinia d vaccinia infection individual skin condition burn impetigo varicella zoster poison ivy individual eczematous skin lesion because either activity extensiveness lesion e aberrant infection induced vaccinia virus include accidental implantation eye except case isolated keratitis mouth area where vaccinia infection would constitute special hazard fda shown effective against hiv herpes simplex virus hepatitis b virus a178330 know more about specific product indication please visit information orally available form alafenamide disoproxil currently approved any fda health canada approved indication db01075 antiemetic db00985 prevention nausea vomiting vertigo motion sickness developed opioid analgesic low abuse potential treating chronic pain application filed fda approval treating chronic lower back pain diagnostic skeletal imaging agent demonstrate area altered osteogenesis pediatric allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing allergenic testing approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved fda within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older schizophrenia related psychotic disorder approved fda within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved fda within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved fda within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older approved within allergenic epicutaneous patch test aid diagnosis allergic contact dermatitis acd person 6 age older ingredient draximage maa kit preparation technetium tc99m injection assessment lung perfusion evaluation peritoneovenous leveen shunt patency source calorie requiring parenteral nutrition vibrio cholerae cvd 103 hgr strain live antigen active oral immunization against infection vibrio cholerae serogroup o1 between 18 64 age prevention control bleeding hemophilia acquired factor viii fviii deficiency surgical invasive procedure pediatric von willebrand disease desmopression either ineffective contraindicated severe i e type 3 von willebrand disease whom undergoing major surgery complex iodine inducing antisepsis prevention infection minor cut scrape burn over counter calcium phosphate supplement antacid source calcium phosphate toothpaste fda zinc prevention zinc deficiency consequence stunted growth diarrhea child slowed wound healing utilized boosting immune system treating common cold recurrent ear infection well preventing lower respiratory tract infection preventing treating iron deficiency anemia preventing treating iron deficiency anemia preventing treating iron deficiency anemia preventing treating iron deficiency anemia potassium regulate hypokalemia primary condition secondary medical condition potassium regulate hypokalemia primary condition secondary medical condition general us variety condition firstly replenish depleted condition but limited malabsorption decreased intake excess sodium intake cause deficiency numerous following indication comprehensive but include main indication nutrient various product preparation contain chloride chloride one main preparation clinical setting oral solution prevention hypokalemia presenting without metabolic alkalosis failed conservative rich food diuretic dose titration injection form chloride replenish feasible candidate oral highly concentrated intended deficiency fluid restricted individual can not tolerate fluid volume normally injected solution contain lower concentration finally extended release tablet preparation chloride hypokalemia without metabolic alkalosis digitalis intoxication manage hypokalemic familial periodic paralysis prevention hypokalemia those high risk negative clinical outcome if hypokalemia occurs digitalis those cardiac arrhythmia would particular risk negative outcome chloride dextrose sodium chloride liquid preparation is clinical setting source water calorie electrolyte acetate solution meant alternative chloride replenishing added large volume infusion fluid intravenous injection citrate citrate preparation renal tubular acidosis rta calcium stone nephrolithiasis calcium oxalate stone any cause uric acid nephrolithiasis without calcium stone regimen includes adequate water intake leading urine out put l day more sodium restriction preventing treating iron deficiency anemia constipation clean bowel before colonoscopy fda constipation clean bowel before colonoscopy fda no fda ema approved therapeutic indication own lithium mood stabilizer depression mania often bipolar disorder lithium mood stabilizer manic episode maintenance bipolar disorder fda there 3 formulation various indication inhaler prophylaxis asthma 4 fda nasal spray treating nasal symptom allergic rhinitis treating symptom nasal congestion from seasonal allergic rhinitis treating nasal polyp 18 prophylaxis seasonal allergic rhinitis 12 f4292 ointment symptomatic dermatitis pruritis f4295 healthy level achieved through well balanced diet but if food source insufficient supplement prevent deficiency medicine various salt laxative antacid product a19349 example citrate available over counter manage occasional constipation sulfate own total parenteral nutrition hypomagnesemia sulfate prevent seizure pregnant woman pre eclampsia manage seizure eclampsia a188087 control serum phosphorous adult chronic kidney disease require dialysis iron deficiency anemia adult chronic kidney disease dialysis supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda supplement intravenous solution given total parenteral nutrition tpn maintain chromium serum level prevent depletion endogenous store subsequent deficiency symptom fda injection total parenteral nutrition maintain zinc serum level prevent deficiency syndrome relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease relief inflammatory pruritic manifestation corticosteroid responsive dermatosis endocrine hormonal disorder adrenal insufficiency addisons disease many immune allergic disorder arthritis lupus severe psoriasis severe asthma ulcerative colitis crohn disease zinc sulfate common zinc supplement parenteral nutrition a216916 following complexation sodium citrate yield gallium citrate ga 67 demonstrate presence hodgkin disease lymphoma bronchogenic carcinoma some inflammatory lesion treated rivaroxaban apixaban reversal anticoagulation needed life threatening uncontrolled bleeding andexxa shown effective bleeding related any factor xa inhibitor than apixaban rivaroxaban approved relapsed refractory aml susceptible idh1 mutation detected fda approved test fda bacterial infection skin skin structure absssi prevent drug resistance should only infection susceptible bacteria t hereditary transthyretin mediated amyloidosis adult fda administered pre medication reduce complication fda these include intravenous corticosteroid equivalent 10 mg dexamethasone 500 mg oral acetaminophen intravenous histamine h1 blocker equivalent 50 mg diphenhydramine intravenous histamine h2 blocker equivalent 50 mg ranitidine ethinyl estradiol female reproductive potential prevent pregnancy hormonal contraceptive chc induces contraception thirteen 28 day cycle year following vaginal administration vaginal system must remain place continuously 3 week 21 day followed week 7 day vaginal system free interval female body mass index gt 29 kg m adequately evaluated fda prophylaxis prevent attack 12 older hereditary angioedema hereditary angioedema hea autosomal dominant disorder resulted from presence c1 deficiency some report high prevalence case result from spontaneous mutation inherited condition manifested attack subcutaneous submucosal edema face larynx gi tract limb genitalia from all type attack most serious laryngeal compromise airway rest attack accompanied pain considerable dysfunction a38679 edetate calcium disodium reduce blood level depot store lead chronic lead poisoning edetate disodium emergency hypercalcemia digitalis toxicity ventricular arrhythmia indication number condition allergic state dermatologic disease edematous state endocrine disorder gastrointestinal disease hematologic disorder neoplastic disease nervous system ophthalmic disease respiratory disease rheumatic disorder no approved therapeutic indication diloxanide alone primary agent asymptomatic cyst passer intestinal amebiasis entamoeba histolytica diloxanide concurrently sequentially agent nitroimidazoles eg metronidazole invasive extraintestinal form amebiasis female palliation androgenresponsive recurrent mammary cancer woman more than one year but le than five postmenopausal intramuscularly allergic state dermatologic disease endocrine disorder gastrointestinal disease hematologic disorder neoplastic disease nervous system condition ophthalmic disease renal disease respiratory disease rheumatic disorder trichinosis neurologic myocardial involvement tuberculous meningitis subarachnoid block impending block intra articularly gouty arthritis subacute bursitis nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis osteoarthritis intralesional betamethasone phospahte alopecia areata discoid lupus erythematosus keloid lichen planus lichen simplex chronicus psoriatic plaque necrobiosis lipoidica diabeticorum localized hypertrophic infiltrated inflammatory lesion granuloma annulare commonly cosmetic product skin hair a19503 polycarbophil constipation help maintain regular bowel movement previously treated adult adolescent 12 age above hemophilia congenital factor viii deficiency demand control bleeding episode fda perioperative bleeding fda routine prophylaxis reduce frequency bleeding episode fda drug programmed death receptor pd blocking antibody metastatic cutaneous squamous cell carcinoma cscc locally advanced cscc candidate curative surgery curative radiation fda a39201 live antigen new york city board health strain vaccinia within acam2000 formulation active immunization against smallpox disease determined high risk contracting smallpox infection approved adenosine deaminase severe combined immune deficiency ada scid pediatric condition previously treated bovine pegamedase part enzyme replacement therapy ada scid genetically inherited disorder very rare characterized deficiency adenosine deaminase enzyme suffering from disease often present compromised immune system condition characterized very low level white blood cell immunoglobulin level result severe recurring infection transthyretin directed antisense oligonucleotide polyneuropathy hereditary transthyretin mediated amyloidosis adult tyrosine kinase inhibitor currently pediatric solid tumor either neurotrophic receptor tyrosine kinase ntrk gene fusion without known acquired resistance mutation b metastatic where surgical resection likely result severe morbidity c no satisfactory alternative treatment progressed following fda moment these us only approved under auspex accelerated approval u fda based overall response rate duration response continuation support these indication contingent upon verification description continued clinical benefit confirmatory trial fda pediatric primary hemophagocytic lymphohistiocytosis hlh refractory recurrent progressive disease intolerance conventional hlh therapy hlh condition hyperinflammatory status characterized overwhelming activation normal t lymphocyte macrophage lead disturbance hematology profile even death part condition profile there report proving massive overexpression interferon gamma thought drive immune hyperactivation leading organ failure a38676 condition usually developed present symptomatic profile within first month life these symptom consist fever enlarged liver spleen lower number blood cell drug is asparagine specific enzyme component multi agent chemotherapeutic regimen lymphoblastic leukemia pediatric young age month 21 fda pharmacokinetics were examined given multiagent chemotherapy 124 b cell lineage all fda approval drug based achievement maintenance nadir serum asparaginase activity above level 0 u ml administering calaspargase 2500 u m2 intravenously 3 week interval blastic plasmacytoid dendritic cell neoplasm bpdcn adult pediatric over old allows alternative previous intense consisted intensive chemotherapy followed bone marrow transplantation bpdcn rare hematologic malignancy derived from plasmacytoid dendritic cell characterized significantly increased expression cell expressing cd4 cd56 cd123 marker restricted plasmacytoid dendritic cell lack expression lymphoid natural killer myeloid lineage antigen a40274 key feature malignant cell overexpression cd123 known interleukin 3 receptor constant requirement il 3 survival current going research suggests natural biochemical compound found endogenously human body play essential role generation critical bodily chemical tyrosine serotonin dopamine epinephrine norepinephrine nitric oxide lipid others a173830 a173833 a173851 research subsequently proposes if could utilized pharmaceutic considered so called putative longevity vitamin age delaying prolonged survival functionality perhaps via maintaining ongoing generation aforementioned bodily chemical human body a173830 a173833 a173851 n8 gp adult child all age hemophilia congenital factor viii deficiency routine prophylaxis reducing frequency bleeding episode demand control bleeding episode perioperative bleeding f3649 subcutaneous fluid administration hydration increasing resorption radiopaque agent subcutaneous urography multiple route increase dispersion injectable drug infection urinary tract meninges blood stream susceptible strain pseudomonas aeruginosa fda approved severe primary insulin like growth factor igf deficiency gh gene deletion developed antibody growth hormone gh a176020 severe primary igf deficiency defined fda height standard deviation sd score le than equal 3 sd below normal b basal igf sd score le than equal 3 sd below normal c normal above normal level growth hormone 2007 insmed manufacturer made agreement tercica mecasermin manufacturer mecasermin would no longer available indication but could developed non short stature condition severe insulin resistance myotonic muscular dystrophy hiv adipose redistribution syndrome a176125 nonprogressive blastomycosis skin mycoses daytime sleepiness obstructive sleep apnea narcolepsy but underlying airway obstruction apnea fda a176534 a176744 pediatric aged 12 over weighing least 40 kg coronavirus disease 2019 covid 19 infection requiring hospitalization under indication should only administered hospital healthcare setting capable providing care comparable inpatient hospital setting originally granted fda emergency authorization eua 2020 adult child suspected confirmed covid 19 hospital setting spo2 94 following fda approval eua revised cover hospitalized pediatric between 3 5 40 kg well those under 12 age weigh least 3 5 kg suspected laboratory confirmed covid 19 under both eua indication needing invasive mechanical ventilation extracorporeal membrane oxygenation ecmo should treated 5 day loading dose day extended up 10 day if they do show improvement requiring invasive mechanical ventilation ecmo should treated 10 day drug moderate severe plaque psoriasis adult eligible receive systemic therapy phototherapy based their disease process fda relapsing form multiple sclerosis m adult specifically active secondary progressive disease clinically isolated syndrome well relapsing remitting m pomalidomide dexamethasone multiple myeloma adult received least two prior therapy lenalidomide proteasome inhibitor adult diagnosed advanced gastrointestinal stromal tumor gist had prior therapy least 3 kinase inhibitor imatinib active moderate severe rheumatoid arthritis alone methotrexate currently reserved unable tolerate responded adequately one more disease modifying anti rheumatic drug dmards monoclonal antibody neovascular age related macular degeneration a187208 complicated urinary tract infection without pyelonephritis fda pain adult severe enough require intravenous opioid analgesic whom no acceptable alternative treatment exist overactive bladder oab symptom urge urinary incontinence urgency urinary frequency adult radioactive agent positron emission tomography pet imaging aggregated tau neurofibrillary tangle nfts under evaluation alzheimer disease under evaluation chronic traumatic encephalopathy her positive breast cancer unresectable metastatic previously treated least anti her2 based regimen while cancer metastatic continued approval will depend result clinical trial result confirming clinical benefit anti her2 monoclonal antibody chemotherapy metastatic her2 positive breast cancer received two more prior anti her2 regimen least one prior regimen metastatic disease sickle cell disease both pediatric aged 12 above drug relapsing form multiple sclerosis m adult includes clinically isolated syndrome relapsing remitting disease well active secondary progressive disease duchenne muscular dystrophy confirmed dmd gene mutation amenable exon 53 skipping indication represents accelerated approval based observed efficacy continued approval indication contingent verification safety efficacy confirmatory trial mantle cell lymphoma mcl received least one prior therapy lenalidomide relapsed refractory diffuse large b cell lymphoma dlbcl otherwise specified whom ineligible autologous stem cell transplant asct adult hepatic porphyria conditionally approved ema adjunct diet adult familial chylomicronemia high risk pancreatitis had inadequate response diet triglyceride lowering therapy adult moderately severely active rheumatoid arthritis had inadequate response intolerance methotrexate do responded well intolerant one more disease modifying anti rheumatic drug dmards monotherapy methotrexate mtx replacement growth hormone growth hormone deficiency unresectable locally advanced metastatic cholangiocarcinoma previously treated fibroblast growth factor receptor fgfr2 fusion rearrangement detected fda approved test unresectable metastatic gastrointestinal stromal tumor platelet derived growth factor receptor alpha exon 18 mutation a189339 desensitization highly sensitized kidney transplant positive crossmatch against available deceased donor reserved unlikely receive transplant under available kidney allocation system prioritization program highly sensitized reduce frequency vaso occlusive crisis sickle cell disease 16 old spinal muscular atrophy sma month age older migraine without aura adult ivacaftor tezacaftor product trikafta lt sup gt tm lt sup gt cystic fibrosis cf 12 age older least one f508del mutation ctfr gene benzyhydrocodone acetaminophen short term pain requiring opioid therapy being investigated treating tumor a182036 a182039 derivative similar dna binding ability reduced myelotoxicity being investigated their antitumor activity a182039 anxiety without psychoneurotic condition a184910 radioactive diagnostic compound positron emission tomography pet diagnose somatostatin receptor positive neuroendocrine tumor pediatrics adult pediatric le than age neonatal infant spinal muscular atrophy sma bi allelic mutation survival motor neuron smn1 gene anti inflammatory immunosuppressive agent allergic dermatologic gastrointestinal hematologic ophthalmologic nervous system renal respiratory rheumatologic infectious condition organ transplant well endocrine neoplastic condition experimental kras inhibitor being investigated kras g12c mutant lung colon adenocarcinoma a187559 being investigated kras g12c mutant non small cell lung cancer colorectal cancer appendix cancer a187547 duchenne muscular dystrophy dmd confirmed mutation dmd gene would benefit from exon 53 skipping continued fda approval drug contingent upon result clinical trial confirm benefit drug selectively staining internal limiting membrane ilm ebola zaire vaccine active immunization individual 18 age older protect against ebola virus disease evd zaire ebolavirus iron deficiency adult drug iron deficiency anemia experienced intolerance oral iron preparation insufficient clinical response orally administered iron ferric derisomaltase non hemodialysis dependent chronic kidney disease australia united kingdom ferric derisomaltase case rapid delivery iron required developed russia potential influenza b infection a191706 experimental drug being researched cardiovascular disease sars cov infection a192426 authorized under emergency authorization eua active immunization prevent coronavirus disease 2019 covid 19 severe respiratory syndrome coronavirus sars cov individual 18 age older administered two dos one month 28 day apart prodrug eidd 2801 being studied activity against number viral infection influenza mers cov sars cov a193014 a193029 n4 hydroxycytidine prodrug being studied activity against number viral infection influenza mers cov sars cov a193014 a193029 ret fusion positive non small cell lung cancer systemic advanced metastatic ret mutant medullary thyroid cancer systemic ret fusion positive radioactive iodine refractory thyroid cancer both pediatric aged 12 over currently approved these indication under accelerated approval scheme continued approval contingent future confirmatory trial radioactive diagnostic agent positron emission tomography pet imaging detection estrogen receptor positive lesion adjunct biopsy recurrent metastatic breast cancer decitabine myelodysplastic syndrome md md refractory anemia md refractory anemia ringed sideroblast md refractory anemia excess blast md scoring intermediate intermediate high risk international prognostic scoring system ip chronic myelomonocytic leukemia cmml tozinameran yet fully approved any country both uk canada tozinameran under interim authorization active immunization prevent covid 19 sars cov individual aged 16 older december 11 2020 u food drug administration granted emergency authorization eua tozinameran prevent covid 19 severe respiratory syndrome coronavirus sars cov aged 16 above safety immune response information adolescent 12 15 age will follow study further explore administration tozinameran pregnant woman child under 12 age those special risk group will evaluated future a225386 vaccine should only administered where appropriate medical immediate allergic reaction immediately available case anaphylactic reaction after vaccine administration tozinameran administration should postponed any individual suffering from febrile illness should carefully considered immunocompromised individual individual bleeding disorder anticoagulant therapy appropriate medical should readily available case anaphylactic reaction following vaccine administration modified autologous chimeric antigen receptor car t cell immunotherapy relapsed refractory mantle cell lymphoma mcl granted accelerated approval based result from single arm open multicentre clinical trial continued approval contingent confirmatory trial currently approved any indication fda authorized under emergency authorization eua mild moderate covid 19 aged 12 older weighing least 40 kg high risk progressing severe covid 19 hospitalization covid 19 should confirmed covid 19 identification sars cov viral load approved test under eua authorized hospitalized covid 19 require oxygen covid 19 oxygen therapy non covid 19 related comorbidity require increased oxygen flow rate covid 19 adult relapsed refractory multiple myeloma received least 4 prior therapy anti cd38 monoclonal antibody proteasome inhibitor immunomodulatory agent neuromyelitis optica spectrum disorder nmosd anti aquaporin 4 aqp4 antibody positive canada adolescent same indication metastatic non small cell lung cancer nsclc confirmed posse rearranged during transfection ret gene fusion determined fda approved test currently approved indication under accelerated approval scheme continued approval contingent future confirmatory trial copper cu 64 dotatate radiopharmaceutical positron emission tomography pet locate somatostatin receptor positive neuroendocrine tumor fabry disease odesivimab maftivimab zaire ebolavirus infection pediatric neonate born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any specie within either ebolavirus marburgvirus genus special care should taken evaluate susceptibility circulating zaire ebolavirus strain before beginning possible emergence resistance should monitored odesivimab atoltivimab zaire ebolavirus infection pediatric neonate born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any specie within either ebolavirus marburgvirus genus special care should taken evaluate susceptibility circulating zaire ebolavirus strain before beginning possible emergence resistance should monitored maftivimab atoltivimab zaire ebolavirus infection pediatric neonate born mother confirmed positive rt pcr zaire ebolavirus infection established efficacious any specie within either ebolavirus marburgvirus genus special care should taken evaluate susceptibility circulating zaire ebolavirus strain before beginning possible emergence resistance should monitored primary hyperoxaluria type according emergency authorization eua fda indevimab only casirivimab mild moderate covid 19 from laboratory confirmed sars cov infection adult child aged 12 age older weighing least 40 kg reserved high risk progressing require hospitalization severe covid 19 only administered intravenous infusion healthcare setting immediate access infusion reaction anaphylaxis ability activate emergency medical system em required limitation casirivimab currently hospitalized covid 19 requiring oxygen therapy covid 19 requiring increase baseline oxygen flow rate from covid 19 oxygen therapy non covid 19 related morbidity according emergency authorization eua fda indevimab only mild moderate covid 19 from laboratory confirmed sars cov infection adult child aged 12 age older weighing least 40 kg reserved high risk progressing require hospitalization severe covid 19 only administered intravenous infusion healthcare setting immediate access infusion reaction anaphylaxis ability activate emergency medical system em required limitation imdevimab currently hospitalized covid 19 requiring oxygen therapy covid 19 requiring increase baseline oxygen flow rate from covid 19 oxygen therapy non covid 19 related morbidity gqgk granulocyte macrophage colony stimulating factor gm csf year age older relapsed refractory high risk neuroblastoma bone bone marrow demonstrated partial response minor response stable disease prior therapy prophylaxis attack hereditary angioedema hae adult pediatric 12 older hae attack gallium ga 68 psma 11 radioactive diagnostic agent positron emission tomography pet prostate specific membrane antigen psma positive lesion suspected prostate cancer metastasis candidate initial surgical radiation therapy suspected prostate cancer recurrence based elevated serum prostate specific antigen psa level\n"
     ]
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('punkt')\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "lemmatizer = WordNetLemmatizer()\n",
    "#lemmatizer.lemmatize(\"drugs\")\n",
    "word_list = nltk.word_tokenize(indication_str)\n",
    "\n",
    "# Lemmatize list of words and join\n",
    "lemmatized_output = ' '.join([lemmatizer.lemmatize(w) for w in word_list])\n",
    "print(lemmatized_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "fcebfbf0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('investigated', 1022),\n",
       " ('disease', 839),\n",
       " ('cancer', 776),\n",
       " ('infection', 699),\n",
       " ('disorder', 546),\n",
       " ('therapy', 482),\n",
       " ('fda', 473),\n",
       " ('chronic', 372),\n",
       " ('adult', 336),\n",
       " ('agent', 297),\n",
       " ('tumor', 277),\n",
       " ('drug', 272),\n",
       " ('pain', 272),\n",
       " ('severe', 263),\n",
       " ('symptom', 241),\n",
       " ('condition', 239),\n",
       " ('cell', 236),\n",
       " ('type', 230),\n",
       " ('syndrome', 226),\n",
       " ('skin', 221),\n",
       " ('prevention', 215),\n",
       " ('approved', 215),\n",
       " ('non', 206),\n",
       " ('hypertension', 199),\n",
       " ('age', 196),\n",
       " ('indication', 192),\n",
       " ('older', 187),\n",
       " ('risk', 185),\n",
       " ('unspecified', 184),\n",
       " ('relief', 183),\n",
       " ('product', 177),\n",
       " ('moderate', 176),\n",
       " ('blood', 176),\n",
       " ('deficiency', 171),\n",
       " ('metastatic', 165),\n",
       " ('arthritis', 162),\n",
       " ('following', 159),\n",
       " ('heart', 153),\n",
       " ('surgery', 150),\n",
       " ('tract', 150),\n",
       " ('allergic', 148),\n",
       " ('adjunct', 146),\n",
       " ('leukemia', 146),\n",
       " ('diabetes', 146),\n",
       " ('pediatric', 145),\n",
       " ('susceptible', 144),\n",
       " ('well', 142),\n",
       " ('oral', 142),\n",
       " ('breast', 142),\n",
       " ('failure', 142),\n",
       " ('lung', 142),\n",
       " ('inflammatory', 139),\n",
       " ('symptomatic', 138),\n",
       " ('form', 136),\n",
       " ('b', 133),\n",
       " ('c', 130),\n",
       " ('primary', 130),\n",
       " ('hiv', 129),\n",
       " ('from', 129),\n",
       " ('chemotherapy', 125),\n",
       " ('control', 124),\n",
       " ('after', 124),\n",
       " ('lymphoma', 123),\n",
       " ('bacterial', 123),\n",
       " ('urinary', 122),\n",
       " ('pulmonary', 118),\n",
       " ('reduce', 118),\n",
       " ('term', 117),\n",
       " ('depression', 117),\n",
       " ('topical', 116),\n",
       " ('active', 115),\n",
       " ('solid', 115),\n",
       " ('advanced', 114),\n",
       " ('effect', 114),\n",
       " ('prophylaxis', 112),\n",
       " ('high', 111),\n",
       " ('rheumatoid', 110),\n",
       " ('myocardial', 110),\n",
       " ('prevent', 110),\n",
       " ('asthma', 108),\n",
       " ('ulcer', 108),\n",
       " ('coronary', 104),\n",
       " ('multiple', 104),\n",
       " ('child', 104),\n",
       " ('respiratory', 104),\n",
       " ('bone', 103),\n",
       " ('various', 103),\n",
       " ('acid', 102),\n",
       " ('some', 102),\n",
       " ('factor', 101),\n",
       " ('anxiety', 101),\n",
       " ('mellitus', 100),\n",
       " ('woman', 99),\n",
       " ('only', 98),\n",
       " ('positive', 97),\n",
       " ('infarction', 94),\n",
       " ('prior', 94),\n",
       " ('mild', 94),\n",
       " ('clinical', 93),\n",
       " ('prostate', 92),\n",
       " ('level', 92),\n",
       " ('inhibitor', 92),\n",
       " ('6', 92),\n",
       " ('diet', 92),\n",
       " ('short', 92),\n",
       " ('without', 91),\n",
       " ('carcinoma', 90),\n",
       " ('hepatitis', 90),\n",
       " ('should', 90),\n",
       " ('during', 88),\n",
       " ('e', 88),\n",
       " ('cardiovascular', 88),\n",
       " ('injection', 87),\n",
       " ('over', 86),\n",
       " ('aid', 86),\n",
       " ('than', 85),\n",
       " ('more', 84),\n",
       " ('include', 84),\n",
       " ('bowel', 84),\n",
       " ('refractory', 83),\n",
       " ('strain', 83),\n",
       " ('medication', 83),\n",
       " ('anti', 82),\n",
       " ('renal', 82),\n",
       " ('no', 82),\n",
       " ('peripheral', 81),\n",
       " ('related', 81),\n",
       " ('alone', 80),\n",
       " ('maintenance', 79),\n",
       " ('treating', 79),\n",
       " ('bleeding', 78),\n",
       " ('first', 77),\n",
       " ('line', 77),\n",
       " ('resistant', 77),\n",
       " ('pneumoniae', 77),\n",
       " ('liver', 76),\n",
       " ('viral', 76),\n",
       " ('12', 76),\n",
       " ('schizophrenia', 76),\n",
       " ('least', 75),\n",
       " ('available', 75),\n",
       " ('3', 75),\n",
       " ('seizure', 75),\n",
       " ('intravenous', 74),\n",
       " ('kidney', 74),\n",
       " ('tissue', 74),\n",
       " ('psoriasis', 73),\n",
       " ('angina', 73),\n",
       " ('procedure', 73),\n",
       " ('dermatitis', 73),\n",
       " ('off', 72),\n",
       " ('formulation', 72),\n",
       " ('virus', 72),\n",
       " ('muscle', 72),\n",
       " ('adjunctive', 71),\n",
       " ('streptococcus', 71),\n",
       " ('small', 70),\n",
       " ('secondary', 70),\n",
       " ('currently', 69),\n",
       " ('exercise', 69),\n",
       " ('case', 68),\n",
       " ('based', 67),\n",
       " ('5', 67),\n",
       " ('reduction', 67),\n",
       " ('therapeutic', 67),\n",
       " ('corticosteroid', 67),\n",
       " ('one', 67),\n",
       " ('diabetic', 67),\n",
       " ('stroke', 67),\n",
       " ('supplement', 66),\n",
       " ('brain', 66),\n",
       " ('gastrointestinal', 65),\n",
       " ('test', 65),\n",
       " ('gastric', 65),\n",
       " ('alzheimer', 65),\n",
       " ('like', 65),\n",
       " ('induced', 64),\n",
       " ('these', 64),\n",
       " ('imaging', 64),\n",
       " ('body', 64),\n",
       " ('regimen', 63),\n",
       " ('post', 63),\n",
       " ('being', 63),\n",
       " ('treated', 63),\n",
       " ('rhinitis', 63),\n",
       " ('recurrent', 62),\n",
       " ('parkinson', 62),\n",
       " ('negative', 61),\n",
       " ('month', 61),\n",
       " ('solution', 61),\n",
       " ('receptor', 61),\n",
       " ('nausea', 61),\n",
       " ('vomiting', 61),\n",
       " ('administered', 60),\n",
       " ('4', 60),\n",
       " ('anemia', 60),\n",
       " ('i', 60),\n",
       " ('response', 60),\n",
       " ('systemic', 60),\n",
       " ('hodgkin', 60),\n",
       " ('coli', 60),\n",
       " ('eye', 59),\n",
       " ('surgical', 59),\n",
       " ('system', 59),\n",
       " ('pressure', 59),\n",
       " ('aged', 58),\n",
       " ('thrombosis', 58),\n",
       " ('anesthesia', 58),\n",
       " ('episode', 58),\n",
       " ('specie', 58),\n",
       " ('mutation', 58),\n",
       " ('monotherapy', 57),\n",
       " ('artery', 57),\n",
       " ('improve', 57),\n",
       " ('cause', 57),\n",
       " ('any', 57),\n",
       " ('study', 57),\n",
       " ('inflammation', 56),\n",
       " ('function', 56),\n",
       " ('dietary', 56),\n",
       " ('counter', 56),\n",
       " ('addition', 55),\n",
       " ('elevated', 55),\n",
       " ('individual', 55),\n",
       " ('osteoarthritis', 55),\n",
       " ('effective', 55),\n",
       " ('but', 55),\n",
       " ('ovarian', 54),\n",
       " ('loss', 54),\n",
       " ('bacteria', 54),\n",
       " ('containing', 54),\n",
       " ('gt', 54),\n",
       " ('cardiac', 53),\n",
       " ('activity', 53),\n",
       " ('administration', 53),\n",
       " ('growth', 53),\n",
       " ('fever', 53),\n",
       " ('g', 53),\n",
       " ('under', 53),\n",
       " ('suspected', 53),\n",
       " ('known', 52),\n",
       " ('certain', 52),\n",
       " ('where', 52),\n",
       " ('sclerosis', 52),\n",
       " ('diagnostic', 52),\n",
       " ('lt', 52),\n",
       " ('melanoma', 52),\n",
       " ('above', 52),\n",
       " ('either', 51),\n",
       " ('total', 51),\n",
       " ('low', 51),\n",
       " ('congestive', 51),\n",
       " ('insomnia', 51),\n",
       " ('organism', 51),\n",
       " ('tablet', 51),\n",
       " ('ventricular', 50),\n",
       " ('atrial', 50),\n",
       " ('us', 50),\n",
       " ('acquired', 50),\n",
       " ('common', 50),\n",
       " ('potential', 50),\n",
       " ('approval', 50),\n",
       " ('human', 49),\n",
       " ('there', 49),\n",
       " ('osteoporosis', 49),\n",
       " ('lesion', 49),\n",
       " ('both', 49),\n",
       " ('vascular', 49),\n",
       " ('trial', 49),\n",
       " ('migraine', 49),\n",
       " ('bronchitis', 49),\n",
       " ('cirrhosis', 49),\n",
       " ('colorectal', 48),\n",
       " ('two', 48),\n",
       " ('within', 48),\n",
       " ('diagnosis', 48),\n",
       " ('hormone', 48),\n",
       " ('nasal', 48),\n",
       " ('day', 48),\n",
       " ('weight', 47),\n",
       " ('transplant', 47),\n",
       " ('increase', 47),\n",
       " ('gram', 47),\n",
       " ('partial', 47),\n",
       " ('against', 47),\n",
       " ('uncomplicated', 47),\n",
       " ('those', 46),\n",
       " ('all', 46),\n",
       " ('medical', 46),\n",
       " ('diarrhea', 46),\n",
       " ('manifestation', 46),\n",
       " ('state', 46),\n",
       " ('analgesic', 46),\n",
       " ('major', 46),\n",
       " ('preparation', 46),\n",
       " ('psoriatic', 45),\n",
       " ('myeloid', 45),\n",
       " ('most', 45),\n",
       " ('fibrillation', 45),\n",
       " ('lower', 45),\n",
       " ('pneumonia', 45),\n",
       " ('idiopathic', 44),\n",
       " ('iron', 44),\n",
       " ('pancreatic', 44),\n",
       " ('dose', 44),\n",
       " ('herpes', 44),\n",
       " ('general', 44),\n",
       " ('myeloma', 44),\n",
       " ('week', 44),\n",
       " ('abdominal', 44),\n",
       " ('glaucoma', 44),\n",
       " ('18', 44),\n",
       " ('given', 44),\n",
       " ('intended', 43),\n",
       " ('progression', 43),\n",
       " ('part', 43),\n",
       " ('result', 43),\n",
       " ('food', 43),\n",
       " ('presence', 43),\n",
       " ('increased', 43),\n",
       " ('obesity', 43),\n",
       " ('postmenopausal', 43),\n",
       " ('copd', 43),\n",
       " ('supplementation', 42),\n",
       " ('conjunction', 42),\n",
       " ('local', 42),\n",
       " ('induction', 42),\n",
       " ('undergoing', 41),\n",
       " ('evidence', 41),\n",
       " ('locally', 41),\n",
       " ('wound', 41),\n",
       " ('replacement', 41),\n",
       " ('ii', 41),\n",
       " ('characterized', 41),\n",
       " ('if', 41),\n",
       " ('staphylococcus', 41),\n",
       " ('aureus', 41),\n",
       " ('group', 41),\n",
       " ('obstructive', 41),\n",
       " ('responsive', 41),\n",
       " ('ingredient', 41),\n",
       " ('hcv', 40),\n",
       " ('head', 40),\n",
       " ('previously', 40),\n",
       " ('pregnancy', 40),\n",
       " ('cholesterol', 40),\n",
       " ('health', 40),\n",
       " ('present', 40),\n",
       " ('rate', 40),\n",
       " ('influenzae', 40),\n",
       " ('opioid', 40),\n",
       " ('reaction', 40),\n",
       " ('temporary', 39),\n",
       " ('attack', 39),\n",
       " ('alternative', 39),\n",
       " ('long', 39),\n",
       " ('nutritional', 39),\n",
       " ('help', 39),\n",
       " ('depressive', 39),\n",
       " ('cold', 39),\n",
       " ('irritable', 39),\n",
       " ('canada', 38),\n",
       " ('calcium', 38),\n",
       " ('genotype', 38),\n",
       " ('onset', 38),\n",
       " ('ophthalmic', 38),\n",
       " ('stage', 38),\n",
       " ('up', 38),\n",
       " ('hyperlipidemia', 38),\n",
       " ('mg', 38),\n",
       " ('minor', 38),\n",
       " ('bipolar', 38),\n",
       " ('ocular', 38),\n",
       " ('serum', 37),\n",
       " ('component', 37),\n",
       " ('considered', 37),\n",
       " ('malignant', 37),\n",
       " ('organ', 37),\n",
       " ('antiretroviral', 37),\n",
       " ('immune', 37),\n",
       " ('sleep', 37),\n",
       " ('ldl', 37),\n",
       " ('complex', 37),\n",
       " ('contact', 37),\n",
       " ('bladder', 37),\n",
       " ('edema', 37),\n",
       " ('constipation', 37),\n",
       " ('sign', 36),\n",
       " ('microorganism', 36),\n",
       " ('congenital', 36),\n",
       " ('19', 36),\n",
       " ('normal', 36),\n",
       " ('conjunctivitis', 36),\n",
       " ('whose', 36),\n",
       " ('beta', 36),\n",
       " ('klebsiella', 36),\n",
       " ('epilepsy', 36),\n",
       " ('m', 36),\n",
       " ('glycemic', 35),\n",
       " ('parenteral', 35),\n",
       " ('ulcerative', 35),\n",
       " ('colitis', 35),\n",
       " ('burn', 35),\n",
       " ('appropriate', 35),\n",
       " ('structure', 35),\n",
       " ('event', 35),\n",
       " ('sodium', 35),\n",
       " ('old', 35),\n",
       " ('resistance', 35),\n",
       " ('acne', 35),\n",
       " ('tinea', 35),\n",
       " ('combined', 35),\n",
       " ('palliative', 34),\n",
       " ('emergency', 34),\n",
       " ('hemophilia', 34),\n",
       " ('reducing', 34),\n",
       " ('complicated', 34),\n",
       " ('covid', 34),\n",
       " ('joint', 34),\n",
       " ('however', 34),\n",
       " ('relieve', 34),\n",
       " ('person', 34),\n",
       " ('dermatosis', 34),\n",
       " ('dental', 34),\n",
       " ('radiation', 33),\n",
       " ('thyroid', 33),\n",
       " ('time', 33),\n",
       " ('adolescent', 33),\n",
       " ('received', 33),\n",
       " ('commonly', 33),\n",
       " ('injury', 33),\n",
       " ('history', 33),\n",
       " ('iii', 33),\n",
       " ('upper', 33),\n",
       " ('standard', 33),\n",
       " ('headache', 33),\n",
       " ('escherichia', 33),\n",
       " ('angle', 32),\n",
       " ('premature', 32),\n",
       " ('several', 32),\n",
       " ('shown', 32),\n",
       " ('vein', 32),\n",
       " ('usually', 32),\n",
       " ('cerebral', 32),\n",
       " ('haemophilus', 32),\n",
       " ('area', 32),\n",
       " ('reflux', 32),\n",
       " ('male', 32),\n",
       " ('relapsed', 32),\n",
       " ('venous', 32),\n",
       " ('initial', 31),\n",
       " ('lymphocytic', 31),\n",
       " ('insufficiency', 31),\n",
       " ('crohn', 31),\n",
       " ('studied', 31),\n",
       " ('le', 31),\n",
       " ('intra', 31),\n",
       " ('dependent', 31),\n",
       " ('stable', 31),\n",
       " ('postoperative', 31),\n",
       " ('pyogenes', 31),\n",
       " ('malaria', 31),\n",
       " ('estrogen', 31),\n",
       " ('large', 31),\n",
       " ('second', 31),\n",
       " ('gene', 31),\n",
       " ('decrease', 30),\n",
       " ('men', 30),\n",
       " ('adjuvant', 30),\n",
       " ('release', 30),\n",
       " ('neurologic', 30),\n",
       " ('dysfunction', 30),\n",
       " ('recommended', 30),\n",
       " ('protein', 30),\n",
       " ('stress', 30),\n",
       " ('neuropathy', 30),\n",
       " ('important', 30),\n",
       " ('patient', 30),\n",
       " ('kg', 30),\n",
       " ('exposure', 30),\n",
       " ('infant', 30),\n",
       " ('medium', 30),\n",
       " ('sore', 30),\n",
       " ('many', 30),\n",
       " ('macular', 30),\n",
       " ('contrast', 30),\n",
       " ('intolerant', 29),\n",
       " ('fibrosis', 29),\n",
       " ('central', 29),\n",
       " ('fluid', 29),\n",
       " ('plasma', 29),\n",
       " ('number', 29),\n",
       " ('duration', 29),\n",
       " ('soft', 29),\n",
       " ('hypercholesterolemia', 29),\n",
       " ('efficacy', 29),\n",
       " ('vaginal', 29),\n",
       " ('candidiasis', 29),\n",
       " ('cough', 29),\n",
       " ('documented', 29),\n",
       " ('diuretic', 29),\n",
       " ('open', 29),\n",
       " ('nsclc', 29),\n",
       " ('benefit', 29),\n",
       " ('stomach', 29),\n",
       " ('nutrition', 29),\n",
       " ('ischemic', 28),\n",
       " ('clinically', 28),\n",
       " ('female', 28),\n",
       " ('cervical', 28),\n",
       " ('neck', 28),\n",
       " ('prophylactic', 28),\n",
       " ('respond', 28),\n",
       " ('production', 28),\n",
       " ('often', 28),\n",
       " ('familial', 28),\n",
       " ('atherosclerosis', 28),\n",
       " ('withdrawal', 28),\n",
       " ('exacerbation', 28),\n",
       " ('pruritic', 28),\n",
       " ('their', 28),\n",
       " ('allergenic', 28),\n",
       " ('schizoaffective', 28),\n",
       " ('single', 27),\n",
       " ('moderately', 27),\n",
       " ('plaque', 27),\n",
       " ('manage', 27),\n",
       " ('treatment', 27),\n",
       " ('maintain', 27),\n",
       " ('abnormal', 27),\n",
       " ('diagnosed', 27),\n",
       " ('healing', 27),\n",
       " ('her2', 27),\n",
       " ('require', 27),\n",
       " ('embolism', 27),\n",
       " ('deep', 27),\n",
       " ('atopic', 27),\n",
       " ('can', 27),\n",
       " ('not', 27),\n",
       " ('spray', 27),\n",
       " ('vitamin', 27),\n",
       " ('note', 27),\n",
       " ('primarily', 27),\n",
       " ('mixed', 27),\n",
       " ('before', 27),\n",
       " ('class', 27),\n",
       " ('fungal', 27),\n",
       " ('gerd', 27),\n",
       " ('extended', 27),\n",
       " ('anesthetic', 27),\n",
       " ('absence', 27),\n",
       " ('hereditary', 27),\n",
       " ('peptic', 27),\n",
       " ('ibs', 27),\n",
       " ('menopause', 26),\n",
       " ('greater', 26),\n",
       " ('setting', 26),\n",
       " ('established', 26),\n",
       " ('arterial', 26),\n",
       " ('into', 26),\n",
       " ('intestinal', 26),\n",
       " ('unresectable', 26),\n",
       " ('hepatic', 26),\n",
       " ('early', 26),\n",
       " ('specifically', 26),\n",
       " ('generalized', 26),\n",
       " ('phase', 26),\n",
       " ('intraocular', 26),\n",
       " ('seasonal', 26),\n",
       " ('p', 26),\n",
       " ('endocrine', 26),\n",
       " ('degeneration', 26),\n",
       " ('kinase', 26),\n",
       " ('cystic', 25),\n",
       " ('severely', 25),\n",
       " ('cosmetic', 25),\n",
       " ('death', 25),\n",
       " ('rheumatic', 25),\n",
       " ('rapid', 25),\n",
       " ('life', 25),\n",
       " ('antihypertensive', 25),\n",
       " ('cream', 25),\n",
       " ('requiring', 25),\n",
       " ('progressive', 25),\n",
       " ('enterobacter', 25),\n",
       " ('ml', 25),\n",
       " ('lymphoid', 25),\n",
       " ('whom', 24),\n",
       " ('genital', 24),\n",
       " ('limited', 24),\n",
       " ('dos', 24),\n",
       " ('trauma', 24),\n",
       " ('controlled', 24),\n",
       " ('infectious', 24),\n",
       " ('damage', 24),\n",
       " ('benign', 24),\n",
       " ('excessive', 24),\n",
       " ('enzyme', 24),\n",
       " ('hemorrhage', 24),\n",
       " ('dementia', 24),\n",
       " ('development', 24),\n",
       " ('adhd', 24),\n",
       " ('mouth', 24),\n",
       " ('testing', 24),\n",
       " ('influenza', 24),\n",
       " ('otitis', 24),\n",
       " ('10', 24),\n",
       " ('mainly', 24),\n",
       " ('regional', 24),\n",
       " ('tuberculosis', 24),\n",
       " ('tomography', 24),\n",
       " ('contraception', 24),\n",
       " ('platinum', 24),\n",
       " ('bronchospasm', 24),\n",
       " ('confirmed', 24),\n",
       " ('h', 24),\n",
       " ('aeruginosa', 24),\n",
       " ('secretion', 24),\n",
       " ('invasive', 24),\n",
       " ('adverse', 24),\n",
       " ('t', 23),\n",
       " ('improvement', 23),\n",
       " ('uterine', 23),\n",
       " ('intolerance', 23),\n",
       " ('autoimmune', 23),\n",
       " ('includes', 23),\n",
       " ('antibody', 23),\n",
       " ('urticaria', 23),\n",
       " ('additionally', 23),\n",
       " ('conventional', 23),\n",
       " ('relapsing', 23),\n",
       " ('had', 23),\n",
       " ('methotrexate', 23),\n",
       " ('produce', 23),\n",
       " ('vulgaris', 23),\n",
       " ('essential', 23),\n",
       " ('variety', 23),\n",
       " ('shortage', 23),\n",
       " ('action', 23),\n",
       " ('lowering', 23),\n",
       " ('triglyceride', 23),\n",
       " ('specific', 23),\n",
       " ('iv', 23),\n",
       " ('spasm', 23),\n",
       " ('alcohol', 23),\n",
       " ('tachycardia', 23),\n",
       " ('through', 23),\n",
       " ('information', 23),\n",
       " ('found', 23),\n",
       " ('incontinence', 23),\n",
       " ('pruritus', 23),\n",
       " ('vasomotor', 23),\n",
       " ('contraceptive', 23),\n",
       " ('bacteroides', 23),\n",
       " ('susceptibility', 23),\n",
       " ('egfr', 22),\n",
       " ('marrow', 22),\n",
       " ('viii', 22),\n",
       " ('gastroesophageal', 22),\n",
       " ('subcutaneous', 22),\n",
       " ('rejection', 22),\n",
       " ('failed', 22),\n",
       " ('adequately', 22),\n",
       " ('nervous', 22),\n",
       " ('united', 22),\n",
       " ('demonstrated', 22),\n",
       " ('skeletal', 22),\n",
       " ('infected', 22),\n",
       " ('penicillin', 22),\n",
       " ('recurrence', 22),\n",
       " ('foot', 22),\n",
       " ('arrhythmia', 22),\n",
       " ('although', 22),\n",
       " ('duodenal', 22),\n",
       " ('operative', 22),\n",
       " ('required', 22),\n",
       " ('antibiotic', 22),\n",
       " ('accelerated', 22),\n",
       " ('fracture', 22),\n",
       " ('lupus', 22),\n",
       " ('chloride', 22),\n",
       " ('thromboembolism', 22),\n",
       " ('irritation', 22),\n",
       " ('metabolic', 22),\n",
       " ('cutaneous', 21),\n",
       " ('spondylitis', 21),\n",
       " ('neutropenia', 21),\n",
       " ('receiving', 21),\n",
       " ('detection', 21),\n",
       " ('complication', 21),\n",
       " ('sarcoma', 21),\n",
       " ('hypogonadism', 21),\n",
       " ('l', 21),\n",
       " ('induce', 21),\n",
       " ('useful', 21),\n",
       " ('very', 21),\n",
       " ('fat', 21),\n",
       " ('do', 21),\n",
       " ('reversible', 21),\n",
       " ('u', 21),\n",
       " ('angioedema', 21),\n",
       " ('proteus', 21),\n",
       " ('mirabilis', 21),\n",
       " ('purpose', 21),\n",
       " ('hyperplasia', 21),\n",
       " ('producing', 21),\n",
       " ('spp', 21),\n",
       " ('pseudomonas', 21),\n",
       " ('serious', 21),\n",
       " ('source', 21),\n",
       " ('d', 21),\n",
       " ('patch', 21),\n",
       " ('antibacterial', 21),\n",
       " ('thrombocytopenia', 20),\n",
       " ('incidence', 20),\n",
       " ('survival', 20),\n",
       " ('inadequate', 20),\n",
       " ('frequency', 20),\n",
       " ('cll', 20),\n",
       " ('antagonist', 20),\n",
       " ('between', 20),\n",
       " ('metastasis', 20),\n",
       " ('nephropathy', 20),\n",
       " ('transplantation', 20),\n",
       " ('care', 20),\n",
       " ('will', 20),\n",
       " ('density', 20),\n",
       " ('left', 20),\n",
       " ('muscular', 20),\n",
       " ('period', 20),\n",
       " ('daily', 20),\n",
       " ('candida', 20),\n",
       " ('catarrhalis', 20),\n",
       " ('statin', 20),\n",
       " ('neuropathic', 20),\n",
       " ('spinal', 20),\n",
       " ('complete', 20),\n",
       " ('salt', 20),\n",
       " ('methicillin', 20),\n",
       " ('pectoris', 20),\n",
       " ('country', 20),\n",
       " ('application', 20),\n",
       " ('pharmaceutical', 20),\n",
       " ('vaccine', 20),\n",
       " ('wart', 19),\n",
       " ('transfusion', 19),\n",
       " ('perennial', 19),\n",
       " ('inhaled', 19),\n",
       " ('they', 19),\n",
       " ('simplex', 19),\n",
       " ('k', 19),\n",
       " ('esophageal', 19),\n",
       " ('functional', 19),\n",
       " ('erosive', 19),\n",
       " ('safety', 19),\n",
       " ('prescription', 19),\n",
       " ('different', 19),\n",
       " ('isolates', 19),\n",
       " ('painful', 19),\n",
       " ('prostatic', 19),\n",
       " ('septicemia', 19),\n",
       " ('allergy', 19),\n",
       " ('possible', 19),\n",
       " ('lead', 19),\n",
       " ('water', 19),\n",
       " ('alk', 19),\n",
       " ('ankylosing', 18),\n",
       " ('compensated', 18),\n",
       " ('dialysis', 18),\n",
       " ('malignancy', 18),\n",
       " ('insulin', 18),\n",
       " ('platelet', 18),\n",
       " ('persistent', 18),\n",
       " ('ointment', 18),\n",
       " ('candidate', 18),\n",
       " ('cisplatin', 18),\n",
       " ('defined', 18),\n",
       " ('mood', 18),\n",
       " ('sulfate', 18),\n",
       " ('similar', 18),\n",
       " ('particularly', 18),\n",
       " ('deficit', 18),\n",
       " ('dry', 18),\n",
       " ('provide', 18),\n",
       " ('adequate', 18),\n",
       " ('antimicrobial', 18),\n",
       " ('poisoning', 18),\n",
       " ('ema', 18),\n",
       " ('heartburn', 18),\n",
       " ('measure', 18),\n",
       " ('trichophyton', 18),\n",
       " ('bronchial', 18),\n",
       " ('continued', 18),\n",
       " ('disturbance', 18),\n",
       " ('while', 18),\n",
       " ('psychotic', 18),\n",
       " ('reversal', 18),\n",
       " ('progressed', 18),\n",
       " ('emission', 18),\n",
       " ('pet', 18),\n",
       " ('vitaminE', 18),\n",
       " ('intervention', 17),\n",
       " ('endometriosis', 17),\n",
       " ('significant', 17),\n",
       " ('upon', 17),\n",
       " ('lymphoblastic', 17),\n",
       " ('need', 17),\n",
       " ('responded', 17),\n",
       " ('physical', 17),\n",
       " ('vitaminD', 17),\n",
       " ('property', 17),\n",
       " ('occur', 17),\n",
       " ('flow', 17),\n",
       " ('attention', 17),\n",
       " ('status', 17),\n",
       " ('levodopa', 17),\n",
       " ('restriction', 17),\n",
       " ('meningitis', 17),\n",
       " ('particular', 17),\n",
       " ('were', 17),\n",
       " ('abnormality', 17),\n",
       " ('manic', 17),\n",
       " ('atrophy', 17),\n",
       " ('orally', 17),\n",
       " ('because', 17),\n",
       " ('congestion', 17),\n",
       " ('preventing', 17),\n",
       " ('substance', 17),\n",
       " ('staphylococci', 17),\n",
       " ('nsaid', 17),\n",
       " ('antacid', 17),\n",
       " ('endogenous', 17),\n",
       " ('hemodialysis', 17),\n",
       " ('itching', 17),\n",
       " ('detected', 17),\n",
       " ('antiseptic', 17),\n",
       " ('coagulation', 17),\n",
       " ('sunscreen', 17),\n",
       " ('epicutaneous', 17),\n",
       " ('acd', 17),\n",
       " ('pre', 16),\n",
       " ('contraindicated', 16),\n",
       " ('db00811', 16),\n",
       " ('pituitary', 16),\n",
       " ('movement', 16),\n",
       " ('juvenile', 16),\n",
       " ('improving', 16),\n",
       " ('nerve', 16),\n",
       " ('once', 16),\n",
       " ('delayed', 16),\n",
       " ('imbalance', 16),\n",
       " ('concentration', 16),\n",
       " ('rickets', 16),\n",
       " ('removal', 16),\n",
       " ('8', 16),\n",
       " ('panic', 16),\n",
       " ('parkinsonism', 16),\n",
       " ('threatening', 16),\n",
       " ('laboratory', 16),\n",
       " ('community', 16),\n",
       " ('year', 16),\n",
       " ('option', 16),\n",
       " ('delay', 16),\n",
       " ('effectiveness', 16),\n",
       " ('leg', 16),\n",
       " ('people', 16),\n",
       " ('tension', 16),\n",
       " ('angiography', 16),\n",
       " ('obstruction', 16),\n",
       " ('hormonal', 16),\n",
       " ('hair', 16),\n",
       " ('block', 16),\n",
       " ('fragilis', 16),\n",
       " ('immediate', 16),\n",
       " ('doe', 16),\n",
       " ('sickness', 16),\n",
       " ('shock', 16),\n",
       " ('traumatic', 16),\n",
       " ('40', 16),\n",
       " ('medicine', 16),\n",
       " ('node', 16),\n",
       " ('especially', 16),\n",
       " ('intermittent', 16),\n",
       " ('further', 16),\n",
       " ('ear', 16),\n",
       " ('throat', 16),\n",
       " ('excess', 16),\n",
       " ('oxygen', 16),\n",
       " ('reduced', 16),\n",
       " ('compound', 16),\n",
       " ('confirmatory', 16),\n",
       " ('x', 16),\n",
       " ('ray', 16),\n",
       " ('positron', 16),\n",
       " ('unstable', 15),\n",
       " ('would', 15),\n",
       " ('experienced', 15),\n",
       " ('emphysema', 15),\n",
       " ('distress', 15),\n",
       " ('remission', 15),\n",
       " ('steroid', 15),\n",
       " ('evaluation', 15),\n",
       " ('same', 15),\n",
       " ('support', 15),\n",
       " ('research', 15),\n",
       " ('formation', 15),\n",
       " ('sometimes', 15),\n",
       " ('lipoprotein', 15),\n",
       " ('spasticity', 15),\n",
       " ('determined', 15),\n",
       " ('hyperactivity', 15),\n",
       " ('typically', 15),\n",
       " ('acting', 15),\n",
       " ('sinus', 15),\n",
       " ('sedative', 15),\n",
       " ('illness', 15),\n",
       " ('birth', 15),\n",
       " ('ability', 15),\n",
       " ('suspension', 15),\n",
       " ('course', 15),\n",
       " ('lipid', 15),\n",
       " ('blocker', 15),\n",
       " ('keratitis', 15),\n",
       " ('vessel', 15),\n",
       " ('dependence', 15),\n",
       " ('designated', 15),\n",
       " ('lactamase', 15),\n",
       " ('topically', 15),\n",
       " ('infusion', 15),\n",
       " ('adrenal', 15),\n",
       " ('plasmodium', 15),\n",
       " ('cmv', 15),\n",
       " ('potassium', 15),\n",
       " ('additive', 15),\n",
       " ('streptococci', 15),\n",
       " ('menstrual', 15),\n",
       " ('using', 15),\n",
       " ('alpha', 15),\n",
       " ('thromboembolic', 15),\n",
       " ('spectrum', 15),\n",
       " ('store', 15),\n",
       " ('thus', 15),\n",
       " ('technetium', 15),\n",
       " ('multi', 14),\n",
       " ('von', 14),\n",
       " ('previous', 14),\n",
       " ('intramuscular', 14),\n",
       " ('impairment', 14),\n",
       " ('antipsychotic', 14),\n",
       " ('psychosis', 14),\n",
       " ('role', 14),\n",
       " ('flutter', 14),\n",
       " ('generally', 14),\n",
       " ('three', 14),\n",
       " ('prescribing', 14),\n",
       " ('hypersensitivity', 14),\n",
       " ('resection', 14),\n",
       " ('16', 14),\n",
       " ('population', 14),\n",
       " ('moraxella', 14),\n",
       " ('sinusitis', 14),\n",
       " ('hypotension', 14),\n",
       " ('esophagitis', 14),\n",
       " ('mri', 14),\n",
       " ('developing', 14),\n",
       " ('prescribed', 14),\n",
       " ('rare', 14),\n",
       " ('hospitalization', 14),\n",
       " ('colon', 14),\n",
       " ('pyelonephritis', 14),\n",
       " ('cluster', 14),\n",
       " ('discomfort', 14),\n",
       " ('regular', 14),\n",
       " ('hypertriglyceridemia', 14),\n",
       " ('emetogenic', 14),\n",
       " ('inhalation', 14),\n",
       " ('eczema', 14),\n",
       " ('15', 14),\n",
       " ('myelodysplastic', 14),\n",
       " ('epidermal', 14),\n",
       " ('sup', 14),\n",
       " ('lymph', 14),\n",
       " ('radioactive', 14),\n",
       " ('inherited', 14),\n",
       " ('percutaneous', 13),\n",
       " ('elevation', 13),\n",
       " ('phosphate', 13),\n",
       " ('menopausal', 13),\n",
       " ('immunodeficiency', 13),\n",
       " ('hemorrhagic', 13),\n",
       " ('30', 13),\n",
       " ('hour', 13),\n",
       " ('slow', 13),\n",
       " ('absorption', 13),\n",
       " ('immunocompromised', 13),\n",
       " ('tolerated', 13),\n",
       " ('labor', 13),\n",
       " ('postpartum', 13),\n",
       " ('widely', 13),\n",
       " ('fibromyalgia', 13),\n",
       " ...]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_indic_words = Counter(nltk.word_tokenize(lemmatized_output))\n",
    "all_indic_words.most_common(2000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "2198e7f0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "8829"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(all_indic_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "1c3a2b9c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('investigated', 1022),\n",
       " ('disease', 839),\n",
       " ('cancer', 776),\n",
       " ('infection', 699),\n",
       " ('disorder', 546),\n",
       " ('therapy', 482),\n",
       " ('fda', 473),\n",
       " ('chronic', 372),\n",
       " ('adult', 336),\n",
       " ('agent', 297),\n",
       " ('tumor', 277),\n",
       " ('drug', 272),\n",
       " ('pain', 272),\n",
       " ('severe', 263),\n",
       " ('symptom', 241),\n",
       " ('condition', 239),\n",
       " ('cell', 236),\n",
       " ('type', 230),\n",
       " ('syndrome', 226),\n",
       " ('skin', 221),\n",
       " ('prevention', 215),\n",
       " ('approved', 215),\n",
       " ('non', 206),\n",
       " ('hypertension', 199),\n",
       " ('age', 196),\n",
       " ('indication', 192),\n",
       " ('older', 187),\n",
       " ('risk', 185),\n",
       " ('unspecified', 184),\n",
       " ('relief', 183),\n",
       " ('product', 177),\n",
       " ('moderate', 176),\n",
       " ('blood', 176),\n",
       " ('deficiency', 171),\n",
       " ('metastatic', 165),\n",
       " ('arthritis', 162),\n",
       " ('following', 159),\n",
       " ('heart', 153),\n",
       " ('surgery', 150),\n",
       " ('tract', 150),\n",
       " ('allergic', 148),\n",
       " ('adjunct', 146),\n",
       " ('leukemia', 146),\n",
       " ('diabetes', 146),\n",
       " ('pediatric', 145),\n",
       " ('susceptible', 144),\n",
       " ('well', 142),\n",
       " ('oral', 142),\n",
       " ('breast', 142),\n",
       " ('failure', 142),\n",
       " ('lung', 142),\n",
       " ('inflammatory', 139),\n",
       " ('symptomatic', 138),\n",
       " ('form', 136),\n",
       " ('b', 133),\n",
       " ('c', 130),\n",
       " ('primary', 130),\n",
       " ('hiv', 129),\n",
       " ('from', 129),\n",
       " ('chemotherapy', 125),\n",
       " ('control', 124),\n",
       " ('after', 124),\n",
       " ('lymphoma', 123),\n",
       " ('bacterial', 123),\n",
       " ('urinary', 122),\n",
       " ('pulmonary', 118),\n",
       " ('reduce', 118),\n",
       " ('term', 117),\n",
       " ('depression', 117),\n",
       " ('topical', 116),\n",
       " ('active', 115),\n",
       " ('solid', 115),\n",
       " ('advanced', 114),\n",
       " ('effect', 114),\n",
       " ('prophylaxis', 112),\n",
       " ('high', 111),\n",
       " ('rheumatoid', 110),\n",
       " ('myocardial', 110),\n",
       " ('prevent', 110),\n",
       " ('asthma', 108),\n",
       " ('ulcer', 108),\n",
       " ('coronary', 104),\n",
       " ('multiple', 104),\n",
       " ('child', 104),\n",
       " ('respiratory', 104),\n",
       " ('bone', 103),\n",
       " ('various', 103),\n",
       " ('acid', 102),\n",
       " ('some', 102),\n",
       " ('factor', 101),\n",
       " ('anxiety', 101),\n",
       " ('mellitus', 100),\n",
       " ('woman', 99),\n",
       " ('only', 98),\n",
       " ('positive', 97),\n",
       " ('infarction', 94),\n",
       " ('prior', 94),\n",
       " ('mild', 94),\n",
       " ('clinical', 93),\n",
       " ('prostate', 92)]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_indic_words.most_common(100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "5d024e80",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('truxima', 1),\n",
       " ('digitoxin', 1),\n",
       " ('lymphomafor', 1),\n",
       " ('strabismus', 1),\n",
       " ('cosmetically', 1),\n",
       " ('frown', 1),\n",
       " ('eyebrow', 1),\n",
       " ('glabellar', 1),\n",
       " ('sweating', 1),\n",
       " ('amylase', 1),\n",
       " ('a32721', 1),\n",
       " ('a32736', 1),\n",
       " ('deterioration', 1),\n",
       " ('parenchyma', 1),\n",
       " ('a32723', 1),\n",
       " ('evolving', 1),\n",
       " ('transmural', 1),\n",
       " ('emolism', 1),\n",
       " ('cannulae', 1),\n",
       " ('campath', 1),\n",
       " ('azathioprine', 1),\n",
       " ('secondly', 1),\n",
       " ('membranous', 1),\n",
       " ('blistering', 1),\n",
       " ('a139', 1),\n",
       " ('a174085', 1),\n",
       " ('a189393', 1),\n",
       " ('a189396', 1),\n",
       " ('a189399', 1),\n",
       " ('psoriasisfor', 1),\n",
       " ('adrenaline', 1),\n",
       " ('localising', 1),\n",
       " ('ischaemia', 1),\n",
       " ('rejectionthis', 1),\n",
       " ('leucocyte', 1),\n",
       " ('neutrophil', 1),\n",
       " ('bmt', 1),\n",
       " ('leukapheresis', 1),\n",
       " ('neupogen', 1),\n",
       " ('myelosuppression', 1),\n",
       " ('flushing', 1),\n",
       " ('vasoactive', 1),\n",
       " ('vipoma', 1),\n",
       " ('lanreotide', 1),\n",
       " ('abbreviation', 1),\n",
       " ('casued', 1),\n",
       " ('zenapax', 1),\n",
       " ('rejectionas', 1),\n",
       " ('endothelial', 1),\n",
       " ('interestingly', 1),\n",
       " ('ali', 1),\n",
       " ('tumorsfor', 1),\n",
       " ('calomist', 1),\n",
       " ('f3736', 1),\n",
       " ('addisonian', 1),\n",
       " ('gluten', 1),\n",
       " ('enteropathy', 1),\n",
       " ('overgrowth', 1),\n",
       " ('gastrectomy', 1),\n",
       " ('f3739', 1),\n",
       " ('entirely', 1),\n",
       " ('unclear', 1),\n",
       " ('uremia', 1),\n",
       " ('adenosylmethionine', 1),\n",
       " ('exacerbate', 1),\n",
       " ('imbalancesupplemental', 1),\n",
       " ('suggesting', 1),\n",
       " ('osteoporotic', 1),\n",
       " ('vitaminC', 1),\n",
       " ('scurvy', 1),\n",
       " ('acidification', 1),\n",
       " ('imbalancethere', 1),\n",
       " ('aspartates', 1),\n",
       " ('enhancer', 1),\n",
       " ('ergogenic', 1),\n",
       " ('improves', 1),\n",
       " ('taurine', 1),\n",
       " ('xanthophyll', 1),\n",
       " ('aosis', 1),\n",
       " ('chondroitin', 1),\n",
       " ('give', 1),\n",
       " ('lift', 1),\n",
       " ('craving', 1),\n",
       " ('imbalancephosphatidylserine', 1),\n",
       " ('phosphatidylserine', 1),\n",
       " ('antispastic', 1),\n",
       " ('acetaminophenfor', 1),\n",
       " ('wernicke', 1),\n",
       " ('a177664', 1),\n",
       " ('derive', 1),\n",
       " ('elastin', 1),\n",
       " ('smoothly', 1),\n",
       " ('assimilation', 1),\n",
       " ('hyperglyceridemic', 1),\n",
       " ('vigor', 1),\n",
       " ('coordination', 1),\n",
       " ('calm', 1),\n",
       " ('emotion', 1),\n",
       " ('minority', 1),\n",
       " ('simply', 1),\n",
       " ('a176104', 1),\n",
       " ('db00951', 1),\n",
       " ('db00366', 1),\n",
       " ('diclectin', 1),\n",
       " ('branched', 1),\n",
       " ('antihepatic', 1),\n",
       " ('anticatabolic', 1),\n",
       " ('antitardive', 1),\n",
       " ('f4027', 1),\n",
       " ('f4042', 1),\n",
       " ('indirectly', 1),\n",
       " ('a176041', 1),\n",
       " ('a176044', 1),\n",
       " ('f4051', 1),\n",
       " ('calcification', 1),\n",
       " ('evident', 1),\n",
       " ('interruption', 1),\n",
       " ('190', 1),\n",
       " ('a250', 1),\n",
       " ('acei', 1),\n",
       " ('f4703', 1),\n",
       " ('microalubinuria', 1),\n",
       " ('t116', 1),\n",
       " ('precancerous', 1),\n",
       " ('flexor', 1),\n",
       " ('clonus', 1),\n",
       " ('rigidity', 1),\n",
       " ('a18540', 1),\n",
       " ('heterogeneity', 1),\n",
       " ('presentation', 1),\n",
       " ('interplay', 1),\n",
       " ('interdependent', 1),\n",
       " ('teenager', 1),\n",
       " ('a174271', 1),\n",
       " ('resenting', 1),\n",
       " ('a174274', 1),\n",
       " ('a174268', 1),\n",
       " ('a174283', 1),\n",
       " ('functionfor', 1),\n",
       " ('gren', 1),\n",
       " ('anticipatory', 1),\n",
       " ('catatonia', 1),\n",
       " ('emergent', 1),\n",
       " ('noncompensatory', 1),\n",
       " ('postencephalitic', 1),\n",
       " ('topiramate', 1),\n",
       " ('controller', 1),\n",
       " ('nearly', 1),\n",
       " ('doubled', 1),\n",
       " ('a174391', 1),\n",
       " ('f4679', 1),\n",
       " ('a173986', 1),\n",
       " ('simplexfor', 1),\n",
       " ('cryptococcal', 1),\n",
       " ('predisposed', 1),\n",
       " ('serology', 1),\n",
       " ('starting', 1),\n",
       " ('isolate', 1),\n",
       " ('permissible', 1),\n",
       " ('adjusting', 1),\n",
       " ('sulfonylurea', 1),\n",
       " ('qualifies', 1),\n",
       " ('pandemic', 1),\n",
       " ('summarized', 1),\n",
       " ('listeriosis', 1),\n",
       " ('monocytogenes', 1),\n",
       " ('whooping', 1),\n",
       " ('bordetella', 1),\n",
       " ('nasopharynx', 1),\n",
       " ('rendering', 1),\n",
       " ('noninfectious', 1),\n",
       " ('diphtheriae', 1),\n",
       " ('antitoxin', 1),\n",
       " ('eradicate', 1),\n",
       " ('emerge', 1),\n",
       " ('erythrasma', 1),\n",
       " ('minutissimum', 1),\n",
       " ('extraenteric', 1),\n",
       " ('stis', 1),\n",
       " ('gonorrheae', 1),\n",
       " ('treponema', 1),\n",
       " ('pallidum', 1),\n",
       " ('ileal', 1),\n",
       " ('vegan', 1),\n",
       " ('macrobiotic', 1),\n",
       " ('restrictive', 1),\n",
       " ('benzoate', 1),\n",
       " ('ect', 1),\n",
       " ('phosphodiesterase', 1),\n",
       " ('pde5', 1),\n",
       " ('a175582', 1),\n",
       " ('f3853', 1),\n",
       " ('f3856', 1),\n",
       " ('f3886', 1),\n",
       " ('71', 1),\n",
       " ('pph', 1),\n",
       " ('hemodynamics', 1),\n",
       " ('afl', 1),\n",
       " ('rhythmfor', 1),\n",
       " ('consideration', 1),\n",
       " ('detailed', 1),\n",
       " ('worked', 1),\n",
       " ('micturition', 1),\n",
       " ('oh', 1),\n",
       " ('beyond', 1),\n",
       " ('trap', 1),\n",
       " ('ankle', 1),\n",
       " ('narrowing', 1),\n",
       " ('ethanol', 1),\n",
       " ('a321', 1),\n",
       " ('a322', 1),\n",
       " ('a323', 1),\n",
       " ('a324', 1),\n",
       " ('a174406', 1),\n",
       " ('a174409', 1),\n",
       " ('a174412', 1),\n",
       " ('pinkeye', 1),\n",
       " ('spasmsused', 1),\n",
       " ('hypoglycemic', 1),\n",
       " ('implementation', 1),\n",
       " ('iib2', 1),\n",
       " ('f4664', 1),\n",
       " ('boy', 1),\n",
       " ('girl', 1),\n",
       " ('189', 1),\n",
       " ('cesarean', 1),\n",
       " ('issued', 1),\n",
       " ('dispensed', 1),\n",
       " ('exceed', 1),\n",
       " ('quantity', 1),\n",
       " ('exceeding', 1),\n",
       " ('tuberculosisfor', 1),\n",
       " ('polycythaemia', 1),\n",
       " ('leukemic', 1),\n",
       " ('reticuloendotheliosis', 1),\n",
       " ('a174940', 1),\n",
       " ('a174898', 1),\n",
       " ('ileo', 1),\n",
       " ('benztropine', 1),\n",
       " ('akathisia', 1),\n",
       " ('bradykinesia', 1),\n",
       " ('a175120', 1),\n",
       " ('clearly', 1),\n",
       " ('headachefor', 1),\n",
       " ('hyperprolactinemic', 1),\n",
       " ('prolactinoma', 1),\n",
       " ('fo', 1),\n",
       " ('a188571', 1),\n",
       " ('episcleritis', 1),\n",
       " ('aerobe', 1),\n",
       " ('lymphogranuloma', 1),\n",
       " ('venereum', 1),\n",
       " ('psittacosis', 1),\n",
       " ('ornithosis', 1),\n",
       " ('immunofluorescence', 1),\n",
       " ('44', 1),\n",
       " ('74', 1),\n",
       " ('propionibacterium', 1),\n",
       " ('rickettsial', 1),\n",
       " ('f3088', 1),\n",
       " ('dipropionate', 1),\n",
       " ('vulvovaginitis', 1),\n",
       " ('repeated', 1),\n",
       " ('disposition', 1),\n",
       " ('gonococcus', 1),\n",
       " ('underdevelopment', 1),\n",
       " ('engorgement', 1),\n",
       " ('childbirth', 1),\n",
       " ('pyelography', 1),\n",
       " ('a188312', 1),\n",
       " ('f4709', 1),\n",
       " ('f4712', 1),\n",
       " ('a185915', 1),\n",
       " ('a174124', 1),\n",
       " ('a185324', 1),\n",
       " ('a185327', 1),\n",
       " ('a185333', 1),\n",
       " ('a185342', 1),\n",
       " ('a185345', 1),\n",
       " ('raas', 1),\n",
       " ('slows', 1),\n",
       " ('renoprotective', 1),\n",
       " ('a185906', 1),\n",
       " ('a185909', 1),\n",
       " ('t3', 1),\n",
       " ('pale', 1),\n",
       " ('puffy', 1),\n",
       " ('coarse', 1),\n",
       " ('croaky', 1),\n",
       " ('voice', 1),\n",
       " ('drowsiness', 1),\n",
       " ('nodule', 1),\n",
       " ('f4349', 1),\n",
       " ('pamidronate', 1),\n",
       " ('acrimation', 1),\n",
       " ('a177229', 1),\n",
       " ('a177238', 1),\n",
       " ('a177232', 1),\n",
       " ('a177235', 1),\n",
       " ('a38238', 1),\n",
       " ('f3061', 1),\n",
       " ('f3064', 1),\n",
       " ('bronchus', 1),\n",
       " ('waldenstrm', 1),\n",
       " ('breastfeeding', 1),\n",
       " ('a175990', 1),\n",
       " ('a176050', 1),\n",
       " ('opiods', 1),\n",
       " ('iatrogenically', 1),\n",
       " ('parasympatholytic', 1),\n",
       " ('tropicamide', 1),\n",
       " ('invections', 1),\n",
       " ('f3418', 1),\n",
       " ('f3421', 1),\n",
       " ('eight', 1),\n",
       " ('menstruation', 1),\n",
       " ('clostridioforme', 1),\n",
       " ('eubacterium', 1),\n",
       " ('lentum', 1),\n",
       " ('distasonis', 1),\n",
       " ('ovatus', 1),\n",
       " ('endomyometritis', 1),\n",
       " ('ab', 1),\n",
       " ('externo', 1),\n",
       " ('pyelocalyceal', 1),\n",
       " ('lg', 1),\n",
       " ('utuc', 1),\n",
       " ('ib', 1),\n",
       " ('erythraemia', 1),\n",
       " ('panmyelosis', 1),\n",
       " ('a177919', 1),\n",
       " ('a177928', 1),\n",
       " ('a177931', 1),\n",
       " ('a177934', 1),\n",
       " ('a177955', 1),\n",
       " ('ctth', 1),\n",
       " ('excluded', 1),\n",
       " ('expertise', 1),\n",
       " ('incurable', 1),\n",
       " ('palpebral', 1),\n",
       " ('bulbar', 1),\n",
       " ('globe', 1),\n",
       " ('addictive', 1),\n",
       " ('step', 1),\n",
       " ('ladder', 1),\n",
       " ('finishing', 1),\n",
       " ('a176471', 1),\n",
       " ('a177871', 1),\n",
       " ('1750', 1),\n",
       " ('xr', 1),\n",
       " ('a176939', 1),\n",
       " ('expiratory', 1),\n",
       " ('pathogenesis', 1),\n",
       " ('understood', 1),\n",
       " ('a176942', 1),\n",
       " ('accompanies', 1),\n",
       " ('drooling', 1),\n",
       " ('a176963', 1),\n",
       " ('nonopioid', 1),\n",
       " ('f4688', 1),\n",
       " ('f4685', 1),\n",
       " ('f4691', 1),\n",
       " ('fluoxetine', 1),\n",
       " ('differentiate', 1),\n",
       " ('extreme', 1),\n",
       " ('mmhg', 1),\n",
       " ('a178156', 1),\n",
       " ('a178141', 1),\n",
       " ('a178162', 1),\n",
       " ('arrythmias', 1),\n",
       " ('arrhythmogenic', 1),\n",
       " ('a178168', 1),\n",
       " ('methimazole', 1),\n",
       " ('a178147', 1),\n",
       " ('a178171', 1),\n",
       " ('a178174', 1),\n",
       " ('a178177', 1),\n",
       " ('pyodermas', 1),\n",
       " ('ppi', 1),\n",
       " ('antituberculous', 1),\n",
       " ('ragweed', 1),\n",
       " ('grass', 1),\n",
       " ('tree', 1),\n",
       " ('pollen', 1),\n",
       " ('dander', 1),\n",
       " ('mold', 1),\n",
       " ('postnasal', 1),\n",
       " ('markedly', 1),\n",
       " ('psvt', 1),\n",
       " ('av', 1),\n",
       " ('reentrant', 1),\n",
       " ('reciprocating', 1),\n",
       " ('extranodal', 1),\n",
       " ('wpw', 1),\n",
       " ('pr', 1),\n",
       " ('erpf', 1),\n",
       " ('interrupted', 1),\n",
       " ('beningn', 1),\n",
       " ('tyrosinemia', 1),\n",
       " ('regrowth', 1),\n",
       " ('stabilisation', 1),\n",
       " ('childbirthfor', 1),\n",
       " ('uine', 1),\n",
       " ('meningitisfor', 1),\n",
       " ('tetrahydrobiopterin', 1),\n",
       " ('bh4', 1),\n",
       " ('tartrate', 1),\n",
       " ('desmoid', 1),\n",
       " ('fibromatosis', 1),\n",
       " ('anthracyline', 1),\n",
       " ('canaidiasis', 1),\n",
       " ('a177655', 1),\n",
       " ('distributed', 1),\n",
       " ('a181976', 1),\n",
       " ('nonemergency', 1),\n",
       " ('mirena', 1),\n",
       " ('menorrhagia', 1),\n",
       " ('vasodilatory', 1),\n",
       " ('vasopressor', 1),\n",
       " ('dysthymia', 1),\n",
       " ('flush', 1),\n",
       " ('a177811', 1),\n",
       " ('a177946', 1),\n",
       " ('a179530', 1),\n",
       " ('counseling', 1),\n",
       " ('carried', 1),\n",
       " ('definite', 1),\n",
       " ('greatest', 1),\n",
       " ('f4567', 1),\n",
       " ('progesterone', 1),\n",
       " ('habitual', 1),\n",
       " ('antianginal', 1),\n",
       " ('angiographically', 1),\n",
       " ('smooth', 1),\n",
       " ('managment', 1),\n",
       " ('risked', 1),\n",
       " ('optimum', 1),\n",
       " ('reserpine', 1),\n",
       " ('sah', 1),\n",
       " ('ruptured', 1),\n",
       " ('berry', 1),\n",
       " ('beclomethasone', 1),\n",
       " ('diproprionate', 1),\n",
       " ('venenata', 1),\n",
       " ('neurodermatitis', 1),\n",
       " ('intertrigo', 1),\n",
       " ('dyshidroses', 1),\n",
       " ('pompholyx', 1),\n",
       " ('stasis', 1),\n",
       " ('agegelatinized', 1),\n",
       " ('gelatinized', 1),\n",
       " ('hysterectomized', 1),\n",
       " ('f3898', 1),\n",
       " ('insert', 1),\n",
       " ('embryo', 1),\n",
       " ('luteal', 1),\n",
       " ('f3901', 1),\n",
       " ('submucous', 1),\n",
       " ('f3907', 1),\n",
       " ('f3904', 1),\n",
       " ('namely', 1),\n",
       " ('barbae', 1),\n",
       " ('cradle', 1),\n",
       " ('caerulein', 1),\n",
       " ('a177973', 1),\n",
       " ('coldsfor', 1),\n",
       " ('a215532', 1),\n",
       " ('intensity', 1),\n",
       " ('bacteriological', 1),\n",
       " ('scarlet', 1),\n",
       " ('oropharynx', 1),\n",
       " ('fusospirochetosis', 1),\n",
       " ('vincent', 1),\n",
       " ('valvular', 1),\n",
       " ('habituated', 1),\n",
       " ('barbituratesfor', 1),\n",
       " ('nonneuropathic', 1),\n",
       " ('constraint', 1),\n",
       " ('niemann', 1),\n",
       " ('pick', 1),\n",
       " ('np', 1),\n",
       " ('aldosterone', 1),\n",
       " ('bilarteral', 1),\n",
       " ('macronodular', 1),\n",
       " ('a178135', 1),\n",
       " ('transgender', 1),\n",
       " ('a178138', 1),\n",
       " ('1500mg', 1),\n",
       " ('a31312', 1),\n",
       " ('islet', 1),\n",
       " ('13th', 1),\n",
       " ('instillation', 1),\n",
       " ('previable', 1),\n",
       " ('infested', 1),\n",
       " ('pediculosis', 1),\n",
       " ('primay', 1),\n",
       " ('tipiracil', 1),\n",
       " ('recommends', 1),\n",
       " ('dermatographism', 1),\n",
       " ('hypoxic', 1),\n",
       " ('tophus', 1),\n",
       " ('exceeds', 1),\n",
       " ('800', 1),\n",
       " ('750', 1),\n",
       " ('reassessed', 1),\n",
       " ('periodically', 1),\n",
       " ('blepharoconjunctivitis', 1),\n",
       " ('nonresectable', 1),\n",
       " ('member', 1),\n",
       " ('calcipotriene', 1),\n",
       " ('leukaemiafor', 1),\n",
       " ('destroys', 1),\n",
       " ('pharyntitis', 1),\n",
       " ('absceses', 1),\n",
       " ('saprphyticus', 1),\n",
       " ('penumoniae', 1),\n",
       " ('a4892', 1),\n",
       " ('a177065', 1),\n",
       " ('chronically', 1),\n",
       " ('predictably', 1),\n",
       " ('eradicating', 1),\n",
       " ('clarithromycin', 1),\n",
       " ('ssed', 1),\n",
       " ('thyrotropin', 1),\n",
       " ('bonjunctivitis', 1),\n",
       " ('meibomianitis', 1),\n",
       " ('removalfor', 1),\n",
       " ('2nd', 1),\n",
       " ('wheal', 1),\n",
       " ('a176435', 1),\n",
       " ('a176438', 1),\n",
       " ('negatively', 1),\n",
       " ('a176630', 1),\n",
       " ('a31900', 1),\n",
       " ('a31904', 1),\n",
       " ('subfoveal', 1),\n",
       " ('choroidal', 1),\n",
       " ('neovascularization', 1),\n",
       " ('myopia', 1),\n",
       " ('caliber', 1),\n",
       " ('clinician', 1),\n",
       " ('choose', 1),\n",
       " ('ailment', 1),\n",
       " ('lowest', 1),\n",
       " ('avoid', 1),\n",
       " ('choosing', 1),\n",
       " ('that', 1),\n",
       " ('ge', 1),\n",
       " ('saprophyticus', 1),\n",
       " ('crampsfor', 1),\n",
       " ('eib', 1),\n",
       " ('chewable', 1),\n",
       " ('instance', 1),\n",
       " ('stability', 1),\n",
       " ('paired', 1),\n",
       " ('olanzapine', 1),\n",
       " ('a178603', 1),\n",
       " ('combativeness', 1),\n",
       " ('hyperexcitable', 1),\n",
       " ('mima', 1),\n",
       " ('herellea', 1),\n",
       " ('aminoglycosides', 1),\n",
       " ('liposome', 1),\n",
       " ('achieving', 1),\n",
       " ('monthly', 1),\n",
       " ('bacteriologic', 1),\n",
       " ('5q', 1),\n",
       " ('oa', 1),\n",
       " ('be', 1),\n",
       " ('ventilationopthalmic', 1),\n",
       " ('brinzolamide', 1),\n",
       " ('disturbing', 1),\n",
       " ('psychotomimetic', 1),\n",
       " ('arrhytmias', 1),\n",
       " ('wearing', 1),\n",
       " ('mural', 1),\n",
       " ('thrombophili', 1),\n",
       " ('vocal', 1),\n",
       " ('utterance', 1),\n",
       " ('combative', 1),\n",
       " ('hyperexcitability', 1),\n",
       " ('accounted', 1),\n",
       " ('psychotherapy', 1),\n",
       " ('f4645', 1),\n",
       " ('nystagmusfor', 1),\n",
       " ('giardia', 1),\n",
       " ('lamblia', 1),\n",
       " ('a31973', 1),\n",
       " ('a31976', 1),\n",
       " ('digitalization', 1),\n",
       " ('enterocolitis', 1),\n",
       " ('brompheniramine', 1),\n",
       " ('guaifenesin', 1),\n",
       " ('dextromethorpahn', 1),\n",
       " ('quinidine', 1),\n",
       " ('pseudobulbar', 1),\n",
       " ('urushiol', 1),\n",
       " ('oak', 1),\n",
       " ('neurocysticercosis', 1),\n",
       " ('hydatid', 1),\n",
       " ('glaucomaindicated', 1),\n",
       " ('monitor', 1),\n",
       " ('adequacy', 1),\n",
       " ('palm', 1),\n",
       " ('sol', 1),\n",
       " ('infusional', 1),\n",
       " ('fu', 1),\n",
       " ('lv', 1),\n",
       " ('hsv', 1),\n",
       " ('retinoblastoma', 1),\n",
       " ('radiolabeled', 1),\n",
       " ('a180739', 1),\n",
       " ('easy', 1),\n",
       " ('fatigability', 1),\n",
       " ('nosocomial', 1),\n",
       " ('intratympanic', 1),\n",
       " ('intraepithelial', 1),\n",
       " ('myofascial', 1),\n",
       " ('a191083', 1),\n",
       " ('liposomal', 1),\n",
       " ('a840', 1),\n",
       " ('splitting', 1),\n",
       " ('vitiligofor', 1),\n",
       " ('carbamazepine', 1),\n",
       " ('primidone', 1),\n",
       " ('aed', 1),\n",
       " ('hypomania', 1),\n",
       " ('lamotirigine', 1),\n",
       " ('radiology', 1),\n",
       " ('vulgatus', 1),\n",
       " ('perfringens', 1),\n",
       " ('micros', 1),\n",
       " ('superimposed', 1),\n",
       " ('choriocarcinoma', 1),\n",
       " ('chorioadenoma', 1),\n",
       " ('destruens', 1),\n",
       " ('hydatiform', 1),\n",
       " ('epidermoid', 1),\n",
       " ('a180301', 1),\n",
       " ('a180415', 1),\n",
       " ('a180421', 1),\n",
       " ('icu', 1),\n",
       " ('45', 1),\n",
       " ('reinfarction', 1),\n",
       " ('histiocytosis', 1),\n",
       " ('subaortic', 1),\n",
       " ('proliferating', 1),\n",
       " ('hemangioma', 1),\n",
       " ('carbamate', 1),\n",
       " ('a180565', 1),\n",
       " ('dependance', 1),\n",
       " ('a180568', 1),\n",
       " ('a180571', 1),\n",
       " ('infectionvalacyclovir', 1),\n",
       " ('valacyclovir', 1),\n",
       " ('meter', 1),\n",
       " ('squared', 1),\n",
       " ('variation', 1),\n",
       " ('portacaval', 1),\n",
       " ('demonstrating', 1),\n",
       " ('galactin', 1),\n",
       " ('scedosporium', 1),\n",
       " ('apiospermum', 1),\n",
       " ('biosynthesis', 1),\n",
       " ('inborn', 1),\n",
       " ('glutaric', 1),\n",
       " ('malonic', 1),\n",
       " ('acylcoa', 1),\n",
       " ('akylosing', 1),\n",
       " ('misoprostol', 1),\n",
       " ('inflamation', 1),\n",
       " ('a180634', 1),\n",
       " ('ureteric', 1),\n",
       " ('a180637', 1),\n",
       " ('f1955', 1),\n",
       " ('a39532', 1),\n",
       " ('oxyuriasis', 1),\n",
       " ('kaliuretic', 1),\n",
       " ('pasteurella', 1),\n",
       " ('diplococcus', 1),\n",
       " ('improved', 1),\n",
       " ('unenhanced', 1),\n",
       " ('narcoanalysis', 1),\n",
       " ('narcosynthesis', 1),\n",
       " ('nondisseminated', 1),\n",
       " ('stercoralis', 1),\n",
       " ('subacromial', 1),\n",
       " ('supraspinatus', 1),\n",
       " ('a191655', 1),\n",
       " ('a191649', 1),\n",
       " ('a191652', 1),\n",
       " ('a191631', 1),\n",
       " ('antitubercular', 1),\n",
       " ('damagefor', 1),\n",
       " ('a180460', 1),\n",
       " ('a180463', 1),\n",
       " ('malarial', 1),\n",
       " ('myeloproliferative', 1),\n",
       " ('cel', 1),\n",
       " ('dermatofibrosarcoma', 1),\n",
       " ('protuberans', 1),\n",
       " ('hexacetonide', 1),\n",
       " ('aponeurosis', 1),\n",
       " ('controlling', 1),\n",
       " ('bullous', 1),\n",
       " ('stevens', 1),\n",
       " ('johnson', 1),\n",
       " ('nonsuppurative', 1),\n",
       " ('diamond', 1),\n",
       " ('blackfan', 1),\n",
       " ('pure', 1),\n",
       " ('aplasia', 1),\n",
       " ('berylliosis', 1),\n",
       " ('sarcoidosis', 1),\n",
       " ('dermatomyositis', 1),\n",
       " ('polymyositis', 1),\n",
       " ('fulminating', 1),\n",
       " ('carditis', 1),\n",
       " ('empyema', 1),\n",
       " ('vitaminDeficiencies', 1),\n",
       " ('multivitamin', 1),\n",
       " ('lovastatin', 1),\n",
       " ('a959', 1),\n",
       " ('a176750', 1),\n",
       " ('35ml', 1),\n",
       " ('mechanically', 1),\n",
       " ('analgesiafor', 1),\n",
       " ('characterised', 1),\n",
       " ('hyperinsulinemia', 1),\n",
       " ('pvst', 1),\n",
       " ('terminating', 1),\n",
       " ('thallous', 1),\n",
       " ('ti', 1),\n",
       " ('201', 1),\n",
       " ('establish', 1),\n",
       " ('undefined', 1),\n",
       " ('nonfamilial', 1),\n",
       " ('mesothelioma', 1),\n",
       " ('chemotherapyfor', 1),\n",
       " ('trichuris', 1),\n",
       " ('trichiura', 1),\n",
       " ('whipworm', 1),\n",
       " ('gonadotropes', 1),\n",
       " ('gonadotropic', 1),\n",
       " ('instrumentation', 1),\n",
       " ('alongside', 1),\n",
       " ('gramicidin', 1),\n",
       " ('triamcinolone', 1),\n",
       " ('viaderm', 1),\n",
       " ('candidal', 1),\n",
       " ('ani', 1),\n",
       " ('a188565', 1),\n",
       " ('counteract', 1),\n",
       " ('overdosages', 1),\n",
       " ('convulsion', 1),\n",
       " ('toxemia', 1),\n",
       " ('myometriat', 1),\n",
       " ('netarsudil', 1),\n",
       " ('approves', 1),\n",
       " ('iridotomy', 1),\n",
       " ('iridoplasty', 1),\n",
       " ('neurotransmitter', 1),\n",
       " ('a31634', 1),\n",
       " ('abstinence', 1),\n",
       " ('abstinent', 1),\n",
       " ('initiationfor', 1),\n",
       " ('vasopastic', 1),\n",
       " ('digoxin', 1),\n",
       " ('tachyarrhythmias', 1),\n",
       " ('a13983', 1),\n",
       " ('exczema', 1),\n",
       " ('conditionsfor', 1),\n",
       " ('distant', 1),\n",
       " ('isosexual', 1),\n",
       " ('stinging', 1),\n",
       " ('hymenoptera', 1),\n",
       " ('bee', 1),\n",
       " ('wasp', 1),\n",
       " ('hornet', 1),\n",
       " ('jacket', 1),\n",
       " ('ant', 1),\n",
       " ('triatoma', 1),\n",
       " ('radiocontrast', 1),\n",
       " ('paroxysm', 1),\n",
       " ('angioneurotic', 1),\n",
       " ('resuscitation', 1),\n",
       " ('accident', 1),\n",
       " ('musculature', 1),\n",
       " ('f2131', 1),\n",
       " ('naproxen', 1),\n",
       " ('accommodative', 1),\n",
       " ('esotropia', 1),\n",
       " ('mitral', 1),\n",
       " ('a179182', 1),\n",
       " ('anxiolysis', 1),\n",
       " ('f2434', 1),\n",
       " ('gonoccocal', 1),\n",
       " ('androgenital', 1),\n",
       " ('a180814', 1),\n",
       " ('a180817', 1),\n",
       " ('habitsfor', 1),\n",
       " ('pheochromocytomectomy', 1),\n",
       " ('manipulation', 1),\n",
       " ('catecholamine', 1),\n",
       " ('clonidine', 1),\n",
       " ('sloughing', 1),\n",
       " ('impedance', 1),\n",
       " ('infarct', 1),\n",
       " ('size', 1),\n",
       " ('papaverine', 1),\n",
       " ('cavernosum', 1),\n",
       " ('nitroglycerin', 1),\n",
       " ('angioscopy', 1),\n",
       " ('vasculature', 1),\n",
       " ('monocytic', 1),\n",
       " ('erythroid', 1),\n",
       " ('abort', 1),\n",
       " ('histaminic', 1),\n",
       " ('cephalalgia', 1),\n",
       " ('interfere', 1),\n",
       " ('f4471', 1),\n",
       " ('hyper', 1),\n",
       " ('aggregability', 1),\n",
       " ('ambulatory', 1),\n",
       " ('capd', 1),\n",
       " ('automated', 1),\n",
       " ('apd', 1),\n",
       " ('voiding', 1),\n",
       " ('a178339', 1),\n",
       " ('sitting', 1),\n",
       " ('anticipated', 1),\n",
       " ('bupivacaine', 1),\n",
       " ('certified', 1),\n",
       " ('center', 1),\n",
       " ('department', 1),\n",
       " ('hbv', 1),\n",
       " ('filarial', 1),\n",
       " ('loiasis', 1),\n",
       " ('filariasis', 1),\n",
       " ('wuchereria', 1),\n",
       " ('bancrofti', 1),\n",
       " ('malayi', 1),\n",
       " ('timori', 1),\n",
       " ('osteorarthritis', 1),\n",
       " ('anklosing', 1),\n",
       " ('tendonitis', 1),\n",
       " ('operatively', 1),\n",
       " ('hypomobility', 1),\n",
       " ('brisdelle', 1),\n",
       " ('a1093', 1),\n",
       " ('a181754', 1),\n",
       " ('a181904', 1),\n",
       " ('leuprolide', 1),\n",
       " ('histological', 1),\n",
       " ('virological', 1),\n",
       " ('serological', 1),\n",
       " ('lamivudine', 1),\n",
       " ('eustachian', 1),\n",
       " ('osteolysis', 1),\n",
       " ('nonhyperkeratotic', 1),\n",
       " ('nonhypertrophic', 1),\n",
       " ('t628', 1),\n",
       " ('a180280', 1),\n",
       " ('a180283', 1),\n",
       " ('a180277', 1),\n",
       " ('sequence', 1),\n",
       " ('threadworm', 1),\n",
       " ('creeping', 1),\n",
       " ('eruption', 1),\n",
       " ('organophosphate', 1),\n",
       " ('adjunctly', 1),\n",
       " ('valproic', 1),\n",
       " ('approach', 1),\n",
       " ('labyrinthitis', 1),\n",
       " ('lou', 1),\n",
       " ('gehrig', 1),\n",
       " ('granule', 1),\n",
       " ('ai', 1),\n",
       " ('irreversible', 1),\n",
       " ('passed', 1),\n",
       " ('bronchitol', 1),\n",
       " ('btt', 1),\n",
       " ('every', 1),\n",
       " ('gadobenate', 1),\n",
       " ('dimeglumine', 1),\n",
       " ('mr', 1),\n",
       " ('wakefulness', 1),\n",
       " ('sialorrhoea', 1),\n",
       " ('flat', 1),\n",
       " ('congenita', 1),\n",
       " ('lamellar', 1),\n",
       " ('palmaris', 1),\n",
       " ('plantaris', 1),\n",
       " ('epidermolytic', 1),\n",
       " ('hyperkeratosis', 1),\n",
       " ('comedo', 1),\n",
       " ('follicularis', 1),\n",
       " ('darier', 1),\n",
       " ('fine', 1),\n",
       " ('wrinkling', 1),\n",
       " ('mottled', 1),\n",
       " ('roughness', 1),\n",
       " ('cleanser', 1),\n",
       " ('brill', 1),\n",
       " ('zinsser', 1),\n",
       " ('chlamydiae', 1),\n",
       " ('meningitidis', 1),\n",
       " ('hyperthyroid', 1),\n",
       " ('lactamases', 1),\n",
       " ('melaninogenicus', 1),\n",
       " ('intraabdominal', 1),\n",
       " ('pnemoniae', 1),\n",
       " ('microbiological', 1),\n",
       " ('appropriateness', 1),\n",
       " ('clavulanate', 1),\n",
       " ('prove', 1),\n",
       " ('antiinflammatory', 1),\n",
       " ('dermatosesfor', 1),\n",
       " ('definitive', 1),\n",
       " ('corrective', 1),\n",
       " ('vasculogenic', 1),\n",
       " ('pediculus', 1),\n",
       " ('humanus', 1),\n",
       " ('ovum', 1),\n",
       " ('ptca', 1),\n",
       " ('atherectomy', 1),\n",
       " ('antihistamininc', 1),\n",
       " ('specify', 1),\n",
       " ('hence', 1),\n",
       " ('best', 1),\n",
       " ('featuring', 1),\n",
       " ('leaden', 1),\n",
       " ('interpersonal', 1),\n",
       " ('melancholic', 1),\n",
       " ('catatonic', 1),\n",
       " ('a31917', 1),\n",
       " ('emotionally', 1),\n",
       " ('personality', 1),\n",
       " ('likewise', 1),\n",
       " ('a31922', 1),\n",
       " ('outlook', 1),\n",
       " ('tend', 1),\n",
       " ('stressful', 1),\n",
       " ('generating', 1),\n",
       " ('a31924', 1),\n",
       " ('db00977', 1),\n",
       " ('changed', 1),\n",
       " ('drastically', 1),\n",
       " ('initiative', 1),\n",
       " ('2002', 1),\n",
       " ('a31626', 1),\n",
       " ('statistically', 1),\n",
       " ('a31627', 1),\n",
       " ('critique', 1),\n",
       " ('hrt', 1),\n",
       " ('postmenopause', 1),\n",
       " ('a31628', 1),\n",
       " ('stimulatory', 1),\n",
       " ('intact', 1),\n",
       " ('unopposed', 1),\n",
       " ('cancersan', 1),\n",
       " ('shortening', 1),\n",
       " ('a39414', 1),\n",
       " ('a39415', 1),\n",
       " ('candesartan', 1),\n",
       " ('anomaliesfor', 1),\n",
       " ('enterobactor', 1),\n",
       " ('deteriorating', 1),\n",
       " ('nervousness', 1),\n",
       " ('lameness', 1),\n",
       " ('immobility', 1),\n",
       " ('ciliary', 1),\n",
       " ('refractive', 1),\n",
       " ('virologic', 1),\n",
       " ('a19644', 1),\n",
       " ('determinant', 1),\n",
       " ('transmucosal', 1),\n",
       " ('tolerant', 1),\n",
       " ('pauciarticular', 1),\n",
       " ('jra', 1),\n",
       " ('a190189', 1),\n",
       " ('microbicidal', 1),\n",
       " ('enveloped', 1),\n",
       " ('semliki', 1),\n",
       " ('forest', 1),\n",
       " ('nonenveloped', 1),\n",
       " ('papillomaviruses', 1),\n",
       " ('poliovirus', 1),\n",
       " ('centrencephalic', 1),\n",
       " ('alcoholismfor', 1),\n",
       " ('solani', 1),\n",
       " ('dominated', 1),\n",
       " ('fear', 1),\n",
       " ('tremens', 1),\n",
       " ('paraplegia', 1),\n",
       " ('athetosis', 1),\n",
       " ('subjecting', 1),\n",
       " ('psychosomatic', 1),\n",
       " ('anorectic', 1),\n",
       " ('49', 1),\n",
       " ...]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_indic_words.most_common()[-4000:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "32129b23",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_indic_words['for']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "6be01ec2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting gensim\n",
      "  Downloading gensim-4.2.0-cp38-cp38-macosx_10_9_x86_64.whl (24.0 MB)\n",
      "\u001b[K     || 24.0 MB 7.6 MB/s eta 0:00:011\n",
      "\u001b[?25hCollecting smart-open>=1.8.1\n",
      "  Using cached smart_open-6.0.0-py3-none-any.whl (58 kB)\n",
      "Requirement already satisfied: numpy>=1.17.0 in /Users/cdonnat/anaconda3/lib/python3.8/site-packages (from gensim) (1.21.0)\n",
      "Requirement already satisfied: scipy>=0.18.1 in /Users/cdonnat/anaconda3/lib/python3.8/site-packages (from gensim) (1.7.0)\n",
      "Installing collected packages: smart-open, gensim\n",
      "Successfully installed gensim-4.2.0 smart-open-6.0.0\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "%pip install gensim"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "a487904b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import gensim\n",
    "from gensim.utils import simple_preprocess\n",
    "import nltk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "752b97f4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB00001\n",
      "DB00002\n",
      "DB00003\n",
      "DB00004\n",
      "DB00005\n",
      "DB00006\n",
      "DB00007\n",
      "DB00008\n",
      "DB00009\n",
      "DB00010\n",
      "DB00011\n",
      "DB00012\n",
      "DB00013\n",
      "DB00014\n",
      "DB00015\n",
      "DB00016\n",
      "DB00017\n",
      "DB00018\n",
      "DB00019\n",
      "DB00020\n",
      "DB00022\n",
      "DB00023\n",
      "DB00024\n",
      "DB00025\n",
      "DB00026\n",
      "DB00027\n",
      "DB00028\n",
      "DB00029\n",
      "DB00030\n",
      "DB00031\n",
      "DB00032\n",
      "DB00033\n",
      "DB00034\n",
      "DB00035\n",
      "DB00036\n",
      "DB00038\n",
      "DB00039\n",
      "DB00040\n",
      "DB00041\n",
      "DB00042\n",
      "DB00043\n",
      "DB00044\n",
      "DB00045\n",
      "DB00046\n",
      "DB00047\n",
      "DB00048\n",
      "DB00049\n",
      "DB00050\n",
      "DB00051\n",
      "DB00052\n",
      "DB00053\n",
      "DB00054\n",
      "DB00055\n",
      "DB00056\n",
      "DB00057\n",
      "DB00058\n",
      "DB00059\n",
      "DB00060\n",
      "DB00061\n",
      "DB00062\n",
      "DB00063\n",
      "DB00065\n",
      "DB00066\n",
      "DB00067\n",
      "DB00068\n",
      "DB00069\n",
      "DB00070\n",
      "DB00071\n",
      "DB00072\n",
      "DB00073\n",
      "DB00074\n",
      "DB00075\n",
      "DB00076\n",
      "DB00078\n",
      "DB00080\n",
      "DB00081\n",
      "DB00082\n",
      "DB00083\n",
      "DB00085\n",
      "DB00086\n",
      "DB00087\n",
      "DB00088\n",
      "DB00089\n",
      "DB00090\n",
      "DB00091\n",
      "DB00092\n",
      "DB00093\n",
      "DB00094\n",
      "DB00095\n",
      "DB00097\n",
      "DB00098\n",
      "DB00099\n",
      "DB00100\n",
      "DB00102\n",
      "DB00103\n",
      "DB00104\n",
      "DB00105\n",
      "DB00106\n",
      "DB00107\n",
      "DB00108\n",
      "DB00109\n",
      "DB00110\n",
      "DB00111\n",
      "DB00112\n",
      "DB00113\n",
      "DB00114\n",
      "DB00115\n",
      "DB00116\n",
      "DB00117\n",
      "DB00118\n",
      "DB00119\n",
      "DB00120\n",
      "DB00121\n",
      "DB00122\n",
      "DB00123\n",
      "DB00125\n",
      "DB00126\n",
      "DB00127\n",
      "DB00128\n",
      "DB00129\n",
      "DB00130\n",
      "DB00131\n",
      "DB00132\n",
      "DB00133\n",
      "DB00134\n",
      "DB00135\n",
      "DB00136\n",
      "DB00137\n",
      "DB00138\n",
      "DB00139\n",
      "DB00140\n",
      "DB00141\n",
      "DB00142\n",
      "DB00143\n",
      "DB00144\n",
      "DB00145\n",
      "DB00146\n",
      "DB00147\n",
      "DB00148\n",
      "DB00149\n",
      "DB00150\n",
      "DB00151\n",
      "DB00152\n",
      "DB00153\n",
      "DB00154\n",
      "DB00155\n",
      "DB00156\n",
      "DB00157\n",
      "DB00158\n",
      "DB00159\n",
      "DB00160\n",
      "DB00161\n",
      "DB00162\n",
      "DB00163\n",
      "DB00165\n",
      "DB00166\n",
      "DB00167\n",
      "DB00168\n",
      "DB00169\n",
      "DB00170\n",
      "DB00171\n",
      "DB00172\n",
      "DB00173\n",
      "DB00174\n",
      "DB00175\n",
      "DB00176\n",
      "DB00177\n",
      "DB00178\n",
      "DB00179\n",
      "DB00180\n",
      "DB00181\n",
      "DB00182\n",
      "DB00183\n",
      "DB00184\n",
      "DB00185\n",
      "DB00186\n",
      "DB00187\n",
      "DB00188\n",
      "DB00189\n",
      "DB00190\n",
      "DB00191\n",
      "DB00192\n",
      "DB00193\n",
      "DB00194\n",
      "DB00195\n",
      "DB00196\n",
      "DB00197\n",
      "DB00198\n",
      "DB00199\n",
      "DB00200\n",
      "DB00201\n",
      "DB00202\n",
      "DB00203\n",
      "DB00204\n",
      "DB00205\n",
      "DB00206\n",
      "DB00207\n",
      "DB00208\n",
      "DB00209\n",
      "DB00210\n",
      "DB00211\n",
      "DB00212\n",
      "DB00213\n",
      "DB00214\n",
      "DB00215\n",
      "DB00216\n",
      "DB00217\n",
      "DB00218\n",
      "DB00219\n",
      "DB00220\n",
      "DB00221\n",
      "DB00222\n",
      "DB00223\n",
      "DB00224\n",
      "DB00225\n",
      "DB00226\n",
      "DB00227\n",
      "DB00228\n",
      "DB00229\n",
      "DB00230\n",
      "DB00231\n",
      "DB00232\n",
      "DB00233\n",
      "DB00234\n",
      "DB00235\n",
      "DB00236\n",
      "DB00237\n",
      "DB00238\n",
      "DB00239\n",
      "DB00240\n",
      "DB00241\n",
      "DB00242\n",
      "DB00243\n",
      "DB00244\n",
      "DB00245\n",
      "DB00246\n",
      "DB00247\n",
      "DB00248\n",
      "DB00249\n",
      "DB00250\n",
      "DB00251\n",
      "DB00252\n",
      "DB00253\n",
      "DB00254\n",
      "DB00255\n",
      "DB00256\n",
      "DB00257\n",
      "DB00258\n",
      "DB00259\n",
      "DB00260\n",
      "DB00261\n",
      "DB00262\n",
      "DB00263\n",
      "DB00264\n",
      "DB00265\n",
      "DB00266\n",
      "DB00267\n",
      "DB00268\n",
      "DB00269\n",
      "DB00270\n",
      "DB00271\n",
      "DB00272\n",
      "DB00273\n",
      "DB00274\n",
      "DB00275\n",
      "DB00276\n",
      "DB00277\n",
      "DB00278\n",
      "DB00279\n",
      "DB00280\n",
      "DB00281\n",
      "DB00282\n",
      "DB00283\n",
      "DB00284\n",
      "DB00285\n",
      "DB00286\n",
      "DB00287\n",
      "DB00288\n",
      "DB00289\n",
      "DB00290\n",
      "DB00291\n",
      "DB00292\n",
      "DB00293\n",
      "DB00294\n",
      "DB00295\n",
      "DB00296\n",
      "DB00297\n",
      "DB00298\n",
      "DB00299\n",
      "DB00300\n",
      "DB00301\n",
      "DB00302\n",
      "DB00303\n",
      "DB00304\n",
      "DB00305\n",
      "DB00306\n",
      "DB00307\n",
      "DB00308\n",
      "DB00309\n",
      "DB00310\n",
      "DB00311\n",
      "DB00312\n",
      "DB00313\n",
      "DB00314\n",
      "DB00315\n",
      "DB00316\n",
      "DB00317\n",
      "DB00318\n",
      "DB00319\n",
      "DB00320\n",
      "DB00321\n",
      "DB00322\n",
      "DB00323\n",
      "DB00324\n",
      "DB00325\n",
      "DB00326\n",
      "DB00327\n",
      "DB00328\n",
      "DB00330\n",
      "DB00331\n",
      "DB00332\n",
      "DB00333\n",
      "DB00334\n",
      "DB00335\n",
      "DB00336\n",
      "DB00337\n",
      "DB00338\n",
      "DB00339\n",
      "DB00340\n",
      "DB00341\n",
      "DB00342\n",
      "DB00343\n",
      "DB00344\n",
      "DB00345\n",
      "DB00346\n",
      "DB00347\n",
      "DB00348\n",
      "DB00349\n",
      "DB00350\n",
      "DB00351\n",
      "DB00352\n",
      "DB00353\n",
      "DB00354\n",
      "DB00355\n",
      "DB00356\n",
      "DB00357\n",
      "DB00358\n",
      "DB00359\n",
      "DB00360\n",
      "DB00361\n",
      "DB00362\n",
      "DB00363\n",
      "DB00364\n",
      "DB00365\n",
      "DB00366\n",
      "DB00367\n",
      "DB00368\n",
      "DB00369\n",
      "DB00370\n",
      "DB00371\n",
      "DB00372\n",
      "DB00373\n",
      "DB00374\n",
      "DB00375\n",
      "DB00376\n",
      "DB00377\n",
      "DB00378\n",
      "DB00379\n",
      "DB00380\n",
      "DB00381\n",
      "DB00382\n",
      "DB00383\n",
      "DB00384\n",
      "DB00385\n",
      "DB00387\n",
      "DB00388\n",
      "DB00389\n",
      "DB00390\n",
      "DB00391\n",
      "DB00392\n",
      "DB00393\n",
      "DB00394\n",
      "DB00395\n",
      "DB00396\n",
      "DB00397\n",
      "DB00398\n",
      "DB00399\n",
      "DB00400\n",
      "DB00401\n",
      "DB00402\n",
      "DB00403\n",
      "DB00404\n",
      "DB00405\n",
      "DB00406\n",
      "DB00407\n",
      "DB00408\n",
      "DB00409\n",
      "DB00410\n",
      "DB00411\n",
      "DB00412\n",
      "DB00413\n",
      "DB00414\n",
      "DB00415\n",
      "DB00416\n",
      "DB00417\n",
      "DB00418\n",
      "DB00419\n",
      "DB00420\n",
      "DB00421\n",
      "DB00422\n",
      "DB00423\n",
      "DB00424\n",
      "DB00425\n",
      "DB00426\n",
      "DB00427\n",
      "DB00428\n",
      "DB00429\n",
      "DB00430\n",
      "DB00431\n",
      "DB00432\n",
      "DB00433\n",
      "DB00434\n",
      "DB00435\n",
      "DB00436\n",
      "DB00437\n",
      "DB00438\n",
      "DB00439\n",
      "DB00440\n",
      "DB00441\n",
      "DB00442\n",
      "DB00443\n",
      "DB00444\n",
      "DB00445\n",
      "DB00446\n",
      "DB00447\n",
      "DB00448\n",
      "DB00449\n",
      "DB00450\n",
      "DB00451\n",
      "DB00452\n",
      "DB00453\n",
      "DB00454\n",
      "DB00455\n",
      "DB00456\n",
      "DB00457\n",
      "DB00458\n",
      "DB00459\n",
      "DB00460\n",
      "DB00461\n",
      "DB00462\n",
      "DB00463\n",
      "DB00464\n",
      "DB00465\n",
      "DB00466\n",
      "DB00467\n",
      "DB00468\n",
      "DB00469\n",
      "DB00470\n",
      "DB00471\n",
      "DB00472\n",
      "DB00473\n",
      "DB00474\n",
      "DB00475\n",
      "DB00476\n",
      "DB00477\n",
      "DB00478\n",
      "DB00479\n",
      "DB00480\n",
      "DB00481\n",
      "DB00482\n",
      "DB00483\n",
      "DB00484\n",
      "DB00485\n",
      "DB00486\n",
      "DB00487\n",
      "DB00488\n",
      "DB00489\n",
      "DB00490\n",
      "DB00491\n",
      "DB00492\n",
      "DB00493\n",
      "DB00494\n",
      "DB00495\n",
      "DB00496\n",
      "DB00497\n",
      "DB00498\n",
      "DB00499\n",
      "DB00500\n",
      "DB00501\n",
      "DB00502\n",
      "DB00503\n",
      "DB00504\n",
      "DB00505\n",
      "DB00507\n",
      "DB00508\n",
      "DB00509\n",
      "DB00511\n",
      "DB00512\n",
      "DB00513\n",
      "DB00514\n",
      "DB00515\n",
      "DB00516\n",
      "DB00517\n",
      "DB00518\n",
      "DB00519\n",
      "DB00520\n",
      "DB00521\n",
      "DB00522\n",
      "DB00523\n",
      "DB00524\n",
      "DB00525\n",
      "DB00526\n",
      "DB00527\n",
      "DB00528\n",
      "DB00529\n",
      "DB00530\n",
      "DB00531\n",
      "DB00532\n",
      "DB00533\n",
      "DB00534\n",
      "DB00535\n",
      "DB00536\n",
      "DB00537\n",
      "DB00538\n",
      "DB00539\n",
      "DB00540\n",
      "DB00541\n",
      "DB00542\n",
      "DB00543\n",
      "DB00544\n",
      "DB00545\n",
      "DB00546\n",
      "DB00547\n",
      "DB00548\n",
      "DB00549\n",
      "DB00550\n",
      "DB00551\n",
      "DB00552\n",
      "DB00553\n",
      "DB00554\n",
      "DB00555\n",
      "DB00556\n",
      "DB00557\n",
      "DB00558\n",
      "DB00559\n",
      "DB00560\n",
      "DB00561\n",
      "DB00562\n",
      "DB00563\n",
      "DB00564\n",
      "DB00565\n",
      "DB00566\n",
      "DB00567\n",
      "DB00568\n",
      "DB00569\n",
      "DB00570\n",
      "DB00571\n",
      "DB00572\n",
      "DB00573\n",
      "DB00574\n",
      "DB00575\n",
      "DB00576\n",
      "DB00577\n",
      "DB00578\n",
      "DB00579\n",
      "DB00580\n",
      "DB00581\n",
      "DB00582\n",
      "DB00583\n",
      "DB00584\n",
      "DB00585\n",
      "DB00586\n",
      "DB00587\n",
      "DB00588\n",
      "DB00589\n",
      "DB00590\n",
      "DB00591\n",
      "DB00592\n",
      "DB00593\n",
      "DB00594\n",
      "DB00595\n",
      "DB00596\n",
      "DB00597\n",
      "DB00598\n",
      "DB00599\n",
      "DB00600\n",
      "DB00601\n",
      "DB00602\n",
      "DB00603\n",
      "DB00604\n",
      "DB00605\n",
      "DB00606\n",
      "DB00607\n",
      "DB00608\n",
      "DB00609\n",
      "DB00610\n",
      "DB00611\n",
      "DB00612\n",
      "DB00613\n",
      "DB00614\n",
      "DB00615\n",
      "DB00616\n",
      "DB00617\n",
      "DB00618\n",
      "DB00619\n",
      "DB00620\n",
      "DB00621\n",
      "DB00622\n",
      "DB00623\n",
      "DB00624\n",
      "DB00625\n",
      "DB00626\n",
      "DB00627\n",
      "DB00628\n",
      "DB00629\n",
      "DB00630\n",
      "DB00631\n",
      "DB00632\n",
      "DB00633\n",
      "DB00634\n",
      "DB00635\n",
      "DB00636\n",
      "DB00637\n",
      "DB00638\n",
      "DB00639\n",
      "DB00640\n",
      "DB00641\n",
      "DB00642\n",
      "DB00643\n",
      "DB00644\n",
      "DB00645\n",
      "DB00646\n",
      "DB00647\n",
      "DB00648\n",
      "DB00649\n",
      "DB00650\n",
      "DB00651\n",
      "DB00652\n",
      "DB00653\n",
      "DB00654\n",
      "DB00655\n",
      "DB00656\n",
      "DB00657\n",
      "DB00658\n",
      "DB00659\n",
      "DB00660\n",
      "DB00661\n",
      "DB00662\n",
      "DB00663\n",
      "DB00664\n",
      "DB00665\n",
      "DB00666\n",
      "DB00668\n",
      "DB00669\n",
      "DB00670\n",
      "DB00671\n",
      "DB00672\n",
      "DB00673\n",
      "DB00674\n",
      "DB00675\n",
      "DB00676\n",
      "DB00677\n",
      "DB00678\n",
      "DB00679\n",
      "DB00680\n",
      "DB00681\n",
      "DB00682\n",
      "DB00683\n",
      "DB00684\n",
      "DB00685\n",
      "DB00686\n",
      "DB00687\n",
      "DB00688\n",
      "DB00689\n",
      "DB00690\n",
      "DB00691\n",
      "DB00692\n",
      "DB00693\n",
      "DB00694\n",
      "DB00695\n",
      "DB00696\n",
      "DB00697\n",
      "DB00698\n",
      "DB00699\n",
      "DB00700\n",
      "DB00701\n",
      "DB00702\n",
      "DB00703\n",
      "DB00704\n",
      "DB00705\n",
      "DB00706\n",
      "DB00707\n",
      "DB00708\n",
      "DB00709\n",
      "DB00710\n",
      "DB00711\n",
      "DB00712\n",
      "DB00713\n",
      "DB00714\n",
      "DB00715\n",
      "DB00716\n",
      "DB00717\n",
      "DB00718\n",
      "DB00719\n",
      "DB00720\n",
      "DB00721\n",
      "DB00722\n",
      "DB00723\n",
      "DB00724\n",
      "DB00725\n",
      "DB00726\n",
      "DB00727\n",
      "DB00728\n",
      "DB00730\n",
      "DB00731\n",
      "DB00732\n",
      "DB00733\n",
      "DB00734\n",
      "DB00735\n",
      "DB00736\n",
      "DB00737\n",
      "DB00738\n",
      "DB00739\n",
      "DB00740\n",
      "DB00741\n",
      "DB00742\n",
      "DB00743\n",
      "DB00744\n",
      "DB00745\n",
      "DB00746\n",
      "DB00747\n",
      "DB00748\n",
      "DB00749\n",
      "DB00750\n",
      "DB00751\n",
      "DB00752\n",
      "DB00753\n",
      "DB00754\n",
      "DB00755\n",
      "DB00756\n",
      "DB00757\n",
      "DB00758\n",
      "DB00759\n",
      "DB00760\n",
      "DB00761\n",
      "DB00762\n",
      "DB00763\n",
      "DB00764\n",
      "DB00765\n",
      "DB00766\n",
      "DB00767\n",
      "DB00768\n",
      "DB00769\n",
      "DB00770\n",
      "DB00771\n",
      "DB00772\n",
      "DB00773\n",
      "DB00774\n",
      "DB00775\n",
      "DB00776\n",
      "DB00777\n",
      "DB00778\n",
      "DB00779\n",
      "DB00780\n",
      "DB00782\n",
      "DB00783\n",
      "DB00784\n",
      "DB00785\n",
      "DB00786\n",
      "DB00787\n",
      "DB00788\n",
      "DB00789\n",
      "DB00790\n",
      "DB00791\n",
      "DB00792\n",
      "DB00793\n",
      "DB00794\n",
      "DB00795\n",
      "DB00796\n",
      "DB00797\n",
      "DB00798\n",
      "DB00799\n",
      "DB00800\n",
      "DB00801\n",
      "DB00802\n",
      "DB00803\n",
      "DB00804\n",
      "DB00805\n",
      "DB00806\n",
      "DB00807\n",
      "DB00808\n",
      "DB00809\n",
      "DB00810\n",
      "DB00811\n",
      "DB00812\n",
      "DB00813\n",
      "DB00814\n",
      "DB00815\n",
      "DB00816\n",
      "DB00817\n",
      "DB00818\n",
      "DB00819\n",
      "DB00820\n",
      "DB00821\n",
      "DB00822\n",
      "DB00823\n",
      "DB00824\n",
      "DB00825\n",
      "DB00826\n",
      "DB00827\n",
      "DB00828\n",
      "DB00829\n",
      "DB00830\n",
      "DB00831\n",
      "DB00832\n",
      "DB00833\n",
      "DB00834\n",
      "DB00835\n",
      "DB00836\n",
      "DB00837\n",
      "DB00838\n",
      "DB00839\n",
      "DB00840\n",
      "DB00841\n",
      "DB00842\n",
      "DB00843\n",
      "DB00844\n",
      "DB00845\n",
      "DB00846\n",
      "DB00847\n",
      "DB00848\n",
      "DB00849\n",
      "DB00850\n",
      "DB00851\n",
      "DB00852\n",
      "DB00853\n",
      "DB00854\n",
      "DB00855\n",
      "DB00856\n",
      "DB00857\n",
      "DB00858\n",
      "DB00859\n",
      "DB00860\n",
      "DB00861\n",
      "DB00862\n",
      "DB00863\n",
      "DB00864\n",
      "DB00865\n",
      "DB00866\n",
      "DB00867\n",
      "DB00868\n",
      "DB00869\n",
      "DB00870\n",
      "DB00871\n",
      "DB00872\n",
      "DB14596\n",
      "DB00874\n",
      "DB00875\n",
      "DB00876\n",
      "DB00877\n",
      "DB00878\n",
      "DB00879\n",
      "DB00880\n",
      "DB00881\n",
      "DB00882\n",
      "DB00883\n",
      "DB00884\n",
      "DB00885\n",
      "DB00886\n",
      "DB00887\n",
      "DB00888\n",
      "DB00889\n",
      "DB00890\n",
      "DB00891\n",
      "DB00892\n",
      "DB00893\n",
      "DB00894\n",
      "DB00895\n",
      "DB00896\n",
      "DB00897\n",
      "DB00898\n",
      "DB00899\n",
      "DB00900\n",
      "DB00901\n",
      "DB00902\n",
      "DB00903\n",
      "DB00904\n",
      "DB00905\n",
      "DB00906\n",
      "DB00907\n",
      "DB00908\n",
      "DB00909\n",
      "DB00910\n",
      "DB00911\n",
      "DB00912\n",
      "DB00913\n",
      "DB00914\n",
      "DB00915\n",
      "DB00916\n",
      "DB00917\n",
      "DB00918\n",
      "DB00919\n",
      "DB00920\n",
      "DB00921\n",
      "DB00922\n",
      "DB00923\n",
      "DB00924\n",
      "DB00925\n",
      "DB00926\n",
      "DB00927\n",
      "DB00928\n",
      "DB00929\n",
      "DB00930\n",
      "DB00931\n",
      "DB00932\n",
      "DB00933\n",
      "DB00934\n",
      "DB00935\n",
      "DB00936\n",
      "DB00937\n",
      "DB00938\n",
      "DB00939\n",
      "DB00940\n",
      "DB00941\n",
      "DB00942\n",
      "DB00943\n",
      "DB00944\n",
      "DB00945\n",
      "DB00946\n",
      "DB00947\n",
      "DB00948\n",
      "DB00949\n",
      "DB00950\n",
      "DB00951\n",
      "DB00952\n",
      "DB00953\n",
      "DB00954\n",
      "DB00955\n",
      "DB00956\n",
      "DB00957\n",
      "DB00958\n",
      "DB00959\n",
      "DB00960\n",
      "DB00961\n",
      "DB00962\n",
      "DB00963\n",
      "DB00964\n",
      "DB00965\n",
      "DB00966\n",
      "DB00967\n",
      "DB00968\n",
      "DB00969\n",
      "DB00970\n",
      "DB00971\n",
      "DB00972\n",
      "DB00973\n",
      "DB00974\n",
      "DB00975\n",
      "DB00976\n",
      "DB00977\n",
      "DB00978\n",
      "DB00979\n",
      "DB00980\n",
      "DB00981\n",
      "DB00982\n",
      "DB00983\n",
      "DB00984\n",
      "DB00985\n",
      "DB00986\n",
      "DB00987\n",
      "DB00988\n",
      "DB00989\n",
      "DB00990\n",
      "DB00991\n",
      "DB00992\n",
      "DB00993\n",
      "DB00994\n",
      "DB00995\n",
      "DB00996\n",
      "DB00997\n",
      "DB00998\n",
      "DB00999\n",
      "DB01000\n",
      "DB01001\n",
      "DB01002\n",
      "DB01003\n",
      "DB01004\n",
      "DB01005\n",
      "DB01006\n",
      "DB01007\n",
      "DB01008\n",
      "DB01009\n",
      "DB01010\n",
      "DB01011\n",
      "DB01012\n",
      "DB01013\n",
      "DB01014\n",
      "DB01015\n",
      "DB01016\n",
      "DB01017\n",
      "DB01018\n",
      "DB01019\n",
      "DB01020\n",
      "DB01021\n",
      "DB01022\n",
      "DB01023\n",
      "DB01024\n",
      "DB01025\n",
      "DB01026\n",
      "DB01028\n",
      "DB01029\n",
      "DB01030\n",
      "DB01031\n",
      "DB01032\n",
      "DB01033\n",
      "DB01034\n",
      "DB01035\n",
      "DB01036\n",
      "DB01037\n",
      "DB01038\n",
      "DB01039\n",
      "DB01041\n",
      "DB01042\n",
      "DB01043\n",
      "DB01044\n",
      "DB01045\n",
      "DB01046\n",
      "DB01047\n",
      "DB01048\n",
      "DB01049\n",
      "DB01050\n",
      "DB01051\n",
      "DB01053\n",
      "DB01054\n",
      "DB01055\n",
      "DB01056\n",
      "DB01057\n",
      "DB01058\n",
      "DB01059\n",
      "DB01060\n",
      "DB01061\n",
      "DB01062\n",
      "DB01063\n",
      "DB01064\n",
      "DB01065\n",
      "DB01066\n",
      "DB01067\n",
      "DB01068\n",
      "DB01069\n",
      "DB01070\n",
      "DB01071\n",
      "DB01072\n",
      "DB01073\n",
      "DB01074\n",
      "DB01075\n",
      "DB01076\n",
      "DB01077\n",
      "DB01078\n",
      "DB01079\n",
      "DB01080\n",
      "DB01081\n",
      "DB01082\n",
      "DB01083\n",
      "DB01084\n",
      "DB01085\n",
      "DB01086\n",
      "DB01087\n",
      "DB01088\n",
      "DB01089\n",
      "DB01090\n",
      "DB01091\n",
      "DB01092\n",
      "DB01093\n",
      "DB01094\n",
      "DB01095\n",
      "DB01096\n",
      "DB01097\n",
      "DB01098\n",
      "DB01099\n",
      "DB01100\n",
      "DB01101\n",
      "DB01102\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB01103\n",
      "DB01104\n",
      "DB01105\n",
      "DB01106\n",
      "DB01107\n",
      "DB01108\n",
      "DB01109\n",
      "DB01110\n",
      "DB01111\n",
      "DB01112\n",
      "DB01113\n",
      "DB01114\n",
      "DB01115\n",
      "DB01116\n",
      "DB01117\n",
      "DB01118\n",
      "DB01119\n",
      "DB01120\n",
      "DB01121\n",
      "DB01122\n",
      "DB01123\n",
      "DB01124\n",
      "DB01125\n",
      "DB01126\n",
      "DB01127\n",
      "DB01128\n",
      "DB01129\n",
      "DB01130\n",
      "DB01131\n",
      "DB01132\n",
      "DB01133\n",
      "DB01134\n",
      "DB01135\n",
      "DB01136\n",
      "DB01137\n",
      "DB01138\n",
      "DB01139\n",
      "DB01140\n",
      "DB01141\n",
      "DB01142\n",
      "DB01143\n",
      "DB01144\n",
      "DB01145\n",
      "DB01146\n",
      "DB01147\n",
      "DB01148\n",
      "DB01149\n",
      "DB01150\n",
      "DB01151\n",
      "DB01152\n",
      "DB01153\n",
      "DB01154\n",
      "DB01155\n",
      "DB01156\n",
      "DB01157\n",
      "DB01158\n",
      "DB01159\n",
      "DB01160\n",
      "DB01161\n",
      "DB01162\n",
      "DB01163\n",
      "DB01164\n",
      "DB01165\n",
      "DB01166\n",
      "DB01167\n",
      "DB01168\n",
      "DB01169\n",
      "DB01170\n",
      "DB01171\n",
      "DB01172\n",
      "DB01173\n",
      "DB01174\n",
      "DB01175\n",
      "DB01176\n",
      "DB01177\n",
      "DB01178\n",
      "DB01179\n",
      "DB01180\n",
      "DB01181\n",
      "DB01182\n",
      "DB01183\n",
      "DB01184\n",
      "DB01185\n",
      "DB01186\n",
      "DB01187\n",
      "DB01188\n",
      "DB01189\n",
      "DB01190\n",
      "DB01191\n",
      "DB01192\n",
      "DB01193\n",
      "DB01194\n",
      "DB01195\n",
      "DB01196\n",
      "DB01197\n",
      "DB01198\n",
      "DB01199\n",
      "DB01200\n",
      "DB01201\n",
      "DB01202\n",
      "DB01203\n",
      "DB01204\n",
      "DB01205\n",
      "DB01206\n",
      "DB01207\n",
      "DB01208\n",
      "DB01209\n",
      "DB01210\n",
      "DB01211\n",
      "DB01212\n",
      "DB01213\n",
      "DB01214\n",
      "DB01215\n",
      "DB01216\n",
      "DB01217\n",
      "DB01218\n",
      "DB01219\n",
      "DB01220\n",
      "DB01221\n",
      "DB01222\n",
      "DB01223\n",
      "DB01224\n",
      "DB01225\n",
      "DB01226\n",
      "DB01227\n",
      "DB01228\n",
      "DB01229\n",
      "DB01230\n",
      "DB01231\n",
      "DB01232\n",
      "DB01233\n",
      "DB01234\n",
      "DB01235\n",
      "DB01236\n",
      "DB01237\n",
      "DB01238\n",
      "DB01239\n",
      "DB01240\n",
      "DB01241\n",
      "DB01242\n",
      "DB01243\n",
      "DB01244\n",
      "DB01245\n",
      "DB01246\n",
      "DB01247\n",
      "DB01248\n",
      "DB01249\n",
      "DB01250\n",
      "DB01251\n",
      "DB01252\n",
      "DB01253\n",
      "DB01254\n",
      "DB01255\n",
      "DB01256\n",
      "DB01257\n",
      "DB01259\n",
      "DB01260\n",
      "DB01261\n",
      "DB01262\n",
      "DB01263\n",
      "DB01264\n",
      "DB01265\n",
      "DB01266\n",
      "DB01267\n",
      "DB01268\n",
      "DB01269\n",
      "DB01270\n",
      "DB01271\n",
      "DB01272\n",
      "DB01273\n",
      "DB01274\n",
      "DB01275\n",
      "DB01276\n",
      "DB01277\n",
      "DB01278\n",
      "DB01279\n",
      "DB01280\n",
      "DB01281\n",
      "DB01282\n",
      "DB01283\n",
      "DB01284\n",
      "DB01285\n",
      "DB01288\n",
      "DB01289\n",
      "DB01291\n",
      "DB01294\n",
      "DB01295\n",
      "DB01296\n",
      "DB01297\n",
      "DB01298\n",
      "DB01299\n",
      "DB01301\n",
      "DB01303\n",
      "DB01306\n",
      "DB01307\n",
      "DB01309\n",
      "DB01319\n",
      "DB01320\n",
      "DB01321\n",
      "DB01322\n",
      "DB01323\n",
      "DB01324\n",
      "DB01325\n",
      "DB01326\n",
      "DB01327\n",
      "DB01328\n",
      "DB01329\n",
      "DB01330\n",
      "DB01331\n",
      "DB01332\n",
      "DB01333\n",
      "DB01336\n",
      "DB01337\n",
      "DB01338\n",
      "DB01339\n",
      "DB01340\n",
      "DB01341\n",
      "DB01342\n",
      "DB01344\n",
      "DB01345\n",
      "DB01346\n",
      "DB01347\n",
      "DB01348\n",
      "DB01349\n",
      "DB01351\n",
      "DB01352\n",
      "DB01353\n",
      "DB01354\n",
      "DB01355\n",
      "DB01356\n",
      "DB01357\n",
      "DB01359\n",
      "DB01362\n",
      "DB01363\n",
      "DB01364\n",
      "DB01365\n",
      "DB01366\n",
      "DB01367\n",
      "DB01369\n",
      "DB01370\n",
      "DB01373\n",
      "DB01375\n",
      "DB01377\n",
      "DB01378\n",
      "DB01380\n",
      "DB01381\n",
      "DB01382\n",
      "DB01384\n",
      "DB01388\n",
      "DB01390\n",
      "DB01392\n",
      "DB01393\n",
      "DB01394\n",
      "DB01395\n",
      "DB01396\n",
      "DB01397\n",
      "DB01399\n",
      "DB01400\n",
      "DB01401\n",
      "DB01403\n",
      "DB01404\n",
      "DB01405\n",
      "DB01406\n",
      "DB01407\n",
      "DB01408\n",
      "DB01409\n",
      "DB01410\n",
      "DB01411\n",
      "DB01412\n",
      "DB01413\n",
      "DB01414\n",
      "DB01415\n",
      "DB01416\n",
      "DB01418\n",
      "DB01419\n",
      "DB01420\n",
      "DB01421\n",
      "DB01422\n",
      "DB01423\n",
      "DB01424\n",
      "DB01425\n",
      "DB01426\n",
      "DB01427\n",
      "DB01428\n",
      "DB01429\n",
      "DB01430\n",
      "DB01431\n",
      "DB01432\n",
      "DB01433\n",
      "DB01434\n",
      "DB01435\n",
      "DB01436\n",
      "DB01437\n",
      "DB01438\n",
      "DB01439\n",
      "DB01440\n",
      "DB01441\n",
      "DB01442\n",
      "DB01443\n",
      "DB01444\n",
      "DB01445\n",
      "DB01446\n",
      "DB01447\n",
      "DB01448\n",
      "DB01450\n",
      "DB01451\n",
      "DB01452\n",
      "DB01453\n",
      "DB01454\n",
      "DB01455\n",
      "DB01456\n",
      "DB01458\n",
      "DB01459\n",
      "DB01460\n",
      "DB01461\n",
      "DB01462\n",
      "DB01463\n",
      "DB01464\n",
      "DB01465\n",
      "DB01466\n",
      "DB01467\n",
      "DB01468\n",
      "DB01469\n",
      "DB01470\n",
      "DB01471\n",
      "DB01472\n",
      "DB01473\n",
      "DB01474\n",
      "DB01475\n",
      "DB01476\n",
      "DB01477\n",
      "DB01478\n",
      "DB01479\n",
      "DB01480\n",
      "DB01481\n",
      "DB01482\n",
      "DB01483\n",
      "DB01484\n",
      "DB01485\n",
      "DB01486\n",
      "DB01487\n",
      "DB01488\n",
      "DB01489\n",
      "DB01490\n",
      "DB01491\n",
      "DB01493\n",
      "DB01494\n",
      "DB01495\n",
      "DB01496\n",
      "DB01497\n",
      "DB01498\n",
      "DB01499\n",
      "DB01500\n",
      "DB01501\n",
      "DB01502\n",
      "DB01503\n",
      "DB01505\n",
      "DB01506\n",
      "DB01509\n",
      "DB01510\n",
      "DB01511\n",
      "DB01512\n",
      "DB01513\n",
      "DB01514\n",
      "DB01515\n",
      "DB01516\n",
      "DB01518\n",
      "DB01520\n",
      "DB01521\n",
      "DB01522\n",
      "DB01523\n",
      "DB01524\n",
      "DB01525\n",
      "DB01526\n",
      "DB01527\n",
      "DB01528\n",
      "DB01529\n",
      "DB01530\n",
      "DB01531\n",
      "DB01532\n",
      "DB01533\n",
      "DB01534\n",
      "DB01535\n",
      "DB01536\n",
      "DB01537\n",
      "DB01538\n",
      "DB01539\n",
      "DB01540\n",
      "DB01541\n",
      "DB01542\n",
      "DB01543\n",
      "DB01544\n",
      "DB01545\n",
      "DB01546\n",
      "DB01547\n",
      "DB01548\n",
      "DB01549\n",
      "DB01550\n",
      "DB01551\n",
      "DB01552\n",
      "DB01553\n",
      "DB01554\n",
      "DB01555\n",
      "DB01556\n",
      "DB01557\n",
      "DB01558\n",
      "DB01559\n",
      "DB01560\n",
      "DB01561\n",
      "DB01562\n",
      "DB01563\n",
      "DB01564\n",
      "DB01565\n",
      "DB01566\n",
      "DB01567\n",
      "DB01568\n",
      "DB01569\n",
      "DB01570\n",
      "DB01571\n",
      "DB01572\n",
      "DB01573\n",
      "DB01574\n",
      "DB01575\n",
      "DB01576\n",
      "DB01577\n",
      "DB01578\n",
      "DB01579\n",
      "DB01580\n",
      "DB01581\n",
      "DB01582\n",
      "DB01583\n",
      "DB01584\n",
      "DB01586\n",
      "DB01587\n",
      "DB01588\n",
      "DB01589\n",
      "DB01590\n",
      "DB01591\n",
      "DB01592\n",
      "DB01593\n",
      "DB01594\n",
      "DB01595\n",
      "DB01597\n",
      "DB01598\n",
      "DB01599\n",
      "DB01600\n",
      "DB01601\n",
      "DB01602\n",
      "DB01603\n",
      "DB01604\n",
      "DB01605\n",
      "DB01606\n",
      "DB01607\n",
      "DB01608\n",
      "DB01609\n",
      "DB01610\n",
      "DB01611\n",
      "DB01612\n",
      "DB01613\n",
      "DB01614\n",
      "DB01615\n",
      "DB01616\n",
      "DB01618\n",
      "DB01619\n",
      "DB01620\n",
      "DB01621\n",
      "DB01622\n",
      "DB01623\n",
      "DB01624\n",
      "DB01625\n",
      "DB01626\n",
      "DB01627\n",
      "DB01628\n",
      "DB01629\n",
      "DB01630\n",
      "DB01631\n",
      "DB01632\n",
      "DB01633\n",
      "DB01634\n",
      "DB01635\n",
      "DB01637\n",
      "DB01638\n",
      "DB01639\n",
      "DB01640\n",
      "DB01641\n",
      "DB01642\n",
      "DB01643\n",
      "DB01644\n",
      "DB01645\n",
      "DB01646\n",
      "DB01647\n",
      "DB01648\n",
      "DB01649\n",
      "DB01650\n",
      "DB01651\n",
      "DB01652\n",
      "DB01655\n",
      "DB01656\n",
      "DB01657\n",
      "DB01658\n",
      "DB01659\n",
      "DB01661\n",
      "DB01662\n",
      "DB01663\n",
      "DB01664\n",
      "DB01665\n",
      "DB01666\n",
      "DB01667\n",
      "DB01668\n",
      "DB01669\n",
      "DB01670\n",
      "DB01671\n",
      "DB01672\n",
      "DB01673\n",
      "DB01674\n",
      "DB01675\n",
      "DB01676\n",
      "DB01677\n",
      "DB01678\n",
      "DB01679\n",
      "DB01681\n",
      "DB01682\n",
      "DB01683\n",
      "DB01684\n",
      "DB01685\n",
      "DB01686\n",
      "DB01687\n",
      "DB01688\n",
      "DB01689\n",
      "DB01690\n",
      "DB01691\n",
      "DB01692\n",
      "DB01694\n",
      "DB01695\n",
      "DB01697\n",
      "DB01698\n",
      "DB01699\n",
      "DB01700\n",
      "DB01701\n",
      "DB01702\n",
      "DB01703\n",
      "DB01704\n",
      "DB01705\n",
      "DB01706\n",
      "DB01707\n",
      "DB01708\n",
      "DB01709\n",
      "DB01710\n",
      "DB01711\n",
      "DB01712\n",
      "DB01713\n",
      "DB01714\n",
      "DB01715\n",
      "DB01716\n",
      "DB01717\n",
      "DB01718\n",
      "DB01719\n",
      "DB01720\n",
      "DB01721\n",
      "DB01723\n",
      "DB01724\n",
      "DB01725\n",
      "DB01726\n",
      "DB01727\n",
      "DB01728\n",
      "DB01729\n",
      "DB01731\n",
      "DB01732\n",
      "DB01733\n",
      "DB01734\n",
      "DB01735\n",
      "DB01736\n",
      "DB01737\n",
      "DB01738\n",
      "DB01739\n",
      "DB01740\n",
      "DB01741\n",
      "DB01742\n",
      "DB01744\n",
      "DB01745\n",
      "DB01746\n",
      "DB01747\n",
      "DB01748\n",
      "DB01749\n",
      "DB01750\n",
      "DB01751\n",
      "DB01752\n",
      "DB01753\n",
      "DB01754\n",
      "DB01755\n",
      "DB01756\n",
      "DB01758\n",
      "DB01759\n",
      "DB01760\n",
      "DB01761\n",
      "DB01762\n",
      "DB01763\n",
      "DB01764\n",
      "DB01765\n",
      "DB01766\n",
      "DB01767\n",
      "DB01768\n",
      "DB01771\n",
      "DB01772\n",
      "DB01773\n",
      "DB01774\n",
      "DB01775\n",
      "DB01776\n",
      "DB01777\n",
      "DB01778\n",
      "DB01779\n",
      "DB01780\n",
      "DB01782\n",
      "DB01783\n",
      "DB01784\n",
      "DB01785\n",
      "DB01786\n",
      "DB01788\n",
      "DB01789\n",
      "DB01790\n",
      "DB01791\n",
      "DB01792\n",
      "DB01793\n",
      "DB01794\n",
      "DB01795\n",
      "DB01796\n",
      "DB01797\n",
      "DB01798\n",
      "DB01799\n",
      "DB01800\n",
      "DB01802\n",
      "DB01803\n",
      "DB01804\n",
      "DB01805\n",
      "DB01806\n",
      "DB01807\n",
      "DB01808\n",
      "DB01809\n",
      "DB01810\n",
      "DB01811\n",
      "DB01812\n",
      "DB01813\n",
      "DB01814\n",
      "DB01815\n",
      "DB01816\n",
      "DB01817\n",
      "DB01818\n",
      "DB01819\n",
      "DB01820\n",
      "DB01821\n",
      "DB01822\n",
      "DB01823\n",
      "DB01824\n",
      "DB01825\n",
      "DB01826\n",
      "DB01827\n",
      "DB01828\n",
      "DB01829\n",
      "DB01830\n",
      "DB01831\n",
      "DB01832\n",
      "DB01833\n",
      "DB01834\n",
      "DB01835\n",
      "DB01836\n",
      "DB01837\n",
      "DB01838\n",
      "DB01839\n",
      "DB01840\n",
      "DB01841\n",
      "DB01842\n",
      "DB01843\n",
      "DB01844\n",
      "DB01846\n",
      "DB01847\n",
      "DB01849\n",
      "DB01850\n",
      "DB01851\n",
      "DB01852\n",
      "DB01853\n",
      "DB01854\n",
      "DB01855\n",
      "DB01856\n",
      "DB01857\n",
      "DB01858\n",
      "DB01859\n",
      "DB01860\n",
      "DB01861\n",
      "DB01862\n",
      "DB01863\n",
      "DB01864\n",
      "DB01865\n",
      "DB01866\n",
      "DB01868\n",
      "DB01870\n",
      "DB01871\n",
      "DB01872\n",
      "DB01873\n",
      "DB01874\n",
      "DB01875\n",
      "DB01876\n",
      "DB01877\n",
      "DB01878\n",
      "DB01879\n",
      "DB01880\n",
      "DB01881\n",
      "DB01882\n",
      "DB01883\n",
      "DB01884\n",
      "DB01885\n",
      "DB01887\n",
      "DB01888\n",
      "DB01889\n",
      "DB01890\n",
      "DB01891\n",
      "DB01892\n",
      "DB01893\n",
      "DB01895\n",
      "DB01896\n",
      "DB01897\n",
      "DB01898\n",
      "DB01899\n",
      "DB01901\n",
      "DB01902\n",
      "DB01903\n",
      "DB01905\n",
      "DB01906\n",
      "DB01908\n",
      "DB01909\n",
      "DB01910\n",
      "DB01911\n",
      "DB01912\n",
      "DB01914\n",
      "DB01915\n",
      "DB01917\n",
      "DB01918\n",
      "DB01919\n",
      "DB01920\n",
      "DB01921\n",
      "DB01922\n",
      "DB01923\n",
      "DB01924\n",
      "DB01925\n",
      "DB01926\n",
      "DB01927\n",
      "DB01929\n",
      "DB01930\n",
      "DB01931\n",
      "DB01932\n",
      "DB01933\n",
      "DB01934\n",
      "DB01935\n",
      "DB01936\n",
      "DB01937\n",
      "DB01938\n",
      "DB01939\n",
      "DB01940\n",
      "DB01941\n",
      "DB01942\n",
      "DB01944\n",
      "DB01945\n",
      "DB01946\n",
      "DB01947\n",
      "DB01948\n",
      "DB01949\n",
      "DB01950\n",
      "DB01951\n",
      "DB01952\n",
      "DB01953\n",
      "DB01954\n",
      "DB01955\n",
      "DB01956\n",
      "DB01957\n",
      "DB01958\n",
      "DB01959\n",
      "DB01960\n",
      "DB01961\n",
      "DB01962\n",
      "DB01963\n",
      "DB01964\n",
      "DB01965\n",
      "DB01966\n",
      "DB01967\n",
      "DB01968\n",
      "DB01969\n",
      "DB01970\n",
      "DB01971\n",
      "DB01972\n",
      "DB01973\n",
      "DB01974\n",
      "DB01975\n",
      "DB01976\n",
      "DB01977\n",
      "DB01978\n",
      "DB01979\n",
      "DB01980\n",
      "DB01981\n",
      "DB01982\n",
      "DB01983\n",
      "DB01984\n",
      "DB01985\n",
      "DB01986\n",
      "DB01987\n",
      "DB01988\n",
      "DB01989\n",
      "DB01990\n",
      "DB01991\n",
      "DB01992\n",
      "DB01993\n",
      "DB01994\n",
      "DB01995\n",
      "DB01996\n",
      "DB01997\n",
      "DB01998\n",
      "DB01999\n",
      "DB02001\n",
      "DB02002\n",
      "DB02004\n",
      "DB02005\n",
      "DB02006\n",
      "DB02007\n",
      "DB02008\n",
      "DB02009\n",
      "DB02010\n",
      "DB02011\n",
      "DB02013\n",
      "DB02014\n",
      "DB02015\n",
      "DB02016\n",
      "DB02017\n",
      "DB02018\n",
      "DB02019\n",
      "DB02020\n",
      "DB02021\n",
      "DB02022\n",
      "DB02023\n",
      "DB02024\n",
      "DB02025\n",
      "DB02026\n",
      "DB02027\n",
      "DB02028\n",
      "DB02029\n",
      "DB02030\n",
      "DB02031\n",
      "DB02032\n",
      "DB02033\n",
      "DB02034\n",
      "DB02035\n",
      "DB02036\n",
      "DB02037\n",
      "DB02038\n",
      "DB02039\n",
      "DB02041\n",
      "DB02042\n",
      "DB02043\n",
      "DB02044\n",
      "DB02045\n",
      "DB02046\n",
      "DB02047\n",
      "DB02048\n",
      "DB02049\n",
      "DB02051\n",
      "DB02052\n",
      "DB02053\n",
      "DB02054\n",
      "DB02055\n",
      "DB02056\n",
      "DB02057\n",
      "DB02058\n",
      "DB02059\n",
      "DB02060\n",
      "DB02061\n",
      "DB02062\n",
      "DB02063\n",
      "DB02065\n",
      "DB02066\n",
      "DB02067\n",
      "DB02068\n",
      "DB02069\n",
      "DB02070\n",
      "DB02071\n",
      "DB02072\n",
      "DB02073\n",
      "DB02074\n",
      "DB02075\n",
      "DB02076\n",
      "DB02077\n",
      "DB02078\n",
      "DB02079\n",
      "DB02080\n",
      "DB02081\n",
      "DB02082\n",
      "DB02083\n",
      "DB02084\n",
      "DB02085\n",
      "DB02086\n",
      "DB02087\n",
      "DB02088\n",
      "DB02089\n",
      "DB02090\n",
      "DB02091\n",
      "DB02092\n",
      "DB02093\n",
      "DB02094\n",
      "DB02095\n",
      "DB02096\n",
      "DB02097\n",
      "DB02098\n",
      "DB02099\n",
      "DB02100\n",
      "DB02101\n",
      "DB02102\n",
      "DB02103\n",
      "DB02104\n",
      "DB02105\n",
      "DB02106\n",
      "DB02107\n",
      "DB02108\n",
      "DB02109\n",
      "DB02110\n",
      "DB02111\n",
      "DB02112\n",
      "DB02113\n",
      "DB02114\n",
      "DB02115\n",
      "DB02116\n",
      "DB02118\n",
      "DB02119\n",
      "DB02120\n",
      "DB02121\n",
      "DB02122\n",
      "DB02123\n",
      "DB02124\n",
      "DB02125\n",
      "DB02126\n",
      "DB02127\n",
      "DB02128\n",
      "DB02129\n",
      "DB02130\n",
      "DB02131\n",
      "DB02132\n",
      "DB02133\n",
      "DB02134\n",
      "DB02135\n",
      "DB02136\n",
      "DB02137\n",
      "DB02138\n",
      "DB02139\n",
      "DB02140\n",
      "DB02141\n",
      "DB02142\n",
      "DB02143\n",
      "DB02144\n",
      "DB02145\n",
      "DB02146\n",
      "DB02147\n",
      "DB02148\n",
      "DB02151\n",
      "DB02152\n",
      "DB02153\n",
      "DB02154\n",
      "DB02155\n",
      "DB02156\n",
      "DB02158\n",
      "DB02159\n",
      "DB02160\n",
      "DB02161\n",
      "DB02162\n",
      "DB02163\n",
      "DB02164\n",
      "DB02165\n",
      "DB02166\n",
      "DB02167\n",
      "DB02168\n",
      "DB02169\n",
      "DB02170\n",
      "DB02172\n",
      "DB02173\n",
      "DB02174\n",
      "DB02175\n",
      "DB02176\n",
      "DB02177\n",
      "DB02178\n",
      "DB02179\n",
      "DB02180\n",
      "DB02181\n",
      "DB02182\n",
      "DB02183\n",
      "DB02184\n",
      "DB02185\n",
      "DB02186\n",
      "DB02187\n",
      "DB02188\n",
      "DB02189\n",
      "DB02190\n",
      "DB02191\n",
      "DB02192\n",
      "DB02194\n",
      "DB02195\n",
      "DB02196\n",
      "DB02197\n",
      "DB02198\n",
      "DB02199\n",
      "DB02200\n",
      "DB02201\n",
      "DB02202\n",
      "DB02203\n",
      "DB02205\n",
      "DB02207\n",
      "DB02209\n",
      "DB02210\n",
      "DB02211\n",
      "DB02213\n",
      "DB02214\n",
      "DB02215\n",
      "DB02216\n",
      "DB02217\n",
      "DB02218\n",
      "DB02219\n",
      "DB02220\n",
      "DB02221\n",
      "DB02222\n",
      "DB02223\n",
      "DB02224\n",
      "DB02225\n",
      "DB02226\n",
      "DB02227\n",
      "DB02228\n",
      "DB02229\n",
      "DB02230\n",
      "DB02232\n",
      "DB02233\n",
      "DB02234\n",
      "DB02235\n",
      "DB02236\n",
      "DB02237\n",
      "DB02238\n",
      "DB02239\n",
      "DB02240\n",
      "DB02241\n",
      "DB02242\n",
      "DB02243\n",
      "DB02245\n",
      "DB02247\n",
      "DB02248\n",
      "DB02249\n",
      "DB02251\n",
      "DB02252\n",
      "DB02253\n",
      "DB02254\n",
      "DB02255\n",
      "DB02256\n",
      "DB02257\n",
      "DB02258\n",
      "DB02259\n",
      "DB02260\n",
      "DB02261\n",
      "DB02262\n",
      "DB02263\n",
      "DB02264\n",
      "DB02265\n",
      "DB02266\n",
      "DB02267\n",
      "DB02268\n",
      "DB02269\n",
      "DB02270\n",
      "DB02271\n",
      "DB02272\n",
      "DB02273\n",
      "DB02274\n",
      "DB02275\n",
      "DB02276\n",
      "DB02277\n",
      "DB02278\n",
      "DB02279\n",
      "DB02280\n",
      "DB02281\n",
      "DB02282\n",
      "DB02283\n",
      "DB02285\n",
      "DB02286\n",
      "DB02287\n",
      "DB02288\n",
      "DB02289\n",
      "DB02290\n",
      "DB02292\n",
      "DB02293\n",
      "DB02294\n",
      "DB02295\n",
      "DB02296\n",
      "DB02297\n",
      "DB02298\n",
      "DB02299\n",
      "DB02300\n",
      "DB02301\n",
      "DB02302\n",
      "DB02303\n",
      "DB02304\n",
      "DB02305\n",
      "DB02306\n",
      "DB02307\n",
      "DB02308\n",
      "DB02309\n",
      "DB02310\n",
      "DB02311\n",
      "DB02312\n",
      "DB02313\n",
      "DB02314\n",
      "DB02315\n",
      "DB02316\n",
      "DB02317\n",
      "DB02318\n",
      "DB02319\n",
      "DB02320\n",
      "DB02321\n",
      "DB02322\n",
      "DB02323\n",
      "DB02324\n",
      "DB02325\n",
      "DB02326\n",
      "DB02327\n",
      "DB02328\n",
      "DB02329\n",
      "DB02331\n",
      "DB02332\n",
      "DB02333\n",
      "DB02334\n",
      "DB02335\n",
      "DB02336\n",
      "DB02337\n",
      "DB02338\n",
      "DB02339\n",
      "DB02340\n",
      "DB02341\n",
      "DB02342\n",
      "DB02343\n",
      "DB02345\n",
      "DB02346\n",
      "DB02347\n",
      "DB02348\n",
      "DB02349\n",
      "DB02350\n",
      "DB02352\n",
      "DB02353\n",
      "DB02354\n",
      "DB02355\n",
      "DB02356\n",
      "DB02357\n",
      "DB02358\n",
      "DB02359\n",
      "DB02360\n",
      "DB02361\n",
      "DB02362\n",
      "DB02363\n",
      "DB02364\n",
      "DB02365\n",
      "DB02366\n",
      "DB02367\n",
      "DB02368\n",
      "DB02369\n",
      "DB02370\n",
      "DB02371\n",
      "DB02372\n",
      "DB02373\n",
      "DB02374\n",
      "DB02375\n",
      "DB02376\n",
      "DB02377\n",
      "DB02378\n",
      "DB02379\n",
      "DB02380\n",
      "DB02381\n",
      "DB02382\n",
      "DB02383\n",
      "DB02384\n",
      "DB02385\n",
      "DB02386\n",
      "DB02388\n",
      "DB02390\n",
      "DB02391\n",
      "DB02393\n",
      "DB02394\n",
      "DB02395\n",
      "DB02396\n",
      "DB02397\n",
      "DB02398\n",
      "DB02399\n",
      "DB02400\n",
      "DB02401\n",
      "DB02402\n",
      "DB02403\n",
      "DB02404\n",
      "DB02405\n",
      "DB02406\n",
      "DB02407\n",
      "DB02408\n",
      "DB02409\n",
      "DB02410\n",
      "DB02411\n",
      "DB02412\n",
      "DB02413\n",
      "DB02414\n",
      "DB02415\n",
      "DB02416\n",
      "DB02417\n",
      "DB02418\n",
      "DB02419\n",
      "DB02420\n",
      "DB02421\n",
      "DB02422\n",
      "DB02423\n",
      "DB02424\n",
      "DB02425\n",
      "DB02426\n",
      "DB02427\n",
      "DB02428\n",
      "DB02429\n",
      "DB02430\n",
      "DB02431\n",
      "DB02432\n",
      "DB02433\n",
      "DB02434\n",
      "DB02435\n",
      "DB02436\n",
      "DB02437\n",
      "DB02438\n",
      "DB02441\n",
      "DB02442\n",
      "DB02443\n",
      "DB02445\n",
      "DB02446\n",
      "DB02447\n",
      "DB02448\n",
      "DB02449\n",
      "DB02450\n",
      "DB02451\n",
      "DB02452\n",
      "DB02453\n",
      "DB02454\n",
      "DB02455\n",
      "DB02456\n",
      "DB02457\n",
      "DB02458\n",
      "DB02459\n",
      "DB02460\n",
      "DB02461\n",
      "DB02462\n",
      "DB02463\n",
      "DB02464\n",
      "DB02465\n",
      "DB02466\n",
      "DB02467\n",
      "DB02468\n",
      "DB02469\n",
      "DB02470\n",
      "DB02471\n",
      "DB02472\n",
      "DB02473\n",
      "DB02474\n",
      "DB02475\n",
      "DB02477\n",
      "DB02479\n",
      "DB02480\n",
      "DB02481\n",
      "DB02482\n",
      "DB02483\n",
      "DB02484\n",
      "DB02485\n",
      "DB02486\n",
      "DB02488\n",
      "DB02489\n",
      "DB02490\n",
      "DB02491\n",
      "DB02492\n",
      "DB02493\n",
      "DB02494\n",
      "DB02495\n",
      "DB02496\n",
      "DB02497\n",
      "DB02498\n",
      "DB02499\n",
      "DB02500\n",
      "DB02501\n",
      "DB02502\n",
      "DB02503\n",
      "DB02504\n",
      "DB02505\n",
      "DB02506\n",
      "DB02508\n",
      "DB02509\n",
      "DB02510\n",
      "DB02511\n",
      "DB02512\n",
      "DB02513\n",
      "DB02514\n",
      "DB02515\n",
      "DB02516\n",
      "DB02517\n",
      "DB02518\n",
      "DB02519\n",
      "DB02520\n",
      "DB02521\n",
      "DB02522\n",
      "DB02523\n",
      "DB02524\n",
      "DB02525\n",
      "DB02526\n",
      "DB02527\n",
      "DB02528\n",
      "DB02529\n",
      "DB02530\n",
      "DB02531\n",
      "DB02532\n",
      "DB02534\n",
      "DB02535\n",
      "DB02536\n",
      "DB02537\n",
      "DB02538\n",
      "DB02540\n",
      "DB02541\n",
      "DB02542\n",
      "DB02543\n",
      "DB02544\n",
      "DB02545\n",
      "DB02546\n",
      "DB02547\n",
      "DB02548\n",
      "DB02549\n",
      "DB02550\n",
      "DB02551\n",
      "DB02552\n",
      "DB02553\n",
      "DB02554\n",
      "DB02555\n",
      "DB02556\n",
      "DB02557\n",
      "DB02558\n",
      "DB02559\n",
      "DB02560\n",
      "DB02561\n",
      "DB02562\n",
      "DB02563\n",
      "DB02565\n",
      "DB02566\n",
      "DB02567\n",
      "DB02568\n",
      "DB02569\n",
      "DB02570\n",
      "DB02571\n",
      "DB02572\n",
      "DB02573\n",
      "DB02574\n",
      "DB02576\n",
      "DB02577\n",
      "DB02578\n",
      "DB02579\n",
      "DB02580\n",
      "DB02581\n",
      "DB02582\n",
      "DB02583\n",
      "DB02585\n",
      "DB02586\n",
      "DB02587\n",
      "DB02588\n",
      "DB02589\n",
      "DB02590\n",
      "DB02591\n",
      "DB02592\n",
      "DB02593\n",
      "DB02594\n",
      "DB02595\n",
      "DB02596\n",
      "DB02597\n",
      "DB02598\n",
      "DB02599\n",
      "DB02600\n",
      "DB02601\n",
      "DB02602\n",
      "DB02603\n",
      "DB02604\n",
      "DB02606\n",
      "DB02607\n",
      "DB02608\n",
      "DB02609\n",
      "DB02610\n",
      "DB02611\n",
      "DB02613\n",
      "DB02614\n",
      "DB02615\n",
      "DB02616\n",
      "DB02617\n",
      "DB02618\n",
      "DB02619\n",
      "DB02620\n",
      "DB02621\n",
      "DB02622\n",
      "DB02623\n",
      "DB02624\n",
      "DB02625\n",
      "DB02626\n",
      "DB02627\n",
      "DB02628\n",
      "DB02629\n",
      "DB02630\n",
      "DB02632\n",
      "DB02633\n",
      "DB02635\n",
      "DB02636\n",
      "DB02637\n",
      "DB02638\n",
      "DB02639\n",
      "DB02640\n",
      "DB02641\n",
      "DB02642\n",
      "DB02643\n",
      "DB02644\n",
      "DB02645\n",
      "DB02646\n",
      "DB02647\n",
      "DB02648\n",
      "DB02649\n",
      "DB02650\n",
      "DB02651\n",
      "DB02652\n",
      "DB02654\n",
      "DB02655\n",
      "DB02656\n",
      "DB02657\n",
      "DB02658\n",
      "DB02659\n",
      "DB02660\n",
      "DB02661\n",
      "DB02662\n",
      "DB02663\n",
      "DB02664\n",
      "DB02665\n",
      "DB02666\n",
      "DB02667\n",
      "DB02668\n",
      "DB02669\n",
      "DB02670\n",
      "DB02671\n",
      "DB02673\n",
      "DB02674\n",
      "DB02675\n",
      "DB02676\n",
      "DB02677\n",
      "DB02678\n",
      "DB02679\n",
      "DB02680\n",
      "DB02681\n",
      "DB02683\n",
      "DB02684\n",
      "DB02685\n",
      "DB02686\n",
      "DB02688\n",
      "DB02689\n",
      "DB02690\n",
      "DB02691\n",
      "DB02693\n",
      "DB02694\n",
      "DB02695\n",
      "DB02696\n",
      "DB02697\n",
      "DB02698\n",
      "DB02699\n",
      "DB02700\n",
      "DB02701\n",
      "DB02702\n",
      "DB02703\n",
      "DB02704\n",
      "DB02705\n",
      "DB02706\n",
      "DB02707\n",
      "DB02709\n",
      "DB02710\n",
      "DB02711\n",
      "DB02712\n",
      "DB02713\n",
      "DB02714\n",
      "DB02715\n",
      "DB02716\n",
      "DB02717\n",
      "DB02719\n",
      "DB02720\n",
      "DB02721\n",
      "DB02722\n",
      "DB02723\n",
      "DB02724\n",
      "DB02725\n",
      "DB02726\n",
      "DB02727\n",
      "DB02728\n",
      "DB02729\n",
      "DB02730\n",
      "DB02731\n",
      "DB02732\n",
      "DB02733\n",
      "DB02734\n",
      "DB02735\n",
      "DB02736\n",
      "DB02738\n",
      "DB02740\n",
      "DB02741\n",
      "DB02742\n",
      "DB02743\n",
      "DB02744\n",
      "DB02745\n",
      "DB02746\n",
      "DB02747\n",
      "DB02749\n",
      "DB02750\n",
      "DB02751\n",
      "DB02752\n",
      "DB02753\n",
      "DB02754\n",
      "DB02755\n",
      "DB02756\n",
      "DB02757\n",
      "DB02758\n",
      "DB02759\n",
      "DB02760\n",
      "DB02761\n",
      "DB02762\n",
      "DB02763\n",
      "DB02765\n",
      "DB02766\n",
      "DB02767\n",
      "DB02768\n",
      "DB02770\n",
      "DB02772\n",
      "DB02773\n",
      "DB02774\n",
      "DB02776\n",
      "DB02777\n",
      "DB02778\n",
      "DB02779\n",
      "DB02780\n",
      "DB02781\n",
      "DB02783\n",
      "DB02784\n",
      "DB02785\n",
      "DB02786\n",
      "DB02787\n",
      "DB02788\n",
      "DB02789\n",
      "DB02790\n",
      "DB02792\n",
      "DB02793\n",
      "DB02794\n",
      "DB02795\n",
      "DB02796\n",
      "DB02797\n",
      "DB02798\n",
      "DB02799\n",
      "DB02800\n",
      "DB02801\n",
      "DB02802\n",
      "DB02803\n",
      "DB02804\n",
      "DB02805\n",
      "DB02806\n",
      "DB02807\n",
      "DB02808\n",
      "DB02809\n",
      "DB02810\n",
      "DB02811\n",
      "DB02812\n",
      "DB02813\n",
      "DB02814\n",
      "DB02816\n",
      "DB02817\n",
      "DB02818\n",
      "DB02819\n",
      "DB02820\n",
      "DB02821\n",
      "DB02822\n",
      "DB02823\n",
      "DB02824\n",
      "DB02825\n",
      "DB02827\n",
      "DB02828\n",
      "DB02829\n",
      "DB02830\n",
      "DB02831\n",
      "DB02832\n",
      "DB02833\n",
      "DB02834\n",
      "DB02835\n",
      "DB02836\n",
      "DB02837\n",
      "DB02838\n",
      "DB02839\n",
      "DB02840\n",
      "DB02841\n",
      "DB02842\n",
      "DB02843\n",
      "DB02844\n",
      "DB02845\n",
      "DB02846\n",
      "DB02847\n",
      "DB02848\n",
      "DB02849\n",
      "DB02850\n",
      "DB02851\n",
      "DB02852\n",
      "DB02853\n",
      "DB02854\n",
      "DB02855\n",
      "DB02856\n",
      "DB02857\n",
      "DB02858\n",
      "DB02859\n",
      "DB02860\n",
      "DB02861\n",
      "DB02862\n",
      "DB02864\n",
      "DB02865\n",
      "DB02866\n",
      "DB02867\n",
      "DB02868\n",
      "DB02869\n",
      "DB02870\n",
      "DB02871\n",
      "DB02872\n",
      "DB02873\n",
      "DB02875\n",
      "DB02876\n",
      "DB02877\n",
      "DB02878\n",
      "DB02879\n",
      "DB02880\n",
      "DB02881\n",
      "DB02882\n",
      "DB02883\n",
      "DB02884\n",
      "DB02885\n",
      "DB02887\n",
      "DB02888\n",
      "DB02889\n",
      "DB02890\n",
      "DB02891\n",
      "DB02892\n",
      "DB02893\n",
      "DB02894\n",
      "DB02895\n",
      "DB02896\n",
      "DB02897\n",
      "DB02898\n",
      "DB02899\n",
      "DB02900\n",
      "DB02901\n",
      "DB02902\n",
      "DB02903\n",
      "DB02904\n",
      "DB02905\n",
      "DB02906\n",
      "DB02907\n",
      "DB02908\n",
      "DB02909\n",
      "DB02910\n",
      "DB02911\n",
      "DB02912\n",
      "DB02914\n",
      "DB02915\n",
      "DB02916\n",
      "DB02917\n",
      "DB02918\n",
      "DB02919\n",
      "DB02920\n",
      "DB02921\n",
      "DB02922\n",
      "DB02923\n",
      "DB02924\n",
      "DB02925\n",
      "DB02927\n",
      "DB02928\n",
      "DB02929\n",
      "DB02930\n",
      "DB02931\n",
      "DB02932\n",
      "DB02933\n",
      "DB02934\n",
      "DB02935\n",
      "DB02936\n",
      "DB02937\n",
      "DB02938\n",
      "DB02940\n",
      "DB02941\n",
      "DB02942\n",
      "DB02943\n",
      "DB02945\n",
      "DB02946\n",
      "DB02947\n",
      "DB02948\n",
      "DB02949\n",
      "DB02950\n",
      "DB02951\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB02952\n",
      "DB02953\n",
      "DB02954\n",
      "DB02955\n",
      "DB02956\n",
      "DB02957\n",
      "DB02958\n",
      "DB02959\n",
      "DB02960\n",
      "DB02961\n",
      "DB02962\n",
      "DB02963\n",
      "DB02964\n",
      "DB02965\n",
      "DB02966\n",
      "DB02967\n",
      "DB02968\n",
      "DB02969\n",
      "DB02970\n",
      "DB02971\n",
      "DB02972\n",
      "DB02973\n",
      "DB02974\n",
      "DB02975\n",
      "DB02976\n",
      "DB02977\n",
      "DB02978\n",
      "DB02979\n",
      "DB02980\n",
      "DB02981\n",
      "DB02982\n",
      "DB02983\n",
      "DB02984\n",
      "DB02985\n",
      "DB02986\n",
      "DB02987\n",
      "DB02988\n",
      "DB02989\n",
      "DB02990\n",
      "DB02991\n",
      "DB02992\n",
      "DB02993\n",
      "DB02994\n",
      "DB02995\n",
      "DB02996\n",
      "DB02998\n",
      "DB02999\n",
      "DB03000\n",
      "DB03001\n",
      "DB03002\n",
      "DB03003\n",
      "DB03004\n",
      "DB03005\n",
      "DB03006\n",
      "DB03007\n",
      "DB03008\n",
      "DB03009\n",
      "DB03010\n",
      "DB03011\n",
      "DB03012\n",
      "DB03013\n",
      "DB03015\n",
      "DB03016\n",
      "DB03017\n",
      "DB03018\n",
      "DB03019\n",
      "DB03020\n",
      "DB03021\n",
      "DB03022\n",
      "DB03023\n",
      "DB03024\n",
      "DB03025\n",
      "DB03026\n",
      "DB03028\n",
      "DB03030\n",
      "DB03031\n",
      "DB03032\n",
      "DB03033\n",
      "DB03034\n",
      "DB03035\n",
      "DB03037\n",
      "DB03038\n",
      "DB03039\n",
      "DB03040\n",
      "DB03041\n",
      "DB03042\n",
      "DB03043\n",
      "DB03044\n",
      "DB03045\n",
      "DB03046\n",
      "DB03047\n",
      "DB03048\n",
      "DB03049\n",
      "DB03051\n",
      "DB03052\n",
      "DB03053\n",
      "DB03054\n",
      "DB03056\n",
      "DB03057\n",
      "DB03058\n",
      "DB03059\n",
      "DB03060\n",
      "DB03061\n",
      "DB03062\n",
      "DB03063\n",
      "DB03064\n",
      "DB03065\n",
      "DB03066\n",
      "DB03067\n",
      "DB03068\n",
      "DB03069\n",
      "DB03070\n",
      "DB03071\n",
      "DB03072\n",
      "DB03073\n",
      "DB03074\n",
      "DB03075\n",
      "DB03076\n",
      "DB03077\n",
      "DB03078\n",
      "DB03079\n",
      "DB03081\n",
      "DB03082\n",
      "DB03083\n",
      "DB03084\n",
      "DB03085\n",
      "DB03086\n",
      "DB03087\n",
      "DB03088\n",
      "DB03090\n",
      "DB03091\n",
      "DB03092\n",
      "DB03093\n",
      "DB03094\n",
      "DB03095\n",
      "DB03096\n",
      "DB03097\n",
      "DB03098\n",
      "DB03099\n",
      "DB03100\n",
      "DB03101\n",
      "DB03102\n",
      "DB03103\n",
      "DB03104\n",
      "DB03105\n",
      "DB03106\n",
      "DB03107\n",
      "DB03108\n",
      "DB03109\n",
      "DB03110\n",
      "DB03111\n",
      "DB03112\n",
      "DB03113\n",
      "DB03114\n",
      "DB03115\n",
      "DB03116\n",
      "DB03117\n",
      "DB03118\n",
      "DB03120\n",
      "DB03121\n",
      "DB03124\n",
      "DB03125\n",
      "DB03126\n",
      "DB03127\n",
      "DB03128\n",
      "DB03129\n",
      "DB03130\n",
      "DB03132\n",
      "DB03133\n",
      "DB03134\n",
      "DB03135\n",
      "DB03136\n",
      "DB03137\n",
      "DB03138\n",
      "DB03139\n",
      "DB03140\n",
      "DB03141\n",
      "DB03142\n",
      "DB03143\n",
      "DB03144\n",
      "DB03145\n",
      "DB03146\n",
      "DB03147\n",
      "DB03148\n",
      "DB03150\n",
      "DB03151\n",
      "DB03152\n",
      "DB03153\n",
      "DB03154\n",
      "DB03155\n",
      "DB03156\n",
      "DB03157\n",
      "DB03158\n",
      "DB03159\n",
      "DB03160\n",
      "DB03161\n",
      "DB03162\n",
      "DB03163\n",
      "DB03164\n",
      "DB03165\n",
      "DB03166\n",
      "DB03167\n",
      "DB03168\n",
      "DB03169\n",
      "DB03170\n",
      "DB03171\n",
      "DB03172\n",
      "DB03173\n",
      "DB03174\n",
      "DB03175\n",
      "DB03176\n",
      "DB03177\n",
      "DB03178\n",
      "DB03179\n",
      "DB03180\n",
      "DB03181\n",
      "DB03182\n",
      "DB03183\n",
      "DB03184\n",
      "DB03185\n",
      "DB03186\n",
      "DB03187\n",
      "DB03189\n",
      "DB03190\n",
      "DB03191\n",
      "DB03192\n",
      "DB03193\n",
      "DB03194\n",
      "DB03195\n",
      "DB03196\n",
      "DB03197\n",
      "DB03198\n",
      "DB03199\n",
      "DB03200\n",
      "DB03201\n",
      "DB03202\n",
      "DB03203\n",
      "DB03204\n",
      "DB03205\n",
      "DB03206\n",
      "DB03207\n",
      "DB03208\n",
      "DB03209\n",
      "DB03210\n",
      "DB03211\n",
      "DB03212\n",
      "DB03213\n",
      "DB03214\n",
      "DB03215\n",
      "DB03216\n",
      "DB03217\n",
      "DB03218\n",
      "DB03219\n",
      "DB03220\n",
      "DB03221\n",
      "DB03222\n",
      "DB03223\n",
      "DB03224\n",
      "DB03225\n",
      "DB03226\n",
      "DB03227\n",
      "DB03228\n",
      "DB03229\n",
      "DB03230\n",
      "DB03231\n",
      "DB03232\n",
      "DB03233\n",
      "DB03234\n",
      "DB03235\n",
      "DB03236\n",
      "DB03237\n",
      "DB03238\n",
      "DB03239\n",
      "DB03240\n",
      "DB03241\n",
      "DB03242\n",
      "DB03243\n",
      "DB03244\n",
      "DB03245\n",
      "DB03246\n",
      "DB03247\n",
      "DB03248\n",
      "DB03249\n",
      "DB03250\n",
      "DB03251\n",
      "DB03252\n",
      "DB03253\n",
      "DB03254\n",
      "DB03255\n",
      "DB03256\n",
      "DB03257\n",
      "DB03258\n",
      "DB03259\n",
      "DB03260\n",
      "DB03262\n",
      "DB03263\n",
      "DB03264\n",
      "DB03266\n",
      "DB03267\n",
      "DB03268\n",
      "DB03269\n",
      "DB03270\n",
      "DB03272\n",
      "DB03273\n",
      "DB03274\n",
      "DB03275\n",
      "DB03276\n",
      "DB03277\n",
      "DB03278\n",
      "DB03279\n",
      "DB03280\n",
      "DB03281\n",
      "DB03283\n",
      "DB03284\n",
      "DB03285\n",
      "DB03286\n",
      "DB03287\n",
      "DB03288\n",
      "DB03289\n",
      "DB03290\n",
      "DB03291\n",
      "DB03292\n",
      "DB03293\n",
      "DB03294\n",
      "DB03295\n",
      "DB03296\n",
      "DB03297\n",
      "DB03298\n",
      "DB03299\n",
      "DB03300\n",
      "DB03301\n",
      "DB03302\n",
      "DB03303\n",
      "DB03304\n",
      "DB03305\n",
      "DB03306\n",
      "DB03307\n",
      "DB03308\n",
      "DB03309\n",
      "DB03310\n",
      "DB03311\n",
      "DB03312\n",
      "DB03313\n",
      "DB03314\n",
      "DB03315\n",
      "DB03316\n",
      "DB03317\n",
      "DB03318\n",
      "DB03319\n",
      "DB03320\n",
      "DB03321\n",
      "DB03322\n",
      "DB03323\n",
      "DB03325\n",
      "DB03326\n",
      "DB03327\n",
      "DB03328\n",
      "DB03329\n",
      "DB03330\n",
      "DB03331\n",
      "DB03332\n",
      "DB03333\n",
      "DB03335\n",
      "DB03336\n",
      "DB03337\n",
      "DB03338\n",
      "DB03339\n",
      "DB03340\n",
      "DB03341\n",
      "DB03342\n",
      "DB03343\n",
      "DB03344\n",
      "DB03345\n",
      "DB03346\n",
      "DB03347\n",
      "DB03348\n",
      "DB03349\n",
      "DB03350\n",
      "DB03351\n",
      "DB03352\n",
      "DB03353\n",
      "DB03354\n",
      "DB03355\n",
      "DB03357\n",
      "DB03358\n",
      "DB03359\n",
      "DB03360\n",
      "DB03361\n",
      "DB03362\n",
      "DB03363\n",
      "DB03364\n",
      "DB03365\n",
      "DB03366\n",
      "DB03367\n",
      "DB03368\n",
      "DB03369\n",
      "DB03370\n",
      "DB03371\n",
      "DB03372\n",
      "DB03373\n",
      "DB03374\n",
      "DB03376\n",
      "DB03378\n",
      "DB03379\n",
      "DB03380\n",
      "DB03381\n",
      "DB03382\n",
      "DB03383\n",
      "DB03384\n",
      "DB03385\n",
      "DB03386\n",
      "DB03387\n",
      "DB03388\n",
      "DB03389\n",
      "DB03390\n",
      "DB03391\n",
      "DB03392\n",
      "DB03393\n",
      "DB03394\n",
      "DB03395\n",
      "DB03396\n",
      "DB03397\n",
      "DB03399\n",
      "DB03400\n",
      "DB03401\n",
      "DB03402\n",
      "DB03403\n",
      "DB03404\n",
      "DB03405\n",
      "DB03406\n",
      "DB03407\n",
      "DB03408\n",
      "DB03409\n",
      "DB03410\n",
      "DB03411\n",
      "DB03412\n",
      "DB03413\n",
      "DB03414\n",
      "DB03415\n",
      "DB03416\n",
      "DB03417\n",
      "DB03418\n",
      "DB03419\n",
      "DB03420\n",
      "DB03421\n",
      "DB03422\n",
      "DB03423\n",
      "DB03424\n",
      "DB03425\n",
      "DB03426\n",
      "DB03427\n",
      "DB03428\n",
      "DB03429\n",
      "DB03430\n",
      "DB03432\n",
      "DB03433\n",
      "DB03434\n",
      "DB03435\n",
      "DB03436\n",
      "DB03437\n",
      "DB03438\n",
      "DB03439\n",
      "DB03440\n",
      "DB03441\n",
      "DB03442\n",
      "DB03443\n",
      "DB03444\n",
      "DB03445\n",
      "DB03446\n",
      "DB03447\n",
      "DB03448\n",
      "DB03449\n",
      "DB03450\n",
      "DB03451\n",
      "DB03452\n",
      "DB03453\n",
      "DB03454\n",
      "DB03455\n",
      "DB03456\n",
      "DB03458\n",
      "DB03459\n",
      "DB03460\n",
      "DB03461\n",
      "DB03462\n",
      "DB03464\n",
      "DB03466\n",
      "DB03467\n",
      "DB03468\n",
      "DB03469\n",
      "DB03470\n",
      "DB03471\n",
      "DB03472\n",
      "DB03473\n",
      "DB03474\n",
      "DB03475\n",
      "DB03476\n",
      "DB03477\n",
      "DB03478\n",
      "DB03479\n",
      "DB03480\n",
      "DB03481\n",
      "DB03482\n",
      "DB03483\n",
      "DB03484\n",
      "DB03485\n",
      "DB03486\n",
      "DB03487\n",
      "DB03488\n",
      "DB03489\n",
      "DB03490\n",
      "DB03491\n",
      "DB03492\n",
      "DB03493\n",
      "DB03495\n",
      "DB03496\n",
      "DB03497\n",
      "DB03498\n",
      "DB03499\n",
      "DB03500\n",
      "DB03501\n",
      "DB03502\n",
      "DB03503\n",
      "DB03504\n",
      "DB03505\n",
      "DB03506\n",
      "DB03507\n",
      "DB03508\n",
      "DB03509\n",
      "DB03510\n",
      "DB03511\n",
      "DB03512\n",
      "DB03513\n",
      "DB03514\n",
      "DB03515\n",
      "DB03516\n",
      "DB03517\n",
      "DB03518\n",
      "DB03520\n",
      "DB03522\n",
      "DB03523\n",
      "DB03524\n",
      "DB03525\n",
      "DB03526\n",
      "DB03528\n",
      "DB03530\n",
      "DB03531\n",
      "DB03532\n",
      "DB03533\n",
      "DB03534\n",
      "DB03535\n",
      "DB03536\n",
      "DB03537\n",
      "DB03539\n",
      "DB03540\n",
      "DB03541\n",
      "DB03542\n",
      "DB03543\n",
      "DB03544\n",
      "DB03546\n",
      "DB03548\n",
      "DB03549\n",
      "DB03550\n",
      "DB03551\n",
      "DB03552\n",
      "DB03553\n",
      "DB03554\n",
      "DB03555\n",
      "DB03556\n",
      "DB03557\n",
      "DB03558\n",
      "DB03559\n",
      "DB03560\n",
      "DB03562\n",
      "DB03564\n",
      "DB03565\n",
      "DB03566\n",
      "DB03567\n",
      "DB03568\n",
      "DB03569\n",
      "DB03570\n",
      "DB03571\n",
      "DB03572\n",
      "DB03573\n",
      "DB03574\n",
      "DB03575\n",
      "DB03576\n",
      "DB03577\n",
      "DB03578\n",
      "DB03581\n",
      "DB03582\n",
      "DB03583\n",
      "DB03584\n",
      "DB03585\n",
      "DB03586\n",
      "DB03587\n",
      "DB03588\n",
      "DB03589\n",
      "DB03590\n",
      "DB03591\n",
      "DB03592\n",
      "DB03593\n",
      "DB03594\n",
      "DB03595\n",
      "DB03596\n",
      "DB03597\n",
      "DB03598\n",
      "DB03600\n",
      "DB03601\n",
      "DB03602\n",
      "DB03603\n",
      "DB03604\n",
      "DB03605\n",
      "DB03606\n",
      "DB03607\n",
      "DB03608\n",
      "DB03609\n",
      "DB03610\n",
      "DB03611\n",
      "DB03612\n",
      "DB03613\n",
      "DB03614\n",
      "DB03615\n",
      "DB03616\n",
      "DB03617\n",
      "DB03618\n",
      "DB03619\n",
      "DB03621\n",
      "DB03622\n",
      "DB03623\n",
      "DB03624\n",
      "DB03626\n",
      "DB03627\n",
      "DB03628\n",
      "DB03629\n",
      "DB03630\n",
      "DB03631\n",
      "DB03632\n",
      "DB03633\n",
      "DB03634\n",
      "DB03635\n",
      "DB03636\n",
      "DB03637\n",
      "DB03638\n",
      "DB03639\n",
      "DB03640\n",
      "DB03641\n",
      "DB03642\n",
      "DB03643\n",
      "DB03644\n",
      "DB03645\n",
      "DB03646\n",
      "DB03647\n",
      "DB03648\n",
      "DB03649\n",
      "DB03650\n",
      "DB03651\n",
      "DB03652\n",
      "DB03653\n",
      "DB03654\n",
      "DB03656\n",
      "DB03657\n",
      "DB03658\n",
      "DB03659\n",
      "DB03660\n",
      "DB03661\n",
      "DB03662\n",
      "DB03663\n",
      "DB03664\n",
      "DB03666\n",
      "DB03667\n",
      "DB03668\n",
      "DB03669\n",
      "DB03670\n",
      "DB03671\n",
      "DB03672\n",
      "DB03673\n",
      "DB03675\n",
      "DB03676\n",
      "DB03677\n",
      "DB03678\n",
      "DB03679\n",
      "DB03680\n",
      "DB03682\n",
      "DB03683\n",
      "DB03685\n",
      "DB03686\n",
      "DB03687\n",
      "DB03688\n",
      "DB03690\n",
      "DB03691\n",
      "DB03692\n",
      "DB03693\n",
      "DB03694\n",
      "DB03695\n",
      "DB03696\n",
      "DB03697\n",
      "DB03698\n",
      "DB03699\n",
      "DB03700\n",
      "DB03701\n",
      "DB03702\n",
      "DB03703\n",
      "DB03704\n",
      "DB03705\n",
      "DB03706\n",
      "DB03707\n",
      "DB03708\n",
      "DB03709\n",
      "DB03710\n",
      "DB03711\n",
      "DB03712\n",
      "DB03714\n",
      "DB03716\n",
      "DB03717\n",
      "DB03718\n",
      "DB03719\n",
      "DB03720\n",
      "DB03721\n",
      "DB03722\n",
      "DB03723\n",
      "DB03724\n",
      "DB03725\n",
      "DB03726\n",
      "DB03727\n",
      "DB03728\n",
      "DB03729\n",
      "DB03730\n",
      "DB03731\n",
      "DB03732\n",
      "DB03733\n",
      "DB03734\n",
      "DB03735\n",
      "DB03736\n",
      "DB03737\n",
      "DB03738\n",
      "DB03739\n",
      "DB03740\n",
      "DB03741\n",
      "DB03742\n",
      "DB03744\n",
      "DB03745\n",
      "DB03746\n",
      "DB03747\n",
      "DB03748\n",
      "DB03749\n",
      "DB03750\n",
      "DB03751\n",
      "DB03752\n",
      "DB03753\n",
      "DB03754\n",
      "DB03755\n",
      "DB03756\n",
      "DB03757\n",
      "DB03758\n",
      "DB03759\n",
      "DB03760\n",
      "DB03761\n",
      "DB03763\n",
      "DB03764\n",
      "DB03765\n",
      "DB03766\n",
      "DB03767\n",
      "DB03768\n",
      "DB03769\n",
      "DB03770\n",
      "DB03771\n",
      "DB03772\n",
      "DB03773\n",
      "DB03774\n",
      "DB03775\n",
      "DB03776\n",
      "DB03777\n",
      "DB03779\n",
      "DB03780\n",
      "DB03781\n",
      "DB03782\n",
      "DB03783\n",
      "DB03784\n",
      "DB03785\n",
      "DB03787\n",
      "DB03788\n",
      "DB03789\n",
      "DB03790\n",
      "DB03791\n",
      "DB03792\n",
      "DB03793\n",
      "DB03794\n",
      "DB03795\n",
      "DB03796\n",
      "DB03797\n",
      "DB03798\n",
      "DB03799\n",
      "DB03800\n",
      "DB03801\n",
      "DB03802\n",
      "DB03803\n",
      "DB03804\n",
      "DB03807\n",
      "DB03808\n",
      "DB03809\n",
      "DB03810\n",
      "DB03811\n",
      "DB03812\n",
      "DB03813\n",
      "DB03814\n",
      "DB03815\n",
      "DB03816\n",
      "DB03817\n",
      "DB03818\n",
      "DB03819\n",
      "DB03820\n",
      "DB03821\n",
      "DB03822\n",
      "DB03823\n",
      "DB03824\n",
      "DB03825\n",
      "DB03826\n",
      "DB03827\n",
      "DB03828\n",
      "DB03829\n",
      "DB03830\n",
      "DB03831\n",
      "DB03832\n",
      "DB03833\n",
      "DB03834\n",
      "DB03835\n",
      "DB03836\n",
      "DB03837\n",
      "DB03839\n",
      "DB03840\n",
      "DB03841\n",
      "DB03842\n",
      "DB03843\n",
      "DB03844\n",
      "DB03845\n",
      "DB03846\n",
      "DB03847\n",
      "DB03848\n",
      "DB03849\n",
      "DB03850\n",
      "DB03851\n",
      "DB03852\n",
      "DB03853\n",
      "DB03854\n",
      "DB03855\n",
      "DB03856\n",
      "DB03857\n",
      "DB03858\n",
      "DB03859\n",
      "DB03860\n",
      "DB03861\n",
      "DB03862\n",
      "DB03863\n",
      "DB03864\n",
      "DB03865\n",
      "DB03866\n",
      "DB03867\n",
      "DB03868\n",
      "DB03869\n",
      "DB03870\n",
      "DB03871\n",
      "DB03872\n",
      "DB03874\n",
      "DB03876\n",
      "DB03877\n",
      "DB03878\n",
      "DB03879\n",
      "DB03880\n",
      "DB03881\n",
      "DB03882\n",
      "DB03883\n",
      "DB03884\n",
      "DB03885\n",
      "DB03886\n",
      "DB03887\n",
      "DB03888\n",
      "DB03889\n",
      "DB03890\n",
      "DB03891\n",
      "DB03892\n",
      "DB03893\n",
      "DB03894\n",
      "DB03895\n",
      "DB03896\n",
      "DB03897\n",
      "DB03898\n",
      "DB03899\n",
      "DB03900\n",
      "DB03901\n",
      "DB03902\n",
      "DB03903\n",
      "DB03904\n",
      "DB03905\n",
      "DB03906\n",
      "DB03907\n",
      "DB03908\n",
      "DB03909\n",
      "DB03910\n",
      "DB03911\n",
      "DB03912\n",
      "DB03913\n",
      "DB03914\n",
      "DB03915\n",
      "DB03916\n",
      "DB03917\n",
      "DB03918\n",
      "DB03919\n",
      "DB03920\n",
      "DB03921\n",
      "DB03923\n",
      "DB03924\n",
      "DB03925\n",
      "DB03926\n",
      "DB03927\n",
      "DB03928\n",
      "DB03929\n",
      "DB03930\n",
      "DB03931\n",
      "DB03932\n",
      "DB03933\n",
      "DB03934\n",
      "DB03935\n",
      "DB03936\n",
      "DB03937\n",
      "DB03938\n",
      "DB03939\n",
      "DB03940\n",
      "DB03941\n",
      "DB03942\n",
      "DB03943\n",
      "DB03944\n",
      "DB03945\n",
      "DB03946\n",
      "DB03947\n",
      "DB03948\n",
      "DB03949\n",
      "DB03950\n",
      "DB03951\n",
      "DB03952\n",
      "DB03953\n",
      "DB03955\n",
      "DB03956\n",
      "DB03957\n",
      "DB03958\n",
      "DB03959\n",
      "DB03960\n",
      "DB03961\n",
      "DB03962\n",
      "DB03963\n",
      "DB03964\n",
      "DB03966\n",
      "DB03967\n",
      "DB03968\n",
      "DB03970\n",
      "DB03971\n",
      "DB03972\n",
      "DB03973\n",
      "DB03974\n",
      "DB03975\n",
      "DB03976\n",
      "DB03977\n",
      "DB03978\n",
      "DB03979\n",
      "DB03980\n",
      "DB03981\n",
      "DB03982\n",
      "DB03983\n",
      "DB03984\n",
      "DB03985\n",
      "DB03986\n",
      "DB03987\n",
      "DB03988\n",
      "DB03989\n",
      "DB03990\n",
      "DB03991\n",
      "DB03992\n",
      "DB03993\n",
      "DB03994\n",
      "DB03995\n",
      "DB03996\n",
      "DB03997\n",
      "DB03998\n",
      "DB03999\n",
      "DB04000\n",
      "DB04001\n",
      "DB04002\n",
      "DB04003\n",
      "DB04004\n",
      "DB04005\n",
      "DB04006\n",
      "DB04007\n",
      "DB04008\n",
      "DB04009\n",
      "DB04010\n",
      "DB04011\n",
      "DB04012\n",
      "DB04013\n",
      "DB04014\n",
      "DB04015\n",
      "DB04016\n",
      "DB04017\n",
      "DB04018\n",
      "DB04020\n",
      "DB04021\n",
      "DB04022\n",
      "DB04023\n",
      "DB04024\n",
      "DB04026\n",
      "DB04027\n",
      "DB04028\n",
      "DB04029\n",
      "DB04030\n",
      "DB04031\n",
      "DB04032\n",
      "DB04033\n",
      "DB04034\n",
      "DB04035\n",
      "DB04036\n",
      "DB04037\n",
      "DB04038\n",
      "DB04039\n",
      "DB04040\n",
      "DB04041\n",
      "DB04042\n",
      "DB04043\n",
      "DB04044\n",
      "DB04045\n",
      "DB04046\n",
      "DB04047\n",
      "DB04048\n",
      "DB04049\n",
      "DB04050\n",
      "DB04051\n",
      "DB04052\n",
      "DB04053\n",
      "DB04054\n",
      "DB04055\n",
      "DB04057\n",
      "DB04058\n",
      "DB04059\n",
      "DB04060\n",
      "DB04061\n",
      "DB04062\n",
      "DB04063\n",
      "DB04064\n",
      "DB04065\n",
      "DB04066\n",
      "DB04067\n",
      "DB04068\n",
      "DB04069\n",
      "DB04070\n",
      "DB04071\n",
      "DB04072\n",
      "DB04073\n",
      "DB04074\n",
      "DB04075\n",
      "DB04076\n",
      "DB04079\n",
      "DB04080\n",
      "DB04081\n",
      "DB04082\n",
      "DB04083\n",
      "DB04084\n",
      "DB04085\n",
      "DB04086\n",
      "DB04087\n",
      "DB04088\n",
      "DB04089\n",
      "DB04090\n",
      "DB04092\n",
      "DB04093\n",
      "DB04094\n",
      "DB04095\n",
      "DB04096\n",
      "DB04097\n",
      "DB04098\n",
      "DB04099\n",
      "DB04100\n",
      "DB04101\n",
      "DB04102\n",
      "DB04103\n",
      "DB04104\n",
      "DB04105\n",
      "DB04106\n",
      "DB04107\n",
      "DB04108\n",
      "DB04109\n",
      "DB04110\n",
      "DB04111\n",
      "DB04112\n",
      "DB04113\n",
      "DB04114\n",
      "DB04115\n",
      "DB04116\n",
      "DB04117\n",
      "DB04118\n",
      "DB04119\n",
      "DB04120\n",
      "DB04121\n",
      "DB04122\n",
      "DB04123\n",
      "DB04124\n",
      "DB04125\n",
      "DB04126\n",
      "DB04127\n",
      "DB04128\n",
      "DB04129\n",
      "DB04130\n",
      "DB04131\n",
      "DB04132\n",
      "DB04133\n",
      "DB04135\n",
      "DB04136\n",
      "DB04137\n",
      "DB04138\n",
      "DB04139\n",
      "DB04140\n",
      "DB04141\n",
      "DB04142\n",
      "DB04143\n",
      "DB04144\n",
      "DB04145\n",
      "DB04146\n",
      "DB04147\n",
      "DB04149\n",
      "DB04150\n",
      "DB04151\n",
      "DB04152\n",
      "DB04153\n",
      "DB04154\n",
      "DB04155\n",
      "DB04156\n",
      "DB04157\n",
      "DB04158\n",
      "DB04159\n",
      "DB04160\n",
      "DB04161\n",
      "DB04162\n",
      "DB04163\n",
      "DB04164\n",
      "DB04165\n",
      "DB04166\n",
      "DB04167\n",
      "DB04168\n",
      "DB04169\n",
      "DB04170\n",
      "DB04171\n",
      "DB04172\n",
      "DB04173\n",
      "DB04174\n",
      "DB04175\n",
      "DB04176\n",
      "DB04177\n",
      "DB04178\n",
      "DB04179\n",
      "DB04180\n",
      "DB04182\n",
      "DB04183\n",
      "DB04185\n",
      "DB04186\n",
      "DB04187\n",
      "DB04188\n",
      "DB04189\n",
      "DB04190\n",
      "DB04191\n",
      "DB04193\n",
      "DB04194\n",
      "DB04195\n",
      "DB04196\n",
      "DB04197\n",
      "DB04198\n",
      "DB04199\n",
      "DB04200\n",
      "DB04201\n",
      "DB04202\n",
      "DB04203\n",
      "DB04204\n",
      "DB04205\n",
      "DB04206\n",
      "DB04207\n",
      "DB04208\n",
      "DB04209\n",
      "DB04210\n",
      "DB04211\n",
      "DB04212\n",
      "DB04213\n",
      "DB04214\n",
      "DB04215\n",
      "DB04216\n",
      "DB04217\n",
      "DB04218\n",
      "DB04219\n",
      "DB04220\n",
      "DB04221\n",
      "DB04222\n",
      "DB04223\n",
      "DB04224\n",
      "DB04225\n",
      "DB04226\n",
      "DB04227\n",
      "DB04228\n",
      "DB04229\n",
      "DB04230\n",
      "DB04231\n",
      "DB04232\n",
      "DB04233\n",
      "DB04234\n",
      "DB04235\n",
      "DB04236\n",
      "DB04237\n",
      "DB04238\n",
      "DB04239\n",
      "DB04240\n",
      "DB04241\n",
      "DB04242\n",
      "DB04243\n",
      "DB04244\n",
      "DB04246\n",
      "DB04248\n",
      "DB04249\n",
      "DB04250\n",
      "DB04252\n",
      "DB04253\n",
      "DB04254\n",
      "DB04255\n",
      "DB04256\n",
      "DB04257\n",
      "DB04258\n",
      "DB04259\n",
      "DB04260\n",
      "DB04261\n",
      "DB04262\n",
      "DB04263\n",
      "DB04264\n",
      "DB04265\n",
      "DB04266\n",
      "DB04267\n",
      "DB04268\n",
      "DB04269\n",
      "DB04270\n",
      "DB04271\n",
      "DB04272\n",
      "DB04273\n",
      "DB04274\n",
      "DB04275\n",
      "DB04276\n",
      "DB04277\n",
      "DB04278\n",
      "DB04279\n",
      "DB04280\n",
      "DB04281\n",
      "DB04282\n",
      "DB04283\n",
      "DB04284\n",
      "DB04285\n",
      "DB04286\n",
      "DB04287\n",
      "DB04288\n",
      "DB04289\n",
      "DB04291\n",
      "DB04292\n",
      "DB04293\n",
      "DB04294\n",
      "DB04295\n",
      "DB04296\n",
      "DB04297\n",
      "DB04298\n",
      "DB04299\n",
      "DB04300\n",
      "DB04301\n",
      "DB04302\n",
      "DB04303\n",
      "DB04304\n",
      "DB04306\n",
      "DB04307\n",
      "DB04308\n",
      "DB04310\n",
      "DB04311\n",
      "DB04312\n",
      "DB04313\n",
      "DB04314\n",
      "DB04315\n",
      "DB04316\n",
      "DB04317\n",
      "DB04318\n",
      "DB04320\n",
      "DB04321\n",
      "DB04322\n",
      "DB04323\n",
      "DB04324\n",
      "DB04325\n",
      "DB04326\n",
      "DB04327\n",
      "DB04328\n",
      "DB04329\n",
      "DB04330\n",
      "DB04331\n",
      "DB04332\n",
      "DB04333\n",
      "DB04334\n",
      "DB04335\n",
      "DB04336\n",
      "DB04337\n",
      "DB04338\n",
      "DB04339\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB04340\n",
      "DB04341\n",
      "DB04342\n",
      "DB04343\n",
      "DB04345\n",
      "DB04346\n",
      "DB04347\n",
      "DB04348\n",
      "DB04349\n",
      "DB04350\n",
      "DB04351\n",
      "DB04352\n",
      "DB04353\n",
      "DB04356\n",
      "DB04357\n",
      "DB04359\n",
      "DB04360\n",
      "DB04361\n",
      "DB04362\n",
      "DB04363\n",
      "DB04364\n",
      "DB04365\n",
      "DB04366\n",
      "DB04367\n",
      "DB04368\n",
      "DB04369\n",
      "DB04370\n",
      "DB04371\n",
      "DB04372\n",
      "DB04373\n",
      "DB04374\n",
      "DB04376\n",
      "DB04377\n",
      "DB04378\n",
      "DB04379\n",
      "DB04380\n",
      "DB04381\n",
      "DB04382\n",
      "DB04383\n",
      "DB04384\n",
      "DB04385\n",
      "DB04386\n",
      "DB04387\n",
      "DB04388\n",
      "DB04389\n",
      "DB04391\n",
      "DB04392\n",
      "DB04393\n",
      "DB04394\n",
      "DB04395\n",
      "DB04396\n",
      "DB04397\n",
      "DB04398\n",
      "DB04400\n",
      "DB04401\n",
      "DB04404\n",
      "DB04405\n",
      "DB04406\n",
      "DB04407\n",
      "DB04408\n",
      "DB04409\n",
      "DB04410\n",
      "DB04411\n",
      "DB04414\n",
      "DB04415\n",
      "DB04416\n",
      "DB04417\n",
      "DB04418\n",
      "DB04419\n",
      "DB04421\n",
      "DB04422\n",
      "DB04423\n",
      "DB04424\n",
      "DB04425\n",
      "DB04426\n",
      "DB04427\n",
      "DB04429\n",
      "DB04430\n",
      "DB04431\n",
      "DB04432\n",
      "DB04433\n",
      "DB04434\n",
      "DB04436\n",
      "DB04437\n",
      "DB04438\n",
      "DB04439\n",
      "DB04440\n",
      "DB04441\n",
      "DB04442\n",
      "DB04444\n",
      "DB04445\n",
      "DB04446\n",
      "DB04447\n",
      "DB04448\n",
      "DB04449\n",
      "DB04450\n",
      "DB04451\n",
      "DB04452\n",
      "DB04453\n",
      "DB04454\n",
      "DB04455\n",
      "DB04456\n",
      "DB04457\n",
      "DB04458\n",
      "DB04459\n",
      "DB04460\n",
      "DB04461\n",
      "DB04462\n",
      "DB04463\n",
      "DB04464\n",
      "DB04465\n",
      "DB04466\n",
      "DB04467\n",
      "DB04468\n",
      "DB04469\n",
      "DB04470\n",
      "DB04471\n",
      "DB04472\n",
      "DB04473\n",
      "DB04474\n",
      "DB04476\n",
      "DB04477\n",
      "DB04478\n",
      "DB04479\n",
      "DB04480\n",
      "DB04481\n",
      "DB04482\n",
      "DB04483\n",
      "DB04484\n",
      "DB04485\n",
      "DB04486\n",
      "DB04487\n",
      "DB04488\n",
      "DB04489\n",
      "DB04490\n",
      "DB04491\n",
      "DB04492\n",
      "DB04493\n",
      "DB04494\n",
      "DB04495\n",
      "DB04496\n",
      "DB04497\n",
      "DB04498\n",
      "DB04499\n",
      "DB04500\n",
      "DB04501\n",
      "DB04502\n",
      "DB04503\n",
      "DB04504\n",
      "DB04505\n",
      "DB04506\n",
      "DB04508\n",
      "DB04509\n",
      "DB04510\n",
      "DB04511\n",
      "DB04512\n",
      "DB04513\n",
      "DB04514\n",
      "DB04515\n",
      "DB04516\n",
      "DB04517\n",
      "DB04518\n",
      "DB04519\n",
      "DB04520\n",
      "DB04521\n",
      "DB04522\n",
      "DB04523\n",
      "DB04524\n",
      "DB04525\n",
      "DB04526\n",
      "DB04527\n",
      "DB04528\n",
      "DB04529\n",
      "DB04530\n",
      "DB04531\n",
      "DB04532\n",
      "DB04533\n",
      "DB04534\n",
      "DB04537\n",
      "DB04538\n",
      "DB04539\n",
      "DB04540\n",
      "DB04541\n",
      "DB04542\n",
      "DB04543\n",
      "DB04544\n",
      "DB04545\n",
      "DB04546\n",
      "DB04547\n",
      "DB04548\n",
      "DB04549\n",
      "DB04551\n",
      "DB04552\n",
      "DB04553\n",
      "DB04554\n",
      "DB04555\n",
      "DB04556\n",
      "DB04557\n",
      "DB04559\n",
      "DB04560\n",
      "DB04561\n",
      "DB04562\n",
      "DB04563\n",
      "DB04564\n",
      "DB04565\n",
      "DB04566\n",
      "DB04567\n",
      "DB04568\n",
      "DB04569\n",
      "DB04570\n",
      "DB04571\n",
      "DB04572\n",
      "DB04573\n",
      "DB04574\n",
      "DB04575\n",
      "DB04576\n",
      "DB04577\n",
      "DB04578\n",
      "DB04579\n",
      "DB04580\n",
      "DB04581\n",
      "DB04582\n",
      "DB04583\n",
      "DB04584\n",
      "DB04585\n",
      "DB04586\n",
      "DB04587\n",
      "DB04588\n",
      "DB04590\n",
      "DB04591\n",
      "DB04592\n",
      "DB04593\n",
      "DB04594\n",
      "DB04595\n",
      "DB04596\n",
      "DB04597\n",
      "DB04598\n",
      "DB04599\n",
      "DB04600\n",
      "DB04601\n",
      "DB04602\n",
      "DB04603\n",
      "DB04604\n",
      "DB04605\n",
      "DB04606\n",
      "DB04607\n",
      "DB04608\n",
      "DB04609\n",
      "DB04610\n",
      "DB04612\n",
      "DB04613\n",
      "DB04614\n",
      "DB04615\n",
      "DB04616\n",
      "DB04617\n",
      "DB04618\n",
      "DB04619\n",
      "DB04620\n",
      "DB04622\n",
      "DB04623\n",
      "DB04624\n",
      "DB04626\n",
      "DB04627\n",
      "DB04628\n",
      "DB04629\n",
      "DB04630\n",
      "DB04631\n",
      "DB04632\n",
      "DB04633\n",
      "DB04634\n",
      "DB04636\n",
      "DB04637\n",
      "DB04638\n",
      "DB04639\n",
      "DB04640\n",
      "DB04641\n",
      "DB04642\n",
      "DB04643\n",
      "DB04644\n",
      "DB04645\n",
      "DB04646\n",
      "DB04647\n",
      "DB04648\n",
      "DB04649\n",
      "DB04650\n",
      "DB04651\n",
      "DB04652\n",
      "DB04653\n",
      "DB04654\n",
      "DB04655\n",
      "DB04656\n",
      "DB04657\n",
      "DB04658\n",
      "DB04659\n",
      "DB04660\n",
      "DB04661\n",
      "DB04662\n",
      "DB04663\n",
      "DB04664\n",
      "DB04665\n",
      "DB04666\n",
      "DB04667\n",
      "DB04668\n",
      "DB04669\n",
      "DB04671\n",
      "DB04672\n",
      "DB04673\n",
      "DB04674\n",
      "DB04676\n",
      "DB04677\n",
      "DB04678\n",
      "DB04679\n",
      "DB04680\n",
      "DB04681\n",
      "DB04682\n",
      "DB04683\n",
      "DB04684\n",
      "DB04685\n",
      "DB04686\n",
      "DB04687\n",
      "DB04688\n",
      "DB04689\n",
      "DB04690\n",
      "DB04691\n",
      "DB04692\n",
      "DB04693\n",
      "DB04694\n",
      "DB04695\n",
      "DB04696\n",
      "DB04697\n",
      "DB04698\n",
      "DB04699\n",
      "DB04700\n",
      "DB04701\n",
      "DB04702\n",
      "DB04703\n",
      "DB04704\n",
      "DB04705\n",
      "DB04706\n",
      "DB04707\n",
      "DB04708\n",
      "DB04709\n",
      "DB04710\n",
      "DB04711\n",
      "DB04712\n",
      "DB04713\n",
      "DB04714\n",
      "DB04715\n",
      "DB04716\n",
      "DB04717\n",
      "DB04718\n",
      "DB04719\n",
      "DB04720\n",
      "DB04721\n",
      "DB04722\n",
      "DB04723\n",
      "DB04724\n",
      "DB04725\n",
      "DB04726\n",
      "DB04727\n",
      "DB04728\n",
      "DB04729\n",
      "DB04731\n",
      "DB04732\n",
      "DB04733\n",
      "DB04734\n",
      "DB04735\n",
      "DB04736\n",
      "DB04737\n",
      "DB04738\n",
      "DB04739\n",
      "DB04740\n",
      "DB04741\n",
      "DB04742\n",
      "DB04743\n",
      "DB04744\n",
      "DB04745\n",
      "DB04746\n",
      "DB04747\n",
      "DB04748\n",
      "DB04749\n",
      "DB04750\n",
      "DB04751\n",
      "DB04752\n",
      "DB04753\n",
      "DB04754\n",
      "DB04755\n",
      "DB04756\n",
      "DB04757\n",
      "DB04758\n",
      "DB04759\n",
      "DB04760\n",
      "DB04761\n",
      "DB04762\n",
      "DB04763\n",
      "DB04764\n",
      "DB04765\n",
      "DB04767\n",
      "DB04768\n",
      "DB04769\n",
      "DB04770\n",
      "DB04771\n",
      "DB04772\n",
      "DB04773\n",
      "DB04774\n",
      "DB04775\n",
      "DB04776\n",
      "DB04777\n",
      "DB04778\n",
      "DB04779\n",
      "DB04780\n",
      "DB04781\n",
      "DB04782\n",
      "DB04783\n",
      "DB04784\n",
      "DB04785\n",
      "DB04786\n",
      "DB04787\n",
      "DB04788\n",
      "DB04789\n",
      "DB04790\n",
      "DB04791\n",
      "DB04792\n",
      "DB04793\n",
      "DB04794\n",
      "DB04795\n",
      "DB04796\n",
      "DB04797\n",
      "DB04798\n",
      "DB04799\n",
      "DB04800\n",
      "DB04801\n",
      "DB04802\n",
      "DB04803\n",
      "DB04804\n",
      "DB04805\n",
      "DB04806\n",
      "DB04807\n",
      "DB04808\n",
      "DB04809\n",
      "DB04810\n",
      "DB04811\n",
      "DB04812\n",
      "DB04813\n",
      "DB04814\n",
      "DB04815\n",
      "DB04816\n",
      "DB04817\n",
      "DB04818\n",
      "DB04819\n",
      "DB04820\n",
      "DB04821\n",
      "DB04822\n",
      "DB04823\n",
      "DB04824\n",
      "DB04825\n",
      "DB04826\n",
      "DB04827\n",
      "DB04828\n",
      "DB04829\n",
      "DB04830\n",
      "DB04831\n",
      "DB04832\n",
      "DB04833\n",
      "DB04834\n",
      "DB04835\n",
      "DB04836\n",
      "DB04837\n",
      "DB04838\n",
      "DB04839\n",
      "DB04840\n",
      "DB04841\n",
      "DB04842\n",
      "DB04843\n",
      "DB04844\n",
      "DB04845\n",
      "DB04846\n",
      "DB04847\n",
      "DB04848\n",
      "DB04849\n",
      "DB04850\n",
      "DB04851\n",
      "DB04852\n",
      "DB04853\n",
      "DB04854\n",
      "DB04855\n",
      "DB04856\n",
      "DB04857\n",
      "DB04858\n",
      "DB04859\n",
      "DB04860\n",
      "DB04861\n",
      "DB04862\n",
      "DB04863\n",
      "DB04864\n",
      "DB04865\n",
      "DB04866\n",
      "DB04867\n",
      "DB04868\n",
      "DB04869\n",
      "DB04870\n",
      "DB04871\n",
      "DB04872\n",
      "DB04873\n",
      "DB04874\n",
      "DB04875\n",
      "DB04876\n",
      "DB04877\n",
      "DB04878\n",
      "DB04879\n",
      "DB04880\n",
      "DB04881\n",
      "DB04882\n",
      "DB04883\n",
      "DB04884\n",
      "DB04885\n",
      "DB04886\n",
      "DB04887\n",
      "DB04888\n",
      "DB04889\n",
      "DB04890\n",
      "DB04891\n",
      "DB04892\n",
      "DB04893\n",
      "DB04894\n",
      "DB04895\n",
      "DB04896\n",
      "DB04897\n",
      "DB04898\n",
      "DB04899\n",
      "DB04900\n",
      "DB04901\n",
      "DB04903\n",
      "DB04904\n",
      "DB04905\n",
      "DB04907\n",
      "DB04908\n",
      "DB04909\n",
      "DB04910\n",
      "DB04911\n",
      "DB04912\n",
      "DB04914\n",
      "DB04915\n",
      "DB04917\n",
      "DB04918\n",
      "DB04919\n",
      "DB04920\n",
      "DB04921\n",
      "DB04923\n",
      "DB04924\n",
      "DB04925\n",
      "DB04926\n",
      "DB04928\n",
      "DB04929\n",
      "DB04930\n",
      "DB04931\n",
      "DB04932\n",
      "DB04933\n",
      "DB04934\n",
      "DB04936\n",
      "DB04938\n",
      "DB04941\n",
      "DB04942\n",
      "DB04943\n",
      "DB04944\n",
      "DB04945\n",
      "DB04946\n",
      "DB04947\n",
      "DB04948\n",
      "DB04949\n",
      "DB04950\n",
      "DB04951\n",
      "DB04952\n",
      "DB04953\n",
      "DB04954\n",
      "DB04955\n",
      "DB04956\n",
      "DB04957\n",
      "DB04958\n",
      "DB04959\n",
      "DB04960\n",
      "DB04961\n",
      "DB04962\n",
      "DB04963\n",
      "DB04964\n",
      "DB04967\n",
      "DB04968\n",
      "DB04969\n",
      "DB04970\n",
      "DB04971\n",
      "DB04972\n",
      "DB04973\n",
      "DB04974\n",
      "DB04975\n",
      "DB04976\n",
      "DB04977\n",
      "DB04978\n",
      "DB04979\n",
      "DB04980\n",
      "DB04981\n",
      "DB04982\n",
      "DB04983\n",
      "DB04985\n",
      "DB04986\n",
      "DB04987\n",
      "DB04988\n",
      "DB04989\n",
      "DB04991\n",
      "DB04992\n",
      "DB04995\n",
      "DB04996\n",
      "DB04997\n",
      "DB04998\n",
      "DB04999\n",
      "DB05000\n",
      "DB05001\n",
      "DB05003\n",
      "DB05004\n",
      "DB05006\n",
      "DB05009\n",
      "DB05010\n",
      "DB05011\n",
      "DB05012\n",
      "DB05013\n",
      "DB05014\n",
      "DB05015\n",
      "DB05016\n",
      "DB05017\n",
      "DB05018\n",
      "DB05019\n",
      "DB05020\n",
      "DB05021\n",
      "DB05022\n",
      "DB05023\n",
      "DB05024\n",
      "DB05025\n",
      "DB05027\n",
      "DB05029\n",
      "DB05032\n",
      "DB05033\n",
      "DB05034\n",
      "DB05035\n",
      "DB05036\n",
      "DB05038\n",
      "DB05039\n",
      "DB05040\n",
      "DB05042\n",
      "DB05043\n",
      "DB05044\n",
      "DB05045\n",
      "DB05046\n",
      "DB05047\n",
      "DB05048\n",
      "DB05049\n",
      "DB05050\n",
      "DB05051\n",
      "DB05052\n",
      "DB05053\n",
      "DB05054\n",
      "DB05055\n",
      "DB05056\n",
      "DB05057\n",
      "DB05059\n",
      "DB05060\n",
      "DB05061\n",
      "DB05063\n",
      "DB05064\n",
      "DB05068\n",
      "DB05069\n",
      "DB05070\n",
      "DB05071\n",
      "DB05072\n",
      "DB05075\n",
      "DB05076\n",
      "DB05077\n",
      "DB05078\n",
      "DB05079\n",
      "DB05080\n",
      "DB05081\n",
      "DB05082\n",
      "DB05084\n",
      "DB05085\n",
      "DB05087\n",
      "DB05088\n",
      "DB05089\n",
      "DB05090\n",
      "DB05091\n",
      "DB05092\n",
      "DB05093\n",
      "DB05095\n",
      "DB05096\n",
      "DB05097\n",
      "DB05098\n",
      "DB05099\n",
      "DB05100\n",
      "DB05101\n",
      "DB05102\n",
      "DB05103\n",
      "DB05104\n",
      "DB05105\n",
      "DB05106\n",
      "DB05107\n",
      "DB05108\n",
      "DB05109\n",
      "DB05110\n",
      "DB05111\n",
      "DB05112\n",
      "DB05113\n",
      "DB05114\n",
      "DB05115\n",
      "DB05116\n",
      "DB05117\n",
      "DB05118\n",
      "DB05119\n",
      "DB05120\n",
      "DB05121\n",
      "DB05122\n",
      "DB05123\n",
      "DB05124\n",
      "DB05125\n",
      "DB05126\n",
      "DB05127\n",
      "DB05128\n",
      "DB05129\n",
      "DB05130\n",
      "DB05131\n",
      "DB05132\n",
      "DB05133\n",
      "DB05134\n",
      "DB05135\n",
      "DB05136\n",
      "DB05137\n",
      "DB05138\n",
      "DB05139\n",
      "DB05140\n",
      "DB05141\n",
      "DB05142\n",
      "DB05143\n",
      "DB05144\n",
      "DB05145\n",
      "DB05146\n",
      "DB05147\n",
      "DB05148\n",
      "DB05149\n",
      "DB05150\n",
      "DB05151\n",
      "DB05152\n",
      "DB05154\n",
      "DB05155\n",
      "DB05156\n",
      "DB05157\n",
      "DB05158\n",
      "DB05159\n",
      "DB05160\n",
      "DB05161\n",
      "DB05163\n",
      "DB05164\n",
      "DB05165\n",
      "DB05166\n",
      "DB05167\n",
      "DB05168\n",
      "DB05169\n",
      "DB05170\n",
      "DB05171\n",
      "DB05172\n",
      "DB05173\n",
      "DB05174\n",
      "DB05177\n",
      "DB05178\n",
      "DB05179\n",
      "DB05180\n",
      "DB05181\n",
      "DB05182\n",
      "DB05183\n",
      "DB05184\n",
      "DB05185\n",
      "DB05186\n",
      "DB05187\n",
      "DB05188\n",
      "DB05189\n",
      "DB05190\n",
      "DB05191\n",
      "DB05192\n",
      "DB05194\n",
      "DB05195\n",
      "DB05196\n",
      "DB05197\n",
      "DB05198\n",
      "DB05199\n",
      "DB05200\n",
      "DB05201\n",
      "DB05202\n",
      "DB05203\n",
      "DB05204\n",
      "DB05205\n",
      "DB05207\n",
      "DB05209\n",
      "DB05210\n",
      "DB05211\n",
      "DB05212\n",
      "DB05214\n",
      "DB05217\n",
      "DB05218\n",
      "DB05219\n",
      "DB05220\n",
      "DB05222\n",
      "DB05223\n",
      "DB05224\n",
      "DB05225\n",
      "DB05226\n",
      "DB05227\n",
      "DB05228\n",
      "DB05229\n",
      "DB05230\n",
      "DB05232\n",
      "DB05233\n",
      "DB05234\n",
      "DB05235\n",
      "DB05236\n",
      "DB05237\n",
      "DB05239\n",
      "DB05241\n",
      "DB05242\n",
      "DB05243\n",
      "DB05244\n",
      "DB05245\n",
      "DB05246\n",
      "DB05249\n",
      "DB05252\n",
      "DB05253\n",
      "DB05254\n",
      "DB05255\n",
      "DB05257\n",
      "DB05258\n",
      "DB05259\n",
      "DB05260\n",
      "DB05262\n",
      "DB05263\n",
      "DB05264\n",
      "DB05265\n",
      "DB05266\n",
      "DB05268\n",
      "DB05271\n",
      "DB05273\n",
      "DB05276\n",
      "DB05282\n",
      "DB05284\n",
      "DB05285\n",
      "DB05288\n",
      "DB05289\n",
      "DB05290\n",
      "DB05292\n",
      "DB05293\n",
      "DB05294\n",
      "DB05295\n",
      "DB05296\n",
      "DB05297\n",
      "DB05298\n",
      "DB05299\n",
      "DB05300\n",
      "DB05301\n",
      "DB05303\n",
      "DB05304\n",
      "DB05305\n",
      "DB05306\n",
      "DB05308\n",
      "DB05309\n",
      "DB05310\n",
      "DB05311\n",
      "DB05312\n",
      "DB05313\n",
      "DB05315\n",
      "DB05316\n",
      "DB05317\n",
      "DB05319\n",
      "DB05320\n",
      "DB05321\n",
      "DB05322\n",
      "DB05325\n",
      "DB05326\n",
      "DB05327\n",
      "DB05328\n",
      "DB05329\n",
      "DB05330\n",
      "DB05332\n",
      "DB05333\n",
      "DB05336\n",
      "DB05337\n",
      "DB05339\n",
      "DB05340\n",
      "DB05343\n",
      "DB05344\n",
      "DB05345\n",
      "DB05346\n",
      "DB05351\n",
      "DB05352\n",
      "DB05353\n",
      "DB05361\n",
      "DB05362\n",
      "DB05363\n",
      "DB05364\n",
      "DB05367\n",
      "DB05368\n",
      "DB05369\n",
      "DB05371\n",
      "DB05374\n",
      "DB05377\n",
      "DB05380\n",
      "DB05381\n",
      "DB05382\n",
      "DB05383\n",
      "DB05384\n",
      "DB05385\n",
      "DB05386\n",
      "DB05387\n",
      "DB05389\n",
      "DB05390\n",
      "DB05391\n",
      "DB05393\n",
      "DB05394\n",
      "DB05395\n",
      "DB05396\n",
      "DB05398\n",
      "DB05399\n",
      "DB05400\n",
      "DB05403\n",
      "DB05404\n",
      "DB05405\n",
      "DB05406\n",
      "DB05407\n",
      "DB05408\n",
      "DB05409\n",
      "DB05410\n",
      "DB05411\n",
      "DB05412\n",
      "DB05413\n",
      "DB05414\n",
      "DB05415\n",
      "DB05416\n",
      "DB05417\n",
      "DB05418\n",
      "DB05419\n",
      "DB05420\n",
      "DB05421\n",
      "DB05422\n",
      "DB05423\n",
      "DB05424\n",
      "DB05426\n",
      "DB05427\n",
      "DB05428\n",
      "DB05429\n",
      "DB05430\n",
      "DB05431\n",
      "DB05432\n",
      "DB05433\n",
      "DB05434\n",
      "DB05437\n",
      "DB05438\n",
      "DB05439\n",
      "DB05440\n",
      "DB05441\n",
      "DB05442\n",
      "DB05443\n",
      "DB05444\n",
      "DB05445\n",
      "DB05446\n",
      "DB05447\n",
      "DB05448\n",
      "DB05449\n",
      "DB05450\n",
      "DB05451\n",
      "DB05452\n",
      "DB05454\n",
      "DB05455\n",
      "DB05456\n",
      "DB05457\n",
      "DB05458\n",
      "DB05459\n",
      "DB05460\n",
      "DB05461\n",
      "DB05462\n",
      "DB05463\n",
      "DB05464\n",
      "DB05465\n",
      "DB05466\n",
      "DB05467\n",
      "DB05468\n",
      "DB05469\n",
      "DB05470\n",
      "DB05471\n",
      "DB05472\n",
      "DB05473\n",
      "DB05474\n",
      "DB05475\n",
      "DB05476\n",
      "DB05477\n",
      "DB05478\n",
      "DB05479\n",
      "DB05480\n",
      "DB05481\n",
      "DB05482\n",
      "DB05483\n",
      "DB05484\n",
      "DB05485\n",
      "DB05487\n",
      "DB05488\n",
      "DB05489\n",
      "DB05490\n",
      "DB05491\n",
      "DB05492\n",
      "DB05493\n",
      "DB05494\n",
      "DB05495\n",
      "DB05496\n",
      "DB05498\n",
      "DB05499\n",
      "DB05500\n",
      "DB05501\n",
      "DB05502\n",
      "DB05505\n",
      "DB05506\n",
      "DB05507\n",
      "DB05509\n",
      "DB05511\n",
      "DB05512\n",
      "DB05513\n",
      "DB05514\n",
      "DB05516\n",
      "DB05518\n",
      "DB05519\n",
      "DB05520\n",
      "DB05521\n",
      "DB05524\n",
      "DB05525\n",
      "DB05528\n",
      "DB05530\n",
      "DB05531\n",
      "DB05532\n",
      "DB05533\n",
      "DB05540\n",
      "DB05541\n",
      "DB05542\n",
      "DB05545\n",
      "DB05549\n",
      "DB05550\n",
      "DB05552\n",
      "DB05553\n",
      "DB05555\n",
      "DB05559\n",
      "DB05560\n",
      "DB05562\n",
      "DB05565\n",
      "DB05575\n",
      "DB05578\n",
      "DB05580\n",
      "DB05584\n",
      "DB05585\n",
      "DB05586\n",
      "DB05590\n",
      "DB05592\n",
      "DB05594\n",
      "DB05595\n",
      "DB05596\n",
      "DB05599\n",
      "DB05606\n",
      "DB05607\n",
      "DB05608\n",
      "DB05611\n",
      "DB05616\n",
      "DB05620\n",
      "DB05624\n",
      "DB05625\n",
      "DB05626\n",
      "DB05630\n",
      "DB05631\n",
      "DB05633\n",
      "DB05638\n",
      "DB05642\n",
      "DB05643\n",
      "DB05644\n",
      "DB05645\n",
      "DB05649\n",
      "DB05650\n",
      "DB05652\n",
      "DB05653\n",
      "DB05656\n",
      "DB05659\n",
      "DB05660\n",
      "DB05662\n",
      "DB05667\n",
      "DB05668\n",
      "DB05670\n",
      "DB05671\n",
      "DB05675\n",
      "DB05676\n",
      "DB05678\n",
      "DB05679\n",
      "DB05680\n",
      "DB05683\n",
      "DB05685\n",
      "DB05686\n",
      "DB05687\n",
      "DB05688\n",
      "DB05695\n",
      "DB05698\n",
      "DB05705\n",
      "DB05706\n",
      "DB05708\n",
      "DB05710\n",
      "DB05712\n",
      "DB05713\n",
      "DB05714\n",
      "DB05718\n",
      "DB05719\n",
      "DB05721\n",
      "DB05722\n",
      "DB05723\n",
      "DB05724\n",
      "DB05730\n",
      "DB05732\n",
      "DB05735\n",
      "DB05736\n",
      "DB05737\n",
      "DB05738\n",
      "DB05739\n",
      "DB05740\n",
      "DB05741\n",
      "DB05742\n",
      "DB05744\n",
      "DB05746\n",
      "DB05747\n",
      "DB05749\n",
      "DB05750\n",
      "DB05751\n",
      "DB05752\n",
      "DB05753\n",
      "DB05754\n",
      "DB05755\n",
      "DB05756\n",
      "DB05757\n",
      "DB05758\n",
      "DB05765\n",
      "DB05766\n",
      "DB05767\n",
      "DB05768\n",
      "DB05769\n",
      "DB05771\n",
      "DB05772\n",
      "DB05773\n",
      "DB05775\n",
      "DB05776\n",
      "DB05777\n",
      "DB05778\n",
      "DB05779\n",
      "DB05780\n",
      "DB05785\n",
      "DB05786\n",
      "DB05787\n",
      "DB05789\n",
      "DB05790\n",
      "DB05791\n",
      "DB05792\n",
      "DB05793\n",
      "DB05794\n",
      "DB05796\n",
      "DB05797\n",
      "DB05798\n",
      "DB05799\n",
      "DB05800\n",
      "DB05801\n",
      "DB05803\n",
      "DB05804\n",
      "DB05805\n",
      "DB05806\n",
      "DB05807\n",
      "DB05808\n",
      "DB05809\n",
      "DB05810\n",
      "DB05811\n",
      "DB05812\n",
      "DB05814\n",
      "DB05815\n",
      "DB05817\n",
      "DB05818\n",
      "DB05819\n",
      "DB05820\n",
      "DB05821\n",
      "DB05824\n",
      "DB05825\n",
      "DB05826\n",
      "DB05827\n",
      "DB05828\n",
      "DB05829\n",
      "DB05830\n",
      "DB05831\n",
      "DB05832\n",
      "DB05834\n",
      "DB05835\n",
      "DB05836\n",
      "DB05837\n",
      "DB05838\n",
      "DB05839\n",
      "DB05840\n",
      "DB05841\n",
      "DB05842\n",
      "DB05843\n",
      "DB05845\n",
      "DB05846\n",
      "DB05848\n",
      "DB05849\n",
      "DB05851\n",
      "DB05852\n",
      "DB05854\n",
      "DB05855\n",
      "DB05856\n",
      "DB05857\n",
      "DB05858\n",
      "DB05859\n",
      "DB05860\n",
      "DB05861\n",
      "DB05863\n",
      "DB05864\n",
      "DB05865\n",
      "DB05866\n",
      "DB05867\n",
      "DB05868\n",
      "DB05869\n",
      "DB05870\n",
      "DB05871\n",
      "DB05873\n",
      "DB05874\n",
      "DB05875\n",
      "DB05879\n",
      "DB05880\n",
      "DB05881\n",
      "DB05882\n",
      "DB05883\n",
      "DB05884\n",
      "DB05885\n",
      "DB05886\n",
      "DB05887\n",
      "DB05888\n",
      "DB05889\n",
      "DB05890\n",
      "DB05892\n",
      "DB05894\n",
      "DB05895\n",
      "DB05896\n",
      "DB05897\n",
      "DB05898\n",
      "DB05899\n",
      "DB05903\n",
      "DB05904\n",
      "DB05905\n",
      "DB05906\n",
      "DB05911\n",
      "DB05912\n",
      "DB05913\n",
      "DB05915\n",
      "DB05916\n",
      "DB05918\n",
      "DB05919\n",
      "DB05920\n",
      "DB05924\n",
      "DB05928\n",
      "DB05929\n",
      "DB05930\n",
      "DB05931\n",
      "DB05932\n",
      "DB05934\n",
      "DB05936\n",
      "DB05938\n",
      "DB05939\n",
      "DB05941\n",
      "DB05942\n",
      "DB05943\n",
      "DB05944\n",
      "DB05945\n",
      "DB05950\n",
      "DB05956\n",
      "DB05959\n",
      "DB05961\n",
      "DB05964\n",
      "DB05966\n",
      "DB05967\n",
      "DB05968\n",
      "DB05969\n",
      "DB05971\n",
      "DB05973\n",
      "DB05974\n",
      "DB05983\n",
      "DB05984\n",
      "DB05990\n",
      "DB05992\n",
      "DB05993\n",
      "DB05996\n",
      "DB06005\n",
      "DB06011\n",
      "DB06013\n",
      "DB06014\n",
      "DB06016\n",
      "DB06021\n",
      "DB06022\n",
      "DB06039\n",
      "DB06040\n",
      "DB06042\n",
      "DB06043\n",
      "DB06045\n",
      "DB06049\n",
      "DB06050\n",
      "DB06058\n",
      "DB06061\n",
      "DB06063\n",
      "DB06064\n",
      "DB06069\n",
      "DB06070\n",
      "DB06071\n",
      "DB06073\n",
      "DB06075\n",
      "DB06077\n",
      "DB06080\n",
      "DB06081\n",
      "DB06082\n",
      "DB06083\n",
      "DB06087\n",
      "DB06089\n",
      "DB06090\n",
      "DB06091\n",
      "DB06093\n",
      "DB06094\n",
      "DB06096\n",
      "DB06097\n",
      "DB06098\n",
      "DB06101\n",
      "DB06103\n",
      "DB06106\n",
      "DB06109\n",
      "DB06111\n",
      "DB06112\n",
      "DB06116\n",
      "DB06117\n",
      "DB06119\n",
      "DB06124\n",
      "DB06127\n",
      "DB06129\n",
      "DB06130\n",
      "DB06133\n",
      "DB06134\n",
      "DB06137\n",
      "DB06138\n",
      "DB06140\n",
      "DB06144\n",
      "DB06145\n",
      "DB06147\n",
      "DB06148\n",
      "DB06149\n",
      "DB06150\n",
      "DB06151\n",
      "DB06152\n",
      "DB06153\n",
      "DB06154\n",
      "DB06155\n",
      "DB06156\n",
      "DB06157\n",
      "DB06159\n",
      "DB06160\n",
      "DB06161\n",
      "DB06162\n",
      "DB06163\n",
      "DB06166\n",
      "DB06168\n",
      "DB06169\n",
      "DB06171\n",
      "DB06174\n",
      "DB06176\n",
      "DB06177\n",
      "DB06178\n",
      "DB06179\n",
      "DB06180\n",
      "DB06181\n",
      "DB06182\n",
      "DB06184\n",
      "DB06185\n",
      "DB06186\n",
      "DB06187\n",
      "DB06188\n",
      "DB06190\n",
      "DB06191\n",
      "DB06192\n",
      "DB06193\n",
      "DB06194\n",
      "DB06195\n",
      "DB06196\n",
      "DB06197\n",
      "DB06198\n",
      "DB06199\n",
      "DB06200\n",
      "DB06201\n",
      "DB06202\n",
      "DB06203\n",
      "DB06204\n",
      "DB06205\n",
      "DB06206\n",
      "DB06207\n",
      "DB06209\n",
      "DB06210\n",
      "DB06211\n",
      "DB06212\n",
      "DB06213\n",
      "DB06215\n",
      "DB06216\n",
      "DB06217\n",
      "DB06218\n",
      "DB06219\n",
      "DB06224\n",
      "DB06225\n",
      "DB06226\n",
      "DB06228\n",
      "DB06229\n",
      "DB06230\n",
      "DB06231\n",
      "DB06233\n",
      "DB06234\n",
      "DB06235\n",
      "DB06236\n",
      "DB06237\n",
      "DB06239\n",
      "DB06240\n",
      "DB06241\n",
      "DB06243\n",
      "DB06244\n",
      "DB06245\n",
      "DB06246\n",
      "DB06247\n",
      "DB06248\n",
      "DB06249\n",
      "DB06250\n",
      "DB06251\n",
      "DB06253\n",
      "DB06255\n",
      "DB06256\n",
      "DB06257\n",
      "DB06258\n",
      "DB06260\n",
      "DB06261\n",
      "DB06262\n",
      "DB06263\n",
      "DB06264\n",
      "DB06266\n",
      "DB06267\n",
      "DB06268\n",
      "DB06270\n",
      "DB06271\n",
      "DB06272\n",
      "DB06273\n",
      "DB06274\n",
      "DB06276\n",
      "DB06280\n",
      "DB06281\n",
      "DB06282\n",
      "DB06283\n",
      "DB06285\n",
      "DB06287\n",
      "DB06288\n",
      "DB06290\n",
      "DB06292\n",
      "DB06293\n",
      "DB06294\n",
      "DB06295\n",
      "DB06297\n",
      "DB06299\n",
      "DB06302\n",
      "DB06303\n",
      "DB06304\n",
      "DB06305\n",
      "DB06306\n",
      "DB06307\n",
      "DB06309\n",
      "DB06310\n",
      "DB06311\n",
      "DB06313\n",
      "DB06314\n",
      "DB06317\n",
      "DB06318\n",
      "DB06321\n",
      "DB06322\n",
      "DB06323\n",
      "DB06324\n",
      "DB06325\n",
      "DB06326\n",
      "DB06328\n",
      "DB06331\n",
      "DB06333\n",
      "DB06334\n",
      "DB06335\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB06336\n",
      "DB06342\n",
      "DB06343\n",
      "DB06345\n",
      "DB06346\n",
      "DB06347\n",
      "DB06350\n",
      "DB06354\n",
      "DB06355\n",
      "DB06356\n",
      "DB06358\n",
      "DB06360\n",
      "DB06361\n",
      "DB06362\n",
      "DB06364\n",
      "DB06365\n",
      "DB06366\n",
      "DB06367\n",
      "DB06368\n",
      "DB06370\n",
      "DB06371\n",
      "DB06372\n",
      "DB06374\n",
      "DB06376\n",
      "DB06379\n",
      "DB06393\n",
      "DB06394\n",
      "DB06395\n",
      "DB06397\n",
      "DB06399\n",
      "DB06400\n",
      "DB06401\n",
      "DB06402\n",
      "DB06403\n",
      "DB06404\n",
      "DB06405\n",
      "DB06406\n",
      "DB06408\n",
      "DB06409\n",
      "DB06410\n",
      "DB06412\n",
      "DB06413\n",
      "DB06414\n",
      "DB06415\n",
      "DB06419\n",
      "DB06420\n",
      "DB06421\n",
      "DB06422\n",
      "DB06423\n",
      "DB06429\n",
      "DB06431\n",
      "DB06433\n",
      "DB06434\n",
      "DB06435\n",
      "DB06436\n",
      "DB06437\n",
      "DB06439\n",
      "DB06440\n",
      "DB06441\n",
      "DB06442\n",
      "DB06444\n",
      "DB06445\n",
      "DB06446\n",
      "DB06447\n",
      "DB06448\n",
      "DB06449\n",
      "DB06451\n",
      "DB06453\n",
      "DB06454\n",
      "DB06455\n",
      "DB06457\n",
      "DB06458\n",
      "DB06460\n",
      "DB06461\n",
      "DB06462\n",
      "DB06463\n",
      "DB06464\n",
      "DB06465\n",
      "DB06467\n",
      "DB06468\n",
      "DB06469\n",
      "DB06470\n",
      "DB06471\n",
      "DB06472\n",
      "DB06474\n",
      "DB06475\n",
      "DB06477\n",
      "DB06478\n",
      "DB06479\n",
      "DB06480\n",
      "DB06481\n",
      "DB06482\n",
      "DB06485\n",
      "DB06486\n",
      "DB06489\n",
      "DB06492\n",
      "DB06493\n",
      "DB06494\n",
      "DB06495\n",
      "DB06496\n",
      "DB06497\n",
      "DB06498\n",
      "DB06499\n",
      "DB06503\n",
      "DB06504\n",
      "DB06506\n",
      "DB06508\n",
      "DB06510\n",
      "DB06511\n",
      "DB06512\n",
      "DB06515\n",
      "DB06518\n",
      "DB06519\n",
      "DB06521\n",
      "DB06523\n",
      "DB06525\n",
      "DB06527\n",
      "DB06529\n",
      "DB06530\n",
      "DB06532\n",
      "DB06533\n",
      "DB06534\n",
      "DB06535\n",
      "DB06536\n",
      "DB06538\n",
      "DB06543\n",
      "DB06545\n",
      "DB06548\n",
      "DB06549\n",
      "DB06550\n",
      "DB06552\n",
      "DB06554\n",
      "DB06555\n",
      "DB06556\n",
      "DB06557\n",
      "DB06558\n",
      "DB06559\n",
      "DB06560\n",
      "DB06562\n",
      "DB06568\n",
      "DB06569\n",
      "DB06573\n",
      "DB06575\n",
      "DB06576\n",
      "DB06578\n",
      "DB06579\n",
      "DB06580\n",
      "DB06581\n",
      "DB06582\n",
      "DB06584\n",
      "DB06585\n",
      "DB06586\n",
      "DB06587\n",
      "DB06588\n",
      "DB06589\n",
      "DB06590\n",
      "DB06592\n",
      "DB06594\n",
      "DB06595\n",
      "DB06597\n",
      "DB06598\n",
      "DB06599\n",
      "DB06600\n",
      "DB06602\n",
      "DB06603\n",
      "DB06604\n",
      "DB06605\n",
      "DB06606\n",
      "DB06607\n",
      "DB06608\n",
      "DB06609\n",
      "DB06610\n",
      "DB06611\n",
      "DB06612\n",
      "DB06614\n",
      "DB06616\n",
      "DB06618\n",
      "DB06619\n",
      "DB06620\n",
      "DB06622\n",
      "DB06623\n",
      "DB06624\n",
      "DB06625\n",
      "DB06626\n",
      "DB06629\n",
      "DB06630\n",
      "DB06633\n",
      "DB06634\n",
      "DB06635\n",
      "DB06636\n",
      "DB06637\n",
      "DB06638\n",
      "DB06640\n",
      "DB06641\n",
      "DB06642\n",
      "DB06643\n",
      "DB06645\n",
      "DB06647\n",
      "DB06649\n",
      "DB06650\n",
      "DB06651\n",
      "DB06652\n",
      "DB06654\n",
      "DB06655\n",
      "DB06656\n",
      "DB06657\n",
      "DB06659\n",
      "DB06660\n",
      "DB06662\n",
      "DB06663\n",
      "DB06666\n",
      "DB06669\n",
      "DB06670\n",
      "DB06673\n",
      "DB06674\n",
      "DB06677\n",
      "DB06678\n",
      "DB06679\n",
      "DB06680\n",
      "DB06681\n",
      "DB06682\n",
      "DB06683\n",
      "DB06684\n",
      "DB06685\n",
      "DB06688\n",
      "DB06689\n",
      "DB06690\n",
      "DB06691\n",
      "DB06692\n",
      "DB06693\n",
      "DB06694\n",
      "DB06695\n",
      "DB06696\n",
      "DB06697\n",
      "DB06698\n",
      "DB06699\n",
      "DB06700\n",
      "DB06701\n",
      "DB06702\n",
      "DB06703\n",
      "DB06704\n",
      "DB06705\n",
      "DB06706\n",
      "DB06707\n",
      "DB06708\n",
      "DB06709\n",
      "DB06710\n",
      "DB06711\n",
      "DB06712\n",
      "DB06713\n",
      "DB06714\n",
      "DB06715\n",
      "DB06716\n",
      "DB06717\n",
      "DB06718\n",
      "DB06719\n",
      "DB06720\n",
      "DB06721\n",
      "DB06723\n",
      "DB06724\n",
      "DB06725\n",
      "DB06726\n",
      "DB06727\n",
      "DB06728\n",
      "DB06729\n",
      "DB06730\n",
      "DB06731\n",
      "DB06732\n",
      "DB06733\n",
      "DB06734\n",
      "DB06735\n",
      "DB06736\n",
      "DB06737\n",
      "DB06738\n",
      "DB06739\n",
      "DB06740\n",
      "DB06741\n",
      "DB06742\n",
      "DB06743\n",
      "DB06744\n",
      "DB06745\n",
      "DB06746\n",
      "DB06747\n",
      "DB06748\n",
      "DB06749\n",
      "DB06750\n",
      "DB06751\n",
      "DB06752\n",
      "DB06753\n",
      "DB06754\n",
      "DB06755\n",
      "DB06756\n",
      "DB06757\n",
      "DB06759\n",
      "DB06760\n",
      "DB06761\n",
      "DB06762\n",
      "DB06763\n",
      "DB06764\n",
      "DB06766\n",
      "DB06767\n",
      "DB06768\n",
      "DB06769\n",
      "DB06770\n",
      "DB06771\n",
      "DB06772\n",
      "DB06773\n",
      "DB06774\n",
      "DB06775\n",
      "DB06776\n",
      "DB06777\n",
      "DB06778\n",
      "DB06779\n",
      "DB06780\n",
      "DB06781\n",
      "DB06782\n",
      "DB06783\n",
      "DB06784\n",
      "DB06785\n",
      "DB06786\n",
      "DB06787\n",
      "DB06788\n",
      "DB06789\n",
      "DB06791\n",
      "DB06792\n",
      "DB06793\n",
      "DB06794\n",
      "DB06795\n",
      "DB06796\n",
      "DB06797\n",
      "DB06799\n",
      "DB06800\n",
      "DB06801\n",
      "DB06802\n",
      "DB06803\n",
      "DB06804\n",
      "DB06807\n",
      "DB06809\n",
      "DB06810\n",
      "DB06811\n",
      "DB06812\n",
      "DB06813\n",
      "DB06814\n",
      "DB06815\n",
      "DB06816\n",
      "DB06817\n",
      "DB06819\n",
      "DB06820\n",
      "DB06821\n",
      "DB06822\n",
      "DB06823\n",
      "DB06824\n",
      "DB06825\n",
      "DB06826\n",
      "DB06827\n",
      "DB06828\n",
      "DB06829\n",
      "DB06830\n",
      "DB06831\n",
      "DB06832\n",
      "DB06833\n",
      "DB06834\n",
      "DB06835\n",
      "DB06836\n",
      "DB06837\n",
      "DB06838\n",
      "DB06839\n",
      "DB06840\n",
      "DB06841\n",
      "DB06842\n",
      "DB06843\n",
      "DB06844\n",
      "DB06845\n",
      "DB06847\n",
      "DB06848\n",
      "DB06849\n",
      "DB06850\n",
      "DB06851\n",
      "DB06852\n",
      "DB06853\n",
      "DB06855\n",
      "DB06856\n",
      "DB06857\n",
      "DB06858\n",
      "DB06859\n",
      "DB06860\n",
      "DB06861\n",
      "DB06862\n",
      "DB06864\n",
      "DB06865\n",
      "DB06866\n",
      "DB06867\n",
      "DB06868\n",
      "DB06869\n",
      "DB06870\n",
      "DB06871\n",
      "DB06872\n",
      "DB06873\n",
      "DB06874\n",
      "DB06875\n",
      "DB06876\n",
      "DB06877\n",
      "DB06878\n",
      "DB06879\n",
      "DB06880\n",
      "DB06881\n",
      "DB06882\n",
      "DB06883\n",
      "DB06884\n",
      "DB06885\n",
      "DB06886\n",
      "DB06887\n",
      "DB06888\n",
      "DB06889\n",
      "DB06890\n",
      "DB06891\n",
      "DB06892\n",
      "DB06893\n",
      "DB06894\n",
      "DB06896\n",
      "DB06897\n",
      "DB06898\n",
      "DB06899\n",
      "DB06900\n",
      "DB06901\n",
      "DB06902\n",
      "DB06903\n",
      "DB06904\n",
      "DB06905\n",
      "DB06906\n",
      "DB06907\n",
      "DB06908\n",
      "DB06909\n",
      "DB06910\n",
      "DB06911\n",
      "DB06912\n",
      "DB06913\n",
      "DB06914\n",
      "DB06915\n",
      "DB06916\n",
      "DB06917\n",
      "DB06918\n",
      "DB06919\n",
      "DB06920\n",
      "DB06921\n",
      "DB06922\n",
      "DB06923\n",
      "DB06924\n",
      "DB06925\n",
      "DB06926\n",
      "DB06927\n",
      "DB06928\n",
      "DB06929\n",
      "DB06930\n",
      "DB06931\n",
      "DB06932\n",
      "DB06933\n",
      "DB06934\n",
      "DB06935\n",
      "DB06936\n",
      "DB06937\n",
      "DB06938\n",
      "DB06939\n",
      "DB06940\n",
      "DB06941\n",
      "DB06942\n",
      "DB06943\n",
      "DB06944\n",
      "DB06945\n",
      "DB06946\n",
      "DB06947\n",
      "DB06948\n",
      "DB06949\n",
      "DB06950\n",
      "DB06951\n",
      "DB06952\n",
      "DB06953\n",
      "DB06954\n",
      "DB06955\n",
      "DB06956\n",
      "DB06957\n",
      "DB06958\n",
      "DB06959\n",
      "DB06960\n",
      "DB06961\n",
      "DB06962\n",
      "DB06963\n",
      "DB06964\n",
      "DB06965\n",
      "DB06966\n",
      "DB06967\n",
      "DB06968\n",
      "DB06969\n",
      "DB06970\n",
      "DB06971\n",
      "DB06972\n",
      "DB06973\n",
      "DB06974\n",
      "DB06976\n",
      "DB06977\n",
      "DB06978\n",
      "DB06979\n",
      "DB06980\n",
      "DB06981\n",
      "DB06982\n",
      "DB06983\n",
      "DB06984\n",
      "DB06985\n",
      "DB06986\n",
      "DB06987\n",
      "DB06988\n",
      "DB06989\n",
      "DB06990\n",
      "DB06991\n",
      "DB06992\n",
      "DB06993\n",
      "DB06994\n",
      "DB06995\n",
      "DB06996\n",
      "DB06997\n",
      "DB06998\n",
      "DB06999\n",
      "DB07000\n",
      "DB07001\n",
      "DB07002\n",
      "DB07003\n",
      "DB07004\n",
      "DB07005\n",
      "DB07006\n",
      "DB07007\n",
      "DB07008\n",
      "DB07009\n",
      "DB07010\n",
      "DB07011\n",
      "DB07012\n",
      "DB07013\n",
      "DB07014\n",
      "DB07015\n",
      "DB07016\n",
      "DB07017\n",
      "DB07018\n",
      "DB07019\n",
      "DB07020\n",
      "DB07021\n",
      "DB07022\n",
      "DB07023\n",
      "DB07024\n",
      "DB07025\n",
      "DB07026\n",
      "DB07027\n",
      "DB07028\n",
      "DB07029\n",
      "DB07030\n",
      "DB07031\n",
      "DB07032\n",
      "DB07033\n",
      "DB07034\n",
      "DB07035\n",
      "DB07036\n",
      "DB07037\n",
      "DB07038\n",
      "DB07039\n",
      "DB07040\n",
      "DB07041\n",
      "DB07042\n",
      "DB07043\n",
      "DB07044\n",
      "DB07045\n",
      "DB07046\n",
      "DB07047\n",
      "DB07048\n",
      "DB07049\n",
      "DB07050\n",
      "DB07051\n",
      "DB07052\n",
      "DB07053\n",
      "DB07054\n",
      "DB07055\n",
      "DB07056\n",
      "DB07057\n",
      "DB07058\n",
      "DB07059\n",
      "DB07060\n",
      "DB07061\n",
      "DB07062\n",
      "DB07063\n",
      "DB07064\n",
      "DB07065\n",
      "DB07066\n",
      "DB07067\n",
      "DB07068\n",
      "DB07069\n",
      "DB07070\n",
      "DB07071\n",
      "DB07072\n",
      "DB07073\n",
      "DB07074\n",
      "DB07075\n",
      "DB07076\n",
      "DB07077\n",
      "DB07078\n",
      "DB07079\n",
      "DB07080\n",
      "DB07081\n",
      "DB07082\n",
      "DB07083\n",
      "DB07084\n",
      "DB07085\n",
      "DB07086\n",
      "DB07087\n",
      "DB07088\n",
      "DB07089\n",
      "DB07090\n",
      "DB07091\n",
      "DB07092\n",
      "DB07093\n",
      "DB07094\n",
      "DB07095\n",
      "DB07096\n",
      "DB07097\n",
      "DB07098\n",
      "DB07099\n",
      "DB07100\n",
      "DB07101\n",
      "DB07102\n",
      "DB07103\n",
      "DB07104\n",
      "DB07105\n",
      "DB07106\n",
      "DB07107\n",
      "DB07108\n",
      "DB07109\n",
      "DB07110\n",
      "DB07111\n",
      "DB07112\n",
      "DB07113\n",
      "DB07114\n",
      "DB07115\n",
      "DB07116\n",
      "DB07117\n",
      "DB07118\n",
      "DB07119\n",
      "DB07120\n",
      "DB07121\n",
      "DB07122\n",
      "DB07123\n",
      "DB07124\n",
      "DB07125\n",
      "DB07126\n",
      "DB07127\n",
      "DB07128\n",
      "DB07129\n",
      "DB07130\n",
      "DB07131\n",
      "DB07132\n",
      "DB07133\n",
      "DB07134\n",
      "DB07135\n",
      "DB07136\n",
      "DB07137\n",
      "DB07138\n",
      "DB07139\n",
      "DB07140\n",
      "DB07141\n",
      "DB07142\n",
      "DB07143\n",
      "DB07144\n",
      "DB07145\n",
      "DB07146\n",
      "DB07147\n",
      "DB07148\n",
      "DB07149\n",
      "DB07150\n",
      "DB07151\n",
      "DB07152\n",
      "DB07153\n",
      "DB07154\n",
      "DB07155\n",
      "DB07156\n",
      "DB07157\n",
      "DB07158\n",
      "DB07159\n",
      "DB07160\n",
      "DB07161\n",
      "DB07162\n",
      "DB07163\n",
      "DB07164\n",
      "DB07165\n",
      "DB07167\n",
      "DB07168\n",
      "DB07169\n",
      "DB07170\n",
      "DB07171\n",
      "DB07172\n",
      "DB07173\n",
      "DB07174\n",
      "DB07175\n",
      "DB07176\n",
      "DB07177\n",
      "DB07178\n",
      "DB07179\n",
      "DB07180\n",
      "DB07181\n",
      "DB07182\n",
      "DB07183\n",
      "DB07184\n",
      "DB07185\n",
      "DB07186\n",
      "DB07187\n",
      "DB07188\n",
      "DB07189\n",
      "DB07190\n",
      "DB07192\n",
      "DB07193\n",
      "DB07194\n",
      "DB07195\n",
      "DB07196\n",
      "DB07197\n",
      "DB07198\n",
      "DB07199\n",
      "DB07200\n",
      "DB07201\n",
      "DB07202\n",
      "DB07203\n",
      "DB07204\n",
      "DB07205\n",
      "DB07206\n",
      "DB07207\n",
      "DB07208\n",
      "DB07209\n",
      "DB07210\n",
      "DB07211\n",
      "DB07212\n",
      "DB07213\n",
      "DB07215\n",
      "DB07216\n",
      "DB07217\n",
      "DB07218\n",
      "DB07219\n",
      "DB07220\n",
      "DB07221\n",
      "DB07222\n",
      "DB07223\n",
      "DB07224\n",
      "DB07225\n",
      "DB07226\n",
      "DB07227\n",
      "DB07228\n",
      "DB07229\n",
      "DB07230\n",
      "DB07231\n",
      "DB07232\n",
      "DB07233\n",
      "DB07234\n",
      "DB07235\n",
      "DB07236\n",
      "DB07237\n",
      "DB07238\n",
      "DB07239\n",
      "DB07240\n",
      "DB07241\n",
      "DB07242\n",
      "DB07243\n",
      "DB07244\n",
      "DB07245\n",
      "DB07246\n",
      "DB07247\n",
      "DB07248\n",
      "DB07249\n",
      "DB07250\n",
      "DB07251\n",
      "DB07252\n",
      "DB07253\n",
      "DB07254\n",
      "DB07255\n",
      "DB07256\n",
      "DB07257\n",
      "DB07258\n",
      "DB07259\n",
      "DB07260\n",
      "DB07261\n",
      "DB07262\n",
      "DB07263\n",
      "DB07264\n",
      "DB07265\n",
      "DB07266\n",
      "DB07267\n",
      "DB07268\n",
      "DB07269\n",
      "DB07270\n",
      "DB07271\n",
      "DB07272\n",
      "DB07273\n",
      "DB07274\n",
      "DB07275\n",
      "DB07276\n",
      "DB07277\n",
      "DB07278\n",
      "DB07279\n",
      "DB07280\n",
      "DB07281\n",
      "DB07282\n",
      "DB07283\n",
      "DB07284\n",
      "DB07285\n",
      "DB07286\n",
      "DB07287\n",
      "DB07288\n",
      "DB07289\n",
      "DB07290\n",
      "DB07291\n",
      "DB07292\n",
      "DB07293\n",
      "DB07294\n",
      "DB07295\n",
      "DB07296\n",
      "DB07297\n",
      "DB07298\n",
      "DB07299\n",
      "DB07300\n",
      "DB07301\n",
      "DB07302\n",
      "DB07303\n",
      "DB07304\n",
      "DB07305\n",
      "DB07306\n",
      "DB07307\n",
      "DB07308\n",
      "DB07309\n",
      "DB07310\n",
      "DB07311\n",
      "DB07312\n",
      "DB07313\n",
      "DB07314\n",
      "DB07315\n",
      "DB07316\n",
      "DB07317\n",
      "DB07318\n",
      "DB07319\n",
      "DB07320\n",
      "DB07321\n",
      "DB07322\n",
      "DB07323\n",
      "DB07324\n",
      "DB07325\n",
      "DB07326\n",
      "DB07327\n",
      "DB07328\n",
      "DB07329\n",
      "DB07330\n",
      "DB07331\n",
      "DB07332\n",
      "DB07333\n",
      "DB07334\n",
      "DB07335\n",
      "DB07336\n",
      "DB07337\n",
      "DB07338\n",
      "DB07339\n",
      "DB07340\n",
      "DB07341\n",
      "DB07342\n",
      "DB07343\n",
      "DB07344\n",
      "DB07345\n",
      "DB07346\n",
      "DB07347\n",
      "DB07348\n",
      "DB07349\n",
      "DB07350\n",
      "DB07351\n",
      "DB07352\n",
      "DB07353\n",
      "DB07354\n",
      "DB07355\n",
      "DB07356\n",
      "DB07357\n",
      "DB07358\n",
      "DB07359\n",
      "DB07360\n",
      "DB07362\n",
      "DB07363\n",
      "DB07364\n",
      "DB07365\n",
      "DB07366\n",
      "DB07367\n",
      "DB07368\n",
      "DB07369\n",
      "DB07370\n",
      "DB07371\n",
      "DB07373\n",
      "DB07374\n",
      "DB07375\n",
      "DB07376\n",
      "DB07377\n",
      "DB07378\n",
      "DB07379\n",
      "DB07380\n",
      "DB07381\n",
      "DB07382\n",
      "DB07383\n",
      "DB07384\n",
      "DB07385\n",
      "DB07387\n",
      "DB07388\n",
      "DB07389\n",
      "DB07390\n",
      "DB07391\n",
      "DB07392\n",
      "DB07393\n",
      "DB07394\n",
      "DB07395\n",
      "DB07396\n",
      "DB07397\n",
      "DB07398\n",
      "DB07400\n",
      "DB07401\n",
      "DB07402\n",
      "DB07403\n",
      "DB07404\n",
      "DB07405\n",
      "DB07406\n",
      "DB07407\n",
      "DB07408\n",
      "DB07409\n",
      "DB07410\n",
      "DB07411\n",
      "DB07412\n",
      "DB07413\n",
      "DB07414\n",
      "DB07415\n",
      "DB07416\n",
      "DB07418\n",
      "DB07419\n",
      "DB07420\n",
      "DB07421\n",
      "DB07422\n",
      "DB07423\n",
      "DB07424\n",
      "DB07425\n",
      "DB07426\n",
      "DB07427\n",
      "DB07428\n",
      "DB07429\n",
      "DB07430\n",
      "DB07431\n",
      "DB07432\n",
      "DB07433\n",
      "DB07434\n",
      "DB07435\n",
      "DB07436\n",
      "DB07437\n",
      "DB07439\n",
      "DB07440\n",
      "DB07441\n",
      "DB07443\n",
      "DB07444\n",
      "DB07445\n",
      "DB07446\n",
      "DB07447\n",
      "DB07448\n",
      "DB07449\n",
      "DB07450\n",
      "DB07451\n",
      "DB07452\n",
      "DB07453\n",
      "DB07454\n",
      "DB07455\n",
      "DB07456\n",
      "DB07457\n",
      "DB07458\n",
      "DB07459\n",
      "DB07460\n",
      "DB07461\n",
      "DB07462\n",
      "DB07463\n",
      "DB07464\n",
      "DB07465\n",
      "DB07466\n",
      "DB07467\n",
      "DB07468\n",
      "DB07469\n",
      "DB07470\n",
      "DB07471\n",
      "DB07472\n",
      "DB07473\n",
      "DB07474\n",
      "DB07476\n",
      "DB07477\n",
      "DB07478\n",
      "DB07479\n",
      "DB07480\n",
      "DB07481\n",
      "DB07482\n",
      "DB07483\n",
      "DB07484\n",
      "DB07485\n",
      "DB07486\n",
      "DB07487\n",
      "DB07488\n",
      "DB07489\n",
      "DB07490\n",
      "DB07491\n",
      "DB07492\n",
      "DB07493\n",
      "DB07494\n",
      "DB07495\n",
      "DB07496\n",
      "DB07497\n",
      "DB07498\n",
      "DB07499\n",
      "DB07500\n",
      "DB07501\n",
      "DB07502\n",
      "DB07503\n",
      "DB07504\n",
      "DB07505\n",
      "DB07506\n",
      "DB07507\n",
      "DB07508\n",
      "DB07509\n",
      "DB07510\n",
      "DB07511\n",
      "DB07512\n",
      "DB07513\n",
      "DB07514\n",
      "DB07515\n",
      "DB07516\n",
      "DB07517\n",
      "DB07518\n",
      "DB07519\n",
      "DB07520\n",
      "DB07521\n",
      "DB07522\n",
      "DB07524\n",
      "DB07525\n",
      "DB07526\n",
      "DB07527\n",
      "DB07528\n",
      "DB07529\n",
      "DB07530\n",
      "DB07531\n",
      "DB07532\n",
      "DB07533\n",
      "DB07534\n",
      "DB07535\n",
      "DB07536\n",
      "DB07537\n",
      "DB07538\n",
      "DB07539\n",
      "DB07540\n",
      "DB07541\n",
      "DB07542\n",
      "DB07543\n",
      "DB07544\n",
      "DB07545\n",
      "DB07546\n",
      "DB07547\n",
      "DB07548\n",
      "DB07549\n",
      "DB07550\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB07551\n",
      "DB07552\n",
      "DB07553\n",
      "DB07555\n",
      "DB07556\n",
      "DB07557\n",
      "DB07558\n",
      "DB07559\n",
      "DB07560\n",
      "DB07561\n",
      "DB07562\n",
      "DB07563\n",
      "DB07564\n",
      "DB07565\n",
      "DB07567\n",
      "DB07568\n",
      "DB07569\n",
      "DB07570\n",
      "DB07571\n",
      "DB07572\n",
      "DB07573\n",
      "DB07574\n",
      "DB07575\n",
      "DB07577\n",
      "DB07578\n",
      "DB07579\n",
      "DB07580\n",
      "DB07581\n",
      "DB07582\n",
      "DB07583\n",
      "DB07584\n",
      "DB07585\n",
      "DB07586\n",
      "DB07587\n",
      "DB07588\n",
      "DB07589\n",
      "DB07590\n",
      "DB07591\n",
      "DB07592\n",
      "DB07593\n",
      "DB07594\n",
      "DB07595\n",
      "DB07596\n",
      "DB07597\n",
      "DB07598\n",
      "DB07599\n",
      "DB07601\n",
      "DB07602\n",
      "DB07603\n",
      "DB07604\n",
      "DB07605\n",
      "DB07606\n",
      "DB07607\n",
      "DB07608\n",
      "DB07609\n",
      "DB07610\n",
      "DB07611\n",
      "DB07612\n",
      "DB07613\n",
      "DB07614\n",
      "DB07615\n",
      "DB07616\n",
      "DB07617\n",
      "DB07618\n",
      "DB07619\n",
      "DB07620\n",
      "DB07621\n",
      "DB07622\n",
      "DB07623\n",
      "DB07624\n",
      "DB07625\n",
      "DB07626\n",
      "DB07627\n",
      "DB07628\n",
      "DB07629\n",
      "DB07630\n",
      "DB07631\n",
      "DB07632\n",
      "DB07633\n",
      "DB07634\n",
      "DB07635\n",
      "DB07636\n",
      "DB07637\n",
      "DB07638\n",
      "DB07639\n",
      "DB07640\n",
      "DB07641\n",
      "DB07642\n",
      "DB07643\n",
      "DB07644\n",
      "DB07645\n",
      "DB07646\n",
      "DB07647\n",
      "DB07648\n",
      "DB07649\n",
      "DB07650\n",
      "DB07651\n",
      "DB07652\n",
      "DB07653\n",
      "DB07654\n",
      "DB07655\n",
      "DB07657\n",
      "DB07658\n",
      "DB07659\n",
      "DB07660\n",
      "DB07661\n",
      "DB07662\n",
      "DB07663\n",
      "DB07664\n",
      "DB07665\n",
      "DB07666\n",
      "DB07667\n",
      "DB07668\n",
      "DB07669\n",
      "DB07670\n",
      "DB07671\n",
      "DB07672\n",
      "DB07673\n",
      "DB07674\n",
      "DB07675\n",
      "DB07676\n",
      "DB07677\n",
      "DB07678\n",
      "DB07679\n",
      "DB07680\n",
      "DB07681\n",
      "DB07683\n",
      "DB07684\n",
      "DB07685\n",
      "DB07686\n",
      "DB07687\n",
      "DB07688\n",
      "DB07689\n",
      "DB07691\n",
      "DB07692\n",
      "DB07693\n",
      "DB07694\n",
      "DB07695\n",
      "DB07696\n",
      "DB07697\n",
      "DB07698\n",
      "DB07700\n",
      "DB07701\n",
      "DB07702\n",
      "DB07703\n",
      "DB07704\n",
      "DB07705\n",
      "DB07706\n",
      "DB07707\n",
      "DB07708\n",
      "DB07710\n",
      "DB07711\n",
      "DB07712\n",
      "DB07713\n",
      "DB07714\n",
      "DB07715\n",
      "DB07716\n",
      "DB07717\n",
      "DB07718\n",
      "DB07719\n",
      "DB07720\n",
      "DB07721\n",
      "DB07722\n",
      "DB07723\n",
      "DB07724\n",
      "DB07726\n",
      "DB07728\n",
      "DB07729\n",
      "DB07730\n",
      "DB07731\n",
      "DB07732\n",
      "DB07733\n",
      "DB07734\n",
      "DB07735\n",
      "DB07736\n",
      "DB07737\n",
      "DB07738\n",
      "DB07739\n",
      "DB07740\n",
      "DB07741\n",
      "DB07742\n",
      "DB07743\n",
      "DB07744\n",
      "DB07745\n",
      "DB07746\n",
      "DB07747\n",
      "DB07748\n",
      "DB07749\n",
      "DB07750\n",
      "DB07751\n",
      "DB07753\n",
      "DB07754\n",
      "DB07755\n",
      "DB07756\n",
      "DB07757\n",
      "DB07758\n",
      "DB07759\n",
      "DB07760\n",
      "DB07761\n",
      "DB07762\n",
      "DB07763\n",
      "DB07764\n",
      "DB07765\n",
      "DB07766\n",
      "DB07767\n",
      "DB07768\n",
      "DB07769\n",
      "DB07770\n",
      "DB07771\n",
      "DB07772\n",
      "DB07773\n",
      "DB07775\n",
      "DB07776\n",
      "DB07778\n",
      "DB07779\n",
      "DB07780\n",
      "DB07781\n",
      "DB07782\n",
      "DB07783\n",
      "DB07784\n",
      "DB07785\n",
      "DB07786\n",
      "DB07787\n",
      "DB07788\n",
      "DB07789\n",
      "DB07790\n",
      "DB07791\n",
      "DB07792\n",
      "DB07793\n",
      "DB07794\n",
      "DB07795\n",
      "DB07796\n",
      "DB07797\n",
      "DB07798\n",
      "DB07800\n",
      "DB07801\n",
      "DB07802\n",
      "DB07803\n",
      "DB07804\n",
      "DB07805\n",
      "DB07806\n",
      "DB07807\n",
      "DB07808\n",
      "DB07809\n",
      "DB07810\n",
      "DB07811\n",
      "DB07812\n",
      "DB07813\n",
      "DB07814\n",
      "DB07815\n",
      "DB07816\n",
      "DB07817\n",
      "DB07818\n",
      "DB07819\n",
      "DB07820\n",
      "DB07821\n",
      "DB07823\n",
      "DB07824\n",
      "DB07825\n",
      "DB07826\n",
      "DB07827\n",
      "DB07829\n",
      "DB07830\n",
      "DB07831\n",
      "DB07832\n",
      "DB07833\n",
      "DB07834\n",
      "DB07835\n",
      "DB07836\n",
      "DB07837\n",
      "DB07838\n",
      "DB07839\n",
      "DB07840\n",
      "DB07841\n",
      "DB07842\n",
      "DB07843\n",
      "DB07844\n",
      "DB07845\n",
      "DB07846\n",
      "DB07847\n",
      "DB07848\n",
      "DB07849\n",
      "DB07850\n",
      "DB07851\n",
      "DB07852\n",
      "DB07853\n",
      "DB07854\n",
      "DB07855\n",
      "DB07856\n",
      "DB07857\n",
      "DB07858\n",
      "DB07859\n",
      "DB07860\n",
      "DB07861\n",
      "DB07862\n",
      "DB07863\n",
      "DB07864\n",
      "DB07865\n",
      "DB07866\n",
      "DB07867\n",
      "DB07868\n",
      "DB07869\n",
      "DB07870\n",
      "DB07871\n",
      "DB07872\n",
      "DB07873\n",
      "DB07874\n",
      "DB07875\n",
      "DB07876\n",
      "DB07877\n",
      "DB07878\n",
      "DB07879\n",
      "DB07880\n",
      "DB07881\n",
      "DB07882\n",
      "DB07883\n",
      "DB07884\n",
      "DB07885\n",
      "DB07887\n",
      "DB07888\n",
      "DB07889\n",
      "DB07890\n",
      "DB07891\n",
      "DB07892\n",
      "DB07893\n",
      "DB07894\n",
      "DB07895\n",
      "DB07896\n",
      "DB07897\n",
      "DB07898\n",
      "DB07899\n",
      "DB07900\n",
      "DB07901\n",
      "DB07902\n",
      "DB07903\n",
      "DB07905\n",
      "DB07906\n",
      "DB07907\n",
      "DB07908\n",
      "DB07909\n",
      "DB07910\n",
      "DB07911\n",
      "DB07912\n",
      "DB07913\n",
      "DB07914\n",
      "DB07915\n",
      "DB07916\n",
      "DB07917\n",
      "DB07918\n",
      "DB07919\n",
      "DB07920\n",
      "DB07921\n",
      "DB07922\n",
      "DB07923\n",
      "DB07924\n",
      "DB07925\n",
      "DB07926\n",
      "DB07927\n",
      "DB07928\n",
      "DB07929\n",
      "DB07930\n",
      "DB07931\n",
      "DB07932\n",
      "DB07933\n",
      "DB07934\n",
      "DB07935\n",
      "DB07936\n",
      "DB07937\n",
      "DB07938\n",
      "DB07939\n",
      "DB07940\n",
      "DB07941\n",
      "DB07942\n",
      "DB07943\n",
      "DB07944\n",
      "DB07945\n",
      "DB07946\n",
      "DB07947\n",
      "DB07949\n",
      "DB07950\n",
      "DB07951\n",
      "DB07952\n",
      "DB07953\n",
      "DB07954\n",
      "DB07955\n",
      "DB07956\n",
      "DB07957\n",
      "DB07958\n",
      "DB07959\n",
      "DB07960\n",
      "DB07961\n",
      "DB07962\n",
      "DB07963\n",
      "DB07964\n",
      "DB07965\n",
      "DB07966\n",
      "DB07967\n",
      "DB07968\n",
      "DB07969\n",
      "DB07970\n",
      "DB07971\n",
      "DB07972\n",
      "DB07973\n",
      "DB07974\n",
      "DB07975\n",
      "DB07976\n",
      "DB07977\n",
      "DB07978\n",
      "DB07979\n",
      "DB07981\n",
      "DB07982\n",
      "DB07983\n",
      "DB07984\n",
      "DB07985\n",
      "DB07986\n",
      "DB07987\n",
      "DB07988\n",
      "DB07989\n",
      "DB07990\n",
      "DB07991\n",
      "DB07992\n",
      "DB07993\n",
      "DB07994\n",
      "DB07995\n",
      "DB07996\n",
      "DB07997\n",
      "DB07999\n",
      "DB08000\n",
      "DB08001\n",
      "DB08003\n",
      "DB08004\n",
      "DB08005\n",
      "DB08006\n",
      "DB08007\n",
      "DB08008\n",
      "DB08009\n",
      "DB08010\n",
      "DB08011\n",
      "DB08012\n",
      "DB08013\n",
      "DB08014\n",
      "DB08015\n",
      "DB08016\n",
      "DB08017\n",
      "DB08018\n",
      "DB08019\n",
      "DB08020\n",
      "DB08021\n",
      "DB08022\n",
      "DB08023\n",
      "DB08024\n",
      "DB08025\n",
      "DB08026\n",
      "DB08027\n",
      "DB08028\n",
      "DB08029\n",
      "DB08030\n",
      "DB08031\n",
      "DB08032\n",
      "DB08033\n",
      "DB08034\n",
      "DB08035\n",
      "DB08036\n",
      "DB08037\n",
      "DB08038\n",
      "DB08039\n",
      "DB08040\n",
      "DB08041\n",
      "DB08042\n",
      "DB08043\n",
      "DB08044\n",
      "DB08045\n",
      "DB08046\n",
      "DB08047\n",
      "DB08048\n",
      "DB08049\n",
      "DB08050\n",
      "DB08051\n",
      "DB08052\n",
      "DB08053\n",
      "DB08054\n",
      "DB08055\n",
      "DB08056\n",
      "DB08057\n",
      "DB08058\n",
      "DB08059\n",
      "DB08060\n",
      "DB08061\n",
      "DB08062\n",
      "DB08063\n",
      "DB08064\n",
      "DB08065\n",
      "DB08066\n",
      "DB08067\n",
      "DB08068\n",
      "DB08069\n",
      "DB08070\n",
      "DB08071\n",
      "DB08072\n",
      "DB08073\n",
      "DB08074\n",
      "DB08075\n",
      "DB08076\n",
      "DB08077\n",
      "DB08078\n",
      "DB08079\n",
      "DB08080\n",
      "DB08081\n",
      "DB08082\n",
      "DB08083\n",
      "DB08084\n",
      "DB08085\n",
      "DB08086\n",
      "DB08087\n",
      "DB08088\n",
      "DB08089\n",
      "DB08090\n",
      "DB08091\n",
      "DB08092\n",
      "DB08093\n",
      "DB08094\n",
      "DB08095\n",
      "DB08096\n",
      "DB08097\n",
      "DB08098\n",
      "DB08099\n",
      "DB08100\n",
      "DB08101\n",
      "DB08102\n",
      "DB08103\n",
      "DB08104\n",
      "DB08105\n",
      "DB08106\n",
      "DB08107\n",
      "DB08108\n",
      "DB08109\n",
      "DB08110\n",
      "DB08111\n",
      "DB08112\n",
      "DB08113\n",
      "DB08114\n",
      "DB08115\n",
      "DB08116\n",
      "DB08118\n",
      "DB08119\n",
      "DB08120\n",
      "DB08121\n",
      "DB08122\n",
      "DB08123\n",
      "DB08124\n",
      "DB08125\n",
      "DB08126\n",
      "DB08127\n",
      "DB08128\n",
      "DB08129\n",
      "DB08130\n",
      "DB08131\n",
      "DB08132\n",
      "DB08133\n",
      "DB08134\n",
      "DB08135\n",
      "DB08136\n",
      "DB08137\n",
      "DB08138\n",
      "DB08139\n",
      "DB08140\n",
      "DB08141\n",
      "DB08142\n",
      "DB08143\n",
      "DB08144\n",
      "DB08145\n",
      "DB08146\n",
      "DB08147\n",
      "DB08148\n",
      "DB08149\n",
      "DB08150\n",
      "DB08151\n",
      "DB08152\n",
      "DB08153\n",
      "DB08154\n",
      "DB08155\n",
      "DB08156\n",
      "DB08157\n",
      "DB08158\n",
      "DB08159\n",
      "DB08160\n",
      "DB08161\n",
      "DB08162\n",
      "DB08163\n",
      "DB08164\n",
      "DB08165\n",
      "DB08166\n",
      "DB08167\n",
      "DB08168\n",
      "DB08169\n",
      "DB08170\n",
      "DB08171\n",
      "DB08172\n",
      "DB08173\n",
      "DB08174\n",
      "DB08175\n",
      "DB08176\n",
      "DB08177\n",
      "DB08178\n",
      "DB08179\n",
      "DB08180\n",
      "DB08181\n",
      "DB08182\n",
      "DB08184\n",
      "DB08185\n",
      "DB08186\n",
      "DB08187\n",
      "DB08188\n",
      "DB08190\n",
      "DB08191\n",
      "DB08192\n",
      "DB08193\n",
      "DB08194\n",
      "DB08195\n",
      "DB08196\n",
      "DB08197\n",
      "DB08198\n",
      "DB08199\n",
      "DB08200\n",
      "DB08201\n",
      "DB08202\n",
      "DB08203\n",
      "DB08204\n",
      "DB08205\n",
      "DB08206\n",
      "DB08207\n",
      "DB08208\n",
      "DB08209\n",
      "DB08210\n",
      "DB08211\n",
      "DB08212\n",
      "DB08213\n",
      "DB08214\n",
      "DB08215\n",
      "DB08216\n",
      "DB08217\n",
      "DB08218\n",
      "DB08219\n",
      "DB08220\n",
      "DB08221\n",
      "DB08222\n",
      "DB08223\n",
      "DB08224\n",
      "DB08226\n",
      "DB08227\n",
      "DB08228\n",
      "DB08229\n",
      "DB08230\n",
      "DB08231\n",
      "DB08232\n",
      "DB08233\n",
      "DB08234\n",
      "DB08235\n",
      "DB08236\n",
      "DB08237\n",
      "DB08238\n",
      "DB08239\n",
      "DB08240\n",
      "DB08241\n",
      "DB08242\n",
      "DB08244\n",
      "DB08245\n",
      "DB08246\n",
      "DB08247\n",
      "DB08248\n",
      "DB08249\n",
      "DB08250\n",
      "DB08251\n",
      "DB08252\n",
      "DB08253\n",
      "DB08254\n",
      "DB08255\n",
      "DB08256\n",
      "DB08257\n",
      "DB08258\n",
      "DB08259\n",
      "DB08260\n",
      "DB08261\n",
      "DB08262\n",
      "DB08263\n",
      "DB08264\n",
      "DB08265\n",
      "DB08266\n",
      "DB08267\n",
      "DB08268\n",
      "DB08270\n",
      "DB08271\n",
      "DB08272\n",
      "DB08273\n",
      "DB08274\n",
      "DB08275\n",
      "DB08276\n",
      "DB08277\n",
      "DB08278\n",
      "DB08279\n",
      "DB08280\n",
      "DB08281\n",
      "DB08282\n",
      "DB08283\n",
      "DB08284\n",
      "DB08285\n",
      "DB08286\n",
      "DB08287\n",
      "DB08288\n",
      "DB08289\n",
      "DB08291\n",
      "DB08292\n",
      "DB08293\n",
      "DB08294\n",
      "DB08295\n",
      "DB08296\n",
      "DB08297\n",
      "DB08299\n",
      "DB08300\n",
      "DB08301\n",
      "DB08302\n",
      "DB08303\n",
      "DB08304\n",
      "DB08305\n",
      "DB08306\n",
      "DB08307\n",
      "DB08308\n",
      "DB08309\n",
      "DB08310\n",
      "DB08312\n",
      "DB08313\n",
      "DB08314\n",
      "DB08315\n",
      "DB08316\n",
      "DB08317\n",
      "DB08318\n",
      "DB08319\n",
      "DB08320\n",
      "DB08321\n",
      "DB08322\n",
      "DB08323\n",
      "DB08324\n",
      "DB08325\n",
      "DB08326\n",
      "DB08327\n",
      "DB08328\n",
      "DB08329\n",
      "DB08330\n",
      "DB08331\n",
      "DB08332\n",
      "DB08333\n",
      "DB08334\n",
      "DB08335\n",
      "DB08336\n",
      "DB08337\n",
      "DB08338\n",
      "DB08339\n",
      "DB08340\n",
      "DB08341\n",
      "DB08342\n",
      "DB08344\n",
      "DB08345\n",
      "DB08346\n",
      "DB08347\n",
      "DB08348\n",
      "DB08349\n",
      "DB08350\n",
      "DB08351\n",
      "DB08352\n",
      "DB08353\n",
      "DB08354\n",
      "DB08355\n",
      "DB08356\n",
      "DB08357\n",
      "DB08358\n",
      "DB08359\n",
      "DB08360\n",
      "DB08361\n",
      "DB08362\n",
      "DB08363\n",
      "DB08364\n",
      "DB08365\n",
      "DB08366\n",
      "DB08367\n",
      "DB08368\n",
      "DB08369\n",
      "DB08370\n",
      "DB08371\n",
      "DB08372\n",
      "DB08373\n",
      "DB08374\n",
      "DB08375\n",
      "DB08376\n",
      "DB08377\n",
      "DB08378\n",
      "DB08379\n",
      "DB08382\n",
      "DB08383\n",
      "DB08384\n",
      "DB08385\n",
      "DB08386\n",
      "DB08387\n",
      "DB08388\n",
      "DB08389\n",
      "DB08390\n",
      "DB08391\n",
      "DB08392\n",
      "DB08393\n",
      "DB08394\n",
      "DB08395\n",
      "DB08396\n",
      "DB08397\n",
      "DB08398\n",
      "DB08399\n",
      "DB08400\n",
      "DB08401\n",
      "DB08402\n",
      "DB08403\n",
      "DB08404\n",
      "DB08405\n",
      "DB08406\n",
      "DB08407\n",
      "DB08408\n",
      "DB08409\n",
      "DB08410\n",
      "DB08411\n",
      "DB08412\n",
      "DB08413\n",
      "DB08414\n",
      "DB08416\n",
      "DB08418\n",
      "DB08419\n",
      "DB08420\n",
      "DB08421\n",
      "DB08422\n",
      "DB08423\n",
      "DB08424\n",
      "DB08426\n",
      "DB08427\n",
      "DB08428\n",
      "DB08429\n",
      "DB08430\n",
      "DB08431\n",
      "DB08432\n",
      "DB08433\n",
      "DB08434\n",
      "DB08435\n",
      "DB08436\n",
      "DB08437\n",
      "DB08438\n",
      "DB08439\n",
      "DB08440\n",
      "DB08441\n",
      "DB08442\n",
      "DB08443\n",
      "DB08444\n",
      "DB08445\n",
      "DB08446\n",
      "DB08447\n",
      "DB08448\n",
      "DB08449\n",
      "DB08450\n",
      "DB08451\n",
      "DB08453\n",
      "DB08454\n",
      "DB08455\n",
      "DB08456\n",
      "DB08457\n",
      "DB08458\n",
      "DB08459\n",
      "DB08460\n",
      "DB08461\n",
      "DB08462\n",
      "DB08463\n",
      "DB08464\n",
      "DB08465\n",
      "DB08466\n",
      "DB08467\n",
      "DB08469\n",
      "DB08470\n",
      "DB08471\n",
      "DB08472\n",
      "DB08473\n",
      "DB08474\n",
      "DB08475\n",
      "DB08476\n",
      "DB08478\n",
      "DB08479\n",
      "DB08480\n",
      "DB08481\n",
      "DB08482\n",
      "DB08484\n",
      "DB08485\n",
      "DB08486\n",
      "DB08487\n",
      "DB08488\n",
      "DB08489\n",
      "DB08490\n",
      "DB08491\n",
      "DB08492\n",
      "DB08493\n",
      "DB08494\n",
      "DB08495\n",
      "DB08496\n",
      "DB08497\n",
      "DB08498\n",
      "DB08499\n",
      "DB08500\n",
      "DB08501\n",
      "DB08502\n",
      "DB08503\n",
      "DB08504\n",
      "DB08505\n",
      "DB08506\n",
      "DB08507\n",
      "DB08508\n",
      "DB08509\n",
      "DB08510\n",
      "DB08511\n",
      "DB08512\n",
      "DB08513\n",
      "DB08514\n",
      "DB08515\n",
      "DB08516\n",
      "DB08517\n",
      "DB08519\n",
      "DB08520\n",
      "DB08521\n",
      "DB08522\n",
      "DB08523\n",
      "DB08524\n",
      "DB08525\n",
      "DB08526\n",
      "DB08527\n",
      "DB08528\n",
      "DB08529\n",
      "DB08530\n",
      "DB08531\n",
      "DB08532\n",
      "DB08533\n",
      "DB08534\n",
      "DB08535\n",
      "DB08536\n",
      "DB08537\n",
      "DB08538\n",
      "DB08539\n",
      "DB08540\n",
      "DB08541\n",
      "DB08542\n",
      "DB08543\n",
      "DB08544\n",
      "DB08545\n",
      "DB08546\n",
      "DB08547\n",
      "DB08548\n",
      "DB08549\n",
      "DB08550\n",
      "DB08551\n",
      "DB08552\n",
      "DB08553\n",
      "DB08554\n",
      "DB08555\n",
      "DB08556\n",
      "DB08557\n",
      "DB08558\n",
      "DB08559\n",
      "DB08560\n",
      "DB08561\n",
      "DB08562\n",
      "DB08564\n",
      "DB08565\n",
      "DB08566\n",
      "DB08568\n",
      "DB08569\n",
      "DB08570\n",
      "DB08571\n",
      "DB08572\n",
      "DB08573\n",
      "DB08574\n",
      "DB08575\n",
      "DB08576\n",
      "DB08577\n",
      "DB08578\n",
      "DB08579\n",
      "DB08580\n",
      "DB08581\n",
      "DB08582\n",
      "DB08583\n",
      "DB08585\n",
      "DB08586\n",
      "DB08587\n",
      "DB08588\n",
      "DB08589\n",
      "DB08590\n",
      "DB08591\n",
      "DB08593\n",
      "DB08594\n",
      "DB08595\n",
      "DB08596\n",
      "DB08597\n",
      "DB08598\n",
      "DB08599\n",
      "DB08600\n",
      "DB08601\n",
      "DB08602\n",
      "DB08603\n",
      "DB08604\n",
      "DB08605\n",
      "DB08606\n",
      "DB08607\n",
      "DB08608\n",
      "DB08609\n",
      "DB08610\n",
      "DB08611\n",
      "DB08612\n",
      "DB08613\n",
      "DB08614\n",
      "DB08615\n",
      "DB08617\n",
      "DB08618\n",
      "DB08619\n",
      "DB08620\n",
      "DB08621\n",
      "DB08622\n",
      "DB08623\n",
      "DB08624\n",
      "DB08626\n",
      "DB08627\n",
      "DB08628\n",
      "DB08629\n",
      "DB08631\n",
      "DB08632\n",
      "DB08633\n",
      "DB08634\n",
      "DB08635\n",
      "DB08636\n",
      "DB08637\n",
      "DB08638\n",
      "DB08639\n",
      "DB08640\n",
      "DB08641\n",
      "DB08642\n",
      "DB08643\n",
      "DB08644\n",
      "DB08645\n",
      "DB08646\n",
      "DB08647\n",
      "DB08648\n",
      "DB08649\n",
      "DB08651\n",
      "DB08652\n",
      "DB08653\n",
      "DB08654\n",
      "DB08655\n",
      "DB08656\n",
      "DB08657\n",
      "DB08658\n",
      "DB08659\n",
      "DB08660\n",
      "DB08661\n",
      "DB08662\n",
      "DB08663\n",
      "DB08664\n",
      "DB08665\n",
      "DB08666\n",
      "DB08667\n",
      "DB08668\n",
      "DB08669\n",
      "DB08670\n",
      "DB08671\n",
      "DB08672\n",
      "DB08673\n",
      "DB08674\n",
      "DB08675\n",
      "DB08676\n",
      "DB08677\n",
      "DB08678\n",
      "DB08680\n",
      "DB08681\n",
      "DB08682\n",
      "DB08683\n",
      "DB08684\n",
      "DB08685\n",
      "DB08686\n",
      "DB08687\n",
      "DB08688\n",
      "DB08689\n",
      "DB08690\n",
      "DB08691\n",
      "DB08692\n",
      "DB08693\n",
      "DB08694\n",
      "DB08695\n",
      "DB08697\n",
      "DB08698\n",
      "DB08699\n",
      "DB08701\n",
      "DB08702\n",
      "DB08703\n",
      "DB08704\n",
      "DB08705\n",
      "DB08706\n",
      "DB08707\n",
      "DB08708\n",
      "DB08709\n",
      "DB08710\n",
      "DB08711\n",
      "DB08712\n",
      "DB08713\n",
      "DB08714\n",
      "DB08715\n",
      "DB08717\n",
      "DB08718\n",
      "DB08719\n",
      "DB08720\n",
      "DB08721\n",
      "DB08722\n",
      "DB08723\n",
      "DB08724\n",
      "DB08725\n",
      "DB08726\n",
      "DB08727\n",
      "DB08728\n",
      "DB08729\n",
      "DB08730\n",
      "DB08731\n",
      "DB08732\n",
      "DB08733\n",
      "DB08734\n",
      "DB08735\n",
      "DB08736\n",
      "DB08737\n",
      "DB08738\n",
      "DB08739\n",
      "DB08740\n",
      "DB08741\n",
      "DB08742\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB08743\n",
      "DB08744\n",
      "DB08745\n",
      "DB08746\n",
      "DB08747\n",
      "DB08748\n",
      "DB08749\n",
      "DB08750\n",
      "DB08751\n",
      "DB08752\n",
      "DB08753\n",
      "DB08754\n",
      "DB08755\n",
      "DB08756\n",
      "DB08757\n",
      "DB08758\n",
      "DB08759\n",
      "DB08760\n",
      "DB08761\n",
      "DB08762\n",
      "DB08763\n",
      "DB08765\n",
      "DB08766\n",
      "DB08767\n",
      "DB08768\n",
      "DB08770\n",
      "DB08771\n",
      "DB08772\n",
      "DB08773\n",
      "DB08774\n",
      "DB08775\n",
      "DB08776\n",
      "DB08777\n",
      "DB08778\n",
      "DB08779\n",
      "DB08780\n",
      "DB08781\n",
      "DB08782\n",
      "DB08783\n",
      "DB08784\n",
      "DB08785\n",
      "DB08786\n",
      "DB08787\n",
      "DB08788\n",
      "DB08789\n",
      "DB08790\n",
      "DB08791\n",
      "DB08792\n",
      "DB08794\n",
      "DB08795\n",
      "DB08796\n",
      "DB08797\n",
      "DB08798\n",
      "DB08799\n",
      "DB08800\n",
      "DB08801\n",
      "DB08802\n",
      "DB08803\n",
      "DB08804\n",
      "DB08805\n",
      "DB08806\n",
      "DB08807\n",
      "DB08808\n",
      "DB08809\n",
      "DB08810\n",
      "DB08811\n",
      "DB08813\n",
      "DB08814\n",
      "DB08815\n",
      "DB08816\n",
      "DB08818\n",
      "DB08819\n",
      "DB08820\n",
      "DB08822\n",
      "DB08823\n",
      "DB08824\n",
      "DB08826\n",
      "DB08827\n",
      "DB08828\n",
      "DB08830\n",
      "DB08831\n",
      "DB08833\n",
      "DB08834\n",
      "DB08835\n",
      "DB08836\n",
      "DB08837\n",
      "DB08838\n",
      "DB08839\n",
      "DB08840\n",
      "DB08841\n",
      "DB08842\n",
      "DB08843\n",
      "DB08844\n",
      "DB08845\n",
      "DB08846\n",
      "DB08847\n",
      "DB08848\n",
      "DB08849\n",
      "DB08855\n",
      "DB08856\n",
      "DB08857\n",
      "DB08858\n",
      "DB08860\n",
      "DB08861\n",
      "DB08862\n",
      "DB08864\n",
      "DB08865\n",
      "DB08867\n",
      "DB08868\n",
      "DB08869\n",
      "DB08870\n",
      "DB08871\n",
      "DB08872\n",
      "DB08873\n",
      "DB08874\n",
      "DB08875\n",
      "DB08876\n",
      "DB08877\n",
      "DB08878\n",
      "DB08879\n",
      "DB08880\n",
      "DB08881\n",
      "DB08882\n",
      "DB08883\n",
      "DB08884\n",
      "DB08885\n",
      "DB08886\n",
      "DB08887\n",
      "DB08888\n",
      "DB08889\n",
      "DB08890\n",
      "DB08891\n",
      "DB08892\n",
      "DB08893\n",
      "DB08894\n",
      "DB08895\n",
      "DB08896\n",
      "DB08897\n",
      "DB08898\n",
      "DB08899\n",
      "DB08900\n",
      "DB08901\n",
      "DB08902\n",
      "DB08903\n",
      "DB08904\n",
      "DB08905\n",
      "DB08906\n",
      "DB08907\n",
      "DB08908\n",
      "DB08909\n",
      "DB08910\n",
      "DB08911\n",
      "DB08912\n",
      "DB08913\n",
      "DB08915\n",
      "DB08916\n",
      "DB08917\n",
      "DB08918\n",
      "DB08921\n",
      "DB08922\n",
      "DB08924\n",
      "DB08925\n",
      "DB08926\n",
      "DB08927\n",
      "DB08928\n",
      "DB08930\n",
      "DB08931\n",
      "DB08932\n",
      "DB08933\n",
      "DB08934\n",
      "DB08935\n",
      "DB08936\n",
      "DB08937\n",
      "DB08938\n",
      "DB08939\n",
      "DB08940\n",
      "DB08941\n",
      "DB08942\n",
      "DB08943\n",
      "DB08944\n",
      "DB08945\n",
      "DB08946\n",
      "DB08947\n",
      "DB08948\n",
      "DB08949\n",
      "DB08950\n",
      "DB08951\n",
      "DB08952\n",
      "DB08953\n",
      "DB08954\n",
      "DB08955\n",
      "DB08956\n",
      "DB08957\n",
      "DB08958\n",
      "DB08960\n",
      "DB08961\n",
      "DB08962\n",
      "DB08964\n",
      "DB08965\n",
      "DB08966\n",
      "DB08967\n",
      "DB08968\n",
      "DB08969\n",
      "DB08970\n",
      "DB08971\n",
      "DB08972\n",
      "DB08973\n",
      "DB08974\n",
      "DB08975\n",
      "DB08976\n",
      "DB08978\n",
      "DB08979\n",
      "DB08980\n",
      "DB08981\n",
      "DB08982\n",
      "DB08983\n",
      "DB08984\n",
      "DB08985\n",
      "DB08986\n",
      "DB08987\n",
      "DB08988\n",
      "DB08989\n",
      "DB08990\n",
      "DB08991\n",
      "DB08992\n",
      "DB08993\n",
      "DB08994\n",
      "DB08995\n",
      "DB08996\n",
      "DB08997\n",
      "DB08998\n",
      "DB08999\n",
      "DB09000\n",
      "DB09001\n",
      "DB09002\n",
      "DB09003\n",
      "DB09004\n",
      "DB09005\n",
      "DB09006\n",
      "DB09007\n",
      "DB09008\n",
      "DB09009\n",
      "DB09010\n",
      "DB09011\n",
      "DB09012\n",
      "DB09013\n",
      "DB09014\n",
      "DB09015\n",
      "DB09016\n",
      "DB09017\n",
      "DB09018\n",
      "DB09019\n",
      "DB09020\n",
      "DB09021\n",
      "DB09022\n",
      "DB09023\n",
      "DB09026\n",
      "DB09027\n",
      "DB09028\n",
      "DB09029\n",
      "DB09030\n",
      "DB09031\n",
      "DB09033\n",
      "DB09034\n",
      "DB09035\n",
      "DB09036\n",
      "DB09037\n",
      "DB09038\n",
      "DB09039\n",
      "DB09040\n",
      "DB09041\n",
      "DB09042\n",
      "DB09043\n",
      "DB09045\n",
      "DB09046\n",
      "DB09047\n",
      "DB09048\n",
      "DB09049\n",
      "DB09050\n",
      "DB09051\n",
      "DB09052\n",
      "DB09053\n",
      "DB09054\n",
      "DB09055\n",
      "DB09056\n",
      "DB09057\n",
      "DB09059\n",
      "DB09060\n",
      "DB09061\n",
      "DB09062\n",
      "DB09063\n",
      "DB09064\n",
      "DB09065\n",
      "DB09066\n",
      "DB09067\n",
      "DB09068\n",
      "DB09069\n",
      "DB09070\n",
      "DB09071\n",
      "DB09072\n",
      "DB09073\n",
      "DB09074\n",
      "DB09075\n",
      "DB09076\n",
      "DB09077\n",
      "DB09078\n",
      "DB09079\n",
      "DB09080\n",
      "DB09081\n",
      "DB09082\n",
      "DB09083\n",
      "DB09084\n",
      "DB09085\n",
      "DB09086\n",
      "DB09087\n",
      "DB09088\n",
      "DB09089\n",
      "DB09090\n",
      "DB09091\n",
      "DB09092\n",
      "DB09093\n",
      "DB09094\n",
      "DB09095\n",
      "DB09096\n",
      "DB09097\n",
      "DB09098\n",
      "DB09099\n",
      "DB09100\n",
      "DB09101\n",
      "DB09102\n",
      "DB09103\n",
      "DB09104\n",
      "DB09105\n",
      "DB09106\n",
      "DB09107\n",
      "DB09108\n",
      "DB09109\n",
      "DB09110\n",
      "DB09111\n",
      "DB09112\n",
      "DB09113\n",
      "DB09114\n",
      "DB09115\n",
      "DB09116\n",
      "DB09117\n",
      "DB09118\n",
      "DB09119\n",
      "DB09120\n",
      "DB09121\n",
      "DB09122\n",
      "DB09123\n",
      "DB09124\n",
      "DB09125\n",
      "DB09126\n",
      "DB09128\n",
      "DB09129\n",
      "DB09130\n",
      "DB09131\n",
      "DB09132\n",
      "DB09133\n",
      "DB09134\n",
      "DB09135\n",
      "DB09136\n",
      "DB09137\n",
      "DB09138\n",
      "DB09139\n",
      "DB09140\n",
      "DB09141\n",
      "DB09142\n",
      "DB09143\n",
      "DB09144\n",
      "DB09145\n",
      "DB09146\n",
      "DB09147\n",
      "DB09148\n",
      "DB09149\n",
      "DB09151\n",
      "DB09152\n",
      "DB09153\n",
      "DB09154\n",
      "DB09155\n",
      "DB09156\n",
      "DB09157\n",
      "DB09158\n",
      "DB09160\n",
      "DB09161\n",
      "DB09163\n",
      "DB09164\n",
      "DB09165\n",
      "DB09166\n",
      "DB09167\n",
      "DB09168\n",
      "DB09169\n",
      "DB09170\n",
      "DB09171\n",
      "DB09172\n",
      "DB09173\n",
      "DB09174\n",
      "DB09175\n",
      "DB09177\n",
      "DB09178\n",
      "DB09179\n",
      "DB09180\n",
      "DB09181\n",
      "DB09182\n",
      "DB09183\n",
      "DB09184\n",
      "DB09185\n",
      "DB09186\n",
      "DB09187\n",
      "DB09188\n",
      "DB09189\n",
      "DB09190\n",
      "DB09191\n",
      "DB09192\n",
      "DB09193\n",
      "DB09194\n",
      "DB09195\n",
      "DB09196\n",
      "DB09197\n",
      "DB09198\n",
      "DB09199\n",
      "DB09200\n",
      "DB09201\n",
      "DB09202\n",
      "DB09203\n",
      "DB09204\n",
      "DB09205\n",
      "DB09206\n",
      "DB09207\n",
      "DB09208\n",
      "DB09209\n",
      "DB09210\n",
      "DB09211\n",
      "DB09212\n",
      "DB09213\n",
      "DB09214\n",
      "DB09215\n",
      "DB09216\n",
      "DB09217\n",
      "DB09218\n",
      "DB09219\n",
      "DB09220\n",
      "DB09221\n",
      "DB09222\n",
      "DB09223\n",
      "DB09224\n",
      "DB09225\n",
      "DB09226\n",
      "DB09227\n",
      "DB09228\n",
      "DB09229\n",
      "DB09230\n",
      "DB09231\n",
      "DB09232\n",
      "DB09233\n",
      "DB09234\n",
      "DB09235\n",
      "DB09236\n",
      "DB09237\n",
      "DB09238\n",
      "DB09239\n",
      "DB09240\n",
      "DB09241\n",
      "DB09242\n",
      "DB09243\n",
      "DB09244\n",
      "DB09245\n",
      "DB09246\n",
      "DB09247\n",
      "DB09248\n",
      "DB09249\n",
      "DB09250\n",
      "DB09251\n",
      "DB09252\n",
      "DB09253\n",
      "DB09254\n",
      "DB09255\n",
      "DB09256\n",
      "DB09257\n",
      "DB09258\n",
      "DB09259\n",
      "DB09260\n",
      "DB09261\n",
      "DB09262\n",
      "DB09263\n",
      "DB09264\n",
      "DB09265\n",
      "DB09266\n",
      "DB09267\n",
      "DB09268\n",
      "DB09269\n",
      "DB09270\n",
      "DB09271\n",
      "DB09272\n",
      "DB09273\n",
      "DB09274\n",
      "DB09275\n",
      "DB09276\n",
      "DB09277\n",
      "DB09278\n",
      "DB09279\n",
      "DB09280\n",
      "DB09281\n",
      "DB09282\n",
      "DB09283\n",
      "DB09284\n",
      "DB09285\n",
      "DB09286\n",
      "DB09287\n",
      "DB09288\n",
      "DB09289\n",
      "DB09290\n",
      "DB09291\n",
      "DB09292\n",
      "DB09293\n",
      "DB09295\n",
      "DB09296\n",
      "DB09297\n",
      "DB09298\n",
      "DB09299\n",
      "DB09300\n",
      "DB09301\n",
      "DB09302\n",
      "DB09303\n",
      "DB09304\n",
      "DB09305\n",
      "DB09306\n",
      "DB09307\n",
      "DB09308\n",
      "DB09309\n",
      "DB09310\n",
      "DB09311\n",
      "DB09312\n",
      "DB09313\n",
      "DB09314\n",
      "DB09315\n",
      "DB09316\n",
      "DB09317\n",
      "DB09318\n",
      "DB09319\n",
      "DB09320\n",
      "DB09321\n",
      "DB09322\n",
      "DB09324\n",
      "DB09325\n",
      "DB09326\n",
      "DB09327\n",
      "DB09328\n",
      "DB09329\n",
      "DB09330\n",
      "DB09331\n",
      "DB09332\n",
      "DB09333\n",
      "DB09334\n",
      "DB09335\n",
      "DB09336\n",
      "DB09337\n",
      "DB09338\n",
      "DB09339\n",
      "DB09340\n",
      "DB09341\n",
      "DB09342\n",
      "DB09343\n",
      "DB09344\n",
      "DB09345\n",
      "DB09346\n",
      "DB09347\n",
      "DB09348\n",
      "DB09349\n",
      "DB09350\n",
      "DB09351\n",
      "DB09352\n",
      "DB09353\n",
      "DB09355\n",
      "DB09357\n",
      "DB09363\n",
      "DB09364\n",
      "DB09366\n",
      "DB09369\n",
      "DB09370\n",
      "DB09371\n",
      "DB09372\n",
      "DB09373\n",
      "DB09374\n",
      "DB09375\n",
      "DB09376\n",
      "DB09377\n",
      "DB09378\n",
      "DB09379\n",
      "DB09380\n",
      "DB09381\n",
      "DB09382\n",
      "DB09383\n",
      "DB09385\n",
      "DB09389\n",
      "DB09393\n",
      "DB09394\n",
      "DB09395\n",
      "DB09397\n",
      "DB09398\n",
      "DB09400\n",
      "DB09401\n",
      "DB09403\n",
      "DB09407\n",
      "DB09409\n",
      "DB09413\n",
      "DB09414\n",
      "DB09415\n",
      "DB09418\n",
      "DB09419\n",
      "DB09420\n",
      "DB09421\n",
      "DB09422\n",
      "DB09423\n",
      "DB09425\n",
      "DB09429\n",
      "DB09430\n",
      "DB09443\n",
      "DB09446\n",
      "DB09447\n",
      "DB09448\n",
      "DB09449\n",
      "DB09456\n",
      "DB09459\n",
      "DB09460\n",
      "DB09461\n",
      "DB09462\n",
      "DB09472\n",
      "DB09473\n",
      "DB09477\n",
      "DB09479\n",
      "DB09480\n",
      "DB09481\n",
      "DB09483\n",
      "DB09484\n",
      "DB09487\n",
      "DB09488\n",
      "DB09490\n",
      "DB09493\n",
      "DB09494\n",
      "DB09495\n",
      "DB09496\n",
      "DB09498\n",
      "DB09499\n",
      "DB09501\n",
      "DB09502\n",
      "DB09507\n",
      "DB09508\n",
      "DB09510\n",
      "DB09511\n",
      "DB09512\n",
      "DB09513\n",
      "DB09516\n",
      "DB09517\n",
      "DB09526\n",
      "DB09527\n",
      "DB09531\n",
      "DB09532\n",
      "DB09534\n",
      "DB09535\n",
      "DB09536\n",
      "DB09537\n",
      "DB09539\n",
      "DB09543\n",
      "DB09546\n",
      "DB09551\n",
      "DB09552\n",
      "DB09555\n",
      "DB09559\n",
      "DB09561\n",
      "DB09563\n",
      "DB09564\n",
      "DB09567\n",
      "DB09568\n",
      "DB09570\n",
      "DB09571\n",
      "DB09876\n",
      "DB09877\n",
      "DB10061\n",
      "DB10062\n",
      "DB10076\n",
      "DB10276\n",
      "DB10283\n",
      "DB10284\n",
      "DB10285\n",
      "DB10286\n",
      "DB10287\n",
      "DB10288\n",
      "DB10289\n",
      "DB10290\n",
      "DB10291\n",
      "DB10292\n",
      "DB10293\n",
      "DB10294\n",
      "DB10295\n",
      "DB10296\n",
      "DB10297\n",
      "DB10298\n",
      "DB10299\n",
      "DB10300\n",
      "DB10301\n",
      "DB10302\n",
      "DB10310\n",
      "DB10311\n",
      "DB10312\n",
      "DB10313\n",
      "DB10314\n",
      "DB10315\n",
      "DB10316\n",
      "DB10317\n",
      "DB10318\n",
      "DB10319\n",
      "DB10320\n",
      "DB10321\n",
      "DB10322\n",
      "DB10323\n",
      "DB10324\n",
      "DB10325\n",
      "DB10326\n",
      "DB10327\n",
      "DB10328\n",
      "DB10329\n",
      "DB10330\n",
      "DB10331\n",
      "DB10332\n",
      "DB10333\n",
      "DB10334\n",
      "DB10335\n",
      "DB10336\n",
      "DB10337\n",
      "DB10338\n",
      "DB10339\n",
      "DB10340\n",
      "DB10341\n",
      "DB10342\n",
      "DB10343\n",
      "DB10344\n",
      "DB10345\n",
      "DB10346\n",
      "DB10348\n",
      "DB10349\n",
      "DB10350\n",
      "DB10351\n",
      "DB10352\n",
      "DB10353\n",
      "DB10354\n",
      "DB10355\n",
      "DB10356\n",
      "DB10357\n",
      "DB10359\n",
      "DB10360\n",
      "DB10361\n",
      "DB10362\n",
      "DB10363\n",
      "DB10364\n",
      "DB10365\n",
      "DB10366\n",
      "DB10368\n",
      "DB10369\n",
      "DB10370\n",
      "DB10371\n",
      "DB10372\n",
      "DB10373\n",
      "DB10374\n",
      "DB10375\n",
      "DB10376\n",
      "DB10377\n",
      "DB10378\n",
      "DB10379\n",
      "DB10380\n",
      "DB10381\n",
      "DB10382\n",
      "DB10383\n",
      "DB10384\n",
      "DB10385\n",
      "DB10386\n",
      "DB10387\n",
      "DB10388\n",
      "DB10389\n",
      "DB10390\n",
      "DB10391\n",
      "DB10392\n",
      "DB10393\n",
      "DB10394\n",
      "DB10395\n",
      "DB10396\n",
      "DB10397\n",
      "DB10398\n",
      "DB10399\n",
      "DB10400\n",
      "DB10401\n",
      "DB10403\n",
      "DB10404\n",
      "DB10406\n",
      "DB10408\n",
      "DB10409\n",
      "DB10410\n",
      "DB10411\n",
      "DB10412\n",
      "DB10413\n",
      "DB10415\n",
      "DB10416\n",
      "DB10417\n",
      "DB10418\n",
      "DB10419\n",
      "DB10420\n",
      "DB10421\n",
      "DB10422\n",
      "DB10423\n",
      "DB10424\n",
      "DB10425\n",
      "DB10426\n",
      "DB10427\n",
      "DB10428\n",
      "DB10429\n",
      "DB10430\n",
      "DB10431\n",
      "DB10432\n",
      "DB10433\n",
      "DB10434\n",
      "DB10435\n",
      "DB10436\n",
      "DB10437\n",
      "DB10438\n",
      "DB10439\n",
      "DB10440\n",
      "DB10441\n",
      "DB10442\n",
      "DB10443\n",
      "DB10444\n",
      "DB10445\n",
      "DB10446\n",
      "DB10447\n",
      "DB10448\n",
      "DB10449\n",
      "DB10450\n",
      "DB10451\n",
      "DB10452\n",
      "DB10453\n",
      "DB10454\n",
      "DB10455\n",
      "DB10456\n",
      "DB10457\n",
      "DB10458\n",
      "DB10459\n",
      "DB10460\n",
      "DB10461\n",
      "DB10462\n",
      "DB10463\n",
      "DB10464\n",
      "DB10465\n",
      "DB10466\n",
      "DB10467\n",
      "DB10468\n",
      "DB10469\n",
      "DB10470\n",
      "DB10471\n",
      "DB10472\n",
      "DB10473\n",
      "DB10474\n",
      "DB10475\n",
      "DB10478\n",
      "DB10479\n",
      "DB10480\n",
      "DB10481\n",
      "DB10482\n",
      "DB10483\n",
      "DB10484\n",
      "DB10485\n",
      "DB10486\n",
      "DB10487\n",
      "DB10488\n",
      "DB10489\n",
      "DB10490\n",
      "DB10491\n",
      "DB10493\n",
      "DB10494\n",
      "DB10495\n",
      "DB10496\n",
      "DB10497\n",
      "DB10498\n",
      "DB10499\n",
      "DB10500\n",
      "DB10501\n",
      "DB10502\n",
      "DB10503\n",
      "DB10504\n",
      "DB10505\n",
      "DB10506\n",
      "DB10508\n",
      "DB10509\n",
      "DB10510\n",
      "DB10511\n",
      "DB10512\n",
      "DB10513\n",
      "DB10514\n",
      "DB10515\n",
      "DB10516\n",
      "DB10517\n",
      "DB10518\n",
      "DB10519\n",
      "DB10520\n",
      "DB10523\n",
      "DB10525\n",
      "DB10526\n",
      "DB10527\n",
      "DB10528\n",
      "DB10529\n",
      "DB10530\n",
      "DB10531\n",
      "DB10532\n",
      "DB10533\n",
      "DB10534\n",
      "DB10535\n",
      "DB10536\n",
      "DB10537\n",
      "DB10538\n",
      "DB10539\n",
      "DB10540\n",
      "DB10541\n",
      "DB10542\n",
      "DB10543\n",
      "DB10544\n",
      "DB10545\n",
      "DB10546\n",
      "DB10547\n",
      "DB10548\n",
      "DB10549\n",
      "DB10550\n",
      "DB10551\n",
      "DB10552\n",
      "DB10553\n",
      "DB10554\n",
      "DB10555\n",
      "DB10556\n",
      "DB10557\n",
      "DB10558\n",
      "DB10559\n",
      "DB10560\n",
      "DB10561\n",
      "DB10562\n",
      "DB10563\n",
      "DB10564\n",
      "DB10566\n",
      "DB10567\n",
      "DB10568\n",
      "DB10569\n",
      "DB10570\n",
      "DB10571\n",
      "DB10572\n",
      "DB10573\n",
      "DB10574\n",
      "DB10575\n",
      "DB10576\n",
      "DB10577\n",
      "DB10578\n",
      "DB10579\n",
      "DB10580\n",
      "DB10581\n",
      "DB10582\n",
      "DB10583\n",
      "DB10584\n",
      "DB10596\n",
      "DB10597\n",
      "DB10598\n",
      "DB10599\n",
      "DB10600\n",
      "DB10601\n",
      "DB10602\n",
      "DB10603\n",
      "DB10604\n",
      "DB10605\n",
      "DB10606\n",
      "DB10607\n",
      "DB10608\n",
      "DB10609\n",
      "DB10610\n",
      "DB10611\n",
      "DB10612\n",
      "DB10613\n",
      "DB10614\n",
      "DB10615\n",
      "DB10616\n",
      "DB10617\n",
      "DB10618\n",
      "DB10619\n",
      "DB10620\n",
      "DB10621\n",
      "DB10622\n",
      "DB10623\n",
      "DB10624\n",
      "DB10625\n",
      "DB10626\n",
      "DB10627\n",
      "DB10628\n",
      "DB10629\n",
      "DB10630\n",
      "DB10631\n",
      "DB10632\n",
      "DB10633\n",
      "DB10634\n",
      "DB10635\n",
      "DB10636\n",
      "DB10637\n",
      "DB10638\n",
      "DB10639\n",
      "DB10640\n",
      "DB10641\n",
      "DB10642\n",
      "DB10643\n",
      "DB10644\n",
      "DB10645\n",
      "DB10646\n",
      "DB10647\n",
      "DB10648\n",
      "DB10650\n",
      "DB10651\n",
      "DB10652\n",
      "DB10653\n",
      "DB10654\n",
      "DB10655\n",
      "DB10656\n",
      "DB10657\n",
      "DB10658\n",
      "DB10659\n",
      "DB10660\n",
      "DB10661\n",
      "DB10662\n",
      "DB10663\n",
      "DB10664\n",
      "DB10666\n",
      "DB10667\n",
      "DB10669\n",
      "DB10670\n",
      "DB10671\n",
      "DB10672\n",
      "DB10673\n",
      "DB10674\n",
      "DB10675\n",
      "DB10676\n",
      "DB10677\n",
      "DB10678\n",
      "DB10679\n",
      "DB10681\n",
      "DB10683\n",
      "DB10685\n",
      "DB10686\n",
      "DB10687\n",
      "DB10688\n",
      "DB10690\n",
      "DB10691\n",
      "DB10693\n",
      "DB10694\n",
      "DB10695\n",
      "DB10696\n",
      "DB10697\n",
      "DB10698\n",
      "DB10699\n",
      "DB10700\n",
      "DB10701\n",
      "DB10702\n",
      "DB10703\n",
      "DB10704\n",
      "DB10705\n",
      "DB10706\n",
      "DB10707\n",
      "DB10708\n",
      "DB10710\n",
      "DB10711\n",
      "DB10712\n",
      "DB10713\n",
      "DB10714\n",
      "DB10715\n",
      "DB10716\n",
      "DB10717\n",
      "DB10718\n",
      "DB10719\n",
      "DB10720\n",
      "DB10721\n",
      "DB10722\n",
      "DB10723\n",
      "DB10724\n",
      "DB10725\n",
      "DB10727\n",
      "DB10728\n",
      "DB10729\n",
      "DB10730\n",
      "DB10731\n",
      "DB10732\n",
      "DB10733\n",
      "DB10734\n",
      "DB10735\n",
      "DB10736\n",
      "DB10737\n",
      "DB10738\n",
      "DB10739\n",
      "DB10740\n",
      "DB10741\n",
      "DB10742\n",
      "DB10743\n",
      "DB10744\n",
      "DB10745\n",
      "DB10746\n",
      "DB10747\n",
      "DB10748\n",
      "DB10749\n",
      "DB10750\n",
      "DB10751\n",
      "DB10752\n",
      "DB10753\n",
      "DB10754\n",
      "DB10755\n",
      "DB10756\n",
      "DB10757\n",
      "DB10758\n",
      "DB10759\n",
      "DB10760\n",
      "DB10761\n",
      "DB10762\n",
      "DB10763\n",
      "DB10764\n",
      "DB10765\n",
      "DB10766\n",
      "DB10767\n",
      "DB10768\n",
      "DB10769\n",
      "DB10770\n",
      "DB10771\n",
      "DB10772\n",
      "DB10773\n",
      "DB10774\n",
      "DB10775\n",
      "DB10776\n",
      "DB10777\n",
      "DB10778\n",
      "DB10779\n",
      "DB10780\n",
      "DB10781\n",
      "DB10782\n",
      "DB10783\n",
      "DB10784\n",
      "DB10785\n",
      "DB10786\n",
      "DB10787\n",
      "DB10788\n",
      "DB10789\n",
      "DB10790\n",
      "DB10791\n",
      "DB10792\n",
      "DB10793\n",
      "DB10794\n",
      "DB10795\n",
      "DB10796\n",
      "DB10797\n",
      "DB10798\n",
      "DB10799\n",
      "DB10800\n",
      "DB10801\n",
      "DB10802\n",
      "DB10803\n",
      "DB10804\n",
      "DB10805\n",
      "DB10806\n",
      "DB10807\n",
      "DB10808\n",
      "DB10809\n",
      "DB10810\n",
      "DB10811\n",
      "DB10812\n",
      "DB10813\n",
      "DB10814\n",
      "DB10815\n",
      "DB10816\n",
      "DB10817\n",
      "DB10818\n",
      "DB10819\n",
      "DB10820\n",
      "DB10821\n",
      "DB10822\n",
      "DB10823\n",
      "DB10824\n",
      "DB10825\n",
      "DB10826\n",
      "DB10827\n",
      "DB10828\n",
      "DB10829\n",
      "DB10830\n",
      "DB10831\n",
      "DB10832\n",
      "DB10833\n",
      "DB10834\n",
      "DB10835\n",
      "DB10836\n",
      "DB10837\n",
      "DB10838\n",
      "DB10839\n",
      "DB10840\n",
      "DB10841\n",
      "DB10842\n",
      "DB10843\n",
      "DB10844\n",
      "DB10845\n",
      "DB10846\n",
      "DB10847\n",
      "DB10848\n",
      "DB10849\n",
      "DB10850\n",
      "DB10851\n",
      "DB10852\n",
      "DB10853\n",
      "DB10855\n",
      "DB10856\n",
      "DB10857\n",
      "DB10858\n",
      "DB10859\n",
      "DB10860\n",
      "DB10861\n",
      "DB10862\n",
      "DB10864\n",
      "DB10865\n",
      "DB10866\n",
      "DB10867\n",
      "DB10868\n",
      "DB10869\n",
      "DB10870\n",
      "DB10871\n",
      "DB10872\n",
      "DB10873\n",
      "DB10874\n",
      "DB10875\n",
      "DB10876\n",
      "DB10877\n",
      "DB10879\n",
      "DB10880\n",
      "DB10881\n",
      "DB10882\n",
      "DB10883\n",
      "DB10884\n",
      "DB10885\n",
      "DB10886\n",
      "DB10887\n",
      "DB10888\n",
      "DB10889\n",
      "DB10890\n",
      "DB10891\n",
      "DB10892\n",
      "DB10893\n",
      "DB10894\n",
      "DB10895\n",
      "DB10896\n",
      "DB10897\n",
      "DB10898\n",
      "DB10899\n",
      "DB10900\n",
      "DB10901\n",
      "DB10902\n",
      "DB10903\n",
      "DB10904\n",
      "DB10905\n",
      "DB10906\n",
      "DB10907\n",
      "DB10908\n",
      "DB10909\n",
      "DB10910\n",
      "DB10911\n",
      "DB10912\n",
      "DB10913\n",
      "DB10914\n",
      "DB10915\n",
      "DB10916\n",
      "DB10917\n",
      "DB10918\n",
      "DB10919\n",
      "DB10921\n",
      "DB10922\n",
      "DB10923\n",
      "DB10924\n",
      "DB10925\n",
      "DB10926\n",
      "DB10927\n",
      "DB10928\n",
      "DB10929\n",
      "DB10930\n",
      "DB10932\n",
      "DB10933\n",
      "DB10934\n",
      "DB10935\n",
      "DB10936\n",
      "DB10937\n",
      "DB10939\n",
      "DB10940\n",
      "DB10941\n",
      "DB10942\n",
      "DB10943\n",
      "DB10945\n",
      "DB10946\n",
      "DB10947\n",
      "DB10948\n",
      "DB10949\n",
      "DB10950\n",
      "DB10952\n",
      "DB10953\n",
      "DB10954\n",
      "DB10955\n",
      "DB10956\n",
      "DB10957\n",
      "DB10958\n",
      "DB10959\n",
      "DB10961\n",
      "DB10962\n",
      "DB10963\n",
      "DB10964\n",
      "DB10965\n",
      "DB10966\n",
      "DB10967\n",
      "DB10968\n",
      "DB10969\n",
      "DB10970\n",
      "DB10971\n",
      "DB10972\n",
      "DB10973\n",
      "DB10974\n",
      "DB10975\n",
      "DB10976\n",
      "DB10977\n",
      "DB10979\n",
      "DB10980\n",
      "DB10981\n",
      "DB10982\n",
      "DB10983\n",
      "DB10984\n",
      "DB10985\n",
      "DB10986\n",
      "DB10987\n",
      "DB10988\n",
      "DB10989\n",
      "DB10990\n",
      "DB10991\n",
      "DB10992\n",
      "DB10994\n",
      "DB10995\n",
      "DB10996\n",
      "DB10997\n",
      "DB10998\n",
      "DB10999\n",
      "DB11000\n",
      "DB11001\n",
      "DB11002\n",
      "DB11003\n",
      "DB11004\n",
      "DB11005\n",
      "DB11006\n",
      "DB11007\n",
      "DB11008\n",
      "DB11009\n",
      "DB11010\n",
      "DB11011\n",
      "DB11014\n",
      "DB11017\n",
      "DB11018\n",
      "DB11019\n",
      "DB11020\n",
      "DB11021\n",
      "DB11022\n",
      "DB11023\n",
      "DB11024\n",
      "DB11025\n",
      "DB11026\n",
      "DB11027\n",
      "DB11028\n",
      "DB11029\n",
      "DB11030\n",
      "DB11031\n",
      "DB11032\n",
      "DB11033\n",
      "DB11034\n",
      "DB11035\n",
      "DB11036\n",
      "DB11037\n",
      "DB11038\n",
      "DB11039\n",
      "DB11040\n",
      "DB11041\n",
      "DB11042\n",
      "DB11043\n",
      "DB11044\n",
      "DB11045\n",
      "DB11046\n",
      "DB11047\n",
      "DB11048\n",
      "DB11050\n",
      "DB11051\n",
      "DB11054\n",
      "DB11056\n",
      "DB11057\n",
      "DB11058\n",
      "DB11059\n",
      "DB11060\n",
      "DB11061\n",
      "DB11062\n",
      "DB11063\n",
      "DB11064\n",
      "DB11065\n",
      "DB11066\n",
      "DB11067\n",
      "DB11068\n",
      "DB11069\n",
      "DB11071\n",
      "DB11072\n",
      "DB11073\n",
      "DB11074\n",
      "DB11075\n",
      "DB11077\n",
      "DB11079\n",
      "DB11080\n",
      "DB11081\n",
      "DB11082\n",
      "DB11085\n",
      "DB11086\n",
      "DB11087\n",
      "DB11088\n",
      "DB11089\n",
      "DB11090\n",
      "DB11091\n",
      "DB11092\n",
      "DB11093\n",
      "DB11094\n",
      "DB11095\n",
      "DB11096\n",
      "DB11097\n",
      "DB11098\n",
      "DB11099\n",
      "DB11100\n",
      "DB11102\n",
      "DB11104\n",
      "DB11105\n",
      "DB11107\n",
      "DB11108\n",
      "DB11109\n",
      "DB11110\n",
      "DB11111\n",
      "DB11112\n",
      "DB11113\n",
      "DB11114\n",
      "DB11115\n",
      "DB11116\n",
      "DB11117\n",
      "DB11118\n",
      "DB11119\n",
      "DB11120\n",
      "DB11121\n",
      "DB11123\n",
      "DB11124\n",
      "DB11125\n",
      "DB11126\n",
      "DB11127\n",
      "DB11128\n",
      "DB11129\n",
      "DB11130\n",
      "DB11131\n",
      "DB11132\n",
      "DB11133\n",
      "DB11134\n",
      "DB11135\n",
      "DB11136\n",
      "DB11137\n",
      "DB11140\n",
      "DB11141\n",
      "DB11142\n",
      "DB11143\n",
      "DB11144\n",
      "DB11145\n",
      "DB11147\n",
      "DB11148\n",
      "DB11149\n",
      "DB11150\n",
      "DB11151\n",
      "DB11152\n",
      "DB11153\n",
      "DB11154\n",
      "DB11155\n",
      "DB11156\n",
      "DB11157\n",
      "DB11158\n",
      "DB11159\n",
      "DB11160\n",
      "DB11161\n",
      "DB11164\n",
      "DB11165\n",
      "DB11166\n",
      "DB11168\n",
      "DB11169\n",
      "DB11171\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB11172\n",
      "DB11174\n",
      "DB11175\n",
      "DB11176\n",
      "DB11178\n",
      "DB11179\n",
      "DB11180\n",
      "DB11181\n",
      "DB11182\n",
      "DB11183\n",
      "DB11184\n",
      "DB11185\n",
      "DB11186\n",
      "DB11187\n",
      "DB11188\n",
      "DB11189\n",
      "DB11190\n",
      "DB11191\n",
      "DB11192\n",
      "DB11193\n",
      "DB11195\n",
      "DB11197\n",
      "DB11198\n",
      "DB11199\n",
      "DB11200\n",
      "DB11201\n",
      "DB11202\n",
      "DB11203\n",
      "DB11204\n",
      "DB11205\n",
      "DB11206\n",
      "DB11207\n",
      "DB11208\n",
      "DB11209\n",
      "DB11210\n",
      "DB11211\n",
      "DB11217\n",
      "DB11218\n",
      "DB11219\n",
      "DB11220\n",
      "DB11221\n",
      "DB11222\n",
      "DB11223\n",
      "DB11224\n",
      "DB11225\n",
      "DB11226\n",
      "DB11227\n",
      "DB11228\n",
      "DB11229\n",
      "DB11230\n",
      "DB11231\n",
      "DB11232\n",
      "DB11233\n",
      "DB11234\n",
      "DB11235\n",
      "DB11236\n",
      "DB11237\n",
      "DB11238\n",
      "DB11239\n",
      "DB11242\n",
      "DB11243\n",
      "DB11244\n",
      "DB11246\n",
      "DB11247\n",
      "DB11248\n",
      "DB11250\n",
      "DB11251\n",
      "DB11252\n",
      "DB11253\n",
      "DB11254\n",
      "DB11255\n",
      "DB11256\n",
      "DB11257\n",
      "DB11259\n",
      "DB11260\n",
      "DB11261\n",
      "DB11262\n",
      "DB11263\n",
      "DB11264\n",
      "DB11265\n",
      "DB11266\n",
      "DB11267\n",
      "DB11268\n",
      "DB11269\n",
      "DB11270\n",
      "DB11271\n",
      "DB11272\n",
      "DB11273\n",
      "DB11274\n",
      "DB11275\n",
      "DB11276\n",
      "DB11277\n",
      "DB11278\n",
      "DB11279\n",
      "DB11281\n",
      "DB11282\n",
      "DB11283\n",
      "DB11284\n",
      "DB11285\n",
      "DB11286\n",
      "DB11288\n",
      "DB11289\n",
      "DB11290\n",
      "DB11291\n",
      "DB11293\n",
      "DB11294\n",
      "DB11295\n",
      "DB11296\n",
      "DB11297\n",
      "DB11298\n",
      "DB11299\n",
      "DB11300\n",
      "DB11301\n",
      "DB11302\n",
      "DB11304\n",
      "DB11305\n",
      "DB11306\n",
      "DB11309\n",
      "DB11311\n",
      "DB11312\n",
      "DB11313\n",
      "DB11315\n",
      "DB11318\n",
      "DB11321\n",
      "DB11323\n",
      "DB11324\n",
      "DB11325\n",
      "DB11326\n",
      "DB11327\n",
      "DB11328\n",
      "DB11329\n",
      "DB11330\n",
      "DB11331\n",
      "DB11332\n",
      "DB11333\n",
      "DB11335\n",
      "DB11336\n",
      "DB11337\n",
      "DB11338\n",
      "DB11340\n",
      "DB11341\n",
      "DB11342\n",
      "DB11343\n",
      "DB11344\n",
      "DB11345\n",
      "DB11346\n",
      "DB11347\n",
      "DB11348\n",
      "DB11349\n",
      "DB11350\n",
      "DB11352\n",
      "DB11355\n",
      "DB11356\n",
      "DB11357\n",
      "DB11358\n",
      "DB11359\n",
      "DB11360\n",
      "DB11361\n",
      "DB11362\n",
      "DB11363\n",
      "DB11364\n",
      "DB11365\n",
      "DB11366\n",
      "DB11367\n",
      "DB11368\n",
      "DB11369\n",
      "DB11371\n",
      "DB11372\n",
      "DB11373\n",
      "DB11374\n",
      "DB11375\n",
      "DB11376\n",
      "DB11377\n",
      "DB11378\n",
      "DB11379\n",
      "DB11380\n",
      "DB11382\n",
      "DB11383\n",
      "DB11385\n",
      "DB11386\n",
      "DB11387\n",
      "DB11389\n",
      "DB11390\n",
      "DB11392\n",
      "DB11393\n",
      "DB11394\n",
      "DB11395\n",
      "DB11396\n",
      "DB11397\n",
      "DB11398\n",
      "DB11399\n",
      "DB11400\n",
      "DB11401\n",
      "DB11403\n",
      "DB11404\n",
      "DB11405\n",
      "DB11408\n",
      "DB11409\n",
      "DB11410\n",
      "DB11411\n",
      "DB11412\n",
      "DB11413\n",
      "DB11414\n",
      "DB11416\n",
      "DB11417\n",
      "DB11419\n",
      "DB11420\n",
      "DB11421\n",
      "DB11423\n",
      "DB11424\n",
      "DB11425\n",
      "DB11426\n",
      "DB11427\n",
      "DB11428\n",
      "DB11429\n",
      "DB11430\n",
      "DB11431\n",
      "DB11432\n",
      "DB11433\n",
      "DB11434\n",
      "DB11436\n",
      "DB11437\n",
      "DB11438\n",
      "DB11440\n",
      "DB11442\n",
      "DB11443\n",
      "DB11446\n",
      "DB11447\n",
      "DB11448\n",
      "DB11449\n",
      "DB11450\n",
      "DB11451\n",
      "DB11452\n",
      "DB11453\n",
      "DB11454\n",
      "DB11455\n",
      "DB11456\n",
      "DB11457\n",
      "DB11458\n",
      "DB11459\n",
      "DB11460\n",
      "DB11461\n",
      "DB11462\n",
      "DB11463\n",
      "DB11464\n",
      "DB11466\n",
      "DB11467\n",
      "DB11468\n",
      "DB11470\n",
      "DB11471\n",
      "DB11472\n",
      "DB11473\n",
      "DB11474\n",
      "DB11475\n",
      "DB11476\n",
      "DB11477\n",
      "DB11478\n",
      "DB11479\n",
      "DB11480\n",
      "DB11481\n",
      "DB11482\n",
      "DB11485\n",
      "DB11487\n",
      "DB11490\n",
      "DB11491\n",
      "DB11493\n",
      "DB11495\n",
      "DB11496\n",
      "DB11497\n",
      "DB11499\n",
      "DB11501\n",
      "DB11502\n",
      "DB11504\n",
      "DB11505\n",
      "DB11507\n",
      "DB11509\n",
      "DB11510\n",
      "DB11511\n",
      "DB11512\n",
      "DB11513\n",
      "DB11516\n",
      "DB11517\n",
      "DB11518\n",
      "DB11519\n",
      "DB11520\n",
      "DB11521\n",
      "DB11522\n",
      "DB11525\n",
      "DB11526\n",
      "DB11528\n",
      "DB11529\n",
      "DB11530\n",
      "DB11531\n",
      "DB11534\n",
      "DB11537\n",
      "DB11540\n",
      "DB11541\n",
      "DB11542\n",
      "DB11543\n",
      "DB11544\n",
      "DB11545\n",
      "DB11547\n",
      "DB11549\n",
      "DB11551\n",
      "DB11552\n",
      "DB11554\n",
      "DB11555\n",
      "DB11556\n",
      "DB11558\n",
      "DB11560\n",
      "DB11561\n",
      "DB11562\n",
      "DB11563\n",
      "DB11564\n",
      "DB11567\n",
      "DB11568\n",
      "DB11569\n",
      "DB11570\n",
      "DB11571\n",
      "DB11572\n",
      "DB11573\n",
      "DB11574\n",
      "DB11575\n",
      "DB11576\n",
      "DB11577\n",
      "DB11578\n",
      "DB11579\n",
      "DB11580\n",
      "DB11581\n",
      "DB11582\n",
      "DB11583\n",
      "DB11584\n",
      "DB11585\n",
      "DB11586\n",
      "DB11587\n",
      "DB11588\n",
      "DB11589\n",
      "DB11590\n",
      "DB11591\n",
      "DB11592\n",
      "DB11593\n",
      "DB11594\n",
      "DB11595\n",
      "DB11596\n",
      "DB11597\n",
      "DB11598\n",
      "DB11599\n",
      "DB11600\n",
      "DB11601\n",
      "DB11602\n",
      "DB11603\n",
      "DB11604\n",
      "DB11605\n",
      "DB11606\n",
      "DB11607\n",
      "DB11608\n",
      "DB11609\n",
      "DB11610\n",
      "DB11611\n",
      "DB11613\n",
      "DB11614\n",
      "DB11616\n",
      "DB11617\n",
      "DB11618\n",
      "DB11619\n",
      "DB11620\n",
      "DB11621\n",
      "DB11622\n",
      "DB11623\n",
      "DB11624\n",
      "DB11625\n",
      "DB11626\n",
      "DB11627\n",
      "DB11628\n",
      "DB11629\n",
      "DB11630\n",
      "DB11631\n",
      "DB11632\n",
      "DB11633\n",
      "DB11634\n",
      "DB11635\n",
      "DB11636\n",
      "DB11637\n",
      "DB11638\n",
      "DB11639\n",
      "DB11640\n",
      "DB11641\n",
      "DB11642\n",
      "DB11643\n",
      "DB11644\n",
      "DB11645\n",
      "DB11646\n",
      "DB11647\n",
      "DB11648\n",
      "DB11649\n",
      "DB11650\n",
      "DB11651\n",
      "DB11652\n",
      "DB11653\n",
      "DB11654\n",
      "DB11655\n",
      "DB11656\n",
      "DB11657\n",
      "DB11658\n",
      "DB11659\n",
      "DB11660\n",
      "DB11661\n",
      "DB11662\n",
      "DB11663\n",
      "DB11664\n",
      "DB11665\n",
      "DB11666\n",
      "DB11667\n",
      "DB11668\n",
      "DB11669\n",
      "DB11670\n",
      "DB11671\n",
      "DB11672\n",
      "DB11673\n",
      "DB11674\n",
      "DB11675\n",
      "DB11676\n",
      "DB11677\n",
      "DB11678\n",
      "DB11679\n",
      "DB11680\n",
      "DB11681\n",
      "DB11682\n",
      "DB11683\n",
      "DB11684\n",
      "DB11685\n",
      "DB11686\n",
      "DB11687\n",
      "DB11688\n",
      "DB11689\n",
      "DB11690\n",
      "DB11691\n",
      "DB11692\n",
      "DB11693\n",
      "DB11694\n",
      "DB11695\n",
      "DB11696\n",
      "DB11697\n",
      "DB11698\n",
      "DB11699\n",
      "DB11700\n",
      "DB11701\n",
      "DB11702\n",
      "DB11703\n",
      "DB11704\n",
      "DB11705\n",
      "DB11706\n",
      "DB11707\n",
      "DB11708\n",
      "DB11709\n",
      "DB11710\n",
      "DB11711\n",
      "DB11712\n",
      "DB11713\n",
      "DB11714\n",
      "DB11715\n",
      "DB11716\n",
      "DB11717\n",
      "DB11718\n",
      "DB11719\n",
      "DB11720\n",
      "DB11721\n",
      "DB11723\n",
      "DB11724\n",
      "DB11725\n",
      "DB11726\n",
      "DB11727\n",
      "DB11729\n",
      "DB11730\n",
      "DB11731\n",
      "DB11732\n",
      "DB11734\n",
      "DB11735\n",
      "DB11736\n",
      "DB11737\n",
      "DB11738\n",
      "DB11739\n",
      "DB11740\n",
      "DB11741\n",
      "DB11742\n",
      "DB11743\n",
      "DB11744\n",
      "DB11745\n",
      "DB11746\n",
      "DB11747\n",
      "DB11748\n",
      "DB11749\n",
      "DB11750\n",
      "DB11751\n",
      "DB11752\n",
      "DB11753\n",
      "DB11754\n",
      "DB11755\n",
      "DB11756\n",
      "DB11757\n",
      "DB11758\n",
      "DB11759\n",
      "DB11760\n",
      "DB11761\n",
      "DB11762\n",
      "DB11763\n",
      "DB11764\n",
      "DB11765\n",
      "DB11766\n",
      "DB11767\n",
      "DB11768\n",
      "DB11769\n",
      "DB11770\n",
      "DB11771\n",
      "DB11772\n",
      "DB11773\n",
      "DB11774\n",
      "DB11775\n",
      "DB11776\n",
      "DB11777\n",
      "DB11778\n",
      "DB11779\n",
      "DB11780\n",
      "DB11781\n",
      "DB11782\n",
      "DB11783\n",
      "DB11784\n",
      "DB11785\n",
      "DB11786\n",
      "DB11787\n",
      "DB11788\n",
      "DB11789\n",
      "DB11790\n",
      "DB11791\n",
      "DB11792\n",
      "DB11793\n",
      "DB11794\n",
      "DB11795\n",
      "DB11796\n",
      "DB11797\n",
      "DB11798\n",
      "DB11799\n",
      "DB11800\n",
      "DB11801\n",
      "DB11803\n",
      "DB11804\n",
      "DB11805\n",
      "DB11806\n",
      "DB11807\n",
      "DB11808\n",
      "DB11809\n",
      "DB11810\n",
      "DB11811\n",
      "DB11812\n",
      "DB11813\n",
      "DB11814\n",
      "DB11815\n",
      "DB11816\n",
      "DB11817\n",
      "DB11818\n",
      "DB11819\n",
      "DB11820\n",
      "DB11821\n",
      "DB11822\n",
      "DB11823\n",
      "DB11824\n",
      "DB11825\n",
      "DB11826\n",
      "DB11827\n",
      "DB11828\n",
      "DB11829\n",
      "DB11830\n",
      "DB11831\n",
      "DB11832\n",
      "DB11833\n",
      "DB11834\n",
      "DB11835\n",
      "DB11836\n",
      "DB11837\n",
      "DB11838\n",
      "DB11839\n",
      "DB11840\n",
      "DB11841\n",
      "DB11842\n",
      "DB11843\n",
      "DB11844\n",
      "DB11845\n",
      "DB11846\n",
      "DB11847\n",
      "DB11848\n",
      "DB11849\n",
      "DB11850\n",
      "DB11851\n",
      "DB11852\n",
      "DB11853\n",
      "DB11854\n",
      "DB11855\n",
      "DB11856\n",
      "DB11857\n",
      "DB11858\n",
      "DB11859\n",
      "DB11860\n",
      "DB11861\n",
      "DB11862\n",
      "DB11863\n",
      "DB11864\n",
      "DB11865\n",
      "DB11866\n",
      "DB11867\n",
      "DB11868\n",
      "DB11869\n",
      "DB11870\n",
      "DB11871\n",
      "DB11872\n",
      "DB11873\n",
      "DB11874\n",
      "DB11875\n",
      "DB11876\n",
      "DB11877\n",
      "DB11878\n",
      "DB11879\n",
      "DB11880\n",
      "DB11881\n",
      "DB11882\n",
      "DB11883\n",
      "DB11884\n",
      "DB11885\n",
      "DB11886\n",
      "DB11888\n",
      "DB11889\n",
      "DB11890\n",
      "DB11891\n",
      "DB11892\n",
      "DB11893\n",
      "DB11894\n",
      "DB11895\n",
      "DB11896\n",
      "DB11898\n",
      "DB11899\n",
      "DB11900\n",
      "DB11901\n",
      "DB11902\n",
      "DB11903\n",
      "DB11904\n",
      "DB11905\n",
      "DB11906\n",
      "DB11907\n",
      "DB11909\n",
      "DB11910\n",
      "DB11911\n",
      "DB11912\n",
      "DB11913\n",
      "DB11914\n",
      "DB11915\n",
      "DB11916\n",
      "DB11917\n",
      "DB11918\n",
      "DB11919\n",
      "DB11920\n",
      "DB11921\n",
      "DB11922\n",
      "DB11923\n",
      "DB11924\n",
      "DB11925\n",
      "DB11926\n",
      "DB11927\n",
      "DB11928\n",
      "DB11929\n",
      "DB11930\n",
      "DB11932\n",
      "DB11933\n",
      "DB11934\n",
      "DB11935\n",
      "DB11936\n",
      "DB11937\n",
      "DB11938\n",
      "DB11939\n",
      "DB11940\n",
      "DB11941\n",
      "DB11942\n",
      "DB11943\n",
      "DB11944\n",
      "DB11945\n",
      "DB11946\n",
      "DB11947\n",
      "DB11948\n",
      "DB11949\n",
      "DB11950\n",
      "DB11951\n",
      "DB11952\n",
      "DB11953\n",
      "DB11954\n",
      "DB11955\n",
      "DB11956\n",
      "DB11957\n",
      "DB11958\n",
      "DB11959\n",
      "DB11960\n",
      "DB11961\n",
      "DB11962\n",
      "DB11963\n",
      "DB11964\n",
      "DB11965\n",
      "DB11966\n",
      "DB11967\n",
      "DB11968\n",
      "DB11969\n",
      "DB11970\n",
      "DB11971\n",
      "DB11972\n",
      "DB11973\n",
      "DB11974\n",
      "DB11975\n",
      "DB11976\n",
      "DB11977\n",
      "DB11978\n",
      "DB11979\n",
      "DB11980\n",
      "DB11981\n",
      "DB11982\n",
      "DB11983\n",
      "DB11984\n",
      "DB11985\n",
      "DB11986\n",
      "DB11987\n",
      "DB11988\n",
      "DB11989\n",
      "DB11990\n",
      "DB11991\n",
      "DB11992\n",
      "DB11993\n",
      "DB11994\n",
      "DB11995\n",
      "DB11996\n",
      "DB11997\n",
      "DB11998\n",
      "DB11999\n",
      "DB12000\n",
      "DB12001\n",
      "DB12002\n",
      "DB12003\n",
      "DB12004\n",
      "DB12005\n",
      "DB12006\n",
      "DB12007\n",
      "DB12008\n",
      "DB12009\n",
      "DB12010\n",
      "DB12011\n",
      "DB12012\n",
      "DB12013\n",
      "DB12014\n",
      "DB12015\n",
      "DB12016\n",
      "DB12017\n",
      "DB12018\n",
      "DB12019\n",
      "DB12020\n",
      "DB12021\n",
      "DB12022\n",
      "DB12023\n",
      "DB12024\n",
      "DB12025\n",
      "DB12026\n",
      "DB12027\n",
      "DB12028\n",
      "DB12029\n",
      "DB12030\n",
      "DB12031\n",
      "DB12032\n",
      "DB12034\n",
      "DB12035\n",
      "DB12036\n",
      "DB12037\n",
      "DB12038\n",
      "DB12039\n",
      "DB12040\n",
      "DB12041\n",
      "DB12042\n",
      "DB12043\n",
      "DB12044\n",
      "DB12045\n",
      "DB12046\n",
      "DB12047\n",
      "DB12048\n",
      "DB12049\n",
      "DB12050\n",
      "DB12051\n",
      "DB12052\n",
      "DB12053\n",
      "DB12054\n",
      "DB12055\n",
      "DB12056\n",
      "DB12057\n",
      "DB12058\n",
      "DB12059\n",
      "DB12060\n",
      "DB12061\n",
      "DB12062\n",
      "DB12063\n",
      "DB12064\n",
      "DB12065\n",
      "DB12066\n",
      "DB12067\n",
      "DB12068\n",
      "DB12069\n",
      "DB12070\n",
      "DB12071\n",
      "DB12072\n",
      "DB12073\n",
      "DB12074\n",
      "DB12075\n",
      "DB12076\n",
      "DB12077\n",
      "DB12078\n",
      "DB12079\n",
      "DB12080\n",
      "DB12081\n",
      "DB12082\n",
      "DB12083\n",
      "DB12084\n",
      "DB12085\n",
      "DB12086\n",
      "DB12087\n",
      "DB12088\n",
      "DB12089\n",
      "DB12090\n",
      "DB12091\n",
      "DB12092\n",
      "DB12093\n",
      "DB12094\n",
      "DB12095\n",
      "DB12096\n",
      "DB12097\n",
      "DB12098\n",
      "DB12099\n",
      "DB12100\n",
      "DB12101\n",
      "DB12102\n",
      "DB12104\n",
      "DB12105\n",
      "DB12106\n",
      "DB12107\n",
      "DB12108\n",
      "DB12109\n",
      "DB12110\n",
      "DB12111\n",
      "DB12112\n",
      "DB12113\n",
      "DB12114\n",
      "DB12115\n",
      "DB12116\n",
      "DB12117\n",
      "DB12118\n",
      "DB12119\n",
      "DB12120\n",
      "DB12121\n",
      "DB12122\n",
      "DB12123\n",
      "DB12124\n",
      "DB12125\n",
      "DB12126\n",
      "DB12127\n",
      "DB12128\n",
      "DB12129\n",
      "DB12130\n",
      "DB12131\n",
      "DB12132\n",
      "DB12133\n",
      "DB12134\n",
      "DB12135\n",
      "DB12136\n",
      "DB12137\n",
      "DB12138\n",
      "DB12139\n",
      "DB12140\n",
      "DB12141\n",
      "DB12142\n",
      "DB12143\n",
      "DB12144\n",
      "DB12145\n",
      "DB12146\n",
      "DB12147\n",
      "DB12148\n",
      "DB12149\n",
      "DB12150\n",
      "DB12151\n",
      "DB12152\n",
      "DB12153\n",
      "DB12154\n",
      "DB12155\n",
      "DB12156\n",
      "DB12157\n",
      "DB12158\n",
      "DB12159\n",
      "DB12160\n",
      "DB12161\n",
      "DB12162\n",
      "DB12163\n",
      "DB12165\n",
      "DB12167\n",
      "DB12168\n",
      "DB12169\n",
      "DB12170\n",
      "DB12171\n",
      "DB12172\n",
      "DB12173\n",
      "DB12174\n",
      "DB12176\n",
      "DB12177\n",
      "DB12178\n",
      "DB12179\n",
      "DB12180\n",
      "DB12181\n",
      "DB12182\n",
      "DB12183\n",
      "DB12184\n",
      "DB12185\n",
      "DB12186\n",
      "DB12187\n",
      "DB12188\n",
      "DB12189\n",
      "DB12190\n",
      "DB12191\n",
      "DB12192\n",
      "DB12193\n",
      "DB12194\n",
      "DB12195\n",
      "DB12196\n",
      "DB12197\n",
      "DB12198\n",
      "DB12199\n",
      "DB12200\n",
      "DB12201\n",
      "DB12202\n",
      "DB12203\n",
      "DB12204\n",
      "DB12205\n",
      "DB12206\n",
      "DB12207\n",
      "DB12208\n",
      "DB12209\n",
      "DB12210\n",
      "DB12211\n",
      "DB12212\n",
      "DB12213\n",
      "DB12214\n",
      "DB12216\n",
      "DB12218\n",
      "DB12219\n",
      "DB12220\n",
      "DB12221\n",
      "DB12222\n",
      "DB12223\n",
      "DB12224\n",
      "DB12225\n",
      "DB12226\n",
      "DB12227\n",
      "DB12228\n",
      "DB12229\n",
      "DB12230\n",
      "DB12231\n",
      "DB12232\n",
      "DB12233\n",
      "DB12234\n",
      "DB12235\n",
      "DB12236\n",
      "DB12237\n",
      "DB12238\n",
      "DB12239\n",
      "DB12240\n",
      "DB12241\n",
      "DB12242\n",
      "DB12243\n",
      "DB12244\n",
      "DB12245\n",
      "DB12246\n",
      "DB12247\n",
      "DB12248\n",
      "DB12249\n",
      "DB12250\n",
      "DB12251\n",
      "DB12252\n",
      "DB12253\n",
      "DB12254\n",
      "DB12255\n",
      "DB12256\n",
      "DB12257\n",
      "DB12258\n",
      "DB12259\n",
      "DB12260\n",
      "DB12261\n",
      "DB12262\n",
      "DB12263\n",
      "DB12264\n",
      "DB12265\n",
      "DB12266\n",
      "DB12267\n",
      "DB12268\n",
      "DB12269\n",
      "DB12270\n",
      "DB12271\n",
      "DB12272\n",
      "DB12273\n",
      "DB12274\n",
      "DB12275\n",
      "DB12276\n",
      "DB12277\n",
      "DB12278\n",
      "DB12279\n",
      "DB12280\n",
      "DB12281\n",
      "DB12282\n",
      "DB12283\n",
      "DB12284\n",
      "DB12285\n",
      "DB12286\n",
      "DB12287\n",
      "DB12288\n",
      "DB12289\n",
      "DB12290\n",
      "DB12291\n",
      "DB12292\n",
      "DB12293\n",
      "DB12294\n",
      "DB12295\n",
      "DB12296\n",
      "DB12297\n",
      "DB12298\n",
      "DB12299\n",
      "DB12300\n",
      "DB12301\n",
      "DB12302\n",
      "DB12303\n",
      "DB12304\n",
      "DB12305\n",
      "DB12306\n",
      "DB12307\n",
      "DB12308\n",
      "DB12309\n",
      "DB12310\n",
      "DB12311\n",
      "DB12312\n",
      "DB12313\n",
      "DB12314\n",
      "DB12316\n",
      "DB12317\n",
      "DB12318\n",
      "DB12319\n",
      "DB12320\n",
      "DB12321\n",
      "DB12322\n",
      "DB12323\n",
      "DB12325\n",
      "DB12326\n",
      "DB12327\n",
      "DB12328\n",
      "DB12329\n",
      "DB12330\n",
      "DB12331\n",
      "DB12332\n",
      "DB12333\n",
      "DB12334\n",
      "DB12335\n",
      "DB12336\n",
      "DB12337\n",
      "DB12338\n",
      "DB12339\n",
      "DB12340\n",
      "DB12341\n",
      "DB12342\n",
      "DB12343\n",
      "DB12344\n",
      "DB12345\n",
      "DB12346\n",
      "DB12347\n",
      "DB12348\n",
      "DB12349\n",
      "DB12350\n",
      "DB12351\n",
      "DB12352\n",
      "DB12353\n",
      "DB12354\n",
      "DB12355\n",
      "DB12356\n",
      "DB12357\n",
      "DB12358\n",
      "DB12359\n",
      "DB12360\n",
      "DB12361\n",
      "DB12362\n",
      "DB12363\n",
      "DB12364\n",
      "DB12365\n",
      "DB12366\n",
      "DB12367\n",
      "DB12368\n",
      "DB12369\n",
      "DB12370\n",
      "DB12371\n",
      "DB12373\n",
      "DB12374\n",
      "DB12375\n",
      "DB12376\n",
      "DB12377\n",
      "DB12378\n",
      "DB12379\n",
      "DB12380\n",
      "DB12381\n",
      "DB12382\n",
      "DB12383\n",
      "DB12384\n",
      "DB12385\n",
      "DB12386\n",
      "DB12387\n",
      "DB12388\n",
      "DB12389\n",
      "DB12390\n",
      "DB12391\n",
      "DB12392\n",
      "DB12393\n",
      "DB12394\n",
      "DB12395\n",
      "DB12396\n",
      "DB12397\n",
      "DB12398\n",
      "DB12399\n",
      "DB12400\n",
      "DB12401\n",
      "DB12402\n",
      "DB12403\n",
      "DB12404\n",
      "DB12405\n",
      "DB12406\n",
      "DB12407\n",
      "DB12408\n",
      "DB12409\n",
      "DB12410\n",
      "DB12411\n",
      "DB12412\n",
      "DB12413\n",
      "DB12414\n",
      "DB12415\n",
      "DB12416\n",
      "DB12417\n",
      "DB12418\n",
      "DB12419\n",
      "DB12420\n",
      "DB12421\n",
      "DB12422\n",
      "DB12423\n",
      "DB12424\n",
      "DB12425\n",
      "DB12426\n",
      "DB12427\n",
      "DB12428\n",
      "DB12429\n",
      "DB12431\n",
      "DB12432\n",
      "DB12433\n",
      "DB12434\n",
      "DB12435\n",
      "DB12436\n",
      "DB12438\n",
      "DB12439\n",
      "DB12440\n",
      "DB12441\n",
      "DB12442\n",
      "DB12443\n",
      "DB12444\n",
      "DB12445\n",
      "DB12446\n",
      "DB12447\n",
      "DB12448\n",
      "DB12449\n",
      "DB12450\n",
      "DB12451\n",
      "DB12452\n",
      "DB12453\n",
      "DB12454\n",
      "DB12455\n",
      "DB12456\n",
      "DB12457\n",
      "DB12458\n",
      "DB12459\n",
      "DB12460\n",
      "DB12461\n",
      "DB12462\n",
      "DB12463\n",
      "DB12464\n",
      "DB12465\n",
      "DB12466\n",
      "DB12467\n",
      "DB12468\n",
      "DB12470\n",
      "DB12471\n",
      "DB12472\n",
      "DB12473\n",
      "DB12474\n",
      "DB12475\n",
      "DB12476\n",
      "DB12477\n",
      "DB12478\n",
      "DB12479\n",
      "DB12480\n",
      "DB12481\n",
      "DB12482\n",
      "DB12483\n",
      "DB12484\n",
      "DB12485\n",
      "DB12486\n",
      "DB12487\n",
      "DB12489\n",
      "DB12490\n",
      "DB12491\n",
      "DB12492\n",
      "DB12493\n",
      "DB12494\n",
      "DB12495\n",
      "DB12497\n",
      "DB12498\n",
      "DB12499\n",
      "DB12500\n",
      "DB12501\n",
      "DB12504\n",
      "DB12505\n",
      "DB12506\n",
      "DB12507\n",
      "DB12508\n",
      "DB12509\n",
      "DB12510\n",
      "DB12511\n",
      "DB12512\n",
      "DB12513\n",
      "DB12514\n",
      "DB12515\n",
      "DB12517\n",
      "DB12518\n",
      "DB12519\n",
      "DB12520\n",
      "DB12521\n",
      "DB12522\n",
      "DB12523\n",
      "DB12524\n",
      "DB12525\n",
      "DB12526\n",
      "DB12527\n",
      "DB12528\n",
      "DB12529\n",
      "DB12530\n",
      "DB12531\n",
      "DB12532\n",
      "DB12533\n",
      "DB12534\n",
      "DB12535\n",
      "DB12536\n",
      "DB12537\n",
      "DB12538\n",
      "DB12539\n",
      "DB12540\n",
      "DB12541\n",
      "DB12542\n",
      "DB12543\n",
      "DB12545\n",
      "DB12547\n",
      "DB12548\n",
      "DB12549\n",
      "DB12550\n",
      "DB12551\n",
      "DB12553\n",
      "DB12554\n",
      "DB12555\n",
      "DB12556\n",
      "DB12557\n",
      "DB12558\n",
      "DB12559\n",
      "DB12560\n",
      "DB12561\n",
      "DB12562\n",
      "DB12563\n",
      "DB12564\n",
      "DB12565\n",
      "DB12566\n",
      "DB12567\n",
      "DB12568\n",
      "DB12569\n",
      "DB12570\n",
      "DB12571\n",
      "DB12572\n",
      "DB12573\n",
      "DB12574\n",
      "DB12575\n",
      "DB12576\n",
      "DB12577\n",
      "DB12578\n",
      "DB12579\n",
      "DB12580\n",
      "DB12581\n",
      "DB12582\n",
      "DB12583\n",
      "DB12584\n",
      "DB12585\n",
      "DB12586\n",
      "DB12587\n",
      "DB12588\n",
      "DB12589\n",
      "DB12590\n",
      "DB12591\n",
      "DB12592\n",
      "DB12593\n",
      "DB12594\n",
      "DB12595\n",
      "DB12596\n",
      "DB12597\n",
      "DB12598\n",
      "DB12601\n",
      "DB12602\n",
      "DB12604\n",
      "DB12605\n",
      "DB12606\n",
      "DB12607\n",
      "DB12608\n",
      "DB12609\n",
      "DB12610\n",
      "DB12611\n",
      "DB12612\n",
      "DB12613\n",
      "DB12614\n",
      "DB12615\n",
      "DB12616\n",
      "DB12617\n",
      "DB12618\n",
      "DB12619\n",
      "DB12620\n",
      "DB12621\n",
      "DB12622\n",
      "DB12623\n",
      "DB12624\n",
      "DB12625\n",
      "DB12626\n",
      "DB12627\n",
      "DB12628\n",
      "DB12629\n",
      "DB12630\n",
      "DB12631\n",
      "DB12632\n",
      "DB12633\n",
      "DB12634\n",
      "DB12635\n",
      "DB12636\n",
      "DB12637\n",
      "DB12638\n",
      "DB12639\n",
      "DB12640\n",
      "DB12641\n",
      "DB12642\n",
      "DB12643\n",
      "DB12644\n",
      "DB12645\n",
      "DB12647\n",
      "DB12648\n",
      "DB12649\n",
      "DB12650\n",
      "DB12651\n",
      "DB12652\n",
      "DB12654\n",
      "DB12655\n",
      "DB12656\n",
      "DB12657\n",
      "DB12658\n",
      "DB12659\n",
      "DB12660\n",
      "DB12661\n",
      "DB12662\n",
      "DB12663\n",
      "DB12664\n",
      "DB12665\n",
      "DB12666\n",
      "DB12667\n",
      "DB12668\n",
      "DB12669\n",
      "DB12670\n",
      "DB12671\n",
      "DB12672\n",
      "DB12673\n",
      "DB12674\n",
      "DB12675\n",
      "DB12676\n",
      "DB12677\n",
      "DB12678\n",
      "DB12679\n",
      "DB12680\n",
      "DB12681\n",
      "DB12682\n",
      "DB12683\n",
      "DB12684\n",
      "DB12685\n",
      "DB12686\n",
      "DB12687\n",
      "DB12688\n",
      "DB12689\n",
      "DB12690\n",
      "DB12691\n",
      "DB12692\n",
      "DB12693\n",
      "DB12694\n",
      "DB12695\n",
      "DB12696\n",
      "DB12697\n",
      "DB12698\n",
      "DB12699\n",
      "DB12700\n",
      "DB12701\n",
      "DB12702\n",
      "DB12703\n",
      "DB12704\n",
      "DB12705\n",
      "DB12706\n",
      "DB12707\n",
      "DB12708\n",
      "DB12709\n",
      "DB12710\n",
      "DB12711\n",
      "DB12712\n",
      "DB12713\n",
      "DB12714\n",
      "DB12715\n",
      "DB12716\n",
      "DB12717\n",
      "DB12718\n",
      "DB12719\n",
      "DB12720\n",
      "DB12721\n",
      "DB12722\n",
      "DB12724\n",
      "DB12725\n",
      "DB12726\n",
      "DB12727\n",
      "DB12728\n",
      "DB12729\n",
      "DB12730\n",
      "DB12731\n",
      "DB12732\n",
      "DB12733\n",
      "DB12734\n",
      "DB12736\n",
      "DB12737\n",
      "DB12738\n",
      "DB12739\n",
      "DB12740\n",
      "DB12741\n",
      "DB12742\n",
      "DB12743\n",
      "DB12744\n",
      "DB12745\n",
      "DB12746\n",
      "DB12747\n",
      "DB12748\n",
      "DB12749\n",
      "DB12750\n",
      "DB12751\n",
      "DB12752\n",
      "DB12753\n",
      "DB12754\n",
      "DB12755\n",
      "DB12756\n",
      "DB12757\n",
      "DB12758\n",
      "DB12759\n",
      "DB12760\n",
      "DB12761\n",
      "DB12762\n",
      "DB12763\n",
      "DB12764\n",
      "DB12765\n",
      "DB12766\n",
      "DB12767\n",
      "DB12768\n",
      "DB12769\n",
      "DB12770\n",
      "DB12771\n",
      "DB12773\n",
      "DB12774\n",
      "DB12775\n",
      "DB12776\n",
      "DB12777\n",
      "DB12778\n",
      "DB12779\n",
      "DB12780\n",
      "DB12781\n",
      "DB12782\n",
      "DB12783\n",
      "DB12784\n",
      "DB12785\n",
      "DB12786\n",
      "DB12787\n",
      "DB12788\n",
      "DB12789\n",
      "DB12791\n",
      "DB12792\n",
      "DB12793\n",
      "DB12794\n",
      "DB12795\n",
      "DB12796\n",
      "DB12797\n",
      "DB12798\n",
      "DB12799\n",
      "DB12800\n",
      "DB12802\n",
      "DB12803\n",
      "DB12804\n",
      "DB12805\n",
      "DB12806\n",
      "DB12807\n",
      "DB12808\n",
      "DB12809\n",
      "DB12810\n",
      "DB12812\n",
      "DB12813\n",
      "DB12814\n",
      "DB12815\n",
      "DB12816\n",
      "DB12817\n",
      "DB12818\n",
      "DB12819\n",
      "DB12820\n",
      "DB12821\n",
      "DB12822\n",
      "DB12823\n",
      "DB12824\n",
      "DB12825\n",
      "DB12826\n",
      "DB12827\n",
      "DB12829\n",
      "DB12830\n",
      "DB12831\n",
      "DB12832\n",
      "DB12833\n",
      "DB12834\n",
      "DB12835\n",
      "DB12836\n",
      "DB12837\n",
      "DB12838\n",
      "DB12839\n",
      "DB12840\n",
      "DB12841\n",
      "DB12842\n",
      "DB12843\n",
      "DB12844\n",
      "DB12845\n",
      "DB12846\n",
      "DB12847\n",
      "DB12848\n",
      "DB12849\n",
      "DB12850\n",
      "DB12851\n",
      "DB12852\n",
      "DB12853\n",
      "DB12854\n",
      "DB12855\n",
      "DB12856\n",
      "DB12857\n",
      "DB12858\n",
      "DB12859\n",
      "DB12860\n",
      "DB12861\n",
      "DB12862\n",
      "DB12863\n",
      "DB12864\n",
      "DB12865\n",
      "DB12866\n",
      "DB12867\n",
      "DB12868\n",
      "DB12869\n",
      "DB12870\n",
      "DB12871\n",
      "DB12872\n",
      "DB12873\n",
      "DB12874\n",
      "DB12875\n",
      "DB12876\n",
      "DB12877\n",
      "DB12878\n",
      "DB12879\n",
      "DB12880\n",
      "DB12881\n",
      "DB12882\n",
      "DB12883\n",
      "DB12884\n",
      "DB12885\n",
      "DB12886\n",
      "DB12887\n",
      "DB12888\n",
      "DB12889\n",
      "DB12890\n",
      "DB12891\n",
      "DB12892\n",
      "DB12893\n",
      "DB12894\n",
      "DB12895\n",
      "DB12896\n",
      "DB12897\n",
      "DB12898\n",
      "DB12899\n",
      "DB12900\n",
      "DB12901\n",
      "DB12902\n",
      "DB12903\n",
      "DB12904\n",
      "DB12905\n",
      "DB12906\n",
      "DB12907\n",
      "DB12908\n",
      "DB12909\n",
      "DB12910\n",
      "DB12911\n",
      "DB12912\n",
      "DB12914\n",
      "DB12915\n",
      "DB12916\n",
      "DB12917\n",
      "DB12919\n",
      "DB12920\n",
      "DB12921\n",
      "DB12923\n",
      "DB12924\n",
      "DB12925\n",
      "DB12926\n",
      "DB12927\n",
      "DB12928\n",
      "DB12929\n",
      "DB12930\n",
      "DB12931\n",
      "DB12932\n",
      "DB12933\n",
      "DB12934\n",
      "DB12935\n",
      "DB12937\n",
      "DB12938\n",
      "DB12939\n",
      "DB12940\n",
      "DB12941\n",
      "DB12942\n",
      "DB12943\n",
      "DB12944\n",
      "DB12945\n",
      "DB12946\n",
      "DB12947\n",
      "DB12948\n",
      "DB12949\n",
      "DB12950\n",
      "DB12951\n",
      "DB12952\n",
      "DB12953\n",
      "DB12954\n",
      "DB12955\n",
      "DB12956\n",
      "DB12957\n",
      "DB12958\n",
      "DB12959\n",
      "DB12960\n",
      "DB12961\n",
      "DB12962\n",
      "DB12963\n",
      "DB12964\n",
      "DB12965\n",
      "DB12966\n",
      "DB12967\n",
      "DB12968\n",
      "DB12969\n",
      "DB12970\n",
      "DB12971\n",
      "DB12972\n",
      "DB12973\n",
      "DB12974\n",
      "DB12975\n",
      "DB12976\n",
      "DB12977\n",
      "DB12978\n",
      "DB12979\n",
      "DB12980\n",
      "DB12981\n",
      "DB12982\n",
      "DB12983\n",
      "DB12984\n",
      "DB12985\n",
      "DB12986\n",
      "DB12987\n",
      "DB12988\n",
      "DB12989\n",
      "DB12990\n",
      "DB12991\n",
      "DB12992\n",
      "DB12993\n",
      "DB12994\n",
      "DB12996\n",
      "DB12997\n",
      "DB12998\n",
      "DB12999\n",
      "DB13000\n",
      "DB13001\n",
      "DB13002\n",
      "DB13003\n",
      "DB13004\n",
      "DB13005\n",
      "DB13006\n",
      "DB13007\n",
      "DB13008\n",
      "DB13009\n",
      "DB13010\n",
      "DB13011\n",
      "DB13012\n",
      "DB13013\n",
      "DB13014\n",
      "DB13016\n",
      "DB13017\n",
      "DB13018\n",
      "DB13019\n",
      "DB13020\n",
      "DB13021\n",
      "DB13022\n",
      "DB13023\n",
      "DB13024\n",
      "DB13025\n",
      "DB13026\n",
      "DB13027\n",
      "DB13028\n",
      "DB13029\n",
      "DB13030\n",
      "DB13031\n",
      "DB13032\n",
      "DB13033\n",
      "DB13034\n",
      "DB13035\n",
      "DB13036\n",
      "DB13037\n",
      "DB13038\n",
      "DB13039\n",
      "DB13040\n",
      "DB13041\n",
      "DB13042\n",
      "DB13044\n",
      "DB13045\n",
      "DB13046\n",
      "DB13047\n",
      "DB13048\n",
      "DB13049\n",
      "DB13050\n",
      "DB13051\n",
      "DB13052\n",
      "DB13053\n",
      "DB13054\n",
      "DB13055\n",
      "DB13056\n",
      "DB13057\n",
      "DB13058\n",
      "DB13059\n",
      "DB13060\n",
      "DB13061\n",
      "DB13062\n",
      "DB13063\n",
      "DB13064\n",
      "DB13065\n",
      "DB13066\n",
      "DB13067\n",
      "DB13068\n",
      "DB13069\n",
      "DB13070\n",
      "DB13071\n",
      "DB13072\n",
      "DB13073\n",
      "DB13074\n",
      "DB13075\n",
      "DB13076\n",
      "DB13077\n",
      "DB13078\n",
      "DB13080\n",
      "DB13082\n",
      "DB13083\n",
      "DB13084\n",
      "DB13085\n",
      "DB13086\n",
      "DB13087\n",
      "DB13088\n",
      "DB13089\n",
      "DB13090\n",
      "DB13091\n",
      "DB13092\n",
      "DB13093\n",
      "DB13094\n",
      "DB13095\n",
      "DB13096\n",
      "DB13097\n",
      "DB13098\n",
      "DB13099\n",
      "DB13100\n",
      "DB13101\n",
      "DB13102\n",
      "DB13103\n",
      "DB13104\n",
      "DB13105\n",
      "DB13106\n",
      "DB13107\n",
      "DB13108\n",
      "DB13109\n",
      "DB13110\n",
      "DB13111\n",
      "DB13112\n",
      "DB13113\n",
      "DB13114\n",
      "DB13115\n",
      "DB13116\n",
      "DB13117\n",
      "DB13118\n",
      "DB13119\n",
      "DB13120\n",
      "DB13121\n",
      "DB13122\n",
      "DB13123\n",
      "DB13124\n",
      "DB13125\n",
      "DB13126\n",
      "DB13127\n",
      "DB13128\n",
      "DB13129\n",
      "DB13131\n",
      "DB13132\n",
      "DB13133\n",
      "DB13134\n",
      "DB13135\n",
      "DB13136\n",
      "DB13137\n",
      "DB13138\n",
      "DB13139\n",
      "DB13140\n",
      "DB13141\n",
      "DB13142\n",
      "DB13143\n",
      "DB13144\n",
      "DB13145\n",
      "DB13146\n",
      "DB13147\n",
      "DB13148\n",
      "DB13149\n",
      "DB13150\n",
      "DB13151\n",
      "DB13152\n",
      "DB13153\n",
      "DB13154\n",
      "DB13155\n",
      "DB13156\n",
      "DB13157\n",
      "DB13158\n",
      "DB13160\n",
      "DB13161\n",
      "DB13163\n",
      "DB13164\n",
      "DB13165\n",
      "DB13166\n",
      "DB13167\n",
      "DB13168\n",
      "DB13169\n",
      "DB13170\n",
      "DB13171\n",
      "DB13172\n",
      "DB13173\n",
      "DB13174\n",
      "DB13175\n",
      "DB13177\n",
      "DB13178\n",
      "DB13179\n",
      "DB13180\n",
      "DB13181\n",
      "DB13182\n",
      "DB13183\n",
      "DB13185\n",
      "DB13189\n",
      "DB13190\n",
      "DB13191\n",
      "DB13192\n",
      "DB13193\n",
      "DB13194\n",
      "DB13195\n",
      "DB13196\n",
      "DB13197\n",
      "DB13198\n",
      "DB13199\n",
      "DB13200\n",
      "DB13201\n",
      "DB13202\n",
      "DB13203\n",
      "DB13204\n",
      "DB13205\n",
      "DB13206\n",
      "DB13207\n",
      "DB13208\n",
      "DB13209\n",
      "DB13210\n",
      "DB13211\n",
      "DB13212\n",
      "DB13213\n",
      "DB13214\n",
      "DB13215\n",
      "DB13216\n",
      "DB13217\n",
      "DB13218\n",
      "DB13219\n",
      "DB13220\n",
      "DB13221\n",
      "DB13222\n",
      "DB13223\n",
      "DB13224\n",
      "DB13225\n",
      "DB13226\n",
      "DB13227\n",
      "DB13228\n",
      "DB13229\n",
      "DB13230\n",
      "DB13231\n",
      "DB13232\n",
      "DB13233\n",
      "DB13234\n",
      "DB13235\n",
      "DB13236\n",
      "DB13237\n",
      "DB13238\n",
      "DB13239\n",
      "DB13240\n",
      "DB13241\n",
      "DB13242\n",
      "DB13243\n",
      "DB13244\n",
      "DB13245\n",
      "DB13246\n",
      "DB13247\n",
      "DB13248\n",
      "DB13249\n",
      "DB13250\n",
      "DB13251\n",
      "DB13252\n",
      "DB13253\n",
      "DB13254\n",
      "DB13255\n",
      "DB13256\n",
      "DB13257\n",
      "DB13258\n",
      "DB13259\n",
      "DB13260\n",
      "DB13261\n",
      "DB13262\n",
      "DB13263\n",
      "DB13264\n",
      "DB13265\n",
      "DB13266\n",
      "DB13267\n",
      "DB13268\n",
      "DB13269\n",
      "DB13270\n",
      "DB13271\n",
      "DB13272\n",
      "DB13273\n",
      "DB13274\n",
      "DB13275\n",
      "DB13276\n",
      "DB13277\n",
      "DB13278\n",
      "DB13279\n",
      "DB13280\n",
      "DB13281\n",
      "DB13282\n",
      "DB13283\n",
      "DB13284\n",
      "DB13285\n",
      "DB13286\n",
      "DB13287\n",
      "DB13288\n",
      "DB13289\n",
      "DB13290\n",
      "DB13291\n",
      "DB13292\n",
      "DB13293\n",
      "DB13294\n",
      "DB13295\n",
      "DB13296\n",
      "DB13297\n",
      "DB13298\n",
      "DB13299\n",
      "DB13300\n",
      "DB13302\n",
      "DB13303\n",
      "DB13304\n",
      "DB13305\n",
      "DB13306\n",
      "DB13307\n",
      "DB13308\n",
      "DB13309\n",
      "DB13310\n",
      "DB13311\n",
      "DB13312\n",
      "DB13313\n",
      "DB13314\n",
      "DB13315\n",
      "DB13316\n",
      "DB13317\n",
      "DB13318\n",
      "DB13319\n",
      "DB13320\n",
      "DB13321\n",
      "DB13322\n",
      "DB13323\n",
      "DB13324\n",
      "DB13325\n",
      "DB13326\n",
      "DB13327\n",
      "DB13328\n",
      "DB13329\n",
      "DB13330\n",
      "DB13331\n",
      "DB13332\n",
      "DB13333\n",
      "DB13334\n",
      "DB13335\n",
      "DB13336\n",
      "DB13337\n",
      "DB13338\n",
      "DB13339\n",
      "DB13340\n",
      "DB13341\n",
      "DB13342\n",
      "DB13343\n",
      "DB13344\n",
      "DB13345\n",
      "DB13346\n",
      "DB13347\n",
      "DB13348\n",
      "DB13349\n",
      "DB13350\n",
      "DB13351\n",
      "DB13352\n",
      "DB13353\n",
      "DB13354\n",
      "DB13355\n",
      "DB13356\n",
      "DB13357\n",
      "DB13358\n",
      "DB13359\n",
      "DB13360\n",
      "DB13361\n",
      "DB13362\n",
      "DB13363\n",
      "DB13364\n",
      "DB13365\n",
      "DB13366\n",
      "DB13367\n",
      "DB13368\n",
      "DB13369\n",
      "DB13370\n",
      "DB13371\n",
      "DB13372\n",
      "DB13373\n",
      "DB13374\n",
      "DB13375\n",
      "DB13376\n",
      "DB13377\n",
      "DB13378\n",
      "DB13379\n",
      "DB13380\n",
      "DB13381\n",
      "DB13382\n",
      "DB13383\n",
      "DB13384\n",
      "DB13385\n",
      "DB13386\n",
      "DB13387\n",
      "DB13388\n",
      "DB13389\n",
      "DB13391\n",
      "DB13392\n",
      "DB13393\n",
      "DB13394\n",
      "DB13395\n",
      "DB13396\n",
      "DB13397\n",
      "DB13398\n",
      "DB13399\n",
      "DB13400\n",
      "DB13401\n",
      "DB13402\n",
      "DB13403\n",
      "DB13404\n",
      "DB13405\n",
      "DB13406\n",
      "DB13407\n",
      "DB13408\n",
      "DB13409\n",
      "DB13410\n",
      "DB13411\n",
      "DB13412\n",
      "DB13413\n",
      "DB13414\n",
      "DB13415\n",
      "DB13416\n",
      "DB13417\n",
      "DB13418\n",
      "DB13419\n",
      "DB13420\n",
      "DB13421\n",
      "DB13422\n",
      "DB13423\n",
      "DB13424\n",
      "DB13425\n",
      "DB13427\n",
      "DB13428\n",
      "DB13429\n",
      "DB13430\n",
      "DB13431\n",
      "DB13432\n",
      "DB13433\n",
      "DB13434\n",
      "DB13435\n",
      "DB13436\n",
      "DB13437\n",
      "DB13438\n",
      "DB13439\n",
      "DB13441\n",
      "DB13442\n",
      "DB13443\n",
      "DB13444\n",
      "DB13445\n",
      "DB13446\n",
      "DB13447\n",
      "DB13448\n",
      "DB13449\n",
      "DB13451\n",
      "DB13452\n",
      "DB13453\n",
      "DB13454\n",
      "DB13455\n",
      "DB13456\n",
      "DB13457\n",
      "DB13458\n",
      "DB13459\n",
      "DB13460\n",
      "DB13461\n",
      "DB13462\n",
      "DB13463\n",
      "DB13464\n",
      "DB13465\n",
      "DB13466\n",
      "DB13467\n",
      "DB13468\n",
      "DB13469\n",
      "DB13470\n",
      "DB13471\n",
      "DB13472\n",
      "DB13473\n",
      "DB13474\n",
      "DB13475\n",
      "DB13476\n",
      "DB13477\n",
      "DB13478\n",
      "DB13479\n",
      "DB13480\n",
      "DB13481\n",
      "DB13482\n",
      "DB13483\n",
      "DB13484\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB13485\n",
      "DB13486\n",
      "DB13487\n",
      "DB13488\n",
      "DB13489\n",
      "DB13490\n",
      "DB13491\n",
      "DB13492\n",
      "DB13493\n",
      "DB13494\n",
      "DB13495\n",
      "DB13496\n",
      "DB13497\n",
      "DB13499\n",
      "DB13500\n",
      "DB13501\n",
      "DB13502\n",
      "DB13503\n",
      "DB13504\n",
      "DB13505\n",
      "DB13506\n",
      "DB13507\n",
      "DB13508\n",
      "DB13509\n",
      "DB13510\n",
      "DB13511\n",
      "DB13512\n",
      "DB13513\n",
      "DB13514\n",
      "DB13515\n",
      "DB13516\n",
      "DB13517\n",
      "DB13518\n",
      "DB13519\n",
      "DB13520\n",
      "DB13521\n",
      "DB13522\n",
      "DB13523\n",
      "DB13524\n",
      "DB13525\n",
      "DB13526\n",
      "DB13527\n",
      "DB13528\n",
      "DB13529\n",
      "DB13530\n",
      "DB13531\n",
      "DB13532\n",
      "DB13533\n",
      "DB13534\n",
      "DB13535\n",
      "DB13536\n",
      "DB13537\n",
      "DB13538\n",
      "DB13539\n",
      "DB13540\n",
      "DB13541\n",
      "DB13542\n",
      "DB13543\n",
      "DB13544\n",
      "DB13545\n",
      "DB13546\n",
      "DB13547\n",
      "DB13548\n",
      "DB13549\n",
      "DB13550\n",
      "DB13551\n",
      "DB13552\n",
      "DB13553\n",
      "DB13554\n",
      "DB13555\n",
      "DB13556\n",
      "DB13557\n",
      "DB13558\n",
      "DB13559\n",
      "DB13560\n",
      "DB13561\n",
      "DB13563\n",
      "DB13564\n",
      "DB13565\n",
      "DB13566\n",
      "DB13567\n",
      "DB13568\n",
      "DB13569\n",
      "DB13570\n",
      "DB13571\n",
      "DB13572\n",
      "DB13573\n",
      "DB13574\n",
      "DB13575\n",
      "DB13576\n",
      "DB13577\n",
      "DB13578\n",
      "DB13579\n",
      "DB13580\n",
      "DB13581\n",
      "DB13582\n",
      "DB13583\n",
      "DB13584\n",
      "DB13585\n",
      "DB13586\n",
      "DB13587\n",
      "DB13588\n",
      "DB13590\n",
      "DB13591\n",
      "DB13592\n",
      "DB13593\n",
      "DB13595\n",
      "DB13596\n",
      "DB13597\n",
      "DB13598\n",
      "DB13599\n",
      "DB13600\n",
      "DB13601\n",
      "DB13602\n",
      "DB13603\n",
      "DB13604\n",
      "DB13605\n",
      "DB13606\n",
      "DB13607\n",
      "DB13608\n",
      "DB13609\n",
      "DB13610\n",
      "DB13611\n",
      "DB13612\n",
      "DB13613\n",
      "DB13614\n",
      "DB13615\n",
      "DB13616\n",
      "DB13617\n",
      "DB13618\n",
      "DB13619\n",
      "DB13620\n",
      "DB13621\n",
      "DB13622\n",
      "DB13623\n",
      "DB13624\n",
      "DB13625\n",
      "DB13626\n",
      "DB13627\n",
      "DB13628\n",
      "DB13629\n",
      "DB13630\n",
      "DB13631\n",
      "DB13632\n",
      "DB13633\n",
      "DB13634\n",
      "DB13635\n",
      "DB13636\n",
      "DB13637\n",
      "DB13638\n",
      "DB13639\n",
      "DB13640\n",
      "DB13641\n",
      "DB13642\n",
      "DB13643\n",
      "DB13644\n",
      "DB13645\n",
      "DB13646\n",
      "DB13647\n",
      "DB13648\n",
      "DB13649\n",
      "DB13650\n",
      "DB13651\n",
      "DB13652\n",
      "DB13653\n",
      "DB13654\n",
      "DB13655\n",
      "DB13656\n",
      "DB13657\n",
      "DB13658\n",
      "DB13659\n",
      "DB13660\n",
      "DB13661\n",
      "DB13662\n",
      "DB13663\n",
      "DB13664\n",
      "DB13665\n",
      "DB13666\n",
      "DB13667\n",
      "DB13668\n",
      "DB13669\n",
      "DB13670\n",
      "DB13671\n",
      "DB13672\n",
      "DB13673\n",
      "DB13674\n",
      "DB13675\n",
      "DB13676\n",
      "DB13677\n",
      "DB13678\n",
      "DB13679\n",
      "DB13680\n",
      "DB13681\n",
      "DB13682\n",
      "DB13683\n",
      "DB13684\n",
      "DB13685\n",
      "DB13686\n",
      "DB13687\n",
      "DB13688\n",
      "DB13689\n",
      "DB13690\n",
      "DB13691\n",
      "DB13692\n",
      "DB13693\n",
      "DB13694\n",
      "DB13695\n",
      "DB13696\n",
      "DB13697\n",
      "DB13698\n",
      "DB13699\n",
      "DB13700\n",
      "DB13701\n",
      "DB13702\n",
      "DB13703\n",
      "DB13704\n",
      "DB13705\n",
      "DB13706\n",
      "DB13707\n",
      "DB13708\n",
      "DB13709\n",
      "DB13710\n",
      "DB13711\n",
      "DB13712\n",
      "DB13713\n",
      "DB13714\n",
      "DB13715\n",
      "DB13716\n",
      "DB13717\n",
      "DB13718\n",
      "DB13719\n",
      "DB13720\n",
      "DB13721\n",
      "DB13722\n",
      "DB13723\n",
      "DB13724\n",
      "DB13725\n",
      "DB13726\n",
      "DB13727\n",
      "DB13728\n",
      "DB13729\n",
      "DB13730\n",
      "DB13731\n",
      "DB13732\n",
      "DB13733\n",
      "DB13734\n",
      "DB13735\n",
      "DB13736\n",
      "DB13737\n",
      "DB13738\n",
      "DB13739\n",
      "DB13740\n",
      "DB13741\n",
      "DB13742\n",
      "DB13743\n",
      "DB13744\n",
      "DB13745\n",
      "DB13746\n",
      "DB13747\n",
      "DB13748\n",
      "DB13749\n",
      "DB13750\n",
      "DB13751\n",
      "DB13752\n",
      "DB13753\n",
      "DB13754\n",
      "DB13755\n",
      "DB13756\n",
      "DB13757\n",
      "DB13758\n",
      "DB13759\n",
      "DB13760\n",
      "DB13761\n",
      "DB13762\n",
      "DB13763\n",
      "DB13764\n",
      "DB13765\n",
      "DB13766\n",
      "DB13767\n",
      "DB13768\n",
      "DB13769\n",
      "DB13770\n",
      "DB13771\n",
      "DB13772\n",
      "DB13773\n",
      "DB13774\n",
      "DB13775\n",
      "DB13776\n",
      "DB13777\n",
      "DB13778\n",
      "DB13779\n",
      "DB13780\n",
      "DB13781\n",
      "DB13782\n",
      "DB13783\n",
      "DB13784\n",
      "DB13785\n",
      "DB13786\n",
      "DB13787\n",
      "DB13788\n",
      "DB13789\n",
      "DB13790\n",
      "DB13791\n",
      "DB13792\n",
      "DB13793\n",
      "DB13794\n",
      "DB13795\n",
      "DB13796\n",
      "DB13797\n",
      "DB13798\n",
      "DB13799\n",
      "DB13800\n",
      "DB13801\n",
      "DB13802\n",
      "DB13803\n",
      "DB13804\n",
      "DB13805\n",
      "DB13806\n",
      "DB13807\n",
      "DB13808\n",
      "DB13809\n",
      "DB13810\n",
      "DB13811\n",
      "DB13812\n",
      "DB13813\n",
      "DB13814\n",
      "DB13815\n",
      "DB13816\n",
      "DB13817\n",
      "DB13818\n",
      "DB13819\n",
      "DB13820\n",
      "DB13821\n",
      "DB13822\n",
      "DB13823\n",
      "DB13824\n",
      "DB13825\n",
      "DB13826\n",
      "DB13827\n",
      "DB13828\n",
      "DB13829\n",
      "DB13830\n",
      "DB13831\n",
      "DB13832\n",
      "DB13833\n",
      "DB13834\n",
      "DB13835\n",
      "DB13836\n",
      "DB13837\n",
      "DB13838\n",
      "DB13839\n",
      "DB13840\n",
      "DB13841\n",
      "DB13842\n",
      "DB13843\n",
      "DB13844\n",
      "DB13845\n",
      "DB13846\n",
      "DB13847\n",
      "DB13848\n",
      "DB13849\n",
      "DB13850\n",
      "DB13851\n",
      "DB13852\n",
      "DB13853\n",
      "DB13854\n",
      "DB13855\n",
      "DB13856\n",
      "DB13857\n",
      "DB13858\n",
      "DB13860\n",
      "DB13861\n",
      "DB13862\n",
      "DB13863\n",
      "DB13864\n",
      "DB13865\n",
      "DB13866\n",
      "DB13867\n",
      "DB13868\n",
      "DB13869\n",
      "DB13871\n",
      "DB13872\n",
      "DB13873\n",
      "DB13874\n",
      "DB13875\n",
      "DB13876\n",
      "DB13877\n",
      "DB13878\n",
      "DB13879\n",
      "DB13881\n",
      "DB13882\n",
      "DB13883\n",
      "DB13884\n",
      "DB13885\n",
      "DB13886\n",
      "DB13887\n",
      "DB13888\n",
      "DB13889\n",
      "DB13890\n",
      "DB13891\n",
      "DB13892\n",
      "DB13893\n",
      "DB13894\n",
      "DB13895\n",
      "DB13896\n",
      "DB13897\n",
      "DB13898\n",
      "DB13899\n",
      "DB13900\n",
      "DB13901\n",
      "DB13902\n",
      "DB13903\n",
      "DB13904\n",
      "DB13905\n",
      "DB13906\n",
      "DB13907\n",
      "DB13908\n",
      "DB13909\n",
      "DB13910\n",
      "DB13911\n",
      "DB13912\n",
      "DB13913\n",
      "DB13914\n",
      "DB13915\n",
      "DB13916\n",
      "DB13917\n",
      "DB13918\n",
      "DB13919\n",
      "DB13920\n",
      "DB13921\n",
      "DB13923\n",
      "DB13924\n",
      "DB13925\n",
      "DB13926\n",
      "DB13927\n",
      "DB13928\n",
      "DB13929\n",
      "DB13930\n",
      "DB13931\n",
      "DB13932\n",
      "DB13933\n",
      "DB13934\n",
      "DB13935\n",
      "DB13936\n",
      "DB13937\n",
      "DB13938\n",
      "DB13939\n",
      "DB13940\n",
      "DB13941\n",
      "DB13943\n",
      "DB13944\n",
      "DB13946\n",
      "DB13947\n",
      "DB13948\n",
      "DB13949\n",
      "DB13950\n",
      "DB13951\n",
      "DB13952\n",
      "DB13953\n",
      "DB13954\n",
      "DB13955\n",
      "DB13956\n",
      "DB13957\n",
      "DB13958\n",
      "DB13959\n",
      "DB13960\n",
      "DB13961\n",
      "DB13962\n",
      "DB13963\n",
      "DB13964\n",
      "DB13965\n",
      "DB13966\n",
      "DB13967\n",
      "DB13968\n",
      "DB13969\n",
      "DB13970\n",
      "DB13971\n",
      "DB13972\n",
      "DB13973\n",
      "DB13974\n",
      "DB13975\n",
      "DB13976\n",
      "DB13977\n",
      "DB13978\n",
      "DB13979\n",
      "DB13980\n",
      "DB13981\n",
      "DB13982\n",
      "DB13983\n",
      "DB13984\n",
      "DB13985\n",
      "DB13987\n",
      "DB13988\n",
      "DB13989\n",
      "DB13990\n",
      "DB13991\n",
      "DB13992\n",
      "DB13993\n",
      "DB13994\n",
      "DB13995\n",
      "DB13996\n",
      "DB13997\n",
      "DB13998\n",
      "DB13999\n",
      "DB14000\n",
      "DB14001\n",
      "DB14002\n",
      "DB14003\n",
      "DB14004\n",
      "DB14005\n",
      "DB14006\n",
      "DB14007\n",
      "DB14008\n",
      "DB14009\n",
      "DB14010\n",
      "DB14011\n",
      "DB14012\n",
      "DB14013\n",
      "DB14014\n",
      "DB14015\n",
      "DB14016\n",
      "DB14017\n",
      "DB14018\n",
      "DB14019\n",
      "DB14020\n",
      "DB14022\n",
      "DB14025\n",
      "DB14026\n",
      "DB14027\n",
      "DB14028\n",
      "DB14029\n",
      "DB14030\n",
      "DB14031\n",
      "DB14033\n",
      "DB14034\n",
      "DB14035\n",
      "DB14037\n",
      "DB14038\n",
      "DB14039\n",
      "DB14040\n",
      "DB14041\n",
      "DB14042\n",
      "DB14043\n",
      "DB14044\n",
      "DB14045\n",
      "DB14046\n",
      "DB14048\n",
      "DB14049\n",
      "DB14050\n",
      "DB14051\n",
      "DB14052\n",
      "DB14054\n",
      "DB14055\n",
      "DB14056\n",
      "DB14057\n",
      "DB14058\n",
      "DB14059\n",
      "DB14060\n",
      "DB14061\n",
      "DB14062\n",
      "DB14063\n",
      "DB14064\n",
      "DB14065\n",
      "DB14066\n",
      "DB14067\n",
      "DB14068\n",
      "DB14069\n",
      "DB14070\n",
      "DB14071\n",
      "DB14072\n",
      "DB14073\n",
      "DB14074\n",
      "DB14075\n",
      "DB14076\n",
      "DB14077\n",
      "DB14078\n",
      "DB14079\n",
      "DB14080\n",
      "DB14081\n",
      "DB14082\n",
      "DB14083\n",
      "DB14084\n",
      "DB14085\n",
      "DB14086\n",
      "DB14087\n",
      "DB14088\n",
      "DB14089\n",
      "DB14090\n",
      "DB14091\n",
      "DB14092\n",
      "DB14093\n",
      "DB14094\n",
      "DB14096\n",
      "DB14097\n",
      "DB14098\n",
      "DB14099\n",
      "DB14100\n",
      "DB14101\n",
      "DB14102\n",
      "DB14103\n",
      "DB14104\n",
      "DB14105\n",
      "DB14106\n",
      "DB14107\n",
      "DB14108\n",
      "DB14109\n",
      "DB14110\n",
      "DB14111\n",
      "DB14112\n",
      "DB14113\n",
      "DB14114\n",
      "DB14115\n",
      "DB14116\n",
      "DB14117\n",
      "DB14119\n",
      "DB14120\n",
      "DB14121\n",
      "DB14122\n",
      "DB14123\n",
      "DB14124\n",
      "DB14125\n",
      "DB14126\n",
      "DB14127\n",
      "DB14128\n",
      "DB14129\n",
      "DB14130\n",
      "DB14131\n",
      "DB14132\n",
      "DB14134\n",
      "DB14135\n",
      "DB14136\n",
      "DB14137\n",
      "DB14138\n",
      "DB14139\n",
      "DB14140\n",
      "DB14141\n",
      "DB14142\n",
      "DB14143\n",
      "DB14144\n",
      "DB14145\n",
      "DB14146\n",
      "DB14148\n",
      "DB14149\n",
      "DB14150\n",
      "DB14151\n",
      "DB14152\n",
      "DB14153\n",
      "DB14154\n",
      "DB14155\n",
      "DB14156\n",
      "DB14157\n",
      "DB14158\n",
      "DB14159\n",
      "DB14160\n",
      "DB14161\n",
      "DB14162\n",
      "DB14163\n",
      "DB14164\n",
      "DB14165\n",
      "DB14166\n",
      "DB14167\n",
      "DB14168\n",
      "DB14169\n",
      "DB14170\n",
      "DB14171\n",
      "DB14172\n",
      "DB14173\n",
      "DB14174\n",
      "DB14175\n",
      "DB14176\n",
      "DB14177\n",
      "DB14178\n",
      "DB14179\n",
      "DB14180\n",
      "DB14181\n",
      "DB14182\n",
      "DB14183\n",
      "DB14184\n",
      "DB14185\n",
      "DB14186\n",
      "DB14187\n",
      "DB14188\n",
      "DB14189\n",
      "DB14190\n",
      "DB14191\n",
      "DB14192\n",
      "DB14193\n",
      "DB14194\n",
      "DB14195\n",
      "DB14196\n",
      "DB14197\n",
      "DB14198\n",
      "DB14199\n",
      "DB14200\n",
      "DB14201\n",
      "DB14202\n",
      "DB14203\n",
      "DB14204\n",
      "DB14205\n",
      "DB14206\n",
      "DB14207\n",
      "DB14208\n",
      "DB14209\n",
      "DB14210\n",
      "DB14211\n",
      "DB14212\n",
      "DB14213\n",
      "DB14214\n",
      "DB14217\n",
      "DB14218\n",
      "DB14219\n",
      "DB14221\n",
      "DB14222\n",
      "DB14223\n",
      "DB14224\n",
      "DB14225\n",
      "DB14226\n",
      "DB14227\n",
      "DB14228\n",
      "DB14229\n",
      "DB14230\n",
      "DB14231\n",
      "DB14232\n",
      "DB14233\n",
      "DB14234\n",
      "DB14235\n",
      "DB14236\n",
      "DB14237\n",
      "DB14238\n",
      "DB14239\n",
      "DB14240\n",
      "DB14241\n",
      "DB14242\n",
      "DB14243\n",
      "DB14244\n",
      "DB14245\n",
      "DB14246\n",
      "DB14247\n",
      "DB14248\n",
      "DB14249\n",
      "DB14250\n",
      "DB14251\n",
      "DB14252\n",
      "DB14253\n",
      "DB14254\n",
      "DB14255\n",
      "DB14256\n",
      "DB14257\n",
      "DB14258\n",
      "DB14259\n",
      "DB14260\n",
      "DB14261\n",
      "DB14262\n",
      "DB14263\n",
      "DB14264\n",
      "DB14265\n",
      "DB14266\n",
      "DB14267\n",
      "DB14268\n",
      "DB14269\n",
      "DB14270\n",
      "DB14271\n",
      "DB14272\n",
      "DB14273\n",
      "DB14274\n",
      "DB14275\n",
      "DB14276\n",
      "DB14277\n",
      "DB14278\n",
      "DB14279\n",
      "DB14280\n",
      "DB14281\n",
      "DB14282\n",
      "DB14283\n",
      "DB14284\n",
      "DB14285\n",
      "DB14286\n",
      "DB14287\n",
      "DB14288\n",
      "DB14289\n",
      "DB14290\n",
      "DB14291\n",
      "DB14292\n",
      "DB14293\n",
      "DB14294\n",
      "DB14295\n",
      "DB14296\n",
      "DB14297\n",
      "DB14298\n",
      "DB14299\n",
      "DB14300\n",
      "DB14301\n",
      "DB14302\n",
      "DB14303\n",
      "DB14304\n",
      "DB14305\n",
      "DB14306\n",
      "DB14307\n",
      "DB14308\n",
      "DB14309\n",
      "DB14310\n",
      "DB14311\n",
      "DB14312\n",
      "DB14313\n",
      "DB14314\n",
      "DB14315\n",
      "DB14316\n",
      "DB14317\n",
      "DB14318\n",
      "DB14319\n",
      "DB14320\n",
      "DB14321\n",
      "DB14322\n",
      "DB14323\n",
      "DB14324\n",
      "DB14325\n",
      "DB14326\n",
      "DB14327\n",
      "DB14328\n",
      "DB14329\n",
      "DB14330\n",
      "DB14331\n",
      "DB14332\n",
      "DB14333\n",
      "DB14334\n",
      "DB14335\n",
      "DB14336\n",
      "DB14337\n",
      "DB14338\n",
      "DB14339\n",
      "DB14340\n",
      "DB14341\n",
      "DB14342\n",
      "DB14343\n",
      "DB14344\n",
      "DB14345\n",
      "DB14346\n",
      "DB14347\n",
      "DB14348\n",
      "DB14349\n",
      "DB14350\n",
      "DB14351\n",
      "DB14352\n",
      "DB14353\n",
      "DB14354\n",
      "DB14355\n",
      "DB14356\n",
      "DB14357\n",
      "DB14358\n",
      "DB14359\n",
      "DB14360\n",
      "DB14361\n",
      "DB14362\n",
      "DB14363\n",
      "DB14364\n",
      "DB14365\n",
      "DB14366\n",
      "DB14367\n",
      "DB14368\n",
      "DB14369\n",
      "DB14370\n",
      "DB14371\n",
      "DB14372\n",
      "DB14373\n",
      "DB14374\n",
      "DB14375\n",
      "DB14376\n",
      "DB14377\n",
      "DB14378\n",
      "DB14379\n",
      "DB14382\n",
      "DB14383\n",
      "DB14384\n",
      "DB14385\n",
      "DB14386\n",
      "DB14387\n",
      "DB14388\n",
      "DB14389\n",
      "DB14390\n",
      "DB14391\n",
      "DB14392\n",
      "DB14393\n",
      "DB14394\n",
      "DB14395\n",
      "DB14396\n",
      "DB14397\n",
      "DB14398\n",
      "DB14399\n",
      "DB14400\n",
      "DB14401\n",
      "DB14402\n",
      "DB14403\n",
      "DB14404\n",
      "DB14405\n",
      "DB14406\n",
      "DB14407\n",
      "DB14408\n",
      "DB14409\n",
      "DB14410\n",
      "DB14411\n",
      "DB14412\n",
      "DB14413\n",
      "DB14414\n",
      "DB14415\n",
      "DB14416\n",
      "DB14417\n",
      "DB14418\n",
      "DB14419\n",
      "DB14420\n",
      "DB14421\n",
      "DB14422\n",
      "DB14423\n",
      "DB14424\n",
      "DB14425\n",
      "DB14426\n",
      "DB14427\n",
      "DB14428\n",
      "DB14429\n",
      "DB14430\n",
      "DB14431\n",
      "DB14432\n",
      "DB14433\n",
      "DB14434\n",
      "DB14435\n",
      "DB14436\n",
      "DB14437\n",
      "DB14438\n",
      "DB14439\n",
      "DB14440\n",
      "DB14441\n",
      "DB14442\n",
      "DB14443\n",
      "DB14444\n",
      "DB14445\n",
      "DB14446\n",
      "DB14447\n",
      "DB14449\n",
      "DB14450\n",
      "DB14451\n",
      "DB14452\n",
      "DB14453\n",
      "DB14454\n",
      "DB14455\n",
      "DB14456\n",
      "DB14457\n",
      "DB14458\n",
      "DB14459\n",
      "DB14460\n",
      "DB14461\n",
      "DB14462\n",
      "DB14463\n",
      "DB14464\n",
      "DB14465\n",
      "DB14466\n",
      "DB14467\n",
      "DB14468\n",
      "DB14469\n",
      "DB14470\n",
      "DB14471\n",
      "DB14472\n",
      "DB14473\n",
      "DB14474\n",
      "DB14475\n",
      "DB14476\n",
      "DB14477\n",
      "DB14478\n",
      "DB14479\n",
      "DB14480\n",
      "DB14481\n",
      "DB14482\n",
      "DB14483\n",
      "DB14484\n",
      "DB14485\n",
      "DB14486\n",
      "DB14487\n",
      "DB14488\n",
      "DB14489\n",
      "DB14490\n",
      "DB14491\n",
      "DB14492\n",
      "DB14493\n",
      "DB14494\n",
      "DB14495\n",
      "DB14496\n",
      "DB14497\n",
      "DB14498\n",
      "DB14499\n",
      "DB14500\n",
      "DB14501\n",
      "DB14502\n",
      "DB14503\n",
      "DB14504\n",
      "DB14505\n",
      "DB14506\n",
      "DB14507\n",
      "DB14508\n",
      "DB14509\n",
      "DB14510\n",
      "DB14511\n",
      "DB14512\n",
      "DB14513\n",
      "DB14514\n",
      "DB14515\n",
      "DB14516\n",
      "DB14517\n",
      "DB14518\n",
      "DB14519\n",
      "DB14520\n",
      "DB14521\n",
      "DB14522\n",
      "DB14523\n",
      "DB14524\n",
      "DB14525\n",
      "DB14526\n",
      "DB14527\n",
      "DB14528\n",
      "DB14529\n",
      "DB14530\n",
      "DB14531\n",
      "DB14532\n",
      "DB14533\n",
      "DB14534\n",
      "DB14535\n",
      "DB14536\n",
      "DB14537\n",
      "DB14538\n",
      "DB14539\n",
      "DB14540\n",
      "DB14541\n",
      "DB14542\n",
      "DB14543\n",
      "DB14544\n",
      "DB14545\n",
      "DB14546\n",
      "DB14547\n",
      "DB14548\n",
      "DB14549\n",
      "DB14550\n",
      "DB14551\n",
      "DB14552\n",
      "DB14553\n",
      "DB14554\n",
      "DB14555\n",
      "DB14556\n",
      "DB14557\n",
      "DB14558\n",
      "DB14559\n",
      "DB14560\n",
      "DB14561\n",
      "DB14562\n",
      "DB14563\n",
      "DB14564\n",
      "DB14565\n",
      "DB14566\n",
      "DB14567\n",
      "DB14568\n",
      "DB14569\n",
      "DB14570\n",
      "DB14571\n",
      "DB14572\n",
      "DB14573\n",
      "DB14574\n",
      "DB14575\n",
      "DB14576\n",
      "DB14577\n",
      "DB14578\n",
      "DB14579\n",
      "DB14580\n",
      "DB14581\n",
      "DB14582\n",
      "DB14583\n",
      "DB14584\n",
      "DB14585\n",
      "DB14586\n",
      "DB14587\n",
      "DB14588\n",
      "DB14589\n",
      "DB14590\n",
      "DB14591\n",
      "DB14592\n",
      "DB14593\n",
      "DB14594\n",
      "DB14595\n",
      "DB00873\n",
      "DB14597\n",
      "DB14598\n",
      "DB14599\n",
      "DB14600\n",
      "DB14601\n",
      "DB14602\n",
      "DB14603\n",
      "DB14604\n",
      "DB14605\n",
      "DB14606\n",
      "DB14607\n",
      "DB14608\n",
      "DB14609\n",
      "DB14610\n",
      "DB14611\n",
      "DB14612\n",
      "DB14613\n",
      "DB14614\n",
      "DB14615\n",
      "DB14616\n",
      "DB14617\n",
      "DB14618\n",
      "DB14619\n",
      "DB14620\n",
      "DB14622\n",
      "DB14623\n",
      "DB14624\n",
      "DB14625\n",
      "DB14626\n",
      "DB14627\n",
      "DB14628\n",
      "DB14629\n",
      "DB14630\n",
      "DB14631\n",
      "DB14632\n",
      "DB14633\n",
      "DB14634\n",
      "DB14635\n",
      "DB14636\n",
      "DB14637\n",
      "DB14638\n",
      "DB14639\n",
      "DB14640\n",
      "DB14641\n",
      "DB14642\n",
      "DB14643\n",
      "DB14644\n",
      "DB14645\n",
      "DB14646\n",
      "DB14647\n",
      "DB14648\n",
      "DB14649\n",
      "DB14650\n",
      "DB14651\n",
      "DB14652\n",
      "DB14653\n",
      "DB14654\n",
      "DB14655\n",
      "DB14656\n",
      "DB14657\n",
      "DB14658\n",
      "DB14659\n",
      "DB14660\n",
      "DB14661\n",
      "DB14662\n",
      "DB14663\n",
      "DB14664\n",
      "DB14665\n",
      "DB14666\n",
      "DB14667\n",
      "DB14668\n",
      "DB14669\n",
      "DB14670\n",
      "DB14671\n",
      "DB14672\n",
      "DB14673\n",
      "DB14674\n",
      "DB14675\n",
      "DB14676\n",
      "DB14677\n",
      "DB14678\n",
      "DB14679\n",
      "DB14680\n",
      "DB14681\n",
      "DB14682\n",
      "DB14683\n",
      "DB14684\n",
      "DB14685\n",
      "DB14686\n",
      "DB14687\n",
      "DB14688\n",
      "DB14689\n",
      "DB14690\n",
      "DB14691\n",
      "DB14692\n",
      "DB14693\n",
      "DB14694\n",
      "DB14695\n",
      "DB14696\n",
      "DB14697\n",
      "DB14698\n",
      "DB14699\n",
      "DB14700\n",
      "DB14701\n",
      "DB14702\n",
      "DB14703\n",
      "DB14704\n",
      "DB14705\n",
      "DB14706\n",
      "DB14707\n",
      "DB14708\n",
      "DB14709\n",
      "DB14710\n",
      "DB14711\n",
      "DB14712\n",
      "DB14713\n",
      "DB14714\n",
      "DB14715\n",
      "DB14716\n",
      "DB14717\n",
      "DB14718\n",
      "DB14719\n",
      "DB14720\n",
      "DB14721\n",
      "DB14722\n",
      "DB14723\n",
      "DB14724\n",
      "DB14725\n",
      "DB14726\n",
      "DB14727\n",
      "DB14728\n",
      "DB14729\n",
      "DB14730\n",
      "DB14731\n",
      "DB14732\n",
      "DB14733\n",
      "DB14734\n",
      "DB14735\n",
      "DB14736\n",
      "DB14737\n",
      "DB14738\n",
      "DB14739\n",
      "DB14740\n",
      "DB14741\n",
      "DB00781\n",
      "DB14743\n",
      "DB14744\n",
      "DB14745\n",
      "DB14746\n",
      "DB14747\n",
      "DB14748\n",
      "DB14749\n",
      "DB14750\n",
      "DB14751\n",
      "DB14752\n",
      "DB14753\n",
      "DB14754\n",
      "DB14755\n",
      "DB14756\n",
      "DB14757\n",
      "DB14758\n",
      "DB14759\n",
      "DB14760\n",
      "DB14761\n",
      "DB14762\n",
      "DB14763\n",
      "DB14764\n",
      "DB14765\n",
      "DB14766\n",
      "DB14767\n",
      "DB14768\n",
      "DB14769\n",
      "DB14770\n",
      "DB14771\n",
      "DB14772\n",
      "DB14773\n",
      "DB14774\n",
      "DB14775\n",
      "DB14776\n",
      "DB14777\n",
      "DB14778\n",
      "DB14779\n",
      "DB14780\n",
      "DB14781\n",
      "DB14782\n",
      "DB14783\n",
      "DB14784\n",
      "DB14785\n",
      "DB14786\n",
      "DB14787\n",
      "DB14788\n",
      "DB14789\n",
      "DB14790\n",
      "DB14791\n",
      "DB14792\n",
      "DB14793\n",
      "DB14794\n",
      "DB14795\n",
      "DB14796\n",
      "DB14797\n",
      "DB14798\n",
      "DB14799\n",
      "DB14800\n",
      "DB14801\n",
      "DB14802\n",
      "DB14803\n",
      "DB14804\n",
      "DB14805\n",
      "DB14806\n",
      "DB14807\n",
      "DB14808\n",
      "DB14809\n",
      "DB14810\n",
      "DB14811\n",
      "DB14812\n",
      "DB14813\n",
      "DB14814\n",
      "DB14815\n",
      "DB14816\n",
      "DB14817\n",
      "DB14818\n",
      "DB14819\n",
      "DB14820\n",
      "DB14821\n",
      "DB14822\n",
      "DB14823\n",
      "DB14824\n",
      "DB14825\n",
      "DB14826\n",
      "DB14827\n",
      "DB14828\n",
      "DB14829\n",
      "DB14830\n",
      "DB14831\n",
      "DB14832\n",
      "DB14833\n",
      "DB14834\n",
      "DB14835\n",
      "DB14836\n",
      "DB14838\n",
      "DB14839\n",
      "DB14840\n",
      "DB14841\n",
      "DB14843\n",
      "DB14844\n",
      "DB14845\n",
      "DB14846\n",
      "DB14847\n",
      "DB14848\n",
      "DB14849\n",
      "DB14850\n",
      "DB14851\n",
      "DB14852\n",
      "DB14853\n",
      "DB14854\n",
      "DB14855\n",
      "DB14856\n",
      "DB14857\n",
      "DB14858\n",
      "DB14859\n",
      "DB14860\n",
      "DB14862\n",
      "DB14864\n",
      "DB14865\n",
      "DB14866\n",
      "DB14867\n",
      "DB14868\n",
      "DB14869\n",
      "DB14870\n",
      "DB14871\n",
      "DB14872\n",
      "DB14873\n",
      "DB14874\n",
      "DB14875\n",
      "DB14876\n",
      "DB14877\n",
      "DB14878\n",
      "DB14879\n",
      "DB14880\n",
      "DB14881\n",
      "DB14882\n",
      "DB14883\n",
      "DB14884\n",
      "DB14885\n",
      "DB14886\n",
      "DB14887\n",
      "DB14888\n",
      "DB14889\n",
      "DB14890\n",
      "DB14891\n",
      "DB14892\n",
      "DB14894\n",
      "DB14895\n",
      "DB14896\n",
      "DB14897\n",
      "DB14898\n",
      "DB14899\n",
      "DB14900\n",
      "DB14901\n",
      "DB14902\n",
      "DB14903\n",
      "DB14904\n",
      "DB14905\n",
      "DB14906\n",
      "DB14907\n",
      "DB14908\n",
      "DB14909\n",
      "DB14910\n",
      "DB14911\n",
      "DB14912\n",
      "DB14913\n",
      "DB14914\n",
      "DB14915\n",
      "DB14916\n",
      "DB14917\n",
      "DB14918\n",
      "DB14919\n",
      "DB14920\n",
      "DB14921\n",
      "DB14922\n",
      "DB14923\n",
      "DB14924\n",
      "DB14925\n",
      "DB14926\n",
      "DB14927\n",
      "DB14928\n",
      "DB14929\n",
      "DB14930\n",
      "DB14931\n",
      "DB14932\n",
      "DB14933\n",
      "DB14934\n",
      "DB14935\n",
      "DB14936\n",
      "DB14937\n",
      "DB14938\n",
      "DB14939\n",
      "DB14940\n",
      "DB14941\n",
      "DB14942\n",
      "DB14943\n",
      "DB14944\n",
      "DB14945\n",
      "DB14946\n",
      "DB14947\n",
      "DB14948\n",
      "DB14949\n",
      "DB14950\n",
      "DB14951\n",
      "DB14952\n",
      "DB14953\n",
      "DB14954\n",
      "DB14955\n",
      "DB14956\n",
      "DB14957\n",
      "DB14958\n",
      "DB14959\n",
      "DB14960\n",
      "DB14961\n",
      "DB14962\n",
      "DB14963\n",
      "DB14964\n",
      "DB14965\n",
      "DB14966\n",
      "DB14967\n",
      "DB14968\n",
      "DB14969\n",
      "DB14970\n",
      "DB14971\n",
      "DB14972\n",
      "DB14973\n",
      "DB14974\n",
      "DB14975\n",
      "DB14976\n",
      "DB14977\n",
      "DB14978\n",
      "DB14979\n",
      "DB14980\n",
      "DB14981\n",
      "DB14982\n",
      "DB14983\n",
      "DB14984\n",
      "DB14985\n",
      "DB14986\n",
      "DB14987\n",
      "DB14988\n",
      "DB14989\n",
      "DB14990\n",
      "DB14991\n",
      "DB14992\n",
      "DB14993\n",
      "DB14995\n",
      "DB14996\n",
      "DB14997\n",
      "DB14998\n",
      "DB14999\n",
      "DB15000\n",
      "DB15001\n",
      "DB15002\n",
      "DB15003\n",
      "DB15004\n",
      "DB15005\n",
      "DB15006\n",
      "DB15007\n",
      "DB15008\n",
      "DB15009\n",
      "DB15010\n",
      "DB15011\n",
      "DB15012\n",
      "DB15013\n",
      "DB15014\n",
      "DB15015\n",
      "DB15016\n",
      "DB15017\n",
      "DB15018\n",
      "DB15019\n",
      "DB15020\n",
      "DB15021\n",
      "DB15022\n",
      "DB15023\n",
      "DB15024\n",
      "DB15025\n",
      "DB15026\n",
      "DB15027\n",
      "DB15028\n",
      "DB15029\n",
      "DB15030\n",
      "DB15031\n",
      "DB15032\n",
      "DB15033\n",
      "DB15034\n",
      "DB15035\n",
      "DB15036\n",
      "DB15037\n",
      "DB15038\n",
      "DB15039\n",
      "DB15040\n",
      "DB15041\n",
      "DB15042\n",
      "DB15043\n",
      "DB15044\n",
      "DB15045\n",
      "DB15046\n",
      "DB15047\n",
      "DB15048\n",
      "DB15049\n",
      "DB15050\n",
      "DB15051\n",
      "DB15052\n",
      "DB15053\n",
      "DB15054\n",
      "DB15055\n",
      "DB15056\n",
      "DB15057\n",
      "DB15058\n",
      "DB15059\n",
      "DB15061\n",
      "DB15062\n",
      "DB15063\n",
      "DB15064\n",
      "DB15065\n",
      "DB15066\n",
      "DB15067\n",
      "DB15068\n",
      "DB15069\n",
      "DB15070\n",
      "DB15071\n",
      "DB15072\n",
      "DB15073\n",
      "DB15074\n",
      "DB15075\n",
      "DB15076\n",
      "DB15077\n",
      "DB15078\n",
      "DB15079\n",
      "DB15080\n",
      "DB15081\n",
      "DB15082\n",
      "DB15083\n",
      "DB15084\n",
      "DB15085\n",
      "DB15086\n",
      "DB15087\n",
      "DB15088\n",
      "DB15089\n",
      "DB15090\n",
      "DB15091\n",
      "DB15092\n",
      "DB15093\n",
      "DB15094\n",
      "DB15095\n",
      "DB15096\n",
      "DB15097\n",
      "DB15098\n",
      "DB15099\n",
      "DB15100\n",
      "DB15101\n",
      "DB15102\n",
      "DB15104\n",
      "DB15105\n",
      "DB15106\n",
      "DB15107\n",
      "DB15108\n",
      "DB15109\n",
      "DB15110\n",
      "DB15111\n",
      "DB15112\n",
      "DB15113\n",
      "DB15114\n",
      "DB15115\n",
      "DB15116\n",
      "DB15117\n",
      "DB15118\n",
      "DB15119\n",
      "DB15120\n",
      "DB15121\n",
      "DB15122\n",
      "DB15123\n",
      "DB15124\n",
      "DB15125\n",
      "DB15126\n",
      "DB15127\n",
      "DB15128\n",
      "DB15129\n",
      "DB15130\n",
      "DB15131\n",
      "DB15132\n",
      "DB15133\n",
      "DB15134\n",
      "DB15135\n",
      "DB15136\n",
      "DB15137\n",
      "DB15138\n",
      "DB15139\n",
      "DB15140\n",
      "DB15141\n",
      "DB15143\n",
      "DB15144\n",
      "DB15145\n",
      "DB15146\n",
      "DB15147\n",
      "DB15148\n",
      "DB15149\n",
      "DB15150\n",
      "DB15151\n",
      "DB15152\n",
      "DB15153\n",
      "DB15154\n",
      "DB15155\n",
      "DB15156\n",
      "DB15157\n",
      "DB15158\n",
      "DB15159\n",
      "DB15160\n",
      "DB15161\n",
      "DB15162\n",
      "DB15163\n",
      "DB15164\n",
      "DB15165\n",
      "DB15166\n",
      "DB15167\n",
      "DB15168\n",
      "DB15169\n",
      "DB15170\n",
      "DB15171\n",
      "DB15172\n",
      "DB15173\n",
      "DB15175\n",
      "DB15176\n",
      "DB15177\n",
      "DB15178\n",
      "DB15182\n",
      "DB15183\n",
      "DB15185\n",
      "DB15186\n",
      "DB15187\n",
      "DB15188\n",
      "DB15189\n",
      "DB15190\n",
      "DB15191\n",
      "DB15192\n",
      "DB15193\n",
      "DB15194\n",
      "DB15195\n",
      "DB15197\n",
      "DB15198\n",
      "DB15199\n",
      "DB15200\n",
      "DB15201\n",
      "DB15202\n",
      "DB15203\n",
      "DB15204\n",
      "DB15205\n",
      "DB15206\n",
      "DB15207\n",
      "DB15208\n",
      "DB15209\n",
      "DB15210\n",
      "DB15211\n",
      "DB15212\n",
      "DB15213\n",
      "DB15214\n",
      "DB15215\n",
      "DB15216\n",
      "DB15217\n",
      "DB15218\n",
      "DB15219\n",
      "DB15220\n",
      "DB15221\n",
      "DB15222\n",
      "DB15223\n",
      "DB15224\n",
      "DB15225\n",
      "DB15226\n",
      "DB15227\n",
      "DB15228\n",
      "DB15229\n",
      "DB15230\n",
      "DB15231\n",
      "DB15232\n",
      "DB15233\n",
      "DB15234\n",
      "DB15235\n",
      "DB15236\n",
      "DB15237\n",
      "DB15238\n",
      "DB15239\n",
      "DB15240\n",
      "DB15241\n",
      "DB15242\n",
      "DB15243\n",
      "DB15244\n",
      "DB15245\n",
      "DB15246\n",
      "DB15247\n",
      "DB15248\n",
      "DB15249\n",
      "DB15250\n",
      "DB15251\n",
      "DB15252\n",
      "DB15253\n",
      "DB15254\n",
      "DB15256\n",
      "DB15257\n",
      "DB15258\n",
      "DB15259\n",
      "DB15260\n",
      "DB15261\n",
      "DB15262\n",
      "DB15263\n",
      "DB15264\n",
      "DB15265\n",
      "DB15266\n",
      "DB15267\n",
      "DB15268\n",
      "DB15269\n",
      "DB15270\n",
      "DB15271\n",
      "DB15272\n",
      "DB15273\n",
      "DB15274\n",
      "DB15275\n",
      "DB15276\n",
      "DB15277\n",
      "DB15278\n",
      "DB15279\n",
      "DB15280\n",
      "DB15281\n",
      "DB15282\n",
      "DB15283\n",
      "DB15284\n",
      "DB15285\n",
      "DB15286\n",
      "DB15287\n",
      "DB15288\n",
      "DB15289\n",
      "DB15290\n",
      "DB15291\n",
      "DB15292\n",
      "DB15293\n",
      "DB15294\n",
      "DB15295\n",
      "DB15296\n",
      "DB15297\n",
      "DB15298\n",
      "DB15299\n",
      "DB15300\n",
      "DB15301\n",
      "DB15302\n",
      "DB15303\n",
      "DB15304\n",
      "DB15305\n",
      "DB15306\n",
      "DB15307\n",
      "DB15308\n",
      "DB15310\n",
      "DB15311\n",
      "DB15312\n",
      "DB15313\n",
      "DB15314\n",
      "DB15315\n",
      "DB15316\n",
      "DB15317\n",
      "DB15318\n",
      "DB15319\n",
      "DB15321\n",
      "DB15322\n",
      "DB15323\n",
      "DB15324\n",
      "DB15325\n",
      "DB15326\n",
      "DB15327\n",
      "DB15328\n",
      "DB15329\n",
      "DB15330\n",
      "DB15331\n",
      "DB15332\n",
      "DB15333\n",
      "DB15334\n",
      "DB15335\n",
      "DB15336\n",
      "DB15338\n",
      "DB15339\n",
      "DB15340\n",
      "DB15341\n",
      "DB15342\n",
      "DB15343\n",
      "DB15344\n",
      "DB15345\n",
      "DB15346\n",
      "DB15347\n",
      "DB15348\n",
      "DB15349\n",
      "DB15350\n",
      "DB15352\n",
      "DB15353\n",
      "DB15354\n",
      "DB15355\n",
      "DB15356\n",
      "DB15357\n",
      "DB15358\n",
      "DB15359\n",
      "DB15360\n",
      "DB15361\n",
      "DB15362\n",
      "DB15363\n",
      "DB15365\n",
      "DB15366\n",
      "DB15367\n",
      "DB15368\n",
      "DB15369\n",
      "DB15370\n",
      "DB15371\n",
      "DB15372\n",
      "DB15373\n",
      "DB15374\n",
      "DB15375\n",
      "DB15376\n",
      "DB15377\n",
      "DB15378\n",
      "DB15379\n",
      "DB15380\n",
      "DB15381\n",
      "DB15382\n",
      "DB15383\n",
      "DB15384\n",
      "DB15385\n",
      "DB15386\n",
      "DB15387\n",
      "DB15388\n",
      "DB15389\n",
      "DB15390\n",
      "DB15391\n",
      "DB15392\n",
      "DB15393\n",
      "DB15394\n",
      "DB15395\n",
      "DB15396\n",
      "DB15397\n",
      "DB15398\n",
      "DB15399\n",
      "DB15400\n",
      "DB15401\n",
      "DB15402\n",
      "DB15403\n",
      "DB15404\n",
      "DB15405\n",
      "DB15406\n",
      "DB15407\n",
      "DB15408\n",
      "DB15409\n",
      "DB15410\n",
      "DB15411\n",
      "DB15412\n",
      "DB15413\n",
      "DB15414\n",
      "DB15415\n",
      "DB15416\n",
      "DB15417\n",
      "DB15418\n",
      "DB15419\n",
      "DB15420\n",
      "DB15421\n",
      "DB15422\n",
      "DB15423\n",
      "DB15424\n",
      "DB15425\n",
      "DB15426\n",
      "DB15427\n",
      "DB15428\n",
      "DB15429\n",
      "DB15430\n",
      "DB15431\n",
      "DB15432\n",
      "DB15433\n",
      "DB15434\n",
      "DB15435\n",
      "DB15436\n",
      "DB15437\n",
      "DB15438\n",
      "DB15439\n",
      "DB15440\n",
      "DB15441\n",
      "DB15442\n",
      "DB15443\n",
      "DB15444\n",
      "DB15445\n",
      "DB15446\n",
      "DB15447\n",
      "DB15448\n",
      "DB15449\n",
      "DB15450\n",
      "DB15451\n",
      "DB15452\n",
      "DB15453\n",
      "DB15455\n",
      "DB15456\n",
      "DB15457\n",
      "DB15458\n",
      "DB15460\n",
      "DB15461\n",
      "DB15462\n",
      "DB15463\n",
      "DB15464\n",
      "DB15465\n",
      "DB15466\n",
      "DB15467\n",
      "DB15468\n",
      "DB15469\n",
      "DB15470\n",
      "DB15471\n",
      "DB15472\n",
      "DB15473\n",
      "DB15474\n",
      "DB15475\n",
      "DB15476\n",
      "DB15477\n",
      "DB15478\n",
      "DB15479\n",
      "DB15480\n",
      "DB15481\n",
      "DB15482\n",
      "DB15483\n",
      "DB15484\n",
      "DB15485\n",
      "DB15486\n",
      "DB15487\n",
      "DB15488\n",
      "DB15489\n",
      "DB15490\n",
      "DB15491\n",
      "DB15492\n",
      "DB15493\n",
      "DB15494\n",
      "DB15495\n",
      "DB15496\n",
      "DB15497\n",
      "DB15498\n",
      "DB15499\n",
      "DB15500\n",
      "DB15501\n",
      "DB15502\n",
      "DB15503\n",
      "DB15504\n",
      "DB15505\n",
      "DB15506\n",
      "DB15507\n",
      "DB15508\n",
      "DB15509\n",
      "DB15510\n",
      "DB15511\n",
      "DB15512\n",
      "DB15513\n",
      "DB15514\n",
      "DB15515\n",
      "DB15516\n",
      "DB15517\n",
      "DB15518\n",
      "DB15519\n",
      "DB15520\n",
      "DB15521\n",
      "DB15522\n",
      "DB15523\n",
      "DB15524\n",
      "DB15525\n",
      "DB15526\n",
      "DB15527\n",
      "DB15528\n",
      "DB15529\n",
      "DB15530\n",
      "DB15531\n",
      "DB15532\n",
      "DB15533\n",
      "DB15534\n",
      "DB15535\n",
      "DB15536\n",
      "DB15537\n",
      "DB15538\n",
      "DB15539\n",
      "DB15540\n",
      "DB15541\n",
      "DB15542\n",
      "DB15543\n",
      "DB15544\n",
      "DB15545\n",
      "DB15546\n",
      "DB15547\n",
      "DB15548\n",
      "DB15549\n",
      "DB15550\n",
      "DB15551\n",
      "DB15552\n",
      "DB15553\n",
      "DB15554\n",
      "DB15555\n",
      "DB15556\n",
      "DB15557\n",
      "DB15558\n",
      "DB15559\n",
      "DB15560\n",
      "DB15561\n",
      "DB15562\n",
      "DB15563\n",
      "DB15564\n",
      "DB15565\n",
      "DB15566\n",
      "DB15567\n",
      "DB15568\n",
      "DB15569\n",
      "DB15570\n",
      "DB15571\n",
      "DB15572\n",
      "DB15573\n",
      "DB15574\n",
      "DB15575\n",
      "DB15576\n",
      "DB15578\n",
      "DB15579\n",
      "DB15580\n",
      "DB15581\n",
      "DB15582\n",
      "DB15583\n",
      "DB15584\n",
      "DB15585\n",
      "DB15586\n",
      "DB15587\n",
      "DB15588\n",
      "DB15589\n",
      "DB15590\n",
      "DB15591\n",
      "DB15592\n",
      "DB15593\n",
      "DB15594\n",
      "DB15595\n",
      "DB15596\n",
      "DB15597\n",
      "DB15598\n",
      "DB15599\n",
      "DB15601\n",
      "DB15602\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DB15603\n",
      "DB15604\n",
      "DB15605\n",
      "DB15606\n",
      "DB15607\n",
      "DB15608\n",
      "DB15609\n",
      "DB15610\n",
      "DB15611\n",
      "DB15612\n",
      "DB15613\n",
      "DB15614\n",
      "DB15615\n",
      "DB15616\n",
      "DB15617\n",
      "DB15618\n",
      "DB15619\n",
      "DB15620\n",
      "DB15621\n",
      "DB15622\n",
      "DB15623\n",
      "DB15624\n",
      "DB15626\n",
      "DB15627\n",
      "DB15628\n",
      "DB15629\n",
      "DB15630\n",
      "DB15631\n",
      "DB15632\n",
      "DB15633\n",
      "DB15634\n",
      "DB15635\n",
      "DB15636\n",
      "DB15637\n",
      "DB15638\n",
      "DB15639\n",
      "DB15640\n",
      "DB15641\n",
      "DB15642\n",
      "DB15643\n",
      "DB15644\n",
      "DB15645\n",
      "DB15646\n",
      "DB15647\n",
      "DB15648\n",
      "DB15649\n",
      "DB15650\n",
      "DB15651\n",
      "DB15652\n",
      "DB15653\n",
      "DB15654\n",
      "DB15655\n",
      "DB15656\n",
      "DB15657\n",
      "DB15658\n",
      "DB15659\n",
      "DB15660\n",
      "DB15661\n",
      "DB15662\n",
      "DB15663\n",
      "DB15664\n",
      "DB15665\n",
      "DB15666\n",
      "DB15667\n",
      "DB15668\n",
      "DB15669\n",
      "DB15670\n",
      "DB15671\n",
      "DB15672\n",
      "DB15673\n",
      "DB15674\n",
      "DB15675\n",
      "DB15676\n",
      "DB15677\n",
      "DB15678\n",
      "DB15679\n",
      "DB15680\n",
      "DB15681\n",
      "DB15682\n",
      "DB15683\n",
      "DB15684\n",
      "DB15685\n",
      "DB15686\n",
      "DB15687\n",
      "DB15688\n",
      "DB15689\n",
      "DB15690\n",
      "DB15691\n",
      "DB15692\n",
      "DB15693\n",
      "DB15694\n",
      "DB15695\n",
      "DB15696\n",
      "DB15697\n",
      "DB15698\n",
      "DB15699\n",
      "DB15700\n",
      "DB15701\n",
      "DB15702\n",
      "DB15703\n",
      "DB15704\n",
      "DB15705\n",
      "DB15706\n",
      "DB15707\n",
      "DB15708\n",
      "DB15709\n",
      "DB15710\n",
      "DB15711\n",
      "DB15712\n",
      "DB15713\n",
      "DB15714\n",
      "DB15715\n",
      "DB15716\n",
      "DB15717\n",
      "DB15718\n",
      "DB15719\n",
      "DB15720\n",
      "DB15721\n",
      "DB15722\n",
      "DB15723\n",
      "DB15724\n",
      "DB15725\n",
      "DB15726\n",
      "DB15727\n",
      "DB15728\n",
      "DB15729\n",
      "DB15730\n",
      "DB15731\n",
      "DB15732\n",
      "DB15733\n",
      "DB15734\n",
      "DB15735\n",
      "DB15736\n",
      "DB15737\n",
      "DB15738\n",
      "DB15739\n",
      "DB15740\n",
      "DB15741\n",
      "DB15742\n",
      "DB15743\n",
      "DB15744\n",
      "DB15745\n",
      "DB15746\n",
      "DB15747\n",
      "DB15748\n",
      "DB15749\n",
      "DB15750\n",
      "DB15751\n",
      "DB15752\n",
      "DB15753\n",
      "DB15756\n",
      "DB15757\n",
      "DB15758\n",
      "DB15759\n",
      "DB15760\n",
      "DB15761\n",
      "DB15762\n",
      "DB15763\n",
      "DB15764\n",
      "DB15765\n",
      "DB15766\n",
      "DB15767\n",
      "DB15768\n",
      "DB15769\n",
      "DB15770\n",
      "DB15771\n",
      "DB15772\n",
      "DB15773\n",
      "DB15774\n",
      "DB15775\n",
      "DB15776\n",
      "DB15777\n",
      "DB15778\n",
      "DB15779\n",
      "DB15780\n",
      "DB15781\n",
      "DB15782\n",
      "DB15783\n",
      "DB15784\n",
      "DB15785\n",
      "DB15786\n",
      "DB15787\n",
      "DB15788\n",
      "DB15789\n",
      "DB15790\n",
      "DB15791\n",
      "DB15793\n",
      "DB15794\n",
      "DB15795\n",
      "DB15796\n",
      "DB15797\n",
      "DB15798\n",
      "DB15799\n",
      "DB15800\n",
      "DB15801\n",
      "DB15802\n",
      "DB15803\n",
      "DB15804\n",
      "DB15805\n",
      "DB15806\n",
      "DB15807\n",
      "DB15808\n",
      "DB15809\n",
      "DB15810\n",
      "DB15811\n",
      "DB15812\n",
      "DB15813\n",
      "DB15814\n",
      "DB15815\n",
      "DB15816\n",
      "DB15817\n",
      "DB15818\n",
      "DB15819\n",
      "DB15820\n",
      "DB15821\n",
      "DB15822\n",
      "DB15823\n",
      "DB15824\n",
      "DB15825\n",
      "DB15826\n",
      "DB15827\n",
      "DB15830\n",
      "DB15831\n",
      "DB15832\n",
      "DB15833\n",
      "DB15834\n",
      "DB15835\n",
      "DB15836\n",
      "DB15838\n",
      "DB15839\n",
      "DB15840\n",
      "DB15841\n",
      "DB15842\n",
      "DB15843\n",
      "DB15844\n",
      "DB15845\n",
      "DB15846\n",
      "DB15847\n",
      "DB15848\n",
      "DB15849\n",
      "DB15850\n",
      "DB15851\n",
      "DB15852\n",
      "DB15853\n",
      "DB15854\n",
      "DB15855\n",
      "DB15856\n",
      "DB15857\n",
      "DB15858\n",
      "DB15859\n",
      "DB15860\n",
      "DB15861\n",
      "DB15862\n",
      "DB15863\n",
      "DB15864\n",
      "DB15865\n",
      "DB15866\n",
      "DB15867\n",
      "DB15868\n",
      "DB15869\n",
      "DB15870\n",
      "DB15871\n",
      "DB15872\n",
      "DB15873\n",
      "DB15874\n",
      "DB15875\n",
      "DB15876\n",
      "DB15877\n",
      "DB15878\n",
      "DB15879\n",
      "DB15880\n",
      "DB15881\n",
      "DB15882\n",
      "DB15883\n",
      "DB15884\n",
      "DB15885\n",
      "DB15886\n",
      "DB15887\n",
      "DB15888\n",
      "DB15889\n",
      "DB15890\n",
      "DB15891\n",
      "DB15892\n",
      "DB15893\n",
      "DB15894\n",
      "DB15895\n",
      "DB15897\n",
      "DB15898\n",
      "DB15899\n",
      "DB15900\n",
      "DB15901\n",
      "DB15902\n",
      "DB15903\n",
      "DB15904\n",
      "DB15905\n",
      "DB15906\n",
      "DB15907\n",
      "DB15908\n",
      "DB15909\n",
      "DB15910\n",
      "DB15911\n",
      "DB15912\n",
      "DB15914\n",
      "DB15915\n",
      "DB15916\n",
      "DB15917\n",
      "DB15918\n",
      "DB15919\n",
      "DB15920\n",
      "DB15921\n",
      "DB15922\n",
      "DB15923\n",
      "DB15924\n",
      "DB15925\n",
      "DB15926\n",
      "DB15927\n",
      "DB15928\n",
      "DB15929\n",
      "DB15930\n",
      "DB15931\n",
      "DB15932\n",
      "DB15933\n",
      "DB15934\n",
      "DB15935\n",
      "DB15936\n",
      "DB15937\n",
      "DB15938\n",
      "DB15939\n",
      "DB15940\n",
      "DB15941\n",
      "DB15942\n",
      "DB15943\n",
      "DB15944\n",
      "DB15945\n",
      "DB15946\n",
      "DB15947\n",
      "DB15948\n",
      "DB15949\n",
      "DB15950\n",
      "DB15951\n",
      "DB15952\n",
      "DB15953\n",
      "DB15954\n",
      "DB15955\n",
      "DB15956\n",
      "DB15957\n",
      "DB15958\n",
      "DB15959\n",
      "DB15960\n",
      "DB15961\n",
      "DB15962\n",
      "DB15963\n",
      "DB15964\n",
      "DB15965\n",
      "DB15966\n",
      "DB15967\n",
      "DB15968\n",
      "DB15969\n",
      "DB15970\n",
      "DB15971\n",
      "DB15972\n",
      "DB15973\n",
      "DB15974\n",
      "DB15975\n",
      "DB15976\n",
      "DB15977\n",
      "DB15978\n",
      "DB15979\n",
      "DB15980\n",
      "DB15981\n",
      "DB15982\n",
      "DB15983\n",
      "DB15984\n",
      "DB15985\n",
      "DB15986\n",
      "DB15987\n",
      "DB15988\n",
      "DB15989\n",
      "DB15990\n",
      "DB15991\n",
      "DB15992\n",
      "DB15993\n",
      "DB15994\n",
      "DB15995\n",
      "DB15996\n",
      "DB15997\n",
      "DB15998\n",
      "DB15999\n",
      "DB16000\n",
      "DB16001\n",
      "DB16002\n",
      "DB16003\n",
      "DB16004\n",
      "DB16005\n",
      "DB16006\n",
      "DB16007\n",
      "DB16008\n",
      "DB16009\n",
      "DB16010\n",
      "DB16011\n",
      "DB16012\n",
      "DB16013\n",
      "DB16014\n",
      "DB16015\n",
      "DB16016\n",
      "DB16017\n",
      "DB16018\n",
      "DB16019\n",
      "DB16020\n",
      "DB16021\n",
      "DB16022\n",
      "DB16023\n",
      "DB16024\n",
      "DB16025\n",
      "DB16026\n",
      "DB16027\n",
      "DB16028\n",
      "DB16029\n",
      "DB16030\n",
      "DB16031\n",
      "DB16032\n",
      "DB16033\n",
      "DB16034\n",
      "DB16035\n",
      "DB16036\n",
      "DB16037\n",
      "DB16038\n",
      "DB16039\n",
      "DB16040\n",
      "DB16041\n",
      "DB16042\n",
      "DB16043\n",
      "DB16044\n",
      "DB16045\n",
      "DB16046\n",
      "DB16047\n",
      "DB16048\n",
      "DB16049\n",
      "DB16050\n",
      "DB16051\n",
      "DB16052\n",
      "DB16053\n",
      "DB16054\n",
      "DB16055\n",
      "DB16056\n",
      "DB16057\n",
      "DB16058\n",
      "DB16059\n",
      "DB16060\n",
      "DB16061\n",
      "DB16062\n",
      "DB16063\n",
      "DB16064\n",
      "DB16065\n",
      "DB16066\n",
      "DB16067\n",
      "DB16068\n",
      "DB16069\n",
      "DB16070\n",
      "DB16071\n",
      "DB16072\n",
      "DB16073\n",
      "DB16074\n",
      "DB16075\n",
      "DB16076\n",
      "DB16077\n",
      "DB16078\n",
      "DB16079\n",
      "DB16080\n",
      "DB16081\n",
      "DB16082\n",
      "DB16083\n",
      "DB16084\n",
      "DB16085\n",
      "DB16086\n",
      "DB16087\n",
      "DB16088\n",
      "DB16089\n",
      "DB16090\n",
      "DB16091\n",
      "DB16092\n",
      "DB16093\n",
      "DB16094\n",
      "DB16095\n",
      "DB16096\n",
      "DB16097\n",
      "DB16098\n",
      "DB16099\n",
      "DB16100\n",
      "DB16101\n",
      "DB16102\n",
      "DB16103\n",
      "DB16104\n",
      "DB16105\n",
      "DB16106\n",
      "DB16107\n",
      "DB16108\n",
      "DB16109\n",
      "DB16110\n",
      "DB16111\n",
      "DB16112\n",
      "DB16113\n",
      "DB16114\n",
      "DB16115\n",
      "DB16116\n",
      "DB16117\n",
      "DB16118\n",
      "DB16119\n",
      "DB16120\n",
      "DB16121\n",
      "DB16122\n",
      "DB16123\n",
      "DB16124\n",
      "DB16125\n",
      "DB16126\n",
      "DB16127\n",
      "DB16128\n",
      "DB16129\n",
      "DB16130\n",
      "DB16131\n",
      "DB16132\n",
      "DB16133\n",
      "DB16134\n",
      "DB16135\n",
      "DB16136\n",
      "DB16137\n",
      "DB16138\n",
      "DB16139\n",
      "DB16140\n",
      "DB16141\n",
      "DB16142\n",
      "DB16143\n",
      "DB16144\n",
      "DB16145\n",
      "DB16146\n",
      "DB16147\n",
      "DB16148\n",
      "DB16149\n",
      "DB16150\n",
      "DB16151\n",
      "DB16152\n",
      "DB16153\n",
      "DB16154\n",
      "DB16155\n",
      "DB16156\n",
      "DB16157\n",
      "DB16158\n",
      "DB16159\n",
      "DB16160\n",
      "DB16161\n",
      "DB16162\n",
      "DB16163\n",
      "DB16164\n",
      "DB16165\n",
      "DB16166\n",
      "DB16167\n",
      "DB16168\n",
      "DB16169\n",
      "DB16170\n",
      "DB16171\n",
      "DB16172\n",
      "DB16173\n",
      "DB16174\n",
      "DB16175\n",
      "DB16176\n",
      "DB16177\n",
      "DB16178\n",
      "DB16179\n",
      "DB16180\n",
      "DB16181\n",
      "DB16182\n",
      "DB16183\n",
      "DB16184\n",
      "DB16185\n",
      "DB16186\n",
      "DB16187\n",
      "DB16188\n",
      "DB16189\n",
      "DB16190\n",
      "DB16191\n",
      "DB16192\n",
      "DB16193\n",
      "DB16194\n",
      "DB16195\n",
      "DB16196\n",
      "DB16197\n",
      "DB16198\n",
      "DB16199\n",
      "DB16200\n",
      "DB16201\n",
      "DB16202\n",
      "DB16203\n",
      "DB16204\n",
      "DB16205\n",
      "DB16206\n",
      "DB16207\n",
      "DB16208\n",
      "DB16209\n",
      "DB16210\n",
      "DB16211\n",
      "DB16212\n",
      "DB16213\n",
      "DB16214\n",
      "DB16215\n",
      "DB16216\n",
      "DB16217\n",
      "DB16218\n",
      "DB16219\n",
      "DB16220\n",
      "DB16221\n",
      "DB16222\n",
      "DB16223\n",
      "DB16224\n",
      "DB16225\n",
      "DB16226\n",
      "DB16227\n",
      "DB16228\n",
      "DB16229\n",
      "DB16230\n",
      "DB16231\n",
      "DB16232\n",
      "DB16233\n",
      "DB16234\n",
      "DB16235\n",
      "DB16236\n",
      "DB16237\n",
      "DB16238\n",
      "DB16239\n",
      "DB16240\n",
      "DB16241\n",
      "DB16242\n",
      "DB16243\n",
      "DB16244\n",
      "DB16245\n",
      "DB16246\n",
      "DB16247\n",
      "DB16248\n",
      "DB16249\n",
      "DB16250\n",
      "DB16251\n",
      "DB16252\n",
      "DB16253\n",
      "DB16254\n",
      "DB16255\n",
      "DB16256\n",
      "DB16257\n",
      "DB16258\n",
      "DB16259\n",
      "DB16260\n",
      "DB16261\n",
      "DB16262\n",
      "DB16263\n",
      "DB16264\n",
      "DB16265\n",
      "DB16266\n",
      "DB16267\n",
      "DB16268\n",
      "DB16269\n",
      "DB16270\n",
      "DB16271\n",
      "DB16272\n",
      "DB16273\n",
      "DB16274\n",
      "DB16275\n",
      "DB16276\n",
      "DB16277\n",
      "DB16278\n",
      "DB16279\n",
      "DB16280\n",
      "DB16281\n",
      "DB16282\n",
      "DB16283\n",
      "DB16284\n",
      "DB16285\n",
      "DB16286\n",
      "DB16287\n",
      "DB16288\n",
      "DB16289\n",
      "DB16290\n",
      "DB16291\n",
      "DB16292\n",
      "DB16293\n",
      "DB16294\n",
      "DB16295\n",
      "DB16296\n",
      "DB16297\n",
      "DB16298\n",
      "DB16299\n",
      "DB16300\n",
      "DB16301\n",
      "DB16302\n",
      "DB16303\n",
      "DB16304\n",
      "DB16305\n",
      "DB16306\n",
      "DB16307\n",
      "DB16308\n",
      "DB16309\n",
      "DB16310\n",
      "DB16311\n",
      "DB16312\n",
      "DB16313\n",
      "DB16314\n",
      "DB16315\n",
      "DB16316\n",
      "DB16317\n",
      "DB16318\n",
      "DB16319\n",
      "DB16320\n",
      "DB16321\n",
      "DB16322\n",
      "DB16323\n",
      "DB16324\n",
      "DB16325\n",
      "DB16326\n",
      "DB16327\n",
      "DB16328\n",
      "DB16329\n",
      "DB16330\n",
      "DB16331\n",
      "DB16332\n",
      "DB16333\n",
      "DB16334\n",
      "DB16335\n",
      "DB16336\n",
      "DB16337\n",
      "DB16338\n",
      "DB16339\n",
      "DB16340\n",
      "DB16341\n",
      "DB16342\n",
      "DB16343\n",
      "DB16344\n",
      "DB16345\n",
      "DB16346\n",
      "DB16347\n",
      "DB16348\n",
      "DB16349\n",
      "DB16350\n",
      "DB16351\n",
      "DB16352\n",
      "DB16353\n",
      "DB16354\n",
      "DB16355\n",
      "DB16356\n",
      "DB16357\n",
      "DB16358\n",
      "DB16359\n",
      "DB16360\n",
      "DB16361\n",
      "DB16362\n",
      "DB16363\n",
      "DB16364\n",
      "DB16365\n",
      "DB16366\n",
      "DB16367\n",
      "DB16368\n",
      "DB16369\n",
      "DB16370\n",
      "DB16371\n",
      "DB16372\n",
      "DB16373\n",
      "DB16374\n",
      "DB16375\n",
      "DB16376\n",
      "DB16377\n",
      "DB16378\n",
      "DB16379\n",
      "DB16380\n",
      "DB16381\n",
      "DB16383\n",
      "DB16384\n",
      "DB16385\n",
      "DB16386\n",
      "DB16387\n",
      "DB16388\n",
      "DB16389\n",
      "DB16390\n",
      "DB16391\n",
      "DB16392\n",
      "DB16393\n",
      "DB16394\n",
      "DB16395\n",
      "DB16396\n",
      "DB16397\n",
      "DB16398\n",
      "DB16399\n",
      "DB16400\n",
      "DB16401\n",
      "DB16402\n",
      "DB16403\n",
      "DB16404\n",
      "DB16405\n",
      "DB16406\n",
      "DB16407\n",
      "DB16408\n",
      "DB16409\n",
      "DB16410\n",
      "DB16411\n",
      "DB16412\n",
      "DB16413\n",
      "DB16414\n",
      "DB16415\n",
      "DB16416\n",
      "DB16417\n",
      "DB16418\n",
      "DB16419\n",
      "DB16420\n",
      "DB16421\n",
      "DB16422\n",
      "DB16423\n",
      "DB16424\n"
     ]
    }
   ],
   "source": [
    "import gensim\n",
    "from gensim.utils import simple_preprocess\n",
    "import nltk\n",
    "indications_list = []\n",
    "for k in dictionary.keys():\n",
    "    print(k)\n",
    "    indication_str = dictionary[k]['indication'] #### same preprocessing\n",
    "    indication_str = indication_str.replace(\"&#13;\", \"\")\n",
    "    indication_str = re.sub(\"l\\d+\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"L\\d+\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"_\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"A\\d+\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"F\\d+\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"G\\d+\", \"\", indication_str )\n",
    "    indication_str = re.sub(\"T\\d+\", \"\", indication_str )\n",
    "    indication_str = indication_str.replace(\"&lt;/i&gt\", \"\")\n",
    "    indication_str = indication_str.replace(\"&lt;i&gt\", \"\")\n",
    "    indication_str = indication_str.replace(\"&lt;b&\", \"\")\n",
    "    indication_str = indication_str.replace(\"vitamin e\", \"vitaminE\")\n",
    "    indication_str = indication_str.replace(\"vitamin a\", \"vitaminA\")\n",
    "    indication_str = indication_str.replace(\"vitamin c\", \"vitaminC\")\n",
    "    indication_str = indication_str.replace(\"vitamin d\", \"vitaminD\")\n",
    "    indication_str = indication_str.replace(\"t cells\", \"tCell\")\n",
    "    indication_str = re.sub(r'[^\\w\\s]', ' ', indication_str).lower()\n",
    "    for w in no_go_words:\n",
    "        indication_str = indication_str.replace(\" \"+ w + \" \", \" \")\n",
    "    new_word_list = nltk.word_tokenize(indication_str)\n",
    "    indications_list += [[lemmatizer.lemmatize(w) for w in new_word_list if all_indic_words[w]>1 ]]\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "ae63eb95",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['for', 'anemia', 'from', 'renal', 'certain', 'hiv']"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indications_list[11]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "6c2c894b",
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim import corpora\n",
    "dictionary_words = corpora.Dictionary(indications_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "id": "bb9edc09",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'for': 0, 'heparin': 1, 'induced': 2, 'thrombocytopenia': 3, 'administered': 4, 'agent': 5, 'based': 6, 'carcinoma': 7, 'chemotherapy': 8, 'colorectal': 9, 'egfr': 10, 'expressing': 11, 'intolerant': 12, 'irinotecan': 13, 'metastatic': 14, 'refractory': 15, 'single': 16, 'adjunct': 17, 'cystic': 18, 'fibrosis': 19, 'therapy': 20, 'cell': 21, 'cutaneous': 22, 'lymphoma': 23, 't': 24, '4': 25, 'active': 26, 'age': 27, 'aged': 28, 'ankylosing': 29, 'arthritis': 30, 'chronic': 31, 'idiopathic': 32, 'manage': 33, 'moderate': 34, 'moderately': 35, 'older': 36, 'plaque': 37, 'polyarticular': 38, 'psoriasis': 39, 'psoriatic': 40, 'rheumatoid': 41, 'severe': 42, 'severely': 43, 'spondylitis': 44, 'those': 45, 'angina': 46, 'coronary': 47, 'elevation': 48, 'high': 49, 'intervention': 50, 'non': 51, 'pci': 52, 'percutaneous': 53, 'planned': 54, 'prevention': 55, 'risk': 56, 'segment': 57, 'st': 58, 'thrombosis': 59, 'undergoing': 60, 'unstable': 61, 'whom': 62, 'advanced': 63, 'cancer': 64, 'central': 65, 'cpp': 66, 'endometriosis': 67, 'finally': 68, 'hematological': 69, 'improvement': 70, 'initial': 71, 'iron': 72, 'known': 73, 'oral': 74, 'palliative': 75, 'pediatric': 76, 'precocious': 77, 'preoperative': 78, 'prostate': 79, 'puberty': 80, 'supplementation': 81, 'uterine': 82, 'well': 83, '5': 84, 'alfa': 85, 'anti': 86, 'antiviral': 87, 'b': 88, 'compensated': 89, 'disease': 90, 'evidence': 91, 'fda': 92, 'hbeag': 93, 'hcv': 94, 'hepatitis': 95, 'infection': 96, 'inflammation': 97, 'intolerance': 98, 'liver': 99, 'monotherapy': 100, 'negative': 101, 'over': 102, 'positive': 103, 'replication': 104, 'significant': 105, 'viral': 106, 'infarction': 107, 'ischemic': 108, 'lysis': 109, 'myocardial': 110, 'pulmonary': 111, 'dwarfism': 112, 'hiv': 113, 'loss': 114, 'weight': 115, 'genital': 116, 'human': 117, 'venereal': 118, 'virus': 119, 'anemia': 120, 'certain': 121, 'from': 122, 'renal': 123, 'canada': 124, 'intravenous': 125, 'massive': 126, 'occlusive': 127, 'patency': 128, 'peripheral': 129, 'restoration': 130, 'bleeding': 131, 'breast': 132, 'confined': 133, 'dysfunctional': 134, 'endometrial': 135, 'locally': 136, 'perimenopausal': 137, 'pre': 138, 'prior': 139, 'intracoronary': 140, 'additional': 141, 'allogeneic': 142, 'ckd': 143, 'concomitant': 144, 'dialysis': 145, 'elective': 146, 'initiation': 147, 'kidney': 148, 'minimum': 149, 'myelosuppressive': 150, 'paediatric': 151, 'rbc': 152, 'reduction': 153, 'surgery': 154, 'there': 155, 'two': 156, 'upon': 157, 'added': 158, 'addition': 159, 'calcitonin': 160, 'calcium': 161, 'cardiac': 162, 'condition': 163, 'contraindicated': 164, 'decreased': 165, 'emergency': 166, 'existing': 167, 'hypercalcemia': 168, 'identified': 169, 'limited': 170, 'menopausal': 171, 'menopause': 172, 'more': 173, 'must': 174, 'osteoporosis': 175, 'paget': 176, 'phosphate': 177, 'post': 178, 'quickly': 179, 'serum': 180, 'symptomatic': 181, 'than': 182, 'therapeutic': 183, 'underlying': 184, 'unresponsive': 185, 'until': 186, 'where': 187, 'would': 188, 'acuminata': 189, 'condylomata': 190, 'external': 191, 'intralesional': 192, 'recurring': 193, 'acutely': 194, 'clinically': 195, 'decrease': 196, 'exposed': 197, 'febrile': 198, 'hematopoietic': 199, 'incidence': 200, 'increase': 201, 'manifested': 202, 'myeloid': 203, 'neutropenia': 204, 'radiation': 205, 'receiving': 206, 'survival': 207, 'syndrome': 208, 'bone': 209, 'marrow': 210, 'transplant': 211, '4a': 212, '6': 213, 'db00811': 214, 'genotype': 215, 'inhibitor': 216, 'ns3': 217, 'protease': 218, 'without': 219, 'all': 220, 'chemotherapeutic': 221, 'component': 222, 'leukemia': 223, 'lymphoblastic': 224, 'multi': 225, 'regimen': 226, 'detection': 227, 'recurrent': 228, 'thyroid': 229, 'deficiency': 230, 'factor': 231, 'hemophilia': 232, 'von': 233, 'willebrand': 234, 'xiii': 235, 'inflammatory': 236, 'neonatal': 237, 'onset': 238, 'eye': 239, 'skin': 240, 'surface': 241, 'autoimmune': 242, 'gravis': 243, 'includes': 244, 'lymphocytic': 245, 'multiple': 246, 'polyneuropathy': 247, 'purpura': 248, 'sclerosis': 249, 'these': 250, 'thrombocytopenic': 251, 'control': 252, 'diabetes': 253, 'glycemic': 254, 'improve': 255, 'insulin': 256, 'mellitus': 257, 'female': 258, 'infertility': 259, '1b': 260, 'gamma': 261, 'interferon': 262, 'arising': 263, 'c': 264, 'hairy': 265, 'kaposi': 266, 'myelogenous': 267, 'related': 268, 'sarcoma': 269, 'activity': 270, 'antidiuretic': 271, 'classic': 272, 'cranial': 273, 'during': 274, 'following': 275, 'greater': 276, 'head': 277, 'hemostasis': 278, 'i': 279, 'insipidus': 280, 'intranasal': 281, 'least': 282, 'maintain': 283, 'mild': 284, 'night': 285, 'nocturia': 286, 'nocturnal': 287, 'parenteral': 288, 'per': 289, 'pituitary': 290, 'polydipsia': 291, 'polyuria': 292, 'postoperatively': 293, 'region': 294, 'replacement': 295, 'surgical': 296, 'temporary': 297, 'trauma': 298, 'type': 299, 'viii': 300, 'hemorrhagic': 301, 'need': 302, 'nonmyeloid': 303, 'platelet': 304, 'mucositis': 305, 'aid': 306, 'diagnostic': 307, 'gastrointestinal': 308, 'hypoglycemia': 309, 'inhibit': 310, 'movement': 311, 'radiologic': 312, 'temporarily': 313, 'tract': 314, 'abnormal': 315, 'cervical': 316, 'dystonia': 317, 'neck': 318, 'pain': 319, 'position': 320, 'reduce': 321, 'severity': 322, '12': 323, 'antibody': 324, 'antihistamine': 325, 'asthma': 326, 'controlled': 327, 'despite': 328, 'drug': 329, 'h1': 330, 'ige': 331, 'inadequately': 332, 'inhaled': 333, 'perennial': 334, 'persistent': 335, 'reactivity': 336, 'remain': 337, 'test': 338, 'urticaria': 339, 'vitro': 340, 'hypogonadism': 341, 'hypogonadotropic': 342, 'hypothalamic': 343, 'insufficiency': 344, 'international': 345, 'l': 346, 'lh': 347, 'lt': 348, 'profound': 349, 'lyme': 350, 'prophylactic': 351, '30': 352, 'additionally': 353, 'angle': 354, 'beginning': 355, 'clostridium': 356, 'collagenase': 357, 'contracture': 358, 'cord': 359, 'debridement': 360, 'deformity': 361, 'degree': 362, 'dermal': 363, 'diagnosed': 364, 'men': 365, 'ointment': 366, 'palpable': 367, 'product': 368, 'tissue': 369, 'acid': 370, 'elevated': 371, 'hyperuricemia': 372, 'plasma': 373, 'reduces': 374, 'uric': 375, 'inhibition': 376, 'ovarian': 377, 'premature': 378, 'stimulation': 379, 'colitis': 380, 'crohn': 381, 'infectious': 382, 'intermediate': 383, 'juvenile': 384, 'off': 385, 'posterior': 386, 'pyoderma': 387, 'the': 388, 'ulcerative': 389, 'acromegaly': 390, 'gaucher': 391, 'glucocerebrosidase': 392, '24': 393, 'aspirin': 394, 'conventional': 395, 'intended': 396, 'medical': 397, 'only': 398, 'responding': 399, 'setting': 400, 'studied': 401, 'within': 402, 'mortality': 403, 'sepsis': 404, '60': 405, 'aml': 406, 'cd33': 407, 'considered': 408, 'cytotoxic': 409, 'experienced': 410, 'first': 411, 'relapse': 412, 'responded': 413, 'diagnosis': 414, 'malignant': 415, 'augmentation': 416, 'clinical': 417, 'emphysema': 418, 'maintenance': 419, 'pi': 420, 'condyloma': 421, 'relapsing': 422, 'remitting': 423, 'adenosine': 424, 'deaminase': 425, 'ascites': 426, 'bypass': 427, 'distress': 428, 'hypovolemia': 429, 'respiratory': 430, 'solution': 431, 'appropriate': 432, 'closure': 433, 'corticosteroid': 434, 'damage': 435, 'disabling': 436, 'draining': 437, 'e': 438, 'eliminating': 439, 'extensive': 440, 'fistula': 441, 'function': 442, 'had': 443, 'healing': 444, 'improving': 445, 'inadequate': 446, 'inducing': 447, 'inhibiting': 448, 'maintaining': 449, 'medically': 450, 'methotrexate': 451, 'mucosal': 452, 'number': 453, 'physical': 454, 'progression': 455, 'reducing': 456, 'remission': 457, 'response': 458, 'structural': 459, 'systemic': 460, 'assist': 461, 'cause': 462, 'failure': 463, 'fertility': 464, 'gonadotropin': 465, 'harvested': 466, 'having': 467, 'induce': 468, 'ovary': 469, 'ovulation': 470, 'primary': 471, 'produce': 472, 'several': 473, 'then': 474, 'enuresis': 475, 'oesophageal': 476, 'beta': 477, 'frequency': 478, 'shown': 479, 'slow': 480, 'melanoma': 481, 'absorption': 482, 'injected': 483, 'rehydration': 484, 'ii': 485, 'adenocarcinoma': 486, 'adjuvant': 487, 'administration': 488, 'anthracycline': 489, 'both': 490, 'capecitabine': 491, 'carboplatin': 492, 'cisplatin': 493, 'consisting': 494, 'cyclophosphamide': 495, 'docetaxel': 496, 'doxorubicin': 497, 'either': 498, 'fluorouracil': 499, 'gastric': 500, 'gastroesophageal': 501, 'her': 502, 'her2': 503, 'hyaluronidase': 504, 'junction': 505, 'line': 506, 'modality': 507, 'one': 508, 'overexpressing': 509, 'paclitaxel': 510, 'part': 511, 'previously': 512, 'received': 513, 'subcutaneous': 514, 'trastuzumab': 515, '2018': 516, '2019': 517, 'along': 518, 'approved': 519, 'cd20': 520, 'cll': 521, 'gpa': 522, 'granulomatosis': 523, 'hodgkin': 524, 'injection': 525, 'microscopic': 526, 'mpa': 527, 'nhl': 528, 'pemphigus': 529, 'polyangiitis': 530, 'pv': 531, 'ra': 532, 'rituximab': 533, 'september': 534, 'vulgaris': 535, 'rejection': 536, 'organ': 537, 'digitalis': 538, 'glycoside': 539, 'overdose': 540, 'toxicity': 541, 'complicated': 542, 'gram': 543, 'structure': 544, 'susceptible': 545, 'follicular': 546, 'antagonist': 547, 'growth': 548, 'hormone': 549, 'receptor': 550, 'above': 551, 'appearance': 552, 'axillary': 553, 'benign': 554, 'between': 555, 'blepharospasm': 556, 'essential': 557, 'excessive': 558, 'hyperhidrosis': 559, 'managed': 560, 'nerve': 561, 'topical': 562, 'underarm': 563, 'vii': 564, 'any': 565, 'attributed': 566, 'defined': 567, 'dual': 568, 'enzyme': 569, 'established': 570, 'malnutrition': 571, 'might': 572, 'once': 573, 'pancreas': 574, 'pancreatic': 575, 'pancreatitis': 576, 'physiological': 577, 'require': 578, 'steatorrhea': 579, 'arterial': 580, 'arteriovenous': 581, 'deep': 582, 'embolism': 583, 'occlusion': 584, 'vein': 585, 'monoclonal': 586, 'intra': 587, 'pelvic': 588, 'mucopolysaccharidosis': 589, 'alone': 590, 'atopic': 591, 'change': 592, 'commonly': 593, 'conjunction': 594, 'connective': 595, 'cyclosporine': 596, 'dependent': 597, 'dermatitis': 598, 'failed': 599, 'firstly': 600, 'focal': 601, 'glomerular': 602, 'glomerulonephritis': 603, 'glomerulosclerosis': 604, 'graft': 605, 'gvhd': 606, 'heart': 607, 'host': 608, 'immunocompromised': 609, 'immunosuppressive': 610, 'include': 611, 'keratoconjunctivitis': 612, 'longer': 613, 'minimal': 614, 'nephropathy': 615, 'nephrotic': 616, 'no': 617, 'ophthalmic': 618, 'prevent': 619, 'previous': 620, 'production': 621, 'prophylaxis': 622, 'recalcitrant': 623, 'resistant': 624, 'respond': 625, 'segmental': 626, 'sicca': 627, 'steroid': 628, 'suffering': 629, 'tear': 630, 'they': 631, 'tolerated': 632, 'uveitis': 633, 'variety': 634, 'various': 635, 'versus': 636, 'alternative': 637, 'local': 638, 'provided': 639, 'phototherapy': 640, 'autologous': 641, 'blood': 642, 'collection': 643, 'congenital': 644, 'consolidation': 645, 'cyclic': 646, 'duration': 647, 'fever': 648, 'followed': 649, 'g': 650, 'incident': 651, 'induction': 652, 'into': 653, 'mobilize': 654, 'myeloablative': 655, 'nuclear': 656, 'oropharyngeal': 657, 'progenitor': 658, 'radiological': 659, 'recovery': 660, 'time': 661, 'transplantation': 662, 'christmas': 663, 'fabry': 664, 'adequately': 665, 'carcinoid': 666, 'delayed': 667, 'diarrhea': 668, 'formulation': 669, 'injectable': 670, 'intestinal': 671, 'long': 672, 'peptide': 673, 'release': 674, 'term': 675, 'tolerate': 676, 'can': 677, 'capability': 678, 'clear': 679, 'evaluation': 680, 'fetal': 681, 'labor': 682, 'not': 683, 'postpartum': 684, 'pregnancy': 685, 'requirement': 686, 'stage': 687, 'termination': 688, 'third': 689, 'antiretroviral': 690, 'syncytial': 691, 'humanized': 692, '19': 693, 'ards': 694, 'covid': 695, 'currently': 696, 'epithelial': 697, 'fallopian': 698, 'glioblastoma': 699, 'injury': 700, 'investigation': 701, 'lung': 702, 'peritoneal': 703, 'small': 704, 'squamous': 705, 'tube': 706, 'under': 707, 'unresectable': 708, 'vascular': 709, 'vegf': 710, 'imaging': 711, 'dietary': 712, 'imbalance': 713, 'nutritional': 714, 'shortage': 715, 'treating': 716, 'absorbed': 717, 'achieved': 718, 'after': 719, 'available': 720, 'b12': 721, 'bacterial': 722, 'bowel': 723, 'dose': 724, 'dysfunction': 725, 'evaluated': 726, 'fish': 727, 'folic': 728, 'form': 729, 'frequently': 730, 'hemolytic': 731, 'hemorrhage': 732, 'hepatic': 733, 'higher': 734, 'infestation': 735, 'intramuscular': 736, 'involvement': 737, 'malabsorption': 738, 'malignancy': 739, 'nasal': 740, 'nervous': 741, 'neurologic': 742, 'newly': 743, 'normal': 744, 'normalization': 745, 'note': 746, 'often': 747, 'partial': 748, 'pathology': 749, 'pernicious': 750, 'primarily': 751, 'recommended': 752, 'spray': 753, 'sprue': 754, 'system': 755, 'tapeworm': 756, 'thyrotoxicosis': 757, 'total': 758, 'usually': 759, 'vitamin': 760, 'widely': 761, 'antioxidant': 762, 'cholesterol': 763, 'immunomodulatory': 764, 'lowering': 765, 'some': 766, 'supplemental': 767, 'being': 768, 'depression': 769, 'emotional': 770, 'europe': 771, 'fibromyalgia': 772, 'health': 773, 'introduced': 774, 'joint': 775, 'market': 776, 'mood': 777, 'osteoarthritis': 778, 'same': 779, 'supplement': 780, 'support': 781, 'united': 782, 'dyskinesia': 783, 'helpful': 784, 'neuroleptic': 785, 'phenylalanine': 786, 'schizophrenic': 787, 'tardive': 788, 'useful': 789, 'vitiligo': 790, 'herpes': 791, 'preliminary': 792, 'putative': 793, 'research': 794, 'simplex': 795, 'effective': 796, 'general': 797, 'suggested': 798, 'urine': 799, 'wound': 800, 'claim': 801, 'exercise': 802, 'performance': 803, 'anabolic': 804, 'athletic': 805, 'claimed': 806, 'enhancing': 807, 'immuno': 808, 'sickle': 809, 'care': 810, 'moisturizing': 811, 'natural': 812, 'cysteine': 813, 'formation': 814, 'homocysteine': 815, 'protein': 816, 'sulfate': 817, 'synthesis': 818, 'act': 819, 'antidepressant': 820, 'combat': 821, 'fatigue': 822, 'however': 823, 'mixed': 824, 'narcolepsy': 825, 'refuted': 826, 'stress': 827, 'tyrosine': 828, 'd': 829, 'familial': 830, 'hypocalcemia': 831, 'hypoparathyroidism': 832, 'hypophosphatemia': 833, 'osteodystrophy': 834, 'rickets': 835, 'taken': 836, 'against': 837, 'animal': 838, 'before': 839, 'date': 840, 'done': 841, 'mostly': 842, 'protect': 843, 'will': 844, 'b2': 845, 'itself': 846, 'alcoholism': 847, 'brain': 848, 'food': 849, 'mental': 850, 'nature': 851, 'schizophrenia': 852, 'speed': 853, 'sugar': 854, 'alzheimer': 855, 'cognitive': 856, 'demonstrated': 857, 'enhancement': 858, 'immune': 859, 'impairment': 860, 'memory': 861, 'needed': 862, 'usefulness': 863, 'antipsychotic': 864, 'early': 865, 'suggest': 866, 'very': 867, 'b6': 868, 'therefore': 869, 'breakdown': 870, 'muscle': 871, 'occur': 872, 'sometimes': 873, 'healthy': 874, 'increasing': 875, 'managing': 876, 'promoting': 877, 'serotonin': 878, 'sleep': 879, 'tolerance': 880, 'acetaminophen': 881, 'overdoses': 882, 'alcoholic': 883, 'delirium': 884, 'korsakov': 885, 'neuritis': 886, 'niacin': 887, 'psychosis': 888, 'altered': 889, 'characterized': 890, 'impaired': 891, 'increased': 892, 'metabolism': 893, 'occurs': 894, 'osteomalacia': 895, 'parathyroid': 896, 'phosphorus': 897, 'presence': 898, 'present': 899, 'produced': 900, 'removal': 901, 'result': 902, 'soft': 903, 'softening': 904, 'transport': 905, 'weak': 906, 'collagen': 907, 'digestive': 908, 'enamel': 909, 'fat': 910, 'proper': 911, 'up': 912, 'cardiovascular': 913, 'parkinson': 914, 'suggests': 915, 'childhood': 916, 'infancy': 917, 'megaloblastic': 918, 'diabetic': 919, 'epa': 920, 'play': 921, 'role': 922, 'similar': 923, 'slowing': 924, 'encephalopathy': 925, 'phenylketonuria': 926, 'promotes': 927, 'abetalipoproteinemia': 928, 'cholestasis': 929, 'diet': 930, 'poor': 931, 'commercially': 932, 'nausea': 933, 'neuropathy': 934, 'pyridoxine': 935, 'vomiting': 936, 'amino': 937, 'chain': 938, 'substitute': 939, 'among': 940, 'body': 941, 'concurrently': 942, 'directly': 943, 'like': 944, 'most': 945, 'others': 946, 'specific': 947, 'sufficient': 948, 'utilized': 949, 'but': 950, 'clotting': 951, 'k': 952, 'extremely': 953, 'functioning': 954, 'important': 955, 'strengthen': 956, '160': 957, '8': 958, 'adjunctive': 959, 'atherosclerosis': 960, 'attack': 961, 'correspond': 962, 'death': 963, 'density': 964, 'development': 965, 'dl': 966, 'do': 967, 'dysbetalipoproteinemia': 968, 'dyslipidemia': 969, 'dyslipidemias': 970, 'flow': 971, 'heterozygous': 972, 'history': 973, 'hypercholesterolemia': 974, 'hypercholesterolemic': 975, 'hyperlipidemia': 976, 'iia': 977, 'iib': 978, 'iii': 979, 'indication': 980, 'iv': 981, 'ldl': 982, 'lipoprotein': 983, 'low': 984, 'mg': 985, 'represents': 986, 'revascularization': 987, 'secondary': 988, 'stroke': 989, 'transient': 990, 'bulimia': 991, 'compulsive': 992, 'disorder': 993, 'nervosa': 994, 'obsessive': 995, 'ocd': 996, 'predominantly': 997, 'angiotensin': 998, 'class': 999, 'converting': 1000, 'fatal': 1001, 'hypertension': 1002, 'left': 1003, 'nonfatal': 1004, 'nyha': 1005, 'ventricular': 1006, 'congestive': 1007, 'develop': 1008, 'few': 1009, 'hemodynamically': 1010, 'overt': 1011, 'rate': 1012, 'stable': 1013, 'actinic': 1014, 'become': 1015, 'if': 1016, 'keratoses': 1017, 'untreated': 1018, 'cerebral': 1019, 'determined': 1020, 'efficacy': 1021, 'muscular': 1022, 'palsy': 1023, 'particularly': 1024, 'promote': 1025, 'relief': 1026, 'residual': 1027, 'resulting': 1028, 'reversible': 1029, 'rheumatic': 1030, 'should': 1031, 'skeletal': 1032, 'spasm': 1033, 'spasticity': 1034, 'adhd': 1035, 'adolescence': 1036, 'attention': 1037, 'complex': 1038, 'daytime': 1039, 'deficit': 1040, 'etiology': 1041, 'genetic': 1042, 'hand': 1043, 'hyperactivity': 1044, 'nowadays': 1045, 'obesity': 1046, 'outcome': 1047, 'sleepiness': 1048, 'substantial': 1049, 'typically': 1050, 'secretory': 1051, 'cessation': 1052, 'nicotine': 1053, 'smoking': 1054, 'withdrawal': 1055, 'amp': 1056, 'dry': 1057, 'mouth': 1058, 'ouml': 1059, 'sj': 1060, 'agitated': 1061, 'alcohol': 1062, 'amnesia': 1063, 'anesthesia': 1064, 'anxiety': 1065, 'depressive': 1066, 'epilepticus': 1067, 'insomnia': 1068, 'panic': 1069, 'patient': 1070, 'premedication': 1071, 'psychogenic': 1072, 'rapid': 1073, 'relieve': 1074, 'sedation': 1075, 'short': 1076, 'status': 1077, 'tranquilization': 1078, 'acting': 1079, 'atrial': 1080, 'desirable': 1081, 'fibrillation': 1082, 'flutter': 1083, 'perioperative': 1084, 'postoperative': 1085, 'requires': 1086, 'sinus': 1087, 'tachycardia': 1088, 'bortezomib': 1089, 'mantle': 1090, 'myeloma': 1091, 'generally': 1092, 'hypnotic': 1093, 'medication': 1094, 'replaced': 1095, 'sedative': 1096, 'week': 1097, 'adequate': 1098, 'carbidopa': 1099, 'carbon': 1100, 'daily': 1101, 'dosage': 1102, 'driven': 1103, 'individual': 1104, 'intoxication': 1105, 'levodopa': 1106, 'manganese': 1107, 'monoxide': 1108, 'parkinsonism': 1109, 'provide': 1110, 'titration': 1111, '27': 1112, 'behavioral': 1113, 'bmi': 1114, 'caloric': 1115, 'consuming': 1116, 'epidemic': 1117, 'exogenous': 1118, 'index': 1119, 'kg': 1120, 'level': 1121, 'm2': 1122, 'mass': 1123, 'obese': 1124, 'overweight': 1125, 'person': 1126, 'restriction': 1127, 'storage': 1128, 'three': 1129, 'world': 1130, 'dysrhythmias': 1131, 'life': 1132, 'sustained': 1133, 'threatening': 1134, 'ejaculation': 1135, 'chickenpox': 1136, 'varicella': 1137, 'zoster': 1138, '3': 1139, 'advised': 1140, 'candida': 1141, 'candidiasis': 1142, 'causative': 1143, 'confirm': 1144, 'culture': 1145, 'eliminated': 1146, 'esophageal': 1147, 'fluconazole': 1148, 'fungal': 1149, 'laboratory': 1150, 'meningitis': 1151, 'necessary': 1152, 'obtaining': 1153, 'order': 1154, 'organism': 1155, 'peritoneum': 1156, 'peritonitis': 1157, 'receive': 1158, 'start': 1159, 'testing': 1160, 'through': 1161, 'treated': 1162, 'urinary': 1163, 'uti': 1164, 'vaginal': 1165, 'yeast': 1166, 'metformin': 1167, '48': 1168, 'according': 1169, 'case': 1170, 'circulating': 1171, 'community': 1172, 'contact': 1173, 'exposure': 1174, 'full': 1175, 'illness': 1176, 'influenza': 1177, 'information': 1178, 'initiated': 1179, 'outbreak': 1180, 'particular': 1181, 'prescribing': 1182, 'specifically': 1183, 'typical': 1184, 'uncomplicated': 1185, 'year': 1186, 'amebiasis': 1187, 'another': 1188, 'antimicrobial': 1189, 'aureus': 1190, 'bacteria': 1191, 'below': 1192, 'carrier': 1193, 'chlamydia': 1194, 'chlamydial': 1195, 'concomitantly': 1196, 'conducted': 1197, 'conjunctivitis': 1198, 'corynebacterium': 1199, 'cough': 1200, 'diphtheria': 1201, 'endocervical': 1202, 'entamoeba': 1203, 'fact': 1204, 'haemophilus': 1205, 'histolytica': 1206, 'hypersensitivity': 1207, 'indicate': 1208, 'infected': 1209, 'influenzae': 1210, 'listeria': 1211, 'lower': 1212, 'mycoplasma': 1213, 'n': 1214, 'newborn': 1215, 'nongonococcal': 1216, 'occurring': 1217, 'option': 1218, 'penicillin': 1219, 'pertussis': 1220, 'pneumonia': 1221, 'pneumoniae': 1222, 'pyogenes': 1223, 'rectal': 1224, 'staphylococcal': 1225, 'staphylococcus': 1226, 'streptococcus': 1227, 'study': 1228, 'syphilis': 1229, 'them': 1230, 'trachomatis': 1231, 'upper': 1232, 'urealyticum': 1233, 'ureaplasma': 1234, 'urethral': 1235, 'urethritis': 1236, 'urogenital': 1237, 'biliary': 1238, 'celiac': 1239, 'cyanide': 1240, 'hyperthyroidism': 1241, 'poisoning': 1242, 'prolonged': 1243, 'resection': 1244, 'suspected': 1245, 'apnea': 1246, 'birth': 1247, 'broad': 1248, 'bronchopulmonary': 1249, 'caffeine': 1250, 'cns': 1251, 'cosmetic': 1252, 'counter': 1253, 'depressant': 1254, 'dysplasia': 1255, 'energy': 1256, 'found': 1257, 'prematurity': 1258, 'range': 1259, 'sodium': 1260, 'brief': 1261, 'intubation': 1262, 'relaxation': 1263, '16': 1264, '17': 1265, '25': 1266, 'ability': 1267, 'already': 1268, 'association': 1269, 'background': 1270, 'canadian': 1271, 'capacity': 1272, 'classified': 1273, 'ctd': 1274, 'delay': 1275, 'effectiveness': 1276, 'ema': 1277, 'employed': 1278, 'epoprostenol': 1279, 'erectile': 1280, 'establishing': 1281, 'functional': 1282, 'group': 1283, 'included': 1284, 'indicates': 1285, 'monograph': 1286, 'new': 1287, 'old': 1288, 'pah': 1289, 'predominately': 1290, 'stabilized': 1291, 'u': 1292, 'were': 1293, 'worsening': 1294, 'york': 1295, 'af': 1296, 'converted': 1297, 'recurrence': 1298, 'rhythm': 1299, 'malaria': 1300, 'pyrimethamine': 1301, 'toxoplasmosis': 1302, 'acquired': 1303, 'agalactiae': 1304, 'catarrhalis': 1305, 'cervicitis': 1306, 'chancroid': 1307, 'chlamydophila': 1308, 'drainage': 1309, 'ducreyi': 1310, 'entry': 1311, 'gonorrhoeae': 1312, 'listed': 1313, 'moraxella': 1314, 'neisseria': 1315, 'obstructive': 1316, 'otitis': 1317, 'pharyngitis': 1318, 'proven': 1319, 'refer': 1320, 'resistance': 1321, 'section': 1322, 'sinusitis': 1323, 'strongly': 1324, 'tonsillitis': 1325, 'ulcer': 1326, 'vary': 1327, 'take': 1328, 'thrombotic': 1329, 'try': 1330, 'bladder': 1331, 'detrusor': 1332, 'incontinence': 1333, 'instability': 1334, 'overactive': 1335, 'urge': 1336, 'urgency': 1337, 'acne': 1338, 'hypotension': 1339, 'orthostatic': 1340, '10': 1341, '7': 1342, 'continue': 1343, 'course': 1344, 'ellison': 1345, 'erosive': 1346, 'esophagitis': 1347, 'five': 1348, 'gerd': 1349, 'healed': 1350, 'heartburn': 1351, 'hypersecretion': 1352, 'hypersecretory': 1353, 'neoplastic': 1354, 'nighttime': 1355, 'pathological': 1356, 'reflux': 1357, 'safety': 1358, 'suspension': 1359, 'taking': 1360, 'unable': 1361, 'zollinger': 1362, 'abdomen': 1363, 'amount': 1364, 'antihypertensive': 1365, 'edema': 1366, 'even': 1367, 'extended': 1368, 'face': 1369, 'fluid': 1370, 'located': 1371, 'mainly': 1372, 'observed': 1373, 'pressure': 1374, 'pumped': 1375, 'swelling': 1376, 'whole': 1377, 'abuse': 1378, 'behavioural': 1379, 'sexual': 1380, 'aura': 1381, 'migraine': 1382, 'bronchitis': 1383, 'visceral': 1384, 'asthmatic': 1385, 'wheezing': 1386, 'glucose': 1387, 'whose': 1388, 'pruritic': 1389, 'responsive': 1390, 'barrier': 1391, 'intracranial': 1392, 'mri': 1393, 'spine': 1394, 'thought': 1395, 'vascularity': 1396, 'visualize': 1397, 'abdominal': 1398, 'accompanied': 1399, 'administering': 1400, 'adolescent': 1401, 'altering': 1402, 'aneurysm': 1403, 'aortic': 1404, 'apolipoprotein': 1405, 'artery': 1406, 'atherosclerotic': 1407, 'average': 1408, 'carotid': 1409, 'claudication': 1410, 'cvd': 1411, 'developing': 1412, 'documented': 1413, 'family': 1414, 'hdl': 1415, 'hefh': 1416, 'lipid': 1417, 'menarche': 1418, 'nonpharmacological': 1419, 'out': 1420, 'people': 1421, 'performed': 1422, 'practice': 1423, 'presenting': 1424, 'profile': 1425, 'remains': 1426, 'restricted': 1427, 'rule': 1428, 'saturated': 1429, 'significantly': 1430, 'standard': 1431, 'statin': 1432, 'strategy': 1433, 'target': 1434, 'tia': 1435, 'trans': 1436, 'trial': 1437, 'analgesia': 1438, 'anesthetic': 1439, 'delivery': 1440, 'month': 1441, 'neuralgia': 1442, 'neuropathic': 1443, 'postherpetic': 1444, 'spinal': 1445, 'asleep': 1446, 'consecutive': 1447, 'difficulty': 1448, 'expected': 1449, 'falling': 1450, 'frequent': 1451, 'furthermore': 1452, 'minor': 1453, 'morning': 1454, 'nor': 1455, 'official': 1456, 'prescribed': 1457, 'regional': 1458, 'specifies': 1459, 'subsequently': 1460, 'supply': 1461, 'cirrhosis': 1462, 'effect': 1463, 'enhance': 1464, 'estrogen': 1465, 'sole': 1466, 'tuberculosis': 1467, 'leukaemia': 1468, 'vera': 1469, 'ongoing': 1470, 'codeine': 1471, 'contraction': 1472, 'headache': 1473, 'opioid': 1474, 'symptom': 1475, 'tension': 1476, 'grade': 1477, 'ace': 1478, 'arrhythmia': 1479, 'channel': 1480, 'microvascular': 1481, 'scientific': 1482, 'supported': 1483, 'yet': 1484, 'uk': 1485, 'extrapyramidal': 1486, 'large': 1487, 'neurological': 1488, 'refers': 1489, 'stiffness': 1490, 'agitation': 1491, 'bipolar': 1492, 'lithium': 1493, 'manic': 1494, 'valproate': 1495, 'parkinsonian': 1496, 'prolactin': 1497, 'secreting': 1498, 'keratitis': 1499, 'herpetiformis': 1500, 'leprosy': 1501, 'vagina': 1502, 'vulva': 1503, 'clonic': 1504, 'ester': 1505, 'grand': 1506, 'mal': 1507, 'neurosurgery': 1508, 'phenytoin': 1509, 'prodrug': 1510, 'tonic': 1511, 'allergic': 1512, 'epinephrine': 1513, 'sensitivity': 1514, 'vernal': 1515, 'although': 1516, 'always': 1517, 'borrelia': 1518, 'choice': 1519, 'complete': 1520, 'faecalis': 1521, 'inclusion': 1522, 'judged': 1523, 'list': 1524, 'major': 1525, 'microbial': 1526, 'microorganism': 1527, 'mountain': 1528, 'percent': 1529, 'psittaci': 1530, 'q': 1531, 'recurrentis': 1532, 'regarding': 1533, 'rickettsialpox': 1534, 'rocky': 1535, 'spotted': 1536, 'streptococcal': 1537, 'tick': 1538, 'trachoma': 1539, 'typhus': 1540, 'unless': 1541, 'miscarriage': 1542, 'pregnant': 1543, 'prone': 1544, 'albicans': 1545, 'betamethasone': 1546, 'combined': 1547, 'corporis': 1548, 'cream': 1549, 'cruris': 1550, 'diaper': 1551, 'epidermophyton': 1552, 'floccosum': 1553, 'furfur': 1554, 'malassezia': 1555, 'mentagrophytes': 1556, 'mycoses': 1557, 'pedis': 1558, 'preparation': 1559, 'radiotherapy': 1560, 'rash': 1561, 'rubrum': 1562, 'solid': 1563, 'tinea': 1564, 'trichophyton': 1565, 'troche': 1566, 'versicolor': 1567, 'acetate': 1568, 'hyperphosphatemia': 1569, 'much': 1570, 'too': 1571, 'avium': 1572, 'mac': 1573, 'mycobacterium': 1574, 'tb': 1575, 'amelioration': 1576, 'beneficial': 1577, 'count': 1578, 'thrombo': 1579, 'thrombocythemia': 1580, 'lasting': 1581, 'meningococcal': 1582, 'nocardiosis': 1583, 'comorbidity': 1584, 'global': 1585, 'involve': 1586, 'lack': 1587, 'leading': 1588, 'lifestyle': 1589, 'scale': 1590, 'storm': 1591, 'supraventricular': 1592, 'variable': 1593, 'eradication': 1594, 'sarcoptes': 1595, 'scabiei': 1596, 'scabies': 1597, 'decreasing': 1598, 'aerobic': 1599, 'anaerobic': 1600, 'gynecologic': 1601, 'obstetric': 1602, 'restless': 1603, 'rare': 1604, 'thiazide': 1605, 'angiography': 1606, 'barium': 1607, 'cholangiography': 1608, 'computed': 1609, 'hysterosalpingography': 1610, 'retrograde': 1611, 'tomography': 1612, 'urography': 1613, 'wide': 1614, 'gastaut': 1615, 'generalized': 1616, 'lennox': 1617, 'blockade': 1618, 'hospitalization': 1619, 'airflow': 1620, 'obstruction': 1621, 'hit': 1622, 'autonomy': 1623, 'brittle': 1624, 'constipation': 1625, 'diffuse': 1626, 'gland': 1627, 'goiter': 1628, 'hair': 1629, 'hormonal': 1630, 'hypothyroidism': 1631, 'insufficient': 1632, 'iodine': 1633, 'irregular': 1634, 'lethargy': 1635, 'never': 1636, 'nontoxic': 1637, 'officially': 1638, 'phase': 1639, 'presented': 1640, 'radioiodine': 1641, 'replace': 1642, 'restore': 1643, 'subacute': 1644, 'suppression': 1645, 'tertiary': 1646, 'thyroidal': 1647, 'thyroiditis': 1648, 'antiarrhythmic': 1649, 'excitation': 1650, 'ia': 1651, 'amide': 1652, 'block': 1653, 'brachial': 1654, 'caudal': 1655, 'epidural': 1656, 'infiltration': 1657, 'intercostal': 1658, 'lidocaine': 1659, 'lumbar': 1660, 'neural': 1661, 'plexus': 1662, 'osteolytic': 1663, 'angioedema': 1664, 'cold': 1665, 'common': 1666, 'pruritus': 1667, 'rhinitis': 1668, 'rhinorrhea': 1669, 'self': 1670, 'sneezing': 1671, 'second': 1672, 'agoraphobia': 1673, 'gad': 1674, 'mdd': 1675, 'phobia': 1676, 'social': 1677, 'vasomotor': 1678, 'androgen': 1679, 'appropriately': 1680, 'atrophy': 1681, 'castration': 1682, 'conjugated': 1683, 'different': 1684, 'hypoestrogenism': 1685, 'postmenopausal': 1686, 'preventive': 1687, 'selected': 1688, 'vulvar': 1689, '18': 1690, 'glaucoma': 1691, 'intraocular': 1692, 'ocular': 1693, 'open': 1694, 'neoplasm': 1695, 'trachea': 1696, 'giant': 1697, 'lymphatic': 1698, 'lymphosarcoma': 1699, 'macroglobulinemia': 1700, 'colon': 1701, 'rectum': 1702, 'contraception': 1703, 'contraceptive': 1704, 'implant': 1705, 'insertion': 1706, 'subdermal': 1707, 'addiction': 1708, 'dependence': 1709, 'monitored': 1710, 'morphine': 1711, 'opioids': 1712, 'obstetrical': 1713, 'adrenergic': 1714, 'mydriasis': 1715, 'phenylephrine': 1716, 'herpesvirus': 1717, 'tenofovir': 1718, 'younger': 1719, 'extraction': 1720, 'tooth': 1721, 'abortion': 1722, 'asaccharolytica': 1723, 'bacteremia': 1724, 'bacteroides': 1725, 'bivia': 1726, 'coli': 1727, 'concurrent': 1728, 'designated': 1729, 'escherichia': 1730, 'foot': 1731, 'fragilis': 1732, 'isolates': 1733, 'klebsiella': 1734, 'lactamase': 1735, 'methicillin': 1736, 'mirabilis': 1737, 'osteomyelitis': 1738, 'peptostreptococcus': 1739, 'porphyromonas': 1740, 'prevotella': 1741, 'proteus': 1742, 'pyelonephritis': 1743, 'septic': 1744, 'thetaiotaomicron': 1745, 'uniformis': 1746, 'contain': 1747, 'ethinylestradiol': 1748, 'mix': 1749, 'progestin': 1750, 'cavity': 1751, 'lip': 1752, 'pharynx': 1753, 'urothelial': 1754, 'ctcl': 1755, 'experience': 1756, 'orally': 1757, 'topically': 1758, 'conversion': 1759, 'recent': 1760, 'diuretic': 1761, 'duodenal': 1762, 'epilepsy': 1763, 'absence': 1764, 'mania': 1765, 'seizure': 1766, 'simple': 1767, 'because': 1768, 'bronchial': 1769, 'causing': 1770, 'dosing': 1771, 'continued': 1772, 'platinum': 1773, 'analgesic': 1774, 'suppressant': 1775, 'syrup': 1776, 'tablet': 1777, 'polymicrobial': 1778, 'cluster': 1779, 'bifida': 1780, 'healthcare': 1781, 'irritable': 1782, 'organic': 1783, 'professional': 1784, 'spina': 1785, 'vasopressin': 1786, 'carefully': 1787, 'continuous': 1788, 'given': 1789, 'infusion': 1790, 'experiencing': 1791, 'reserved': 1792, 'anterior': 1793, 'conjunctiva': 1794, 'cornea': 1795, 'hypertensive': 1796, 'immediate': 1797, 'alkalosis': 1798, 'exchange': 1799, 'replenish': 1800, 'tetany': 1801, 'potential': 1802, 'proposed': 1803, 'strong': 1804, '500': 1805, 'arteriosus': 1806, 'bursitis': 1807, 'ductus': 1808, 'etc': 1809, 'gouty': 1810, 'indometacin': 1811, 'ineffective': 1812, 'painful': 1813, 'patent': 1814, 'shoulder': 1815, 'tendinitis': 1816, 'usual': 1817, 'weighing': 1818, '2020': 1819, 'adjunctively': 1820, 'containing': 1821, 'empagliflozin': 1822, 'january': 1823, 'linagliptin': 1824, 'agonist': 1825, 'alleviate': 1826, 'breathlessness': 1827, 'bronchodilator': 1828, 'bronchospasm': 1829, 'burden': 1830, 'congestion': 1831, 'cost': 1832, 'debilitating': 1833, 'discharge': 1834, 'diverse': 1835, 'progressive': 1836, 'requiring': 1837, 'salivation': 1838, 'seasonal': 1839, 'sialorrhea': 1840, 'watery': 1841, 'detoxification': 1842, 'eg': 1843, 'enough': 1844, 'heroin': 1845, 'otherwise': 1846, 'substitution': 1847, '13': 1848, 'biochemical': 1849, 'categorized': 1850, 'disturbed': 1851, 'initially': 1852, 'intramuscularly': 1853, 'psychiatric': 1854, 'psychomotor': 1855, 'reality': 1856, 'thinking': 1857, 'while': 1858, '100': 1859, '50': 1860, 'cardiomyopathy': 1861, 'pectoris': 1862, 'qt': 1863, 'right': 1864, 'systolic': 1865, 'ee': 1866, 'helicobacter': 1867, 'mediated': 1868, 'pathologic': 1869, 'proton': 1870, 'pump': 1871, 'dust': 1872, 'effectively': 1873, 'occurrence': 1874, 'redness': 1875, 'tearing': 1876, 'hay': 1877, 'accessory': 1878, 'anal': 1879, 'dilated': 1880, 'leg': 1881, 'nodal': 1882, 'paroxysmal': 1883, 'pathway': 1884, 'prinzmetal': 1885, 'proteinuria': 1886, 'rest': 1887, 'variant': 1888, 'determine': 1889, 'excretory': 1890, 'measure': 1891, 'mechanism': 1892, 'tubular': 1893, 'emptying': 1894, 'hyperplasia': 1895, 'incomplete': 1896, 'prostatic': 1897, 'sensation': 1898, 'straining': 1899, 'stream': 1900, 'petit': 1901, 'hereditary': 1902, 'difficult': 1903, 'alopecia': 1904, 'androgenic': 1905, 'anorexia': 1906, 'cachexia': 1907, 'immunodeficiency': 1908, 'inoperable': 1909, 'unexplained': 1910, 'nonlymphocytic': 1911, 'dizziness': 1912, 'motion': 1913, 'sickness': 1914, 'vertigo': 1915, 'septicemia': 1916, 'discomfort': 1917, 'musculoskeletal': 1918, 'adrenal': 1919, 'cushing': 1920, 'situ': 1921, 'chloroquine': 1922, 'falciparum': 1923, 'plasmodium': 1924, 'vivax': 1925, 'aggressive': 1926, 'everolimus': 1927, 'nsclc': 1928, 'relapsed': 1929, 'taxane': 1930, 'tumor': 1931, 'abscess': 1932, 'aspergillus': 1933, 'candidemia': 1934, 'dyspepsia': 1935, 'gastritis': 1936, 'gastro': 1937, 'peptic': 1938, 'preventing': 1939, 'purpose': 1940, 'allergy': 1941, '72': 1942, '96': 1943, 'child': 1944, 'confirmed': 1945, 'designed': 1946, 'estradiol': 1947, 'ethinyl': 1948, 'example': 1949, 'intercourse': 1950, 'intrauterine': 1951, 'labeling': 1952, 'possible': 1953, 'prescription': 1954, 'ranging': 1955, 'regular': 1956, 'releasing': 1957, 'soon': 1958, 'unprotected': 1959, 'benefit': 1960, 'critical': 1961, 'dopamine': 1962, 'neurogenic': 1963, 'shock': 1964, 'cmv': 1965, 'retinitis': 1966, 'hot': 1967, 'ptsd': 1968, 'substance': 1969, 'traumatic': 1970, 'able': 1971, 'diminish': 1972, 'abnormality': 1973, 'begin': 1974, 'concern': 1975, 'formally': 1976, 'fredrickson': 1977, 'hyperlipoproteinemia': 1978, 'hypertriglyceridemia': 1979, 'intensive': 1980, 'nevertheless': 1981, 'shorter': 1982, 'six': 1983, 'emetogenic': 1984, 'highly': 1985, 'operation': 1986, 'repeat': 1987, '300': 1988, 'anthracyclines': 1989, 'cumulative': 1990, 'extravasation': 1991, 'hydrochloride': 1992, 'm': 1993, '40': 1994, 'ejection': 1995, 'fraction': 1996, 'vasospastic': 1997, 'dementia': 1998, 'allows': 1999, 'balance': 2000, 'hydrochlorothiazide': 2001, 'hyperaldosteronism': 2002, 'hypokalemia': 2003, 'loop': 2004, 'potassium': 2005, 'dilate': 2006, 'priapism': 2007, 'vasoconstriction': 2008, 'prepare': 2009, 'thyroidectomy': 2010, 'subarachnoid': 2011, 'aerosol': 2012, 'anogenital': 2013, 'chronicus': 2014, 'eczema': 2015, 'eczematous': 2016, 'exfoliative': 2017, 'infantile': 2018, 'inhalation': 2019, 'lichen': 2020, 'nonallergic': 2021, 'planus': 2022, 'seborrheic': 2023, 'senile': 2024, 'solar': 2025, 'amenorrhea': 2026, 'art': 2027, 'assisted': 2028, 'concentration': 2029, 'corpus': 2030, 'gel': 2031, 'implantation': 2032, 'infertile': 2033, 'program': 2034, 'reproductive': 2035, 'technology': 2036, 'hepatocellular': 2037, 'sorafenib': 2038, 'glucocorticoid': 2039, 'cap': 2040, 'fungi': 2041, 'microsporum': 2042, 'ringworm': 2043, 'ileus': 2044, 'malfunction': 2045, 'paralytic': 2046, 'premenstrual': 2047, 'additive': 2048, 'inside': 2049, 'thrush': 2050, 'transmission': 2051, 'knee': 2052, 'psychotic': 2053, 'atypical': 2054, 'impetigo': 2055, 'rls': 2056, 'enterococci': 2057, 'gi': 2058, 'gononhoeae': 2059, 'h': 2060, 'nonpenicillinase': 2061, 'p': 2062, 'producing': 2063, 'salmonella': 2064, 'shigella': 2065, 'staphylococci': 2066, 'streptococci': 2067, 'typhosa': 2068, 'convulsive': 2069, 'dental': 2070, 'endocarditis': 2071, 'erysipelas': 2072, 'gingivitis': 2073, 'pneumococcus': 2074, 'sensitive': 2075, 'undergo': 2076, 'intractable': 2077, 'access': 2078, 'now': 2079, 'venous': 2080, 'elderly': 2081, 'restlessness': 2082, 'add': 2083, 'antiandrogenic': 2084, 'cirrhotic': 2085, 'hirsutism': 2086, 'male': 2087, 'many': 2088, 'micro': 2089, 'pattern': 2090, 'preoperatively': 2091, 'america': 2092, 'sold': 2093, 'colic': 2094, 'cystitis': 2095, 'diverticulitis': 2096, 'immunocompetent': 2097, 'mucocutaneous': 2098, '20th': 2099, 'aborting': 2100, 'absent': 2101, 'atony': 2102, 'calculated': 2103, 'day': 2104, 'expulsion': 2105, 'fetus': 2106, 'gestation': 2107, 'inadvertent': 2108, 'last': 2109, 'menstrual': 2110, 'method': 2111, 'period': 2112, 'rupture': 2113, 'spontaneous': 2114, 'trimester': 2115, 'aeruginosa': 2116, 'capitis': 2117, 'biological': 2118, 'fluoropyrimidine': 2119, 'oxaliplatin': 2120, 'wild': 2121, '20': 2122, 'american': 2123, 'society': 2124, 'steroidal': 2125, 'anaphylactic': 2126, 'inhalant': 2127, '34': 2128, 'gt': 2129, 'near': 2130, 'assessed': 2131, 'destruction': 2132, 'discontinued': 2133, 'each': 2134, 'excretion': 2135, 'gout': 2136, 'lithiasis': 2137, 'outweigh': 2138, 'overproduction': 2139, 'oxalate': 2140, 'pharmacological': 2141, 'blepharitis': 2142, 'coagulase': 2143, 'enteritis': 2144, 'enterobacter': 2145, 'enterotoxigenic': 2146, 'jiroveci': 2147, 'pneumocystis': 2148, 'polymyxin': 2149, 'spp': 2150, 'sulfamethoxazole': 2151, 'susceptibility': 2152, 'trimethoprim': 2153, 'completion': 2154, 'gemcitabine': 2155, 'iiia': 2156, 'iiib': 2157, 'alt': 2158, 'ast': 2159, 'histologically': 2160, 'analog': 2161, 'endocrine': 2162, 'node': 2163, 'cholera': 2164, 'tetracycline': 2165, 'amoxicillin': 2166, 'nsaid': 2167, 'oesophagitis': 2168, 'prevents': 2169, 'secretion': 2170, 'triple': 2171, 'differentiated': 2172, 'corneal': 2173, 'foreign': 2174, 'brucellosis': 2175, 'dermatologic': 2176, 'generation': 2177, 'blocking': 2178, 'copd': 2179, 'impact': 2180, 'posttraumatic': 2181, 'degeneration': 2182, 'destroy': 2183, 'histoplasmosis': 2184, 'macular': 2185, 'presumed': 2186, 'competent': 2187, 'dilation': 2188, 'show': 2189, 'varicose': 2190, 'antipyretic': 2191, 'appear': 2192, 'ideally': 2193, 'initiate': 2194, 'offered': 2195, 'operative': 2196, 'potency': 2197, 'regardless': 2198, 'using': 2199, 'antidote': 2200, 'especially': 2201, 'internally': 2202, 'relieving': 2203, 'epidermidis': 2204, 'gonorrhea': 2205, 'pseudomonas': 2206, 'backache': 2207, 'antiemetic': 2208, '14': 2209, '15': 2210, 'acetylsalicylic': 2211, 'bronchoconstriction': 2212, 'demonstrate': 2213, 'moreover': 2214, 'regulatory': 2215, 'required': 2216, 'still': 2217, 'independent': 2218, 'whether': 2219, 'application': 2220, 'anaesthetic': 2221, 'apprehension': 2222, 'back': 2223, 'prostatectomy': 2224, 'accompanying': 2225, 'aggressivity': 2226, 'behavior': 2227, 'conduct': 2228, 'explosive': 2229, 'frustration': 2230, 'hyperactive': 2231, 'impulsivity': 2232, 'intermittent': 2233, 'lability': 2234, 'marked': 2235, 'motor': 2236, 'porphyria': 2237, 'proportion': 2238, 'sustaining': 2239, 'tetanus': 2240, 'accelerated': 2241, 'acinetobacter': 2242, 'approval': 2243, 'identify': 2244, 'indole': 2245, 'population': 2246, 'principal': 2247, 'providencia': 2248, 'route': 2249, 'serious': 2250, 'serratia': 2251, 'sputum': 2252, 'their': 2253, 'toxic': 2254, 'cytogenetic': 2255, 'deletion': 2256, 'dexamethasone': 2257, 'lenalidomide': 2258, 'myelodysplastic': 2259, 'transfusion': 2260, 'invasive': 2261, 'dysmenorrhea': 2262, 'event': 2263, 'facilitate': 2264, 'mechanical': 2265, 'ventilation': 2266, 'erythema': 2267, 'facial': 2268, 'iop': 2269, 'opthalmic': 2270, 'rosacea': 2271, 'penicillinase': 2272, 'genitourinary': 2273, 'gonococcal': 2274, 'alkylating': 2275, 'hyperglycemia': 2276, 'niddm': 2277, 'microalbuminuria': 2278, 'gonorrhoea': 2279, 'end': 2280, 'immunovirus': 2281, 'anticoagulant': 2282, 'd2': 2283, 'indigestion': 2284, 'provocation': 2285, 'tourette': 2286, 'narcotic': 2287, 'reversal': 2288, 'cryptosporidium': 2289, 'parvum': 2290, 'placebo': 2291, 'protozoa': 2292, 'protozoan': 2293, 'superior': 2294, 'fast': 2295, 'a': 2296, 'difficile': 2297, 'exist': 2298, 'lactam': 2299, 'liquid': 2300, 'unique': 2301, 'affect': 2302, 'pseudoephedrine': 2303, 'testicular': 2304, 'allergenic': 2305, 'ivy': 2306, 'poison': 2307, 'resin': 2308, 'sumac': 2309, 'further': 2310, 'histamine': 2311, 'sub': 2312, 'dog': 2313, 'echinococcus': 2314, 'granulosus': 2315, 'larval': 2316, 'parenchymal': 2317, 'pork': 2318, 'solium': 2319, 'taenia': 2320, 'chf': 2321, 'mi': 2322, 'aspergillosis': 2323, 'exocrine': 2324, 'screening': 2325, 'athlete': 2326, 'itch': 2327, 'jock': 2328, 'powder': 2329, 'scalp': 2330, 'undergone': 2331, 'raynaud': 2332, 'acyclovir': 2333, '21': 2334, 'epidermal': 2335, 'exon': 2336, 'r': 2337, 'showing': 2338, 'biopsy': 2339, 'disseminated': 2340, 'fungoides': 2341, 'mycosis': 2342, 'neuroblastoma': 2343, 'tool': 2344, 'ca': 2345, 'ear': 2346, 'maxillary': 2347, 'nose': 2348, 'parainfluenzae': 2349, 'throat': 2350, 'eaton': 2351, 'lambert': 2352, 'myasthenia': 2353, 'myasthenic': 2354, 'weakness': 2355, 'anthrax': 2356, 'bilateral': 2357, 'drop': 2358, 'effusion': 2359, 'externa': 2360, 'hydrocortisone': 2361, 'otic': 2362, 'pediatrics': 2363, 'placed': 2364, 'plague': 2365, 'prostatitis': 2366, 'tympanostomy': 2367, 'contrast': 2368, 'visualization': 2369, 'neoplasia': 2370, 'preventative': 2371, 'unknown': 2372, 'chromosome': 2373, 'ph': 2374, 'philadelphia': 2375, 'rhabdomyosarcoma': 2376, 'treatment': 2377, 'wilms': 2378, 'endogenous': 2379, 'neurotic': 2380, 'reactive': 2381, 'basal': 2382, 'impractical': 2383, 'stomach': 2384, 'strength': 2385, 'superficial': 2386, 'grave': 2387, 'urea': 2388, 'alpha': 2389, 'antiepileptic': 2390, 'context': 2391, 'delaying': 2392, 'phenobarbital': 2393, 'process': 2394, 'cardiology': 2395, 'ultrasound': 2396, 'excluding': 2397, 'anginosus': 2398, 'citrobacter': 2399, 'constellatus': 2400, 'enterococcus': 2401, 'freundii': 2402, 'grp': 2403, 'intermedius': 2404, 'oxytoca': 2405, 'vancomycin': 2406, 'hospitalized': 2407, 'free': 2408, 'gestational': 2409, 'leucovorin': 2410, 'mole': 2411, 'osteosarcoma': 2412, 'prolong': 2413, 'tumour': 2414, 'trigeminal': 2415, 'true': 2416, 'unapproved': 2417, 'tracheal': 2418, 'arsenic': 2419, 'lead': 2420, 'mercury': 2421, 'meniere': 2422, 'vestibular': 2423, 'catheter': 2424, 'dvt': 2425, 'fracture': 2426, 'guiding': 2427, 'hip': 2428, 'nstemi': 2429, 'orthopedic': 2430, 'pe': 2431, 'reperfusion': 2432, 'stemi': 2433, 'subsequent': 2434, 'thromboembolic': 2435, 'ua': 2436, 'vte': 2437, 'hypertrophic': 2438, 'pheochromocytoma': 2439, 'stenosis': 2440, 'tremor': 2441, 'cholinesterase': 2442, 'organophosphorous': 2443, 'dravet': 2444, 'opiate': 2445, 'transdermal': 2446, 'dna': 2447, 'episode': 2448, 'labialis': 2449, 'nucleoside': 2450, 'polymerase': 2451, 'asymptomatic': 2452, 'bacteriuria': 2453, 'height': 2454, 'modification': 2455, 'sup': 2456, 'dysmenorrhoea': 2457, 'anticancer': 2458, 'bind': 2459, 'coma': 2460, 'experimental': 2461, 'geriatric': 2462, 'involved': 2463, 'laxative': 2464, 'minimize': 2465, 'novel': 2466, 'owing': 2467, 'portal': 2468, 'pse': 2469, 'supportive': 2470, 'fusarium': 2471, 'acidemia': 2472, 'aciduria': 2473, 'carnitine': 2474, 'dehydrogenase': 2475, 'error': 2476, 'fatty': 2477, 'medium': 2478, 'methyl': 2479, 'propionic': 2480, 'stimulate': 2481, 'therapeutically': 2482, 'utilization': 2483, '35': 2484, 'renovascular': 2485, 'protective': 2486, 'varying': 2487, 'protection': 2488, 'inhaler': 2489, 'propionate': 2490, 'hypertrophy': 2491, 'acetonide': 2492, 'affecting': 2493, 'announced': 2494, 'dermatology': 2495, 'dermatosis': 2496, 'extensively': 2497, 'intravitreal': 2498, 'keloid': 2499, 'october': 2500, 'rise': 2501, 'shampoo': 2502, 'vasoprotective': 2503, 'ascariasis': 2504, 'ascaris': 2505, 'enterobiasis': 2506, 'enterobius': 2507, 'lumbricoides': 2508, 'pinworm': 2509, 'roundworm': 2510, 'vermicularis': 2511, 'pestis': 2512, 'lotion': 2513, 'compared': 2514, 'disruption': 2515, 'enhanced': 2516, 'surrounding': 2517, 'balanced': 2518, 'hypnosis': 2519, 'minute': 2520, 'neurosurgical': 2521, 'color': 2522, 'faecium': 2523, 'blindness': 2524, 'nematode': 2525, 'onchocerca': 2526, 'onchocerciasis': 2527, 'parasite': 2528, 'river': 2529, 'strongyloides': 2530, 'strongyloidiasis': 2531, 'volvulus': 2532, 'extraintestinal': 2533, 'malariae': 2534, 'ovale': 2535, 'zika': 2536, 'extrapulmonary': 2537, 'protozoal': 2538, 'gum': 2539, 'hyponatremia': 2540, 'inappropriate': 2541, 'rarely': 2542, 'registered': 2543, 'siadh': 2544, 'cml': 2545, 'eosinophilic': 2546, 'gist': 2547, 'hypereosinophilic': 2548, 'mastocytosis': 2549, 'stromal': 2550, '10mg': 2551, '40mg': 2552, 'adrenocortical': 2553, 'annulare': 2554, 'areata': 2555, 'arteritis': 2556, 'articularly': 2557, 'diabeticorum': 2558, 'discoid': 2559, 'diuresis': 2560, 'epicondylitis': 2561, 'erythematosus': 2562, 'erythroderma': 2563, 'granuloma': 2564, 'infiltrated': 2565, 'lipoidica': 2566, 'localized': 2567, 'lupus': 2568, 'ml': 2569, 'necrobiosis': 2570, 'nonspecific': 2571, 'ophthalmia': 2572, 'red': 2573, 'sympathetic': 2574, 'synovitis': 2575, 'temporal': 2576, 'tendon': 2577, 'tenosynovitis': 2578, 'trichinosis': 2579, 'tuberculous': 2580, 'vitrectomy': 2581, 'gain': 2582, 'testosterone': 2583, 'formulated': 2584, 'neomycin': 2585, 'occasionally': 2586, 'bile': 2587, 'binding': 2588, 'nutrition': 2589, 'simvastatin': 2590, 'clearance': 2591, 'creatinine': 2592, 'min': 2593, 'orphan': 2594, 'intubated': 2595, 'ventilated': 2596, 'vaginitis': 2597, 'hematologic': 2598, 'ophthalmologic': 2599, 'prednisone': 2600, 'rheumatologic': 2601, 'triglyceride': 2602, 'withdrawn': 2603, 'filtration': 2604, 'help': 2605, 'historically': 2606, 'vulvovaginal': 2607, 'assessment': 2608, 'chloride': 2609, 'narrow': 2610, 'perfusion': 2611, 'scintigraphy': 2612, 'svt': 2613, 'thallium': 2614, 'vagal': 2615, 'apo': 2616, 'cerebrovascular': 2617, 'hofh': 2618, 'homozygous': 2619, 'morbidity': 2620, 'tg': 2621, 'vessel': 2622, 'curative': 2623, 'pleural': 2624, 'potentially': 2625, 'americanus': 2626, 'ancylostoma': 2627, 'duodenale': 2628, 'hookworm': 2629, 'necator': 2630, 'evaluating': 2631, 'irradiation': 2632, 'accessible': 2633, 'blister': 2634, 'canker': 2635, 'endoscopy': 2636, 'esophagus': 2637, 'examination': 2638, 'gag': 2639, 'involving': 2640, 'laryngeal': 2641, 'larynx': 2642, 'mucous': 2643, 'reflex': 2644, 'suppress': 2645, 'metronidazole': 2646, 'though': 2647, 'trichomonas': 2648, 'vaginalis': 2649, 'elimination': 2650, 'eclampsia': 2651, 'hypomagnesemia': 2652, 'magnesium': 2653, 'nephritis': 2654, 'relaxant': 2655, 'kinase': 2656, 'laser': 2657, 'rho': 2658, 'eating': 2659, 'hemodialysis': 2660, 'neuron': 2661, 'intravenously': 2662, 'repetitive': 2663, 'gastroenteritis': 2664, 'lymph': 2665, 'gnrh': 2666, 'precocity': 2667, 'action': 2668, 'allergen': 2669, 'anaphylaxis': 2670, 'arrest': 2671, 'biting': 2672, 'breath': 2673, 'cardiogenic': 2674, 'chest': 2675, 'fire': 2676, 'hemostatic': 2677, 'immunotherapy': 2678, 'otc': 2679, 'restoring': 2680, 'selection': 2681, 'shortness': 2682, 'syncope': 2683, 'tightness': 2684, 'urgent': 2685, 'yellow': 2686, 'ductal': 2687, 'tamoxifen': 2688, 'kill': 2689, 'responsible': 2690, 'african': 2691, 'extend': 2692, 'heritage': 2693, 'thromboembolism': 2694, 'valve': 2695, 'distinct': 2696, 'stereotypic': 2697, 'investigated': 2698, 'interstitial': 2699, 'addison': 2700, 'losing': 2701, 'salt': 2702, 'sleeping': 2703, 'cocaine': 2704, 'crisis': 2705, 'excess': 2706, 'immediately': 2707, 'mao': 2708, 'necrosis': 2709, 'norepinephrine': 2710, 'oxygen': 2711, 'reverse': 2712, 'sympathomimetic': 2713, 'fundus': 2714, 'iris': 2715, 'desired': 2716, 'called': 2717, 'so': 2718, 'recommendation': 2719, 'reserve': 2720, 'ischemia': 2721, 'origin': 2722, 'behaviour': 2723, 'formerly': 2724, 'physically': 2725, 'successfully': 2726, 'supervised': 2727, 'warranted': 2728, 'ureteral': 2729, 'favorable': 2730, 'follows': 2731, 'sublingual': 2732, 'warrant': 2733, 'brugia': 2734, 'eosinophilia': 2735, 'tropical': 2736, 'intraoperative': 2737, 'miosis': 2738, 'ibs': 2739, 'applied': 2740, 'patch': 2741, 'via': 2742, 'decompensated': 2743, 'perianal': 2744, 'h2': 2745, 'disturbance': 2746, 'anginal': 2747, 'peri': 2748, 'variceal': 2749, 'routine': 2750, 'larva': 2751, 'migrans': 2752, 'endotracheal': 2753, 'anticholinesterase': 2754, 'overdosage': 2755, 'aggression': 2756, 'autistic': 2757, 'irritability': 2758, 'tonsurans': 2759, 'bleeds': 2760, 'carinii': 2761, 'ampicillin': 2762, 'antibiotic': 2763, 'amyotrophic': 2764, 'lateral': 2765, 'auditory': 2766, 'canal': 2767, 'edematous': 2768, 'enema': 2769, 'becomes': 2770, 'promotion': 2771, 'aluminum': 2772, 'bradycardia': 2773, 'colicky': 2774, 'dentistry': 2775, 'itching': 2776, 'melancholia': 2777, 'apl': 2778, 'british': 2779, 'classification': 2780, 'et': 2781, 'fab': 2782, 'french': 2783, 'hyperpigmentation': 2784, 'ichthyosis': 2785, 'icthyosis': 2786, 'keratosis': 2787, 'm3': 2788, 'photodamage': 2789, 'promyelocytic': 2790, 'bacteriostatic': 2791, 'scrub': 2792, 'unsuccessful': 2793, 'clopidogrel': 2794, 'burgdorferi': 2795, 'pneumophila': 2796, 'appendicitis': 2797, 'viridans': 2798, 'electrolyte': 2799, 'replenisher': 2800, 'multinodular': 2801, 'radioactive': 2802, 'antibacterial': 2803, 'detected': 2804, 'determining': 2805, 'empiric': 2806, 'likely': 2807, 'marcescens': 2808, 'normally': 2809, 'noted': 2810, 'selecting': 2811, 'ticarcillin': 2812, 'depend': 2813, 'multiforme': 2814, 'largely': 2815, 'majority': 2816, 'appetite': 2817, 'category': 2818, 'feature': 2819, 'fit': 2820, 'generate': 2821, 'keep': 2822, 'living': 2823, 'nonendogenous': 2824, 'paralysis': 2825, 'predict': 2826, 'prevalence': 2827, 'service': 2828, 'spectrum': 2829, 'suicidal': 2830, 'tends': 2831, 'about': 2832, 'endometrium': 2833, 'follow': 2834, 'palliation': 2835, 'possibly': 2836, 'raised': 2837, 'synthetic': 2838, 'uterus': 2839, 'whi': 2840, 'buccal': 2841, 'herpetic': 2842, 'lesion': 2843, 'magnetic': 2844, 'resonance': 2845, 'antineoplastic': 2846, 'epileptic': 2847, 'isolated': 2848, 'may': 2849, 'damaged': 2850, 'sun': 2851, 'hospital': 2852, 'retention': 2853, 'cycloplegia': 2854, 'measurement': 2855, 'pupil': 2856, '1a': 2857, 'achieve': 2858, 'cure': 2859, 'intent': 2860, 'ribavirin': 2861, 'svr': 2862, 'technivie': 2863, 'around': 2864, 'breakthrough': 2865, 'clock': 2866, 'reovirus': 2867, 'rotavirus': 2868, 'surfactant': 2869, 'compromised': 2870, 'anaesthesia': 2871, 'reliever': 2872, 'elect': 2873, 'irritation': 2874, 'occasional': 2875, 'sore': 2876, 'aggressiveness': 2877, 'expression': 2878, 'impending': 2879, 'kingdom': 2880, 'man': 2881, 'myoclonus': 2882, 'psychoneurosis': 2883, 'somatic': 2884, 'stiff': 2885, 'unacceptable': 2886, 'itchy': 2887, 'runny': 2888, 'volume': 2889, 'satisfactorily': 2890, 'artificial': 2891, 'dryness': 2892, 'lubricant': 2893, 'reduced': 2894, 'decompensation': 2895, 'depressed': 2896, '23': 2897, 'lepromatous': 2898, 'leprosum': 2899, 'nodosum': 2900, 'scaling': 2901, 'accumulation': 2902, 'crystal': 2903, 'cystine': 2904, 'cystinosis': 2905, 'cystinuria': 2906, 'anticonvulsant': 2907, 'amine': 2908, 'decongestant': 2909, 'anaplastic': 2910, 'astrocytoma': 2911, 'progressed': 2912, 'blue': 2913, 'illumination': 2914, 'light': 2915, 'minimally': 2916, 'douloureux': 2917, 'modulator': 2918, 'tic': 2919, 'canis': 2920, 'nail': 2921, 'wilson': 2922, 'raise': 2923, 'expanded': 2924, 'limb': 2925, 'since': 2926, 'labour': 2927, 'insufficiently': 2928, 'airway': 2929, 'preterm': 2930, 'euvolemic': 2931, 'hypervolemic': 2932, 'breathing': 2933, 'expectorant': 2934, 'providing': 2935, 'antiseptic': 2936, 'depth': 2937, 'inserted': 2938, 'periodontal': 2939, 'periodontitis': 2940, 'pocket': 2941, 'rinse': 2942, 'root': 2943, 'sponge': 2944, '35kg': 2945, 'emtricitabine': 2946, 'receptive': 2947, 'sex': 2948, 'anovulation': 2949, 'polycystic': 2950, 'osteoperosis': 2951, 'bronchogenic': 2952, 'myelocytic': 2953, 'polycythemia': 2954, 'atrophic': 2955, 'membrane': 2956, 'measured': 2957, 'erythropoietin': 2958, 'impossible': 2959, 'unsatisfactory': 2960, 'air': 2961, '65': 2962, 'equal': 2963, 'ie': 2964, 'odt': 2965, 'hyperparathyroidism': 2966, 'giardiasis': 2967, 'trichomoniasis': 2968, 'except': 2969, 'vaginosis': 2970, '28': 2971, 'evacuation': 2972, 'nonmetastatic': 2973, 'gonorrheal': 2974, 'proctitis': 2975, 'fixed': 2976, 'originating': 2977, 'du': 2978, 'ill': 2979, 'myelomonocytic': 2980, 'ringed': 2981, 'subtypes': 2982, 'transformation': 2983, 'partum': 2984, 'coa': 2985, 'hmg': 2986, 'reductase': 2987, 'involutional': 2988, 'neurosis': 2989, 'performing': 2990, 'procedure': 2991, 'restorative': 2992, 'teeth': 2993, 'weigh': 2994, 'key': 2995, 'heavy': 2996, 'succinylcholine': 2997, 'adhesion': 2998, 'aggregation': 2999, 'asa': 3000, 'atherothrombotic': 3001, 'cad': 3002, 'extra': 3003, 'flu': 3004, 'silicone': 3005, 'site': 3006, 'acceptable': 3007, 'aplastic': 3008, 'conferred': 3009, 'season': 3010, 'tonsilitis': 3011, 'septicaemia': 3012, 'ibuprofen': 3013, 'cataract': 3014, 'maximally': 3015, 'prophylactically': 3016, '131': 3017, 'lymphography': 3018, 'radio': 3019, 'predominant': 3020, 'dandruff': 3021, 'ezetimibe': 3022, 'depot': 3023, 'coumarin': 3024, 'pneumococcal': 3025, 'dysphoric': 3026, 'anticholinergic': 3027, 'nodular': 3028, 'basis': 3029, 'budesonide': 3030, 'furoate': 3031, 'muscarinic': 3032, 'antithrombin': 3033, 'deficient': 3034, 'fibrinogen': 3035, 'turner': 3036, 'inhibitory': 3037, 'pharyngeal': 3038, 'salivary': 3039, 'blast': 3040, 'correction': 3041, 'nm': 3042, 'ammonia': 3043, 'exists': 3044, 'forming': 3045, 'generalization': 3046, 'histologic': 3047, 'transitional': 3048, 'cytomegalovirus': 3049, 'hr': 3050, 'letrozole': 3051, 'conditioning': 3052, 'differential': 3053, 'acth': 3054, 'aerogenes': 3055, 'bartonella': 3056, 'cholerae': 3057, 'francisella': 3058, 'tularensis': 3059, 'vibrio': 3060, 'yersinia': 3061, 'sufficiently': 3062, 'oedema': 3063, 'aphthous': 3064, 'blastomycosis': 3065, 'coccidioidomycosis': 3066, 'uncontrolled': 3067, 'amenable': 3068, 'recurred': 3069, 'dramatic': 3070, 'enl': 3071, 'amyloidosis': 3072, 'resectable': 3073, 'transit': 3074, 'analysis': 3075, 'review': 3076, 'conditioned': 3077, 'db11274': 3078, 'decline': 3079, 'ergoloid': 3080, 'know': 3081, 'labeled': 3082, 'mixture': 3083, 'please': 3084, 'visit': 3085, 'alteration': 3086, 'aorta': 3087, 'close': 3088, 'e2': 3089, 'enantiomer': 3090, 'investigational': 3091, 'main': 3092, 'prostaglandin': 3093, 'put': 3094, 'racemic': 3095, 'reported': 3096, 'pericarditis': 3097, 'physician': 3098, 'iridectomy': 3099, 'schistosoma': 3100, 'overactivity': 3101, 'disorganized': 3102, 'appears': 3103, 'autism': 3104, 'benzodiazepine': 3105, 'blind': 3106, 'circadian': 3107, 'cycle': 3108, 'fall': 3109, 'il': 3110, 'jet': 3111, 'lag': 3112, 'retardation': 3113, 'sunburn': 3114, 'wake': 3115, 'work': 3116, 'exacerbation': 3117, 'alternatively': 3118, 'data': 3119, 'generalised': 3120, 'myoclonic': 3121, 'secondarily': 3122, 'v': 3123, 'value': 3124, 'dermographism': 3125, 'acidosis': 3126, 'nonoccupational': 3127, 'occupational': 3128, 'postexposure': 3129, 'centrally': 3130, 'insect': 3131, 'potent': 3132, 'pruritis': 3133, 'reaction': 3134, 'vision': 3135, 'enterococcal': 3136, 'tularemia': 3137, 'adverse': 3138, 'calorie': 3139, 'pending': 3140, 'revision': 3141, 'xerostomia': 3142, 'interdigital': 3143, 'pityriasis': 3144, 'again': 3145, 'aromatase': 3146, 'possibility': 3147, 'chd': 3148, 'schistosomiasis': 3149, 'ratio': 3150, 'amphotericin': 3151, 'preferred': 3152, 'diagnosing': 3153, 'elicit': 3154, 'leishmaniasis': 3155, 'pd': 3156, 'sad': 3157, 'permanent': 3158, 'coagulation': 3159, 'extension': 3160, 'glycoprotein': 3161, 'wave': 3162, 'four': 3163, 'suppository': 3164, 'impotence': 3165, 'pcp': 3166, 'smx': 3167, 'tmp': 3168, 'bph': 3169, 'enlarged': 3170, 'analogue': 3171, 'lhrh': 3172, 'together': 3173, 'alkaline': 3174, 'future': 3175, 'limit': 3176, 'phosphatase': 3177, 'examined': 3178, 'anthracis': 3179, 'bacillus': 3180, 'inhalational': 3181, 'ent': 3182, 'sp': 3183, 'stem': 3184, 'anxious': 3185, 'complication': 3186, 'danger': 3187, 'interest': 3188, 'provokes': 3189, 'rather': 3190, 'state': 3191, 'towards': 3192, 'unpleasant': 3193, 'dysuria': 3194, 'affective': 3195, 'comorbid': 3196, 'marketed': 3197, 'arterially': 3198, 'incompatible': 3199, 'vasodilator': 3200, 'deleterious': 3201, 'extracellular': 3202, 'hyperkalemia': 3203, 'alleviation': 3204, 'walking': 3205, 'onychomycosis': 3206, 'gene': 3207, 'androgenresponsive': 3208, 'mammary': 3209, '2007': 3210, 'locate': 3211, 'inpatient': 3212, 'outpatient': 3213, 'tretinoin': 3214, 'hyperprolactinemia': 3215, 'special': 3216, 'serve': 3217, '': 3218, 'ethylene': 3219, 'glycol': 3220, 'ingestion': 3221, 'methanol': 3222, 'transurethral': 3223, 'characteristic': 3224, 'hyperthermia': 3225, '2015': 3226, 'noninvasive': 3227, 'traveller': 3228, 'area': 3229, 'involves': 3230, 'foam': 3231, 'terminal': 3232, 'inner': 3233, 'labyrinthine': 3234, 'middle': 3235, 'ritonavir': 3236, 'saquinavir': 3237, 'allowing': 3238, 'gastroparesis': 3239, 'interferes': 3240, 'intestine': 3241, 'radiographic': 3242, 'stimulates': 3243, 'traditional': 3244, 'decarboxylase': 3245, 'dopa': 3246, 'own': 3247, 'bring': 3248, 'make': 3249, 'phlegm': 3250, 'productive': 3251, 'occuring': 3252, 'scleroderma': 3253, 'cataplexy': 3254, 'unlabeled': 3255, 'effort': 3256, 'everyday': 3257, 'handle': 3258, 'haemorrhage': 3259, 'lymphoid': 3260, '9': 3261, 'complement': 3262, 'hemoglobinuria': 3263, 'neuromyelitis': 3264, 'nmosd': 3265, 'optica': 3266, 'pnh': 3267, 'sitagliptin': 3268, 'prognostic': 3269, 'scoring': 3270, 'em': 3271, 'hsct': 3272, 'co': 3273, 'darunavir': 3274, 'imatinib': 3275, 'mesylate': 3276, 'retinal': 3277, 'wet': 3278, 'gaa': 3279, 'developed': 3280, 'gh': 3281, 'igfd': 3282, 'neutralizing': 3283, 'dmards': 3284, 'tnf': 3285, 'upset': 3286, 'needing': 3287, 'fosamprenavir': 3288, 'cover': 3289, 'cocci': 3290, 'endometritis': 3291, 'just': 3292, 'resulted': 3293, 'satisfactory': 3294, 'tested': 3295, 'vivo': 3296, 'zone': 3297, 'abnormally': 3298, 'regulate': 3299, 'stabilizer': 3300, 'arteriography': 3301, 'arthrography': 3302, 'myelography': 3303, 'anatomy': 3304, 'physiology': 3305, 'signal': 3306, 'signaling': 3307, 'signalling': 3308, 'vital': 3309, 'antacid': 3310, 'neuromuscular': 3311, 'addisons': 3312, 'alleviating': 3313, 'visual': 3314, 'young': 3315, 'suitable': 3316, 'alkalinization': 3317, 'bicarbonate': 3318, 'circulation': 3319, 'circulatory': 3320, 'dehydration': 3321, 'extracorporeal': 3322, 'metabolic': 3323, 'mydriatic': 3324, 'european': 3325, 'hyperlipidaemia': 3326, 'behcet': 3327, 'consider': 3328, 'desire': 3329, 'salicylate': 3330, 'tone': 3331, 'choline': 3332, 'fibrocystic': 3333, 'metered': 3334, 'stimulant': 3335, 'cephalosporin': 3336, 'building': 3337, 'original': 3338, 'mucolytic': 3339, 'rheumatism': 3340, 'water': 3341, 'ingredient': 3342, 'sunscreen': 3343, 'unsubstantiated': 3344, 'consequence': 3345, 'endoscopic': 3346, 'maximum': 3347, 'current': 3348, 'recreational': 3349, 'usa': 3350, 'illicit': 3351, 'mdma': 3352, 'compound': 3353, 'usage': 3354, 'veterinary': 3355, 'antidiarrheal': 3356, 'atropine': 3357, 'cautioned': 3358, 'conservative': 3359, 'cramping': 3360, 'loperamide': 3361, 'motofen': 3362, 'thus': 3363, 'did': 3364, 'exhibit': 3365, 'manageable': 3366, 'showed': 3367, 'side': 3368, 'nmda': 3369, 'radiolabelled': 3370, 'tranquilizer': 3371, 'powerful': 3372, 'brazilian': 3373, 'combine': 3374, 'sale': 3375, 'coughing': 3376, 'http': 3377, 'experimentally': 3378, 'medicine': 3379, 'reason': 3380, 'africa': 3381, 'china': 3382, 'south': 3383, 'angiocardiography': 3384, 'cisternography': 3385, 'column': 3386, 'computerized': 3387, 'ct': 3388, 'digital': 3389, 'direct': 3390, 'thoracic': 3391, 'ventriculography': 3392, 'antithyroid': 3393, 'stimulating': 3394, 'dissolve': 3395, 'could': 3396, 'neuroendocrine': 3397, 'rcc': 3398, 'sunitinib': 3399, 'tsc': 3400, 'tuberous': 3401, 'boosting': 3402, 'slowed': 3403, 'stunted': 3404, 'zinc': 3405, 'awakening': 3406, 'cilastatin': 3407, 'imipenem': 3408, 'relebactam': 3409, 'arthritic': 3410, 'antiretrovirals': 3411, 'brand': 3412, 'name': 3413, 'gynecological': 3414, 'typhoid': 3415, 'ceftolozane': 3416, 'conferring': 3417, 'mutation': 3418, 'piperacillin': 3419, 'tazobactam': 3420, 'ventilator': 3421, 'overload': 3422, 'transfusional': 3423, '1950s': 3424, 'citrate': 3425, 'proteasome': 3426, 'duodenitis': 3427, 'pylorospasm': 3428, 'spastic': 3429, 'japan': 3430, 'ache': 3431, 'bmd': 3432, 'dhea': 3433, 'flare': 3434, 'india': 3435, 'mineral': 3436, 'moisture': 3437, 'promise': 3438, 'seems': 3439, 'sle': 3440, 'thickness': 3441, 'torsion': 3442, 'ulceration': 3443, 'carbohydrate': 3444, 'deprivation': 3445, 'nutrient': 3446, 'pharmaceutical': 3447, 'alimentary': 3448, 'gastrostomy': 3449, 'nitrogen': 3450, 'substantially': 3451, 'oesophagus': 3452, 'stop': 3453, 'soluble': 3454, 'extent': 3455, 'humectant': 3456, 'kind': 3457, 'lens': 3458, 'obtain': 3459, 'teysuno': 3460, 'phenol': 3461, 'nasopharyngeal': 3462, 'unspecified': 3463, 'fullness': 3464, 'dha': 3465, 'docosahexaenoic': 3466, 'cervix': 3467, 'consumption': 3468, 'excipient': 3469, 'feed': 3470, 'great': 3471, 'inositol': 3472, 'pharmacokinetics': 3473, 'preservative': 3474, 'separate': 3475, 'similarly': 3476, 'spread': 3477, '2010': 3478, 'accelerate': 3479, 'br': 3480, 'break': 3481, 'degradation': 3482, 'down': 3483, 'fibrin': 3484, 'li': 3485, 'proteolytic': 3486, 'ul': 3487, 'cardioprotective': 3488, 'enhances': 3489, 'made': 3490, 'bronchiectasis': 3491, 'mastalgia': 3492, 'ultraviolet': 3493, 'haematopoietic': 3494, 'hpct': 3495, 'cholecystography': 3496, 'antifungal': 3497, 'past': 3498, 'originally': 3499, 'enable': 3500, 'arteriosclerosis': 3501, 'chorea': 3502, 'huntington': 3503, 'hyperkinetic': 3504, 'crc': 3505, 'diagnose': 3506, 'pharmacologic': 3507, 'spect': 3508, 'restenosis': 3509, 'multidrug': 3510, 'thereby': 3511, 'mast': 3512, 'ad': 3513, 'neovascular': 3514, 'here': 3515, 'reuptake': 3516, 'selective': 3517, 'rds': 3518, 'dyspnea': 3519, 'immunization': 3520, 'vaccine': 3521, 'hypoactive': 3522, 'premenopausal': 3523, 'parasitic': 3524, 'relevant': 3525, 'feasible': 3526, 'miscellaneous': 3527, 'hearing': 3528, 'erythropoietic': 3529, 'protoporphyria': 3530, 'dyspareunia': 3531, 'discontinuation': 3532, 'lacrimation': 3533, 'manifestation': 3534, 're': 3535, 'ipf': 3536, 'late': 3537, 'schizoaffective': 3538, 'baseline': 3539, 'ptcl': 3540, 'agency': 3541, 'defect': 3542, 'duchenne': 3543, 'dystrophin': 3544, 'dystrophy': 3545, 'assay': 3546, 'capillary': 3547, 'confirmatory': 3548, 'contingent': 3549, 'description': 3550, 'galactosidase': 3551, 'verification': 3552, 'vertebral': 3553, 'output': 3554, 'resorption': 3555, 'v2': 3556, 'lipodystrophy': 3557, 'prosthetic': 3558, 'repair': 3559, 'rethrombosis': 3560, 'thrombolytic': 3561, 'ifosfamide': 3562, 'korea': 3563, 'russia': 3564, 'unsuitable': 3565, 'burn': 3566, 'latent': 3567, 'mdr': 3568, 'nonresponsive': 3569, 'inherited': 3570, 'lysosomal': 3571, 'relatively': 3572, 'auto': 3573, 'mrsa': 3574, 'braf': 3575, 'v600e': 3576, 'v600k': 3577, 'interval': 3578, 'gall': 3579, 'hae': 3580, 'stdis': 3581, 'stent': 3582, 'tobacco': 3583, 'neurodegenerative': 3584, 'aging': 3585, 'manufacturer': 3586, 'hbsag': 3587, 'saliva': 3588, 'targeting': 3589, 'db00008': 3590, 'db00022': 3591, 'eligible': 3592, 'blocker': 3593, 'immunomodulator': 3594, 'neutropenics': 3595, 'retinopathy': 3596, 'scar': 3597, 'precursor': 3598, 'cd4': 3599, 'cytokine': 3600, 'mediate': 3601, 'recently': 3602, 'seen': 3603, 'hypoxia': 3604, 'pbc': 3605, 'udca': 3606, 'dmd': 3607, 'skipping': 3608, 'mestastatic': 3609, 'attp': 3610, 'capacizumab': 3611, 'immunosuppression': 3612, 'wilebrand': 3613, 'cattle': 3614, 'paracetamol': 3615, 'obliterans': 3616, 'thrombophlebitis': 3617, 'anomaly': 3618, 'cryopyrin': 3619, 'periodic': 3620, 'overall': 3621, 'microsatellite': 3622, 'mismatch': 3623, 'attractive': 3624, 'equivalent': 3625, 'lifetime': 3626, 'naive': 3627, 'safe': 3628, 'address': 3629, 'dispersion': 3630, 'hydration': 3631, 'radiopaque': 3632, 'bromide': 3633, '75': 3634, 'radionuclide': 3635, 'absssi': 3636, 'modifying': 3637, 'pathogen': 3638, 'nonvalvular': 3639, 'rivaroxaban': 3640, 'drinking': 3641, 'cystoscopy': 3642, 'papillary': 3643, 'amyloid': 3644, 'fainting': 3645, 'hypogonadal': 3646, 'peg': 3647, 'polymorphism': 3648, 'sofosbuvir': 3649, 'seborrhea': 3650, 'neoadjuvant': 3651, '0': 3652, '11': 3653, 'amputation': 3654, 'c1': 3655, 'esterase': 3656, 'myelofibrosis': 3657, '29': 3658, 'designation': 3659, 'granted': 3660, 'mucus': 3661, 'removing': 3662, 'processing': 3663, 'anorectal': 3664, 'blockage': 3665, 'cic': 3666, 'hard': 3667, 'trypanosomiasis': 3668, 'fl': 3669, 'mcl': 3670, 'phenotype': 3671, 'february': 3672, 'apixaban': 3673, 'dormant': 3674, 'endemic': 3675, 'virulent': 3676, 'mucormycosis': 3677, 'modifier': 3678, 'prolia': 3679, 'chlorambucil': 3680, 'fludarabine': 3681, 'psa': 3682, 'uc': 3683, 'seropositive': 3684, 'castrate': 3685, 'cellular': 3686, 'dabigatran': 3687, 'model': 3688, 'demonstration': 3689, 'mra': 3690, 'readily': 3691, 'evaluate': 3692, 'vasoconstrictor': 3693, 'iodide': 3694, 'uptake': 3695, 'arthroscopy': 3696, 'hydrolytic': 3697, 'cleared': 3698, 'ease': 3699, 'easily': 3700, 'chemonucleolysis': 3701, 'digestion': 3702, 'disc': 3703, 'herniation': 3704, 'nucleus': 3705, 'outer': 3706, 'portion': 3707, 'pulposus': 3708, 'formula': 3709, 'infant': 3710, 'photosensitivity': 3711, 'source': 3712, 'betaine': 3713, 'homocystinuria': 3714, 'synthase': 3715, 'depletion': 3716, 'tpn': 3717, 'ammonium': 3718, 'base': 3719, 'ion': 3720, 'nh4': 3721, 'place': 3722, 'usp': 3723, 'scaly': 3724, 'ulesfia': 3725, 'cdc': 3726, 'lugdunensis': 3727, 'striatum': 3728, 'coupled': 3729, 'provoke': 3730, 'titer': 3731, 'turnover': 3732, 'chenodiol': 3733, 'pigment': 3734, 'radiolucent': 3735, 'copper': 3736, 'elemental': 3737, 'bed': 3738, 'gp': 3739, 'mobility': 3740, '': 3741, 'disodium': 3742, 'edetate': 3743, 'gold': 3744, 'contamination': 3745, 'internal': 3746, '67': 3747, 'detecting': 3748, 'ga': 3749, 'gallium': 3750, 'organization': 3751, 'somatostatin': 3752, 'antitussive': 3753, 'referred': 3754, 'hepatobiliary': 3755, 'fluke': 3756, 'colony': 3757, 'csf': 3758, 'filgrastim': 3759, 'granulocyte': 3760, 'extremity': 3761, 'cps': 3762, 'efficiency': 3763, 'clot': 3764, 'intake': 3765, 'stone': 3766, 'penicillamine': 3767, 'cocktail': 3768, 'dangerous': 3769, 'household': 3770, 'personnel': 3771, 'sanitizers': 3772, 'cyst': 3773, 'diloxanide': 3774, 'nitroimidazoles': 3775, 'sequentially': 3776, 'chicken': 3777, 'dimethindene': 3778, 'pox': 3779, 'lining': 3780, 'hydrochloric': 3781, 'motility': 3782, 'spain': 3783, 'ophthalmology': 3784, '2017': 3785, '33': 3786, 'cf': 3787, 'cftr': 3788, 'elexacaftor': 3789, 'ivacaftor': 3790, 'orkambi': 3791, 'tezacaftor': 3792, 'trikafta': 3793, 'w': 3794, 'distinguish': 3795, 'emission': 3796, 'photon': 3797, 'thalassemia': 3798, 'tc': 3799, '2013': 3800, 'fiber': 3801, 'looking': 3802, 'australia': 3803, 'italy': 3804, 'portugal': 3805, 'supranuclear': 3806, 'ketoglutarate': 3807, 'france': 3808, 'gallbladder': 3809, 'secretin': 3810, 'rilpivirine': 3811, 'rna': 3812, 'suppressed': 3813, 'alk': 3814, 'crizotinib': 3815, 'asct': 3816, 'classical': 3817, 'medullary': 3818, 'proliferation': 3819, 'better': 3820, 'later': 3821, 'yielding': 3822, '600': 3823, 'chester': 3824, 'erdheim': 3825, 'valine': 3826, 'ketoacidosis': 3827, 'characterize': 3828, 'detect': 3829, 'aforementioned': 3830, 'asparaginase': 3831, 'fragile': 3832, 'x': 3833, 'oab': 3834, 'antirheumatic': 3835, 'hemoglobin': 3836, 'traveling': 3837, 'hcc': 3838, 'kras': 3839, 'differentiation': 3840, 'mediator': 3841, 'migration': 3842, 'regulator': 3843, 'albuminuria': 3844, 'db08911': 3845, 'tafinlar': 3846, 'histology': 3847, 'progressing': 3848, 'tki': 3849, 'ferric': 3850, 'amoebiasis': 3851, 'cteph': 3852, 'db11613': 3853, 'depending': 3854, 'epclusa': 3855, 'genoptypes': 3856, 'harvoni': 3857, 'dilatation': 3858, 'facilitating': 3859, 'created': 3860, 'focus': 3861, 'mentally': 3862, 'tonsillectomy': 3863, 'gord': 3864, 'cleansing': 3865, 'colonoscopy': 3866, 'braziliensis': 3867, 'donovani': 3868, 'leishmania': 3869, 'lost': 3870, 'hhv': 3871, 'mcd': 3872, 'express': 3873, 'genomic': 3874, 'mediastinal': 3875, 'score': 3876, 'targeted': 3877, 'tps': 3878, 'metabolizers': 3879, 'tedizolid': 3880, 'leptin': 3881, '2014': 3882, 'palonosetron': 3883, 'iva': 3884, '17p': 3885, 'allele': 3886, 'develops': 3887, 'inactivated': 3888, 'macroglobulin': 3889, 'p53': 3890, 'spleen': 3891, 'wm': 3892, 'sll': 3893, 'globulin': 3894, '3cm': 3895, 'authorization': 3896, 'compliance': 3897, 'delta': 3898, 'highest': 3899, 'marketing': 3900, 'meaningful': 3901, 'noc': 3902, 'notice': 3903, 'promising': 3904, 'sativex': 3905, 'verify': 3906, 'atazanavir': 3907, 'cobicistat': 3908, 'cyp3a': 3909, 'preclude': 3910, 'tipranavir': 3911, 'twice': 3912, 'mature': 3913, 'hour': 3914, 'fulvestrant': 3915, 'grow': 3916, 'location': 3917, 'metastasis': 3918, 'brca': 3919, 'companion': 3920, 'gbrcam': 3921, 'germline': 3922, 'mutated': 3923, 'select': 3924, '95': 3925, 'crcl': 3926, 'warfarin': 3927, 'gm': 3928, 'interleukin': 3929, 'macrophage': 3930, 'multiagent': 3931, 'eu': 3932, 'leber': 3933, 'breo': 3934, 'ellipta': 3935, 'contraindication': 3936, 'resting': 3937, 'mouthwash': 3938, 'dermatological': 3939, 'is': 3940, 'oxide': 3941, 'toothache': 3942, 'antiperspirant': 3943, 'astringent': 3944, 'atp': 3945, 'medicated': 3946, 'tincture': 3947, 'f': 3948, 'ghd': 3949, 'recombinant': 3950, 'stature': 3951, 'extract': 3952, 'ns5a': 3953, 'capable': 3954, 'engraftment': 3955, 'sour': 3956, 'perinatal': 3957, 'haemophilia': 3958, 'generated': 3959, 'albumin': 3960, 'expansion': 3961, 'sequential': 3962, '1350': 3963, 'immaturity': 3964, 'rescue': 3965, 'clobazam': 3966, 'cox': 3967, 'slowly': 3968, 'valuable': 3969, 'nephrolithiasis': 3970, 'cryptorchidism': 3971, 'woman': 3972, 'cholangiopancreatography': 3973, 'conray': 3974, 'mediastinum': 3975, 'space': 3976, 'subtraction': 3977, 'tomographic': 3978, 'venography': 3979, '240': 3980, '320': 3981, '350': 3982, 'aortography': 3983, 'optiray': 3984, 'mgi': 3985, '99m': 3986, 'technetium': 3987, 'delineate': 3988, 'osteogenesis': 3989, 'avascular': 3990, 'earlier': 3991, 'image': 3992, 'problem': 3993, 'ray': 3994, 'scan': 3995, 'across': 3996, 'gas': 3997, 'whenever': 3998, 'aspiration': 3999, 'concentrated': 4000, 'meal': 4001, 'sample': 4002, 'bcc': 4003, 'coagulopathy': 4004, 'ectoparasitism': 4005, 'endoparasitism': 4006, 'epistaxis': 4007, 'erythropoiesis': 4008, 'hematuria': 4009, 'homeostasis': 4010, 'meet': 4011, 'thrombocytopathia': 4012, 'estimate': 4013, 'neuritic': 4014, 'pet': 4015, 'positron': 4016, '18f': 4017, 'acidic': 4018, 'getting': 4019, '370': 4020, 'staining': 4021, 'infarcted': 4022, 'myocardium': 4023, 'tetrofosmin': 4024, 'localizing': 4025, 'exametazime': 4026, 'leukocyte': 4027, 'localization': 4028, 'methylene': 4029, 'stabilization': 4030, 'tc99m': 4031, 'cholecystitis': 4032, 'jaundice': 4033, 'quadrant': 4034, 'tenderness': 4035, 'gated': 4036, 'db00503': 4037, 'db09296': 4038, 'db09297': 4039, 'pak': 4040, 'viekira': 4041, 'anxiolytic': 4042, 'chemical': 4043, 'delusion': 4044, 'hallucination': 4045, 'aqueous': 4046, 'chamber': 4047, 'closed': 4048, 'embolus': 4049, 'explained': 4050, 'meshwork': 4051, 'pupillary': 4052, 'thrombus': 4053, 'trigger': 4054, 'stated': 4055, 'transmitted': 4056, 'cortical': 4057, 'irrespective': 4058, 'feeling': 4059, 'confused': 4060, 'discussion': 4061, 'how': 4062, 'loose': 4063, 'describe': 4064, 'force': 4065, 'cheese': 4066, 'half': 4067, 'monoamine': 4068, 'oxidase': 4069, 'rich': 4070, 'vehicle': 4071, 'folinate': 4072, 'antihyperglycemic': 4073, 'handheld': 4074, 'scintigraphic': 4075, 'sentinel': 4076, 'mucosa': 4077, 'ulcerous': 4078, 'informative': 4079, 'tolerability': 4080, 'ascorbic': 4081, 'arb': 4082, 'db09183': 4083, 'virologically': 4084, 'cartilage': 4085, 'nutraceutical': 4086, 'kexin': 4087, 'proprotein': 4088, 'subtilisin': 4089, 'medicinal': 4090, 'pertechnetate': 4091, 'radiopharmaceutical': 4092, 'caries': 4093, 'contains': 4094, 'fluoride': 4095, 'antihemophilic': 4096, 'demand': 4097, 'hypoprothrombinemia': 4098, 'limiting': 4099, 'prothrombin': 4100, 'clean': 4101, 'sweetener': 4102, 'burning': 4103, 'depends': 4104, 'difference': 4105, 'property': 4106, 'disinfectant': 4107, 'milk': 4108, 'ferrous': 4109, 'distention': 4110, 'moisturizer': 4111, 'rauwolfia': 4112, 'douche': 4113, 'heat': 4114, 'biocide': 4115, 'correct': 4116, 'met': 4117, 'colloid': 4118, 'leveen': 4119, 'shunt': 4120, 'degenerative': 4121, 'pharmaceutic': 4122, 'dextrose': 4123, 'determination': 4124, 'material': 4125, 'paper': 4126, 'agar': 4127, 'buffer': 4128, 'dairy': 4129, 'soy': 4130, 'absorbing': 4131, 'derived': 4132, 'ingested': 4133, 'properly': 4134, 'enteral': 4135, '111': 4136, 'indium': 4137, 'iodinated': 4138, 'delineation': 4139, 'cleanse': 4140, 'dermatitides': 4141, 'emetic': 4142, 'emollient': 4143, 'radiolabeling': 4144, 'practical': 4145, 'pool': 4146, 'commercial': 4147, 'indirect': 4148, 'damaging': 4149, 'closely': 4150, 'correlated': 4151, 'marker': 4152, 'monitoring': 4153, 'urease': 4154, 'utilizes': 4155, 'flatulence': 4156, 'content': 4157, 'melasma': 4158, 'identification': 4159, 'filter': 4160, 'uva': 4161, 'uvb': 4162, 'omega': 4163, 'irritant': 4164, 'lumbago': 4165, 'detergent': 4166, 'antigen': 4167, 'rabies': 4168, 'hdm': 4169, 'house': 4170, 'licensed': 4171, 'mite': 4172, 'capsule': 4173, 'dermis': 4174, 'device': 4175, 'bovine': 4176, 'cultured': 4177, 'donor': 4178, 'keratinocytes': 4179, 'matrix': 4180, 'orcel': 4181, 'page': 4182, 'actual': 4183, 'certificate': 4184, 'contracting': 4185, 'report': 4186, 'travel': 4187, 'vaccination': 4188, 'valid': 4189, 'booster': 4190, 'skeleton': 4191, 'oil': 4192, 'chapped': 4193, 'protectant': 4194, 'antisepsis': 4195, 'provides': 4196, 'db00085': 4197, 'bloating': 4198, 'conditioner': 4199, 'dimethicone': 4200, 'perspiration': 4201, 'contemporary': 4202, 'derivative': 4203, 'insecticide': 4204, 'pesticide': 4205, 'absorb': 4206, 'layer': 4207, 'reflect': 4208, 'uv': 4209, 'fissure': 4210, 'ileostomy': 4211, 'perhaps': 4212, 'neutralize': 4213, 'soothing': 4214, 'emulsion': 4215, 'cleaning': 4216, 'implemented': 4217, 'multidose': 4218, 'molecule': 4219, 'get': 4220, 'obtained': 4221, 'selenium': 4222, 'wax': 4223, 'alkaloid': 4224, 'chromium': 4225, 'serving': 4226, 'biocidal': 4227, 'koh': 4228, 'braziliense': 4229, 'caninum': 4230, 'embonate': 4231, 'leonina': 4232, 'nomenclature': 4233, 'pamoate': 4234, 'stenocephala': 4235, 'toxascaris': 4236, 'toxocara': 4237, 'uncinaria': 4238, 'researched': 4239, 'flowing': 4240, 'see': 4241, 'gelatin': 4242, 'manufacturing': 4243, 'tocopherol': 4244, 'contained': 4245, 'db01373': 4246, 'confer': 4247, 'db01049': 4248, 'isomer': 4249, 'deet': 4250, 'repel': 4251, '64': 4252, 'absorbable': 4253, 'cautery': 4254, 'ligature': 4255, 'oozing': 4256, 'suture': 4257, 'concentrate': 4258, 'ix': 4259, 'composite': 4260, 'eicosapentaenoic': 4261, 'growing': 4262, 'literature': 4263, 'flavoring': 4264, 'nonivamide': 4265, 'tetradecyl': 4266, 'toothpaste': 4267, 'pulp': 4268, 'radical': 4269, 'worm': 4270, 'xanthine': 4271, 'lipase': 4272, 'zepatier': 4273, 'sporting': 4274, 'emulsifier': 4275, 'infective': 4276, 'fixation': 4277, 'etoposide': 4278, 'ineligible': 4279, 'itp': 4280, 'rh': 4281, 'rh0': 4282, 'olive': 4283, 'sterile': 4284, 'white': 4285, 'antispasmodic': 4286, 'db08934': 4287, 'born': 4288, 'cld': 4289, 'hematology': 4290, 'illicitly': 4291, 'nursing': 4292, 'oncology': 4293, 'personal': 4294, 'sexually': 4295, 'staff': 4296, 'waste': 4297, 'failing': 4298, 'fusion': 4299, 'transthyretin': 4300, 'pro': 4301, 'sclc': 4302, 'activated': 4303, 'cdk4': 4304, 'cyclin': 4305, 'ensuring': 4306, 'element': 4307, 'elucidated': 4308, 'he': 4309, 'none': 4310, 'mention': 4311, 'stool': 4312, 'mtx': 4313, 'pointed': 4314, 'overexpressed': 4315, 'fully': 4316, 'limitation': 4317, 'cd38': 4318, 'lymphocyte': 4319, 'restrained': 4320, 'overexpression': 4321, 'comparable': 4322, 'ntrk': 4323, 'scheduled': 4324, 'smallpox': 4325, 'activation': 4326, 'th2': 4327, 'cuti': 4328, 'accepted': 4329, 'cascade': 4330, 'directed': 4331, 'gsk': 4332, 'importance': 4333, 'neuronal': 4334, 'tau': 4335, 'fgfr': 4336, 'fgfr2': 4337, 'fibroblast': 4338, 'kit': 4339, 'pcr': 4340, 'rt': 4341, 'sb': 4342, 'aberrant': 4343, 'microtubule': 4344, 'contagiosum': 4345, 'elucidate': 4346, 'molluscum': 4347, 'periungual': 4348, 'plantar': 4349, 'ebola': 4350, 'mf': 4351, 'szary': 4352, 'aqp4': 4353, 'aquaporin': 4354, 'immunoglobulin': 4355, 'hernia': 4356, 'hiatus': 4357, 'oxygenation': 4358, 'hcl': 4359, 'mutant': 4360, 'ret': 4361, 'suppresses': 4362, 'exception': 4363, 'ep4': 4364, 'pge2': 4365, 'autosomal': 4366, 'misfunction': 4367, 'recessive': 4368, 'vwf': 4369, 'finding': 4370, 'ligand': 4371, 'programmed': 4372, 'butyrate': 4373, 'sma': 4374, 'cln2': 4375, 'naturally': 4376, 'utility': 4377, 'hydrolysis': 4378, 'sheep': 4379, 'industry': 4380, 'perborate': 4381, 'feel': 4382, 'ioxitalamate': 4383, 'elsewhere': 4384, 'cov': 4385, 'sars': 4386, 'poorly': 4387, 'inability': 4388, 'lactose': 4389, 'ultimately': 4390, 'anethol': 4391, 'gallstone': 4392, 'trithione': 4393, 'mavyret': 4394, 'pugh': 4395, 'antivenin': 4396, 'coral': 4397, 'envenomation': 4398, 'fulvius': 4399, 'micrurus': 4400, 'fix': 4401, 'rix': 4402, 'crofab': 4403, 'crotalid': 4404, 'crotalidae': 4405, 'crotalinae': 4406, 'north': 4407, 'subfamily': 4408, 'venomous': 4409, 'genetically': 4410, 'modified': 4411, 'botulinum': 4412, 'indicted': 4413, 'serotype': 4414, 'toxin': 4415, 'deodorant': 4416, 'dlbcl': 4417, 'specified': 4418, 'induces': 4419, '68': 4420, 'dotatate': 4421, 'neurotrophic': 4422, 'isomerohydrolase': 4423, 'lca': 4424, 'rpe65': 4425, 'rzyl': 4426, 'vn': 4427, 'orchidectomy': 4428, 'orchitis': 4429, 'testis': 4430, 'vanishing': 4431, 'linked': 4432, 'femring': 4433, 'constitute': 4434, 'mcts': 4435, 'cat': 4436, 'ppfh': 4437, 'agvhd': 4438, '1500': 4439, 'continues': 4440, 'genuine': 4441, 'quite': 4442, 'denture': 4443, 'rat': 4444, 'vaccinia': 4445, 'acd': 4446, 'epicutaneous': 4447, 'live': 4448, 'strain': 4449, 'cscc': 4450, 'ada': 4451, 'scid': 4452, 'hlh': 4453, 'lineage': 4454, 'bpdcn': 4455, 'cd123': 4456, 'dendritic': 4457, 'plasmacytoid': 4458, 'bodily': 4459, 'igf': 4460, 'mecasermin': 4461, 'sd': 4462, 'coronavirus': 4463, 'ecmo': 4464, 'eua': 4465, '53': 4466, 'sensitized': 4467, 'ebolavirus': 4468, 'zaire': 4469, 'derisomaltase': 4470, 'authorized': 4471, 'mers': 4472, 'scheme': 4473, 'country': 4474, 'tozinameran': 4475, 'atoltivimab': 4476, 'efficacious': 4477, 'emergence': 4478, 'maftivimab': 4479, 'marburgvirus': 4480, 'mother': 4481, 'odesivimab': 4482, 'activate': 4483, 'casirivimab': 4484, 'indevimab': 4485, 'psma': 4486}\n"
     ]
    }
   ],
   "source": [
    "print(dictionary_words.token2id)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "c00a8a50",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4487"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(dictionary_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "14d3b3bd",
   "metadata": {},
   "outputs": [],
   "source": [
    "corpus = [dictionary_words.doc2bow(text) for text in indications_list]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "54b23a2b",
   "metadata": {},
   "outputs": [],
   "source": [
    "corpus = [dictionary_words.doc2bow(text) for text in indications_list]\n",
    "numpy_indic = gensim.matutils.corpus2dense(corpus, num_terms=len(dictionary_words))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "40cb1fb0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[(0, '0.013*\"investigated\" + 0.009*\"bacterial\" + 0.009*\"disease\" + 0.008*\"severe\" + 0.008*\"arthritis\" + 0.008*\"therapy\" + 0.007*\"fda\" + 0.007*\"active\" + 0.006*\"age\" + 0.006*\"tract\"'), (21, '0.011*\"fda\" + 0.009*\"investigated\" + 0.009*\"disease\" + 0.008*\"failure\" + 0.007*\"severe\" + 0.007*\"for\" + 0.006*\"cancer\" + 0.006*\"non\" + 0.006*\"therapy\" + 0.006*\"agent\"'), (35, '0.039*\"cancer\" + 0.022*\"investigated\" + 0.013*\"unspecified\" + 0.010*\"drug\" + 0.009*\"solid\" + 0.008*\"disease\" + 0.008*\"for\" + 0.007*\"during\" + 0.007*\"allergic\" + 0.006*\"fda\"'), (24, '0.030*\"for\" + 0.015*\"disorder\" + 0.009*\"therapy\" + 0.008*\"urinary\" + 0.007*\"adjunct\" + 0.006*\"eye\" + 0.006*\"relief\" + 0.006*\"prevention\" + 0.006*\"skin\" + 0.005*\"syndrome\"'), (7, '0.016*\"for\" + 0.012*\"fda\" + 0.010*\"susceptible\" + 0.009*\"streptococcus\" + 0.009*\"pneumoniae\" + 0.009*\"approved\" + 0.008*\"skin\" + 0.007*\"disease\" + 0.006*\"metastatic\" + 0.006*\"therapy\"'), (23, '0.059*\"cancer\" + 0.021*\"investigated\" + 0.014*\"breast\" + 0.014*\"disease\" + 0.011*\"metastatic\" + 0.010*\"therapy\" + 0.010*\"lung\" + 0.009*\"for\" + 0.007*\"non\" + 0.007*\"fda\"'), (37, '0.015*\"investigated\" + 0.014*\"fda\" + 0.012*\"disease\" + 0.010*\"mg\" + 0.008*\"i\" + 0.007*\"disorder\" + 0.006*\"for\" + 0.006*\"cancer\" + 0.006*\"anxiety\" + 0.006*\"deficiency\"'), (6, '0.033*\"cancer\" + 0.015*\"investigated\" + 0.015*\"hypertension\" + 0.013*\"for\" + 0.010*\"therapy\" + 0.007*\"disease\" + 0.007*\"angina\" + 0.007*\"lung\" + 0.006*\"pulmonary\" + 0.006*\"unspecified\"'), (2, '0.013*\"disease\" + 0.011*\"fda\" + 0.011*\"for\" + 0.010*\"approved\" + 0.009*\"chronic\" + 0.007*\"no\" + 0.006*\"investigated\" + 0.006*\"disorder\" + 0.005*\"lung\" + 0.005*\"cancer\"'), (18, '0.019*\"investigated\" + 0.016*\"disease\" + 0.016*\"pain\" + 0.014*\"chronic\" + 0.012*\"therapy\" + 0.011*\"for\" + 0.011*\"severe\" + 0.009*\"moderate\" + 0.008*\"skin\" + 0.008*\"fda\"'), (34, '0.020*\"disease\" + 0.010*\"fda\" + 0.010*\"investigated\" + 0.010*\"deficiency\" + 0.008*\"chronic\" + 0.008*\"for\" + 0.007*\"therapy\" + 0.006*\"age\" + 0.006*\"older\" + 0.006*\"muscle\"'), (4, '0.022*\"fda\" + 0.020*\"for\" + 0.011*\"pain\" + 0.008*\"chronic\" + 0.008*\"approved\" + 0.008*\"cirrhosis\" + 0.007*\"investigated\" + 0.007*\"product\" + 0.006*\"disease\" + 0.006*\"relief\"'), (11, '0.027*\"for\" + 0.022*\"investigated\" + 0.011*\"therapy\" + 0.009*\"infection\" + 0.009*\"allergic\" + 0.008*\"cancer\" + 0.008*\"prevention\" + 0.007*\"age\" + 0.007*\"older\" + 0.006*\"fda\"'), (29, '0.029*\"investigated\" + 0.018*\"disease\" + 0.014*\"chronic\" + 0.012*\"cancer\" + 0.012*\"fda\" + 0.007*\"hepatitis\" + 0.007*\"infection\" + 0.006*\"viral\" + 0.006*\"metastatic\" + 0.006*\"skin\"'), (17, '0.023*\"for\" + 0.018*\"investigated\" + 0.014*\"disease\" + 0.010*\"hepatitis\" + 0.009*\"prophylaxis\" + 0.008*\"viral\" + 0.008*\"heart\" + 0.007*\"failure\" + 0.007*\"b\" + 0.006*\"risk\"'), (30, '0.015*\"for\" + 0.010*\"investigated\" + 0.010*\"tract\" + 0.009*\"coli\" + 0.009*\"severe\" + 0.008*\"following\" + 0.008*\"disorder\" + 0.007*\"anxiety\" + 0.007*\"fda\" + 0.007*\"susceptible\"'), (13, '0.021*\"investigated\" + 0.019*\"disease\" + 0.008*\"chronic\" + 0.008*\"for\" + 0.007*\"older\" + 0.007*\"fda\" + 0.007*\"leukemia\" + 0.007*\"peripheral\" + 0.006*\"non\" + 0.006*\"virus\"'), (31, '0.017*\"for\" + 0.011*\"cancer\" + 0.009*\"symptomatic\" + 0.009*\"anesthesia\" + 0.009*\"prevention\" + 0.008*\"investigated\" + 0.008*\"older\" + 0.007*\"allergic\" + 0.006*\"peripheral\" + 0.006*\"optiray\"'), (19, '0.027*\"for\" + 0.022*\"investigated\" + 0.017*\"cancer\" + 0.017*\"disease\" + 0.012*\"chronic\" + 0.007*\"infection\" + 0.007*\"therapy\" + 0.006*\"syndrome\" + 0.005*\"breast\" + 0.005*\"term\"'), (36, '0.018*\"disease\" + 0.013*\"investigated\" + 0.010*\"for\" + 0.010*\"chronic\" + 0.008*\"therapy\" + 0.007*\"agent\" + 0.007*\"moderate\" + 0.007*\"severe\" + 0.007*\"pain\" + 0.007*\"acid\"')]\n"
     ]
    }
   ],
   "source": [
    "# number of topics\n",
    "num_topics = 40\n",
    "# Build LDA model\n",
    "lda_model = gensim.models.LdaMulticore(corpus=corpus,\n",
    "                                       id2word=dictionary_words,\n",
    "                                       num_topics=num_topics)\n",
    "# Print the Keyword in the 10 topics\n",
    "print(lda_model.print_topics())\n",
    "doc_lda = lda_model[corpus]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "3eacf10e",
   "metadata": {},
   "outputs": [],
   "source": [
    "model = gensim.models.HdpModel(corpus, id2word=dictionary_words)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "1005ef68",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(0,\n",
       "  '0.005*disease + 0.003*c + 0.003*investigated + 0.003*coronary + 0.002*risk + 0.002*myocardial + 0.002*type + 0.002*stroke + 0.002*intravenous + 0.002*ldl'),\n",
       " (1,\n",
       "  '0.004*fda + 0.003*cancer + 0.003*metastatic + 0.002*therapy + 0.002*disease + 0.002*paracetamol + 0.002*approved + 0.001*chemotherapy + 0.001*prior + 0.001*test'),\n",
       " (2,\n",
       "  '0.003*susceptible + 0.002*streptococcus + 0.002*pneumoniae + 0.002*professional + 0.002*disease + 0.002*bacterial + 0.002*skin + 0.002*urea + 0.002*result + 0.002*therapy'),\n",
       " (3,\n",
       "  '0.002*bind + 0.001*fda + 0.001*sicca + 0.001*concurrent + 0.001*demand + 0.001*nonmyeloid + 0.001*for + 0.001*chromium + 0.001*error + 0.001*indirect'),\n",
       " (4,\n",
       "  '0.002*mediate + 0.002*urealyticum + 0.001*cancer + 0.001*gland + 0.001*researched + 0.001*dose + 0.001*color + 0.001*fix + 0.001*nevertheless + 0.001*toxoplasmosis'),\n",
       " (5,\n",
       "  '0.002*disease + 0.002*prepare + 0.002*ileus + 0.002*delay + 0.001*hypertension + 0.001*fast + 0.001*neuritis + 0.001*sex + 0.001*lugdunensis + 0.001*formulation'),\n",
       " (6,\n",
       "  '0.002*release + 0.002*cancer + 0.002*chronic + 0.002*effectively + 0.002*vaginitis + 0.002*scabiei + 0.002*dementia + 0.002*transfusional + 0.002*mucocutaneous + 0.002*cause'),\n",
       " (7,\n",
       "  '0.002*tenofovir + 0.002*pathogen + 0.002*susceptible + 0.002*anterior + 0.001*contraindicated + 0.001*peg + 0.001*40mg + 0.001*leukemia + 0.001*epicondylitis + 0.001*pneumoniae'),\n",
       " (8,\n",
       "  '0.002*disorder + 0.002*suppressed + 0.002*history + 0.001*digitalis + 0.001*under + 0.001*profile + 0.001*labor + 0.001*address + 0.001*repeat + 0.001*psychiatric'),\n",
       " (9,\n",
       "  '0.002*puberty + 0.002*obtain + 0.002*pork + 0.002*bulimia + 0.002*placed + 0.001*oxygenation + 0.001*obstruction + 0.001*pressure + 0.001*interdigital + 0.001*periungual'),\n",
       " (10,\n",
       "  '0.003*classical + 0.002*proliferation + 0.002*spinal + 0.002*dietary + 0.002*cancer + 0.001*sinus + 0.001*antiemetic + 0.001*dysphoric + 0.001*during + 0.001*acid'),\n",
       " (11,\n",
       "  '0.002*old + 0.002*bph + 0.002*continued + 0.001*rise + 0.001*traveling + 0.001*sars + 0.001*larval + 0.001*disease + 0.001*lactose + 0.001*skeleton'),\n",
       " (12,\n",
       "  '0.002*intended + 0.002*spray + 0.002*arsenic + 0.001*rubrum + 0.001*terminal + 0.001*pharyngitis + 0.001*acd + 0.001*cancer + 0.001*mydriatic + 0.001*pedis'),\n",
       " (13,\n",
       "  '0.002*abetalipoproteinemia + 0.002*aromatase + 0.002*amenorrhea + 0.002*intermedius + 0.002*db00811 + 0.001*antiperspirant + 0.001*haemorrhage + 0.001*serving + 0.001*valine + 0.001*e'),\n",
       " (14,\n",
       "  '0.002*cervicitis + 0.002*cancer + 0.002*end + 0.002*weight + 0.002*db00022 + 0.002*lung + 0.001*fix + 0.001*dementia + 0.001*some + 0.001*pulposus'),\n",
       " (15,\n",
       "  '0.002*number + 0.002*sinus + 0.002*resulted + 0.002*structure + 0.001*investigated + 0.001*unspecified + 0.001*culture + 0.001*cancer + 0.001*upon + 0.001*registered'),\n",
       " (16,\n",
       "  '0.002*fraction + 0.002*providencia + 0.002*enterococcal + 0.002*cure + 0.002*gonorrhoeae + 0.002*2019 + 0.001*operative + 0.001*investigated + 0.001*unacceptable + 0.001*donor'),\n",
       " (17,\n",
       "  '0.002*subfamily + 0.002*young + 0.002*composite + 0.002*retrograde + 0.001*hyperlipoproteinemia + 0.001*pedis + 0.001*alfa + 0.001*overt + 0.001*action + 0.001*barrier'),\n",
       " (18,\n",
       "  '0.002*anaerobic + 0.002*south + 0.002*microvascular + 0.002*injury + 0.002*gpa + 0.002*narcotic + 0.002*sanitizers + 0.002*ferric + 0.002*asthma + 0.001*articularly'),\n",
       " (19,\n",
       "  '0.002*hyperpigmentation + 0.001*fever + 0.001*capacity + 0.001*includes + 0.001*measured + 0.001*reduces + 0.001*vein + 0.001*chloroquine + 0.001*line + 0.001*identify')]"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "model.print_topics()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 415,
   "id": "0de31161",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('egfr-expressing, metastatic colorectal carcinoma', 'patients'),\n",
       " ('egfr-expressing, metastatic colorectal carcinoma', 'patients')]"
      ]
     },
     "execution_count": 415,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ss = 'drug, used in combination with irinotecan, is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. drug administered as a single agent is indicated for the treatment of egfr-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy'\n",
    "re.findall(r'for the treatment of\\ (.*?)\\ in (adults|patients)', ss)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 406,
   "id": "54968926",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('moderately to severely active rheumatoid arthritis', 'adults'), ('chronic moderate to severe plaque psoriasis', 'patients')]\n"
     ]
    }
   ],
   "source": [
    "ss = 'drug is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older'\n",
    "ind = re.findall(r'for the treatment of\\ (.*?)\\ in (adults|patients)', ss)\n",
    "ind += re.findall(r' and in\\ (.*?)\\ in (adults|patients)', ss)\n",
    "print(ind)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 401,
   "id": "7cd4eba7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['drug is indicated ',\n",
       " 'moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[l14862] it is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 2 years and older. drug is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis. ']"
      ]
     },
     "execution_count": 401,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "s.split(\"for the treatment of \")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 398,
   "id": "cedc1d8e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False"
      ]
     },
     "execution_count": 398,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(re.findall(r'for treatment of \\ (.*?)', 'for treatment of cutaneous t-cell lymphoma'))>0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1025,
   "id": "014255c2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['component', 'blood microparticle'],\n",
       " ['component', 'cytosol'],\n",
       " ['component', 'endoplasmic reticulum lumen'],\n",
       " ['component', 'extracellular exosome'],\n",
       " ['component', 'extracellular matrix'],\n",
       " ['component', 'extracellular region'],\n",
       " ['component', 'extracellular space'],\n",
       " ['component', 'Golgi lumen'],\n",
       " ['component', 'plasma membrane'],\n",
       " ['function', 'calcium ion binding'],\n",
       " ['function', 'growth factor activity'],\n",
       " ['function', 'receptor binding'],\n",
       " ['function', 'serine-type endopeptidase activity'],\n",
       " ['function', 'thrombospondin receptor activity'],\n",
       " ['process', 'acute-phase response'],\n",
       " ['process', 'blood coagulation'],\n",
       " ['process', 'blood coagulation, intrinsic pathway'],\n",
       " ['process', 'cell surface receptor signaling pathway'],\n",
       " ['process', 'cellular protein metabolic process'],\n",
       " ['process', 'cellular response to mechanical stimulus'],\n",
       " ['process', 'cytosolic calcium ion homeostasis'],\n",
       " ['process', 'fibrinolysis'],\n",
       " ['process', 'leukocyte migration'],\n",
       " ['process', 'multicellular organismal development'],\n",
       " ['process', 'negative regulation of astrocyte differentiation'],\n",
       " ['process', 'negative regulation of fibrinolysis'],\n",
       " ['process', 'negative regulation of platelet activation'],\n",
       " ['process', 'negative regulation of proteolysis'],\n",
       " ['process', 'peptidyl-glutamic acid carboxylation'],\n",
       " ['process', 'platelet activation'],\n",
       " ['process', 'positive regulation of blood coagulation'],\n",
       " ['process', 'positive regulation of cell growth'],\n",
       " ['process', 'positive regulation of cell proliferation'],\n",
       " ['process', 'positive regulation of collagen biosynthetic process'],\n",
       " ['process', 'positive regulation of phosphatidylinositol 3-kinase signaling'],\n",
       " ['process',\n",
       "  'positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway'],\n",
       " ['process', 'positive regulation of protein phosphorylation'],\n",
       " ['process',\n",
       "  'positive regulation of reactive oxygen species metabolic process'],\n",
       " ['process',\n",
       "  'positive regulation of release of sequestered calcium ion into cytosol'],\n",
       " ['process', 'post-translational protein modification'],\n",
       " ['process', 'proteolysis'],\n",
       " ['process', 'regulation of blood coagulation'],\n",
       " ['process', 'regulation of cell shape'],\n",
       " ['process', 'regulation of gene expression'],\n",
       " ['process', 'response to inactivity'],\n",
       " ['process', 'response to wounding']]"
      ]
     },
     "execution_count": 1025,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001']['go_classifiers']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "32308f0a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['drugbank_id', 'name', 'description', 'indication', 'pharmacodynamics', 'toxicity', 'metabolism', 'absorption', 'half_life', 'market_start', 'affected_organism', 'market_end', 'mechanism_of_action', 'route_of_elimination', 'volume_of_distribution', 'classification', 'carriers', 'targets', 'transporters', 'enzymes', 'go_classifiers', 'food_interactions', 'ddi', 'pathways'])"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "###\n",
    "dictionary['DB00001'].keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1019,
   "id": "aae89ae3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['drugbank_id', 'name', 'description', 'indication', 'pharmacodynamics', 'toxicity', 'metabolism', 'absorption', 'half_life', 'market_start', 'affected_organism', 'market_end', 'mechanism_of_action', 'route_of_elimination', 'volume_of_distribution', 'classification', 'carriers', 'transporters', 'enzymes', 'go_classifiers', 'food_interactions', 'ddi', 'pathways'])"
      ]
     },
     "execution_count": 1019,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00001'].keys()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "46901a95",
   "metadata": {},
   "source": [
    "## Food Interactions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9a62113c",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_foods = []\n",
    "for index_name in dictionary.keys():\n",
    "     if dictionary[index_name]['food_interactions']!='None':\n",
    "        for j in dictionary[index_name]['food_interactions'].keys():\n",
    "            all_foods += re.split('\\W+', dictionary[index_name]['food_interactions'][j].lower())\n",
    "             "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c319a5a4",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_foods"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "86a9244f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "86175faa",
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary[index_name]['food_interactions']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d101d904",
   "metadata": {},
   "outputs": [],
   "source": [
    "nltk.download('wordnet')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b7083453",
   "metadata": {},
   "outputs": [],
   "source": [
    "#### Might use knwown resources to select the foods: https://vchoo.github.io/\n",
    "flavor_df = pd.read_csv('flavordb.csv')\n",
    "flavor_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "94775444",
   "metadata": {},
   "outputs": [],
   "source": [
    "set(all_foods).difference(stop_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "86c931ef",
   "metadata": {},
   "outputs": [],
   "source": [
    " foods=['garlic', 'ginger', 'bilberry ', 'alcohol',\n",
    "         'piracetam', 'whitefish']\n",
    "\n",
    "# check if any food matches (or is a substring of) an alias in the database\n",
    "{f : any([f in alias for alias in flavor_df['alias']])\n",
    " for f in foods}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "322b677a",
   "metadata": {},
   "outputs": [],
   "source": [
    "list(flavor_df['alias'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "35a4d694",
   "metadata": {},
   "outputs": [],
   "source": [
    "food_interections={}\n",
    "for index_name in dictionary.keys():\n",
    "    newfood = []\n",
    "    foodall=[]\n",
    "    if dictionary[index_name]['food_interactions']!='None':\n",
    "        for j in dictionary[index_name]['food_interactions'].keys():\n",
    "            food1 = re.split('\\W+', dictionary[index_name]['food_interactions'][j].lower())\n",
    "            food1 = list(filter(None, food1))\n",
    "            if len(food1)==2:\n",
    "                fooda = food1[1]\n",
    "                newfood.append(fooda)\n",
    "            foodall = food1+foodall\n",
    "        for word in foodall:\n",
    "            for alias in list(flavor_df['alias']):\n",
    "                if word == alias :\n",
    "                    newfood.append(word)\n",
    "            for category in list(flavor_df['category']):\n",
    "                if len(word)!=0 and word[-1]=='s' and word[:-1] == category:\n",
    "                        newfood.append(word[:-1])\n",
    "    food_interections[index_name]=dict(Counter(set(newfood)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "02930b5e",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "108baf6a",
   "metadata": {},
   "outputs": [],
   "source": [
    "food_interactions_x = pd.DataFrame.from_dict(food_interections, orient= 'index',dtype=int).fillna(0)\n",
    "food_interactions_x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b29cab4d",
   "metadata": {},
   "outputs": [],
   "source": [
    "food_interactions_x.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0196a9d9",
   "metadata": {
    "executionInfo": {
     "elapsed": 98803,
     "status": "ok",
     "timestamp": 1656128817788,
     "user": {
      "displayName": "Yumeng Shao",
      "userId": "13244839590576145111"
     },
     "user_tz": 300
    },
    "id": "K9AmUuNQ8tdK"
   },
   "outputs": [],
   "source": [
    "interactions = []\n",
    "type_of_interaction_list =[]\n",
    "interaction_types = {}\n",
    "descrip=[]\n",
    "for index_name in dictionary.keys():\n",
    "    if dictionary[index_name]['drug_interactions']!='None':\n",
    "        name1 = re.split('\\W+',dictionary[index_name]['name'].lower())\n",
    "        for index_j in dictionary[index_name]['drug_interactions'].keys():\n",
    "            newdescrip=[]\n",
    "            interactions += [[index_name, dictionary[index_name]['drug_interactions'][index_j]['drug_bank_id in DDI']]]\n",
    "            description = re.split('\\W+', dictionary[index_name]['drug_interactions'][index_j]['description in DDI'].lower())\n",
    "            name2 = re.split('\\W+',dictionary[index_name]['drug_interactions'][index_j]['name in DDI'].lower())\n",
    "            #type_of_interaction_list += description\n",
    "            pattern0=r'^[0-9]+[0-9]$'\n",
    "            regex=re.compile(pattern0)\n",
    "            for word in description:\n",
    "                h=regex.match(word)\n",
    "                if word not in stop_words_ddi and word not in name1 and word not in name2 and h==None and len(word)!=0 and len(word)!=1:\n",
    "                    newdescrip.append(word) \n",
    "            #interaction_types[(index_name, dictionary[index_name]['drug_interactions'][index_j]['drug_bank_id in DDI'])] =  dict(Counter(description))\n",
    "            interaction_types[(index_name, dictionary[index_name]['drug_interactions'][index_j]['drug_bank_id in DDI'])] =  dict(Counter(newdescrip))\n",
    "            type_of_interaction_list += newdescrip"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b7f46054",
   "metadata": {},
   "outputs": [],
   "source": [
    "type_of_interaction_list = set(type_of_interaction_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "313c0107",
   "metadata": {},
   "outputs": [],
   "source": [
    "interaction_types[('DB00001', 'DB06605')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9ce3e4f1",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "80bd0a94",
   "metadata": {},
   "outputs": [],
   "source": [
    "type_of_interaction_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c025db7e",
   "metadata": {},
   "outputs": [],
   "source": [
    "interactions_x =pd.DataFrame(0, index=interaction_types.keys(), columns=type_of_interaction_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5020362a",
   "metadata": {},
   "outputs": [],
   "source": [
    "for interactid, wordict in interaction_types.items():\n",
    "    for interactword,times in wordict.items():\n",
    "        interactions_x.at[interactid,interactword]=times"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ad8c0908",
   "metadata": {},
   "outputs": [],
   "source": [
    "interactions_x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "48b94279",
   "metadata": {
    "id": "mLVoWMrG8tdL"
   },
   "outputs": [],
   "source": [
    "import networkx as nx\n",
    "import matplotlib.pyplot as plt\n",
    "from collections import *\n",
    "is_dict = lambda x: type(x) in {dict, OrderedDict, defaultdict}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "97ce9825",
   "metadata": {},
   "outputs": [],
   "source": [
    "G = nx.from_edgelist(interactions)\n",
    "nx.set_node_attributes(G, X.to_dict(orient='index'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "58e3e4a0",
   "metadata": {},
   "outputs": [],
   "source": [
    "nx.set_node_attributes(G, X.to_dict(orient='index'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a9ea6e5e",
   "metadata": {},
   "outputs": [],
   "source": [
    "nx.set_node_attributes(G, ['Drug']*G.number_of_nodes(), \"node_type\") ### Make sure that the node is identified as a drug"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "07945f3b",
   "metadata": {},
   "outputs": [],
   "source": [
    "G.nodes['DB00001']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bf4d6d21",
   "metadata": {},
   "outputs": [],
   "source": [
    "G.edges('DB00001')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d0afdd2a",
   "metadata": {},
   "outputs": [],
   "source": [
    "#### Now need to add the pathways\n",
    "for index_name in dictionary.keys():\n",
    "    if dictionary[index_name]['pathways'] !='None':\n",
    "        for index_ in dictionary[index_name]['pathways'].keys():\n",
    "            drugbank_id_in_pathway=[]\n",
    "            enzeyme = []\n",
    "            pathways=[]\n",
    "            for a,level1 in dictionary[index_name]['pathways'][index_].items():\n",
    "                if is_dict(level1):\n",
    "                    if a[:5]=='drugs':\n",
    "                        for level2,level3 in level1.items():\n",
    "                             if level2=='drugbank_id in pathway':\n",
    "                                    drugbank_id_in_pathway.append(level3)#trying to extract all drugbank id in order\n",
    "                    if a[:7]=='enzymes':\n",
    "                        for level2,level3 in level1.items():\n",
    "                             enzeyme.append(level3)#trying to extract all enzeymes in order\n",
    "            if len(drugbank_id_in_pathway)>1:\n",
    "                for i in range(len(drugbank_id_in_pathway)-1):\n",
    "                    G.add_edge(drugbank_id_in_pathway[i],drugbank_id_in_pathway[i+1])\n",
    "                if len(enzeyme)!=0:\n",
    "                    G.add_edge(drugbank_id_in_pathway[-1],enzeyme[0])\n",
    "                    if len(enzeyme)>1:\n",
    "                        for i in range(len(enzeyme)-1):\n",
    "                            G.add_edge(enzeyme[i],enzeyme[i+1])\n",
    "                    \n",
    "            else:\n",
    "                if len(enzeyme)!=0:\n",
    "                    G.add_edge(drugbank_id_in_pathway[-1],enzeyme[0])\n",
    "                    if len(enzeyme)>1:\n",
    "                        for i in range(len(enzeyme)-1):\n",
    "                            G.add_edge(enzeyme[i],enzeyme[i+1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5f9491c8",
   "metadata": {},
   "outputs": [],
   "source": [
    "enzeyme"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9523f1de",
   "metadata": {},
   "outputs": [],
   "source": [
    "list(G.edges('DB00004'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "98c3e0a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "G.edges('DB16058')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fff1b60d",
   "metadata": {
    "id": "6zIaKBLY8tdN"
   },
   "outputs": [],
   "source": [
    "#It's too large to draw the whole graph, so we draw subgraph\n",
    "\n",
    "H = G.edge_subgraph(list(G.edges('DB00004')))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3ae66594",
   "metadata": {
    "id": "qcf1ynW88tdN"
   },
   "outputs": [],
   "source": [
    "nx.draw(H, with_labels=True, font_weight='bold', node_color='lightblue', node_size=500)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "59f9e404",
   "metadata": {},
   "outputs": [],
   "source": [
    "G.nodes['DB00004']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b21908d9",
   "metadata": {
    "id": "N2sACSQZ8tdN"
   },
   "outputs": [],
   "source": [
    "#For nodes graph of DB00004\n",
    "Hn =nx.subgraph(G,list(G.nodes['DB00004']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8a026f35",
   "metadata": {
    "id": "plPQy5rG8tdN"
   },
   "outputs": [],
   "source": [
    "nx.draw(Hn, with_labels=True, font_weight='bold', node_color='lightblue', node_size=500)\n",
    "#Too Large to show"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1269,
   "id": "88a0b7de",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Help on function read_csv in module pandas.io.parsers.readers:\n",
      "\n",
      "read_csv(filepath_or_buffer: 'FilePath | ReadCsvBuffer[bytes] | ReadCsvBuffer[str]', sep=<no_default>, delimiter=None, header='infer', names=<no_default>, index_col=None, usecols=None, squeeze=None, prefix=<no_default>, mangle_dupe_cols=True, dtype: 'DtypeArg | None' = None, engine: 'CSVEngine | None' = None, converters=None, true_values=None, false_values=None, skipinitialspace=False, skiprows=None, skipfooter=0, nrows=None, na_values=None, keep_default_na=True, na_filter=True, verbose=False, skip_blank_lines=True, parse_dates=None, infer_datetime_format=False, keep_date_col=False, date_parser=None, dayfirst=False, cache_dates=True, iterator=False, chunksize=None, compression: 'CompressionOptions' = 'infer', thousands=None, decimal: 'str' = '.', lineterminator=None, quotechar='\"', quoting=0, doublequote=True, escapechar=None, comment=None, encoding=None, encoding_errors: 'str | None' = 'strict', dialect=None, error_bad_lines=None, warn_bad_lines=None, on_bad_lines=None, delim_whitespace=False, low_memory=True, memory_map=False, float_precision=None, storage_options: 'StorageOptions' = None)\n",
      "    Read a comma-separated values (csv) file into DataFrame.\n",
      "    \n",
      "    Also supports optionally iterating or breaking of the file\n",
      "    into chunks.\n",
      "    \n",
      "    Additional help can be found in the online docs for\n",
      "    `IO Tools <https://pandas.pydata.org/pandas-docs/stable/user_guide/io.html>`_.\n",
      "    \n",
      "    Parameters\n",
      "    ----------\n",
      "    filepath_or_buffer : str, path object or file-like object\n",
      "        Any valid string path is acceptable. The string could be a URL. Valid\n",
      "        URL schemes include http, ftp, s3, gs, and file. For file URLs, a host is\n",
      "        expected. A local file could be: file://localhost/path/to/table.csv.\n",
      "    \n",
      "        If you want to pass in a path object, pandas accepts any ``os.PathLike``.\n",
      "    \n",
      "        By file-like object, we refer to objects with a ``read()`` method, such as\n",
      "        a file handle (e.g. via builtin ``open`` function) or ``StringIO``.\n",
      "    sep : str, default ','\n",
      "        Delimiter to use. If sep is None, the C engine cannot automatically detect\n",
      "        the separator, but the Python parsing engine can, meaning the latter will\n",
      "        be used and automatically detect the separator by Python's builtin sniffer\n",
      "        tool, ``csv.Sniffer``. In addition, separators longer than 1 character and\n",
      "        different from ``'\\s+'`` will be interpreted as regular expressions and\n",
      "        will also force the use of the Python parsing engine. Note that regex\n",
      "        delimiters are prone to ignoring quoted data. Regex example: ``'\\r\\t'``.\n",
      "    delimiter : str, default ``None``\n",
      "        Alias for sep.\n",
      "    header : int, list of int, None, default 'infer'\n",
      "        Row number(s) to use as the column names, and the start of the\n",
      "        data.  Default behavior is to infer the column names: if no names\n",
      "        are passed the behavior is identical to ``header=0`` and column\n",
      "        names are inferred from the first line of the file, if column\n",
      "        names are passed explicitly then the behavior is identical to\n",
      "        ``header=None``. Explicitly pass ``header=0`` to be able to\n",
      "        replace existing names. The header can be a list of integers that\n",
      "        specify row locations for a multi-index on the columns\n",
      "        e.g. [0,1,3]. Intervening rows that are not specified will be\n",
      "        skipped (e.g. 2 in this example is skipped). Note that this\n",
      "        parameter ignores commented lines and empty lines if\n",
      "        ``skip_blank_lines=True``, so ``header=0`` denotes the first line of\n",
      "        data rather than the first line of the file.\n",
      "    names : array-like, optional\n",
      "        List of column names to use. If the file contains a header row,\n",
      "        then you should explicitly pass ``header=0`` to override the column names.\n",
      "        Duplicates in this list are not allowed.\n",
      "    index_col : int, str, sequence of int / str, or False, optional, default ``None``\n",
      "      Column(s) to use as the row labels of the ``DataFrame``, either given as\n",
      "      string name or column index. If a sequence of int / str is given, a\n",
      "      MultiIndex is used.\n",
      "    \n",
      "      Note: ``index_col=False`` can be used to force pandas to *not* use the first\n",
      "      column as the index, e.g. when you have a malformed file with delimiters at\n",
      "      the end of each line.\n",
      "    usecols : list-like or callable, optional\n",
      "        Return a subset of the columns. If list-like, all elements must either\n",
      "        be positional (i.e. integer indices into the document columns) or strings\n",
      "        that correspond to column names provided either by the user in `names` or\n",
      "        inferred from the document header row(s). If ``names`` are given, the document\n",
      "        header row(s) are not taken into account. For example, a valid list-like\n",
      "        `usecols` parameter would be ``[0, 1, 2]`` or ``['foo', 'bar', 'baz']``.\n",
      "        Element order is ignored, so ``usecols=[0, 1]`` is the same as ``[1, 0]``.\n",
      "        To instantiate a DataFrame from ``data`` with element order preserved use\n",
      "        ``pd.read_csv(data, usecols=['foo', 'bar'])[['foo', 'bar']]`` for columns\n",
      "        in ``['foo', 'bar']`` order or\n",
      "        ``pd.read_csv(data, usecols=['foo', 'bar'])[['bar', 'foo']]``\n",
      "        for ``['bar', 'foo']`` order.\n",
      "    \n",
      "        If callable, the callable function will be evaluated against the column\n",
      "        names, returning names where the callable function evaluates to True. An\n",
      "        example of a valid callable argument would be ``lambda x: x.upper() in\n",
      "        ['AAA', 'BBB', 'DDD']``. Using this parameter results in much faster\n",
      "        parsing time and lower memory usage.\n",
      "    squeeze : bool, default False\n",
      "        If the parsed data only contains one column then return a Series.\n",
      "    \n",
      "        .. deprecated:: 1.4.0\n",
      "            Append ``.squeeze(\"columns\")`` to the call to ``read_csv`` to squeeze\n",
      "            the data.\n",
      "    prefix : str, optional\n",
      "        Prefix to add to column numbers when no header, e.g. 'X' for X0, X1, ...\n",
      "    \n",
      "        .. deprecated:: 1.4.0\n",
      "           Use a list comprehension on the DataFrame's columns after calling ``read_csv``.\n",
      "    mangle_dupe_cols : bool, default True\n",
      "        Duplicate columns will be specified as 'X', 'X.1', ...'X.N', rather than\n",
      "        'X'...'X'. Passing in False will cause data to be overwritten if there\n",
      "        are duplicate names in the columns.\n",
      "    dtype : Type name or dict of column -> type, optional\n",
      "        Data type for data or columns. E.g. {'a': np.float64, 'b': np.int32,\n",
      "        'c': 'Int64'}\n",
      "        Use `str` or `object` together with suitable `na_values` settings\n",
      "        to preserve and not interpret dtype.\n",
      "        If converters are specified, they will be applied INSTEAD\n",
      "        of dtype conversion.\n",
      "    engine : {'c', 'python', 'pyarrow'}, optional\n",
      "        Parser engine to use. The C and pyarrow engines are faster, while the python engine\n",
      "        is currently more feature-complete. Multithreading is currently only supported by\n",
      "        the pyarrow engine.\n",
      "    \n",
      "        .. versionadded:: 1.4.0\n",
      "    \n",
      "            The \"pyarrow\" engine was added as an *experimental* engine, and some features\n",
      "            are unsupported, or may not work correctly, with this engine.\n",
      "    converters : dict, optional\n",
      "        Dict of functions for converting values in certain columns. Keys can either\n",
      "        be integers or column labels.\n",
      "    true_values : list, optional\n",
      "        Values to consider as True.\n",
      "    false_values : list, optional\n",
      "        Values to consider as False.\n",
      "    skipinitialspace : bool, default False\n",
      "        Skip spaces after delimiter.\n",
      "    skiprows : list-like, int or callable, optional\n",
      "        Line numbers to skip (0-indexed) or number of lines to skip (int)\n",
      "        at the start of the file.\n",
      "    \n",
      "        If callable, the callable function will be evaluated against the row\n",
      "        indices, returning True if the row should be skipped and False otherwise.\n",
      "        An example of a valid callable argument would be ``lambda x: x in [0, 2]``.\n",
      "    skipfooter : int, default 0\n",
      "        Number of lines at bottom of file to skip (Unsupported with engine='c').\n",
      "    nrows : int, optional\n",
      "        Number of rows of file to read. Useful for reading pieces of large files.\n",
      "    na_values : scalar, str, list-like, or dict, optional\n",
      "        Additional strings to recognize as NA/NaN. If dict passed, specific\n",
      "        per-column NA values.  By default the following values are interpreted as\n",
      "        NaN: '', '#N/A', '#N/A N/A', '#NA', '-1.#IND', '-1.#QNAN', '-NaN', '-nan',\n",
      "        '1.#IND', '1.#QNAN', '<NA>', 'N/A', 'NA', 'NULL', 'NaN', 'n/a',\n",
      "        'nan', 'null'.\n",
      "    keep_default_na : bool, default True\n",
      "        Whether or not to include the default NaN values when parsing the data.\n",
      "        Depending on whether `na_values` is passed in, the behavior is as follows:\n",
      "    \n",
      "        * If `keep_default_na` is True, and `na_values` are specified, `na_values`\n",
      "          is appended to the default NaN values used for parsing.\n",
      "        * If `keep_default_na` is True, and `na_values` are not specified, only\n",
      "          the default NaN values are used for parsing.\n",
      "        * If `keep_default_na` is False, and `na_values` are specified, only\n",
      "          the NaN values specified `na_values` are used for parsing.\n",
      "        * If `keep_default_na` is False, and `na_values` are not specified, no\n",
      "          strings will be parsed as NaN.\n",
      "    \n",
      "        Note that if `na_filter` is passed in as False, the `keep_default_na` and\n",
      "        `na_values` parameters will be ignored.\n",
      "    na_filter : bool, default True\n",
      "        Detect missing value markers (empty strings and the value of na_values). In\n",
      "        data without any NAs, passing na_filter=False can improve the performance\n",
      "        of reading a large file.\n",
      "    verbose : bool, default False\n",
      "        Indicate number of NA values placed in non-numeric columns.\n",
      "    skip_blank_lines : bool, default True\n",
      "        If True, skip over blank lines rather than interpreting as NaN values.\n",
      "    parse_dates : bool or list of int or names or list of lists or dict, default False\n",
      "        The behavior is as follows:\n",
      "    \n",
      "        * boolean. If True -> try parsing the index.\n",
      "        * list of int or names. e.g. If [1, 2, 3] -> try parsing columns 1, 2, 3\n",
      "          each as a separate date column.\n",
      "        * list of lists. e.g.  If [[1, 3]] -> combine columns 1 and 3 and parse as\n",
      "          a single date column.\n",
      "        * dict, e.g. {'foo' : [1, 3]} -> parse columns 1, 3 as date and call\n",
      "          result 'foo'\n",
      "    \n",
      "        If a column or index cannot be represented as an array of datetimes,\n",
      "        say because of an unparsable value or a mixture of timezones, the column\n",
      "        or index will be returned unaltered as an object data type. For\n",
      "        non-standard datetime parsing, use ``pd.to_datetime`` after\n",
      "        ``pd.read_csv``. To parse an index or column with a mixture of timezones,\n",
      "        specify ``date_parser`` to be a partially-applied\n",
      "        :func:`pandas.to_datetime` with ``utc=True``. See\n",
      "        :ref:`io.csv.mixed_timezones` for more.\n",
      "    \n",
      "        Note: A fast-path exists for iso8601-formatted dates.\n",
      "    infer_datetime_format : bool, default False\n",
      "        If True and `parse_dates` is enabled, pandas will attempt to infer the\n",
      "        format of the datetime strings in the columns, and if it can be inferred,\n",
      "        switch to a faster method of parsing them. In some cases this can increase\n",
      "        the parsing speed by 5-10x.\n",
      "    keep_date_col : bool, default False\n",
      "        If True and `parse_dates` specifies combining multiple columns then\n",
      "        keep the original columns.\n",
      "    date_parser : function, optional\n",
      "        Function to use for converting a sequence of string columns to an array of\n",
      "        datetime instances. The default uses ``dateutil.parser.parser`` to do the\n",
      "        conversion. Pandas will try to call `date_parser` in three different ways,\n",
      "        advancing to the next if an exception occurs: 1) Pass one or more arrays\n",
      "        (as defined by `parse_dates`) as arguments; 2) concatenate (row-wise) the\n",
      "        string values from the columns defined by `parse_dates` into a single array\n",
      "        and pass that; and 3) call `date_parser` once for each row using one or\n",
      "        more strings (corresponding to the columns defined by `parse_dates`) as\n",
      "        arguments.\n",
      "    dayfirst : bool, default False\n",
      "        DD/MM format dates, international and European format.\n",
      "    cache_dates : bool, default True\n",
      "        If True, use a cache of unique, converted dates to apply the datetime\n",
      "        conversion. May produce significant speed-up when parsing duplicate\n",
      "        date strings, especially ones with timezone offsets.\n",
      "    \n",
      "        .. versionadded:: 0.25.0\n",
      "    iterator : bool, default False\n",
      "        Return TextFileReader object for iteration or getting chunks with\n",
      "        ``get_chunk()``.\n",
      "    \n",
      "        .. versionchanged:: 1.2\n",
      "    \n",
      "           ``TextFileReader`` is a context manager.\n",
      "    chunksize : int, optional\n",
      "        Return TextFileReader object for iteration.\n",
      "        See the `IO Tools docs\n",
      "        <https://pandas.pydata.org/pandas-docs/stable/io.html#io-chunking>`_\n",
      "        for more information on ``iterator`` and ``chunksize``.\n",
      "    \n",
      "        .. versionchanged:: 1.2\n",
      "    \n",
      "           ``TextFileReader`` is a context manager.\n",
      "    compression : str or dict, default 'infer'\n",
      "        For on-the-fly decompression of on-disk data. If 'infer' and '%s' is\n",
      "        path-like, then detect compression from the following extensions: '.gz',\n",
      "        '.bz2', '.zip', '.xz', or '.zst' (otherwise no compression). If using\n",
      "        'zip', the ZIP file must contain only one data file to be read in. Set to\n",
      "        ``None`` for no decompression. Can also be a dict with key ``'method'`` set\n",
      "        to one of {``'zip'``, ``'gzip'``, ``'bz2'``, ``'zstd'``} and other\n",
      "        key-value pairs are forwarded to ``zipfile.ZipFile``, ``gzip.GzipFile``,\n",
      "        ``bz2.BZ2File``, or ``zstandard.ZstdDecompressor``, respectively. As an\n",
      "        example, the following could be passed for Zstandard decompression using a\n",
      "        custom compression dictionary:\n",
      "        ``compression={'method': 'zstd', 'dict_data': my_compression_dict}``.\n",
      "    \n",
      "        .. versionchanged:: 1.4.0 Zstandard support.\n",
      "    \n",
      "    thousands : str, optional\n",
      "        Thousands separator.\n",
      "    decimal : str, default '.'\n",
      "        Character to recognize as decimal point (e.g. use ',' for European data).\n",
      "    lineterminator : str (length 1), optional\n",
      "        Character to break file into lines. Only valid with C parser.\n",
      "    quotechar : str (length 1), optional\n",
      "        The character used to denote the start and end of a quoted item. Quoted\n",
      "        items can include the delimiter and it will be ignored.\n",
      "    quoting : int or csv.QUOTE_* instance, default 0\n",
      "        Control field quoting behavior per ``csv.QUOTE_*`` constants. Use one of\n",
      "        QUOTE_MINIMAL (0), QUOTE_ALL (1), QUOTE_NONNUMERIC (2) or QUOTE_NONE (3).\n",
      "    doublequote : bool, default ``True``\n",
      "       When quotechar is specified and quoting is not ``QUOTE_NONE``, indicate\n",
      "       whether or not to interpret two consecutive quotechar elements INSIDE a\n",
      "       field as a single ``quotechar`` element.\n",
      "    escapechar : str (length 1), optional\n",
      "        One-character string used to escape other characters.\n",
      "    comment : str, optional\n",
      "        Indicates remainder of line should not be parsed. If found at the beginning\n",
      "        of a line, the line will be ignored altogether. This parameter must be a\n",
      "        single character. Like empty lines (as long as ``skip_blank_lines=True``),\n",
      "        fully commented lines are ignored by the parameter `header` but not by\n",
      "        `skiprows`. For example, if ``comment='#'``, parsing\n",
      "        ``#empty\\na,b,c\\n1,2,3`` with ``header=0`` will result in 'a,b,c' being\n",
      "        treated as the header.\n",
      "    encoding : str, optional\n",
      "        Encoding to use for UTF when reading/writing (ex. 'utf-8'). `List of Python\n",
      "        standard encodings\n",
      "        <https://docs.python.org/3/library/codecs.html#standard-encodings>`_ .\n",
      "    \n",
      "        .. versionchanged:: 1.2\n",
      "    \n",
      "           When ``encoding`` is ``None``, ``errors=\"replace\"`` is passed to\n",
      "           ``open()``. Otherwise, ``errors=\"strict\"`` is passed to ``open()``.\n",
      "           This behavior was previously only the case for ``engine=\"python\"``.\n",
      "    \n",
      "        .. versionchanged:: 1.3.0\n",
      "    \n",
      "           ``encoding_errors`` is a new argument. ``encoding`` has no longer an\n",
      "           influence on how encoding errors are handled.\n",
      "    \n",
      "    encoding_errors : str, optional, default \"strict\"\n",
      "        How encoding errors are treated. `List of possible values\n",
      "        <https://docs.python.org/3/library/codecs.html#error-handlers>`_ .\n",
      "    \n",
      "        .. versionadded:: 1.3.0\n",
      "    \n",
      "    dialect : str or csv.Dialect, optional\n",
      "        If provided, this parameter will override values (default or not) for the\n",
      "        following parameters: `delimiter`, `doublequote`, `escapechar`,\n",
      "        `skipinitialspace`, `quotechar`, and `quoting`. If it is necessary to\n",
      "        override values, a ParserWarning will be issued. See csv.Dialect\n",
      "        documentation for more details.\n",
      "    error_bad_lines : bool, optional, default ``None``\n",
      "        Lines with too many fields (e.g. a csv line with too many commas) will by\n",
      "        default cause an exception to be raised, and no DataFrame will be returned.\n",
      "        If False, then these \"bad lines\" will be dropped from the DataFrame that is\n",
      "        returned.\n",
      "    \n",
      "        .. deprecated:: 1.3.0\n",
      "           The ``on_bad_lines`` parameter should be used instead to specify behavior upon\n",
      "           encountering a bad line instead.\n",
      "    warn_bad_lines : bool, optional, default ``None``\n",
      "        If error_bad_lines is False, and warn_bad_lines is True, a warning for each\n",
      "        \"bad line\" will be output.\n",
      "    \n",
      "        .. deprecated:: 1.3.0\n",
      "           The ``on_bad_lines`` parameter should be used instead to specify behavior upon\n",
      "           encountering a bad line instead.\n",
      "    on_bad_lines : {'error', 'warn', 'skip'} or callable, default 'error'\n",
      "        Specifies what to do upon encountering a bad line (a line with too many fields).\n",
      "        Allowed values are :\n",
      "    \n",
      "            - 'error', raise an Exception when a bad line is encountered.\n",
      "            - 'warn', raise a warning when a bad line is encountered and skip that line.\n",
      "            - 'skip', skip bad lines without raising or warning when they are encountered.\n",
      "    \n",
      "        .. versionadded:: 1.3.0\n",
      "    \n",
      "            - callable, function with signature\n",
      "              ``(bad_line: list[str]) -> list[str] | None`` that will process a single\n",
      "              bad line. ``bad_line`` is a list of strings split by the ``sep``.\n",
      "              If the function returns ``None``, the bad line will be ignored.\n",
      "              If the function returns a new list of strings with more elements than\n",
      "              expected, a ``ParserWarning`` will be emitted while dropping extra elements.\n",
      "              Only supported when ``engine=\"python\"``\n",
      "    \n",
      "        .. versionadded:: 1.4.0\n",
      "    \n",
      "    delim_whitespace : bool, default False\n",
      "        Specifies whether or not whitespace (e.g. ``' '`` or ``'    '``) will be\n",
      "        used as the sep. Equivalent to setting ``sep='\\s+'``. If this option\n",
      "        is set to True, nothing should be passed in for the ``delimiter``\n",
      "        parameter.\n",
      "    low_memory : bool, default True\n",
      "        Internally process the file in chunks, resulting in lower memory use\n",
      "        while parsing, but possibly mixed type inference.  To ensure no mixed\n",
      "        types either set False, or specify the type with the `dtype` parameter.\n",
      "        Note that the entire file is read into a single DataFrame regardless,\n",
      "        use the `chunksize` or `iterator` parameter to return the data in chunks.\n",
      "        (Only valid with C parser).\n",
      "    memory_map : bool, default False\n",
      "        If a filepath is provided for `filepath_or_buffer`, map the file object\n",
      "        directly onto memory and access the data directly from there. Using this\n",
      "        option can improve performance because there is no longer any I/O overhead.\n",
      "    float_precision : str, optional\n",
      "        Specifies which converter the C engine should use for floating-point\n",
      "        values. The options are ``None`` or 'high' for the ordinary converter,\n",
      "        'legacy' for the original lower precision pandas converter, and\n",
      "        'round_trip' for the round-trip converter.\n",
      "    \n",
      "        .. versionchanged:: 1.2\n",
      "    \n",
      "    storage_options : dict, optional\n",
      "        Extra options that make sense for a particular storage connection, e.g.\n",
      "        host, port, username, password, etc. For HTTP(S) URLs the key-value pairs\n",
      "        are forwarded to ``urllib`` as header options. For other URLs (e.g.\n",
      "        starting with \"s3://\", and \"gcs://\") the key-value pairs are forwarded to\n",
      "        ``fsspec``. Please see ``fsspec`` and ``urllib`` for more details.\n",
      "    \n",
      "        .. versionadded:: 1.2\n",
      "    \n",
      "    Returns\n",
      "    -------\n",
      "    DataFrame or TextParser\n",
      "        A comma-separated values (csv) file is returned as two-dimensional\n",
      "        data structure with labeled axes.\n",
      "    \n",
      "    See Also\n",
      "    --------\n",
      "    DataFrame.to_csv : Write DataFrame to a comma-separated values (csv) file.\n",
      "    read_csv : Read a comma-separated values (csv) file into DataFrame.\n",
      "    read_fwf : Read a table of fixed-width formatted lines into DataFrame.\n",
      "    \n",
      "    Examples\n",
      "    --------\n",
      "    >>> pd.read_csv('data.csv')  # doctest: +SKIP\n",
      "\n"
     ]
    }
   ],
   "source": [
    "help(pd.read_csv)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c2527ff2",
   "metadata": {},
   "source": [
    "## code from ICD list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "431c498e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#### Import dictionary of all ICD disease\n",
    "icd_data = pd.read_csv(\"/Users/cdonnat/Dropbox/My Mac (Claires MacBook Pro)/Downloads/ICD-10-CSV-master/codes.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "4a8dd9c0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                                  Cholera\n",
       "1                                                  Cholera\n",
       "2                                                  Cholera\n",
       "3                                            Typhoid fever\n",
       "4                                            Typhoid fever\n",
       "                               ...                        \n",
       "71699                             Dependence on respirator\n",
       "71700                         Dependence on renal dialysis\n",
       "71701                             Dependence on wheelchair\n",
       "71702    Dependence on other enabling machines and devices\n",
       "71703    Dependence on other enabling machines and devices\n",
       "Name: Category, Length: 71704, dtype: object"
      ]
     },
     "execution_count": 100,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "icd_data[\"Category\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "eec6439e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "15331\n"
     ]
    }
   ],
   "source": [
    "unique_icd_categories = np.unique([u.split(\",\")[0] for u in icd_data[\"Category\"]])\n",
    "print(len(unique_icd_categories))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1290,
   "id": "71b4e61c",
   "metadata": {},
   "outputs": [],
   "source": [
    "icd_str = \"\"\n",
    "for ind in unique_icd_categories:\n",
    "    icd_str += ind + \" \""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1308,
   "id": "76009ce4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "8714"
      ]
     },
     "execution_count": 1308,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 1314,
   "id": "cef2afbe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['(Induced) termination of pregnancy with other and unspecified complications',\n",
       "       '2-part displaced fracture of surgical neck of left humerus',\n",
       "       '2-part displaced fracture of surgical neck of right humerus',\n",
       "       '2-part displaced fracture of surgical neck of unspecified humerus',\n",
       "       '2-part nondisplaced fracture of surgical neck of left humerus',\n",
       "       '2-part nondisplaced fracture of surgical neck of right humerus',\n",
       "       '2-part nondisplaced fracture of surgical neck of unspecified humerus',\n",
       "       '3-part fracture of surgical neck of left humerus',\n",
       "       '3-part fracture of surgical neck of right humerus',\n",
       "       '3-part fracture of surgical neck of unspecified humerus',\n",
       "       '4-part fracture of surgical neck of left humerus',\n",
       "       '4-part fracture of surgical neck of right humerus',\n",
       "       '4-part fracture of surgical neck of unspecified humerus',\n",
       "       'ABO incompatibility reaction due to transfusion of blood or blood products',\n",
       "       'ABO incompatibility with acute hemolytic transfusion reaction',\n",
       "       'ABO incompatibility with delayed hemolytic transfusion reaction',\n",
       "       'ABO incompatibility with hemolytic transfusion reaction',\n",
       "       'Abdominal and pelvic pain', 'Abdominal aortic aneurysm',\n",
       "       'Abdominal migraine', 'Abdominal pregnancy', 'Abdominal rigidity',\n",
       "       'Abdominal tenderness', 'Abdominal testis',\n",
       "       'Abnormal and inconclusive findings on diagnostic imaging of breast',\n",
       "       'Abnormal blood-pressure reading', 'Abnormal bowel sounds',\n",
       "       'Abnormal cytologic smear of anus',\n",
       "       'Abnormal cytological findings in specimens from cervix uteri',\n",
       "       'Abnormal cytological findings in specimens from other digestive organs and abdominal cavity',\n",
       "       'Abnormal cytological findings in specimens from other female genital organs',\n",
       "       'Abnormal cytological findings in specimens from vagina',\n",
       "       'Abnormal finding of blood chemistry',\n",
       "       'Abnormal findings in cerebrospinal fluid',\n",
       "       'Abnormal findings in other body fluids and substances',\n",
       "       'Abnormal findings in specimens from digestive organs and abdominal cavity',\n",
       "       'Abnormal findings in specimens from female genital organs',\n",
       "       'Abnormal findings in specimens from male genital organs',\n",
       "       'Abnormal findings in specimens from other organs',\n",
       "       'Abnormal findings in specimens from respiratory organs and thorax',\n",
       "       'Abnormal findings on antenatal screening of mother',\n",
       "       'Abnormal findings on cytological and histological examination of urine',\n",
       "       'Abnormal findings on diagnostic imaging of central nervous system',\n",
       "       'Abnormal findings on diagnostic imaging of limbs',\n",
       "       'Abnormal findings on diagnostic imaging of lung',\n",
       "       'Abnormal findings on diagnostic imaging of other abdominal regions',\n",
       "       'Abnormal findings on diagnostic imaging of other body structures',\n",
       "       'Abnormal findings on diagnostic imaging of other parts of musculoskeletal system',\n",
       "       'Abnormal findings on diagnostic imaging of other specified body structures',\n",
       "       'Abnormal findings on diagnostic imaging of urinary organs',\n",
       "       'Abnormal findings on microbiological examination of urine',\n",
       "       'Abnormal findings on neonatal screening', 'Abnormal glucose',\n",
       "       'Abnormal glucose complicating pregnancy',\n",
       "       'Abnormal hard tissue formation in pulp',\n",
       "       'Abnormal histological findings in specimens from digestive organs and abdominal cavity',\n",
       "       'Abnormal histological findings in specimens from female genital organs',\n",
       "       'Abnormal immunological finding in serum',\n",
       "       'Abnormal innervation syndrome', 'Abnormal involuntary movements',\n",
       "       'Abnormal product of conception',\n",
       "       'Abnormal radiologic findings on diagnostic imaging of kidney',\n",
       "       'Abnormal radiologic findings on diagnostic imaging of other urinary organs',\n",
       "       'Abnormal results of cardiovascular function studies',\n",
       "       'Abnormal results of function studies of central nervous system',\n",
       "       'Abnormal results of function studies of ear and other special senses',\n",
       "       'Abnormal results of function studies of eye',\n",
       "       'Abnormal results of function studies of other organs and systems',\n",
       "       'Abnormal results of function studies of peripheral nervous system',\n",
       "       'Abnormal results of kidney function studies',\n",
       "       'Abnormal results of liver function studies',\n",
       "       'Abnormal results of other endocrine function studies',\n",
       "       'Abnormal results of pulmonary function studies',\n",
       "       'Abnormal results of thyroid function studies',\n",
       "       'Abnormal serum enzyme levels', 'Abnormal sputum',\n",
       "       'Abnormal tumor markers', 'Abnormalities of forces of labor',\n",
       "       'Abnormalities of gait and mobility',\n",
       "       'Abnormalities of heart beat',\n",
       "       'Abnormality in fetal heart rate and rhythm complicating labor and delivery',\n",
       "       'Abnormality of red blood cells', 'Abrasion',\n",
       "       'Abrasion of abdominal wall', 'Abrasion of anus',\n",
       "       'Abrasion of breast', 'Abrasion of left back wall of thorax',\n",
       "       'Abrasion of left ear', 'Abrasion of left elbow',\n",
       "       'Abrasion of left eyelid and periocular area',\n",
       "       'Abrasion of left forearm',\n",
       "       'Abrasion of left front wall of thorax', 'Abrasion of left hand',\n",
       "       'Abrasion of left index finger', 'Abrasion of left little finger',\n",
       "       'Abrasion of left middle finger', 'Abrasion of left ring finger',\n",
       "       'Abrasion of left shoulder', 'Abrasion of left thumb',\n",
       "       'Abrasion of left upper arm'], dtype='<U165')"
      ]
     },
     "execution_count": 1314,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unique_icd_categories[:100]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1319,
   "id": "17773fd3",
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary['DB00001']['indication_final'] = \"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a47477c4",
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary['DB00001']['indication_final'][]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1305,
   "id": "5db2f3cd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['is',\n",
       " 'for',\n",
       " 'the',\n",
       " 'treatment',\n",
       " 'of',\n",
       " 'to',\n",
       " 'active',\n",
       " 'rheumatoid',\n",
       " 'arthritis',\n",
       " 'in',\n",
       " 'adults',\n",
       " 'and',\n",
       " 'in',\n",
       " 'chronic',\n",
       " 'moderate',\n",
       " 'to',\n",
       " 'severe',\n",
       " 'plaque',\n",
       " 'psoriasis',\n",
       " 'in',\n",
       " '4',\n",
       " 'of',\n",
       " 'age',\n",
       " 'and',\n",
       " 'is',\n",
       " 'used',\n",
       " 'to',\n",
       " 'manage',\n",
       " 'signs',\n",
       " 'and',\n",
       " 'symptoms',\n",
       " 'of',\n",
       " 'idiopathic',\n",
       " 'arthritis',\n",
       " 'in',\n",
       " '2',\n",
       " 'and',\n",
       " 'is',\n",
       " 'used',\n",
       " 'to',\n",
       " 'manage',\n",
       " 'the',\n",
       " 'symptoms',\n",
       " 'of',\n",
       " 'arthritis',\n",
       " 'and',\n",
       " 'ankylosing',\n",
       " 'spondylitis.',\n",
       " '']"
      ]
     },
     "execution_count": 1305,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[u for u in dictionary['DB00005']['indication'].split(\" \") if len(re.findall(u, icd_str))>0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1304,
   "id": "6c5981cd",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.'"
      ]
     },
     "execution_count": 1304,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary['DB00002']['indication']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1316,
   "id": "50b06e8f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 1316,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[u  for u in unique_icd_categories if re.findall(\"colorectal carcinoma\", u)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1331,
   "id": "4e5c9138",
   "metadata": {},
   "outputs": [],
   "source": [
    "indication_data= [[k, dictionary[k]['indication']] for k in dictionary.keys() ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 222,
   "id": "b7c47a33",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 222,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "4b2a1722",
   "metadata": {},
   "outputs": [],
   "source": [
    "##### Break down the indication into a word matrix\n",
    "#### Find closest neighbour in icd codes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "99996e5c",
   "metadata": {},
   "outputs": [],
   "source": [
    "word_indications = "
   ]
  }
 ],
 "metadata": {
  "colab": {
   "name": "drugsimulation.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
